

27.09.2019

10:00 - 12:00 **Type: Special session** **Alicante Auditorium (Hall 3)**
Title: ai

11:45 - 13:30 **Type: Opening ceremony** **Barcelona Auditorium (Hall 2)**
Title: ESMO 2019 Opening ceremony

11:45 - 11:45 **Session DOI**

11:45 - 12:05 **Welcome to ESMO 2019**

14:00 - 15:30 **Type: Educational session** **Alicante Auditorium (Hall 3)**
Title: CNS complications and management in systemic cancer patients

Chair(s): Matthias Preusser, AT; Martin van den Bent, NL

14:00 - 14:00 **Session DOI**

14:00 - 14:25 **Cerebral edema and steroids in the era of immunotherapy**
P. Roth, University of Zurich, Zürich, CH

14:25 - 14:50 **Vascular complications in brain tumor patients: Etiology, management and prevention**
E. Le Rhun, Roger Salengro Hospital, Lille, FR

14:50 - 15:15 **Neurological complications of immunotherapy**
M. Preusser, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

15:15 - 15:30 **Discussion**

14:00 - 15:30 **Type: Educational session** **Barcelona Auditorium (Hall 2)**
Title: Current markers in immunotherapy
Chair(s): Samra Turajlic, GB

14:00 - 14:00 **Session DOI**

14:00 - 14:25 **The value of PD-L1 as a biomarker beyond lung cancers**
K. Harrington, Institute of Cancer Research ICR, London, GB

14:25 - 14:50 **The clonal evolution and its impact on immunotherapy**
S. Turajlic, The Francis Crick Institute, London, GB

14:50 - 15:15 **Targeting the microenvironment**
F. Petitprez, Centre de Recherche des Cordeliers, Paris, FR

15:15 - 15:30 **Discussion**

14:00 - 15:30 **Type: Proffered Paper session** **Madrid Auditorium**
Title: Proffered Paper 1 - Gastrointestinal tumours, non- **(Hall 2)**
colorectal

14:00 - 14:00 **Session DOI**

14:00 - 14:15 **One LBA TBC**

14:15 - 14:30 **One LBA TBC**

14:30 - 14:45 **Invited Discussant 2 LBAs TBC**

14:45 - 15:00 **One LBA TBC**

15:00 - 15:15 **6710 - Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-Paclitaxel/Gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP) - Final Results of a multicenter randomised Phase 2 AIO trial -**

V. Kunzmann¹, H. Algül², E. Goekkurt³, G. Siegler⁴, U. Martens⁵, D. Waldschmidt⁶, U. Pelzer⁷, E. Hennes⁸, M. Fuchs⁹, J. Siveke¹⁰, F. Kullmann¹¹, S. Boeck¹², T. Ettrich¹³, P. Ferenczy¹⁴, R. Keller¹⁵, C.-T. Germer¹⁶, H. Stein¹⁷, I. Hartlapp¹⁶, I. Klein¹⁸, V. Heinemann¹⁹, ¹University Clinic Würzburg-Medizinische Klinik und Poliklinik II Zentrum fuer Innere Medizin (ZIM), Würzburg, DE, ²Technical University Munich, Munich, DE, ³Facharztzentrum Eppendorf, Hamburg, DE, ⁴Klinikum Nuernberg Nord, Nürnberg, DE, ⁵SLK-Kliniken Heilbronn GmbH, Heilbronn, DE, ⁶Uniklinik Köln, Cologne, DE, ⁷Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ⁸Asklepios Klinik Hamburg Barmbek, Hamburg, DE, ⁹Krankenhaus München Bogenhausen II Med. Abteilung, Munich, DE, ¹⁰University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ¹¹Klinikum Weiden, Weiden in der Oberpfalz, DE, ¹²LMU Klinikum der Universität München, Munich, DE, ¹³Ulm Medical University, Ulm, DE, ¹⁴ClinAssess GmbH, Leverkusen, DE, ¹⁵AIO Studien gGmbH, Berlin, DE, ¹⁶University Hospital Wuerzburg, Wuerzburg, DE, ¹⁷Paracelsus Medical University, Nuernberg, DE, ¹⁸University Hospital of Wuerzburg, Wuerzburg, DE, ¹⁹Ludwig Maximilians University - Grosshadern, Munich, DE

15:15 - 15:30 **Invited Discussant 6170 and one LBA TBC**

14:00 - 15:45 **Type: Proffered Paper session** **Sevilla Auditorium (Hall**
Title: Proffered Paper - Genitourinary tumours, **2)**
prostate

- 14:00 - 14:00 **Session DOI**
- 14:00 - 14:12 **One LBA TBC**
- 14:12 - 14:24 **One LBA TBC**
- 14:24 - 14:39 **Invited Discussant 2 LBAs TBC**
- 14:39 - 14:51 **8430 - Apalutamide (APA) and Overall Survival (OS) in Patients (pts) With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Updated Results From the Phase 3 SPARTAN Study**
M. Smith¹, F. Saad², S. Chowdhury³, S. Oudard⁴, B. Hadaschik⁵, J. Graff⁶, D. Olmos⁷, P. Mainwaring⁸, J.Y. Lee⁹, H. Uemura¹⁰, P. De Porre¹¹, A. Smith¹², K. Zhang¹², A. Lopez-Gitlitz¹³, E. Small¹⁴, ¹Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, US, ²Hospital St. Luc du CHUM, Montreal, CA, ³Guy's and St. Thomas' Hospital NHS Trust, London, GB, ⁴Hopital European George Pompidou, Paris, FR, ⁵University Hospital of Essen, Essen, DE, ⁶OHSU Knight Cancer Institute, Portland, US, ⁷Spanish National Cancer Research, Málaga, ES, ⁸ICON Cancer Care, Brisbane, AU, ⁹St. Mary's Hospital of Catholic University, Seoul, KR, ¹⁰Yokohama City University Medical Center, Yokohama, JP, ¹¹Janssen EMEA Belgium, Beerse, BE, ¹²Janssen Research & Development, San Diego, US, ¹³Janssen Research & Development, Los Angeles, US, ¹⁴UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
- 14:51 - 15:03 **8440 - Docetaxel for hormone-naïve prostate cancer: results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burden**
N. Clarke¹, A. Ali¹, F. Ingleby², A. Hoyle¹, J. Calvert², G. Attard³, S. Chowdhury⁴, D. Dearnaley⁵, H. Douis⁶, S. Gillessen⁷, R. Jones⁸, Z. Malik⁹, M. Mason¹⁰, R. Millman¹¹, C. Parker¹², H. Rush², A. Omlin¹³, M. Sydes², M. Parmar², N. James¹⁴, ¹The Christie and Salford Royal Hospitals, Manchester, GB, ²MRC Clinical Trials Unit at UCL, London, GB, ³The Institute of Cancer Research (Sutton Site), Sutton, GB, ⁴Guy's and St. Thomas' Hospital NHS Trust, London, GB, ⁵The Institute of Cancer Research (ICR), London, GB, ⁶University Hospital Birmingham, Birmingham, GB, ⁷The Christie NHS Foundation Trust, Manchester, GB, ⁸University of Glasgow, Glasgow, GB, ⁹Royal Liverpool University Hospital, Liverpool, GB, ¹⁰Velindre Cancer Centre Velindre Hospital, Cardiff, GB, ¹¹Medical Research Council - MRC Clinical Trials Unit, London, GB, ¹²The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ¹³Kantonsspital St. Gallen, St. Gallen, CH, ¹⁴Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, Birmingham, GB
- 15:03 - 15:13 **Invited Discussant 8430 and 8440**

15:13 - 15:25 **One LBA TBC**

15:25 - 15:33 **Invited Discussant one LBA TBC**

14:00 - 15:30 **Type: Educational session** **Cordoba Auditorium**
Title: Special clinical scenarios in management of **(Hall 7)**
advanced melanoma
Chair(s): Paul Lorigan, GB

14:00 - 14:00 **Session DOI**

14:00 - 14:25 **What is the current systemic approach in poor prognostic advanced melanomas?**
P. Lorigan, The Christie NHS Foundation Trust, Manchester, GB

14:25 - 14:50 **Checkpoint inhibitors in special populations**
A. Menzies, Melanoma Institute Australia, University of Sydney, North Sydney, AU

14:50 - 15:15 **When can we stop immunotherapy in patients with clinical benefit?**
D. Schadendorf, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

15:15 - 15:30 **Discussion**

14:00 - 15:30	Type: Educational session Title: Preclinical models and imaging to guide clinical therapy Chair(s): Sergio Quezada, GB	Granada Auditorium (Hall 3)
14:00 - 14:00	Session DOI	
14:00 - 14:25	Mouse models to study cancer immunology <u>S. Quezada</u> , University College London, London, GB	
14:25 - 14:50	Ex-vivo and 3D models: From mice to men <u>J. Jonkers</u> , Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL	
14:50 - 15:15	Imaging of the immune system <u>T. Lahoutte</u> , UZ Brussel, Brussels, BE	
15:15 - 15:30	Discussion	

14:00 - 15:30 **Type: Collaborative session** **Valencia Auditorium (Hall 5)**
Title: ESMO-EACR Collaborative session: From cancer genomes to combinatorial therapies
Chair(s): Josep Tabernero, ES; Daniel Peeper, NL

14:00 - 14:00 **Session DOI**

14:00 - 14:05 **Introduction**

J. Tabernero, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES

14:05 - 14:25 **Towards rational cancer and immune cell treatment combinations: A functional genomics approach**

D. Peeper, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

14:25 - 14:45 **How much genomics data have translated into treatment decision**

R. Dienstmann, Vall d'Hebron University Hospital, Barcelona, ES

14:45 - 15:05 **Role of stromal heterogeneity in immunosuppression and resistance to immunotherapy**

F. Mehta-Grigoriou, Institut Curie, Paris, FR

15:05 - 15:25 **Overview of the ESMO Precision Medicine Working Group accomplishments in 2018**

F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

15:25 - 15:30 **Conclusions**

D. Peeper, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

14:00 - 15:30 **Type: Collaborative session** **Cartagena Auditorium (Hall 3)**
Title: ESMO-ESTRO Collaborative session: RTCT in stage III NSCLC: Prevention and management of toxicity including the use of immunotherapy
Chair(s): Dirk De Ruyscher, NL

- 14:00 - 14:05 **Introduction**
D. De Ruyscher, Maastric Clinic, Maastricht, NL
- 14:05 - 14:20 **Nutrition before and during CCRT, including treatment and prevention of anorexia**
- 14:20 - 14:35 **Life style recommendation: Physical exercise, smoking cessation**
- 14:35 - 14:55 **Prevention and management of “in-field” toxicities: Oesophagus, nausea and vomiting, lung, skin, heart**
- 14:55 - 15:10 **Prevention and treatment of fatigue**
- 15:10 - 15:25 **Radiotherapy techniques and chemotherapy adjustments to prevent toxicity in the era of immune therapy**
- 15:25 - 15:30 **Conclusions**

14:00 - 15:30	Type: Special session Title: The role of the medical oncologist in health policy: Using national cancer control plans to translate science into better patient care Chair(s): Giuseppe Curigliano, IT; Jose Martin-Moreno, ES	Salamanca Auditorium (Hall 3)
14:00 - 14:00	Session DOI	
14:00 - 14:15	Introduction: Where can patient care plans/national guidelines fit into NCCP? <u>J. Martin-Moreno</u> , Hospital Clinico Universitario de Valencia, Valencia, ES	
14:15 - 14:30	The National Cancer Control Plan of Uzbekistan: Update on progress from 2015 to 2019 <u>M. Tillyashaykhov</u> , National Cancer Research Center of Uzbekistan, Tashkent, UZ	
14:30 - 14:45	Russia outlook: Features of the NCCP - Work in progress <u>V. Matveev</u> , N. N. Blokhin Russian Cancer Research Center, Moscow, RU	
14:45 - 15:00	Profile from Eastern Europe: Latvia <u>G. Purkalne</u> , Pauls Stradins Clinical University Hospital, Riga, LV	
15:00 - 15:10	Everything you always wanted to know about National Cancer Control Plans but were afraid to ask <u>J. Martin-Moreno</u> , Hospital Clinico Universitario de Valencia, Valencia, ES	
15:10 - 15:30	Closing remarks, overview, summary and interactive Q&A <u>G. Curigliano</u> , Istituto Europeo di Oncologia, Milan, IT	

14:00 - 15:30 **Type: Patient Advocay Track** **Leon Auditorium (Hall 3)**
Title: Placing the patient at the center of care
Chair(s): Nicolas Philippou, CY

14:00 - 14:00 **Session DOI**

14:00 - 14:15 **Introduction - Integrated oncology and palliative care from time of diagnosis: The PASYKAF Model**
N. Philippou, The Cyprus Association of Cancer Patients & Friends (PASYKAF), Nicosia, CY

14:15 - 14:30 **Putting the patient in the center: Measuring outcomes**

14:30 - 14:45 **Patient center care plan: The best care for every patient**
N. Cherny, Shaare Zedek Medical Center, Jerusalem, IL

14:45 - 15:00 **Educating the oncologists and health professionals on compassionate care: Care with dignity**
G. Samoutis, University of Nicosia Medical School-St George's, University of London, Nicosia, CY

15:00 - 15:15 **Caregivers perspective: When oncology and palliative care are fully integrated from time of diagnosis**
K. Oliver, International Brain Tumour Alliance, Tadworth, GB

15:15 - 15:30 **Conclusions and Q&A**

14:15 - 15:15 **Type: Multidisciplinary session** **Pamplona Auditorium (Hall 2)**
Title: Multidisciplinary management of germline and somatic gene alterations in patients with metastatic breast cancer
Chair(s): Judith Balmana, ES

14:15 - 14:15 **Session DOI**

14:15 - 14:20 **Presentation of case/condition**

J. Balmana, Vall d'Hebron University Hospital, Barcelona, ES

14:20 - 14:35 **Germline testing: Who should we test and for what?**

C. Turnbull, The Institute of Cancer Research (ICR), London, GB

14:35 - 14:50 **Complex management of germline BRCA associated breast cancer**

S. Paluch-Shimon, Shaare Zedek M.C, Jerusalem, IL

14:50 - 15:05 **DNA repair mutations beyond germline BRCA: Do they matter for patient management?**

J. Balmana, Vall d'Hebron University Hospital, Barcelona, ES

15:05 - 15:15 **General discussion**

14:15 - 15:15 **Type: Challenge your expert** **Malaga Auditorium (Hall 5)**
Title: Practical use of liquid biopsy for advanced NSCLC
Chair(s): Maurice Perol, FR

14:15 - 14:15 **Session DOI**

14:15 - 14:25 **Presentation by expert**

D.S.W. Tan, National Cancer Center Singapore, Singapore, SG

14:25 - 15:15 **Discussion led by Chair**

M. Perol, Centre Léon Bérard, Lyon, FR

14:15 - 15:15 **Type: Challenge your expert** **Tarragona Auditorium (Hall 7)**
Title: SCLC: Is it time for novel therapies?
Chair(s): Fiona Blackhall, GB

14:15 - 14:15 **Session DOI**

14:15 - 14:25 **Presentation by expert**
C. Rudin, Memorial Sloan-Kettering Cancer Center, New York, US

14:25 - 15:15 **Discussion led by Chair**
F. Blackhall, The Christie NHS Foundation Trust, Manchester, GB

14:15 - 15:15 **Type: Young Oncologist session** **Santander Auditorium (Hall 3)**
Title: YO Mentorship session: Career paths in oncology
Chair(s): Kevin Punie, BE; Teresa Amaral, PT

14:15 - 14:15 **Topic 1: Building a career at a centre of reference**

M. Schmidinger¹, E. De Azambuja², ¹Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, ²Institute Jules Bordet, Brussels, BE

14:15 - 14:15 **Topic 2: Building a career in basic science**

L. Trusolino¹, T. Sorlie², ¹IRCCS Candiolo, Candiolo, IT, ²Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO

14:15 - 14:15 **Topic 3: Building a career in translational research**

L. De Mattos-Arruda¹, L. Albiges², ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Institut Gustave Roussy, Villejuif, FR

14:15 - 14:15 **Topic 4: Transitioning from academia to industry**

G. Schiavon¹, J.-C. Soria², ¹AstraZeneca UK, Cambridge, GB, ²Medimmune, Gaithersburg, US

14:15 - 14:15 **Topic 5: Oncology in the private practice setting**

M. Strijbos¹, S. Rauh², ¹A.Z. Klina, Brasschaat, BE, ²Centre Hospitalier Emile Mayrisch CHEM, Esch sur Alzette, LU

14:15 - 14:15 **Topic 6: Working in palliative care**

S. Kaasa¹, C. Ripamonti², ¹Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ²Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

14:15 - 14:15 **Topic 7: Working in secondary / tertiary care centres**

R.-O. Curca¹, J. Kappes², ¹County Hospital Alba, Alba Iulia, RO, ²Thoraxklinik Heidelberg, Heidelberg, DE

16:00 - 17:30 **Type: Proffered Paper session** **Barcelona Auditorium (Hall 2)**
Title: Proffered Paper 1 - NSCLC, metastatic

16:00 - 16:00 **Session DOI**

16:00 - 16:15 **14780 - Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain**

L. Chow¹, F. Barlesi², E. Bertino³, M. Van Den Bent⁴, H. Wakelee⁵, P. Wen⁶, C.-H. Chiu⁷, S. Orlov⁸, M. Majem⁹, R. Chiari¹⁰, M. Mckeage¹¹, C.-J. Yu¹², F. Hurtado¹³, P. Cazorla Arratia¹⁴, Y. Song¹⁵, F. Branle¹⁶, M. Shi¹⁵, D.-W. Kim¹⁷, ¹University of Washington Seattle Cancer Care Alliance, Seattle, US, ²Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, ³The Ohio State University Medical Center, Columbus, US, ⁴Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ⁵Stanford University, Stanford, US, ⁶Dana-Farber Cancer Institute, Boston, US, ⁷Taipei Veterans General Hospital, Taipei City, TW, ⁸Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, RU, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹⁰Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, IT, ¹¹University of Auckland, Auckland, NZ, ¹²National Taiwan University Hospital, Taipei, TW, ¹³Novartis Institutes for Biomedical Research, East Hanover, US, ¹⁴Novartis Pharmaceuticals Corporation, East Hanover, US, ¹⁵Novartis Pharmaceuticals Corporation, East Hanover, US, ¹⁶Novartis AG, Basel, CH, ¹⁷Seoul National University Hospital, Seoul, KR

16:15 - 16:30 **14790 - Integrated Genomic and DNA Methylation Analyses of Non-Small Cell Lung Cancer Patients with Brain Metastases**

Y. Fan¹, Y. Xu¹, Z. Huang², K. Chen³, H. Han-Zhang⁴, J. Ye⁴, N. Han², L. Gong², X. Xu², H. Lu², J. Qin¹, F. Xie¹, ¹Zhejiang cancer hospital, Hangzhou, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN, ³ZHEJIANG CANCER HOSPITAL, Hangzhou, CN, ⁴Burning Rock Biotech, Guangzhou, CN

16:30 - 16:45 **Invited Discussant 14780 and 14790**

16:45 - 17:00 **One LBA TBC**

17:00 - 17:15 **One LBA TBC**

17:15 - 17:30 **Invited Discussant 2 LBAs TBC**

16:00 - 17:30 **Type: Educational session** **Madrid**
Title: The clinical utility of analysing circulating tumor DNA in patients with colorectal cancer (CRC) **Auditorium (Hall 2)**
Chair(s): Takayuki Yoshino, JP; Julien Taieb, FR

16:00 - 16:00 **Session DOI**

16:00 - 16:25 **Methodological principles and current technological advances**
M. Speicher, Medical University of Graz, Graz, AT

16:25 - 16:50 **Potential clinical utility of analysing circulating tumor DNA for CRC**
C. Montagut, , US

16:50 - 17:15 **Ongoing pivotal trials using liquid biopsy**
T. Yoshino, National Cancer Center Hospital East, Kashiwa, JP

17:15 - 17:30 **Discussion**

16:00 - 17:00 **Type: Young Oncologist session** **Palma & Tenerife**
Title: YO Clinical cases of solid tumours: Discussion forum for young oncologists **(CC5)**
Chair(s): Claudia Cardone, IT; Mehmet Ozturk, TR; Radu Vidra, RO

16:00 - 16:00 **Topic 1: Colorectal cancer**
E. Elez Fernández, 7Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES

16:00 - 16:00 **Topic 2: Toxicity of immunotherapy**
J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

16:00 - 16:00 **Topic 3: Melanoma**
T. Troiani, Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT

16:00 - 17:30 **Type: Educational session** **Sevilla Auditorium (Hall 2)**
Title: Frontline in mRCC: Ready to select treatment?
 Chair(s): Camillo Guglielmo Porta, IT

16:00 - 16:00 **Session DOI**

16:00 - 16:25 **How to select patients for immunotherapy doublet**
C.G. Porta, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, IT

16:25 - 16:50 **How to select patients for immunotherapy + VEGF inhibition**
L. Albiges, Institut Gustave Roussy, Villejuif, FR

16:50 - 17:15 **Biomarker in RCC: Clinical perspective**
T. Choueiri, Dana-Farber Cancer Institute, Boston, US

17:15 - 17:30 **Discussion**

16:00 - 17:30 **Type: Proffered Paper session** **Pamplona Auditorium (Hall 2)**
Title: Proffered Paper 1 - Gynaecological cancers

16:00 - 16:00 **Session DOI**

16:00 - 16:12 **9920 - FORWARD I (GOG 3011): A Phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)**
K. Moore¹, A. Oza², N. Colombo³, A. Oaknin⁴, G. Scambia⁵, D. Lorusso⁶, R. Farias-Eisner⁷, S. Banerjee⁸, C. Murphy⁹, J. Tanyi¹⁰, H. Hirte¹¹, J. Konner¹², P. Lim¹³, M. Prasad Hayes¹⁴, B. Monk¹⁵, S. Kim¹⁶, J. Wang¹⁷, K. Malek¹⁷, I. Vergote¹⁸, M. Birrer¹⁹,
¹Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, ²Princess Margaret Cancer Centre, University Health Network, Toronto, CA, ³Istituto Europeo di Oncologia, Milan, IT, ⁴Vall d'Hebron University Hospital, Barcelona, ES, ⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, IT, ⁶Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁷University of California at Los Angeles, Los Angeles, US, ⁸Royal Marsden Hospital NHS Foundation Trust, London, GB, ⁹Bon Secours Hospital, Cork, IE, ¹⁰University of Pennsylvania, Philadelphia, US, ¹¹Juravinski Cancer Centre, Hamilton, CA, ¹²Memorial Sloan Kettering Cancer Center, New York, US, ¹³The Center of Hope, Reno, US, ¹⁴Icahn School of Medicine at Mount Sinai, New York, US, ¹⁵University of Arizona Cancer Center, Tucson, US, ¹⁶University of Texas, Houston, US, ¹⁷ImmunoGen Inc., Waltham, US, ¹⁸University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹⁹University of Alabama at Birmingham, Birmingham, US

16:12 - 16:24 **One LBA TBC**

16:24 - 16:36 **One LBA TBC**

16:36 - 16:51 **Invited Discussant 9920 and 2 LBAs TBC**

16:51 - 17:03 **One LBA TBC**

17:03 - 17:15 **9930 - OCTOPUS - A Randomised, Multi-centre Phase II Umbrella Trial of Weekly Paclitaxel+/- Novel Agents in Platinum-Resistant Ovarian Cancer: vistusertib**

S. Banerjee¹, L.-A. Lewsley², A. Clamp³, J. Krell⁴, R. Herbertson⁵, R. Glasspool⁶, C. Orbegoso¹, C. Green⁷, R. Kristeleit⁸, C. Gourley⁹, C. Cambell², U. Banerji¹⁰, C. Shepherd¹¹, W. Brugger¹¹, L. Chudleigh², A. Hanif², I. Mcneish¹², J. Paul², ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²University of Glasgow, Glasgow, GB, ³The Christie NHS Foundation Trust and University of Manchester, Manchester, GB, ⁴Imperial College London - Hammersmith Hospital, London, GB, ⁵Sussex Cancer Centre, BB, GB, ⁶Beatson West of Scotland Cancer Centre, Glasgow, GB, ⁷University Hospital Southampton NHS Foundation Trust, SO YD, GB, ⁸UCL Cancer Institute, University College London and UCL Hospitals, Middletown, US, ⁹Edinburgh Cancer Research UK Centre, Edinburgh, GB, ¹⁰The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ¹¹Astrazeneca, Cambridge, GB, ¹²Imperial College London, London, GB

17:15 - 17:30 **Invited Discussant 9930 and one LBA TBC**

16:00 - 17:30 **Type: Special session** **Valencia Auditorium (Hall 5)**
Title: Biosimilars use in oncology: Clarifying concepts

16:00 - 16:05 **Introduction**

16:05 - 16:20 **Biosimilars use in clinical practice: State of play**

16:20 - 16:35 **Clarifying immunogenicity and switching for oncology biosimilars**

16:35 - 16:50 **Extrapolation of indications in oncology biosimilars**

16:50 - 17:05 **Impact of biosimilars on the sustainability of healthcare systems**

17:05 - 17:25 **Panel Discussion / Q&A**

17:25 - 17:30 **Conclusions**

16:00 - 17:30 **Type: Proffered Paper session** **Bilbao Auditorium (Hall 5)**
Title: Proffered Paper - CNS tumours

16:00 - 16:00 **Session DOI**

16:00 - 16:12 **3900 - Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study**

F. Barlesi¹, D.-W. Kim², E. Bertino³, M. Van Den Bent⁴, H. Wakelee⁵, P. Wen⁶, P. Garrido Lopez⁷, S. Orlov⁸, M. Majem⁹, M. Mckeage¹⁰, C.-J. Yu¹¹, F. Hurtado¹², P. Cazorla Arratia¹³, Y. Song¹⁴, F. Branle¹⁵, M. Shi¹⁶, L. Chow¹⁷, ¹Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, ²Seoul National University Hospital, Seoul, KR, ³The Ohio State University Medical Center, Columbus, US, ⁴Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ⁵Stanford University, Stanford, US, ⁶Dana-Farber Cancer Institute, Boston, US, ⁷Hospital Ramón Y Cajal, Madrid, ES, ⁸Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, RU, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹⁰University of Auckland, Auckland, NZ, ¹¹National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TW, ¹²Novartis Institutes for Biomedical Research, East Hanover, US, ¹³Novartis Pharmaceuticals Corporation, East Hanover, US, ¹⁴Novartis Pharmaceuticals

Corporation, East Hanover, US, ¹⁵Novartis AG, Basel, CH, ¹⁶Novartis Pharmaceuticals Corp, East Hanover, US, ¹⁷University of Washington Seattle Cancer Care Alliance, Seattle, US

16:12 - 16:24

3910 - Prognostic role of the EANO ESMO classification of leptomeningeal metastases

E. Le Rhun¹, P. Devos², J. Weller³, K. Seystahl⁴, F. Mo⁵, A. Compter⁶, A.S. Berghoff⁷, J. Jongen⁸, F. Wolpert⁴, R. Rudà⁵, D. Brandsma⁹, M. Preusser¹⁰, M. Van Den Bent¹¹, U. Herrlinger¹², M. Weller¹³, ¹Roger Salengro Hospital, Lille, FR, ²Lille University Hospital, Lille, FR, ³University Hospital of Bonn, Bonn, DE, ⁴University Hospital and University of Zurich, Zurich, CH, ⁵City of Health and Science and University of Turin, Turin, IT, ⁶Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NL, ⁷Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT, ⁸Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, NL, ⁹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ¹⁰Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, ¹¹Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ¹²Universitätsklinikum Bonn, Bonn, DE, ¹³Universitätsspital Zürich - Klinik für Neurologie, Zurich, CH

16:24 - 16:39

Invited Discussant 3900 and 3910

16:39 - 16:51

3920 - A Phase 0/2 Clinical Trial of a CDK4/6 Inhibitor in Aggressive Meningioma Patients

N. Sanai¹, A.-C. Tien², J. Li³, X. Bao³, A. Derogatis⁴, Y. Fujita⁴, C. Pennington-Krygier⁴, S. Kim³, S. Mehta⁴, ¹Barrow Neurological Institute, Phoenix, US, ²Barrow Brain and Spine, Phoenix, US, ³Karmanos Cancer Institute, Detroit, US, ⁴Barrow Neurological Institute, Phoenix, US

16:51 - 17:03

3930 - Is Immuno-Oncology Therapy Effective in Hypermutator Glioblastomas with Somatic or Germline mutations ?

C. Kamiya-Matsuoka¹, N. Metrus¹, S.-P. Weathers¹, K. Shaw¹, M. Penas-Prado¹, M. Loghin¹, K. Alfaro-Munoz¹, B. O'Brien¹, R. Harrison¹, Z. Sadighi², N. Majd¹, W. Yung¹, F. Meric-Bernstam³, D. Hambarzumyan⁴, J. De Groot¹, ¹University of Texas MD Anderson Cancer Center, Houston, US, ²MD Anderson Cancer Center, Houston, US, ³The University of Texas MD Anderson Cancer Center, Houston, US, ⁴Emory University School of Medicine, Atlanta, US

17:03 - 17:15

3940 - Health-related quality of life (HRQoL) evaluation in the REGOMA trial: a randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients

G. Lombardi¹, P. Del Bianco², A. Brandes³, M. Eoli⁴, R. Rudà⁵, T. Ibrahim⁶, I.R. Lolli⁷, A. Pace⁸, B. Daniele⁹, F. Pasqualetti¹⁰, S. Rizzato¹¹, E. Bergo¹², M. Caccese¹², M. Padovan¹², R. Soffietti⁵, G.L. De Salvo², V. Zagone¹, ¹Department of Oncology, Veneto Institute of Oncology, IOV - IRCCS, Padova, IT, ²Veneto Institute of Oncology IOV - IRCCS, Padova, IT, ³Ospedale Bellaria, Bologna, IT, ⁴Besta Institute, Milano, Italy, Milano, IT, ⁵University of Turin and City of Health and Science Hospital, Torino, IT, ⁶Istituto

Tumori della Romagna I.R.S.T., Meldola, IT, ⁷Azienda Ospedaliero-Universitaria
Consortiale Policlinico di Bari, Bari, IT, ⁸Regina Elena Cancer Institute - IRCCS, Roma, IT,
⁹Azienda Ospedaliera G. Rummo, Benevento, IT, ¹⁰Azienda Ospedaliera Universitaria
S. Chiara, Pisa, IT, ¹¹Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT,
¹²Istituto Oncologico Veneto IRCCS, Padova, IT

17:15 - 17:30 **Invited Discussant 3920, 3930 and 3940**

16:00 - 17:30 **Type: Special symposium** **Tarragona Auditorium (Hall 7)**
Title: Innate immune system and anti-mitotic agents: Two fields getting together
Chair(s): Joan Seoane, ES; Iain Hagan, GB

16:00 - 16:00 **Session DOI**

16:00 - 16:05 **Introduction**

I. Hagan, Cancer Research UK Manchester Institute, Manchester, GB

16:05 - 16:25 **Chromosome mis-segregation in cancer**

H. Funabiki, The Rockefeller University, New York, US

16:25 - 16:45 **Cytoplasmic DNA and c-GAS STING signalling**

A. Ablasser, EPFL - École polytechnique fédérale de Lausanne, Morges, CH

16:45 - 17:05 **Myeloid cells in tumours**

V. Bronte, Ospedale Universitario Verona, Verona, IT

17:05 - 17:25 **TGFb and PD1: The relevance of tumour associated macrophages**

T. Powles, St. Bartholomew's Hospital, London, GB

17:25 - 17:30 **Conclusions and perspectives**

J. Seoane, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

16:00 - 17:30 **Type: Collaborative session** **Cartagena Auditorium (Hall 3)**
Title: ESMO-MASCC Collaborative session: Management of cancer and anticancer therapy induced side effects
Chair(s): Karin Jordan, DE; Rajesh Lalla, US

16:00 - 16:00 **Session DOI**

16:00 - 16:05 **Introduction**

K. Jordan, University of Heidelberg, Heidelberg, DE

16:05 - 16:25 **Bone health in cancer patients: Improving survival**

R. Coleman, Weston Park Hospital Cancer Research Centre, Sheffield, GB

16:25 - 16:45 **Prevention and treatment of cancer and cancer-treatment related nausea and vomiting**

K. Jordan, University of Heidelberg, Heidelberg, DE

16:45 - 17:05 **Prevention of febrile neutropenia: The updated guidelines**

M. Aapro, Clinique de Genolier, Genolier, CH

17:05 - 17:25 **Safe usage of immunotherapy**

S. Champiat, Gustave Roussy, Villejuif, FR

17:25 - 17:30 **Conclusions and perspectives**

R. Lalla, UConn Health, Farmington, US

16:00 - 17:30 **Type: Special session** **Salamanca Auditorium (Hall 3)**
Title: Universal health coverage and cancer: What you and your country need to know
Chair(s): Rosa Giuliani, GB; André Ilbawi, CH

16:00 - 16:00 **Session DOI**

16:00 - 16:05 **Introduction**

R. Giuliani, The Christie NHS Foundation Trust, Manchester, GB

16:05 - 16:20 **Outcome of the 2019 United Nation's high-level meeting on universal health coverage**

R. Giuliani, The Christie NHS Foundation Trust, Manchester, GB

16:20 - 16:35 **The WHO global report on cancer: Policy recommendations for universal health coverage**

A. Ilbawi, WHO - World Health Organization, Geneva, CH

16:35 - 16:50 **Did you know there are positive returns on investing in cancer services to achieve universal health coverage?**

M. Bertram, WHO - World Health Organization, Geneva, CH

16:50 - 17:05 **The methodology for setting priorities for universal health coverage**

D. Trapani, Istituto Europeo di Oncologia, Milan, IT

17:05 - 17:10 **Conclusions**

A. Ilbawi, WHO - World Health Organization, Geneva, CH

17:10 - 17:30 **Q&A**

R. Giuliani, The Christie NHS Foundation Trust, Manchester, GB

16:00 - 17:30 **Type: Collaborative session** **Toledo Auditorium (Hall 5)**
Title: ESMO-ESOI Collaborative session: Gastrointestinal stromal tumours: Imaging and treatment
Chair(s): Emile Voest, NL; Regina Beets-Tan, NL

16:00 - 16:00 **Session DOI**

16:00 - 16:15 **Imaging of gastrointestinal stromal tumours**
D. Regge, IRCCS Istituto di Candiolo, Candiolo, IT

16:15 - 16:30 **Systemic treatment**
G. Grignani, Istituto di Candiolo - FPO - IRCCS, Candiolo, IT

16:30 - 16:45 **Surgical management**
W. Allum, Royal Marsden Hospital NHS Foundation Trust, London, GB

16:45 - 16:45 **Case-based panel discussion**
D. Regge, IRCCS Istituto di Candiolo, Candiolo, IT

16:45 - 17:30 **Panel discussion**
W. Allum¹, G. Grignani², J.-Y. Blay³, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²Istituto di Candiolo - FPO - IRCCS, Candiolo, IT, ³Centre Léon Bérard, Lyon, FR

16:00 - 17:30 **Type: Patient Advocay Track** **Leon Auditorium (Hall 3)**
Title: Drugs in combination
Chair(s): Ananda Plate, BE; Bettina Ryll, SE

16:00 - 16:00 **Session DOI**

16:00 - 16:15 **When it takes more than one drug to survive: The myeloma experience**
A. Plate, Myeloma Patients Europe, Charleroi, BE

16:15 - 16:30 **Testing drugs in combinations. Intelligently.**

16:30 - 16:45 **Establishing cost-effectiveness in combinations**
C. Deakin, National Institute for Health and Care Excellence, London, GB

16:45 - 17:00 **And who is going to pay for it all? A payor's perspective**
L. Van Saase, Zorginstituut Nederland, Diemen, NL

17:00 - 17:15 **TBC**

17:15 - 17:30 **Conclusion**

16:15 - 17:15 **Type: Challenge your expert** **Malaga Auditorium (Hall 5)**
Title: Combination and sequence in advanced melanoma
Chair(s): Caroline Robert, FR

16:15 - 16:15 **Session DOI**

16:15 - 16:25 **Presentation by expert**
B. Chmielowski, UCLA - David Geffen School of Medicine, Los Angeles, US

16:25 - 17:15 **Discussion led by Chair**
C. Robert, Institut Gustave Roussy, Villejuif, FR

16:15 - 17:15 **Type: Challenge your expert** **Alicante Auditorium (Hall 3)**
Title: Partial breast radiation therapy: Which patients, when, and with what technique?
Chair(s): Charlotte Coles, GB

16:15 - 16:15 **Session DOI**

16:15 - 16:25 **Presentation by expert**
P. Poortmans, Institut Curie, Paris, FR

16:25 - 17:15 **Discussion led by Chair**
C. Coles, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB

17:30 - 18:30 **Type: Young Oncologist session** **Foyer (CC4)**
Title: YO Vesalius talk: How to start your own group: Moving from fellow to PI without burnout
Chair(s): Guillem Argiles Martinez, ES

17:30 - 18:30 **How to start your own group: Moving from fellow to PI without burnout**
S. Banerjee¹, M. Strijbos², F. Cardoso³, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²A.Z. Klina, Brasschaat, BE, ³Champalimaud Foundation Cancer Center, Lisbon, PT

18:00 - 20:00 **Type: Industry Satellite Symposium** **Pamplona**
Title: Bristol-Myers Squibb - Understanding the Emerging **Auditorium (Hall 2)**
Role of I-O in GI Cancers
Chair(s): Ian Chau, GB

- 18:00 - 18:10 **Welcome, introductions and agenda**
I. Chau, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB
- 18:10 - 18:25 **I-O Studies in CRC: Patient populations of today and tomorrow**
M. Koopman, University Hospital Utrecht, Utrecht, NL
- 18:25 - 18:40 **Evolving treatment options and the potential of I-O for patients with HCC**
R.K. Kelley, University of California San Francisco, San Francisco, US
- 18:40 - 19:05 **Panel discussion and audience Q&A**
- 19:05 - 19:20 **From trials to practice: The possible future of I-O in Gastric/GEJ cancer**
K. Shitara, National Cancer Center Hospital, Kashiwa, JP
- 19:20 - 19:30 **Clinical Data with I-O in esophageal cancer**
I. Chau, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB
- 19:30 - 20:00 **Panel discussion and audience Q&A**

- 18:00 - 19:30** **Type: Industry Satellite Symposium** **Cordoba Auditorium (Hall 7)**
Title: F. Hoffmann-La Roche - Multi-disciplinary perspectives on optimising patient outcomes in HER2-positive eBC: Join our MDT and choose your agenda
Chair(s): Giampaolo Bianchini, IT
- 18:00 - 18:10 **Introduction and welcome**
G. Bianchini, IRCCS San Raffaele, Milano, IT
- 18:10 - 19:22 **Panel discussion**
G. Bianchini¹, A. Schneeweiss², H. Cain³, F. Penault-Llorca⁴, I. De Rooij-Van Haaren⁵,
¹IRCCS San Raffaele, Milano, IT, ²University Hospital Heidelberg, Heidelberg, DE,
³Newcastle Freeman Hospital, Newcastle-upon-Tyne, GB, ⁴Centre Jean Perrin, Clermont-Ferrand, FR, ⁵Hoffmann- La Roche Ltd - Oman, Muscat, OM
- 19:22 - 19:30 **Conclusions**
G. Bianchini, IRCCS San Raffaele, Milano, IT
- 18:00 - 20:00** **Type: Industry Satellite Symposium** **Malaga Auditorium (Hall 5)**
Title: Bristol Myers-Squibb - Immuno-Oncology: Helping to shape melanoma treatment - Now and in the future
Chair(s): Eva Muñoz-Couselo, ES
- 18:00 - 18:10 **Welcome and introduction**
E. Muñoz-Couselo, Vall d'Hebron University Hospital, Barcelona, ES
- 18:10 - 18:45 **Keynote Lecture: An oncologist's perspective on the melanoma treatment journey**
M. Atkins, Lombardi Cancer Center Georgetown University, Washington, US
- 18:45 - 19:05 **New data for the early treatment of melanoma**
E. Muñoz-Couselo, Vall d'Hebron University Hospital, Barcelona, ES
- 19:05 - 19:20 **Early treatment interactive discussion and Q&A**
- 19:20 - 19:40 **Survival data, subpopulations, and beyond: What's new in the metastatic setting?**
P. Ascierto, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT
- 19:40 - 19:55 **Metastatic treatment interactive discussion and Q&A**
- 19:55 - 20:00 **Summary and close**

18:00 - 20:00	Type: Industry Satellite Symposium Title: Bristol-Myers Squibb - Long term experience and survival: An overview of I-O therapy in RCC and future research in GU cancers Chair(s): Thomas Powles, GB	Bilbao Auditorium (Hall 5)
18:00 - 18:20	Welcome and introduction <u>T. Powles</u> , St. Bartholomew's Hospital, London, GB	
18:20 - 18:40	RCC treatment landscape: How did we get here and where do we need to go? <u>T. Powles</u> , St. Bartholomew's Hospital, London, GB	
18:40 - 19:00	I-O Combinations: Evolving treatment options in advanced RCC <u>L. Albiges</u> , Institut Gustave Roussy, Villejuif, FR	
19:00 - 19:20	Extending I-O: Emerging options in bladder cancer <u>I. Duran Martinez</u> , Hospital Universitario Marques de Valdecilla, Santander, ES	
19:20 - 19:40	Bringing learnings from I-O research into the future GU landscape <u>T. Powles</u> , St. Bartholomew's Hospital, London, GB	
19:40 - 20:00	Summary and close <u>T. Powles</u> , St. Bartholomew's Hospital, London, GB	

18:00 - 20:00 **Type: Industry Satellite Symposium** **Tarragona Auditorium**
Title: F. Hoffmann-La Roche - Cracking the code of personalised healthcare **(Hall 7)**
Chair(s): Arndt Vogel, DE

18:00 - 18:15 **The ongoing cancer care revolution**
A. Vogel, Hannover Medical School, Hannover, DE

18:15 - 18:15 **Interactive session: Transforming the patient journey**

18:15 - 18:35 **Taking diagnostics to the next level**
L. De Mattos-Arruda, Vall d'Hebron University Hospital, Barcelona, ES

18:35 - 18:55 **Generating meaningful evidence with novel trial designs and real-world data**
R. Dienstmann, Vall d'Hebron University Hospital, Barcelona, ES

18:55 - 19:15 **Integrating the ever-increasing amount of information**

19:15 - 19:30 **Using artificial intelligence to put patients at the heart of healthcare**
D. Mcclintock, University of Michigan, Ann Arbor, US

19:30 - 19:55 **Panel discussion: Ensuring we know how to use today's key technologies**

19:55 - 20:00 **Closing remarks**
A. Vogel, Hannover Medical School, Hannover, DE

- 18:00 - 20:00** **Type: Industry Satellite Symposium** **Alicante Auditorium (Hall 3)**
Title: Pfizer - Real world data in oncology: Its growing role in research and patient care
Chair(s): George Demetri, US
- 18:00 - 18:20 **Introduction**
G. Demetri, Dana-Farber Cancer Institute, Boston, US
- 18:20 - 18:40 **Using real world data to translate research into practice: Realizing the benefits of learning health systems**
B. Delaney, Imperial College London - Hammersmith Hospital, London, GB
- 18:40 - 19:00 **Opportunities and challenges in the use of real world data in oncology**
D. Schrag, Dana Farber Cancer Institute, Boston, US
- 19:00 - 19:20 **Integrating real world clinical outcomes and genomic data: The cancer programme of the 100,000 genomes project and the NHS genomic medicine service**
N. Murugaesu, Institute of Cancer Research ICR, London, GB
- 19:20 - 19:40 **Real world data as a tool to develop new therapies in rare cancers and improve precision cancer medicine**
G. Demetri, Dana-Farber Cancer Institute, Boston, US
- 19:40 - 20:00 **Panel discussion and Q+A**

18:00 - 20:00 **Type: Industry Satellite Symposium** **Cartagena Auditorium (Hall 3)**
Title: Merck - Putting it into perspective: How should I be treating my SCCHN patients?
Chair(s): Ezra Cohen, US

18:00 - 18:05 **Introduction**
E. Cohen, The University of Chicago Medical Centre, Chicago, US

18:05 - 18:25 **Looking closer at the LA SCCHN treatment landscape**
S. Porceddu, School of Medicine, University of Queensland, Herston, AU

18:25 - 18:45 **Expanding the angle of cetuximab + platinum-based CT in R/M SCCHN**
N. Magné, Centre Oscar Lambret, Lille, FR

18:45 - 19:05 **Promises for patients: Customising care and understanding the options in R/M SCCHN**
A.F. Castro, Lenitudes Medical Center & Research, Espargo, PT

19:05 - 19:25 **Discussion**
E. Cohen, The University of Chicago Medical Centre, Chicago, US

19:25 - 19:30 **Conclusions**
E. Cohen, The University of Chicago Medical Centre, Chicago, US

18:00 - 20:00	Type: Industry Satellite Symposium Title: Fresenius Kabi - Tackling sarcopenia and cachexia: Does it matter for treatment toxicity and overall survival? Chair(s): Matti Aapro, CH	Toledo Auditorium (Hall 5)
18:00 - 18:15	Introduction: Challenges in supportive cancer care <u>M. Aapro</u> , Clinique de Genolier, Genolier, CH	
18:15 - 18:45	New biomarkers for cancer cachexia and sarcopenia: Relevant for cancer therapy? <u>J. Argiles</u> , Universitat de Barcelona, Barcelona, ES	
18:45 - 19:15	Sarcopenia: A determinant of dose-limiting toxicity in cancer treatment <u>V. Baracos</u> , University of Alberta Cross Cancer Institute, Edmonton, CA	
19:15 - 19:45	Management of cachexia and sarcopenia to optimize therapy goals <u>P. Österlund</u> , Tampere University Hospital, Tampere, FI	
19:45 - 20:00	Q&A and concluding remarks <u>M. Aapro</u> , Clinique de Genolier, Genolier, CH	

18:00 - 20:00	Type: Industry Satellite Symposium Title: Bayer - Shaping the GI cancer treatment landscape: The power and potential of kinase inhibition Chair(s): Eric Van Cutsem, BE	Oviedo Auditorium (CC5)
18:00 - 18:10	Opening remarks <u>E. Van Cutsem</u> , University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, BE	
18:10 - 18:30	The evolving role of kinase inhibition in GI cancers <u>H.J. Lenz</u> , USC - Norris Comprehensive Cancer Center, Los Angeles, US	
18:30 - 18:40	Building on evidence to optimise treatment outcomes with multikinase inhibition in mCRC <u>A. Grothey</u> , West Cancer Center, Germantown, US	
18:40 - 19:00	Building on evidence to optimize treatment outcomes with multikinase inhibition in mCRC: first cycle dose optimization <u>T. Bekaii-Saab</u> , Mayo Clinic Cancer Center, Phoenix, US	
19:00 - 19:10	Optimizing treatment outcomes with multikinase inhibition in mCRC: Real world evidence <u>M. Ducreux</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
19:10 - 19:15	Conclusions <u>A. Grothey</u> , West Cancer Center, Germantown, US	
19:15 - 19:35	Navigating the HCC treatment landscape: optimizing outcomes with multikinase inhibitors	
19:35 - 19:55	Kinase inhibition in GIST: significance in clinical practice <u>J.-Y. Blay</u> , Centre Léon Bérard, Lyon, FR	
19:55 - 20:00	Faculty panel Q&A	
20:00 - 20:00	Final comments and meeting close <u>E. Van Cutsem</u> , University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, BE	

18:00 - 20:00 **Type: Industry Satellite Symposium** **Leon Auditorium (Hall 3)**
Title: Servier - From trial evidence to clinical practice: Focusing on patients with mGC and mCRC
Chair(s): Fernando Rivera, ES; Thierry Andre, FR

18:00 - 18:10 **Introduction**

F. Rivera, HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES

18:10 - 18:35 **Using new evidence to guide clinical decisions in patients with mGC**

E. Smyth, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB

18:35 - 18:55 **Improving patient survival and maintaining QoL upon late-line mCRC treatment**

G. Prager, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

18:55 - 19:15 **Applying clinical trial data to real-world practice in patients with pretreated mCRC**

A. Falcone, Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT

19:15 - 19:35 **Panel discussion**

19:35 - 19:55 **Exploring a new opportunity to improve outcomes in patients with mCRC**

T. Andre, Hopital Saint-Antoine, Paris, FR

19:55 - 20:00 **Conclusions**

T. Andre, Hopital Saint-Antoine, Paris, FR

18:00 - 20:00	Type: Industry Satellite Symposium Title: Janssen Pharmaceutical Companies of Johnson & Johnson - Integrating precision medicine: Are we ready for a paradigm shift in advanced urothelial carcinoma? Chair(s): Maria De Santis, DE; Joaquim Bellmunt, US	Santander Auditorium (Hall 3)
18:00 - 18:10	Introduction: Welcome to the future? <u>J. Bellmunt</u> , Harvard Medical School, Boston, US	
18:10 - 18:35	The path to now: How did the current management of advanced urothelial carcinoma develop? <u>S.F. Shariat</u> , Medizinische Universitaet Wien, Vienna, AT	
18:35 - 19:00	What is today's understanding of the molecular landscape of advanced urothelial carcinoma? <u>E. Comperat</u> , Sorbonne University, GRC n°5, ONCOTYPE-URO, PARIS, FR	
19:00 - 19:25	How could targeted therapies influence the management landscape? <u>Y. Loriot</u> , Institut Gustave Roussy, Villejuif, FR	
19:25 - 19:50	Can the molecular biology knowledge be integrated into the clinical practice today? <u>A. Siefker-Radtke</u> , The M. D. Anderson Cancer Center, Houston, US	
19:50 - 19:50	Advanced urothelial carcinoma 2.0: Are we ready for a paradigm shift?	
19:50 - 20:00	Closing remarks <u>J. Bellmunt</u> ¹ , <u>M. De Santis</u> ² , ¹ Harvard Medical School, Boston, US, ² Charité - Universitätsmedizin Berlin, Berlin, DE	

- 18:30 - 20:00** **Type: Industry Satellite Symposium** **Salamanca Auditorium (Hall 3)**
Title: Medscape Oncology - The challenge of thrombo-inflammation in cancer. The interplay of factors that impact outcome
Chair(s): Paris Kosmidis, GR; Agnes Lee, CA
- 18:30 - 18:40 **Welcome and introduction**
A. Lee, University of British Columbia, Vancouver, CA
- 18:40 - 18:55 **Inflammation and thrombosis in cancer: Partners in crime?**
J. O'Donnell, Trinity College Dublin, Dublin, IE
- 18:55 - 19:10 **Managing patients with cancer-associated thrombosis: Current and future clinical challenges**
A. Lee, University of British Columbia, Vancouver, CA
- 19:10 - 19:55 **Moving from biological understanding to clinical solutions: A case clinic**
A. Lee¹, P. Kosmidis², P. Jimenez-Fonseca³, J. O'Donnell⁴, F. Scotté⁵, ¹University of British Columbia, Vancouver, CA, ²Hygeia Hospital, Marousi, GR, ³Hospital Universitario Central de Oviedo, Oviedo, ES, ⁴Trinity College Dublin, Dublin, IE, ⁵Hopital Foch, Suresnes, FR
- 19:55 - 20:00 **Summary and conclusions**
A. Lee¹, P. Kosmidis², ¹University of British Columbia, Vancouver, CA, ²Hygeia Hospital, Marousi, GR

28.09.2019

08:00 - 10:15 **Type: Proffered Paper session** **Cordoba Auditorium (Hall 7)**
Title: Proffered Paper - Melanoma and other skin tumours

08:00 - 08:00 **Session DOI**

08:00 - 08:12 **One LBA TBC**

08:12 - 08:24 **One LBA TBC**

08:24 - 08:36 **13100 - Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase 3 CheckMate 238 trial**

J. Weber¹, M. Del Vecchio², M. Mandala³, H. Gogas⁴, A. Arance⁵, S. Dalle⁶, C.L. Cowey⁷, M. Schenker⁸, J.J. Grob⁹, V. Chiarion-Sileni¹⁰, I. Marquez-Rodas¹¹, M. Butler¹², M. Maio¹³, M. Middleton¹⁴, T. Tang¹⁵, A. Saci¹⁶, V. De Pril¹⁵, M. Lobo¹⁵, J. Larkin¹⁷, P. Ascierto¹⁸, ¹NYU Langone Medical Center, New York, US, ²Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ³Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT, ⁴Laiko General Hospital of Athens, Athens, GR, ⁵Hospital Clínic Barcelona, Barcelon, ES, ⁶Centre Hospitalier Lyon Sud, Pierre Bénite, FR, ⁷Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, ⁸Emergency Clinical Hospital Craiova, Craiova, RO, ⁹Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ¹⁰Istituto Oncologico Veneto - IRCCS, Padua, IT, ¹¹Hospital General Universitario Gregorio Marañon, Madrid, ES, ¹²Princess Margaret Hospital, Toronto, CA, ¹³Azienda Ospedaliera Universitaria Senese - Santa Maria delle Scotte, Siena, IT, ¹⁴Churchill Hospital University of Oxford, Oxford, GB, ¹⁵Bristol-Myers Squibb, Princeton, US, ¹⁶Bristol-Myers Squibb, Lawrenceville, US, ¹⁷Royal Marsden Hospital NHS Foundation Trust, London, GB, ¹⁸Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

08:36 - 08:51 **Invited Discussant 13100 and 2 LBAs TBC**

08:51 - 09:03 **One LBA TBC**

09:03 - 09:15 **One LBA TBC**

09:15 - 09:27 **13110 - Long-term Outcomes from the Randomized Ph 2 Study of Nivolumab (nivo) or Nivo+Ipilimumab (ipi) in Patients (pts) with Melanoma Brain Metastases (mets): Anti-PD1 Brain Collaboration (ABC)**

G. Long¹, V. Atkinson², S. Lo³, S. Sandhu⁴, M. Brown⁵, M. Gonzalez⁶, A. Guminski⁷, R.

Scolyer⁸, L. Emmett⁹, A. Menzies⁶, G. Mearthur⁴, ¹Melanoma Institute Australia, Wollstonecraft, AU, ²Princess Alexandra Hospital, Woolloongabba, AU, ³The University of Sydney School of Public Health, Sydney, AU, ⁴Peter MacCallum Cancer Centre, Melbourne, AU, ⁵Royal Adelaide Hospital RAH Cancer Centre, Adelaide, AU, ⁶Melanoma Institute Australia, University of Sydney, North Sydney, AU, ⁷Royal North Shore Hospital, St Leonards, AU, ⁸Royal Prince Alfred Hospital, Camperdown, AU, ⁹St. Vincent's Hospital, Darlinghurst, AU

09:27 - 09:42 **Invited Discussant 13110 and 2 LBAs TBC**

08:05 - 09:05 Type: Poster Discussion session Toledo Auditorium (Hall 5)
Title: Poster Discussion - CNS tumours

08:05 - 08:05 **Session DOI**

08:05 - 08:05 **395PD - Circulating PD-L1 levels vary across brain tumor entities and are oppositely linked to survival in glioblastoma and lower grade glioma patients**

M. Mair¹, A. Ilhan-Mutlu², S. Pajenda¹, G. Widhalm¹, K. Dieckmann², J. Hainfellner¹, C. Marosi², L. Wagner¹, M. Preusser², A.S. Berghoff¹, ¹Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT, ²Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

08:05 - 08:05 **396PD - Characterization of a novel BBB-permeable mutant IDH1 inhibitor, DS-1001b.**

H. Matsunaga¹, Y. Machida², M. Nakagawa², M. Yamaguchi³, Y. Ogawara², Y. Shima², K. Yamagata², T. Katsumoto², A. Hattori², M. Itoh¹, T. Seki¹, Y. Nishiya¹, K. Nakamura¹, K. Suzuki¹, T. Imaoka¹, M. Suzuki⁴, O. Sampetean⁵, H. Saya⁵, K. Ichimura², I. Kitabayashi², ¹Daiichi Sankyo Co., Ltd., Tokyo, JP, ²National Cancer Center Research Institute, Tokyo, JP, ³National Cancer Center Hospital East, Chiba, JP, ⁴Daiichi Sankyo RD Novare Co., Ltd., Tokyo, JP, ⁵Keio University School of Medicine, Tokyo, JP

08:05 - 08:05 **397PD - Precision medicine for patients with primary brain tumors: Molecular Screening for Cancer Treatment Optimization (MOSCATO) prospective trial**

W. Boulfoul¹, C. Baldini², I. Borget³, P. Martin Romano², L. Verlingue³, L. Lacroix³, E. Angevin¹, E. Rouleau¹, A. Varga², S. Postel Vinay³, A. Gazzah⁴, R. Bahleda¹, A. Marabelle³, V. Ribrag³, P. Vuagnat³, S. Champiat², J.-M. Michot³, A. Hollebecque², J.-C. Soria⁵, C. Massard¹, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Gustave Roussy, Villejuif, FR, ³Institut Gustave Roussy, Villejuif, FR, ⁴Gustave Roussy, Université Paris-Saclay, Villejuif, FR, ⁵Medimmune, Gaithersburg, US

08:05 - 08:20 **Invited Discussant 395PD, 396PD and 397PD**

08:20 - 08:25 **Q&A led by Discussant**

- 08:25 - 08:25 **398PD - Extending temozolomide longer than six cycles in glioblastoma: results of the randomized GEINO-014 TRIAL.**
- M.A. Salgado¹, J. Sepulveda Sanchez², S. Del Barco³, E. Pineda⁴, J. Fuster⁵, M. Navarro Martin⁶, A. Herrero Ibañez⁷, M. Alonso⁸, J. Perez⁹, C. Mesia¹⁰, J. Munoz-Langa¹¹, R. De Las Penas Bataller¹², S. Peralta¹³, C. Olier¹⁴, P. Pérez-Segura¹⁵, A. Estival¹⁶, C. Carrato¹⁷, C. Saez¹⁸, M. Gil¹⁹, C. Balana²⁰, ¹Hospital Universitario Ramon y Cajal, Madrid, ES, ²University Hospital 12 De Octubre, Madrid, ES, ³ICO Girona, Girona, ES, ⁴Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁵Hospital Son Espases, Palma de Mallorca, ES, ⁶IBSAL - Instituto de Investigación Biomédica de Salamanca, Salamanca, ES, ⁷Hospital Miguel Servet, Zaragoza, ES, ⁸Hospital Universitario Virgen del Rocío, Sevilla, ES, ⁹ICO hospitalet, Barcelona, ES, ¹⁰ICO Hospitalet, Barcelona, ES, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, ES, ¹²Hospital Provincial Castellon, Castellón, ES, ¹³Hospital Sant Joan de Reus, Tarragona, ES, ¹⁴Hospital de Alcorcon, Madrid, ES, ¹⁵Hospital Clinico Universitario San Carlos, Madrid, ES, ¹⁶H German Trias i Pujol, Barcelona, ES, ¹⁷Hospital Universitari Germans Trias i Pujol, Badalona, ES, ¹⁸German Trias i Pujol, Barcelona, ES, ¹⁹Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, ²⁰Germans Trias i Pujol, Barcelona, ES
- 08:25 - 08:25 **399PD - Association of systemic inflammation with local tumor characteristics and survival in glioma patients**
- P. Mir Seyed Nazari¹, C. Ay¹, M. Preusser², J. Riedl¹, C. Marosi², F. Moik³, G. Ricken⁴, J. Hainfellner¹, I. Pabinger-Fasching¹, A.S. Berghoff¹, ¹Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT, ²Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, ³Medizinische Universität Wien, Vienna, AT, ⁴Medical University of Vienna, Vienna, AT
- 08:25 - 08:25 **400PD - Characteristics and patterns of care of high-grade IDH-mutant gliomas in elderly patients: a French POLA network study.**
- C. Montégut¹, J.-S. Guillamo², F. Ducray³, C. Dehais⁴, O. Chinot⁵, E. Cohen-Jonathan Moyal⁶, E. Le Rhun⁷, H. Loiseau⁸, R. Appay⁹, D. Figarella-Branger⁹, J.-Y. Delattre⁴, E. Tabouret¹⁰, ¹Assistance Publique Hopitaux de Marseille, Marseille, FR, ²Centre Hospitalier Universitaire Carémeau, Nimes, FR, ³Hospices civils de lyon Hôpital neurologique pierre wertheimer, Bron, FR, ⁴Centre Hospitalier Universitaire Paris, La Pitié Salpêtrière-Charles Foix, Paris, FR, ⁵AP-HM - CHU La Timone Enfants, Marseille, FR, ⁶Centre Claudius-Regaud, Toulouse, FR, ⁷Roger Salengro Hospital, Lille, FR, ⁸Centre Hospitalier Universitaire Bordeaux, Bordeaux, FR, ⁹CHU de Marseille - Hôpital de la Timone, Marseille, FR, ¹⁰CHU La Timone Adultes, Marseille, FR
- 08:25 - 08:25 **401PD - GEINO 1402: A Phase Ib Dose-Escalation Study Followed by an Extension Phase to Evaluate Safety and Efficacy of Crizotinib in Combination with Temozolomide (TMZ) and Radiotherapy (RT) in Patients with Newly Diagnosed Glioblastoma (GB)**
- M. Martinez Garcia¹, M. Gil², E. Pineda³, M. Martin Soberón⁴, C. Mesia Barroso⁵, P. Foro¹, J. Capellades¹, B. Sarmiento⁴, J. Bruna², E. Verger³, A. Taus Garcia¹, F. Alameda¹, A. Hernandez Lain⁴, G. Velasco⁶, J. Sepulveda Sanchez⁴, ¹Hospital del Mar, Barcelona, ES, ²Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, ³Hospital Clinic

y Provincial de Barcelona, Barcelona, ES, ⁴University Hospital 12 De Octubre, Madrid, ES, ⁵ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ⁶Universidad Complutense de Madrid, Madrid, ES

08:25 - 08:43 **Invited Discussant 398PD, 399PD, 400PD and 401PD**

08:43 - 08:50 **Q&A led by Discussant**

08:50 - 08:50 **402PD - Impact of neurological symptom burden on the survival prognosis in a real-life cohort of patients with non-small cell lung cancer brain metastases**

A. Steindl¹, S. Yadavalli², K. Gruber², M. Seiwald², J. Frischer², B. Gatterbauer², K. Dieckmann³, C. Marosi³, G. Widhalm¹, M. Preusser³, A.S. Berghoff¹, ¹Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT, ²Medical University of Vienna, Vienna, AT, ³Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

08:50 - 08:50 **403PD - Tumor mutational burden and immune infiltrates in primary renal cell carcinoma and matched brain metastases**

A. Steindl¹, E. Bergen², D. Alpar³, B. Gatterbauer², K. Dieckmann⁴, G. Widhalm¹, J. Hainfellner¹, M. Schmidinger⁴, C. Bock³, L. Müllauer⁴, M. Preusser⁴, A.S. Berghoff¹, ¹Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT, ²Medical University of Vienna, Vienna, AT, ³Austrian Academy of Sciences, Vienna, AT, ⁴Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

08:50 - 09:00 **Invited Discussant 402PD and 403PD**

09:00 - 09:05 **Q&A led by Discussant**

08:30 - 10:00 **Type: Proffered Paper session** **Barcelona Auditorium**
Title: Proffered Paper 1 - Genitourinary tumours, **(Hall 2)**
non-prostate

08:30 - 08:30 **Session DOI**

08:30 - 08:45 **One LBA TBC**

08:45 - 09:00 **One LBA TBC**

09:00 - 09:15 **Invited Discussant 2 LBAs TBC**

09:15 - 09:30 **9010 - EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.**

C. Hoimes¹, J. Rosenberg², S. Srinivas³, D. Petrylak⁴, M. Milowsky⁵, J. Merchan⁶, M. Bilen⁷, S. Gupta⁸, A.-S. Carret⁹, N. Yuan⁹, A. Melhem-Bertrandt¹⁰, T. Flaig¹¹, ¹Case Western Reserve University / University Hospitals, Cleveland, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Stanford University, Palo Alto, US, ⁴Yale Cancer Center, New Haven, US, ⁵University of North Carolina at Chapel Hill, Chapel Hill, US, ⁶University of Miami, Miami, US, ⁷Emory University Winship Cancer Institute, Atlanta, US, ⁸University of Minnesota, Minneapolis, US, ⁹Seattle Genetics, Bothell, US, ¹⁰Astellas Pharma USA, Northbrook, US, ¹¹University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, US

09:30 - 09:45 **9020 - An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies**

T. Powles¹, A. Balar², G. Gravis³, R. Jones⁴, A. Ravaud⁵, J. Florence⁶, P. Grivas⁷, D. Petrylak⁸, M. Galsky⁹, J. Carles¹⁰, S. Sridhar¹¹, H.-T. Arkenau¹², D. Carroll¹³, J. Decesare¹⁴, F. Mercier¹⁴, D. Hodgson¹⁵, J. Stone¹⁶, J. Cosaert¹⁷, D. Landers¹⁸, ¹Barts Cancer Institute, London, GB, ²NYU Langone, New York, US, ³Institute Paoli Calmettes, Marseille, FR, ⁴University of Glasgow, Glasgow, GB, ⁵CHU Bordeaux Hopital St. André, Bordeaux, FR, ⁶Centre Francois Balesse, CAEN, FR, ⁷University of Washington Seattle Cancer Care Alliance, Seattle, US, ⁸Yale Cancer Center, New Haven, US, ⁹Icahn School of Medicine at Mount Sinai Hospital, New York, US, ¹⁰Vall d'Hebron University Hospital, Barcelona, ES, ¹¹Princess Margaret Hospital, Toronto, CA, ¹²Sarah Cannon Research Institute UK, London, GB, ¹³AstraZeneca, Cambridge, GB, ¹⁴AstaZeneca, Melbourn, GB, ¹⁵AstraZeneca, Boston, US, ¹⁶AstraZeneca Academy House, Cambridge, GB, ¹⁷AstraZeneca UK, Melbourn, GB, ¹⁸Astrazeneca, Macclesfield, GB

09:45 - 10:00 **Invited Discussant 9010 and 9020**

08:30 - 10:00	Type: Special symposium Title: Beyond initial radical treatment of patients with lung cancer Chair(s): Thierry Berghmans, BE	Madrid Auditorium (Hall 2)
08:30 - 08:30	Session DOI	
08:30 - 08:35	Introduction	
08:35 - 08:55	Active management of patient's comorbidities including cardiac toxicity <u>A.-M. Dingemans</u> , Maastricht University Medical Center (MUMC), Maastricht, NL	
08:55 - 09:15	Role of imaging follow-up <u>V. Westeel</u> , CHU Besançon, Hôpital Jean Minjoz, Besançon, FR	
09:15 - 09:35	Role of patient reported outcome in patients' follow-up <u>L. Hendriks</u> , Maastricht University Medical Center (MUMC), Maastricht, NL	
09:35 - 09:55	Patient perspective/expectations <u>R. Ihlen</u> , LuCE, Bern, CH	
09:55 - 10:00	Conclusions and perspectives <u>T. Berghmans</u> , Institute Jules Bordet, Brussels, BE	

08:30 - 10:00 **Type: Special symposium** **Sevilla Auditorium (Hall 2)**
Title: Next challenges for cancer immunotherapy
Chair(s): Aurélien Marabelle, FR

08:30 - 08:30 **Session DOI**

08:30 - 08:35 **Introduction**

A. Marabelle, Institut Gustave Roussy, Villejuif, FR

08:35 - 08:55 **Immunotherapy for locally advanced cancer**

B. Besse, Institut Gustave Roussy, Villejuif, FR

08:55 - 09:15 **Turning cold into hot tumours**

A. Marabelle, Institut Gustave Roussy, Villejuif, FR

09:15 - 09:35 **Working on the microbiome**

B. Routy, University of Montreal Research Center, Montreal, CA

09:35 - 09:55 **Cell therapies**

G. Coukos, Ludwig Center for Cancer Research of the UNIL (LICR@UNIL), Epalinges, CH

09:55 - 10:00 **Conclusions and perspectives**

08:30 - 10:00 Type: Proffered Paper session Pamplona Auditorium (Hall 2)
Title: Proffered Paper - Translational research

08:30 - 08:30 **Session DOI**

08:30 - 08:43 **One LBA TBC**

08:43 - 08:53 **Invited Discussant one LBA TBC**

08:53 - 09:06 **One LBA TBC**

09:06 - 09:16 **Invited Discussant one LBA TBC**

09:16 - 09:31 **18730 - PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors**

B. Pellegrino¹, A. Llop-Guevara², F. Pedretti², C. Cruz², M. Castroviejo³, A. Cedro-Tanda⁴, R. Fasani², F. Mateo⁵, A. Musolino⁶, M.A. Pujana⁵, P. Nuciforo⁷, A. Gros², J. Balmana³, M. O'Connor⁸, V. Serra Elizalde⁷, ¹University Hospital of Parma, Parma, IT, ²Vall d` Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴National Institute of Genomic Medicine, Ciudad de Mexico, MX, ⁵Institut Català d'Oncologia, Hospitalet de Llobregat, ES, ⁶Azienda Ospedaliera di Parma, Parma, IT, ⁷Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁸AstraZeneca R&D UK, Cambridge, GB

09:31 - 09:46 **18740 - Interferon γ (IFN- γ) gene signature and tryptophan 2,3-dioxygenase 2 (TDO2) gene expression: a potential predictive composite biomarker for linrodostat mesylate (BMS-986205; indoleamine 2,3-dioxygenase 1 inhibitor [IDO1i]) + nivolumab (NIVO)**

J. Luke¹, L. Siu², J. Santucci-Pereira³, D. Nelson³, E. Kandoussi³, B. Fischer³, M. Wind-Rotolo³, D. Greenawalt³, Y. Ishii³, ¹University of Pittsburg Medical Center, Pittsburgh, US, ²Princess Margaret Cancer Centre, Toronto, CA, ³Bristol-Myers Squibb, Princeton, US

09:46 - 10:01 **Invited Discussant 18730 and 18740**

08:30 - 10:00 **Type: Educational session** **Granada Auditorium (Hall 3)**
Title: Meeting the liquid biopsy family
Chair(s): Michail Ignatiadis, BE

08:30 - 08:30 **Session DOI**

08:30 - 08:55 **The famous ones: Circulating tumour cells (CTCs) and circulating free DNA (cfDNA)**

M. Ignatiadis, Institute Jules Bordet, Brussels, BE

08:55 - 09:20 **The truly Pandora's box: Exosomes**

C. Rolfo, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, US

09:20 - 09:45 **New frontiers: Spliced variants**

M. Lolkema, Erasmus University Medical Center, Rotterdam, NL

09:45 - 10:00 **Discussion**

08:30 - 10:00	Type: EONS session Title: EONS 12: Opening session Chair(s): Andreas Charalambous, CY; Lena Sharp, SE	Oviedo Auditorium (CC5)
08:30 - 08:30	Session DOI	
08:30 - 08:35	Welcome by EONS <u>A. Charalambous</u> ¹ , <u>L. Sharp</u> ² , ¹ CYPRUS UNIVERSITY OF TECHNOLOGY, Limassol, CY, ² Regional Cancer Center Stockholm Gotland, Stockholm, SE	
08:35 - 08:40	Welcome by Spanish Oncology Nursing Society (Sociedad Española de Enfermería Oncológica, SEEO) <u>N. Domenech</u> , Spanish Oncology Nursing Society (Sociedad Española de Enfermería Oncológica, SEEO), Barcelona, ES	
08:40 - 09:00	Cancer nursing research, closing the gap between science and clinical practice <u>M.T. Moreno-Casbas</u> , Instituto de Salud Carlos III (ISCIII), Madrid, ES	
09:00 - 09:20	Leadership, combining research with daily practice <u>H. Vermeulen</u> , Radboud University Medical Center, Nijmegen, NL	
09:20 - 09:35	CN68 - Genetics, Biomarkers and Symptoms During Breast Cancer: Sytematic Review of Literature <u>S. Pasalak</u> ¹ , <u>M. Seven</u> ² , <u>G. Bagcivan</u> ³ , ¹ Koc University Hospital - Koc Universitesi Hastanesi, Istanbul, TR, ² Koç University, Istanbul, TR, ³ Gulhane Training and Reseach Hospital, Ankara, TR	
09:35 - 09:50	CN45 - The Cost of Survival Study: A Mixed Methods Exploration of Quality of Life Outcomes in Colorectal Cancer Survivorship <u>A. Drury</u> ¹ , <u>S. Payne</u> ² , <u>A.-M. Brady</u> ¹ , ¹ Trinity College Dublin, Dublin, IE, ² Lancaster University, YG, GB	
09:50 - 10:00	Discussion	

08:30 - 10:00 **Type: Educational session** **Leon Auditorium (Hall 3)**
Title: Essential medicines, but not always available
Chair(s): Alexandru Eniu, RO; Vlad Voiculescu, RO

08:30 - 08:30 **Session DOI**

08:30 - 08:40 **Introduction**

V. Voiculescu, Romanian Health Observatory, Bucharest, RO

08:40 - 09:00 **Results of ESMO survey/collection of data regarding shortage essential medicines in Europe and beyond, along with EIU reports on specific countries**

A. Eniu, The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca, RO

09:00 - 09:20 **Market failure: Why do the shortages exist?**

09:20 - 09:40 **Case study: State of play in Pakistan**

Z. Aziz, Hameed Latif Hospital, Lahore, PK

09:40 - 10:00 **WHO perspective: What can be done to mitigate shortages?**

N. Magrini, WHO Consultant, Geneva, CH

08:45 - 09:45 **Type: Multidisciplinary session** **Valencia Auditorium (Hall 5)**
Title: A family with MEN1 syndrome
Chair(s): Marianne Pavel, DE

08:45 - 08:45 **Session DOI**

08:45 - 08:50 **Presentation of index case and family history**
A. Grossman, Churchill Hospital University of Oxford, Oxford, GB

08:50 - 09:05 **Genetic counselling and screening**
A. Grossman, Churchill Hospital University of Oxford, Oxford, GB

09:05 - 09:20 **The surgical perspective: Who to operate on, when and to what extent**
A. Frilling, Imperial College London - Hammersmith Hospital, London, GB

09:20 - 09:35 **The endocrinologist and oncologist perspective: How to manage a patient with multiple NETs**
M. Pavel, Universitätsklinik Erlangen, Erlangen, DE

09:35 - 09:45 **General discussion**

08:45 - 09:45 **Type: Poster Discussion session** **Bilbao Auditorium (Hall 5)**
Title: Poster Discussion - Head and neck cancer

08:45 - 08:45 **Session DOI**

08:45 - 08:45 **1112PD - Efficacy Evaluation of Optimal Patient Selection for Hypopharyngeal Cancer Organ Preservation Therapy using MRI-derived Radiomic Signature: Bi-institutional Propensity Score Matched Analysis**
S.-M. Lin¹, C. Hsu², Y. Lee³, T.-C. Li⁴, S.-H. Kuo⁴, W. Wang³, ¹Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, ²National Taiwan university hospital, Taipei, TW, ³National Taiwan University, Taipei, TW, ⁴National Taiwan University Hospital, Taipei City, TW

08:45 - 08:45 **1113PD - Survival and prognostic factors of nasopharyngeal cancer patients in non-endemic countries: a large multicentric database analysis**
P. Bossi¹, S. Grisanti¹, I. Mohamad², I. Linares Galiana³, E. Ozyar⁴, P. Franco⁵, S. Vecchio⁶, L. Livi⁷, B. Cirauqui Cirauqui⁸, M. El-Sherify⁹, S. Ursino¹⁰, A. Argiris¹¹, J. Pan¹², C. Wittekindt¹³, E. D'Angelo¹⁴, M. Buglione¹, M. Airolidi¹⁵, R. Mesia Nin¹⁶, L. Licitra¹⁷, E. Orlandi¹⁷, ¹Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT, ²King Hussein Cancer Center, Amman, JO, ³Hospital Universitario Virgen de las Nieves, Granada, ES, ⁴ACIBADEM University, Istanbul, TR, ⁵University of Turin, Torino, IT, ⁶IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT,

⁷AOU Careggi - Radioterapia Oncologica, Firenze, IT, ⁸Catalan Institute of Oncology (ICO), Badalona, ES, ⁹Damietta Cancer Institute (DCI), Damietta, EG, ¹⁰Azienda Ospedaliero-Universitaria Pisana, Pisa, IT, ¹¹Hygeia Hospital, Athens, GR, ¹²Thomas Jefferson University, Philadelphia, US, ¹³University Hospital Giessen, Giessen, DE, ¹⁴Azienda Ospedaliero-Universitaria Modena Policlinico, Modena, IT, ¹⁵AOU S. Giovanni Battista - Molinette, Torino, IT, ¹⁶Institut Català d'Oncologia, Badalona, ES, ¹⁷Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

- 08:45 - 08:45 **1114PD - High Immunoscore is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced Head and Neck cancer patients.**
H. Mirghani¹, C. Mure², B. Mlecnik³, F. Hermitte⁴, E. Martel⁵, O. Casiraghi⁵, M. Iacob⁵, C. Even⁶, J. Galon⁷, ¹European George Pompidou Hospital, Paris, FR, ²Gustave Roussy Cancer Center, Villejuif, FR, ³Inserm, Paris, FR, ⁴HaliDx, Marseille, FR, ⁵Gustave Roussy Cancer Center, Villejuif, FR, ⁶Institut Gustave Roussy, Villejuif, FR, ⁷Laboratory of Integrative Cancer Immunology, Paris, FR
- 08:45 - 09:00 **Invited Discussant 1112PD, 1113PD and 1114PD**
- 09:00 - 09:05 **Q&A led by Discussant**
- 09:05 - 09:05 **1115PD - Analysis of Efficacy Outcomes Based on Programmed Death Ligand 1 (PD-L1) Scoring Techniques in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) From KEYNOTE-040**
E. Cohen¹, K. Harrington², D. Soulières³, C. Le Tourneau⁴, L. Licitra⁵, B. Burtneess⁶, T. Bal⁷, J. Juco⁷, D. Aurora-Garg⁷, L. Huang⁷, R. Swaby⁷, K. Emancipator⁷, ¹The University of Chicago Medical Centre, Chicago, US, ²Institute of Cancer Research ICR, London, GB, ³Centre Hospitalier de l'Université de Montréal, Montréal, CA, ⁴Institut Curie, Paris and Saint-Cloud, INSERM U900 Research Unit, Saint-Cloud, FR, ⁵Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁶Yale University School of Medicine, New Haven, US, ⁷Merck & Co., Inc., Kenilworth, US
- 09:05 - 09:05 **1116PD - A window of opportunity trial of preoperative nivolumab with or without tadalafil in squamous cell carcinoma of the head and neck (SCCHN): safety, clinical, and correlative outcomes**
A. Luginbuhl¹, J. Johnson¹, L. Harshyne¹, M. Tuluc¹, S. Mardekian¹, B. Leiby², J. Curry¹, D. Cognetti¹, Y. Kim³, K. Mannion³, U. Rodeck¹, A. Argiris⁴, ¹Thomas Jefferson University, Philadelphia, US, ²Kimmel Cancer Center-Thomas Jefferson University, Philadelphia, US, ³Vanderbilt University, Nashville, US, ⁴Hygeia Hospital, Athens, GR
- 09:05 - 09:05 **1117PD - Pembrolizumab and radiotherapy for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with contraindication to cisplatin therapy**
S. Sheth¹, J. Bauman², A. Deal³, B. Chera³, C. Shen³, T. Galloway², T. Hackman³, J. Blumberg³, W. Yarbrough³, M. Weissler³, C. Hilliard³, R. Mehra⁴, J. Grilley-Olson³, J. Weiss³, ¹UNC - Lineberger Cancer Center, Chapel Hill, US, ²Fox Chase Cancer Center,

Philadelphia, US, ³University of North Carolina-Lineberger Cancer Center, Chapel Hill, US, ⁴Johns Hopkins University, Baltimore, US

- 09:05 - 09:05 **1118PD - Avelumab-cetuximab-radiotherapy versus standards of care (SoC) in patients (pts) with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): safety phase of randomized trial GORTEC 2017-01 (REACH)**
- Y. Tao¹, A. Auperin¹, X. Sun², C. Sire³, L. Martin⁴, A. Coutte⁵, C. Lafond⁶, J. Miroir⁷, X. Liem⁸, F. Rolland⁹, A. Maillard¹⁰, N. Colin-Barailhou¹¹, C. Michel¹¹, J. Thariat¹², J. Guigay¹³, J. Bourhis¹⁴, ¹Institut Gustave Roussy, Villejuif, FR, ²Hopital Nord Franche-Comté de Montbéliard, Montbéliard, FR, ³Centre Hospitalier de Bretagne Sud - Hôpital du Scorff, Lorient, FR, ⁴Clinique des Ormeaux, Le Havre, FR, ⁵CHU Amiens-Picardie Site Nord, Amiens, FR, ⁶Centre Jean Bernard, Le Mans, FR, ⁷Centre Jean Perrin, Clermont-Ferrand, FR, ⁸Centre Oscar Lambret, Lille, FR, ⁹ICO Rene-Gauducheau, Nantes, FR, ¹⁰Gustave Roussy, Villejuif, FR, ¹¹GORTEC, Tours, FR, ¹²Centre François Baclesse, Caen, FR, ¹³Centre Anticancer Antoine Lacassagne, Nice, FR, ¹⁴Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH
- 09:05 - 09:23 **Invited Discussant 1115PD, 1116PD, 1117PD and 1118PD**
- 09:23 - 09:30 **Q&A led by Discussant**
- 09:30 - 09:30 **1119PD - Inducible T cell Costimulatory (ICOS) Receptor Agonist, GSK3359609 (GSK609) alone and in combination with Pembrolizumab (pembro): preliminary results from INDUCE-1 expansion cohorts (EC) in Head and Neck Squamous Cell Carcinoma (HNSCC)**
- D. Rischin¹, S. Groenland², A. Lim³, J. Martin-Liberal⁴, V. Moreno⁵, J. Trigo Perez⁶, C. Le Tourneau⁷, M. Mathew⁸, D. Cho⁹, A. Hansen¹⁰, D. Vincente-Baz¹¹, M. Maio¹², A. Italiano¹³, J. Bauman¹⁴, M. Chisamore¹⁵, H. Zhou¹⁶, C. Ellis¹⁶, M. Ballas¹⁶, A. Hoos¹⁶, E. Angevin¹⁷, ¹Peter MacCallum Cancer Centre, Melbourne, AU, ²Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ³Peter MacCallum Cancer Center, Melbourne, AU, ⁴Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, ES, ⁵University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ⁶Hospital Universitario Virgen de la Victoria, Málaga, ES, ⁷Institut Curie, Paris, FR, ⁸Columbia University Irving Medical Center, New York, US, ⁹NYU Langone Health, New York, US, ¹⁰Princess Margaret Cancer Center, Toronto, CA, ¹¹Universitario Virgen Macarena, Seville, ES, ¹²Azienda Ospedaliera Universitaria Senese - Santa Maria delle Scotte, Siena, IT, ¹³Institute Bergonié, Bordeaux, FR, ¹⁴Fox Chase Cancer Center, Philadelphia, US, ¹⁵Merck Sharp & Dohme Corp. USA, Whitehouse Station, US, ¹⁶GlaxoSmithKline USA, Collegeville, US, ¹⁷Gustave Roussy - Cancer Campus, Villejuif, FR
- 09:30 - 09:30 **1120PD - Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: a phase II multicenter trial**
- J. Fayette¹, L. Digue², C. Ségura-Ferlay¹, I. Treilleux¹, Q. Wang¹, G. Lefebvre³, A. Daste², C. Even⁴, S. Couchon Thauinat¹, A. Guyennon¹, F. Peyrade⁵, D. Cupissol⁶, B. You⁷, C. Le

Tourneau⁸, L. Jaouen¹, E. Grinand¹, S. Tabone-Eglinger⁹, G. Garin¹, D. Perol¹, ¹Centre Léon Bérard, Lyon, FR, ²CHU Bordeaux Hopital St. André, Bordeaux, FR, ³Centre Oscar Lambret, Lille, FR, ⁴Institut Gustave Roussy, Villejuif, FR, ⁵Centre Anticancer Antoine Lacassagne, Nice, FR, ⁶Laboratoire de Radio-Analyse du C.R.L.C., Montpellier, FR, ⁷Centre Hospitalier Lyon Sud, Pierre Bénite, FR, ⁸Institut Curie, Paris, FR, ⁹Centre Léon-Bérard, Lyon, FR

09:30 - 09:40 **Invited Discussant 1119PD and 1120PD**

09:40 - 09:45 **Q&A led by Discussant**

08:45 - 09:45 **Type: Challenge your expert** **Tarragona Auditorium (Hall 7)**
Title: Locally advanced rectal cancer: What is the best perioperative treatment in 2019?
Chair(s): Ramon Salazar, ES

08:45 - 08:45 **Session DOI**

08:45 - 08:55 **Presentation by expert**
C. Rödel, , US

08:55 - 09:45 **Discussion led by Chair**
R. Salazar, ICO - Institut Catala d'Oncologia Hospital Duran i Reynals, Hospitalet de Llobregat, ES

08:45 - 10:00 **Type: Special session** **Alicante Auditorium (Hall 3)**
Title: Artificial intelligence

08:45 - 09:00 **11760 - Artificial intelligence combining radiomics and clinical data for predicting response to immunotherapy**

M. Liger¹, A. Garcia-Ruiz¹, C. Viaplana², M.V. Raciti², I. Matos³, J. Martín Liberal³, C. Hierro³, M. Gonzalez³, R. Morales Barrera³, C. Suárez³, E. Elez³, I. Brana³, E. Muñoz-Couselo⁴, A. Oaknin³, E. Felip³, J. Tabernero⁵, J. Carles³, R. Dienstmann³, E. Garralda⁶, R. Perez Lopez⁷, ¹Vall d'Hebron Institute of Oncology, Barcelona, ES, ²Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Vall d'Hebron University Hospital, Barcelona, ES, ⁵Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁶Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁷Vall d'Hebron University Hospital - Vall d'Hebron Institute of Oncology VHIO, Barcelona, ES

09:00 - 09:15 **Invited Discussant 11760**

09:15 - 09:30 **1760 - Machine learning-assisted prognostication based on genomic expression in the tumor microenvironment of estrogen receptor positive and HER2 negative breast cancer**

Y. Abdou¹, A. Baird², J. Dolan³, S. Lee⁴, S. Park¹, S. Lee¹, ¹Roswell Park Comprehensive Cancer Center, Buffalo, US, ²University of Pittsburgh School of Medicine, Pittsburgh, US, ³University at Buffalo School of Medicine, Buffalo, US, ⁴National Institutions for Mathematical Sciences, Daejeon, KR

09:30 - 09:45 **Invited Discussant 1760**

08:45 - 09:45 **Type: Challenge your expert** **Cartagena Auditorium**
Title: Challenges in advanced GIST: Are we approaching cure? **(Hall 3)**

Chair(s): Sylvie Bonvalot, FR

08:45 - 08:45 **Session DOI**

08:45 - 08:55 **Presentation by expert**

S. Bauer, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

08:55 - 09:45 **Discussion led by Chair**

S. Bonvalot, Institut Curie, Paris, FR

08:45 - 09:45 **Type: Challenge your expert** **Salamanca Auditorium (Hall 3)**
Title: Tackling the treatment options in triple negative metastatic breast cancer
Chair(s): Lisa Carey, US

08:45 - 08:45 **Session DOI**

08:45 - 08:55 **Presentation by expert**
S. Delaloge, Gustave Roussy, Villejuif, FR

08:55 - 09:45 **Discussion led by Chair**
L. Carey, UNC - Lineberger Cancer Center, Chapel Hill, US

09:00 - 10:30 **Type: Young Oncologist session** **Santander Auditorium (Hall 3)**
Title: YO “boxing” session
Chair(s): Matteo Lambertini, IT; Anna Sophie Berghoff, AT

09:00 - 09:00 **Session DOI**

09:00 - 09:00 **Debate 1: How should patients with early stage HER2-positive breast cancer be treated?**

09:00 - 09:05 **Introduction**

09:05 - 09:20 **Escalation is the key**

E. De Azambuja, Institute Jules Bordet, Brussels, BE

09:20 - 09:35 **De-escalation is the key**

C. Criscitiello, Istituto Europeo di Oncologia, Milan, IT

09:35 - 09:45 **Take-home messages & discussion**

J. Cortés, Vall d'Hebron University Hospital, Barcelona, ES

09:45 - 09:45 **Debate 2: Are biomarkers needed to select lung cancer patients for immunotherapy?**

09:45 - 09:50 **Introduction**

09:50 - 10:05 **Pro**

A. Addeo, Hopitaux Universitaires de Geneve - HUG, Geneva, CH

10:05 - 10:20 **Contra**

E. Felip, Vall d'Hebron University Hospital, Barcelona, ES

10:20 - 10:30 **Take-home messages & discussion**

S. Peters, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

10:15 - 11:45 **Type: Proffered Paper session** **Barcelona Auditorium (Hall 2)**
Title: Proffered Paper - Breast cancer, metastatic

10:15 - 10:15 **Session DOI**

10:15 - 10:30 **One LBA TBC**

10:30 - 10:45 **One LBA TBC**

10:45 - 11:00 **Invited Discussant 2 LBAs TBC**

11:00 - 11:15 **One LBA TBC**

11:15 - 11:30 **3050 - Overall survival (OS) in KATE2, a phase 2 study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)**

L. Emens¹, F. Esteva², M. Beresford³, C. Saura⁴, M. De Laurentiis⁵, S.-B. Kim⁶, S.-A. Im⁷, Y. Wang⁸, A. Mani⁹, J. Shah⁹, H. Liu⁹, S. De Haas¹⁰, M. Patre¹⁰, S. Loi¹¹, ¹UPMC Hillman Cancer Center, Pittsburgh, US, ²Perlmutter Cancer Center, New York, US, ³Royal United Hospitals Bath NHS Foundation trust, Bath, GB, ⁴Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁵IRCCS Istituto Nazionale Tumori Fondazione Pascale, Naples, IT, ⁶Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ⁷SNUH-Seoul National University Hospital, Seoul, KR, ⁸Roche (China) Holding Ltd, Shanghai, CN, ⁹Genentech, Inc., South San Francisco, US, ¹⁰F. Hoffmann-La Roche, Basel, CH, ¹¹Peter MacCallum Cancer Center, Melbourne, AU

11:30 - 11:45 **Invited Discussant 3050**

10:15 - 11:45	Type: Special symposium Title: Next immunotherapy strategies for lung cancer Chair(s): Marina Garassino, IT	Madrid Auditorium (Hall 2)
10:15 - 10:15	Session DOI	
10:15 - 10:20	Introduction <u>M. Garassino</u> , Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT	
10:20 - 10:40	Bridging the gut microbiome and immune response in lung cancer	
10:40 - 11:00	Personalised vaccines <u>N. Rizvi</u> , Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US	
11:00 - 11:20	Cell therapy in thoracic tumours <u>G. Dotti</u> , , US	
11:20 - 11:40	Bispecific agents and other checkpoint inhibitors <u>M. Garassino</u> , Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT	
11:40 - 11:45	Conclusions and perspectives	

10:15 - 11:45 **Type: Special symposium** **Pamplona Auditorium**
Title: Pushing forward with immunotherapy in upper GI cancers **(Hall 2)**
Chair(s): Markus Moehler, DE; Kei Muro, JP

10:15 - 10:15 **Session DOI**

10:15 - 10:20 **Introduction**

K. Muro, Aichi Cancer Center Hospital, Nagoya, JP

10:20 - 10:40 **Overview of the current landscape of immunotherapy in upper GI cancers**

M. Moehler, Universitätsmedizin Mainz, Mainz, DE

10:40 - 11:00 **Tackling resistance mechanisms as a priority**

R. Petty, Clinical Research Centre - Ninewells Hospital - NHS Tayside, Dundee, GB

11:00 - 11:20 **Combination strategies: Primary tumour location specific or agnostic**

K. Muro, Aichi Cancer Center Hospital, Nagoya, JP

11:20 - 11:40 **Precision immunotherapy: Biomarker and patient selection**

Y. Janjigian, Memorial Sloan-Kettering Cancer Center, New York, US

11:40 - 11:45 **Conclusions and perspectives**

M. Moehler, Universitätsmedizin Mainz, Mainz, DE

10:15 - 11:45 **Type: Special symposium** **Cordoba Auditorium (Hall 7)**
Title: Precision medicine in melanoma therapy
Chair(s): Paolo Ascierto, IT; Olivier Michielin, CH

10:15 - 10:15 **Session DOI**

10:15 - 10:20 **Introduction**

P. Ascierto, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

10:20 - 10:40 **Prediction of toxicity of immunotherapy**

C. Robert, Institut Gustave Roussy, Villejuif, FR

10:40 - 11:00 **Prediction of resistance to immunotherapy**

A. Ribas, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US

11:00 - 11:20 **Prediction of resistance to targeted therapies**

C. Blank, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

11:20 - 11:40 **Who are the long-term responders to immunotherapy and targeted therapy?**

P. Ascierto, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

11:40 - 11:45 **Conclusions and perspectives**

O. Michielin, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

10:15 - 12:00 **Type: Proffered Paper session** **Valencia Auditorium (Hall 5)**
Title: Proffered Paper - Supportive and palliative care

10:15 - 10:15 **Session DOI**

10:15 - 10:27 **17530 - Long term follow-up (F/U) report of symptomatic cardiac events (SCEs) in 2,809 breast cancer (BC) patients (pts) treated with adjuvant trastuzumab (T) in real world (RW) practice**

S. Di Cosimo¹, A. Trama¹, I. Merlo², P. Minicozzi³, L. Tarantini⁴, G. Apolone⁵, G. Corrao², M. Franchi², ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ²University of Milano-Bicocca, Milan, IT, ³Fondazione IRCCS Istituto Nazionale dei Tumori - Milano, Milan, IT, ⁴Azienda Ospedale San Martino, ASL n. 1, Belluno, IT, ⁵Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

10:27 - 10:39 **17540 - Prediction of serious complications in patients with cancer and pulmonary embolism: validation of the EIPHANY index in a prospective cohort**

of patients from the PERSEO study.

M. Sanchez Canovas¹, A. Fernández Montes², R. Morales Giménez³, M. Cejuela Solís⁴, D. Casado Elia⁵, E. Coma Salvans⁶, D. Gómez Sánchez⁷, C. Sánchez Cendra⁸, S. Sequero López⁹, M. Orrillo Sarmiento¹⁰, V. Arrazubi Arrula¹¹, M. Justo De La Peña¹², M. Biosca¹³, D. Fernández Garay¹⁴, A. Bernal Vidal¹⁵, D. Moreno Muñoz¹⁶, E. Martínez De Castro¹⁷, P. Jimenez-Fonseca¹⁸, A. Carmona Bayonas¹, ¹Hospital Universitario Morales Meseguer, Murcia, ES, ²Complejo Hospitalario Universitario de Ourense, Ourense, ES, ³Hospital General Universitario de Elche, Elche, ES, ⁴Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, ES, ⁵Complejo Hospitalario de Salamanca, Salamanca, ES, ⁶CO Institut Català d'Oncologia. Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ⁷Hospital Universitario Central de Asturias, Oviedo, ES, ⁸Hospital Universitario de Fuenlabrada, Fuenlabrada, ES, ⁹Hospital Universitario San Cecilio, Granada, ES, ¹⁰Hospital del Mar, Barcelona, ES, ¹¹Complejo Hospitalario de Navarra, Pamplona, ES, ¹²Hospital Universitari Son Espases, Palma de Mallorca, ES, ¹³Vall d'Hebron University Hospital, BARCELONA, ES, ¹⁴Complejo Hospitalario de Jaén, Jaén, ES, ¹⁵Hospital Universitario San Juan De Alicante, San Juan de Alicante, ES, ¹⁶Fundación Hospital Alcorcón, Alcorcón, ES, ¹⁷Hospital Universitario Marqués de Valdecilla, Santander, ES, ¹⁸Hospital Universitario Central de Oviedo, Oviedo, ES

10:39 - 10:51 **16710 - Assessment of Cardiotoxicity (CT) Associated with Doxorubicin (dox) in Patients (pts) with Advanced Soft Tissue Sarcoma (STS) in a Phase 3 Randomized Trial**

R. Jones¹, W.D. Tap², A. Wagner³, A. Kawai⁴, A. Shahir⁵, V. Soldatenkova⁶, J. Wright⁶, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²Memorial Sloan-Kettering Cancer Center, New York, US, ³Dana Farber Cancer Institute, Boston, US, ⁴National Cancer Center Hospital, Tokyo, JP, ⁵Eli Lilly and Company, Erl Wood, GB, ⁶Eli Lilly and Company, Indianapolis, US

10:51 - 11:06 **Invited Discussant 17530, 17540 and 16710**

11:06 - 11:18 **One LBA TBC**

11:18 - 11:30 **16160 - 5-year adherence to adjuvant endocrine therapy among women with breast cancer: a nationwide study using group-based trajectory modeling.**

V. Memoli¹, G. Lailier², C. Le Bihan-Bejamin², M. Bendiane¹, S. Lauzier³, J. Mancini¹, P.-J. Bousquet², A.-D. Bouhnik⁴, ¹UMR 1252 SESSTIM AMU, INSERM, IRD, Marseille, FR, ²French National Cancer Institute (INCa), Boulogne Billancourt, FR, ³Population Health and Optimal Health Practices Research Unit, Quebec city, CA, ⁴SESSTIM-INSERMUMR912-IRD-AMU, Marseille, FR

11:30 - 11:42 **One LBA TBC**

11:42 - 11:57 **Invited discussant 16160 and 2 LBAs TBC**

10:15 - 11:45	Type: Special symposium Title: Biology and early diagnosis of blood malignancies Chair(s): Leticia Quintanilla Fend, DE; Liran Shlush, IL	Malaga Auditorium (Hall 5)
10:15 - 10:15	Session DOI	
10:15 - 10:20	Introduction <u>L. Shlush</u> , The Weizmann Institute of Science, Rehovot, IL	
10:20 - 10:40	Early lesions in haematological neoplasms <u>L. Quintanilla Fend</u> , University of Tuebingen, Tübingen, DE	
10:40 - 11:00	Early diagnosis of secondary myeloid malignancies <u>L. Shlush</u> , The Weizmann Institute of Science, Rehovot, IL	
11:00 - 11:20	Clonal evolution in lymphoma <u>J. Fitzgibbon</u> , , US	
11:20 - 11:40	Early molecular and computational diagnostics by liquid biopsies <u>D. Rossi</u> , , US	
11:40 - 11:45	Conclusions and perspectives <u>L. Quintanilla Fend</u> , University of Tuebingen, Tübingen, DE	

10:15 - 11:45 **Type: EONS session** **Oviedo Auditorium (CC5)**
Title: EONS 12: Patient safety in cancer care
Chair(s): Daniel Kelly, GB

10:15 - 10:15 **Session DOI**

10:15 - 10:30 **Patient safety and healthcare quality**
C. Kirke, Health Service Executive, Dublin, IE

10:30 - 10:45 **Error reporting in cancer care**
O. Papinaho, Oulu University Hospital, Oulu, FI

10:45 - 11:00 **Being safe - Feeling safe: The importance of supporting carers - Barriers/ enablers**
R. Verity, King's College London, London, GB

11:00 - 11:15 **CN31 - Adverse events in oncology and haemato-oncology inpatients of Swiss hospitals: a descriptive study**

A. Gerber¹, A.M. Da Silva Lopes², N. Szüts³, V. Ribordy-Baudat³, A. Ebnetter³, C. Perrinjaquet⁴, D. Betticher³, M. Cote⁴, M.A. Duchosal⁴, C. Brennan⁵, S. Decosterd⁶, S. Peters⁷, R. Koelliker³, F. Ninane⁴, M.-M. Jeitziner⁸, S. Colomer-Lahiguera¹, P.-Y. Dietrich⁶, M. Simon⁹, M.-E. Gaignard⁶, M. Eicher¹, ¹University of Lausanne, Lausanne, CH, ²University of Applied Sciences (HESAV), Lausanne, CH, ³Regional Hospital of Fribourg (HFR), Fribourg, CH, ⁴University hospital of Lausanne (CHUV), Lausanne, CH, ⁵National Institutes of Health Clinical Center, Bethesda, US, ⁶University hospital of Geneva (HUG), Genève, CH, ⁷Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ⁸University hospital of Bern (Inselspital), Bern, CH, ⁹University of Basel, Basel, CH

11:15 - 11:30 **CN32 - Safe administration of 5-fluorouracil with elastomeric pumps**
P. Sessink¹, H. Levert², N. Jourdan², O. Albert², ¹Exposure Control Sweden AB, Bohus-Björkö, SE, ²University Hospital Saint-Louis, Paris, FR

11:30 - 11:45 **Discussion**

10:15 - 11:45	Type: Educational session Title: How can truly innovative drugs be available for all patients? Chair(s): E.G. Elisabeth De Vries, NL	Leon Auditorium (Hall 3)
10:15 - 10:15	Session DOI	
10:15 - 10:30	What is a fair price? An economist's view <u>B. Jönsson</u> , Stockholm School of Economics, Stockholm, SE	
10:30 - 10:45	Effectiveness of reimbursement decisions and disparities across countries/financial toxicities <u>R. Lopert</u> , OECD, Paris, FR	
10:45 - 11:00	Role of patients and their impact on decision making <u>S. Lindsell</u> , The Brain Tumour Charity, Farnborough, GB	
11:00 - 11:15	New innovative pricing mechanisms	
11:15 - 11:40	Discussion	
11:40 - 11:45	Conclusions	
10:30 - 11:30	Type: Challenge your expert Title: How to sequence treatment in platinum-sensitive relapsed ovarian cancer Chair(s): Robert Coleman, US	Bilbao Auditorium (Hall 5)
10:30 - 10:30	Session DOI	
10:30 - 10:40	Presentation by expert <u>S. Pignata</u> , Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT	
10:40 - 11:30	Discussion led by Chair <u>R. Coleman</u> , The M. D. Anderson Cancer Center, Houston, US	

10:30 - 11:30 **Type: Multidisciplinary session** **Tarragona Auditorium**
Title: WHO grade II and III gliomas: State of the art **(Hall 7)**
management
Chair(s): Anna Sophie Berghoff, AT

10:30 - 10:30 **Session DOI**

10:30 - 10:35 **Presentation of case/condition**

A.S. Berghoff, Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT

10:35 - 10:50 **Diagnostics and molecular pathology: IDHwt and other subgroups**

F. Sahm, , US

10:50 - 11:05 **Proton therapy for low grade gliomas**

F. Dhermain, Institut Gustave Roussy, Villejuif, FR

11:05 - 11:20 **Survivorship and delayed effects**

A.S. Berghoff, Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT

11:20 - 11:30 **General discussion**

10:30 - 11:30 **Type: Challenge your expert** **Alicante Auditorium (Hall 3)**
Title: Metastasis, dormancy and late recurrence
Chair(s): David Cameron, GB

10:30 - 10:30 **Session DOI**

10:30 - 10:40 **Presentation by expert**

C. Klein, Institut Für Immunologie, München, DE

10:40 - 11:30 **Discussion led by Chair**

D. Cameron, The University of Edinburgh, Edinburgh, GB

10:30 - 11:30 **Type: Challenge your expert** **Cartagena Auditorium**
Title: Radiopharmaceuticals to treat lethal prostate cancer **(Hall 3)**
Chair(s): Aristotelis Bamias, GR

10:30 - 10:30 **Session DOI**

10:30 - 10:40 **Presentation by expert**

C. Parker, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

10:40 - 11:30 **Discussion led by Chair**

A. Bamias, Alexandra Hospital - National & Kapodistrian University of Athens, Athens, GR

10:30 - 11:30 **Type: Challenge your expert** **Salamanca Auditorium (Hall 3)**
Title: Biomarkers for patient selection for checkpoint inhibitors in HNSCC: Where do we stand?
Chair(s): Amanda Psyrri, GR

10:30 - 10:30 **Session DOI**

10:30 - 10:40 **Presentation by expert**

T. Seiwert, The University of Chicago Medical Centre, Chicago, US

10:40 - 11:30 **Discussion led by Chair**

A. Psyrri, Attikon University Hospital, Athens, GR

11:00 - 11:45 **Type: Young Oncologist session** **Santander Auditorium (Hall 3)**
Title: YO Brunch: Survivorship care for young adults with cancer
 Chair(s): Christoph Oing, DE; Ioannis Litos, GR

11:00 - 11:00 **Session DOI**

11:00 - 11:15 **A field of growing importance**
H. Sagstuen Haugnes, University Hospital of North Norway, Tromso, NO

11:15 - 11:30 **Survivorship care in young breast cancer patients**
I. Luis, Centro Hospitalar Lisboa Norte - Hospital Sta Maria (HSM-CHLN), Lisbon, PT

11:30 - 11:45 **General discussion / Q&A**

12:00 - 12:45 **Type: Keynote lecture** **Madrid Auditorium (Hall 2)**
Title: HPV vaccination for everybody?
 Chair(s): Lisa Licitra, IT

12:00 - 12:00 **Session DOI**

12:00 - 12:45 **HPV vaccination for everybody?**
J. Cuzick, Barts Cancer Institute-Queen Mary University of London, London, GB

12:00 - 13:00 **Type: Poster Display session** **Poster Area (Hall 4)**
Title: Poster Display session 1

12:00 - 12:00 **Basic Science**

12:00 - 12:00 **10P - Development of chimeric antigenic receptor (CAR) against VEGFR2 for solid tumor treatment**
L.-S. Ai¹, Y.-Y. Wu², J.-Y. Huang³, ¹Development Center for Biotechnology, New Taipei city, TW, ²Development Center for Biotechnology, Taipei, TW, ³Development Center for Biotechnology, Taipei, TW

12:00 - 12:00 **11P - Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells.**
N. Matrone¹, S. Napolitano¹, V. Belli¹, G. Barra², E. Giunta¹, V. De Falco¹, M. Terminiello¹, P.P. Vitiello¹, D. Ciardiello¹, M. Turano³, M. Furia³, A.S. Muddassir⁴, S. Kopetz⁵, E. Martinelli¹, F. Ciardiello¹, T. Troiani¹, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²AOU Seconda Università degli Studi di Napoli (AOU-SUN),

Napoli, IT, ³University of Naples Federico II, Naples, IT, ⁴MD Anderson, Houston, US,
⁵Private Practice - Kopetz, Houston, US

- 12:00 - 12:00 **12P - EGFR-mediated PD-L1 upregulation in HER2+ breast cancer (BC) cell line models**
N. Gaynor¹, M. Mc Dermott², A. Canonici¹, J. Crown³, D. Collins¹, ¹Dublin City University, Dublin, IE, ²University of California Los Angeles, Los Angeles, US, ³St Vincents University Hospital, Dublin, IE
- 12:00 - 12:00 **13P - The impact of cortisol on immune cells and its effect on cancer-immune cells co-culture in a 3D spheroid of ovarian cancer**
M. Al-Natsheh, University of Brighton - Moulsecoomb campus, Brighton, GB
- 12:00 - 12:00 **14P - Application of sonoporation to increase anticancer drug efficacy in 2D and 3D NSCLC cell cultures**
V. Petrikaite¹, M. Paškevičiūtė¹, R. Raišutis², K. Sakalauskienė², ¹Lithuanian University of Health Sciences, Kaunas, LT, ²Kaunas University of Technology, Kaunas, LT
- 12:00 - 12:00 **15P - Tr1-like cells in human peripheral blood are part of the T effector memory pool and are preferentially stimulated via CD55**
I. Charles, J. Ramage, I. Spendlove, City Hospital Campus - Nottingham University Hospitals NHS Trust, Nottingham, GB
- 12:00 - 12:00 **16P - Functional analysis of tumor infiltrating lymphocytes in triple negative breast cancer focusing on granzyme B**
H. Kawaji¹, M. Kubo², Y. Motoyama², A. Shimazaki², S. Hayashi², K. Kurata², M. Yamada², K. Kaneshiro², M. Kai², M. Nakamura², ¹Kyushu University - Graduate School of Medical Sciences - Faculty of medical Sciences, Fukuoka, JP, ²Kyushu University Hospital, Fukuoka, JP
- 12:00 - 12:00 **17P - Aberrant glycolysis associates with inflammatory tumor microenvironment and promotes metastasis in triple-negative breast cancer**
C. Lin, Taipei Medical University, Taipei City, TW
- 12:00 - 12:00 **18P - Anti-cancer effects of differentiation-inducing factor-1 in triple negative breast cancer.**
F. Tetsuo¹, M. Arioka², F. Takahashi³, F. Nishimura², T. Sasaguri², ¹Kyushu University Hospital, Fukuoka, JP, ²Kyushu University, Fukuoka, JP, ³University of Occupational and Environmental Health, Kitakyushu, JP
- 12:00 - 12:00 **19P - The Inhibitory Effect in Oral Squamous Cell Carcinoma Cells by Knocking down Matrix Metalloproteinase 9**
X. Zhang, J. Wen, P. Yin, Beijing Stomatological Hospital and School of Stomatology, Capital Medical University, Beijing, CN
- 12:00 - 12:00 **20P - Matrix metalloproteinases and their tissue inhibitors genes abnormal DNA methylation in breast cancer**

O. Simonova¹, E. Kuznetsova², A. Tanas¹, V. Rudenko¹, E. Poddubskaya³, T. Kekeeva¹, G. Chesnokova¹, S. Kutsev¹, D. Zaletaev⁴, M. Nemtsova², V. Strelnikov⁵, ¹Federal State Budgetary Institution "Research Centre for Medical Genetics", Moscow, RU, ²IM Sechenov First Moscow State Medical University, Moscow, RU, ³I.M. Sechenov First Moscow State Medical University, Moscow, RU, ⁴Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, RU, ⁵Research Centre for Medical Genetics, Moscow, RU

- 12:00 - 12:00 **21P - Uveal melanoma cell lines depend on multiple signaling pathways for survival**
J. Park¹, A. Stewart¹, M. Irvine¹, B. Pedersen¹, R. Kefford¹, R. Diefenbach¹, M. Carlino², H. Rizos¹, ¹Macquarie University, Sydney, AU, ²The Crown Princess Mary Cancer Centre, Westmead, AU
- 12:00 - 12:00 **22P - XAF1 and ZNF313 complex stimulates ER stress-induced apoptosis via direct GRP78 inhibition.**
S. Jang, K.-W. Lee, T.K. Magdalene, J. Ahn, M.-G. Lee, S.-G. Chi, KOREA UNIVERSITY, Seoul, KR
- 12:00 - 12:00 **23P - XAF1 assembles a destructive complex to induce BRCA1-mediated apoptosis via suppressing ERα and switching estrogen function**
S.-H. Jang, J.-S. Lim, S. Jang, M. Lee, S.-G. Chi, KOREA UNIVERSITY, Seoul, KR
- 12:00 - 12:00 **24P - Cancer associated fibroblasts promote cancer progression via Wnt2 secretion in colorectal cancer**
H. Karasawa¹, T. Aizawa¹, K. Sato¹, H. Suzuki¹, T. Kajiwara¹, A. Yamamura¹, T. Kamei¹, T. Naitoh¹, M. Unno², ¹Tohoku University Hospital, Sendai, JP, ²Tohoku University, Aoba-ku, Sendai, JP
- 12:00 - 12:00 **25P - Paired-related homeobox 1 overexpression promotes invasion and metastasis and is a prognostic factor for worse disease-free survival in patients with lung cancer**
J.-J. Hung, Y.-S. Kao, W.-H. Hsu, Taipei Veterans General Hospital, Taipei City, TW
- 12:00 - 12:00 **26P - Regulation of Hox genes repression in human chondrosarcoma cells is independent from inactivation of CDKN2A encoded p16 INK4A and p14ARF tumor suppressor proteins.**
K. Galoian¹, A. Moran², A. Sedani², J. Brown², ¹Um Miller School of Medicine Jackson Memorial Hospital, Miami, US, ²University of Miami, Miller School of Medicine, Miami, US
- 12:00 - 12:00 **27P - LncRNA-GC1 contributes to gastric cancer chemo-resistance through inhibition of miR-551b-3p and the overexpression of dysbindin**
X. Guo, X. Wang, S. Li, Y. Lu, T. Xie, Z. Qiu, D. Wu, Chinese PLA General Hospital (301 Military Hospital), Beijing, CN
- 12:00 - 12:00 **28P - GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer**

cell lines belonging to the CMS4/mesenchymal-like subtype

P.P. Vitiello¹, L. Mele², C. Prisco², C. Cardone¹, D. Ciardiello¹, L. Poliero¹, C. Borrelli¹, N. Zanaletti³, P. Vitale¹, V. Tirino², G. Papaccio², T. Troiani¹, F. Ciardiello¹, F. Marampon⁴, V. Desiderio², E. Martinelli¹, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²Università degli studi della Campania "Luigi Vanvitelli", Napoli, IT, ³INCLIVA Biomedical Research Institute, Valencia, ES, ⁴Università di Roma "La Sapienza", Roma, IT

12:00 - 12:00

29P - Characterisation of growth hormone signal transduction in primary melanoma cell lines

K. Sousa¹, K. Tran², S. Kolekar², L. Jain², Y. Wang², P. Shepherd², J. Perry², ¹University of Auckland Faculty of Medical & Health Sciences, Auckland, NZ, ²The University of Auckland, Auckland, NZ

12:00 - 12:00

30P - LAPTM5 protein can regulate TGF- β mediated MAPK and Smad signaling pathways in ovarian cancer cell

Y. Gao¹, Q. Chen¹, W. Yue², ¹Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, CN, ²Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, CN

12:00 - 12:00

31P - Effects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism

S. Aydinlik¹, A. Uvez², E.İ. Armutak², E. Dere³, E. Ulukaya⁴, ¹Tübitak Marmara research center gene engineering biotechnology institute, Kocaeli, TR, ²Istanbul University, Istanbul, TR, ³Uludag University, Bursa, TR, ⁴Istinye University, Istanbul, TR

12:00 - 12:00

32P - Delineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer

Q. Chen¹, Y. Gao¹, W. Yue², ¹Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, CN, ²Beijing Obstetrics and Gynecology Hospital, Capital Medical University, CN

12:00 - 12:00

33P - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer

M. Nuncia-Cantarero¹, C. Nieto-Jiménez², M. Burgos², J.C. Montero³, A. Ocaña⁴, E.M. Galán-Moya⁵, ¹Centro Regional de Investigaciones Biomédicas (CRIB), Albacete, ES, ²Complejo Hospitalario Universitario de Albacete, Albacete, ES, ³Centro de investigación del cáncer, Salamanca, ES, ⁴Hospital Clínico San Carlos, Madrid, ES, ⁵Universidad de Castilla-La Mancha, Albacete, ES

12:00 - 12:00

34P - NORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex

J. Ahn, K.-P. Ko, M. Lee, S.-G. Chi, KOREA UNIVSERSITY, Seoul, KR

12:00 - 12:00

35P - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small-cell lung cancer cell models

J. Codony-Servat¹, C. Codony-Servat², S. Viteri², M. Ito², I. Chaib³, J. Bracht², M.A. Molina-Vila², N. Karachaliou⁴, R. Rosell³, ¹Pangaea Oncology, Barcelona, ES, ²Quirón-Dexeus University Institute, Barcelona, ES, ³Institut for Health Sciences Germans Trias i Pujol, Badalona, ES, ⁴Merck KgaA, Darmstadt, DE

- 12:00 - 12:00 **36P - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation**
C.-Y. Yang¹, C.-H. Lin², J.-K. Jiang³, ¹Taipei City Hospital, Taipei, TW, ²National Yang-Ming University, Taipei, TW, ³Taipei Veterans General Hospital, Taipei City, TW
- 12:00 - 12:00 **37P - Adaption of Pancreatic Cancer Cells to AKT1 Inhibition Induces the Acquisition of Cancer Stem-Cell Like Phenotype Through Upregulation of Mitochondrial Functions**
H. Arasan¹, M. Zuazo², E. Santamaría³, A.I. Bocanegra², M. Gato-Cañas³, G. Fernández-Hinojal¹, C. Hernández-Saez², J. Fernández-Irigoyen², E. Santamaria², C. Rodríguez-Ortigosa³, G. Kochan², R. Vera⁴, D. Escors², ¹Complejo Hospitalario de Navarra, Pamplona, ES, ²Navarrabiomed, Pamplona, ES, ³Centro de Investigación Médica Aplicada, Pamplona, ES, ⁴Complejo Hospitalario de Navarra - Royal Navarre Hospital, Pamplona, ES
- 12:00 - 12:00 **38P - Bub3 is phosphorylated by the Ataxia-Telangiectasia Mutated Kinase in mitosis and required for activation of the mitotic spindle checkpoint in Breast Cancer**
M. Xiao, B. Xu, Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN
- 12:00 - 12:00 **39P - The regulation of INK4 locus by long non-coding RNAs**
Y. Kotake, N. Matsunaga, Kindai University, Iizuka, JP
- 12:00 - 12:00 **40P - Vascular Endothelial Growth Factor in Colorectal Cancer Pathology, Survival and Treatment**
L. Baker¹, N. Robinson², D. Wilson², M. Tabaqchali², D. Leaper², ¹University Hospital Of North Tees - North Tees and Hartlepool NHS Foundation Trust, Stockton on Tees, GB, ²North Tees and Hartlepool NHS Foundation Trust, Stockton on Tees, GB
- 12:00 - 12:00 **41P - LCSCAF1 maintains cancer stem-like traits by stabilizing c-Myc protein and promotes metastasis and recurrence in lung cancer**
T. Guo¹, L. Zhao², S. Zhao¹, C. Gu², ¹1st Affiliated Hospital of Dalian Medical University, Dalian, CN, ²THE FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIVERSITY, Dalian, CN
- 12:00 - 12:00 **43P - XAF1 Enhances Temozolomide Induced Autophagic Cell Death through AMPK signaling pathway**
M. Lee, K.-P. Ko, S.-G. Chi, KOREA UNIVSERSITY, Seoul, KR
- 12:00 - 12:00 **44P - The effect of cortisol on methylation patterns in breast cancer cell lines**
H. Intabli¹, M. Flint², M. Allen², A. Qattan³, M. Yeoman¹, ¹University of Brighton - Moulsecoomb campus, Brighton, GB, ²University of Brighton-Moulsecoomb campus,

Brighton, GB, ³King Faisal Specialist Hospital and Research Center, Riyadh, SA

- 12:00 - 12:00 **45P - Global and sex-specific epigenome-wide association studies for the identification of the main methylated loci related to smoking in a Mediterranean population**
J.B. Ramirez Sabio¹, O. Coltell², E. Asensio³, C. Ortega-Azorín³, O. Portoles³, I. Gonzalez-Monje³, D. Corella³, J. Sorli³, ¹Hospital de Sagunt y C.E., Sagunto, ES, ²Universitat Jaume I, Castellon, ES, ³University of Valencia, Valencia, ES
- 12:00 - 12:00 **46P - Whole transcriptomics analyses of mimicking Circulating Tumor Cells (CTCs) by single-cell RNA sequencing (scRNAseq)**
J. Garcia¹, F. Monjaret², F. Geiguer³, J.-P. Aurel⁴, A. Puisieux⁵, A.P. Morel⁵, C. Bardel⁶, G. Vilchez⁶, M. Brigitte⁵, S. Couraud⁷, A. Vigneron⁵, G. Tourniaire², L. Payen-Gay¹, ¹Hospices Civiles de Lyon, Lyon, FR, ²cellenion SASU, LYON, FR, ³Hospices Civiles de Lyon, Pierre Benite, FR, ⁴Bioledics, Singapoure, FR, ⁵CRCL, LYON, FR, ⁶Hospices Civiles de Lyon, LYON, FR, ⁷Centre Hospitalier Lyon Sud, Pierre Bénite, FR
- 12:00 - 12:00 **47P - Comparison of enzymatic- and bisulfite conversion to map the plasma cell-free methylome in cancer**
N. Lambert, A. Robertson, R. Srivas, N. Peterman, J. Close, T. Wilson, P. George, H. Wood, B. Wong, A. Tezcan, H. Tezcan, Lexent Bio Inc. - Laboratories, San Diego, US
- 12:00 - 12:00 **48P - Detection of low mutations in hepatocellular carcinoma by using circulating tumor DNA**
E. Kim¹, J.R. Choi², S.-T. Lee², ¹Yonsei University College of Medicine, Seoul, KR, ²Yonsei University College of Medicine Severance Hospital, Seoul, KR
- 12:00 - 12:00 **49P - Variants in the JAK1 and JAK2 genes in the risk and prognosis of patients with cutaneous melanoma**
B. Carvalho¹, G. Gomez², G. Lourenço², A. Moraes², C. Passos Lima¹, ¹Universidade Estadual de Campinas-UNICAMP, Campinas, BR, ²Faculty of Medical Sciences, University of Campinas, Campinas, BR
- 12:00 - 12:00 **50P - P-Rex1 expression in breast cancer patients.**
A. Lara Montero¹, N. Gonzalez², K. Cicinelli³, G. Acosta⁴, S. Vornetti⁴, L. Leguina⁴, D. Maltagliatti⁴, V. Sanchotena⁴, M. Carrasco⁴, D. Flaks⁴, C. Temple⁴, F. Costa⁴, C. Gon⁴, N. Cuneo⁴, M. Abba⁴, E. Kordon⁵, P. Lorenzano², C. Arias⁴, A. De Laurentiis³, E. Wertheimer³, ¹CEFYO-Centro de Estudios Farmacológicos y Botánicos, Buenos Aires, AR, ²University of Quilmes, Buenos Aires, AR, ³Center of Pharmacological and Botanical Studies (CEFYO-CONICET)-School of Medicine, University of Buenos Aires, Caba, AR, ⁴Hospital de Oncologia Maria Curie, Caba, AR, ⁵Instituto de Fisiología, Biología Molecular y Neurociencias (IFIBYNE), Caba, AR
- 12:00 - 12:00 **51P - Modulation of Risk of Cutaneous Melanoma Patients by Variants in STAT3 Gene and Functional Analysis**
G. Gomez¹, L.M. Monteiro², R. Rocha², G. Lourenço¹, C. Lima¹, ¹University of Campinas, São Paulo, BR, ²University of São Paulo, São Paulo, BR

- 12:00 - 12:00 **52P - Spectrum of pathogenic germline mutations in Chinese lung cancer patients through next-generation sequencing**
Y. Huang¹, P. Tian², Y. Zhang³, Z. Zhao⁴, S. Cai⁵, ¹First Affiliated Hospital of Army Military Medical University, Chongqing, CN, ²West China Hospital, Sichuan University, Chengdu, CN, ³Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ⁴3D Medcines Inc, Shanghai, CN, ⁵3D Medcines Inc., Shanghai, CN
- 12:00 - 12:00 **53P - Poor prognostic impact of NTRK2 gene variation in Esophageal Squamous Cell Carcinoma**
Y. Chen, Y. Hou, D. Jiang, W. Chen, X. Zhang, L. Luan, J. Xu, J. Su, F. Gao, Z. Ni, H. Wang, L. Tan, Zhongshan Hospital, Fudan University, Shanghai, CN
- 12:00 - 12:00 **54P - Mutation profile of Tibetan lung cancer revealed by Whole Exome Sequencing**
X. Wang¹, Y. Lai², G. Che³, F. Zhao⁴, F. Yang⁴, ¹West China Hospital of Sichuan University, Chengdu, CN, ²West China Hospital, Sichuan University, CHENGDU, CN, ³West China Hospital - Sichuan University, Chengdu, CN, ⁴Genetron Health (Beijing) Co. Ltd., Beijing, CN
- 12:00 - 12:00 **55P - Synergistic activity between niraparib and chemotherapy in colorectal cancer: molecular determinants from a preclinical model**
P.P. Vitiello, D. Ciardiello, C. Cardone, G. Martini, V. Belli, C. Borrelli, L. Poliero, G. Arrichiello, V. De Falco, E. Giunta, M. Terminiello, T. Troiani, F. Ciardiello, E. Martinelli, Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT
- 12:00 - 12:00 **56P - cRGDfK (cRGD) conjugated Pyropheophorbide-a (Pyro), a new tumor photodynamic agent, is highly accumulated and specific in tumor cell killing**
F. Wang¹, S. Tan², Z. Hong², ¹Tianjin people's hospital, Tianjin, CN, ²Nankai University, Tianjin, CN
- 12:00 - 12:00 **57P - The expression of MMR, CD133 and the presence of p53 wt predict the response to Cabazitaxel in malignant neural tumors cell lines.**
K. Doello¹, C. Mestas², G. Perazzoli², C. García-Collado¹, M.J. Gándara¹, R. García-Fumero¹, M. Fuel², R. Luque¹, R. Ortiz², C. Melguizo², J.C. Prados², ¹Hospital Universitario Virgen de las Nieves, Granada, ES, ²University of Granada, Granada, ES
- 12:00 - 12:00 **58P - IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression**
J. Thirlway¹, A. Lodge¹, A. Pelava¹, D. Williamson¹, D. Carta¹, M. Al Nakeeb¹, J. Mysliwy¹, P. Jackson², D. Thurston², R. Lutz¹, ¹Iksuda Therapeutics Ltd, Newcastle-upon-Tyne, GB, ²FemtoGenix, JQ, GB
- 12:00 - 12:00 **59P - Novel Non-Camptothecin Compounds with Antiproliferative Activities against Breast Cancer Cells**
W.-S. Li¹, H.-C. Wu², C.-T. Yeh³, ¹Academia Sinica, Taipei City, TW, ²Academia Sinica, Taipei, TW, ³Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital,

Taoyuan City, TW

- 12:00 - 12:00 **60P - Sensitization of estrogen receptor-positive breast cancer cells to tamoxifen by novel epi-oligomycin A**
M. Yastrebova¹, O. Omelchuk², L. Lysenkova², E. Mikhaevich³, A. Scherbakov³, A. Shchekotikhin², ¹Institute of Gene Biology of the Russian Academy of Sciences, Moscow, RU, ²Gause Institute of New Antibiotics, Moscow, RU, ³N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU
- 12:00 - 12:00 **61P - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells**
L. Cheng, First Affiliated Hospital of Wannan Medical College, Wuhu, CN
- 12:00 - 12:00 **62P - mTOR inhibition in the treatment of resistant breast cancer**
M. Rodriguez¹, M. Perrone², M. Riggio², V. Novaro², ¹Instituto de Biología y Medicina Experimental, Ciudad Autónoma De Buenos Aires, AR, ²Instituto de Biología y Medicina Experimental, Buenos Aires, AR
- 12:00 - 12:00 **63P - Study of Photodynamic therapy in vitro**
I. Jiménez Munguía¹, I. Meshkov², Y. Gorbunova², V. Sokolov², ¹National University of Science and Technology, Moscow, RU, ²A. N. Frumkin Institute of Physical Chemistry and Electrochemistry, Russian Academy of Sciences,, Moscow, RU
- 12:00 - 12:00 **64P - The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models**
N. Conlon¹, A. Browne², L. Breen³, M. Lowry⁴, L. O'Driscoll⁴, M. Cremona⁵, B. Hennessy⁶, A. Eustace³, N. O'Donovan³, J. Crown⁷, D. Collins³, ¹National Institute for Cellular Biotechnology - Dublin City University, Dublin, IE, ²Dublin City University, DNR, IE, ³Dublin City University, Dublin, IE, ⁴Trinity College Dublin, Dublin, IE, ⁵RCSI Molecular Medicine Laboratories, Dublin, IE, ⁶Beaumont Hospital Cancer Centre, Dublin, IE, ⁷St Vincents University Hospital, Dublin, IE
- 12:00 - 12:00 **65P - Novel HDACi, MHY446, induces apoptosis via regulation of mitochondria-endoplasmic reticulum interaction in HCT116 human colorectal cancer cells**
N.D. Kim, Y.R. Ahn, Y.J. Kang, B. Sung, J.Y. Jang, M.J. Kim, Pusan National University, Busan, KR
- 12:00 - 12:00 **66P - Dual inhibition of TGF- β and AXL as a novel treatment for colorectal cancer**
D. Ciardiello¹, V. Belli², C. Cardone¹, P.P. Vitiello¹, G. Martini¹, L. Poliero¹, C. Borrelli¹, G. Arrichiello¹, V. Ciaramella¹, N. Matrone¹, G. Barra³, V. De Falco¹, E. Giunta¹, F. Morgillo¹, T. Troiani¹, M. Terminiello¹, D. Melisi⁴, F. Ciardiello¹, E. Martinelli¹, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²Università degli studi della Campania "Luigi Vanvitelli", Naples, IT, ³AOU Seconda Università degli Studi di Napoli (AOU-SUN), Napoli, IT, ⁴AOU Integrata Verona "Borgo Roma", Verona, IT

- 12:00 - 12:00 **67P - PARP inhibition enhances cisplatin sensitivity in cervical cancer by modulating β -catenin signaling**
M. Mann, S. Kumar, A. Sharma, S. Chauhan, N. Bhatla, S. Kumar, S. Bakhshi, R. Gupta, L. Kumar, All India Institute of Medical Sciences, Delhi, IN
- 12:00 - 12:00 **68P - Synergistic effect of DSF combined treatment with cisplatin in atypical teratoid/rhabdoid tumors (AT/RT)**
S.A. Choi¹, A. Jangra², S.-K. Kim¹, ¹Seoul National University Hospital, Seoul, KR, ²Seoul National University, Seoul, KR
- 12:00 - 12:00 **69P - Reactive oxygen species induced by OSU-A9 inhibit the growth of duodenal cancer and gastric cancer cells through dephosphorylating intranuclear pyruvate kinase muscle isozyme M2**
L.-Y. Bai¹, C.-Y. Wu¹, P.-C. Chu¹, J.-R. Weng², C.-F. Chiu¹, ¹China Medical University Hospital, Taichung, TW, ²National Sun Yat-sen University, Kaohsiung, TW
- 12:00 - 12:00 **70P - New therapy for intrahepatic cholangiocarcinoma targeted to cancer associated fibroblasts**
T. Yamanaka¹, N. Harimoto¹, K. Hoshino¹, R. Muranushi¹, K. Hagiwara¹, D. Gantumur¹, N. Ishii², M. Tsukagoshi³, T. Igarashi¹, A. Watanabe¹, N. Kubo¹, K. Araki¹, K. Shirabe⁴, ¹Graduate School of Medicine and Faculty of Medicine, Maebashi, JP, ²Gunma University, Gunma, JP, ³Gunma University, Maebashi, JP, ⁴Gunma University, Graduate School of Medicine, Maebashi, JP
- 12:00 - 12:00 **71P - Macrophage-cancer cell fusion is mediated by Phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation**
I. Shabo¹, K. Midtbö², E. Hedayati³, S. Garvin⁴, A. Lindström⁴, ¹Karolinska University Hospital-Solna, Stockholm, SE, ²University Hospital Linköping, Linköping, SE, ³Karolinska Institute, Stockholm, SE, ⁴Faculty of Medicine and Health Sciences, Linköping University, Linköping, SE
- 12:00 - 12:00 **72P - Effects of Three Products in the Prevention and Treatment of Chemotherapy and Radiation Therapy-Induced Oral Mucositis**
F. Zannier, S. Di Bella, S. Della Torre, P. Candido, M. Pelliccione, A. Della Vedova, C. Cozzi, R. Bollina, Azienda Ospedaliera G. Salvini, Rho, IT
- 12:00 - 12:00 **73P - Boiling Histotripsy-induced Mechanical Ablation Modulates Tumour Microenvironment by Promoting Immunogenic Cell Death of Cancers**
C.-H. Shin, K.J. Pahk, S.-H. Kim, H. Kim, S.J. Oh, KIST-Korea Institute of Science and Technology, Seoul, KR
- 12:00 - 12:00 **74P - The bacterial receptor NOD2 mediates LGR5+ intestinal stem cells protection against irradiation via mitophagy activation**
A. Levy¹, E. Deutsch², P. Sansonetti³, G. Nigro³, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Institut Pasteur, Paris, FR
- 12:00 - 12:00 **75P - Pulse mode irradiation regimen of PDT results in high progression free and overall survival in mice with model tumor**

A. Bogdanov, V. Klimenko, N. Verlov, A. Bogdanov, N. Knyazev, St. Petersburg Clinical Research and Practical Center of Specialized Types of Medical Care (Oncologic), Saint-Petersburg, RU

- 12:00 - 12:00 **76P - Proton-sensitizing effect of small molecule inhibitor of P300 histone acetyltransferase C646 in human pancreatic cancer cells.**
S. Shin, C. Choi, S.-Y. Kim, H.C. Park, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR
- 12:00 - 12:00 **77P - Red-Blood-Cell-Membrane-Enveloped Magnetic Nanoclusters as a Biomimetic Theranostic Nanoplatfom for Bimodal Imaging Guided Cancer Photothermal Therapy**
S. Wang, Fudan University Shanghai Cancer Center, Shanghai, CN
- 12:00 - 12:00 **78P - Urine cell-free and extracellular vesicle cargo miRNAs as biomarkers for prostate cancer diagnosis**
I. Zaporozhchenko¹, O. Bryzgunova¹, M. Konoshenko¹, E. Lekchnov¹, E. Amelina², O. Pashkovskaya³, S. Yarmoschuk³, A. Zheravin³, E. Rykova³, P. Laktionov¹, ¹Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, RU, ²Federal State Autonomous Educational Institution of Higher Education "Novosibirsk National Research University", Novosibirsk, RU, ³Meshalkin National Medical Research Center, Ministry of Health of the Russian Federation, Novosibirsk, RU
- 12:00 - 12:00 **79P - Parkin, APEX1 and BCL2L1 Tissue Expression in Southern Brazilian Patients with Different Breast Cancer Molecular Subtypes**
B. Cabral¹, F. Riva¹, Í. Rabinovich², M. Olandoski¹, L. Noronha¹, V. Sotomaior¹, ¹Pontificia Universidade Católica do Paraná, Curitiba, BR, ²Universidade Federal do Paraná, Curitiba, BR
- 12:00 - 12:00 **80P - Obesity and prognosis in breast cancer**
N. Ibrahim¹, S. Talima¹, D. Naguib², ¹NEMROCK Cairo University, Cairo, EG, ²Minia oncology center, Menia, EG
- 12:00 - 12:00 **81P - SIPA1 is a modulator of HGF induced tumor metastasis via the regulation of tight junctions in lung adenocarcinoma cells**
C. Liu¹, W.G. Jiang², R. Hargest², T. Martin², ¹Cardiff University - School of Medicine, Cardiff, GB, ²Cardiff China Medical Research Collaborative, Cardiff, GB
- 12:00 - 12:00 **82P - Dose differential modulation of the autophagic behavior of estrogen expressing breast carcinoma cells**
M. Fouad¹, M. Kamel², M. El Sawalhi³, S. Shouman¹, ¹National Cancer Institute-Cairo University, Cairo, EG, ²National Cancer Institute, Cairo University, Cairo, EG, ³Faculty of Pharmacy, Cairo, EG
- 12:00 - 12:00 **83P - Synthetic peptide of tumor-associated antigen L6 formulated with polymer-based adjuvant enhances anti-tumor effects in mice**
S.-J. Liu, S.-I. Lin, M.-H. Huang, National Health Research Institutes - Zhunan Campus, Zhunan, TW

- 12:00 - 12:00 **84P - trols PTEN expression through DMNT1/EZH2 pathway in radioresistant HNSCC.**
S. Kim¹, D.S. Seong¹, J.H. An¹, J.W. Kim², M.W. Han¹, ¹Ulsan University Hospital, Ulsan, KR, ²Inha University Hospital, Incheon, KR
- 12:00 - 12:00 **85P - Improving detection level of somatic mosaicism in neurofibromatosis type 1**
K. Karandasheva¹, M. Pashchenko², A. Tanas¹, V. Strelnikov², E. Kuznetsova³, ¹Federal State Budgetary Institution "Research Centre for Medical Genetics", Moscow, RU, ²Research Centre for Medical Genetics, Moscow, RU, ³IM Sechenov First Moscow State Medical University, Moscow, RU
- 12:00 - 12:00 **87P - Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship of ABN401, a highly selective Met inhibitor, in gastric and non-small-cell lung cancer models**
J. Kim¹, Y. Kim², K. Park², Y. Jeong¹, J. Choi², S.-J. Chung¹, Y. Shin¹, S. Hong¹, ¹Seoul National University, Seoul, KR, ²ABION INC, Seoul, KR
- 12:00 - 12:00 **88P - Transcription factors of Snail family in the regulation of resistance of breast cancer cells to hypoxic conditions**
A. Khamidullina¹, M. Yastrebova², A. Scherbakov³, V. Tatarskiy¹, ¹Institute of Gene Biology, Moscow, RU, ²Institute of Gene Biology of the Russian Academy of Sciences, Moscow, RU, ³N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU
- 12:00 - 12:00 **Tumour biology and pathology**
- 12:00 - 12:00 **1987P - Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumour cells**
L. Mendonça¹, A. Trindade², C. Carvalho², J. Correia², M. Badenes², J. Gigante², A. Duarte², ¹Unidade de Saude Familiar (USF) Vida + (ACeS Cávado II, Gerês/ Cabreira), Vila Verde, PT, ²FMV - ULisboa (Faculdade de Medicina Veterinária da Universidade de Lisboa), Lisboa, PT
- 12:00 - 12:00 **1988P - Identification of novel and known FGFR gene fusions in Chinese non-small cell lung cancer**
W. Zhao¹, Q. Ou², X. Wu², X. Wang³, Y. Shao⁴, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Geneseeq Technology Inc, Toronto, CA, ³Nanjing Geneseeq Technology Inc., Nanjing, CN, ⁴Geneseeq Technology Inc., Nanjing, CN
- 12:00 - 12:00 **1989P - WNT pathway mutations (APC/CTNNB1) and immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients.**
F.J. Ros Montana¹, P. Iranzo², A. Pedrola³, A. Callejo⁴, N. Pardo⁵, R. Amat¹, C. Carbonell¹, A. Martinez², A. Navarro⁴, S. Cedres¹, R. Dienstmann¹, H. Palmer⁶, A. Vivancos¹, E.

Felip¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron Institute of Oncology and University Hospital, barcelona, ES, ³Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁴Vall d'Hebron Institute of Oncology and University Hospital, Barcelona, ES, ⁵Vall d'Hebron University Hospital, Barcelona, ES, ⁶Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

- 12:00 - 12:00 **1990P - Leukocytosis as a negative prognostic factor in patients with lung cancer: Which subpopulation of leukocytes is responsible?**
F. Kohutek¹, B. Bystricky², ¹Faculty Hospital TN, Trencin, SK, ²Faculty Hospital TN-Fakultná nemocnica Trenčín, Trencin, SK
- 12:00 - 12:00 **1991P - Identification of MET gene amplifications using next-generation sequencing in non-small cell lung cancer patients**
S. Clavé¹, M. Salido¹, P. Rocha¹, M. Hardy-Werbin², J. Gibert³, X. Riera¹, E. Weingartner⁴, G. Cerqueira⁴, D. Nichol⁴, J. Simmons⁴, Á. Taus¹, L. Pijuan¹, B. Bellosillo¹, E. Arriola⁵, ¹Hospital del Mar, Barcelona, ES, ²The Mar Institute of Medical Research Foundation, Barcelona, ES, ³Hospital del Mar Medical Research Institute, Barcelona, ES, ⁴Personal Genome Diagnostics, Baltimore, US, ⁵GLOBAL BUSSINESS TRAVEL, madrid, ES
- 12:00 - 12:00 **1992P - Prognostic role of CD73 in metastatic Non Small Cell Lung Cancer according to the presence of driver alterations**
G. Galli¹, R. Ferrara¹, F. Pagani¹, A. De Toma², G. Lo Russo², D. Signorelli¹, A. Prelaj¹, N. Zilembo¹, M. Ganzinelli¹, S. Brich¹, A. Fabbri¹, S. Sangaletti¹, G. Pruneri³, M.P. Colombo¹, F.G. De Braud¹, M. Garassino¹, C. Proto¹, ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ²Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, IT, ³Istituto Nazionale Tumori, Milano, IT
- 12:00 - 12:00 **1993P - JAK-STAT inhibitor overcomes interferon γ -reduced, NK cell-mediated cytotoxicity in non-small-cell lung cancer cells**
R. Okita, K. Shimizu, Y. Nojima, S. Saisho, M. Nakata, Kawasaki Medical School Hospital, Kurashiki, JP
- 12:00 - 12:00 **1994P - Low LATS2 expression is associated with poor prognosis in non small cell lung cancer**
S.-H. Jang, M.-H. Oh, J.-H. Lee, H.J. Lee, H.D. Cho, H. Ahn, Soon Chun Hyang University Cheonan Hospital, Cheonan, KR
- 12:00 - 12:00 **1995P - Application of ESCAT and OncoKB scales in Liquid biopsy (LB) in Advanced NSCLC patients (pts): Is it feasible and reliable?**
M. Mccusker¹, A. Russo², J. Chen¹, K. Scilla¹, R. Mehra³, C. Rolfo⁴, ¹Maryland Medical Center, Baltimore, US, ²Centro Oncologico Ospedale Papardo, Messina, IT, ³Johns Hopkins University, Baltimore, US, ⁴University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, US
- 12:00 - 12:00 **1996P - IDH1R132H mutation induces a less aggressive phenotype of glioma cells and affects the radiosensitivity by interacting with Wnt/ β -catenin signaling**
X. Han, X. Xue, H. Zhou, L. Hou, The second hospital of hebei medical University,

Shijiazhuang, CN

- 12:00 - 12:00 **1997P - Impact of Angiopoietin-2 on glioblastoma response to combined chemo-radiotherapy**
C. Helaine¹, A. Ferré¹, M. Leblond², E. Pérès², M. Bernaudin², S. Valable², E. Petit²,
¹ISTCT UMR 6030 - CERVoxyTeam, Caen, FR, ²ISTCT UMR 6030 - CERVoxyTeam, CAEN, FR
- 12:00 - 12:00 **1998P - The Discovery of RNA-aptamers That Selectively Bind and Inhibit Glioblastoma Stem Cells by targeting EphA2**
A. Affinito¹, C. Quintavalle¹, C. Esposito², G. Roscigno³, C. Vilaro³, S. Nuzzo⁴, L. Ricci Vitiani⁵, G. De Luca⁵, Z. Minic⁶, S. Giannetti⁷, R. Pallini⁸, M.V. Berezovski⁶, A.S. Kichkailo⁹, I.N. Lapin¹⁰, V. De Franciscis², G. Condorelli¹¹, ¹Università degli Studi di Napoli Federico II, Napoli, IT, ²IEOS CNR, Naples, IT, ³Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, Napoli, IT, ⁴IRCCS SDN SpA, Naples, IT, ⁵Istituto Superiore di Sanità, Rome, IT, ⁶University of Ottawa, Ottawa, CA, ⁷Università Cattolica del Sacro Cuore, Rome, IT, ⁸Università Cattolica del Sacro Cuore, Rome, IT, ⁹Academy of Science, Krasnoyarsk, RU, ¹⁰Tomsk State University, Tomsk, RU, ¹¹Università degli Studi di Napoli Federico II, Naples, IT
- 12:00 - 12:00 **1999P - Impact of tumor reoxygenation by nanoparticles on Tumor Associated Macrophages (TAMs)**
A. Ferré¹, C. Anfray², M. Leblond³, H. Ozcelik², C. Helaine¹, S. Komaty⁴, E. Petit², M. Bernaudin², Z. Mintova⁴, S. Valable², ¹ISTCT UMR 6030 - CERVoxyTeam, Caen, FR, ²ISTCT UMR 6030 - CERVoxyTeam, Caen FRANCE, FR, ³ISTCT UMR 6030 - CERVoxyTeam, CAEN, FR, ⁴LCS, Caen, FR
- 12:00 - 12:00 **2000P - Prognostic significance of c-Rel/p50 heterodimer in the tumor microenvironment of uveal melanoma**
S. Kashyap¹, M. Singh², L. Singh³, N. Pushker⁴, S. Sen², R. Meel⁴, S. Bakhshi², B. Chawla⁴, J. Kaur², ¹All India Institute of Medical Sciences, New Delhi, IN, ²All India Institute of Medical Sciences, Delhi, IN, ³Jamia Millia Islamia, Delhi, IN, ⁴All India Institute of Medical Sciences, New delhi, IN
- 12:00 - 12:00 **2001P - Synergistic role of BAP1 and DNA damage response pathway in uveal melanoma and its prognostic significance.**
J. Jha¹, M. Singh², L. Singh³, N. Pushker², S. Sen², S. Kashyap², ¹AIIMS - All India Institute of Medical Sciences, Delhi, IN, ²All India Institute of Medical Sciences, Delhi, IN, ³Jamia Millia Islamia, Delhi, IN
- 12:00 - 12:00 **2002P - CXCR4, CCR2 and CCR5 expression in subsets of tumor cells with stem and/or EMT features**
O. Savelieva¹, L. Tashireva¹, E. Kaigorodova², N. Tarabanovskaya², V. Perelmuter³,
¹Cancer Research Institute - Tomsk National Research Medical Center, Tomsk, RU, ²Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, RU, ³Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, RU

- 12:00 - 12:00 **2003P - Expression of mutant p53 affects cancer cell sensitivity to topotecan**
R. Mingaleeva, A. Sagdeeva, R. Sayarova, E. Bulatov, R. Miftakhova, A. Rizvanov, Kazan Federal University, Kazan, RU
- 12:00 - 12:00 **2004P - Breast cancer organoids a new tool for the prediction of drugs penetration and patient'outcome**
G. Roscigno¹, C. Quintavalle², A. Affinito², A. Cirella², A. Cuccuru³, R. Thomas⁴, G. Condorelli⁵, ¹Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, Napoli, IT, ²Università degli Studi di Napoli Federico II, Napoli, IT, ³Clinica Mediterranea, Napoli, IT, ⁴Clinica Mediterranea Spa, Naples, IT, ⁵Università degli Studi di Napoli Federico II, Naples, IT
- 12:00 - 12:00 **2005P - Aptamer-mediated exosomes detection for early breast cancer identification.**
C. Quintavalle¹, C. Esposito², F. Ingenito³, A. Affinito⁴, G. Roscigno³, I. Scognamiglio³, S. Nuzzo⁵, S. Catuogno², R. Thomas⁶, G. Condorelli³, ¹Università degli Studi di Napoli Federico II, Napoli, IT, ²IEOS CNR, Naples, IT, ³Università degli Studi di Napoli Federico II, Naples, IT, ⁴Percuros BV, LEIDEN, NL, ⁵IRCCS SDN SpA, Naples, IT, ⁶Clinica Mediterranea Spa, Naples, IT
- 12:00 - 12:00 **2006P - MicroRNA-181c promotes tamoxifen resistance in breast cancer cells via upregulation Akt/mTOR axis**
A. Scherbakov¹, Y. Shchegolev², D. Sorokin¹, A. Shunaev¹, O. Andreeva³, M. Krasil'nikov¹, ¹N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ²N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia, Moscow, RU, ³N.N. Blokhin National Medical Research Centre of Oncology, Moscow, RU
- 12:00 - 12:00 **2007P - Spatio-temporal separation of tumor infiltrating CD8+ T-cells and HER2/neu+ tumor cells in tumor-immune milieu of Infiltrating ductal carcinoma, Breast.**
S. Sreedharan¹, M. Biswas², S. Thiyagarajan², N. Basak², A. Basu², P. Ghosh³, ¹MITRA BIOTECH, Bangalore, IN, ²MITRA RXDX INC., Bangalore, IN, ³IPGME&R & SSKM Hospital, Kolkata, IN
- 12:00 - 12:00 **2008P - Large genomic rearrangements in BRCA1 and BRCA2 genes in the Portuguese population.**
J. Pinto¹, S. Santos², S. Fragoso², A. Luis³, A. Clara⁴, P. Rodrigues⁵, J. Parreira⁵, S. Bento⁶, P. Louro⁵, F. Vaz⁷, ¹Hospital Beatriz Angelo-Loures, Loures, PT, ²Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPOLFG EPE), Lisbon, PT, ³Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisboa, PT, ⁴Instituto Português de Oncologia de Lisboa, Lisboa, PT, ⁵Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, PT, ⁶Hospital Distrital de Santarem (HDS), Santarem, PT, ⁷Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, PT
- 12:00 - 12:00 **2009P - Non-BRCA1/2 hereditary breast and ovarian cancer: findings from a multidisciplinary program**

A. Monteiro¹, P. Machado¹, A. Clara², A. Opinião², A. Luis³, I. Miguel⁴, P. Louro², S. Santos¹, S. Fragoso¹, P. Rodrigues¹, F. Rodrigues², I. Coelho², J. Parreira², F. Vaz²,
¹Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPOLFG EPE), Lisbon, PT, ²Instituto Português de Oncologia de Lisboa, Lisboa, PT, ³Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisboa, PT, ⁴Hospital Distrital de Santarem (HDS), Santarem, PT

12:00 - 12:00 **2010P - Quantitative imaging and characterization of collagen patterns in high grade serous ovarian carcinoma (HGSOC)**

R. Huang¹, T.Z. Tan², J. Ye², D. Lim³, D.S. Tan³, ¹NTU - National Taiwan University - College of Medicine, Taipei City, TW, ²National University Singapore (NUS), Singapore, SG, ³NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG

12:00 - 12:00 **2011P - Semiquantitative assessment of vimentin expression in prostate cancer (PC)**

M. Puchinskaya¹, D. Salavei², ¹Belarusian State Medical University, Minsk, BY, ²International Sakharov Environmental Institute of Belarusian State University, Minsk, BY

12:00 - 12:00 **2012P - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development**

A. Varga, B. Bártai, P. Gyulavári, M.T. Nguyen, C. Sóti, T. Vántus, Semmelweis University, Budapest, HU

12:00 - 12:00 **2013P - The SWI/SNF driven reprogramming for the AR cistrome is Nsd2 dependent**

K. Ruggero¹, A. Martinez¹, X. Chen¹, R. El Bizri¹, S. Farran¹, L. Palomero¹, J. Piulats², A. Villanueva¹, M.A. Pujana¹, A. Aytes¹, ¹Catalan Institute of Oncology. Hospital Dr. Guàrdia y Reynals, Barcelona, ES, ²Institut Català d'Oncologia-IDIBELL-CIBERONC, Barcelona, ES

12:00 - 12:00 **2014P - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling**

G. Múzes¹, A. Sebestyén², Á. Simon¹, L. Nagy¹, B. Barta¹, T. Dankó², A. Kiss³, F. Sipos¹, ¹Semmelweis University, 2nd Dept. of Internal Medicine, Budapest, HU, ²1st Department of Pathology and Experimental Cancer Research, Budapest, HU, ³Semmelweis University, Budapest, HU

12:00 - 12:00 **2015P - Characterization of atypical dMMR (deficient Mismatch Repair) tumors: a study from a large cohort of 4948 cases**

M. Jaffrelot¹, J. Selves², N. Fares³, A. Staub⁴, A.P. Laurenty⁵, M. Danjoux², J. Meilleroux², E. Chipoulet², C. Toulas², R. Guimbaud⁶, ¹Institut Universitaire du Cancer -Toulouse-Oncopole, Toulouse, FR, ²Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse, Toulouse, FR, ³Hospital Rangueil, Toulouse, FR, ⁴CH de Montauban, Montauban, FR, ⁵Clinique Croix du sud, QUINT FONSEGRIVES, FR, ⁶Centre Claudius-Regaud, Toulouse, FR

12:00 - 12:00 **2016P - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells**

F. Sipos¹, L. Nagy¹, B. Barta¹, Á. Simon¹, T. Dankó², A. Sebestyén², A. Kiss³, G. Múzes¹,
1Semmelweis University, 2nd Dept. of Internal Medicine, Budapest, HU, 21st Department
of Pathology and Experimental Cancer Research, Budapest, HU, 3Semmelweis University,
Budapest, HU

- 12:00 - 12:00 **2017P - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity**
D. Chu¹, Z. Zhang¹, J. Zhang¹, Y. Wang¹, Y. Li¹, X. Bu¹, E. Li², J. Zhang¹, 1First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, CN, 2First affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN
- 12:00 - 12:00 **2018P - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma**
L.H.C. Cheng, F.H.C. Tsang, L. Wei, C.T. Law, I.O.L. Ng, C.M. Wong, The University of Hong Kong, Hong Kong, HK
- 12:00 - 12:00 **2019P - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.**
A. Yamasaki, S. Koga, S. Ichimiya, K. Nakayama, Y. Oyama, Y. Fujioka, H. Onishi, Kyushu University Hospital, FUKUOKA, JP
- 12:00 - 12:00 **2020P - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine secretion**
Z. Li¹, Q. Li², G. Zhang¹, X. Ma², Z. Li¹, X. Hu¹, K. Ouyang², B. Li¹, Z. Liu¹, 1Lunan Pharmaceutical Group, Linyi, CN, 2Ampsource Biopharma (SHANGHAI) INC, shanghai, CN
- 12:00 - 12:00 **2021P - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors**
C. Hedvat, G. Lee, V. Baxi, K. Dziuba, D. Locke, B. Li, R. Edwards, Bristol-Myers Squibb, Princeton, US
- 12:00 - 12:00 **2023P - Evaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx**
K. Ota¹, T. Ueno², T. Nakanishi², T. Nakano², T. Yamashita², M. Yoshimi², A. Fujita², H. Okabayashi², Y. Tao², S. Takata², 1National Kyushu Cancer Center, Fukuoka, JP, 2National Hospital Organization Fukuokahigashi Medical Center, Koga, JP
- 12:00 - 12:00 **2024P - [18F]-FDG PET/CT in predicting PD-L1 status in nasopharyngeal carcinoma**
L. Zhao¹, H. Chen², Q. Lin¹, K. Fu¹, Y. Zhuang¹, 1The 1st Affiliated Hospital of Xiamen University, Xiamen, CN, 2The first affiliated hospital of Xiamen university, Xiamen, CN
- 12:00 - 12:00 **2025P - Expression of PD-L1 in Chinese Patients with Common Cancers**
M. Zheng¹, S. Wang², X. Chen³, N. Mao², H. Zhong⁴, J. Guo⁵, X. Pan⁶, Y. Dai⁶, D. Chen⁶, K. Wang⁷, X. Dong⁶, 1The Affiliated Hospital of Guilin Medical College, Guilin, CN,

²Affiliated Tumor Hospital of Guangxi Medical University, Nanning, CN, ³The First Affiliated Hospital of Guangxi Medical University, Nanning, CN, ⁴People's Hospital of Beihai, the 9th Affiliated Hospital of Guangxi Medical University, Beihai, CN, ⁵First Affiliated Hospital of Guangxi Medical University, Nanning, CN, ⁶OrigiMed, Shanghai, CN, ⁷OrigiMed, Shanghai, Shanghai, CN

- 12:00 - 12:00 **2026P - The clearance of EGF by tumor-associated macrophages is suppressed by chemotherapeutic agent cisplatin**
I. Larionova¹, T. Liu², V. Riabov², D.M. Mossel², M. Patysheva³, A. Kiselev⁴, E. Kazakova⁵, N. Cherdyntseva⁶, J. Kzhyshkowska², ¹National Research Tomsk State University, Tomsk, RU, ²University of Heidelberg, Medical Faculty Mannheim, Mannheim, DE, ³Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RU, ⁴Almazov National Medical Research Centre, St. Petersburg, RU, ⁵National Research Tomsk State University, Tomsk, RU, ⁶Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, RU
- 12:00 - 12:00 **2027P - VHIO-300 and a thousand one nights, a tale of Precision Medicine**
G. Caratù¹, F. Mancuso¹, M. Sansó¹, J. Matito¹, R. Fasani², A. Oaknin³, M. Alsina Maqueda³, J. Capdevila³, E. Elez Fernández⁴, T. Macarulla Mercade¹, J. Carles³, C. Saura⁵, J. Rodon⁶, R. Dienstmann³, P. Nuciforo¹, E. Garralda², E. Felip³, J. Tabernero⁷, A. Vivancos³, ¹Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ²Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁵Vall d'Hebron University Hospital Institut d'Oncologia, Barcelona, ES, ⁶The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁷Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES
- 12:00 - 12:00 **2028P - Matched Whole-Genome Sequencing and Whole-Exome Sequencing with Circulating Tumor DNA (ctDNA) Analysis are complementary modalities in clinical practice**
R. Imperial¹, M. Nazer¹, S. Pappas², T. Kuzel², B. El-Rayes³, T. Pluard⁴, M. Levy², J. Subramanian⁵, A. Masood⁶, ¹UMKC(University of Missouri Kansas City), Kansas City, US, ²Rush University, Chicago, US, ³Winship Cancer Institute, Atlanta, GA, Atlanta, US, ⁴Saint Luke's Primary Care-Plaza, Kansas City, US, ⁵St. Luke's Hospital, Kansas City, US, ⁶University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, US
- 12:00 - 12:00 **2029P - Exploring the role of genes associated with familial cancer syndromes on the development of multiple primary tumors**
A. Mitkova¹, R. Dodova¹, M. Koleva², A. Andreeva³, M. Tzekova-Chernopolska³, S. Giragosyan¹, V. Petkova¹, I. Terziev³, S. Rangelov³, C. Slavov³, V. Mitev⁴, R. Kaneva¹, ¹Medical University Sofia, Sofia, BG, ²University Hospital Queen Giovanna UMHAT Tsaritsa Yoanna- ISUL, Sofia, BG, ³University Hospital "Queen Joanna - ISUL", Sofia, BG, ⁴Department of Medical Chemistry and Biochemistry, Medical University, Sofia, Bulgaria, Sofia, BG
- 12:00 - 12:00 **2030P - Doxorubicin resistance: early and advanced tumors can use two different**

strategies based on initial and profound abnormalities in microRNA expression signature

V. Halytskiy, Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, Kiev, UA

- 12:00 - 12:00 **2031P - From tumor transcriptomes to underlying cell type proportions to better predict prognosis and response to treatments**
Y. Blum¹, S. Job¹, A. Kamoun¹, N. Elarouci¹, M. Ayadi¹, F. Petitprez², R. Nicolle¹, E. Brambilla³, A. De Reyniès¹, ¹Ligue Contre le Cancer, Paris, FR, ²Centre de Recherche des Cordeliers, Paris, FR, ³CHU Grenoble Alpes - Site Nord La Tronche, La Tronche, FR
- 12:00 - 12:00 **2032P - Optimization of automated germline DNA extraction from non-tumoral formalin-fixed paraffin embedded (FFPE) tissues**
O. Youssef, University of Helsinki - Faculty of medicine, Helsinki, FI
- 12:00 - 12:00 **2033P - HIV, HBV and HCV screening practices in oncology: a cross-sectional interregional survey**
I. Poizot-Martin¹, M. Taouqi², M. Veyri³, S. Brégigeon¹, M. Pibarot², C. Solas⁴, A. Makinson⁵, A.-G. Marcelin⁶, S. Choquet⁷, J.-P. Spano³, ¹Ste Marguerite Hospital (APHM), Marseille, FR, ²Réseau Régional de Cancérologie OncoPaca-Corse, Marseille, FR, ³AP-HP Hôpital Universitaire Pitié Salpêtrière - Charles Foix, Paris, FR, ⁴Hôpital Nord (APHM), Marseille, FR, ⁵Gui de Chauliac Hospital, Montpellier, FR, ⁶APHP.6 Hôpital Universitaire Pitié Salpêtrière, Paris, FR, ⁷Groupe Hospitalier Pitié Salpetriere, Paris, FR
- 12:00 - 12:00 **2034P - Genetic landscape of KEAP1 and NFE2L2 mutated cancers from the AACR GENIE database**
M. Zaki, V. Pahalyants, Harvard Medical School, Boston, US
- 12:00 - 12:00 **2035P - β -arrestin1 is involved in the Ras-induced malignant transformation**
T. Shibano¹, S. Cismas², C. Worrall², A. Girnita², L. Girnita², ¹Karolinska Institute, Stockholm, SE, ²Karolinska Institute, Solna, SE
- 12:00 - 12:00 **2036P - Incidence of second cancer among PLWHIV: retrospective observational study of a series of 601 patients in the French CANCEVIV network**
J.-P. Spano¹, M. Veyri¹, D. Costagliola², S. Choquet², I. Poizot-Martin³, ¹AP-HP Hôpital Universitaire Pitié Salpêtrière - Charles Foix, Paris, FR, ²Groupe Hospitalier Pitié Salpetriere, Paris, FR, ³Ste Marguerite Hospital (APHM), Marseille, FR
- 12:00 - 12:00 **2037P - A challenging task - Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: the CUPISCO trial experience**
C. Pauli¹, T. Bochtler², L. Mileschkin³, G. Baciarello⁴, F. Losa⁵, J. Ross⁶, G. Pentheroudakis⁷, G. Zarkavelis⁷, S. Yalcin⁸, M. Özgüroğlu⁹, A. Beringer¹⁰, S. Foser¹⁰, H. Moch¹¹, A. Krämer¹², J. Scarato¹⁰, M. Mueller-Ohldach¹⁰, ¹University Hospital Zurich, Zurich, GB, ²Institute of Pathology, Heidelberg, DE, ³Peter MacCallum Cancer Center, Melbourne, AU, ⁴Gustave Roussy, Villejuif, FR, ⁵Hospital de Sant Joan Despí Moisès Broggi, Barcelona, ES, ⁶Foundation Medicine, Cambridge, US, ⁷University Hospital of

Ioannina, Ioannina, GR, ⁸Hacettepe University Faculty of Medicine, Ankara, TR, ⁹Istanbul University - School of Medicine, Istanbul, TR, ¹⁰F. Hoffmann-La Roche Ltd, Basel, CH, ¹¹University Hospital Zurich, Zurich, CH, ¹²German Cancer Research Center, Heidelberg, DE

- 12:00 - 12:00 **2038P - Incidence and Outcome of chronic lymphocytic leukemia with Deletion 17p: An Indian experience; challenges and opportunities**
A. Gogia, L. Kumar, A. Sharma, R. Gupta, L. Rani, B.R. Ambedkar Institute Rotary Cancer Hospital (AIMS), New Delhi, IN
- 12:00 - 12:00 **2039P - Driving solo? Investigation into collaborating mutations in SDH-deficient neoplasia**
J. Killian¹, D. Pavlick¹, E. Sokol¹, M. Montesion¹, D. Jin¹, B. Kaplan¹, D. Lin¹, J.-A. Vergilio¹, J. Elvin¹, N. Ngo¹, E. Severson¹, S. Ramkissoon¹, D. Duncan¹, C. Edgerly¹, A. Hemmerich¹, G. Frampton¹, G. Bratslavsky², V. Miller¹, S. Ali¹, J. Ross¹, ¹Foundation Medicine, Cambridge, US, ²Upstate Medical University, Syracuse, US
- 12:00 - 12:00 **2040P - The potential of a novel antiangiogenic VEGFR1-D2 binding peptide in oncology therapeutics**
A. Sadre Momtaz¹, S.M. Asghari¹, M.R. Groves², ¹University of Guilan, Rasht, IR, ²University of Groningen, Groningen, NL
- 12:00 - 12:00 **Developmental therapeutics**
- 12:00 - 12:00 **456P - First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors**
M. Yunokawa¹, S. Takahashi², D. Aoki³, K. Yonemori⁴, H. Hara⁵, K. Hasegawa⁶, K. Takehara⁷, K. Harano⁸, H. Nomura⁹, E. Noguchi⁴, K. Horie⁵, A. Ogasawara⁶, S. Okame⁷, T. Doi¹⁰, ¹Cancer Institute Hospital of Japanese Foundation For Cancer Research, Tokyo, JP, ²Cancer Institute Hospital of JFCR, Tokyo, JP, ³Keio University Hospital, Shinjuku-ku, Tokyo, JP, ⁴National Cancer Center Hospital, Tokyo, JP, ⁵Saitama Cancer Center, Saitama, JP, ⁶Saitama Medical University International Medical Center, Saitama, JP, ⁷National Hospital Organization Shikoku Cancer Center, Ehime, JP, ⁸National Cancer Center Hospital East, Kashiwa, JP, ⁹Keio University Hospital, Tokyo, JP, ¹⁰National Cancer Center Hospital East, Chiba, JP
- 12:00 - 12:00 **457P - First-in-human study of ABBV-621 in patients (pts) with previously treated solid tumors: Dose-optimization cohorts**
E. Calvo¹, M. De Jonge², D. Rasco³, V. Moreno⁴, Y.-W. Chang⁵, M. Chiney⁵, M. Motwani⁵, S. Penugonda⁵, A. Petrich⁶, M. Ratain⁷, P. Lorusso⁸, ¹Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, ²Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ³The START Center for Cancer Care, San Antonio, US, ⁴University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ⁵AbbVie Incorporated, Chicago, US, ⁶AbbVie Inc., North Chicago, US, ⁷The University of Chicago Medical Centre, Chicago, US, ⁸Yale Cancer Center, New Haven, US

- 12:00 - 12:00 **458P - Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours**
- W. Wick¹, G. Tabatabai², M. Schuler³, K. Rorhberg⁴, S. Chawla⁵, F. Janku⁶, D. Schiff⁷, V. Heinemann⁸, Y. Narita⁹, Y. Ando¹⁰, H.J. Lenz¹¹, M. Ikeda¹², I. Genvresse¹³, C. Rentzsch¹³, S. Reschke¹³, C. Cyris¹⁴, C. Cai¹⁵, M. Jeffers¹⁶, C. Peña¹⁷, O. Bähr¹⁸,
1University of Heidelberg, Heidelberg, DE, 2Universitätsfrauenklinik Tübingen, Tübingen, DE, 3Westdeutsches Tumorzentrum Essen, Essen, DE, 4Rigshospitalet, Copenhagen, Denmark, Copenhagen, DK, 5Sarcoma Oncology Research Center, Santa Monica, US, 6The University of Texas MD Anderson Cancer Center, Houston, US, 7University of Virginia, Charlottesville, US, 8Ludwig Maximilians University - Grosshadern, Munich, DE, 9National cancer center hospital, Tokyo, JP, 10Nagoya University Hospital, 名古屋市緑区, JP, 11USC - Norris Comprehensive Cancer Center, Los Angeles, US, 12National Cancer Center Hospital East, Kashiwa, JP, 13Bayer AG, Berlin, DE, 14CHRESTOS Concept GmbH & Co. KG, Essen, DE, 15Bayer HealthCare Pharmaceuticals, Inc., Whippany, US, 16Bayer Corporation, Whippany, US, 17Bayer HealthCare, Whippany, US, 18University Hospital Frankfurt, Goethe University, Frankfurt, DE
- 12:00 - 12:00 **459P - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer**
- M. Hidalgo¹, M. Bazan-Peregrino², B. Laquente³, R. Alvarez Gallego⁴, A. Mato-Berciano², M. Giménez-Alejandre², V. Maliandi², M.C. Riesco Martinez⁵, R. Moreno⁶, M. Morell⁶, M. Perez-Carreras⁵, J. Gornals⁷, S. Prados⁴, G. Capella⁸, R. Alemany⁹, R. Salazar³, E. Blasi², C. Blasco², M. Cascallo², R. Garcia-Carbonero⁵, 1CNIO - Centro Nacional de Investigaciones Oncológicas, Madrid, ES, 2VCN Biosciences, Sant Cugat del Valles, ES, 3ICO - Institut Catala d'Oncologia Hospital Duran i Reynals, Hospitalet de Llobregat, ES, 4Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES, 5University Hospital 12 De Octubre, Madrid, ES, 6Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, ES, 7Hospital Universitari de Bellvitge, Hospitalet de Llobregat, ES, 8Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, 9Institut Catala de Oncologia, Barcelona, ES
- 12:00 - 12:00 **460P - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors**
- J. Sarantopoulos¹, G. Fotopoulos², F. Tsai³, M. Beg⁴, A.A. Adjei⁵, Y. Lou⁶, M. Seetharam⁷, M. Villalona-Calero⁸, J. Melear⁹, M. Janat-Amsbury¹⁰, H. Beever¹⁰, L. Mouritsen¹⁰, M. Wade¹⁰, B. Bryan¹⁰, D. Bearss¹⁰, 1Institute for Drug Development Cancer Therapy Research Center, San Antonio, US, 2Institute for Drug Development Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, US, 3Virginia G. Piper Cancer Center Clinical Trials, Scottsdale, US, 4University of Texas Southwestern Medical Center at Dallas, Dallas, US, 5Mayo Clinic, Rochester, US, 6Mayo Clinic, Jacksonville, US, 7Mayo Clinic in Arizona, Phoenix, US, 8Miami Cancer Institute Baptist Health, Miami, US, 9Texas Oncology Austin-Midtown, Austin, US, 10Tolero Pharmaceuticals, Inc., Lehi, US
- 12:00 - 12:00 **461P - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand - SN38 conjugate for patients with advanced solid tumors: Phase**

1 results

J. Bendell¹, G. Falchook², S. Sen², M. Johnson³, G. Jerkovic⁴, N. Sarapa¹, R. Vilimas⁵, K. Kriksciukaite⁶, L. Mei⁶, R. Wooster⁶, J. Bloss⁶, A. Thomas⁵, ¹Sarah Cannon Research Institute, Nashville, US, ²Sarah Cannon Research Institute at HealthONE, Denver, US, ³Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ⁴Sarah Cannon Development Innovations, Nashville, US, ⁵National Cancer Institute, Bethesda, US, ⁶Tarveda, Watertown, US

12:00 - 12:00

462P - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors

A. Seet¹, M.C.F. Macapagal¹, A. Ahmad¹, G. Li¹, M.L. Goh², M. Ng², T. Tan¹, D.S.W. Tan³, S.P. Choo², W. Lim¹, D. Tai², ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²National Cancer Centre Singapore, Singapore, SG, ³National Cancer Center Singapore, Singapore, SG

12:00 - 12:00

463P - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)

J.O. Eu¹, K. Yadav¹, Y.-C. Lim¹, J. Hirpara¹, L.R. Kong¹, Z.C. Ng¹, V. Lee¹, S.C. Lee², D.S. Tan², R. Soo³, C.E. Chee⁴, W.P. Yong¹, R. Sundar¹, J. Lim², L. Wang¹, N. Ohi⁵, T. Tsunoda⁶, S. Pervaiz¹, B.-C. Goh³, A. Wong⁷, ¹National University of Singapore, Singapore, SG, ²NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG, ³National University Cancer Institute Singapore (NCIS), Singapore, SG, ⁴National University Hospital, Singapore, SG, ⁵Otsuka Pharmaceutical Co. Ltd., Shiga, JP, ⁶Otsuka Pharmaceutical Co. Ltd, Tokyo, JP, ⁷NUH-National University Hospital (S) Pte. Ltd., Singapore, SG

12:00 - 12:00

464P - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours

N. Cook¹, U. Banerji², J. Evans³, A. Biondo⁴, T. Germetaki¹, M. Randhawa³, L. Godfrey⁵, S. Leslie⁵, P. Jeffrey⁶, M. Rigby⁶, G. Bennett⁶, S. Blakemore⁷, M. Koehler⁸, A. Niewiarowski⁵, M. Pittman⁵, S. Symeonides⁹, ¹The Christie NHS Foundation Trust, Manchester, GB, ²The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ³Beatson West of Scotland Cancer Centre, Glasgow, GB, ⁴Royal Marsden Hospital Institute of Cancer Research, Sutton, GB, ⁵Cancer Research UK, London, GB, ⁶Bicycle Therapeutics, Cambridge, GB, ⁷Bicycle Therapeutics, Lexington, US, ⁸Pfizer - USA, New York, US, ⁹Edinburgh Cancer Centre Western General Hospital, Edinburgh, GB

12:00 - 12:00

465P - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.

W. Harb¹, A. Patnaik², D. Mahalingam³, J. Liu⁴, P. Wen⁵, G. Shapiro⁴, A. Bullock⁶, D. Juric⁷, L. Zheng⁸, K. Moore⁹, M. Patel¹⁰, R. Guttendorf¹¹, S. Wang¹², K. Kerstein¹², G. Berk¹², M. Cieslewicz¹², J. Watnick¹², ¹Horizon Oncology Center, Lafayette, US, ²South Texas Accelerated Research Therapeutics (START), San Antonio, US, ³Robert H Lurie Cancer Center, Chicago, US, ⁴Dana Farber Cancer Institute, Boston, US, ⁵Dana-Farber Cancer Institute, Boston, US, ⁶Beth Israel Deaconess Medical Center, Boston, US,

⁷Massachusetts General Hospital, Boston, US, ⁸Johns Hopkins Hospital, Baltimore, US, ⁹Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, US, ¹⁰Florida Cancer Specialists, Sarasota, US, ¹¹Aclairo Pharmaceutical Development Group, Vienna, US, ¹²Vigeo Therapeutics, Cambridge, US

12:00 - 12:00 **466P - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors**

J. Wang¹, M. Barve², E. Chiorean³, P. Lorusso⁴, K. Courtney⁵, D. Qi⁶, J. Bullington⁶, M. Sardone⁶, J. Chen⁶, C. Brooks⁷, S. Shemesh⁶, T. Bauer⁸, ¹Florida Cancer Specialists, Sarasota, US, ²Mary Crowley Cancer Center, Dallas, US, ³Seattle Cancer Care Alliance, Seattle, US, ⁴Yale Cancer Center, New Haven, US, ⁵The University of Texas Southwestern Medical Center, Dallas, US, ⁶Stemline Therapeutics, New York, US, ⁷Memorial Sloan Kettering Memorial Hospital, New York, US, ⁸Sarah Cannon Cancer Research Institute/Tennessee Oncology, Nashville, US

12:00 - 12:00 **467P - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase**

A. Wang-Gillam¹, H. Yeckes-Rodin², M. Kosmo³, T. Stanton⁴, H. Park¹, F. Songhua⁵, N. Sauter⁶, M. Kania⁶, ¹Washington University School of Medicine, St. Louis, US, ²Cleveland Clinic, Port St. Lucie, US, ³California Cancer Associates, Escondido, US, ⁴St Joseph Health Medical Group, Santa Rosa, US, ⁵Hutchison Medipharma, Shanghai, CN, ⁶Hutchison Medipharma US, Florham Park, US

12:00 - 12:00 **468P - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors**

A. Tolcher¹, G. Falchook², J. Bendell³, D. Ungar⁴, J. Boni⁴, G. Chao⁴, M. Patel⁵, ¹NEXT Oncology™, San Antonio, US, ²Sarah Cannon Research Institute at HealthONE, Denver, US, ³Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, ⁴ADC Therapeutics Inc, Murray Hill, US, ⁵Florida Cancer Specialists, Sarasota, Florida, USA and Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US

12:00 - 12:00 **469P - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti-PD-L1 antibody, in patients (pts) with advanced cancers**

P. Clingan¹, A. Mant², G. Richardson³, D. Kowalski⁴, P. Koralewski⁵, I. Lugowska⁶, A. Dechaphunkul⁷, C. Charoentum⁸, A. Sookprasert⁹, V. Sriuranpong¹⁰, A. Akopov¹¹, V. Kozlov¹², N. Fadeeva¹³, B. Kasparov¹⁴, N. Kovalenko¹⁵, V. Oschepkov¹⁶, L. Gorelik¹⁷, Y. Kunes¹⁷, J. Oliviero¹⁸, D. Harris¹⁹, ¹Wollongong Hospital, Wollongong, AU, ²Eastern Health, Box Hill, AU, ³Cabrini Hospital, Malvern, AU, ⁴Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, ⁵Szpital Specjalistyczny Ludwika Rydygiera, Krakow, PL, ⁶Maria Skłodowska-Curie Memorial Cancer Centre-Institute of Oncology, Warsaw, PL, ⁷Prince of Songkla University, Songkhla, TH, ⁸Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, TH, ⁹Srinagarind Hospital, Khon Kaen, TH, ¹⁰King Chulalongkorn Memorial Hospital, Bangkok, TH, ¹¹First St. Petersburg State Medical University n.a. I.P. Pavlov, Saint-Petersburg, RU, ¹²Novosibirsk Regional Clinical Oncology Dispensary, Novosibirsk, RU, ¹³Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk, RU, ¹⁴NMRC of Oncology n.a. N.N. Petrov, Saint-Petersburg, RU, ¹⁵Volgograd Regional Clinical Oncology Dispensary, Volgograd, RU, ¹⁶Multidisciplinary Clinical Medical Center

"Medical City", Tyumen, RU, ¹⁷Checkpoint Therapeutics, Inc., New York, US,
¹⁸Checkpoint Therapeutics, New York, US, ¹⁹Christchurch Hospital, Christchurch, NZ

- 12:00 - 12:00 **470P - A Phase I study of tinoastamustine in patients (pts) with advanced solid tumours**
A. Mita¹, M. Loeffler², N. Bui³, D. Remmy², T. Mehring², M. Mita¹, B. Rimel⁴, R. Natale¹, S. Kummar³, ¹Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center, Los Angeles, US, ²Mundipharma EDO GmbH, Basel, CH, ³Stanford University, Stanford, US, ⁴Cedars-Sinai Medical Center, West Hollywood, US
- 12:00 - 12:00 **471P - Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors**
S. Ponce Aix¹, M.J. Flor², A. Falcón², I. Sánchez Simón², E. Jimenez¹, G. Coté³, R. Nuñez⁴, M. Siguero⁴, M. Insa⁴, M. Cullell-Young⁴, C. Kahatt⁵, A. Zeaiter⁵, L. Paz-Ares¹, ¹University Hospital 12 De Octubre, Madrid, ES, ²Hospital Universitario Virgen del Rocío, Sevilla, ES, ³Massachusetts General Hospital, Boston, US, ⁴PharmaMar, Colmenar Viejo, Madrid, ES, ⁵PharmaMar - Spain, Colmenar Viejo, ES
- 12:00 - 12:00 **472P - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors**
A. Tan¹, A. Seet², S.P. Choo², D. Tai², Y.C. Lam², W.T. Teng², C. Lim², K.H. Lim³, M. Ng², ¹Royal North Shore Hospital, St Leonards, AU, ²National Cancer Centre Singapore, Singapore, SG, ³Singapore General Hospital, Singapore, SG
- 12:00 - 12:00 **473P - Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer**
S. Huijberts¹, E. Van Brummelen¹, R. Van Geel², F. Opdam³, S. Marchetti¹, N. Steeghs¹, S. Pulleman¹, B. Thijssen⁴, H. Rosing¹, K. Monkhorst⁵, A. Huitema⁶, J. Beijnen⁵, R. Bernards⁵, J. Schellens⁵, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²Maastricht university medical centre, Maastricht, NL, ³NKI-AVL, Amsterdam, NL, ⁴Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ⁵The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁶Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 12:00 - 12:00 **474P - Pharmacokinetic (PK) and updated survival data from the Canadian Cancer Trials Group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy**
D. Hao¹, P. Ellis², S. Laurie³, R. Juergens², M. Mates⁴, P. Bradbury⁵, M. Tsao⁵, M. Tehfe⁶, C. Kollmannsberger⁷, J. Goffin², P. Wheatley-Price⁸, J. Hilton⁸, A.G. Robinson⁹, P. Brown-Walker¹⁰, D. Tu¹¹, M. Smoragiewicz¹¹, L. Seymour¹⁰, ¹Tom Baker Cancer Centre, Calgary, CA, ²Juravinski Hospital and Cancer Centre, Hamilton, CA, ³The Ottawa Hospital Cancer Centre, Ottawa, CA, ⁴Cancer Centre of Southeastern Ontario, Kingston, CA, ⁵Princess Margaret Cancer Centre, University Health Network, Toronto, CA, ⁶CRCHUM, Montreal, CA, ⁷BC Cancer Agency - Vancouver, Vancouver, CA, ⁸The Ottawa Hospital Regional Cancer Centre, Ottawa, CA, ⁹Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, CA, ¹⁰Canadian Cancer Trials Group, Kingston, CA,

11Queen's University, Kingston, CA

- 12:00 - 12:00 **475P - A Phase 2a clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification**
F. Meric-Bernstam¹, N. Somaiah², S. Dubois³, E. Ileana Dumbrava¹, G. Shapiro⁴, M. Patel⁵, S. Goel⁶, T. Bauer⁷, D. Pinchasik⁸, A. Annis⁹, M. Aivado⁹, V. Vukovic⁹, M. Saleh¹⁰,
¹The University of Texas MD Anderson Cancer Center, Houston, US, ²Medical University of South Carolina, Charleston, US, ³Dana-Farber and Boston Children's, Boston, US, ⁴Dana Farber Cancer Institute, Boston, US, ⁵Florida Cancer Specialists and Research Institute, Sarasota, US, ⁶Montefiore Medical Center(East campus) - Medical Park at Eastchester Albert Einstein Cancer Center, Bronx, US, ⁷Sarah Cannon Research Institute, Nashville, US, ⁸Aileron Therapeutics, Inc., Cambridge, US, ⁹Aileron Therapeutics, Inc., Watertown, US, ¹⁰Univ of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, US
- 12:00 - 12:00 **476P - Updated Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Tumors: Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001**
C. Rolfo¹, R. Dziadziuszko², R.C. Doebele³, G. Demetri⁴, B. Simmons⁵, X. Huang⁶, C. Ye⁶, L. Paz-Ares⁷,
¹Maryland University, Baltimore, US, ²Medical University of Gdansk, Gdansk, PL, ³University of Colorado Cancer Center, Aurora, US, ⁴Dana-Farber Cancer Institute, Boston, US, ⁵Genentech, South San Francisco, US, ⁶Genentech, Inc., South San Francisco, US, ⁷University Hospital 12 De Octubre, Madrid, ES
- 12:00 - 12:00 **477P - An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors**
C. Jackson¹, S. Deva², K. Bayston³, B. McLaren⁴, P. Barlow², N. Hung¹, K. Clarke⁵, E. Segelov⁶, T.-Y. Chao⁷, M.-S. Dai⁸, H.-T. Yen⁹, D. Cutler¹⁰, D. Kramer¹⁰, J. Zhi¹⁰, W.-K. Chan¹⁰, M.-F. Kwan¹⁰, C.-T. Hung¹¹,
¹University of Otago, Dunedin, NZ, ²Auckland District Health Board, Auckland, NZ, ³Southern DHB, Invercargill, NZ, ⁴Southern DHB, Dunedin, NZ, ⁵Capital and Coast DHB, Wellington, NZ, ⁶Monash Medical Centre, Clayton, AU, ⁷Shuang-Ho Hospital, New Taipei City, TW, ⁸Tri-Service General Hospital, Taiwan, TW, ⁹Lotung Poh-Ai Hospital, Taiwan, TW, ¹⁰Athenex Inc, Buffalo, US, ¹¹Zenith Technology Corporation Limited, Dunedin, NZ
- 12:00 - 12:00 **478P - Clinical Evaluation of Drug-Eluting Bead Transcatheter Arterial Chemoembolization(D-TACE) versus Conventional TACE in Treatment of unresectable Hepatocellular Carcinoma**
Y. Chen, Zhongshan Hospital, Fudan University, Shanghai, CN
- 12:00 - 12:00 **479P - Safety profile of tepotinib in patients with advanced solid tumors: pooled analysis of phase I and II data**
T. Decaens¹, B.-Y. Ryoo², G. Falchook³, R. Veillon⁴, T. Doi⁵, K. Yamazaki⁶, D. Hong⁷, S. Qin⁸, J. Scheele⁹, R. Bruns⁹, K. Berghoff⁹, S. Faivre¹⁰, P. Paik¹¹,
¹CHU de Grenoble-Alpes- Le site nord à La Tronche - Hopital Michallon, La Tronche, FR, ²Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ³Sarah Cannon Research Institute at HealthONE, Denver, US, ⁴service des maladies du Sang - CHU du Ht

Leveque, FR, ⁵National Cancer Center Hospital East, Chiba, JP, ⁶Sizuoka Cancer Center, Sundogun, JP, ⁷MD Anderson Cancer Center, Houston, US, ⁸Cancer Center of People's Liberation Army, Nanjing, CN, ⁹Merck KGaA, Darmstadt, DE, ¹⁰Beaujon University Hospital, Assistance Publique—Hôpitaux de Paris, Clichy, FR, ¹¹Memorial Sloan Kettering Cancer Center, New York, US

- 12:00 - 12:00 **480P - Drug-drug interaction profile of tepotinib with CYP3A and P-gp substrates**
Ö. Yalkinoglu¹, J. Heuer², A. Becker¹, A. Krebs-Brown¹, R. Strotmann¹, ¹Merck Healthcare KGaA, Darmstadt, DE, ²Nuvisan GmbH, Neu-Ulm, DE
- 12:00 - 12:00 **481P - Bioavailability of tepotinib: impact of omeprazole and food**
R. Strotmann¹, J. Heuer², A. Becker¹, A. Krebs-Brown¹, N. Mammasse¹, Ö. Yalkinoglu¹, ¹Merck Healthcare KGaA, Darmstadt, DE, ²Nuvisan GmbH, Neu-Ulm, DE
- 12:00 - 12:00 **482P - Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors**
C.-Y. Wu¹, N. Budha², Y. Gao³, H. Castro¹, A. Nkobena¹, Y. Ben², S. Sahasranaman², ¹BeiGene USA, Inc., San Mateo, US, ²BeiGene, Ltd., San Mateo, US, ³Shanghai Qiang shi Information Technology, Shanghai, CN
- 12:00 - 12:00 **483P - Population Pharmacokinetics of Tislelizumab in Patients with Advanced Tumors**
C.-Y. Wu¹, T. Tang², L. Liu³, Y. Ben², S. Sahasranaman², Y. Gao³, ¹BeiGene USA, Inc., San Mateo, US, ²BeiGene, Ltd., San Mateo, US, ³Shanghai Qiang shi Information Technology, Shanghai, CN
- 12:00 - 12:00 **484P - The Addition of Metformin to Systemic Anticancer Therapy**
J.H. Kim, Private Practice, Seoul, KR
- 12:00 - 12:00 **485P - Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients**
A. Italiano¹, S. Nanda², K. Keating², B. Childs², M. Fellous², A. Drilon³, D. Hyman⁴, ¹Institute Bergonié, Bordeaux, FR, ²Bayer HealthCare Pharmaceuticals, Inc., Whippany, US, ³Memorial Sloan-Kettering Cancer Center, New York, US, ⁴MSKCC, New York, US
- 12:00 - 12:00 **486P - Analysis of the overall survival and main surrogates used for FDA approvals in solid and hematological malignancies.**
M. Kleniewska-Wieczor¹, L. Mendoza², ¹Iqvia RDS Poland sp. z o.o., Warsaw, PL, ²IQVIA RDS Czech Republic s.r.o., Prague, CZ
- 12:00 - 12:00 **487P - Comparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): the CriTax study**
R. Van Eerden¹, F. Atrafi¹, M. Van Hylckama Vlieg¹, E. Oomen-De Hoop¹, P. De Bruijn¹, A.

Moelker¹, M. Lolkema², C. Rijcken³, R. Hanssen⁴, F. Eskens², R. Mathijssen¹, S. Koolen²,
¹Erasmus MC Cancer Institute, Rotterdam, NL, ²Erasmus University Medical Center, Rotterdam, NL, ³Cristal Therapeutics, Amsterdam, NL, ⁴Cristal Therapeutics, Maastricht, NL

- 12:00 - 12:00 **488P - Correlation of progression free survival-2 and overall survival in solid tumors**
P. Mainwaring¹, L. Zhang², S. Mundle³, K. Liu², E. Pollozi⁴, A. Gray⁵, M. Wildgust³,
¹ICON Cancer Care, Brisbane, AU, ²Janssen R&D/Johnson & Johnson Pharmaceutical R&D, Raritan, US, ³Janssen Research & Development, Raritan, US, ⁴Idea Pharma, San Francisco, US, ⁵Idea Pharma, Cranfield, GB
- 12:00 - 12:00 **489P - High performance of serial tumor biopsies in first in human (FIH) phase I trials.**
J. Sato, T. Koyama, T. Shimizu, N. Yamamoto, National Cancer Center Hospital, Tokyo, JP
- 12:00 - 12:00 **490P - Response rates and lesion-level progression patterns of solid tumor patients in an academic phase 1 program: implications for tumor heterogeneity**
C. Chen¹, C. Pinto², C. Walmsley¹, R. Allen¹, A. Muzikansky², L. Henderson¹, M. Broudo²,
J. Wolfgang², D. Fitzgerald², T. Hong², D. Juric¹, ¹Massachusetts General Hospital, Boston, US, ²Massachusetts General Hospital, Harvard Medical School, Boston, US
- 12:00 - 12:00 **491P - Clinical Benefit and Response Rate in Early Phase Clinical Trials: First Report from a Single-Institution Study**
A. Marra¹, E. Ferraro¹, M. Repetto¹, E. Nicolò¹, P. D'Amico¹, E. Marrucci², I. Caramella¹,
P. Tarantino¹, S. Morganti¹, G. Viale¹, D. Trapani¹, G. Curigliano¹, ¹Istituto Europeo di Oncologia, Milan, IT, ²Campus Bio-Medico di Roma, Roma, IT
- 12:00 - 12:00 **492P - Patient (pt) selection for immunotherapeutic early-phase clinical trials (ieCTs): a single Phase I Unit experience**
M. Simonelli¹, E. Lorenzi², A. Dipasquale³, P. Persico³, G. Ninatti¹, L. Giordano², M. Bertossi², A. Santoro⁴, ¹Istituto Clinico Humanitas, Rozzano, IT, ²Humanitas Clinical and Research Hospital, Rozzano, IT, ³Humanitas University, Humanitas Clinical and Research Hospital - IRCCS, Milan, IT, ⁴Humanitas University, Rozzano-Milan, IT
- 12:00 - 12:00 **493P - Improving patient selection for immuno-oncology phase 1 trials: an external validation of five prognostic scores at Claudius Regaud Institute of Toulouse, Oncopôle (IUCT-O).**
G. Al Darazi¹, E. Martin¹, J.-P. Delord¹, I. Korakis¹, S. Betrian², M. Poublanc¹, F. Ollivier¹,
T. Filleron³, C. Gomez-Roca¹, ¹Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ²Institut Claudius Regaud, Toulouse, FR, ³Centre Claudius-Regaud, Toulouse, FR
- 12:00 - 12:00 **494P - Demonstrating the Changing Trends in Phase 1 Clinical Trials**
C. Guo, R. Kelly, J. Desai, B. Tran, Peter MacCallum Cancer Centre, Melbourne, AU

- 12:00 - 12:00 **495P - Participation of Women in phase 1 oncology clinical trials**
L. Vidal¹, R. Berg², Z. Yang³, K. Moss⁴, ¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ²Syneos Health, Amsterdam, NL, ³Syneos Health, Ohio, US, ⁴Syneos Health, Kiryat Ono, IL
- 12:00 - 12:00 **496P - Predictors for early trial discontinuation of patients with cancer participating in phase I clinical trials**
J. Douma¹, L. Buffart², M. Labots³, C. Menke-Van Der Houven Van Oordt¹, M. Skardhamar², H. Verheul¹, ¹Vrije University Medical Centre (VUMC), Amsterdam, NL, ²Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, NL, ³Amsterdam University Medical Centers, Amsterdam, NL
- 12:00 - 12:00 **497P - Safety of Tumor Treating Fields delivery to the torso: Meta analysis from TTFields clinical trials**
F. Grosso¹, M. Pless², G.L. Ceresoli³, ¹Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT, ²Kantonsspital Winterthur, Winterthur, CH, ³Humanitas Gavazzeni, Bergamo, IT
- 12:00 - 12:00 **498P - Proteomic Profiling Identifies Molecular Basis of Adverse Event to BPM31510 Exposure: Rationale for Comprehensive Molecular Pharmacodynamics (PD) in Phase 1 Clinical Trial Design**
V. Subbiah¹, E. Granger², M. Kiebish², R. Zinner³, D. Hong⁴, G. Miller², L. Zhang², V. Vemulapalli², L. Rodrigues², N. Narain², R. Sarangarajan², ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²BERG, LLC, Framingham, US, ³Thomas Jefferson University, Philadelphia, US, ⁴University of Texas MD Anderson Cancer Center, Houston, US
- 12:00 - 12:00 **500P - Are Epigenetic therapies modifying sensitivity to conventional chemotherapy?**
A. Bizot¹, P. Romano-Martin², C. Baldini³, S. Champiat³, A. Varga³, A. Gazzah⁴, R. Bahleda⁵, P. Vuagnat², A. Hollebecque³, J.-M. Michot², V. Ribrag², C. Massard⁵, S. Postel Vinay², ¹Hôpital Saint-Antoine, Paris, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Gustave Roussy, Villejuif, FR, ⁴Gustave Roussy, Université Paris-Saclay, Villejuif, FR, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR
- 12:00 - 12:00 **501P - Oncogenic mutations at the dimer interface of EGFR lead to formation of covalent homo-dimers and allosteric activation of the kinase domain: A mechanism which alters the selectivity profile of oncogenic EGFR.**
E. Buck¹, M. O'Connor¹, A. Flohr², R. Iacone², T. Nicolaides³, J. Zhang⁴, A. Mayweg², D. Epstein⁵, ¹Black Diamond Therapeutics, New York, US, ²Black Diamond Therapeutics, Basel, CH, ³NYU Langone Health, New York, US, ⁴UCSF, San Francisco, US, ⁵Black Diamond Therapeutics, Boston, US
- 12:00 - 12:00 **502P - Basic selective estrogen receptor degraders (B-SERDs) in combination with novel BET inhibitors in ER+ breast cancer**
R. Xiong, Y. Li, J. Zhao, F. Huang, Z. Shen, Y. Lu, L. Gutgesell, D. Tonetti, G. Thatcher, University of Illinois at Chicago (UIC), Chicago, US

- 12:00 - 12:00 **503P - EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer**
R. Le Moigne¹, C. Banuelos², N. Mawji², T. Tam², J. Wang², K. Jian³, R. Andersen³, A. Cesano⁴, M. Sadar², H.-J. Zhou¹, P. Virsik¹, ¹ESSA Pharmaceuticals Corp., Houston, US, ²BC Cancer Agency, Vancouver, CA, ³University of British Columbia, Vancouver, CA, ⁴NanoString Technologies, Seattle, US
- 12:00 - 12:00 **504P - AVID200 neutralizes TGF-beta1 and -beta3, the principal immunosuppressive TGF-beta isoforms overexpressed by tumors, and sensitizes tumors to immune checkpoint inhibitors.**
T. Gruosso¹, M. O'Connor¹, J.-F. Denis¹, R. Figueredo², J. Koropatnick³, G. Tremblay¹, I. Tikhomirov⁴, ¹Forbius Canada, Montreal, CA, ²University of Western Ontario, London, CA, ³University of Western Ontario, London, CA, ⁴Formation Biologics, Austin, US
- 12:00 - 12:00 **505P - High NAMPT expression and anti-tumor activity of NAMPT inhibitor in adult T-cell leukemia/lymphoma**
T. Kozako¹, T. Ohsugi², Y.-I. Uchida³, M. Yoshimitsu³, K. Ishitsuka³, N. Kato¹, K. Sato¹, A. Aikawa¹, S.-I. Honda¹, ¹Fukuoka University School of Medicine, Fukuoka, JP, ²Rakuno Gakuen University, Hokkaido, JP, ³Kagoshima University, Kagoshima, JP
- 12:00 - 12:00 **506P - TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers**
A. Drilon¹, E. Rogers², D. Zhai², W. Deng², X. Zhang², D. Lee², J. Ung², J. Whitten², H. Zhang², J. Liu², T. Hu², H. Zhuang², Y. Lu², Z. Huang², A. Graber², Z. Zimmerman², R. Xin², J.J. Cui³, V. Subbiah⁴, ¹Memorial Sloan-Kettering Cancer Center, New York, US, ²Turning Point Therapeutics, Inc., San Diego, US, ³TP Therapeutics, Inc., San Diego, US, ⁴The University of Texas MD Anderson Cancer Center, Houston, US
- 12:00 - 12:00 **507P - In Vivo Evaluation of Cisplatin-loaded PEG-PCL Block Copolymeric Nanoparticles for Anticancer Drug Delivery**
Y. Yen¹, L. Yu², H. Qian², L. Wang³, B. Liu⁴, R. Li², ¹Nanjing University, Nanjing, CN, ²Nanjing Drum Tower Hospital - Nanjing University, School Of Medicine, Nanjing, CN, ³Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, CN, ⁴Nanjing Drum Tower Hospital, Nanjing, CN
- 12:00 - 12:00 **508P - Inhibition of Rspo-Wnt pathway Facilitates Checkpoint Blockade Therapy by anti-RSPO3 antibody (DBPR117)**
J. Hsu¹, H.-C. Hung², C.-T. Chen³, W.-C. Yen³, T.-Y. Chang³, P.-K. Chao¹, H. Chin-Ting¹, K.-J. Yen³, Y.-R. Tsai¹, C.-Y. Chang¹, M.-Y. Fang¹, Y.-L. Lai¹, J. Shih¹, ¹National Health Research Institutes - Zhunan Campus, Zhunan, TW, ²National Health Research Institutes, Hunan, TW, ³National Health Research Institutes, Zhunan, TW
- 12:00 - 12:00 **509TiP - A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumors**
J. Krauss¹, T. Eigentler², J. Schreiber³, C. Weishaupt⁴, P. Terheyden⁵, L. Heinzerling⁶, P. Mohr⁷, B. Weide⁸, S. Ochsenreither⁹, R. Gutzmer¹⁰, J. Becker¹¹, F. Kiecker⁹, F. Funkner¹², R. Heidenreich¹², S.-K. Kays¹³, U. Klinkhardt¹⁴, U. Gnad-Vogt¹⁵, B. Scheel¹⁶,

O. Schönborn-Kellenberger¹⁷, T. Seibel¹³, ¹Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, ²Universitätsklinikum Tübingen, Tübingen, DE, ³No place of work provided Iran, Tehran, IR, ⁴University Clinic Münster, Münster, DE, ⁵University SH.-Lübeck, Lübeck, DE, ⁶Universitätsklinik Erlangen, Erlangen, DE, ⁷Dermatologic Center Buxtehude, Buxtehude, DE, ⁸Universitäts-Hautklinik Tübingen, Tübingen, DE, ⁹Charite-Universitätsmedizin Berlin, Berlin, DE, ¹⁰Hannover Medical School, Klinik für Dermatologie, Allergologie und Venerologie, Hannover, DE, ¹¹West german cancer center, Essen, DE, ¹²CureVac AG, Tübingen, DE, ¹³CureVac AG, Frankfurt, DE, ¹⁴CureVac GmbH, Frankfurt am Main, DE, ¹⁵Curevac GmbH, Frankfurt am Main, DE, ¹⁶CureVac AG, Frankfurt am Main, DE, ¹⁷Cogitars GmbH, Heidelberg, DE

12:00 - 12:00 **510TiP - Phase 1/2 Study of 9-ING-41, a small molecule selective Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors**

B. Carneiro¹, L. Cavalcante², P. Munster³, A. De Souza⁴, H. Safran⁵, F. Giles⁶, ¹Warren Alpert Medical School of Brown University, Providence, US, ²Miami Cancer Institute, Miami, US, ³University of California San Francisco, San Francisco, US, ⁴Lifespan Cancer Institute, Brown University, Providence, US, ⁵Lifespan Cancer Institute, Providence, US, ⁶Northwestern University, Chicago, US

12:00 - 12:00 **511TiP - Trial in progress: a Phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumors (NCT03447314).**

A. Hansen¹, J. Strauss², J. Chaves³, S. Piha-Paul⁴, H. Park⁵, E. Garralda⁶, C. Matheny⁷, J. Carver⁸, A. Moore⁷, B. Hug⁷, ¹Princess Margaret Cancer Center, Toronto, CA, ²Mary Crowley Medical Research Center, Dallas, US, ³Northwest Medical Specialties, LLC, Tacoma, US, ⁴The University of Texas, MD Anderson Cancer Center, Houston, US, ⁵Department of Internal Medicine, Washington University School of Medicine, St. Louis, US, ⁶Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO, Barcelona, ES, ⁷GlaxoSmithKline, Colleagueville, US, ⁸GlaxoSmithKline, Colleagueville, US

12:00 - 12:00 **CNS tumours**

12:00 - 12:00 **404P - Radiographic Phenotyping to Identify Intracranial Disseminated Recurrence in Brain metastases Treated With Radiosurgery Using Contrast-enhanced MR Imaging**

C. Hsu¹, S.-H. Kuo², W. Wang³, T.W.-W. Chen⁴, Y. Lee³, ¹National Taiwan university hospital, Taipei, TW, ²National Taiwan University Hospital, Taipei City, TW, ³National Taiwan University, Taipei, TW, ⁴NTU - National Taiwan University - College of Medicine, Taipei City, TW

12:00 - 12:00 **405P - Association between TP53 mutations and efficacy of Osimertinib for brain metastasis from EGFR-mutant lung cancer**

L. Chen¹, X. Mu², H. Wu², Y. Zhao¹, ¹Henan Cancer Hospital, Zhengzhou, CN, ²Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN

- 12:00 - 12:00 **406P - Response assessment of melanoma brain metastases treated by stereotactic radiotherapy or immunotherapy or both: a comparison of RECIST 1.1, RANO and iRANO criteria**
E. Le Rhun¹, F. Wolpert², M. Fialek³, P. Devos³, N. Andratschke⁴, N. Reyns³, R. Dummer⁵, L. Mortier⁶, ¹Roger Salengro Hospital, Lille, FR, ²University Hospital and University of Zurich, Zurich, CH, ³Lille University Hospital, Lille, FR, ⁴University Hospital Zürich, Zurich, CH, ⁵Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, ⁶Hopital Claude Huriez, Lille, FR
- 12:00 - 12:00 **407P - Management of multiple brain metastases by Staged SRS focusing on utmost risk lesions**
S. Li, M. Lai, L. Wen, J. Zhen, Guangdong Sanjiu 999 Brain Hospital, Guangzhou, CN
- 12:00 - 12:00 **408P - Whole brain radiotherapy plus simultaneous in-field boost versus whole brain radiotherapy plus fractionated stereotactic radiotherapy for multiple brain metastases of non-small cell lung cancer**
L. Li¹, M. Feng², P. Xu², J. Yin², Y. Huang², X. Peng², J. Lang², ¹Sichuan Cancer Hospital, Chengdu, CN, ²sichuan cancer hospital, chengdu, CN
- 12:00 - 12:00 **409P - 3D based texture analysis serving as potential diagnostic factor in discriminating primary central nervous system lymphoma from metastatic brain tumors: A preliminary study**
W. Guo, X. Ma, West China Hospital, Sichuan University, Chengdu, CN
- 12:00 - 12:00 **410P - Global trends in population-based survival for 303,169 adults diagnosed with glioblastoma in 44 countries during 2000-2014 (CONCORD-3)**
F. Girardi¹, N. Fersht², M. Coleman¹, C. Allemani¹, Working Group Concord¹, ¹London School of Hygiene and Tropical Medicine, London, GB, ²University College London Hospitals NHS Foundation Trust, London, GB
- 12:00 - 12:00 **411P - Spanish Survey of treatment recommendations for elderly patients with glioblastoma**
M.Á. Vaz Salgado¹, Á. Rodríguez Sánchez², I. Fernandez Perez³, T. Quintanar⁴, M. Navarro Martin⁵, M. Vieito Villar⁶, J. Cano⁷, S. Gonzalez⁸, S. Ros⁹, A. Herrero Ibañez¹⁰, M.A. Ivars¹¹, M. Lloret¹², M. Alonso¹³, I. Moya¹⁴, R. Luque¹⁵, M. Benavides¹⁶, M. Gutiérrez Toribio¹⁷, J. García - Gómez¹⁸, J. Esteban Villarrubia¹, J. Torres Jimenez¹, ¹Hospital Universitario Ramon y Cajal, Madrid, ES, ²Complejo Asistencial Universitario de León, Leon, ES, ³CHUVI - Complejo Hospitalario Universitario de Vigo, Vigo, ES, ⁴Hospital General Universitario de Elche, Elche, ES, ⁵IBSAL - Instituto de Investigación Biomédica de Salamanca, Salamanca, ES, ⁶Vall d'Hebron University Hospital - Vall d'Hebron Institute of Oncology VHIO, Barcelona, ES, ⁷Hospital General Ciudad Real, Ciudad Real, ES, ⁸Hospital Mutua de Terrassa, Terrassa, ES, ⁹Hospital Universitario Virgen de la Arrixaca, Murcia, ES, ¹⁰Hospital Miguel Servet, Zaragoza, ES, ¹¹Hospital Universitario Morales Meseguer, Murcia, ES, ¹²Hospital General Universitario Morales Meseguer, Murcia, ES, ¹³Hospital Universitario Virgen del Rocío, Sevilla, ES, ¹⁴H. General Catalunya Instituto Oncológico Dr Rosell, Barcelona, ES, ¹⁵Hospital Universitario Virgen de las Nieves, Granada, ES, ¹⁶Universitario Regional Virgen de la

Victoria, Malaga, ES, ¹⁷Hospital Universitario de Alava, Alava, ES, ¹⁸Complejo Hospitalario Universitario de Orense, Orense, ES

- 12:00 - 12:00 **412P - Updated analysis of the National Registry of Nervous System Tumors in Spain (RETSINE). RETSINE: National Registry of Nervous System Tumors of the Spanish Research Group in Neuro-oncology (GEINO) and Spanish Infrequent and Orphan Tumors Group (GETHI)**
I. Ceballos Lenza¹, P. Perez Segura², M.A. Salgado³, S. Del Barco⁴, O. Gallego⁵, T. Quintanar⁶, M.A. Ivars⁷, I. Fernandez Perez⁸, F. García-Piñon⁹, R. De Las Penas Bataller⁹, ¹Hospital Universitario de Canarias, San Cristobal de la Laguna, ES, ²Hospital Clinico Universitario San Carlos, Madrid, ES, ³Hospital Universitario Ramon y Cajal, Madrid, ES, ⁴ICO Girona, Girona, ES, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁶Hospital General Universitario de Elche, Elche, ES, ⁷Hospital Universitario Morales Meseguer, Murcia, ES, ⁸CHUVI - Complejo Hospitalario Universitario de Vigo, Vigo, ES, ⁹Hospital Provincial Castellon, Castellón, ES
- 12:00 - 12:00 **413P - Development and validation of novel nomograms predicting survival of malignant ependymoma patients: A population-based study**
A. Abbas¹, M. Dibas², S. Ghozy³, ¹Minia University, Minia, EG, ²Sulaiman Al-Rajhi Colleges, Al Bukayriyah, SA, ³El Sheikh Zayed Specialized Hospital, Giza, EG
- 12:00 - 12:00 **414P - Characteristics, incidence, and survival of primary cerebral lymphoma: A population based study**
S. Ghozy¹, M. Dibas², A. Afifi³, M. A. Hashim⁴, A. Abbas⁵, M. M. Abdel-Daim⁶, ¹El Sheikh Zayed Specialized Hospital, Giza, EG, ²Sulaiman Al-Rajhi Colleges, Al Bukayriyah, SA, ³Ain Shams university Faculty of medicine, Cairo, EG, ⁴University of Kentucky, Lexington, US, ⁵Minia University, Minia, EG, ⁶Suez Canal University, Ismailia, EG
- 12:00 - 12:00 **415P - Trends in Incidence and Survival Analyses of Adult-onset Medulloblastoma**
F. Lin¹, Q. Zhuang¹, X. Lin¹, X. Zhang¹, Y. Huang², L. Tang², W. Junxin¹, J. Li³, ¹Fujian Cancer Hospital, Fuzhou, CN, ²Fujian Medical University Cancer Hospital, Fuzhou, CN, ³Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, CN
- 12:00 - 12:00 **416P - Meta of classical chemotherapy compared with high-dose chemotherapy combined with autologous stem cell transplantation in newly diagnosed medulloblastoma patients after radiotherapy**
M. Zhang, C. Liu, X. Xue, H. Zhou, W. Wang, L. Wang, The second hospital of hebei medical University, Shijiazhuang, CN
- 12:00 - 12:00 **417P - Effect of cumulative dose of maintenance temozolomide on overall survival in patients with high grade glioma tumors: a single institution analysis**
M. Nerone¹, F. Caspani², A.C. Tralongo³, A. Tuzi¹, G. Pinotti², ¹ASST - Sette Laghi, Varese, IT, ²University of Pavia-Ospedale del Circolo, Varese, IT, ³University of Insubria-Ospedale del Circolo, Varese, IT

12:00 - 12:00

418P - Markers of systemic inflammation correlate with survival prognosis in patients with newly diagnosed brain metastases

A. Starzer¹, C. Deischinger², A. Steindl¹, M. Mair¹, G. Widhalm¹, J. Frischer², B. Gatterbauer², C. Marosi³, K. Dieckmann³, M. Preusser³, A.S. Berghoff¹, ¹Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT, ²Medical University of Vienna, Vienna, AT, ³Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

12:00 - 12:00 **419P - Venous Thromboembolism and Intracranial Hemorrhage in Patients with High-grade Glioma**

C. Borges¹, J. Simões², J. Reis³, I. Costa³, C. Lemos⁴, P. Soares³, R. Silva³, B. Carvalho³, C. Fernandes³, A. Costa³, C. Caeiro³, C. Sarmiento³, ¹HSJ - Hospital de São João, EPE, Porto, PT, ²Hospital de S. João, Porto, PT, ³Centro Hospitalar Universitário de São João, EPE, Porto, PT, ⁴Polytechnic Institute of Viseu, Viseu, PT

12:00 - 12:00 **420P - Comprehensive Geriatric Assessment (CGA) can categorize elderly glioblastoma (GBM) patients into three groups predicting survival: a monoinstitutional study**

E. Bergo¹, M. Caccese¹, M. Padovan², L. Bellu², A. Brunello³, V. Zagonel¹, G. Lombardi², ¹Istituto Oncologico Veneto IRCCS, Padova, IT, ²Department of Oncology, Veneto Institute of Oncology, IOV - IRCCS, Padova, IT, ³Veneto Institute of Oncology IOV-IRCCS, Padova, IT

12:00 - 12:00 **421P - Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy**

G. Kramer-Marek¹, J. Maczynska¹, F. Raes¹, K. Malarz², C. Da Pieve¹, M. De Mezer³, M. Niedbala⁴, K. Harrington⁵, W. Kaspera⁴, ¹The Institute of Cancer Research (Sutton Site), Sutton, GB, ²University of Silesia, Chorzow, PL, ³Adam Mickiewicz University, Poznan, PL, ⁴Medical University of Silesia, Sosnowiec, PL, ⁵Institute of Cancer Research ICR, London, GB

12:00 - 12:00 **422P - Upregulation of sFRP3 circulating expression levels correlates survival outcomes in glioblastoma**

G. Bruixola¹, S. Dolz², E. Sanmartín², T. Fleitas¹, J. Font De Mora², G. Reynés², ¹Hospital Clinico Universitario de Valencia, Valencia, ES, ²Instituto de Investigación Sanitaria La Fe, Valencia, ES

12:00 - 12:00 **423P - Characterization and pre-clinical modeling of genetic aberrations in pediatric gliomas**

I. Moshe¹, O. Zohar¹, B. Ismer², L. Rousso-Noori¹, D. Jones², D. Friedmann- Morvinski¹, ¹Faculty of Life Sciences Tel-Aviv University, Tel Aviv, IL, ²DKFZ, Heidelberg, DE

12:00 - 12:00 **424P - Preclinical Study of Novel Tetracyclic Small Molecule, CC12, for Brain Cancer**

L. Fann, Taipei City Hospital - Renai Branch, Taipei City, TW

12:00 - 12:00 **425P - CHLOROBRAIN phase IB trial: The addition of chloroquine, an autophagy inhibitor, to concurrent radiation and temozolomide for newly diagnosed**

glioblastoma

I. Compter¹, D. Eekers¹, A. Hoeben², K. Rouschop¹, B. Reymen², L. Ackermans³, J. Beckervordersantforth³, N. Bauer³, M. Anten³, P. Wesseling⁴, A. Postma³, D. De Ruyscher², P. Lambin⁵, ¹Maastricht Clinic, Maastricht, NL, ²Maastricht University Medical Centre (MUMC)-MAASTRO clinic, Maastricht, NL, ³Maastricht University Medical Center (MUMC), Maastricht, NL, ⁴Vrije University Medical Centre (VUMC), Amsterdam, NL, ⁵The D-Lab: Decision Support for Precision Medicine, Maastricht, NL

12:00 - 12:00 **426P - A Phase II Clinical Trial Evaluating the Efficacy and Safety of Apatinib Combined with dose-dense Temozolomide in Recurrent Glioblastoma**

Y. Wang, R. Tao, Shandong Cancer Hospital and Institute, Jinan, CN

12:00 - 12:00 **427P - Phase 0 Trial of Ceritinib in Brain Metastases and Recurrent Glioblastoma**

S. Mehta¹, R. Fiorelli¹, J. Li², X. Bao², A. Derogatis¹, C. Pennington-Krygier¹, S. Kim², N. Sanai³, ¹Barrow Neurological Institute, Phoenix, US, ²Karmanos Cancer Institute, Detroit, US, ³Barrow Neurological Institute, Phoenix, US

12:00 - 12:00 **428P - Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients with mismatch repair deficiency (MMRd): an observational study**

M. Caccese¹, M. Simonelli², M. Fassan³, M. Padovan⁴, P. Persico², L. Bellu⁴, A. Dipasquale², M.P. Gardiman⁵, S. Indraccolo⁶, V. Zagonel⁴, G. Lombardi⁴, ¹Istituto Oncologico Veneto IRCCS, Padova, IT, ²Humanitas University, Humanitas Clinical and Research Hospital - IRCCS, Milan, IT, ³University of Padua, Padua, IT, ⁴Department of Oncology, Veneto Institute of Oncology, IOV - IRCCS, Padova, IT, ⁵University Hospital of Padua, Padua, IT, ⁶Veneto Institute of Oncology IOV - IRCCS, Padua, IT

12:00 - 12:00 **429P - Outcome of high-grade gliomas (HGGs) treated into immunotherapeutic early-phase clinical trials (ieCTs): a single-center experience**

M. Simonelli¹, P. Persico², A. Dipasquale², E. Lorenzi³, L. Giordano³, F. Pessina⁴, P. Navarra¹, M. Scorsetti⁴, L. Bello³, A. Santoro⁵, ¹Istituto Clinico Humanitas, Rozzano, IT, ²Humanitas University, Humanitas Clinical and Research Hospital - IRCCS, Milan, IT, ³Humanitas Clinical and Research Hospital, Rozzano, IT, ⁴Humanitas University, Humanitas Clinical and Research Hospital - IRCCS, Pieve Emanuele (Milan), IT, ⁵Humanitas University, Rozzano-Milan, IT

12:00 - 12:00 **430P - Tolerability of PCV in Low Grade Glioma: a Real World Experience**

R. Aslam¹, R. Keogh², M. Hennessy³, Z. Coyne³, B. Hennessy⁴, O. Breathnach³, L. Grogan⁵, P. Morris⁵, ¹St James's Hospital, Dublin, IE, ²Beaumont Hospital, DUBLIN, IE, ³Beaumont Hospital, Dublin, IE, ⁴Beaumont Hospital Cancer Centre, Dublin, IE, ⁵BEAUMONT HOSPITAL CANCER CENTRE, DUBLIN, IE

12:00 - 12:00 **431P - Molecular EGFR/PD-L1 profile of glioblastoma: Hints for therapeutic strategies**

W. Szopa¹, P. Czeka², K. Malarz³, A. Mrozek-Wilczkiewicz³, D. Plewka², M. Niedbała⁴, M. De Mezer⁵, G. Kramer-Marek⁶, W. Kaspera⁴, ¹Medical University of Silesia, Katowice, PL, ²Medical University of Silesia, Medyków, PL, ³University of Silesia, Chorzow, PL,

⁴Medical University of Silesia, Sosnowiec, PL, ⁵Adam Mickiewicz University, Poznan, PL,
⁶The Institute of Cancer Research (Sutton Site), Sutton, GB

- 12:00 - 12:00 **432P - Role of Intraoperative MRI (iMRI) in neurosurgery, potential imaging tool for maximizing gross total resection (GTR) rate of CNS tumours.**
S. Wadhwa¹, M. Malhotra², B. Walia³, B. Aggarwal³, ¹Tata Memorial Hospital, Mumbai, IN, ²Tata Memorial Hospital, Parel, IN, ³Max Superspeciality Hospital, New Delhi, IN
- 12:00 - 12:00 **433P - Tumor related impairments of neurocognitive functions in patients with brain metastases**
L. Wen, S. Li, M. Lai, J. Zhen, Guangdong Sanjiu 999 Brain Hospital, Guangzhou, CN
- 12:00 - 12:00 **434P - Is radiation therapy influencing Alzheimer's in Brain and Head and Neck Cancers?**
A. Saad¹, A. Alfaar², ¹Ain shams university hospital, Cairo, EG, ²Charité - Universitätsmedizin Berlin, Berlin, DE
- 12:00 - 12:00 **435P - Mature Treatment Results of 120 Cases of Acoustic Neuroma Treated with Cyberknife at a single institution.**
S. Malone¹, J. Zheng¹, J. Sinclair², F. Alkherayf², J. Malone¹, V. Nair¹, J. Szanto¹, J. Gratton¹, E. Gavioli¹, ¹The Ottawa Hospital Regional Cancer Centre, Ottawa, CA, ²The Ottawa Hospital, Ottawa, CA
- 12:00 - 12:00 **436TiP - A phase II/III trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma: the STELLAR study**
C. Brahm¹, M. Van Linde², M. Labots¹, M. Kouwenhoven³, E. Sanchez Aliaga³, R. Enting⁴, A. Appelman⁴, J. Nuver⁵, A. Walenkamp⁴, H. Verheul², ¹Amsterdam University Medical Centers, Amsterdam, NL, ²Vrije University Medical Centre (VUMC), Amsterdam, NL, ³Amsterdam University Medical Centres, Amsterdam, NL, ⁴University Hospital Groningen (UMCG), Groningen, NL, ⁵University Medical Center Groningen, Groningen, NL
- 12:00 - 12:00 **437TiP - CNS penetration and Preliminary Efficacy of Sacutinib and Govitecan in Breast Brain Metastasis and Glioblastoma: A Surgical Study**
A. Brenner¹, J. Floyd², P. Surapaneni², V. Kaklamani³, V. Madhusudanan-Kunnuparampil³, S. Tiziani⁴, ¹Institute for Drug Development Cancer Therapy Research Center, San Antonio, US, ²UT Health San Antonio, San Antonio, US, ³Mays Cancer Center at UTHSCSA, San Antonio, US, ⁴UT Austin, Austin, US
- 12:00 - 12:00 **NSCLC, early stage**
- 12:00 - 12:00 **1442P - Wedge resection with omission of lymph node dissection as an optional treatment strategy in octogenarians or older with early stage non-small cell lung cancers**
T. Mimae¹, Y. Miyata², Y. Tsutani³, K. Imai⁴, H. Ito⁵, H. Nakayama⁵, N. Ikeda⁴, M.

Okada³, ¹Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, JP, ²Hiroshima University, Hiroshima, JP, ³Hiroshima University, Hiroshima, JP, ⁴Tokyo Medical University, Tokyo, JP, ⁵Kanagawa Cancer Center, Yokohama, JP

- 12:00 - 12:00 **1443P - Characterization of lung tumorspheres reveals cancer stem-like cells potential targets and prognostic markers in non-small cell lung cancer**
A. Herreros Pomares¹, E. Jantus-Lewintre², S. Calabuig-Fariñas³, J.D. De-Maya-Girones⁴, R. Lucas⁵, A. Blasco⁶, R. Guijarro⁶, M. Martorell⁶, E. Escorihuela², S. Alonso⁷, M.D. Chiara⁸, E. Duréndez², C. Gandia⁴, R. Sirera⁹, R. Farràs⁴, C. Camps³, ¹FIHGUV - Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES, ²Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES, ³Fundación de Investigación Hospital General Universitario de Valencia, Molecular Oncology Laboratory-CIBERONC, Valencia, ES, ⁴Centro de Investigación Príncipe Felipe, Valencia, ES, ⁵Department of History of Science and Documentation, Valencia, ES, ⁶Hospital General Universitario de Valencia, Valencia, ES, ⁷Institut de Reserca Germans Trias i Pujol (PMPPC-IGTP), Badalona, ES, ⁸Hospital Central de Asturias, Oviedo, ES, ⁹Universidad Politécnica de Valencia, Valencia, ES
- 12:00 - 12:00 **1444P - Pulmonary tumor-draining vein exosomal lincRNA-p21 levels impacts non-small cell lung cancer prognosis**
J. Castellano¹, A. Navarro², L. Molins³, J. Canals², R. Marrades³, N. Viñolas⁴, J. Moises³, M. Casadevall², Y. Li², B. Han², D. Martinez⁴, J. Martin², A. Garisoain², C. Muñoz², J. Ramirez⁴, M. Monzo², ¹Universitat de Barcelona, Barcelona, ES, ²Univeristy of Barcelona, School of Medicine, Barcelona, ES, ³Hospital Clinic of Barcelona, Barcelona, ES, ⁴Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 12:00 - 12:00 **1446P - Immunological impact of surgery in NSCLC patients**
A. Yanagihara¹, H. Kagamu², H. Sakaguchi¹, H. Ishida², H. Nitanda¹, R. Taguchi¹, R. Yoshimura¹, O. Yamaguchi¹, K. Hashimoto¹, K. Kodaira¹, ¹Saitama Medical University International Medical Center, Hidaka, JP, ²Saitama Medical University Internatl Medical Centre, Saitama, JP
- 12:00 - 12:00 **1447P - The prognostic value of selected immunological panel in predicting the prognosis of early-stage resectable non-small cell lung cancer**
S. Zhao¹, Y. He¹, X. Zhang¹, C. Zhou², ¹Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN, ²Tongji University, Shanghai, CN
- 12:00 - 12:00 **1448P - Genomic Heterogeneity and Clonality Analysis of Multiple synchronous lung cancers (MSLCs)**
F. Zhou¹, C. Gu¹, J. Wang¹, Y. Zhang¹, P. Wang¹, C. Lv¹, D. Bi², L. Zhao¹, Y. Zhu¹, ¹THE FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIVERSITY, Dalian, CN, ²Genetronhealth Technologies Inc., Beijing, CN
- 12:00 - 12:00 **1449P - Analysis of immunosuppressive factors produced by tumorspheres in NSCLC. Prognostic value of Galectin-3 in adenocarcinoma**
S. Torres Martinez¹, A. Herreros Pomares², F. Zhang¹, S. Calabuig-Fariñas³, Á. González¹, R. Sirera⁴, A. Moreno-Manuel¹, M. Mosqueda⁵, E. Escorihuela¹, E.

Duréndez¹, S. Gallach⁵, J. Garde⁶, R. Guijarro⁶, E. Jantus-Lewintre¹, C. Camps³,
¹Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES,
²FIHGUV - Fundación de Investigación Hospital General Universitario de Valencia,
Valencia, ES, ³Fundación de Investigación Hospital General Universitario de Valencia,
Molecular Oncology Laboratory-CIBERONC, Valencia, ES, ⁴Universidad Politécnica de
Valencia, Valencia, ES, ⁵Fundación de Investigación Hospital General Universitario de
Valencia, Valencia, ES, ⁶Hospital General Universitario de Valencia, Valencia, ES

12:00 - 12:00

1450P - Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB-IIIA EGFR mutation positive non-small-cell lung cancer (NSCLC) after complete tumour resection

M. Tsuboi¹, R.S. Herbst², T. John³, C. Grohe⁴, M. Majem⁵, J. Goldman⁶, S.-W. Kim⁷, C.-J. Yu⁸, J. Miziara⁹, S. Novello¹⁰, D. Urban¹¹, C. Akewanlop¹², A. Öztürk¹³, B.V. Quang¹⁴, D. Kowalski¹⁵, D. Marmol¹⁶, M. Marotti¹⁷, G. Laus¹⁸, Y.-L. Wu¹⁹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Yale University School of Medicine, New Haven, US, ³Austin Health, Melbourne, AU, ⁴Evangelische Lungenklinik ELK Berlin Chest Hospital, Berlin, DE, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁶David Geffen School of Medicine at UCLA, Santa Monica, US, ⁷Asan Medical Center, Seoul, KR, ⁸National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TW, ⁹Barretos Cancer Hospital, Barretos, BR, ¹⁰Università Degli Studi Di Torino - Orbassano, Orbassano, IT, ¹¹Chaim Sheba Medical Center, Ramat Gan, IL, ¹²Siriraj Hospital, Mahidol University, Bangkok, TH, ¹³Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, TR, ¹⁴Hanoi Oncology Hospital, Hanoi, VN, ¹⁵Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, PL, ¹⁶AstraZeneca, Cambridge, GB, ¹⁷AZ GMed, Royston, GB, ¹⁸AstraZeneca UK, Melbourn, GB, ¹⁹Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN

12:00 - 12:00

1451P - EGFR mutation is not a prognostic factor in completely resected lymph node-negative pulmonary adenocarcinoma (LNNPA)

N. Leeladejkul¹, P. Chantranuwat², P. Sitthideatphaiboon², C. Teerapakpinyo², S. Shuangshoti², V. Benjacholamas², N. Pornpattanakorn², C. Vinayanuwattikun³, V. Sriuranpong², ¹King Chulalongkorn Memorial Hospital, Pathumwan, TH, ²King Chulalongkorn Memorial Hospital, Bangkok, TH, ³Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, TH

12:00 - 12:00

1452P - Prognostic significance of elements of the adaptive immunity in the microenvironment of early-stage non small cell lung cancer

A. Liakea¹, E. Tsagari², A. Spathis², A. Kampoli², J. Durán Moreno³, E. Kefalidi², E. Kapetanakis², K. Kostopanagiotou², A. Koumariou², I. Panayiotides², N. Kavantzias¹, P. Tomos², P. Foukas⁴, ¹National and Kapodistrian University of Athens School of Medicine, Athens, GR, ²Attikon University Hospital, Athens, GR, ³Agii Anargiri General Oncological Hospital of Kifissia, Kifissia, GR, ⁴Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

12:00 - 12:00

1453P - Association between Pre-existing Conditions and Major Genetic Drivers of NSCLC

Y. Jiang¹, Z. Su¹, C. Li², H. Liang², W. Liang², J. He³, ¹The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ²The First Affiliated Hospital of

Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou/China, Guangzhou, CN,
3The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN

- 12:00 - 12:00 **1454P - Combined immunoscore for prognostic stratification of early stage NSCLC patients**
G. Pasello¹, A. Boscolo², F. Fortarezza², F. Lunardi², L. Urso², S. Frega¹, G. Comacchio², L. Bonanno¹, V. Guarneri¹, F. Rea², F. Calabrese², P.F. Conte¹, ¹Istituto Oncologico Veneto IRCCS, Padova, IT, ²University of Padova, Padova, IT
- 12:00 - 12:00 **1455P - Radiation-induced lung injury and misdiagnosis rate after SBRT**
X. Fu, X. Zhu, X. Li, Shanghai Chest Hospital, Shanghai, CN
- 12:00 - 12:00 **1456P - Significance of the red blood cell distribution width in resected pathological stage I non-small cell lung cancer**
G. Toyokawa¹, F. Shoji², K. Yamazaki², M. Shimokawa³, S. Takeo², ¹National Kyushu Cancer Center, FUKUOKA, JP, ²National Hospital Organization, Kyushu Medical Center, FUKUOKA, JP, ³National Hospital Organization, National Kyushu Cancer Center, Fukuoka, JP
- 12:00 - 12:00 **NSCLC, locally advanced**
- 12:00 - 12:00 **1460P - Survival outcome of non-small cell lung cancer (NSCLC) patients: Comparing results between the database of the Comprehensive Cancer Center Zürich (CCCZ) and the Epidemiological Cancer Registry Zurich and Zug (KKR)**
R.A. Stahel¹, A. Curioni¹, S. Rohrman¹, U. Dafni², U. Sandner³, N. Andratschke¹, G. Dimopoulou², M. Guckenberger¹, M. Kohler⁴, K. Matthes¹, I. Schmitt-Opitz¹, W. Weder¹, ¹University Hospital Zürich, Zurich, CH, ²University of Athens, Athens, GR, ³University Hospital Zurich, Zürich, CH, ⁴University Hospital Zurich, Zurich, CH
- 12:00 - 12:00 **1461P - NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)**
M. Guirado¹, M. Majem², B. Massuti Sureda³, R. De Las Penas Bataller⁴, A.L. Ortega Granados⁵, M.D. Isla Casado⁶, M. Domine Gomez⁷, R. Marse Fabregat⁸, M.A. Sala⁹, A. Paredes Lario¹⁰, M.T. Moran Bueno¹¹, S. Vazquez Estevez¹², J. Coves Sarto¹³, J. Gonzalez-Larriba¹⁴, J.M. Sanchez Torres¹⁵, D. Vicente¹⁶, N. Farre Bernado², L. Fernandez-Fornos³, F. Varcарcel¹⁷, M. Provencio¹⁷, ¹Hospital General Universitario de Elche, Elche, ES, ²Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ³Hospital General Universitario de Alicante, Alicante, ES, ⁴Hospital Provincial Castellon, Castellón, ES, ⁵Complejo Hospitalario de Jaen Universidad de Jaen, Jaen, ES, ⁶Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, ⁷University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ⁸Hospital Universitario Son Espases, Palma de Mallorca, ES, ⁹Hospital de Basurto, Bilbao, ES, ¹⁰Hospital Universitario Donostia, San Sebastián, ES, ¹¹Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, ¹²Hospital Xeral Calde of Lugo, Lugo, ES, ¹³Hospital Son Llatzer, Palma de Mallorca, ES,

¹⁴Hospital Clinico Universitario San Carlos, Madrid, ES, ¹⁵Hospital Universitario de La Princesa, Madrid, ES, ¹⁶Hospital Universitario Virgen Macarena, Sevilla, ES, ¹⁷Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES

- 12:00 - 12:00 **1462P - A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators set by principle component analysis**
B. Cheng¹, X. Meng¹, J. Yu², ¹Shandong Cancer Hospital, Jinan, CN, ²Shandong Cancer Hospital and Institute, Jinan, CN
- 12:00 - 12:00 **1463P - Prognostic and predictive value of 18F-PET/CT on the response to treatment in locally advanced non-small cell lung cancer (NSCLC)**
C. Alfaro Autor¹, M. Soriano², R. Gómez Bravo³, M. Méndez García¹, A. Royuela³, A. Cruz-Bermudez³, J.M. García³, V. Calvo De Juan³, F. Franco³, M. Provencio¹, ¹Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES, ²Hosp. Puerta de Hierro, Madrid, ES, ³Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, ES
- 12:00 - 12:00 **1464P - Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non small cell lung cancer**
A. Işıkdoğan¹, N. Akdeniz², M. Küçüköner³, M. Kaplan³, Z. Uraççı³, O. Karhan³, Y. Sezgin³, E. Bilen³, S. Ebinç³, F. Teke³, Ş. Laçın⁴, O. Alan⁵, O. Ercelep⁶, F. Yumuk⁷, ¹Dicle University, Diyarbakır, TR, ²Dicle University Medical Faculty, Diyarbakır, TR, ³Dicle University Medical Faculty, Diyarbakır/türkiye, TR, ⁴Gazi Yasargil Education and Training Hospital, Diyarbakır, Turkey, Diyarbakır, TR, ⁵Marmara University Hospital, Istanbul, TR, ⁶Marmara University Hospital, İstanbul, TR, ⁷Marmara University School of medicine, İstanbul, TR
- 12:00 - 12:00 **1465P - Predicting the first failure pattern in patients with inoperable local advanced non-small cell lung cancer (LA-NSCLC) receiving definitive chemoradiotherapy: Establishment and internal validation of a nomogram based on the clinicopathological factors**
X. Zhu, X. Fu, Shanghai Chest Hospital, Shanghai, CN
- 12:00 - 12:00 **1466P - Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) pre and post chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC)**
V. Palomar Abril¹, T. Soria-Comes¹, M. Martin Ureste², I. Maestu Maiques¹, ¹Hospital Dr. Peset Aleixandre, Valencia, ES, ²Hospital Universitario Doctor Peset, Valencia, ES
- 12:00 - 12:00 **1467P - Meta-analysis evaluating neutropenia incidence with EGFR inhibitors and chemotherapy in patients with NSCLC**
B. Rapoport¹, R. Arani², M. Natek³, A. Krendyukov⁴, ¹The Medical Oncology Centre of Rosebank, Johannesburg, ZA, ²Sandoz Inc., Princeton, US, ³Sandoz, Holzkirchen, DE, ⁴Hexal AG, Holzkirchen, DE
- 12:00 - 12:00 **1468P - Effector CD4+ T-cell induction by thoracic radiotherapy for patients with NSCLC**
Y. Miura¹, K. Kodaira¹, M. Kenmochi², T. Yamashiro², O. Yamaguchi¹, A. Shiono¹, A. Mouri¹, F. Nishihara¹, S. Shinomiya¹, K. Hashimoto¹, Y. Murayama¹, K. Kobayashi³, K.

Kaira⁴, H. Kagamu³, ¹Saitama Medical University International Medical Center, Hidaka, JP, ²ImmuniT Research Inc., Land Work Aoyama, 2-7-26, Kita-Aoyama, Minatoku, Tokyo, JP, ³Saitama Medical University Internatl Medical Centre, Saitama, JP, ⁴Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, JP

- 12:00 - 12:00 **1469P - Circulating tumor DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met**
R. Heist¹, M. Motwani², L. Naumovski³, J. Wu², B. Bach², X. Lu², K. Kelly⁴,
¹Massachusetts General Hospital, Harvard Medical School, Boston, US, ²AbbVie Inc., North Chicago, US, ³Genentech, South San Francisco, US, ⁴Davis Comprehensive Cancer Center, Sacramento, US
- 12:00 - 12:00 **1470P - First Real Life Data on Durvalumab after definitive concomitant ChemoRadiotherapy (cCRT) in unresectable Stage (St) III Non-Small Cell Lung Cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) Temporary Authorization of Use (ATU)**
V. Avrillon¹, S. Bota Ouchlif², P. Merle³, E. Pichon⁴, A. Stancu⁵, C. Chouaid⁶, C. Sire⁷, H. Boudabous⁸, A. Lagrange⁹, M. Sabatini¹⁰, G. Eberst¹¹, P. Boisselier¹², A. Gourion¹³, A. Lion¹⁴, A. Lahouegue¹³, K. Belkhiria¹⁴, I. De La Porte¹³, M. Urbietta¹⁵, F. Mornex¹⁶, N. Girard¹⁷, ¹Centre Léon Bérard, Lyon, FR, ²Hop. Charles Nicolle, Rouen, FR, ³Centre Jean Perrin, Clermont-Ferrand, FR, ⁴CHRU Bretonneau, Tours, FR, ⁵Institut Sainte-Catherine, Avignon, FR, ⁶CH Intercommunal de Créteil, Créteil, FR, ⁷Centre Hospitalier de Bretagne Sud - Hôpital du Scorff, Lorient, FR, ⁸Hôpital Avicennes, Bobigny, FR, ⁹Centre Georges-François Leclerc, DIJON, FR, ¹⁰Centre Hospitalier de la Côte Basque, Bayonne, FR, ¹¹CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, ¹²ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ¹³AstraZeneca, Courbevoie, FR, ¹⁴Astrazeneca, Paris, FR, ¹⁵Astrazeneca France, Courbevoie, FR, ¹⁶Centre Hospitalier Lyon Sud, Pierre Bénite, FR, ¹⁷Institut Curie, Paris, FR
- 12:00 - 12:00 **1471P - EGFR Inhibitor Versus Chemotherapy as Adjuvant Treatment for Locally-advanced EGFR-mutant Non-Small Cell Lung Cancer**
P. Xie¹, W. Tang¹, X. Li¹, Y. Dong¹, X. Sun¹, J. Zhang², J. Yu¹, ¹Shandong Cancer Hospital and Institute, Jinan, CN, ²Linshu People's Hospital, Linyi, CN
- 12:00 - 12:00 **1472P - Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: interim analysis of a Phase IIIb, multi-national, open-label study**
F. De Marinis¹, K.K. Laktionov², A. Poltoratskiy³, I. Egorova⁴, M. Hochmair⁵, A. Passaro⁶, M.R. Migliorino⁷, G. Metro⁸, M. Gottfried⁹, D. Tsoi¹⁰, G. Ostoros¹⁰, S. Rizzato¹¹, G.Z. Mukhametshina¹², M. Schumacher¹³, S. Novello¹⁴, W. Tang¹⁵, L. Clementi¹⁶, A. Cseh¹⁷, D. Kowalski¹⁸, ¹Istituto Europeo di Oncologia, Milan, IT, ²Russian Academy of Medical Sciences, Moscow, RU, ³Petrov Research Institute of Oncology, St Petersburg, RU, ⁴Clinical Oncology Dispensary, St Petersburg, RU, ⁵Otto Wagner Hospital, Vienna, AT, ⁶European Institute of Oncology, Milan, IT, ⁷San Camillo-Forlanini Hospital, Rome, IT, ⁸Santa Maria della Misericordia Hospital, Perugia, IT, ⁹Tel Aviv University, Tel Aviv, IL, ¹⁰National Korányi Institute for Pulmonology, Budapest, HU, ¹¹Azienda Sanitaria-Universitaria Integrata, Udine, IT, ¹²Ministry of Health of the Republic of Tatarstan,

Kazan, RU, ¹³Ordensklinikum Elisabethinen, Linz, AT, ¹⁴University of Turin, Turin, IT, ¹⁵Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, US, ¹⁶Boehringer Ingelheim Italia S.p.A., Milan, IT, ¹⁷Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, AT, ¹⁸Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL

12:00 - 12:00 **1473P - First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis**

D.S. Tan¹, S. Geater², C.J. Yu³, C.M. Tsai⁴, T.C. Hsia⁵, J. Zhou⁶, J. Chen⁷, M.C. Lin⁸, P. Yu⁹, J. He¹⁰, W. Li¹¹, Y. Lu¹², V. Sriuranpong¹³, C.T. Yang¹⁴, P. Sen¹⁵, F. Branle¹⁶, M. Shi¹⁷, Y.L. Wu¹⁸, ¹National Cancer Centre Singapore, Singapore, SG, ²Prince of Songkla University, Hat Yai, Songkhla, TH, ³National Taiwan University Hospital, Taipei, TW, ⁴Taipei Veterans General Hospital, Taipei, TW, ⁵China Medical University Hospital, Taichung, TW, ⁶The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CN, ⁷Tianjin Medical University General Hospital, Tianjin, CN, ⁸Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TW, ⁹Sichuan Cancer Hospital, Chengdu, CN, ¹⁰The First Affiliated Hospital of Guangzhou Medical University, Guangdong Sheng, CN, ¹¹The First Hospital of Jilin University, Changchun, CN, ¹²West China Hospital, Chengdu, CN, ¹³King Chulalongkorn Memorial Hospital, Bangkok, TH, ¹⁴Chang Gung Memorial Hospital (Linko), Taoyuan, TW, ¹⁵Novartis Pharmaceutical Corporation, East Hanover, US, ¹⁶Novartis Pharma AG, Basel, CH, ¹⁷Novartis Pharmaceuticals Corp, East Hanover, US, ¹⁸Guangdong Provincial People's Hospital, Guangzhou, CN

12:00 - 12:00 **1474P - A combined analysis of two Phase IIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC**

F. De Marinis¹, H. Tu², K.K. Laktionov³, J. Feng⁴, A. Poltoratskiy⁵, J. Zhao⁶, I. Egorova⁷, E.-H. Tan⁸, M. Gottfried⁹, V. Lee¹⁰, D. Kowalski¹¹, C.-T. Yang¹², B.J. Srinivasa¹³, A. Passaro¹⁴, L. Clementi¹⁵, W. Tang¹⁶, D.C.-L. Huang¹⁷, A. Cseh¹⁸, C. Zhou¹⁹, Y.-L. Wu², ¹Istituto Europeo di Oncologia, Milan, IT, ²Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, ³Russian Academy of Medical Sciences, Moscow, RU, ⁴Nanjing, Jiangsu, CN, ⁵Petrov Research Institute of Oncology, St Petersburg, RU, ⁶Department 1 of Thoracic Oncology Medicine, Peking University Cancer Hospital & Institute, Beijing, CN, ⁷Clinical Oncology Dispensary, St Petersburg, RU, ⁸National Cancer Centre, Singapore, SG, ⁹Tel Aviv University, Tel Aviv, IL, ¹⁰The University of Hong Kong, Hong Kong, CN, ¹¹Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, ¹²Chang Gung Memorial Hospital, Guishan, Taoyuan, TW, ¹³HCG Hospital, Bangalore, IN, ¹⁴European Institute of Oncology, Milan, IT, ¹⁵Boehringer Ingelheim Italia S.p.A., Milan, IT, ¹⁶Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, US, ¹⁷Boehringer Ingelheim Taiwan Limited, Taipei, TW, ¹⁸Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, AT, ¹⁹Tongji University, Shanghai, CN

12:00 - 12:00 **1475P - Impact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients**

X. Wang¹, Y. Liu¹, Z. Meng¹, Y. Wu², S. Wang², G. Jin³, Y. Qin³, F. Wang⁴, J. Wang⁴, L. Wang⁵, J. Bai⁵, X. Shi⁶, Z. Wen⁷, X. Jia⁷, X. Fu⁸, X. Wang⁸, Q. Qin⁹, Y. Gao⁹, W. Guo¹⁰, S. Lu¹¹, ¹Baotou Cancer Hospital, Baotou, CN, ²Baotou Central Hospital, Baotou, CN, ³Inner Mongolia Autonomous Region People's Hospital, Hohhot, CN, ⁴The Affiliated Third Hospital of Baotou Medical College, Baotou, CN, ⁵BerryOncology Corporation, Beijing,

CN, ⁶Bayan Nur Hospital, Bayan Nur, CN, ⁷Inner Mongolia Cancer Hospital, Hohhot, CN, ⁸Affiliated Hospital of Inner Mongolia Medical University, Hohhot, CN, ⁹People's Hospital of Da La Te Banner, Inner Mongolia Autonomous Region, Da La Te Banner, CN, ¹⁰Inner Mongolia Baogang Hospital, Baotou, CN, ¹¹Shanghai Chest Hospital, Shanghai, CN

12:00 - 12:00 **1476P - Definition of an afatinib trough concentration threshold in the treatment of NSCLC**

S. Bouchet¹, C. Favary², C. Frohn³, C. Maritaz⁴, R. Lassalle², M. Molimard², ¹CHU de Bordeaux Pellegrin, Bordeaux, FR, ²University of Bordeaux, Bordeaux, FR, ³Boehringer Ingelheim Pharma- Germany, Ingelheim am Rhein, DE, ⁴Boehringer Ingelheim France, Paris, FR

12:00 - 12:00 **1477TiP - A Phase Ib Trial of Neoadjuvant Chemoradiotherapy and Durvalumab(MEDI4736) for Potentially Resectable stage III Non-Small Cell Lung Cancer (NSCLC)**

B.C. Ahn¹, S. Lee², J.W. Seo³, C.Y. Lee³, J.G. Lee³, S.Y. Park³, D.J. Kim³, C.G. Lee⁴, J. Cho⁴, H.I. Yoon⁴, B.Y. Shim⁵, D.G. Cho⁶, S.W. Kim⁶, H.S. Park⁶, Y.J. Chun², M.H. Hong², H.R. Kim⁴, B.C. Cho⁷, ¹Severance Hospital, Seoul, KR, ²Yonsei Cancer Center Yonsei University, Seoul, KR, ³Yonsei University College of Medicine, Seoul, KR, ⁴Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁵The Catholic University of Korea-St. Vincent's Hospital, Suwon-Si Gyeonggi-do, KR, ⁶St. Vincent Hospital, College of Medicine, The Catholic University of Korea, Suwon, KR, ⁷Yonsei University, Seoul, KR

12:00 - 12:00 **SCLC**

12:00 - 12:00 **1743P - Low expression of Notch1 and combined Notch1/HES1 are associated with adverse survival factor for limited stage small cell lung cancer**

J. Lee¹, S.A. Hong², H.W. Hwang², S.-H. Hong¹, ¹Seoul St. Mary's Hospital, of the Catholic University, Seoul, KR, ²Chung-Ang University, Seoul, KR

12:00 - 12:00 **1744P - Mutational profiling of tumor tissue and sequential plasma illustrates emergent clones during treatment in late stage small cell lung cancer (SCLC)**

S. Yaung¹, C. Woestmann², L. Xi³, C. Ju⁴, B. Hinzmann², M. Thomas⁵, F. Lasitschka⁶, M. Meister⁵, M. Schneider⁵, F. Herth⁵, T. Muley⁵, B. Wehnl⁷, J. Palma⁸, X. Ma³, ¹F. Hoffmann LaRoche, Ltd, Pleasanton, US, ²Roche Sequencing Solutions, Inc., Potsdam, DE, ³Roche Sequencing Solutions, Inc., Pleasanton, US, ⁴Roche Molecular Systems, Inc., Pleasanton, US, ⁵Thoraxklinik Heidelberg, Heidelberg, DE, ⁶Thoraxklinik at Heidelberg University Hospital, Heidelberg, DE, ⁷Roche Diagnostics GmbH, Penzberg, DE, ⁸Roche Molecular Systems Inc - USA, Pleasanton, US

12:00 - 12:00 **1745P - Association between serum HGF levels and neutrophil counts in small cell lung cancer and their impact on survival**

L. Moliner¹, M. Hardy-Werbin¹, X. Duran², O. Arpi², Á. Taus¹, P. Rocha¹, R. Del Rey², M.A. Galindo-Campos², A. Rovira³, J. Albanell³, E. Arriola¹, ¹Hospital del Mar, Barcelona,

ES, ²IMIM (Hospital del Mar Medical Research Institute), Barcelona, ES, ³University Hospital del Mar, Barcelona, ES

12:00 - 12:00

1746P - Prognostic role of RLF/MYCL1 and circPVT1 in SCLC.

C.T. Storlazzi¹, V. Longo², S. Tommasi², D. Tolomeo¹, D. Traversa¹, G. Visci¹, A. Lonoce¹, G. Macchia¹, A. Labbate¹, P. D'Addabbo¹, P. Pizzutilo², L. Muscarella³, D. Petriella², R. Lacalamita², F.A. Zito², M.A. Botticella², A.M. Catino², D. Galetta², ¹University of Bari "Aldo Moro", Bari, Italy, Bari, IT, ²Istituto Tumori Giovanni Paolo II, Bari, IT, ³IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, IT

12:00 - 12:00

1747P - High-biologically effective dose radiotherapy improve the survival of small cell lung cancer patients with brain metastases: a propensity-matching analysis

Q. Zhuang¹, F. Lin¹, X. Lin¹, X. Zhang¹, Y. Huang², L. Tang², J. Li³, J. Wu², ¹Fujian Cancer Hospital, Fuzhou, CN, ²Fujian Medical University Cancer Hospital, Fuzhou, CN, ³Xiamen Cancer Hospital, Xiamen, CN

12:00 - 12:00

1748P - Phase 1 open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer

E. Calvo¹, A. Spira², H. Prenen³, Y. Ohe⁴, S. Rottey⁵, A. Gazzah⁶, M. Millward⁷, V. Moreno⁸, A. Italiano⁹, T. Alanko¹⁰, K. Yoh¹¹, P. Cassier¹², T. Seto¹³, D. Afar¹⁴, S. Englert¹⁵, P. Komarnitsky¹⁶, S. Lambert¹⁴, A. Parikh¹⁴, G. Vosganian¹⁴, B. Gao¹⁷, ¹Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, ²Virginia Cancer Specialist, Fairfax, US, ³University Hospital Antwerp, Edegem, BE, ⁴National Cancer Center Hospital, Tokyo, JP, ⁵Heymans Institute of Pharmacology, Ghent, BE, ⁶Gustave Roussy, Université Paris-Saclay, Villejuif, FR, ⁷Linear Clinical Research, Perth, AU, ⁸University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ⁹Institute Bergonié, Bordeaux, FR, ¹⁰Docrates Cancer Center, Helsinki, FI, ¹¹National Cancer Center Hospital East, Kashiwa, JP, ¹²Léon Bérard Cancer Center, Lyon, FR, ¹³National Kyushu Cancer Center, Fukuoka, JP, ¹⁴AbbVie Inc., Redwood City, US, ¹⁵AbbVie Inc., Ludwigshafen, DE, ¹⁶AbbVie Inc., North Chicago, US, ¹⁷Blacktown and Westmead Hospitals, Sydney, AU

12:00 - 12:00

1749P - Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer

C.M. Della Corte¹, L. Ajpacaja², R. Cardnell², C. Gay², Q. Wang², L. Shen², K. Ramkumar², A. Stewart², Y.-H. Fan², C. Adelman³, J. Travers³, J. Wang², J. Heymach⁴, L. Byers², ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²MD Anderson Cancer Center, Houston, US, ³AstraZeneca, Cambridge, GB, ⁴MD Anderson, texas, US

12:00 - 12:00

1750P - Multi-level proteomics identifies FABP5 as a primary chemoresistance mediator in extensive-stage small cell lung cancer

Y. Chen¹, Y. Jin², M. Chen², ¹Zhejiang cancer hospital, Hangzhou, CN, ²Zhe Jiang Cancer Hospital, Hangzhou, CN

12:00 - 12:00

1751TiP - CLEPSIDRA trial: a pilot, biomarker-guided study to assess safety, tolerability, dose finding and efficacy of iadademstat in combination with

platinum-etoposide in patients with relapsed, extensive-stage small cell lung cancer

A. Navarro Mendivil¹, S. Gutierrez², T. Maes², R. Bullock², M. Ropacki², C. Buesa², ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Oryzon Genomics SA, Cornellà de Llobregat, ES

12:00 - 12:00 **1752TiP - Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer (SCLC): The PAVE study, a Hellenic Cooperative Oncology Group Study**

H. Linardou¹, G. Mountzios², A. Psyrri³, A. Christopoulou⁴, K. Sakellariou⁵, H. Vaja³, A. Grivas⁶, T. Makatsoris⁷, G. Aravantinos⁸, E. Samantas⁸, ¹Metropolitan Hospital, Athens, GR, ²University of Athens School of Medicine Clinical Therapeutics, Athens, GR, ³Attikon University Hospital, Athens, GR, ⁴Hellenic Cooperative Oncology Group (HeCOG), Athens, GR, ⁵Royal Free Hospital School of Medicine, London, GB, ⁶Metaxa Cancer Hospital of Piraeus, Athens, GR, ⁷University Hospital Patras, Patras, GR, ⁸General Oncological Hospital of Kifisia "Agioli Anargyroi", Kifisia, GR

12:00 - 12:00 **Thoracic malignancies, other**

12:00 - 12:00 **1845P - Tobacco use in lung cancer (LC) patients (p) in Spain**

E. Carcereny Costa¹, M. Guirado², C.J. Camps Herrero³, J. Bosch Barrera⁴, M.-R. García-Campelo⁵, A.L. Ortega Granados⁶, J. Gonzalez-Larriba⁷, N. De Dios Alvarez⁸, M. Domine Gomez⁹, B. Massuti Sureda¹⁰, M.A. Sala¹¹, R. Bernabé¹², J. Oramas Rodriguez¹³, E. Del Barco Morillo¹⁴, A. Padilla¹⁵, D. Aguiar Bujanda¹⁶, S. Cerezo Gonzalez¹⁷, R. Lopez Castro¹⁸, D. Rodriguez Abreu¹⁶, M. Provencio¹⁹, ¹Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, ²Hospital General Universitario de Elche, Elche, ES, ³Hospital General Universitario Valencia, Valencia, ES, ⁴ICO - Institut Català d'Oncologia Girona (Hospital Universitari Josep Trueta Hospital Universitari Josep Trueta), Girona, ES, ⁵Complejo Hospitalario Universitario A Coruna (CHUAC), La Coruña, ES, ⁶Complejo Hospitalario de Jaen Universidad de Jaen, Jaen, ES, ⁷Hospital Clinico Universitario San Carlos, Madrid, ES, ⁸Hospital Universitario Alvaro Cunqueiro, Vigo, ES, ⁹University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ¹⁰Hospital General Universitario de Alicante, Alicante, ES, ¹¹Hospital de Basurto, Bilbao, ES, ¹²Hospital Universitario Virgen del Rocío, Sevilla, ES, ¹³Hospital Universitario de Canarias, San Cristobal de la Laguna, ES, ¹⁴Instituto de Investigación Biomédica de Salamanca, Salamanca, ES, ¹⁵Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, ES, ¹⁶Hospital Universitario Insular de Gran Canaria, Las Palmas, ES, ¹⁷Hospital General Mancha Centro, Alcazar de San Juan, ES, ¹⁸University Clinical Hospital of Valladolid, Valladolid, ES, ¹⁹Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES

12:00 - 12:00 **1846P - Biomarker testing of lung cancer in Spain**

D. Rodriguez Abreu¹, M. Guirado², C.J. Camps Herrero³, J. Bosch Barrera⁴, R. Bernabé⁵, J. Casal⁶, M.-R. García-Campelo⁷, J. Gonzalez-Larriba⁸, B. Massuti Sureda⁹, A.L. Ortega Granados¹⁰, M. Domine Gomez¹¹, M.A. Sala¹², A. Padilla¹³, E. Del Barco Morillo¹⁴, J. Oramas Rodriguez¹⁵, R. Blanco Guerrero¹⁶, D. Aguiar Bujanda¹, R. López Castro¹⁷, E. Carcereny Costa¹⁸, M. Provencio¹⁹, ¹Hospital Universitario Insular de Gran Canaria, Las

Palmas, ES, ²Hospital General Universitario de Elche, Elche, ES, ³Hospital General Universitario Valencia, Valencia, ES, ⁴ICO - Institut Català d'Oncologia Girona (Hospital Universitari Josep Trueta Hospital Universitari Josep Trueta), Girona, ES, ⁵Hospital Universitario Virgen del Rocío, Sevilla, ES, ⁶Hospital Universitario Alvaro Cunqueiro, Vigo, ES, ⁷Complejo Hospitalario Universitario A Coruna (CHUAC), La Coruña, ES, ⁸Hospital Clinico Universitario San Carlos, Madrid, ES, ⁹Hospital General Universitario de Alicante, Alicante, ES, ¹⁰Complejo Hospitalario de Jaen Universidad de Jaen, Jaen, ES, ¹¹University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ¹²Hospital de Basurto, Bilbao, ES, ¹³Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, ES, ¹⁴IBSAL - Instituto de Investigación Biomédica de Salamanca, Salamanca, ES, ¹⁵Hospital Universitario de Canarias, San Cristobal de la Laguna, ES, ¹⁶Hospital Terrassa-Consorci Sanitari de Terrassa, Terrassa, ES, ¹⁷Hospital Clínico Universitario de Valladolid, Valladolid, ES, ¹⁸Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, ¹⁹Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES

12:00 - 12:00 **1847P - Mendelian Randomization Study of Alzheimer's Disease and Lung Cancer**

H. Zhou¹, J. Shen², Y. Zhang¹, J. Liu², Y. Huang¹, L. Zhang¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Sun Yat-sen University, Guangzhou, CN

12:00 - 12:00 **1848P - Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer**

R. Lopez Castro¹, P. Lianes², E. Nogueron Martinez³, P. Diz Tain⁴, J. Calzas⁵, O.J. Juan Vidal⁶, M. Sereno Moyano⁷, M.A. Muñoz⁸, M. Guillot Morales⁹, L. Capdevila Riera¹⁰, J.A. Campillo Fuentes¹¹, J. Valdivia-Bautista¹², M. Cobo Dols¹³, A. Paredes Lario¹⁴, X. Mielgo Rubio¹⁵, M. Majem Tarruella¹⁶, M. Martínez¹⁷, J.M. Sanchez Torres¹⁸, B. Rubio-Viqueira¹⁹, M. Provencio²⁰, ¹University Clinical Hospital of Valladolid, Valladolid, ES, ²Hospital de Mataro - Consorcio Sanitario del Maresme, Mataro, ES, ³Complejo Hospitalario Universitario de Albacete, Albacete, ES, ⁴Complejo Asistencial Universitario de León, Leon, ES, ⁵Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, ES, ⁶Hospital Universitari i Politècnic La Fe, Valencia, ES, ⁷Hospital Infanta Sofia, Madrid, ES, ⁸IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, ⁹Hospital Universitario Son Espases, Palma de Mallorca, ES, ¹⁰Hospitals Santa Tecla, Tarragona, ES, ¹¹Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar, ES, ¹²Hospital Universitario Virgen de las Nieves, Granada, ES, ¹³Hospital Regional Universitario de Málaga, Málaga, ES, ¹⁴Hospital Universitario Donostia, San Sebastián, ES, ¹⁵Hospital Universitario Fundación Alcorcón, Alcorcon, ES, ¹⁶Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹⁷Hospital Universitario de Araba, Vitoria-Gasteiz, ES, ¹⁸Hospital Universitario de La Princesa, Madrid, ES, ¹⁹Hospital Universitario Quirón Madrid, Pozuelo de Alarcon, ES, ²⁰Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES

12:00 - 12:00 **1849P - Pleural effusion TGF-beta is highly diagnostic and prognostic in malignant pleural mesothelioma**

P. Stockhammer¹, T. Ploenes², M. Schuler³, S. Langer⁴, C. Aigner⁵, B. Hegedus⁵, ¹Medizinische Universitaet Wien, Vienna, AT, ²Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, Freiburg im

Breisgau, DE, ³Westdeutsches Tumorzentrum Essen, Essen, DE, ⁴Fujirebio Germany GmbH, Hannover, DE, ⁵University Medicine Essen - Ruhrlandklinik, Essen, DE

- 12:00 - 12:00 **1850P - Immune microenvironment modulation by p14/ARF in Malignant Pleural Mesothelioma**
G. Pasello¹, L. Urso², A. Boscolo², F. Pezzuto², M. Silic-Benussi¹, S. Vuljian², S. Frega¹, L. Bonanno¹, M. Schiavon², F. Rea², V. Ciminale¹, P.F. Conte¹, F. Calabrese², ¹Istituto Oncologico Veneto IRCCS, Padova, IT, ²University of Padova, Padova, IT
- 12:00 - 12:00 **1851P - Tumor Treating Fields plus chemotherapy for first-line malignant pleural mesothelioma (MPM): radiological responses in the STELLAR trial**
F. Grosso¹, G.L. Ceresoli², ¹Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT, ²Humanitas Gavazzeni, Bergamo, IT
- 12:00 - 12:00 **1852P - Effects of Tumor Treating Fields (TTFields; 150 kHz) and Cisplatin or Pemetrexed Combination Therapy on Mesothelioma cells In Vitro and In Vivo**
M. Munster¹, K. Gotlib¹, R. Schneiderman¹, Y. Porat¹, T. Voloshin¹, S. Davidi¹, A. Shteingauz¹, N. Kaynan¹, E. Zeevi¹, M. Giladi¹, E. Kirson¹, U. Weinberg¹, A. Kinzel², Y. Palti¹, ¹Novocure, Haifa, IL, ²Novocure GmbH, Munich, DE
- 12:00 - 12:00 **1853P - Real world use of systemic therapy in elderly patients with malignant pleural mesothelioma (MPM)**
S. Cedres¹, J. Assaf², P. Iranzo³, A. Callejo⁴, N. Pardo⁵, A. Navarro⁴, A. Martinez-Marti⁴, G. Rodriguez⁴, V. Monton⁴, J. Gonzalo⁶, J. Miquel⁶, A. Pedrola⁶, R. Dienstmann¹, E. Felip¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron University Hospital, BARCELONA, ES, ³Vall d'Hebron Institute of Oncology and University Hospital, barcelona, ES, ⁴Vall d'Hebron Institute of Oncology and University Hospital, Barcelona, ES, ⁵Vall d'Hebron University Hospital, Barcelona, ES, ⁶Vall d'Hebron Institute of Oncology, Barcelona, ES
- 12:00 - 12:00 **1854P - Pemetrexed/Cisplatin versus Gemcitabine/Cisplatin as first-line treatment for Egyptian patients with malignant pleural mesothelioma**
M. Alorabi¹, H. El Wakil¹, M. El-Mahdy², D. Salem², A. Essa², A. Gaballah³, ¹Ain Shams University Faculty of Medicine, Cairo, EG, ²Ain Shams Faculty of Medicine, Cairo, EG, ³Ain Shams university Faculty of medicine, Cairo, EG
- 12:00 - 12:00 **1855P - Accuracy of pathologic evaluation for thymic epithelial tumors in an Italian reference Centre**
G. Galli¹, A. Fabbri¹, R. Ferrara¹, A. Prelaj¹, C. Proto¹, D. Signorelli¹, A. De Toma¹, F. Pagani¹, N. Zilembo¹, M. Ganzinelli¹, G. Pruneri², F.G. De Braud¹, M. Garassino¹, G. Lo Russo¹, ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ²Istituto Nazionale Tumori, Milano, IT
- 12:00 - 12:00 **1856P - Comprehensive genomic profiling of thymic carcinoma in Chinese population**
B. Han, W. Fang, W. Zhang, S. Wang, L.Z. Zhang, B. Zhang, M. Hu, Y. Zhao, J. Qian, Shanghai Chest Hospital, Shanghai, CN

- 12:00 - 12:00 **1857P - The analysis of treatment sequences and clinical outcomes of thymic carcinoma**
A. Motoko¹, Y. Goto², Y. Shinno², T. Yoshida², S. Kanda², H. Horinouchi², N. Yamamoto², Y. Ohe², ¹National Cancer Center Hospital, Tokyo, Japan, Tokyo, JP, ²National Cancer Center Hospital, Tokyo, JP
- 12:00 - 12:00 **1858P - Transcriptomic Difference of Thymoma and Thymic Carcinoma**
N. Liang¹, L. Liu¹, H. Liu¹, W. Wang¹, Y. Bi¹, Z. Liang¹, N. Li², R. Lin², T. Wang², S. Li², ¹Peking Union Medical College Hospital, Beijing, CN, ²Hangzhou Repugene Technology Inc., Beijing, CN
- 12:00 - 12:00 **1859P - A Phase II Trial of Preoperative Chemoradiotherapy and Pembrolizumab for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)**
S. Lee¹, B.C. Ahn², S.Y. Park³, D.J. Kim³, C.G. Lee⁴, J. Cho⁴, J.H. Kim⁵, H.R. Kim⁵, Y.-H. Kim⁵, S.R. Park⁵, Y.J. Chun¹, M.H. Hong¹, H.R. Kim⁴, B. Cho⁶, ¹Yonsei Cancer Center Yonsei University, Seoul, KR, ²Severance Hospital, Seoul, KR, ³Yonsei University College of Medicine, Seoul, KR, ⁴Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁵Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁶Yonsei Cancer Center, Seoul, KR
- 12:00 - 12:00 **1860P - The study of tumor associated exosomes in crosstalk between esophageal carcinoma and lymphatic endothelial cells**
W. Mao¹, A. Zhao², ¹Zhejiang cancer hospital, Hangzhou, CN, ²Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, CN
- 12:00 - 12:00 **1861P - Up-regulation of IBSP expression predicts poor prognosis of Esophageal Squamous Cell Carcinoma patients**
M. Wang, Zhengzhou University, Zhengzhou, CN
- 12:00 - 12:00 **NSCLC, metastatic**
- 12:00 - 12:00 **1491P - PD-L1 expression in primary tumour vs metastatic samples in the Phase 3 MYSTIC study in first-line metastatic (m) NSCLC**
N. Reinmuth¹, A.-M. Boothman², B.C. Cho³, K.H. Lee⁴, A. Luft⁵, M.-J. Ahn⁶, M. Scott⁷, J. Whiteley⁸, J. Walker⁹, V. Karwe¹⁰, P. Mukhopadhyay¹⁰, P. Thiyagarajah⁸, U. Scheuring², N. Rizvi¹¹, ¹Asklepios Clinics Munich-Gauting, Gauting, DE, ²AstraZeneca UK, Melbourn, GB, ³Yonsei University, Seoul, KR, ⁴Chungbuk National University Hospital, Cheongju, KR, ⁵Leningrad Regional Clinical Hospital, St. Petersburg, RU, ⁶Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ⁷Astrazeneca, Cambridge, GB, ⁸AstraZeneca, Cambridge, GB, ⁹AstraZeneca Netherlands, Zoetermeer, NL, ¹⁰AstraZeneca, Gaithersburg, US, ¹¹Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US
- 12:00 - 12:00 **1492P - Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: post hoc analyses from the phase 3 JAVELIN Lung**

200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)

F. Barlesi¹, M. Özgüroğlu², J. Vansteenkiste³, D. Spigel⁴, J. Yang⁵, M. Bajars⁶, M. Ruisi⁷, J. Manitz⁶, K. Park⁸, ¹Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, ²Istanbul University, Istanbul, TR, ³University Hospital KU Leuven, Leuven, BE, ⁴Sarah Canon Research Institute, Nashville, US, ⁵National Taiwan University Hospital, Taipei, Taiwan, Taipei, TW, ⁶EMD Serono, Inc, Billerica, US, ⁷EMD Serono, Billerica, US, ⁸Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR

12:00 - 12:00

1493P - Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): post hoc analyses from JAVELIN Solid Tumor

B. Hrinchenko¹, D. Spigel², N. Iannotti³, H. Safran⁴, M. Taylor⁵, J. Bennouna⁶, S. Goel⁷, J. Leach⁸, D. Wong⁹, K. Kelly¹⁰, C. Verschraegen¹¹, M. Bajars¹², J. Manitz¹², M. Ruisi¹³, J. Gulley¹⁴, ¹Michigan State University, Michigan, US, ²Sarah Canon Research Institute, Nashville, US, ³Hematology/Oncology Associates of the Treasure Coast, Port St Lucie, US, ⁴Lifespan Cancer Institute, Providence, US, ⁵OHSU Knight Cancer Institute - Northwest Portland, Portland, US, ⁶CHU du Nantes - Hôtel-Dieu, Nantes, FR, ⁷Montefiore Medical Center(East campus) - Medical Park at Eastchester Albert Einstein Cancer Center, Bronx, US, ⁸Virginia Piper Cancer Institute, Minneapolis, US, ⁹UCLA - School of Medicine, Los Angeles, US, ¹⁰Davis Comprehensive Cancer Center, Sacramento, US, ¹¹University of Vermont College of Medicine, Burlington, US, ¹²EMD Serono, Inc, Billerica, US, ¹³EMD Serono, Billerica, US, ¹⁴National Cancer Institute, Bethesda, US

12:00 - 12:00

1494P - Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study

F. Barlesi¹, A. Dixmier², D. Debieuvre³, C. Raspaud⁴, J.B. Auliac⁵, N. Benoit⁶, P. Bombaron⁷, D. Moro-Sibilot⁸, C. Audigier-Valette⁹, B. Asselain¹⁰, P. Lamoureux¹¹, F.-E. Cotté¹², V. Allan¹³, M. Daumont¹², N. Ozan¹², C. Calvet¹², M. Perol¹⁴, ¹Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, ²C.H.R. Orleans - La Source, Orleans, FR, ³Hopital Emile Muller, Mulhouse, FR, ⁴Clinique Pasteur, Toulouse, FR, ⁵CH François Quesnay, Mantes La Jolie, FR, ⁶Clinique de l'Europe, Amiens, FR, ⁷Hôpital privé Jean Mermoz, Lyon, FR, ⁸CHU Grenoble, La Tronche, FR, ⁹Hôpital Sainte Musse, Toulon, FR, ¹⁰Institut Curie, Paris, FR, ¹¹Bristol-Myers Squibb, Vandoeuvre les Nancy, FR, ¹²Bristol-Myers Squibb, Rueil-Malmaison, FR, ¹³Bristol Myers Squibb, Uxbridge, GB, ¹⁴Centre Léon Bérard, Lyon, FR

12:00 - 12:00

1495P - Outcomes with Concomitant Antibiotic Use in a Large Real World Cohort of Patients with NSCLC treated with Immune Checkpoint Inhibitors

P. Patil, X. Jia, B. Hobbs, N. Pennell, Cleveland Clinic, Cleveland, US

12:00 - 12:00

1496P - IO-Synthesise NSCLC: A pooled analysis of real-world survival outcomes for non-small cell lung cancer patients treated with nivolumab in France and Germany

A. Dixmier¹, B. Asselain², F. Barlesi³, D. Debieuvre⁴, C. Audigier Valette⁵, A. Gröschel⁶, S. Gütz⁷, R. Liersch⁸, D. Moro-Sibilot⁹, H. Müller-Huesmann¹⁰, M. Perol¹¹, C. Raspaud¹², C. Schulte¹³, H. Schulz¹⁴, C. Schumann¹⁵, V. Allan¹⁶, C. Calvet¹⁷, K. Rothnie¹⁸, V.

Wünsch¹⁹, M. Sebastian²⁰, ¹C.H.R. Orleans - La Source, Orleans, FR, ²Institut Curie, Paris, FR, ³Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, ⁴Hopital Emile Muller, Mulhouse, FR, ⁵Hospital Sainte Musse, Toulon, FR, ⁶Clemenshospital, Münster, DE, ⁷Ev. Diakonissenkrankenhaus gGmbH, Leipzig, DE, ⁸Hämatologische-Onkologische Gemeinschaftspraxis, Münster, DE, ⁹CHU Grenoble, La Tronche, FR, ¹⁰Brüderkrankenhaus St. Josef, Paderborn, DE, ¹¹Centre Léon Bérard, Lyon, FR, ¹²Clinique Pasteur, Toulouse, FR, ¹³Gemeinschaftspraxis für Hämatologie und Onkologie, Dortmund, DE, ¹⁴Praxis Internistischer Onkologie und Hämatologie,, Frechen, DE, ¹⁵Klinikum Kempten-Oberallgaeu gGmbH, Kempten, DE, ¹⁶Bristol Myers Squibb, Uxbridge, GB, ¹⁷Bristol-Myers Squibb, Paris, FR, ¹⁸Bristol Myers Squibb, London, GB, ¹⁹Bristol-Myers Squibb, Munich, DE, ²⁰Universitätsklinikum Frankfurt,, Frankfurt, DE

12:00 - 12:00

1497P - Second-line (2L) real-world treatment (tx) patterns and outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) treated with first line (1L) immuno-oncology (IO) monotherapy (mono tx)

D. Talbot¹, S. Fish², T. Jin Ong², E. Flick², D. Waterhouse³, ¹Oxford University Hospitals Trust Churchill Hospital, Oxford, GB, ²Celgene Corporation, Summit, US, ³Oncology Hematology Care, Cincinnati, US

12:00 - 12:00

1498P - Real-world effectiveness of nivolumab monotherapy after prior systemic therapy in advanced non-small cell lung cancer (NSCLC) in the United States

D. Stenehjem¹, S. Lubinga², K. Gupte-Singh², Y. Zhang², K. Le Trong², J. Penrod², ¹University of Minnesota, Duluth, US, ²Bristol-Myers Squibb, Princeton, US

12:00 - 12:00

1499P - Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population

N. Frost¹, J. Kollmeier², D. Pultermann³, A. Tessmer⁴, A. Schmittel⁵, B. Schmidt⁶, C. Grah⁷, M. De Wit⁸, D. Misch², T. Blum⁹, N. Suttorp³, C. Grohe⁴, ¹Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ²Helios Klinikum Emil von Behring, Berlin, DE, ³Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, DE, ⁴Evangelische Lungenklinik ELK Berlin Chest Hospital, Berlin, DE, ⁵Schwerpunkt Hamatologie und Onkologie - Berlin Facharzt für Innere Medizin, Berlin, DE, ⁶DRK Kliniken Berlin, Berlin, DE, ⁷Gemeinschaftskrankenhaus Havelhöhe, Berlin, DE, ⁸Vivantes Klinikum Neukölln, Berlin, DE, ⁹HELIOS Klinikum Emil von Behring Berlin-Zehlendor, Berlin, DE

12:00 - 12:00

1500P - Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)

F. Griesinger¹, W. Eberhardt², H.-R. Bruch³, J. Rauh⁴, E. Von Der Heyde⁵, N. Marschner⁶, M. Jänicke⁷, A. Fleitz⁶, L. Spring⁷, J. Sahlmann⁸, A. Karatas⁹, A. Hipper⁹, W. Weichert¹⁰, P. Sadjadian¹¹, M. Metzenmacher², W. Gleiber¹², M. Sebastian¹³, M. Thomas¹⁴, ¹Pius Hospital, Oldenburg, DE, ²University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ³Facharzt fuer Innere Medizin Haematologie und Onkologie, Berlin, DE, ⁴Gemeinschaftspraxis Innere Medizin, Witten, DE, ⁵Onkologische Schwerpunktpraxis, Hannover, DE, ⁶iOMEDICO AG, Freiburg, DE, ⁷iOMEDICO, Freiburg, DE, ⁸iOMEDICO AG, Freiburg im Breisgau, DE, ⁹AIO Studien gGmbH, Berlin, DE, ¹⁰Technische Universität München-Institute of Pathology, Munich, DE, ¹¹Johannes Weseling klinikum,

Minden, DE, ¹²University Hospital Frankfurt, Frankfurt, DE, ¹³Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, ¹⁴Thoraxklinik Heidelberg, Heidelberg, DE

- 12:00 - 12:00 **1501P - Impact of second-line (2L) immune checkpoint inhibitors (ICIs) on the treatment (Tx) of advanced non-small cell lung cancer (NSCLC) in a UK centre: a REAL-Oncology analysis from the I-O Optimise initiative**
M. Snee¹, S. Cheeseman², M. Thompson², R. Bowman², L. Lacoïn³, W. Sopwith², C. Chaib⁴, M. Daumont⁵, J. Penrod⁶, J. O'Donnell⁶, G. Hall², ¹St. James's University Hospital Leeds, Leeds, GB, ²Leeds Teaching Hospitals NHS Trust, Leeds, GB, ³Bristol-Myers Squibb, Ladeuze, BE, ⁴BMS - Bristol-Myers Squibb Spain, Madrid, ES, ⁵Bristol-Myers Squibb, Rueil-Malmaison, FR, ⁶Bristol-Myers Squibb, Princeton, US
- 12:00 - 12:00 **1502P - First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort**
K. Amrane¹, M. Geier², R. Corre³, G. Lèveiller⁴, G. Florence⁵, R. Lamy⁶, J.L. Bizec⁷, E. Goarant⁸, G. Robinet¹, S. Ulrike¹, G. Quere¹, C. Bernier⁹, R. Descourt¹, ¹C.H.U. Brest - Hôpital Morvan, Brest, FR, ²CHRU Morvan Brest, Brest, FR, ³CHU de Pontchaillou, Rennes, FR, ⁴CH Yves le Foll, Saint Briec, FR, ⁵CH Pays de Morlaix, Morlaix, FR, ⁶CH Sud Bretagne, Lorient, FR, ⁷Centre d'Oncologie Saint-Yves, Vannes, FR, ⁸Hospital of Saint-Malo, Saint Malo, FR, ⁹CH Rene Pleven, Dinan, FR
- 12:00 - 12:00 **1503P - Interstitial lung disease induced by immune-checkpoint inhibitors correlates with prognosis of advanced non-small-cell lung cancer patients**
T. Sugano¹, M. Seike², Y. Saito², N. Takano², K. Hisakane², S. Takahashi², T. Tanaka², T. Kashiwada², S. Nakamichi³, S. Takeuchi², A. Miyanaga², Y. Minegishi², R. Noro⁴, K. Kubota², A. Gemma², ¹Nippon Medical School Hospita, Tokyo, JP, ²Nippon Medical School, Tokyo, JP, ³Nippon Medical School Main Hospital, Tokyo, JP, ⁴Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JP
- 12:00 - 12:00 **1504P - Phase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE)**
Y. Kawashima¹, O. Yamaguchi², T. Kozuki³, N. Furuya⁴, F. Kurimoto⁵, T. Okuno⁶, T. Yamada⁷, K. Komiyama⁸, R. Ko⁹, Y. Nagai¹⁰, N. Ishikawa¹¹, T. Harada¹², K. Watanabe¹³, M. Seike¹⁴, K. Yoshimura¹⁵, K. Kobayashi¹⁶, H. Kagamu¹⁶, ¹Sendai Kousei Hospital, Sendai, JP, ²Saitama Medical University International Medical Center, Hidaka, JP, ³NHO Shikoku Cancer Center, Matsuyama, JP, ⁴St. Marianna University School of Medicine, Kawasaki, JP, ⁵Saitama Cancer Center, Saitama, JP, ⁶Shimane University Faculty of Medicine, Izumo, JP, ⁷Kyoto Prefectural University of Medicine, Kyoto, JP, ⁸Saitama Medical University Hospital, Saitama, JP, ⁹Juntendo University Graduate School of Medicine, Tokyo, JP, ¹⁰Jichi Medical University, Tochigi, JP, ¹¹Hiroshima Prefectural Hospital, Hiroshima, JP, ¹²JCHO Hokkaido Hospital, Sapporo, JP, ¹³Miyagi Cancer Center, Natori, JP, ¹⁴Nippon Medical School, Tokyo, JP, ¹⁵Kanazawa University, Kanazawa, JP, ¹⁶Saitama Medical University Internatl Medical Centre, Saitama, JP
- 12:00 - 12:00 **1505P - Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma**

**patients (pts) following treatment with immune checkpoint inhibitors (ICIs):
Updated results of the ongoing non-interventional study (NIS) VARGADO
(NCT02392455)**

C. Grohe¹, W. Gleiber², S. Haas³, S. Krüger⁴, M. Schulze⁵, J. Atz⁶, R. Kaiser⁶,
¹Evangelische Lungenklinik ELK Berlin Chest Hospital, Berlin, DE, ²University Hospital Frankfurt, Frankfurt, DE, ³FEK - Friedrich-Ebert-Krankenhaus, Neumünster, DE, ⁴Florence Nightingale Hospital, Duesseldorf, DE, ⁵Ambulante Onkologie Ostsachsen, Zittau, DE, ⁶Boehringer Ingelheim Pharma- Germany, Ingelheim am Rhein, DE

12:00 - 12:00 **1506P - Upfront atezolizumab chemoimmunotherapy-associated Immune-related adverse events in patients with advanced non-small cell lung cancer**

F. Mogollon-Duffo¹, K. Thein¹, A.M. Tun², S. Swarup¹, N. Jahan¹, N. Adhikari¹, T. Win Htut³, T.W. Naing⁴, P. Hlaing¹, Y. Mon Myat⁵, P.T. Naing⁶, F. Hardwicke¹, L. Tijani¹, N. D'Cunha¹, S. Awasthi¹, ¹Texas Tech University, Lubbock, US, ²Brooklyn Hospital Center, Brooklynn, US, ³Colchester Hospital, Colchester, GB, ⁴Icahn School of Medicine at Mount Sinai, New York City, US, ⁵University College Dublin, Ireland, Dublin, IE, ⁶New York-Presbyterian Hospital Queens, Queens, US

12:00 - 12:00 **1507P - Nivolumab-induced and radiation recall pneumonitis in patients with non-small cell lung cancer: a multicenter real world analysis of 669 patients**

N. Mamesaya¹, S. Narita², T. Naito³, H. Udagawa³, K. Goto³, T. Miyawaki¹, K. Nakashima¹, H. Kenmotsu¹, T. Shimokawaji⁴, T. Kato⁴, T. Hakozaiki⁵, Y. Okuma⁵, Y. Nakayama⁴, H. Watanabe², M. Kusumoto², Y. Ohe², H. Horinouchi², ¹Shizuoka Cancer Center, Shizuoka, JP, ²National Cancer Center Hospital, Tokyo, JP, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴Kanagawa Cancer Center, Yokohama, JP, ⁵Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP

12:00 - 12:00 **1508P - Retrospective analysis of immunotherapy prognostic scores in advanced NSCLC at Nottingham University Hospitals (UK)**

C. Lopez Escola, O. Sheikh, H. Franks, K. Mengoli, S. Karim, S. Khan, A. Arora, I. Hennig, Nottingham University Hospitals NHS Trust-City Hospital Campus, Nottingham, GB

12:00 - 12:00 **1509P - Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC)**

X. Mielgo Rubio¹, A. Gomez Rueda², M. Antoñanzas³, S. Falagan⁴, J.A. Núñez⁵, A.M. Sánchez Peña⁶, I. Gómez-Barreda⁷, E. Martinez Moreno⁸, S. Cerezo Gonzalez⁹, L. Cabezón Gutiérrez¹⁰, J.M. Sanchez Torres¹¹, B. Jimenez Munarriz¹², R. Cervera¹³, C. Pangua Mendez¹⁴, A. Calles Blanco¹⁵, A. Lopez Martin¹⁶, R. López Castro¹⁷, M. Sotelo Lezama³, E. Pérez Fernández¹, P. Cruz¹⁸, ¹Hospital Universitario Fundación Alcorcón, Alcorcon, ES, ²Hospital Universitario Ramon y Cajal, Madrid, ES, ³Hospital Clinico Universitario San Carlos, Madrid, ES, ⁴Hospital Universitario Infanta Sofía, Madrid, ES, ⁵Hospital Universitario 12 de Octubre, Madrid, ES, ⁶Hospital Universitario Getafe, Getafe, ES, ⁷Hospital Universitario Guadalajara, Guadalajara, ES, ⁸Hospital Nuestra Señora del Prado, Toledo, ES, ⁹Hospital General Mancha Centro, Alcazar de San Juan, ES, ¹⁰Hospital Universitario de Torrejón, Madrid, ES, ¹¹Hospital Universitario de La Princesa, Madrid, ES, ¹²Centro Integral Oncologico Clara Campal, Madrid, ES, ¹³Hospital Universitario del Henares, Coslada, ES, ¹⁴Hospital Universitario Infanta Leonor, Madrid, ES, ¹⁵Hospital General Universitario Gregorio Marañón, Madrid, ES, ¹⁶Hospital Universitario Severo Ochoa, Leganes, ES, ¹⁷Hospital Clínico Universitario de

Valladolid, Valladolid, ES, ¹⁸Hospital Universitario La Paz, Madrid, ES

- 12:00 - 12:00 **1510P - Delayed Onset Immune Related Adverse Effects (IRAEs) of Pembrolizumab in Non-Small Cell Lung Cancer**
H. Yan¹, Y. Jiang², M. Luong³, N. Naban⁴, C. Kane², J. Conibear², D. Papadatos-Pastos⁵, T. Ahmad⁶, D. Chao¹, U. Asghar⁷, G. Anand¹, ¹North Middlesex University Hospital NHS Trust, London, GB, ²St. Bartholomew's Hospital, London, GB, ³University College Hospital, PG, GB, ⁴The Princess Alexandra Hospital, QX, GB, ⁵Guy's and St. Thomas' Hospital NHS Trust, London, GB, ⁶University College Hospital, London, GB, ⁷University College London Hospital, London, GB
- 12:00 - 12:00 **1511P - Clinical implication of multiplex IHC and serologic biomarkers on Hyperprogression in NSCLC patients receiving Immune checkpoint blockers in real world.**
J. Kim¹, S. Kim², J.H. Kang¹, S. Chun¹, S.-Y. Kim³, ¹Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, KR, ²St.Mary hospital collage of medicine the catholic university of korea, Seoul, KR, ³University of Ulsan College of Medicine, Asan Medical Center, Seoul, KR
- 12:00 - 12:00 **1512P - Local ablative treatment and treatment beyond progression for oligo-progression in stage IV non-small cell lung cancer after tumor response to anti-PD1 treatment**
F. Guisier¹, R. Gervais², K. El Hussein³, J.-B. Assié⁴, M. Geier⁵, C. Decroisette⁶, R. Corre⁷, R. Descourt⁸, C. Chouaid⁴, M. Salaun³, L. Thiberville¹, ¹Hop. Charles Nicolle, Rouen, FR, ²Centre Francois Baclesse, Caen, FR, ³Hop. Charles Nicolle, Rouen University Hospital, Rouen, FR, ⁴CH Intercommunal de Créteil, Créteil, FR, ⁵CHRU Morvan Brest, Brest, FR, ⁶Le Centre Hospitalier Annecy Genevois, Metz-Tessy, FR, ⁷CHU de Pontchaillou, Rennes, FR, ⁸C.H.U. Brest - Hôpital Morvan, Brest, FR
- 12:00 - 12:00 **1513P - Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)**
F. Mogollon-Duffo¹, A. Sultan¹, S. Swarup¹, N. Jahan¹, A.M. Tun², T. Win Htut³, T.W. Naing⁴, P.T. Naing⁵, Y. Mon Myat⁶, F. Hardwicke¹, S. Rehman¹, L. Tijani¹, N. D'Cunha¹, K. Thein¹, ¹Texas Tech University, Lubbock, US, ²Brooklyn Hospital Center, Brooklyn, US, ³Colchester Hospital, Colchester, GB, ⁴Icahn School of Medicine at Mount Sinai, New York City, US, ⁵New York-Presbyterian Hospital Queens, Queens, US, ⁶University College Dublin, Ireland, Dublin, IE
- 12:00 - 12:00 **1514P - Prognostic Impact of Metastatic Sites for Pembrolizumab Efficacy as First-line therapy in Patients with PD-L1 tumor proportion score (TPS) ≥ 50% Advanced Non-Small Cell Lung Cancer: A Retrospective Multicenter Study**
H. Kawachi¹, M. Tamiya², A. Tamiya³, S. Ishii³, K. Hirano⁴, H. Matsumoto⁵, T. Yokoyama⁶, T. Ishida⁶, K. Ryota⁷, D. Fujimoto¹, K. Hosoya¹, H. Suzuki⁸, T. Hirashima², M. Kanazu⁹, N. Sawa⁹, J. Uchida¹⁰, M. Morita¹¹, T. Makio¹², S. Hara¹², T. Kumagai¹³, ¹Kobe City Medical Center General Hospital, Kobe, JP, ²Osaka Prefectural Habikino Hospital, Habikino, JP, ³Kinki-chuo Chest Medical Center, Sakai, JP, ⁴Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, JP, ⁵Hyogo Prefectural Amagasaki Hospital,

Amagasaki, JP, ⁶Kurashiki Central Hospital, Kurashiki, JP, ⁷Himeji Medical Center, Himeji, JP, ⁸Osaka Habikino Medical Center, Habikino, JP, ⁹Toneyama National Hospital, Toyonaka, JP, ¹⁰Osaka General Medical Center, Osaka, JP, ¹¹Kobe City Medical Center West Hospital, Kobe, JP, ¹²Itami City Hospital, Itami, JP, ¹³Osaka International Cancer Institute, Osaka, JP

- 12:00 - 12:00 **1515P - Impact of visceral fat area as independent predictive factor in patients with advanced non-small cell lung cancer treated with nivolumab**
Y. Sato, D. Fujimoto, K. Hosoya, K. Nagata, A. Nakagawa, R. Tachikawa, K. Tomii, Kobe City Medical Center General Hospital, Kobe, JP
- 12:00 - 12:00 **1516P - Effect and safety of immune checkpoint inhibitors for brain metastases from non-small cell lung cancer**
T. Iuchi, H. Ashinuma, Y. Yoshida, S. Mizuno, J. Hosono, T. Setoguchi, Y. Hasegawa, T. Sakaida, M. Shingyoji, Chiba Cancer Center Hospital, Chiba, JP
- 12:00 - 12:00 **1517P - Impact of Radiotherapy on efficacy of anti-programmed death 1 (PD-1) antibodies in metastatic NSCLC**
E. Samuel¹, Y.J. So², A. Hiong³, A. Balasubramanian⁴, S. Parakh², ¹Epworth Healthcare, Melbourne, AU, ²Monash Health, Melbourne, AU, ³Alfred Health, Melbourne, AU, ⁴Royal Melbourne Hospital, Melbourne, AU
- 12:00 - 12:00 **1518P - Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real World Data from a European Cohort with focus on subgroups of interest**
G. Mountzios¹, D. Signorelli², J. Rey Cobo³, M. Banini⁴, P. Economopoulou⁵, G. Lo Russo², P. Baxevanos⁶, F. Roila⁴, A. De Toma², G. Banna⁷, A. Christopoulou⁸, B. Jimenez⁹, H. Linardou¹⁰, A. Calles¹¹, D. Galetta¹², A. Addeo¹³, A. Camerini¹⁴, P. Kosmidis¹⁵, M. Garassino², G. Metro¹⁶, ¹University of Athens School of Medicine Clinical Therapeutics, Athens, GR, ²Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ³Geneva University Hospital, Geneva, CH, ⁴Ospedale Santa Maria della Misericordia, Perugia, IT, ⁵Attikon University Hospital, Athens, GR, ⁶Agios Savvas Regional Cancer Hospital, Athens, GR, ⁷Ospedale Cannizzaro, Catania, IT, ⁸Hellenic Cooperative Oncology Group (HeCOG), Athens, GR, ⁹Hospital HM Sanchinarro, Madrid, ES, ¹⁰Metropolitan Hospital, Athens, GR, ¹¹Hospital General Universitario Gregorio Maranon, Madrid, ES, ¹²IRCCS Istituto Oncologico "Giovanni Paolo II", Bari, IT, ¹³Hopitaux Universitaires de Geneve - HUG, Geneva, CH, ¹⁴Ospedale "Versilia", Lido di Camaiore, IT, ¹⁵Hygeia Hospital, Marousi, GR, ¹⁶Santa Maria della Misericordia Hospital, Perugia, IT
- 12:00 - 12:00 **1519P - Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)**
M. Sebastian¹, W. Eberhardt², C. Losem³, C. Bernhardt⁴, C. Maintz⁵, N. Marschner⁶, M. Jänicke⁷, A. Fleitz⁶, L. Spring⁷, J. Sahlmann⁸, A. Karatas⁹, A. Hipper⁹, W. Weichert¹⁰, P. Hoffknecht¹¹, C. Grah¹², A. Rittmeyer¹³, F. Griesinger¹⁴, M. Thomas¹⁵, ¹Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, ²University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ³Facharztzentrum Neuss, Berlin, DE, ⁴Gemeinschaftspraxis für, Dortmund, DE, ⁵MVZ

Duisburg-West (Medizinisches Versorgungszentrum), Duisburg, DE, ⁶iOMEDICO AG, Freiburg, DE, ⁷iOMEDICO, Freiburg, DE, ⁸iOMEDICO AG, Freiburg im Breisgau, DE, ⁹AIO Studien gGmbH, Berlin, DE, ¹⁰Technische Universität München-Institute of Pathology, Munich, DE, ¹¹Niels Stensen Kliniken, Franziskus Hospital Harderberg, Georgsmarienhütte, DE, ¹²Gemeinschaftskrankenhaus Havelhöhe, Berlin, DE, ¹³LKI Lungenfachklinik Immenhausen, Immenhausen, DE, ¹⁴Pius Hospital, Oldenburg, DE, ¹⁵Thoraxklinik Heidelberg, Heidelberg, DE

12:00 - 12:00 **1520P - The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)**

M. Tamiya¹, A. Tamiya², K. Hosoya³, Y. Taniguchi², T. Yokoyama⁴, Y. Fukuda⁴, K. Hirano⁵, H. Matsumoto⁶, R. Kominami⁷, H. Suzuki⁸, T. Hirashima¹, J. Uchida⁹, M. Morita¹⁰, M. Kanazu¹¹, N. Sawa¹¹, S. Hara¹², Y. Kinoshita¹², T. Kumagai¹³, D. Fujimoto³, ¹Osaka Prefectural Habikino Hospital, Habikino, JP, ²Kinki-chuo Chest Medical Center, Sakai, JP, ³Kobe City Medical Center General Hospital, Kobe, JP, ⁴Kurashiki Central Hospital, Kurashiki, JP, ⁵Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, JP, ⁶Hyogo Prefectural Amagasaki Hospital, Amagasaki, JP, ⁷Himeji Medical Center, Himeji, JP, ⁸Osaka Habikino Medical Center, Habikino, JP, ⁹Osaka General Medical Center, Osaka, JP, ¹⁰Kobe City Medical Center West Hospital, Kobe, JP, ¹¹Toneyama National Hospital, Toyonaka, JP, ¹²Itami City Hospital, Itami, JP, ¹³Osaka International Cancer Institute, Osaka, JP

12:00 - 12:00 **1521P - Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS)**

G. Metro¹, M. Provencio², D.-W. Kim³, B. Cho⁴, K. Park⁵, Y. Pan⁶, Y. Shi⁷, R. Migliorino⁸, M. Tiseo⁹, J. Yu¹⁰, Q. Zhou¹¹, A. Santo¹², A. Ardizzoni¹³, Y. Hu¹⁴, Y.-L. Wu¹⁵, S.-W. Kim¹⁶, M. Miranda¹⁷, A. Fernandes¹⁸, F. De Marinis¹⁹, ¹Santa Maria della Misericordia Hospital, Perugia, IT, ²Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES, ³Seoul National University Hospital, Seoul, KR, ⁴Yonsei Cancer Center, Seoul, KR, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁶1st Hospital Affiliated to Anhui Medical University, Hefei, CN, ⁷Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, CN, ⁸San Camillo-Forlanini Hospitals, Rome, IT, ⁹AOU di Parma, Parma, IT, ¹⁰Shandong Cancer Hospital and Institute, Jinan, CN, ¹¹Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, ¹²University of Verona Hospital Trust, Verona, IT, ¹³Policlinico S. Orsola-Malpighi, Bologna, IT, ¹⁴Hubei Cancer Hospital, Wuhan, CN, ¹⁵Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, ¹⁶Asan Medical Center, Seoul, KR, ¹⁷AstraZeneca, Cambridge, GB, ¹⁸AstraZeneca US, Gaithersburg, US, ¹⁹Istituto Europeo di Oncologia, Milan, IT

12:00 - 12:00 **1522P - Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)**

R. Shah¹, N. Girard², S. Nagar³, F. Griesinger⁴, J. Roeper⁵, K. Davis³, N. Bakker⁶, B. Thakrar⁶, A. Taylor⁶, J. Feliciano⁷, ¹Kent Oncology Centre, Maidstone, GB, ²Institut

Curie, Paris, FR, ³RTI Health Solutions, Research Triangle Park, Durham, US, ⁴Pius Hospital, Oldenburg, DE, ⁵Pius Hospital Oldenburg, University of Oldenburg, Berlin, DE, ⁶AstraZeneca, Cambridge, GB, ⁷Johns Hopkins Bayview Medical Center, Baltimore, US

- 12:00 - 12:00 **1523P - Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumor DNA - The 1st report of a biomarker study in Japanese patients from RELAY: Global Ph3 study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations**
K. Nishio¹, K. Sakai¹, T. Seto², M. Nishio³, M. Reck⁴, E. Garon⁵, C. Visseren-Grul⁶, R. Hozak⁷, S. Wijayawardana⁷, S. Enatsu⁸, K. Nakagawa⁹, ¹Kindai University Faculty of Medicine, Osaka-sayama, JP, ²National Kyushu Cancer Center, Fukuoka, JP, ³Cancer Institute Hospital of JFCR, Tokyo, JP, ⁴Krankenhaus Grosshansdorf, Grosshansdorf, DE, ⁵UCLA Hematology/Oncology Santa Monica, Santa Monica, US, ⁶Eli Lilly Netherlands, Utrecht, NL, ⁷Eli Lilly and Company, Indianapolis, US, ⁸Eli Lilly Japan K.K., Tokyo, JP, ⁹Kindai University School of Medicine, Osaka, JP
- 12:00 - 12:00 **1524P - Apatinib combined with EGFR - TKI in treating advanced non-small cell lung cancer with EGFR - TKI resistance**
R. Tian¹, W. Guo², Y. Guo³, X. Zhang³, H. Zhu², F. Shen³, J. Xu³, X. Zhang³, R. Wang³, X. Ren³, J. Li³, X. Song², ¹Second Hospital of Shanxi Medical University, Taiyuan, CN, ²Shanxi Cancer Hospital, Taiyuan, CN, ³Shanxi Tumor Hospital, Taiyuan, CN
- 12:00 - 12:00 **1525P - Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404**
T. Ninomiya¹, N. Nogami², T. Kozuki², D. Harada², T. Kubo¹, K. Ohashi³, S. Kuyama⁴, K. Kudo⁴, A. Bessho⁵, N. Fujimoto⁶, K. Aoe⁷, T. Shibayama⁸, D. Minami⁸, K. Sugimoto⁹, N. Ochi¹⁰, N. Takigawa¹⁰, K. Hotta¹, K. Kiura¹, ¹Okayama University Hospital, Okayama, JP, ²Shikoku Cancer Center, Matsuyama, JP, ³Okayama, Okayama, JP, ⁴NHO Iwakuni Medical Center, Iwakuni, JP, ⁵Japanese Red Cross Okayama Hospital, Okayama, JP, ⁶Okayama Rosai Hospital, Okayama, JP, ⁷Yamaguchi-Ube Medical Center, Ube, JP, ⁸Okayama Medical Center, Okayama, JP, ⁹Japanese Red Cross Kobe Hospital, Kobe, JP, ¹⁰Kawasaki Medical School, Okayama, JP
- 12:00 - 12:00 **1526P - Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: insights of the MATCH-R study**
D. Enrico¹, L. Lacroix¹, E. Rouleau², J.-Y. Scoazec¹, Y. Loriot¹, L. Tselikas¹, C. Jovelet¹, D. Planchard¹, A. Gazzah³, L. Mezquita⁴, M. Ngo¹, S. Michiels⁴, C. Massard², F. Facchinetti¹, J. Chen¹, J.-C. Soria¹, F. André², G. Vassal¹, L. Friboulet¹, B. Besse¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³Gustave Roussy, Université Paris-Saclay, Villejuif, FR, ⁴Gustave Roussy, Villejuif, FR
- 12:00 - 12:00 **1527P - Sequential treatment with afatinib followed by 3rd generation EGFR-TKI - subgroup analysis of the GIDEON trial: a prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany**
W. Brückl¹, M. Reck², E. Laack³, B. Hermes⁴, J. Rawluk⁵, R. Huber⁶, C. Hoffmann⁷, A. Schueler⁸, ¹Klinikum Nuernberg Nord, Nürnberg, DE, ²Krankenhaus Grosshansdorf,

Grosshansdorf, DE, ³Hämatologie Hamburg, Hamburg, DE, ⁴Universitätsklinikum Tübingen Medizinische Universitätsklinik, Tübingen, DE, ⁵Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, Freiburg im Breisgau, DE, ⁶LMU Klinikum der Universität München, Munich, DE, ⁷Boehringer Ingelheim - Germany, Ingelheim am Rhein, DE, ⁸Boehringer Ingelheim Pharma- Germany, Ingelheim am Rhein, DE

- 12:00 - 12:00 **1528P - Effectiveness of sequencing TKIs in patients with EGFR mutation-positive Non-small-Cell Lung Cancer (NSCLC): A French National medico administrative claim database analysis**
N. Girard¹, S. Bouee², D. Moro-Sibilot³, C. Emery², K. Le Lay⁴, L. Luciani⁴, C. Maritaz⁵, C. Chouaid⁶, ¹Institut Curie, Paris, FR, ²CEMKA, Bourg-la-Reine, FR, ³CHU Grenoble, La Tronche, FR, ⁴Boehringer Ingelheim, Paris, FR, ⁵Boehringer Ingelheim France, Paris, FR, ⁶CH Intercommunal de Créteil, Créteil, FR
- 12:00 - 12:00 **1529P - Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)**
T.M. Kim¹, C.-Y. Ock¹, M. Kim², S.H. Kim³, B. Keam¹, Y.J. Kim³, D.-W. Kim¹, J.-S. Lee³, D.S. Heo¹, ¹Seoul National University Hospital, Seoul, KR, ²National University College of Medicine, Seoul, KR, ³Seoul National University Bundang Hospital, Seongnam, KR
- 12:00 - 12:00 **1530P - Different stories for different EGFR exon 19 deletion variants**
C. Zhao¹, T. Jiang¹, J. Li¹, Y. Wang¹, M. Qiao¹, X. Chen¹, C. Su¹, C. Zhou², X. Li³, ¹Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN, ²Tongji University, Shanghai, CN, ³Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, CN
- 12:00 - 12:00 **1531P - Safety and activity of aflutinib in patients with advanced EGFR T790M mutation non-small cell lung cancer who progressed after EGFR-TKI therapy**
Y.-K. Shi¹, S. Zhang², X. Hu³, J. Feng⁴, Z. Ma⁵, J. Zhou⁶, N. Yang⁷, L. Wu⁷, W. Liao⁸, X. Han³, Z. Wang⁹, X. Zhang¹⁰, S. Qin¹¹, K. Ying¹², J. Feng¹³, J. Fang⁹, L. Liu¹⁴, Y. Jiang¹⁵, ¹Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing, CN, ²Beijing Chest Hospital, Capital Medical University, Beijing, CN, ³National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ⁴Jiangsu Cancer Hospital, Nanjing, China, Beijing, CN, ⁵The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, CN, ⁶The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China, Hangzhou, CN, ⁷Hunan Cancer Hospital, Changsha, CN, ⁸Nanfang Hospital, Nanfang Medical University, Guangzhou, China, Guangzhou, CN, ⁹Peking University Cancer Hospital, Beijing, China, Beijing, CN, ¹⁰Nantong Tumor Hospital, Nantong, China, Nantong, CN, ¹¹Cancer Center of People's Liberation Army, Nanjing, CN, ¹²11. Sir Run Run Shaw Hospital, Affiliated With Zhejiang University School of Medicine, Hangzhou, China, Hangzhou, CN, ¹³Affiliated Hospital of Nantong University, Nantong, China, Nantong, CN, ¹⁴Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Wuhan, CN, ¹⁵Clinical Affairs and Regulatory Department, Shanghai Allist Pharmaceuticals Inc., Shanghai, China, Shanghai, CN

- 12:00 - 12:00 **1532P - Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm+) advanced NSCLC: updated data from the GioTag real-world study**
M. Hochmair¹, A. Morabito², D. Hao³, C.-T. Yang⁴, R. Soo⁵, J.C.-H. Yang⁶, R. Gucalp⁷, B. Halmos⁸, L. Wang⁹, A. Golembesky¹⁰, A. Märten¹⁰, T. Cufer¹¹, ¹Otto Wagner Spital, Vienna, AT, ²Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, ³Tom Baker Cancer Centre, Calgary, CA, ⁴Chang Gung Memorial Hospital, Guishan, Taoyuan, TW, ⁵National University Hospital, Singapore, SG, ⁶National Taiwan University Cancer Center, Taipei, TW, ⁷Montefiore/Albert Einstein Cancer Center, New York, US, ⁸Montefiore Medical Center, New York City, US, ⁹Limited, Taipei, TW, ¹⁰GmbH, Ingelheim am Rhein, DE, ¹¹University Clinic Golnik, Golnik, SI
- 12:00 - 12:00 **1533P - Treatment patterns of EGFR mt+ NSCLC IV pts: Real world data of the NOWEL network**
J. Roeper¹, M. Falk², S. Schatz², M. Tiemann², C. Wesseler³, G.H. Wiest³, S. Sackmann⁴, D. Ukena⁴, F. Griesinger⁵, ¹Pius Hospital Oldenburg, University of Oldenburg, Berlin, DE, ²Hematopathology Hamburg, Hamburg, DE, ³Asklepios Klinik Harburg, Hamburg, DE, ⁴Klinikum Bremen Ost, Bremen, DE, ⁵Pius Hospital, Oldenburg, DE
- 12:00 - 12:00 **1534P - TP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment**
M. Canale¹, N. De Luigi², E. Petracci¹, A. Delmonte³, V. Ludovini⁴, A. Dubini⁵, S. Baglivo⁴, E. Minenza⁶, E. Chiadini³, L. Landi⁷, M. Papi⁸, G. Bronte⁹, L. Crinò³, P. Ulivi¹, ¹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, ²State Hospital - Istituto per la Sicurezza Sociale, Cailungo, SM, ³Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ⁴Ospedale S. Maria della Misericordia, Perugia, IT, ⁵Ospedale Morgagni-Pierantoni, Forlì, IT, ⁶Private Practice - Dr. Elisa Minenza, Perugia, IT, ⁷Ospedali Riuniti Livorno, Livorno, IT, ⁸Ospedale Infermi, Rimini, IT, ⁹AOU Policlinico "Paolo Giaccone", Palermo, IT
- 12:00 - 12:00 **1535P - HER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors**
K. Yonesaka¹, E. Iwama², H. Hayashi³, S. Suzuki³, R. Kato³, S. Watanabe³, T. Takahama³, J. Tanizaki³, K. Tanaka³, M. Takeda³, K. Sakai³, K. Azuma⁴, Y. Chiba³, S. Atagi⁵, K. Nishio³, I. Okamoto², K. Nakagawa⁶, ¹Kindai University Hosipital, Osakasayama, JP, ²Kyushu University Faculty of Medicine, Fukuoka, JP, ³Kindai University Faculty of Medicine, Osaka-sayama, JP, ⁴Kurume University Faculty of Medicine, Kurume, JP, ⁵Kinki-chuo Respiratory Medical Center, Sakai, JP, ⁶Kindai University School of Medicine, Osaka, JP
- 12:00 - 12:00 **1536P - Patients with brain metastases treated with afatinib in clinical practice - results from the prospective non-interventional study GIDEON**
E. Laack¹, C. Hoffmann², M. Reck³, H. Schaefer⁴, C. Kortsik⁵, F. Griesinger⁶, A. Schueler⁷, W. Brückl⁸, ¹HämatO-Onkologie Hamburg, Hamburg, DE, ²Boehringer Ingelheim - Germany, Ingelheim am Rhein, DE, ³Krankenhaus Grosshansdorf, Grosshansdorf, DE, ⁴LungenZentrum Saar, SHG Kliniken Völklingen, Völklingen, DE, ⁵KKM St.Hildegardis Krankenhaus, Mainz, DE, ⁶Pius Hospital, Oldenburg, DE,

⁷Boehringer Ingelheim Pharma- Germany, Ingelheim am Rhein, DE, ⁸Klinikum Nuernberg Nord, Nürnberg, DE

- 12:00 - 12:00 **1537P - Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: initial Phase 1b results**
- D. Berz¹, A. Spira², S. Gadgeel³, I. Anderson⁴, J. Goldman⁵, J. Thompson⁶, T. Foster⁴, Y. Pritchett⁷, C. Cisneros⁷, C. Li⁷, J. Sorrentino⁷, R. Malik⁸, A. Beelen⁷, ¹Beverly Hills Cancer Center, Beverly Hills, US, ²Virginia Cancer Specialist, Fairfax, US, ³University of Michigan, Ann Arbor, US, ⁴St Joseph Heritage Healthcare, Santa Rosa, US, ⁵David Geffen School of Medicine at UCLA, Santa Monica, US, ⁶Medical College of Wisconsin, Milwaukee, US, ⁷G1 Therapeutics, Inc, Research Triangle Park, US, ⁸G1 Therapeutics, Inc, Research Triangle Park, US
- 12:00 - 12:00 **1538P - Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC**
- P. Christopoulos¹, A.-L. Volckmar², F. Bozorgmehr¹, N. Magios¹, J. Kuon¹, M. Kirchner³, D. Kazdal², V. Endris², T. Bochtler⁴, F. Herth¹, C.-P. Heussel¹, H. Winter¹, T. Muley¹, M. Meister¹, J. Fischer⁵, S. Rieken⁶, M. Faehling⁷, H. Bischoff¹, A. Stenzinger⁸, M. Thomas¹, ¹Thoraxklinik Heidelberg, Heidelberg, DE, ²Institute of Pathology, Heidelberg, DE, ³University Hospital Heidelberg, Institute of Pathology, DE, ⁴Institute of Pathology, Heidelberg, DE, ⁵Klinik Loewenstein GmbH Med Klinik II Onkologie, Löwenstein, DE, ⁶Department of Radiation Oncology, Heidelberg, DE, ⁷Klinikum Esslingen, Esslingen, DE, ⁸University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE
- 12:00 - 12:00 **1539P - A Phase II Open-Label, Multicentre Study to Assess the Anti-tumour Activity of Afatinib in Patients with Activating Epidermal Growth Factor Receptor mutation (EGFRm) from Circulating Tumor DNA (CtDNA)**
- Y.-C. Kim¹, C.-K. Park¹, I.-J. Oh¹, S.Y. Lee², J.C. Lee³, C.-M. Choi³, S.Y. Lee⁴, T.W. Jang⁵, ¹Chonnam National University Medical School & Chonnam National University Hwasun Hospital, Hwasun, KR, ²Korean University Guro Hospital, Seoul, KR, ³Asan Medical Center, Seoul, KR, ⁴Kyungpook National University, Daegu, KR, ⁵Kosin University Medical College, Gospel Hospital, Pusan, KR
- 12:00 - 12:00 **1540P - Influence of cow's milk on the absorption and exposure of erlotinib in NSCLC patients**
- G. Veerman¹, K. Hussaarts², R. Peric³, E. Oomen-De Hoop², K. Landa², C. Van Der Leest⁴, S. Broerse⁵, H. Rutten⁶, M. Paats³, T. Van Gelder², S. Koolen³, J. Aerts³, R. Van Leeuwen³, R. Mathijssen¹, ¹Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ²Erasmus MC Cancer Institute, Rotterdam, NL, ³Erasmus University Medical Center, Rotterdam, NL, ⁴Amphia Ziekenhuis-location Molengracht, Breda, NL, ⁵Franciscus Gasthuis & Vlietland Hospital, Rotterdam, NL, ⁶Bravis Ziekenhuis-Roosendaal, Roosendaal, NL
- 12:00 - 12:00 **1541P - PTEN loss as Predictor of Tumor Heterogeneity (TH) and Poor Prognosis in EGFR-mutant Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients (pts) Receiving Tyrosine-Kinase Inhibitors (TKIs).**
- M. Ferrara¹, E. Vita², E. D'Argento¹, M. Martini¹, V. Di Noia², I. Sperduti³, M. Bilotta¹, A.

Virtuoso⁴, M. Ribelli⁴, P. Damiano¹, M. Cannella⁵, S. Pilotto⁶, M. Milella⁷, G. Tortora⁸, E. Bria⁹, ¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, IT, ²Università Cattolica del Sacro Cuore, Roma, IT, ³Bio-Statistics Unit, Regina Elena National Cancer Institute, Roma, IT, ⁴Policlinico Universitario A. Gemelli, Rome, IT, ⁵Policlinico Agostino Gemelli, Rome, IT, ⁶AOU Integrata Borgo Roma Verona, Verona, IT, ⁷Università degli Studi di Verona, Verona, IT, ⁸Fondazione Policlinico Universitario Agostino Gemelli -IRCCS Rome, Rome, IT, ⁹Fondazione Policlinico Universitario Agostino Gemelli, Rome, IT

12:00 - 12:00

1542P - Safety of lorlatinib in subgroups of patients from a phase 1/2 trial

E. Felip¹, B. Solomon², B. Besse³, T. Bauer⁴, R. Soo⁵, D.R. Camidge⁶, R. Chiari⁷, A. Bearz⁸, C.-C. Lin⁹, S. Gadgeel¹⁰, E.-H. Tan¹¹, T. Seto¹², G. Oxnard¹³, G. Peltz¹⁴, A. Abbattista¹⁵, H. Thurm¹⁶, F. Toffalorio¹⁵, S.-H. Ou¹⁷, A. Shaw¹⁸, ¹Vall d'Hebron Institute of Oncology, Barcelona, ES, ²Peter MacCallum Cancer Centre, Melbourne, AU, ³Gustave Roussy Cancer Campus, Villejuif, FR, ⁴Sarah Cannon Cancer Research Institute/Tennessee Oncology, Nashville, US, ⁵National University Hospital Singapore, Singapore, SG, ⁶University of Colorado, Aurora, US, ⁷Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, IT, ⁸National Institute for Cancer Research, Aviano, IT, ⁹National Taiwan University Hospital, Taipei, TW, ¹⁰University of Michigan, Ann Arbor, US, ¹¹National Cancer Center, Singapore, SG, ¹²National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ¹³Dana-Farber Cancer Institute, Boston, US, ¹⁴Pfizer Oncology, Groton, US, ¹⁵Pfizer Oncology, Milan, IT, ¹⁶Pfizer Oncology, La Jolla, US, ¹⁷University of California Irvine, Irvine, US, ¹⁸Massachusetts General Hospital, Boston, US

12:00 - 12:00

1543P - Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase 2 ALTA trial

D.H. Lee¹, D.-W. Kim², D.R. Camidge³, C. Langer⁴, R. Huber⁵, M. Tiseo⁶, H. West⁷, H. Groen⁸, K. Reckamp⁹, M. Hochmair¹⁰, N. Leigh¹¹, K. Hansen¹², S. Gettinger¹³, L. Paz-Ares¹⁴, E. Kim¹⁵, E. Smit¹⁶, S.-W. Kim¹⁷, Q. Ni¹⁸, P. Zhang¹⁸, M.-J. Ahn¹⁹, ¹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ²Seoul National University Hospital, Seoul, KR, ³University of Colorado, Aurora, US, ⁴University of Pennsylvania-Perelman Center for Advanced Medicine, Philadelphia, US, ⁵LMU Klinikum der Universität München, Munich, DE, ⁶AOU di Parma, Parma, IT, ⁷Swedish Cancer Institute, Seattle, US, ⁸University Hospital Groningen (UMCG), Groningen, NL, ⁹City of Hope, Duarte, US, ¹⁰Otto Wagner Spital, Vienna, AT, ¹¹Princess Margaret Cancer Centre, Toronto, CA, ¹²Odense University Hospital, Odense, DK, ¹³Yale University School of Medicine, New Haven, US, ¹⁴University Hospital 12 De Octubre, Madrid, ES, ¹⁵Atrium Health, Charlotte, US, ¹⁶Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ¹⁷Asan Medical Center, Seoul, KR, ¹⁸Millennium Pharmaceuticals, Inc., Cambridge, US, ¹⁹Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

12:00 - 12:00

1544P - The safety assessment of crizotinib and alectinib from real world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).

K. Kunimasa¹, K. Ito², T. Yamanaka³, D. Fujimoto⁴, M. Mori⁵, K. Maeno⁶, K. Tomomatsu⁷, A. Tamura⁸, H. Tanaka⁹, S. Watanabe¹⁰, S. Teraoka¹¹, O. Hataji¹², K. Suzuki¹³, S.

Hontsu¹⁴, S. Hara¹⁵, A. Bessho¹⁶, A. Kubo¹⁷, M. Okuno¹⁸, K. Nakagawa¹⁹, N. Yamamoto¹¹, ¹Osaka International Cancer Institute, Osaka, JP, ²Matsusaka City Hospital, Matsusaka, JP, ³Yokohama City University Hospital, Yokohama, JP, ⁴Kobe City Medical Center General Hospital, Kobe, JP, ⁵National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, JP, ⁶Nagoya City University Graduate School of Medical Sciences, Aichi, JP, ⁷Tokai University School of Medicine, Kanagawa, JP, ⁸National Hospital Organization Tokyo National Hospital, Tokyo, JP, ⁹Niigata Cancer Center Hospital, Niigata, JP, ¹⁰Niigata University Medical and Dental Hospital, Niigata, JP, ¹¹Wakayama Medical University, Wakayama, JP, ¹²Matsusaka Municipal Hospital, Matsusaka, JP, ¹³Toyama prefectural central hospital, Toyama, JP, ¹⁴Nara Medical University, Nara, JP, ¹⁵Itami City Hospital, Hyogo, JP, ¹⁶Japanese Red Cross Okayama Hospital, Okayama, JP, ¹⁷Aichi Medical University School of Medicine, Aichi, JP, ¹⁸Okazaki City Hospital, Aichi, JP, ¹⁹Kindai University School of Medicine, Osaka, JP

12:00 - 12:00

1545P - Brigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): the Use Via Expanded Access to Brigatinib (UVEA-Brig) study

S. Novello¹, O.T. Brustugun², J. Cadranel³, F. Griesinger⁴, M. Hochmair⁵, M. Pérol⁶, S. Popat⁷, N. Bent-Enakhil⁸, C. Kruhl⁹, E. Felip¹⁰, ¹Università Degli Studi Di Torino - Orbassano, Orbassano, IT, ²Radiumhospitalet, Oslo, NO, ³Hôpital Tenon, Paris, FR, ⁴Pius Hospital, Oldenburg, DE, ⁵Otto Wagner Spital, Vienna, AT, ⁶Léon Bérard Cancer Center, Lyon, FR, ⁷Royal Marsden Hospital NHS Foundation Trust, London, GB, ⁸Takeda Pharmaceuticals International, Zurich, CH, ⁹Takeda Pharmaceuticals International AG, Glattpark-Opfikon, CH, ¹⁰Vall d'Hebron University Hospital, Barcelona, ES

12:00 - 12:00

1546P - Treatment patterns and outcomes for patients (pts) with anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer (NSCLC) in US clinical practice

M. Krebs¹, L. Polito², V. Smoljanović³, H. Trinh⁴, G. Crane⁵, ¹The Christie NHS Foundation Trust, Manchester, GB, ²F. Hoffmann-La Roche Ltd., Basel, CH, ³F. Hoffmann-La Roche, Basel, CH, ⁴Genentech Inc., South San Francisco, US, ⁵F. Hoffmann-La Roche Ltd, Welwyn Garden City, GB

12:00 - 12:00

1547P - Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?

S. Kilickap¹, F. Buğdaycı Başal², A. Demirkazık³, P. GURSOY⁴, U. Demirci⁵, M. Erman¹, F. Yumuk⁶, F. Cay Senler³, B. Cakar⁷, I. Cicin⁸, A. Ozturk⁹, H. Coskun¹⁰, E. Çubukçu¹¹, A. Işıkdoğan¹², O.F. Olmez¹³, A. Tatlı¹⁴, M. Karaagac¹⁵, T. Şakalar¹⁶, Y. Eralp¹⁷, T. Korkmaz¹⁸, ¹Hacettepe University Cancer Institute, Ankara, TR, ²Abdurrahman Yurtarslan Research and Training Hospital, Ankara, TR, ³Ankara University Faculty of Medicine, Ankara, TR, ⁴Suat Seren Chest Disease Hospital, İzmir, TR, ⁵Health Sciences University, Ankara, TR, ⁶Marmara University School of medicine, İstanbul, TR, ⁷Ege University Medical School, İzmir, TR, ⁸Trakya University Rektörlüğü, Edirne, TR, ⁹Sureyyapasa Chest Disease Hospital, İstanbul, TR, ¹⁰Akdeniz University Medical Oncology, Antalya, TR, ¹¹Ali Osman Sönmez Oncology Hospital, Bursa, TR, ¹²Dicle University, Diyarbakır, TR, ¹³Medipol Mega Hospitals Complex (University Hospital), İstanbul, TR, ¹⁴Antalya Education and Training Hospital, Antalya, TR, ¹⁵Konya Meram Faculty of Medicine, Konya, TR, ¹⁶Erciyes University School of Medicine, Kayseri, TR, ¹⁷Istanbul University, Institute of Oncology, Surgical Oncology Unit, İstanbul, TR, ¹⁸Kartal Dr. Lütfi Kırdar Eğitim Ve Arastırma Hastanesi, İstanbul, TR

- 12:00 - 12:00 **1548P - Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial - Updated progression-free survival, overall survival and mechanisms of resistance**
S. Michels¹, B. Massuti Sureda², H.-U. Schildhaus³, J. Franklin⁴, M. Sebastian⁵, E. Felip⁶, C. Grohe⁷, D. Rodríguez-Abreu⁸, H. Bischoff⁹, E. Carcereny Costa¹⁰, J. Corral Jaime¹¹, A. Insa¹², M. Reck¹³, M. Scheffler¹⁴, N. Karachaliou¹⁵, S. Merkelbach-Bruse¹⁶, L. Nogova¹⁶, R. Büttner¹, R. Rosell¹⁷, J. Wolf¹⁴, ¹University Hospital Cologne, Köln, DE, ²Hospital General Universitario de Alicante, Alicante, ES, ³University Hospital of Essen, Essen, DE, ⁴University of Cologne, Köln, DE, ⁵Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, ⁶Vall d'Hebron University Hospital, Barcelona, ES, ⁷Evangelische Lungenklinik ELK Berlin Chest Hospital, Berlin, DE, ⁸Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, ES, ⁹Thoraxklinik Heidelberg, Heidelberg, DE, ¹⁰Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, ¹¹Clínica Universitaria de Navarra, Madrid, ES, ¹²Biomedical Research Institute-INCLIVA - Hospital Clínico Universitario, University of Valencia, Valencia, Spain., Valencia, ES, ¹³Krankenhaus Grosshansdorf, Grosshansdorf, DE, ¹⁴Uniklinik Köln, Cologne, DE, ¹⁵Hospital Universitari Sagrat Cor - Group Quirónsalud, Barcelona, ES, ¹⁶University Hospital Cologne, Köln, DE, ¹⁷Institut for Health Sciences Germans Trias i Pujol, Badalona, ES
- 12:00 - 12:00 **1549P - NTRK1-3 Genomic Fusions in Non-Small Cell Lung Cancer (NSCLC) Determined by Comprehensive Genomic Profiling**
S.-H. Ou¹, E. Sokol², S. Trabucco², D. Jin², G. Frampton², S. Graziano³, J. Elvin², J.-A. Vergilio², J.K. Killian², N. Ngo², D. Lin², S. Ramkissoon², E. Severson², S. Ali², A. Schrock², J. Chung², P. Reddy², K. Mcgregor², B. Alexander², J. Ross⁴, ¹University of California Irvine, Irvine, US, ²Foundation Medicine, Cambridge, US, ³Upstate Medical University, Syracuse, US, ⁴Albany Medical Center, Albany, US
- 12:00 - 12:00 **1550P - Preferential expression of the affected MET allele in lung carcinomas with heterozygous MET exon 14 skipping mutations: implications for clinical testing**
E. Imyanitov¹, N. Mitiushkina², M. Kholmatov², V. Tiurin², A. Romanko², T. Strelkova², A. Ivantsov², E. Kuligina², A. Togo², ¹N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU, ²N.N. Petrov Institute of Oncology, St.-Petersburg, RU
- 12:00 - 12:00 **1551P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers**
M.G. Krebs¹, L. Perez², A. Surinach³, R.C. Doebele⁴, R. Martina⁵, M. Martinec², T. Riehl⁶, N.J. Meropol⁷, W. Wong⁶, G. Crane⁸, ¹Manchester Academic Health Science Centre, Manchester, GB, ²F. Hoffmann-La Roche Ltd, Basel, CH, ³Genesis Research, Hoboken, US, ⁴University of Colorado Cancer Center, Aurora, US, ⁵University of Liverpool, Liverpool, GB, ⁶Genentech, South San Francisco, US, ⁷Flatiron Health, New York, US, ⁸F. Hoffmann-La Roche Ltd, Welwyn Garden City, GB
- 12:00 - 12:00 **1552P - Patients with metastatic non-small cell lung cancer and targetable molecular alterations in Germany. Treatment and first outcome data from the prospective German Registry Platform CRISP (AIO-TRK-0315)**

F. Griesinger¹, W. Eberhardt², A. Nusch³, M. Reiser⁴, M.-O. Zahn⁵, N. Marschner⁶, M. Jänicke⁷, A. Fleitz⁶, L. Spring⁷, J. Sahlmann⁸, A. Karatas⁹, A. Hipper⁹, W. Weichert¹⁰, C. Waller¹¹, M. Reck¹², P. Christopoulos¹³, M. Sebastian¹⁴, M. Thomas¹³, ¹Pius Hospital, Oldenburg, DE, ²University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ³Onkologische Praxis Velbert, Velbert, DE, ⁴PIOH (Köln Zentrum) - Praxis Internistischer Onkologie und Hämatologie, Köln, DE, ⁵MVZ Onkologische Kooperation Harz, Goslar, DE, ⁶iOMEDICO AG, Freiburg, DE, ⁷iOMEDICO, Freiburg, DE, ⁸iOMEDICO AG, Freiburg im Breisgau, DE, ⁹AIO Studien gmbH, Berlin, DE, ¹⁰Technische Universität München-Institute of Pathology, Munich, DE, ¹¹Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, Freiburg im Breisgau, DE, ¹²Krankenhaus Grosshansdorf, Grosshansdorf, DE, ¹³Thoraxklinik Heidelberg, Heidelberg, DE, ¹⁴Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE

12:00 - 12:00

1553P - Crizotinib vs Platinum-based Chemotherapy as First-line Treatment for Advanced Non-small Cell Lung Cancer with Different ROS1 Fusion Variants

H. Xu¹, Q. Zhang², L. Liang³, J. Li¹, Z. Liu⁴, G. Yang⁵, L. Yang¹, J. Ying⁶, S. Zhang⁷, Y. Wang⁶, ¹Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ²Beijing Chest Hospital, Beijing, CN, ³Peking University Third Hospital, Beijing, CN, ⁴Chinese PLA General Hospital, Beijing, CN, ⁵Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ⁶Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ⁷Beijing Chest Hospital, Capital Medical University, Beijing, CN

12:00 - 12:00

1554P - Genomic and clinical characterization of Non-small cell lung cancer (NSCLC) patients harboring mutations in FGFR2 and FGFR3

M. Scheffler¹, T. Chanra¹, A. Kron¹, S. Koleczko¹, D. Abdulla¹, M. Ihle¹, A. Holzem², R. Riedel¹, S. Michels³, R. Fischer², S. Merkelbach-Bruse², R. Büttner¹, L. Nogova², J. Wolf¹, ¹Uniklinik Köln, Cologne, DE, ²University Hospital Cologne, Köln, DE, ³University Hospital Cologne, Köln, DE

12:00 - 12:00

1555P - The expression of HER2-gene polymorphisms -1985G>T and P1170A C>G and their association with the risk of development of lung adenocarcinoma

I. Aleric¹, D. Katalinic², A. Vcev³, E. Kattner⁴, S. Bildat⁴, V. Krieger-Borgstaedt⁴, L. Toetome⁵, ¹Faculty of Medicine; Faculty of Dental Medicine and Health, Osijek, HR, ²KBC - University Hospital Centre Zagreb, Zagreb, HR, ³Faculty of Dental Medicine and Health, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, HR, ⁴Herford Teaching Hospital, Medical Campus OWL, Herford, DE, ⁵Center for Cancer Medicine, Oslo, NO

12:00 - 12:00

1556P - Circulating tumor DNA (ctDNA) analysis depicts mechanisms of resistance and tumor response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC)

S. Ortiz - Cuaran¹, L. Mezquita², A. Swalduz¹, M. Aldea², J. Mazieres³, C. Jovelet², L. Lacroix⁴, A. Pradines⁵, V. Avrillon¹, C. Mahier-Aït Oukhatar⁶, N. Hoog-Labouret⁷, K. Howarth⁸, J.-F. Guichou⁹, C. Morris⁸, E. Green⁸, M. Perol¹, B. Besse⁴, J.-Y. Blay¹, P. Saintigny¹, D. Planchard⁴, ¹Centre Léon Bérard, Lyon, FR, ²Gustave Roussy, Villejuif, FR, ³Hospital Larrey, Toulouse, FR, ⁴Institut Gustave Roussy, Villejuif, FR, ⁵IUCT, Toulouse,

FR, ⁶Unicancer, Paris, FR, ⁷Institut National du Cancer (INCa), Boulogne-Billancourt, FR, ⁸Inivata Ltd., Cambridge, GB, ⁹Université de Montpellier, Montpellier, FR

- 12:00 - 12:00 **1557P - A large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC).**
- R. Itotani¹, S. Matsumoto¹, H. Udagawa¹, K. Nishino², I. Nakachi³, S. Miyamoto⁴, S. Hara⁵, S. Kuyama⁶, N. Ebi⁷, Y. Tsubata⁸, M. Shingyoji⁹, T. Kato¹⁰, Y. Ohe¹¹, K. Nishi¹², S. Hashimoto¹³, K. Goto¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Osaka International Cancer Institute, Oosaka, JP, ³Saiseikai Utsunomiya Hospital, Utsunomiya, JP, ⁴Japanese Red Cross Medical Center, Tokyo, JP, ⁵Itami City Hospital, Itami, JP, ⁶NHO Iwakuni Medical Center, Iwakuni, JP, ⁷Iizuka Hospital, Iizuka, JP, ⁸Shimane University Hospital, Izumo, JP, ⁹Chiba Cancer Center Hospital, Chiba, JP, ¹⁰Kanagawa Cancer Center, Yokohama, JP, ¹¹National Cancer Center Hospital, Tokyo, JP, ¹²Ishikawa Prefecture Central Hospital, Kanazawa, JP, ¹³Ikeda City Hospital, Ikeda, JP
- 12:00 - 12:00 **1558P - Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)**
- A. Cohen¹, B. Neri¹, B. Adamson¹, C. Scanlon¹, C. Gross², N. Meropol³, R. Miksad³, ¹Flatiron Health, New York City, US, ²Yale Medicine, New Haven, US, ³Flatiron Health, New York, US
- 12:00 - 12:00 **1560P - Disease monitoring of EGFR mutation-positive NSCLC patients via circulating tumor DNA**
- W.F. Hsu¹, H.-L. Ho², C.L. Chiang², Y. Jiang³, S. Karwowska⁴, R. Yerram⁵, K. Sharma⁵, A. Sharma⁵, S. Scudder⁵, C.-M. Tsai², J. Palma⁶, C.-H. Chiu¹, T.-Y. Chou², ¹Taipei Veterans General Hospital, Taipei City, TW, ²Taipei Veterans General Hospital, Taipei, TW, ³Pfizer Inc - USA, San Diego, US, ⁴Roche, Pleasanton, US, ⁵Roche, California, US, ⁶Roche Molecular Systems Inc - USA, Pleasanton, US
- 12:00 - 12:00 **1561P - Incidence of T790M in NSCLC patients progressed to gefitinib, erlotinib, and afatinib: a study on circulating tumor DNA**
- R. Danesi¹, I. Petrini², F. Mazzoni³, S. Valleggi⁴, G. Gianfilippo⁵, D. Pozzessere⁶, S. Crucitta², G. Restante⁵, A. Chella⁷, M. Garassino⁸, M. Miccoli⁵, M. Del Re², ¹Università di Pisa, Pisa, IT, ²Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT, ³Azienda Ospedaliera Universitaria Careggi, Firenze, IT, ⁴Azienda Ospedaliero Universitaria Pisana, Pisa, IT, ⁵University of Pisa, Pisa, IT, ⁶Ospedale Misericordia e Dolce, Prato, IT, ⁷Cisanello University hospital Pisa, Pisa, IT, ⁸Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT
- 12:00 - 12:00 **1562P - Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based therapy in patients with non-squamous non-small cell lung cancer**
- X. Chen¹, F. Zhou², X. Li³, C. Zhao³, W. Li³, F. Wu³, J. Yu², G. Gao¹, J. Li¹, A. Li¹, S. Ren¹, C. Zhou⁴, ¹Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN, ²Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, CN, ³Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, CN, ⁴Shanghai Pulmonary Hospital, Shanghai, CN

- 12:00 - 12:00 **1563P - Carcinoembryonic Antigen of Cerebrospinal Fluid Predict Prognosis of Leptomeningeal Metastasis from Non-Small Cell Lung Cancer**
J. Zhen, L. Wen, S. Li, M. Lai, C. Zhou, L. Cai, Guangdong Sanjiu 999 Brain Hospital, Guangzhou, CN
- 12:00 - 12:00 **1564P - Liquid biopsy in clinical practice of Non-Small-Cell-Lung Cancer (NSCLC): a multi-institutional experience**
G. De Maglio¹, G. Pasello², A. Follador³, G. Nardo², F. Cortiula¹, A. Del Conte⁴, A. D'Urso⁵, G. Petros⁵, S. Girlando⁶, M. Miorin⁷, V. Polo⁸, E. Scquizzato⁹, G. Settanni¹⁰, V. Picece¹¹, A. Veccia¹², S. Indraccolo¹³, ¹Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT, ²Istituto Oncologico Veneto IRCCS, Padova, IT, ³Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia, Udine, IT, ⁴Centro di Riferimento Oncologico (CRO) - IRCCS, Aviano, IT, ⁵ULSS1 Dolomiti - Presidio Ospedaliero di Feltre, Feltre, IT, ⁶U.O. Anatomia Patologica, Trento, IT, ⁷AAS5 - Presidio ospedaliero di Pordenone, Pordenone, IT, ⁸AULSS 2 Marca Trevigiana, Ca' Foncello Hospital, Treviso, IT, ⁹ULSS 2 Marca Trevigiana, Treviso, Treviso, IT, ¹⁰IRCCS Ospedale Sacro Cuore Don Calabria - Negrar, Verona, IT, ¹¹IRCCS Ospedale Sacro Cuore Don Calabria - Negrar, Negrar (VR), IT, ¹²Ospedale Santa Chiara, Trento, IT, ¹³Istituto Oncologico Veneto IOV IRCCS, Padova, IT
- 12:00 - 12:00 **1565P - A Phase III Study Comparing SB8, a Proposed Bevacizumab Biosimilar, and Reference Bevacizumab in Patients with Metastatic or Recurrent Non-squamous NSCLC**
M. Reck¹, A. Luft², I. Bondarenko³, S. Shevnia⁴, D. Trukhin⁵, N. Kovalenko⁶, K. Vacharadze⁷, F. Andrea⁸, A. Hontsa⁹, J. Choi¹⁰, D. Shin¹⁰, ¹Krankenhaus Grosshansdorf, Grosshansdorf, DE, ²Leningrad Regional Clinical Hospital, St. Petersburg, RU, ³Dnipropetrovsk city multidisciplinary clinical hospital №4, Dnipro, UA, ⁴Podillia Regional Oncology Center, Vinnytsia, UA, ⁵Odessa Regional Oncology Center, Odessa, UA, ⁶Volgograd Regional Clinical Oncology Dispensary, Volgograd, RU, ⁷Research Institute of Clinical Medicine, Tbilisi, GE, ⁸Duna medical center, Budapest, HU, ⁹Chernivtsi Regional Oncology Center, Chernivtsi, UA, ¹⁰Samsung Bioepis-Suwon Site, Suwon, KR
- 12:00 - 12:00 **1566P - Retrospective comparative study of the efficacy and safety in docetaxel and ramucirumab combination chemotherapy with or without previous immune checkpoint inhibitor treatment.**
D. Harada¹, K. Takata², S. Mori³, T. Kozuki⁴, Y. Takechi³, S. Moriki³, Y. Asakura³, T. Ono³, N. Nogami¹, ¹Shikoku Cancer Center, Matsuyama, JP, ²National Hospital Organization Okayama Medical Center, Okayama, JP, ³National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, ⁴NHO Shikoku Cancer Center, Matsuyama, JP
- 12:00 - 12:00 **1567P - Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) : a retrospective multicentric study.**
G. Bilger¹, P. Boré², S. Valery³, J. Pinsolle⁴, R. Descourt⁵, M. Geier⁶, I. Monnet⁷, A.C. Toffart⁸, V. Bocquillon⁹, G. Rousseau Bussac³, C. Chouaid⁷, G. Robinet⁵, F. Ennahdi⁹, I. Zaccaria⁹, C. Decroisette¹⁰, ¹CH d'Annecy, Annecy, FR, ²CHRU Brest, Brest, FR, ³CHI Creteil, Creteil, FR, ⁴Institut Daniel Hollard, Grenoble, FR, ⁵C.H.U. Brest - Hôpital

Morvan, Brest, FR, ⁶CHRU Morvan Brest, Brest, FR, ⁷CH Intercommunal de Créteil, Créteil, FR, ⁸CHU de Grenoble-Alpes- Le site nord à La Tronche - Hopital Michallon, La Tronche, FR, ⁹CH Annecy Genevois, Metz Tussy, FR, ¹⁰Le Centre Hospitalier Annecy Genevois, Metz-Tussy, FR

12:00 - 12:00 **1568P - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial**

E. Capelletto¹, A. Morabito², F. Grossi³, F. Di Costanzo⁴, G. Osman⁵, R. Chiari⁶, P. Bordi⁷, V. Scotti⁸, G. Romano⁹, A. Delmonte¹⁰, D. Galetta¹¹, L. Ciuffreda¹², A. Manzo¹³, C. Genova¹⁴, F. Mazzoni¹⁵, A.M. Morelli¹, R. Critelli¹⁶, I. Stura¹⁷, G. Migliaretti¹⁷, S. Novello¹⁸, ¹Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT, ²Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, ³IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ⁴Azienda Ospedaliero-Universitaria Careggi, Firenze, IT, ⁵San Camillo Forlanini Hospital, Roma, IT, ⁶Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, IT, ⁷University Hospital of Parma, Parma, IT, ⁸Azienda Ospedaliero Universitaria Careggi, Firenze, IT, ⁹Ospedale Vito Fazzi, Lecce, IT, ¹⁰Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ¹¹IRCCS Istituto Oncologico "Giovanni Paolo II", Bari, IT, ¹²AOU Città della Salute e della Scienza Torino, Torino, IT, ¹³Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ¹⁴San Martino Hospital, Genova, IT, ¹⁵Azienda Ospedaliera Universitaria Careggi, Firenze, IT, ¹⁶Azienda Ospedaliero Universitaria San Luigi Gonzaga, Orbassano, IT, ¹⁷University of Turin, Torino, IT, ¹⁸Università Degli Studi Di Torino - Orbassano, Orbassano, IT

12:00 - 12:00 **1569P - Final results of randomized phase II trial of metronomic vs weekly oral vinorelbine (OV) as first-line chemotherapy (CT) in advanced NSCLC patients unfit to platinum-based CT (P-CT): Tempo-Lung EudraCT Number: 2014-003859-61**

D. Kowalski¹, A. Morabito², A. Montanino³, R. Bernabé⁴, F. Grossi⁵, R. Ramlau⁶, T.-E. Ciuleanu⁷, G.L. Ceresoli⁸, G. Pasello⁹, F. De Marinis¹⁰, J. Bosch Barrera¹¹, P. Landreau¹², S. Gautier¹³, C. Ta Thanh Minh¹⁴, A. Camerini¹⁵, ¹Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, ²Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, ³Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁴Hospital Universitario Virgen del Rocío, Sevilla, ES, ⁵IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ⁶Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu Oddział Chemioterapii, Poznań, PL, ⁷Ion Chiricuta Oncology Institute-IOCN, Cluj-Napoca, RO, ⁸Humanitas Gavazzeni, Bergamo, IT, ⁹Istituto Oncologico Veneto IRCCS, Padova, IT, ¹⁰Istituto Europeo di Oncologia, Milan, IT, ¹¹ICO - Institut Català d'Oncologia Girona (Hospital Universitari Josep Trueta Hospital Universitari Josep Trueta), Girona, ES, ¹²Pierre Fabre Oncology, Boulogne-Billancourt, FR, ¹³IRPF, Pierre Fabre, Toulouse, FR, ¹⁴Pierre Fabre Oncologie France, Boulogne-Billancourt, FR, ¹⁵Ospedale "Versilia", Lido di Camaiore, IT

12:00 - 12:00 **1570P - Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non-small-cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)**

D. Heudobler¹, C. Schulz², J. Fischer³, P. Staib⁴, T. Wehler⁵, T. Südhoff⁶, T. Schichtl⁷, J. Wilke⁸, J. Hahn², F. Lüke², M. Vogelhuber², S. Klobuch², T. Pukrop², W. Herr², S. Held⁹,

K. Beckers¹⁰, G. Bouche¹¹, A. Reichle², ¹University of Regensburg, Regensburg, DE, ²University Hospital Regensburg, Regensburg, DE, ³Klinik Loewenstein GmbH Med Klinik II Onkologie, Löwenstein, DE, ⁴St. Antonius Hospital Klinik für Hämatologie/Onkologie, Eschweiler, DE, ⁵University Hospital Saarland, Homburg, DE, ⁶Klinikum Passau, Passau, DE, ⁷Medizinische Versorgungszentrum, Weiden in der Oberpfalz, DE, ⁸Schwerpunktpraxis für Hämatologie und internistische Onkologie, Fürth, DE, ⁹ClinAssess, Leverkusen, DE, ¹⁰The Anticancer Fund, Strombeek-Bever, BE, ¹¹Anticancer Fund, Brussels, BE

12:00 - 12:00

1571P - Predicting Chemotherapy Toxicity in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Prospective Multicenter Study of the National Hospital Organization in Japan

M. Kanazu¹, M. Shimokawa², R. Saito³, M. Mori⁴, A. Tamura⁵, Y. Okano⁶, Y. Fujita⁷, T. Endo⁸, M. Motegi⁹, S. Takata¹⁰, T. Kita¹¹, N. Sukoh¹², M. Takenoyama¹³, S. Atagi¹⁴, ¹Toneyama National Hospital, Toyonaka, JP, ²National Hospital Organization, National Kyushu Cancer Center, Fukuoka, JP, ³National Hospital Organization Shibukawa Medical Center, Shibukawa, JP, ⁴National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, JP, ⁵National Hospital Organization Tokyo National Hospital, Kiyose, JP, ⁶National Hospital Organization Kochi National Hospital, Kochi, JP, ⁷National Hospital Organization Asahikiwa Medical Center, Asahikawa, JP, ⁸National Hospital Organization Mito Medical Center, Higashi-Ibaraki, JP, ⁹National Hospital Organization Takasaki General Medical Center, Takasaki, JP, ¹⁰National Hospital Organization Fukuoka-Higashi Medical Center, Koga, JP, ¹¹National Hospital Organization Kanazawa Medical Center, Kanazawa, JP, ¹²National Hospital Organization Hokkaido Medical Center, Sapporo, JP, ¹³National Hospital Organization National Kyusyu Cancer Center, Fukuoka, JP, ¹⁴Kinki-chuo Respiratory Medical Center, Sakai, JP

12:00 - 12:00

1572P - A prospective phase II trial of carboplatin (CBDCA) and nab-paclitaxel (nabPTX) for advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD)

T. Harada¹, H. Asahina², S. Oizumi², K. Takamura³, M. Harada⁴, K. Kanazawa⁵, Y. Fujita⁶, T. Kojima⁷, F. Sugaya⁸, H. Tanaka⁹, H. Ryoichi¹⁰, T. Ogi³, T. Ikari¹, H. Yokouchi⁴, E. Kikuchi², H. Akita¹¹, H. Isobe⁷, M. Nishimura², ¹JCHO Hokkaido Hospital, Sapporo, JP, ²Hokkaido University Hospital, Sapporo, JP, ³Obihiro-Kosei General Hospital, Obihiro, JP, ⁴National Hospital Organization Hokkaido Cancer Center, Sapporo, JP, ⁵Fukushima Medical University School of Medicine, Fukushima, JP, ⁶National Hospital Organization Asahikiwa Medical Center, Asahikawa, JP, ⁷KKR Sapporo Medical Center, Sapporo, JP, ⁸Teine Keijinkai Hospital, Sapporo, JP, ⁹Hirosaki University Graduate School of Medicine, Hirosaki, JP, ¹⁰Asahi Chuo Hospital, Asahi, JP, ¹¹Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JP

12:00 - 12:00

1573P - Weekly Epirubicin as palliative treatment in elderly patients with malignant pleural mesothelioma.

P. Candido, P. Belloni, M. Pelliccione, G. Corradini, D. Toniolo, C. Cozzi, R. Bollina, Azienda Ospedaliera G. Salvini, Rho, IT

12:00 - 12:00

1574P - Survival Prolongation by Rationale INnovative Genomics (SPRING): An international WIN Consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates.

B. Solomon¹, A. Callejo², J. Bar³, G. Berchem⁴, L. Bazhenova⁵, P. Saintigny⁶, E. Raymond⁷, N. Girard⁸, R. Sulaiman¹, C. Bresson⁹, F. Wunder⁹, J.J. Lee¹⁰, J. Raynaud¹¹, E. Rubin¹², B. Young¹³, V. Lazar⁹, E. Felip¹⁴, A. Onn³, B. Leyland-Jones¹, R. Kurzrock⁵,
¹Avera Cancer Institute, Sioux Falls, US, ²Vall d'Hebron Institute of Oncology and University Hospital, Barcelona, ES, ³Chaim Sheba Medical Center, Ramat Gan, IL, ⁴Centre Hospitalier de Luxembourg, Luxembourg, LU, ⁵UC San Diego Moores Cancer Center, University of California, La Jolla, US, ⁶Centre Léon Bérard, Lyon, FR, ⁷Centre Hospitalier Paris Saint-Joseph, Paris, FR, ⁸Institut Curie, Paris, FR, ⁹Worldwide Innovative Networking in personalized cancer medicine, Villejuif, FR, ¹⁰The University of Texas M.D. Anderson Cancer Center, Houston, US, ¹¹ARC Foundation for cancer research, Villejuif, FR, ¹²Ben-Gurion University of the Negev, Beer-Sheva, IL, ¹³Bowden WIN Laboratory, Murrieta, US, ¹⁴Vall d'Hebron University Hospital, Barcelona, ES

12:00 - 12:00

1575P - Preliminary results from phase 1b study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)

A. Santoro¹, P. Garrido Lopez², D.S.W. Tan³, L. Paz-Ares⁴, F. Shepherd⁵, A. Bearz⁶, F. Barlesi⁷, J. Vansteenkiste⁸, T.M. Kim⁹, T. Overbeck¹⁰, I. Rybkin¹¹, E. Felip¹², W. Zhou¹³, L. Santarpia¹⁴, S. Eddy¹³, E. Schaefer¹⁵,
¹Humanitas University, Rozzano-Milan, IT, ²Hospital Ramón Y Cajal, Madrid, ES, ³National Cancer Center Singapore, Singapore, SG, ⁴University Hospital 12 De Octubre, Madrid, ES, ⁵Princess Margaret Cancer Centre, University Health Network, Toronto, CA, ⁶Centro di Riferimento Oncologico - CRO, Aviano, IT, ⁷Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, ⁸University Hospital KU Leuven, Leuven, BE, ⁹Seoul National University Hospital, Seoul, KR, ¹⁰Universitätsmedizin Göttingen, Göttingen, DE, ¹¹Henry Ford Health System, Detroit, US, ¹²Vall d'Hebron University Hospital, Barcelona, ES, ¹³Novartis Pharmaceuticals Corporation, East Hanover, US, ¹⁴Novartis Pharma Services AG, Basel, CH, ¹⁵Highlands Oncology Group, Fayetteville, US

12:00 - 12:00

1576P - Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC

J. Trigo Perez¹, E. Felip², P. Brunsvig³, A. Helland⁴, N. Viñolas⁵, S. Ponce Aix⁶, E. Carcereny Costa⁷, M. Domine Gomez⁸, E. Arriola⁹, R. Garcia Campelo¹⁰, J. Spicer¹¹, J. Thompson¹², A.L. Ortega Granados¹³, R. Holt¹⁴, J. Lorens¹⁵, M. Shoaib¹⁴, A. Siddiqui¹⁴, E. Schmidt¹⁶, M. Chisamore¹⁷, M. Krebs¹⁸,
¹Hospital Universitario Virgen de la Victoria, Málaga, ES, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Oslo University Hospital, Oslo, NO, ⁴University of Oslo, Institute of Clinical medicine, Oslo, NO, ⁵Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁶University Hospital 12 De Octubre, Madrid, ES, ⁷Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, ⁸University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ⁹GLOBAL BUSSINESS TRAVEL, madrid, ES, ¹⁰CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ¹¹King's College London, Guy's Hospital, London, GB, ¹²Medical College of Wisconsin Affiliated Hospitals, Menomonee Falls, WI, US, ¹³Complejo Hospitalario de Jaen Universidad de Jaen, Jaen, ES, ¹⁴BerGenBio ASA, Bergen, NO, ¹⁵University of Bergen, Bergen, NO, ¹⁶Merck & Co., Inc., Kenilworth, US, ¹⁷Merck & Co., Inc., Rahway, US, ¹⁸The Christie NHS Foundation Trust, Manchester, GB

12:00 - 12:00

1577P - Analysis of the tumor microenvironment and tumor genotype through different stages of lung adenocarcinoma

P. Zink, M. Falk, S. Schatz, M. Tiemann, Hematopathology Hamburg, Hamburg, DE

12:00 - 12:00

1578P - Does Progress achieved in the Treatment of Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) reach the Elderly Population?

J. Suipyte¹, S. Schmidt², C. Herrmann³, M. Mousavi³, F. Hitz², M. Fruh⁴, ¹Hospital of Lithuanian University of Health Sciences, Kaunas, LT, ²Kantonsspital St. Gallen, St. Gallen, CH, ³Krebsliga Ostschweiz, St. Gallen, CH, ⁴Kantonsspital St. Gallen,, Gallen, CH

12:00 - 12:00

1579P - Prognostic factors for non-small cell lung cancer patients with driver mutation negative and brain metastases (HOT 1701)

Y. Ohhara¹, T. Kojima², O. Honjo³, N. Yamada⁴, T. Sato², M. Kunisaki¹, K. Takamura⁵, T. Takashina⁶, N. Sukoh⁷, H. Tanaka⁸, Y. Kawai⁹, Y. Fujita¹⁰, F. Sugaya¹¹, F. Hommura¹², T. Harada¹³, H. Ryoichi¹⁴, I. Kinoshita¹⁵, T. Amano¹, S. Oizumi¹, H. Akita¹⁶, ¹Hokkaido University Hospital, Sapporo, JP, ²KKR Sapporo Medical Center, Sapporo, JP, ³Sapporo Minami-Sanjo Hospital, Sapporo, JP, ⁴National Hospital Organization Hokkaido Cancer Center, Sapporo, JP, ⁵Obihiro-Kosei General Hospital, Obihiro, JP, ⁶Iwamizawa Municipal General Hospital, Iwamizawa, JP, ⁷National Hospital Organization Hokkaido Medical Center, Sapporo, JP, ⁸Hirosaki University Graduate School of Medicine, Hirosaki, JP, ⁹Oji General Hospital, Tomakomai, JP, ¹⁰National Hospital Organization Asahikiwa Medical Center, Asahikawa, JP, ¹¹Teine Keijinkai Hospital, Sapporo, JP, ¹²Sapporo City General Hospital, Sapporo, JP, ¹³JCHO Hokkaido Hospital, Sapporo, JP, ¹⁴Asahi Chuo Hospital, Asahi, JP, ¹⁵Hokkaido University, Sapporo, JP, ¹⁶Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JP

12:00 - 12:00

1580P - A novel risk classification system basing nomogram scores to predict survival of patients presenting with brain metastases at the first diagnosis of NSCLC

P. Cui¹, Z. Liu², ¹The First Hospital of Jilin University, Changchun, CN, ²the First Hospital of Jilin University, Changchun, CN

12:00 - 12:00

1581P - Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)

X. Ma, N. Nussbaum, K. Magee, A. Bourla, M. Tucker, L. Bellomo, C. Bennette, Flatiron Health Inc., New York City, US

12:00 - 12:00

1582P - Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model

P.K. Cheema¹, W. Evans², R. Burkes³, R. Sangha⁴, C. Ho⁵, P. Wheatley-Price⁶, D. Boehm⁷, J. Venkatesh⁷, S. Walisser⁸, D. Grima⁹, D. Moldaver⁹, M. Hurry¹⁰, ¹William Osler Health System, University of Toronto, Toronto, CA, ²McMaster University, Hamilton, CA, ³Mount Sinai Hospital, Toronto, CA, ⁴University of Alberta Cross Cancer Institute, Edmonton, CA, ⁵BC Cancer Agency, Vancouver, CA, ⁶The Ottawa Hospital Regional Cancer Centre, Ottawa, CA, ⁷Saskatchewan Cancer Agency, Regina, CA, ⁸BC Cancer Agency (retired), Vancouver, CA, ⁹Cornerstone Research Group, Burlington, CA, ¹⁰AstraZeneca Canada, Mississauga, CA

12:00 - 12:00

1583P - SMARCA4 Deficient Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Genomic Profiling (CGP) Study

S. Graziano¹, D. Lin², J. Elvin², J.-A. Vergilio², J.K. Killian², N. Ngo², S. Ramkissoon², E. Severson², A. Hemmerich², D. Duncan², C. Edgerly², S. Ali², A. Schrock², J. Chung², E. Sokol², P. Reddy², K. Mcgregor², V. Miller², B. Alexander², J. Ross³, ¹Upstate Medical University, Syracuse, US, ²Foundation Medicine, Cambridge, US, ³Albany Medical Center, Albany, US

12:00 - 12:00 **1584P - Exploring Resistance to Nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]**

S. Pilotto¹, E. Vita², I. Sperduti³, V. Di Noia², G. Grizzi⁴, E. D'Argento⁵, M. Simbolo⁴, C. Vicentini⁴, A. Caliò⁴, A. Mafficini⁴, L. Carbognin⁶, V. Corbo⁴, A. Gkoutakos⁴, A. Santo⁴, M. Brunelli⁴, M. Martini⁴, A. Scarpa⁴, M. Milella⁴, G. Tortora⁷, E. Bria⁶, ¹AOU Integrata Borgo Roma Verona, Verona, IT, ²Università Cattolica del Sacro Cuore, Roma, IT, ³Bio-Statistics Unit, Regina Elena National Cancer Institute, Roma, IT, ⁴University of Verona Hospital Trust, Verona, IT, ⁵Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, IT, ⁶Fondazione Policlinico Universitario A. Gemelli, I.R.C.C.S., Università Cattolica del Sacro Cuore, Roma, IT, ⁷Fondazione Policlinico Universitario Agostino Gemelli -IRCCS Rome, Rome, IT

12:00 - 12:00 **1585P - DNA damage repair deficiency is associated with early resistance to crizotinib: whole-genome analysis in non-small cell lung cancer patients with ALK-fusion**

D. He¹, H. Yang², Q. Deng², Z. Xie², D. Xiao², ¹1st Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, CN, ²First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN

12:00 - 12:00 **1586TiP - Phase 3 ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)**

S. Popat¹, G. Liu², S. Lu³, G. Song⁴, V. Samnotra⁴, J. Yang⁵, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²Princess Margaret Cancer Centre, Toronto, CA, ³Shanghai Chest Hospital, Shanghai, CN, ⁴Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, US, ⁵National Taiwan University Hospital, Taipei, Taiwan, Taipei, TW

12:00 - 12:00 **1587TiP - CANOPY phase 3 program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)**

L. Paz-Ares¹, E. Garon², A. Ardizzoni³, F. Barlesi⁴, B. Cho⁵, G. De Castro Junior⁶, P. De Marchi⁷, E. Felip⁸, Y. Goto⁹, A. Greystoke¹⁰, S. Lu¹¹, D. Lim¹², V. Papadimitrakopoulou¹³, M. Reck¹⁴, B. Solomon¹⁵, D. Spigel¹⁶, D.S.W. Tan¹⁷, M. Thomas¹⁸, J. Yang¹⁹, B. Johnson²⁰, ¹University Hospital 12 De Octubre, Madrid, ES, ²UCLA Hematology/Oncology Santa Monica, Santa Monica, US, ³Policlinico S. Orsola-Malpighi, Bologna, IT, ⁴Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, ⁵Yonsei Cancer Center, Seoul, KR, ⁶Instituto do Câncer do Estado de São Paulo, São Paulo, BR, ⁷Barretos Cancer Hospital, Barretos, BR, ⁸Vall d'Hebron University Hospital, Barcelona, ES, ⁹National Cancer Center Hospital, Tokyo, JP, ¹⁰Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, GB, ¹¹Shanghai Chest Hospital, Shanghai, CN, ¹²NCCS - National Cancer Centre, Singapore, SG, ¹³UT/MD Anderson Cancer Center, Houston, US, ¹⁴Krankenhaus Grosshansdorf, Grosshansdorf, DE, ¹⁵Peter MacCallum Cancer Center, Melbourne, AU, ¹⁶Sarah Canon Research Institute, Nashville, US, ¹⁷National Cancer

Center Singapore, Singapore, SG, ¹⁸Thoraxklinik Heidelberg, Heidelberg, DE, ¹⁹National Taiwan University Hospital, Taipei, Taiwan, Taipei, TW, ²⁰Dana-Farber Cancer Institute, Boston, US

12:00 - 12:00

1588TiP - The Elderly Patient Individualized Chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer.

F. Passiglia¹, E. Capelletto², F. Grossi³, P. Bidoli⁴, D. Galetta⁵, A. Follador⁶, G. Valmadre⁷, C. Defferrari⁸, O. Caffo⁹, A. Bearz¹⁰, I. Colantonio¹¹, V. Gregorc¹², V. Scotti¹³, F. Cognetti¹⁴, L. Cordero¹⁵, F. Arizio¹⁶, S. Novello¹⁷, V. Torri¹⁸, G. Scagliotti², ¹AOU Policlinico "Paolo Giaccone", Palermo, IT, ²Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT, ³IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ⁴Azienda Ospedaliera S. Gerardo, Monza, IT, ⁵Istituto Tumori Giovanni Paolo II, Bari, IT, ⁶Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia, Udine, IT, ⁷Ospedale E. Morelli AOVV Azienda Ospedaliera Valtellina e Valchiavenna, Sondalo, IT, ⁸Ospedali Galliera, GENOVA, IT, ⁹Ospedale Santa Chiara, Trento, IT, ¹⁰National Institute for Cancer Research, Aviano, IT, ¹¹Santa Croce e Carle Hospital, Cuneo, IT, ¹²IRCCS Ospedale San Raffaele, Milan, IT, ¹³Azienda Ospedaliero Universitaria Careggi, Firenze, IT, ¹⁴Istituto Nazionale Tumori Regina Elena, Rome, IT, ¹⁵University of Sassari, Sassari, IT, ¹⁶San Luigi Hospital, Orbassano, IT, ¹⁷Università Degli Studi Di Torino - Orbassano, Orbassano, IT, ¹⁸IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, IT

12:00 - 12:00

1589TiP - KEYNOTE-495/KeyImPaCT: A Randomized, Biomarker-Directed, Phase 2 Trial of Pembrolizumab-Based Therapy for Non-Small Cell Lung Cancer (NSCLC)

M. Gutierrez¹, W.-S. Lam², M.D. Hellmann³, M.A. Gubens⁴, C. Aggarwal⁵, D.S.W. Tan⁶, E. Felip⁷, J.W.Y. Chiu⁸, J.S. Lee⁹, J. Yang¹⁰, E.B. Garon¹¹, A. Basso¹², H. Ma¹², L. Fong¹³, A. Snyder¹², J. Yuan¹², R.S. Herbst¹⁴, ¹The John Theurer Cancer Center, Hackensack, US, ²Fiona Stanley Hospital, Perth, AU, ³Memorial Sloan Kettering Cancer Center, New York, US, ⁴UCSF Medical Center, San Francisco, US, ⁵University of Pennsylvania, Philadelphia, US, ⁶National Cancer Center Singapore, Singapore, SG, ⁷Vall d'Hebron University Hospital, Barcelona, ES, ⁸University of Hong Kong, Hong Kong, HK, ⁹Seoul National University, Seoul, KR, ¹⁰National Taiwan University Hospital, Taipei, Taiwan, Taipei, TW, ¹¹Los Angeles, Los Angeles, US, ¹²Merck & Co., Inc., Kenilworth, US, ¹³University of California, San Francisco, San Francisco, US, ¹⁴Yale University School of Medicine, New Haven, US

12:00 - 12:00

1590TiP - Safety, tolerability and activity of autologous T cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non small cell lung cancer: A Phase 1b/2a randomised pilot study

K. Reckamp¹, W. Akerley², E. Calvo³, J. Clarke⁴, M. Edelman⁵, K. He⁶, V. Moreno⁷, J. Neal⁸, T. Owonikoko⁹, J. Patel¹⁰, S. Patel¹¹, J. Riess¹², A. Sacher¹³, S. Turcotte¹⁴, L. Villaruz¹⁵, M. Zauderer¹⁶, B. Farsaci¹⁷, N. Skoura¹⁷, M. Chisamore¹⁸, M.L. Johnson¹⁹, ¹City of Hope, Duarte, US, ²Huntsman Cancer Institute, Salt Lake City, US, ³Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, ⁴Duke University School of Medicine, Durham, US, ⁵Fox Chase Cancer Center, Philadelphia, US, ⁶The Ohio State University College of Medicine, Columbus, US, ⁷University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ⁸Stanford Cancer Institute

Stanford University, Stanford, US, ⁹Winship Cancer Institute of Emory University, Atlanta, US, ¹⁰University of Chicago, Chicago, US, ¹¹UC San Diego Moores Cancer Center, La Jolla, US, ¹²UC Davis School of Medicine / UC Davis Comprehensive Cancer Center, Sacramento, US, ¹³Princess Margaret Cancer Centre, Toronto, CA, ¹⁴Université de Montréal, Montréal, CA, ¹⁵University of Pittsburgh, Pittsburgh, US, ¹⁶Memorial Sloan Kettering Cancer Center, Division of Solid Tumor Oncology, New York, US, ¹⁷GSK, Collegeville, US, ¹⁸Merck Sharp & Dohme Corp. USA, Whitehouse Station, US, ¹⁹Sarah Cannon Research Institute, Nashville, US

12:00 - 12:00

1591TiP - IFCT-1701 DICIPLÉ: a randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment

G. Zalcman¹, A.C. Toffart², A.-C. Madroszyk Flandin³, O. Molinier⁴, C. Dayen⁵, T. Egenod⁶, A. Dixmier⁷, E. Giroux Leprieur⁸, P. Masson⁹, N. Cloarec¹⁰, L. Thibonnier¹¹, L. Favier¹², D. Debievre¹³, J. Mazieres¹⁴, S. Van Hulst¹⁵, E. Pichon¹⁶, E. Amour¹⁷, F. Morin¹⁸, P.-J. Souquet¹⁹, ¹Hopital Bichat Claude Bernard, Paris, FR, ²CHU de Grenoble-Alpes- Le site nord à La Tronche - Hopital Michallon, La Tronche, FR, ³Institute Paoli Calmettes, Marseille, FR, ⁴Centre Hospitalier Du Mans, Le Mans, FR, ⁵CH, Saint-Quentin, FR, ⁶CHU Limoges - Hopital Dupuytren, Limoges, FR, ⁷C.H.R. Orleans - La Source, Orleans, FR, ⁸Hopital Ambroise Pare, Boulogne-Billancourt, FR, ⁹CH Cholet, Cholet, FR, ¹⁰CH, Avignon, FR, ¹¹Hôpital Gabriel Montpied, FR, ¹²CLCC, Dijon, FR, ¹³Hopital Emile Muller, Mulhouse, FR, ¹⁴Hospital Larrey, Toulouse, FR, ¹⁵CHU Nimes, Caremeau, Nimes, FR, ¹⁶CHRU Bretonneau, Tours, FR, ¹⁷IFCT, PARIS, FR, ¹⁸French Cooperative Thoracic Intergroup, Paris, FR, ¹⁹Centre Hospitalier Lyon Sud, Pierre Bénite, FR

12:00 - 12:00

1592TiP - ATALANTE-1 randomized phase 3 trial, OSE-2101 versus standard treatment as second or third line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients

E. Felip¹, B. Besse², R. Dziadziuszko³, M. Cobo Dols⁴, F. Denis⁵, M.-R. García-Campelo⁶, D. Debievre⁷, A. Catino⁸, M.T. Moran Bueno⁹, A.-C. Madroszyk Flandin¹⁰, P. Masson¹¹, C. Chouaid¹², P. Lianes¹³, F. Cappuzzo¹⁴, A. Delmonte¹⁵, G. Robinet¹⁶, G. Romano¹⁷, V. Gabarre¹⁸, J. Remon Masip¹⁹, G. Giaccone²⁰, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Institut Gustave Roussy, Villejuif, FR, ³Medical University of Gdansk, Gdansk, PL, ⁴Hospital Regional Universitario de Málaga, Málaga, ES, ⁵Clinique Victor Hugo, Le Mans, FR, ⁶Complejo Hospitalario Universitario A Coruna (CHUAC), La Coruña, ES, ⁷Hopital Emile Muller, Mulhouse, FR, ⁸Istituto Tumori Giovanni Paolo II, Bari, IT, ⁹Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, ¹⁰Institute Paoli Calmettes, Marseille, FR, ¹¹CH Cholet, Cholet, FR, ¹²CH Intercommunal de Créteil, Créteil, FR, ¹³Hospital de Mataro - Consorcio Sanitario del Maresme, Mataro, ES, ¹⁴Ospedale Santa Maria delle Croci, Ravenna, IT, ¹⁵Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ¹⁶C.H.U. Brest - Hôpital Morvan, Brest, FR, ¹⁷Ospedale Vito Fazzi, Lecce, IT, ¹⁸OSE Immunotherapeutics, Paris, FR, ¹⁹CIOCC- Centro Integral Oncológico Clara Campal, Barcelona, ES, ²⁰Lombardi Cancer Center Georgetown University, Washington DC, US

12:00 - 12:00

1593TiP - Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours

N. Girard¹, B. Hackanson², M. Wermke³, F. Barlesi⁴, H. Landsteiner⁵, G. Jayadeva⁶, J. Alt⁷, ¹Institut Curie, Paris, FR, ²University Hospital Augsburg, Augsburg, DE, ³University Hospital Carl-Gustav-Carus, Dresden, DE, ⁴Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, ⁵Boehringer Ingelheim RCV GmbH & Co KG, Vienna, AT, ⁶Boehringer Ingelheim, Ingelheim am Rhein, DE, ⁷Universitätsmedizin Mainz, Mainz, DE

12:00 - 12:00 **1594TiP - Radiosurgery followed by Tumor Treating Fields (TTFields) for brain metastases (1-10) from NSCLC in the phase 3 METIS trial**

M. Mehta¹, V. Gondi², M. Ahluwalia³, P. Brown⁴, ¹Northwestern University Feinberg School of Medicine, Chicago, US, ²Northwestern Medicine Cancer Center, Warrenville, US, ³Cleveland Clinic, Cleveland, US, ⁴Mayo Clinic, Rochester, US

12:00 - 12:00 **1595TiP - Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): the SQUINT trial**

L. Landi¹, L. Bonanno², A. Delmonte³, P. Maximilian⁴, V. Stati⁵, V. Minotti⁶, C. Bennati⁷, F. D'Incà⁸, M. Migliorino⁹, S. Gori¹⁰, A. Santo¹¹, F. Piantedosi¹², A. Russo¹³, F. Cappuzzo⁷, ¹Ospedali Riuniti Livorno, Livorno, IT, ²Istituto Oncologico Veneto IRCCS, Padova, IT, ³Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ⁴AUSL Romagna, Rimini, IT, ⁵Istituto Tumori della Romagna I.R.S.T., Milano, IT, ⁶Azienda Ospedaliera di Perugia S. Maria della Misericordia, Perugia, IT, ⁷Ospedale Santa Maria delle Croci, Ravenna, IT, ⁸Fondazione Ricerca Traslazionale, Roma, IT, ⁹San Camillo-Forlanini Hospital, Rome, IT, ¹⁰IRCCS Ospedale Sacro Cuore Don Calabria, Meldola, IT, ¹¹University of Verona Hospital Trust, Verona, IT, ¹²Azienda Ospedaliera Dei Colli-Monaldi, Napoli, IT, ¹³University of Palermo, Palermo, IT

12:00 - 12:00 **1596TiP - DUBLIN-3, a Stage IIIb/IV NSCLC Phase (Ph)3 Trial Comparing the Plinabulin (P)/Docetaxel(D) Combination with D Alone**

R. Mohanlal¹, L. Huang², ¹BeyondSpring Pharmaceuticals, New York, US, ²BeyonsSpring Pharmaceuticals, Inc, New York, US

12:00 - 12:00 **Palliative care**

12:00 - 12:00 **1598P - Escalation plans and DNACPR discussions in the unwell oncology patient**

R. Elghadi¹, S. Uppal², M. Chotalia³, J. Grant¹, ¹University Hospitals of Leicester NHS Trust Leicester Royal Infirmary, Leicester, GB, ²Nottingham University Hospitals NHS Trust-City Hospital Campus, Nottingham, GB, ³Leicester Royal Infirmary, Leicester, GB

12:00 - 12:00 **1599P - The Relation between the Symptom Burden of Hospitalized Patients with Incurable Cancer and the Quality-of-Life of Their Family Caregivers**

E. Tawfik¹, S. Al Hassanin¹, S. Gohar¹, S. Alsirafy², S. Abou El Kheir³, D. Harhash⁴, ¹Menoufia oncology department, Berkit El Sabee, EG, ²Palliative Medicine Unit Palliative Medicine Unit, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, EG, ³Menoufia national liver institute, Berkit El Sabee, EG, ⁴Menoufia oncology department, Monoufia Shebin El Kom, EG

- 12:00 - 12:00 **1600P - Efficacy of a decision aid consisting of a video and booklet on advance care planning for advanced cancer patients: randomized controlled trial**
Y.H. Yun, Seoul National University Hospital, Seoul, KR
- 12:00 - 12:00 **1601P - Clinical predictors for analgesic response to radiotherapy in patients with painful bone metastases**
R. Habberstad¹, T.C. Frøseth¹, N. Aass², E. Bjerkeset³, T. Abramova⁴, E. Garcia-Alonso⁵, M. Caputo⁶, R. Rossi⁷, J. Boland⁸, C. Brunelli⁹, J.-Å. Lund¹⁰, S. Kaasa¹¹, P. Klepstad¹²,
1NTNU-Norwegian University of Science and Technology, Trondheim, NO, 2Oslo University Hospital, and Institute of Clinical Medicine, Oslo, NO, 3Oslo University Hospital, and Institute of Clinical Medicine, Nydalen, NO, 4Ålesund Hospital, Møre and Romsdal Hospital Trust, Ålesund, NO, 5Arnau de Vilanova University Hospital, Lleida, ES, 6Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, 7Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, 8Wolfson University of Hull, Hull, GB, 9Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, IT, 10Ålesund hospital and Faculty of Medicine and Health Sciences, Ålesund, NO, 11Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, 12St Olavs hospital, Trondheim University Hospital, Trondheim, NO
- 12:00 - 12:00 **1602P - 30-Day Mortality in Palliative Radiotherapy**
S.F. Lee¹, F.C.S. Wong², 1Tuen Mun Hospital, Tuen Mun, HK, 2Tuen Mun Hospital, Hong Kong, HK
- 12:00 - 12:00 **1603P - The relationship between Naldemedine administration and the maximum dose of oral opioids**
S. Kajiura, S. Chikaoka, T. Yokota, A. Kadota, S. Fukai, T. Matsushita, N. Hayashi, Y. Yagi, N. Ryu, H. Horikawa, K. Takemura, A. Furuichi, K. Nakajima, I. Moto, S. Nanjyo, H. Mihara, T. Ando, N. Murakami, I. Yasuda, R. Hayashi, Toyama University Hospital, Toyama, JP
- 12:00 - 12:00 **1604P - Exposure to low energy amplitude modulated radiofrequency electromagnetic fields (EMF) is associated with rapid improvement in quality of life (QoL) status in patients with advanced hepatocellular carcinoma (HCC), using various analyses of EORTC-C30.**
E. Santana¹, F. Costa¹, Y. Setogute², L. Carvalho², P. Lima², M. Sousa¹, B. Gunz¹, F. Azevedo¹, J. Sabbaga¹, M. Santos¹, T. Biachi¹, D. Jardim¹, D. Freitas¹, N. Horvat¹, R. Otaviano¹, L. Testagrossa¹, A. Iemma³, F. Soares⁴, J. Tuszynski⁵, 1Hospital Sirio Libanes, Sao Paulo, BR, 2Hospital Sirio Libanês, São Paulo, BR, 3University of São Paulo, Piracicaba, BR, 4University of São Paulo, São Paulo, BR, 5University of Alberta, Edmonton, CA
- 12:00 - 12:00 **1605P - Olanzapine Combined with 5-HT3 RA Plus Dexamethasone for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in High and Moderate Emetogenic Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials**
J.-G. Zhou, Zunyi Medical College Affiliated Hospital, Zunyi, CN
- 12:00 - 12:00 **1606P - Early Palliative care in advanced cancer, is it really effective?**

R. Gómez Bravo¹, J. Sánchez González¹, B. Núñez García¹, A.M. Morito Aguilar¹, F. García Recio¹, A. Ruano Raviña², M. Méndez García³, B. Cantos³, M. Provencio³,
¹Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, ES, ²Universidad de Santiago de Compostela, Santiago de Compostela, ES, ³Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES

12:00 - 12:00 **1607P - Deprescribing Potentially Inappropriate Medication in Cancer Patients**

S. Reuter, T. Petersen, Bispebjerg Hospital, Copenhagen, DK

12:00 - 12:00 **1608P - Spirituality and religious coping for Cancer patients and providers: An 'Almighty' belief for palliative care**

V. Pareek, R. Bhalavat, M. Chandra, Jupiter Hospital, Mumbai, IN

12:00 - 12:00 **1609P - Is there a difference of Palliative care problems and needs between cancer and non-cancer hospitalized elderly patients?**

I. Chatzi¹, E. Patiraki², P. Sourtzi², I. Tsatsou³, A. Tsompanoglou¹, S. Katsaragakis²,
¹General Hospital Konstantopoulou-Agia Olga, Athens, GR, ²National and Kapodistrian University of Athens, Athens, GR, ³Hellenic AirForce General Hospital, Athens, GR

12:00 - 12:00 **1610P - There is a lack of clinical research for patients with cancer in palliative care**

M. Vinches¹, A. Neven², L. Fenwarth³, M. Terada³, G. Rossi², S. Kelly², J. Peron⁴, M. Thomaso⁵, M. Groenvold⁶, T. De Rojas², ¹ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ²EORTC, Bruxelles, BE, ³EORTC - European Organisation for Research and Treatment of Cancer, Brussels, BE, ⁴Lyon Sud Hospital Center, Pierre Bénite, FR, ⁵Institut Régional du Cancer de Montpellier, Montpellier, FR, ⁶Bispebjerg Hospital, Copenhagen, DK

12:00 - 12:00 **1611P - Specialist Palliative Care (SPC) in Haematological Malignancy: Establishing practices in a UK Tertiary Cancer Centre (TCC)**

E. Kedgley¹, M. Nanda Kumar², P. Sriskandarajah³, S. Bird², M. Ethell², J. Droney⁴, A. Halley², ¹Royal Brompton Hospital, London, GB, ²Royal Marsden Hospital, London, GB, ³The Institute of Cancer Research (Sutton Site), Sutton, GB, ⁴Royal Marsden Hospital NHS Foundation Trust, London, GB

12:00 - 12:00 **1612P - Evaluation of the relationship between the attachment styles and psychological resilience of cancer patients receiving chemotherapy**

F. Bugdayci Basal¹, S. Onur², D. Yamac³, C. Karacin⁴, İ. Bilgetekin⁵, B. Çakmak Öksüzoğlu⁶, U. Demirci⁷, ¹Ataturk Egitim ve Arastirma Hastanesi tibbi onkoloji klinik, Izmir, TR, ²Ankara Atatürk Chest and Surgery Education and Research Hospital, Ankara, TR, ³Ankara Güven Hospital, Ankara, TR, ⁴Ankara Yıldırım Beyazıt Dışkapı Research and Training Hospital, Ankara, TR, ⁵Dr. A.Y.Ankara Oncology Research and Training Hospital, Ankara, TR, ⁶Dr.Abdurrahman Yurtarslan Research and Training Hospital, Ankara, TR, ⁷Health Sciences University, Ankara, TR

12:00 - 12:00 **1613P - Gefitinib along with Methotrexate as palliative therapy in PS 3 and above in metastatic squamous cell carcinoma head and neck cancer patients**

V. Dusi, D. Pallanki, S. Nirni, S. Atilli, V. Andra, V. Ch, Omega Hospitals, Hyderabad, IN

- 12:00 - 12:00 **1614P - High intensity end-of-life care in pediatrics, adolescent and young adult patients with cancer using an administrative database.**
S. Bun¹, S. Kunisawa¹, N. Sasaki¹, K. Matsumoto², A. Yamatani², Y. Imanaka¹, ¹Kyoto University, Kyoto, JP, ²National Center for Child Health and Development, Tokyo, JP
- 12:00 - 12:00 **1615P - Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital**
D.C. Guven¹, O.H. Aktepe², Z. Berk², G. Guner², H. Taban², B.Y. Aktas², Z.C. Duran², S. Akin², Z. Arik², N. Kertmen², S. Kilickap², A. Turker², O. Dizdar², ¹Hacettepe University Faculty of Medicine, Ankara, TR, ²Hacettepe University Cancer Institute, Ankara, TR
- 12:00 - 12:00 **Psycho-oncology**
- 12:00 - 12:00 **1618P - Internet-based stepped care for individuals with cancer and concurrent anxiety or depression symptoms - results from a randomized controlled trial**
B. Johansson¹, A. Hauffman², A. Bill-Axelsson³, S. Alfnsson⁴, L. Von Essen⁵, H. Nygren¹, H. Igelström⁶, ¹Uppsala University - Rudbecklaboratoriet, Uppsala, SE, ²Akademiska Sjukhuset Uppsala, Uppsala, SE, ³Uppsala University, Uppsala, SE, ⁴Section of Clinical Psychology in Healthcare, UPPSALA, SE, ⁵Uppsala University, UPPSALA, SE, ⁶Experimental and Clinical Oncology, Uppsala, SE
- 12:00 - 12:00 **1619P - Impact of Cognitive-Behavioral-Therapy (CBT) on levels of anxiety, depression and distress in cancer patients (pts)**
D. Tregnago¹, L. Carbognin², I. Trestini¹, A. Avancini¹, G. Sartori¹, E. Fiorio³, V. Parolin³, M. Lanza¹, M. Rimondini¹, L. Del Piccolo⁴, E. Bria⁵, M. Milella⁶, S. Pilotto³, ¹University of Verona Hospital Trust, Verona, IT, ²Fondazione Policlinico Universitario A. Gemelli, I.R.C.C.S., Università Cattolica del Sacro Cuore, Roma, IT, ³AOU Integrata Borgo Roma Verona, Verona, IT, ⁴University of Verona, Verona, IT, ⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, IT, ⁶Università degli Studi di Verona, Verona, IT
- 12:00 - 12:00 **1620P - Cytokine genetic variations and worse quality of life among family caregivers of head and neck cancer patients in palliative care**
D. Pequeno¹, J. Carron², K. Gaspar³, C. Lima³, G. Lourenço³, ¹Universidade Estadual de Campinas, Campinas, BR, ²Faculty of Medical Sciences, University of Campinas, Sao Paulo, BR, ³Faculty of Medical Sciences, University of Campinas, Campinas, BR
- 12:00 - 12:00 **1621P - Health-related quality of life of advanced melanoma survivors treated with CTLA-4 immune checkpoint inhibition: a matched cohort study**
A. Boekhout¹, A. Rogiers², K. Jozwiak¹, M. Boers-Sonderen³, A.J.M. Van Den Eertwegh⁴, G. Hospers⁵, J. De Groot⁶, M. Aarts⁷, E. Kapiteijn⁸, A. Ten Tije⁹, D. Piersma¹⁰, G. Vreugdenhil¹¹, A. Van Der Veldt¹², K. Suijkerbuijk¹³, E. Rozeman¹, B. Neyns¹⁴, K. Janssen¹⁵, L. Van De Poll-Franse¹⁶, C. Blank¹⁷, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²Centre Hospitalier Universitaire

Brugmann, Brussels, BE, ³Radboud University Medical Centre, Nijmegen, NL, ⁴Amsterdam UMC, Vrije Universiteit, Amsterdam, NL, ⁵University Medical Centre Groningen, Groningen, NL, ⁶Isala Clinics, Zwolle, NL, ⁷Atrium Medisch Centrum, Maastricht, NL, ⁸Leids Universitair Medisch Centrum (LUMC), Leiden, NL, ⁹Amphia Ziekenhuis-location Molengracht, Breda, NL, ¹⁰Medisch Spectrum Twente (MST) - Radiological Examination (only), Enschede, NL, ¹¹Maxima Medisch Centrum -Veldhoven, Veldhoven, NL, ¹²Erasmus University Medical Center, Rotterdam, NL, ¹³University Hospital Utrecht, Utrecht, NL, ¹⁴Universitair Ziekenhuis, Brussels, BE, ¹⁵Bristol-Myers Squibb, Utrecht, NL, ¹⁶Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ¹⁷The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

- 12:00 - 12:00 **1622P - Capecitabine vs Cisplatin along with concurrent radiotherapy in the treatment of inoperable lower esophageal cancers focusing on TWISTT score and QOL**
G. Anugu, S. Dattatreya Palanki, S. Atilli, Omega Hospitals, Hyderabad, IN
- 12:00 - 12:00 **1623P - Cancer, Mental Health and End Life Simulation (CAMhELS): A novel effectiveness evaluation.**
A. Fernando¹, T. Benepal², K. Thillai³, O. Minton², J. Kelly², L. Breeze¹, C. Broom¹, N. Gosling², ¹St George's University of London, London, GB, ²St George's Hospital NHS Trust, London, GB, ³Guys and St Thomas' NHS Trust, EH, GB
- 12:00 - 12:00 **1624P - Cancer patients' expectations and understanding about their disease**
M. Pinho, J. Godinho, CHEDV - Centro Hospitalar de Entre o Douro e Vouga E.P.E., Santa Maria da Feira, PT
- 12:00 - 12:00 **1625P - Impact of patients' death on oncologists and coping strategies: An online survey**
S. Labidi¹, H. El Benna², S. Sghaier¹, N. Nsiri¹, M. Nesrine¹, Y. Berrazega², N. Daoud², H. Boussen¹, ¹Abderrahmen Mami Hospital, Ariana, TN, ²Abderrahmen Mami Hospital, Tunis, TN
- 12:00 - 12:00 **Supportive care**
- 12:00 - 12:00 **1759P - Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre**
A. Sbrana¹, F. Paolieri¹, E. Sammarco¹, F. Bloise¹, G. Zucchelli¹, V. Massa², G. Lorenzini¹, B. Borelli³, A. Boccaccino⁴, S. Catanese¹, I. Pecora¹, L. Galli⁵, A. Fontana¹, A. Falcone¹, A. Antonuzzo¹, ¹Azienda Ospedaliera Universitaria S.Chiara, Pisa, IT, ²Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Pisa, IT, ³Univeristy Degli Studi di Pisa, Pisa, IT, ⁴University of Pisa, Pisa, IT, ⁵Azlenda Ospendaliero-Universitaria Pisana, Santa Maria, IT
- 12:00 - 12:00 **1760P - The relationships among decisional conflict, decisional role preference and preference for advance care planning**
E. Kang, Y.H. Yun, Seoul National University Hospital, Seoul, KR

- 12:00 - 12:00 **1761P - Preparedness for caregiving in caregivers of cancer patients**
H. Yakar¹, S. Oguz², B. Tavsan², C. Er², H.M. Catalbas², M. Sari², ¹Marmara University Faculty of Health Sciences, Istanbul, TR, ²Marmara University Faculty of Health Sciences, istanbul, TR
- 12:00 - 12:00 **1762P - Oncologic Emergency Medicine in the real world: A survey and proposal for improvement**
C. Dorta Pérez, M. Pulido Torrente, I. Castellano Carneiro, A. Martín Quesada, M. Morales González, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, ES
- 12:00 - 12:00 **1763P - The Reality of Critical Cancer Patients in a Polyvalent Intensive Care Unit**
T.F. Da Cruz Tomas¹, I. Eiriz¹, M. Neves², F. Gama³, G. Almeida², M. Rebelo², T. Lamas², I. Gaspar², I. Simões², E. Carmo², ¹Hospital Prof. Dr Fernando Fonseca E.P.E (Amadora/Sintra), Amadora, PT, ²Centro Hospitalar Lisboa Ocidental, Lisboa, PT, ³Centro Hospitalar Lisboa Ocidental, Carnaxide, PT
- 12:00 - 12:00 **1764P - A phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE Study**
H. Hashimoto¹, M. Abe², M. Nakao³, H. Mizutani⁴, Y. Sakata⁵, Y. Fujita⁶, T. Nishimura⁷, K. Hirano⁸, H. Okada⁹, N. Inui¹⁰, Y. Sakata¹¹, H. Iihara¹², S. Zenda¹, Y. Uchitomi¹, T. Yamaguchi¹³, Y. Hoshina¹, T. Yanai¹, S. Iwasa¹, N. Yamamoto¹, Y. Ohe¹, ¹National Cancer Center Hospital, Tokyo, JP, ²Shizuoka Cancer Center, Shizuoka, JP, ³Osaka City General Hospital, Osaka, JP, ⁴Saitama Cancer Center, Saitama, JP, ⁵Hiroshima City Hiroshima Citizens Hospital, Hiroshima, JP, ⁶Gunma Prefectural Cancer Center, Gunma, JP, ⁷Wakayama Medical University Hospital, Wakayama, JP, ⁸Hyogo Prefectural Amagasaki General Medical Center, Hyogo, JP, ⁹Kobe Minimally Invasive Cancer Center, Hyogo, JP, ¹⁰Hamamatsu University Hospital, Shizuoka, JP, ¹¹Hakodate Municipal Hospital, Hokkaido, JP, ¹²Gifu University Hospital, Gifu, JP, ¹³Tohoku University Graduate School of Medicine, Miyagi, JP
- 12:00 - 12:00 **1765P - Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)**
L. Schwartzberg¹, M. Aapro², ¹West Cancer Center, Germantown, US, ²Clinique de Genolier, Genolier, CH
- 12:00 - 12:00 **1766P - Efficacy of olanzapine combination in prevention of nausea & vomiting in highly emetogenic chemotherapy**
S. Saldanha¹, L. Dasappa¹, L. Jacob¹, S. Babu¹, K.N. Lokesh¹, A. Rudresha¹, R. Lakkavalli², J. Kumar¹, ¹Kidwai Memorial Institute of Oncology, Bangalore, IN, ²Kidwai Cancer Institute, Bangalore, IN
- 12:00 - 12:00 **1767P - Patient-reported outcome data during real-world use of NEPA for prevention of chemotherapy-induced nausea and vomiting in high-risk platin-**

receiving patients - A prospective multicenter trial

M. Karthaus¹, V. Heilmann², M. Klausmann³, G. Kaltenecker⁴, B. Whitlock⁵, J. Schilling⁶,
¹Klinikum Neuperlach-Staedtisches Klinikum Muenchen, Munich, DE, ²Praxis, Günzburg, DE, ³Gemeinschaftspraxis, Berlin, DE, ⁴Städtisches Klinikum, Karlsruhe, DE, ⁵Ontologische Tagesklinik, Balingen, DE, ⁶No place of work provided, No City Provided, NA

- 12:00 - 12:00 **1768P - A study evaluating steroid induced metabolic syndrome after antiemetic dexamethasone therapy in patients received high emetic risk chemotherapy**
H.J. Kim, S.E. Park, Chung-Ang University Hospital, Seoul, KR
- 12:00 - 12:00 **1769P - High incidence of nausea during initial and repeated courses if intravenous chemotherapy in patients receiving guideline consistent antiemetic prophylaxis - a prospective, observational, real world study.**
T. Smit¹, R. Van Eeden², B. Rapoport¹, ¹The Medical Oncology Centre of Rosebank, Sandton, ZA, ²The Medical Oncology Centre of Rosebank, Johannesburg, ZA
- 12:00 - 12:00 **1770P - "Randomised controlled trial of Scalp Cooling (SC) for the prevention of Chemotherapy Induced Alopecia (CIA)"**
J. Bajpai¹, S. Kagwade¹, S. Dandekar¹, A. Chandrashekharan², S. Kannan¹, J. Ghosh¹, S. Banavali³, S. Gupta¹, ¹Tata Memorial Centre, Mumbai, IN, ²Aster MIMS Hospital, Kozhikode, IN, ³Tata Memorial Hospital, Mumbai, IN
- 12:00 - 12:00 **1771P - Performance of the '4S rule' to predict short-term outcomes in cancer outpatients with unsuspected pulmonary embolism.**
D. Pesántez Coronel¹, D. Muñoz Guglielmetti¹, F. Posch², C. Ay³, M. Aramberri⁴, M.D.C. Beato Zambrano⁵, C. Font¹, ¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ²Medical University of Graz, Graz, AT, ³Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT, ⁴Hospital Universitario 12 de Octubre, Madrid, ES, ⁵Hospital Nisa Castilleja de la Cuesta, Castilleja de la Cuesta, ES
- 12:00 - 12:00 **1772P - Prevalence of venous thromboembolism based on intensive screening for patients with advanced solid tumor in prospective observational study**
S. Omori¹, H. Kenmotsu¹, A. Notsu¹, K. Mori¹, T. Tsushima¹, Y. Satake², Y. Miki³, M. Abe¹, M. Ogiku⁴, T. Nakamura⁵, M. Takagi⁶, H. Ochiai⁷, H. Yasui¹, T. Takahashi¹,
¹Shizuoka Cancer Center, Shizuoka, JP, ²Shizuoka City Shizuoka Hospital, Shizuoka, JP, ³Seirei Hamamatsu General Hospital, Hamamatsu, JP, ⁴Hamamatsu Medical Center, Hamamatsu, JP, ⁵Fujieda Municipal General Hospital, Fujieda, JP, ⁶Shizuoka General Hospital, Shizuoka, JP, ⁷Iwata City Hospital, Iwata, JP
- 12:00 - 12:00 **1773P - Short-term outcomes of cancer patients with pulmonary embolism according to the setting (hospital-acquired vs. outpatient) at diagnosis.**
D. Muñoz Guglielmetti¹, D. Pesántez¹, F. Posch², C. Ay³, M. Aramberri⁴, M.D.C. Beato Zambrano⁵, C. Diaz-Pedroche⁴, C. Font¹, ¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ²Medical University of Graz, Graz, AT, ³Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT, ⁴Hospital Universitario 12 de Octubre, Madrid, ES, ⁵Hospital Nisa Castilleja de la Cuesta, Castilleja de la Cuesta, ES

- 12:00 - 12:00 **1774P - Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer**
A. Cohen¹, A. Maraveyas², J. Beyer-Westendorf³, A. Lee⁴, L. Mantovani⁵, K. Folkerts⁶, M. Bach⁷, Y. De Sanctis⁸, K. Abdelgawad⁶, ¹Guys and St Thomas NHS Trust, London, GB, ²Castle Hill Hospital, Cottingham, GB, ³University Hospital “Carl Gustav Carus” Dresden, Dresden, DE, ⁴University of British Columbia, Vancouver, CA, ⁵University of Milan-Bicocca, Milano MI, IT, ⁶Bayer AG, Berlin, DE, ⁷Bayer Pharma AG, Berlin, DE, ⁸Bayer AG, Whippany, US
- 12:00 - 12:00 **1775P - Incidence of Vascular Thromboembolism Events in Cancer Patients Receiving Immunotherapy: A Single Institution Experience.**
L. Gutiérrez Sainz, V. Martínez-Marin, D. Viñal Lozano, D. Martínez Pérez, J. Pedregosa Barbas, J.A. García Cuesta, J. Villamayor Sánchez, P. Zamora, A. Pinto Marin, B. Castelo, A. Redondo, A. Gallego Martínez, P. Cruz, O. Higuera Gomez, A. Custodio, D. Sánchez Cabrero, J. De Castro Carpeno, E. Espinosa, J. Feliu Batlle, Hospital Universitario La Paz, Madrid, ES
- 12:00 - 12:00 **1776P - High Incidence of Venous Thromboembolic Events (VTE) in Patients with Diffuse Large B-Cell Lymphoma.**
A. Abufara¹, M. Ma'Koseh¹, A. Mansour¹, M. Manasrah¹, M. Al-Rawashdeh¹, M. Almomani¹, M. Zmaily¹, R. Amarin¹, H. Abdel-Razeq², ¹King Hussein Cancer Center KHCC, Amman, JO, ²KHCC, Amman, JO
- 12:00 - 12:00 **1777P - Weight Loss over Time in Non-Small Cell Lung Cancer: Results from a Landmark Analysis of 800+ Prospectively-Treated Patients**
J. Le-Rademacher, C. Lopez, E. Wolfe, A. Jatoi, Mayo Clinic, Rochester, US
- 12:00 - 12:00 **1778P - The prognostic significance of preoperative nutritional status in resected pancreatic ductal adenocarcinoma (PDAC).**
S. Paiella¹, I. Trestini¹, I. Sperduti², M. Sandini³, G. Elio¹, D. Melisi¹, A. Auriemma¹, C. Soldà¹, D. Tregnago¹, A. Avancini¹, E. Secchettin¹, D. Bonamini¹, G. Malleo¹, L. Gianotti³, S. Pilotto⁴, C. Bassi¹, M. Milella¹, ¹University of Verona Hospital Trust, Verona, IT, ²Bio-Statistics Unit, Regina Elena National Cancer Institute, Roma, IT, ³University of Milano-Bicocca, Monza, IT, ⁴AOU Integrata Borgo Roma Verona, Verona, IT
- 12:00 - 12:00 **1779P - Impact of Timing and Technique of Gastrostomy Placement on the Outcome of Patients (pts) with Head and Neck Cancer (HNC)**
M.J. Lostes Bardaji¹, N. Diaz², A. Hernando², C. Puiggrós², G. Vilacampa², J. Assaf², N. Saudi², J. Ros¹, A. Garcia², C. Bescós-Atin², J. Lorente², J. Giralt², C. Viaplana¹, M. Biosca², J. Taberner³, E. Felip¹, R. Dienstmann¹, I. Brana¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron University Hospital, BARCELONA, ES, ³Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES
- 12:00 - 12:00 **1780P - Clinical & nutritional determinants of quality of life in patients with incurable cancer**
L. Daly¹, E.S. Sullivan¹, R. Dolan², É. Ní Bhuachalla¹, S. Cushen¹, M. Fallon³, C.

Simmons³, D. Mcmillan², B. Laird³, A. Ryan¹, D. Power⁴, ¹University College Cork, Cork, IE, ²University of Glasgow, Glasgow, GB, ³University of Edinburgh, Edinburgh, GB, ⁴Cork & Mercy University Hospitals, Cork, IE

12:00 - 12:00 **1781P - Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer**

I.G. Hwang¹, S.E. Park¹, S.-C. Lee², J.H. Choi¹, ¹Chung-Ang University Hospital, Seoul, KR, ²Soonchunhyang University Hospital Cheonan, Cheonan, KR

12:00 - 12:00 **1782P - Impact of nutritional derangement on treatment outcome in advanced non-small-cell lung cancer (A-NSCLC) patients (pts).**

I. Trestini¹, I. Sperduti², M. Sposito³, D. Kadrija³, A. Drudi³, D. Tregnago³, A. Avancini³, A. Gkoutakos³, L. Carbognin⁴, A. Santo³, M. D'Onofrio³, M. Lanza³, G. Tortora⁵, E. Bria⁶, M. Milella³, S. Pilotto³, ¹Ospedale Borgo Roma - Policlinico Giovanni Battista Rossi, Verona, IT, ²Bio-Statistics Unit, Regina Elena National Cancer Institute, Roma, IT, ³University of Verona Hospital Trust, Verona, IT, ⁴Fondazione Policlinico Universitario A. Gemelli, I.R.C.C.S., Università Cattolica del Sacro Cuore, Roma, IT, ⁵Fondazione Policlinico Universitario Agostino Gemelli -IRCCS Rome, Rome, IT, ⁶Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, IT

12:00 - 12:00 **1783P - Sarcopenia and pretreatment anemia as prognostic factors for patients with localized muscle invasive bladder cancer treated by neoadjuvant chemotherapy and radical cystectomy**

E. Billon¹, P. Regnier², V. De Luca³, S. Brunelle³, J. Walz², S. Dermeche², M. Guerin², C. Vicier³, T. Maubon², S. Rybikowski², N. Branger², S. Fakhfakh², G. Pignot², G. Gravis², ¹Assistance Publique Hopitaux de Marseille, Marseille, FR, ²Institute Paoli Calmettes, Marseille, FR, ³Institut Paoli-Calmettes, Marseille, FR

12:00 - 12:00 **1784P - Gender effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of anamorelin (ANAM) in healthy volunteers and cancer patients with cachexia**

J.M. Garcia¹, A. Bernareggi², ¹University of Washington School of Medicine, Seattle, US, ²Helsinn Healthcare SA, Pazzallo, CH

12:00 - 12:00 **1785P - The Patient Voice: An Irish Survey of Nutrition Attitudes & Access to Dietetic Care Throughout the Cancer Journey**

E.S. Sullivan¹, N. Rice², E. Kingston¹, A. Kelly¹, L. Daly¹, J. Reynolds³, D. Power⁴, A. Ryan¹, ¹University College Cork, Cork, IE, ²Irish Society of Clinical Nutrition & Metabolism, Dublin, IE, ³Trinity College Dublin, Dublin, IE, ⁴Cork & Mercy University Hospitals, Cork, IE

12:00 - 12:00 **1786P - Homcology: home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients**

C. Chini¹, O. Nigro², A. Giaquinto², E. Magni³, G. Tinelli⁴, L. Bascialla², S. Gobba⁴, G. Pinotti², ¹ASST - Sette Laghi, Varese, IT, ²Ospedale di Circolo Fondazione Macchi, Varese, IT, ³Istituto Europeo di Oncologia, Milan, IT, ⁴ASST-Settelaghi, Ospedale di Circolo Fondazione Macchi, Varese, IT

- 12:00 - 12:00 **1787P - Treatment-related adverse events and tolerability in patients with advanced non-squamous non-small cell lung cancer treated with first-line checkpoint inhibitors in combination with chemotherapy**
R. D'Cunha¹, P. D'Cunha², S. Swarup¹, A. Sultan¹, F. Mogollon-Duffo¹, N. Jahan¹, T. Win Htut³, S. Wongsasengsak¹, N. Adhikari¹, A. Mon⁴, P. Hlaing¹, A.M. Tun⁵, N. D'Cunha¹, K. Thein¹, ¹Texas Tech University, Lubbock, US, ²UT Southwestern Medical Center, Dallas, US, ³Colchester Hospital, Colchester, GB, ⁴Lincoln Medical Center, Brooklyn, US, ⁵Brooklyn Hospital Center, Brooklyn, US
- 12:00 - 12:00 **1788P - Clinical utility of a systematic toxicity assessment form (STAF) in patients with breast cancer receiving adjuvant or neoadjuvant therapy.**
J.H. Kim¹, S. Seo¹, H.-S. Im², J.H. Lim², W.R. Jo², B.B. Im², S.R. Park², ¹Asan Medical Center, Seoul, KR, ²Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR
- 12:00 - 12:00 **1789P - Physicians' satisfaction with Health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients.**
G. Mouillet¹, J. Fritsch², A. Thiery-Vuillemin³, N. Meneveau³, H. Almotlak¹, L. Mansi¹, E. Curtit³, S. Kim³, M. Jary³, T. Maurina¹, G. Eberst³, P. Barthelemy⁴, J.-C. Eymard⁵, L. Geoffrois⁶, O. Djoumakh², A. Anota³, O. Adotevi⁷, V. Westeel³, S. Paget-Bailly², ¹CHRU Besançon - Hopital Jean Minjoz, Besançon, FR, ²University Hospital of Besançon, Besançon, FR, ³CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, ⁴C.H.U. Strasbourg-Nouvel Hopital Civil, Strasbourg, FR, ⁵Institut Jean Godinot, Reims, FR, ⁶Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, ⁷UMR1098, Besançon, FR
- 12:00 - 12:00 **1790P - Predictors of Survival in Patients with Incurable Cancer**
E.S. Sullivan¹, L. Daly¹, R. Dolan², É. Ní Bhuachalla¹, M. Fallon³, C. Simmons³, D. Mcmillan², B. Laird³, A. Ryan¹, D. Power⁴, ¹University College Cork, Cork, IE, ²University of Glasgow, Glasgow, GB, ³University of Edinburgh, Edinburgh, GB, ⁴Cork & Mercy University Hospitals, Cork, IE
- 12:00 - 12:00 **1791P - Patients and Physicians' Satisfaction with Telemedicine (TM) in Cancer Care and Factors that Correlate with a Positive Patient's Experience**
H. Gondal¹, H. Choquette², T. Abbas¹, D. Le¹, H. Chalchal³, N. Iqbal¹, S. Ahmed¹, ¹Saskatoon Cancer Centre University of Saskatchewan, Saskatoon, CA, ²Saskatchewan Cancer Agency, Regina, CA, ³Saskatchewan Cancer Agency-Allan Blair Cancer Centre at Pasqua Hosp, Regina, CA
- 12:00 - 12:00 **1792P - Adherence to ESMO 2014 guidelines on bone-targeting agent (BTA) initiation for breast and prostate cancer patients: real-world insights from practicing European physicians**
A. Seesaghur¹, K. Lewis², D. Bluff², A. Marongiu³, G. Demonty⁴, A. Rider², ¹AMGEN Ltd, Uxbridge, GB, ²Adelphi Group Ltd, Cheshire, GB, ³Amgen Ltd, Uxbridge, GB, ⁴Amgen GmbH, Rotkreuz, CH

- 12:00 - 12:00 **1793P - Use of skeletal-related events preventive agents in patients with solid tumours and bone metastases in central Denmark**
A. Boysen¹, I. Andersen¹, J. Acquavella¹, A. Seesaghur², R. Hernandez³, V. Ehrenstein¹,
¹Aarhus University Hospital, Aarhus, DK, ²AMGEN Ltd, Uxbridge, GB, ³Amgen Inc.,
Thousand Oaks, US
- 12:00 - 12:00 **1794P - Inadequacy of current definition and staging system of Medication-Related Osteonecrosis of Jaw (MRONJ) released by AAOMS : a Computed Tomography study in 151 cancer and myeloma patients**
V. Fusco¹, A. Fasciolo¹, A. Gambino², M. Cabras², F. Erovigni², C. Bianchi², L. Benzi¹, I. De Martino¹, F. Monaco¹, M. Rossi¹, G. Numico¹, S. Carossa², ¹Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT, ²Azienda Ospedaliera Città della Salute, Torino, IT
- 12:00 - 12:00 **1795P - Does bevacizumab increase joint pain ? Preliminary results of BEVARTHRALGIA Study**
V. Enora¹, A. Turpin², L. Lebellec³, A. Mouamnia⁴, F. Machuron⁴, M.H. Vieillard⁵,
¹Centre Hospitalier Régional Universitaire de Lille, Lille, FR, ²Hopital Claude Huriez, Lille, FR, ³DRC / CHRU of Lille, Lille, FR, ⁴Lille University Hospital, Lille, FR, ⁵CHRU de Lille - Hôpital Roger Salengro, Lille, FR
- 12:00 - 12:00 **1796P - Prostatic cancer androgen deprivation therapy and bone health in carcinoma prostate.**
G.S. Bhattacharyya¹, H. Malhotra², K.G. Babu³, A. Ranade⁴, A. Vora⁵, G. Biswas⁶, S. Basu⁷, ¹G M Cancer Research Trust Palliative Care Unit, Salt Lake City Medical Center,, Kolkata, IN, ²Sri Ram Cancer Center, Mahatma Gandhi Hospital,, Jaipur, IN, ³HCG Hospitals, Bangalore, Bengaluru, IN, ⁴Jupiter Hospital, Pune, IN, ⁵W Pratiksha Hospital, Gurugram, Haryana, IN, ⁶Sparsh Hospital, Bhubaneswar, IN, ⁷Fortis Hospital, Kolkata, IN
- 12:00 - 12:00 **1797P - Patterns of care for patients with metastatic bone disease in solid tumors - a cross-sectional study (SAKK 95/16)**
M. Mark¹, B. Thuerlimann², K. Ribi³, C. Schaer⁴, D. Dietrich⁴, U. Zuerrer⁵, R. Von Moos¹,
¹Kantonsspital Graubünden, Chur, CH, ²Brustzentrum Kantonsspital St. Gallen, St. Gallen, CH, ³IBCSG International Breast Cancer Study Group, Bern, CH, ⁴SAKK, Bern, CH, ⁵Kantonsspital St. Gallen, St. Gallen, CH
- 12:00 - 12:00 **1798P - Infection-Related Mortality in Different Types of Cancers**
M. Gouda¹, A. Gouda², ¹Faculty of Medicine - Menoufia University, Shebin El Kom, EG, ²Egyptian Ministry of Health, Tala, EG
- 12:00 - 12:00 **1799P - Survival Trends in Critically ill Oncology Patients: impact of patient's eligibility to post-ICU chemotherapy**
E. Borcoman¹, V. Lemiale², A. Dupont², E. Mariotte², C. Pichereau², L. Doucet³, A. Joseph², A. Chermak², S. Valade², M. Resche-Rigon², E. Azoulay², ¹Institut Curie, Paris, FR, ²APHP Hôpital Saint Louis, Paris, FR, ³Hôpital Saint Louis AP-HP, Paris, FR

- 12:00 - 12:00 **1800P - Development and validation of a multivariable prediction model for 6-month mortality in older cancer patients: the GeriAtrIc-Tumor Score of PrEdiction for Early Death (GAIT SPEED)**
A. Angeli, F. Pamoukdjian, G. Bousquet, Hôpital Avicenne, Bobigny, FR
- 12:00 - 12:00 **1801P - A Longitudinal Tracking and Quantitative Assessment of Paclitaxel-Induced Peripheral Neurotoxicity**
A. Matsuoka¹, A. Mitsuma², O. Maeda², N. Tsunoda¹, T. Kikumori³, Y. Ando², ¹Nagoya University, Graduate School of Medicine, Nagoya, JP, ²Nagoya University Hospital, 名古屋市緑区, JP, ³Nagoya University Hospital, Nagoya, JP
- 12:00 - 12:00 **1802P - Efficiency of controlled cryotherapy in prevention of chemotherapy induced peripheral neuropathy (CIPN)**
T. Schaper¹, M. Rezai², G. Petruschke², B. Gross¹, L. Franzmann¹, M. Darsow¹, ¹Luisenkrankenhaus GmbH & Co KG, Düsseldorf, DE, ²Luisenkrankenhaus, Düsseldorf, DE
- 12:00 - 12:00 **1804P - The Validity of Evaluations for Chemotherapy-Induced Peripheral Neuropathy (CIPN)**
T. Yamada¹, Y. Yoshida², A. Satoh¹, N. Aisu², T. Matsuoka², T. Koganemaru², R. Kajitani², T. Munechika², Y. Matsumoto², H. Nagano², A. Komono², R. Sakamoto², M. Morimoto², H. Arima², S. Hasegawa², ¹Fukuoka University School of Medicine, Fukuoka, JP, ²Fukuoka University School of Medicine, FUKUOKA, JP
- 12:00 - 12:00 **1805P - Prevention of chemoradiation-related mucositis in patients with head and neck cancer using dexamethasone-based mouthwash (Miracle mouthwash): A phase II randomized double-blind, placebo-controlled study**
N. Prasongsook¹, P. Kaewvatee², C. Ajalanond², S. Srichamchan², K. Seetalarom², ¹Phramongkutklao Hospital, Pathumwan, TH, ²Phramongkutklao Hospital, Bangkok, TH
- 12:00 - 12:00 **1806P - Salivary cytokines and oral mucosa cells apoptosis in patients during hematopoietic cell transplantation: possible relationship with oral mucositis**
L. Corrêa¹, L. Bezinelli², F.C. Rosin², M. Ferreira², D. Carvalho², R. Lopes², N. Hamerschlak², F. Eduardo², ¹Universidade de Sao Paulo, Sao Paulo, BR, ²Hospital Israelita Albert Einstein, São Paulo, BR
- 12:00 - 12:00 **1807P - A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401**
T. Yokoyama¹, K. Ninomiya², I. Oze³, T. Hata¹, A. Tanaka¹, A. Bessho⁴, S. Hosokawa⁴, S. Kuyama⁵, K. Kudo⁵, T. Kozuki⁶, D. Harada⁶, M. Yasugi⁷, T. Murakami⁸, M. Nakanishi⁹, N. Takigawa¹⁰, K. Katsui¹¹, Y. Maeda¹¹, K. Hotta¹², K. Kiura¹², ¹Kurashiki Central Hospital, Kurashiki, JP, ²Okayama university of Science, Okayama, JP, ³Aichi Cancer Center, Nagoya, JP, ⁴Japanese Red Cross Okayama Hospital, Okayama, JP, ⁵NHO Iwakuni Medical Center, Iwakuni, JP, ⁶NHO Shikoku Cancer Center, Matsuyama, JP, ⁷Chugoku Central Hospital, Fukuyama, JP, ⁸Onomichi Municipal Hospital, Onomichi, JP, ⁹NHO Yamaguchi-

Ube Medical Center, Ube, JP, ¹⁰Kawasaki Medical School, Okayama, JP, ¹¹Okayama University Graduate School of Medicine, Okayama, JP, ¹²Okayama University Hospital, Okayama, JP

- 12:00 - 12:00 **1808P - Taste and smell alterations (TSAs) in patients (pts) with stage II-III colon cancer (CC): a pilot within the PROTECT study**
J. Derksen¹, M. Koopman², D. Ten Bokkel Huinink³, D. Sommeijer⁴, B. Dorresteijn⁵, M. Jourdan⁵, A. May¹, ¹UMC-University Medical Center Utrecht, Utrecht, NL, ²University Hospital Utrecht, Utrecht, NL, ³Diakonessenhuis Utrecht, Utrecht, NL, ⁴Flevo hospital Almere, Almere, NL, ⁵Danone Nutricia Research, Utrecht, NL
- 12:00 - 12:00 **1809P - Clinical characteristics are associated with acupuncture treatment response for xerostomia in cancer patients**
W. Liu¹, A. Qdaisat², G. Lopez², S. Narayanan², S.U. Susan Underwood², M. Spano², A. Reddy², Y. Guo², E. Bruera², L. Cohen³, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²MD Anderson Cancer Center, Houston, US, ³The University of Texas M. D. Anderson Cancer Center, Houston, US
- 12:00 - 12:00 **1810P - Psychosocial Distress of Adolescent and Young Adults with Cancer at Diagnosis: A Case-Matched Retrospective Cohort of 2045 Patients in British Columbia.**
A. Smrke¹, B. Leung², A. Bates², A. Srikanthan³, C. Ho², ¹BC Cancer, Vancouver, CA, ²BC Cancer Agency, Vancouver, CA, ³The Ottawa Hospital, Ottawa, CA
- 12:00 - 12:00 **1811P - Accuracy of distress thermometer to measure cancer-related mood disorders in Chinese patients with cancer**
S. Thapa, Wuhan Tongji Hospital, Wuhan, CN
- 12:00 - 12:00 **1812P - Modalities of biosimilar filgrastim use in clinical practice in >1000 patients receiving chemotherapy regimens with a rest period of ≤14 days: the TOPAZE study**
J.M. Phelip¹, P.-J. Souquet², S. Bordenave³, M. Declerck⁴, E. Nabirotkina⁴, O. Tredan⁵, ¹Centre Hospitalier Universitaire de Saint-Étienne, Saint-Priest-en-Jarez, FR, ²Hospices Civils de Lyon, Lyon, FR, ³Centre Hospitalier Universitaire de Nantes, Nantes, FR, ⁴Sandoz, Paris, FR, ⁵Centre Léon Bérard, Lyon, FR
- 12:00 - 12:00 **1813P - The Effect of Increasing Doses of Pegfilgrastim (Peg) on Thrombocytopenia (T) in Breast Cancer (BC) Patients (pts) Receiving Taxotere (Doc), Doxorubicin, Cyclophosphamide (TAC) and Plinabulin (Plin)**
D. Blayney¹, I. Bondarenko², Y. Shi³, S. Ogenstad⁴, L. Du⁵, L. Huang⁶, R. Mohanlal⁷, ¹Stanford Cancer Institute, Stanford, US, ²Dnipropetrovsk city multidisciplinary clinical hospital №4, Dnipro, UA, ³Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, ⁴Statogen Consulting, LLC, Zebulon, US, ⁵Wanchun Bulin Pharmaceuticals Limited, Dalian, CN, ⁶BeyonsSpring Pharmaceuticals, Inc, New York, US, ⁷BeyondSpring Pharmaceuticals, New York, US
- 12:00 - 12:00 **1814P - The use of intravenous ferric carboxymaltose without erythropoiesis-stimulating agents in the treatment of anemia in cancer patients undergoing**

chemotherapy with or without radiotherapy

H. Abdel-Razek¹, S. Saadeh², R. Malhis², O. Al-Natour², S. Yaser², H. Abdulelah², R. Eljaber², G. Khalaf², ¹KHCC, Amman, JO, ²King Hussein Cancer Center KHCC, Amman, JO

12:00 - 12:00 **1815P - Randomized, double-blind, cross-over Phase I study comparing pharmacokinetics, pharmacodynamics, safety and immunogenicity of a biosimilar pegfilgrastim with EU and US references**

M. Velinova¹, A. Bellon², R. Nakov², S. Schussler³, S. Schier-Mumzhiu², C. Schelcher², S. Koch², A. Skerjanec⁴, J. Wang³, A. Krendyukov², G.P. Otto², ¹PRA Health Science, Groningen, NL, ²Hexal AG, Holzkirchen, DE, ³Sandoz Inc., Princeton, US, ⁴Novartis AG, Basel, CH

12:00 - 12:00 **1816P - Prophylaxis with Lipegfilgrastim in patients with primary breast cancer receiving dose dense chemotherapy: results from the German NIS NADENS**

M. Kiechle¹, C. Schem², D. Lüftner³, X. Hamann⁴, R. Jünemann⁵, M. Tölg⁶, U. Köhler⁷, ¹Rechts der Isar Hospital, TUM, Munich, DE, ²UK-SH, Campus Kiel, Kiel, DE, ³Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE, ⁴Teva Health GmbH, Ulm, DE, ⁵Teva GmbH, Ulm, DE, ⁶Mediveritas GmbH, Munich, DE, ⁷Klinikum St. Georg, Leipzig, DE

12:00 - 12:00 **1817P - Randomized phase 2 trial evaluating the safety of peripherally inserted central catheters vs implanted port catheters during adjuvant chemotherapy in early breast cancer patients.**

F. Clatot¹, M. Fontanilles¹, L. Lefebvre¹, J. Lequesne¹, C. Veyret¹, C. Alexandru¹, M. Leheurteur¹, C. Guillemet¹, S. Gouérent¹, C. Petrau¹, J.-C. Thery¹, O. Rigal², C. Moldovan¹, I. Tennevet Bouilly¹, O. Rastelli¹, M. Bubenheim³, D. Georgescu¹, J. Gouérent¹, M. Gilles-Baray¹, F. Di Fiore⁴, ¹Centre Henri Becquerel, Rouen, FR, ²Centre Henri-Becquerel, Rouen, FR, ³Rouen University Hospital, Rouen, FR, ⁴Hop. Charles Nicolle, Rouen, FR

12:00 - 12:00 **1818P - Simultaneous intravenous fluid infusion to prevent oxaliplatin infusion-related venous pain**

S. Van Ravensteijn, B. Van Merrienboer, S. Van Asten, J. Pruijt, M. Hilbink, J. Tol, Jeroen Bosch Hospital, 's-Hertogenbosch, NL

12:00 - 12:00 **1819P - Clinical practice evaluation of opioids induced constipation management in cancer patients: The EIO-Praxis project.**

E. Aranda Aguilar¹, J. Garcia Foncillas², A. Antón³, C.J. Camps Herrero⁴, A. Carrato Mena⁵, M. Constenla Figueiras⁶, J.J. Cruz Hernandez⁷, E. Diaz Rubio⁸, P. Gascon⁹, V. Guillem Porta¹⁰, R. López¹¹, M. Feyjóo¹², J. Puente⁸, ¹University Hospital Reina Sofia, Cordoba, ES, ²University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ³Hospital Universitario Miguel Servet, Zaragoza, ES, ⁴Hospital General Universitario Valencia, Valencia, ES, ⁵Hospital Universitario Ramon y Cajal, Madrid, ES, ⁶Complejo Hospitalario de Pontevedra, Pontevedra, ES, ⁷Hospital Universitario de Salamanca, Salamanca, ES, ⁸Hospital Clinico Universitario San Carlos, Madrid, ES, ⁹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹⁰IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, ¹¹Hospital Clínico Universitario de Santiago (CHUS), Santiago de Compostela, ES,

¹²Fundación ECO, Hospital Universitario La Moraleja Sanitas, Madrid, ES

12:00 - 12:00 **1820P - Development of a composite cancer pain prognostication model**

R. D. Arora, All India Institute of Medical Sciences, Delhi, IN

12:00 - 12:00 **1821P - Analysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxative-inadequate response.**

M. Cobo Dols¹, M.D.C. Beato Zambrano², L. Cabezón Gutiérrez³, R. Chicas Sett⁴, I. Blancas⁵, F. García Navalón⁶, J. Firvida Pérez⁷, G. Serrano Bermúdez⁸, P. Togores Torres⁹, I. Delgado Mingorance¹⁰, A. Giraldo Marín¹¹, A. Librán Oriol¹², A. Paredes Lario¹³, P. Sánchez Mauriño¹⁴, O. Higuera Gomez¹⁵, D. Moreno Muñoz¹⁶, A. Jiménez López¹⁷, I. Huerta González¹⁷, A. Sanz Yagüe¹⁷, B. Soler López¹⁸, ¹¹ Hospital Regional Universitario de Málaga, Málaga, ES, ²Hospital Nisa Castilleja de la Cuesta, Castilleja de la Cuesta, ES, ³Hospital Universitario de Torrejón, Madrid, ES, ⁴Hospital Campo Grande. Grupo Recoletas, Valladolid, ES, ⁵Hospital Clinico San Cecilio, Granada, ES, ⁶Hospital son Llatzer, Palma de Mallorca, ES, ⁷COSAGA-Ourense, Ourense, ES, ⁸ICO Hospitalet, Barcelona, ES, ⁹Centro Oncológico de Galicia - COG, A Coruña, ES, ¹⁰Hospital Universitario Infanta Cristina, Badajoz, ES, ¹¹Hospital Universitari Vall d'Hebron, Barcelona, ES, ¹²Consorci Sanitari de Tarrasa, Tarrasa, ES, ¹³Hospital Universitario Donostia, San Sebastián, ES, ¹⁴Hospital Reina Sofía, Córdoba, ES, ¹⁵Hospital Universitario La Paz, Madrid, ES, ¹⁶Hospital Universitario Fundación Alcorcón, Alcorcón, ES, ¹⁷Kyowa Kirin Farmacéutica, S.L.U., Madrid, ES, ¹⁸E-C-BIO, S.L., Las Rozas, ES

12:00 - 12:00 **1822P - Consensus on strategies in the management of opioid-induced constipation in cancer patients**

R. Girones Sarrio¹, E. Falcó², A. Gozalvo³, J.M. Esparza Miñana⁴, A. Calsina-Berna⁵, J. Porta Sales⁵, ¹Hospital Luis Alcanyís De Xativa, Xativa, ES, ²Hospital Son Llatzer, Mallorca, ES, ³Hospital Universitario Dr Peset, Valencia, ES, ⁴Hospital de Manises, Manises, ES, ⁵Institut Català d'Oncologia, Barcelona, ES

12:00 - 12:00 **1823P - Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial**

Y. Lou¹, L. Jia¹, J. Wang², H. Sun³, G. Yang⁴, R. Yu¹, X. Wu¹, T. He³, ¹China-Japan Friendship Hospital, Beijing, CN, ²Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, ³Beijing Cancer Hospital, Beijing, CN, ⁴Beijing Hospital of Chinese Medicine, Beijing, CN

12:00 - 12:00 **1824P - A prospective study about the complementary medicine among patients with cancers**

W. Ben Kridis, A. Mnif, A. Khanfir, University of Sfax - Hopital Habib Bourguiba, Sfax, TN

12:00 - 12:00 **1825P - Prevalence and management of Potentially Inappropriate Medication use and Potential Omissions in Medication in older cancer patients - the PIM POM study**

F. Van Loveren¹, I. Van Berlo - Van De Laar², A. Imholz¹, K. Taxis³, F. Jansman²,

¹Deventer Ziekenhuis, Deventer, NL, ²Deventer Hospital, Deventer, NL, ³University of Groningen, Groningen, NL

12:00 - 12:00

1826P - Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer : A randomized controlled trial

W. Choi¹, J.G. Kim², S.-H. Beom³, J.E. Hwang⁴, H.-J. Shim⁵, S.-H. Cho⁵, M.-H. Shin⁶, S.-H. Jung⁷, I.-J. Chung⁵, J.Y. Song⁸, W.K. Bae¹, ¹Chonnam National University Hwasun Hospital, Hwasun, KR, ²Kyungpook National University Hospital, Daegu, KR, ³Yonsei Cancer Center, Seoul, KR, ⁴Chonnam National University Medical School & Chonnam National University Hwasun Hospital, Hwasun, KR, ⁵Chonnam National University Hwasun Hospital, Jeonnam, KR, ⁶Chonnam National University Medical School, Hwasun, KR, ⁷Duke University, Durham, US, ⁸Korea University College of Medicine, Seoul, KR

12:00 - 12:00

1827P - Tobacco Retail Access and Tobacco Cessation Among Head and Neck Cancer (HNC) Survivors

L. Eng¹, J. Su², K. Hueniken², M.C. Brown², D.P. Saunders³, J. De Almeida², A. Hope², P. Selby⁴, A. Spreafico¹, A. Hansen¹, D. Goldstein², W. Xu², M. Giuliani², W. Evans⁵, G. Liu¹, M. Chaiton⁴, ¹Princess Margaret Cancer Center, Toronto, CA, ²Princess Margaret Cancer Centre, Toronto, CA, ³Northeast Cancer Centre of Health Sciences North, Sudbury, CA, ⁴Centre for Addiction and Mental Health, Toronto, CA, ⁵McMaster University, Hamilton, CA

12:00 - 12:00

1828P - ASSERT: A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Patients Treated for Moderate to Severe Hyponatremia Secondary to Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) in Italy (Lung Cancer Cohort)

R. Berardi¹, G. Lo Russo², M. Tiseo³, L. Cavanna⁴, D. Ferrari⁵, E. Rijavec⁶, G. Altavilla⁷, A. Morabito⁸, G. Pinotti⁹, R. Buosi¹⁰, M. Scartozzi¹¹, C. Ferrara¹², M.G. Giustra¹², R. Evans¹³, V. De Marino¹⁴, ¹AOU Ospedali Riuniti Ancona, Torrette di Ancona, IT, ²Fondazione IRCCS Istituto Nazionale Tumori Via Giacomo Venezian, Milan, IT, ³Azienda Ospedaliero-Universitaria di Parma, Parma, IT, ⁴AUSL di Piacenza, Piacenza, IT, ⁵Azienda Ospedaliera San Paolo, Milan, IT, ⁶IRCCS Azienda Ospedaliera Universitaria San Martino IST - Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ⁷Azienda Ospedaliera Universitaria Policlinico G. Martino di Messina, Messina, IT, ⁸Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale, Napoli, IT, ⁹Ospedale di Circolo e Fondazione Macchi, Varese, IT, ¹⁰ASL Alessandria Santo Spirito Hospital, Casale Monferrato AL, IT, ¹¹Policlinico Universitario Duilio Casula, Monserrato, IT, ¹²Otsuka Pharmaceutical Italy, Milan, IT, ¹³Otsuka Pharmaceutical Europe, Wexham, GB, ¹⁴Azienda Ospedaliera Specialistica dei Colli "Monaldi - Cotugno - CTO", Napoli, IT

12:00 - 12:00

1829P - Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: A systematic review and meta-analysis.

B. Bonardi¹, M. Bruzzone², O. Goldrat³, L. Del Mastro⁴, P. Anserini², C. Massarotti², G. Mangili⁵, M. Ceppi², I. Demeestere⁶, M. Lambertini⁴, ¹Università Vita e Salute San Raffaele Milano, Milan, IT, ²Policlinico San Martino, Genova, IT, ³Clinique Universitaire de Bruxelles-Hôpital Erasme, Bruxelles, BE, ⁴IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ⁵IRCCS Ospedale San Raffaele, Milan,

IT, ⁶Université Libre de Bruxelles-Erasme, Bruxelles, BE

12:00 - 12:00

1830P - Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy

T. Vandembroucke¹, M. Verheecke¹, M. Van Gerwen², K. Van Calsteren³, M. Halaska⁴, M. Fumagalli⁵, R. Fruscio⁶, M. Veening⁷, L. Lagae⁸, P. Ottevanger⁹, J.-U. Voigt¹⁰, J. De Haan¹¹, M. Gziri¹², A. Gandhi¹³, C. Maggen¹, L. Mertens¹⁴, G. Naulaers¹⁰, L. Claes¹³, F. Amant¹⁵, ¹University Hospitals Leuven and Department of Oncology, KU Leuven, Leuven, BE, ²The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ³University Hospitals Leuven and Department of Development and Regeneration, KU Leuven, Leuven, BE, ⁴3rd Medical Faculty Charles University and Faculty Hospital Kralovske Vinohrady, Prague, CZ, ⁵Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, IT, ⁶University of Milan-Bicocca, San Gerardo Hospital, Monza, Milan, IT, ⁷Princess Máxima Center for pediatric oncology, Utrecht, NL, ⁸University Hospitals Leuven, Leuven, Leuven, BE, ⁹Radboud UMC Nijmegen, Nijmegen, NL, ¹⁰University Hospitals Leuven, Leuven, BE, ¹¹Amsterdam UMC, Location VU University Medical Center, Amsterdam, NL, ¹²Cliniques Universitaires St Luc, Brussels, BE, ¹³KU Leuven, Leuven, BE, ¹⁴The Hospital for Sick Children, University of Toronto, Toronto, CA, ¹⁵University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

12:00 - 12:00

1831P - Update of the registry of young women with cancer by the International Network of Cancer, Infertility and Pregnancy

C. Maggen¹, K. Van Calsteren², E. Cardonick³, R. Shmakov⁴, M. Gziri⁵, A. Garcia⁶, R. Fruscio⁷, C. Lok⁸, M. Halaska⁹, I. Boere¹⁰, P. Zola¹¹, P. Ottevanger¹², C. De Groot¹³, G. Scarfone¹⁴, M. Fumagalli¹⁵, R. Painter¹⁶, J. De Haan¹³, F. Amant¹⁷, ¹University Hospitals Leuven and Department of Oncology, KU Leuven, Leuven, BE, ²University Hospitals Leuven and Department of Development and Regeneration, KU Leuven, Leuven, BE, ³Cooper University Hospital, Philadelphia, US, ⁴National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, RU, ⁵Cliniques Universitaires St Luc, Brussels, BE, ⁶Hospital Regional de Alta Especialidad de Ixtapaluca (HRAEI), Mexico City, MX, ⁷University of Milan-Bicocca, San Gerardo Hospital, Monza, Milan, IT, ⁸Antoni Van Leeuwenhoek Hospital - The Netherlands Cancer Institute, Amsterdam, NL, ⁹3rd Medical Faculty Charles University and Faculty Hospital Kralovske Vinohrady, Prague, CZ, ¹⁰Erasmus University Medical Center, Rotterdam, NL, ¹¹University of Turin, Turin, IT, ¹²Radboud UMC Nijmegen, Nijmegen, NL, ¹³Amsterdam UMC, Location VU University Medical Center, Amsterdam, NL, ¹⁴Dept Ob-Gyn University of Milan, Milan, IT, ¹⁵Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, IT, ¹⁶University Medical Centers Amsterdam -location AMC, Amsterdam, NL, ¹⁷University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

12:00 - 12:00

1832P - Erectile dysfunction in patients with metastatic renal cell carcinoma

I. Tsimafeyeu¹, R. Zukov², L. Demidov³, P. Borisov⁴, V. Kuznetsov⁵, V. Leonenko⁵, A. Bondarenko⁶, K. Zakurdaeva⁷, Y. Tishova⁸, ¹Russian Society of Clinical Oncology, Moscow, RU, ²A.I. Kryzhanovskiy Krasnoyarsk Cancer Center, Krasnoyarsk, RU, ³N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ⁴City Clinical Oncology Center, St. Petersburg, RU, ⁵Stolichnaya Diagnostica Clinic, Tuchkovo, RU, ⁶I.M. Sechenov First Moscow State Medical University, Moscow, RU, ⁷RakFond, Moscow, RU, ⁸RUDN University, Moscow, RU

- 12:00 - 12:00 **1833P - Exercise level, interest and preferences in cancer patients.**
A. Avancini¹, V.M. Pala², V. Krogh², S. Sieri², L. Mariani², D. Tregnago¹, G. Sartori¹, I. Trestini³, E. Bria⁴, M. Milella¹, M. Lanza¹, S. Pilotto⁵, ¹University of Verona Hospital Trust, Verona, IT, ²Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, IT, ³Ospedale Borgo Roma - Policlinico Giovanni Battista Rossi, Verona, IT, ⁴Università Cattolica del Sacro Cuore, Roma, IT, ⁵AOU Integrata Borgo Roma Verona, Verona, IT
- 12:00 - 12:00 **1834P - Filling the Gaps in Informed Consent for Advanced Cancer Patients considering Phase 1 Oncology Trials - an in-depth Qualitative Study of Key Stakeholders at a large United Kingdom Phase 1 unit**
A. Pal¹, S. Stapleton², J. Lopez³, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²The Royal Marsden Foundation Trust, London, GB, ³The Royal Marsden Foundation Trust and The Institute of Cancer Research, London, GB
- 12:00 - 12:00 **1835P - Breast Cancer Patients' Quality of Life: Real World Data**
T. Kosmidis¹, B. Athanasakou², P. Kosmidis³, ¹(private address), Rafina-Pikermi, GR, ²Care Across Ltd, London, GB, ³Hygeia Hospital, Marousi, GR
- 12:00 - 12:00 **1836P - High-sensitivity troponin as a cardiotoxicity biomarker in breast cancer treatment**
J. Simões¹, N. Tavares², C. Borges², R. Pinto¹, M. Silva¹, M. Paiva¹, C. Sousa¹, I. Sousa¹, D. Almeida¹, I. Augusto¹, C. Caeiro³, S. Meireles², ¹Hospital de S. João, Porto, PT, ²HSJ - Hospital de São João, EPE, Porto, PT, ³Centro Hospitalar Universitário de São João, EPE, Porto, PT
- 12:00 - 12:00 **1837P - Impact of routine screening and preemptive treatment on hepatitis B virus reactivation (HBVr) in patients receiving chemotherapy**
C. Marty¹, D. Martel², V. Martel-Laferrière², S. Doucet², P. Cébaillos³, J.-P. Adam², ¹Aix-Marseille Université, Marseille, FR, ²Centre hospitalier de l'Université de Montréal (CHUM), Montreal, CA, ³Centre Hospitalier Universitaire Saint-Eloi, Montpellier, FR
- 12:00 - 12:00 **1838P - The uptake, patient satisfaction and efficacy of scalp cooling among patients receiving chemotherapy in an Irish oncology day ward.**
W. Maher, K. Murphy, D. O Connor, C. Murphy, Bon Secours Hospital, Cork, IE
- 12:00 - 12:00 **1839P - Placebo adverse events (AEs) in targeted and immune cancer therapy in the adjuvant and advanced setting: A systematic review and meta-analysis**
D. Enrico¹, F. Waisberg², J. Burton², P. Mando², M. Chacón², ¹Institut Gustave Roussy, Villejuif, FR, ²Argentine Association of Clinical Oncology, Buenos Aires, AR
- 12:00 - 12:00 **1840P - Reduced antibody levels and high seronegativity rates against vaccine preventable diseases pose a risk factor for infections in patients with solid and hematologic cancers**
A. Guzek¹, A.S. Berghoff², J. Jasinska¹, E. Garner-Spitzer¹, A. Wagner¹, H. Holzmann¹, M. Kundi¹, C. Zielinski³, U. Wiedermann¹, ¹Medizinische Universität Wien, Vienna, AT,

²Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT, ³Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

12:00 - 12:00 **Haematological malignancies**

12:00 - 12:00 **1072P - Mutational profiling through exome sequencing along with MYD88 L265P analysis could facilitate the diagnosis of Vitreoretinal lymphoma**

H. Lee¹, B. Kim², S.-T. Lee³, J.R. Choi³, ¹Yonsei University, Seoul, KR, ²Severance Hospital, Seoul, KR, ³Yonsei University College of Medicine Severance Hospital, Seoul, KR

12:00 - 12:00 **1073P - Prognostic Factors Influencing Outcome After Therapy With Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin's Lymphoma**

V. Goranova - Marinova¹, K. Ignatova², P. Ganeva³, E. Spasov¹, G. Arnaudov², I. Micheva⁴, L. Gercheva⁴, A. Radinov⁵, R. Petrova⁶, G. Tzvetkova⁷, E. Hadzhiev⁷, L. Bogdanov⁸, N. Tzvetkov⁹, B. Spasov², Z. Grudeva-Popova¹, D. Tumbeva¹⁰, ¹Medical University Plovdiv, Plovdiv, BG, ²SBALHZ, Sofia, BG, ³National Center of Oncology-SBALO EAD, Sofia, BG, ⁴Medical University Varna, Varna, BG, ⁵Univesrity Hospital "Sv.Ivan Rilski, Sofia, BG, ⁶University Hospital "Sv.Ivan Rilski, Sofia, BG, ⁷UMBAL "Alexandrovska", Sofia, BG, ⁸Medical University Pleven, Pleven, BG, ⁹UMHAT Georgi Stranski, Pleven, BG, ¹⁰UMBAL Sv.Georgi, Plovdiv, BG

12:00 - 12:00 **1074P - Prognostic value of microRNA-21/ Ki-67 in non- Hodgkin`s lymphoma; NCI experience**

M. Rahouma, R. Rashed, H. Asker, L. Abdel-Azim, E. Naguib, H. Khaled, National Cancer Institute-Cairo University, Cairo, EG

12:00 - 12:00 **1075P - Phase I Study of CC-90010 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)**

V. Moreno¹, I. Brana², J. Sepulveda Sanchez³, M. Vieito Villar⁴, T. Hernández-Guerrero⁵, B. Doger⁶, O. Saavedra⁷, A. Italiano⁸, J.-M. Michot⁹, G. Musuraca¹⁰, P. Asierto¹¹, C. Carlo-Stella¹², R. Sarmiento¹³, J. De Alvaro¹³, J. Di Martino¹⁴, M. Zuraek¹⁴, T. Sánchez Pérez¹³, E. Filvaroff¹⁴, B. Hanna¹⁵, Z. Nikolova¹⁶, ¹University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ²Vall d'Hebron University Hospital, Barcelona, ES, ³University Hospital 12 De Octubre, Madrid, ES, ⁴Vall d'Hebron University Hospital - Vall d'Hebron Institute of Oncology VHIO, Barcelona, ES, ⁵START Madrid - FJD, Hospital Fundación Jimenez Diaz, Madrid, ES, ⁶START Madrid, Madrid, ES, ⁷Vall d'Hebron University Hospital, NO City, ES, ⁸Institute Bergonié, Bordeaux, FR, ⁹Institut Gustave Roussy, Villejuif, FR, ¹⁰Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (IRST), Meldola (FC), IT, ¹¹Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Naples, IT, ¹²Humanitas Cancer Center, Humanitas Clinical and Research Center, Milan, IT, ¹³Celgene Institute Translational Research Europe-CITRE, Sevilla, ES, ¹⁴Celgene Corporation, San Francisco, US, ¹⁵Celgene Corporation, Summit, US, ¹⁶Celgene International Switzerland, Boudry, CH

12:00 - 12:00

1076P - Pretreatment coagulation factors related to prognosis in patients with natural killer/T cell lymphoma

Y. Chai, M. Dong, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN

12:00 - 12:00 **1077P - Diffuse large B cell lymphoma in the elderly. A retrospective analysis of standard versus alternative treatments**

I. Sillero¹, N. Lopetegui Lia², P. Gonzalez³, L.F. Sánchez-Cousido³, M. López Flores³, M. Rojas Piedra³, S. Medina³, A. López González³, M. Pedraza Lorenzo³, Á. Rodríguez Sánchez³, B. Nieto Mangudo³, C. Castañón González³, L. De Sande³, P. Diz Tain³, A. García-Palomo³, S. Fernandez³, F. Ramos³, F. Escalante³, ¹Hospital Universitario de León, León, ES, ²University of Connecticut, Hartford, US, ³Complejo Asistencial Universitario de León, León, ES

12:00 - 12:00 **1078P - MIPI as a superior prognostic tool in Mantle Cell Lymphoma compared to monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratios**

F. Macedo¹, A. Monteiro¹, D. Coelho², D. Luis², R. Guilherme², M. Gomes², L. Ribeiro², ¹Instituto Português Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT, ²Centro Hospitalar Universitário de Coimbra, Coimbra, PT

12:00 - 12:00 **1079P - Dose adjustment of chemotherapy in aggressive lymphoma using automated and standardized analysis and evaluation of DNA double strand breaks**

J. Schröder¹, S. Rödiger², M. Ruhe², P.M. Deckert³, ¹Städtisches Klinikum Brandenburg, Brandenburg an der Havel, DE, ²Brandenburg University of Technology Cottbus - Senftenberg, Senftenberg, DE, ³Städtisches Klinikum Brandenburg / Havel, Brandenburg, DE

12:00 - 12:00 **1081P - Efficacy of salvage therapy in the treatment of Helicobacter pylori-positive gastric low-grade mucosa-associated lymphoid tissue lymphoma**

S.-N. Lim¹, S. Ko¹, B.S. Sohn², ¹Inje University Haeundae Paik Hospital, Busan, KR, ²Inje University Sanggye Paik Hospital, Seoul, KR

12:00 - 12:00 **1082P - Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing**

S.J. Huh, Dong-A University Medical Center, Busan, KR

12:00 - 12:00 **1083P - Clinical features, treatment and outcomes of colon and rectum mucosa-associated lymphoid tissue (MALT) lymphoma: Literature reviews published in English between 1993 and 2017**

J.Y. Kim, Private Practice, Kyung Go Do Hwasung Si, KR

12:00 - 12:00 **1084P - Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 52 patients**

G. Cengiz Seval¹, P. Topcuoglu², O. Arslan², G. Gurman², T. Demirer², I. Kuzu², M. Ozcan², ¹Ankara University School of Medicine Ibn-i Sina, Cebeci, Abidinpasa, Ankara, TR, ²Ankara University School of Medicine, Ankara, TR

- 12:00 - 12:00 **1085P - Safety and efficacy of Bendamustine and Rituximab (BR) regimen in Indian Chronic Lymphocytic Leukemia patients**
A. Gogia¹, L. Kumar¹, A. Sharma¹, V. Raina², R. Gupta¹, L. Rani¹, ¹B.R. Ambedkar Institute Rotary Cancer Hospital (AIMS), New Delhi, IN, ²FMRI, GURGAON, IN
- 12:00 - 12:00 **1086P - N-terminal B-type natriuretic peptide (NT-proBNP) as an independent prognostic marker for patients with newly diagnosed multiple myeloma complicated by dialysis-dependent renal failure**
S. Semochkin¹, E. Zhelnova², E. Misyurina², A. Cherkasova², D. Gagloeva², O. Kotenko², A. Ushakova², N. Arefeva², T. Tolstykh², E. Baryakh², K. Yatskov², D. Sinyavkin², I. Samsonova², M. Lysenko², ¹N.I. Pirogov Russian National Research Medical University, Moscow, RU, ²City Clinical Hospital #52, Moscow, RU
- 12:00 - 12:00 **1087P - The first-line effect of Bortezomib-based Therapy on Clinical Outcomes for Taiwanese Patients with multiple myeloma**
C.-L. Ho, J.-H. Chen, Tri-Service General Hospital, National Defense Medical Center, Taipei, TW
- 12:00 - 12:00 **1088P - Impact of Donor Lymphocyte Infusion in Relapsing Myeloid Neoplasms Post Allogeneic Hematopoietic Stem Cell Transplantation**
H. Hafez¹, A. Abdalla¹, M. Hammad¹, N. Hamdy¹, N. Elsharkawy¹, M. Khaled², A. Elhaddad¹, ¹National Cancer Institute-Cairo University, Cairo, EG, ²Children Cancer Hospital Egypt, Cairo, EG
- 12:00 - 12:00 **1089P - Invasive fungal diseases in patients with Hodgkin's lymphoma before and after allogeneic hematopoietic stem cell transplantation**
M. Popova¹, Y. Rogacheva², A. Volkova¹, I. Markova¹, I. Nikolaev¹, S. Ignatieva¹, T. Bogomolova¹, A. Kozlov¹, K. Lepik¹, L. Stelmakh³, A. Beynarovich¹, E. Borzenkova¹, E. Darskaya¹, E. Kondakova¹, N. Mikhailova³, S. Bondarenko¹, I. Moiseev¹, L. Zubarovskaya¹, N. Klimko⁴, B. Afanasyev¹, ¹Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Saint Petersburg, RU, ²Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, RU, ³Scientific Research Institute of Pediatric Oncology, Hematology and Transplantology R.M. Gorbacheva, RU, ⁴I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg, RU
- 12:00 - 12:00 **1090P - Invasive fungal diseases caused by rare pathogens in patients after hematopoietic stem cell transplantation (HSCT) & chemotherapy**
Y. Rogacheva¹, M. Popova², A. Volkova², A. Frolova², I. Markova², I. Nikolaev², S. Ignatieva², T. Bogomolova², A. Gevorgian², O. Paina², T. Bykova², E. Darskaya², O. Goloshchapov², E. Morozova², M. Vladovskaya², S. Bondarenko², I. Moiseev², L. Zubarovskaya², N. Klimko³, B. Afanasyev², ¹Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, RU, ²Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Saint Petersburg, RU, ³I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg, RU

12:00 - 12:00

1091P - Safety and pharmacokinetics of novel CXCR4 antagonist YF-H-2015005 in the mobilization of hematopoietic stem cells in patients with non-Hodgkin's lymphoma

W. Liu¹, Y. Xie¹, L. Ping¹, M. Jiang¹, G. Zhang¹, Y. Cui², J. Xu², M. Wu¹, X. Leng¹, X. Wang¹, S. Wang³, G. Zhang³, J. Zhu¹, Y. Song¹, ¹Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, ²Peking University First Hospital, Beijing, CN, ³Hefei Yifan Biopharmaceuticals Inc., Hefei, CN

12:00 - 12:00 **1092P - Chemotherapy associated Hyponatremia in Hematological Malignancies: A retrospective study of 189 patients treated in a single medical center**

V. Lesan¹, D. Schmit², M. Bewarder¹, G. Assmann¹, S. Stilgenbauer³,
¹Universitätsklinikum des Saarlandes, Homburg, DE, ²Universitätsklinikum des Saarlandes, Homburg, DE, ³Ulm Medical University, Ulm, DE

12:00 - 12:00 **1093P - Risk factors for Bacteremia-Associated Mortality of Aeromonas sobria in Hematologic Malignancies**

G. De La Cruz-Kú¹, B. Valcarcel², M. Luján¹, A. Saavedra¹, R. Luque¹, E. Eyzaguirre¹, M. Sultanov³, Z. Morante², S. Quintana⁴, S. Neciosup Delgado², A. Holguín Ruíz², W. Vicente², D. Enriquez², ¹UCSUR, Lima, PE, ²Instituto Nacional de Enfermedades Neoplásicas, INEN, Lima, PE, ³Tashkent Medical Academy, uzbekistan, UZ, ⁴INEN, Lima, PE

12:00 - 12:00 **1094P - Use of droplet digital polymerase chain reaction for detecting minimal residual disease: a prospective, multi-institutional study**

H. Park¹, D.-Y. Shin², I. Kim², S.-K. Sohn³, Y. Koh², J.-H. Lee⁴, K.-H. Lee⁴, D.-Y. Kim⁴, H.-J. Kim⁵, J.-S. Ahn⁵, J.-O. Lee⁶, S.-M. Bang⁶, J.-W. Cheong⁷, S.-G. Park⁸, S. Park⁹, Y.J. Lee³, S.-Y. Ahn⁵, ¹Inha University Hospital, Incheon, KR, ²Seoul National University Hospital, Seoul, KR, ³Kyungpook National University Hospital, Daegu, KR, ⁴Asan Medical Center, Seoul, KR, ⁵Chonnam National University, Hwasun Hospital, Hwasun, KR, ⁶Seoul National University, Bundang Hospital, Seongnam, KR, ⁷Yonsei University, Severance Hospital, Seoul, KR, ⁸Chosun University Hospital, Gwangju, KR, ⁹Haeundae Paik Hospital, Busan, KR

12:00 - 12:00 **1095P - RUBIH2 — Use of NGS in haematological malignancies: from real world data to national recommendations, an innovative program to evaluate the impact of healthcare technology on patient care**

S. Coquerelle¹, M. Darlington², I. Durand-Zaleski¹, ¹Assistance Publique - Hopitaux De Paris, Paris, FR, ²Assistance Publique - Hopitaux De Paris, paris, FR

12:00 - 12:00 **1096P - Outcomes of chronic myeloid leukemia with T315I mutation in the absence of targeted therapy or hematopoietic stem cell transplantation**

N. Palukuri, B. Stalin, R. Chennamaneni, S. Prasad, M. Konatam, S. Gundeti, Nizam's Institute of Medical Sciences, Hyderabad, IN

12:00 - 12:00 **1097P - Is bone marrow examination indispensable in chronic myeloid Leukemia at diagnosis ?**

N. Palukuri, S. Prasad, R. Chennamaneni, B. Stalin, M. Konatam, S. Gundeti, Nizam's Institute of Medical Sciences, Hyderabad, IN

- 12:00 - 12:00 **1098P - Incidence of Imatinib Resistance in Chronic Myeloid Leukemia (CML) Patients: Experience from Resource Poor Centre of Eastern India**
D. Bhattacharyya¹, R. Ghosh², P. Gupta², A. Gupta², S. Roychoudhury², S. Nath², ¹Saroj Gupta Cancer Centre & Research Institute, Kolkata, IN, ²Saroj Gupta Cancer Centre and Research Institute, Kolkata, IN
- 12:00 - 12:00 **1099P - BCR-ABL transcript variant's significance in chronic myeloid leukemia in chronic phase: Institutional experience from a developing country**
S. Prasad, R. Chennamaneni, B. Stalin, M. Konatam, S. Gundeti, Nizam's Institute of Medical Sciences, Hyderabad, IN
- 12:00 - 12:00 **1100P - Interleukin-6 as a Predictive Marker for Early Response to Induction Chemotherapy in Acute Myeloblastic Leukaemia**
S. Khallaf¹, Z. Abdelhafez², T. Ahmed², M. Abdou², S. Mansour¹, M. Salah Eldeen², ¹South Egypt Cancer Institute SECI Assiut University, Assiut, EG, ²Faculty of Medicine-Assiut University, Assiut, EG
- 12:00 - 12:00 **1101P - Impact of FLT3-ITD mutation on post-transplant outcome of adult AML is modified by the concomitant NPM1 mutation and pre-transplant remission status: A report from Taiwan Bone Marrow Transplant Registry (TBMTR)**
S.-P. Yeh, China Medical University Hospital, Taichung City, TW
- 12:00 - 12:00 **1102P - Efficacy endpoints studied in clinical trials for early-onset leukaemia**
D. Said¹, J. Borg², M. Attard Pizzuto¹, A. Serracino-Inglott¹, ¹University of Malta, Msida, MT, ²Malta Medicines Authority, San Gwann, MT
- 12:00 - 12:00 **1104P - High triglyceride is a major risk factor of DIC and differentiation syndrome in acute promyelocytic leukemia**
T. Yamakawa, Sapporo Hokuyu Hospital, Sapporo, JP
- 12:00 - 12:00 **1105TiP - DREAMM 4: A Phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)**
S. Trudel¹, A. Nooka², D. Fecteau³, M. Talekar⁴, R. Jewell⁵, D. Williams⁴, J. Evans⁶, J. Opalinska⁴, ¹Princess Margaret Cancer Centre, Toronto, CA, ²Winship Cancer Institute, Atlanta, US, ³GlaxoSmithKline USA, Collegeville, US, ⁴GlaxoSmithKline, Collegeville, US, ⁵GlaxoSmithKline, Research Triangle Park, US, ⁶GlaxoSmithKline, Uxbridge, GB
- 12:00 - 12:00 **1106TiP - A Phase 1 Study of HMPL-523, a Selective Oral Anti-Spleen Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Lymphoma**
N. Fowler¹, W. Jurczak², R. Cordoba Mascunano³, P. Abrisqueta Costa⁴, P. Strati¹, C. Yang⁵, M. Kania⁶, J. Kauh⁶, A. Ferreri⁷, ¹MD Anderson Cancer Center, Houston, US, ²Jagiellonian University Collegium Medicum, Krakow, PL, ³University Hospital Fundacion Jimenez Diaz, Madrid, ES, ⁴Hospital Vall d'Hebron de Barcelona, Barcelona, ES, ⁵Hutchison Medipharma Ltd, Shanghai, CN, ⁶Hutchison Medipharma US, Florham Park,

US, ⁷IRCCS Ospedale San Raffaele, Milan, IT

- 12:00 - 12:00 **1107TiP - A Phase 1 Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Patients with Relapsed or Refractory Lymphoma**
J. Cohen¹, R. Cordoba Mascunano², A. Ferreri³, C. Yang⁴, M. Kania⁵, J. Kauh⁵, N. Ghosh⁶,
¹Emory University, Atlanta, US, ²University Hospital Fundacion Jimenez Diaz, Madrid, ES, ³IRCCS Ospedale San Raffaele, Milan, IT, ⁴Hutchison Medipharma Ltd, Shanghai, CN, ⁵Hutchison Medipharma US, Florham Park, US, ⁶Levine Cancer Institute-Morehead, Charlotte, US
- 12:00 - 12:00 **Sarcoma**
- 12:00 - 12:00 **1680P - A global patient-driven Facebook study in a very rare sarcoma: Health-related quality of life in Epithelioid Hemangioendothelioma (EHE) patients**
M. Weidema¹, O. Husson², W. Van Der Graaf³, H. Leonard⁴, B. De Rooij⁵, L. Hartle De Young⁶, I. Desar¹, L. Van De Poll-Franse⁷, ¹Radboud University Medical Center, Nijmegen, NL, ²Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ³Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁴EHE Rare Cancer Charity, Surrey, GB, ⁵The Netherlands Comprehensive Cancer Organization, Utrecht, NL, ⁶EHE Foundation, Anchorage, US, ⁷Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 12:00 - 12:00 **1681P - Qualitative study of patients' experiences of living with and beyond a soft tissue sarcoma diagnosis: the impact of sarcoma specialist services**
A. Martins¹, L. Storey², M. Wells³, L. Fern¹, C. Gerrand⁴, L. Bennister⁵, J. Woodford⁴, M. Onasanya⁶, R. Windsor¹, J. Whelan¹, R. Taylor¹, ¹University College London Hospital UCLH NHS Foundation Trust, London, GB, ²Queens University Belfast, Belfast, GB, ³University of Stirling, Stirling, GB, ⁴The Royal National Orthopaedic Hospital NHS Trust, London, GB, ⁵Sarcoma UK, London, GB, ⁶Patient Representative, London, GB
- 12:00 - 12:00 **1682P - Health-related quality of life issues of patients affected by desmoid-type fibromatosis; experiences from two countries**
M. Timbergen¹, W. Van Der Graaf², D. Grünhagen¹, E. Younger³, S. Sleijfer⁴, A. Dunlop³, L. Dean³, C. Verhoef¹, L. Van De Poll-Franse⁵, O. Husson⁶, ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ³Royal Marsden Hospital NHS Foundation Trust, London, GB, ⁴Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ⁵Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁶Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL
- 12:00 - 12:00 **1683P - One-year follow-up results of eribulin for soft-tissue sarcoma including rare subtypes in a real-world observational study in Japan**
S. Takahashi¹, Y. Megumi², Y. Sakata³, H. Ikezawa⁴, T. Matsuoka², A. Kawai⁵, ¹Cancer Institute Hospital of JFCR, Tokyo, JP, ²Eisai Co., Ltd., Tokyo, JP, ³Eisai Co., Ltd., Bunkyo-ku, JP, ⁴EISAI, Bunkyo-ku, JP, ⁵National Cancer Center Hospital, Tokyo, JP

- 12:00 - 12:00 **1684P - Prevalence of chemotherapy use and its impact on overall survival in patients with bone- and soft tissue sarcomas -A population-based analysis of 3746 patients**
H. Loong¹, C. Wong², C.-W. Ho², L. Leung³, T. Tse³, S. Kwan³, Y.-M. Lau³, ¹The Chinese University of Hong Kong, Shatin, HK, ²The University of Hong Kong, Hong Kong, HK, ³The Chinese University of Hong Kong, Hong Kong, HK
- 12:00 - 12:00 **1685P - Clinical course and therapeutic management of classical and endemic Kaposi's Sarcoma (C/E KS)**
L. Benajiba¹, J. Lambert¹, R. La Selva¹, D. Cochereau², B. Baroudjian³, J. Roux¹, N. Basset-Seguin⁴, C. Pages Laurent⁵, M. Battistella⁶, J. Delyon⁶, C. Lebbe⁶, ¹Hopital Saint Louis AP-HP, Paris, FR, ²Hôpital Saint-Antoine, Paris, FR, ³Hôpital Saint-Louis, Paris, FR, ⁴Hôpital St. Louis, Paris, FR, ⁵CHU Toulouse - Hôpital Larrey, Toulouse, FR, ⁶Hôpital Saint Louis, Paris, FR
- 12:00 - 12:00 **1686P - The final outcomes of study on combined therapy of adult patients with localized synovial sarcoma**
K. Kozak¹, I. Lugowska², P. Teterycz³, H. Kosela Paterczyk¹, T. Switaj⁴, T. Goryn⁵, W. Dziewirski³, T. Morysinski⁶, S. Falkowski¹, P. Rutkowski⁷, ¹Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, ²Maria Skłodowska-Curie Memorial Cancer Centre-Institute of Oncology, Warsaw, PL, ³The Maria Skłodowska-Curie Memorial Institute and Oncology Centre, Warsaw, PL, ⁴No place of work provided Iran, Teheran, IR, ⁵Pfizer - Poland, Warsaw, PL, ⁶Maria Skłodowska Curie Institute - Oncology Centre (MSCI), Warsaw, PL, ⁷The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL
- 12:00 - 12:00 **1687P - Real-world Outcomes of Patients with Locally Advanced or Metastatic Epithelioid Sarcoma**
M. Gounder¹, P. Merriam², R. Ratan³, S.R. Patel³, R. Chugh⁴, V. Villalobos⁵, M. Thorton⁶, B. Van Tine⁷, A.H. Abdelhamid², P. Joshi⁸, J. Whalen⁸, J. Yang⁸, A. Rajarethinam⁸, M.S. Duh⁹, P.J. Bobbili⁹, C.L. Cavanaugh⁹, L. Huynh⁹, T. Totev⁹, G. Demetri¹⁰, ¹Memorial Sloan-Kettering Cancer Center, New York, US, ²Dana Farber Cancer Institute and Harvard Medical School, Boston, US, ³The University of Texas M.D. Anderson Cancer Center, Houston, US, ⁴Michigan Medicine Comprehensive Cancer Center, Ann Arbor, US, ⁵University of Colorado, Denver, US, ⁶Sarcoma Foundation of America, Damascus, US, ⁷Washington University in St. Louis School of Medicine, St. Louis, US, ⁸Epizyme, Cambridge, US, ⁹Ananalysis Group, Inc., Boston, US, ¹⁰Dana Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, US
- 12:00 - 12:00 **1688P - SAKK 57/16 Nab-Paclitaxel And Gemcitabine in soft tissue sarcoma (NAPAGE): results from the phase I part of a phase I/II trial**
A. Digkila¹, C. Britschgi², Y. Metaxas³, A. Kollar⁴, F. Krasniqi⁵, A. Stathis⁶, T. Rordorf², I. Colombo⁷, N. Mach⁸, S. Hofer⁹, M. Montemurro¹, N. Stojcheva¹⁰, D. Dietrich¹¹, C. Rothermundt¹², ¹Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ²University Hospital Zürich, Zurich, CH, ³Kantonsspital Graubünden, Chur, CH, ⁴Inselspital - Universitätsspital Bern, Bern, CH, ⁵Universitätsspital Basel, Basel, CH, ⁶IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH, ⁷Ospedale Regionale di Bellinzona e Valli, San Giovanni, Bellinzona, CH, ⁸University Hospital Geneva, Geneva,

CH, ⁹Luzerner Kantonsspital, Luzern, CH, ¹⁰SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, ¹¹SAKK, Bern, CH, ¹²Kantonsspital St. Gallen, St. Gallen, CH

12:00 - 12:00

1689P - Outcome of 98 patients with epithelioid sarcoma treated in curative intent: a retrospective study from the French Sarcoma Group (GSF-GETO)

M. Pedrono¹, O. Mir², L. Chaltiel³, M. Brahmi⁴, A. Italiano⁵, G. Decanter⁶, P. Boudou Rouquette⁷, M. Ropars⁸, E. Bompas⁹, N. Firmin¹⁰, N. Isambert¹¹, T. Valentin¹², F. Duffaud¹³, J. Gantzer¹⁴, A. Thyss¹⁵, C. Guillemet¹⁶, J.-Y. Blay⁴, A. Le Cesne², C. Chevreau¹², C. Perrin¹⁷, ¹Centre Hospitalier de Bretagne Sud - Site du Scorff, Lorient, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole,, Toulouse, FR, ⁴Centre Léon Bérard, Lyon, FR, ⁵Institute Bergonié, Bordeaux, FR, ⁶centre oscar lambret, lille, FR, ⁷Hôpital Cochin, Paris, FR, ⁸CHU Pontchaillou, Rennes, FR, ⁹ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹⁰institut du cancer de Montpellier, Montpellier, FR, ¹¹Centre Georges-François Leclerc (Dijon), Dijon, FR, ¹²Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ¹³CHU La Timone Adultes, Marseille, FR, ¹⁴C.H.U. Strasbourg-Nouvel Hopital Civil, Strasbourg, FR, ¹⁵Centre Anticancer Antoine Lacassagne, Nice, FR, ¹⁶Centre Henri Becquerel, Rouen, FR, ¹⁷Centre Eugene - Marquis, Rennes, FR

12:00 - 12:00

1690P - Comparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy.

P. Tarantino¹, P. Zagami¹, P. Trillo¹, F. Conforti¹, L. Pala¹, S. Morganti¹, E. Ferraro¹, G. Viale¹, B. Duso¹, P. D'Amico¹, A. Marra¹, D. Trapani¹, T. De Pas², ¹Istituto Europeo di Oncologia, Milan, IT, ²Istituto Europeo di Oncologia, Milano, IT

12:00 - 12:00

1691P - Access to clinical trials for soft tissue sarcoma patients in Western and Eastern Europe

V. Ostafichuk, S. Korovin, M. Kukushkina, National Cancer Institute, Kiev, UA

12:00 - 12:00

1692P - Treatment outcomes for adult patients with localized osteosarcoma treated with chemotherapy without methotrexate

M. Silva¹, R. Bonadio¹, G. Matos², V. Camargo¹, ¹ICESP - Instituto do Câncer do Estado de São Paulo, Sao Paulo, BR, ²Hospital Sírio Libanês, Brasília, BR

12:00 - 12:00

1693P - Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203)

Y. Chi¹, Y. Yao², Z. Fang³, S. Wang⁴, G. Huang⁵, Q. Cai⁶, G. Shang⁷, G. Wang⁸, G. Qu⁹, Q. Wu¹⁰, Y. Jiang¹¹, J. Song¹², J. Chen¹³, X. Zhu¹⁴, Z. Cai¹⁵, C. Bai¹⁶, Y. Lu¹⁷, Z. Yu¹⁸, J. Shen¹⁹, J. Cai¹, ¹Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ²Affiliated Sixth People's Hospital, Shanghai Jiaotong University, shanghai, CN, ³Peking University Cancer Hospital, Beijing, CN, ⁴Sun Yat-sen University Cancer Center, Guangzhou, CN, ⁵Hunan Cancer Hospital, Changsha, China, changsha, CN, ⁶Henan Cancer Hospital, zhengzhou, CN, ⁷Liaoning Cancer Hospital and Institute, shenyang, CN, ⁸Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, ⁹Harbin Medical University Cancer Hospital, Harbin, CN, ¹⁰The First Affiliated Hospital of Bengbu Medical College, Bengbu, CN, ¹¹West China Hospital, Sichuan University, Chengdu, CN, ¹²Gansu Provincial Cancer Hospital, Lanzhou, CN, ¹³Wuhan

Union Hospital, Wuhan, CN, ¹⁴The First Affiliated Hospital of Fujian Medical University, Fuzhou, CN, ¹⁵The First People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, CN, ¹⁶Peking Union Medical College Hospital/ Chinese Academy of Medical Sciences, Beijing, CN, ¹⁷Affiliated Tumor Hospital of Guangxi Medical University, Nanning, CN, ¹⁸Jiangxi Cancer Hospital, Nanchang, CN, ¹⁹The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, CN

12:00 - 12:00 **1694P - The effect of treatment line on the efficacy of Anlotinib hydrochloride in advanced alveolar soft part sarcoma patients**

Z. Fang¹, Y. Yao², J. Cai³, Y. Chi³, S. Wang⁴, G. Huang⁵, Q. Cai⁶, G. Shang⁷, G. Wang⁸, G. Qu⁹, Q. Wu¹⁰, Y. Jiang¹¹, J. Song¹², J. Chen¹³, Z. Cai¹⁴, X. Zhu¹⁵, C. Bai¹⁶, Y. Lu¹⁷, Z. Yu¹⁸, J. Shen¹⁹, ¹Peking University Cancer Hospital, Beijing, CN, ²Affiliated Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, CN, ³Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ⁴Sun Yat-sen University Cancer Center, Guangzhou, CN, ⁵Hunan Cancer Hospital, Changsha, China, Changsha, CN, ⁶Henan Cancer Hospital, Zhengzhou, CN, ⁷Liaoning Cancer Hospital and Institute, Shenyang, CN, ⁸Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, ⁹Harbin Medical University Cancer Hospital, Harbin, CN, ¹⁰The First Affiliated Hospital of Bengbu Medical College, Bengbu, CN, ¹¹West China Hospital, Sichuan University, Chengdu, CN, ¹²Gansu Provincial Cancer Hospital, Lanzhou, CN, ¹³Wuhan Union Hospital, Wuhan, CN, ¹⁴The First People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, CN, ¹⁵The First Affiliated Hospital of Fujian Medical University, Fuzhou, CN, ¹⁶Beijing Union Medical College Hospital (Xiehe Hospital), Beijing, CN, ¹⁷Affiliated Tumor Hospital of Guangxi Medical University, Nanning, CN, ¹⁸Jiangxi Cancer Hospital, Nanchang, CN, ¹⁹The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, CN

12:00 - 12:00 **1695P - Prior exposure to pazopanib (PAZ) did not minor efficacy of regorafenib (REG) in non-adipocytic soft tissue sarcoma patients (pts)**

N. Penel¹, J.-Y. Blay², J. Wallet¹, O. Mir³, A. Italiano⁴, F. Bertucci⁵, S. Piperno-Neumann⁶, T. Brodowicz⁷, E. Bompas⁸, B. Liegl-Atzwanger⁹, C. Chevreau¹⁰, I. Ray-Coquard², S. Taieb¹, E. Decoupigny¹, M.C. Le Deley¹, A. Le Cesne³, ¹Centre Oscar Lambret, Lille, FR, ²Centre Léon Bérard, Lyon, FR, ³Institut Gustave Roussy, Villejuif, FR, ⁴Institute Bergonié, Bordeaux, FR, ⁵Institute Paoli Calmettes, Marseille, FR, ⁶Institut Curie, Paris, FR, ⁷Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, ⁸ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁹Medical University of Graz, Graz, AT, ¹⁰Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR

12:00 - 12:00 **1696P - Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumor (TGCT): characterization of hepatic adverse reactions (ARs)**

S. Bauer¹, J. Lewis², H. Gelderblom³, M. Van De Sande⁴, S. Stacchiotti⁵, J. Healey⁶, W.D. Tap⁷, A. Wagner⁸, A. Lopez Pousa⁹, M. Druta¹⁰, C.-C. Lin¹¹, H. Baba¹², A. Yver¹³, D. Shuster¹⁴, J. McGill¹⁴, X. Gu¹⁴, L. Deleve¹⁵, ¹University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ²Georgetown University Hospital, Washington, US, ³Leids Universitair Medisch Centrum (LUMC), Leiden, NL, ⁴Leiden University Medical Center, Leiden, NL, ⁵Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁶Memorial Sloan Kettering Cancer Center, New York, US, ⁷Memorial Sloan-Kettering

Cancer Center, New York, US, ⁸Dana Farber Cancer Institute, Boston, US, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹⁰Moffitt Cancer Center, Tampa, US, ¹¹National Taiwan University Hospital, Taipei City, TW, ¹²University Hospital Essen, University of Duisburg-Essen, Essen, DE, ¹³Daiichi Sankyo Pharma Development USA, Edison, US, ¹⁴Daiichi Sankyo, Inc., Basking Ridge, US, ¹⁵Keck School of Medicine, University of Southern California, Los Angeles, US

- 12:00 - 12:00 **1697P - VEGFR2 and ITGA polymorphisms as novel pan-sarcoma biomarkers for sensitivity prediction as well as toxicity prevention anti-angiogenesis therapy in pediatric and young adult**
Q. Bao¹, Y. Shen², W. Zhang², ¹Jiangshan City People's Hospital, Jiangshan City, CN, ²Ruijin Hospital, shanghai, CN
- 12:00 - 12:00 **1698P - Reversion of resistance to mTOR inhibitors with the addition of exemestane in patients with malignant PEComa.**
R. Sanfilippo¹, C. Fabbroni¹, E. Fumagalli¹, R. Bertulli², S. Stacchiotti¹, G. Baldi¹, G. Fucà¹, C. Morosi³, A. Gronchi³, A.P. Dei Tos⁴, P. Collini⁵, P.G. Casali¹, ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ²Fondazione IRCCS Istituto Nazionale de Tumori, Milan, IT, ³Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁴Treviso Regional Hospital, Treviso, IT, ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT
- 12:00 - 12:00 **1699P - Efficacy and Safety of VEGFR2 Inhibitor Apatinib combined with chemotherapy for Sarcoma in Stage IV**
Z. Ren, J. Yang, Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN
- 12:00 - 12:00 **1700P - Outcomes of metastatic soft tissue sarcoma treated with Pazopanib from dedicated medical oncology sarcoma clinic: A holistic care approach from a developing country**
A. Kapoor, S. Kumar M., J. Ghosh, B. Rekhi, J. Bajpai, Tata Memorial Centre, Mumbai, IN
- 12:00 - 12:00 **1701P - Inhibition of mTOR signaling enhances Trabectedin activity in Soft Tissue Sarcoma**
D. Moura¹, P. Sanchez-Bustos¹, M. Lopez-Alvarez¹, T. Ramos¹, J. Mondaza-Hernandez¹, N. Hindi², J. Martin-Broto³, ¹Instituto de Biomedicina de Sevilla, Sevilla, ES, ²Hospital Universitario Virgen del Rocío, Sevilla, ES, ³Hospital Univ. Virgen de Rocío, Seville, ES
- 12:00 - 12:00 **1702P - Efficacy and safety of apatinib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial**
Z. Cai¹, B. Zhang¹, Y. Yin¹, D. Cao², ¹West China Hospital, Sichuan University, Chengdu, CN, ²Sichuan University, Chengdu, CN
- 12:00 - 12:00 **1703P - Long-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP)**
J. Beaziz¹, M. Battistella², J. Delyon², C. Le Maignan³, O. Marco², D. Kérob², C. Pages Laurent⁴, L. Da Meda², C. Farges², N. Basset-Seguín⁵, C. Lebbe², B. Baroudjian⁵,

¹Hôpitaux Paris Centre AP-HP, Paris, FR, ²Hôpital Saint Louis, Paris, FR, ³Hôpital Saint Louis AP-HP, Paris, FR, ⁴CHU Toulouse - Hôpital Larrey, Toulouse, FR, ⁵Hôpital Saint-Louis, Paris, FR

- 12:00 - 12:00 **1704P - Neo-adjuvant (NA) Imatinib for gastrointestinal stromal tumours (GISTs): What is the optimal length of treatment?**
T. Wilson¹, H. Lyons¹, H. Winter¹, T. Bird¹, S. Falk², S. Gangadhara³, ¹University Hospitals Bristol NHS Trust - Bristol Haematology and Oncology Centre, Bristol, GB, ²University Hospitals Bristol NHS Trust Bristol Haematology and Oncology Centre, Bristol, GB, ³Royal United Hospitals Bath NHS Foundation trust, Bath, GB
- 12:00 - 12:00 **1705P - Gastrointestinal Stromal Tumours (GIST) in adolescents and young adults (AYA)**
N. Ijzerman¹, C. Drabbe², D. Den Hollander³, M. Mohammadi⁴, H. Van Boven¹, I. Desar⁵, H. Gelderblom⁴, D. Grünhagen⁶, A. Reyners⁷, R. Mathijssen⁶, N. Steeghs¹, W. Van Der Graaf⁸, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²3. Radboud University Medical Center, Nijmegen, NL, ³Radboud University Medical Centre Nijmegen, Nijmegen, NL, ⁴4. Leiden University Medical Center, Leiden, NL, ⁵Radboud University Medical Center, Nijmegen, NL, ⁶Erasmus MC Cancer Institute, Rotterdam, NL, ⁷7. University of Groningen, University Medical Center Groningen, Groningen, NL, ⁸1. Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, NL
- 12:00 - 12:00 **1706P - Radiomics improves response evaluation for desmoid tumors treated with chemotherapy**
A. Crombe¹, M. Kind¹, I. Ray-Coquard², N. Isambert³, C. Chevreau⁴, T. Andre⁵, C. Lebbe⁶, A. Le Cesne⁷, E. Bompas⁸, S. Piperno-Neumann⁹, E. Saada-Bouzid¹⁰, J.-Y. Blay², A. Italiano¹¹, ¹Bergonie Institute, Bordeaux, FR, ²Centre Léon Bérard, Lyon, FR, ³Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁴Institut Universitaire du Cancer -Toulouse-Oncopole, Toulouse, FR, ⁵Hopital Saint-Antoine, Paris, FR, ⁶Hôpital Saint Louis, Paris, FR, ⁷Gustave Roussy - Cancer Campus, Villejuif, FR, ⁸ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁹Institut Curie, Paris, FR, ¹⁰Hopital Lacassagne, Nice, FR, ¹¹Institute Bergonié, Bordeaux, FR
- 12:00 - 12:00 **1707P - Radiomics of gastrointestinal stromal tumors; risk classification based on computed tomography images - a pilot study**
M. Timbergen¹, M. Starmans², M. Vos³, M. Renckens², D. Grünhagen¹, G. Van Leenders², W. Niessen², C. Verhoef¹, S. Sleijfer³, S. Klein², J. Visser², ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²Erasmus MC, Rotterdam, NL, ³Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL
- 12:00 - 12:00 **1708P - Differentiating well-differentiated liposarcomas from lipomas using a radiomics approach**
M. Vos¹, M. Starmans², M. Timbergen³, S. Van Der Voort², G. Padmos³, W. Kessels⁴, W. Niessen², G. Van Leenders², D. Grünhagen³, S. Sleijfer¹, C. Verhoef³, S. Klein², J. Visser², ¹Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ²Erasmus MC, Rotterdam, NL, ³Erasmus MC Cancer Institute, Rotterdam, NL, ⁴Delft University of Technology, Delft, NL

- 12:00 - 12:00 **1709P - The immune landscape of chondrosarcoma reveals an anti inflammatory environment**
I. Richert¹, C. Bouvier², A. Gomez-Brouchet³, G. Du Bouexic De Pinieux⁴, K. Marie⁵, J.-Y. Blay¹, A. Dutour¹, ¹Centre Léon Bérard, Lyon, FR, ²AP-HM CHU NORD, Marseille, FR, ³IUCT, Toulouse, FR, ⁴CHRU Tours, Tours, FR, ⁵Centre Leon Berard, Lyon, FR
- 12:00 - 12:00 **1710P - Impact of Immunotherapy and Targeted Therapy on Tumor Growth Rate in Sarcoma**
E. Al-Ezzi¹, K. Alshammari², Y. Kanjanapan³, Z. Veitch², S. Fasih², E. Malone², E. Amir², A.R. Albiruni², ¹Princess Margaret Cancer Centre, Toronto, CA, ²Princess Margaret Cancer Center, Toronto, CA, ³The Canberra hospital, Garran, AU
- 12:00 - 12:00 **1711P - DNA methylation profiles of angiosarcoma subtypes.**
M. Weidema¹, E. De Jong², C. Koelsche³, I. Desar¹, M. Hillebrandt-Roeffen¹, W. Van Der Graaf⁴, Y. Versleijen-Jonkers¹, A. Von Deimling⁵, U. Flucke¹, ¹Radboud University Medical Center, Nijmegen, NL, ²Princess Máxima Center for Pediatric Oncology, Utrecht, NL, ³Institute of Pathology, Heidelberg, DE, ⁴Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁵University of Heidelberg, Heidelberg, DE
- 12:00 - 12:00 **1712P - Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumors (mGISTs)**
D. Fanale¹, L. Incorvaia¹, G. Badalamenti¹, J.L. Iovanna², D. Olive², I. De Luca³, M. Silletta⁴, B. Vincenzi⁵, V. Bazan³, A. Russo³, ¹AOU Policlinico "Paolo Giaccone", Palermo, IT, ²Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, FR, ³University of Palermo, Palermo, IT, ⁴Campus Bio-Medico di Roma, Rome, IT, ⁵Policlinico Universitario Campus Bio-Medico, Rome, IT
- 12:00 - 12:00 **1713P - PD-L1 expression in resected undifferentiated pleomorphic sarcoma and its clinical implications**
K. Lee, J.E. Kim, W. Kim, J.-S. Lee, S.Y. Song, M.H. Lee, H.W. Chung, J.S. Song, K.-J. Cho, J.-H. Ahn, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR
- 12:00 - 12:00 **1714P - PD-L1 expression as a potential therapeutic target and prognostic biomarker in well-differentiated and dedifferentiated liposarcoma.**
H. Chae, J.E. Kim, W. Kim, J.-S. Lee, S.Y. Song, M.H. Lee, H.W. Chung, J.S. Song, J.-H. Ahn, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR
- 12:00 - 12:00 **1715P - Soft tissue sarcomas express a distinct mRNA immune profile**
V. Grünwald¹, F. Laenger², A. Kunitz³, M. Schuler⁴, P. Schoeffski⁵, H.-G. Kopp⁶, S. Bauer¹, B. Kasper⁷, L. Lindner⁸, J. Chemnitz⁹, M. Crysandt¹⁰, A. Stein¹¹, B. Steffen¹², M. Kneba¹³, G. Egerer¹⁴, S. Zimmermann², P. Ivanyi¹⁵, A. Karch², ¹University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ²Medical School Hannover, Hannover, DE, ³Vivantes Klinikum Spandau, Berlin, DE, ⁴Helios Klinikum Emil von Behring, Berlin, DE, ⁵University Hospitals Leuven, Leuven, BE, ⁶Robert-Bosch-Krankenhaus, Stuttgart, DE, ⁷University Hospital Mannheim, Mannheim, DE, ⁸University Hospital Munich, Munich, DE, ⁹Gemeinschaftsklinikum Mittelrhein, Koblenz, DE, ¹⁰University Hospital

Aachen, Aachen, DE, ¹¹UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ¹²University Hospital Frankfurt, Frankfurt, DE, ¹³UK-SH, Campus Kiel, Kiel, DE, ¹⁴University Hospital Heidelberg, Heidelberg, DE, ¹⁵Hannover Medical School, Hannover, DE

- 12:00 - 12:00 **1716P - The molecular landscape of fusion genes in endometrial stromal sarcomas include three nosological entities with different natural history**
M. Brahm¹, T. Franceschi², I. Treilleux¹, D. Pissaloux², I. Ray-Coquard¹, A. Dufresne¹, P. Meeus¹, M.-P. Sunyach², K. Marie³, A. Meurgey², J.-Y. Blay¹, F. Tirede², ¹Centre Léon Bérard, Lyon, FR, ²Centre Léon Bérard, LYON, FR, ³Centre Leon Berard, Lyon, FR
- 12:00 - 12:00 **1717P - Clinical validation of a novel assay for the detection of diagnostic alterations in sarcomas**
L. Mc Connell¹, O. Houghton², M. Catherwood², J. Gazdova¹, P. Stewart¹, A. Oniscu³, P. Groenen⁴, L. Kroeze⁴, P. Tanriere⁵, A. Flanagan⁶, A. Stobl⁶, M. Salto-Tellez⁷, D. Gonzalez De Castro⁸, ¹Centre for Cancer Research and Cell Biology - Queen's University Belfast, Belfast, GB, ²Belfast Health and Social Care Trust, Belfast, GB, ³Royal Infirmary of Edinburgh, Edinburgh, GB, ⁴Radboud University Medical Center, Nijmegen, NL, ⁵Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, Birmingham, GB, ⁶Royal National Orthopaedic Hospital, London, GB, ⁷Belfast City Hospital, Belfast, GB, ⁸Queen's University Belfast, Belfast, GB
- 12:00 - 12:00 **1718P - A prospective correlative trial of personalized patient-derived xenograft (PDX) as avatars for drug therapy in patients with metastatic or recurrent soft tissue sarcomas (STS).**
K. Alshammari¹, E. Al-Ezzi², J. Lewin³, S. Salah⁴, Z. Veitch¹, E. Malone¹, G. Paris⁵, M. Mancini⁵, A. Zer¹, M. Ahmad¹, R. Beercroft¹, A.R. Albiruni¹, ¹Princess Margaret Cancer Center, Toronto, CA, ²Princess Margaret Cancer Centre, Toronto, CA, ³Peter MacCallum Cancer Center, Melbourne, AU, ⁴King Hussain Cancer Foundation and Center, Amman, JO, ⁵Champions Oncology, rockville, US
- 12:00 - 12:00 **1719P - Fusion of immortalized myoblasts induces genomic instability that drives tumor development and progression.**
C. Merle¹, J. Baud², N. Thebaud³, T. Lesluyes³, G. Pérot³, L. Delespaul³, L. Lartigue², F. Chibon⁴, ¹Centre de Recherche en Cancérologie de Toulouse, Toulouse, FR, ²Bergonie Institute, Bordeaux, FR, ³Cancer Research Center in Toulouse (CRCT), Toulouse, FR, ⁴Institute Bergonié, Bordeaux, FR
- 12:00 - 12:00 **1720P - let-7a suppress Ewing sarcoma CSCs' malignant phenotype through forms a positive feedback regulation loop with lin28 via STAT3**
C. Kai, X. Jiang, 2nd Affiliated Hospital of Nanchang University, Nanchang, CN
- 12:00 - 12:00 **1721P - Myoepithelial Tumors of Soft Tissues and Extraskeletal Myxoid Chondrosarcomas feature a distinct transcriptional pattern**
D. Racanelli¹, S. Stacchiotti², M. Brenca³, M. Sbaraglia⁴, K. Fassetta³, D. Baldazzi³, S. Piccinin³, S. Brich⁵, P.G. Casali², P. Collini⁵, G.P. Dagrada⁵, M. Fiore², A. Gronchi⁶, A. Astolfi⁷, M.A. Pantaleo⁷, A. Righi⁸, S. Pilotti², A.P. Dei Tos⁴, R. Maestro⁹, ¹Centro di

Riferimento Oncologico - CRO, Aviano, IT, ²Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ³Centro di Riferimento Oncologico - CRO, aviano, IT, ⁴Treviso Regional Hospital, Treviso, IT, ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁶Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁷University of bologna, Bologna, IT, ⁸IRCCS, Istituto ortopedico Rizzoli Bologna, Bologna, IT, ⁹Centro di Riferimento Oncologico, Aviano, IT

- 12:00 - 12:00 **1722P - In Vivo Efficacy and Enhanced Tumor Accumulation of Liposomal Vinorelbine (TLC178) in Human Sarcoma Xenograft Mice Model**
W.-N. Yu¹, J.-H. Tang², Y.-C. Tsai², H.-T. Wang², ¹TLC - Taiwan Liposome Company, Taipei City, TW, ²Taiwan Liposome Company, Taipei, TW
- 12:00 - 12:00 **1723P - MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma**
M. Vos¹, R. Boers², A. Vriends³, J. Boers², P. Van Kuijk³, W. Van Houdt⁴, G. Van Leenders², M. Wagrodzki⁵, W. Van Ijcken², J. Gribnau², D. Grünhagen³, C. Verhoef³, S. Sleijfer¹, E. Wiemer³, ¹Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ²Erasmus MC, Rotterdam, NL, ³Erasmus MC Cancer Institute, Rotterdam, NL, ⁴Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ⁵Oncology Center in Warsaw, Warsaw, PL
- 12:00 - 12:00 **1724P - Epigenetic mechanism of chondrosarcoma stem cell targeting by toll like receptor ligand, proline rich polypeptide 1 (PRP-1).**
K. Galoian¹, A. Moran², C. Granger³, A. Sedani², ¹Um Miller School of Medicine Jackson Memorial Hospital, Miami, US, ²University of Miami, Miller School of Medicine, Miami, US, ³University of Miami, Miller School of Medicine, Miami, US
- 12:00 - 12:00 **1725P - Genomic Alterations, Tumor Mutation Burden and Prognosis of Chinese Cardiac Sarcoma Patients**
N. Zhu¹, Y. Hou¹, Y. Ji¹, Y. Qu², Q. Cui², C. Hui², ¹Zhongshan Hospital, Fudan University, Shanghai, CN, ²OrigiMed, Shanghai, CN
- 12:00 - 12:00 **1726P - Evaluation of a peptide-conjugated alkylator melflufen in osteosarcoma preclinical models**
A. Slipicevic¹, K. Byrgazov², F. Lehmann¹, L. Kager³, T. Lion², S. Taschner-Mandl², ¹Oncopeptides AB, Stockholm, SE, ²St. Anna Children's Cancer Research Institute CCRI, Vienna, AT, ³St. Anna Children's Hospital, Vienna, AT
- 12:00 - 12:00 **1727P - Expression analysis of NHEJ and HR genes in Ewing sarcomas: indications of DSB repair dysfunction**
A. Kyriazoglou¹, V. Konteles², M. Lontos¹, G. Sofianidis³, F. Zagouri⁴, K. Koutsoukos¹, G. Tsironis¹, A. Tsiara¹, M. Kaparelou¹, R. Zakopoulou¹, A. Cohen¹, E. Dimitriadis², L. Mahaira², D. Michali², N. Arnogiannaki², K. Stefanaki⁵, M. Dimopoulos¹, A. Kattamis⁵, ¹Alexandra Hospital, Athens, GR, ²Aghios Savvas Hospital, Athens, GR, ³Aristotle University of Thessaloniki, Thessaloniki, GR, ⁴General Hospital Konstantopoulio-Agia Olga, Athens, GR, ⁵Aghia Sofia Children's Hospital, Athens, GR

- 12:00 - 12:00 **1728P - Epidemiology of Synovial Sarcoma in EU28 countries**
N. Joseph¹, S. St. Laurent², S. Zheng², H. Stirnadel-Farrant³, C. Dharmani²,
¹GlaxoSmithKline USA, Collegeville, US, ²GlaxoSmithKline, Collegeville, US,
³GlaxoSmithKline, Stevenage, Hertfordshire, GB
- 12:00 - 12:00 **1729P - Resection Of High-Grade Large Soft Tissue Sarcoma With Adequate Wide Margin Can Lead To Good Local Control Without Adjuvant Radiotherapy**
T. Kunisada, E. Nakata, J. Hasei, T. Ozaki, Okayama University Hospital, Okayama, JP
- 12:00 - 12:00 **1730P - Influence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models**
M. Mendiola¹, V. Heredia-Soto², J. Escudero², R. Crespo², P. Ruiz², A. Gallego Martínez¹,
V. Martínez-Marin¹, J. Pozo¹, A. Berjón¹, E. Ortiz-Cruz¹, D. Bernabeu¹, A. Redondo¹,
¹Hospital Universitario La Paz, Madrid, ES, ²Instituto de investigación del Hospital
Universitario La Paz, IdiPAZ, Madrid, ES
- 12:00 - 12:00 **1731TiP - EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT)**
N. Penel¹, J.-Y. Blay², J. Wallet¹, A. Le Cesne³, A. Italiano⁴, O. Mir³, S. Taieb¹, M.
Vanseymortier¹, P. Desmet¹, E. Decoupigny¹, J. Courtial¹, M.C. Le Deley¹, ¹Centre Oscar
Lambret, Lille, FR, ²Centre Léon Bérard, Lyon, FR, ³Institut Gustave Roussy, Villejuif,
FR, ⁴Institute Bergonié, Bordeaux, FR
- 12:00 - 12:00 **1732TiP - A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need**
K. Yonemori¹, T. Shimizu¹, T. Koyama¹, N. Matsui¹, H. Okuma¹, E. Noguchi¹, K. Sudo¹, A.
Hirakawa², T. Sukigara¹, S. Fujitani³, K. Nakamura¹, K. Tamura¹, N. Yamamoto¹, Y.
Fujiwara⁴, ¹National Cancer Center Hospital, Tokyo, JP, ²The University of Tokyo, Tokyo,
JP, ³Daiichi Sankyo Co.,Ltd, Tokyo, JP, ⁴Pharmaceutical and Medical Devices Agency,
Tokyo, JP
- 12:00 - 12:00 **1733TiP - A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010)**
H. Loong¹, R. Mennel², M. Wagner³, T. Tse⁴, Y.-M. Lau⁴, C. Yuen⁴, R. Moore³, M.-F.
Kwan⁵, D. Cutler⁵, D. Kramer⁵, W.-K. Chan⁵, V. Ravi⁶, ¹The Chinese University of Hong
Kong, Shatin, HK, ²Texas Oncology-Baylor Charles A. Sammons Cancer Center, TX, US,
³University of Washington, Seattle, US, ⁴The Chinese University of Hong Kong, Hong
Kong, HK, ⁵Athenex Inc, Buffalo, US, ⁶The University of Texas MD Anderson Cancer
Center, Houston, US
- 12:00 - 12:00 **1734TiP - Pulmonary Resectable Metastases of Osteosarcoma With Apatinib and Chemotherapy (PROACH) : A Multi-Center Phase II Randomized Clinical Trial**
Q. Bao¹, Y. Hu², Y. Shen², W. Zhang², ¹Jiangshan City People's Hospital, Jiangshan City,
CN, ²Ruijin Hospital, shanghai, CN

- 12:00 - 12:00 **1735TiP - National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis, AF (ALTITUDES)**
T. Ryckewaert¹, N. Penel¹, M.C. Le Deley¹, J. Thery¹, E. Decoupigny¹, M. Vanseymortier¹, A. Dufresne², N. Corradini³, J.-Y. Blay², D. Orbach⁴, S. Salas⁵, ¹Centre Oscar Lambret, Lille, FR, ²Centre Léon Bérard, Lyon, FR, ³IHOPE - Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, FR, ⁴Institut Curie, Paris, FR, ⁵Ap-hm, Marseille, FR
- 13:00 - 14:30** **Type: Industry Satellite Symposium** **Pamplona Auditorium (Hall 2)**
Title: Pfizer - From Clinical Trials to Practice: Changing the Trajectory for Patients with Breast Cancer
Chair(s): Miguel Martín, ES
- 13:00 - 13:15 **Introduction: Blazing the Trail in the Treatment of Breast Cancer**
M. Martín, Hospital General Universitario Gregorio Marañón, Madrid, ES
- 13:15 - 13:35 **Charting the Course: Novel Treatment Options for Patients with Germline BRCA-Mutated Locally Advanced or Metastatic Breast Cancer**
H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
- 13:35 - 13:55 **Advancing the Path: Selecting Treatment for Patients with gBRCA-mutated Locally Advanced/Metastatic Breast Cancer**
J. Ettl, Technische Universität München, München, DE
- 13:55 - 14:25 **Paving the Way in the Clinic: Real-world Outcomes With CDK 4/6 Inhibitor Treatments for Locally Advanced/Metastatic Breast Cancer**
A. Brufsky, Magee-Womens Hospital of UPMC, Pittsburgh, US
- 14:25 - 14:30 **Panel Q&A**

13:00 - 14:30	Type: Industry Satellite Symposium Title: GSK-TESARO - DNA repair deficiency as an immunotherapy target in gynaecological cancers Chair(s): Christian Marth, AT; Isabelle Ray-Coquard, FR	Cordoba Auditorium (Hall 7)
13:00 - 13:05	Introduction <u>C. Marth</u> , University Hospital Innsbruck, Innsbruck, AT	
13:05 - 13:25	Targeting DNA repair deficiency in gynaecological cancer therapy <u>A. Leary</u> , Gustave Roussy Cancer Center, INSERM U981, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Villejuif, FR	
13:25 - 13:45	Immunotherapy in gynaecological cancers: what are the latest clinical data? <u>N. Colombo</u> , Istituto Europeo di Oncologia, Milan, IT	
13:45 - 14:05	Efficacy of anti-PD-1 therapy in endometrial cancer: an update on dostarlimab from the GARNET trial <u>R. Kristeleit</u> , UCL Cancer Institute, University College London and UCL Hospitals, Middletown, US	
14:05 - 14:25	Future prospects of immunotherapy in gynaecological cancers <u>M.R. Mirza</u> , Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK	
14:25 - 14:45	Conclusions <u>I. Ray-Coquard</u> , Centre Léon Bérard, Lyon, FR	

13:00 - 14:30 **Type: Industry Satellite Symposium** **Bilbao Auditorium (Hall 5)**
Title: MSD - Redefining survival expectations in lung cancer
Chair(s): Martin Reck, DE

13:00 - 13:05 **Welcome and introductions**

M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

13:05 - 13:20 **Scientific rationale for combining Immune Check Point Inhibitors and chemotherapy**

M. Garassino, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

13:20 - 13:50 **Role of IO in mNSCLC**

M. Reck¹, N. Pennell², ¹Krankenhaus Grosshansdorf, Grosshansdorf, DE, ²Cleveland Clinic, Cleveland, US

13:50 - 13:50 **Pro: Use of IO/chemotherapy combinations or monotherapy in 1L**

13:50 - 13:50 **Con: Preserve option of IO use for 2nd line**

13:50 - 14:05 **Patient cases**

M. Reck¹, N. Pennell², ¹Krankenhaus Grosshansdorf, Grosshansdorf, DE, ²Cleveland Clinic, Cleveland, US

14:05 - 14:20 **Beyond NSCLC - SCLC, Mesothelioma**

C. Langer, University of Pennsylvania-Perelman Center for Advanced Medicine, Philadelphia, US

14:20 - 14:30 **Q&A**

M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

- 13:00 - 14:30** **Type: Industry Satellite Symposium** **Tarragona Auditorium**
Title: Bristol-Myers Squibb - The evolving I-O **(Hall 7)**
landscape in NSCLC
Chair(s): Matthew Hellmann, US; Enriqueta Felip, ES
- 13:00 - 13:05 **Welcome and Introductions**
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES
- 13:05 - 13:30 **Navigating the 1L NSCLC Landscape**
M. Hellmann, Memorial Sloan Kettering, New York, US
- 13:30 - 13:55 **2L NSCLC: From I-O-Naïve to I-O-Experienced**
F. Cappuzzo, Ospedale Santa Maria delle Croci, Ravenna, IT
- 13:55 - 14:20 **Emerging Endpoints and Novel Approaches in Early NSCLC**
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES
- 14:20 - 14:30 **Closing Remarks and Audience Q&A**
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES

13:00 - 14:30 **Type: Industry Satellite Symposium** **Alicante Auditorium (Hall 3)**
Title: Lilly Oncology - The ABCs of CDK 4/6 Inhibitors: Who, when, and why in HR-positive/HER2-negative MBC
Chair(s): Nadia Harbeck, DE

- 13:00 - 13:05 **Introduction**
N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE
- 13:05 - 13:10 **Case Presentation: Consideration of Initial Combination Therapy With CDK 4/6 Inhibitors**
S. Tolaney, Dana Farber Cancer Institute, Boston, US
- 13:10 - 13:35 **Panel Discussion: Clinical efficacy and safety data of upfront combination therapy used in HR-positive/HER2-negative MBC**
- 13:35 - 13:40 **Case continuation: Addition of CDK4/6 inhibitor therapy upon initial endocrine therapy progression**
N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE
- 13:40 - 14:05 **Panel discussion: Clinical efficacy and safety data of CDK 4/6 inhibitor therapy after progression on initial endocrine therapy in HR-positive/HER2-negative MBC**
- 14:05 - 14:10 **Case Follow-up: Management of CDK 4/6 Inhibitor Therapy Toxicities**
V. Guarneri, Istituto Oncologico Veneto IRCCS, Padova, IT
- 14:10 - 14:25 **Panel Discussion: Differentiation of dosing administration, monitoring, and mitigation of AEs for CDK 4/6 inhibitor therapy**
- 14:25 - 14:30 **Concluding Remarks and Audience Q&A**
N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE

- 13:00 - 14:30** **Type: Industry Satellite Symposium** **Cartagena Auditorium (Hall 3)**
Title: IPSEN - International multidisciplinary team approaches to HCC management
Chair(s): Bruno Sangro, ES
- 13:00 - 13:10 **Welcome and introduction**
B. Sangro, Clinica Universidad de Navarra, Pamplona, ES
- 13:10 - 13:30 **HCC management from diagnosis to locoregional therapy**
R.K. Kelley¹, J. Ricke², B. Sangro³, T. Yau⁴, ¹University of California San Francisco, San Francisco, US, ²LMU Klinikum der Universität München, Munich, DE, ³Clinica Universidad de Navarra, Pamplona, ES, ⁴University of Hong Kong, Hong Kong, CN
- 13:30 - 13:50 **Systemic therapies in naïve patients and transition from locoregional therapies**
R.K. Kelley¹, J. Ricke², B. Sangro³, T. Yau⁴, ¹University of California San Francisco, San Francisco, US, ²LMU Klinikum der Universität München, Munich, DE, ³Clinica Universidad de Navarra, Pamplona, ES, ⁴University of Hong Kong, Hong Kong, CN
- 13:50 - 14:10 **Systemic therapies in second line and beyond**
R.K. Kelley¹, J. Ricke², B. Sangro³, T. Yau⁴, ¹University of California San Francisco, San Francisco, US, ²LMU Klinikum der Universität München, Munich, DE, ³Clinica Universidad de Navarra, Pamplona, ES, ⁴University of Hong Kong, Hong Kong, CN
- 14:10 - 14:25 **Future perspectives: How will ongoing trials shape HCC treatment?**
R.K. Kelley¹, J. Ricke², B. Sangro³, T. Yau⁴, ¹University of California San Francisco, San Francisco, US, ²LMU Klinikum der Universität München, Munich, DE, ³Clinica Universidad de Navarra, Pamplona, ES, ⁴University of Hong Kong, Hong Kong, CN
- 14:25 - 14:30 **Close**
B. Sangro, Clinica Universidad de Navarra, Pamplona, ES

13:00 - 14:30 **Type: Industry Satellite Symposium** **Salamanca Auditorium**
Title: Astellas - Adding life to years for patients with **(Hall 3)**
CRPC
Chair(s): Bertrand Tombal, BE

- 13:00 - 13:05 **Welcome and introduction**
B. Tombal, Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE
- 13:05 - 13:25 **Delaying disease progression in CRPC: Adding quality to life**
B. Tombal, Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE
- 13:25 - 13:45 **Early treatment for CRPC: which endpoints matter**
F. Saad, Centre Hospitalier de l'Université de Montréal/CRCHUM, Montreal, CA
- 13:45 - 14:05 **Endocrine metabolic effects: Considerations for patients with prostate cancer**
A. Giustina, Università Vita e Salute San Raffaele Milano, Milan, IT
- 14:05 - 14:25 **Putting patient centricity into clinical practice**
A. Morgans, Northwestern University Feinberg School of Medicine, Chicago, US
- 14:25 - 14:30 **Summary and close**
B. Tombal, Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE

13:00 - 14:30	Type: ESMO Colloquium Title: ESMO Colloquium supported by Eisai Europe - Emerging Biotherapy Strategies in the treatment of solid tumours: Hope, Hype and Hurdles Chair(s): Laurence Albiges, FR	Toledo Auditorium (Hall 5)
13:00 - 13:00	Session DOI	
13:00 - 13:05	Introduction <u>L. Albiges</u> , Institut Gustave Roussy, Villejuif, FR	
13:05 - 13:25	Evolving role and practices changes with TKI in management of solid tumours <u>J. Evans</u> , Beatson West of Scotland Cancer Centre, Glasgow, GB	
13:25 - 13:30	Q&A	
13:30 - 13:50	How far can immuno-oncology go on its own?	
13:50 - 13:55	Q&A	
13:55 - 14:15	TKI and immunotherapy combination: A cross-fire approach <u>V. Grünwald</u> , University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE	
14:15 - 14:20	Q&A	
14:20 - 14:30	Speaker panel discussion: Questions and answers	

13:00 - 14:30	Type: Patient Advocay Track Title: Common but still rare: What happens when common cancers split into subgroups? Chair(s): Fredrik Johansson, SE; Simon Ekman, SE	Leon Auditorium (Hall 3)
13:00 - 13:00	Session DOI	
13:00 - 13:15	When common cancers become rare- the lung cancer experience <u>S. Ekman</u> , Karolinska University Hospital-Solna, Solna, SE	
13:15 - 13:30	The Ros1ders: An advocacy experience <u>M. Hennink</u> , Longkanker Nederland, Utrecht, NL	
13:30 - 13:45	How to deal with diversity early on: Personalised early clinical trials <u>M. Scheffler</u> , Uniklinik Köln, Cologne, DE	
13:45 - 14:00	What common cancer advocates can learn from the rare cancer community <u>I. Galloway</u> , MPNE Ocular, London, GB	
14:00 - 14:15	Panel Discussion	
14:15 - 14:30	Conclusions <u>F. Johansson</u> , Lungcancerförbundet Stödet Sweden, Stockholm, SE	

14:00 - 15:30 **Type: EONS session** **Oviedo Auditorium (CC5)**
Title: EONS 12: Living with and beyond cancer
Chair(s): Patricia Fox, IE

14:00 - 14:00 **Session DOI**

14:00 - 14:25 **Sexuality training for nurses in acute and palliative care**
C. Papadopoulou, University of the West of Scotland-UWS Paisley, Paisley, GB

14:25 - 14:50 **Suicide in patients with cancer. How to assess patients at risk?**
P. D'Alton, University College Dublin, Dublin, IE

14:50 - 15:05 **CN46 - HIV positive and treated for cancer: a qualitative study exploring the experiences of HIV related stigma in the cancer clinical setting**
E. Hainsworth¹, M. Shahmanesh², F. Stevenson¹, ¹University College London Hospital, London, GB, ²UCL, London, GB

15:05 - 15:25 **Discussion**

14:45 - 16:15 **Type: Proffered Paper session** **Barcelona Auditorium**
Title: Proffered Paper 1 - Gastrointestinal tumours, **(Hall 2)**
colorectal

14:45 - 14:45 **Session DOI**

14:45 - 15:00 **One LBA TBC**

15:00 - 15:15 **5220 - Mutation tracking in circulating tumor DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype.**

N. Tarazona Llaveró¹, F. Gimeno-Valiente², V. Gambardella¹, M. Huerta¹, S. Rosello Keranen¹, G. Bruixola², E. Fontana³, C. Martinez Ciarpaglini⁴, S. Zuñiga², P. Rentero⁵, T. Fleitas¹, F. Papaccio², D. Moro², V. Pla², G. Nyamundanda³, J. Castillo¹, A. Sadanadam³, A. Espí², D. Roda⁵, A. Cervantes¹, ¹Hospital Clínico Universitario de Valencia, Valencia, ES, ²INCLIVA Biomedical Research Institute, Valencia, ES, ³Institute of cancer Research, London, GB, ⁴INCLIVA Instituto de investigación sanitaria, Valencia, ES, ⁵Biomedical Research Institute INCLIVA, Hospital Clínico València, University of Valencia, Valencia, ES

15:15 - 15:30 **Invited Discussant 5520 and one LBA TBC**

15:30 - 15:45 **5230 - FOxTROT: an international randomised controlled trial in 1053 patients evaluating neoadjuvant chemotherapy (NAC) for colon cancer.**

D. Morton, University of Birmingham, Birmingham, GB

15:45 - 16:00 **Invited Discussant 5230**

14:45 - 16:15	Type: Special symposium Title: Optimal delivery of immuno-oncology (I-O) in advanced NSCLC Chair(s): Solange Peters, CH	Madrid Auditorium (Hall 2)
14:45 - 14:45	Session DOI	
14:45 - 14:50	Introduction	
14:50 - 15:10	Biomarkers for I-O: Can we and should we? <u>S. Peters</u> , Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH	
15:10 - 15:30	Optimal combination for firstline NSCLC <u>M. Reck</u> , Krankenhaus Grosshansdorf, Grosshansdorf, DE	
15:30 - 15:50	Can we combine radiotherapy with I-O? <u>R. Dziadziuszko</u> , Medical University of Gdansk, Gdansk, PL	
15:50 - 16:10	Challenging I-O after toxicity or resistance <u>B. Besse</u> , Institut Gustave Roussy, Villejuif, FR	
16:10 - 16:15	Conclusions and perspectives <u>S. Peters</u> , Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH	

14:45 - 16:15	Type: Proffered Paper session Title: Proffered Paper 2 - Genitourinary tumours, non-prostate	Sevilla Auditorium (Hall 2)
14:45 - 14:45	Session DOI	
14:45 - 15:00	One LBA TBC	
15:00 - 15:15	One LBA TBC	
15:15 - 15:30	One LBA TBC	
15:30 - 15:48	Invited Discussant 3 LBAs TBC	
15:48 - 16:03	<p>9030 - Redefining the IGCCCG Classification in advanced Non-Seminoma</p> <p>S. Gillessen¹, L. Collette², G. Daugaard³, R. De Wit⁴, A. Tryakin⁵, C. Albany⁶, O. Stahl⁷, K. Fizazi⁸, J. Gietema⁹, U. De Giorgi¹⁰, A. Hansen¹¹, D. Feldman¹², F. Cafferty¹³, T. Tandstad¹⁴, X. Garcia Del Muro¹⁵, R. Huddart¹⁶, C. Sweeney¹⁷, D. Heng¹⁸, N. Sauve², J. Beyer¹⁹, ¹The Christie NHS Foundation Trust, Manchester, GB, ²EORTC - European Organisation for Research and Treatment of Cancer, Brussels, BE, ³Rigshospitalet, Copenhagen University Hospital, Copenhagen, DK, ⁴Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ⁵N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ⁶Indiana University, Indianapolis, US, ⁷Skane University Hospital, Lund, SE, ⁸Institut Gustave Roussy, Villejuif, FR, ⁹University Hospital Groningen (UMCG), Groningen, NL, ¹⁰Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ¹¹Princess Margaret Cancer Center, Toronto, CA, ¹²Memorial Sloan Kettering Cancer Centre, New York, US, ¹³Medical Research Council, London, GB, ¹⁴St Olav's University Hospital, Trondheim, NO, ¹⁵ICO - Institut Catala d'Oncologia Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ¹⁶Royal Marsden Hospital Institute of Cancer Research, Sutton, GB, ¹⁷Dana Farber Cancer Institute, Boston, US, ¹⁸University of Calgary, Calgary, CA, ¹⁹University Hospital Zürich, Zurich, CH</p>	
16:03 - 16:15	Invited Discussant 9030	

14:45 - 16:15 **Type: Educational session** **Pamplona Auditorium (Hall 2)**
Title: Treating endometrial cancer in the molecular age
 Chair(s): Mansoor Raza Mirza, DK; Susana Banerjee, GB

14:45 - 14:45 **Session DOI**

14:45 - 15:10 **Has molecular classification changed the surgical approach in endometrial cancer?**
C. Marth, University Hospital Innsbruck, Innsbruck, AT

15:10 - 15:35 **Has molecular classification changed the medical approach in endometrial cancer?**
C. Creutzberg, Leiden University Medical Center (LUMC), Leiden, NL

15:35 - 16:00 **Endometrial cancer enters the immunotherapy era**
M.R. Mirza, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK

16:00 - 16:15 **Discussion**

14:45 - 16:15 **Type: Educational session** **Cordoba Auditorium (Hall 7)**
Title: Novel therapeutic strategies in ABC: Immunotherapy, Antibody Drug Conjugates (ADCs) and beyond
 Chair(s): Giuseppe Curigliano, IT

14:45 - 14:45 **Session DOI**

14:45 - 15:10 **Triple negative breast cancer (TNBC)**
G. Curigliano, Istituto Europeo di Oncologia, Milan, IT

15:10 - 15:35 **HER2 overexpressing breast cancer**
S. Loi, Peter MacCallum Cancer Center, Melbourne, AU

15:35 - 16:00 **DNA repair strategies: Beyond PARP inhibition**
A. Tutt, The Institute of Cancer Research (ICR), London, GB

16:00 - 16:15 **Discussion**

14:45 - 16:00 **Type: Poster Discussion session** **Granada Auditorium (Hall 3)**
Title: Poster Discussion - Melanoma and other skin tumours

14:45 - 14:45 **Session DOI**

14:45 - 14:45 **One LBA TBC**

14:45 - 14:45 **1312PD - Safety and Efficacy of TRIPlet combination of Nivolumab (N) with Dabrafenib (D) and Trametinib (T) [TRIDeNT] in Patients (pts) with BRAF-mutated Metastatic Melanoma (MM): A Single Center Phase II Study**

E. Burton¹, R. Amaria², I. Glitza³, M. Shephard³, A. Diab³, D. Milton¹, S. Patel⁴, J. Mcquade⁴, M. Wong⁴, P. Hwu³, J. Wargo³, M. Davies³, H. Tawbi⁴, ¹UT MD Anderson Cancer Center, Houston, US, ²The M. D. Anderson Cancer Center, Houston, US, ³The University of Texas MD Anderson Cancer Center, Houston, US, ⁴The University of Texas M. D. Anderson Cancer Center, Houston, US

14:45 - 14:57 **Invited Discussant 1312PD and one LBA TBC**

14:57 - 15:02 **Q&A led by Discussant**

15:02 - 15:02 **One LBA TBC**

15:02 - 15:02 **One LBA TBC**

15:02 - 15:02 **One LBA TBC**

15:02 - 15:17 **Invited Discussant 3 LBAs TBC**

15:17 - 15:22 **Q&A led by Discussant**

15:22 - 15:22 **One LBA TBC**

15:22 - 15:22 **1313PD - 3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)**

C. Blank¹, J. Versluis², I. Reijers³, K. Sikorska², W. Van Houdt⁴, J. Van Thienen², S. Adriaansz⁵, H. Mallo³, H. Van Tinteren², B. Van De Wiel², L. Grijpink-Ongering⁵, A.

Bruining⁵, J. Haanen², A. Van Akkooi⁵, T. Schumacher¹, E. Rozeman², ¹The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ³Netherlands Cancer Institute, Amsterdam, NL, ⁴Royal Marsden Hospital NHS Foundation Trust, London, GB, ⁵Netherlands Cancer Institute/Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL

15:22 - 15:34 **Invited Discussant 1313PD and one LBA TBC**

15:34 - 15:39 **Q&A led by Discussant**

15:39 - 15:39 **1314PD - Cell Phenotypes Associated with Response and Toxicity Defined by High Resolution Flow Cytometry in Melanoma Patients receiving Checkpoint Inhibition**

J. Weber¹, S. Hodi², M. Wind-Rotolo³, D. Woods⁴, A. Winter⁵, P. Chattopadhyay⁴, A. Laino⁵, ¹new york university school of medicine, New York City, US, ²Dana Farber Cancer Institute, Boston, US, ³Bristol-Myers Squibb, Princeton, US, ⁴New York University School of Medicine, New York, US, ⁵NYU School of Medicine, New York, US

15:39 - 15:39 **1315PD - Unsorted single-cell RNA sequencing profiles of metastatic melanoma patients reveal the heterogeneity of melanoma-associated fibroblasts**

K. Homicsko¹, D. Barras², V. Aedo Lopez³, B. Gautron Moura⁴, G. Berthod⁵, M. Matter², O. Gaide², G. Coukos⁶, D. Hanahan⁷, O. Michielin⁴, ¹Centre Multidisciplinaire d'Oncologie-CePo, Lausanne, CH, ²CHUV, Lausanne, CH, ³CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ⁴Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ⁵Hôpital Régional Sion-Hérens-Conthey, Site de Champsec Centre du Cancer Lausanne, Sion, CH, ⁶Ludwig Center for Cancer Research of the UNIL (LICR@UNIL), Epalinges, CH, ⁷Swiss Institute of Experimental Cancer Research, EPFL, Lausanne, CH

15:39 - 15:39 **1316PD - Plasma proteomics in patients with metastatic cutaneous melanoma treated with immune checkpoint inhibitors**

H. Eriksson¹, H. Babic², J. Lehtiö², M. Pernemalm², ¹Karolinska University Hospital and Karolinska Institute - Huddinge, Stockholm, SE, ²Karolinska Institutet, STOCKHOLM, SE

15:39 - 15:54 **Invited Discussant 1314PD, 1315PD, and 1316PD**

15:54 - 15:59 **Q&A led by Discussant**

14:45 - 16:00 Type: Poster Discussion session Valencia Auditorium (Hall 5)
Title: Poster Discussion - Breast cancer, early stage

- 14:45 - 14:45 **Session DOI**
- 14:45 - 14:45 **177PD - Prospective, multicenter registry trial to evaluate the clinical feasibility of targeted axillary dissection (TAD) in patients (pts) with breast cancer (BC) and core biopsy proven axillary involvement (cN+)**
M. Reinisch¹, J. Heil², A. Rüländ³, C. Seiberling¹, H. Harrach¹, D. Schindowski¹, J. Lubitz¹, C. Ankel⁴, S.-T. Graßhoff⁵, P. Deuschle⁶, V. Hanf⁷, J. Holtschmidt⁸, E. Traut¹, T. Kuehn⁹, S. Kuemmel¹⁰, ¹Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, ²Universitätsklinikum Heidelberg, Heidelberg, DE, ³St. Marien-Hospital Düren, Düren, DE, ⁴Rotkreuzklinikum München gGmbH, München, DE, ⁵Harzklinikum Dorothea Christiane Erxleben, Wernigerode, DE, ⁶Marienhaus Klinikum Hetzelstift Neustadt/Weinstraße, Neustadt, DE, ⁷Frauenklinik Nathanstift, Fürth, DE, ⁸University Hospital of Cologne, Köln, DE, ⁹Klinikum Esslingen, Esslingen am Neckar, DE, ¹⁰Clinics Essen-Mitte, Essen, DE
- 14:45 - 14:45 **178PD - Long-term results of the PACS 04 trial evaluating adjuvant Epirubicin plus Docetaxel in node-positive breast cancer and Trastuzumab in the HER2-positive subgroup**
V. D'Hondt¹, J.-L. Canon², L. Roca¹, C. Levy³, J.-Y. Pierga⁴, F. Le Du⁵, M. Campone⁶, I. Desmoulin⁷, P. Viens⁸, M. Debled⁹, J.-M. Ferrero¹⁰, D. Serin¹¹, A.-C. Hardy Bessard¹², E. Brain¹³, N. Dohollou¹⁴, H. Orfeuvre¹⁵, J. Lemonnier¹⁶, H. Roche¹⁷, S. Delalogue¹⁸, F. Dalenc¹⁹, ¹ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ²Grand Hopital de Charleroi Site Notre Dame, Charleroi, BE, ³Centre Francois Baclesse, Caen, FR, ⁴Institut Curie, Paris, FR, ⁵Centre Eugène Marquis, Rennes, FR, ⁶ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁷Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁸Institute Paoli Calmettes, Marseille, FR, ⁹Institut Bergonié, Bordeaux, FR, ¹⁰Centre Anticancer Antoine Lacassagne, Nice, FR, ¹¹Institut Ste Catherine, Avignon, FR, ¹²Hôpital Privé des Côtes d'Armor, Plérin, FR, ¹³Hôpital René Huguenin - Institut Curie, St. Cloud, FR, ¹⁴Polyclinique Bordeaux Nord Aquitaine, Bordeaux, FR, ¹⁵Centre Hospitalier de Bourg-en-Bresse (Fleyriat) CH De Fleyriat, Bourg en Bresse, FR, ¹⁶UNICANCER, Paris, FR, ¹⁷Institut Universitaire du Cancer -Toulouse-Oncopole, Toulouse, FR, ¹⁸Gustave Roussy, Villejuif, FR, ¹⁹Centre Claudius-Regaud, Toulouse, FR
- 14:45 - 14:55 **Invited Discussant 177PD and 178PD**
- 14:55 - 15:05 **Q&A led by Discussant**
- 15:05 - 15:05 **179PD - Tumor size and overall survival in a cohort of young (≤40 years), node negative, systemically untreated breast cancer patients; by the PARADIGM study group.**
V. De Jong¹, N. Ter Hoeve², M. Opdam¹, W. Vreuls³, E. Koop⁴, Z. Varga⁵, S. Willems⁶, C. Van Deurzen⁷, A. Cordoba⁸, A. Broeks¹, N. Stathonikos², A. Voogd⁹, K. Jozwiak¹, M. Hauptmann¹, G. Sonke¹⁰, E. Van Der Wall⁶, S. Siesling¹¹, P. Van Diest², S. Linn¹, G. Dackus¹, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL),

Amsterdam, NL, ²University Medical Center Utrecht, Utrecht, NL, ³Canisius Wilhelmina Ziekenhuis, Nijmegen, NL, ⁴Gelre Ziekenhuizen, Apeldoorn, NL, ⁵University Hospital Zurich, Zurich, CH, ⁶UMC-University Medical Center Utrecht, Utrecht, NL, ⁷Erasmus University Medical Center, Rotterdam, NL, ⁸Complejo Hospitalario de Navarra, Pamplona, ES, ⁹Maastricht University Medical Center (MUMC), Maastricht, NL, ¹⁰The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ¹¹Netherlands Comprehensive Cancer Organization, Utrecht, NL

15:05 - 15:05 **180PD - Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC)**

J. Furlanetto¹, V. Nekljudova¹, A. Schneeweiss², C. Thode³, C. Denkert⁴, M. Untch⁵, M. Bassy³, T. Karn⁶, P.A. Fasching⁷, E. Stickeler⁸, C. Schem⁹, F. Marmé¹⁰, E.-M. Grischke¹¹, M. Van Mackelenbergh¹², D. Strik¹³, S. Schmatloch¹⁴, V. Müller¹⁵, S. Loibl¹, ¹German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, ²University Hospital Heidelberg, Heidelberg, DE, ³amedes MVZ wagnerstibbe für Laboratoriumsmedizin, medizinische Mikrobiologie und Immunologie, Göttingen, DE, ⁴Uniklinikum Giessen und Marburg, Marburg, DE, ⁵Helios Klinikum Berlin Buch, Berlin, DE, ⁶Universitätsklinikum Frankfurt, Frankfurt am Main, DE, ⁷University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, ⁸Uniklinik RWTH Aachen, Aachen, DE, ⁹UK-SH, Campus Kiel, Kiel, DE, ¹⁰Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, ¹¹Universitätsklinikum Tübingen, Tübingen, DE, ¹²Universitätsklinikum Schleswig-Holstein, Kiel, DE, ¹³Endokrinologikum Berlin, Berlin, DE, ¹⁴Elisabeth Krankenhaus Kassel, Kassel, DE, ¹⁵Hamburg-Eppendorf University Medical Center, Hamburg, DE

15:05 - 15:05 **181PD - Improved survival of older patients with advanced breast cancer due to an increase in systemic treatments - a population-based study**

N. De Glas¹, E. Bastiaannet², A. De Boer¹, S. Siesling³, G.-J. Liefers², J. Portielje¹, ¹Leids Universitair Medisch Centrum (LUMC), Leiden, NL, ²Leiden University Medical Center, Leiden, NL, ³Netherlands Comprehensive Cancer Organization, Utrecht, NL

15:05 - 15:15 **Invited Discussant 179PD, 180PD and 181PD**

15:15 - 15:25 **Q&A led by Discussant**

15:25 - 15:25 **182PD - Utility of the CPS+EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy**

F. Marmé¹, C. Solbach², L. Michel³, P.A. Fasching⁴, A. Schneeweiss⁵, J.-U. Blohmer⁶, M. Rezaei⁷, J. Huober⁸, C. Jackisch⁹, V. Nekljudova¹⁰, T. Link¹¹, K. Rhiem¹², C. Denkert¹³, C. Hanusch¹⁴, H. Tesch¹⁵, B. Lederer¹⁰, S. Loibl¹⁰, M. Untch¹⁶, ¹Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, ²Universitätsklinik Frankfurt, Frankfurt, DE, ³Universitätsklinikum Heidelberg, Heidelberg, DE, ⁴University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, ⁵University Hospital Heidelberg, Heidelberg, DE, ⁶St.

Gertrauden-Krankenhaus, Berlin, DE, ⁷Luisenkrankenhaus, Düsseldorf, DE, ⁸Universitätsfrauenklinik Ulm, Ulm, DE, ⁹Sana Klinikum, Offenbach, DE, ¹⁰German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, ¹¹Universitätsklinikum Dresden, Dresden, DE, ¹²Uniklinik Köln, Köln, DE, ¹³Uniklinikum Giessen und Marburg, Marburg, DE, ¹⁴Klinikum zum Roten Kreuz München, Germany, München, DE, ¹⁵Private practice - Dr. Hans Tesch, Frankfurt am Main, DE, ¹⁶Helios Klinikum Berlin Buch, Berlin, DE

15:25 - 15:25 **183PD - Neoadjuvant endocrine therapy with palbociclib in patients with high-risk breast cancer**
P.E. Lønning¹, C. Clausen², E.S. Blix³, S. Lundgren⁴, G. Vagstad⁵, H. Espelid⁶, B. Gilje⁷, E.A. Janssen⁷, J. Geisler⁸, T. Aas¹, H. Aase¹, S. Knappskog², H. Eikesdal⁹, ¹Haukeland University Hospital, Bergen, NO, ²University of Bergen, Bergen, NO, ³University Hospital of North Norway, Tromsø, NO, ⁴St.Olavs University Hospital, Trondheim, NO, ⁵Helse Førde, Førde, NO, ⁶Helse Fonna, Haugesund, NO, ⁷Stavanger University Hospital, Stavanger, NO, ⁸University of Oslo, Akershus, NO, ⁹Helse Bergen - Haukeland University Hospital, Bergen, NO

15:25 - 15:25 **184PD - Neoadjuvant olaparib monotherapy in primary triple negative breast cancer**
H. Eikesdal¹, S. Yndestad², E.S. Blix³, S. Lundgren⁴, G. Vagstad⁵, H. Espelid⁶, B. Gilje⁷, E.A. Janssen⁷, J. Geisler⁸, T. Aas⁹, H. Aase⁹, S. Knappskog², P.E. Lønning⁹, ¹Helse Bergen - Haukeland University Hospital, Bergen, NO, ²University of Bergen, Bergen, NO, ³University Hospital of North Norway, Tromsø, NO, ⁴St.Olavs University Hospital, Trondheim, NO, ⁵Helse Førde, Førde, NO, ⁶Helse Fonna, Haugesund, NO, ⁷Stavanger University Hospital, Stavanger, NO, ⁸University of Oslo, Akershus, NO, ⁹Haukeland University Hospital, Bergen, NO

15:25 - 15:25 **185PD - Immunological differences between immune-rich estrogen receptor-positive and -negative breast cancers**
T. O'Meara¹, M. Marczyk¹, K. Blenman¹, V. Yaghoobi¹, V. Pelenkanou², D. Rimm¹, L. Pusztai³, ¹Yale University School of Medicine, New Haven, US, ²Sanofi, Cambridge, US, ³The University of Texas MD Anderson Cancer Center, Houston, US

15:25 - 15:35 **Invited Discussant 182PD, 183PD, 184PD and 185PD**

15:35 - 15:45 **Q&A led by Discussant**

14:45 - 16:15 **Type: Special session** **Cartagena Auditorium (Hall 3)**
Title: Decision making at the point of care: When evidence-based medicines can't help
 Chair(s): Stefan Rauh, LU; Dirk Arnold, DE

14:45 - 14:45 **Session DOI**

- 14:45 - 14:50 **Introduction**
D. Arnold, Asklepios Klinik Altona, Hamburg, DE
- 14:50 - 14:55 **1st clinical case: “Get the dreamer out of here”**
J.-L. Molitor, CHU Antoine Beclere, Clamart, FR
- 14:55 - 15:00 **Discussant**
M. Perol, Centre Léon Bérard, Lyon, FR
- 15:00 - 15:10 **General discussion**
- 15:10 - 15:15 **2nd clinical case: “A liver’s life”**
S. Rauh, Centre Hospitalier Emile Mayrisch CHEM, Esch sur Alzette, LU
- 15:15 - 15:20 **Discussant**
J. Taieb, Hopital European George Pompidou, Paris, FR
- 15:20 - 15:30 **General discussion**
- 15:30 - 15:35 **3rd clinical case: “Fear of blood”**
S. Rauh, Centre Hospitalier Emile Mayrisch CHEM, Esch sur Alzette, LU
- 15:35 - 15:40 **Discussant**
M. Aapro, Clinique de Genolier, Genolier, CH
- 15:40 - 15:50 **General discussion**
- 15:50 - 15:55 **4th clinical case: “Running dry on platinum”**
J.-L. Molitor, CHU Antoine Beclere, Clamart, FR
- 15:55 - 16:00 **Discussant**
J. Arends, Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, Freiburg, DE
- 16:00 - 16:10 **General discussion**
- 16:10 - 16:15 **Conclusions**
D. Arnold, Asklepios Klinik Altona, Hamburg, DE

14:45 - 16:15 **Type: Special session** **Salamanca Auditorium (Hall 3)**
Title: ESMO-MCBS
Chair(s): E.G. Elisabeth De Vries, NL; Nathan Cherny, IL

14:45 - 14:45 **Session DOI**

14:45 - 14:50 **Introduction**

E.G.E. De Vries, University Hospital Groningen (UMCG), Groningen, NL

14:50 - 15:10 **Lessons learned from ESMO-MCBS testing of multiple adjuvant breast cancer trials**

S. Paluch-Shimon, Shaare Zedek M.C, Jerusalem, IL

15:10 - 15:30 **Lessons learned from ESMO-MCBS testing of multiple adjuvant colon cancer**

D.J. De Groot, University Hospital Groningen (UMCG), Groningen, NL

15:30 - 15:50 **Taking toxicity into account in the curative setting**

N. Cherny, Shaare Zedek Medical Center, Jerusalem, IL

15:50 - 16:10 **Challenges in grading based on disease free survival**

U. Dafni, University of Athens, Athens, GR

16:10 - 16:15 **Conclusions**

E.G.E. De Vries, University Hospital Groningen (UMCG), Groningen, NL

14:45 - 16:25 **Type: Proffered Paper session** **Toledo Auditorium**
Title: Proffered Paper - Haematological malignancies & **(Hall 5)**
pediatric oncology

14:45 - 14:45 **Session DOI**

14:45 - 14:57 **10650 - Interim Evaluation of a Targeted Radiotherapeutic, CLR 131, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients (R/R DLBCL)**

J. Longcor¹, K. Oliver¹, J. Friend¹, N. Callandar², ¹Collectar Biosciences, Inc, Florham Park, US, ²University of Wisconsin Madison, Madison, US

14:57 - 15:09 **10660 - Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Low-Dose Cytarabine or Decitabine in Patients with Relapsed/Refractory Acute Myeloid Leukaemia in Phase 1b**

A. Zeidan¹, P. Becker², P. Patel³, G. Schiller⁴, M. Tsai⁵, T. Lin⁶, E. Wang⁷, M. Erlander⁸, J. Cortes⁹, ¹Yale University Hospital, New Haven, US, ²Seattle Cancer Care Alliance, Seattle, US, ³UT Southwestern, Dallas, US, ⁴David Geffen School of Medicine, Los

Angeles, US, ⁵Minneapolis Clinic, Minneapolis, US, ⁶University of Kansas Cancer Center, Kansas City, US, ⁷Roswell Park Comprehensive Cancer Center, Buffalo, US, ⁸Trovagene, San Diego, US, ⁹MD Anderson Cancer Center, Houston, US

15:09 - 15:29 **Invited Discussant 10650 and 10660**

15:29 - 15:41 **10670 - The influence of TDM on achieving busulfan target exposure and related determinants, in both children and adults who underwent an allogeneic hematopoietic cell transplantation**

J. Boss¹, J. Langenhorst², A. Lalmohamed³, P. Van Der Linden⁴, J.J. Boelens⁵, E. Van Maarseveen⁶, ¹St. Jansdal Ziekenhuis, Harderwijk, NL, ²UMC Utrecht, Utrecht, NL, ³UMC - University Medical Center Utrecht, Utrecht, NL, ⁴Tergooi Ziekenhuis, Hilversum, NL, ⁵Memorial Sloan Kettering Cancer Center, New York, US, ⁶UMC-University Medical Center Utrecht, Utrecht, NL

15:41 - 15:53 **Bevacizumab for children with relapsed & refractory high risk neuroblastoma (RR-HRNB). Results of the BEACON-Neuroblastoma randomized phase 2 trial, a European ITCC-SIOPEN trial**

L. Moreno¹, V. Moroz², C. Owens³, D. Valteau-Couanet⁴, M. Gambart⁵, V. Castel⁶, N. Van Eijkelenburg⁷, A. Castellano⁸, K. Nysom⁹, N. Gerber¹⁰, G. Laureys¹¹, R. Ladenstein¹², E. Thebaud¹³, D. Murphy¹⁴, B. Morland¹⁵, S. Vaidya¹⁶, M. Elliott¹⁷, A. Pearson¹⁸, K. Wheatley², ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, GB, ³Our Lady Children's Hospital, Dublin, IE, ⁴Institut Gustave Roussy, Villejuif, FR, ⁵CHU de Toulouse - Hôpital des Enfants, Toulouse, FR, ⁶Instituto de Investigacion Sanitaria La Fe, Valencia, ES, ⁷Princess Maxima Center for Pediatric Oncology, Utrecht, NL, ⁸Ospedale Bambino Gesù, Rome, IT, ⁹Rigshospitalet, Copenhagen, DK, ¹⁰University Children's Hospital, Zurich, CH, ¹¹Ghent University Hospital, Ghent, BE, ¹²St. Anna Children's Hospital, Vienna, AT, ¹³CHU Nantes - Hôpital Mère-Enfant, Nantes, FR, ¹⁴NHS Greater Glasgow and Clyde, Glasgow, GB, ¹⁵Birmingham Children's Hospital, Birmingham, GB, ¹⁶Royal Marsden NHS Foundation Trust, London, GB, ¹⁷Leeds Teaching Hospitals, Leeds, GB, ¹⁸Institute of Cancer Research (retired), London, GB

15:53 - 16:03 **Invited Discussant 10670 and 4267**

15:00 - 16:00 Type: Poster Discussion session Malaga Auditorium (Hall 5)
Title: Poster Discussion - Sarcoma

15:00 - 15:00 **Session DOI**

15:00 - 15:00 **1672PD - Improved survival with secondary surgery in a reference center after a first R1 or R2 resection in soft tissue sarcoma (STS) of the limbs or trunk wall: an analysis 10931 patients (pts) in NETSARC.**

F. Gouin¹, E. Stoeckle², S. Bonvalot³, C. Honoré⁴, A. Decanter⁵, P. Anract⁶, E. Bompas⁷,

G. Ferron⁸, F. Sirveaux⁹, A. Rochwerger¹⁰, S. Carrere¹¹, A. Di Marco¹², M. Ropars¹³, L. Le Nail¹⁴, O. Marco¹⁵, J. Guiramand¹⁶, A. Italiano¹⁷, N. Penel⁵, A. Le Cesne¹⁸, J.-Y. Blay¹,
¹Centre Léon Bérard, Lyon, FR, ²Institut Bergonié, Bordeaux, FR, ³Institut Curie, Paris, FR, ⁴Gustave Roussy - Cancer Campus, Villejuif, FR, ⁵Centre Oscar Lambret, Lille, FR, ⁶Hopital cochin, Paris, FR, ⁷ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁸Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ⁹Centre chirurgical Emile Gallé, Nancy, FR, ¹⁰Hopital Nord Marseille, Marseille, FR, ¹¹Institut du Cancer de Montpellier, Montpellier, FR, ¹²Hopital de haute pierre, Strasbourg, FR, ¹³CHU Pontchaillou, Rennes, FR, ¹⁴Hôpital Trousseau, Tours, FR, ¹⁵Hôpital Saint Louis, Paris, FR, ¹⁶guiramandj@ipc.unicancer.fr), Chirurgie oncologique, Institut Paoli Calmettes, 232 boulevard de Sainte Marguerite, 13009 Marseille,, Marseille, FR, ¹⁷Institute Bergonié, Bordeaux, FR, ¹⁸Institut Gustave Roussy, Villejuif, FR

15:00 - 15:00 **1673PD - Impact of abstention of diagnostic biopsy in sarcoma**

A. Dufresne¹, G. Decanter², G. Ferron³, O. Marco⁴, E. Stoeckle⁵, P. Meeus¹, F. Gouin¹, F. Sirveaux⁶, A. Rochwerger⁷, S. Bonvalot⁸, C. Honoré⁹, P. Anract¹⁰, M. Ropars¹¹, S. Carrere¹², A. Di Marco¹³, F. Ducimetière¹⁴, A. Italiano¹⁵, A. Le Cesne¹⁶, N. Penel¹⁷, J.-Y. Blay¹, ¹Centre Léon Bérard, Lyon, FR, ²centre oscar lambret, lille, FR, ³Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ⁴Hôpital Saint Louis, Paris, FR, ⁵Institut Bergonié, Bordeaux, FR, ⁶Centre chirurgical Emile Gallé, Nancy, FR, ⁷Hopital Nord Marseille, Marseille, FR, ⁸Institut Curie, Paris, FR, ⁹Gustave Roussy - Cancer Campus, Villejuif, FR, ¹⁰Hopital cochin, Paris, FR, ¹¹CHU Pontchaillou, Rennes, FR, ¹²Institut du Cancer de Montpellier, Montpellier, FR, ¹³Hopital de haute pierre, Strasbourg, FR, ¹⁴Centre Léon Bérard, LYON, FR, ¹⁵Institute Bergonié, Bordeaux, FR, ¹⁶Institut Gustave Roussy, Villejuif, FR, ¹⁷Centre Oscar Lambret, Lille, FR

15:00 - 15:15 **Invited Discussant 1672PD and 1673PD**

15:15 - 15:20 **Q&A led by Discussant**

15:20 - 15:20 **1674PD - Trabectedin with concurrent low-dose of radiation therapy for metastatic soft tissue sarcomas: A phase II trial of Spanish, French and Italian sarcoma groups**

J. Martin Broto¹, A. Italiano², R.M. Alvarez Alvarez³, I. Rincon⁴, J. Peinado⁴, P. Sargos², A. Alvarez³, P. Luna⁵, A. Lopez Pousa⁶, A. Redondo⁷, I. Alastuey⁵, J. Isern⁶, B. Belinchon⁷, A. Gutierrez⁵, C. Romagosa⁸, K. Marie⁹, C. Morosi¹⁰, J.-Y. Blay¹¹, A. Gronchi¹⁰, N. Hindi¹²,
¹Hospital Universitario Son Espases, Palma de Mallorca, ES, ²Institute Bergonié, Bordeaux, FR, ³Hospital General Universitario Gregorio Marañón, Madrid, ES, ⁴University Hospital Virgen del Rocío, Seville, ES, ⁵Hospital Son Espases, Palma de Mallorca, ES, ⁶Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁷Hospital Universitario La Paz, Madrid, ES, ⁸Universitary Hospital Vall d'Hebron, Barcelona, ES, ⁹Centre Leon Berard, Lyon, FR, ¹⁰Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ¹¹Centre Léon Bérard, Lyon, FR, ¹²Hospital Universitario Virgen del Rocío, Sevilla, ES

15:20 - 15:20 **1675PD - EURO-B.O.S.S.: Outcome in rare non-osteosarcoma bone sarcoma**

P. Reichardt¹, K. Sundby Hall², R. Bertulli³, S. Bielack⁴, A. Comandone⁵, G. Egerer⁶, A. Hansmeier⁷, E. Palmerini⁸, S. Smeland⁹, S. Ferrari⁸, ¹Helios Klinikum Berlin Buch, Berlin, DE, ²Norwegian Radium Hospital, Oslo University Hospital, Oslo, NO, ³Fondazione IRCCS Istituto Nazionale de Tumori, Milan, IT, ⁴Cooperative Osteosarcoma Study Group COSS, Klinikum Stuttgart - Olgahospital, Stuttgart, DE, ⁵Ospedale Humanitas Gradenigo, Torino, IT, ⁶University Hospital Heidelberg, Heidelberg, DE, ⁷University Hospital of Muenster, Muenster, DE, ⁸Istituto Ortopedico Rizzoli, Bologna, IT, ⁹Oslo University Hospital, Oslo, NO

15:20 - 15:20 **1676PD - Phase 1 combination dose-finding/phase 2 expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤25 years with relapsed/refractory (r/r) osteosarcoma**

N. Gaspar¹, F.J. Bautista Sirvent², R. Venkatramani³, A. Longhi⁴, C. Lervat⁵, M. Casanova⁶, I. Aerts⁷, S. Bielack⁸, N. Entz-Werle⁹, S. Strauss¹⁰, C. He¹¹, E. Thebaud¹², F. Locatelli¹³, B. Morland¹⁴, S. Gallego Melcon¹⁵, A. Cañete Nieto¹⁶, P. Marec- Bérard¹⁷, M. Gambart¹⁸, C. Rossig¹⁹, Q. Campbell-Hewson²⁰, ¹Gustave Roussy Cancer Campus, Villejuif, FR, ²Hospital Universitario Infantil Niño Jesús, Madrid, ES, ³Texas Children's Hospital, Housston, US, ⁴Istituto Ortopedico Rizzoli, Bologna, IT, ⁵Centre Oscar Lambret, Lili, FR, ⁶Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, IT, ⁷Institut Curie, PSL Research University, Oncology Center SIREDO, Paris, FR, ⁸Klinikum Stuttgart - Olgahospital, Stuttgart, DE, ⁹CHRU of Strasbourg - Hospital of Hautepierre Onco-Hematological Pediatrics, Strasbourg, DE, ¹⁰University College London Hospital, London, GB, ¹¹Eisai Co., Ltd., Woodcliff, US, ¹²CHU Nantes - Hôpital Mère-Enfant, Nantes, FR, ¹³Ospedale Pediatrico Bambino Gesù, Roma, university of Pavia, IT, ¹⁴Birmingham Children's Hospital, Birmingham, GB, ¹⁵University Hospital Vall d'Hebron, Barcelona, ES, ¹⁶Hospital Universitario y Politécnico La Fe. GICT-Cáncer IIS La Fe, Valencia, ES, ¹⁷Institut Curie, PSL Research University, Oncology Center SIREDO, Toulouse, FR, ¹⁸CHU de Toulouse - Hôpital des Enfants, Toulouse, FR, ¹⁹University Hospital of Münster, Münster, DE, ²⁰The Great North Children's Hospital, Royal Victoria Infirmary, Newcastle Upon Tyne, GB

15:20 - 15:20 **1677PD - A Phase II Study of Pazopanib as Front-Line Therapy in Patients with Non-resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy**

A. Hirbe¹, J. Luo¹, M. Seetharam², J. Toeniskoetter¹, T. Kershner¹, M. Agulnik³, M. Varun⁴, M. Milhem⁴, A. Parkes⁵, S. Robinson⁶, S. Okuno⁶, S. Attia⁷, B. Van Tine¹, ¹Washington University School of Medicine, St. Louis, US, ²Mayo Clinic in Arizona, Phoenix, US, ³Northwestern University, Chicago, US, ⁴University of Iowa Hospitals And Clinics, Iowa City, US, ⁵University Of Wisconsin School of Medicine and Public Health, Madison, US, ⁶Mayo Clinic, Rochester, US, ⁷Mayo Clinic in Florida, Jacksonville, US

15:20 - 15:35 **Invited Discussant 1674PD, 1675PD, 1676PD and 1677PD**

15:35 - 15:40 **Q&A led by Discussant**

- 15:40 - 15:40 **1678PD - Immune classification of soft tissue sarcoma predicts clinical outcome**
 F. Petitprez¹, A. De Reyniès², E. Keung³, T.W.-W. Chen⁴, C.-M. Sun⁵, Y.-M. Jeng⁴, L.-P. Hsiao⁴, L. Lacroix⁵, C. Lucchesi⁶, M. Toulmonde⁷, M. Burgess⁸, V. Bolejack⁹, D. Reinke¹⁰, A. Lazar³, C. Roland³, J. Wargo¹¹, A. Italiano⁷, C. Sautès-Fridman⁵, H. Tawbi¹², W.H. Fridman¹³, ¹Centre de Recherche des Cordeliers, Paris, FR, ²Ligue Contre le Cancer, Paris, FR, ³University of Texas MD Anderson Cancer Center, Houston, US, ⁴NTU - National Taiwan University - College of Medicine, Taipei City, TW, ⁵Cordeliers Research Center, Paris, FR, ⁶Bergonie Institute, Bordeaux, FR, ⁷Institut Bergonié, Bordeaux, FR, ⁸University of Pittsburgh, Pittsburgh, US, ⁹Cancer Research and Biostatistics, Seattle, US, ¹⁰Sarcoma Alliance for Research Through Collaboration, Ann Arbor, US, ¹¹The University of Texas MD Anderson Cancer Center, Houston, US, ¹²The University of Texas M. D. Anderson Cancer Center, Houston, US, ¹³INSERM U1138, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, FR
- 15:40 - 15:40 **1679PD - Unravelling omics landscape and targeting oncogenic pathways in undifferentiated pleomorphic sarcomas (UPS)**
 M. Toulmonde¹, C. Lucchesi², S. Verbeke³, A. Crombe², V. Chaire³, A. Laroche³, F. Le Loarer³, F. Bertucci⁴, J. Adam⁵, F. Bertolo³, D. Geneste³, L. Bianchini⁶, B. Dadone-Montaudie⁷, T. Hembrough⁸, F. Cecchi⁹, F. Giles¹⁰, A. Italiano¹, ¹Institut Bergonié, Bordeaux, FR, ²Bergonie Institute, Bordeaux, FR, ³Institut Bergonié, Bordeaux, FR, ⁴Institut Paoli Calmettes, Marseille, FR, ⁵Institut Gustave Roussy, Villejuif, FR, ⁶Nice University Hospital, Nice, FR, ⁷University of Nice-Sophia Antipolis, Nice, FR, ⁸NantOmics, LLC, Rockville, US, ⁹NantOmics, LLC., New York, US, ¹⁰Northwestern University, Chicago, US
- 15:40 - 15:55 **Invited Discussant 1678PD and 1679PD**
- 15:55 - 16:00 **Q&A led by Discussant**
- | | | |
|---------------|--|-----------------------------------|
| 15:00 - 16:00 | Type: Poster Discussion session
Title: Poster Discussion - Supportive and palliative care | Bilbao Auditorium (Hall 5) |
|---------------|--|-----------------------------------|
- 15:00 - 15:00 **Session DOI**
- 15:00 - 15:00 **1755PD - Implementation of PRO-CTCAE in phase I clinical trials identifies under reporting of adverse events**
 Z. Veitch¹, D. Shepshelovich¹, C. Gallagher¹, L. Wang², A.A. Razak², A. Spreafico², P. Bedard², L. Siu¹, L. Minasian³, A. Hansen², ¹Princess Margaret Cancer Centre, Toronto, CA, ²Princess Margaret Cancer Center, Toronto, CA, ³National Institutes of Health, Bethesda, US
- 15:00 - 15:00 **1756PD - The ImmunoTOX multidisciplinary board, a descriptive study of collaborative management of immune-related adverse events.**

J.-M. Michot¹, A. Lappara¹, A. Simonaggio², F.-X. Danlos¹, R. Belkhir³, M. Collins⁴, A. Berdelou¹, C. Cauquil⁵, S. Edhery⁶, J. Le Pavec⁷, D.M. Eleonora⁸, C. Mateus¹, A. Hollebecque⁹, A. Varga⁹, J.-C. Soria¹⁰, C. Massard¹¹, A.-L. Voisin⁹, A. Marabelle¹, S. Champiat⁹, O. Lambotte⁴, ¹Institut Gustave Roussy, Villejuif, FR, ²Hopital European George Pompidou, Paris, FR, ³Kremlin Bicetre, Kremlin Bicetre, FR, ⁴CHU de Bicêtre, Le Kremlin Bicetre, FR, ⁵Hôpital Kremlin-Bicêtre, Paris, FR, ⁶Assistance Publique, Paris, FR, ⁷Centre Marie Lannelongue, le plessis robinson, FR, ⁸Centre Hepato-Biliaire, Villejuif, FR, ⁹Gustave Roussy, Villejuif, FR, ¹⁰Medimmune, Gaithersburg, US, ¹¹Gustave Roussy - Cancer Campus, Villejuif, FR

15:00 - 15:00 **1757PD - Development of GOLD (Geriatric Oncology Liaison Development) service to improve outcomes in older people with cancer**

M. Kapiris, L. Karapanagiotou, J. Mansi, D. Harari, T. Kalsi, C. Pye, R. Finch, G. Babic-Illman, Guy's and St. Thomas' Hospital NHS Trust, London, GB

15:00 - 15:12 **Invited Discussant 1755PD, 1756PD and 1757PD**

15:12 - 15:20 **Q&A led by Discussant**

15:20 - 15:20 **One LBA TBC**

15:20 - 15:20 **1758PD - Complementary Medicine (CM) Use in Phase III Clinical Trials (P3T) Conducted by the Canadian Cancer Trials Group (CCTG)**

J. Wells¹, A. Sidhu², K. Ding¹, D. Heng³, F. Shepherd⁴, P. Ellis⁵, P. Bradbury⁶, D. Jonker⁷, M. Moore⁸, L. Siu⁹, K. Gelmon⁸, C. Karapetis¹⁰, J. Shapiro¹¹, L. Nott¹², C. O'Callaghan¹, W. Parulekar¹, L. Seymour¹, M. Smoragiewicz¹, J. Monzon³, ¹Canadian Cancer Trials Group, Kingston, CA, ²Fraser Health, Surrey, CA, ³University of Calgary, Calgary, CA, ⁴Princess Margaret Cancer Centre, University Health Network, Toronto, CA, ⁵Juravinski Hospital and Cancer Centre, Hamilton, CA, ⁶Princess Margaret Cancer Centre, University Health Network, Toronto, CA, ⁷Ottawa Hospital Research Institute, University of Ottawa, Ottawa, CA, ⁸BC Cancer Agency, Vancouver, CA, ⁹Princess Margaret Cancer Centre, Toronto, CA, ¹⁰Flinders Medical Centre and Flinders University, Adelaide, AU, ¹¹Cabrini Health, Malvern, AU, ¹²Royal Hobart Hospital, Tasmania, AU

15:20 - 15:20 **One LBA TBC**

15:20 - 15:32 **Invited Discussant 1758PD and 2 LBAs TBC**

15:32 - 15:40 **Q&A led by Discussant**

- 15:40 - 15:40 **One LBA TBC**
- 15:40 - 15:40 **1617PD - Worse Patient- Physician Relationship Is Associated With More Fear Of Cancer Recurrence (Deimos Study): A Study Of The Palliative Care Working Committee Of The Turkish Oncology Group (TOG)**
- A. Alkan¹, A. Yaşar², Z.G. Güç³, M. Gürbüz⁴, T. Başoğlu⁵, S. Sezgin Göksu⁶, F. Buğdaycı Başal⁷, H.M. Türk⁸, Ö. Özdemir⁹, H. Yeşil Çınkır¹⁰, D.C. Güven¹¹, T. Kuş¹², S. Türker¹³, L. Koral¹⁴, Y. Karakaş¹⁵, N. Ak¹⁶, S. Paydaş¹⁷, E. Karcı¹⁸, Ö. Tanrıverdi¹⁹, F. Çay Şenler²,
¹Muğla Sıtkı Kocman University - Faculty of Medicine, Muğla, TR, ²Ankara University School of Medicine, Ankara, TR, ³Dokuz Eylül University School of Medicine, İzmir, TR, ⁴Ankara University School of Medicine, ANKARA, TR, ⁵Marmara University School of Medicine, İstanbul, TR, ⁶Akdeniz University School of Medicine, Antalya, TR, ⁷Abdurrahman Yurtarslan Research and Training Hospital, Ankara, TR, ⁸Bezmialem University School of Medicine, İstanbul, TR, ⁹İzmir Bozyak Research and Training Hospital, İzmir, TR, ¹⁰Gaziantep University School of Medicine, GAZiantep, TR, ¹¹Hacettepe University School of Medicine, Ankara, TR, ¹²Adıyaman Research and Training Hospital, Adıyaman, TR, ¹³DIŞKAPI YILDIRIM BEYAZIT Research and Training Hospital, Ankara, TR, ¹⁴Çanakkale Onsekiz Mart University School of Medicine, Çanakkale, TR, ¹⁵Bodrum Acıbadem Hospital, Muğla, TR, ¹⁶İstanbul University School of Medicine, İstanbul, TR, ¹⁷Çukurova University School of Medicine, Adana, TR, ¹⁸Bağcılar Research and Training Hospital, İstanbul, TR, ¹⁹Muğla Sıtkı Koçman University School of Medicine, Muğla, TR
- 15:40 - 15:40 **1597PD - Emergency admissions and bad news disclosure as precipitators of suicide: a territory-wide cohort analysis of 458 oncology patients who completed suicides**
- E. Kwan, T.C. Lam, H. Luo, P.S. Yip, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, HK
- 15:40 - 15:52 **Invited Discussant 1617PD, 1597PD and one LBA TBC**
- 15:52 - 16:00 **Q&A led by Discussant**

15:00 - 16:00 **Type: Multidisciplinary session** **Tarragona Auditorium (Hall 7)**
Title: Managing the frail patients

15:00 - 15:00 **Session DOI**

15:00 - 15:05 **Presentation of case/condition: Defining the issues of frail patients**

15:05 - 15:20 **Defining tolerability of immuno-oncology in frail patients**

F. Gomes, The Christie NHS Foundation Trust, Manchester, GB

15:20 - 15:35 **Prehabilitation: The impact in surgery and medical oncology**

S. Rostoft, Oslo University Hospital, Oslo, NO

15:35 - 15:50 **Data from geriatricians and others on the positive outcomes after proper evaluation**

M. Hamaker, Vermaat - Diaconessenhuis Zeist, Zeist, NL

15:50 - 16:00 **General Discussion: Can society afford to treat frail patients?**

15:00 - 16:00 **Type: Multidisciplinary session** **Alicante Auditorium**
Title: Is randomisation of clinical trials still the gold standard? **(Hall 3)**

15:00 - 15:00 **Session DOI**

15:00 - 15:05 **Presentation of case/condition: Review of novel agents licensed for use in the 21st century**

15:05 - 15:20 **Why we need randomization**
U. Dafni, University of Athens, Athens, GR

15:20 - 15:35 **The voice of the regulator (EMA)**
F. Pignatti, European Medicines Agency (EMA), London, GB

15:35 - 15:50 **How non-randomized studies can lead to registration**
C. Massard, Gustave Roussy - Cancer Campus, Villejuif, FR

15:50 - 16:00 **General discussion / Q&A**

15:00 - 16:00 **Type: Young Oncologist session** **Room 1.1 (CC1)**
Title: ESMO for medical students and young physicians
 Chair(s): Andres Cervantes, ES; Anna Sophie Berghoff, AT

15:00 - 15:00 **Session DOI**

15:00 - 15:20 **ESMO-ESO Medical Students Course**
A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

15:20 - 15:40 **How to prepare and present your first poster at a congress**
A.S. Berghoff, Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT

15:40 - 16:00 **Guided poster walk**
K.H.J. Lim¹, M. Petrova², T. Amaral³, L. Poulsen⁴, K. Punie⁵, ¹The Christie NHS Foundation Trust, Manchester, GB, ²MHAT Nadezhda, Sofia, BG, ³Hospital dos Lusíadas - Lisboa, Lisbon, PT, ⁴Aalborg University Hospital, Aalborg, DK, ⁵University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

15:45 - 17:15 **Type: EONS session** **Oviedo Auditorium (CC5)**
Title: EONS 12: Recent trends in palliative care
Chair(s): Wendy Oldenmenger, NL

15:45 - 15:45 **Session DOI**

15:45 - 16:00 **Anxiety in the terminal stages of cancer**
D. Zweers, UMC-University Medical Center Utrecht, Utrecht, NL

16:00 - 16:15 **Introducing palliative care in Estonia: How the RECaN project is facilitating the process?**
K. Karp, East Tallinn Central Hospital, Tallinn, EE

16:15 - 16:30 **CN20 - Opinions of palliative care patients and nurses regarding dignified care**
Y. Eskigulek¹, S. Kav², ¹Gazi University - Faculty of Medicine, Ankara, TR, ²Baskent University, Ankara, TR

16:30 - 16:45 **CN21 - Development of Core Indicators of Non-Specialist Palliative Care in Hospitals - An International Modified Delphi Study**
M. Nevin¹, G. Hynes², S. Payne³, V. Smith², ¹School of Nursing and Midwifery, Trinity College Dublin, Dublin, IE, ²Trinity College Dublin, Dublin, IE, ³Lancaster University, YG, GB

16:45 - 17:00 **CN22 - Psychological Distress among Patients with Advanced Cancer: a Concept Analysis**
N. Huda, University of Riau, Pekanbaru, ID

17:00 - 17:15 **Discussion**

16:30 - 18:00 **Type: Proffered Paper session** **Barcelona Auditorium (Hall 2)**
Title: Presidential Symposium I

16:30 - 16:30 **Session DOI**

16:30 - 18:00	Type: Educational session Title: Challenges in the management of luminal ER + MBC Chair(s): Fatima Cardoso, PT	Madrid Auditorium (Hall 2)
16:30 - 16:30	Session DOI	
16:30 - 16:55	Addressing optimal firstline therapy options in luminal ABC (endocrine alone vs. endocrine + targeted vs. chemotherapy) <u>F. Cardoso</u> , Champalimaud Foundation Cancer Center, Lisbon, PT	
16:55 - 17:20	Management options after progression on CDK 4/6 inhibitors <u>A. Di Leo</u> , Nuovo Ospedale di Prato, Prato, IT	
17:20 - 17:45	Mutation directed therapy for ER + breast cancer <u>M. Ellis</u> , Baylor College of Medicine, Houston, US	
17:45 - 18:00	Discussion	

16:30 - 18:00 **Type: Educational session** **Sevilla Auditorium (Hall 2)**
Title: Pancreatic cancer: Where are we now and where are we going?

16:30 - 16:30 **Session DOI**

16:30 - 16:50 **Molecular profiling of pancreatic cancer in guiding tumour biology understanding and drug target discovery**

16:50 - 17:10 **Can we be more precise in peri-operative therapy?**
M. Ducreux, Gustave Roussy - Cancer Campus, Villejuif, FR

17:10 - 17:30 **Locally advanced disease: Drugs alone or with the addition of radiotherapy?**
S. Cascinu, Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT

17:30 - 17:50 **New targets on the horizon: Integrating genomics with tumour microenvironment**
E. O'Reilly, Memorial Sloan-Kettering Cancer Center, New York, US

17:50 - 18:00 **Discussion**

16:30 - 18:00 **Type: Proffered Paper session** **Cordoba Auditorium (Hall 7)**
Title: Proffered Paper 1 - Non-metastatic NSCLC and other thoracic malignancies (SCLC)

16:30 - 16:30 **Session DOI**

16:30 - 16:42 **One LBA TBC**

16:42 - 16:54 **17360 - IMpower133: updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)**

M. Reck¹, S. Liu², A. Mansfield³, T.S.K. Mok⁴, A. Scherpereel⁵, N. Reinmuth⁶, M. Garassino⁷, J. De Castro Carpeno⁸, R. Califano⁹, M. Nishio¹⁰, F. Orlandi¹¹, J. Alatorre Alexander¹², T. Leal¹³, Y. Cheng¹⁴, J.-S. Lee¹⁵, S. Lam¹⁶, M. McClelland¹⁶, Y. Deng¹⁶, S. Phan¹⁶, L. Horn¹⁷, ¹Krankenhaus Grosshansdorf, Grosshansdorf, DE, ²Georgetown University, Washington D.C., US, ³Mayo Clinic, Rochester, US, ⁴Prince of Wales Hospital, Shatin, HK, ⁵CHU Lille, Inserm, U1189 - ONCO-THAI - F-59000, Lille, FR, ⁶Asklepios Clinics Munich-Gauting, Gauting, DE, ⁷Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁸Hospital Universitario La Paz, Madrid, ES, ⁹The Christie NHS Foundation Trust, Manchester, GB, ¹⁰Cancer Institute Hospital of JFCR, Tokyo, JP

¹¹Prosalud Oncología, Santiago, CL, ¹²Instituto Nacional de Enfermedades Respiratorias, Mexico City, MX, ¹³University of Wisconsin Carbone Cancer Center, Madison, US, ¹⁴Jilin Cancer Hospital, Changchun, CN, ¹⁵Seoul National University Bundang Hospital, Seongnam, KR, ¹⁶Genentech, Inc., South San Francisco, US, ¹⁷Vanderbilt University Medical Center, Nashville, US

16:54 - 17:06 **17370 - Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on the experimental thoracic radiotherapy (TRT) arms of CALGB 30610 (Alliance) / RTOG 0538**

J. Bogart¹, X. Wang², G. Masters³, H. Zhu², R. Komaki⁴, L. Gaspar⁵, M. Dobelbower⁶, C. Kuzma⁷, J. Heymach⁸, E. Vokes⁹, T. Stinchcombe¹⁰, ¹SUNY Upstate Medical University, Syracuse, US, ²Alliance for Clinical Trials in Oncology, Durham, US, ³Helen Graham Cancer Center, Newark, US, ⁴The University of Texas MD Anderson Cancer Center, Houston, US, ⁵UC Denver, denver, US, ⁶UAB, Birmingham, US, ⁷Outpatient Cancer Center of FirstHealth, Pinehurst, US, ⁸MD Anderson, texas, US, ⁹University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ¹⁰Duke Cancer Center, Durham, US

17:06 - 17:21 **Invited Discussant 17360, 17370 and one LBA TBC**

17:21 - 17:33 **17380 - Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)**

Y. Cheng¹, Q. Wang², K. Li³, J. Shi⁴, Y. Liu¹, L. Wu⁵, B. Han⁶, G. Chen⁷, J. He⁸, J. Wang⁹, D. Lou¹⁰, H. Yu¹⁰, H. Qin¹¹, X.-L. Li¹², ¹Jilin Cancer Hospital, Changchun, CN, ²Henan Cancer Hospital, Zhengzhou, CN, ³Tianjin Medical University Cancer Hospital, Tianjin, CN, ⁴Linyi Cancer Hospital, Linyi, CN, ⁵Hunan Cancer Hospital, Changsha, CN, ⁶Shanghai Chest Hospital, Shanghai, CN, ⁷Harbin Medical University Cancer Hospital, Harbin, CN, ⁸The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ⁹Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ¹⁰School of public health, nanjing medical university, Nanjing, CN, ¹¹The fifth medical center of chinese PLA general hospital, Beijing, CN, ¹²Cancer Hospital of China Medical University Liaoning Cancer Hospital & Institute, Shenyang, CN

17:33 - 17:45 **17390 - A phase 1 study evaluating rovalpituzumab tesirine (ROVA-T) in frontline treatment of patients (pts) with extensive stage small cell lung cancer (ES-SCLC)**

C. Hann¹, T. Burns², A. Dowlati³, D. Morgensztern⁴, M. Koch⁵, Y.-W. Chang⁶, P. Komarnitsky⁷, C. Ludwig⁵, H. Nimeiri⁸, D.R. Camidge⁹, ¹Johns Hopkins University, Baltimore, US, ²UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, US, ³UH Case Medical Center, Cleveland, US, ⁴Washington University School of Medicine, St. Louis, US, ⁵AbbVie Inc., North Chicago, US, ⁶AbbVie Incorporated, Chicago, US, ⁷AbbVie, Cambridge, US, ⁸AbbVie Inc USA, North Chicago, US, ⁹University of Colorado, Aurora, US

17:45 - 18:00 **Invited Discussant 17380 and 17390**

16:30 - 18:00	Type: Multidisciplinary session Title: Treatment of the primary tumour in the metastatic setting Chair(s): Bertrand Tombal, BE	Granada Auditorium (Hall 3)
16:30 - 16:30	Session DOI	
16:30 - 16:45	The prostate cancer model <u>B. Tombal</u> , Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE	
16:45 - 17:00	Biological rationale for treating the primary tumour <u>C. Swanton</u> , The Francis Crick Institute, London, GB	
17:00 - 17:15	The radiation perspective: Bladder carcinoma model <u>N. James</u> , Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, Birmingham, GB	
17:15 - 17:30	The medical oncologist perspective <u>A. Necchi</u> , Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT	
17:30 - 17:45	The urologist perspective: The RCC model <u>A. Bex</u> , Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL	
17:45 - 18:00	General discussion	

16:30 - 18:00 **Type: Proffered Paper session** **Valencia Auditorium (Hall 5)**
Title: Proffered Paper session - Basic Science

16:30 - 16:30 **Session DOI**

16:30 - 16:42 **10 - Suppression of KRAS-G12D and BRAF-V600E Oncogene Transcription with PNA-conjugates**

J. Rothman, G. Schwartz, O. Surriga, G. Ambrosini, Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US

16:42 - 16:54 **20 - Strategic inhibition of CEP55 in aggressive breast cancer leads to mitotic catastrophe**

D. Sinha, QIMR Berghofer Medical Research Institute, Brisbane, AU

16:54 - 17:06 **19810 - The m(6)A Methyltransferase METTL3 promotes gastric cancer progression through facilitating primary microRNA maturation**

Y. Sun, S. Li, W. Yu, Z. Zhao, J. Gao, C. Chen, M. Wei, L. Liu, Qilu Hospital of Shandong University, Jinan, CN

17:06 - 17:24 **Invited Discussant 10, 20 and 19810**

17:24 - 17:36 **30 - Systemic gut microbial metabolites limit the anti-tumor effect of CTLA-4 blockade in hosts with cancer.**

C. Coutzac¹, J.-M. Jouniaux², A. Paci², V. Asvatourian², P. Saulnier³, L. Lacroix⁴, F. Carbonnel⁵, P. Ascierto⁶, C. Robert⁴, N. Chaput⁷, ¹HEGP, Paris, FR, ²Gustave Roussy Cancer Campus, Villejuif, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR, ⁴Institut Gustave Roussy, Villejuif, FR, ⁵Hôpital Bicêtre, Le Kremlin Bicetre, FR, ⁶Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁷Gustave Roussy Institut de Cancérologie, Villejuif, FR

17:36 - 17:48 **40 - Novel Dendritic Cell based Immunotherapy for Advanced Cancer**

A. Kaur¹, J. Adhikaree², H. Franks², P. Patel², A. Jackson³, ¹University of Nottingham, School of Medicine, Nottingham, GB, ²Nottingham University Hospitals NHS Trust-City Hospital Campus, Nottingham, GB, ³University of Nottingham, Nottingham, GB

17:48 - 18:00 **Invited Discussant 30 and 40**

16:30 - 18:00 **Type: Special symposium** **Malaga Auditorium (Hall 5)**
Title: The even rarer sarcomas: Treating the untreatable
Chair(s): Suzanne George, US

16:30 - 16:30 **Session DOI**

16:30 - 16:35 **Introduction: Why differentiation matters**
S. George, Dana-Farber Cancer Institute, Boston, US

16:35 - 16:55 **The pathologist's point of view: Methodology to make a difference**
H.-U. Schildhaus, University Hospital of Essen, Essen, DE

16:55 - 17:15 **Offering treatment without evidence and financial coverage**
S. Stacchiotti, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

17:15 - 17:35 **"Rare sarcoma is pants": Help and comfort through new media**
M. Wartenberg, SPAEN, Wölfersheim, DE

17:35 - 17:55 **Clinical trials for the ultra-rare cancers: The regulator's perspective**
R. Herold, European Medicines Agency - Amsterdam, Amsterdam, NL

17:55 - 18:00 **Conclusions and perspectives**

16:30 - 17:30 **Type: Poster Discussion session** **Bilbao Auditorium (Hall 5)**
Title: Poster Discussion 1 - Immunotherapy of cancer

16:30 - 16:30 **Session DOI**

16:30 - 16:30 **1177PD - Clinical study of personalized neoantigen peptide vaccination in advanced NSCLC patients**
F. Li¹, G. Lizee², P. Hwu², X. Du³, L. Deng⁴, A. Talukder², D. Hawke², Q. Zou⁴, J. Roszik², M. Stairs⁵, W. Feng³, K. Jackson², C. Chen⁴, M. Zhang², C. Huo⁴, Y. Chiu², Y. Wang⁴, S. Zhou⁶, Y. Zhang⁷, J. Xu³, ¹Baylor College of Medicine, Houston, US, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³Tianjin Beichen Hospital, Tianjin, CN, ⁴Tianjin HengJia Biotechnology Development Co., Ltd., Tianjin, CN, ⁵Our Lady of the Lake Regional Medical Center, Los Angeles, US, ⁶Fujian Provincial Clinical Hospital, Fuzhou, CN, ⁷Nankai University, Tianjin, CN

16:30 - 16:30 **1178PD - A phase 1 trial of GEN-009, a neoantigen vaccine using ATLAS™, an autologous immune assay, to identify immunogenic and inhibitory tumor**

mutations.

P. Twardowski¹, M. Johnson², M. Stein³, U. Vaishampayan⁴, M. Gillison⁵, L. Mcneil⁶, L. Dowal⁶, D. Deoliveira⁶, M. Jain⁶, J. Price⁶, R. Hernandez⁶, A. Decillis⁷, N. Singh⁶, T. Davis⁶, J. Flechtner⁶, R. Cohen⁸, ¹City of Hope, Duarte, US, ²Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ³Columbia University Medical Center, New York, US, ⁴Barbara Ann Karmanos Cancer Institute, Detroit, US, ⁵Tzagournis Research Facility -Ohio State Univ Medical Centre, Columbus, US, ⁶Genocea Biosciences, Cambridge, US, ⁷Exelixis, Inc., South San Francisco, US, ⁸Abramson Cancer Center, Philadelphia, US

16:30 - 16:30 **1179PD - Natural dendritic cell vaccinations generate immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer**

J. Creemers¹, H. Westdorp², I. Van Oort¹, G. Schreibelt¹, M. Gorris¹, N. Mehra³, M. Simons¹, A. De Goede³, M. Van Rossum¹, S. Croockewit¹, C. Figdor¹, J.A. Witjes¹, E. Aarntzen², R. Mus², M. Gotthardt², J. Barentsz², J. De Vries², W. Gerritsen², ¹Radboudumc, Nijmegen, NL, ²Radboud University Medical Centre Nijmegen, Nijmegen, NL, ³Radboud University Medical Center, Nijmegen, NL

16:30 - 16:30 **1180PD - Active immunization with immune checkpoint inhibitors-mimotope elicits strong anti-tumor effect against Her-2/neu-expressing tumors**

J. Tobias¹, C. Battin¹, A. De Sousa Linhares¹, M. Lebens², K. Baier¹, K. Ambroz¹, S. Högl³, A. Inic-Kanada¹, E. Garner-Spitzer¹, M. Preusser⁴, L. Kenner³, M. Kundi¹, C. Zielinski⁴, P. Steinberger¹, U. Wiedermann¹, ¹Medizinische Universität Wien, Vienna, AT, ²University of Gothenburg, Gothenburg, SE, ³University of Veterinary Medicine Vienna, Vienna, AT, ⁴Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

16:30 - 16:30 **1181PD - Personal Antigen Selection Calculator (PASCAL) for the design of personal cancer vaccines**

E. Somogyi¹, Z. Csiszovszki², O. Lorincz³, J. Toth², L. Molnar², W. Schönharting⁴, S. Urban⁴, T. Röhnisch⁵, K. Pántya², P. Pales², M. Megyesi², E. Tóke², ¹Treos Bio Zrt., Veszprem, HU, ²Treos Bio Zrt., Veszprém, HU, ³Treos Bio Inc., Bethesda, US, ⁴PMCR GmbH, Karlsruhe, DE, ⁵Interdisciplinary Oncology Center, Munich, DE

16:30 - 16:50 **Invited Discussant 1177PD, 1178PD, 1179PD, 1180PD and 1181PD**

16:50 - 17:00 **Q&A led by Discussant**

17:00 - 17:00 **1182PD - A novel affinity-enhanced NY-ESO-1-targeting TCR-redirectioned T cell transfer exhibited early-onset cytokine release syndrome and subsequent tumor responses in synovial sarcoma patients**

H. Hattori¹, M. Ishihara², S. Kitano³, Y. Miyahara⁴, H. Kato⁵, H. Mishima⁵, N. Yamamoto³, T. Funakoshi⁶, T. Kojima⁷, T. Sasada⁸, E. Sato⁹, S. Okamoto¹⁰, D. Tomura¹⁰, H. Chono¹⁰, I. Nukaya¹⁰, J. Mineno¹⁰, H. Ikeda¹¹, T. Watanabe², S. Kageyama², H. Shiku⁴, ¹National Hospital Organization, Nagoya Medical Center, Nagoya, JP, ²Mie University Hospital, Tsu, JP, ³National Cancer Center Hospital, Tokyo, JP, ⁴Mie University,

Tsu, JP, ⁵Aichi Medical University, Nagakute, JP, ⁶Keio University School of Medicine, Tokyo, JP, ⁷National Cancer Center Hospital East, Kashiwa, JP, ⁸Kanagawa Cancer Center, Yokohama, JP, ⁹Tokyo Medical University, Tokyo, JP, ¹⁰Takara Bio, Inc., Kusatsu, JP, ¹¹Nagasaki University, Nagasaki, JP

17:00 - 17:00 **1183PD - Adoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumor responses in patients with NY-ESO-1 expressing solid tumors.**

M. Butler¹, V. Sotov¹, S. Saibil², L. Bonilla², S. Boross-Harmer², M. Fyrsta², D. Gray², M. Nelles², M. Le², D. Lemiashkova², D. Liu², A. Sacher², A. Trang², K. Vakili², B. Van As², E. Scheid², L. Nguyen², S. Takahashi³, S. Tanaka³, N. Hirano², ¹Princess Margaret Hospital, Toronto, CA, ²Princess Margaret Cancer Centre, Toronto, CA, ³Takara Bio, Inc, Kusatsu, JP

17:00 - 17:00 **1184PD - Results of a phase I trial with MART-1 T cell receptor modified T cells in patients with metastatic melanoma**

M. Rohaan¹, R. Gomez-Eerland², M. Geukes Foppen¹, M. Van Zon², R. De Boer², N. Bakker², L. Pronk², A. Sari², H. Mallo², B. Van De Wiel¹, F. Lalezari¹, J. Beijnen³, B. Nuijen¹, H. Van Tinteren¹, J. Van Thienen¹, C. Blank³, S. Wilgenhof⁴, T. Schumacher³, J. Van Den Berg⁵, J. Haanen¹, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²Netherlands Cancer Institute, Amsterdam, NL, ³The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁴Antoni van Leeuwenhoek, Amsterdam, NL, ⁵The Netherlands Cancer Institute, Amsterdam, NL

17:00 - 17:00 **1185PD - Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted chimeric antigen receptor-T cells for B-cell non-Hodgkin lymphoma**

Z. Ying¹, T. He², X. Wang¹, W. Zheng¹, N. Lin¹, M. Tu¹, Y. Xie¹, L. Ping¹, C. Zhang¹, W. Liu¹, L. Deng¹, F. Qi², X. Lu², Y. Ding², Y. Song¹, J. Zhu¹, ¹Peking University Cancer Hospital & Institute, Beijing, CN, ²Beijing Immunochina Pharmaceuticals Co., Ltd., Beijing, CN

17:00 - 17:20 **Invited Discussant 1182PD, 1183PD, 1184PD and 1185PD**

17:20 - 17:30 **Q&A led by Discussant**

16:30 - 17:50 Type: Poster Discussion session Tarragona Auditorium
Title: Poster Discussion - Gastrointestinal tumours, non-colorectal (Hall 7)

16:30 - 16:30 **Session DOI**

16:30 - 16:30 **One LBA TBC**

- 16:30 - 16:30 **672PD - Randomized Phase III Study of S-1 Concurrent With Radiotherapy Versus Radiotherapy alone in Elderly Patients With Esophageal Cancer**
Y. Ji¹, W. Zhu², H. Tao³, J. Ma⁴, J. Li⁵, J. Huang⁶, M. Zeng⁷, W. Hu⁸, R. Huang⁹, D. Du¹⁰, J. Pu¹¹, L. Zhang¹², C. Li¹³, X. Yang¹⁴, Y. Bao¹⁵, Y. Yang¹⁶, H. Yang¹⁷, Z. Liu¹⁸, X. Du¹, M. Chen¹, ¹Zhejiang Cancer Hospital, Hangzhou, CN, ²Huaian First People's Hospital, Huaian, CN, ³Jiangsu Cancer Hospital, nanjin, CN, ⁴Anhui Provincial Hospital, hefei, CN, ⁵Fujian Provincial Cancer Hospital, fuzhou, CN, ⁶First People's Hospital of Changzhou, changzhou, CN, ⁷Sichuan Provincial People's Hospital, chengdu, CN, ⁸Jinhua Municipal Central Hospital, jinhua, CN, ⁹First People's Hospital of Foshan, foshan, CN, ¹⁰Lishui Municipal Central Hospital, -, CN, ¹¹Lianshui County People's Hospital, lianshui, CN, ¹²Chongqing Sanxia Central Hospital, sanxia, CN, ¹³Maoming People's Hospital, maoming, CN, ¹⁴First Hospital of Jiaxing, jiaxing, CN, ¹⁵The First Affiliated Hospital of Sun Yat-sen University, guangzhou, CN, ¹⁶Nantong Tumor Hospital, nantong, CN, ¹⁷Taizhou Hospital of Zhejiang Province, taizhou, CN, ¹⁸Hunan Cancer Hospital, changsha, CN
- 16:30 - 16:30 **673PD - Nab-paclitaxel (Nab) plus Gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): the GAP trial, a GISCAD phase II comparative randomized trial.**
S. Cascinu¹, R. Berardi², R. Bianco³, D. Bilancia⁴, A. Zaniboni⁵, D. Ferrari⁶, S. Mosconi⁷, A. Spallanzani¹, L. Cavanna⁸, S. Leo⁹, F. Negri¹⁰, G. Beretta¹¹, A. Sobrero¹², M. Banzi¹³, A. Morabito¹⁴, A. Bittoni², R. Marciano¹⁵, D. Ferrara⁴, S. Noventa⁵, M.C. Piccirillo¹⁶, ¹Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ²AOU Ospedali Riuniti Ancona, Torrette di Ancona, IT, ³Università Federico II, Napoli, IT, ⁴AZ. OSPEDALIERA SAN CARLO, Potenza, IT, ⁵Casa di Cura Poliambulanza, Brescia, IT, ⁶A. O. San Paolo, Milano, IT, ⁷A.O. Papa Giovanni XXIII, Bergamo, IT, ⁸USL di Piacenza - Ospedale Guglielmo da Saliceto, Piacenza, IT, ⁹A.O. Vito Fazi, Lecce, IT, ¹⁰Azienda Ospedaliera Universitaria di Parma, Parma, IT, ¹¹Humanitas Gavazzeni, Bergamo, IT, ¹²IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ¹³Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, ¹⁴Ospedale Civile, Camposampiero, IT, ¹⁵Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ¹⁶Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT
- 16:30 - 16:30 **674PD - Perioperative FLOT + anti-PD-L1 avelumab (FLOT-A) chemotherapy in resectable oesophagogastric adenocarcinoma (OGA): safety and biomarker data from the ICONIC trial safety run-in**
M. Davidson¹, S. Mansukhani¹, N. Starling², I. Chau³, D. Watkins², D. Cunningham¹, S. Rao¹, B. Griffiths⁴, L. Barber⁴, D. Morganstein¹, M. Forster⁵, S. Davies⁶, R. Begum², A. Gillbanks¹, E. Kalaitzaki⁷, A. Wotherspoon¹, K. Von Loga⁸, A. Chaudry¹, M. Gerlinger⁴, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²Royal Marsden NHS Foundation Trust, Sutton, GB, ³Royal Marsden Hospital, London, GB, ⁴Institute of Cancer Research, London, GB, ⁵University College London Cancer Institute, London, GB, ⁶Royal Brompton and Harefield NHS Foundation Trust, London, GB, ⁷Research data and Statistics Unit, Sutton, GB, ⁸Biomedical Research Centre, The Royal Marsden NHS Foundation Trust, Sutton, GB
- 16:30 - 16:42 **Invited Discussant 672PD, 673PD, 674PD and one LBA TBC**

16:42 - 16:50 **Q&A led by Discussant**

16:50 - 16:50 **One LBA TBC**

16:50 - 16:50 **One LBA TBC**

16:50 - 16:50 **675PD - POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC)**

P. Hammel¹, H. Kindler², M. Reni³, E. Van Cutsem⁴, T. Macarulla Mercade⁵, M. Hall⁶, J.O. Park⁷, D. Hochhauser⁸, D. Arnold⁹, D.-Y. Oh¹⁰, A. Reinacher-Schick¹¹, G. Tortora¹², H. Algül¹³, E. O'Reilly¹⁴, D. McGuinness¹⁵, K. Cui¹⁶, S. Joo¹⁷, H.K. Yoo¹⁵, N. Patel¹⁶, T. Golan¹⁸, ¹Beaujon Hospital APHP, Clichy, FR, ²University of Chicago, Chicago, US, ³IRCCS Ospedale San Raffaele, Milan, IT, ⁴University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, BE, ⁵Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁶Fox Chase Cancer Center, Philadelphia, US, ⁷Samsung Medical Center, Seoul, KR, ⁸UCL Cancer Institute/Paul O'Gorman Building, London, GB, ⁹Asklepios Klinik Altona, Hamburg, DE, ¹⁰Seoul National University Hospital, Seoul, KR, ¹¹Katholisches Klinikum Bochum - St. Josef-Hospital, Bochum, DE, ¹²Fondazione Policlinico Universitario Agostino Gemelli -IRCCS Rome, Rome, IT, ¹³Technical University Munich, Munich, DE, ¹⁴Memorial Sloan-Kettering Cancer Center, New York, US, ¹⁵AstraZeneca, Cambridge, GB, ¹⁶AstraZeneca, Gaithersburg, US, ¹⁷Merck & Co., Inc., Kenilworth, US, ¹⁸Chaim Sheba Medical Center, Ramat Gan, IL

16:50 - 16:50 **676PD - Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240**

P. Merle¹, A.S. Kulkarni², B.-Y. Ryoo³, A.-L. Cheng⁴, M. Kudo⁵, M. Bouattour⁶, H.Y. Lim⁷, V. Breder⁸, J. Edeline⁹, Y. Chao¹⁰, S. Ogasawara¹¹, T. Yau¹², M. Garrido¹³, S. Chan¹⁴, B. Daniele¹⁵, J. Norquist², E. Chen², A. Siegel¹⁶, A. Zhu¹⁷, R. Finn¹⁸, ¹Hôpital de la Croix-Rousse, Lyon, FR, ²Merck & Co., Inc., Kenilworth, US, ³Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁴National Taiwan University Hospital, New Taipei city, TW, ⁵Kindai University Faculty of Medicine, Osaka, JP, ⁶Hôpital Beaujon, Clichy, FR, ⁷Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ⁸N. N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ⁹Centre Eugene - Marquis, Rennes, FR, ¹⁰Taipei Veterans General Hospital, Taipei City, TW, ¹¹Chiba University, School of Medicine, Chiba, JP, ¹²Queen Mary Hospital, Hong Kong, HK, ¹³Red de Salud UC Christus - Centro de Cancer, Santiago, CL, ¹⁴The Chinese University of Hong Kong, Hong Kong, HK, ¹⁵Azienda Ospedaliera G. Rummo, Benevento, IT, ¹⁶Merck & Co, Rahway, US, ¹⁷Massachusetts General Hospital, Harvard Medical School, Boston, US, ¹⁸UCLA - School of Medicine, Los Angeles, US

- 16:50 - 17:02 **Invited Discussant 675PD, 676PD and 2 LBAs TBC**
- 17:02 - 17:10 **Q&A led by Discussant**
- 17:10 - 17:10 **677PD - Comprehensive Genomic Profiling (CGP) of mixed hepatocellular cholangiocarcinomas (cHCC-CCA)**
K. Murugesan¹, M. Javle², A. Schrock³, N. Ngo³, G. Frampton³, B. Alexander³, V. Miller³, T. Bekaii-Saab⁴, L. Albacker³, J. Ross³, S. Ali³, ¹Foundation Medicine, Inc., Cambridge, US, ²MD Anderson Cancer Center, Houston, US, ³Foundation Medicine, Cambridge, US, ⁴Mayo Clinic Cancer Center, Phoenix, US
- 17:10 - 17:10 **678PD - Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)**
L. Rimassa¹, R.K. Kelley², T. Meyer³, B.-Y. Ryoo⁴, P. Merle⁵, J.-W. Park⁶, J.-F. Blanc⁵, H.Y. Lim⁷, A. Tran⁸, A. Borgman-Hagey⁹, D. Clary⁹, E. Wang⁹, A.-L. Cheng¹⁰, A. El-Khoueiry¹¹, G. Abou-Alfa¹², ¹Istituto Clinico Humanitas, Rozzano, IT, ²University of California San Francisco, San Francisco, US, ³UCL Cancer Institute/Paul O'Gorman Building, London, GB, ⁴Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁵Groupement Hospitalier Lyon Nord, Lyon, FR, ⁶National Cancer Center, Goyang, KR, ⁷Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ⁸Groupe Hospitalier L'Archet, Nice, FR, ⁹Exelixis, Alameda, US, ¹⁰National Taiwan University Hospital, New Taipei city, TW, ¹¹USC, Los Angeles, US, ¹²Memorial Sloan-Kettering Cancer Center, New York, US
- 17:10 - 17:10 **679PD - Large-scale analysis of CDH1 mutations define a distinctive molecular subset in gastric cancer (GC)**
J. Wang¹, J. Xiu², H. Arai³, F. Battaglin⁴, K. Poorman², R. Tokunaga¹, W. Zhang¹, W.M. Korn², H.J. Lenz¹, ¹USC - Norris Comprehensive Cancer Center, Los Angeles, US, ²Caris Life Sciences, Phoenix, US, ³Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, US, ⁴University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US
- 17:10 - 17:10 **680PD - Genomic alterations predict clinical response to systemic chemotherapy and immune checkpoint blockade in biliary tract cancer**
M.H. Kim¹, J. Yoon², M. Jang², H. Kim², Y.N. Park², M.G. Lee², H.K. Hwang², C.M. Kang², W.J. Lee², B. Kang³, H.C. Chung⁴, H.J. Choi⁴, ¹Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, ²Yonsei University College of Medicine, Seoul, KR, ³Yonsei Cancer Center, Seoul, KR, ⁴Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR
- 17:10 - 17:22 **Invited Discussant 677PD, 678PD, 679PD and 680PD**
- 17:22 - 17:30 **Q&A led by Discussant**

17:30 - 17:30 **681PD - Low-dose aspirin and risk of gastric and oesophageal cancer: a population-based study**
 L. Garcia Rodriguez¹, P. Vora², M. Soriano-Gabarró², L. Cea Soriano³, ¹Abbvie Farmaceutica S L U Spain, Madrid, ES, ²Bayer AG, Berlin, DE, ³Spanish Centre for Pharmacoepidemiologic Research, Madrid, ES

17:30 - 17:30 **One LBA TBC**

17:30 - 17:30 **One LBA TBC**

17:30 - 17:42 **Invited Discussant 681PD and 2LBAs TBC**

17:42 - 17:50 **Q&A led by Discussant**

16:30 - 18:00 Type: Poster Discussion session **Alicante Auditorium (Hall 3)**
Title: Poster Discussion - Developmental therapeutics

16:30 - 16:30 **Session DOI**

16:30 - 16:30 **443PD - Genomic characteristics and predicted ancestry of NTRK1/2/3 and ROS1 fusion-positive tumors from >165,000 pan-solid tumors**
 T.R. Wilson¹, E.S. Sokol², S.E. Trabucco², J.Y. Newberg², B. Simmons¹, T. Riehl³, S.L. Maund¹, ¹Genentech, South San Francisco, US, ²Foundation Medicine, Cambridge, US, ³Genentech Inc., South San Francisco, US

16:30 - 16:30 **One LBA TBC**

16:30 - 16:30 **444PD - Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)**
 A. Drilon¹, B. Cho², D.-W. Kim³, J. Lee⁴, J. Lin⁵, V. Zhu⁶, R. Camidge⁷, S. Stopatschinskaja⁸, J.J. Cui⁸, D. Hyman⁹, S.-H. Ou¹⁰, A. Shaw¹¹, R.C. Doebele¹², ¹Memorial Sloan-Kettering Cancer Center, New York, US, ²Yonsei Cancer Center, Seoul, KR, ³Seoul National University Hospital, Seoul, KR, ⁴Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ⁵Mass General Hospital Cancer Center, Boston, US, ⁶University of California, Orange, US, ⁷University of Colorado, Aurora, US, ⁸TP Therapeutics, Inc., San Diego, US, ⁹MSKCC, New York, US, ¹⁰University

of California, Irvine, US, ¹¹Massachusetts General Hospital, Boston, US, ¹²University of Colorado Cancer Center, Aurora, US

- 16:30 - 16:30 **445PD - Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer**
- D. Hyman¹, C. Van Tilburg², C. Albert³, D.S.W. Tan⁴, B. Georger⁵, A. Farago⁶, T. Laetsch⁷, S. Kummar⁸, F. Doz⁹, U. Lassen¹⁰, S. Dubois¹¹, R. Mcdermott¹², L. Mascarenhas¹³, J. Berlin¹⁴, E. Rudzinski³, M. Cox¹⁵, S. Nanda¹⁶, B. Childs¹⁶, A. Drilon¹⁷, D. Hong¹⁸, ¹MSKCC, New York, US, ²Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, DE, ³University of Washington, Seattle, US, ⁴National Cancer Center Singapore, Singapore, SG, ⁵Université Paris-Sud, Université Paris-Saclay, Villejuif, FR, ⁶Massachusetts General Hospital, Boston, US, ⁷University of Texas, Dallas, US, ⁸Stanford University, Stanford, US, ⁹SIREDO Oncology Center (Care, Innovation and research for children and AYA with cancer), Paris, FR, ¹⁰Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, ¹¹Dana-Farber and Boston Children's, Boston, US, ¹²Adelaide and Meath Hospital, Tallaght, IE, ¹³University of Southern California Keck School of Medicine, Los Angeles, US, ¹⁴Vanderbilt-Ingram Cancer Center, Nashville, US, ¹⁵Loxo Oncology, Inc., South San Francisco, US, ¹⁶Bayer HealthCare Pharmaceuticals, Inc., Whippany, US, ¹⁷Memorial Sloan-Kettering Cancer Center, New York, US, ¹⁸University of Texas MD Anderson Cancer Center, Houston, US
- 16:30 - 16:42 **Invited Discussant 443PD, 444PD, 445PD and one LBA TBC**
- 16:42 - 16:50 **Q&A led by Discussant**
- 16:50 - 16:50 **446PD - Phase 1 Study of AMG 510, a Novel Molecule Targeting KRAS G12C Mutant Solid Tumors**
- R. Govindan¹, M. Fakih², T. Price³, G. Falchook⁴, J. Desai⁵, J. Kuo⁶, J. Strickler⁷, J. Krauss⁸, B. Li⁹, C. Denlinger¹⁰, G. Durm¹¹, J. Ngang¹², H. Henary¹², G. Ngarmchamnanrith¹², E. Rasmussen¹², P. Morrow¹², D. Hong¹³, ¹Alvin J Siteman Cancer Center at Washington University School of Medicine, St Louis, US, ²City of Hope National Medical Center, Duarte, US, ³The Queen Elizabeth Hospital, Woodville South, AU, ⁴Sarah Cannon Research Institute at HealthONE, Denver, US, ⁵Peter MacCallum Cancer Centre, Melbourne, AU, ⁶Scientia Clinical Research, Randwick, AU, ⁷Duke Cancer Center, Durham, US, ⁸University of Michigan, Ann Arbor, US, ⁹Memorial Sloan Kettering Cancer Center, New York, US, ¹⁰Fox Chase Cancer Center, Philadelphia, US, ¹¹Indiana University, Simon Cancer Center, Indianapolis, US, ¹²Amgen (Headquarters) - USA, Thousand Oaks, US, ¹³University of Texas MD Anderson Cancer Center, Houston, US
- 16:50 - 16:50 **447PD - Phase 1/2 study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumors**
- R. Corcoran¹, K. Do², J. Cleary³, A. Parikh⁴, O. Yeku¹, C. Weekes¹, J. Veneris², L. Ahronian¹, G. Mauri⁵, E. Van Seventer¹, I. Fetter¹, J. Gurski¹, U. Matulonis², D. Juric⁴, K. Flaherty¹, R. Sullivan¹, J. Clark¹, R. Heist¹, G. Shapiro², ¹Massachusetts General

Hospital, Harvard Medical School, Boston, US, ²Dana Farber Cancer Institute, Boston, US, ³Dana-Farber Cancer Institute, Boston, US, ⁴Massachusetts General Hospital, Boston, US, ⁵Niguarda Cancer Center, Milan, IT

16:50 - 16:50 **448PD - Genomic Profiling of Three Pathways through Molecular Profiling-based Assignment of Cancer Therapy (NCI- MPACT)**

A. Chen¹, S. Kummar², S. Khan¹, N. Moore¹, L. Rubinstein¹, G. O'Sullivan Coyne¹, Y. Zhao¹, A. Palmisano¹, P. Williams³, V. Datta³, D. Sims³, C. Karlovich³, C.-J. Lih³, K.P.S. Raghav⁴, F. Meric-Bernstam⁴, S. Leong⁵, S. Waqar⁶, N. Takebe¹, E. Sharon¹, J. Doroshow¹, ¹National Cancer Institute, Bethesda, US, ²Stanford University, Stanford, US, ³Frederick National Laboratory for Cancer Research, Frederick, US, ⁴The University of Texas MD Anderson Cancer Center, Houston, US, ⁵University of Colorado Denver School of Medicine, Aurora, US, ⁶Washington University School of Medicine, St Louis, US

16:50 - 16:50 **449PD - Precision Medicine: Preliminary Results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT 2) Study.**

A.M. Tsimberidou¹, D. Hong², S. Fu³, D. Karp⁴, S. Piha-Paul⁵, M. Kies⁶, V. Ravi¹, V. Subbiah¹, S. Patel³, S.-M. Tu¹, F. Janku¹, J. Heymach⁷, A. Johnson⁶, L. Zhao⁶, J. Zhang⁶, D. Berry⁶, D. Vining⁶, A. Futreal⁶, V. Miller⁸, F. Meric-Bernstam¹, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²University of Texas MD Anderson Cancer Center, Houston, US, ³MD Anderson Cancer Center, Houston, US, ⁴UT MD Anderson Cancer Center, Houston, US, ⁵The University of Texas, MD Anderson Cancer Center, Houston, US, ⁶MD Anderson, Houston, US, ⁷MD Anderson, texas, US, ⁸Foundation Medicine, Cambridge, US

16:50 - 17:02 **Invited Discussant 446PD, 447PD, 448PD and 449PD**

17:02 - 17:10 **Q&A led by Discussant**

17:10 - 17:10 **450PD - A Phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT Part A, B)**

M. Dillon¹, J. Guevara², K. Mohammed², S. Smith³, E. Dean³, L. Mclellan⁴, Z. Boylan⁴, J. Spicer⁵, M. Forster⁶, K. Harrington⁷, ¹The Institute of Cancer Research, London, London, GB, ²Royal Marsden NHS Foundation Trust, Sutton, GB, ³AstraZeneca, Cambridge, GB, ⁴Cancer Research UK, London, GB, ⁵King's College London Guy's Hospital, London, GB, ⁶University College London Cancer Institute, London, GB, ⁷Institute of Cancer Research ICR, London, GB

17:10 - 17:10 **451PD - Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors**

A. Stradella¹, M. Johnson², S. Goel³, S.R. Chandana⁴, M.D. Galsky⁵, E. Calvo⁶, V. Moreno⁷, H. Park⁸, H.-T. Arkenau⁹, A. Cervantes¹⁰, L. Fariñas Madrid¹¹, L. Mileskin¹², R. Plummer¹³, J. Evans¹⁴, L. Horvath¹⁵, A. Prawira¹⁶, R. Pelham¹⁷, S. Mu¹⁷, C. Andreu-Vieyra¹⁷, M. Barve¹⁸, ¹ICO - Institut Catala d'Oncologia Hospital Duran i Reynals,

Hospitalet de Llobregat, ES, ²Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ³Montefiore Medical Center(East campus) - Medical Park at Eastchester Albert Einstein Cancer Center, Bronx, US, ⁴START Midwest, Grand Rapids, US, ⁵Icahn School of Medicine at Mount Sinai, New York, US, ⁶Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, ⁷University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ⁸Washington University Medical School, St. Louis, US, ⁹Sarah Cannon Research Institute UK, London, GB, ¹⁰Hospital Clinico Universitario de Valencia, Valencia, ES, ¹¹Vall d'Hebron University Hospital, Barcelona, ES, ¹²Peter MacCallum Cancer Center, Melbourne, AU, ¹³The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle upon Tyne, GB, ¹⁴Beatson West of Scotland Cancer Centre, Glasgow, GB, ¹⁵Chris O'Brien Lifehouse, Sydney, AU, ¹⁶Kinghorn Cancer Centre, Darlinghurst, AU, ¹⁷BeiGene USA, Inc., San Mateo, US, ¹⁸Mary Crowley Cancer Center, Dallas, US

17:10 - 17:10

452PD - Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumors: updated phase 1 dose-escalation/expansion results

M. Voskoboynik¹, L. Mileskin², H. Gan³, M. Millward⁴, G. Au-Yeung⁵, T.M. Meniawy⁶, G. Kichenadasse⁷, K. Zhang⁸, M. Zhang⁸, S. Mu⁸, J.D. Lickliter⁹, ¹Alfred Hospital, Melbourne, AU, ²Peter MacCallum Cancer Center, Melbourne, AU, ³Austin Hospital, Heidelberg, AU, ⁴Linear Clinical Research, Perth, AU, ⁵Peter MacCallum Cancer Centre, Melbourne, AU, ⁶Linear Clinical Research, Nedlands, AU, ⁷Flinders Centre for Innovation in Cancer, Bedford Park, AU, ⁸BeiGene USA, Inc., Emeryville, US, ⁹Nucleus Network, Melbourne, AU

17:10 - 17:22

Invited Discussant 450PD, 451PD and 452PD

17:22 - 17:30

Q&A led by Discussant

17:30 - 17:30

One LBA TBC

17:30 - 17:30

453PD - Safety, Anti-Tumor Activity, and Biomarker Results of the HER2-Targeted Bispecific Antibody ZW25 in HER2-Expressing Solid Tumors

F. Meric-Bernstam¹, D. Hanna², M. Beeram³, K.-W. Lee⁴, Y.-K. Kang⁵, J. Chaves⁶, J. Lee⁷, R. Goodwin⁸, C. Vaklavas⁹, D.-Y. Oh¹⁰, S.Y. Rha¹¹, E. Elimova¹², J. Mayordomo¹³, C. Ferrario¹⁴, M. Cobleigh¹⁵, A. Fortenberry¹⁶, G. Rowse¹⁷, T. Gray¹⁶, R. Lai¹⁶, E. Hamilton¹⁸, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²USC Norris Comprehensive Cancer Center, Los Angeles, US, ³The START Center for Cancer Care, San Antonio, US, ⁴National University of Seoul Bundang Hospital, Seoul, KR, ⁵Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁶Northwest Medical Specialties, LLC, Tacoma, US, ⁷Samsung Medical Center, Seoul, KR, ⁸University of Ottawa Cancer Centre, Ottawa, CA, ⁹University of Alabama Cancer Center, Birmingham, US, ¹⁰Seoul National University Hospital, Seoul, KR, ¹¹Yonsei University, Seoul, KR, ¹²Princess Margaret Cancer Centre, Toronto, CA, ¹³University of Colorado, Denver, US, ¹⁴Jewish General Hospital McGill University, Montreal, CA, ¹⁵Rush University Medical

Center, Chicago, US, ¹⁶Zymeworks, Inc., Seattle, US, ¹⁷Zymeworks, Inc., Vancouver, CA,
¹⁸Sarah Cannon Research Institute-Cancer Centre, Nashville, US

17:30 - 17:30 **One LBA TBC**

17:30 - 17:30 **454PD - First in human, a phase I study of ISU104, a novel ErbB3 monoclonal antibody, in patients with advanced solid tumors**

S.-B. Kim¹, B. Keam², S. Shin³, Y.S. Chae⁴, T.M. Kim², M.-S. Kim⁵, J.G. Kim⁴, K. Park⁶, J.S. Ahn⁷, L.C. Park³, E. Lee³, J. Juhn⁸, S. Kim⁸, S.-B. Hong⁹, M.-J. Ahn¹⁰, ¹Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ²Seoul National University Hospital, Seoul, KR, ³Kosin University Gospel, Busan, KR, ⁴Kyungpook National University Hospital, Daegu, KR, ⁵University of Ulsan College of Medicine, Seoul, KR, ⁶Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁷Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ⁸ISU ABXIS Co., Ltd., Seongnam, KR, ⁹ISU Abxis, Sungnam-si, KR, ¹⁰Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

17:30 - 17:30 **455PD - First-in-human, first-in-class phase I study of MTL-CEBPA, a RNA oligonucleotide targeting the myeloid cell master regulator C/EBP- α , in patients with advanced hepatocellular cancer (HCC)**

D. Sarker¹, R. Plummer², B. Basu³, T. Meyer⁴, Y.-T. Ma⁵, J. Evans⁶, D. Palmer⁷, K.-W. Huang⁸, C.E. Chee⁹, D. Spalding¹⁰, M. Sodergren¹¹, N. Habib¹¹, ¹Guy's and St. Thomas' Hospital NHS Trust, London, GB, ²The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle upon Tyne, GB, ³Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB, ⁴UCL Cancer Institute/Paul O'Gorman Building, London, GB, ⁵University of Birmingham, Birmingham, GB, ⁶Beatson West of Scotland Cancer Centre, Glasgow, GB, ⁷Royal Liverpool University Hospital, Liverpool, GB, ⁸NATIONAL TAIWAN UNIVERSITY HOSPITAL, TAIPEI, TW, ⁹National University Hospital, Singapore, SG, ¹⁰IMPERIAL COLLEGE, LONDON, GB, ¹¹Imperial College London - Hammersmith Hospital, London, GB

17:30 - 17:45 **Invited Discussant 453PD, 454PD, 455PD and 2 LBAs TBC**

17:45 - 17:55 **Q&A led by Discussant**

16:30 - 18:00	Type: Educational session Title: Bedside rationing: To prescribe or not to prescribe? Chair(s): Paolo G. Casali, IT	Leon Auditorium (Hall 3)
16:30 - 16:30	Session DOI	
16:30 - 16:50	Responsibilities of the physician <u>W. Evans</u> , McMaster University, Hamilton, CA	
16:50 - 17:10	Responsibilities of the health economist <u>G. Lopez Casasnovas</u> , Barcelona Graduate School of Economics, Barcelona, ES	
17:10 - 17:30	The patient advocates' perspective <u>V. Voiculescu</u> , Romanian Health Observatory, Bucharest, RO	
17:30 - 17:50	View of an expert in bioethics <u>J.H. Solbakk</u> , Centre for Molecular Medicine Norway (NCMM), UiO, Oslo, NO	
17:50 - 18:00	Discussion	

18:15 - 19:45	Type: Patient Advocay Track Title: Fertility and pregnancy of cancer patients during and after treatment Chair(s): Tanja Spanic, SI	Leon Auditorium (Hall 3)
18:15 - 18:15	Session DOI	
18:15 - 18:30	Setting the scene: The patient perspective <u>A. Plate</u> , Myeloma Patients Europe, Charleroi, BE	
18:30 - 18:45	Fertility preservation (what should be done when diagnosed at childbearing age) <u>M. Lambertini</u> , IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT	
18:45 - 19:00	Pregnancy after cancer	
19:00 - 19:15	What are my options after diagnosis? <u>T. Spanic</u> , Europa Donna Slovenia, Ljubljana, SI	
19:15 - 19:30	TBC	
19:30 - 19:45	Discussion	

18:30 - 20:00	Type: Industry Satellite Symposium Title: Merck KGaA - Exploring patient cases: Challenging the status quo in mCRC for optimal patient outcomes Chair(s): Dirk Arnold, DE	Cordoba Auditorium (Hall 7)
18:30 - 18:40	Precision medicine in mCRC: Setting the scene <u>D. Arnold</u> , Asklepios Klinik Altona, Hamburg, DE	
18:40 - 18:55	What is the recommended sequence of targeted therapies? <u>S. Kopetz</u> , Private Practice - Kopetz, Houston, US	
18:55 - 19:05	Audience questions and discussion	
19:05 - 19:20	Why are Anti-EGFR agents not the same? <u>J. Garcia Foncillas</u> , University Hospital "Fundacion Jimenez Diaz", Madrid, ES	
19:20 - 19:30	Audience questions and discussion	
19:30 - 19:40	Why should precision medicine be applied across the continuum of care? <u>M. Scartozzi</u> , AOU Ospedali Riuniti Ancona, Torrette di Ancona, IT	
19:40 - 19:50	Audience questions and discussion	
19:50 - 20:00	Precision medicine in mCRC: Closing the conversation. Led by <u>D. Arnold</u> , Asklepios Klinik Altona, Hamburg, DE	

18:30 - 20:00 **Type: Industry Satellite Symposium** **Bilbao Auditorium (Hall 5)**
Title: Novartis Oncology - Removing the brakes on the immune system: gearing up for tumor-promoting inflammation inhibitors in NSCLC
Chair(s): Luis Paz-Ares, ES

18:30 - 18:35 **Welcome and introduction**

L. Paz-Ares, University Hospital 12 De Octubre, Madrid, ES

18:35 - 18:55 **Immunotherapy in the rearview mirror: successes and remaining unmet needs**

A. Greystoke, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, GB

18:55 - 19:15 **Navigating towards the future of Immunotherapy**

E. Garon, UCLA Hematology/Oncology Santa Monica, Santa Monica, US

19:15 - 19:40 **Interleukin-1: gearing up in NSCLC**

L. Paz-Ares, University Hospital 12 De Octubre, Madrid, ES

19:40 - 19:55 **Q&A**

19:55 - 20:00 **Summary and close**

L. Paz-Ares, University Hospital 12 De Octubre, Madrid, ES

18:30 - 20:00 **Type: Industry Satellite Symposium** **Tarragona Auditorium (Hall 7)**
Title: MSD - A new generation of treatments for head and neck cancers
Chair(s): Jean-Pascal Machiels, BE

18:30 - 18:35 **Welcome and Introduction**

18:35 - 19:05 **Advances in Treatment of 1L R/M HNSCC**

J.-P. Machiels, Cliniques Universitaires St. Luc, Brussels, BE

19:05 - 19:25 **Biomarkers in 1L R/M HNSCC**

19:25 - 19:45 **Recent data and ongoing trials in other cSCCs**

D. Rischin, Peter MacCallum Cancer Centre, Melbourne, AU

19:45 - 20:00 **Q&A and Closing Remarks**

J.-P. Machiels, Cliniques Universitaires St. Luc, Brussels, BE

18:30 - 20:00 **Type: Industry Satellite Symposium** **Alicante Auditorium (Hall 3)**
Title: Takeda - Expert insights in advanced ALK-positive NSCLC.
Addressing questions faced by physicians in clinical practice
Chair(s): Enriqueta Felip, ES

- 18:30 - 18:35 **Introduction**
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES
- 18:35 - 18:45 **Expert insights in 3 patient cases with advanced ALK-positive NSCLC**
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES
- 18:45 - 19:05 **The patient presenting with de novo ALK-positive metastatic NSCLC: what are the best options for your patient?**
M. Garassino, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT
- 19:05 - 19:25 **The patient with ALK-positive metastatic NSCLC at risk of CNS progression: how can we determine and reduce the risk?**
S. Popat, Royal Marsden Hospital NHS Foundation Trust, London, GB
- 19:25 - 19:45 **The patient progressing after first line treatment with ALK-targeted therapy: what are the current possibilities?**
T.S.K. Mok, Prince of Wales Hospital, Shatin, HK
- 19:45 - 19:55 **Addressing your questions**
- 19:55 - 20:00 **Closing remarks**
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES

18:30 - 20:00	Type: Industry Satellite Symposium Title: prIME - HER2 - positive early breast cancer: A personalized approach to treatment Chair(s): Martine Piccart, BE	Cartagena Auditorium (Hall 3)
18:30 - 18:32	Welcome and introduction <u>M. Piccart</u> , Institute Jules Bordet, Brussels, BE	
18:32 - 18:35	“Test your knowledge” interactive quiz <u>M. Piccart</u> , Institute Jules Bordet, Brussels, BE	
18:35 - 18:50	Getting to grips with the biology of HER2-positive breast cancer <u>S. Hurvitz</u> , UCLA Hematology/Oncology Santa Monica, Santa Monica, US	
18:50 - 18:55	Q&A	
18:55 - 19:15	Neoadjuvant treatment strategies for HER2-positive early breast cancer: Should treatment recommendations be response based? <u>S. Loibl</u> , German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE	
19:15 - 19:20	Q&A	
19:20 - 19:40	Risk-adapted treatments for HER2-positive early breast cancer <u>J. Cortés</u> , Vall d'Hebron University Hospital, Barcelona, ES	
19:40 - 19:45	Q&A	
19:45 - 19:55	Developing a roadmap for the treatment of HER2-positive early breast cancer: One size no longer fits all <u>M. Piccart</u> , Institute Jules Bordet, Brussels, BE	
19:55 - 20:00	Conclusions and prIME Points™ <u>M. Piccart</u> , Institute Jules Bordet, Brussels, BE	
20:00 - 20:00	Adjourn	

18:30 - 20:00 **Type: Industry Satellite Symposium** **Salamanca Auditorium (Hall 3)**
Title: IPSEN - NET talks: Real-world evidence and the patient journey: What does the future hold?
Chair(s): Nicola Fazio, IT

18:30 - 18:40 **Chairperson's welcome and introduction**
N. Fazio, Istituto Europeo di Oncologia, Milan, IT

18:40 - 19:05 **The impact of RWE in better understanding and managing neuroendocrine tumours**
T. Halfdanarson, Mayo Clinic, Rochester, US

19:05 - 19:30 **Integrating novel treatments into clinical practice: The role of RWE**
C. Toumpanakis, Royal Free Hospital School of Medicine, London, GB

19:30 - 19:50 **RWE and the impact on patient experience**
N. Pavlakis, Royal North Shore Hospital, St Leonards, AU

19:50 - 20:00 **Closing remarks and panel discussion**
N. Fazio, Istituto Europeo di Oncologia, Milan, IT

18:30 - 20:00 **Type: Industry Satellite Symposium** **Toledo Auditorium (Hall 5)**
Title: Bayer - New treatments, new considerations: Understanding the changing nmCRPC landscape
Chair(s): Karim Fizazi, FR

18:30 - 18:35 **Introduction**
K. Fizazi, Institut Gustave Roussy, Villejuif, FR

18:35 - 19:05 **The impact of new and emerging data in nmCRPC**
N. Mottet, CHU University hospital of St Etienne, Saint-Étienne, FR

19:05 - 19:35 **The importance of patient preference and optimal patient selection in nmCRPC**
K. Fizazi, Institut Gustave Roussy, Villejuif, FR

19:35 - 20:00 **Discussion and Q&A**
K. Fizazi, Institut Gustave Roussy, Villejuif, FR

- 18:30 - 20:00** **Type: Industry Satellite Symposium** **Santander Auditorium (Hall 3)**
Title: Menarini Silicon Biosystems - New clinical perspectives of CTC in the precision medicine era
Chair(s): Massimo Cristofanilli, US
- 18:30 - 18:45 **Clinical utility of CTC count in the staging of metastatic breast cancer**
M. Cristofanilli, Northwestern University Feinberg School of Medicine, Chicago, US
- 18:45 - 19:00 **Clinical utility of CTC count in the management of HR+ metastatic breast cancer**
J.-Y. Pierga, Institut Curie, Paris, FR
- 19:00 - 19:15 **The CTC role as a predictive biomarker of late recurrence in early breast cancer**
W. Janni, Ulm Medical University, Ulm, DE
- 19:15 - 19:30 **CTC count and single cells evaluation in metastatic prostate cancer**
J. De Bono, The Institute of Cancer Research (ICR), London, GB
- 19:30 - 20:00 **The current value of CTCs in patients' management**

29.09.2019

08:30 - 10:00 **Type: Special symposium** **Barcelona Auditorium (Hall 2)**
Title: Stratified treatment in metastatic colorectal cancer

Chair(s): Claus-Henning Koehne, DE; Livio Trusolino, IT

08:30 - 08:30 **Session DOI**

08:30 - 08:35 **Introduction**

C.-H. Koehne, Klinikum Oldenburg, Oldenburg, DE

08:35 - 08:55 **Resistance mechanisms as targets of therapy**

S. Siena, ASST Grande Ospedale Metropolitano Niguarda, Milan, IT

08:55 - 09:15 **Immunotherapy: Microsatellite instability high (MSI-H), microsatellite instability low (MSI-L)**

C.-H. Koehne, Klinikum Oldenburg, Oldenburg, DE

09:15 - 09:35 **New molecular stratification**

R. Dienstmann, Vall d'Hebron University Hospital, Barcelona, ES

09:35 - 09:55 **New models for colon cancer in preclinical research**

O. Sansom, Beatson Institute for Cancer Research, Glasgow, GB

09:55 - 10:00 **Conclusions and perspectives**

L. Trusolino, IRCCS Candiolo, Candiolo, IT

08:30 - 10:00 **Type: Proffered Paper session** **Madrid Auditorium (Hall 2)**
Title: Proffered Paper 2 - Gynaecological cancers

08:30 - 08:30 **Session DOI**

08:30 - 08:45 **One LBA TBC**

08:45 - 09:00 **One LBA TBC**

09:00 - 09:15 **Invited Discussant 2 LBAs TBC**

09:15 - 09:30 **One LBA TBC**

09:30 - 09:45 **9940 - Lenvatinib (LEN) and Pembrolizumab (PEMBRO) in Advanced Endometrial Cancer (EC)**

V. Makker¹, M. Taylor², C. Aghajanian¹, A. Oaknin³, J. Mier⁴, A. Cohn⁵, M. Romeo Marin⁶, R. Bratos Lorenzo⁷, M. Brose⁸, C. Disimone⁹, M. Messing¹⁰, D. Stepan¹¹, C. Dutcus¹¹, J. Wu¹¹, E. Schmidt¹², R. Orłowski¹³, P. Sachdev¹¹, R. Shumaker¹¹, A. Casado Herraiz¹⁴, ¹Memorial Sloan-Kettering Cancer Center, New York, US, ²OHSU Knight Cancer Institute - Northwest Portland, Portland, US, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Dana-Farber/Harvard Cancer Center, Beth Israel Deaconess Medical Center, Boston, US, ⁵Rocky Mountain Cancer Centers, Denver, US, ⁶Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, ⁷MD Anderson Cancer Center Center Espana, Madrid, ES, ⁸University of Pennsylvania- Clinical Research Building, Philadelphia, US, ⁹Arizona Oncology, Tucson, US, ¹⁰Texas Oncology-Bedford, Bedford, US, ¹¹Eisai Inc, Woodcliff Lake, US, ¹²Merck & Co Inc, North Wales, US, ¹³MSD-Merck Sharp & Dohme, Kenilworth, US, ¹⁴Hospital Clinico Universitario San Carlos, Madrid, ES

09:45 - 10:00 **Invited Discussant 9940 and one LBA TBC**

08:30 - 09:50 **Type: Poster Discussion session** **Sevilla Auditorium (Hall 2)**
Title: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies

08:30 - 08:30 **Session DOI**

08:30 - 08:30 **1439PD - BRCA1 expression level as prognostic factor for recurrence in resected NSCLC with adjuvant chemotherapy. SCAT Trial**

B. Massuti Sureda¹, J.M. Sanchez Torres², M. Cobo Dols³, M.T. Moran Bueno⁴, J. Gonzalez-Larriba⁵, I.C. Barneto Aranda⁶, J. De Castro Carpeno⁷, L. Iglesias⁸, M.A. Muñoz⁹, G. López Vivanco¹⁰, M.D. Isla Casado¹¹, R. López¹², R. De Las Penas Bataller¹³, D. Rodriguez Abreu¹⁴, A. Artal-Cortes¹⁵, E. Esteban¹⁶, M. Provencio¹⁷, E. Pereira¹⁸, J. Sanchez-Paya¹⁹, R. Rosell²⁰, ¹Hospital General Universitario de Alicante, Alicante, ES, ²Hospital Universitario de La Princesa, Madrid, ES, ³ Hospital Regional Universitario de Málaga, Málaga, ES, ⁴Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, ⁵Hospital Clinico Universitario San Carlos, Madrid, ES, ⁶University Hospital Reina Sofia, Cordoba, ES, ⁷Hospital Universitario La Paz, Madrid, ES, ⁸University Hospital 12 de Octubre, Madrid, ES, ⁹IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, ¹⁰Hospital Universitario Cruces, Barakaldo, ES, ¹¹Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, ¹²Hospital Clínico Universitario de Santiago (CHUS), Santiago de Compostela, ES, ¹³Hospital Provincial Castellon, Castellón, ES, ¹⁴Hospital Universitario Insular de Gran Canaria, Las Palmas, ES, ¹⁵Hospital Miguel Servet, Zaragoza, ES, ¹⁶Hospital Universitario Central de Asturias, Oviedo, ES, ¹⁷Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES, ¹⁸Spanish Lung Cancer Group Office, Barcelona, ES, ¹⁹ISABIAL, Alicante, ES, ²⁰Institut for Health Sciences Germans Trias i Pujol, Badalona, ES

08:30 - 08:30

1440PD - JIPANG study: Randomized Phase III Study of pemetrexed/cisplatin (PEM/Cis) versus vinorelbine /cisplatin (VNR/Cis) for completely resected p-stage II-IIIa non-squamous non-small cell lung cancer (Ns-NSCLC): Outcomes based on EGFR mutation status

M. Tsuboi¹, H. Kenmotsu², T. Yamanaka³, K. Yoshiya⁴, T. Takahashi², T. Ueno⁵, K. Goto¹, H. Daga⁶, N. Ikeda⁷, K. Sugio⁸, T. Seto⁹, S. Toyooka¹⁰, H. Date¹¹, T. Mitsudomi¹², I. Okamoto¹³, K. Yokoi¹⁴, H. Saka¹⁵, H. Okamoto¹⁶, Y. Takiguchi¹⁷, N. Yamamoto¹⁸, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Shizuoka Cancer Center, Shizuoka, JP, ³Yokohama City University Hospital, Yokohama, JP, ⁴Niigata Cancer Center Hospital, Niigata, JP, ⁵National Hospital Organization, Shikoku Cancer Center, Matsuyama, JP, ⁶Osaka City General Hospital, Osaka, JP, ⁷Tokyo Medical University, Tokyo, JP, ⁸Oita University Faculty of Medicine, Yufu, JP, ⁹National Kyushu Cancer Center, Fukuoka, JP, ¹⁰Okayama University, Okayama, JP, ¹¹Graduate School of Medicine, Kyoto University, Kyoto, JP, ¹²KIndai University Faculty of Medicine, Osaka-Sayama, JP, ¹³Kyushu University Faculty of Medicine, Fukuoka, JP, ¹⁴Nagoya University, Nagaoya, JP, ¹⁵National Hospital Organization Nagoya Medical Center, Nagoya, JP, ¹⁶Yokohama Municipal Citizen's Hospital, Yokohama, JP, ¹⁷Chiba University, Chiba, JP, ¹⁸Wakayama Medical University, Wakayama, JP

08:30 - 08:30

1441PD - A Comprehensive Model of Genetic-Features Predicts Outcome of Personalized Adjuvant Treatment in Resected EGFR-mutant Stage II-IIIa NSCLC: Results from a Phase 3 Trial (CTONG 1104-ADJUVANT)

Y.-L. Wu¹, S.-Y. Liu², Q. Wang³, W. Mao⁴, L. Wu⁵, Y. Shen⁶, Y. Cheng⁷, C. Chen⁸, L. Xu⁹, J. Wang¹⁰, H.-X. Liu¹¹, H. Bao¹², Y.-D. Chen¹³, X. Zhang², Z.-H. Chen¹⁴, H.-H. Yan¹⁴, J.-J. Yang², Y. Shao¹³, Q. Zhou¹⁵, W.-Z. Zhong², ¹Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, ²Guangdong General Hospital, Guangzhou, CN, ³Fudan University Affiliated Zhongshan Hospital, Shanghai, CN, ⁴Zhejiang cancer hospital, Hangzhou, CN, ⁵Hunan Cancer Hospital, Changsha, CN, ⁶The Affiliated Hospital of Medical College Qingdao University, Qingdao, CN, ⁷Jilin Cancer Hospital, Changchun, CN, ⁸Fujian Medical University Union Hospital, Fuzhou, CN, ⁹Jiangsu Cancer Hospita, Nanjing, CN, ¹⁰Peking University People's Hospital, Beijing,

CN, ¹¹Liaoning Cancer Hospital & Institute, Shenyang, CN, ¹²ANALYSIS, Nanjing, CN, ¹³Geneseeq Technology Inc., Nanjing, CN, ¹⁴Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, CN, ¹⁵Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN

08:30 - 08:42 **Invited Discussant 1439PD, 1440PD and 1441PD**

08:42 - 08:50 **Q&A led by Discussant**

08:50 - 08:50 **1457PD - Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC - Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial.**

S. Peters¹, E. Felip², U. Dafni³, A. Tufman⁴, M. Guckenberger⁵, A. Irigoyen⁶, E. Nadal⁷, A. Becker⁸, H. Veer⁹, M. Pless¹⁰, A. Martinez-Marti¹¹, M. Lambrecht¹², N. Andratschke⁵, Z. Tsourti¹³, A.-C. Piguet¹⁴, H. Roschitzki-Voser¹⁵, M. Rabaglio-Poretti¹⁴, R.A. Stahel⁵, J. Vansteenkiste¹², D. De Ruyscher¹⁶, ¹Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ²Vall d'Hebron Institute of Oncology, Barcelona, ES, ³University of Athens, Athens, GR, ⁴Ludwig Maximilian University of Munich (LMU), Medizinische Klinik and Poliklinik V, Munich, DE, ⁵University Hospital Zürich, Zurich, CH, ⁶Hospital Virgen De La Salud, Toledo, ES, ⁷Institut Catala d'Oncologia (ICO), Barcelona, ES, ⁸Amsterdam University Medical Center, Amsterdam, NL, ⁹Clinic Hirslanden, Zurich, CH, ¹⁰Kantonsspital Winterthur, Winterthur, CH, ¹¹Vall d'Hebron Institute of Oncology and University Hospital, Barcelona, ES, ¹²University Hospital KU Leuven, Leuven, BE, ¹³Frontier Science Foundation Hellas, Athens, GR, ¹⁴European Thoracic Oncology Platform (ETOP), Bern, Switzerland, Bern, CH, ¹⁵ETOP - European Thoracic Oncology Platform, Bern, CH, ¹⁶Maastro Clinic, Maastricht, NL

08:50 - 08:50 **1458PD - Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: 10-year follow-up of West Japan Thoracic Oncology Group WJTOG0105**

Y. Zenke¹, M. Tsuboi¹, Y. Chiba², M. Satouchi³, S. Mitsuoka⁴, J. Shimizu⁵, H. Daga⁶, D. Fujimoto⁷, M. Mori⁸, T. Aoki⁹, T. Sawa¹⁰, S. Omori¹¹, H. Saka¹², Y. Iwamoto¹³, M. Okuno¹⁴, T. Hirashima¹⁵, K. Kshiwabara¹⁶, M. Tachihara¹⁷, N. Yamamoto¹⁸, K. Nakagawa¹⁹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Kindai University Faculty of Medicine, Osaka-sayama, JP, ³Hyogo Cancer Center, Hyogo, JP, ⁴Osaka City University Medical School, Osaka, JP, ⁵Aichi Cancer Center Hospital, Nagoya, JP, ⁶Osaka City General Hospital, Osaka, JP, ⁷Kobe City Medical Center General Hospital, Kobe, JP, ⁸National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, JP, ⁹okai University School of Medicine, Kanagawa, JP, ¹⁰Gifu Municipal Hospital, Gifu, JP, ¹¹Shizuoka Cancer Center, Shizuoka, JP, ¹²National Hospital Organization Nagoya Medical Center, Nagoya, JP, ¹³Hiroshima City Hospital, Hiroshima, JP, ¹⁴Okazaki City Hospital, Aichi, JP, ¹⁵Osaka Prefectural Habikino Hospital, Habikino, JP, ¹⁶Kumamoto Regional Medical Center, Kumamoto, JP, ¹⁷Kobe University Graduate School of Medicine,

Kobe, JP, ¹⁸Wakayama Medical University, Wakayama, JP, ¹⁹Kindai University School of Medicine, Osaka, JP

- 08:50 - 08:50 **1459PD - Efficacy of durvalumab in patients with Stage III NSCLC who experience pneumonitis (PACIFIC)**
J. Vansteenkiste¹, J. Naidoo², C. Faivre-Finn³, M. Özgüroğlu⁴, A. Villegas⁵, D. Daniel⁶, S. Murakami⁷, R. Hui⁸, K. Lee⁹, B. Cho¹⁰, K. Kubota¹¹, M. Taboada¹², C. Wadsworth¹³, P. Dennis¹⁴, S. Antonia¹⁵, ¹University Hospital KU Leuven, Leuven, BE, ²Johns Hopkins Bayview Center, Baltimore, US, ³The Christie NHS Foundation Trust, Manchester, GB, ⁴Istanbul University - School of Medicine, Istanbul, TR, ⁵Cancer Specialists of North Florida, Jacksonville, US, ⁶Tennessee Oncology, Chattanooga, US, ⁷Kanagawa Cancer Center, Yokohama, JP, ⁸Westmead Hospital and the University of Sydney, Sydney, AU, ⁹Chungbuk National University Hospital, Cheongju, KR, ¹⁰Yonsei Cancer Center, Seoul, KR, ¹¹Nippon Medical School Hospital, Tokyo, JP, ¹²AstraZeneca, Cambridge, GB, ¹³AstraZeneca, Alderley Park, GB, ¹⁴AstraZeneca, Gaithersburg, US, ¹⁵H. Lee Moffitt Cancer Center and Research Institute, Tampa, US
- 08:50 - 09:02 **Invited Discussant 1457PD, 1458PD and 1459PD**
- 09:02 - 09:10 **Q&A led by Discussant**
- 09:10 - 09:10 **One LBA TBC**
- 09:10 - 09:10 **One LBA TBC**
- 09:10 - 09:22 **Invited Discussant 2 LBAs TBC**
- 09:22 - 09:30 **Q&A led by Discussant**
- 09:30 - 09:30 **1740PD - Differential expression of B7-H4, VISTA, B7-H6, HHLA2, IDO-1, PD-L1 and CD8 in EGFR mutant and wild-type lung adenocarcinoma**
S. Yu, M. Shi, J. Feng, Jiangsu Cancer Hospital, Nanjing, CN
- 09:30 - 09:30 **1741PD - Randomized phase II trial of CODE or AP after chemoradiotherapy for LD-SCLC: long-term survival and toxicity analysis**
I. Sekine¹, H. Harada², N. Yamamoto³, M. Wakabayashi³, H. Murakami², K. Goto⁴, N. Nogami⁵, T. Seto⁶, F. Oshita⁷, H. Okamoto⁸, H. Tanaka⁹, T. Tamura¹⁰, S. Ishikura¹¹, Y. Ohe³, ¹University of Tsukuba Hospital, Tsukuba, JP, ²Shizuoka Cancer Center, Nagaizumi, JP, ³National Cancer Center Hospital, Tokyo, JP, ⁴National Cancer Center Hospital East, Kashiwa, JP, ⁵National Hospital Organization Shikoku Cancer Center, Matsuyama, JP,

⁶National Kyushu Cancer Center, Fukuoka, JP, ⁷Kanagawa Cancer Center, Yokohama, JP, ⁸Yokohama Municipal Citizen's Hospital, Yokohama, JP, ⁹Niigata Cancer Center Hospital, Niigata, JP, ¹⁰St. Luke's International Hospital, Tokyo, JP, ¹¹Nagoya City University Graduate School of Medical Sciences, Nagoya, JP

09:30 - 09:30 **1742PD - Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving 1st line chemotherapy plus atezolizumab**

D. Daniel¹, V. Kuchava², I. Bondarenko³, O. Ivashchuk⁴, D. Spigel⁵, A. Dasgupta⁶, S. Reddy⁷, T. Melkadze⁸, J. Jaal⁹, I. Kudaba¹⁰, L. Hart¹¹, A. Matitashvili¹², K. Koynov¹³, Z. Yang¹⁴, S. Wolfe¹⁴, R. Malik¹⁵, S. Morris¹⁴, J. Antal¹⁶, J. Goldschmidt¹⁷, ¹Sarah Cannon Research Institute, Tennessee Oncology-Chattanooga, Chattanooga, US, ²National Cancer Center of Georgia (NCCG), Tbilisi, GE, ³Dnipropetrovsk city multidisciplinary clinical hospital №4, Dnipro, UA, ⁴Chernivtsi Regional Clinical Oncology Center, Chernivtsi, UA, ⁵Sarah Cannon Research Institute, Tennessee, US, ⁶Millennium Oncology, Houston, TX, US, ⁷Northside Hospital, Inc, Atlanta, US, ⁸Research Institute of Clinical Medicine, Tbilisi, GE, ⁹Tartu University Hospital, Tartu, EE, ¹⁰Latvian Oncology Center Rakus Gailezers, Riga, LV, ¹¹Florida Cancer Specialists, Fort Myers, US, ¹²Mardaleishvili medical centre, Tbilisi, GE, ¹³Serdika Hospital / Serdika Medical Center, Sofia, BG, ¹⁴G1 Therapeutics, Research Triangle Park, US, ¹⁵G1 Therapeutics, Inc, Research Triangle Park, US, ¹⁶G1 Therapeutics, Inc., Research Triangle Park, US, ¹⁷Blue Ridge Cancer Center, Blacksburg, US

09:30 - 09:42 **Invited Discussant 1740PD, 1741PD and 1742PD**

09:42 - 09:50 **Q&A led by Discussant**

08:30 - 10:00 **Type: Special symposium** **Pamplona Auditorium (Hall 2)**
Title: DNA damage response modification as a therapeutic strategy in head and neck cancer
 Chair(s): Irene Brana, ES

08:30 - 08:30 **Session DOI**

08:30 - 08:35 **Introduction**

I. Brana, Vall d'Hebron University Hospital, Barcelona, ES

08:35 - 08:55 **Synthetic lethal approaches to enhancing chemotherapy and radiotherapy**

E. Deutsch, Institut Gustave Roussy, Villejuif, FR

08:55 - 09:15 **Clinical trials of ATR inhibition**

M. Dillon, The Institute of Cancer Research, London, London, GB

09:15 - 09:35 **Nucleic acid sensing as a driver of tumour immunogenicity**

K. Harrington, Institute of Cancer Research ICR, London, GB

09:35 - 09:55 **Windows of opportunity studies and basket trials on DNA damage modifiers**

I. Brana, Vall d'Hebron University Hospital, Barcelona, ES

09:55 - 10:00 **Conclusions and perspectives**

08:30 - 09:50 **Type: Poster Discussion session** **Cordoba Auditorium (Hall 7)**
Title: Poster Discussion - Breast cancer, metastatic

08:30 - 08:30 **Session DOI**

08:30 - 08:30 **306PD - PIK3CA Alterations in Metastatic Breast Cancer (mBC)**

J. Albanell¹, D. Casadevall¹, E. Sokol², L. Albacker², J. Elvin², J.-A. Vergilio², J.K. Killian², N. Ngo², D. Lin², S. Ramkissoon², E. Severson², S. Ali², A. Schrock², J. Chung², P. Reddy², V. Miller², B. Alexander², K. Mcgregor², J. Ross³, B. Leyland-Jones⁴, ¹University Hospital del Mar, Barcelona, ES, ²Foundation Medicine, Cambridge, US, ³Albany Medical Center, Albany, US, ⁴Avera Cancer Institute, Sioux Falls, US

08:30 - 08:30 **307PD - Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: an exploratory analysis of the PADA-1 trial**

F.-C. Bidard¹, C. Callens¹, B. Pistilli², F. Dalenc³, T. De La Motte Rouge⁴, R. Sabatier⁵, J.-S. Frenel⁶, S. Ladoire⁷, C. Dubot⁸, J.-M. Ferrero⁹, F. Clatot¹⁰, D. Nierges¹¹, S. Everhard¹², J. Lemonnier¹³, I. Bieche¹, A. Pradines¹⁴, J.-Y. Pierga¹, F. Berger¹⁵, T.

Bachelot¹⁶, S. Delaloge¹⁷, ¹Institut Curie, Paris, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Centre Claudius-Regaud, Toulouse, FR, ⁴Centre Eugene - Marquis, Rennes, FR, ⁵Institute Paoli Calmettes, Marseille, FR, ⁶ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁷Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁸Hôpital René Huguenin - Institut Curie, St. Cloud, FR, ⁹Centre Anticancer Antoine Lacassagne, Nice, FR, ¹⁰Centre Henri Becquerel, Rouen, FR, ¹¹Hôpitaux privé de Metz - Site HBI, Metz, FR, ¹²UNICANCER, Paris, FR, ¹³Unicancer, Paris, FR, ¹⁴IUCT, Toulouse, FR, ¹⁵Institut Curie, Saint Cloud, FR, ¹⁶Centre Léon Bérard, Lyon, FR, ¹⁷Gustave Roussy, Villejuif, FR

08:30 - 08:40 **Invited Discussant 306PD and 307PD**

08:40 - 08:50 **Q&A led by Discussant**

08:50 - 08:50 **One LBA TBC**

08:50 - 08:50 **308PD - Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial**

Y.-S. Lu¹, A. Bardia², R. Vázquez³, M. Colleoni⁴, P. Wheatley-Price⁵, Y.-H. Im⁶, G. Babu⁷, D. Tripathy⁸, B. Lanoue⁹, D. Chandiwana⁹, A. Ridolfi¹⁰, G. Hughes¹¹, J.P. Zarate¹², I. Gounaris¹¹, N. Harbeck¹³, ¹National Taiwan University Hospital, Taipei, TW, ²Massachusetts General Hospital, Boston, US, ³Institut Català d'Oncologia, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, ES, ⁴Istituto Europeo di Oncologia, Milan, IT, ⁵The Ottawa Hospital Regional Cancer Centre, Ottawa, CA, ⁶Sungkyunkwan University School of Medicine, Seoul, KR, ⁷Kidwai Memorial Institute of Oncology, Bangalore, IN, ⁸The University of Texas MD Anderson Cancer Center, Houston, US, ⁹Novartis, East Hanover, US, ¹⁰Novartis Pharmaceuticals Corporation, Rueil-Malmaison, FR, ¹¹Novartis, Basel, CH, ¹²Novartis, US, ¹³Ludwig Maximilians University - Grosshadern, Munich, DE

08:50 - 09:00 **Invited Discussant 308PD and one LBA TBC**

09:00 - 09:10 **Q&A led by Discussant**

09:10 - 09:10 **309PD - Efficacy and Safety of First China-Manufactured Trastuzumab Biosimilar HLX02 for Metastatic Breast Cancer: A Phase 3 Trial**

B. Xu¹, Q. Zhang², T. Sun³, W. Li⁴, Y. Teng⁵, X. Hu⁶, I. Bondarenko⁷, H. Adamchuk⁸, L. Zhang⁹, D. Trukhin¹⁰, B. Li¹¹, B. Shan¹¹, J. Cheng¹¹, T. Peng¹¹, W. Jiang¹², S. Liu¹¹, X. Zhang¹¹, Q. Wang¹¹, E. Liu¹³, A. Luk¹¹, ¹Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, ²Harbin Medical University Cancer Hospital, Harbin, CN, ³Liaoning Cancer Hospital and Institution, Liaoning, CN, ⁴The first Bethune Hospital of

Jilin University, Changchun, CN, ⁵The first hospital of China Medical University, Shengyang, CN, ⁶Fudan University Shanghai Cancer Center, Shanghai, CN, ⁷CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipro, UA, ⁸CI Kryvyi Rih Oncological Dispensary of DRC, Dnipropetrovsk, UA, ⁹Yantai Yuhuangding Hospital, Yantai, CN, ¹⁰Odesa Regional Oncologic Dispensary, Odesa, UA, ¹¹Shanghai Henlius Biotech, Inc., Shanghai, CN, ¹²Shanghai Henlius Biotech, Inc., Shanghai, CN, ¹³Henlix Biotech, Inc., Taipei, TW

09:10 - 09:10 **310PD - The importance of primary surgery in patients with de novo stage IV BC survived at least 5- Year; Protocol MF07-01 Randomized Clinical Trial.**

V. Ozmen¹, S. Ozbas², H. Karanlik³, M. Muslumanoglu⁴, A. Igci⁴, Z. Canturk⁵, Z. Utkan⁵, C. Ozaslan⁶, T. Evrensel⁷, C. Uras⁸, E. Aksaz⁹, A. Soyder¹⁰, U.M. Ugurlu¹¹, C. Col¹², N. Cabioglu⁴, B. Bozkurt⁶, A. Uzunkoy¹³, E. Sezgin¹⁴, G. Gurleyik¹⁵, A. Soran¹⁶, ¹Istanbul University - Faculty of Medicine, Istanbul, TR, ²Guyen Hospital, Ankara, TR, ³Istanbul University Institute of Oncology, Istanbul, TR, ⁴Istanbul University Istanbul Faculty of Medicine, Istanbul, TR, ⁵Kocaeli University Medical School, Kocaeli, TR, ⁶Ankara Oncology Hospital, Ankara, TR, ⁷Uludag University Medical School, Bursa, TR, ⁸Acibadem University, Istanbul, TR, ⁹MAMER, Bursa, TR, ¹⁰Adnan Menderes University School of Medicine, Aydin, TR, ¹¹Marmara University Medical School, Istanbul, TR, ¹²Izzet Baysal University, Bolu, TR, ¹³Harran University, SanliUrfa, TR, ¹⁴Ege University, Izmir, TR, ¹⁵Numune Hospital, Istanbul, TR, ¹⁶University of Pittsburgh, Pittsburgh, US

09:10 - 09:20 **Invited Discussant 309PD and 310PD**

09:20 - 09:30 **Q&A led by Discussant**

09:30 - 09:30 **311PD - Leuprorelin (LEUP) combined with Letrozole (LET) with/without Everolimus (EVE) in Ovarian suppressed premenopausal women with hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC): Primary analysis of LEO Trial (NCT02344550)**

J. Jeong¹, J.E. Kim¹, J.-H. Ahn¹, K.H. Jung¹, S.-J. Koh², J. Cheon², J. Sohn³, G.M. Kim⁴, K.S. Lee⁵, I.H. Park⁵, S.H. Sim⁵, S.-B. Kim⁶, ¹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ²Ulsan University Hospital, Ulsan, KR, ³Yonsei University, Seoul, KR, ⁴Yonsei Cancer Center Yonsei University, Seoul, KR, ⁵National Cancer Center, Goyang-Si, KR, ⁶Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR

09:30 - 09:30 **One LBA TBC**

09:30 - 09:40 **Invited Discussant 311PD and one LBA TBC**

09:40 - 09:50 **Q&A led by Discussant**

08:30 - 09:45 **Type: Poster Discussion session** **Malaga Auditorium (Hall 5)**
Title: Poster Discussion - Genitourinary tumours, prostate

08:30 - 08:30 **Session DOI**

08:30 - 08:30 **One LBA TBC**

08:30 - 08:30 **845PD - CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors**
E. Antonarakis¹, P. Isaacsson Velho², N. Agarwal³, V. Sacristan Santos³, B. Maughan³, R. Pili⁴, N. Adra⁴, C. Sternberg⁵, P. Vlachostergios⁵, S. Tagawa⁶, A. Bryce⁷, A. McNatty⁷, Z. Reichert⁸, R. Dreicer⁹, O. Sartor¹⁰, T. Lotan², M. Hussain¹¹, ¹Johns Hopkins University, Baltimore, US, ²Johns Hopkins University School of Medicine, Baltimore, US, ³Huntsman Cancer Institute, Salt Lake City, US, ⁴Indiana University School of Medicine, Indianapolis, US, ⁵Weill Cornell Medicine, New York, US, ⁶NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, ⁷Mayo Clinic/Scottsdale, Scottsdale, US, ⁸University of Michigan, Ann Arbor, US, ⁹University of Virginia Cancer Center, Charlottesville, US, ¹⁰Tulane University, New Orleans, US, ¹¹Northwestern University Feinberg School of Medicine, Chicago, US

08:30 - 08:30 **846PD - Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses**
W. Abida¹, D. Campbell², A. Patnaik³, B. Sautois⁴, J. Shapiro⁵, N. Vogelzang⁶, A. Bryce⁷, R. Mcdermott⁸, F. Ricci⁹, J. Rowe¹⁰, J. Zhang¹¹, A. Simmons¹², D. Despain¹², M. Dowson¹³, T. Golsorkhi¹², S. Chowdhury¹⁴, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²University Hospital Geelong, Geelong, AU, ³The University of Chicago, Chicago, US, ⁴Centre Hospitalier Universitaire Sart Tilman, Liège, BE, ⁵Cabrini Health, Malvern, AU, ⁶US Oncology Research c/o Comprehensive Cancer Crts of NV, Las Vegas, US, ⁷Mayo Clinic, Phoenix, US, ⁸Adelaide and Meath Hospital (Incorporating the National Children's Hospital), Dublin, IE, ⁹Institut Curie, Paris, FR, ¹⁰The University of Texas Health Science Center at Houston and Memorial Hermann Cancer Center, Houston, US, ¹¹Moffit Cancer Center, Tampa, US, ¹²Clovis Oncology, Inc., Boulder, US, ¹³Clovis Oncology UK Ltd., Cambridge, GB, ¹⁴Guy's and St. Thomas' Hospital NHS Trust, London, GB

08:30 - 08:30 **847PD - Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study**
J. De Bono¹, K. Fizazi², F. Saad³, N. Shore⁴, S. Sandhu⁵, N. Mehra⁶, M. Kolinsky⁷, G. Roubaud⁸, M. Özgüroğlu⁹, N. Matsubara¹⁰, C. Gedye¹¹, Y.D. Choi¹², C. Padua¹³, C. Goessl¹⁴, A. Kohlmann¹⁵, C. Corcoran¹⁶, C. Adelman¹⁷, A. Allen¹⁸, J. Burgents¹⁹, M. Hussain²⁰, ¹The Institute of Cancer Research (ICR), London, GB, ²Institut Gustave

Roussy, Villejuif, FR, ³Hospital St. Luc du CHUM, Montreal, CA, ⁴Medical Director, Myrtu Beach, US, ⁵Peter MacCallum Cancer Centre, Melbourne, AU, ⁶Radboud University Medical Center, Nijmegen, NL, ⁷University of Alberta Cross Cancer Institute, Edmonton, CA, ⁸Institute Bergonié, Bordeaux, FR, ⁹Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, TR, ¹⁰National Cancer Center East, Chiba, JP, ¹¹School of Medicine and Public Health, University of Newcastle, Callaghan, AU, ¹²Yonsei University College of Medicine, Seoul, KR, ¹³Cetus Medicina Oncológica, Betim, BR, ¹⁴BN ImmunoTherapeutics, Inc., Mountain View, US, ¹⁵AstraZeneca UK, Royston, GB, ¹⁶AstraZeneca UK, Cambridge, GB, ¹⁷AstraZeneca, Cambridge, GB, ¹⁸AstraZeneca, Gaithersburg, US, ¹⁹Merck, Sharpe & Dohme NA, Kenilworth, US, ²⁰Northwestern University Feinberg School of Medicine, Chicago, US

08:30 - 08:45 **Invited Discussant 845PD, 846PD, 847PD and one LBA TBC**

08:45 - 08:55 **Q&A led by Discussant**

08:55 - 08:55 **One LBA TBC**

08:55 - 08:55 **848PD - Phase II Study of Pembrolizumab with Enzalutamide (Enz) in Metastatic, Castration Resistant Prostate Cancer (mCRPC): 30 patient expansion with examination of tumor infiltrating immune cells and fecal microbiota**

J. Graff¹, A. Moran², R. Slottke¹, G. Thomas², J. Alumkal², R. Thompson², M. Wood², L. Peiffer³, R. Bergan², K. Sfanos³, T. Beer², ¹OHSU Knight Cancer Institute, Portland, US, ²Oregon Health & Science University, Portland, US, ³Johns Hopkins University, Baltimore, US

08:55 - 08:55 **849PD - Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)**

S. Tagawa¹, J. Osborne², A. Hackett², M. Niaz², V. Cooley², P. Christos², P. Vlachostergios³, C. Thomas², L. Gracey², H. Beltran⁴, A. Molina¹, D.M. Nanus³, J. Babich², S. Vallabhajosula², O. Sartor⁵, K. Ballman², N. Bander², ¹NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, ²Weill Cornell Medical College, New York, US, ³Weill Cornell Medicine, New York, US, ⁴Dana Farber Cancer Institute and Harvard Medical School, Boston, US, ⁵Tulane University, New Orleans, US

08:55 - 08:55 **One LBA TBC**

08:55 - 09:10 **Invited Discussant 448PD, 449PD and 2 LBAs TBC**

09:10 - 09:20 **Q&A led by Discussant**

09:20 - 09:20 **One LBA TBC**

09:20 - 09:20 **850PD - Benefit of prostate radiotherapy for patients with lymph node only or < 4 bone metastasis and no visceral metastases: Exploratory analyses of metastatic site and number in the STAMPEDE “M1|RT comparison”**

S.A. Ali¹, A. Hoyle², N. James³, C. Parker⁴, C. Brawley⁵, G. Attard⁶, H. Douis⁷, M. Mason⁸, M. Parmar⁵, M. Sydes⁵, N. Clarke², ¹Genito-Urinary Cancer Research Group Manchester Cancer Research Centre The University of Manchester, Manchester, GB, ²The Christie and Salford Royal Hospitals, Manchester, GB, ³Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, Birmingham, GB, ⁴The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ⁵MRC Clinical Trials Unit at UCL, London, GB, ⁶University College London Cancer Institute, London, GB, ⁷University Hospital Birmingham, Birmingham, GB, ⁸Velindre Cancer Centre Velindre Hospital, Cardiff, GB

09:20 - 09:20 **One LBA TBC**

09:20 - 09:20 **851PD - Patient-Reported Outcomes (PROs) From TITAN: a Phase 3, Randomized, Double-Blind Study of Apalutamide (APA) Versus Placebo (PBO) Added to Androgen Deprivation Therapy (ADT) in Patients (pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)**

N. Agarwal¹, K. Mcquarrie², A. Bjartell³, S. Chowdhury⁴, A. Gomes⁵, B.H. Chung⁶, M. Özgüroğlu⁷, Á. Juárez Soto⁸, A. Merseburger⁹, H. Uemura¹⁰, D. Ye¹¹, R. Given¹², B. Miladinovic¹³, L. Dearden¹⁴, K. Deprince¹⁵, V. Naini¹⁶, A. Lopez-Gitlitz¹⁷, K. Chi¹⁸, ¹Huntsman Cancer Institute, Salt Lake City, US, ²Janssen Research & Development, Horsham, US, ³Skåne University Hospital Malmö, Malmö, SE, ⁴Guy's and St. Thomas' Hospital NHS Trust, London, GB, ⁵Liga Norteriograndense contra o cancer, Natal, BR, ⁶Yonsei University College of Medicine and Gangnam Severance Hospital, Seoul, KR, ⁷Istanbul University - School of Medicine, Istanbul, TR, ⁸Hospital Universitario de Jerez de la Frontera, Cadiz, ES, ⁹University SH.-Lübeck, Lübeck, DE, ¹⁰Kindai University Faculty of Medicine, Osaka, JP, ¹¹Fudan University - Shanghai Cancer Center (FUSCC), Shanghai, CN, ¹²Urology of Virginia, Eastern Virginia Medical School, Norfolk, US, ¹³Janssen Research & Development, San Diego, US, ¹⁴Janssen, High Wycombe, GB, ¹⁵Janssen EMEA Belgium, Beerse, BE, ¹⁶Janssen Research and Development, San Diego, US, ¹⁷Janssen Research & Development, Los Angeles, US, ¹⁸BC Cancer Agency - Vancouver, Vancouver, CA

09:20 - 09:35 **Invited Discussant 450PD, 451PD and 2 LBAs TBC**

09:35 - 09:45 **Q&A led by Discussant**

08:30 - 10:00	Type: Special symposium Title: Molecular tumour board: Where do we stand? What's next? Chair(s): Sabine Linn, NL; Fabrice André, FR	Bilbao Auditorium (Hall 5)
08:30 - 08:30	Session DOI	
08:30 - 08:50	Personalised oncogenomics: Is a precision approach necessary for every cancer or is there a therapy-driven bottleneck? <u>D. Huntsman</u> , British Columbia Cancer Agency, Vancouver, CA	
08:50 - 09:10	Building of a comprehensive clinical and molecular genomics database for patients with treatment-refractory cancers enrolled in clinical trials <u>P. Bedard</u> , Princess Margaret Cancer Center, Toronto, CA	
09:10 - 09:30	Liquid biopsy for diagnostic and longitudinal tracking of metastatic patients <u>G. Siravegna</u> , , US	
09:30 - 09:50	Tissue and liquid biopsies with MTB for phase 1 trial selection: Experience in the TARGET trial <u>M. Krebs</u> , The Christie NHS Foundation Trust, Manchester, GB	
09:50 - 10:00	General discussion	

08:30 - 10:00 **Type: Collaborative session** **Tarragona Auditorium (Hall 7)**
Title: ESMO-SIOG Collaborative session: Immunotherapy in older patients: Challenges and opportunities
Chair(s): Demetris Papamichael, CY; Siri Rostoft, NO

08:30 - 08:30 **Session DOI**

08:30 - 08:35 **Introduction**

D. Papamichael, Bank of Cyprus Oncology Centre, Nicosia, CY

08:35 - 09:00 **Frailty: Concept, biology, assessment and corrective measures**

S. Rostoft, Oslo University Hospital, Oslo, NO

09:00 - 09:25 **Innate and adaptive immunity in older patients**

09:25 - 09:50 **An overview of immunotherapy in older patients**

R. Kanavar, NCCS - National Cancer Centre Singapore, Singapore, SG

09:50 - 10:00 **Conclusions**

S. Rostoft, Oslo University Hospital, Oslo, NO

08:30 - 10:00 **Type: Special session** **Toledo Auditorium**
Title: Level playing field: Working for gender balance in oncology **(Hall 5)**

08:30 - 08:35 **Introduction**

08:35 - 08:45 **Keynote lecture**

08:45 - 09:00 **Lessons from other organisations: testimonies about “best practice” in the field of health**

09:00 - 09:05 **Conclusions**

09:05 - 09:40 **Discussion tables**

09:40 - 09:40 **National Initiatives: what can be done at the local level to promote gender equality?**

09:40 - 09:40 **How do you find a good mentor?**

09:40 - 09:40 **Time management: how to combine clinic and family?**

09:40 - 09:40 **Fostering individual resilience and dealing with burnout**

08:30 - 10:00	Type: Educational session Title: Immunotherapies: A revolution in cancer treatment, but are they accessible for all patients? Chair(s): Bettina Ryll, SE	Leon Auditorium (Hall 3)
08:30 - 08:30	Session DOI	
08:30 - 08:45	Immunotherapy 101 <u>C. Blank</u> , The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL	
08:45 - 09:00	Case study: NSCLC <u>S. Peters</u> , Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH	
09:00 - 09:15	State of play in the EU & beyond: Accessible or not? <u>A. Ilbawi</u> , WHO - World Health Organization, Geneva, CH	
09:15 - 09:30	Patient perspective <u>B. Ryll</u> , Melanoma Patient network Europe, Uppsala, SE	
09:30 - 09:45	Innovative Medicines Initiative: Calling for research on immunotherapies?	
09:45 - 10:00	Discussion	

08:45 - 09:45 **Type: Multidisciplinary session** **Valencia Auditorium (Hall 5)**
Title: Toxicity profiling of immunotherapy of cancer
Chair(s): John Haanen, NL

08:45 - 08:45 **Session DOI**

08:45 - 08:50 **Presentation of case/condition**

J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

08:50 - 09:05 **Life-threatening immune toxicities**

S. Champiat, Gustave Roussy, Villejuif, FR

09:05 - 09:10 **Presentation of case/condition**

J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

09:10 - 09:25 **Managing patients with irAEs unresponsive to corticosteroids**

C. Ribi, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

09:25 - 09:45 **General discussion**

08:45 - 09:45 **Type: Challenge your expert** **Alicante Auditorium (Hall 3)**
Title: Early diagnosis of neuroendocrine tumours (NETs): Increasing awareness and optimising diagnostic work up
Chair(s): Kjell Oeberg, SE

08:45 - 08:45 **Session DOI**

08:45 - 08:55 **Presentation by expert**

C. Toumpanakis, Royal Free Hospital School of Medicine, London, GB

08:55 - 09:45 **Discussion led by Chair**

K. Oeberg, University Hospital Uppsala Akademiska Sjukhuset, Uppsala, SE

08:45 - 09:45 **Type: Challenge your expert** **Cartagena Auditorium**
Title: Specificity of upper tract urothelial carcinoma **(Hall 3)**
biology and management
Chair(s): Javier Puente, ES

08:45 - 08:45 **Session DOI**

08:45 - 08:55 **Presentation by expert**

M. De Santis, Charité - Universitätsmedizin Berlin, Berlin, DE

08:55 - 09:45 **Discussion led by Chair**

J. Puente, Hospital Clinico Universitario San Carlos, Madrid, ES

08:45 - 09:45 **Type: Poster Discussion session** **Salamanca Auditorium (Hall**
Title: Poster Discussion 1 - Translational **3)**
research

08:45 - 08:45 **Session DOI**

08:45 - 08:45 **One LBA TBC**

08:45 - 08:45 **1876PD - Immunogenicity of BRCA1-deficient Ovarian Cancers is Driven through DNA Sensing and is Augmented by PARP Inhibition**

M. Bruand¹, D. Barras², M. Mina³, E. Lanitis⁴, C. Chong⁴, J. Dorier⁵, J. Walton⁶, M. Bassani-Sternberg⁴, L. Kandalaf⁷, I. Mcneish⁶, E. Swisher⁸, M. Delorenzi⁵, B. Ren⁹, G. Ciriello³, M. Irving⁴, S. Rusakiewicz¹⁰, P. Foukas⁷, F. Martinon³, D. Dangaj¹¹, G. Coukos⁴,
¹Ludwig Institute for Cancer Research - Lausanne Branch, Epalinges, CH, ²CHUV, Lausanne, CH, ³University of Lausanne, Lausanne, CH, ⁴Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, CH, ⁵University of Lausanne, Epalinges, CH, ⁶Imperial College London, London, GB, ⁷Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ⁸University of Washington/Seattle Cancer Care Alliance, Seattle, US, ⁹Ludwig Institute for Cancer Research and University of California, La Jolla, US, ¹⁰Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ¹¹Ludwig Center for Cancer Research of the UNIL (LICR@UNIL), Epalinges, CH

08:45 - 08:55 **Invited Discussant 1876PD and one LBA TBC**

08:55 - 09:05 **Q&A led by Discussant**

09:05 - 09:05 **One LBA TBC**

- 09:05 - 09:05 **89PD - Prognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: a systematic review and meta-analysis**
M. Mcnamara¹, T. Jacobs¹, M. Frizziero¹, R. Pihlak¹, A. Lamarca¹, R. Hubner², J. Valle¹, E. Amir³, ¹The Christie NHS Foundation Trust, Manchester, GB, ²Christie NHS Foundation Trust, Manchester, GB, ³Princess Margaret Cancer Center, Toronto, CA
- 09:05 - 09:05 **1877PD - Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset**
D. Backenroth¹, C. Shao², G. Li³, L. Huang⁴, S. Pruitt⁴, E. Castellanos¹, G. Frampton³, K. Carson¹, T. Snow¹, G. Singal⁵, D. Fabrizio³, B. Alexander³, F. Jin⁶, W. Zhou⁷, ¹Flatiron Health, New York, US, ²Merck & Co Inc, North Wales, US, ³Foundation Medicine, Cambridge, US, ⁴Merck & Co Inc, Rahway, US, ⁵Foundation Medicine, Boston, US, ⁶Merck Sharp & Dohme Corp. USA, Whitehouse Station, US, ⁷Merck & Co., Inc., Kenilworth, US
- 09:05 - 09:05 **90PD - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) in Patients With Non-Small Cell Lung Cancer (NSCLC)**
J. Baden¹, C. Zhao², J. Pratt³, S. Kirov¹, S. Pant⁴, A. Seminara³, G. Green³, S. Bilke², I. Deras², D. Fabrizio (Co-Senior Author)⁵, T. Pawlowski (Co-Senior Author)², ¹Bristol-Myers Squibb, Princeton, US, ²Illumina Inc, San Diego, US, ³Bristol-Myers Squibb, Lawrenceville, US, ⁴Bristol-Myers Squibb, Hopewell, US, ⁵Foundation Medicine Inc, Cambridge, US
- 09:05 - 09:15 **Invited Discussant 89PD, 1877PD and 90PD**
- 09:15 - 09:25 **Q&A led by Discussant**

09:00 - 10:00	Type: EONS session Title: EONS 12: Collaborative session EONS YCN-ESMO YOC: Translating the YCN survey results into clinical practice: What is the way forward? Chair(s): Merel van Klinken, NL	Oviedo Auditorium (CC5)
09:00 - 09:00	Session DOI	
09:00 - 09:20	Invited EONS <u>S. Parreira</u> , Hospital CUF Infante Santo, Lisbon, PT	
09:20 - 09:40	Assessing and addressing the needs of young oncology specialists - The “burn-out experience” of the ESMO Young Oncologist Committee <u>C. Oing</u> , UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE	
09:40 - 10:00	Discussion	
09:45 - 11:45	Type: Clinical Practice Guidelines Title: ESMO Clinical Practice Guidelines 1 Chair(s): George Pentheroudakis, GR; Cristiana Sessa, CH	Granada Auditorium (Hall 3)
09:45 - 09:45	Session DOI	
09:45 - 09:55	Introduction <u>G. Pentheroudakis</u> , University Hospital of Ioannina, Ioannina, GR	
09:55 - 10:05	Questionnaire <u>C. Sessa</u> , EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH	
10:05 - 10:15	Stage III ovarian cancer, BRCA wild type germline and somatic, platinum-sensitive relapse and molecular profiling <u>I. Tsibulak</u> , Medical University of Innsbruck, Innsbruck, AT	
10:15 - 10:25	Discussion <u>M.R. Mirza</u> , Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK	
10:25 - 10:30	Q&A	
10:30 - 10:40	Metastatic NSCLC: Immunotherapy	

R. Ferrara, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

10:40 - 10:50 **Discussion**

N. Reguart, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

10:50 - 10:55 **Q&A**

10:55 - 11:05 **Metastatic renal cancer**

R. Pereira Mestre, IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH

11:05 - 11:15 **Discussion**

T. Powles, St. Bartholomew's Hospital, London, GB

11:15 - 11:20 **Q&A**

11:20 - 11:30 **Urothelial cancer: Bladder-preserving strategies followed by systemic relapse**

B. Szabados, Barts Cancer Institute-Queen Mary University of London, London, GB

11:30 - 11:40 **Discussion**

S.F. Shariat, Medizinische Universitaet Wien, Vienna, AT

11:40 - 11:45 **Q&A**

10:15 - 11:45 **Type: Special symposium** **Barcelona Auditorium**
Title: Tackling the diversity of triple negative early breast cancer (TNBC) **(Hall 2)**
Chair(s): Rebecca Dent, SG; Veronique Dieras, FR

10:15 - 10:15 **Session DOI**

10:15 - 10:20 **Introduction**

R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

10:20 - 10:35 **Getting to grips with the biology of TNBC**

C. Denkert, Uniklinikum Giessen und Marburg, Marburg, DE

10:35 - 10:50 **Neoadjuvant vs adjuvant approaches in early TNBC**

J. Cortés, Vall d'Hebron University Hospital, Barcelona, ES

10:50 - 11:05 **PARP inhibitors and DNA - damaging cytotoxic**

V. Dieras, Centre Eugene - Marquis, Rennes, FR

11:05 - 11:20 **Should we incorporate immunotherapy in early breast cancer?**

R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

11:20 - 11:35 **Future directions in TNBC early breast cancer trials**

S. Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

11:35 - 11:45 **Conclusions and perspectives**

V. Dieras, Centre Eugene - Marquis, Rennes, FR

10:15 - 11:45 **Type: Proffered Paper session** **Madrid Auditorium**
Title: Proffered Paper 2 - Gastrointestinal tumours, non- **(Hall 2)**
colorectal

10:15 - 10:15 **Session DOI**

10:15 - 10:27 **One LBA TBC**

10:27 - 10:39 **One LBA TBC**

10:39 - 10:54 **Invited Discussant 2 LBAs TBC**

10:54 - 11:06 **One LBA TBC**

11:06 - 11:18 **One LBA TBC**

11:18 - 11:30 **One LBA TBC**

11:30 - 11:45 **Invited Discussant 3 LBAs TBC**

10:15 - 11:45 **Type: Educational session** **Sevilla Auditorium**
Title: Genomic tumour boards towards delivering a better **(Hall 2)**
prostate cancer
Chair(s): Joaquin Mateo, ES; Mark Rubin, CH

10:15 - 10:15 **Session DOI**

10:15 - 10:20 **Introduction**

M. Rubin, University of Bern, Bern, CH

10:20 - 10:40 **Setting up genomic tumour boards: What can be done and what needs to be done?**

S. Tomlins, University of Michigan, Ann Arbor, US

10:40 - 11:00 **How genomic data can result in the better delivery of prostate cancer care and research**

J. De Bono, The Institute of Cancer Research (ICR), London, GB

11:00 - 11:20 **Homogenising genomic reports: What clinicians need to know**

M. Rubin, University of Bern, Bern, CH

11:20 - 11:40 **Managing incidental germline findings: Ethical and practical challenges**

R. Eeles, Royal Marsden Hospital Institute of Cancer Research, Sutton, GB

11:40 - 11:45 **Conclusions and perspectives**

J. Mateo, Vall d'Hebron University Hospital, Barcelona, ES

10:15 - 11:45	Type: Educational session Title: DNA repair: From basic science to the clinic and back Chair(s): Thomas Helleday, SE; Ivan Dikic, DE	Pamplona Auditorium (Hall 2)
10:15 - 10:15	Session DOI	
10:15 - 10:40	Exploiting DNA-repair vulnerabilities in cancer therapy <u>S. Jackson</u> , Gurdon Institute - Wellcome Trust/Cancer Research UK, Cambridge, GB	
10:40 - 11:05	DNA repair enzymes as anti-cancer drug targets <u>T. Halazonetis</u> , University of Geneva - Fondation Pour Recherches Medicales, Geneva, CH	
11:05 - 11:30	MTHFD2 as a target in leukemia <u>T. Helleday</u> , Karolinska Institutet Innovations AB, Stockholm, SE	
11:30 - 11:45	Discussion	

10:15 - 11:45	Type: Special symposium Title: Glioblastoma treatment: Where should the future lead? Chair(s): Nicolaus Andratschke, CH; Emilie Le Rhun, FR	Malaga Auditorium (Hall 5)
10:15 - 10:15	Session DOI	
10:15 - 10:20	Introduction <u>E. Le Rhun</u> , Roger Salengro Hospital, Lille, FR	
10:20 - 10:40	Antibody drug conjugates in neuro-oncology: A new road? <u>M. Van Den Bent</u> , Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL	
10:40 - 11:00	New developments in radiation oncology: Promise and limitations <u>N. Andratschke</u> , University Hospital Zürich, Zurich, CH	
11:00 - 11:20	Improving by combining old agents? <u>U. Herrlinger</u> , , US	
11:20 - 11:40	Cancer stem cells: Are they a valid therapeutic target? <u>S. Niclou</u> , Luxembourg institute of Health, Luxembourg, LU	
11:40 - 11:45	Conclusions and perspectives <u>N. Andratschke</u> , University Hospital Zürich, Zurich, CH	

10:15 - 11:45	Type: Special session Title: Practicing oncology in elderly cancer patients Chair(s): Hendrik van Halteren, NL; Etienne Brain, FR	Alicante Auditorium (Hall 3)
10:15 - 10:15	Session DOI	
10:15 - 10:20	Introduction <u>H. Van Halteren</u> , Adrz-Admiraal de Ruijter Hospital-Goes, Goes, NL	
10:20 - 10:30	Case presentation: Frailty assessment in daily practice and opportunities for frailty reversal <u>H. Van Halteren</u> , Adrz-Admiraal de Ruijter Hospital-Goes, Goes, NL	
10:30 - 10:45	Discussion <u>E. Brain</u> , Hôpital René Huguenin - Institut Curie, St. Cloud, FR	
10:45 - 10:55	Case presentation: Shared decision making: How can we explore the patients' needs/expectations and jointly collaborate a tailor-made plan? How can we keep the SDM machine rolling throughout the treatment process? <u>H. Van Halteren</u> , Adrz-Admiraal de Ruijter Hospital-Goes, Goes, NL	
10:55 - 11:10	Discussion <u>S. Rostoft</u> , Oslo University Hospital, Oslo, NO	
11:10 - 11:20	Case presentation: Treatment compliance, interaction between oncolytic and other medications, how to best balance treatment toxicity and benefit <u>H. Van Halteren</u> , Adrz-Admiraal de Ruijter Hospital-Goes, Goes, NL	
11:20 - 11:35	Discussion <u>E. Brain</u> , Hôpital René Huguenin - Institut Curie, St. Cloud, FR	
11:35 - 11:45	Conclusion <u>E. Brain</u> , Hôpital René Huguenin - Institut Curie, St. Cloud, FR	

10:15 - 11:45 **Type: EONS session** **Oviedo Auditorium (CC5)**
Title: EONS 12: Cancer nursing workforce issues
 Chair(s): Patrick Crombez, BE

10:15 - 10:15 **Session DOI**

10:15 - 10:30 **Cancer nursing at the sharp end of care: How can we keep passion for our work?**
L. Smeds Alenius, Karolinska Institutet Innovations AB, Stockholm, SE

10:30 - 10:45 **Decision making in cancer nursing**
E. Trigoso Arjona, Hospital Universitari i Politècnic La Fe, Valencia, ES

10:45 - 11:00 **How to improve collaboration between experienced and novice cancer nurses**
M. Van Klinken, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

11:00 - 11:15 **Cancer nursing workforce issues**
P. Crombez, Institute Jules Bordet, Brussels, BE

11:15 - 11:30 **CN107 - Work related empowerment and collaboration in multiprofessional cancer centre**
V. Sulosaari¹, P. Ahonen¹, H. Heikkilä², A. Jekunen³, H. Leino-Kilpi⁴, P. Rautava⁵, M. Rekunen⁵, M. Siekkinen⁵, M. Stolt⁴, T. Vahlberg⁴, L. Walta¹, ¹Turku University of Applied Sciences, Turku, FI, ²Finnish Institute of Occupational Health, Työterveyslaitos, FI, ³Vaasa Oncology Clinic, Vaasa, FI, ⁴University of Turku, Turku, FI, ⁵Turku University Hospital, Turku, FI

11:30 - 11:45 **Discussion**

10:15 - 11:45 **Type: Poster Discussion session** **Leon Auditorium (Hall 3)**
Title: Poster Discussion - Public policy

10:15 - 10:15 **Session DOI**

10:15 - 10:15 **1631PD - Clinical Benefit and Prices of Cancer Drugs in the US and Europe**
K. Vokinger¹, T. Hwang², A. Tibau³, T. Rosemann⁴, A. Kesselheim², ¹University Hospital Zurich - Institute of Neuropathology, Zurich, CH, ²Harvard Medical School, Boston, US, ³Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁴University of Zurich/University Hospital of Zurich, Zürich, CH

10:15 - 10:15 **1632PD - Determinants of the Cancer Drug Funding Process in Canada**
J. Gotfrit¹, J. Shin², R. Mallick², P. Wheatley-Price¹, ¹The Ottawa Hospital Regional

Cancer Centre, Ottawa, CA, ²University of Ottawa, Ottawa, CA

- 10:15 - 10:15 **1633PD - Biosimilar Substitution: European Prescriber Perspectives**
M. Reilly, Alliance for Safe Biologic Medicines, Alexandria, US
- 10:15 - 10:15 **1634PD - Cost avoided in drugs derived from participation in clinical trials in colorectal cancer**
L. Sánchez-Rubio Ferrández, N. Rodríguez Salas, E. Villamañán Bueno, G. Casado Abad, A. Sierra Muñoz, S. Feliú Torres, A. Herrero Ambrosio, Hospital Universitario La Paz, Madrid, ES
- 10:15 - 10:30 **Invited Discussant 1631PD, 6132PD, 1633PD and 1634PD**
- 10:30 - 10:37 **Q&A led by Discussant**
- 10:37 - 10:37 **1635PD - Accessibility and Affordability to Trastuzumab for Breast cancer patients: voices of the Global Oncology community from ONCOLLEGE 001 survey - part 2**
S. Altuna¹, D. Trapani², C. Lengyel³, B. Habeeb⁴, S. Hussain⁵, S. Mazher⁶, E. Elfaham⁷, A. Petrillo⁸, K. El Bairi⁹, S. Khan¹⁰, ¹Unidad Oncológica Molecular Venezuela, Caracas, VE, ²Istituto Europeo di Oncologia, Milan, IT, ³National Institute of Oncology Hungary, Budapest, HU, ⁴Shaqlaw Teaching Hospital, Erbil, IQ, ⁵King Abdulaziz Medical City, Riyadh, SA, ⁶Baptist health, Little Rock, US, ⁷Alexandria University Hospitals, Alexandria, EG, ⁸Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ⁹Hassan II Oncology Regional Center, Oujda, MA, ¹⁰BINOR Cancer Hospital, Bannu, PK
- 10:37 - 10:37 **1636PD - Analysis of 105.000 cancer patients; have they been discussed in oncologic multidisciplinary team meetings? A nationwide population-based study in the Netherlands**
J. Walraven¹, I. Desar², K. Hoeven, Van Der¹, K. Aben³, R. Hillegersberg, Van⁴, C. Rasch⁵, V. Lemmens⁶, R. Verhoeven⁷, ¹Radboudumc, Nijmegen, NL, ²Radboud University Medical Center, Nijmegen, NL, ³Netherlands Comprehensive Cancer Organization, Nijmegen, NL, ⁴University Medical Center Utrecht, Utrecht, NL, ⁵Leiden University Medical Center, Leiden, NL, ⁶Integraal Kankercentrum Nederland, Eindhoven, NL, ⁷Netherlands Comprehensive Cancer Organization, Eindhoven, NL
- 10:37 - 10:37 **1637PD - Reaching sustainable oncology care via the National Cancer Control Program (NCCP)**
B. Zakotnik¹, V. Zadnik¹, T. Žagar¹, M. Primic Žakelj¹, U. Ivanuš¹, T. Jerman¹, J. Maučec Zakotnik², D. Novak Mlakar², T. Kofol Bric², M. Kadivec¹, K. Jarm¹, ¹Institute of Oncology Ljubljana, Ljubljana, SI, ²National Institute of Public Health, Ljubljana, SI
- 10:37 - 10:52 **Invited Discussant 1635PD, 1636PD and 1637PD**

- 10:52 - 10:59 **Q&A led by Discussant**
- 10:59 - 10:59 **1638PD - Changing landscape of clinical cancer trials in Germany**
S. Burock¹, T. Füreder², S. Schauer¹, U. Keilholz¹, ¹Charité - Universitätsmedizin Berlin, Berlin, DE, ²Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT
- 10:59 - 10:59 **1639PD - Comparison between phase III randomized clinical trials and their preceding phase II studies.**
I. Lyra-Gonzalez¹, O. Espin-Garcia¹, M. Krzyzanowska¹, R. Jang², E. Elimova¹, ¹Princess Margaret Cancer Centre, Toronto, CA, ²Princess Margaret Cancer Center, Toronto, CA
- 10:59 - 10:59 **1640PD - Projecting overall survival data for health-economic models in oncology: do maturity levels impact uncertainty?**
I. Borget¹, S. Roze², N. Bertrand³, L. Eberst⁴, ¹Institut Gustave Roussy, Villejuif, FR, ²HEVA HEOR, LYON, FR, ³CHU Lille, Lille, FR, ⁴Centre Léon Bérard, Lyon, FR
- 10:59 - 11:14 **Invited Discussant 1638PD, 1639PD and 1640PD**
- 11:14 - 11:21 **Q&A led by Discussant**
- 11:21 - 11:21 **1641PD - Implementation Frameworks to effectively transition complex research interventions into clinical practice in Oncology, Nuclear Medicine, Diagnostic and Interventional Radiology; A scoping Systematic Review**
G. Delanerolle¹, L. Gelling², ¹Anglia Ruskin University, Cambridge, GB, ²Anglia Ruskin University, PT, GB
- 11:21 - 11:21 **1642PD - Measuring the cancer burden in Europe: the European Cancer Information System (ECIS)**
M. Bettio¹, R. Carvalho¹, N. Dimitrova¹, T. Dyba¹, M. Flego¹, F. Giusti¹, C. Martos¹, L. Neamtiu², N. Nicholson¹, G. Randi¹, C. Nicholl¹, ¹European Commission - Joint Research Centre, Ispra, IT, ²JRC - ISPRA, Ispra, IT
- 11:21 - 11:21 **1643PD - Association between socioeconomic factors and one-month mortality after cancer-directed surgery in solid tumors**
Z. Qiu¹, H. Zhou², W. Sun³, ¹The First Affiliated Hospital of Shantou University Medical college, Shantou, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN, ³The First Affiliated Hospital of Shantou University Medical College, Shantou, CN
- 11:21 - 11:36 **Invited Discussant 1641PD, 1642PD and 1643PD**

11:36 - 11:43 **Q&A led by Discussant**

10:30 - 11:30 **Type: Challenge your expert** **Cordoba Auditorium**
Title: How to choose between single agent and combination immunotherapy **(Hall 7)**
 Chair(s): John Haanen, NL

10:30 - 10:30 **Session DOI**

10:30 - 10:40 **Presentation by expert**

I. Melero, Clinica Universitaria de Navarra, Pamplona, ES

10:40 - 11:30 **Discussion led by Chair**

J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

10:30 - 11:30 **Type: Poster Discussion session** **Valencia Auditorium (Hall 5)**
Title: Poster Discussion - Gynaecological cancers

10:30 - 10:30 **Session DOI**

10:30 - 10:30 **995PD - Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola) - Phase III SOLO1 trial**

A. Oaknin¹, K. Moore², N. Colombo³, G. Scambia⁴, B.-G. Kim⁵, M. Friedlander⁶, A. Lisyanskaya⁷, A. Floquet⁸, A. Leary⁹, G. Sonke¹⁰, C. Gourley¹¹, S. Banerjee¹², A. Oza¹³, A. González-Martín¹⁴, C. Aghajanian¹⁵, W. Bradley¹⁶, E. Lowe¹⁷, R. Bloomfield¹⁸, P. Disilvestro¹⁹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Stephenson Oklahoma Cancer Center, Oklahoma, US, ³Istituto Europeo di Oncologia, Milan, IT, ⁴Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, IT, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁶Prince of Wales Clinical School UNSW, Sydney, AU, ⁷St Petersburg City Oncology Dispensary, St Petersburg, RU, ⁸Institute Bergonié, Bordeaux, FR, ⁹Gustave Roussy Cancer Center, INSERM U981, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Villejuif, FR, ¹⁰The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ¹¹Edinburgh Cancer Research UK Centre, Edinburgh, GB, ¹²Royal Marsden Hospital NHS Foundation Trust, London, GB, ¹³Princess Margaret Cancer Centre, University Health Network, Toronto, CA, ¹⁴Clínica Universidad de Navarra, Madrid, ES, ¹⁵Memorial Sloan-Kettering Cancer Center, New York, US, ¹⁶Froedtert and the Medical College of Wisconsin, Milwaukee, US, ¹⁷AstraZeneca, Gaithersburg, US, ¹⁸AstraZeneca, Cambridge, GB, ¹⁹Women & Infants Hospital, Providence, US

10:30 - 10:30 **996PD - Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation**

(BRCAm) in the Phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)

M. Friedlander¹, K. Moore², N. Colombo³, G. Scambia⁴, B.-G. Kim⁵, A. Oaknin⁶, A. Lisyanskaya⁷, A. Floquet⁸, A. Leary⁹, G. Sonke¹⁰, C. Gourley¹¹, S. Banerjee¹², A. Oza¹³, A. González-Martín¹⁴, C. Aghajanian¹⁵, W. Bradley¹⁶, E. Lowe¹⁷, R. Hettle¹⁸, E. Flood¹⁷, P. Disilvestro¹⁹, ¹Prince of Wales Hospital, Randwick, AU, ²Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, US, ³Istituto Europeo di Oncologia, Milan, IT, ⁴Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, IT, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁶Vall d'Hebron University Hospital, Barcelona, ES, ⁷St Petersburg City Oncology Dispensary, St Petersburg, RU, ⁸Institute Bergonié, Bordeaux, FR, ⁹Gustave Roussy Cancer Center, INSERM U981, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Villejuif, FR, ¹⁰The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ¹¹Edinburgh Cancer Research UK Centre, Edinburgh, GB, ¹²Royal Marsden Hospital NHS Foundation Trust, London, GB, ¹³Princess Margaret Cancer Centre, Toronto, CA, ¹⁴Clínica Universidad de Navarra, Madrid, ES, ¹⁵Memorial Sloan-Kettering Cancer Center, New York, US, ¹⁶Froedtert and the Medical College of Wisconsin, Milwaukee, US, ¹⁷AstraZeneca, Gaithersburg, US, ¹⁸PAREXEL Access, London, GB, ¹⁹Women & Infants Hospital, Providence, US

10:30 - 10:30 **1190PD - Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)**

Y. Drew¹, B. Kaufman², S. Banerjee³, A. Lortholary⁴, S.H. Hong⁵, Y.H. Park⁶, S. Zimmermann⁷, P. Roxburgh⁸, M. Ferguson⁹, R.H. Alvarez¹⁰, S. Domchek¹¹, C. Gresty¹², H.K. Angell¹², V. Rocher Ros¹³, K. Meyer¹³, M. Lanasa¹⁴, P. Herbolzheimer¹³, M. De Jonge¹⁵, ¹Northern Institute for Cancer Research University of Newcastle, Newcastle-upon-Tyne, GB, ²Sheba Medical Center, Tel Hashomer, IL, ³Royal Marsden Hospital NHS Foundation Trust, London, GB, ⁴Centre Catherine de Sienne, Nantes, FR, ⁵Seoul St Mary's Hospital, Catholic University of Korea, Seoul, KR, ⁶Samsung Medical Center, Seoul, KR, ⁷Lausanne University Hospital, University of Lausanne, Lausanne, CH, ⁸Beatson West of Scotland Cancer Centre, Glasgow, GB, ⁹NHS Tayside, Dundee, GB, ¹⁰Cancer Treatment Centers of America-Atlanta and Augusta University, Augusta, US, ¹¹Private Practice - Domchek, Philadelphia, US, ¹²AstraZeneca, Cambridge, GB, ¹³AstraZeneca, Gaithersburg, US, ¹⁴AstraZeneca USA, Gaithersburg, US, ¹⁵Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

10:30 - 10:30 **997PD - Validation of the Geriatric Vulnerability Score (GVS) in older ovarian cancer (oOC) patients: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study**

F. Tinquaut¹, G. Freyer², F. Pommeret³, L. Gladieff⁴, D. Lorusso⁵, M.A. Mouret Reynier⁶, V. D'Hondt⁷, D. Mollon-Grange⁸, A. Floquet⁹, S. Abadie Lacourtoisie¹⁰, P.E. Brachet¹¹, L. Stefani¹², F. Rousseau¹³, J.-S. Frenel¹⁴, F. Del Piano¹⁵, J. Herrstedt¹⁶, T. Warkus¹⁷, O. Tredan¹⁸, E. Pujade-Lauraine¹⁹, C. Falandry², ¹Institut de Cancérologie de la Loire Lucien Neuwirth, Saint-Priest-en-Jarez, FR, ²Centre Hospitalier Lyon Sud, Pierre Bénite, FR, ³Gustave Roussy - GINECO, VILLEJUIF, FR, ⁴Institut Universitaire du Cancer - Toulouse- Oncopole, Toulouse, FR, ⁵Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁶Centre Jean Perrin, Clermont-Ferrand, FR, ⁷ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ⁸Centre Hospitalier Intercommunal de Cornouaille, Quimper Cédex, FR, ⁹Institute Bergonié, Bordeaux, FR, ¹⁰Centre Paul Papin, Angers, FR,

¹¹Centre Francois Baclesse, Caen, FR, ¹²Centre Hospitalier Annecy Genevois - GINECO, PRINGY, FR, ¹³Institut Paoli Calmettes - GINECO, MARSEILL, FR, ¹⁴ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹⁵HOPITAUX DU LEMAN - GINECO, THONON-LES-BAINS, FR, ¹⁶University Hospital Zealand, Roskilde, DK, ¹⁷Centre Hospitalier de L'Université de Montréal - CHUM, Montréal, CA, ¹⁸Centre Léon Bérard, Lyon, FR, ¹⁹Groupe hospitalier Hôtel Dieu (AP-HP), Paris, FR

10:30 - 10:50 **Invited Discussant 995PD, 996PD, 1190PD and 997PD**

10:50 - 11:00 **Q&A led by Discussant**

11:00 - 11:00 **One LBA TBC**

11:00 - 11:00 **998PD - Analysis of tumor samples from SOLO1: frequency of BRCA specific loss of heterozygosity (LOH) and progression-free survival (PFS) according to homologous recombination repair deficiency (HRD)-LOH score**

C. Gourley¹, J. Brown², Z. Lai³, P. Lao-Sirieix⁴, C. Elks⁵, H. Mcgarvey², T. French², T. Milenkova⁶, R. Bloomfield², P. Rowe², D. Hodgson³, J.C. Barrett³, K. Moore⁷, P. Disilvestro⁸, E. Harrington², ¹Edinburgh Cancer Research UK Centre, Edinburgh, GB, ²AstraZeneca, Cambridge, GB, ³AstraZeneca, Boston, US, ⁴AstraZeneca UK, Melbourn, GB, ⁵AstraZeneca UK, Cambridge, GB, ⁶Astrazeneca, Macclesfield, GB, ⁷Stephenson Oklahoma Cancer Center, Oklahoma, US, ⁸Women & Infants Hospital, Providence, US

11:00 - 11:00 **999PD - Immune-related gene expression signatures (irGES) in patients (pts) with ovarian clear cell carcinomas (OCCC) - a multicenter analysis**

V. Heong¹, T.Z. Tan², J. Ye², M. Miwa³, D. Lim⁴, C. Herrington⁵, Y. Iida⁶, A. Okamoto⁷, J. Low⁸, J. Ng⁴, S.E. Lim⁹, Y.W. Lim¹⁰, C. Gourley⁶, K. Hasegawa³, D.S. Tan⁴, R. Huang¹¹, ¹NHG-National Healthcare Group-Tan Tock Seng Hospital, Singapore, SG, ²National University Singapore (NUS), singapore, SG, ³Saitama Medical University International Medical Center, Hidaka, JP, ⁴NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG, ⁵Edinburgh Cancer Research Centre, EHXR, GB, ⁶Edinburgh Cancer Research UK Centre, Edinburgh, GB, ⁷The Jikei University School of Medicine, Tokyo, JP, ⁸National University Cancer Institute, Singapore, Singapore, SG, ⁹National University Hospital, Singapore, SG, ¹⁰National University Cancer Institute Singapore (NCIS), Singapore, SG, ¹¹National Taiwan University, Taipei, TW

11:00 - 11:15 **Invited Discussant 998PD, 999PD and one LBA TBC**

11:15 - 11:25 **Q&A led by Discussant**

10:30 - 11:30 **Type: Multidisciplinary session** **Bilbao Auditorium (Hall 5)**
Title: Oligorecurrent and oligoprogressive NSCLC
Chair(s): Lizza Hendriks, NL

10:30 - 10:30 **Session DOI**

10:30 - 10:35 **Presentation of case/condition**

L. Hendriks, Maastricht University Medical Center (MUMC), Maastricht, NL

10:35 - 10:50 **The radiotherapist's perspective**

S. Senan, Vrije University Medical Centre (VUMC), Amsterdam, NL

10:50 - 11:05 **The surgeon's perspective**

R. Rami-Porta, Hospital Mutua de Terrassa, Terrassa, ES

11:05 - 11:20 **The medical oncologist's perspective**

M. O'Brien, Royal Marsden Hospital NHS Foundation Trust, London, GB

11:20 - 11:30 **General discussion**

10:30 - 11:30 **Type: Challenge your expert** **Tarragona Auditorium (Hall 7)**
Title: Improving the outcomes from anal cancer treatment: Radiotherapy strategies and systemic therapies
Chair(s): David Sebag-Montefiore, GB

10:30 - 10:30 **Session DOI**

10:30 - 10:45 **Presentation by expert**

D. Sebag-Montefiore, University of Leeds, Leeds, GB

10:45 - 11:00 **Presentation by expert**

D. Modest, Ludwig Maximilians University - Grosshadern, Munich, DE

11:00 - 11:30 **Discussion led by Chair**

D. Sebag-Montefiore, University of Leeds, Leeds, GB

10:30 - 11:30	Type: Multidisciplinary session Title: Radiation-associated sarcoma Chair(s): Rick L. Haas, NL	Cartagena Auditorium (Hall 3)
10:30 - 10:30	Session DOI	
10:30 - 10:35	Presentation of case/condition <u>R.L. Haas</u> , Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL	
10:35 - 10:50	The chameleon of chameleons: The good, the bad and the most challenging <u>S. George</u> , Dana-Farber Cancer Institute, Boston, US	
10:50 - 11:05	Contemplating being a fisherman <u>U. Kneser</u> , University of Heidelberg, Heidelberg, DE	
11:05 - 11:20	Our profession's worst nightmare <u>R.L. Haas</u> , Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL	
11:20 - 11:30	General discussion	

10:30 - 11:30 **Type: Multidisciplinary session** **Salamanca Auditorium (Hall 3)**
Title: Defining optimal response in myeloma
 Chair(s): Jesus San Miguel, ES

10:30 - 10:30 **Session DOI**

10:30 - 10:35 **Presentation of case/condition**
J. San Miguel, Clinica Universidad de Navarra, Salamanca, ES

10:35 - 10:50 **Molecular biology**
H. Avet-Loiseau, Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR

10:50 - 11:05 **Imaging**
S. Barrington, King's College London, London, GB

11:05 - 11:20 **Haematology**
J. San Miguel, Clinica Universidad de Navarra, Salamanca, ES

11:20 - 11:30 **General discussion**

11:00 - 11:45 **Type: Young Oncologist session** **Santander Auditorium**
Title: YO Brunch: Beyond PDFS: New endpoints in immuno-oncology **(Hall 3)**
 Chair(s): Kok Haw Jonathan Lim, GB; Laurids Poulsen, DK

11:00 - 11:00 **Session DOI**

11:00 - 11:30 **Beyond PDFS: New endpoints in immuno-oncology**
A. Marabelle, Institut Gustave Roussy, Villejuif, FR

11:30 - 11:45 **General discussion / Q&A**

12:00 - 12:45 **Type: Keynote lecture** **Madrid Auditorium (Hall 2)**
Title: RAS signalling and cancer
 Chair(s): Caroline Dive, GB

12:00 - 12:00 **Session DOI**

12:00 - 12:45 **Ras signalling and cancer**
 D. Bar-Sagi, , US

12:00 - 13:00 **Type: Poster Display session** **Poster Area (Hall 4)**
Title: Poster Display session 2

12:00 - 12:00 **Breast cancer, early stage**

12:00 - 12:00 **186P - Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: an exploratory analysis of the GIM2 trial.**

B. Conte¹, M. Bruzzone², M. Lambertini¹, F. Poggio², E. Blondeaux², M. De Laurentiis³, E. Valle⁴, F. Cognetti⁵, C. Nisticò⁶, S. De Placido⁷, M. Merlano⁸, T. Gamucci⁹, F. Montemurro¹⁰, M. Ceppi², L. Del Mastro¹, ¹IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ²Policlinico San Martino, Genova, IT, ³Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, ⁴Businco Hospital, Cagliari, IT, ⁵La Sapienza University, Rome, IT, ⁶Istituto Nazionale Tumori Regina Elena, Rome, IT, ⁷Azienda Universitaria Ospedaliera Federico II, Napoli, IT, ⁸Azienda Ospedaliera St. Croce e Carle, Cuneo, IT, ⁹Azienda Sanitaria Locale (ASL) Frosinone, Presidio Ospedaliero Servizi Sanitari (SS) Trinità, Sora, IT, ¹⁰Candiolo Cancer Institute, FPO-IRCCS, Torino, IT

12:00 - 12:00 **187P - High dose Neo-adjuvant chemotherapy in Triple-Negative breast cancer with evidence of homologous recombination deficiency (HRD).**

S. Vlieg¹, E. Van Werkhoven², I. Mandjes³, T. Westphal³, E. Lips², L. Mulder¹, C. Loo¹, N. Russel², M. Holtkamp³, M. Schot³, J. Baars², M. Karger², A. Honkoop⁴, M. Bos⁵, A. Imholz⁶, S. Vrijaldenhoven⁷, V. Dezentje³, P. Nederlof¹, S. Linn¹, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²The Netherlands Cancer Institute, Amsterdam, NL, ³The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁴Isala Klinieken, Zwolle, NL, ⁵ErasmusMC, Rotterdam, NL, ⁶Deventer Ziekenhuis, Deventer, NL, ⁷Medisch Centrum Alkmaar, Alkmaar, NL

12:00 - 12:00 **188P - Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials**

G. Werutsky¹, M. Untch², C. Hanusch³, P.A. Fasching⁴, J.-U. Blohmer⁵, S. Seiler⁶, C. Denkert⁷, H. Tesch⁸, C. Jackisch⁹, B. Gerber¹⁰, A. Schneeweiss¹¹, T. Link¹², J. Huober¹³, K. Rhiem¹⁴, V. Vladimirova⁶, V. Nekljudova⁶, S. Loibl⁶, ¹Latin American Cooperative

Oncology Group (LACOG), Porto Alegre, BR, ²Helios Klinikum Berlin Buch, Berlin, DE, ³Klinikum zum Roten Kreuz München, Germany, München, DE, ⁴University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, ⁵St. Gertrauden-Krankenhaus, Berlin, DE, ⁶German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, ⁷Uniklinikum Giessen und Marburg, Marburg, DE, ⁸Private practice - Dr. Hans Tesch, Frankfurt am Main, DE, ⁹Klinikum Offenbach GmbH, Offenbach am Main, DE, ¹⁰Universitätsfrauenklinik am Klinikum Südstadt, Rostock, DE, ¹¹University Hospital Heidelberg, Heidelberg, DE, ¹²Universitätsklinikum Dresden, Dresden, DE, ¹³Universitätsfrauenklinik Ulm, Ulm, DE, ¹⁴Uniklinik Köln, Köln, DE

12:00 - 12:00 **189P - Estimating radiotherapy-induced cardiovascular mortality in female breast cancer patients.**

M. De Ridder¹, T. Mulliez², ¹UZ Brussel, Brussels, BE, ²Institut Andrée Dutreix, Dunkerque, FR

12:00 - 12:00 **190P - 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)**

J. Stebbing¹, Y. Baranau², V. Baryash², A. Manikhas³, V. Moiseyenko⁴, G. Dzagnidze⁵, E. Zhavrid⁶, D. Boliukh⁷, D. Stroyakovskiy⁸, J. Pikiel⁹, A. Eniu¹⁰, D. Komov¹¹, S.J. Lee¹², M.J. Kim¹², S. Kim¹², S. Park¹², J.H. Bae¹², F. Esteva¹³, ¹Imperial College London, London, GB, ²Minsk City Clinical Oncological Dispensary, Minsk, BY, ³City Clinical Oncology Dispensary, St. Petersburg, RU, ⁴GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology), Saint Petersburg, RU, ⁵S. Khechinashvili University Clinic, Ltd., Tbilisi, GE, ⁶N.N. Alexandrov Research Institute, Minsk, BY, ⁷Vinnitsya Regional Clinical Oncology Dispensary, Vinnitsya, UA, ⁸Moscow City Oncology Hospital No. 62, Moscow, RU, ⁹Szpital Morski, Gdynia, PL, ¹⁰The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca, RO, ¹¹N.N. Blokhin Russian Cancer Research Center, Moscow, RU, ¹²Celltrion, Incheon, KR, ¹³Perlmutter Cancer Center, New York, US

12:00 - 12:00 **191P - Adjuvant chemotherapy in elderly breast cancer patients: pattern of use and impact on overall survival**

A. Berthelot¹, A. De Nonneville¹, J.-M. Classe², M. Cohen¹, F. Reyat³, C. Mazouni⁴, M.P. Chauvet⁵, A. Martinez⁶, N. Chopin⁷, E. Daraï⁸, C. Coutant⁹, R. Rouzier³, A.-S. Azuar¹⁰, P. Guimbergues¹¹, C. Tunon De Lara¹², R. Villet¹³, M. Bannier¹, A. Gonçalves¹⁴, G. Houvenaeghel¹, ¹Institute Paoli Calmettes, Marseille, FR, ²ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ³Institut Curie, Paris, FR, ⁴Gustave-Roussy Cancer Campus, Villejuif, FR, ⁵Institute Oscar Lambret, Lille, FR, ⁶IUCT Oncopole, Toulouse, FR, ⁷Centre Léon Berard, Lyon, FR, ⁸Hopital Tenon, Paris, FR, ⁹Centre Georges-François Leclerc (Dijon), Dijon, FR, ¹⁰CH de Grasse, Grasse, FR, ¹¹Institute Jean Perrin, Clermont-Ferrand, FR, ¹²Institute Bergonie, Bordeaux, FR, ¹³Hopital Diaconesses, Paris, FR, ¹⁴Institut Paoli Calmettes, Marseille, FR

12:00 - 12:00 **192P - Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): a propensity score-matched study.**

M.V. Dieci¹, C.A. Giorgi¹, G. Griguolo¹, S. Angelini², F. Miglietta², T. Giarratano¹, C. Falci¹, G. Faggioni³, G. Tasca¹, E. Mioranza¹, G. Vernaci¹, A. Menichetti¹, M. Mantiero¹,

E. Genovesi⁴, S. Frezzini⁵, T. Saibene¹, S. Michieletto¹, V. Guarneri¹, ¹Istituto Oncologico Veneto IRCCS, Padova, IT, ²University of Padova, Padova, IT, ³Ospedale dell'Angelo - Mestre, Venezia, IT, ⁴IIOV PADOVA, Padova, IT, ⁵University of Padua, School of Medicine, Padova, IT

12:00 - 12:00 **193P - Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): an epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)**

M. Williamson¹, A. Tomar², G.S. Jhuti³, C. Revil³, A. Kotzeva³, K. Gururaj², ¹Genentech, South San Francisco, US, ²ZS Associates International Inc., Frankfurt, DE, ³F. Hoffmann-La Roche Ltd, Basel, CH

12:00 - 12:00 **(Withdrawn)**

12:00 - 12:00 **195P - Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study**

H. Tesch¹, S. Loibl², K. Kast³, C. Jackisch⁴, V. Möbus⁵, S. Buchen⁶, M. Untch⁷, C. Hanusch⁸, S. Seiler², M. Weigel⁹, P.A. Fasching¹⁰, K. Rhiem¹¹, J. Huober¹², J.-U. Blohmer¹³, C. Solbach¹⁴, C. Denkert¹⁵, V. Nekljudova², T. Link³, A. Schneeweiss¹⁶, ¹Private practice - Dr. Hans Tesch, Frankfurt am Main, DE, ²German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, ³Universitätsklinikum Dresden, Dresden, DE, ⁴Klinikum Offenbach GmbH, Offenbach am Main, DE, ⁵Klinikum Frankfurt-Höchst, Frankfurt am Main, DE, ⁶Asklepio Paulinen Klinik Wiesbaden, Wiesbaden, DE, ⁷Helios Klinikum Berlin Buch, Berlin, DE, ⁸Klinikum zum Roten Kreuz München, Germany, München, DE, ⁹Leopoldina-Krankenhaus, Schweinfurt, Schweinfurt, DE, ¹⁰University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, ¹¹Uniklinik Köln, Köln, DE, ¹²Universitätsfrauenklinik Ulm, Ulm, DE, ¹³St. Gertrauden-Krankenhaus, Berlin, DE, ¹⁴Universitätsklinik Frankfurt, Frankfurt, DE, ¹⁵Uniklinikum Giessen und Marburg, Marburg, DE, ¹⁶University Hospital Heidelberg, Heidelberg, DE

12:00 - 12:00 **196P - The clinical impact of adjuvant dose-dense sequential chemotherapy (dds-CT) in patients with high-risk operable breast cancer (BC); pooled analysis of 6 clinical trials.**

E. Fountzilas¹, G.-A. Koliou², F. Zagouri², G. Pentheroudakis³, C. Christodoulou⁴, A. Koutras², D. Pectasides⁵, D. Bafaloukos⁴, E. Samantas⁶, G. Aravantinos², P. Papakostas⁵, A. Psyrris⁷, P. Kosmidis⁸, A. Koumariou⁷, E. Razis², H. Linardou⁴, A. Christopoulou², C. Karanikiotis⁹, H. Gogas¹⁰, G. Fountzilas², ¹Papageorgiou Hospital - Aristotle University of Thessaloniki, Thessaloniki, GR, ²Hellenic Cooperative Oncology Group (HeCOG), Athens, GR, ³University Hospital of Ioannina, Ioannina, GR, ⁴Metropolitan Hospital, Athens, GR, ⁵Hippokraton General Hospital, Athens, GR, ⁶General Oncological Hospital of Kifisia "Agiou Anargyroi", Kifisia, GR, ⁷Attikon University Hospital, Athens, GR, ⁸Hygeia Hospital, Marousi, GR, ⁹424 Army General Hospital, Thessaloniki, GR, ¹⁰Laiko General Hospital of Athens, Athens, GR

12:00 - 12:00 **197P - The efficacy of preoperative breast cancer chemotherapy without anti-HER2-targeted treatment - single center experience in setting of no**

reimbursement in Poland (2011-2015)

A. Badora-Rybicka¹, A. Polakiewicz-Gilowska¹, A. Leśniak¹, W. Bał², M. Kubeczko², K. Świdorska¹, M. Mianowska-Malec¹, B. Grandys¹, E. Stobiecka¹, E. Chmielik¹, A. Kuś¹, R. Tarnawski¹, M. Jarzab³, ¹Maria Skłodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, Gliwice, PL, ²Maria Skłodowska Curie MSC Memorial Cancer Institute in Gliwice, Gliwice, PL, ³Maria Skłodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, Gliwice, PL

12:00 - 12:00

198P - A Multicentre, International Neoadjuvant (NA), Randomized, Double-blind Phase III Trial comparing FULVESTRANT to a combination of FULVESTRANT and PALBOCICLIB in patients with operable Luminal Breast Cancer (SAFIA Trial)

J.-M. Nabholz¹, K. Alsaleh², A. Bounedjar³, M. Oukkal⁴, H. El-Zawahry⁵, K. Bouzid⁶, H. Abdel Razeq⁷, H. Mahfouf⁸, A. Bensalem⁹, A. Saadeddin¹⁰, T. Filali¹¹, B. Larbaoui¹², O. Abulkhair¹³, M. Al-Foheidi¹⁴, H. Boussen¹⁵, J. Ayari¹⁶, M. Ghosn¹⁷, N. Abdel-Aziz¹⁸, F. Dabouz¹⁹, S. Kullab²⁰, ¹King Saud University Medical City, Riyadh, SA, ²King Khalid University Hospital - King Saud University Medical City, Riyadh, SA, ³CHU Blida, Blida, DZ, ⁴CHU Beni-Messous, Algiers, DZ, ⁵National Cancer Institute-Cairo University, Cairo, EG, ⁶Centre Pierre et Marie Curie, Algiers, DZ, ⁷KHCc, Amman, JO, ⁸EPH Rouiba, Rouiba, DZ, ⁹CHU Dr Benbadis, Constantine, DZ, ¹⁰King Abdulaziz Medical City-Riyadh, Riyadh, SA, ¹¹CHU Constantine, Constantine, DZ, ¹²CAC Emir Abdelkader, Oran, DZ, ¹³Specialized Hospital Medical Center, Riyadh, SA, ¹⁴King Khalid National Guard Hospital - King Abdul Aziz Medical City, Jeddah, SA, ¹⁵Abderrahmen Mami Hospital, Ariana, TN, ¹⁶Université de Tunis El Manar, Faculté de Médecine de Tunis, 1007, Tunis, Tunisie The military hospital of Tunis,, tunis, TN, ¹⁷Hotel Dieu de France Hospital, Beirut, LB, ¹⁸King Saud University Medical City (KSUMC), Riyadh, SA, ¹⁹International Cancer Research Group, sharja, AE, ²⁰Centre Jean Perrin, Clermont-Ferrand, FR

12:00 - 12:00

199P - Outcome of Non-metastatic Male Breast Cancer: 222 patients

U.Y. Arslan¹, F. Aslan², M. Ayhan³, N. Akdeniz⁴, G. Tahtacı⁵, H. Yeşil Çinkır⁶, M. Inanc⁷, G. Imamoglu⁸, N. Alkış¹, N. Turan³, M. Kaplan⁹, N. Ozdemir¹⁰, O.B. Cakmak Oksuzoglu¹, ¹Dr. Abdurrahman Yurtaslan Ankara Onkoloji Training and Research Hospital, Ankara, TR, ²Medikal Park Hospital, Ankara, TR, ³Kartal Lütfi Kırdar Training and Research Hospital, İstanbul, TR, ⁴Dicle University Medical Faculty, Diyarbakır, TR, ⁵Gazi University Faculty of Medicine, Ankara, TR, ⁶Gaziantep University Medical Faculty, Gaziantep, TR, ⁷School of Medicine Erciyes University, kayseri, TR, ⁸Diskapi Yıldırım Beyazıt Teaching and Research Hospital, Ankara, TR, ⁹Dicle University Medical Faculty, Diyarbakır/türkiye, TR, ¹⁰ankara training and research hospital, ankara, TR

12:00 - 12:00

200P - Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, Her2 positive breast cancer in a limited resources setting: ML25232 study final results

S. Beslija¹, T. Ceric¹, B. Hasanbegovic¹, F. Skenderi², J. Alidžanović³, D. Koprivic⁴, I. Marjanović⁵, A. Mekic-Abazovic⁶, I. Sisic⁶, M. Hammami⁷, A. Pasic¹, A. Rasic¹, E. Kapisazović², ¹Clinical Centre University of Sarajevo, Sarajevo, BA, ²Clinical Centre of Sarajevo University, Sarajevo, BA, ³Clinical Centre of Tuzla University, Tuzla, BA, ⁴University Clinical Centar Tuzla, Tuzla, BA, ⁵Clinical Hospital Mostar, Mostar, BA, ⁶Kantonalna bolnica Zenica, Zenica, BA, ⁷Cantonal Hospital Irfan Ljubijankic Bihac, Bihac, BA

- 12:00 - 12:00 **201P - Final results of scalp cooling for hair preservation: A single- institution prospective study.**
D. Loparco¹, L. Orlando², M. Caloro², C. Caliolo², A. Quaranta³, P. Schiavone², P. Fedele², M. Rendini², R. Varriano², A. Morleo², L.L. Falcone², G. Lotti², M. Cinefra², P. Ferrara², P. Rizzo¹, A. Marino¹, N. Calvani¹, E. Mazzoni¹, M. D'Amico², S. Cinieri¹, ¹Ospedale A. Perrino, Brindisi, IT, ²A. Perrino Hospital, BRINDISI, IT, ³ASL Brindisi, Brindisi, IT
- 12:00 - 12:00 **202P - Adjuvant Systemic Therapy in Women with Early Breast Cancer and Intermediate Prosigna ROR Scores: Is Chemotherapy Use Declining? Evidence From a Large Practice**
L. Hart¹, M. Den Bergh², ¹Florida Cancer Specialists, Ft. Myers, US, ²Florida Cancer Specialists, Fort Myers, US
- 12:00 - 12:00 **203P - Management of early breast cancer in women over 90: A 10 year experience**
E. Coffey, H. Shaker, M. Absar, N. Nasir, North Manchester General Hospital, Manchester, GB
- 12:00 - 12:00 **204P - Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early- stage breast cancer.**
D. Reinhorn¹, E. Amir², H. Goldvaser², R. Yerushalmi³, ¹Davidoff Cancer Center - Rabin Medical Center, Petach Tikva, IL, ²Princess Margaret Cancer Center, Toronto, CA, ³Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL
- 12:00 - 12:00 **205P - Hepatitis B screening and incidence of flare among non-metastatic breast cancer patients treated with anthracyclines**
Z. Zhang¹, W. Lian¹, E. Lim¹, R. Kumar², F.Y. Wong¹, T. Tang¹, R. Dent¹, T. Tan¹, ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²Singapore General Hospital, Singapore, SG
- 12:00 - 12:00 **206P - Effect of denosumab on low bone mineral density in postmenopausal Japanese early breast cancer patients receiving aromatase inhibitors : 36-month results**
K. Sakaguchi¹, K. Nakatsukasa², H. Koyama³, T. Matsuda⁴, M. Kato⁵, Y. Ouchi¹, M. Morita¹, T. Taguchi¹, ¹Kyoto Prefectural University of Medicine, Kyoto, JP, ²Nakatsukasa Adachi Clinic, Kyoto, JP, ³Nara City Hospital, Nara, JP, ⁴Saiseikai Kyoto Hospital, Kyoto, JP, ⁵Kato Breast Surgery Clinic, Shiga, JP
- 12:00 - 12:00 **207P - Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL STUDY**
M.A. Fabbri¹, A. Botticelli², C. Omarini³, E. Cretella⁴, A. Fabi⁵, D. Alesini⁶, L. Pizzuti⁵, G. Piesco⁷, A. Vaccaro⁸, F. Atzori⁹, F. Piacentini³, L. Moscetti³, A. Orlandi¹⁰, V. Sini¹¹, A. Mercanti¹², M.L. Framarino⁷, M. Persano¹³, R. Ceccherini¹⁴, E. Ruggeri¹⁵, ¹Policlinico Umberto I - Unità di Neonatologia, Patologia e Terapia Intensiva Neonatale, Rome, IT, ²Azienda Ospedaliera St. Andrea, Rome, IT, ³Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ⁴Ospedale Centrale di Bolzano ASDAA/SABES,

Bolzano, IT, ⁵Istituto Nazionale Tumori Regina Elena, Rome, IT, ⁶Central Hospital of Belcolle, Viterbo, IT, ⁷policlinico Umberto I, rome, IT, ⁸Frosinone, frosinone, IT, ⁹Azienda Ospedaliero Universitaria di Cagliari, Monserrato, IT, ¹⁰Policlinico Universitario A. Gemelli, Rome, IT, ¹¹ospedale santo spirito, rome, IT, ¹²Ospedale di Legnago, Legnago, IT, ¹³Azienda Ospedaliero Universitaria di Cagliari, Cagliari, IT, ¹⁴Centro Sociale Oncologico (CSO), Trieste, IT, ¹⁵Ospedale Belcolle, Viterbo, IT

- 12:00 - 12:00 **208P - Real world comparison of the impact of adjuvant capecitabine in women with high-risk triple-negative breast cancer after neoadjuvant chemotherapy**
M. Vilbert¹, M. Corassa¹, R. Saleh², R. Coelho¹, M. Teixeira¹, E. Amir², ¹A. C. Camargo Cancer Center, Sao Paulo, BR, ²Princess Margaret Cancer Center, Toronto, CA
- 12:00 - 12:00 **209P - Influence of age on the indication of adjuvant chemotherapy in early breast cancer using Oncotype DX. An analysis of 240 patients treated in the Institut Catala d'Oncologia (ICO) hospitals**
S. Recalde¹, V. Quiroga², S. Del Barco³, C. Falo¹, J. Dorca³, M. Margeli⁴, A. Stradella¹, T. Soler⁵, I. Teruel García⁶, G. Viñas⁷, A. Fernandez¹, R. Villanueva Vázquez⁸, A. Vethencourt¹, M. Romeo Marin⁹, M. Gil-Gil¹, ¹ICO - Institut Catala d'Oncologia Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ²Catalan Institute of Oncology, Badalona, ES, ³ICO Girona, Girona, ES, ⁴Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, ES, ⁵Hospital de Bellvitge, Hospitalet de Llobregat, ES, ⁶Institut Catala d'Oncologia (ICO), Barcelona, ES, ⁷Catalan Institute of Oncology (ICO) and Girona Biomedical Research Institute, Girona, ES, ⁸Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, ES, ⁹Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES
- 12:00 - 12:00 **210P - Impact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients**
M. Chavez Mac Gregor¹, X. Lei¹, D. Gagliato², V. Valero¹, C. Barcenas¹, G. Hortobagyi¹, S. Giordano¹, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²A Beneficência Portuguesa de São Paulo, Sao Paulo, BR
- 12:00 - 12:00 **211P - Clinical Confirmation of Higher Exposure to Niraparib in Tumor vs Plasma in Patients With Breast Cancer**
L. Spring¹, M. Shan², M. Liu³, E. Hamilton⁴, C. Santa-Maria⁵, H. Irie⁶, S. Isakoff¹, J. Reeves⁷, L.W. Ellison¹, A. Liem⁸, A. Milillo Naraine⁹, J. Nangia¹⁰, D. Page¹¹, P. Pan², K. Sun², J. Graham², H. Han¹², ¹Massachusetts General Hospital, Boston, US, ²TESARO: A GSK Company, Waltham, US, ³Mayo Clinic Rochester, Rochester, US, ⁴Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ⁵Sidney Kimmell Comprehensive Cancer Center at Johns Hopkins, Baltimore, US, ⁶Icahn School of Medicine at Mount Sinai, New York, US, ⁷Florida Cancer Specialists-South, Fort Myers, US, ⁸Pacific Shores Medical Group, Long Beach, US, ⁹Massachusetts General Hospital, Hollywood, US, ¹⁰Baylor College of Medicine, Houston, US, ¹¹Providence Portland, Portland, US, ¹²Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, US
- 12:00 - 12:00 **212P - The rationale for the effectiveness of systemic treatment of breast cancer depending on the body weight index**
M. Hojouj, Dnipropetrovsk city multidisciplinary clinical hospital №4, Dnipro, UA

- 12:00 - 12:00 **213P - Response to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes**
S.M. Ilie¹, I. Desmoulins², A. Hennequin², K. Courèche-Guillaume³, L. Arnould⁴, B. Nathalie³, A. Bertaut⁴, S. Ladoire², ¹Institutul Oncologic "Profesor Doctor Alexandru Trestioreanu", Bucharest, RO, ²Centre Georges-François Leclerc (Dijon), Dijon, FR, ³Georges Francois Leclerc Cancer Center, Dijon, FR, ⁴Centre Georges-François Leclerc, DIJON, FR
- 12:00 - 12:00 **214P - Pre-specified interim analysis of the SAFE trial (NCT2236806): a 4-arm randomized, double-blind, controlled study evaluating the efficacy and safety of cardiotoxicity prevention in non-metastatic breast cancer patients treated with anthracyclines with or without trastuzumab.**
L. Livi¹, G. Barletta², F. Martella³, I. Desideri⁴, V. Scotti², C. Becherini⁵, C. Saieva⁶, F. Terziani⁴, C. Bacci⁷, M. Airoidi⁸, G. Allegrini⁹, D. Amoroso¹⁰, F. Venditti², R. Tarquini¹¹, L. Orzalesi², L. Sanchez², M. Bernini², J. Nori¹², L. Fioretto⁷, I. Meattini¹³, ¹AOU Careggi - Radioterapia Oncologica, Firenze, IT, ²Azienda Ospedaliero Universitaria Careggi, Firenze, IT, ³Istituto Toscano Tumori, Firenze, IT, ⁴University of Florence, Firenze, IT, ⁵Azienda Ospedaliera Careggi, Firenze, IT, ⁶Institute for cancer research, prevention and clinical network (ISPRO), Firenze, IT, ⁷SOC Oncologia Medica, Firenze, IT, ⁸AOU S. Giovanni Battista - Molinette, Torino, IT, ⁹Dipartimento Oncologico - Azienda USL Toscana Nord Ovest, Livorno, IT, ¹⁰Ospedale Versilia USL12, Lido di Camaiore (LU), IT, ¹¹ospedale San Giuseppe, Empoli, IT, ¹²Diagnostic Senology, Firenze, IT, ¹³Azienda Ospedaliera Universitaria Careggi, Firenze, IT
- 12:00 - 12:00 **215P - Safety of hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: a multi-center comparative study.**
I. Meattini¹, L. Livi², K. Kim³, J. Kim³, W. Jung³, E. Olmetto⁴, I. Desideri⁴, C. Saieva⁵, C. Becherini⁶, V. Salvestrini⁴, A. Fourquet⁷, Y. Kirova⁸, P. Poortmans⁷, ¹Azienda Ospedaliera Universitaria Careggi, Firenze, IT, ²AOU Careggi - Radioterapia Oncologica, Firenze, IT, ³Ewha Womans University College of Medicine, Seoul, KR, ⁴University of Florence, Firenze, IT, ⁵Institute for cancer research, prevention and clinical network (ISPRO), Firenze, IT, ⁶Azienda Ospedaliera Careggi, Firenze, IT, ⁷Institut Curie, Paris, FR, ⁸(private address), Paris, FR
- 12:00 - 12:00 **216P - Usefulness of NT-ProBNP as a biomarker of cardiotoxicity in breast cancer patients treated with trastuzumab**
I. Blancas¹, C. Martín², F. Martín-Pérez², M. Legerén¹, M. Martos², S. Sequero¹, S. Carnenero¹, M. Pérez-García¹, C. Rodríguez-González¹, J. Jurado¹, M. Delgado¹, B. González-Astorga¹, I. González-Cebrián¹, J. Garrido², C. Prieto¹, V. Bayo-Martin¹, M. Fernández-Gutiérrez¹, G. Ayala-Carbonero¹, S. Reyes-Larzagui¹, F. Rodríguez-Serrano², ¹Hospital Clinico San Cecilio, Granada, ES, ²University of Granada, Granada, ES
- 12:00 - 12:00 **217P - The routine use of sentinel lymph node biopsy in high risk DCIS lesions is not justified**
F. Preat, A. Bohlok, V. Donckier, J.M. Nogaret, Institute Jules Bordet, Brussels, BE
- 12:00 - 12:00 **218P - Oncological impact of re-excision for positive margin status after breast**

conserving surgery in invasive breast cancer

K. Jimbo¹, C. Watase², U. Nakadaira², T. Murata², S. Shiino², S. Takayama², A. Suto²,
¹National Cancer Center Hospital, Tokyo, JP, ²National Cancer Center, Tokyo, JP

12:00 - 12:00 **219P - Pneumonitis and fibrosis after breast cancer radiation.**

J. Karlsen, NTNU-Norwegian University of Science and Technology, Trondheim, NO

12:00 - 12:00 **220P - Prognosis of mastectomy with reconstruction after neoadjuvant chemotherapy: a nationwide study in Korean Breast Cancer Society**

S. Park¹, S.Y. Bae², ¹Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ²Korea University Anam Hospital, Seoul, KR

12:00 - 12:00 **221P - A negative prognosis of radiotherapy-induced lower lymphocyte to monocyte ratio in patients with breast cancer**

C.-I. Yoon¹, S.J. Bae², C.H. Cha², S.E. Park², S.G. Ahn², J. Jeong², ¹Yonsei University, Seoul, KR, ²Gangnam Severance Hospital, Seoul, KR

12:00 - 12:00 **222P - Toxicity of Locoregional Radiotherapy in combination with Bevacizumab in patients with non-metastatic breast cancer (TOLERAB): final long-term evaluation**

A. Clément-Zhao¹, M.-L. Tanguy¹, P. Cottu¹, B. De La Lande², P. Bontemps³, C. Lemanski⁴, P. Baumann⁵, A. Savignoni¹, C. Levy⁶, K. Peignaux⁷, A. Bougnoux Reynaud⁸, A. Gobillion¹, Y. Kirova⁹, ¹Institut Curie, Paris, FR, ²Institut Curie, Saint Cloud, FR, ³CHU Jean Minjoz, Besançon, FR, ⁴Laboratoire de Radio-Analyse du C.R.L.C., Montpellier, FR, ⁵Centre d'oncologie de Gentilly, Nancy, FR, ⁶Centre Francois Baclesse, Caen, FR, ⁷Centre Georges François Leclerc, Dijon, FR, ⁸CHRU Bretonneau, Tours, FR, ⁹(private address), Paris, FR

12:00 - 12:00 **223P - Patient data to monitor clinical patterns in early and advanced breast cancer in Europe**

F. Giusti¹, C. Martos¹, E. Crocetti², N. Dimitrova¹, G. Randi¹, L. Neamtiu³, R. Carvalho¹, T. Dyba¹, M. Flego¹, N. Nicholson¹, M. Bettio¹, ¹European Commission - Joint Research Centre, Ispra, IT, ²University of Florence, Florence, IT, ³JRC - ISPRA, Ispra, IT

12:00 - 12:00 **224P - A critical appraisal of quality indicators of breast cancer treatment in Belgium**

D. Verhoeven¹, F. Duhoux², E. De Azambuja³, L. Van Walle⁴, K. Punie⁵, H. Wildiers⁵, P. Vuylsteke⁶, A. Barbeaux⁷, N. Van Damme⁸, L. Van Eycken⁴, ¹A.Z. Klina, Brasschaat, BE, ²Cliniques Universitaires St. Luc, Brussels, BE, ³Institute Jules Bordet, Brussels, BE, ⁴Belgian Cancer Registry, Brussels, BE, ⁵University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁶CHU-UCL-Namur Clinique Ste Elisabeth, Namur, BE, ⁷CHR Verviers, Verviers, BE, ⁸Gent University Hospital, Gent, BE

12:00 - 12:00 **225P - Predictors of adherence among post-menopausal women receiving adjuvant endocrine therapy for breast cancer in Ontario, Canada**

P. Blanchette¹, M. Lam², L. Richard², B. Allen³, S. Shariff³, T. Vandenberg¹, K.

Pritchard⁴, K. Chan⁴, A. Louie⁴, D. Desautels⁵, J. Raphael⁶, C. Earle⁷, ¹London Regional Cancer Program (LRCP) - London Health Science Center (LHSC), London, CA, ²Western, London, CA, ³ICES, London, CA, ⁴Sunnybrook Odette Cancer Centre, Toronto, CA, ⁵Cancer Care Manitoba, Winnipeg, CA, ⁶London Regional Cancer Program, London, CA, ⁷ICES, Toronto, CA

12:00 - 12:00 **226P - Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study**

E. Montagna¹, E. Pagan², V. Bagnardi², M. Colleoni¹, G. Canello¹, E. Munzone³, S. Dellapasqua¹, N. Bianco¹, G. Campenni¹, M. Iorfida¹, M. Mazza¹, A. De Maio¹, M. Milano⁴, P. Veronesi⁵, C. Sangalli³, B. Scateni¹, G. Pravettoni¹, K. Mazzocco¹, V. Galimberti¹, ¹Istituto Europeo di Oncologia, Milan, IT, ²University of Milan-Bicocca, Milan, IT, ³Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁴Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ⁵Istituto Europeo di Oncologie, Milan, IT

12:00 - 12:00 **227P - Baseline Quality of life (QoL) and chemotherapy related toxicities (CRT) in localized breast cancer (BC) patients (pts): the French multicentric prospective CANTO cohort study**

I. Licaj¹, S. Dabakuyo², S. Dauchy³, I. Vaz Luis³, C. Charles³, C. Lemogne⁴, O. Tredan⁵, L. Vanlemmens⁶, C. Jouannaud⁷, C. Levy¹, O. Rigal⁸, M. Fournier⁹, T. Petit¹⁰, F. Dalenc¹¹, P. Rouanet¹², A. Arnaud¹³, J. Lemonnier¹⁴, S. Everhard¹⁴, P. Cottu¹⁵, F. Joly¹⁶, ¹Centre Francois Baclesse, Caen, FR, ²Centre Georges François Leclerc, Dijon, FR, ³Gustave Roussy, Villejuif, FR, ⁴APHP, Paris, FR, ⁵Centre Leon Berard, Lyon, FR, ⁶CENTRE OSCAR LAMBRET, Lille, FR, ⁷Institut Jean Godinot, Reims, FR, ⁸Centre Henri-Becquerel, Rouen, FR, ⁹Institut Bergonié, Bordeaux, FR, ¹⁰Centre Paul Strauss, Strasbourg, FR, ¹¹Centre Claudius-Regaud, Toulouse, FR, ¹²ICM, Montpellier, FR, ¹³Clinique Ste Catherine, Avignon, FR, ¹⁴Unicancer, Paris, FR, ¹⁵Institut Curie, Paris, FR, ¹⁶Centre Francois Baclesse, CAEN, FR

12:00 - 12:00 **228P - Effects of Aerobic and Resistance Exercise on Android:Gynoid Fat Ratio in Breast Cancer Survivors**

C. Dieli-Conwright, N. Sami, K. Lee, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US

12:00 - 12:00 **229P - Impact of Education for Breast self examination in Rural Indian Women on Early Detection - results of POC study**

S. Parchuri, S. Dattatreya Palanki, S. Nirni, S. Atilli, V. A, V. Ch, Omega Hospitals, Hyderabad, IN

12:00 - 12:00 **230P - Breast cancer incidence and survival in renal transplant patients: 35-year experience**

M. Kontos¹, E. Riza², T. Tsiampalis³, G. Kirkilesis², I. Bokos⁴, D. Moris⁵, M. Darema⁴, A. Andriopoulos⁴, A. Varletzidou⁴, S. Vernadakis⁴, C. Nikolaidis⁴, S. Lionaki⁴, X. Sarantzi⁴, C. Anagnostopoulou⁴, I. Boletis⁴, G. Zavos⁴, ¹Private Practice - Michail, Athens, GR, ²National and Kapodistrian University of Athens, Athens, GR, ³Institute of Preventive Medicine, Environmental & Occupational Health, Marousi, GR, ⁴Laiko General Hospital, Athens, GR, ⁵Duke University Medical Center, Durham, US

- 12:00 - 12:00 **231P - The changing landscape of breast cancer incidence after treatment for Hodgkin's disease**
A. Benjamin¹, S. Cleator², P. Thiruchelvam¹, D. Gujral³, ¹Imperial College Healthcare NHS Trust, London, GB, ²St. Mary's Hospital Imperial College Healthcare NHS Trust, London, GB, ³Imperial College Healthcare NHS Trust - Charing Cross Hospital, London, GB
- 12:00 - 12:00 **232P - Is axillary lymph node dissection necessary in breast cancer patients with mastectomy and false-negative frozen section in sentinel lymph node biopsy?**
J. Si, Jiaying First Hospital of Zhejiang, Jiaying, CN
- 12:00 - 12:00 **233P - Number of deliveries as a prognostic factor in different breast cancer subtypes**
A. Jääskeläinen¹, N. Roininen¹, A. Jukkola², P. Karihtala³, ¹Medical Research Center, Oulu University Hospital and University of Oulu, Oulu University Hospital, FI, ²Tampere University Hospital and University of Tampere, Tampere, FI, ³Oulu University Hospital, Oulu, FI
- 12:00 - 12:00 **234P - Effects of supervised and adapted exercise program in the quality of life and strength of breast cancer survivors: MAMA MOVE Gaia trial**
A. Joaquim¹, P. Antunes¹, C. Garcia¹, V. Afreixo², A. Amarelo¹, B. Duarte¹, M. Vieira³, R. Lopes¹, I. Leão⁴, A. Baptista Capela⁵, L. Helguero², A. Alves¹, ¹Centro Hospitalar de Vila Nova de Gaia/Espinho (CHVNG/E)-Unidade 1, Vila Nova de Gaia, PT, ²Aveiro University, Aveiro, PT, ³SC Fitness, S.A. e Pump, Vila Nova de Gaia, PT, ⁴Centro Hospitalar de Vila Nova de Gaia/Espinho (CHVNG/E), Vila Nova de Gaia, PT, ⁵HSJ - Hospital de Sao Joao, EPE, Porto, PT
- 12:00 - 12:00 **235P - Study On the Socioeconomic and Clinical Factors Affecting the Proportion of Breast Conserving Surgery in Chinese Women Breast Cancer**
J. Zhang, Tianjin Cancer Hospital, Tianjin, CN
- 12:00 - 12:00 **236P - Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program?**
M. Giavarra¹, E. Bertoli², V. Buoro³, D. Zara⁴, G. Targato⁴, L. Palmero¹, M.G. Vitale¹, G. Pelizzari⁵, D. Basile⁶, L. Gerratana⁵, M. Bonotto³, C. Andreetta³, M. Cinausero¹, G. Pascoletti³, E. Poletto³, S. Russo³, F. Puglisi⁷, G. Fasola¹, M. Mansutti³, A.M. Minisini³, ¹Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT, ²Dipartimento di Oncologia, Azienda Sanitaria Universitaria Integrata di Udine; University of Udine, Udine, IT, ³Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia, Udine, IT, ⁴University of Udine, Udine, IT, ⁵Centro di Riferimento Oncologico - CRO, Aviano, IT, ⁶CRO di Aviano, Aviano, IT, ⁷Department of Medicine (DAME), University of Udine, Udine, Italy;, Aviano, IT
- 12:00 - 12:00 **237P - The value of genetic counselling in breast cancer genetic testing and clinical management**

V. Kiesel¹, G. Wishart², ¹Genehealth UK, Cambridge, GB, ²Check4Cancer, Cambridge, GB

- 12:00 - 12:00 **238P - Elderly patients in the Japanese Breast Cancer Registry**
M. Sawaki¹, A. Yamada², H. Kumamaru³, H. Miyata³, C. Shimizu⁴, M. Miyashita⁵, N. Honma⁶, N. Taira⁷, S. Saji⁸, ¹Aichi Cancer Center Hospital, Nagoya, JP, ²Yokohama City University School of Medicine, Yokohama, JP, ³Graduate School of Medicine, Tokyo University, Tokyo, JP, ⁴National Center for Global Health and Medicine, Tokyo, JP, ⁵Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, JP, ⁶Toho University School of Medicine, Tokyo, JP, ⁷Okayama University Hospital, Okayama, JP, ⁸Fukushima Medical University, Fukushima, JP
- 12:00 - 12:00 **239P - Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy**
L. De Boo¹, A. Cimino-Mathews², Y. Lubeck¹, A. Daletzakis¹, M. Opdam¹, J. Sanders¹, E. Hooijberg³, A. Van Rossum¹, Z. Loncova⁴, D. Rieder⁴, Z. Trajanoski⁵, M. Vollebergh⁶, M. Sobral-Leite¹, K. Van De Vijver⁷, A. Broeks¹, R. Van Der Wiel¹, H. Van Tinteren¹, S. Linn¹, H. Horlings¹, M. Kok⁸, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²The Johns Hopkins Hospital, Baltimore, US, ³Vrije University Medical Centre (VUMC), Amsterdam, NL, ⁴Medical University of Innsbruck, innsbruck, AT, ⁵Medical University of Innsbruck, Innsbruck, AT, ⁶The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁷Ghent University Hospital, Gent, BE, ⁸Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL
- 12:00 - 12:00 **240P - Unravelling the biological characteristics of MammaPrint extreme risk subgroups**
R. Bhaskaran, C. Griffioen, D. Wehkamp, L. Mittempergher, A. Glas, Agendia Inc., Amsterdam, NL
- 12:00 - 12:00 **241P - Residual Cancer burden as a prognostic factor in a large series of Neoadjuvant chemotherapy. Subgroup analysis per molecular surrogated subtypes**
C. Falo¹, S. Fernández², E. Garrigós², A. Vethencourt Casado³, S. Vázquez⁴, A. Stradella⁵, S. Recalde⁵, M.J. Pla², M. Campos⁶, A. Gumà⁶, R. Ortega⁶, A. Petit⁶, T. Soler⁷, J. Perez⁸, E. Fernandez⁶, M. Bergamino¹, S. Pernas Simon⁹, M. Gil¹⁰, J. Ponce⁶, A. Garcia Tejedor⁶, ¹ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ²Hospital Universitari Bellvitge, L'Hospitalet, ES, ³Institut Catala de Oncologia, Barcelona, ES, ⁴Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, ONCOBELL, IDIBELL, L'Hospitalet Barcelona, ES, ⁵ICO - Institut Catala d'Oncologia Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ⁶Hospital Universitari Bellvitge, Hospitalet de Llobregat, ES, ⁷Hospital de Bellvitge, Hospitalet de Llobregat, ES, ⁸ICO - Institut Catala d'Oncologia Hospital Duran i Reynals, L'Hospitalet Barcelona, ES, ⁹Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, ES, ¹⁰Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES
- 12:00 - 12:00 **242P - Clinical validation of CanAssist Breast in a Spanish cohort**
M. Bakre, OncoStem Diagnostics Pvt Ltd, Bangalore, IN

- 12:00 - 12:00 **243P - Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer**
P.A. Fasching¹, M. Huang², J. Cortés³, J. Zhao², J. O'Shaughnessy⁴, P. Hu², A. Haiderali⁵, V. Karantza⁶, G. Aktan⁷, A. Briggs⁸, S. Ramsey⁹, C. Qi¹⁰, J. Xie¹¹, C. Gu¹¹, K. Qian¹¹, M. Yuan¹⁰, E. Wu¹⁰, ¹University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, ²Merck & Co Inc, North Wales, US, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, ⁵MSD-Merck Sharp & Dohme, Kenilworth, US, ⁶Merck & Co., Inc., Kenilworth, US, ⁷Merck Sharp & Dohme Corp. USA, Whitehouse Station, US, ⁸University of Glasgow, Glasgow, GB, ⁹Fred Hutchinson Cancer Research Center, Seattle, US, ¹⁰Analysis Group Inc., Boston, US, ¹¹Analysis Group Inc., Los Angeles, US
- 12:00 - 12:00 **244P - Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial**
G. Griguolo¹, M.V. Dieci¹, L. Paré², F. Miglietta³, D. Generali⁴, A. Frassoldati⁵, G. Bisagni⁶, F. Piacentini⁷, E. Tagliafico⁸, K. Cagossi⁹, G. Ficarra¹⁰, A. Prat¹¹, P.F. Conte¹, V. Guarneri¹, ¹Istituto Oncologico Veneto IRCCS, Padova, IT, ²Hospital Clinic de Barcelona/IDIBAPS - SOLTI Breast Cancer Research Group, Barcelona, ES, ³University of Padova, Padova, IT, ⁴Istituti Ospitalieri di Cremona, Cremona, IT, ⁵Azienda Ospedaliera di Ferrara St. Anna, Ferrara, IT, ⁶Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, ⁷Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ⁸University of Modena and Reggio Emilia, Modena, IT, ⁹Ramazzini Hospital, Carpi, IT, ¹⁰Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, IT, ¹¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 12:00 - 12:00 **245P - Frequency of germline mutations in women's cancer susceptibility genes in a large cohort of Chinese breast cancer patients**
N. Liao¹, B. Chen¹, G. Zhang¹, C. Ren¹, Y. Wang¹, L. Guo¹, L. Cao¹, L. Wen¹, K. Li¹, M. Jia¹, C. Li¹, H. Mok¹, X. Chen¹, G. Wei¹, J. Lin¹, Z. Zhang², T. Hou², X. Shi², H. Hanzhang², H. Liu², ¹Guangdong General Hospital, Guangzhou, CN, ²Burning Rock Biotech, Guangzhou, CN
- 12:00 - 12:00 **246P - Triple blinded Prospective Study assessing the Impact of Genomics & Artificial Intelligence Watson For Oncology (WFO) on MDT's Decision of Adjuvant Systemic Therapy for Hormone Receptor Positive Early Breast Carcinoma-**
S. Sampige Prasannakumar, Y. Ramya, C. Rohit, K. Ashwin, P. Patil, A. Rauthan, Manipal Comprehensive Cancer Center Manipal Hospital, Bangalore, IN
- 12:00 - 12:00 **247P - Prognostic significance of Progesterone Receptor levels in luminal-like Her2- early Breast Cancer patients. A retrospective single Cancer Center analysis.**
A. Diana¹, F. Carlino¹, E. Franzese¹, S. Centonze¹, L.P. Guerrera¹, A. Perrone¹, F. De Vita², F. Ciardiello¹, M. Orditura², ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²Università degli Studi della Campania Luigi Vanvitelli, Naples, IT

- 12:00 - 12:00 **248P - PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a meta-analysis**
F. Schettini¹, T. Pascual², N. Chic³, B. Conte⁴, O. Martínez³, B. Adamo³, M. Vidal³, M. Muñoz³, A. Fernández-Martínez⁵, G. Griguolo⁶, V. Guarneri⁶, P.F. Conte⁶, S. De Placido¹, L. Carey⁷, C. Perou⁷, A. Prat⁸, ¹Azienda Universitaria Ospedaliera Federico II, Napoli, IT, ²Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES, ³Hospital Clinic, Barcelona, ES, ⁴Ospedale Policlinico San Martino, University of Genova, Genova, IT, ⁵University of North Carolina, Chapel Hill, Chapel Hill, US, ⁶Istituto Oncologico Veneto IRCCS, Padova, IT, ⁷UNC - Lineberger Cancer Center, Chapel Hill, US, ⁸Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 12:00 - 12:00 **249P - Assessment of CPS+EG, Neo-Bioscore and modified Neo-Bioscore in breast cancer patients treated with preoperative systemic therapy: a multicenter cohort study**
L. Xu¹, Y. Liu¹, Z. Fan², Z. Jiang³, Y. Liu⁴, R. Ling⁵, J. Zhang⁶, Z. Yu⁷, F. Jin⁸, C. Wang⁹, S. Cui¹⁰, S. Wang¹¹, D. Mao¹², Q. Xiang¹, Z. Zhang¹, B. Zhou¹, Z. Liu¹³, C. Ma¹³, X. Duan¹, Y. Cui¹, ¹Peking University First Hospital, Beijing, CN, ²The First Hospital of Jilin University, Changchun, CN, ³Affiliated Hospital of Academy of Military Medical Sciences, Beijing, CN, ⁴Hebei Breast Cancer Center, Shijiazhuang, CN, ⁵Department of Thyroid, Breast and Vascular Surgery, Xi'an, CN, ⁶The Second Affiliated Hospital of Harbin Medical University, Harbin, CN, ⁷The Second Hospital of Shandong University, Jinan, CN, ⁸The First Hospital of China Medical University, Shenyang, CN, ⁹Affiliated Union Hospital of Fujian Medical University, Fuzhou, CN, ¹⁰Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, CN, ¹¹Peking University People's Hospital, Beijing, CN, ¹²The Affiliated Hospital of Guizhou Medical University, Guiyang, CN, ¹³Peking University, Beijing, CN
- 12:00 - 12:00 **250P - The concordance of treatment decision guided by Oncotype and the PREDICT tool in early stage breast cancer**
H. Goldvaser¹, R. Yerushalmi², T. Shochat³, M. Sarfaty³, D. Goldstein³, C. Mayer³, ¹Princess Margaret Cancer Center, Toronto, CA, ²Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL, ³Rabin Medical Center, Peth Tikva, IL
- 12:00 - 12:00 **251P - Influence of first treatment delay on survival among breast cancer subtypes**
I. Zarcos Pedrinaci¹, D. Perez¹, F. Rivas-Ruiz¹, M. Sala², M. Padilla-Ruiz¹, J. Alcaide-Garcia¹, E. Perez-Ruiz¹, R. Villatoro¹, V. Navarro¹, M. Redondo¹, ¹Hospital Costa del Sol, Marbella, ES, ²Hospital del Mar, Barcelona, ES
- 12:00 - 12:00 **252P - Clinical features of early-stage (I-III) triple-negative breast cancer (TNBC) patients with tumors exhibiting low-overall change in molecular profile after neoadjuvant therapy.**
N. Abuhadra¹, S. Seth¹, S. Moulder², ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²MD Anderson Cancer Center, Houston, US
- 12:00 - 12:00 **253P - Meta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective**

M. Magalhaes¹, P. Aguiar¹, B. Haaland², A. Del Giglio¹, G. Lopes³, ¹ABC Medical School-Santo Andre, Santo Andre, BR, ²Industrial and Systems Engineering, Atlanta, BR, ³Sylvester Comprehensive Cancer, Miami, US

- 12:00 - 12:00 **254P - Anti-mullerian hormone (AMH) levels and antral follicle counts (AFC) may predict ovarian reserves before systemic chemotherapy (SC) in women with breast cancer(BC); a prospective clinical study**
C. Ordu¹, F. Gachayev², F. Elbuken³, B. Baysal², K.N. Pilanci⁴, G. Alco⁵, A.S. Ilgun⁶, M. Ucuncu², A. Ozturk⁷, Z. Erdogan⁸, F. Agacayak⁹, G. Ozdem¹⁰, T. Kayan⁸, T. Uyar¹¹, E. Hocaoglu², G. Soybir⁴, F. Aktepe⁵, V. Ozmen¹², ¹Ozel Gayrettepe Florence Nightingale Hospital, Istanbul, TR, ²Istanbul FN Hospital, istanbul, TR, ³Gayrettepe Florence Nightingale Hospiatl, Istanbul, TR, ⁴Memorial Hospital, Istanbul, TR, ⁵Gayrettepe Florence Nightingale Hospital, Istanbul, TR, ⁶Taksim Hospital, Istanbul, TR, ⁷Biruni University, Istanbul, TR, ⁸Bilim University, Istanbul, TR, ⁹Istanbul Florence Hospital, Istanbul, TR, ¹⁰Ozel Gayrettepe Florence Nightingale Hospital, istanbul, TR, ¹¹Istanbul Bilgi Universirty, Istanbul, TR, ¹²Istanbul University - Faculty of Medicine, Istanbul, TR
- 12:00 - 12:00 **255P - Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.**
G. Canello¹, E. Montagna¹, E. Pagan², V. Bagnardi², E. Munzone³, S. Dellapasqua¹, M. Iorfida¹, M. Mazza¹, A. De Maio¹, G. Viale¹, G. Mazzarol¹, P. Veronesi⁴, V. Galimberti¹, G. Santomauro¹, M. Colleoni¹, ¹Istituto Europeo di Oncologia, Milan, IT, ²University of Milan-Bicocca, Milan, IT, ³Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁴Istituto Europeo di Oncologie, Milan, IT
- 12:00 - 12:00 **256P - Novel Blood Based Circulating Tumor Cell Biomarker For Breast Cancer Detection**
C.-Y. Liu¹, Y.-F. Tsai¹, F.-M. Lin², J.-C. Wu², Y.-S. Lin¹, T.-C. Chao¹, K.-L. King¹, P.-J. Lien¹, J. Wang¹, Y.-H. Lin¹, Y.-C. Lai¹, H. Hsieh², A. Saklecha², J.-M. Lai², S.-E. Chang², M. Javey², D. Watson², R. Mei², L.-M. Tseng¹, ¹Taipei Veterans General Hospital, Taipei, TW, ²CellMax Life, Sunnyvale, US
- 12:00 - 12:00 **257P - Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response of ER-Positive HER2-Negative Breast Cancer Patients to Neo-Adjuvant Chemotherapy**
C. Mazo, University College Dublin, Dublin, IE
- 12:00 - 12:00 **258P - Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy**
A. Papakonstantinou¹, A. Matikas¹, M. Hellström¹, H. Johansson², G. Steger³, R. Greil⁴, S. Loibl⁵, M. Gnant⁶, V. Moebus⁷, M. Untch⁸, T. Foukakis⁹, J. Bergh¹⁰, ¹Karolinska University Hospital-Solna, Stockholm, SE, ²karolinska University Hospital-Solna, Stockholm, SE, ³Medical Oncology, Medical University, Vienna, Austria and Gaston H. Glock Research Center, Medical University, Vienna, AT, ⁴Paracelsus Medical University, Salzburg, AT, ⁵German Breast Group, Neu-Isenburg, DE, ⁶Medical University of Vienna, Vienna Austria, Vienna, AT, ⁷Klinikum Frankfurt Höchst, Academic Hospital Goethe University, Frankfurt, Germany, Frankfurt, DE, ⁸Helios Klinikum Berlin Buch, Berlin, DE, ⁹Karolinska University Hospital-Radiumhemmet, Stockholm, SE, ¹⁰Karolinska Institutet -

Bioclinicum, Solna, SE

- 12:00 - 12:00 **259P - Progesterone Receptor Isoform Ratio Dictates Antiprogestins/Progestins Effects on Metastatic Breast Cancer Models**
M. Abascal¹, S. Giulianelli², M. Alvarez¹, G. Sequeira³, S. Vanzulli⁴, A. Elia¹, G. Pataccini¹, M. Lombes⁵, C. Lanari¹, ¹IBYME - Instituto de Biología y Medicina Experimental, Buenos Aires, AR, ²IBIOMAR-CCT CONICET-CENPAT, Puerto Madryn, AR, ³Hospital de autogestión Dr. Arturo Oñativia, Salta, AR, ⁴Academia de Medicina, CABA, AR, ⁵Université Paris Saclay Le Kremlin Bicêtre, Paris, FR
- 12:00 - 12:00 **260P - PAM50 and CGH-array genomic characterization of HER2-Equivocal Breast Cancers defined by the 2018 ASCO/CAP recommendations.**
C. Ngo¹, E. Borcoman¹, A. Rapinat¹, F. Simaga¹, N. Mouterfi¹, O. Mariani¹, L. Fuhrmann¹, E. Jeannot¹, M. Lae¹, J.-Y. Pierga¹, D. Gentien¹, G. Pierron¹, P. Morel², H.A. Brauer², A. Vincent-Salomon¹, ¹Institut Curie, Paris, FR, ²NanoString Technologies, Paris, FR
- 12:00 - 12:00 **261P - OncotypeDX® predictive nomogram for recurrence score output: a machine learning system based on quantitative immunochemistry analysis - ADAPTED01**
F. Marazzi¹, V. Masiello², R. Barone³, V. Magri⁴, A. Mulé¹, A. Santoro¹, F. Cacciatori¹, L. Boldrini¹, G. Franceschini¹, F. Moschella¹, G. Naso⁴, S. Tomao⁴, G. Mantini¹, R. Masetti¹, D. Smaniotto¹, V. Valentini¹, ¹Fondazione Policlinico Gemelli IRCSS, Roma, IT, ²Policlinico Universitario A. Gemelli, Rome, IT, ³Radius, Budrio, IT, ⁴Università LaSapienza, Roma, IT
- 12:00 - 12:00 **262P - Geriatric parameters predict both disease-related and patient-reported outcomes in older patients with breast cancer**
W. Van Der Plas-Krijgsman¹, A. De Boer¹, P. De Jong², E. Bastiaannet³, F. Van Den Bos⁴, G.-J. Liefers³, J. Portielje³, N. De Glas¹, ¹Leids Universitair Medisch Centrum (LUMC), Leiden, NL, ²Haaglanden Medisch Centrum, Den Haag, NL, ³Leiden University Medical Center, Leiden, NL, ⁴University Medical Center Utrecht, Utrecht, NL
- 12:00 - 12:00 **263P - Patients with a 21-gene assay in South East London differ from the TAILORx trial population**
C. Gousis¹, R. Sylva², H. Kristeleit³, ¹Kavala General Hospital, Kavala, GR, ²Queen Elizabeth Hospital, Woolwich, London, GB, ³Complete Cancer Care Limited, London, GB
- 12:00 - 12:00 **264P - Predictive tools in adjuvant breast cancer - what is the standard of evidence supporting their utility? A literature review examining validation of Adjuvant!, Cancermath and NHS Predict**
A. Loft, R. Strother, Christchurch Hospital, Christchurch, NZ
- 12:00 - 12:00 **265P - Oncologic outcome of invasive lobular carcinoma: Is it different from that of invasive ductal carcinoma?**
H.J. Choi¹, S.W. Kim², J.M. Ryu², S.J. Nam², J. Yu², S.K. Lee², J.E. Lee², ¹Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ²Sungkyunkwan

University School of Medicine, Samsung Changwon Hospital, Changwon, KR

- 12:00 - 12:00 **266P - Pathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer**
S. Morales Murillo, A. Gasol Cudos, J. Veas Rodriguez, F. Vilardell Villellas, D.-R. Sánchez Guzmán, C. Canosa Morales, J. Melé Olivé, I. El Koulali, E. Iglesias Martínez, Hospital Universitario Arnau de Vilanova, Lleida, ES
- 12:00 - 12:00 **267P - Chemotherapy-induced amenorrhea: prognostic impact on premenopausal Egyptian patients with breast cancer**
K. Abdel Karim, D. Abdel Al, C. Reda, H. Nohran, Ain Shams University Faculty of Medicine, Cairo, EG
- 12:00 - 12:00 **268P - Concordance rates between the progesterone receptor isoform ratio determined in core needle biopsy and the corresponding surgical excision in patients with breast cancer.**
A. Elia¹, P. Rojas², M. Liguori³, E. Spengler³, G. San Martin³, I. Caillet³, P. Martínez Vazquez³, J. Burruchaga³, H. Gass³, C. Lanari², ¹IBYME - Instituto de Biología y Medicina Experimental, Buenos Aires, AR, ²Instituto de Biología y Medicina Experimental, Ciudad Autónoma de Buenos Aires, AR, ³Hospital General de Agudos "Magdalena V Martínez", Gral. Pacheco, Tigre, AR
- 12:00 - 12:00 **269P - Predicting the presence of breast cancer using circulating small RNA in the serum**
Y. Koi¹, Y. Tsutani², Y. Nishiyama², S. Sasada², T. Akita², N. Masumoto³, T. Kadoya³, R.-U. Takahashi², M. Okada², H. Tahara², ¹JA Hiroshima General Hospital, Hatsukaichi, JP, ²Hiroshima University, Hiroshima, JP, ³Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, JP
- 12:00 - 12:00 **270P - Evaluation of germ line mutational status among women with triple-negative breast cancer in Russia**
E. Shagimardanova¹, L. Shigapova¹, A. Nikitin², R. Enikeev³, M. Druzhkov⁴, O. Gusev¹, M. Gordiev⁴, ¹Kazan Federal University, Kazan, RU, ²Federal Research and Clinical Center, FMBA, Moscow, RU, ³Clinical Oncologic Dispensary of Tatarstan, Breast Center, Kazan, RU, ⁴Tatarstan Cancer Center, Kazan, RU
- 12:00 - 12:00 **271P - Association of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT)**
A. Ocaña¹, J.I. Chacón², L. Calvo³, A. Antón⁴, M. Mansutti⁵, E. Alba⁶, A. Lluch⁷, A. Lahuerta⁸, G. Bisagni⁹, B. Bermejo⁷, V. Semiglazov¹⁰, M. Thill¹¹, A. Chan¹², S. Morales¹³, J. Albanell¹⁴, J. Herranz¹⁵, I. Tusquets Trias Bes¹⁶, P. Valagussa¹⁷, M. Chiesa¹⁵, L. Gianni¹⁸, ¹GEICAM, San Sebastian de los Reyes, ES, ²Hospital Hospital Virgen de la Salud, Toledo, Toledo, ES, ³Complejo Hospitalario Universitario de A Coruña, A Coruña, ES, ⁴Hospital Universitario Miguel Servet, Zaragoza, ES, ⁵Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia, Udine, IT, ⁶Hospital Clínico Universitario Virgen de la Victoria, Málaga, ES, ⁷Biomedical Research Institute INCLIVA, Hospital Clínico València, University of Valencia, Valencia, ES, ⁸Fundación Onkológica, San Sebastián, ES, ⁹Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, ¹⁰N.N. Petrov National Medical Research Center

of Oncology, Saint-Petersburg, RU, ¹¹Kliniken Markus-Krankenhaus, Agaplesion, Frankfurt am Main, DE, ¹²Breast Cancer Research Centre BCRC - WA, Nedlands, AU, ¹³Hospital Universitario Arnau de Vilanova de Lleida, Lleida, ES, ¹⁴University Hospital del Mar, Barcelona, ES, ¹⁵GEICAM Spanish Breast Cancer Group, Madrid, ES, ¹⁶Hospital del Mar, Barcelona, ES, ¹⁷Fondazione Michelangelo, Milan, IT, ¹⁸IRCCS Ospedale San Raffaele, Milan, IT

- 12:00 - 12:00 **272P - Competing nomogram for late-period breast cancer-specific death in patients with early-stage hormone receptor-positive breast cancer**
J. Fu¹, D. Li², L. Wu², K. Yu³, J. Du³, ¹Central Hospital of Jinhua, Jinhua, CN, ²Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, ³Central Hospital of Jinhua, Jinhua, CN
- 12:00 - 12:00 **273P - A Nomogram to Predict Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Blood Indicators**
F. Zhang¹, M. Huang², H. Zhou¹, K. Chen³, J. Jin⁴, X. Ding¹, D. Su⁴, D. Zou¹, ¹Zhejiang Cancer Hospital, Hangzhou, CN, ²The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, CN, ³ZHEJIANG CANCER HOSPITAL, Hangzhou, CN, ⁴Department of Pathology, Hangzhou, CN
- 12:00 - 12:00 **274P - Identification of GSTP1 transferred by extracellular vesicles responsible for adriamycin-resistance in breast cancer cells**
S. Yang¹, J. Tang², ¹First Affiliated Hospital of Nanjing Medical University, Jiangsu, CN, ²First Affiliated Hospital with Nanjing Medical University, Jiangsu, CN
- 12:00 - 12:00 **275P - Expression of X-linked Inhibitor of Apoptosis Protein (XIAP) and its Association with Clinicopathological Parameters in Invasive Breast Cancers**
G. Devi¹, P. Finetti², J. Geradts¹, S. McCall¹, M. Morse¹, S. Van Laere³, F. Bertucci⁴, ¹Duke University Medical Center - Trent Center, Durham, US, ²Institut Paoli-Calmettes,, Marseille, FR, ³University of Antwerp, Antwerp, BE, ⁴Institute Paoli Calmettes, Marseille, FR
- 12:00 - 12:00 **276P - The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients**
S.Y. Bae¹, W. Lim², J. Jeong³, S. Lee⁴, J. Choi⁵, H. Park⁶, Y.S. Jung⁷, S.P. Jung¹, S. Nam⁸, ¹Korea University Anam Hospital, Seoul, KR, ²Ewha Womans University Mokdong Hospital,, Seoul, KR, ³Gangnam Severance Hospital, Seoul, KR, ⁴Center for Breast Cancer, Seoul, KR, ⁵Yeungnam University College of Medicine, Seoul, KR, ⁶Gachon University, Gil Medical Center, Seoul, KR, ⁷Ajou University, School of Medicine, Seoul, KR, ⁸Konkuk University Medical Center, Seoul, KR
- 12:00 - 12:00 **277P - Correlation of Clinical and pathological features with the Tumor microenvironment in DCIS. An Institutional Experience**
A. Eapen, Y. Lyou, L. Eisenbud, R. Mehta, K. Lane, T. Lama, P. Daroui, E. Lin, A. Ziogas, R. Parajuli, UCI Health Chao Family Comprehensive Cancer Center, Orange, US
- 12:00 - 12:00 **278P - Correlation between radiologic complete response (rCR) in contrast-**

enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer and pathologic complete response and their impact in recurrence-free survival

A. Gasol Cudos, S. Morales Murillo, J. Veas Rodriguez, J.F. Córdoba Ortega, M.I. Gil García, C. Canosa Morales, J. Melé Olivé, I. El Koulali, E. Iglesias Martínez, Hospital Universitario Arnau de Vilanova, Lleida, ES

12:00 - 12:00 **279P - Ring-like uptake appearance on dedicated breast positron emission tomography before chemotherapy predicts outcome of neoadjuvant chemotherapy in breast cancer**

N. Masumoto¹, T. Kadoya¹, M. Nishina¹, Y. Kimura², A. Amioka², T. Itagaki², S. Sasada², A. Emi², M. Okada², ¹Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, JP, ²Hiroshima University, Hiroshima, JP

12:00 - 12:00 **280P - Defining a SUV decrease cut-off in PET/CT response monitoring after one cycle of preoperative breast cancer chemotherapy**

M. Kubeczko¹, K. Świdorska², A. D'Amico³, M. Di Pietro¹, O. Chrabański¹, A. Polakiewicz-Gilowska², M. Mianowska-Malec², W. Bal¹, A. Badora-Rybicka², A. Leśniak², A. Pasierbek¹, A. Kuś², R. Tarnawski², B. Bobek-Billewicz¹, M. Jarzab³, ¹Maria Skłodowska Curie MSC Memorial Cancer Institute in Gliwice, Gliwice, PL, ²Maria Skłodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, Gliwice, PL, ³Maria Skłodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, Gliwice, PL

12:00 - 12:00 **281P - Effect of thioredoxin 1 quantity detection to complement the mammography in breast cancer diagnosis**

Y. Lee¹, J. Lee¹, J. Kim¹, M. Lee², Y. Kim³, K. Suh³, ¹Chungnam national university hospital, Daejeon, KR, ²Chungnam National University Hospital, Daejeon, KR, ³E&S Healthcare Co. Ltd, Daejeon, KR

12:00 - 12:00 **282P - Identification of ultralow risk breast cancer patients (probable overdiagnosis)**

S. Gamez Casado¹, M. Bernal Gómez¹, A. Campini Bermejo¹, L. Rodriguez Perez², A. Quilez², J. Calvete Candenias³, G. Martínez Bernal⁴, E. Benítez Rodríguez⁵, J.M. Baena-Canada², ¹Hospital Universitario Puerta del Mar, Cadiz, ES, ²Hospital Puerta del Mar, Cadiz, ES, ³Hospital Universitario Virgen Macarena, Sevilla, ES, ⁴Hospital Virgen del Rocío, Sevilla, ES, ⁵Registro Provincial del cáncer, Cádiz, Cadiz, ES

12:00 - 12:00 **283P - Prevalence of Vitamin D3 deficiency among women with early breast cancer receiving chemotherapy in an oncology dayward.**

W. Finstad, K. Murphy, G. Markey, D. O Connor, C. Murphy, Bon Secours Hospital, Cork, IE

12:00 - 12:00 **284P - Changes in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival (DFS) in ER positive breast cancer patients**

A. Turnbull¹, M. A. Inda², A. Van De Stolpe², D. Keizer³, D. Clout², H. Van Zon², M. Akse⁴, A. Fernando¹, C. Martinez-Perez¹, J.M. Dixon⁵, A. Sims¹, ¹University of Edinburgh, Edinburgh, GB, ²Philips Research, Eindhoven, NL, ³Philips Healthcare, Eindhoven, NL,

⁴Philips, Eindhoven, NL, ⁵Western General Hospital, Edinburgh, GB

- 12:00 - 12:00 **285P - Second primary malignancies in patients with breast cancer.**
C. Erasun Lecuona¹, M. Hardy-Werbin², E. Felip Falgas¹, J.J. García Mosquera³, M. Cucurull Salamero¹, I. Teruel García¹, M. Margeli Vila¹, ¹Institut Catala d'Oncologia (ICO), Barcelona, ES, ²The Mar Institute of Medical Research Foundation, Barcelona, ES, ³Hospital Dexeus - Instituto Oncológico Rosell, Barcelona, ES
- 12:00 - 12:00 **286TiP - Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib + letrozole (Pal+L) or paclitaxel (Pac) for elderly patients with estrogen receptor & HER2 positive (ER+/HER2+) Breast Cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH)**
L. Biganzoli¹, E. Brain², L. Malorni¹, E. Risi³, M. Regan⁴, ¹Ospedale di Prato Sandro Pitigliani Med. Oncology Unit, Prato, IT, ²Hôpital René Huguenin - Institut Curie, St. Cloud, FR, ³Nuovo Ospedale di Prato, Prato, IT, ⁴Dana Farber Cancer Institute, Boston, US
- 12:00 - 12:00 **287TiP - Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): an open label randomized phase 2 trial**
H. Mcarthur¹, J. Leal², D. Page³, A. Bardia⁴, L. Spring⁴, C. Abaya⁵, R. Basho⁵, L. Ristow⁵, H. Coleman⁵, S. Shiao⁵, S. Knott⁵, M. Tighiouart⁵, F. Dadmanesh⁵, S. Verma⁶, A. Giuliano⁵, ¹Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center, Los Angeles, US, ²CLION, Salvador, BR, ³Providence Portland, Portland, US, ⁴Massachusetts General Hospital, Boston, US, ⁵Cedars-Sinai Medical Center, Los Angeles, US, ⁶Tom Baker Cancer Centre, Calgary, CA
- 12:00 - 12:00 **288TiP - A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy**
H. Mcarthur¹, E. Comen², Y. Bryce², S. Solomon³, J. Leal⁴, M. Rodine³, C. Abaya⁵, S. Patil², D. Page⁶, L. Norton⁷, ¹Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center, Los Angeles, US, ²Memorial Sloan Kettering Cancer Center, New York City, US, ³Memorial Sloan Kettering Cancer Center, New York City, US, ⁴CLION, Salvador, BR, ⁵Cedars-Sinai Medical Center, Los Angeles, US, ⁶Providence Portland, Portland, US, ⁷Memorial Sloan-Kettering Cancer Center, New York, US
- 12:00 - 12:00 **289TiP - ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer.**
M. Ignatiadis¹, H. Mcarthur², A. Bailey³, J. Martinez⁴, E. De Azambuja¹, O. Metzger⁵, C. Lai⁶, M. Franzoi⁷, T. Goulioti⁴, F. Daly⁸, A. Bouhlel⁹, V. Balta⁴, M. Maetens⁴, G. Viale¹⁰, B. André¹¹, C. Dufrane¹², D.A. Nguyen⁹, R. Gelber⁵, M. Piccart¹, E. Winer¹³, ¹Institute Jules Bordet, Brussels, BE, ²Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center, Los Angeles, US, ³Frontier Sciences, Kingussie, GB, ⁴Breast International Group, Brussels, BE, ⁵Dana Farber Cancer Institute, Boston, US, ⁶Genentech, San Francisco, US, ⁷Hospital de Clinicas de Porto Alegre Universidade Federal Do Rs, Porto Alegre, BR, ⁸Frontier Science Scotland, Kingussie, GB, ⁹Roche,

Basel, CH, ¹⁰Istituto Europeo di Oncologia, Milan, IT, ¹¹Institut Jules Bordet, Bruxelles, BE, ¹²Alliance Foundation Trials, LLC, Boston, US, ¹³Harvard Medical School, Boston, US

- 12:00 - 12:00 **290TiP - Role of Individualized Intervention(s) on Quality of Life (QOL) and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women with Early-Stage Breast Cancer (BC): MyChoice Study**
S. Ahmed¹, H. Chalchal², L. Dwernychuk¹, N. Iqbal¹, M. Salim², D. Gowan-Moody³, T. Asif¹, M. Khan², J. Lim³, D. Bulych⁴, O. Ahmed¹, A. Sami¹, S. Kontulainen³, A. Leis³, ¹Saskatoon Cancer Centre University of Saskatchewan, Saskatoon, CA, ²Saskatchewan Cancer Agency-Allan Blair Cancer Centre at Pasqua Hosp, Regina, CA, ³University of Saskatchewan, Saskatoon, CA, ⁴Saskatchewan Cancer Agency, Saskatoon, CA
- 12:00 - 12:00 **291TiP - Correlation between the density of tumor-infiltrating lymphocytes, immune cell subsets in tumor stroma and response to systemic therapy in breast cancer**
C. Grasic Kuhar, K. Gersak, B. Gazic, Institute of Oncology Ljubljana, Ljubljana, SI
- 12:00 - 12:00 **Breast cancer, locally advanced**
- 12:00 - 12:00 **292P - BRCA1/2 Testing in HER2- Advanced Breast Cancer (ABC): Results from the European Component of a Multi-Country Real World Study**
M.P. Lux¹, K. Lewis², A. Rider², A. Niyazov³, ¹Frauenklinik St. Louise, Paderborn; St. Josefs-Krankenhaus, Salzkotten; Frauen- und Kinderklinik St. Louise, Paderborn, DE, ²Adelphi Group Ltd, Cheshire, GB, ³Pfizer, New York, US
- 12:00 - 12:00 **293P - In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer.**
C. Nieto-Jiménez¹, E.M. Galán-Moya², V. Corrales-Sanchez¹, M.D.M. Noblejas López¹, M. Burgos¹, B. Domingo², J.C. Montero³, J. Perez-Peña², M. Gómez-Juárez¹, A. Pandiella³, A. Ocaña⁴, ¹Complejo Hospitalario Universitario de Albacete, Albacete, ES, ²Universidad de Castilla-La Mancha, Albacete, ES, ³Centro de investigación del cáncer, Salamanca, ES, ⁴Hospital Clínico San Carlos, Madrid, ES
- 12:00 - 12:00 **294P - Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer**
T. Semiglazova¹, M. Osipov², P. Krivorotko¹, S. Protsenko¹, V. Semiglazov³, R. Donskih², V. Klimenko¹, E. Tsirlina², L. Berstein², V. Anisimov², V. Semiglazov¹, A. Belyaev², ¹N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU, ²Federal State Budget Institution "National Medical Research Center of Oncology na N.N. Petrov" Ministry of Healthcare of Russian Federation, Saint-Petersburg, RU, ³Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, RU
- 12:00 - 12:00 **295P - Melatonin and metformin in neoadjuvant chemotherapy in locally advanced breast cancer**
T. Semiglazova¹, M. Osipov², P. Krivorotko¹, V. Semiglazov¹, S. Protsenko¹, L. Berstein², E. Tsirlina², V. Klimenko¹, R. Donskih², V. Anisimov², A. Belyaev², ¹N.N. Petrov National

Medical Research Center of Oncology, Saint-Petersburg, RU, ²Federal State Budget Institution "National Medical Research Center of Oncology na N.N. Petrov" Ministry of Healthcare of Russian Federation, Saint-Petersburg, RU

- 12:00 - 12:00 **296P - Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach**
A. Mueller-Schoell¹, L. Klopp-Schulze², W. Huisinga³, M. Joerger⁴, P. Neven⁵, S. Koolen⁶, R. Mathijssen⁷, S. Schmidt⁸, C. Kloft², ¹Freie Universitat - Institut fur Pharmazie, Berlin, DE, ²Freie Universitaet Berlin, Berlin, DE, ³University of Potsdam, Potsdam, DE, ⁴Kantonsspital St. Gallen, St. Gallen, CH, ⁵University of Leuven, Leuven, BE, ⁶Erasmus University Medical Center, Rotterdam, NL, ⁷Erasmus MC Cancer Institute, Rotterdam, NL, ⁸University of Florida, Orlando, US
- 12:00 - 12:00 **297P - Lack of benefit of neoadjuvant pertuzumab in high risk HER2 positive breast cancer. A retrospective case-control study of 355 cases with biomarker analysis.**
M. Tiako Meyo¹, M. Lavigne¹, P. Leclerc¹, M.-L. Tanguy¹, Y. Kirova², A. Hurgon¹, A. Lalli¹, V. Fourchette¹, A. Vincent-Salomon¹, L. Escalup¹, P. Cottu¹, ¹Institut Curie, Paris, FR, ²(private address), Paris, FR
- 12:00 - 12:00 **298P - Targeting CDCA3 to improve chemotherapy response in triple-negative breast cancer patients**
K. O'Byrne¹, M. Adams², J. Burgess³, D. Richard⁴, ¹Princess Alexandra Hospital, Woolloongabba, AU, ²Queensland University of Technology, Woolloongabba, AU, ³Institute of Health and Biomedical Innovation, Queensland University of Technology, Woolloongabba, AU, ⁴Queensland University of Technology, Brisbane, AU
- 12:00 - 12:00 **299P - Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer**
M.D.M. Noblejas López¹, C. Nieto-Jiménez¹, E.M. Galán-Moya², M. Burgos¹, J.C. Montero³, M. Gómez-Juárez¹, A. Pandiella³, A. Ocaña⁴, ¹Complejo Hospitalario Universitario de Albacete, Albacete, ES, ²Universidad de Castilla-La Mancha, Albacete, ES, ³Centro de investigación del cáncer, Salamanca, ES, ⁴Hospital Clínico San Carlos, Madrid, ES
- 12:00 - 12:00 **300P - Outcome of triple negative inflammatory breast cancers (TNIBC) treated with dose dense neoadjuvant epirubicin cyclophosphamide, prognostic impact of pre and post neoadjuvant chemotherapy (NAC) tumor infiltrating lymphocytes (TIL) and post NAC lymphovascular invasion**
L. Campedel¹, P. Blanc-Durand², A. Binasker³, S. Bécourt⁴, F. Ledoux⁵, C. Cuvier³, C. Gardair³, L. Teixeira⁵, A. De Roquancourt³, J. Lehmann Che⁶, M. Espié⁵, S. Giacchetti³, ¹Hôpitaux Paris Centre AP-HP, Paris, FR, ²Paris Descartes University, Paris, FR, ³APHP Hôpital Saint-Louis, Paris, FR, ⁴Hôpital Saint Louis AP-HP, Paris, FR, ⁵Hôpital St. Louis, Paris, FR, ⁶Hôpital Saint-Louis, Paris, FR
- 12:00 - 12:00 **301P - A novel PET parameter for cancer stem cell metabolism: early prediction of chemosensitivity to neoadjuvant chemotherapy in locally advanced breast**

cancer

C. Kim¹, H.J. Choi², ¹Kyung Hee University Hospital at Gangdong, Seoul, KR, ²Hanyang University Medical Center, Seoul, KR

12:00 - 12:00 **302P - Using nodal ratio to predict recurrence in patients with 4 or more positive lymph nodes early stage breast cancer**

B. Graja¹, M. Nesrine², A. Ghorbel¹, H. El Benna¹, Y. Berrazega¹, N. Daoud¹, S. Labidi², H. Boussen², ¹Abderrahmen Mami Hospital, Tunis, TN, ²Abderrahmen Mami Hospital, Ariana, TN

12:00 - 12:00 **303P - Re-sentinel node biopsy for local recurrence after breast-conserving surgery**

Y. Matsubara¹, T. Yamanaka², T. Yamashita³, S. Okamoto², S. Toda², K. Kohagura², Y. Sugawara², A. Yamanaka², N. Suganuma², H. Nakayama⁴, T. Yoshida⁴, H. Iwasaki², Y. Rino⁴, M. Masuda⁴, ¹Kanagawa Cancer Center, Yokohama, JP, ²Kanagawa Cancer Center, Kanagawa, JP, ³Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JP, ⁴Yokohama City University, Yokohama, JP

12:00 - 12:00 **304P - Assessment of prognostic and therapeutic factors in men with breast cancer**

D. Herrero Rivera¹, M.D.R. Morales Herrero¹, C. Almeida González¹, A. Sánchez Camacho-Mejías¹, I. Carrasco García¹, J. Benedetti Pedroza², A. Falcon Gonzalez¹, Á. Montaña Periañez¹, F.J. Salvador Bofil¹, M. Ruiz Borrego¹, ¹Hospital Universitario Virgen del Rocío, Sevilla, ES, ²Novartis, Barcelona, ES

12:00 - 12:00 **Breast cancer, metastatic**

12:00 - 12:00 **312P - Genomic Profiling of Chinese Breast Cancer Patients**

Z. Tao¹, T. Li¹, Z. Feng¹, B. Li², H. Zhang², J. Zhang¹, X. Hu¹, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Burning Rock Dx Ltd., Guangzhou, CN

12:00 - 12:00 **313P - Genome copy number alteration burden represents predictor of response in long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer**

N. Walsh¹, S. Furney², C. Quinn³, G. Gullo³, J. Crown³, ¹Dublin City University, Dublin, IE, ²Royal College of Surgeons, Ireland, Dublin, IE, ³St Vincents University Hospital, Dublin, IE

12:00 - 12:00 **314P - Next-generation DNA Sequencing (NGS) Results for Tumors From Phase 2 ABRAZO Study of Talazoparib After Platinum or Cytotoxic Non-Platinum Regimens in Patients (pts) With Advanced Breast Cancer (ABC) and Germline BRCA1/2 (gBRCA) Mutations**

N.C. Turner¹, A.D. Laird², M.L. Telli³, H. Rugo⁴, A. Mailliez⁵, J. Ettl⁶, E.-M. Grischke⁷, L.A. Mina⁸, J. Balmaña⁹, P.A. Fasching¹⁰, S.A. Hurvitz¹¹, L.A. Albacker¹², G.M. Frampton¹², J. Chelliserry¹³, P. Bycott¹³, U. Conte¹⁴, A.M. Wardley¹⁵, M.E. Robson¹⁶, ¹Royal Marsden Hospital, The Institute of Cancer Research, London, GB, ²Pfizer

Oncology, San Francisco, US, ³Stanford University, San Francisco, US, ⁴UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ⁵Centre Oscar Lambret, Lille, FR, ⁶Technische Universität München, München, DE, ⁷Universitätsklinikum Tübingen, Tübingen, DE, ⁸Banner MD Anderson Cancer Center, Gilbert, US, ⁹Hospital Vall d'Hebron, and Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, ES, ¹⁰University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, ¹¹University of California Los Angeles, Los Angeles, US, ¹²Foundation Medicine Inc., Cambridge, US, ¹³Pfizer Inc., San Diego, US, ¹⁴Pfizer Inc., New York, US, ¹⁵The NIHR Manchester Cancer Research UK Clinical Research Facility at The Christie NHS Foundation Trust & Division of Cancer Sciences University of Manchester, Manchester, GB, ¹⁶Memorial Sloan Kettering Cancer Center, New York, US

- 12:00 - 12:00 **315P - FGFR1 and CCND1 gene amplifications are associated with breast cancer resistance to aromatase inhibitors**
E. Imyanitov¹, M. Kramchaninov², T. Akhapkina³, T. Sokolova⁴, S. Aleksakhina⁴, A. Togo⁴, A. Iyevleva⁴, ¹N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU, ²St.-Petersburg City Cancer Center, St.-Petersburg, RU, ³St.-Petersburg Pediatric Medical University, St.-Petersburg, RU, ⁴N.N. Petrov Institute of Oncology, St.-Petersburg, RU
- 12:00 - 12:00 **316P - Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe Experience**
S. Aksoy¹, R. Degirmenciler¹, B. Aktas¹, D.C. Guven¹, O.H. Aktepe², G. Guner², H. Taban², N. Kertmen², Z. Arik², O. Dizdar³, ¹Hacettepe University Faculty of Medicine, Ankara, TR, ²Hacettepe University Cancer Institute, Ankara, TR, ³Hacettepe University - Faculty of Medicine, Ankara, TR
- 12:00 - 12:00 **317P - Novel fusion genes identified from matched primary and recurred breast cancers by RNA-sequencing**
S. Choi¹, J. Kim², I.Y. Chung¹, W.G. Jo¹, K.W. Yun¹, H.J. Park¹, S.B. Lee¹, H.J. Kim¹, B.S. Ko¹, J.W. Lee¹, B.H. Son¹, S.H. Ahn¹, ¹Asan Medical Center, Seoul, KR, ²University of Ulsan, College of Medicine, Asan Medical Center, Seoul, KR
- 12:00 - 12:00 **318P - Association between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer**
D. Fitzgerald¹, A. Muzikansky¹, C. Pinto¹, L. Henderson², C. Walmsley², R. Allen², G. Ferraro², S. Isakoff², B. Moy², K. Oh¹, H. Shih¹, D. Dias-Santagata², A. Iafrate¹, A. Bardia², P. Brastianos¹, D. Juric², ¹Massachusetts General Hospital, Harvard Medical School, Boston, US, ²Massachusetts General Hospital, Boston, US
- 12:00 - 12:00 **319P - The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: a translational approach.**
A. Adam-Artigues¹, E. Tormo¹, F. Rojo², J.A. Perez-Fidalgo³, S. Zazo², P. Gonzalez-Alonso², C. Hernando¹, M.T. Martínez¹, V. Gambardella⁴, J. Poveda¹, S. Simón¹, S. Moragon¹, E. Alonso⁵, A. Rovira⁶, J. Albanell⁶, O. Burgues⁵, B. Bermejo¹, P. Eroles¹, A. Lluch¹, J.M. Cejalvo⁴, ¹Biomedical Research Institute INCLIVA, Hospital Clínico València, University of Valencia, Valencia, ES, ²IIS-Fundación Jiménez Díaz, Madrid, ES,

³Biomedical Research Institute INCLIVA, Hospital Clínico València, University of Valencia. Center for Biomedical Network Research on Cancer (CIBERONC), Valencia, ES, ⁴Hospital Clínico Universitario de Valencia, Valencia, ES, ⁵Hospital Clínico Valencia, University of Valencia, Valencia, ES, ⁶University Hospital del Mar, Barcelona, ES

12:00 - 12:00

320P - Untargeted assessment of tumor fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment

M. Balic¹, C. Suppan², I. Brcic², V. Tiran², D. Mueller², F. Posch³, P. Ulz², E. Heitzer², N. Dandachi², ¹LKH-Univ. Klinikum Graz, Graz, AT, ²Medical University Graz, Graz, AT, ³LKH-Univ.Klinikum Graz - Universitätsklinik für Innere Medizin, Graz, AT

12:00 - 12:00

321P - Clinical application of mutational analysis in breast cancer patients: the relevance of PIK3CA analysis for precision medicine.

J.M. Cejalvo¹, S. Moragon², B. Ortega², C. Hernando², M. Martínez², V. Gambardella¹, N. Tarazona Llaveró¹, D. Roda², O. Burgues³, E. Alonso³, S. Simón², J. Poveda², P. Rentero², S. Zuñiga², B. Bermejo², A. Lluch², A. Cervantes¹, ¹Hospital Clínico Universitario de Valencia, Valencia, ES, ²Biomedical Research Institute INCLIVA, Hospital Clínico València, University of Valencia, Valencia, ES, ³Hospital Clínico Valencia, University of Valencia, Valencia, ES

12:00 - 12:00

322P - A retrospective gene expression analysis of surgically-removed Breast Cancer Brain Metastasis (BCBM)

M. Mallafré-Larrosa¹, T. Pascual², N. Chic³, O. Martínez³, P. Galvan², B. Gonzalez-Farre³, M. Vidal³, M. Muñoz³, B. Adamo³, A. Prat⁴, ¹Universitat de Barcelona, Barcelona, ES, ²Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES, ³Hospital Clinic, Barcelona, ES, ⁴Hospital Clinic y Provincial de Barcelona, Barcelona, ES

12:00 - 12:00

323P - Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: meta-analysis of Phase II and III randomized clinical trials

C. Omarini¹, I. Sperduti², M. Barbolini¹, C. Isca¹, A. Bocconi¹, A. Toss¹, L. Cortesi¹, E. Barbieri¹, F. Piacentini¹, S. Cascinu¹, L. Moscetti¹, ¹Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ²Bio-Statistics Unit, Regina Elena National Cancer Institute, Roma, IT

12:00 - 12:00

324P - Alpelisib (ALP) + fulvestrant (FUL) for patients with hormone receptor-positive (HR+), HER2– advanced breast cancer (ABC): management and time course of key adverse events of special interest (AESIs) in SOLAR-1

H. Rugo¹, F. André², T. Yamashita³, H. Cerda⁴, I. Toledano⁵, S. Stemmer⁶, J. Cruz Jurado⁷, D. Juric⁸, I. Mayer⁹, E. Ciruelos¹⁰, H. Iwata¹¹, P.F. Conte¹², M. Campone¹³, C. Wilke¹⁴, D. Mills¹⁵, I. Lorenzo¹⁶, M. Miller¹⁶, S. Loibl¹⁷, ¹UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JP, ⁴Centro Internacional de Estudios Clínicos, Santiago, CL, ⁵Centre de Cancérologie du Grand Montpellier, Montpellier, FR, ⁶Rabin Medical Center Belinson, Petach Tikva, IL, ⁷Hospital Universitario de Canarias, San Cristobal de la Laguna, ES, ⁸Massachusetts General Hospital, Boston, US, ⁹Vanderbilt University, Nashville, US,

¹⁰University Hospital 12 De Octubre, Madrid, ES, ¹¹Aichi Cancer Center Hospital, Nagoya, JP, ¹²Istituto Oncologico Veneto IRCCS, Padova, IT, ¹³ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹⁴Novartis Pharma AG - Novartis Campus, Basel, CH, ¹⁵Novartis Pharma AG, Basel, CH, ¹⁶Novartis Pharmaceuticals Corp., East Hanover, US, ¹⁷German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

12:00 - 12:00 **325P - Changes in Hormone-Receptor status in Luminal breast cancers between primary tumor and metastases: results of the observational cohort GIM-13 AMBRA Study**

M. Cazzaniga¹, P. Pronzato², L. Del Mastro³, C. Natoli⁴, F. Montemurro⁵, G. Bisagni⁶, L. Blasi⁷, A. Turletti⁸, M. Giordano⁹, L. Biganzoli¹⁰, A. Michelotti¹¹, O. Garrone¹², P. Marchetti¹³, F. Riccardi¹⁴, A. Bernardo¹⁵, L. Livi¹⁶, F. Cognetti¹⁷, M. Donadio¹⁸, E. Romagnoli¹⁹, G. Mustacchi²⁰, ¹Azienda Ospedaliera S. Gerardo - Oncologia Medica, Monza, IT, ²Ospedale St. Andrea, La Spezia, IT, ³IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ⁴Ospedale Clinicizzato SS. Annunziata - Chieti - Policlinico, Chieti, IT, ⁵Istituto di Candiolo - FPO - IRCCS, Candiolo, IT, ⁶Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, ⁷Fondazione Istituto San Raffaele - G. Giglio di Cefalù, Cefalù, IT, ⁸ASL "Città di Torino", Torino, IT, ⁹Presidio Ospedaliero Ospedale Sant'Anna, San Fermo della Battaglia, IT, ¹⁰Ospedale di Prato Sandro Pitigliani Med. Oncology Unit, Prato, IT, ¹¹Azienda Ospedaliera Universitaria S. Chiara, Pisa, IT, ¹²Azienda Ospedaliera St. Croce e Carle, Cuneo, IT, ¹³Azienda Ospedaliera St. Andrea, Rome, IT, ¹⁴AORN Cardarelli, UOC di Oncologia, Napoli, IT, ¹⁵Fondazione S. Maugeri IRCCS, Pavia, IT, ¹⁶AOU Careggi - Radioterapia Oncologica, Firenze, IT, ¹⁷Istituto Nazionale Tumori Regina Elena, Rome, IT, ¹⁸AOU Città della Salute e della Scienza Torino, Torino, IT, ¹⁹Ospedale Generale Provinciale Macerata, Macerata, IT, ²⁰University of Trieste-Ospedale di Cattinara, Trieste, IT

12:00 - 12:00 **326P - MONARCH 3: Updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR+, HER2- advanced breast cancer (ABC)**

M. Martín¹, S. Johnston², J. Huober³, A. Di Leo⁴, J. Sohn⁵, V. Andre⁶, H. Martin⁷, M. Hardebeck⁷, M. Goetz⁸, ¹Hospital General Universitario Gregorio Marañón, Madrid, ES, ²The Royal Marsden NHS Foundation Trust, London, GB, ³Universitätsfrauenklinik Ulm, Ulm, DE, ⁴Nuovo Ospedale di Prato, Prato, IT, ⁵Yonsei University, Seoul, KR, ⁶Eli Lilly and Company, Paris, FR, ⁷Eli Lilly and Company, Indianapolis, US, ⁸Mayo Clinic, Rochester, US

12:00 - 12:00 **327P - Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis**

M. Torres¹, X. Liu², J. Mardekian³, L. Mcroy³, ¹Winship Cancer Institute, Emory University School of Medicine, Atlanta, US, ²Pfizer Inc, Peapack, US, ³Pfizer Inc, New York, US

12:00 - 12:00 **328P - Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) from the CompLEement-1 trial**

M. Campone¹, M. De Laurentiis², C. Zamagni³, I. Kudryavcev⁴, M. Agterof⁵, U. Brown-

Glaberman⁶, M. Palácová⁷, S. Chatterjee⁸, L. Menon-Singh⁹, J. Wu⁹, K. Zhou⁹, M. Martin¹⁰, ¹Institute of Cancer Research in Western France (ICO), Nantes, FR, ²IRCCS Istituto Nazionale Tumori Fondazione Pascale, Naples, IT, ³The Bologna University Hospital Authority St. Orsola-Malpighi Polyclinic, Bologna, IT, ⁴Kaluga Regional Clinical Oncology Center, Kaluga, RU, ⁵St. Antonius Hospital, Utrecht/Nieuwegein, NL, ⁶University of New Mexico Cancer Center, New Mexico, US, ⁷Masaryk Memorial Cancer Institute, Brno, CZ, ⁸Tata Medical Centre, Kolkata, IN, ⁹Novartis, East Hanover, US, ¹⁰Hospital General Universitario Gregorio Marañón, Madrid, ES

12:00 - 12:00

329P - Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices

R. Layman¹, X. Liu², J. Mardekian³, L. Mcroy³, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²Pfizer Inc, Peapack, US, ³Pfizer Inc, New York, US

12:00 - 12:00

330P - Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumors

Y.-J. Bang¹, M. Karayama², M. Takahashi³, J. Watanabe⁴, H. Minami⁵, N. Yamamoto⁶, I. Kinoshita⁷, C.-C. Lin⁸, Y.-H. Im⁹, T. Fujiki¹⁰, I. Achiwa¹⁰, E. Kamiyama¹⁰, Y. Okuda¹⁰, C. Lee¹¹, S. Takahashi¹², ¹Seoul National University Hospital, Seoul, KR, ²Hamamatsu University School of Medicine, Hamamatsu, JP, ³Hokkaido Cancer Center, Sapporo, JP, ⁴Shizuoka Cancer Center, Shizuoka, JP, ⁵Kobe University Hospital, Kobe, JP, ⁶National Cancer Center Hospital, Tokyo, JP, ⁷Hokkaido University, Sapporo, JP, ⁸National Taiwan University Hospital, Taipei City, TW, ⁹Samsung Medical Center, Seoul, KR, ¹⁰Daiichi Sankyo, Co., Ltd., Tokyo, JP, ¹¹Daiichi Sankyo, Inc., Basking Ridge, US, ¹²Cancer Institute Hospital of JFCR, Tokyo, JP

12:00 - 12:00

331P - A Phase 2 study of abemaciclib in patients (pts) with brain metastases (BM) secondary to non-small cell lung cancer (NSCLC) or melanoma (MEL).

S. Sahebjam¹, E. Le Rhun², P. Queirolo³, G. Jerusalem⁴, D. Subramaniam⁵, M. Bear⁶, Z. Yang⁶, Y. Chen⁶, P.F. Conte⁷, ¹Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, US, ²Roger Salengro Hospital, Lille, FR, ³IRCCS Ospedale Policlinico San Martino, Genova, IT, ⁴Sart-CHU Sart Tilman Liege, Liege, BE, ⁵Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., US, ⁶Eli Lilly and Company, Indianapolis, US, ⁷Istituto Oncologico Veneto IRCCS, Padova, IT

12:00 - 12:00

332P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis from the CompleEment-1 trial

M. De Laurentiis¹, A. Ring², M. Campone³, T. Bachelot⁴, W. Jacot⁵, P. Marchetti⁶, C. Timcheva⁷, B. De Valk⁸, A. Gombos⁹, L. Menon-Singh¹⁰, J. Wu¹⁰, K. Zhou¹⁰, P. Neven¹¹, ¹IRCCS Istituto Nazionale Tumori Fondazione Pascale, Naples, IT, ²The Royal Marsden Hospital NHS Foundation Trust, Surrey, GB, ³Institute of Cancer Research in Western France (ICO), Nantes, FR, ⁴Centre Léon Bérard, Lyon, FR, ⁵ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ⁶Azienda Ospedaliera St. Andrea, Rome, IT, ⁷Multiprofile Hospital for Active Treatment and Women's Health, Sofia, BG, ⁸Spaarne Ziekenhuis, Hoofddorp, NL, ⁹Institute Jules Bordet, Brussels, BE, ¹⁰Novartis, East Hanover, US, ¹¹University of Leuven, Leuven, BE

- 12:00 - 12:00 **333P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase 3b CompLEEment-1 trial**
P. Cottu¹, M. De Laurentiis², P. Marchetti³, L. Coltelli⁴, N. Califaretti⁵, M. Debled⁶, S. Patil⁷, E. Evron⁸, F. Duhoux⁹, L. Menon-Singh¹⁰, J. Wu¹⁰, K. Zhou¹⁰, J. Salvador Bofill¹¹,
1Institut Curie, Paris, FR, 2IRCCS Istituto Nazionale Tumori Fondazione Pascale, Naples, IT, 3Azienda Ospedaliera St. Andrea, Rome, IT, 4presidio ospedaliero livorno, livorno, IT, 5Grand River Regional Cancer Center, Kitchener, CA, 6Institut Bergonié, Bordeaux, FR, 7Bangalore Institute of Oncology, Bangalore, IN, 8Assaf Harofeh Medical Center, Tel Aviv, IL, 9Cliniques Universitaires St. Luc, Brussels, BE, 10Novartis, East Hanover, US, 11Hospital Universitario Virgen Valme, Sevilla, ES
- 12:00 - 12:00 **334P - Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting.**
E. Fountzilas¹, G.-A. Koliou², V. Rapti², A. Nikolakopoulos², A. Christopoulou², E. Moirogiorgou², I. Binas², G. Aravantinos², L. Kostadima², A. Nikolaidi², S. Karteri³, F. Zagouri², Z. Saridaki², A. Molfeta², P. Oikonomopoulou², E. Res², D. Tryfonopoulos², G. Koumakis², G. Fountzilas², E. Razis²,
1Papageorgiou Hospital - Aristotle University of Thessaloniki, Thessaloniki, GR, 2Hellenic Cooperative Oncology Group (HeCOG), Athens, GR, 3University Hospital Patras, Patras, GR
- 12:00 - 12:00 **335P - Safety and efficacy of Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study.**
M. De Laurentiis¹, M. Mazza², M. Mansutti³, R. Masetti⁴, Z. Ballatore⁵, R. Torrisi⁶, A. Michelotti⁷, A. Zambelli⁸, A. Ferro⁹, D. Generali¹⁰, P. Vici¹¹, L. Coltelli¹², A. Fabi¹¹, P. Marchetti¹³, A. Ballestrero¹⁴, S. Spazzapan¹⁵, A. Frassoldati¹⁶, G. Sarobba¹⁷, D. Grasso¹⁸, C. Zamagni¹⁹,
1Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, 2Istituto Europeo di Oncologia, Milan, IT, 3Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia, Udine, IT, 4Fondazione Policlinico Gemelli IRCSS, Roma, IT, 5AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, IT, 6Istituto Clinico Humanitas, Rozzano, IT, 7Azienda Ospedaliera Universitaria S. Chiara, Pisa, IT, 8Presidio Ospedaliero Papa Giovanni XXIII, Bergamo, IT, 9Ospedale Santa Chiara, Trento, IT, 10Istituti Ospitalieri di Cremona, ASST di Cremona, Cremona, IT, 11Istituto Nazionale Tumori Regina Elena, Rome, IT, 12presidio ospedaliero livorno, livorno, IT, 13Azienda Ospedaliera St. Andrea, Rome, IT, 14Ospedale Policlinico San Martino IRCCS, Genova, IT, 15Azienda Ospedaliera Sta Maria degli Angeli, Pordenone, IT, 16Azienda Ospedaliera di Ferrara St. Anna, Ferrara, IT, 17ASL 3, Nuoro, IT, 18Novartis Farma SpA, Origgio, IT, 19The Bologna University Hospital Authority St. Orsola-Malpighi Polyclinic, Bologna, IT
- 12:00 - 12:00 **336P - Interim Results From CompLEEment-1 (A Phase 3b Study of Ribociclib and Letrozole as First-Line Therapy for Advanced Breast Cancer in an Expanded Population): Spanish cohort results**
J. Salvador¹, E. Ciruelos², B. Jiménez-Rodríguez³, L. De La Cruz⁴, R. Villanueva Vázquez⁵,

R. De Toro⁶, A. Antón⁷, F. Moreno⁸, I. Álvarez⁹, V. Quiroga¹⁰, J. De La Haba¹¹, S. González-Santiago¹², N. Díaz¹³, A. Barnadas¹⁴, B. Cantos¹⁵, I. Delgado Mingorance¹⁶, M. Bellet Ezquerro¹⁷, M. Martín¹⁸, N. Martínez¹⁹, E. Vicente²⁰, ¹Hospital Universitario Virgen del Rocío, Sevilla, ES, ²University Hospital 12 De Octubre, Madrid, ES, ³Virgen de la Victoria University Hospital, Malaga, ES, ⁴Virgen de la Macarena University Hospital, Sevilla, ES, ⁵Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, ES, ⁶Jerez University Hospital, Jerez, ES, ⁷Hospital Universitario Miguel Servet, Zaragoza, ES, ⁸Hospital Clínico San Carlos, Madrid, ES, ⁹Donostia University Hospital, Donostia, ES, ¹⁰Catalan Institute of Oncology, Badalona, ES, ¹¹Hospital Universitario Reina Sofía, Córdoba, ES, ¹²San Pedro de Alcantara University Hospital, Cáceres, ES, ¹³San Juan de Alicante University Hospital, Alicante, ES, ¹⁴Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹⁵Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES, ¹⁶Hospital Universitario Infanta Cristina, Badajoz, ES, ¹⁷Vall d'Hebron University Hospital Institut d'Oncologia, Barcelona, ES, ¹⁸Hospital General Universitario Gregorio Marañón, Madrid, ES, ¹⁹Ramon y Cajal University Hospital, Madrid, ES, ²⁰Insular Gran Canaria University Hospital, Las Palmas de Gran Canaria, ES

12:00 - 12:00

337P - First Canadian Interim Analysis from the Phase IIIb CompLEement-1 Ribociclib + Letrozole HR+ HER2- Advanced Breast Cancer Trial

C. Ferrario¹, E. Warner², N. Califaretti³, A.A. Joy⁴, S. Chia⁵, J. Wu⁶, J.P. Zarate⁷, M. Lakshmi⁶, S. Perri⁸, S. Haftchenary⁸, S. Dent⁹, ¹Jewish General Hospital McGill University, Montreal, CA, ²Sunnybrook Odette Cancer Center, Toronto, CA, ³Grand River Regional Cancer Center, Kitchener, CA, ⁴University of Alberta Cross Cancer Institute, Edmonton, CA, ⁵University of British Columbia, Vancouver, CA, ⁶Novartis, East Hanover, US, ⁷Novartis, US, ⁸Novartis Pharma Canada, Dorval, CA, ⁹The Ottawa Hospital Regional Cancer Centre, Ottawa, CA

12:00 - 12:00

338P - Real-world effectiveness of first-line palbociclib + letrozole for metastatic breast cancer 4 years post approval in the US

J. Kish¹, J. Trocio², T. Miller¹, D. Nero¹, D. Liassou¹, X. Liu³, L. Mcroy², B. Feinberg¹, ¹Cardinal Health Specialty Solutions, Dublin, US, ²Pfizer Inc, New York, US, ³Pfizer Inc, Peapack, US

12:00 - 12:00

339P - Palbociclib-Fulvestrant (PALBO-FUL) and Everolimus -Exemestane (EVE-EXE) for Second line Hormonal Treatment (HT) of Metastatic Breast Cancer (MBC) with Lobular Histology: a Propensity Score Matched Analysis of a Multicenter 'Real-World' Patients (pts) Series.

A. Orlandi¹, E. Iattoni², L. Pizzuti³, M. Fabbri⁴, A. Botticelli⁵, C. Di Dio¹, A. Palazzo², G. Garufi¹, G. Indelicati¹, D. Alesini⁴, L. Carbognin⁶, I. Paris⁷, A. Vaccaro⁸, L. Moscetti⁹, A. Cassano¹, P. Vici³, D. Giannarelli¹⁰, P. Marchetti⁵, E. Bria¹¹, G. Tortora¹², ¹Policlinico Universitario A. Gemelli, Rome, IT, ²Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, IT, ³Istituto Nazionale Tumori Regina Elena, Rome, IT, ⁴Central Hospital of Belcolle, Viterbo, IT, ⁵Azienda Ospedaliera St. Andrea, Rome, IT, ⁶Fondazione Policlinico Universitario A. Gemelli, I.R.C.C.S., Università Cattolica del Sacro Cuore, Roma, IT, ⁷Università Cattolica del Sacro Cuore, Rome, IT, ⁸Frosinone, frosinone, IT, ⁹Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ¹⁰Regina Elena National Cancer Institute, Rome, IT, ¹¹Università Cattolica del Sacro Cuore, Roma, IT, ¹²Fondazione Policlinico Universitario Agostino Gemelli -IRCCS Rome, Rome, IT

- 12:00 - 12:00 **340P - Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)**
E. Dees¹, P. Aftimos², C. Menke-Van Der Houven Van Oordt³, E.G.E. De Vries⁴, P. Neven⁵, M. Pegram⁶, R. Iqbal³, J. Boers⁴, J. Xiao⁷, C. Sipes⁷, C. Li⁸, J. Sorrentino⁸, R. Malik⁷, A. Beelen⁸, ¹UNC Lineberger Comprehensive Cancer Center, Chapel Hill, US, ²Institute Jules Bordet, Brussels, BE, ³Vrije University Medical Centre (VUMC), Amsterdam, NL, ⁴University Hospital Groningen (UMCG), Groningen, NL, ⁵University of Leuven, Leuven, BE, ⁶Stanford Comprehensive Cancer Institute, Stanford, US, ⁷G1 Therapeutics, Inc, Research Triangle Park, US, ⁸G1 Therapeutics, Inc, Research Triangle Park, US
- 12:00 - 12:00 **341P - Final results of the STEM trial: SFX-01 in the Treatment and Evaluation of ER+ Her2- Metastatic breast cancer (mBC)**
S. Howell¹, M. Campone², J. Cortés³, F. Duhoux⁴, S. Ross⁵, T. Morris⁵, S. Franklin⁵, ¹The University of Manchester, Manchester, GB, ²ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Cliniques Universitaires St. Luc, Brussels, BE, ⁵Evgen Pharma PLC, Liverpool, GB
- 12:00 - 12:00 **342P - Alpelisib (ALP) + Fulvestrant (FUL) in Hormone-Receptor Positive (HR+), Human Epidermal Growth Factor Receptor-2-Negative (HER2-) Advanced Breast Cancer (ABC): Subgroup Analysis by Presence of Visceral Metastasis (VM) in the SOLAR-1 Trial**
M. Campone¹, H. Rugo², G. Rubovszky³, F. André⁴, S. Loibl⁵, H. Iwata⁶, P.F. Conte⁷, I. Mayer⁸, D. Juric⁹, T. Yamashita¹⁰, I. Lorenzo¹¹, A. Ridolfi¹², E. Ciruelos¹³, ¹ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ²UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ³Orszagos Onkologiai Intezet, Budapest, HU, ⁴Gustave Roussy - Cancer Campus, Villejuif, FR, ⁵German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, ⁶Aichi Cancer Center Hospital, Nagoya, JP, ⁷Istituto Oncologico Veneto IRCCS, Padova, IT, ⁸Vanderbilt University, Nashville, US, ⁹Massachusetts General Hospital, Boston, US, ¹⁰Kanagawa Cancer Center, Tokyo, JP, ¹¹Novartis Pharmaceuticals Corporation, Madrid, ES, ¹²Novartis Pharmaceuticals Corporation, Rueil-Malmaison, FR, ¹³University Hospital 12 De Octubre, Madrid, ES
- 12:00 - 12:00 **343P - Phase 1 Dose Escalation Study of a Selective Androgen Receptor Modulator RAD140 in Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) Breast Cancer (BC)**
E. Hamilton¹, N. Vidula², C. Ma³, P. Lorusso⁴, R. Bagley⁵, Z. Yu⁶, M. Annett⁵, A. Weitzman⁵, M. Conlan⁵, A. Weise⁷, ¹Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ²Massachusetts General Hospital, Boston, US, ³Washington University School of Medicine, Saint Louis, US, ⁴Yale Cancer Center, New Haven, US, ⁵Radius Health, Inc., Waltham, US, ⁶Radius Health Inc, Waltham, US, ⁷Barbara Ann Karmanos Cancer Center, Detroit, US
- 12:00 - 12:00 **344P - A Phase I study of XZP-3287, a novel oral CDK4/6 Inhibitor, administered on a continuous dosing schedule, in patients with advanced solid tumours**
B. Xu¹, J. Wang², X. Liu³, J. Fang⁴, Z. Yao⁵, J. Wang⁵, ¹Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, ²National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ³the fifth

Medical Centre, Chinese PLA General Hospital, Beijing, CN, ⁴Peking University Cancer Hospital & Institute, Beijing, Beijing, CN, ⁵Xuanzhu Biopharmaceutical Ltd., Beijing, Beijing, CN

12:00 - 12:00

345P - Phase-I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors

H. Li¹, J. Xu², B. Shao³, R. Liu⁴, R. Ran³, G. Song³, H. Jiang⁵, K. Wang⁶, Y. Shi⁶, J. Liu⁷, W. Hu⁸, F. Chen³, G. Zhang⁹, Y. Wang⁹, C. Zhao¹⁰, J. Ru¹⁰, Q. Wang¹¹, H. Rugo¹², G. Li¹¹, ¹Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, ²Fifth Medical Center, General Hospital of the People's Liberation Army, Beijing, CN, ³Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, CN, ⁴307 Hospital of PLA, Beijing, China ³⁰⁷ Hospital of PLA, Beijing, CN, ⁵Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, BEIJING, CN, ⁶Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjing, CN, ⁷Sun Yat-sen University Cancer Center, Guangzhou, CN, ⁸The Comprehensive Cancer Centre of Drum Tower Hospital, Clinical College of Nanjing Medical University,, Nanjing, CN, ⁹307 Hospital of PLA, Beijing, CN, ¹⁰307 Hospital of PLA, Beijing, Beijing, CN, ¹¹Jiangsu Hengrui Medicine Co, Jiangsu Lianyungang, CN, ¹²UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

12:00 - 12:00

346P - Phase 2 study of DHP107 (Liporaxel®, oral paclitaxel) in first-line, HER2 negative recurrent/metastatic breast cancer (OPTIMAL study, NCT03315364)

J.-H. Ahn¹, K.S. Lee², K.-H. Lee³, J.H. Seo⁴, S.Y. Kang⁵, J. Sohn⁶, Y. Yang⁷, K.H. Park⁸, Y.W. Moon⁹, S.T. Lim¹⁰, K.E. Yoon¹¹, H.J. Cho¹², S.-B. Kim¹³, ¹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ²National Cancer center, Ilsandong-gu, KR, ³Seoul National University Hospital, Seoul, KR, ⁴Korea University Guro Hospital, Seoul, KR, ⁵Ajou University School of Medicine, Suwon, KR, ⁶Yonsei University, Seoul, KR, ⁷Chungbuk National University Hospital, Cheongju, KR, ⁸Korea University Anam University, Seoul, KR, ⁹Bundang Cha Medical Center, Seongnam, KR, ¹⁰Wonju Severance Christian Hospital, Gangwon-do, KR, ¹¹DAE HWA Pharmaceutical Co., Ltd., Seoul, KR, ¹²Daehwa Pharmaceutical Co., Ltd., Seoul, KR, ¹³Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR

12:00 - 12:00

347P - Multicenter Phase I Trial of Trastuzumab Emtansine (T-DM1) in Combination with Non-Pegylated Liposomal Doxorubicin (NPLD) in HER2[+] Metastatic Breast Cancer (MBC). THELMA Study

E. López-Miranda¹, S. Di Cosimo², E. Brain³, M. Ravnik⁴, S. Escrivá-De-Romaní⁵, M. Vidal⁶, J. Gligorov⁷, S. Borstnar⁸, L. Calabuig⁹, M. Sampayo⁹, J.M. Pérez-García¹⁰, F. Riva⁹, A. Malfettone⁹, A. Llombart Cussac¹¹, T. Suter¹², J. Cortés¹³, ¹Hospital Universitario Ramón y Cajal, Madrid, Spain, Madrid, ES, ²Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ³Hôpital René Huguenin - Institut Curie, St. Cloud, FR, ⁴University Medical Centre Maribor,, Maribor, SI, ⁵Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁶Hospital Clinic, Barcelona, ES, ⁷APHP, CancerEst, Tenon University Hospital, Paris, FR, ⁸Institute of Oncology Ljubljana, Ljubljana, SI, ⁹Medica Scientia Innovation Research (MedSIR), Barcelona, Spain and Ridgewood, New Jersey, USA, Barcelona, ES, ¹⁰Medica Scientia Innovation Research (MedSIR), Barcelona, Spain and Ridgewood, New Jersey, USA; IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain, Barcelona, ES, ¹¹Hospital

Universitario Arnau de Vilanova, Lleida, ES, ¹²Inselspital - Universitätsspital Bern, Bern, CH, ¹³Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain and Ridgewood, New Jersey, USA, Barcelona, ES

12:00 - 12:00 **348P - Phase 1 study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumors: primary results of dose-escalation part**

N. Yamamoto¹, J. Sato¹, T. Koyama¹, S. Iwasa¹, A. Shimomura¹, S. Kondo¹, S. Kitano¹, K. Yonemori¹, Y. Fujiwara¹, K. Tamura¹, T. Suzuki², T. Takase², Y. Nishiwaki², K. Nakai², T. Shimizu¹, ¹National Cancer Center Hospital, Tokyo, JP, ²Eisai Co., Ltd., Bunkyo-ku, JP

12:00 - 12:00 **349P - Polo-like Kinase 1 inhibitor onvansertib synergizes with paclitaxel in breast cancer carrying p53 mutation**

A. Giordano¹, Y. Liu¹, C. Kappler¹, Y. Park¹, E. Yeh¹, M. Erlander², S. Ethier¹, ¹Hollings Cancer Center at the Medical University of South Carolina, Charleston, US, ²Trovagene, San Diego, US

12:00 - 12:00 **350P - Phase 1b study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173).**

R. Wesolowski¹, A. Brufsky², M. Chambers³, S. Bhattacharya⁴, M. Lustberg⁵, J. Vandeusen¹, S. Sardesai¹, N. Williams¹, A. Noonan⁶, M. Phelps¹, M. Grever⁷, J. Stephens⁷, W. Carson⁷, B. Ramaswamy¹, ¹Ohio State Univ Medical Center, Columbus, US, ²Magee-Womens Hospital of UPMC, Pittsburgh, US, ³University of Kentucky, Lexington, US, ⁴Thomas Jefferson University, Philadelphia, US, ⁵The Ohio State Comprehensive Cancer Center, Columbus, US, ⁶The Ohio State University James Cancer Hospital, Columbus, US, ⁷Ohio State Univ Medical Center, columbus, US

12:00 - 12:00 **351P - Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: results from the AGMT_MBC-Registry**

S.P. Gampenrieder¹, G. Rinnerthaler¹, A. Petzer², C. Tinchon³, D. Fuchs⁴, M. Balic⁵, S. Heibl⁶, H. Rumpold⁷, D. Egle⁸, A. Zabernigg⁹, C. Singer¹⁰, J. Andel¹¹, M. Hubalek¹², M. Knauer¹³, R. Greil¹, ¹Paracelsus Medical University, Salzburg, AT, ²Ordensklinikum Linz Barmherzige Schwestern - Elisabethinen, Linz, AT, ³LKH Hochsteiermark, Leoben, AT, ⁴Johannes Kepler University Linz, Linz, AT, ⁵Medical University Graz, Graz, AT, ⁶Klinikum Wels-Grieskirchen GmbH, Wels, AT, ⁷Academic Teaching Hospital Feldkirch, Feldkirch, AT, ⁸Medical University Innsbruck, Innsbruck, AT, ⁹County Hospital Kufstein, Kufstein, AT, ¹⁰Medical University of Vienna, Vienna, AT, ¹¹Landeskrankenhaus Steyr, Steyr, AT, ¹²Country Hospital Schwaz, Schwaz, AT, ¹³Breast Center St. Gallen, St. Gallen, CH

12:00 - 12:00 **352P - Clinical profile and outcome of HER2 positive breast cancer patients with brain metastases treated with HER2 targeted therapy: Real world experience.**

P. Bhargava¹, R. Shenoy², N. Rathnasamy², S. Gulia³, J. Bajpai⁴, J. Ghosh⁴, S. Rath⁴, A. Budrukkar⁴, T. Shet⁴, A. Patil⁴, N. Nair⁴, P. Popat⁴, T. Wadasadawala⁴, R. Sarin⁴, S. Kannan⁴, R. Badwe⁴, S. Gupta¹, ¹Tata Memorial Hospital Centre, Mumbai, IN, ²Tata Memorial Centre, MUMBAI, IN, ³Tata Memorial Hospital, Mumbai, IN, ⁴Tata Memorial Centre, Mumbai, IN

- 12:00 - 12:00 **353P - Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: results of single arm phase IV COMACHI study**
N. Masuda¹, S. Ohtani², S. Nagai³, S. Takashima⁴, M. Yamaguchi⁵, M. Tsuneizumi⁶, Y. Komoike⁷, T. Osako⁸, Y. Ito⁹, M. Ikeda¹⁰, K. Ishida¹¹, T. Nakayama¹², T. Takashima¹³, T. Asakawa¹⁴, S. Matsumoto¹⁴, D. Shimizu¹⁴, M. Takahashi¹⁵, ¹National Hospital Organization Osaka National Hospital, Osaka, JP, ²Hiroshima City Hospital, Hiroshima, JP, ³Saitama Cancer Center, Saitama, JP, ⁴National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, ⁵JCHO KURUME GENERAL HOSPITAL, Kurume, JP, ⁶Shizuoka General Hospital, Shizuoka, JP, ⁷Kindai University Hospital, Sayama, JP, ⁸Kumamoto Shinto General Hospital, Kumamoto, JP, ⁹Cancer Institute Hospital of JFCR, Tokyo, JP, ¹⁰Fukuyama City Hospital, Hiroshima, JP, ¹¹Iwate Medical University, Morioka, JP, ¹²Osaka International Cancer Institution, Osaka, JP, ¹³Osaka City University Medical School, Osaka, JP, ¹⁴Chugai Pharmaceuticals, Tokyo, JP, ¹⁵Hokkaido Cancer Center, Sapporo, JP
- 12:00 - 12:00 **354P - Anti HER-2 Therapies and Left Ventricular Dysfunction The Renaissance Study**
A. Daniele¹, V. Gregoriotti², A. Aguilar¹, C. Almada¹, V. Lopez¹, M. Savignano¹, G. Roganovich¹, N. Kassis¹, A. D'ortencio¹, S. Daniele³, M.V. Cáceres¹, ¹Roffo institute, Caba, AR, ²Sagrado Corazón, Caba, AR, ³Hospital Italiano, Buenos Aires, AR
- 12:00 - 12:00 **355P - Safety and efficacy of T-DM1 in 128 patients with advanced HER2+ breast cancer: The Royal Marsden experience.**
N. Battisti¹, K. Lee², S. Shepherd², F. Rogerson³, K. Mohammed⁴, M. Allen³, A. Ring¹, ¹The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ²Royal Marsden Hospital NHS Foundation Trust, London, GB, ³Royal Marsden Hospital NHS Foundation Trust, Sutton, GB, ⁴Royal Marsden NHS Foundation Trust, Sutton, GB
- 12:00 - 12:00 **356P - Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): challenges in assessing effectiveness of treatment sequencing in the real world (RW)**
T. Sanglier¹, A. Fabi², C. Flores³, E. Flahavan⁴, N. Lindegger⁵, F. Montemurro⁶, ¹F. Hoffmann-La Roche AG, Basel, CH, ²Istituto Nazionale Tumori "Regina Elena", Roma, IT, ³Genentech, Inc., South San Francisco, US, ⁴F. Hoffmann-La Roche Ltd., Welwyn Garden City, GB, ⁵F. Hoffmann-La Roche Ltd., Basel, CH, ⁶Candiolo Cancer Institute, Candiolo, IT
- 12:00 - 12:00 **357P - Patient Reported Outcomes (PRO) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/ without visceral disease**
J. Ettl¹, R.G.W. Quek², H. Bhattacharyya³, H. Rugo⁴, S.A. Hurvitz⁵, A. Gonçalves⁶, ¹Technische Universität München, München, DE, ²Pfizer Inc., San Francisco, US, ³Pfizer Inc., New York, US, ⁴UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ⁵University of California Los Angeles, Los Angeles, US, ⁶Institut Paoli Calmettes, Marseille, FR

- 12:00 - 12:00 **358P - Complete Responses in Patients With 2nd-Line or Greater Metastatic Triple-Negative Breast Cancer (TNBC) Following First-in-Human Immunotherapy Combining NK and T Cell Activation with Off-the-Shelf High-Affinity CD16 NK Cell Line (haNK)**
C. Nangia¹, P. Soon-Shiong², S. Rabizadeh², J. Lee², L. Sender³, F. Jones², M. Kistler⁴, K. Niazi⁵, T. Seery¹, A. Rock², O. Jafari⁶, ¹Chan Soon-Shiong Institute for Medicine, Costa Mesa, US, ²NantCell, Culver City, US, ³NantKwest, CULVER CITY, US, ⁴Chan Soon-Shiong Institute for Medicine, El Segundo, US, ⁵NantBio, Culver City, US, ⁶Medical Imaging Center of Southern California, Santa Monica, US
- 12:00 - 12:00 **359P - Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple-negative breast cancer (TNBC)**
A. Noske¹, J. Ammann², D.-C. Wagner³, C. Denkert⁴, A. Lebeau⁵, P. Sinn⁶, H.-H. Kreipe⁷, G. Baretton⁸, K. Steiger¹, M. Kiechle¹, S. Hieke-Schulz², W. Roth³, W. Weichert¹, ¹Technische Universität München, Munich, DE, ²Roche Pharma AG, Grenzach-Wyhlen, DE, ³Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, ⁴Universitätsklinikum Marburg, Marburg, DE, ⁵Gemeinschaftspraxis für Pathologie and b) Universitätsklinikum Hamburg-Eppendorf, Lübeck and Hamburg, DE, ⁶Universitätsklinikum Heidelberg, Heidelberg, DE, ⁷Medizinische Hochschule Hannover, Hannover, DE, ⁸Universitätsklinikum Carl Gustav Carus Dresden, Technische Universität Dresden, Dresden, DE
- 12:00 - 12:00 **360P - Systemic Therapy in 2nd-Line Metastatic Triple Negative Breast Cancer (mTNBC): A Systematic Literature Review (SLR) and Meta-Analysis (MA) of Efficacy**
P. Kaufman¹, C. Kwon², J. Feliciano³, T. Westley², A. Forsythe², P. Garfin³, L. Brown³, ¹Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, US, ²Purple Squirrel Economics, New York, US, ³Seattle Genetics, Inc., Bothell, US
- 12:00 - 12:00 **361P - Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia**
Y. Chen, J. Zhang, J. Zhang, X. Hu, Fudan University Shanghai Cancer Center, Shanghai, CN
- 12:00 - 12:00 **362P - Patterns and predictors of first-line (1L) taxane use in US patients with metastatic triple-negative breast cancer (mTNBC)**
J. O'Shaughnessy¹, L. Emens², S. Chui³, K. Russell⁴, S.-W. Lin⁵, C. Flores Avile⁶, P. Luhn⁵, A. Schneeweiss⁷, ¹Texas Oncology, Dallas, US, ²UPMC Hillman Cancer Center, Pittsburgh, US, ³Genentech Inc. - Roche - USA, South San Francisco, US, ⁴F. Hoffmann-La Roche, Ltd., Basel, CH, ⁵Genentech, Inc., South San Francisco, US, ⁶Genesis Research, Hoboken, US, ⁷University Hospital Heidelberg, Heidelberg, DE
- 12:00 - 12:00 **363P - Maintenance Chemotherapy is effective in Patients with Metastatic Triple Negative Breast Cancer After First-line Platinum-based Chemotherapy**
J. Zhang, Y. Chen, X. Hu, Fudan University Shanghai Cancer Center, Shanghai, CN
- 12:00 - 12:00 **364P - Using the Patient-Reported Outcomes Measurement Information System**

(PROMIS) to investigate symptom burden enrichment in Stage IV patients at an academic center

M. Matthys, A. Dempsey, A. Basu, N. Dreher, L. Esserman, L. Van 'T Veer, M. Melisko, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

12:00 - 12:00 **365P - Measures of functional status in adults aged ≥ 70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS**

M. Karuturi¹, J. Blum², J. Wallmark³, S. Mccune⁴, S. Lakhanpal⁵, B. Telivala⁶, M. Tsai⁷, T. Rakowski⁸, A. Bardia⁹, J. Cappelleri¹⁰, E. Richardson¹¹, Y. Wang¹², D. Tripathy¹, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, Dallas, US, ³Maryland Oncology Hematology, Rockville, US, ⁴Northwest Georgia Oncology Centers, Marietta, US, ⁵Saint Vincent's Birmingham, Birmingham, US, ⁶Cancer Specialists of North Florida, Jacksonville, US, ⁷Minnesota Oncology, Minneapolis, US, ⁸Valley Health System, Paramus, US, ⁹Massachusetts General Hospital Cancer Center, Harvard Medical, Boston, US, ¹⁰Pfizer Inc, Groton, US, ¹¹CPi Global CRO, Princeton, US, ¹²Pfizer Inc, New York, US

12:00 - 12:00 **366P - Real-World 1-Year Survival Analysis of Patients with Metastatic Breast Cancer with Liver or Lung Metastasis Treated with Eribulin, Gemcitabine or Capecitabine**

S. Kazmi¹, D. Chatterjee², K. Alexis², D. Raju³, E. Wang⁴, R. Knoth⁴, R. Hauser¹, P. Kaufman⁵, ¹Cancer Treatment Centers of America, Philadelphia, US, ²Eisai Inc, Woodcliff Lake, US, ³Cancer Treatment Centers of America Global, Inc., Boca Raton, US, ⁴Eisai, Inc, Woodcliff Lake, US, ⁵Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, US

12:00 - 12:00 **367P - Prognostic impact of Body Mass Index (BMI) on overall survival in patients with metastatic breast cancer**

K. Saleh¹, M. Carton², V. Dieras³, P.-E. Heudel⁴, E. Brain⁵, N. Firmin⁶, A. Mailliez⁷, A. Patsouris⁸, M.A. Mouret Reynier⁹, A. Gonçalves¹⁰, J.-M. Ferrero¹¹, T. Petit¹², C. Levy¹³, L. Uwer¹⁴, P. Cottu¹⁵, L. Veron¹⁶, E. Deluche¹⁷, A. Savignoni¹⁵, M. Robain¹⁸, S. Delaloge¹⁹, ¹Institut Gustave Roussy, Villejuif, FR, ²Institut Curie, Saint-Cloud, Paris, FR, ³Centre Eugene - Marquis, Rennes, FR, ⁴Centre Léon Bérard, Lyon, FR, ⁵Hôpital René Huguenin - Institut Curie, St. Cloud, FR, ⁶institut du cancer de Montpellier, Montpellier, FR, ⁷Centre Oscar Lambret, Lille, FR, ⁸Centre Paul Papin, Angers, FR, ⁹Centre Jean Perrin, Clermont-Ferrand, FR, ¹⁰Institut Paoli Calmettes, Marseille, FR, ¹¹Centre Anticancer Antoine Lacassagne, Nice, FR, ¹²Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, ¹³Centre Francois Baclesse, Caen, FR, ¹⁴Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, ¹⁵Institut Curie, Paris, FR, ¹⁶Paris Descartes University, Paris, FR, ¹⁷CHU Limoges - Hopital Dupuytren, Limoges, FR, ¹⁸Institut Curie, Saint-Cloud, St. Cloud, FR, ¹⁹Gustave Roussy, Villejuif, FR

12:00 - 12:00 **368P - Clinicopathological characteristics, survival and prognostic factors of breast cancer-related microangiopathic haemolytic anemia: a multicenter study**

M. Alhenc Gelas¹, F.C. Bidard², P.-E. Heudel³, J.-Y. Pierga², L. Cabel⁴, S. Delaloge⁵, J.-S. Frenel⁶, C. Levy⁷, F. Dalenc⁸, ¹Hôpital Saint-Antoine, Paris, FR, ²Institut Curie, Paris, FR, ³Centre Léon Bérard, Lyon, FR, ⁴Hôpital René Huguenin - Institut Curie, St. Cloud, FR,

⁵Gustave Roussy, Villejuif, FR, ⁶ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁷Centre Francois Baclesse, Caen, FR, ⁸Centre Claudius-Regaud, Toulouse, FR

- 12:00 - 12:00 **369P - Metabolic tumor volume by 18F-FDG PET/CT is an independent prognostic factor in metastatic breast cancer**
H. Ahn¹, S.H. Hyun², S. Park², S.J. Lee³, J.Y. Kim², J.S. Ahn², Y.-H. Im⁴, Y.H. Park²,
¹Gachon University Gil Hospital, Incheon, KR, ²Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ³EWHA Womans University Seoul Hospital, Seoul, KR, ⁴Samsung Medical Center, Seoul, KR
- 12:00 - 12:00 **370P - Patient Preferences for breast cancer treatments: A Discrete Choice Experiment from four European countries**
T. Konstantopoulou¹, E. Stamuli², D. Ross³, R. Pacheco⁴, ¹Novartis Farma Italy, Origgio, IT, ²Pharmecons Easy Access, YOAA, GB, ³Trinity University, Dublin, IE, ⁴Novartis Farma - Produtos Farmaceuticos S.A., Porto Salvo, PT
- 12:00 - 12:00 **371P - Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study**
D. Lüftner¹, M. Welslau², R. Liersch³, M. Deryal⁴, C. Brucker⁵, J. Rauh⁶, A. Welt⁷, M. Zaiss⁸, J. Sahlmann⁹, L. Houet⁹, C. Vannier⁹, K. Potthoff⁹, N. Marschner¹⁰, ¹Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE, ²Klinikum Aschaffenburg, Aschaffenburg, DE, ³Hämatologische-Onkologische Gemeinschaftspraxis, Münster, DE, ⁴Caritasklinik St. Theresia, Saarbrücken, DE, ⁵Klinikum Nürnberg, Nürnberg, DE, ⁶Gemeinschaftspraxis Innere Medizin, Witten, DE, ⁷University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ⁸Praxis für Interdisziplinäre Onkologie, Freiburg, DE, ⁹iOMEDICO AG, Freiburg im Breisgau, DE, ¹⁰iOMEDICO AG, Freiburg, DE
- 12:00 - 12:00 **372P - Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype**
H.K. Kim, Y.H. Park, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR
- 12:00 - 12:00 **373P - Administration of chemotherapy for metastatic breast cancer near the end of life: a population registry study**
L. Edman Kessler¹, J. Sigfridsson², J. Bergh³, T. Foukakis¹, A. Matikas⁴, ¹Karolinska University Hospital-Radiumhemmet, Stockholm, SE, ²Karolinska University Hospital, Stockholm, SE, ³Karolinska Institutet - Bioclinicum, Solna, SE, ⁴Karolinska University Hospital-Solna, Stockholm, SE
- 12:00 - 12:00 **374P - Prognostic value of histological growth pattern in patients operated for breast cancer liver metastases**
A. Bohlok¹, L. Botzenhart¹, V. Lucidi², J.C. Noël², P. Demetter³, D. Larsimont¹, V. Donckier¹, P. Vermeulen⁴, ¹Institute Jules Bordet, Brussels, BE, ²Erasmus University Hospital-(Universite Libre de Bruxelles), Brussels, BE, ³Institut Jules Bordet, Brussels, BE, ⁴University of Antwerp, Antwerpen, BE

- 12:00 - 12:00 **375P - Illness perceptions, quality of life and mood in metastatic breast cancer patients**
I. Domingues¹, J. Carvalho², E. Pratas³, S. Pinheiro², S. Amaral², T. Pereira², F. Pontes², R. Félix², A. Chaves², M. Mariano², T. Carvalho², P. Madeira², A. Pêgo², S. Broco², R. Garcia², I. Pazos², A. Pais², G. Sousa², ¹Instituto Português Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT, ²IPOC, Coimbra, PT, ³Portuguese Oncology Institute of Coimbra, Coimbra, PT
- 12:00 - 12:00 **376P - Multidisciplinary Treatments Increases Overall Survival in Patients with Newly Diagnosed Stage IV Breast Cancer : An Analysis of 2010-2014 SEER Data**
J. Zhang¹, M. Li², H. Gong², ¹Shandong Cancer Hospital, Jinan, CN, ²Shandong Tumor Hospital, Jinan, CN
- 12:00 - 12:00 **377P - Correlation of radiotherapy with the prognosis of elderly patients with hormone receptor-positive breast cancer according to immunohistochemical subtyping**
J. Zhang, Tianjin Cancer Hospital, Tianjin, CN
- 12:00 - 12:00 **378P - Real world treatment sequencing patterns in secondary breast cancer (SBC): Pathway visualisation using national datasets.**
A. Horne¹, M. Mcmenemy¹, E. Holly², N. Rigglesford¹, P. Linksted¹, L. Murdoch², O. Oikonomidou³, C. Michie¹, L. Hayward¹, C. Lilley¹, P. Hall⁴, ¹NHS Lothian, Edinburgh, GB, ²University of Edinburgh, Edinburgh, GB, ³Edinburgh Cancer Centre Western General Hospital, Edinburgh, GB, ⁴Edinburgh Cancer Research UK Centre, Edinburgh, GB
- 12:00 - 12:00 **379P - Utilization Pattern of Bone Targeting Agents in Patients with Solid Tumor in Taiwan, Hong Kong and Korea**
S.J. Lai¹, P.C.M. Au², Y.H. Baek³, C.L. Cheung², S.N. Gao⁴, Y.H. Kao Yang¹, N. Kleinman⁴, J.H. Kim³, J. Lange⁵, T.C. Liao¹, T.C. Lin⁶, K.K. Man², J.Y. Shin⁷, C.W. Sing², I.C.K. Wong², E.C.C. Lai¹, ¹NCKU - National Cheng Kung University, Tainan City, TW, ²The University of Hong Kong, Hong Kong, HK, ³SungKyunKwan University (SKKU), Seoul, KR, ⁴Amgen Asia Holding Limited, Hong Kong, HK, ⁵Amgen Inc., Thousand Oaks, CA, US, ⁶Amgen Inc., Thousand Oaks, CA, USA, Thousand Oaks, US, ⁷SungKyunKwan University (SKKU), Soeul, KR
- 12:00 - 12:00 **380P - Clinico-pathological Features and Prognosis of Patients with Pregnancy Associated Breast Cancer - A Matched Case Control Study**
R. Zhang¹, X.-R. Liu¹, H. Li², ¹Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, ²Peking University Cancer Hospital & Institute, Beijing, CN
- 12:00 - 12:00 **381TiP - TRYbeCA-2: A Randomized Phase 2/3 Study of Eryaspase in Combination with Gemcitabine and Carboplatin Chemotherapy versus Chemotherapy Alone As First-Line Treatment in Patients with Metastatic or Locally Recurrent Triple-Negative Breast Cancer**
A. Awada¹, J. Cortés², S. Slater³, I. Macpherson³, T. Csoszi⁴, J.-B. Bertrand⁵, A.-S. Clermont⁵, R. Pollard⁶, R. Chrestia-Blanchine⁵, N. Biswas-Baldwin⁵, H. Youssoufian⁷, I.

El-Hariry⁸, ¹Institute Jules Bordet, Brussels, BE, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Beatson West of Scotland Cancer Centre, Glasgow, GB, ⁴Hetenyi Geza Korhaz, Onkologiai Kozpont, Szolnok, HU, ⁵Erytech Pharma, Lyon, FR, ⁶Erytech Pharma, Boston, US, ⁷Youssoufian Hagop, Boston, US, ⁸Erytech Pharma, Inc, Cambridge, US

12:00 - 12:00 **382TiP - CONTESSA TRIO: A Multinational, Multicenter, Phase 2 Study of Tese taxel plus 3 Different PD-(L)1 Inhibitors in Patients with Metastatic Triple-Negative Breast Cancer (TNBC) and Tese taxel Monotherapy in Elderly Patients with HER2- Metastatic Breast Cancer (MBC)**

S. Tolaney¹, J.L. Blum², I. Bondarenko³, A. Chan⁴, N. Dacosta⁵, Y.-H. Feng⁶, Y. Izarzugaza⁷, S.-B. Kim⁸, M.-C. Liu⁹, M. Oliveira¹⁰, S.G.W. Ow¹¹, M. Pavic¹², M.E. Pérez López¹³, H. Rugo¹⁴, L. Schwartzberg¹⁵, A. Stradella¹⁶, S. Kroll¹⁷, J. O'Connell¹⁷, T. Wei¹⁷, E.A. Mittendorf¹⁸, ¹Dana Farber Cancer Institute, Boston, US, ²Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, ³Dnipropetrovsk city multidisciplinary clinical hospital №4, Dnipro, UA, ⁴Breast Cancer Research Centre BCRC - WA, Nedlands, AU, ⁵North Shore Hematology Oncology Associates, East Setauket, US, ⁶Chi-Mei Medical Center, Tainan, TW, ⁷University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ⁸Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ⁹Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan, CN, ¹⁰Vall d'Hebron University Hospital, Barcelona, ES, ¹¹National University Cancer Institute, Singapore, Singapore, SG, ¹²Centre hospitalier universitaire de Sherbrooke, Sherbrooke, CA, ¹³A Coruña University Hospital, La Coruña, ES, ¹⁴UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ¹⁵West Cancer Center, Germantown, US, ¹⁶ICO - Institut Catala d'Oncologia Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ¹⁷Odonate Therapeutics, LLC, San Diego, US, ¹⁸MD Anderson Cancer Center, Houston, US

12:00 - 12:00 **383TiP - Bintrafusp alfa (M7824) and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer (TNBC)(NCT03579472)**

J. Litton¹, S. Damodaran², I. Wistuba², F. Yang², A. Contreras², A. Tam², L. Ojalvo³, I. Dussault³, C. Helwig⁴, S. Moulder¹, ¹MD Anderson Cancer Center, Houston, US, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³EMD Serono Research Center, Billerica, US, ⁴Merck KGaA - Germany, Darmstadt, DE

12:00 - 12:00 **384TiP - Effectiveness of Olaparib Plus Trastuzumab in HER2[+], BRCA-mutated (BRCAm) or Homologous Recombination Deficient (HRD) Advanced Breast Cancer (ABC) patients (pts). The OPHELIA Study**

J.E. Alés-Martínez¹, S. Morales², M. Fernández Abad³, P. Sánchez-Rovira⁴, F.J. Salvador Bofill⁵, A. Lahuerta⁶, J.A. García-Sáenz⁷, I. Garau Llinas⁸, T. Díaz Redondo⁹, N. Ferrer¹⁰, V. Carañana¹¹, R. López¹², S.E. Alonso Soler¹³, B. Bermejo¹⁴, J. De La Haba¹⁵, P. Zamora¹⁶, J. Balmana¹⁷, E. López-Miranda¹⁸, J. Cortés¹⁹, A. Llombart Cussac²⁰, ¹Hospital Nuestra Señora de Sonsoles, Ávila, ES, ²Hospital Universitari Arnau de Vilanova de Lleida, Lleida, ES, ³Hospital Universitario Ramón y Cajal, Madrid, ES, ⁴Complejo Hospitalario de Jaén, Jaén, ES, ⁵Hospital Universitario Virgen del Rocío, Sevilla, ES, ⁶Fundación Onkologikoa, San Sebastián, ES, ⁷Hospital Clínico San Carlos, Madrid, ES, ⁸Hospital Son Llatzer, Palma de Mallorca, ES, ⁹Hospital Universitario Virgen de la Victoria, Malaga, ES, ¹⁰Hospital Universitari Son Espases, Palma de Mallorca, ES, ¹¹FISABIO, Hospital Arnau de Vilanova, Valencia, ES, ¹²Hospital Clínico Universitario de

Santiago (CHUS), Santiago de Compostela, ES, ¹³Hospital San Pedro de Alcántara, Cáceres, ES, ¹⁴Hospital Clínic Universitari de València, València, ES, ¹⁵Hospital Universitario Reina Sofía, Córdoba, ES, ¹⁶Hospital Universitario La Paz, Madrid, ES, ¹⁷Vall d'Hebron University Hospital, Barcelona, ES, ¹⁸Hospital Universitario Ramón y Cajal, Madrid, Spain, Madrid, ES, ¹⁹Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), Ridgewood, New Jersey, USA, & Barcelona, ES, ²⁰Hospital Universitario Arnau de Vilanova, Lleida, ES

12:00 - 12:00 **385TiP - RIBOB : A Study on the efficacy and safety of Ribociclib in combination with letrozole in Older women (≥70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced Breast cancer (aBC) with no prior systemic therapy for advanced disease**

C. Kenis¹, N. Ponde², L. Decoster³, E. De Azambuja², G. Jerusalem⁴, P. Neven⁵, L. Dal Lago², H. Denys⁶, P. Vuylsteke⁷, F. Duhoux⁸, H. Wildiers¹, ¹University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ²Institute Jules Bordet, Brussels, BE, ³UZ Brussel, Brussels, BE, ⁴Sart-CHU Sart Tilman Liege, Liege, BE, ⁵University of Leuven, Leuven, BE, ⁶UZ Gent, Gent, BE, ⁷CHU-UCL-Namur Clinique Ste Elisabeth, Namur, BE, ⁸Cliniques Universitaires St. Luc, Brussels, BE

12:00 - 12:00 **386TiP - Ribociclib plus Goserelin with Hormonal Therapy versus physician Choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2- inoperable locally advanced or metastatic breast cancer - RIGHT Choice study**

N. El Saghir¹, S. Malwinder², H. Azim³, Y. Eralp⁴, S.-A. Im⁵, Y.S. Yap⁶, T. Delgar Alfaro⁷, M. Gao⁷, Y.-S. Lu⁸, ¹American University of Beirut Medical Center, Beirut, LB, ²University Malaya Medical Center, Kuala Lumpur, MY, ³Cairo Oncology Center Cairo Hospital-CairoCure, Giza, EG, ⁴Istanbul University, Institute of Oncology, Surgical Oncology Unit, Istanbul, TR, ⁵SNUH-Seoul National University Hospital, Seoul, KR, ⁶NCCS - National Cancer Centre Singapore, Singapore, SG, ⁷Novartis, East Hanover, US, ⁸National Taiwan University Hospital, Taipei, TW

12:00 - 12:00 **387TiP - Palbociclib Rechallenge in Hormone Receptor (HR)[+]/HER2[-] Advanced Breast Cancer (ABC). PALMIRA Trial**

A. Llombart Cussac¹, J. Medioni², M. Colleoni³, J. Ettl⁴, P. Schmid⁵, I. Macpherson⁶, J. Gligorov⁷, J. Albanell⁸, M. Bellet Ezquerra⁹, A. Fernández¹⁰, M. Ruiz Borrego¹¹, J. Gavilá-Gregori¹², D. Wheatley¹³, P. Zamora¹⁴, E. Martínez¹⁵, M. Sampayo¹⁶, F. Riva¹⁶, A. Malfettone¹⁶, J.M. Pérez-García¹⁷, J. Cortés¹⁸, ¹Hospital Universitario Arnau de Vilanova, Lleida, ES, ²Hopital Européen Georges Pompidou, Paris, FR, ³Istituto Europeo di Oncologia, Milan, IT, ⁴Klinikum rechts der Isar, Technical University of Munich, Munich, DE, ⁵Barts Cancer Institute, London, GB, ⁶Beatson West of Scotland Cancer Centre, Glasgow, GB, ⁷APHP, CancerEst, Tenon University Hospital, Paris, FR, ⁸University Hospital del Mar, Barcelona, ES, ⁹Vall d'Hebron University Hospital Institut d'Oncologia, Barcelona, ES, ¹⁰ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, ES, ¹¹Hospital Universitario Virgen del Rocío, Sevilla, ES, ¹²Valencian Institute of Oncology, Valencia, ES, ¹³Royal Cornwall Hospitals NHS Trust, Truro, GB, ¹⁴Hospital Universitario La Paz, Madrid, ES, ¹⁵Hospital Provincial Centre de Castelló, Castelló de la Plana, ES, ¹⁶Medica Scientia Innovation Research (MedSIR), Barcelona, Spain and Ridgewood, New Jersey, USA, Barcelona, ES, ¹⁷Medica Scientia Innovation Research (MedSIR), Barcelona, Spain and Ridgewood, New Jersey, USA; IOB Institute of Oncology, Quironsalud Group, Madrid

and Barcelona, Spain, Barcelona, ES, ¹⁸Vall d'Hebron University Hospital, Barcelona, ES

- 12:00 - 12:00 **388TiP - Alpelisib (ALP) + Endocrine Therapy (ET) by Last Prior Therapy in Patients (pts) With PIK3CA-Mutated Hormone-Receptor Positive (HR+) Human Epidermal Growth Factor Receptor-2-Negative (HER2-) Advanced Breast Cancer (ABC): Additional Study Cohort in BYLieve**
- E. Ciruelos¹, F. Lerebours², M. Ruiz Borrego³, T. Bachelot⁴, J. Polikoff⁵, S. Chia⁶, D. Juric⁷, N. Turner⁸, A. Ridolfi⁹, N. Sophos¹⁰, B. Cooper¹⁰, A. Thuerigen¹¹, H. Rugo¹², ¹University Hospital 12 De Octubre, Madrid, ES, ²Hôpital René Huguenin - Institut Curie, St. Cloud, FR, ³Hospital Universitario Virgen del Rocío, Sevilla, ES, ⁴Centre Léon Bérard, Lyon, FR, ⁵Kaiser Permanente Southern California, San Diego, US, ⁶University of British Columbia, Vancouver, CA, ⁷Massachusetts General Hospital, Boston, US, ⁸The Francis Crick Institute, London, GB, ⁹Novartis Pharmaceuticals Corporation, Rueil-Malmaison, FR, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, US, ¹¹Novartis Pharmaceuticals Corporation, Basel, CH, ¹²UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
- 12:00 - 12:00 **389TiP - PRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy.**
- T. Degenhardt¹, P.A. Fasching², D. Lüftner³, V. Müller⁴, C. Thomssen⁵, C. Schem⁶, I. Witzel⁷, T. Decker⁸, H. Tesch⁹, S. Kuemmel¹⁰, C. Uleer¹¹, R. Wuerstlein¹², C. Riese¹³, T. Schinköthe¹², R. Kates¹⁴, J. Schumacher¹⁵, N. Harbeck¹, M. Schmidt¹⁶, ¹Ludwig Maximilians University - Grosshadern, Munich, DE, ²University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, ³Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE, ⁴Hamburg-Eppendorf University Medical Center, Hamburg, DE, ⁵Martin Luther University of Halle, Halle (Saale), DE, ⁶UK-SH, Campus Kiel, Kiel, DE, ⁷UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ⁸Onkologie Ravensburg, Ravensburg, DE, ⁹Private practice - Dr. Hans Tesch, Frankfurt am Main, DE, ¹⁰Clinics Essen-Mitte, Essen, DE, ¹¹Private Practice, Hildesheim, DE, ¹²LMU Klinikum der Universität München, Munich, DE, ¹³CANKADO Service, München, DE, ¹⁴REK Consulting, Otterfing, DE, ¹⁵Palleos Healthcare Services Gmbh, Wiesbaden,, DE, ¹⁶University Hospital Mainz, Mainz, DE
- 12:00 - 12:00 **Gynaecological cancers**
- 12:00 - 12:00 **1000P - Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and platinum sensitive recurrent ovarian cancer**
- N. Li¹, L. Wu¹, Y. Zhang², J. Liu³, Q. Zhou⁴, J. Zhu⁵, R. Yin⁶, L. Wang⁷, G. Li⁸, X. Wu⁹, H. Pan¹⁰, S. Yao¹¹, Q. Wu¹², K. Gu¹³, H. Zhang¹⁴, X. Wan¹⁵, R. An¹⁶, J. Zou¹⁷, Q. Wang¹⁷, ¹National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ²Qilu Hospital of Shandong University, shandong, CN, ³Sun Yat-sen University Cancer Center, Guangzhou, CN, ⁴Chongqing Cancer Hospital, Chongqing, CN, ⁵Zhejiang Cancer Hospital, Hangzhou, CN, ⁶West China Second University Hospital, Sichuan university, Chengdu, CN, ⁷Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ⁸Union Hospital

of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ⁹Fudan University Shanghai Cancer Center, Shanghai, CN, ¹⁰Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Zhejiang, CN, ¹¹The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN, ¹²Jiangsu Cancer Hospital, Nanjing, CN, ¹³The First Affiliated Hospital of Anhui Medical University, Hefei, CN, ¹⁴Fourth Hospital of Hebei Medical University, Shijiazhuang, CN, ¹⁵Shanghai Frist Maternity And Infant Hospital, Shanghai, CN, ¹⁶The first affiliated hospital of xi'an jiaotong university, xian, CN, ¹⁷Jiangsu Hengrui Medicine Co. LTD, Shanghai, CN

12:00 - 12:00

1001P - Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase 3 study ARIEL3 of rucaparib maintenance treatment

J. Ledermann¹, A. Oza², D. Lorusso³, C. Aghajanian⁴, A. Oaknin⁵, A. Dean⁶, N. Colombo⁷, J. Weberpals⁸, A. Clamp⁹, G. Scambia¹⁰, A. Leary¹¹, R. Holloway¹², M. Amedeo Gancedo¹³, P. Fong¹⁴, J. Goh¹⁵, D. O'Malley¹⁶, T. Cameron¹⁷, L. Maloney¹⁸, S. Goble¹⁸, R. Coleman¹⁹, ¹University College London Cancer Institute, London, GB, ²Princess Margaret Cancer Centre, University Health Network, Toronto, CA, ³Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁴Memorial Sloan-Kettering Cancer Center, New York, US, ⁵Vall d'Hebron University Hospital, Barcelona, ES, ⁶St John of God Subiaco, Subiaco, AU, ⁷Istituto Europeo di Oncologia, Milan, IT, ⁸Ottawa Hospital Research Institute, Ottawa, CA, ⁹The Christie NHS Foundation Trust and University of Manchester, Manchester, GB, ¹⁰Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, IT, ¹¹Gustave Roussy Cancer Center, INSERM U981, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Villejuif, FR, ¹²Florida Hospital Cancer Institute, Orlando, US, ¹³Fundacion Centro Oncologico de Galicia, A Coruña, ES, ¹⁴Auckland City Hospital, Grafton, Auckland, NZ, ¹⁵Royal Brisbane and Women's Hospital, Herston, QLD, Australia, and University of Queensland, St Lucia, AU, ¹⁶The Ohio State University, James Cancer Center, Columbus, US, ¹⁷Clovis Oncology UK Ltd., Cambridge, GB, ¹⁸Clovis Oncology, Inc., Boulder, US, ¹⁹The M. D. Anderson Cancer Center, Houston, US

12:00 - 12:00

1002P - Integrated safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings

R. Kristeleit¹, A. Oza², A. Oaknin³, C. Aghajanian⁴, A. Tinker⁵, O. Tredan⁶, D. O'Malley⁷, A. Leary⁸, G. Konecny⁹, D. Lorusso¹⁰, J. Weberpals¹¹, S. Goble¹², L. Maloney¹², T. Cameron¹³, E. Swisher¹⁴, I. Mcneish¹⁵, R. Shapira-Frommer¹⁶, J. Ledermann¹⁷, R. Coleman¹⁸, ¹UCL Cancer Institute, University College London and UCL Hospitals, Middletown, US, ²Princess Margaret Cancer Centre, University Health Network, Toronto, CA, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Memorial Sloan-Kettering Cancer Center, New York, US, ⁵BC Cancer Agency, Vancouver, CA, ⁶Centre Léon Bérard and University Claude Bernard and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon, FR, ⁷The Ohio State University, James Cancer Center, Columbus, US, ⁸Gustave Roussy Cancer Center, INSERM U981, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Villejuif, FR, ⁹University of California Los Angeles, Los Angeles, US, ¹⁰Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ¹¹Ottawa Hospital Research Institute, Ottawa, CA, ¹²Clovis Oncology, Inc., Boulder, US, ¹³Clovis Oncology UK Ltd., Cambridge, GB, ¹⁴University of Washington/Seattle Cancer Care Alliance, Seattle, US, ¹⁵Imperial College London, London, GB, ¹⁶Chaim Sheba Medical Center, Ramat Gan, IL, ¹⁷University

College London Cancer Institute, London, GB, ¹⁸The M. D. Anderson Cancer Center, Houston, US

12:00 - 12:00 **1003P - Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers**

S.I. Labidi-Galy¹, T. De La Motte Rouge², O. Derbel³, A. Wolfer⁴, E. Kalbacher⁵, T. Olivier¹, J.-D. Combes⁶, K. Hu-Heimgartner¹, O. Tredan⁷, H. Guevara⁷, V. Heinzelmann-Schwarz⁸, M. Fehr⁹, V. De Castelbajac¹⁰, P. Vaflard¹⁰, L. Crivelli², V. Bonadona⁷, V. Viassolo¹, F. Bazan¹¹, M. Rodrigues¹⁰, I. Ray-Coquard⁷, ¹Hôpitaux Universitaires de Genève - HUG, Geneva, CH, ²Centre Eugene - Marquis, Rennes, FR, ³Hôpital privé Jean mermoz, Lyon, FR, ⁴CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ⁵CHRU Besançon - Hopital Jean Minjoz, Besançon, FR, ⁶IARC, Lyon, FR, ⁷Centre Léon Bérard, Lyon, FR, ⁸Universitätsspital Basel, Basel, CH, ⁹Kantonsspital Frauenfeld, Frauenfeld, CH, ¹⁰Institut Curie, Paris, FR, ¹¹CHU Besançon, Hôpital Jean Minjoz, Besançon, FR

12:00 - 12:00 **1004P - A Prospective Evaluation of Tolerability of Niraparib Dosing Based on Baseline Body Weight (BW) and Platelet (plt) Count: Blinded Pooled Interim Safety Data from the NORA Study**

X. Wu¹, J. Zhu², R. Yin³, J. Yang⁴, L. Wu⁵, J. Liu⁶, Z. Liu⁷, J. Wang⁸, Y. Gao⁹, D. Wang¹⁰, G. Lou¹¹, H. Yang¹², B. Kong¹³, Y. Huang¹⁴, Q. Zhou¹⁵, H. Wen¹, J. Hou¹⁶, C. Zhang¹⁶, Y. Hei¹⁶, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN, ³West China Second University Hospital, Sichuan university, Chengdu, CN, ⁴Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ⁵National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ⁶Sun Yat-sen University Cancer Center, Guangzhou, CN, ⁷the First Hospital of Jilin University, Changchun, CN, ⁸Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, ⁹Department of Gynecology, Peking University Cancer Hospital & Institute, Beijing, CN, ¹⁰Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, CN, ¹¹The Affiliated Tumor Hospital of Harbin Medical University, Harbin, CN, ¹²Yunnan Cancer Hospital & Yunnan Cancer Center & The Third Affiliated Hospital of Kunming Medical University, Kunming, CN, ¹³Qilu Hospital, Shandong University, Jinan, CN, ¹⁴Hubei Cancer Hospital, Wuhan, CN, ¹⁵Chongqing Cancer Hospital, Chongqing, CN, ¹⁶Zai Lab (Shanghai) Co., Ltd, Shanghai, CN

12:00 - 12:00 **1006P - Niraparib initial dose and its' management in patients with recurrent high-grade serous ovarian cancer.**

J. Grabowski¹, J. Glajzer¹, E.I. Braicu², J. Sehouli¹, ¹Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ²Charité - Universitätsmedizin Berlin, Berlin, DE

12:00 - 12:00 **1007P - Results of the 3rd interim analysis of C-Patrol: A non-interventional study on olaparib in German routine clinical practice**

J. Sehouli¹, F. Hilpert², M. Welslau³, J. Grabowski⁴, J. Seitz⁵, A. El-Balat⁶, A. Hartkopf⁷, R. Glowik⁸, F. Marmé⁹, ¹Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ²Krankenhaus Jerusalem, Hamburg, DE, ³Klinikum Aschaffenburg, Aschaffenburg, DE, ⁴Charité Medical University, Berlin, Berlin, DE, ⁵University Hospital Heidelberg, Heidelberg, DE, ⁶Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute),

Frankfurt am Main, DE, ⁷Universitätsfrauenklinik Tübingen, Tübingen, DE, ⁸AstraZeneca Germany, Wedel, DE, ⁹Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE

- 12:00 - 12:00 **1008P - A real-world analysis of the treatment of advanced ovarian cancer with PARPIs**
A. Martinez De Pinillos¹, C. Anger², L. Mendoza³, ¹IQVIA, London, GB, ²QuintilesIMS (UK), London, GB, ³IQVIA RDS Czech Republic s.r.o., Prague, CZ
- 12:00 - 12:00 **1009P - Incidence of tumour BRCA1/2 variants in relapsed, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer**
R. Morgan¹, M. Bulman², A. Clamp¹, S. Macmohon³, L. Thompson³, S. Ribeiro³, A. Davies⁴, R. Best⁴, S. Palmer-Smith⁴, B. Frugtniet⁴, D.G. Evans², G. Jayson¹, A. Wallace², ¹The Christie NHS Foundation Trust, Manchester, GB, ²Manchester Centre for Genomic Medicine, JH, GB, ³The Royal Marsden NHS Trust, JJ, GB, ⁴All Wales Genetics Laboratory, Institute of Medical Genetics, AY, GB
- 12:00 - 12:00 **1011P - BRCA testing of 1,284 Brazilian patients for hereditary breast and ovarian cancer in a routine diagnostic setting**
F. Milanezi¹, J. Silva¹, S. De Marsillac², P. Monfredini¹, V. Nakano¹, M. D'Andrea², R. Guarischi-Sousa¹, B. Schnabel¹, W. Correia³, G. Campana¹, G. Da Fonseca⁴, E. Perrone¹, I. Zalcberg⁵, ¹GeneOne, Dasa Brazil, São Paulo, BR, ²GeneOne, Dasa Brazil, Rio de Janeiro, BR, ³GeneOne, Dasa Brazil, Duque de Caxias, RJs, BR, ⁴Dasa Brazil, Rio de Janeiro, BR, ⁵GeneOne, Dasa Brazil, Duque de Caxias, RJ, BR
- 12:00 - 12:00 **1012P - A multi-center integrative study on cancer predisposition genes in Chinese patients with epithelial ovarian carcinoma**
C. Zhu¹, L. Li², D. Shao³, J.H. Lang⁴, S. Ma², X. Tan², S. Zhong², M. Wu², ¹BGI, Shenzhen, CN, ²Peking Union Medical College Hospital, Beijing, CN, ³BGI-Shenzhen, Shenzhen, CN, ⁴Peking Union Medical College Hospital Chinese Academy of Medical Sciences-Eastern branch, Beijing, CN
- 12:00 - 12:00 **1013P - Incidental Early Occult Ovarian Cancer after Risk-Reducing Salpingo-Oophorectomy in BRCA1/2 Mutation Carriers followed in a Community Public Hospital**
B. Grana Suarez¹, A. Molina¹, J. Prato¹, C. Czeszkowa¹, C. Conde¹, C. Reboredo Rendo¹, M. Quindos¹, E. Perez¹, R. Lesta Mellid², P. Cordeiro¹, I. Gomez-Randulfe¹, S. Antolin¹, L. Calvo¹, ¹CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ²Complejo Hospitalario Universitario A Coruna, Hospital Teresa Herrera, A Coruña, ES
- 12:00 - 12:00 **1014P - Response to chemotherapy in ovarian cancer (OC) patients with or without prior breast cancer (BC), stratified by BRCA mutation (BRCAm) status**
A. George¹, F. Chilcott², C. Pate², S. Banerjee³, ¹The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ²The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, London, GB, ³Royal Marsden Hospital NHS Foundation Trust, London, GB

- 12:00 - 12:00 **1015P - Advanced ovarian cancer: is residual disease after debulking surgery affected by genetics factors involved in angiogenesis and immunity pathways?**
M. Bartoletti¹, S. Gagno², E. Poletto³, M. Garziera⁴, S. Scalone¹, E. Dreussi², C. Zanusso², R. Roncato², E. Cecchin², E. De Mattia², R. Sorio¹, G. Giorda², L. Quartuccio⁵, S. De Vita⁵, C. Romualdi⁶, F. Puglisi⁷, G. Toffoli⁴, ¹Centro di Riferimento Oncologico - CRO, Aviano, IT, ²Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, IT, ³Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia, Udine, IT, ⁴Centro di Riferimento Oncologico, CRO Aviano National Cancer Institute, IRCCS, Aviano, IT, ⁵University Hospital "Santa Maria della Misericordia", Udine, IT, ⁶University of Padova, Padova, IT, ⁷Department of Medicine (DAME), University of Udine, Udine, Italy; Aviano, IT
- 12:00 - 12:00 **1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study**
F. Lecuru¹, E. Pujade-Lauraine², S. Hamizi³, A. Caumont-Prim⁴, N. Raban⁵, E. Mauraie⁶, P. Pautier⁷, M.-C. Kaminsky-Forrett⁸, J. Meunier⁹, J. Alexandre¹⁰, D. Berton-Rigaud¹¹, N. Dohollou¹², C. Dubot¹³, A. Floquet¹⁴, L. Favier¹⁵, L. Venat-Bouvet¹⁶, M. Fabbro¹⁷, C. Louvet¹⁸, A. Lortholary¹⁹, G. Ferron²⁰, ¹Hopital European George Pompidou, Paris, FR, ²Groupe hospitalier Hôtel Dieu (AP-HP), Paris, FR, ³Centre Hospitalier Lyon Sud, Pierre Bénite, FR, ⁴Exystat, Malakoff, FR, ⁵CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR, ⁶CH Intercommunal de Créteil, Créteil, FR, ⁷Gustave Roussy, Villejuif, FR, ⁸Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, ⁹C.H.R. Orleans - La Source, Orleans, FR, ¹⁰Hôpital Cochin, PARIS Cédex, FR, ¹¹ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹²Polyclinique Bordeaux Nord Aquitaine, Bordeaux, FR, ¹³Hôpital René Huguenin - Institut Curie, St. Cloud, FR, ¹⁴Institute Bergonié, Bordeaux, FR, ¹⁵CLCC, Dijon, FR, ¹⁶Centre Hospitalier Universitaire Dupuytren, Limoges Cédex, FR, ¹⁷ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ¹⁸Institute Mutualiste Montsouris, Paris, FR, ¹⁹Centre Catherine de Sienné, Nantes, FR, ²⁰Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR
- 12:00 - 12:00 **1017P - Immune-Related Gene Expression Profiling after Neoadjuvant Chemotherapy (NACT) of Ovarian High-Grade Serous Carcinoma**
L. Manso¹, I. Lodewijk², E. Bernal Hertfelder³, C. Suárez-Cabrera², J.L. Garcia¹, S. Wang⁴, J.M. Paramio², M. Dueñas¹, ¹University Hospital 12 De Octubre, Madrid, ES, ²Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, ES, ³Hospital General de Mostoles, Mostoles, ES, ⁴TESARO Inc, Massachusetts, US
- 12:00 - 12:00 **1018P - Tumor-infiltrating lymphocytes (TILs) in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy: A retrospective study**
S. Giovannoni¹, A. Garbi², G. Parma², M. Lapresa², E. Zaccarelli², A. Vingiani², I. Ardoino³, G. Pruneri⁴, N. Colombo⁵, ¹Policlinico Umberto I, Rome, IT, ²IEO- Istituto Europeo di Oncologia, milan, IT, ³University of Milan, milan, IT, ⁴INT Istituto Nazionale Tumori, milan, IT, ⁵Istituto Europeo di Oncologia, Milan, IT
- 12:00 - 12:00 **1019P - Prognostic significance of elements of the adaptive immunity in the**

microenvironment of epithelial ovarian cancer.

P. Foukas¹, G.-A. Koliou², A. Papoudou-Bai², A. Charchanti², E. Vrettou², C. Poulis², K. Chatzopoulos², V. Kotoula³, E. Fountzilas⁴, R. Zakopoulou⁵, A. Visvikis⁶, G. Pentheroudakis⁷, D. Pectasides⁸, G. Aravantinos², G. Oikonomopoulos⁹, A. Papanikolaou², D. Haidopoulos², F. Zagouri², G. Fountzilas¹⁰, A. Goussia², ¹Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ²Hellenic Cooperative Oncology Group (HeCOG), Athens, GR, ³Aristotle University of Thessaloniki, Thessaloniki, GR, ⁴Papageorgiou Hospital - Aristotle University of Thessaloniki, Thessaloniki, GR, ⁵Alexandra Hospital, Athens, GR, ⁶General Oncological Hospital of Kifisia "Agioi Anargyroi", Kifisia, GR, ⁷University Hospital of Ioannina, Ioannina, GR, ⁸Hippokraton General Hospital, Athens, GR, ⁹Metropolitan Hospital, Athens, GR, ¹⁰Papageorgiou Hospital Aristotle University of Thessaloniki, Thessaloniki, GR

12:00 - 12:00 **1020P - Neutrophil-to-lymphocyte ratio predicts platinum sensitivity in epithelial ovarian cancer patients: a MITO24 retrospective study**

A. Farolfi¹, E. Scarpi¹, F. Greco², A. Bergamini³, L. Longo⁴, S. Pignata⁵, C. Casanova⁶, V. Del Vecchio⁷, A. Bologna⁸, M. Orditura⁹, L. Zavallone¹⁰, J. Ventriglia⁵, V. Gallà¹, E. Franzese¹¹, E. Pigozzi², V. Loizzi⁷, G. Giorda¹², D. Giardina⁴, R. Cioffi³, U. De Giorgi¹³, ¹Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ²ULSS 9 Regione Veneto, Legnago, IT, ³San Raffaele Scientific Institute, Milano, IT, ⁴Ramazzini Hospital, Carpi, IT, ⁵Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, ⁶Santa Maria delle Croci Hospital, Ravenna, IT, ⁷Università degli Studi di Bari & IRCCS Istituto Oncologico Giovanni Paolo II[^], Bari, IT, ⁸IRCCS- Arcispedale S. Maria Nuova, Reggio Emilia, IT, ⁹Università degli Studi della Campania "Luigi Vanvitelli", Caserta, IT, ¹⁰Infermi Hospital, Ponderano, IT, ¹¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ¹²Centro di Riferimento Oncologico (CRO) IRCCS, Aviano, IT, ¹³Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl - IRCCS, Meldola, IT

12:00 - 12:00 **1021P - The prognostic impact of monocyte to lymphocyte ratio (MLR) in advanced epithelial ovarian cancer (EOC)**

M. Cucurull Salamero¹, I. Teruel García², A. Arroyo³, B. Pardo³, M. Gil³, J. Piulats⁴, H. Pla⁵, C. Fina⁵, M.P. Barretina Ginesta⁶, L. Angelats¹, E. Felip Falgas², C. Erasun Lecuona², J.J. García Mosquera⁷, S. Martinez Román⁸, E. Carballas⁹, J. Hernandez¹⁰, A. Esteve¹⁰, M. Romeo¹, ¹Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, ²Institut Catala d'Oncologia (ICO), Barcelona, ES, ³Institut Català d'Oncologia, L'Hospitalet, Barcelona, ES, ⁴Institut Català d'Oncologia-IDIBELL-CIBERONC, Barcelona, ES, ⁵Institut Català d'Oncologia, Girona, Girona, ES, ⁶ICO - Institut Català d'Oncologia Girona (Hospital Universitari Josep Trueta Hospital Universitari Josep Trueta), Girona, ES, ⁷Hospital Dexeus - Instituto Oncológico Rosell, Barcelona, ES, ⁸Hospital Germans Trias I Pujol, Badalona, Badalona, ES, ⁹Hospital Universitario Germans Trias i Pujol, Badalona, ES, ¹⁰Hospital-based Cancer Registry, Institut Català d'Oncologia Badalon, Badalona, ES

12:00 - 12:00 **1022P - TP53 Hotspot mutations as immunoreactive neoantigens define a signature with differential survival outcomes in advanced ovarian cancer**

M. Garziera¹, E. Cecchin², J. Polesel², V. Canzonieri², R. Sorio³, S. Gagno², S. Scalone³, R. Roncato², E. De Mattia², E. Poletto⁴, G. Giorda², ¹Centro di Riferimento Oncologico, CRO Aviano National Cancer Institute, IRCCS, Aviano, IT, ²Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, IT, ³Centro di Riferimento Oncologico - CRO, Aviano,

IT, ⁴Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia, Udine, IT

12:00 - 12:00

1023P - Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC)/ The GINECO ENCOURAGE cohort of 500 French patients

D. Berton-Rigaud¹, A. Floquet², D. Mollon-Grange³, A. Dechartres⁴, W. Lescaut⁵, M.-C. Kaminsky-Forrett⁶, O. Tredan⁷, R. Largillier⁸, A.M. Savoye⁹, J. Alexandre¹⁰, C. Delbaldo¹¹, E. Mauraie¹², H. Barletta¹³, C. Bosacki¹⁴, C. Garnier Tixidre¹⁵, P. Follana¹⁶, H. Laharie-Mineur¹⁷, C.-B. Levaché¹⁸, E. Pujade-Lauraine¹⁹, F. Selle²⁰, ¹ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ²Institute Bergonié, Bordeaux, FR, ³Centre Hospitalier Intercommunal de Cornouaille, Quimper Cédex, FR, ⁴Hôpital Hôtel-Dieu, Paris, FR, ⁵Centre Hospitalier Princesse Grâce CHPG-Monaco, Monaco, MC, ⁶Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, ⁷Centre Léon Bérard, Lyon, FR, ⁸Centre Azuréen de Cancérologie, Mougins Cédex, FR, ⁹Institut Jean Godinot, Reims, FR, ¹⁰Hôpital Cochin, PARIS Cédex, FR, ¹¹Dr. Catherine Delbaldo, La Défense, FR, ¹²CH Intercommunal de Créteil, Créteil, FR, ¹³Centre Mistral, Guilhaud-Granges, FR, ¹⁴Institute de Cancerologie de la Loire, Saint-Priest-en-Jarez, FR, ¹⁵Groupe Hospitalier Mutualiste de Grenoble, Grenoble Cédex, FR, ¹⁶Centre Anticancer Antoine Lacassagne, Nice, FR, ¹⁷Clinique Tivoli, Bordeaux, FR, ¹⁸Clinique Francheville, Périgueux Cédex, FR, ¹⁹Groupe hospitalier Hôtel Dieu (AP-HP), Paris, FR, ²⁰HOPITAL DES DIACONESSES, FR

12:00 - 12:00

1024P - Phase II study: Letrozole maintenance therapy after first line chemotherapy in patients with advanced serous and endometrioid ovarian cancer

A. Tyulyandina¹, A. Romyantsev², I. Pokataev¹, V. Nechushkina³, K. Morkhov³, Y. Sergeev³, V. Mochalnikova³, A. Bulanov⁴, M. Stenina¹, S. Tjulandin⁵, ¹FSBI-N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ²N.N. Blokhin National Medical Research Centre of Oncology, Moscow, RU, ³N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ⁴No place of work provided Iran, Teheran, IR, ⁵N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU

12:00 - 12:00

1025P - Baseline IPI (Immune Prognostic Index) predicts survival in patients with advanced cervical cancer treated with immune checkpoint inhibitors (ICI).

F. Blanc-Durand¹, M. Richardson², P. Vuagnat³, P. Pautier⁴, A. Hollebecque⁴, A. Varga⁴, C. Massard⁵, A. Leary⁶, ¹Institut Curie, Paris, FR, ²Stanford University School of Medicine, Stanford, US, ³Institut Gustave Roussy, Villejuif, FR, ⁴Gustave Roussy, Villejuif, FR, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR, ⁶Gustave Roussy Cancer Center, INSERM U981, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Villejuif, FR

12:00 - 12:00

1026P - Preselecting tumor-infiltrating lymphocyte subsets to implement adoptive immunotherapy in ovarian cancer

D. Salas-Benito¹, C. De Andrea², J. Aramendia¹, U. Mancheño³, E. Elizalde³, E. Conde³, I. Tamayo³, F. Guillén¹, M. Jurado², J.Á. Mínguez², A. González Martín⁴, M. Ponz-Sarvisé², S. Hervás-Stubbs³, ¹Clinica Universitaria de Navarra, Pamplona, ES, ²Clínica Universidad de Navarra, Pamplona, ES, ³Center for Applied Medicine Research, Pamplona, ES, ⁴Clínica Universidad de Navarra, Madrid, ES

- 12:00 - 12:00 **1027P - Early prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: a pooled analysis of AGO-OVAR 7 & 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials).**
- O. Colombari¹, M. Tod², A. Leary³, I. Ray-Coquard⁴, A. Lortholary⁵, A.-C. Hardy-Bessard⁶, J. Pfisterer⁷, A. Du Bois⁸, C. Kurzeder⁹, A. Burges¹⁰, J. Peron¹¹, G. Freyer¹², B. You¹²,
¹Université Claude Bernard Lyon 1, OULLINS, FR, ²Hôpital de la Croix Rousse, Hospices civils de Lyon, LYON, FR, ³Institut Gustave Roussy, Villejuif, FR, ⁴Centre Léon Bérard, Lyon, FR, ⁵Centre Catherine de Sienne, Nantes, FR, ⁶Clinique Armoricaine de Radiologie, St. Briec, FR, ⁷Womens Cancer Center, Kiel, DE, ⁸Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, ⁹University Hospital Basel, 4031 Basel, Switzerland, Basel, CH, ¹⁰11. University of Munich, Campus Großhadern, Munich, DE, ¹¹Lyon Sud Hospital Center, Pierre Bénite, FR, ¹²Centre Hospitalier Lyon Sud, Pierre Bénite, FR
- 12:00 - 12:00 **1028P - Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a Phase 1b study in patients (pts) with ovarian cancer**
- D. Omalley¹, D. Richardson², I. Vergote³, L. Gilbert⁴, L. Martin⁵, G. Mantia-Smaldone⁶, C. Castro⁷, D. Provencher⁸, U. Matulonis⁹, K. Malek¹⁰, K. Moore¹¹, ¹The Ohio State University James Cancer Hospital, Columbus, US, ²Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, US, ³University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁴McGill University Health Centre, Montreal, CA, ⁵University of Pennsylvania, Philadelphia, US, ⁶Fox Chase Cancer Center, Philadelphia, US, ⁷Massachusetts General Hospital, Boston, US, ⁸Centre Hospitalier de L'Université de Montréal (CHUM), Montréal, CA, ⁹Dana Farber Cancer Institute, Boston, US, ¹⁰ImmunoGen Inc., Waltham, US, ¹¹Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US
- 12:00 - 12:00 **1029P - Response to Pegylated Liposomal Doxorubicin (PLD) and Weekly Paclitaxel (wpac) in Platinum Resistant (PR) Ovarian Cancer (OC) by BRCA mutation status**
- L. Bremer¹, C. Pate², S. Banerjee², A. George³, ¹Dunedin Hospital, Dunedin, NZ, ²Royal Marsden Hospital NHS Foundation Trust, London, GB, ³The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB
- 12:00 - 12:00 **1030P - Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006)**
- B. Monk¹, T. Herzog², S. Triantos³, S. Maul⁴, G. Wang⁵, M.J. Pontes Valero⁶, T. MCGowan⁷, W. Shalaby⁸, R. Coleman⁹, ¹Arizona Oncology (US Oncology Network), Phoenix, US, ²University of Cincinnati, Cincinnati, US, ³Clinical Research, Spring House, US, ⁴Clinical Project Scientist at Janssen, Titusville, US, ⁵Clinical Biostatistics, Raritan, US, ⁶PharmaMar SA, Madrid, ES, ⁷Oncology Medical Affairs, Horsham, US, ⁸Janssen Biotech, Inc, Horsham, US, ⁹The M. D. Anderson Cancer Center, Houston, US
- 12:00 - 12:00 **1031P - OCTAVE - A phase I study of enadenotucirev, an oncolytic group B**

adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer

I. Mcneish¹, V. Moreno², G. Jayson³, P. Roxburgh⁴, M.P. Barretina Ginesta⁵, J. Garcia-Donas⁶, A. Anton Torres⁷, A. Michael⁸, R. Brown⁹, D. Krige⁹, J. Bendall⁹, G. Di Genova⁹, H. Mcelwaine-John⁹, ¹Imperial College London, London, GB, ²University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ³The Christie NHS Foundation Trust, Manchester, GB, ⁴Beatson West of Scotland Cancer Centre, Glasgow, GB, ⁵ICO - Institut Català d'Oncologia Girona (Hospital Universitari Josep Trueta Hospital Universitari Josep Trueta), Girona, ES, ⁶Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES, ⁷Hospital Miguel Servet, Zaragoza, ES, ⁸Royal Surrey County Hospital NHS Foundation Trust, Guildford, GB, ⁹PsiOxus Therapeutics Ltd, Abingdon, GB

12:00 - 12:00 **1032P - Phase I study of low dose whole abdominal radiation therapy (LDWART) in combination with weekly paclitaxel (wP) for platinum resistant ovarian cancer (PROC)**

N. Ngoi¹, V. Heong², N. Kumarakulasinghe³, P.S. Phyu³, E. Peh³, S.E. Lim⁴, Y.W. Lim², J. Tang⁵, B.A. Choo², V. Koh², A. Ilancheran⁶, J. Low⁷, J. Ng⁷, Y.L. Thian⁶, D.S. Tan¹, ¹NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG, ²National University Cancer Institute Singapore (NCIS), Singapore, SG, ³National University Cancer Institute, Singapore (NCIS), Singapore, SG, ⁴National University Hospital, Singapore, SG, ⁵SSO, Singapore, SG, ⁶National University Health System, Singapore, SG, ⁷National University Cancer Institute, Singapore, Singapore, SG

12:00 - 12:00 **1033P - Phase 1b/2a study assessing the safety and efficacy of adding AL3818 (Anlotinib) to standard platinum-based chemotherapy in subjects with recurrent or metastatic endometrial, ovarian or cervical carcinoma**

D. Miller¹, D. Miller², E. Cheung³, M. Huang⁴, M. Schlumbrecht⁴, A. Garcia⁵, M. Loch⁵, A. Jernigan⁵, Z. Li⁶, M. Chen⁶, J. Chen⁶, ¹McKesson Corporation, San Francisco, US, ²University of Texas Southwestern Medical Center at Dallas, Dallas, US, ³Institution Innovative Clinical Research Institute, Whittier, US, ⁴University of Miami, Miami, US, ⁵Louisiana State University, New Orleans, US, ⁶Advenchen laboratories, Moorpark, US

12:00 - 12:00 **1034P - Phase I Study of Intraperitoneal TRX-E-002-1 in Subjects with Persistent or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer: Three-month Follow-up Results of the Dose Escalation Phase**

J. Coward¹, G. Kichenadasse², P. Harnett³, K. Moore⁴, M. Barve⁵, D. Berg⁶, J. Garner⁶, D. Dizon⁷, ¹Icon Cancer Centre, South Brisbane, AU, ²Flinders Medical Centre, Adelaide, AU, ³Westmead Hospital, Westmead, AU, ⁴Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, US, ⁵Mary Crowley Cancer Center, Dallas, US, ⁶Kazia Therapeutics Limited, Sydney, AU, ⁷Lifespan Cancer Institute, Rhode Island, US

12:00 - 12:00 **1035P - Hybrid capture-based genomic profiling of circulating tumor DNA (ctDNA) from patients with ovarian cancer**

M. Yang¹, Z. Jiang², Y. Zhang³, S. Cai⁴, ¹Cancer Center of NanJing GaoChun People's Hospital; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, CN, ²Jiangsu cancer institute, Medical university nanjing cancer center, Jiangsu red cross cancer center, Nanjing, CN, ³Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ⁴3D Medicines Inc., Shanghai, CN

- 12:00 - 12:00 **1036P - Tumor Microvessel Density for predicting Nintedanib activity: data from the randomized CHIVA trial (a GINECO study)**
M. Villemin¹, N. Elie², C. Blanc-Fournier³, G. De Rauglaudre⁴, N. Raban⁵, A. Chevalier⁶, G. Ferron⁷, M.-C. Kaminsky-Forrett⁸, F. Beurrier⁹, S. Hamizi¹⁰, P. Combe¹¹, S. Abadie Lacourtoisie¹², J. Meunier¹³, A. Floquet¹⁴, J. Alexandre¹⁵, L. Venat-Bouvet¹⁶, C. Louvet¹⁷, L. Favier¹⁸, I. Licaj¹, J. Florence¹⁹, ¹Centre Francois Baclesse, Caen, FR, ²Université Caen Normandie, CAEN cedex, FR, ³Centre Francois Baclesse, CAEN Cedex, FR, ⁴Institut Sainte-Catherine, Avignon, FR, ⁵CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR, ⁶Centre Oscar Lambret, Lille, FR, ⁷Institut Universitaire du Cancer -Toulouse-Oncopole, Toulouse, FR, ⁸Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, ⁹Centre Léon Bérard, Lyon, FR, ¹⁰Centre Hospitalier Lyon Sud, Pierre Bénite, FR, ¹¹Hopital European George Pompidou, Paris, FR, ¹²Centre Paul Papin, Angers, FR, ¹³C.H.R. Orleans - La Source, Orleans, FR, ¹⁴Institute Bergonié, Bordeaux, FR, ¹⁵Hôpital Cochin, PARIS Cédex, FR, ¹⁶Centre Hospitalier Universitaire Dupuytren, Limoges Cédex, FR, ¹⁷Institute Mutualiste Montsouris, Paris, FR, ¹⁸CLCC, Dijon, FR, ¹⁹Centre Francois Balesse, CAEN, FR
- 12:00 - 12:00 **1037P - Post-hoc analysis of the nintedanib exposure-response relationships in the CHIVA trial in advanced ovarian cancer: (a GINECO study)**
S. Haviari¹, B. Blanchet², O. Colombar³, L. Venat-Bouvet⁴, N. Dohollou⁵, A. Floquet⁶, C. Louvet⁷, J.-P. Lotz⁸, S. Abadie Lacourtoisie⁹, L. Favier¹⁰, M. Fabbro¹¹, N. Bonichon-Lamichhane¹², J.E. Kurtz¹³, P. Follana¹⁴, M. Leheurteur¹⁵, F. Del Piano¹⁶, C.R. Alliot¹⁷, J. Alexandre¹⁸, B. You¹⁹, M. Tod²⁰, ¹Faculté de Médecine et Maïeutique Lyon-Sud, OULLINS, FR, ²Hôpital Cochin, Paris, FR, ³Université Claude Bernard Lyon 1, OULLINS, FR, ⁴Centre Hospitalier Universitaire Dupuytren, Limoges Cédex, FR, ⁵Polyclinique Bordeaux Nord Aquitaine, Bordeaux, FR, ⁶Institute Bergonié, Bordeaux, FR, ⁷Institute Mutualiste Montsouris, Paris, FR, ⁸Hopital Tenon, Paris, FR, ⁹Centre Paul Papin, Angers, FR, ¹⁰CLCC, Dijon, FR, ¹¹ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ¹²Clinique Tivoli, Bordeaux, FR, ¹³CHU Hautepierre, Strasbourg, FR, ¹⁴Centre Anticancer Antoine Lacassagne, Nice, FR, ¹⁵Centre Henri Becquerel, Rouen, FR, ¹⁶Hôpitaux de LEMAN, THONON LES BAINS, FR, ¹⁷Hospital Center Alpes Léman, Contamine-sur-Arve, FR, ¹⁸Hôpital Cochin, PARIS Cédex, FR, ¹⁹Centre Hospitalier Lyon Sud, Pierre Bénite, FR, ²⁰Hôpital de la Croix Rousse, Hospices civils de Lyon, LYON, FR
- 12:00 - 12:00 **1038P - The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian insufficiency in patient with malignant ovarian germ cell tumors**
M.K. Kim, Samsung Changwon Hospital Sung Kyun Kwan University, Changwon, KR
- 12:00 - 12:00 **1039P - Ex vivo cytotoxicity and in vivo antitumor activity of a novel highly selective STAT3 inhibitor YHO-1701 for ovarian and endometrial cancer**
K. Hasegawa¹, K. Taniguchi², S. Sato¹, A. Yoshinaga², M. Tsugane², M. Nishiyama³, K. Fujiwara⁴, ¹Saitama Medical University International Medical Center, Hidaka, JP, ²Yakult Honsha Co., Ltd., Kunitachi, Tokyo, JP, ³Gunma University, Maebashi, JP, ⁴Saitama Medical University Internatl Medical Centre, Saitama, JP
- 12:00 - 12:00 **1040P - Mutational landscapes and tumor mutational burden expression in endometrial cancer**

Y. Zhang¹, J. Zhang¹, Z. Shao¹, L. Zhao¹, Y. Zhang², S. Zhang², S. Zhao², F. Guo², F. Pang², L. Zhang², X. Dong², K. Wang², ¹Zhejiang Cancer Hospital, Hangzhou, CN, ²OrigiMed, Shanghai, CN

- 12:00 - 12:00 **1041P - Clinical features and frequency of mismatch repair protein deficiency in ovarian clear cell and endometrioid carcinoma patients.**
K. Takehara, Shikoku Cancer Center, Matsuyama, JP
- 12:00 - 12:00 **1042P - Prospective study evaluating white adipose tissue inflammation and clinicopathologic features in endometrial cancer**
L. Moukarzel¹, A. Stylianou¹, M. Wu¹, S. Nobre¹, N. Abu-Rustum¹, V. Broach¹, D. Giri², N. Iyengar³, B. Weigelt², V. Makker², ¹Memorial Sloan Kettering Cancer Center, New York City, US, ²Memorial Sloan-Kettering Cancer Center, New York, US, ³Memorial Sloan-Kettering Cancer Center, New York City, US
- 12:00 - 12:00 **1043P - Cancer-specific survival with or without adjuvant chemotherapy in high-risk stage I endometrial cancer**
J. Ko¹, B. Lester², N. Le³, G. Bowering², C. Rugayan², A. Kumar⁴, ¹Abbotsford Regional Hospital and Cancer Centre, Abbotsford, CA, ²BC Cancer - Abbotsford, Abbotsford, CA, ³BC Cancer Research Centre, Vancouver, CA, ⁴BC Cancer - Surrey, Surrey, CA
- 12:00 - 12:00 **1044P - Pembrolizumab in Patients with MSI-H Advanced Endometrial Cancer from the KEYNOTE-158 Study**
D. Omalley¹, A. Marabelle², A. De Jesus-Acosta³, S. Piha-Paul⁴, A. Arkhipov⁵, F. Longo⁶, D. Motola-Kuba⁷, R. Shapira-Frommer⁸, R. Geva⁹, B. Rimel¹⁰, J. Lopez-Martin¹¹, A. Hansen¹², J. Mehnert¹³, X. Chen¹⁴, F. Jin¹⁴, K. Norwood¹⁴, P. Ott¹⁵, ¹The Ohio State University James Cancer Hospital, Columbus, US, ²Institut Gustave Roussy, Villejuif, FR, ³Johns Hopkins Hospital, Baltimore, US, ⁴The University of Texas, MD Anderson Cancer Center, Houston, US, ⁵Federal State Autonomous Institution "Treatment and Rehabilitation Center" of the Ministry of Health of Russian Federation, Moscow, RU, ⁶Hospital Universitario Ramon y Cajal, Madrid, ES, ⁷COMOP A.C., Mexico City, MX, ⁸Chaim Sheba Medical Center, Ramat Gan, IL, ⁹Tel Aviv Sourasky Medical Center (Ichilov), Tel Aviv, IL, ¹⁰Cedars-Sinai Medical Center, Los Angeles, US, ¹¹University Hospital 12 De Octubre, Madrid, ES, ¹²Princess Margaret Cancer Center, Toronto, CA, ¹³Rutgers Cancer Institute of New Jersey, New Brunswick, US, ¹⁴Merck & Co., Inc., Kenilworth, US, ¹⁵Dana-Farber Cancer Institute, Boston, US
- 12:00 - 12:00 **1045P - Who drops out of cervical cancer screening? Results from the EDIFICE 6 survey**
T. De La Motte Rouge¹, F. Eisinger², S. Couraud³, L. Greillier⁴, C. Touboul⁵, C. Lhomel⁶, M. Rouprêt⁷, J. Viguier⁸, J.-F. Morere⁹, ¹Centre Eugene - Marquis, Rennes, FR, ²Institute Paoli Calmettes, Marseille, FR, ³Centre Hospitalier Lyon Sud, Pierre Bénite, FR, ⁴Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ⁵KantarHealth, Paris, FR, ⁶Products Roche - France, Neuilly-sur-Seine, FR, ⁷Sorbonne University, GRC n °5, ONCOTYPE-URO, PARIS, FR, ⁸CHRU Bretonneau, Tours, FR, ⁹Hôpital Paul Brousse AP-HP, Villejuif, FR

- 12:00 - 12:00 **1046P - Identification of a RNA-Seq Based Signature to Improve Prognostic for Uterine Sarcoma**
J.-G. Zhou¹, H. Ma², ¹Zunyi Medical College Affiliated Hospital, Zunyi, CN, ²Zunyi Medical University Affiliated Hospital, Zunyi, CN
- 12:00 - 12:00 **1047P - The Effect Of Multiple Interventions For Women At Risk For Cervical Cancer On Their Health Responsibility, Beliefs Regarding Cervical Cancer, And Having Screening: A Randomized Controlled Experiment**
B. Altinel, B. Akin, Selcuk University, Konya, TR
- 12:00 - 12:00 **1048P - Quantifying the Effects of the Korean National Cancer Screening Program on Cervical Cancer Mortality**
N. Bui¹, E. Choi², M. Suh², K.-W. Jung², J.K. Jun², K.S. Choi², ¹National Cancer Center, Goyang, KR, ²National Cancer Center, Goyang-si, KR
- 12:00 - 12:00 **1049P - Spread of tumor and adverse events after modified radical hysterectomy for FIGO Stage IB1 cervical cancer patients with tumor diameter preoperatively estimated 2 cm or less: Japan Clinical Oncology Group trial (JCOG1101); exploratory analysis before primary analysis.**
T. Arimoto¹, K. Takahiro², T. Toita³, H. Kobayashi⁴, R. Machida⁵, T. Mizutani⁵, T. Onda⁶, M. Mizuno⁷, H. Yokota⁸, S. Kamiura⁹, K. Takehara¹⁰, H. Takano¹¹, T. Saito¹², M. Mandai¹³, T. Satoh¹⁴, S. Yamaguchi¹⁵, T. Nakamura¹⁶, K. Ushijima¹⁷, D. Aoki¹⁸, N. Yaegashi¹⁹, ¹Toranomon Hospital, Minato-ku, JP, ²Tokyo Metropolitan Bokutoh Hospital, Tokyo, JP, ³Okinawa Chubu Hospital, Uruma, Okinawa, JP, ⁴Kagoshima University Hospital, Kagoshima, JP, ⁵National Cancer Center Hospital, Chuo-ku, Tokyo, JP, ⁶Kitasato University Hospital, Sagami-hara, Kanagawa, JP, ⁷Aichi Cancer Center hospital, Aichi, JP, ⁸Saitama Cancer Center Hospital, Saitama, JP, ⁹Osaka International Cancer Institute, Osaka, JP, ¹⁰Shikoku Cancer Center, Ehime, JP, ¹¹The Jikei University Kashiwa Hospital, Kashiwa, Chiba, JP, ¹²Kyushu Cancer Center, Fukuoka, JP, ¹³Kyoto University Hospital, Kyoto, JP, ¹⁴University of Tsukuba Hospital, Tsukuba, Ibaraki, JP, ¹⁵Hyogo Cancer Center, Akashi, Hyogo, JP, ¹⁶Kagoshima City Hospital, Kagoshima, JP, ¹⁷Kurume University Hospital, Kurume, Fukuoka, JP, ¹⁸Keio University Hospital, Shinjuku-ku, Tokyo, JP, ¹⁹Tohoku University Hospital, Sendai, Miyagi, JP
- 12:00 - 12:00 **1050P - Impact of Combined Interstitial and Intracavitary Brachytherapy in locally advanced Cervical cancer: A Survival and toxicity profile assessment**
V. Pareek, M. Chandra, R. Bhalavat, Jupiter Hospital, Mumbai, IN
- 12:00 - 12:00 **1051P - Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer**
C.H. Choi, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR
- 12:00 - 12:00 **1052P - Disparities starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)**
L. Mileshkin¹, E. Barnes², K. Moore³, V. GebSKI⁴, M. King², K. Narayan⁵, I. Kolodziej², K. Sjoquist², A. Fyles⁶, W. Small⁷, D. Gaffney⁸, M. Quinn⁵, J. Andrews⁹, S. Thompson³, W.

Huh¹⁰, M. Carlson¹¹, P. Disilvestro¹², D. Rischin⁵, M. Stockler¹³, B. Monk¹⁴, ¹Peter MacCallum Cancer Center, Melbourne, AU, ²University of Sydney, Sydney, AU, ³University of Oklahoma Health Sciences Center, Oklahoma, US, ⁴NHMRC Clinical Trials Centre, Camperdown, AU, ⁵Peter MacCallum Cancer Centre, Melbourne, AU, ⁶Princess Margaret Cancer Centre, University of Toronto, Toronto, CA, ⁷Stritch School of Medicine, Loyola University Chicago Director, Cardinal Bernardin Cancer Center, Chicago, US, ⁸Huntsman Cancer Institute, University of Utah, Salt Lake City, US, ⁹Australia New Zealand Gynaecological Oncology Group, Sydney, AU, ¹⁰University Of Alabama at Birmingham, Birmingham, US, ¹¹University of Texas Southwestern Medical Center, Dallas, US, ¹²Women and Infants Rhode Island, Providence, US, ¹³Chris O'Brien Lifeshouse, Camperdown, AU, ¹⁴Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital, Phoenix, US

12:00 - 12:00 **1053P - Primary results from CECILIA, a global single-arm phase 2 study evaluating bevacizumab (BEV), carboplatin (C) and paclitaxel (P) for advanced cervical cancer (aCC)**

A. Redondo¹, N. Colombo², L. Dreosti³, M. McCormack⁴, A. Nogueira Rodrigues⁵, G. Scambia⁶, A. Roszak⁷, M. Donica⁸, B. Ulker⁹, A. González Martín¹⁰, ¹Hospital Universitario La Paz, Madrid, ES, ²Istituto Europeo di Oncologia, Milan, IT, ³Pretoria Academic Hospital, Pretoria, ZA, ⁴University College London Hospital, London, GB, ⁵Federal University of Minas Gerais Brazil and Brazilian Group of Gynecologic Oncology, Belo Horizonte, BR, ⁶Policlinico Universitario A. Gemelli, Roma, IT, ⁷Wielkopolskie Centrum Onkologii, Poznań, PL, ⁸F Hoffmann-La Roche Ltd, Basel, CH, ⁹F. Hoffmann-La Roche AG, Basel, CH, ¹⁰Clínica Universidad de Navarra, Madrid, ES

12:00 - 12:00 **1054P - Prognostic and clinicopathological significance of PD-L1 in patients with cervical cancer: a meta-analysis**

X. Gu¹, Y. Shi², ¹1st Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ²The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN

12:00 - 12:00 **1055P - Clinical impact of molecular profiling of cervical cancer (CC) patients (pts) in a dedicated Phase I (P1) unit**

M. Scaranti¹, R. Caldwell², M. Selvi Miralles², R. Shinde², A. Pal², J.E. Ang², A. Biondo², C. Guo², E. Cojocar², S. Gennatas², F. Lockie², C. Bertan³, C. Baker³, S. Carreira³, S. Banerjee⁴, S. Kaye², J. De Bono⁵, U. Banerji², A. Minchom², J. Lopez², ¹The Royal Marsden Hospital, London, GB, ²The Royal Marsden Foundation Trust and The Institute of Cancer Research, London, GB, ³The Institute of Cancer Research, London, GB, ⁴Royal Marsden Hospital NHS Foundation Trust, London, GB, ⁵The Institute of Cancer Research (ICR), London, GB

12:00 - 12:00 **1056P - Comparative proteomic profiles of cervical cancer and paired paracancerous tissue and the potential effects of DUSP7 over-expression through inhibiting RAS pathway on the biological characteristics of human cervical cancer cell line SIHA**

X. Jiang¹, H. Bai², Z. Zhang², ¹Beijing Chaoyang Hospital - Capital Medical University, Beijing, CN, ²Beijing Chaoyang Hospital, Capital Medical University, Beijing, CN

12:00 - 12:00

1057P - Molecular profiling reveals novel targetable biomarkers in neuroendocrine carcinoma of the uterine cervix

S. Vranic¹, D. Arguello², E. Contreras², A. Cimic³, Z. Gatalica⁴, ¹Clinical Centre of Sarajevo University, Sarajevo, BA, ²Caris Life Sciences, Phoenix, US, ³Maimonides Medical Center, New York, US, ⁴Caris Life Sciences, New York, US

12:00 - 12:00 **1058P - Changes in clinico-pathological characteristics of vulvar cancer in Japan: increasing oldest-old, stage-shifting, and decreasing cohort-level survival**

S. Nishio¹, K. Matsuo², T. Shibata³, S. Yamaguchi⁴, H. Kanao⁵, K. Takehara⁶, N. Kado⁷, A. Tozawa⁸, H. Tokunaga⁹, T. Matsunaga¹⁰, H. Kato¹¹, K. Horie¹², A. Kikuchi¹³, T. Enomoto¹⁴, M. Mikami¹⁵, ¹Kurume University, Kurume, JP, ²University of Southern California, Los Angeles, US, ³Tokai University, Isehara, JP, ⁴Hyogo Cancer Center, Akashi, Hyogo, JP, ⁵Cancer Institute Hospital, Tokyo, JP, ⁶Shikoku Cancer Center, Ehime, JP, ⁷Shizuoka Cancer Center, Shizuoka, JP, ⁸St. Marianna University, Kawasaki, JP, ⁹Tohoku University, Sendai, JP, ¹⁰Yokohama City University Hospital, Yokohama, JP, ¹¹Kanagawa Cancer Center, Yokohama, JP, ¹²Saitama Cancer Center, Saitama, JP, ¹³Niigata Cancer Center Hospital, Niigata, JP, ¹⁴Niigata University Medical and Dental Hospital, Niigata, JP, ¹⁵Tokai University Hospital, Isehara, JP

12:00 - 12:00 **1059TiP - Tumor Treating Fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: Phase 3 INNOVATE-3/ENGOT-ov50 study**

I. Vergote¹, L. Copeland², B. Monk³, R. Coleman⁴, D. Cibula⁵, J. Sehouli⁶, E.P. Samartzis⁷, M. Radoslaw⁸, A. González Martín⁹, J. Korach¹⁰, V. Salutari¹¹, P. Witteveen¹², D. O'Malley², ¹University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ²Ohio State University Comprehensive Cancer Center, Hilliard, US, ³University of Arizona Cancer Center, Tucson, US, ⁴The M. D. Anderson Cancer Center, Houston, US, ⁵Charles University and General University Hospital, Prague, CZ, ⁶Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ⁷Universitätsspital Zürich, Zurich, CH, ⁸Uniwersytet Medyczny im K. Marcinkowskiego w Poznaniu, Poznań, PL, ⁹Clínica Universidad de Navarra, Madrid, ES, ¹⁰Tel HaShomer, Ramat Gan, IL, ¹¹Policlinico Universitario Agostino Gemelli, Rome, IT, ¹²UMC Utrecht Cancer Center, Utrecht, NL

12:00 - 12:00 **1060TiP - Randomized, phase 1b/2 study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer**

S. Banerjee¹, I. Vergotte², N. Colombo³, M. Barve⁴, R. Grisham⁵, K. Mehr⁶, M. Falk⁶, F. Beier⁶, M. Hennessy⁷, A. Schroeder⁶, M. Birrer⁸, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²University Hospital Leuven, Leuven Cancer Institute, Leuven, BE, ³Istituto Europeo di Oncologia, Milan, IT, ⁴Mary Crowley Cancer Center, Dallas, US, ⁵Memorial Sloan Kettering Cancer Center, New York, US, ⁶Merck Healthcare KGaA, Darmstadt, DE, ⁷EMD Serono Research Center, Billerica, US, ⁸The University of Alabama at Birmingham, Birmingham, US

12:00 - 12:00 **1061TiP - An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: A Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION**

J.-Y. Lee¹, J.W. Kim², B.G. Kim³, S. Kim¹, H.S. Kim², C.H. Choi⁴, ¹Yonsei Cancer Center Yonsei University, Seoul, KR, ²Seoul National University Hospital, Seoul, KR,

³Sungkyunkwan University, Seoul, KR, ⁴Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

12:00 - 12:00

1062TiP - A phase 2 study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer

A. Oaknin¹, M.J. Rubio Perez², L. Fariñas Madrid¹, A. Redondo³, A. Yubero Esteban⁴, M. Gil Martín⁵, A. González Martín⁶, I. Romero⁷, J. Garcia-Donas⁸, R. Serrano⁹, A. Gallego Martínez³, M. Ocariz Diez⁴, M.L. Sanchez Lorenzo⁶, M.D. Fenor De La Maza Lopez Olmedo¹⁰, V. Rodriguez Freixinos¹, J.M. Piulats Rodriguez¹¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²University Hospital Reina Sofia, Cordoba, ES, ³Hospital Universitario La Paz, Madrid, ES, ⁴Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, ⁵ICO - Institut Catala d'Oncologia Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ⁶Clínica Universidad de Navarra, Madrid, ES, ⁷IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, ⁸Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES, ⁹Hospital Universitario Reina Sofía, Córdoba, ES, ¹⁰Hospital Universitario de La Princesa, Madrid, ES, ¹¹ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES

12:00 - 12:00

1063TiP - ENGOT-EN9/LEAP-001: a phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer

C. Marth¹, C. Vulsteke², M. Rubio³, V. Makker⁴, E.I. Braicu⁵, I. Mcneish⁶, M. Radoslaw⁷, A. Ayhan⁸, K. Hasegawa⁹, X. Wu¹⁰, L. Dutta¹¹, C. Xu¹², S. Keefe¹³, J. Lee¹², S. Pignata¹⁴, ¹University Hospital Innsbruck, Innsbruck, AT, ²AZ Maria Middelaes AZMMSJ, Gent, BE, ³H. Reina Sofía de Córdoba, Córdoba, ES, ⁴Memorial Sloan-Kettering Cancer Center, New York, US, ⁵Charité - Universitätsmedizin Berlin, Berlin, DE, ⁶Imperial College London, London, GB, ⁷Uniwersytet Medyczny im K. Marcinkowskiego w Poznaniu, Poznań, PL, ⁸Ankara Baskent University Hospital, Ankara, TR, ⁹Saitama Medical University International Medical Center, Hidaka, JP, ¹⁰Fudan University Shanghai Cancer Center, Shanghai, CN, ¹¹Eisai Inc., Woodcliff Lake, US, ¹²Merck & Co., Inc., Kenilworth, US, ¹³Merck Sharp & Dohme Corp. USA, Whitehouse Station, US, ¹⁴Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT

12:00 - 12:00

1064TiP - Phase 1/2 trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)

I. Vergote¹, N. Concin², M.R. Mirza³, A. Malmberg⁴, L. Eaton⁵, L. Nicacio⁶, D. Lorusso⁷, I. Soumaoro⁸, B. Monk⁹, D. O'Malley¹⁰, ¹University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ²Belgium and Luxembourg Gynaecological Oncology Group, University of Leuven, Leuven Cancer Institute, Leuven, BE, ³Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, ⁴Genmab, Copenhagen, DK, ⁵Genmab, Princeton, US, ⁶Seattle Genetics, Inc, Bothell, US, ⁷Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁸Genmab US, Inc., Princeton, US, ⁹University of Arizona Cancer Center, Tucson, US, ¹⁰The Ohio State University Comprehensive Cancer Center, Columbus, US

12:00 - 12:00

Gastrointestinal tumours, colorectal

- 12:00 - 12:00 **534P - Updated data of Epitopes-HPV02 trial and external validation of efficacy of DCF in prospective Epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients**
S. Kim¹, A. Meurisse², M. Stouvenot³, M. Jary¹, T. Nguyen Tan Hon³, E. Francois⁴, B. Buecher⁵, T. Andre⁶, E. Samalin⁷, F. Boulbair⁸, B. De Bari¹, H. Almotlak³, E. Klajer¹, F. Calcagno³, E. Chatillon¹, L. Spehner⁹, M. Jacquin¹, V. Vendrely¹⁰, D. Vernerey¹¹, C. Borg¹, ¹CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, ²Besançon University Hospital, Besançon, FR, ³CHRU Besançon - Hopital Jean Minjoz, Besançon, FR, ⁴Centre Antoine Lacassagne, Nice Cedex, FR, ⁵Institut Curie, Paris, FR, ⁶Hopital Saint-Antoine, Paris, FR, ⁷ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ⁸Hospital Nord Franche Comté, Montbéliard, FR, ⁹UMR1098, Besançon, FR, ¹⁰Chu Bordeaux, Pessac, FR, ¹¹MSD, FR
- 12:00 - 12:00 **535P - Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5)**
A. Gilbert¹, L. Mcparland¹, J. Webster¹, S. Bell¹, J. Copeland¹, R. Adams², M. Harrison³, R. Muirhead⁴, A. Renehan⁵, D. Sebag-Montefiore⁶, M. Hawkins⁷, ¹University of Leeds-Clinical Trials Research Unit, Leeds, GB, ²Velindre Cancer Centre Velindre Hospital, Cardiff, GB, ³Mount Vernon Hospital, London, GB, ⁴Churchill Hospital University of Oxford, Oxford, GB, ⁵Manchester Cancer Research Centre, Manchester, GB, ⁶University of Leeds, Leeds, GB, ⁷University of Oxford, Oxford, GB
- 12:00 - 12:00 **536P - A prospective study of diffusion-weighted magnetic resonance imaging for predicting outcome following chemoradiotherapy, in squamous cell carcinomas of the anus.**
R. Muirhead¹, D. Bulte², R. Cook³, K.-Y. Chu³, L. Durrant³, V. Goh⁴, C. Jacobs³, S. Ng², V. Strauss², P. Virdee², C. Qi², M. Hawkins², ¹Churchill Hospital University of Oxford, Oxford, GB, ²University of Oxford, Oxford, GB, ³Oxford University NHS Foundation Trust, Oxford, GB, ⁴King's College London, London, GB
- 12:00 - 12:00 **537P - Timing to achieve complete response (CR) after definitive chemoradiotherapy (ChRT) in patients with squamous cell carcinoma of the anal (SCCAC) with and without HIV infection: a multicenter retrospective study**
M. Camandaroba¹, S. Iseas², R. Taboada¹, C. Oliveira¹, C. Mauro¹, M. Xerfan¹, M. Barros³, V.H. De Jesus¹, T. Felismino¹, C. Mello¹, R. Riechelmann⁴, ¹A. C. Camargo Cancer Center, Sao Paulo, BR, ²Bonorino Udaondo Hospital, Buenos Aires, AR, ³AC Camargo Cancer Center, Sao Paulo, BR, ⁴Hospital Sírio-Libanês, Sao Paulo, BR
- 12:00 - 12:00 **538P - Planned organ preservation for T2 T3 M0 rectal adenocarcinoma. A possible option using chemoradiotherapy (CRT) and Contact X-ray Brachytherapy (CXB). A French multicenter study.**
J.-P. Gérard¹, K. Benezery², N. Barbet³, L. Montagne¹, J.-M. Hannoun-Levi¹, E. Francois², ¹Centre Anticancer Antoine Lacassagne, Nice, FR, ²Centre Antoine Lacassagne, Nice Cedex, FR, ³Centre Baclesse, Lyon-Villeurbanne, FR
- 12:00 - 12:00 **539P - (Withdrawn)**

- 12:00 - 12:00 **540P - A Phase 1b Study of E7046 (AN0025) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Rectal Cancer**
L. Wyrwicz¹, M. Saunders², M. Hall³, J. Ng⁴, V. Bhagawati Prasad⁵, N. Lautermilch⁶, M. Rashford⁷, J. Jin⁶, S. Formenti⁸, R. Glynne-Jones³, ¹M Sklodowska Curie Memorial Cancer Center, Warsaw, PL, ²The Christie NHS Foundation Trust, Manchester, GB, ³Mount Vernon Cancer Centre, Northwood, GB, ⁴Weill Cornell Medicine, New York, US, ⁵University College London Hospital UCLH NHS Foundation Trust, London, GB, ⁶Adlai Nortye USA, North Brunswick, US, ⁷Adlai Nortye, North Brunswick, US, ⁸Weill Cornell Medical College, New York, US
- 12:00 - 12:00 **541P - Upfront radical surgery with total mesorectal excision (TME) versus preoperative chemoradiotherapy followed by TME in clinical stage II/III patients with rectal cancer: a propensity score analysis**
A. Ham¹, H.S. Kim¹, J.S. Chang¹, S.J. Shin², S.-H. Beom³, W.S. Koom¹, T. Kim¹, H. Hur³, B.S. Min³, K.Y. Lee³, N.K. Kim³, J.S. Lim³, J.-B. Ahn¹, ¹Yonsei Cancer Center Yonsei University, Seoul, KR, ²Yonsei University College of Medicine, Seoul, KR, ³Yonsei Cancer Center, Seoul, KR
- 12:00 - 12:00 **542P - Neoadjuvant chemoradiotherapy with/without lateral lymph node dissection for low rectal cancer: Which patients can benefit?**
D. Nishizaki¹, K. Hida¹, A. Sumii¹, Y. Sakai¹, T. Konishi², T. Akagi³, T. Yamaguchi², T. Akiyoshi², M. Fukuda⁴, S. Yamamoto⁵, S. Maruyama⁶, M. Okajima⁷, Y. Miyakura⁸, R. Okamura¹, S. Arizono¹, M. Yamamoto⁹, K. Kawada¹, S. Morita¹⁰, M. Watanabe¹¹, ¹Kyoto University-Graduate school of medicine, Kyoto, JP, ²Cancer Institute Hospital, Tokyo, JP, ³Oita University Faculty of Medicine, Yufu, JP, ⁴Kitano Hospital, Osaka, JP, ⁵Hiratsuka Municipal Hospital, Hiratsuka, JP, ⁶Niigata Cancer Center Hospital, Niigata, JP, ⁷Hiroshima City Hiroshima Citizens Hospital, Hiroshima, JP, ⁸Jichi Medical University Saitama Medical Center, Saitama, JP, ⁹Okayama University Graduate School of Environmental and Life Science, Okayama, JP, ¹⁰Kyoto University Graduate School of Medicine, Kyoto, JP, ¹¹Kitasato University Kitasato Institute Hospital, Tokyo, JP
- 12:00 - 12:00 **543P - The impact of completeness of chemotherapy on the efficacy of irinotecan in the preoperative chemoradiotherapy of locally advanced rectal cancer.**
J. Wang¹, J. Fan¹, C. Li¹, L. Shen¹, L. Yang¹, F. Xia¹, J. Wan¹, Z. Zhang¹, J. Zhu², ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Fudan University Shanghai Cancer Center, Shanghai, CN
- 12:00 - 12:00 **544P - Feasibility of robot-assisted surgery in elderly patients with rectal cancer**
W.-C. Su¹, C.-W. Huang², C.-J. Ma¹, C. Po-Jung³, H.-L. Tsai⁴, T.-K. Chang¹, Y.-C. Chen¹, C.-C. Li¹, Y.-S. Yeh³, J.-Y. Wang⁵, ¹Kaohsiung Medical University Hospital, Kaohsiung City, TW, ²Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TW, ³Kaohsiung Medical University Hospital, Kaohsiung City, TW, ⁴Chung-Ho Memorial Hospital, Kaohsiung Medical University Hospital, Kaohsiung City, TW, ⁵Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TW
- 12:00 - 12:00 **545P - Feasibility of chemoradiotherapy in rectal cancer patients with**

peritumoral abscesses and fistulas: a case-control non-inferiority trial

V. Ivanov¹, S. Gordeyev², Z. Mamedli³, M. Chernykh⁴, A. Perevoschikov³, Y. Surayeva⁴, P. Bulychkin³, G. Haqverdiyeva³, ¹N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ²N.N.Blokhin Russian Cancer Research Center, Moscow, RU, ³N.N.Blokhin National Medical Research Center of Oncology, Moscow, RU, ⁴Podolsk “PET-technology” cancer center, Podolsk, RU

12:00 - 12:00 **546P - Differential of the nutritional index before and after neoadjuvant chemoradiotherapy as a prognostic factor of recurrence in patients with locally advanced adenocarcinoma of the rectum**

L. Navia-Ortuño¹, M. Díaz², M. Ramos Ramirez¹, ¹The National Cancer Institute, Ciudad de Mexico, MX, ²The National Cancer Institute, CIUDAD DE MEXICO, MX

12:00 - 12:00 **547P - Short-term Clinical Outcomes of Robotic-Assisted Total Mesorectal Excision in Rectal Cancer after concurrent chemoradiotherapy**

P. Chen¹, J.-Y. Wang², ¹Kaohsiung Municipal Siaogang Hospital, Kaohsiung City, TW, ²Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TW

12:00 - 12:00 **548P - Local immune status in cancer cell nests can be a predictor of survival for rectal cancer with neoadjuvant radiotherapy**

X. Lin¹, F. Lin², Q. Zhuang², X. Zhang², Y. Huang³, L. Tang³, J. Li⁴, W. Junxin², ¹Fujian Medical University, Fuzhou, Fujian, CN, ²Fujian Cancer Hospital, Fuzhou, CN, ³Fujian Medical University Cancer Hospital, Fuzhou, CN, ⁴Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, CN

12:00 - 12:00 **549P - Impact of concomitant medications on disease free survival (DFS) and overall survival (OS) in patients from the PETACC8 study.**

B. Clémence¹, J. Taieb², M. Boulin¹, K. Le Malicot³, L.M. Dourthe⁴, B. Avisse⁵, P. Laplaige⁶, C. Borel⁷, D. Arsene⁸, F. Kikolski⁹, B. Denis¹⁰, P. Geoffroy¹¹, R. Coriat¹², G. Piot¹³, C. Lepage¹, ¹CHU Dijon, Dijon, FR, ²Hopital European George Pompidou, Paris, FR, ³FFCD-, Dijon, FR, ⁴Clinique de l'Orangerie, Strasbourg, FR, ⁵Centre Hospitalier Pierre Oudot, Bourgoin-Jallieu, FR, ⁶Polyclinique de Blois, La Chaussee St. Victor, FR, ⁷Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, ⁸CHU de Caen - Hôpital Côte de Nacre, Caen, FR, ⁹CH Libourne, Libourne, FR, ¹⁰Hôpital Louis Pasteur, Colmar, FR, ¹¹Clinique Saint-Vincent, Epernay Cedex, FR, ¹²Hôpital Cochin, Paris, FR, ¹³Clinique des Ormeaux, Le Havre, FR

12:00 - 12:00 **550P - Updated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer.**

P. Pfeiffer¹, J. Bjerregaard¹, C. Qvortrup², H. Sorbye³, B. Glimelius⁴, C. Kersten⁵, ¹Odense University Hospital, Odense C, DK, ²Finsen Center - Rigshospitalet, Copenhagen, DK, ³Haukeland Universitetssykehus, Bergen, NO, ⁴Dept of Immunology, Genetics and Pathology, Uppsala, SE, ⁵Sorlandet Hospital, Kristiansand, NO

12:00 - 12:00 **551P - Clinical impact of mucinous and poorly differentiated tumors on the outcome of patients with stage II colon cancer: a TOSCA subgroup analysis**

G. Rosati¹, F. Galli², M. Cantore³, S. Lonardi⁴, M. Banzi⁵, M.G. Zampino⁶, R. Mattioli⁷, N. Pella⁸, M. Ronzoni⁹, M. Di Bartolomeo¹⁰, S. Tamperi¹¹, P. Marchetti¹², S. Bozzarelli¹³, D. Corsi¹⁴, A.M. Bochicchio¹⁵, F. Artioli¹⁶, R. Labianca¹⁷, F. Galli¹⁸, D. Bilancia¹⁹, G. Bregni²⁰, ¹Azienda Ospedaliera Regionale S. Carlo di Potenza, Potenza, IT, ²Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, IT, ³Azienda USL 1 di Massa e Carrara, Carrara, IT, ⁴Istituto Oncologico Veneto IRCCS, Padova, IT, ⁵Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, ⁶Istituto Europeo di Oncologia, Milan, IT, ⁷Ospedale St. Croce, Fano, IT, ⁸Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia, Udine, IT, ⁹IRCCS Ospedale San Raffaele, Milan, IT, ¹⁰Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ¹¹Ospedale degli Infermi, Faenza, IT, ¹²Azienda Ospedaliera St. Andrea, Rome, IT, ¹³Istituto Clinico Humanitas, Rozzano, IT, ¹⁴Ospedale San Giovanni Calibita - Fatebenefratelli, Rome, IT, ¹⁵Centro di Riferimento Oncologico Basilicata IRCCS, Rionero in Vulture, IT, ¹⁶Ospedale Ramazzini, Carpi, IT, ¹⁷Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT, ¹⁸IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milano, IT, ¹⁹AZ. OSPEDALIERA SAN CARLO, Potenza, IT, ²⁰IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

12:00 - 12:00 **552P - Exercise improved adjuvant treatment completion rates and treatment-related toxicities in colorectal cancer: A prospective pilot study**

H.J. Kim¹, Y.J. Shim², J. Kim³, ¹Korea University Guro Hospital, Seoul, KR, ²Sungshin Women's University, Seoul, KR, ³Kyung Hee University School of Medicine, Seoul, KR

12:00 - 12:00 **553P - Bevacizumab plus Oxaliplatin-Based Chemotherapy as Adjuvant Treatment for Colon Cancer (CC): Updated analysis of stage II disease from the AVANT Phase III Randomized trial by the GERCOR Group**

A. De Gramont¹, J. Henriques², B. Baruch³, T.W. Kim⁴, M. Martinez-Villacampa⁵, J. Gallego-Plazas⁶, A. Cervantes⁷, K. Shim⁸, D. Jonker⁹, V. Guerin-Meyer¹⁰, L. Mineur¹¹, M. Banzi¹², A. Dewdney¹³, T. (Sirisingha) Dejthevaporn¹⁴, H.J. Bloemendal¹⁵, A. Roth¹⁶, P. Thompson¹⁷, M. Moehler¹⁸, E. Aranda Aguilar¹⁹, T. André²⁰, ¹Institut hospitalier Franco-Britannique, Levallois Perret, FR, ²CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, ³Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, affiliated with Sackler School of Medicine, Tel Aviv, IL, ⁴Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁵Institut Català d'Oncologia-IDIBELL, L'Hospitalet, Barcelona, ES, ⁶General Universitario de Elche Hospital, Elche, ES, ⁷Hospital Clinico Universitario de Valencia, Valencia, ES, ⁸Lakeridge Health R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, CA, ⁹Ottawa Hospital Research Institute, University of Ottawa, Ottawa, CA, ¹⁰Institut de Cancérologie de l'Ouest Paul Papin, Angers, FR, ¹¹Institut Ste Catherine, Avignon, FR, ¹²Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, ¹³Weston Park Hospital Cancer Research Centre, Sheffield, GB, ¹⁴Ramathibodi Hospital, Bangkok, TH, ¹⁵Meander Medical Center, Amersfoort, NL, ¹⁶Hôpitaux Universitaires de Genève - HUG, Geneva, CH, ¹⁷Auckland City Hospital, Auckland, NZ, ¹⁸Universitätsmedizin Mainz, Mainz, DE, ¹⁹University Hospital Reina Sofia, Cordoba, ES, ²⁰Hôpital Saint-Antoine, Paris, FR

12:00 - 12:00 **554P - Multicenter Validation of the Postoperative Carcinoembryonic Antigen Combined Prognostic Model for Stage III Colon Cancer**

J. Zhu¹, Y. Liu², R. Zhang³, J. Fan⁴, ¹Fudan University Shanghai Cancer Center, Shanghai,

CN, ²Harbin medical university cancer hospital, Harbin, CN, ³Liaoning Cancer Hospital & Institute, Shenyang, CN, ⁴Fudan University Shanghai Cancer Center, Shanghai, CN

12:00 - 12:00

555P - Impact of the IDEA study on clinical practice for stage III colon cancer patients: a French GERCOR - FFCD - GI UNICANCER national survey.

K. Ouali¹, R. Cohen², A. Turpin³, C. Neuzillet⁴, B. Rousseau⁵, M.-L. Garcia-Larnicol⁶, C. Tournigand⁷, E. Samalin⁸, J. Taieb⁹, T. André¹⁰, ¹AP-HP Hôpital Universitaire Pitié Salpêtrière - Charles Foix, Paris, FR, ²Hôpital Saint-Antoine, Paris, FR, ³Hopital Claude Huriez, Lille, FR, ⁴Hôpital Beaujon, Clichy, FR, ⁵Mortimer B. Zuckerman Research Center /Memorial Sloan Kettering Cancer Center, New-York, US, ⁶GERCOR, Paris, FR, ⁷Centre hospitalier universitaire Henri-Mondor, Créteil, FR, ⁸ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ⁹Hopital European George Pompidou, Paris, FR, ¹⁰Saint-Antoine hospital, AP-HP, Paris, FR

12:00 - 12:00

556P - Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer

P. Falk¹, M. Severin¹, M. Gronlie Guren², P. Österlund³, E. Hofslid⁴, A. Giwercman⁵, J. Eberhard⁶, H. Sorbye⁷, ¹Skanes universitetssjukhus - Onkologiska Klinik, Lund, SE, ²Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ³Tampere University Hospital, Tampere, FI, ⁴Norwegian University of Science and Technology, Trondheim, NO, ⁵Molecular Reproductive Medicine, Malmö, SE, ⁶Skanes universitetssjukhus Lund, Lund, SE, ⁷Haukeland Universitetssykehus, Bergen, NO

12:00 - 12:00

557P - Loss of CDX-2 expression is an independent poor prognostic biomarker in colorectal cancer

K. Korhaisarn¹, A. Pongpaibul², K. Sukhokanjanachusak³, C. Akewanlop⁴, ¹Faculty of Medicine Siriraj Hospital, Mahidol University, Pathumwan, TH, ²Siriraj Hospital, Bangkok, TH, ³Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, TH, ⁴Siriraj Hospital, Mahidol University, Bangkok, TH

12:00 - 12:00

558P - Robot-assisted natural orifice specimen extraction surgery for radical resection of colorectal cancer

Z. Niu, Y. Wei, Q. Feng, D. Zhu, J. Xu, Zhongshan Hospital, Fudan University, Shanghai, CN

12:00 - 12:00

559P - Bevacizumab as adjuvant treatment for colon cancer: Updated results from the AVANT phase III Study by the GERCOR Group

T. André¹, D. Vernerey², S.-A. Im³, G.M. Bodoky⁴, R. Buzzoni⁵, S. Reingold⁶, F. Rivera⁷, J. Mckendrick⁸, W. Scheithauer⁹, R. Geva¹⁰, G. Fountzilas¹¹, W.P. Yong¹², R. Isaacs¹³, L.-M. Soveri¹⁴, J.-T. Liang¹⁵, G.-J. Creemers¹⁶, E. Van Cutsem¹⁷, D. Cunningham¹⁸, J. Taberero¹⁹, A. De Gramont²⁰, ¹Hôpital Saint-Antoine, Paris, FR, ²MSD, FR, ³SNUH-Seoul National University Hospital, Seoul, KR, ⁴Combined Szent István and Szent László Hospitals, Budapest, HU, ⁵Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁶William Osler Health Centre Brampton Civic Hospital, Brampton, CA, ⁷HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES, ⁸Eastern Health, Box Hill Hospital, Melbourne, AU, ⁹Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, ¹⁰Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL, ¹¹Papageorgiou Hospital Aristotle University of Thessaloniki, Thessaloniki, GR,

¹²National University of Singapore, Singapore, SG, ¹³Palmerston North & Crest Hospitals, Palmerston North, NZ, ¹⁴Helsinki University Central Hospital, Helsinki, FI, ¹⁵National Taiwan University Hospital, Taipei, TW, ¹⁶Catharina Hospital Eindhoven, Eindhoven, NL, ¹⁷University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, BE, ¹⁸The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ¹⁹Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ²⁰Institut hospitalier Franco-Britannique, Levallois Perret, FR

- 12:00 - 12:00 **560P - Real world data on adjuvant chemotherapy for high-risk stage II colorectal cancer - the role of tumor side**
C. Araujo De Carvalho¹, C. Moniz¹, G. Watarai¹, J. Crespo¹, P. Nogueira¹, J. Martinez¹, P. Moraes¹, R. Bonadio², M. Braghiroli¹, J. Sabbaga¹, P. Hoff¹, ¹ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR, ²ICESP - Instituto do Câncer do Estado de São Paulo, Sao Paulo, BR
- 12:00 - 12:00 **561P - Oncological Outcome and Safety of Bevacizumab (BV) Therapy in Patients with Occlusive Colon Cancer and Self-Expandable Metal Stents (SEMS)**
V. Pacheco-Barcia¹, R. Mondejar¹, O. Martinez-Saez², F. Longo Munoz², J.A. Moreno Monteagudo¹, J. Rogado¹, O. Donnay¹, C. Santander¹, A. Carrato Mena², R. Colomer Bosch¹, ¹Hospital Universitario de La Princesa, Madrid, ES, ²Hospital Universitario Ramon y Cajal, Madrid, ES
- 12:00 - 12:00 **562P - Active chronic hepatitis B increases the risk of liver metastasis of colorectal cancer- a retrospective clinical study of 7187 consecutive cases of newly diagnosed colorectal cancer**
L. Zhao¹, L. Song², J. Cao³, Y. Yang⁴, ¹Shandong Cancer Hospital and Institute, Jinan, CN, ²1st Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ³The Affiliated Hospital of Qingdao University, Qingdao, CN, ⁴Shandong Cancer Hospital and I, Jian, CN
- 12:00 - 12:00 **563P - Comprehensive Evaluation of Recurrence Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation**
W. Ye¹, Y. Chen¹, J. Xu², ¹Zhongshan Hospital, Fudan University, Shanghai, CN, ²Zhongshan Hospital, Fudan University, Shanghai, China, shanghai, CN
- 12:00 - 12:00 **564P - BRAF-mutated colorectal metastases: what is the benefit of liver surgery? Results from a cohort of 91 patients.**
S. Javed¹, S. Benoist², C. De La Fouchardiere³, S. Truant⁴, D. Sefrioui⁵, M.P. Galais⁶, V. Hautefeuille⁷, P. Artru⁸, R. Guimbaud⁹, R. Cohen¹⁰, A. Lievre¹¹, J. Edeline¹², J.-B. Bachet¹³, M. Gelli¹⁴, A. Herrero¹⁵, U. Marchese¹⁶, M. El Amrani⁴, P. Devos¹⁷, A. Turpin¹⁸, A. Ploquin¹⁸, ¹CHRU de Lille, Lille, FR, ²Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, FR, ³Centre Léon Bérard, Lyon, FR, ⁴Huriez hospital, Lille, FR, ⁵CHU Hôpitaux de Rouen-Charles Nicolle, Rouen, FR, ⁶Centre Francois Baclesse, Caen, FR, ⁷CHU Amiens-Picardie Site Nord, Amiens, FR, ⁸Hôpital privé Jean Mermoz, Lyon, FR, ⁹Centre Claudius-Regaud, Toulouse, FR, ¹⁰Hôpital Saint-Antoine, Paris, FR, ¹¹CHU de Pontchaillou, Rennes, FR, ¹²Centre Eugene - Marquis, Rennes, FR, ¹³Groupe Hospitalier Pitié Salpêtrière, Paris, FR, ¹⁴Gustave Roussy, Villejuif cedex, FR, ¹⁵University Hospital Center, University of Montpellier-Nîmes, Montpellier, FR, ¹⁶Institut Paoli-Calmettes, Marseille, FR, ¹⁷Lille University Hospital, Lille, FR, ¹⁸Hopital Claude Huriez, Lille, FR

- 12:00 - 12:00 **565P - The smallest colorectal liver metastasis size as a prognosis factor after laparoscopic liver resection**
B. Cervantes¹, B. Gayet², F. Frosio², N. Tabchouri², M. Bennamoun³, N. Alexandra², C. Louvet³, D. Fuks², ¹AP-HP Hôpital Universitaire Pitié Salpêtrière - Charles Foix, Paris, FR, ²Institut Mutualiste Montsouris, Paris, FR, ³Institute Mutualiste Montsouris, Paris, FR
- 12:00 - 12:00 **566P - Validation of GAME score risk groups in resected colorectal cancer liver metastases and the prognostic relevance of KRAS, NRAS and BRAF mutation analysis**
B. Martin-Cullell¹, C. Fumagalli¹, R. Teres¹, P. Gallardo Melo¹, A. Sebio Garcia¹, A.C. Virgili Manrique¹, O. Mirallas², S. Sánchez Cabús¹, V. Molina¹, J. Szafranska¹, D. Paez Lopez Bravo¹, ¹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ²Vall Hebron University Hospital, Barcelona, ES
- 12:00 - 12:00 **567P - Predictive factors and survival outcomes with stereotactic body radiation therapy in treatment of oligometastases in colorectal cancer**
V. Pareek, R. Bhalavat, M. Chandra, Jupiter Hospital, Mumbai, IN
- 12:00 - 12:00 **568P - Factors of importance in procuring tumoroids from colorectal liver metastasis biopsies for precision medicine.**
L.H. Jensen¹, C. Dam², G. Hagel³, C. Vagn-Hansen², H. Harling³, B. Havelund¹, A. Jakobsen⁴, J. Lindebjerg², S. Rafaelsen², O. Thastrup⁵, T. Hansen⁴, ¹Vejle Sygehus Hospital, Vejle, DK, ²Vejle University Hospital, Vejle, DK, ³cureX, Copenhagen, DK, ⁴Vejle University Hospital Sygehus Lillebaelt, Vejle Sygehus, Vejle, DK, ⁵University of Copenhagen - Department of Drug Design and Pharmacology, Copenhagen, DK
- 12:00 - 12:00 **569P - FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity**
M.-C. Etienne-Grimaldi¹, N. Cozic², J.-C. Boyer³, V. Boige⁴, R. Diasio⁵, J. Taieb⁶, D. Meulendijks⁷, C. Palles⁸, U. Zanger⁹, M. Deenen¹⁰, C. Largiader¹¹, M. Boisdron-Celle¹², A. Marinaki¹³, B. Jennings¹⁴, E. Gross¹⁵, F. Thomas¹⁶, M.-A. Lorient¹⁷, G. Le Teuff², J.-P. Pignon¹⁸, ¹Centre Anticancer Antoine Lacassagne, Nice, FR, ²Gustave Roussy, Villejuif, FR, ³CHU de Nîmes, Nîmes, FR, ⁴Institut Gustave Roussy, Villejuif, FR, ⁵Mayo Clinic, MN, US, ⁶Hopital European George Pompidou, Paris, FR, ⁷Medicines Evaluation Board, Utrecht, NL, ⁸The University of Birmingham - Medical School, Birmingham, GB, ⁹Dr Margarete Fischer-Bosch Institute, Stuttgart, DE, ¹⁰Catharina Ziekenhuis, Eindhoven, NL, ¹¹Inselspital Bern University Hospital, Bern, CH, ¹²ICO Paul Papin, Angers, FR, ¹³St Thomas' Hospital, London, GB, ¹⁴Norwich Medical School, University of East Anglia, Norwich, GB, ¹⁵LMU University Hospital, Munich, DE, ¹⁶Institut Claudius Regaud, Toulouse, FR, ¹⁷Hopital Européen Georges Pompidou, Paris, FR, ¹⁸Gustave Roussy - Cancer Campus, Villejuif, FR
- 12:00 - 12:00 **570P - Treatments (tx) after progression to first-line FOLFOXIRI + bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and TRIBE-2 studies by GONO.**
D. Rossini¹, S. Lonardi², C. Antoniotti³, D. Santini⁴, G. Tomasello⁵, G. Aprile⁶, R.

Moretto³, A. Prete⁷, C. Granetto⁸, F. Urbano⁷, B. Borelli⁹, A. Zaniboni¹⁰, G. Randon¹¹, A. Buonadonna¹², G. Ritorto¹³, C. Barbara¹⁴, T. Latiano¹⁵, R. Bordonaro¹⁶, A. Falcone³, C. Cremolini³, ¹DIPINT - Università di Pisa, Pisa, IT, ²Istituto Oncologico Veneto IRCCS, Padova, IT, ³Azienda Ospedaliera Universitaria S. Chiara, Pisa, IT, ⁴Policlinico Universitario Campus Bio-Medico, Rome, IT, ⁵ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, ⁶ULSS 8 Berica - Vicenza-Ospedale Civile "San Bortolo", Vicenza, IT, ⁷Policlinico Umberto I - Unità di Neonatologia, Patologia e Terapia Intensiva Neonatale, Rome, IT, ⁸Azienda Ospedaliera St. Croce e Carle, IT, ⁹Univeristy Degli Studi di Pisa, Pisa, IT, ¹⁰Casa di Cura Poliambulanza, Brescia, IT, ¹¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ¹²Centro di Riferimento Oncologico - CRO, Aviano, IT, ¹³AOU Città della Salute e della Scienza di Torino, Turin, IT, ¹⁴Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, IT, ¹⁵IRCCS Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT, ¹⁶Azienda Ospedaliera ARNAS Garibaldi, Catania, IT

12:00 - 12:00

571P - Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+ BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study

T. Nagasaka¹, R. Inada², H. Ojima³, S. Noura⁴, H. Tanioka¹, Y. Munemoto⁵, Y. Shimada², K. Ishibashi⁶, Y. Shindo⁷, Y. Kagawa⁸, A. Tomibayashi⁹, K. Okamoto¹⁰, A. Tsuji¹¹, Y. Tsuji¹², S. Yamaguchi¹³, A. Sawaki¹⁴, H. Mishima¹⁵, M. Shimokawa¹⁶, M. Okajima¹⁷, Y. Yamaguchi¹, ¹Kawasaki Medical School Hospital, Kurashiki, JP, ²Kochi Health Sciences Center, Kochi, JP, ³Gunma Prefectural Cancer Center, Ota, JP, ⁴Osaka Rosai Hospital, Sakai, JP, ⁵Fukui-ken Saiseikai Hospital, Fukui, JP, ⁶Saitama Medical University, Saitama, JP, ⁷Nakadori General Hospital, Akita, JP, ⁸Kansai Rosai Hospital, Amagasaki, JP, ⁹Tokushima Red Cross Hospital, Tokushima, JP, ¹⁰Kochi Medical School Hospital, Nangoku, JP, ¹¹Kagawa University Faculty of Medicine/Graduate School of Medicine, Miki, JP, ¹²KKR Tonan Hospital, Sapporo, JP, ¹³Saitama Medical University International Medical Center, Hidaka, JP, ¹⁴Fujita Health University, Toyoake, JP, ¹⁵Aichi Medical University, Nagakute, JP, ¹⁶National Hospital Organization, National Kyushu Cancer Center, Fukuoka, JP, ¹⁷Hiroshima City Hiroshima Citizens Hospital, Hiroshima, JP

12:00 - 12:00

572P - Early tumour shrinkage (ETS), depth of response (DpR) and associated survival outcomes in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) classified according to Köhne prognostic category: retrospective analysis of the panitumumab (Pmab) PRIME study

A. Sartore-Bianchi¹, M. Peeters², M. Geissler³, J. Taieb⁴, P. García-Alfonso⁵, T. Price⁶, P. Burdon⁷, Y. Zhang⁸, C.-H. Koehne⁹, ¹Grande Ospedale Metropolitano Niguarda and University of Milan, Milan, IT, ²Antwerp University Hospital/Antwerp University, Edegem, BE, ³Klinikum Esslingen, Esslingen am Neckar, DE, ⁴Hopital European George Pompidou, Paris, FR, ⁵General Universitario Gregorio Marañón, Madrid, ES, ⁶Queen Elizabeth Hospital/University of Adelaide, Adelaide, AU, ⁷Amgen (Europe) GmbH, Rotkreuz, CH, ⁸Amgen Inc, Thousand Oaks, US, ⁹Klinikum Oldenburg, Oldenburg, DE

12:00 - 12:00

573P - Randomized phase II trial of CAPOX with planned oxaliplatin stop-and-go strategy as adjuvant chemotherapy after curative resection of colon cancer (CCOG-1302 study)

H. Yokoyama¹, G. Nakayama², K. Ishigure³, N. Hayashi⁴, K. Tanaka⁵, M. Tsutsuyama², N. Hattori², S. Yamada², Y. Kodera², ¹Komaki City Hospital, Komaki, JP, ²Nagoya University,

Graduate School of Medicine, Nagoya, JP, ³Konan Kosei Hospital, Konan, JP, ⁴Tosei General Hospital, Seto, JP, ⁵Yokkaichi Municipal Hospital, Yokkaichi, JP

- 12:00 - 12:00 **574P - A metabolomic recurrence score for risk-stratification of elderly patients (pts) with early colorectal cancer (eCRC)**
S. Di Donato¹, A. Vignoli², E. Mori³, L. Tenori², L. Malorni⁴, S. Cantafio³, G. Mottino³, D. Becheri³, A. McCartney⁴, C. Biagioni³, F. Del Monte³, A. Di Leo¹, C. Luchinat², L. Biganzoli⁴, ¹Nuovo Ospedale di Prato, Prato, IT, ²University of Florence, Sesto Fiorentino, IT, ³Nuovo Ospedale di Prato S. Stefano, Prato, IT, ⁴Ospedale di Prato Sandro Pitigliani Med. Oncology Unit, Prato, IT
- 12:00 - 12:00 **575P - RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first line treatment in metastatic colorectal cancer**
G. Martini¹, E. Elez², F. Mancuso³, M.A. Gomez España⁴, G. Caratù³, J. Matito³, G. Argiles Martinez², N. Mulet Margalef⁵, M.J. Ortiz Morales⁶, F.J. Ros Montana², A. Garcia², R. Comas⁷, C. Santos Vivas⁸, R. Perez-Lopez⁷, P. Nuciforo³, O. Casanovas⁵, R. Dienstmann², J. Tabernero⁹, E. Aranda Aguilar⁶, A. Vivancos², ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁴University Hospital Reina Sofia, ES, ⁵Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, ⁶University Hospital Reina Sofia, Cordoba, ES, ⁷Vall d'Hebron Institute of Oncology (VHIO),, Barcelona, ES, ⁸Catalan Institute of Oncology. Hospital Druan y Reynals, Barcelona, ES, ⁹Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES
- 12:00 - 12:00 **576P - Impact of prophylactic systemic antibiotics (SA) on outcome of patients (pts) with RAS-wildtype (RAS-wt) metastatic colorectal carcinoma (mCRC) treated with cetuximab-based first-line therapy. Subgroup analysis of the german non-interventional study ERBITAG**
S. Sahm¹, M.-O. Zahn², C. Maintz³, T. Goehler⁴, J. Janssen⁵, C. Hering-Schubert⁶, O. Rubanov⁷, I. Zander⁸, K. Stenzel⁹, F. Overkamp¹⁰, ¹Ketteler Krankenhaus, Offenbach am Main, DE, ²MVZ Onkologische Kooperation Harz, Goslar, DE, ³MVZ Duisburg-West (Medizinisches Versorgungszentrum), Duisburg, DE, ⁴Onkozentrum Dresden / Freiberg, Dresden, DE, ⁵Hämatologie und internistische Onkologie Westerstede, Westerstede, DE, ⁶St. Georg Klinikum Eisenach, Eisenach, DE, ⁷Praxis für Hämatologie und Onkologie, Hameln, DE, ⁸Dres. Zander und Buchholz, Hannover, DE, ⁹Merck Serono GmbH, Darmstadt, DE, ¹⁰OncoConsult.Hamburg, Hamburg, DE
- 12:00 - 12:00 **577P - Intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): A randomized, multicenter, prospective, phase III trial**
R. Zhang¹, X.-J. Wu², D. Wan², J. Lin², P. Ding², J. Lei³, Z. Lu², L. Li², G. Chen², L. Kong², F. Wang², D. Zhang⁴, W. Fan², W. Jiang², W. Zhou², C. Li², Y. Li², X. Li², Z. Pan², ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN, ³The First A liated Hospital of Guangzhou Medical University, Guangzhou, CN, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, US

- 12:00 - 12:00 **578P - Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): a pooled analysis of TRIBE and TRIBE-2 studies by GONO**
- E. Dell'Aquila¹, D. Rossini², M. Stellato³, F. Bergamo⁴, G. Aprile⁵, F. Morano⁶, R. Intini⁴, E. Fea⁷, M. Ronzoni⁸, M. Libertini⁹, A. Buonadonna¹⁰, L. Fanchini¹¹, L. Marcucci¹², E. Maiello¹³, F. Marmorino¹⁴, A. Boccaccino¹⁵, S. Cordio¹⁶, G. Masi¹⁷, A. Falcone¹⁸, D. Santini¹⁹, ¹Policlinico Universitario Campus Bio-Medico, Rome, IT, ²DIPINT - Università di Pisa, Pisa, IT, ³Campus Bio-Medico University, Rome, IT, ⁴Veneto Institute of Oncology IRCCS, Padua, IT, ⁵University Hospital, Udine, IT, ⁶Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁷Azienda Ospedaliera S Croce e Carle, Cuneo, IT, ⁸IRCCS Ospedale San Raffaele, Milan, IT, ⁹Fondazione Poliambulanza, Brescia, IT, ¹⁰Centro di Riferimento Oncologico - CRO, Aviano, IT, ¹¹AOU Città della Salute e della Scienza di Torino, Turin, IT, ¹²Azienda USL Toscana Nord Ovest, Pontedera, IT, ¹³Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT, ¹⁴Univeristy Degli Studi di Pisa, Pisa, IT, ¹⁵University of Pisa, Pisa, IT, ¹⁶ARNAS Garibaldi, Catania, IT, ¹⁷Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT, ¹⁸Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, IT, ¹⁹Campus Bio-Medico University of Rome, Rome, IT
- 12:00 - 12:00 **579P - Drug holidays and overall survival in patients treated for metastatic colorectal cancer**
- S.K. Garattini¹, M. Bonotto¹, D. Basile², L. Porcu³, E. Ongaro⁴, L. Gerratana⁵, F. Cortiula⁴, G. Pelizzari⁵, A. Parnofiello¹, E. Bertoli¹, C. Corvaja⁴, C. Lisanti⁴, M. Casagrande⁴, D. Iacono¹, G. Cardellino¹, A. Buonadonna⁵, G. Aprile⁶, N. Pella¹, F. Puglisi⁷, G. Fasola⁴, ¹Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia, Udine, IT, ²CRO di Aviano, Aviano, IT, ³IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, IT, ⁴Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT, ⁵Centro di Riferimento Oncologico - CRO, Aviano, IT, ⁶ULSS 8 Berica - Vicenza-Ospedale Civile "San Bortolo", Vicenza, IT, ⁷Centro di Riferimento Oncologico - CRO, aviano, IT
- 12:00 - 12:00 **580P - Quality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer: Results from the randomized VOLFI trial (AIO KRK-0109)**
- M. Geissler¹, T. Klingler², D. Modest³, J. Riera Knorrenschild⁴, T. Ettrich⁵, S. Kanzler⁶, V. Heinemann³, S. Held⁷, U. Martens⁸, ¹Klinikum Esslingen, Esslingen am Neckar, DE, ²Klinikum Esslingen, Esslingen, DE, ³Ludwig Maximilians University - Grosshadern, Munich, DE, ⁴Uniklinikum Giessen und Marburg, Marburg, DE, ⁵Ulm Medical University, Ulm, DE, ⁶Leopoldina Krankenhaus Medizinische Klinik II, Schweinfurt, DE, ⁷ClinAssess, Leverkusen, DE, ⁸SLK-Kliniken Heilbronn GmbH, Heilbronn, DE
- 12:00 - 12:00 **581P - A biomarker combination indicating resistance to FOLFOX plus bevacizumab in metastatic colorectal cancer : results of phase I of the PERMAD trial**
- T. Seufferlein¹, T. Ettrich¹, A. Stein², D. Arnold³, G. Prager⁴, S. Kasper⁵, M. Niedermeier⁶, L. Mueller⁷, S. Kubicka⁸, A.-O. König⁹, P. Büchner-Steudel¹⁰, K. Wille¹¹, A. Kestler¹², A. Hann¹², L. Perkhofer¹, A. Berger¹³, L. Lausser¹⁴, H. Kestler¹⁴, ¹Ulm Medical University, Ulm, DE, ²UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ³Asklepios Klinik Altona, Hamburg, DE, ⁴Vienna General Hospital (AKH) -

Medizinische Universität Wien, Vienna, AT, ⁵University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ⁶Klinikum Memmingen, Memmingen, DE, ⁷Onkologische Schwerpunktpraxis Leer-Emden, Leer, DE, ⁸Klinikum am Steinenberg Reutlingen, Reutlingen, DE, ⁹Universitätsmedizin Göttingen, Göttingen, DE, ¹⁰Martin-Luther-University Halle-Wittenberg, Halle, DE, ¹¹Johannes Weseling klinikum, Minden, DE, ¹²Ulm University Hospital, Ulm, DE, ¹³Martin Luther Universität Halle-Wittenberg, Halle (Saale), DE, ¹⁴Ulm University, Ulm, DE

12:00 - 12:00 **582P - Microsatellite Instability (MSI) status and prognosis in colorectal cancer: meta-analysis**

J. Toh¹, K. Spring², ¹Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, AU, ²Ingham Institute, Liverpool, AU

12:00 - 12:00 **583P - Choosing the right strategy based on individualized treatment effect predictions: Combination versus sequential chemotherapy in patients with metastatic colorectal cancer.**

M. Koopman¹, J. Kwakman², R. Van Kruijsdijk³, S. Elias⁴, M. Seymour⁵, A. Meade⁶, F. Visseren⁷, C. Punt⁸, ¹University Hospital Utrecht, Utrecht, NL, ²Academic Medical Center (AMC), Amsterdam, NL, ³UMC-University Medical Center Utrecht, Utrecht, NL, ⁴Julias Center for Health Sciences and Primary Care, Utrecht, NL, ⁵St. James's University Hospital Leeds, Leeds, GB, ⁶University College London, London, GB, ⁷University Medical Center Utrecht, Utrecht, NL, ⁸Academic Medical Center, University of Amsterdam, Amsterdam, NL

12:00 - 12:00 **584P - Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer**

S. Kasper¹, A.-L. Cheng², F. Overkamp³, M. Rouyer⁴, C. Foch⁵, F.-X. Lamy⁶, R. Esser⁶, D. Messinger⁷, V. Rothe⁷, W. Chen⁸, T. Brodowicz⁹, C. Zielinski¹⁰, ¹University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ²National Taiwan University Hospital, New Taipei city, TW, ³OncoConsult.Hamburg, Hamburg, DE, ⁴Bordeaux PharmacoEpi, University of Bordeaux, Bordeaux cedex, FR, ⁵Merck Healthcare KGaA, Darmstadt, DE, ⁶Merck KGaA - Germany, Darmstadt, DE, ⁷Prometris GmbH, Mannheim, DE, ⁸Merck Serono, Shanghai, CN, ⁹Internal Medicine 1, General Hospital - Medical University of Vienna, Vienna, AT, ¹⁰Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

12:00 - 12:00 **585P - POLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers**

M.E. Elez Fernandez¹, M.A. Gómez-España², C. Grávalos³, P. García-Alfonso⁴, B. Rodríguez², F. Losa⁵, I. Ales-Díaz⁶, B. Graña Suarez⁷, M. Toledano², M. Valladares-Ayerbes⁸, E. Polo Marques⁹, M. Salgado Fernandez¹⁰, E. Martínez De Castro¹¹, M. Gil Raga¹², M.A. Salud Salvia¹³, A. Ruiz-Casado¹⁴, A. Rodríguez-Ariza², E. Aranda Aguilar⁸, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²IMIBIC, Reina Sofía Hospital, Córdoba, ES, ³University Hospital 12 De Octubre, Madrid, ES, ⁴General Universitario Gregorio Marañón, Madrid, ES, ⁵Hospital de Sant Joan Despí Moisès Broggi, Barcelona, ES, ⁶Servicio de Oncología Médica, Hospital Regional Universitario, Málaga, ES, ⁷CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ⁸University

Hospital Reina Sofia, Cordoba, ES, ⁹Hospital Miguel Servet, Zaragoza, ES, ¹⁰Complejo Hospitalario De Ourense, Ourense, ES, ¹¹Hospital Universitario Marqués de Valdecilla, Santander, ES, ¹²Hospital de Sagunt, Sagunt, ES, ¹³Hospital Universitario Arnau de Vilanova, Lleida, ES, ¹⁴Hospital Universitario Puerta de Hierro, Malaga, ES

- 12:00 - 12:00 **586P - The accuracy of the clinical PCI score in patients with peritoneal carcinomatosis of colorectal cancer**
N. De Boer¹, A. Brandt-Kerkhof¹, E. Madsen², K. Verhoef³, J. Burger¹, ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ³Erasmus University Medical Center, Rotterdam, NL
- 12:00 - 12:00 **587P - The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC).**
T. Kawakami¹, T. Masuishi², Y. Kawamoto³, H. Go⁴, H. Shirasu¹, K. Kato², R. Kumanishi², K. Sawada³, K. Yamamoto⁴, S. Yuki³, Y. Komatsu⁵, H. Yasui¹, K. Muro², T. Yamanaka⁶, K. Yamazaki⁷, ¹Shizuoka Cancer Center, Shizuoka, JP, ²Aichi Cancer Center Hospital, Nagoya, JP, ³Hokkaido University Hospital, Sapporo, JP, ⁴Yokohama City University School of Medicine, Yokohama, JP, ⁵Hokkaido University Hospital Cancer Center, Sapporo, JP, ⁶Yokohama City University Hospital, Yokohama, JP, ⁷Sizuoka Cancer Center, Sundogun, JP
- 12:00 - 12:00 **588P - Efficacy and safety of FOLFIRI/Aflibercept (FA) in elderly population with mCRC after failure of oxaliplatin-based chemotherapy.**
N. Martinez Lago¹, M. Carmona Campos², P. Gonzalez Villarroya³, M. Salgado Fernandez⁴, J. De La Camara Gomez⁵, C. Romero Reinoso⁶, A. Cousillas Castiñeiras⁷, Y. Vidal Insua⁸, J.C. Mendez Mendez⁹, C. Reboredo Rendo¹, M. Covela Rúa², G. Quintero Aldana², B. Graña Suarez¹, A. Carral Maseda², M. Jorge Fernandez³, M.L. Pellon Augusto¹⁰, C. Grande Ventura³, M.E. Gallardo Martin⁷, A. Fernández Montes¹¹, M. Reboredo Lopez¹, ¹CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ²Hospital Universitario Lucus Augusti, Lugo, ES, ³Hospital Universitario Alvaro Cunqueiro, Vigo, ES, ⁴Complejo Hospitalario De Ourense, Ourense, ES, ⁵Complejo Hospitalario Universitario de Ferrol, Ferrol, ES, ⁶POVISA, Vigo, ES, ⁷Complejo Hospitalario Universitario de Pontevedra, Pontevedra, ES, ⁸Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, ES, ⁹Centro Oncologico de Galicia, A Coruña, ES, ¹⁰Complejo Hospitalario Arquitecto Marcide-Prof. Novoa Santos, A Coruña, ES, ¹¹Complejo Hospitalario Universitario de Ourense, Orense, ES
- 12:00 - 12:00 **589P - Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: preliminary data from the prospective observational CHECKPOINT trial (NCT02665312)**
P. Lombardi¹, G. Aimar², I. Depetris¹, A. Bonzano², R. Filippi³, E. Fenocchio¹, V. Quarà⁴, M. Milanese⁵, R. Ferraris⁵, C. Cagnazzo⁶, C. Peraldo Neia⁷, M. Basiricò², G. Cavalloni⁵, M. Aglietta¹, F. Leone¹, ¹Istituto di Candiolo - FPO - IRCCS, Candiolo, IT, ²Candiolo Cancer Institute, FPO-IRCCS, Candiolo, IT, ³Candiolo Cancer Institute, Candiolo, IT, ⁴IRCCS Candiolo, Candiolo (TO), IT, ⁵Candiolo Cancer Insitute, FPO - IRCCS, Candiolo, IT, ⁶AOU Città della Salute e della Scienza - Presidio Ospedaliero Infantile Regina Margherita, Torino, IT, ⁷Fondazione Edo ed Elvo Tempia Valenta, Biella, IT

- 12:00 - 12:00 **590P - Comparable survival outcome between Thai patients with sporadic young adult and adult onset colorectal cancer**
K. Sukhokanjanachusak¹, K. Korphaisarn², C. Akewanlop³, A. Pongpaibul², A. Nimmannit², ¹Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, TH, ²Siriraj Hospital, Bangkok, TH, ³Siriraj Hospital, Mahidol University, Bangkok, TH
- 12:00 - 12:00 **591P - Impact of primary tumor side on 3-year survival outcomes of first-line (1L) FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial**
S. Qin¹, T. Liu², J. Xu³, Q. Li⁴, Y. Cheng⁵, J. Nippgen⁶, W. Chen⁷, J. Li⁸, ¹Cancer Center of People's Liberation Army, Nanjing, CN, ²Zhongshan Hospital affiliated to Fudan University, Shanghai, CN, ³Fifth Medical Center, General Hospital of the People's Liberation Army, Beijing, CN, ⁴Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ⁵Jilin Cancer Hospital, Changchun, CN, ⁶Merck Serono, Beijing, CN, ⁷Merck Serono, Shanghai, CN, ⁸Shanghai East Hospital, Tongji University School of Medicine, Shanghai, CN
- 12:00 - 12:00 **592P - Undetectable RAS mutant clones in plasma: possible implication for therapy and prognosis in the patient with RAS mutant metastatic colorectal cancer?**
M. Bouchahda¹, A. Karaboué², R. Saffroy³, J. Hamelin³, N. Bosselut³, A. Lemoine³, ¹Clinique Saint Jean l'Ermitage, Melun, FR, ²Centre hospitalier intercommunal Le Raincy-Montfermeil, Montfermeil, FR, ³Paul Brousse hospital, Villejuif, FR
- 12:00 - 12:00 **593P - Dihydropyrimidine dehydrogenase (DPD) determination prior the administration of medicines containing fluorouracil: a single Spanish hospital experience.**
M.D. Mediano Rambla¹, J.A. Marcos², R. Carrillo², M. Espinosa², F. Sanchez², M.D. Alvardado², L. Rendon², J.J. Reina Zoilo³, A. Albero², ¹Hospital Universitario Virgen del Rocio, Sevilla, ES, ²Hospital Universitario Virgen Macarena, Sevilla, ES, ³Hospital Universitario Virgen Macarena, Sevilla, ES
- 12:00 - 12:00 **594P - Differences in survival between right and left-sided colorectal cancer (CRC) in every stage, a CARESS-CCR Group Study.**
J. Alcaide-Garcia¹, F. Rivas-Ruiz¹, J.M. Quintana², E. Perez-Ruiz¹, M. Redondo¹, ¹Hospital Costa del Sol, Marbella, ES, ²Hospital Galdakao-Usansolo, Galdakao, ES
- 12:00 - 12:00 **595P - Quality of Life (QoL) in patients with aflibercept (AFL) and FOLFIRI for metastatic colorectal cancer (mCRC) - Interim analysis with focus on mutational status of the non-interventional study QoLiTrap (AIO-LQ-0113)**
R. Von Moos¹, F. Scholten², H.-G. Derigs², B. Grünberger³, J. Thaler⁴, R.D. Hofheinz⁵, ¹Kantonsspital Graubünden, Chur, CH, ²Klinikum Frankfurt Hoechst, Frankfurt am Main, DE, ³Krankenhaus Wiener Neustadt, Wiener Neustadt, AT, ⁴Klinikum Wels-Grieskirchen GmbH, Wels, AT, ⁵Universitätsklinikum Mannheim, Mannheim, DE
- 12:00 - 12:00 **596P - The cost of adverse event management in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab and panitumumab:**

an Italian healthcare payer perspective

K. Patterson¹, S. Bhattacharyya¹, N. Personeni², V. Gebbia³, P. Novelli⁴, S. Di Matteo⁵, G. Colombo⁶, C. Pescott⁷, ¹BresMed, Sheffield, GB, ²Istituto Clinico Humanitas, Rozzano, IT, ³La Maddalena Hospital, Palermo, IT, ⁴Merck Serono S.p.A., Rome, IT, ⁵S.A.V.E. Studi Analisi Valutazioni Economiche srl, Milan, IT, ⁶University of Pavia, Pavia, IT, ⁷Merck KGaA - Germany, Darmstadt, DE

12:00 - 12:00

597P - Meta-analysis of KRAS Mutation as prognostic factor in patients (pts.) with resection of colorectal (CRC) liver metastases: Tumor burden and Sideness analysis.

M.R. Luca¹, M. Angel², F. Estes³, J. Mariani⁴, F. Sanchez Loria², M. Chacon², J.M. O'Connor², ¹Alexander Fleming Institute, Buenos Aires, AR, ²Alexander Fleming Institute, CABA, AR, ³Alexander Fleming Institute, caba, AR, ⁴Alexander Fleming Institute, caba, AR

12:00 - 12:00

598P - Clinical implications of regorafenib-induced hypothyroidism in metastatic colorectal cancer refractory to standard therapies: A prospective evaluation

J.H. Kim¹, J.E. Kim², S.Y. Kim², K.-P. Kim², Y.S. Hong², T.W. Kim², ¹Asan Medical Center, Seoul, KR, ²Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR

12:00 - 12:00

599P - Clinical impact of BRAF V600E mutations in patients (pts) with resectable solitary colorectal liver metastases (CRLM)

S. Kobayashi, S. Takahashi, M. Kojima, M. Sugimoto, M. Konishi, M. Ito, T. Yoshino, N. Gotohda, H. Taniguchi, National Cancer Center Hospital East, Kashiwa, JP

12:00 - 12:00

600P - Trifluridine/tipiracil in metastatic colorectal cancer: an updated multicentre real-world analysis on efficacy, safety and predictive factors.

C. Stavraka¹, A. Poupstis², A. Synowiec³, V. Aggelis⁴, L. Satterthwaite⁵, S. Khan⁶, M. Chauhan⁷, C. Holden⁸, S. Young⁹, C. Karampera¹⁰, M. Martinou¹¹, T. Mills-Baldock¹¹, M. Baxter¹², B. Eccles¹³, T. Iveson¹⁴, K.-K. Shiu¹⁵, M. Hill¹⁶, S. Abdel-Raouf¹⁷, A. Thomas¹⁸, P. Ross¹, ¹Guy's and St. Thomas' Hospital NHS Trust, London, GB, ²Theagenio Cancer Hospital, Thessaloniki, GR, ³Maidstone and Tunbridge Wells NHS Trust, Maidstone, Maidstone, GB, ⁴Royal Marsden Hospital NHS Foundation Trust, London, GB, ⁵MidCentral Health Palmerston North Hospital, Palmerston North, NZ, ⁶Leicester Royal Infirmary, Leicester, GB, ⁷University Hospitals of Leicester NHS Trust Leicester Royal Infirmary, Leicester, GB, ⁸Queen Alexandra Hospital Portsmouth Oncology Centre, Portsmouth, GB, ⁹Poole Hospital NHS Foundation Trust, Poole, GB, ¹⁰Guy's and St. Thomas' NHS Foundation Trust, London, GB, ¹¹Barking Havering and Redbridge University Hospital NHS Trust, Romford, GB, ¹²Ninewells Hospital, Dundee, GB, ¹³Poole hospital NHS Foundation Trust, Poole, GB, ¹⁴Southampton General Hospital Southampton University Hospitals NHS Trust, Southampton, GB, ¹⁵University College London Hospital, London, GB, ¹⁶Maidstone Hospital Maidstone & Tunbridge NHS TRUST, Maidstone, GB, ¹⁷Queen's Hospital, Essex, GB, ¹⁸University of Leicester, Leicester, GB

12:00 - 12:00

601P - Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab

E. Lai¹, M. Schirripa², M. Puzzoni³, F. Loupakis⁴, P. Ziranu¹, A. Pretta¹, R. Giampieri⁵, S. Mariani⁶, N. Liscia⁷, P. Soro¹, V. Pusceddu³, G. Astara³, V. Impera³, S. Camera¹, F. Musio⁶, A. Zaniboni⁸, M. Fassan⁹, S. Lonardi⁴, V. Zagonel¹⁰, M. Scartozzi¹¹, ¹Azienda Ospedaliero Universitaria di Cagliari, Cagliari, IT, ²Veneto Institute of Oncology - IRCCS, Padova, Italy, PADOVA, IT, ³Azienda Ospedaliero Universitaria di Cagliari, Monserrato, IT, ⁴Istituto Oncologico Veneto IRCCS, Padova, IT, ⁵AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, IT, ⁶University Hospital and University of Cagliari, Cagliari, Italy, MONSERRATO, IT, ⁷Sapienza University of Rome - University Hospital and University of Cagliari, Cagliari, Italy, MONSERRATO, IT, ⁸Casa di Cura Poliambulanza, Brescia, IT, ⁹University of Padua, Padua, IT, ¹⁰Department of Oncology, Veneto Institute of Oncology, IOV - IRCCS, Padova, IT, ¹¹AOU Ospedali Riuniti Ancona, Torrette di Ancona, IT

12:00 - 12:00

602P - Safety and effectiveness of aflibercept + FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): OZONE secondary analyses

I. Chau¹, M. Fakhri², P. García-Alfonso³, Z. Linke⁴, A. Ruiz-Casado⁵, E. Polo Marques⁶, P. Picard⁷, M. Celanovic⁸, T. Cartwright⁹, ¹The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ²City of Hope National Medical Center, Duarte, US, ³General Universitario Gregorio Marañón, Madrid, ES, ⁴Motol University Hospital, Prague, CZ, ⁵Hospital Universitario Puerta de Hierro, Malaga, ES, ⁶Hospital Miguel Servet, Zaragoza, ES, ⁷Ividat, Levallois Perret, FR, ⁸Sanofi, Cambridge, US, ⁹Ocala Oncology, Ocala, US

12:00 - 12:00

603P - A Phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)

J. Bendell¹, C. Lieu², K.P.S. Raghav³, G. Argilés⁴, A. Cubillo⁵, X. Qu⁶, Y. Yan⁶, M. Merchant⁶, H. Zeuner⁷, J.D. Gallo⁷, N. Segal⁸, ¹Sarah Cannon Research Institute, Nashville, US, ²University of Colorado, Denver, US, ³The University of Texas MD Anderson Cancer Center, Houston, US, ⁴Vall d'Hebron University Hospital and Institute of Oncology VHIO, Barcelona, ES, ⁵Servicio de Oncología Médica HM CIOCC, Madrid, ES, ⁶Genentech, Inc., South San Francisco, US, ⁷F. Hoffmann-La Roche, Ltd., Basel, CH, ⁸Memorial Sloan Kettering Cancer Center, New York, US

12:00 - 12:00

604P - Development and validation of a metastasis-associated immune prognostic model for concurrent metastatic colorectal cancer

Z. Luo¹, H. Zhao², Z. Li², R. Mao², J. Zhao², D. Ge², X. Chen², F. Zhang², Y. Zhou², J. Cai³, X. Bi², ¹Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ²Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ³Department of Hepatobiliary Surgery, Beijing, CN

12:00 - 12:00

605P - Prognostic role of blood cell count-based immuno-inflammatory parameters in the Valentino trial

G. Fuca¹, V. Guarini², S. Corallo², S. Lonardi³, A. Raimondi¹, G. Peverelli², L. Rimassa⁴, C. Antoniotti⁵, R. Murialdo⁶, A. Zaniboni⁷, A. Sartore-Bianchi⁸, G. Tomasello⁹, P. Racca¹⁰, M. Clavarezza¹¹, V. Adamo¹², M. Prisciandaro¹, F. Palermo², M. Di Bartolomeo¹, F.G. De Braud¹, F. Pietrantonio¹³, ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ²Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, IT, ³Istituto

Oncologico Veneto IRCCS, Padova, IT, ⁴Humanitas Cancer Center, Rozzano, IT, ⁵Azienda Ospedaliero-Universitaria Pisana, Pisa, IT, ⁶IRCCS AOU San Martino-IST, Genoa, IT, ⁷Casa di Cura Poliambulanza, Brescia, IT, ⁸Grande Ospedale Metropolitano Niguarda and University of Milan, Milan, IT, ⁹ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, ¹⁰AOU S.Giovanni Battista - Molinette, Torino, IT, ¹¹Ente ospedaliero Ospedali Galliera, Genova, IT, ¹²A.O. Papardo, Messina, IT, ¹³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT

- 12:00 - 12:00 **606P - Evaluation of safety, immunogenicity and preliminary efficacy of PolyPEPI1018 vaccine in subjects with metastatic colorectal cancer (mCRC) with a predictive biomarker**
J. Hubbard¹, C. Cremolini², R. Graham¹, R. Moretto², J. Mitchell¹, J. Wessling¹, E. Tóke³, Z. Csiszovszki³, O. Lorincz⁴, L. Molnar³, E. Somogyi³, M. Megyesi³, K. Pántya³, J. Toth³, P. Pales³, I. Miklos⁵, A. Falcone², ¹Mayo Clinic, Rochester, US, ²Azienda Ospedaliera Universitaria S.Chiara, Pisa, IT, ³Treos Bio Zrt., Veszprém, HU, ⁴Treos Bio Inc., Bethesda, US, ⁵MTA Rényi Institute, Budapest, HU
- 12:00 - 12:00 **607P - Morphology of tumor-associated macrophages dictates the prognosis of patients with colorectal liver metastases.**
M. Donadon¹, L. Di Tommaso¹, N. Cortese², C. Soldani², B. Franceschini³, R. Carriero³, M. Barbagallo³, A. Rigamonti³, A. Anselmo², F. Colombo³, G. Maggi³, M. Roncalli¹, G. Torzilli¹, A. Mantovani³, F. Marchesi³, ¹Humanitas University, Milan, IT, ²Huomanitas Clinical and Research Center, Rozzano - Milan, IT, ³Humanitas Clinical and Research Center, Rozzano - Milan, IT
- 12:00 - 12:00 **608P - Pembrolizumab (pembro) Plus mFOLFOX or FOLFIRI in Patients With Metastatic Colorectal Cancer (mCRC): KEYNOTE-651 Cohorts B and D**
R. Kim¹, J. Chaves², P. Kavan³, M. Fakih⁴, J. Kortmansky⁵, K. Spencer⁶, L. Wong⁷, M. Tehfe⁸, J. Li⁹, M. Lee⁹, C. Mayo⁹, P. Marinello⁹, E. Chiorean¹⁰, ¹H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ²Northwest Medical Specialties, LLC, Tacoma, US, ³Jewish General Hospital, Montreal, CA, ⁴City of Hope National Medical Center, Duarte, US, ⁵Yale Cancer Center, New Haven, US, ⁶Rutgers Cancer Institute of New Jersey, New Brunswick, US, ⁷Baylor Scott & White Health, Temple, US, ⁸Centre Hospitalier de l'Université de Montréal, Montréal, CA, ⁹Merck & Co., Inc., Kenilworth, US, ¹⁰University of Washington, Fred Hutchinson Cancer Research Center, Seattle, US
- 12:00 - 12:00 **609P - Romidepsin (FK228) Regulates the Expression of the Immune Checkpoint Ligand PD-L1 and Exerts Synergistic Anti-Tumor Activity with an Anti-PD-1 Antibody in Colon Cancer**
H. Li, Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN
- 12:00 - 12:00 **610P - Prognostic significance of circulating regulatory T lymphocytes (Tregs) in patients with metastatic colorectal cancer (mCRC) under treatment with first line chemotherapy.**
Z. Zafeiriou¹, A. Koutoulaki², F. Koinis³, D. Aggouraki⁴, N. Vardakis⁵, E. Vetsika⁵, K. Kotta⁶, D. Mavroudis³, V. Georgoulis³, A. Kotsakis³, ¹The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ²School of Medicine, University of Crete, Heraklion Greece, Heraklion, GR, ³University Hospital of Heraklion,

Heraklion, GR, ⁴chool of Medicine, University of Crete, Heraklion, GR, ⁵University Hospital of Heraklion (PAGNI), Heraklion, GR, ⁶Institute of Applied Biosciences, Thessaloniki, GR

12:00 - 12:00

611P - The SAFFO study: Sex-related prognostic role And cut-off deFinition of monocyte-to-lymphocyte ratio (MLR) in metastatic colOrectal cancer

C. Lisanti¹, D. Basile², S.K. Garattini³, A. Parnofiello³, C. Corvaja¹, F. Cortiula¹, G. Pelizzari⁴, M. Cattaneo¹, V. Andreotti¹, E. Bertoli³, E. Ongaro¹, D. Iacono³, L. Foltran⁵, M. Casagrande¹, G. Miolo⁴, G. Cardellino³, G. Fasola¹, N. Pella³, A. Buonadonna⁴, F. Puglisi⁶, ¹Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT, ²CRO di Aviano, Aviano, IT, ³Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia, Udine, IT, ⁴Centro di Riferimento Oncologico - CRO, Aviano, IT, ⁵Azienda Ospedaliera Sta Maria degli Angeli, Pordenone, IT, ⁶Department of Medicine (DAME), University of Udine, Udine, Italy;, Aviano, IT

12:00 - 12:00

612P - SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumors of epithelial origin: analysis of the metastatic colorectal cancer patients in the dose escalation phase

M. Fakh¹, D. Wang², W. Harb³, L. Rosen⁴, D. Mahadevan⁵, J. Berlin⁶, P. Basciano⁷, R. Brown⁸, O. Arogundade⁸, C. Cox⁸, G. Di Genova⁸, D. Krige⁸, H. Mcelwaine-Johnn⁸, ¹City of Hope National Medical Center, Duarte, US, ²Henry Ford Cancer Institute, Detroit, US, ³Horizon Oncology Center, Lafayette, US, ⁴UCLA Medical Center, Santa Monica, US, ⁵The University of Arizona Cancer Center, Tucson, US, ⁶Vanderbilt-Ingram Cancer Center, Nashville, US, ⁷Bristol Myers Squibb, Prinecton, US, ⁸PsiOxus Therapeutics Ltd, Abingdon, GB

12:00 - 12:00

613P - Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer

N. Halama¹, U. Prüfer¹, A. Froemming², D. Beyer², D. Eulberg², J.U. Jungnelius², A. Mangasarian², ¹Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, ²NOXXON Pharma AG, Berlin, DE

12:00 - 12:00

614P - Microsatellite Instability Status in Metastatic Colorectal Cancer and Effect of Immune Checkpoint Inhibitors on Survival in MSI-High Metastatic Colorectal Cancer

W. Okamoto¹, Y. Nakamura¹, M. Shiozawa², Y. Komatsu³, T. Denda⁴, H. Hara⁵, Y. Kagawa⁶, Y. Narita⁷, H. Kawakami⁸, T. Esaki⁹, T. Nishina¹⁰, N. Izawa¹¹, K. Ando¹², T. Moriwaki¹³, T. Kato¹⁴, F. Nagashima¹⁵, T. Satoh¹⁶, S. Nomura¹⁷, T. Yoshino¹, K. Akagi⁵, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Kanagawa Cancer Center, Yokohama, JP, ³Hokkaido University Hospital Cancer Center, Sapporo, JP, ⁴Chiba Cancer Center Hospital, Chiba, JP, ⁵Saitama Cancer Center, Saitama, JP, ⁶Kansai Rosai Hospital, Amagasaki, JP, ⁷Aichi Cancer Center Hospital, Nagoya, JP, ⁸Kindai University Faculty of Medicine, Osaka, JP, ⁹National Kyushu Cancer Center, Fukuoka, JP, ¹⁰Shikoku Cancer Center, Matsuyama, JP, ¹¹St. Marianna University School of Medicine, Kawasaki, JP, ¹²Kyushu University, Fukuoka, JP, ¹³Faculty of Medicine, University of Tsukuba, Tsukuba, JP, ¹⁴Osaka National Hospital, Osaka, JP, ¹⁵Kyorin university Hospital, Tokyo, JP, ¹⁶Graduate School of Medicine / Faculty of Medicine, Osaka University, Osaka, JP, ¹⁷National Cancer Center, Kashiwa, JP

- 12:00 - 12:00 **615P - Phase II trial of Trametinib (T) and Panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC)**
K. Alshammari¹, K. Aung¹, T. Zhang¹, A.R. Albiruni¹, S. Serra¹, T. Stockley², L. Wang¹, J. Nguyen¹, A. Spreafico¹, A. Hansen¹, D. Zwir³, L. Siu⁴, P. Bedard¹, ¹Princess Margaret Cancer Center, Toronto, CA, ²Toronto General Hospital, Toronto, CA, ³Princess Margaret Hospital, Toronto, CA, ⁴Princess Margaret Cancer Centre, Toronto, CA
- 12:00 - 12:00 **616P - Microsatellite instability and immunogenicity in colorectal cancer - do resident memory Tcells (Trm) play a role in colorectal cancer**
W. Toh¹, J. Toh², A. Ferguson³, K. Spring⁴, H. Mehajan¹, M. Palendira³, ¹Westmead Hospital, Westmead, AU, ²Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, AU, ³Centenary Institute, Sydney, AU, ⁴Ingham Institute, Liverpool, AU
- 12:00 - 12:00 **617P - Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer (mCRC)**
C. Qvortrup¹, M. Yilmaz², S. Möller³, D. Zitnjak⁴, L. Maltha¹, M. Krogh⁵, L. Noergaard Petersen⁶, F. Hejlesen², S. Winther⁵, K. Thomsen⁵, P. Pfeiffer⁵, ¹Finsen Center - Rigshospitalet, Copenhagen, DK, ²Aalborg University hospital, Aalborg, DK, ³Odense University Hospital, Odense, DK, ⁴Hospital of Southern Jutland, Sønderborg, DK, ⁵Odense University Hospital, Odense C, DK, ⁶Rigshospitalet, University of Copenhagen, Copenhagen, DK
- 12:00 - 12:00 **618P - Updated survival analysis of the randomized phase III trial comparing S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (SALTO) by the Dutch Colorectal Cancer Group.**
J. Kwakman¹, E. Van Werkhoven², L. Simkens¹, J. Van Rooijen³, A. Van De Wouw⁴, A. Ten Tije⁵, G.-J. Creemers⁶, M. Hendriks⁷, M. Los⁸, R. Van Alphen⁹, M. Poley¹⁰, E. Muller¹¹, A. Van Der Velden¹², T. Van Voorthuizen¹³, M. Koopman¹⁴, L. Mol¹⁵, C. Punt¹⁶, ¹Academic Medical Center (AMC), Amsterdam, NL, ²The Netherlands Cancer Institute, Amsterdam, NL, ³University Hospital Groningen (UMCG), Groningen, NL, ⁴VieCuri MC, Venlo, NL, ⁵Amphia Ziekenhuis-location Molengracht, Breda, NL, ⁶Catharina Hospital Eindhoven, Eindhoven, NL, ⁷Medisch Centrum Alkmaar, Alkmaar, NL, ⁸Sint Antonius Hospital, Nieuwegein, NL, ⁹ETZ Twee Steden, Tilburg, NL, ¹⁰Medical Center Leeuwarden, Leeuwarden, NL, ¹¹Slingeland Ziekenhuis, Doetinchem, NL, ¹²Tergooi Ziekenhuizen, Hilversum, NL, ¹³Mr. Theo Van Voorthuizen, Arnhem, NL, ¹⁴University Hospital Utrecht, Utrecht, NL, ¹⁵Netherlands Comprehensive Cancer Organisation, Nijmegen, NL, ¹⁶Academic Medical Center, University of Amsterdam, Amsterdam, NL
- 12:00 - 12:00 **619P - JFMC51-1702-C7: Phase II study investigating efficacy and safety of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in patients (pts) with metastatic colorectal cancer (mCRC) refractory or intolerant to standard chemotherapies.**
K. Kazama¹, M. Nakamura², R. Tanaka³, H. Ojima⁴, A. Makiyama⁵, N. Matsushashi⁶, Y. Kagawa⁷, H. Okuda⁸, M. Asayama⁹, Y. Yuasa¹⁰, Y. Negoro¹¹, H. Mushiake¹², D. Manaka¹³, K. Oba¹⁴, T. Yoshino¹⁵, K. Yoshida¹⁶, Y. Maehara¹⁷, K. Yamazaki¹⁸, E. Oki⁵, T. Takahashi¹⁶, ¹Kanagawa Cancer Center, Yokohama, JP, ²Sapporo City General Hospital,

Sapporo, JP, ³Hamanomachi Hospital, Fukuoka, JP, ⁴Gunma Prefectural Cancer Center, Ota, JP, ⁵National Kyushu Cancer Center, Fukuoka, JP, ⁶Gifu University, Gifu, JP, ⁷Hyogo Prefectural Amagasaki Hospital, Amagasaki, hyogo, JP, ⁸Keiyukai Sapporo Hospital, Sapporo, JP, ⁹Saitama Cancer Center, Ina, JP, ¹⁰Tokushima Red Cross Hospital, Tokushima, JP, ¹¹Kochi Health Sciences Center, Kochi, JP, ¹²Teikyo University School of Medicine, Tokyo, JP, ¹³Kyoto-Katsura Hospital, Kyoto, JP, ¹⁴The University of Tokyo, Tokyo, JP, ¹⁵National Cancer Center Hospital East, Kashiwa, JP, ¹⁶Gifu University Hospital, Gifu, JP, ¹⁷Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, JP, ¹⁸Shizuoka Cancer Center, Shizuoka, JP

12:00 - 12:00 **620P - Bevacizumab plus trifluridine/tipiracil in elderly patients with previously untreated metastatic colorectal cancer (KSCC 1602): A single-arm, Phase 2 study**

A. Makiyama¹, E. Oki¹, Y. Miyamoto², M. Kotaka³, H. Kawanaka⁴, K. Miwa⁵, A. Kabashima⁶, T. Noguchi⁷, K. Yuge⁸, T. Kashiwada⁹, M. Shimokawa¹⁰, H. Saeki¹¹, Y. Akagi⁵, H. Baba¹², M. Mori¹³, ¹National Kyushu Cancer Center, Fukuoka, JP, ²Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JP, ³Sano Hospital-Gastrointestinal Cancer Centre, Kobe, JP, ⁴National Hospital Organization Beppu Medical Center, Beppu, JP, ⁵Kurume University, Kurume, JP, ⁶Oita Medical Center, Oita, JP, ⁷Imakiire general hospital, Kagoshima, JP, ⁸Social Insurance Tagawa Hospital, Tagawa, JP, ⁹Saga Univ Faculty of Medicine-Nabeshima, Saga, JP, ¹⁰Yamaguchi University Graduate School of Medicine, Ube, JP, ¹¹Gunma University, Maebashi, JP, ¹²Graduate school of Life Sciences Kumamoto University, Kumamoto, JP, ¹³Kyushu University, Fukuoka, JP

12:00 - 12:00 **621P - Biweekly TAS-102 and Bevacizumab as a Third-Line Chemotherapy for metastatic colorectal cancer: A Phase II Multicenter Clinical Trial (TAS-CC4 study)**

Y. Yoshida¹, T. Yamada², H. Matsuoka³, K. Hirata⁴, H. Kuramochi⁵, C. Kosugi⁶, M. Takahashi⁷, A. Fukazawa⁸, H. Sonoda⁹, A. Matsuda¹⁰, T. Watanabe⁴, M. Koizumi¹¹, N. Aisu¹, S. Hasegawa¹, H. Yoshida², K. Sakamoto⁷, H. Ishida¹², K. Koda⁶, ¹Fukuoka University School of Medicine, FUKUOKA, JP, ²Nippon Medical University, Tokyo, JP, ³Fujita Health University, Toyoake, JP, ⁴University of Occupational & Environmental Health, Fukuoka, JP, ⁵Tokyo Women's Medical University Yachiyo Medical Center, Chiba, JP, ⁶Teikyo University Chiba Comprehensive Medical Center, Chiba, JP, ⁷Juntendo University School of Medicine, Tokyo, JP, ⁸Iwata City Hospital, Shizuoka, JP, ⁹Shiga Medical University, Shiga, JP, ¹⁰Nippon Medical School Chiba Hokusoh Hospital, Inzai, JP, ¹¹Nippon Medical School Main Hospital, Tokyo, JP, ¹²Saitama Medical University, Saitama, JP

12:00 - 12:00 **622P - Liquid biopsy concordance based on clonality and timing of testing in patients with metastatic colorectal cancer**

P. Kasi¹, S. Kamatham², F. Shahjehan², Z. Li², P. Johnson², A. Merchea², D. Colibaseanu², ¹Holden Comprehensive Cancer Center, University of Iowa, Iowa City, US, ²Mayo Clinic, Jacksonville, US

12:00 - 12:00 **623P - Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer**

E. Moati¹, H. Blons¹, V. Taly², F. Garlan², W.-R. Shu-Fang², D. Pietrasz³, A. Didelot², S. Garrigou², A. Saint⁴, S. Pernot¹, J. Taieb¹, P. Laurent-Puig⁵, A. Zaanani¹, ¹Hopital European George Pompidou, Paris, FR, ²Centre de Recherche des Cordeliers, INSERM, CNRS, Paris, FR, ³Groupe Hospitalier Pitié Salpetriere, Paris, FR, ⁴Hopital del l'Archet, Nice, FR, ⁵Paris Descartes University, Paris, FR

12:00 - 12:00 **624P - High Circulating miR-1247 is a marker for poor prognosis in patients with metastatic colorectal cancer treated with chemotherapy and cetuximab**

J. Schou¹, Z. Sztupinszki², J. Johansen¹, D. Nielsen¹, B. Glimelius³, C. Qvortrup⁴, H. Sorbye⁵, B. Vittrup Jensen⁶, P. Pfeiffer⁷, ¹Herlev Hospital, Herlev, DK, ²Danish Cancer Society, Copenhagen, DK, ³Dept of Immunology, Genetics and Pathology, Uppsala, SE, ⁴Finsen Center - Rigshospitalet, Copenhagen, DK, ⁵Haukeland Universitetssykehus, Bergen, NO, ⁶Herlev and Gentofte Hospital, Herlev, DK, ⁷Odense University Hospital, Odense C, DK

12:00 - 12:00 **625P - Clinical relevance of circulating tumor (ct)DNA genotyping for first line cetuximab-based treatment monitoring in metastatic colorectal cancer (mCRC): a prospective multicentric study**

J. Vidal Barrull¹, D. Casadevall², M.C. Fernandez¹, M. Castro-Henriques¹, P. García-Alfonso³, B. Martin-Cullell⁴, V. Alonso-Orduna⁵, R.M. Rodríguez Alonso⁶, M. Benavides⁷, C. Santos Vivas⁸, E. Elez Fernández⁹, R. Garcia-Carbonero¹⁰, R. Ferreiro¹¹, J.L. Manzano¹², F. Losa¹³, R. Salazar¹⁴, J. Tabernero¹⁵, E. Aranda Aguilar¹⁶, B. Bellosillo¹, C. Montagut Viladot¹, ¹Hospital del Mar, Barcelona, ES, ²University Hospital del Mar, Barcelona, ES, ³General Universitario Gregorio Marañón, Madrid, ES, ⁴Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁵Hospital Miguel Servet, Zaragoza, ES, ⁶IMIBIC, Reina Sofía Hospital, University of Córdoba, Cordoba, ES, ⁷Universitario Regional Virgen de la Victoria, Malaga, ES, ⁸Catalan Institute of Oncology. Hospital Druan y Reynals, Barcelona, ES, ⁹Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ¹⁰University Hospital 12 De Octubre, Madrid, ES, ¹¹Merck Spain, S.L.U., Madrid, ES, ¹²Hospital Universitario Germans Trias i Pujol, Badalona, ES, ¹³Hospital de Sant Joan Despí Moisès Broggi, Barcelona, ES, ¹⁴ICO - Institut Català d'Oncologia Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ¹⁵Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ¹⁶University Hospital Reina Sofia, Cordoba, ES

12:00 - 12:00 **626P - Clonal hematopoiesis mutations in plasma cfDNA RAS/BRAF genotyping of metastatic colorectal cancer**

B. Wang, F. Huang, M. Shen, S. Wu, H. Wang, H. Jiang, Y. Yu, Q. Yu, Y. Yang, Y. Zhao, Y. Zhou, B. Pan, T. Liu, W. Guo, Zhongshan Hospital, Fudan University, Shanghai, CN

12:00 - 12:00 **627P - Immune status of patients with different stages of colorectal cancer with and without circulating tumor cells**

A. Sitkovskaya, E. Zlatnik, I. Novikova, E. Bondarenko, A. Sagakyants, O. Kit, L. Vladimirova, Rostov Research Institute of Oncology, Rostov-on-Don, RU

12:00 - 12:00 **628P - Detection of 5-hydroxymethylcytosine in Circulating-Free DNA for Early Diagnosis of Colorectal Cancer**

T. Liu¹, W. Chang², W. Ye¹, G. He¹, L. Ren¹, W. Tang¹, J. Chen¹, J. Xu³, ¹Zhongshan Hospital, Fudan University, Shanghai, CN, ²Zhongshan Hospital, Fudan University, shanghai, CN, ³Zhongshan Hospital, Fudan University, Shanghai, China, shanghai, CN

12:00 - 12:00 **629P - Detection of 5-hydroxymethylcytosine in Circulating-Free DNA for Prediction of The Efficacy of Conversion Therapy for Colorectal Cancer Liver Metastases**

W. Chang¹, T. Liu², W. Ye², L. Ren², G. He², J. Xu³, ¹Zhongshan Hospital, Fudan University, shanghai, CN, ²Zhongshan Hospital, Fudan University, Shanghai, CN, ³Zhongshan Hospital, Fudan University, Shanghai, China, shanghai, CN

12:00 - 12:00 **630P - mCRC gene profiling using the Idylla platform**

C. Bricogne¹, M. Rodriguez-Justo¹, A. Agarwal², S. Khan¹, D. Patel¹, N. Bhuvu², K.-K. Shiu¹, ¹University College London Hospital, London, GB, ²Mount Vernon Hospital, London, GB

12:00 - 12:00 **631P - PIK3CA mutation in metastatic colorectal cancer (mCRC): association with clinico-pathological features and outcome**

V. Fanotto¹, G. Zucchelli², M. Germani³, D. Rossini⁴, E. Sensi², C. Lupi⁵, C. Ugolini⁵, C. Antoniotti², F. Marmorino³, R. Moretto², A. Boccaccino⁶, B. Borelli³, V. Conca⁶, E. Ongaro⁷, G. Masi², G. Fontanini³, A. Falcone², C. Cremolini², ¹Centro di Riferimento Oncologico - CRO, Aviano, IT, ²Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT, ³Univeristy Degli Studi di Pisa, Pisa, IT, ⁴DIPINT - Università di Pisa, Pisa, IT, ⁵Azienda Ospedaliero-Universitaria Pisana, Pisa, IT, ⁶University of Pisa, Pisa, IT, ⁷Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT

12:00 - 12:00 **632P - Patient-Derived Xenografts (PDX) Identifies JMJD6 Inhibitor as an Effective Therapeutic Medicine in Colorectal Cancer.**

F. Ye¹, J. You², L. Xia², J. Lian², R. Xiao³, T. Ran³, X. Gao³, J. Li², X. Zhao², J. Gao², H. Lin², J. Zheng², W. Liu³, ¹The 1st Affiliated Hospital of Xiamen University, Xiamen, CN, ²The First Affiliated Hospital of Xiamen University, Xiamen, CN, ³Xiamen University, Xiamen, CN

12:00 - 12:00 **633P - DACH1 induced stemness of intestinal organoids by directly suppressing BMP signaling and contributes to intestinal tumorigenesis**

X. Hu, S.-J. Cai, J.-J. Peng, Fudan University Shanghai Cancer Center, Shanghai, CN

12:00 - 12:00 **634P - miR-148a inhibits early relapsed colorectal cancers and the secretion of VEGF by indirectly targeting HIF-1 α under non-hypoxia/hypoxia conditions**

H.-L. Tsai¹, C.-W. Huang², W.-C. Su³, K.-L. Li³, J.-Y. Wang³, ¹Chung-Ho Memorial Hospital, Kaohsiung Medical University Hospital, Kaohsiung City, TW, ²Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiunh, TW, ³Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TW

12:00 - 12:00 **635P - Long noncoding RNA CASC21 promotes cell proliferation and metastasis in colon cancer.**

Q. Zhang¹, Y. Bian², J. Hu³, L. Li⁴, M. Yang⁵, B. Liu⁶, X. Qian³, ¹Medical School of

Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, CN, ²First People's Hospital of Yancheng, Yancheng, CN, ³Medical school of Nanjing university & Clinical Cancer Institute of Nanjing University, Nanjing, CN, ⁴Medical school of Nanjing university & Clinical Cancer Institute of Nanjing university, Nanjing, CN, ⁵Medical school of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, CN, ⁶Medical school of Nanjing university & Clinical Cancer Institute of Nanjing university, Nan Jing, CN

12:00 - 12:00

636P - Prognostic and Predictive Impact On FMS-like Tyrosine Kinase 3 (FLT3) Amplification In Patients With Metastatic Colorectal Cancer

H. Hasegawa¹, H. Taniguchi², T. Kato³, S. Fujii⁴, H. Ebi⁵, M. Shiozawa⁶, S. Yuki⁷, T. Masuishi⁸, K. Kato⁹, N. Izawa¹⁰, T. Moriwaki¹¹, Y. Kagawa¹², Y. Sakamoto², W. Okamoto¹³, Y. Nakamura², K. Yamazaki¹⁴, T. Yoshino², ¹National Hospital Organization Osaka National Hospital, Osaka, JP, ²National Cancer Center Hospital East, Kashiwa, JP, ³Osaka National Hospital, Osaka, JP, ⁴National Cancer Center, Kashiwa, JP, ⁵Aichi Cancer Center Research Institute, Nagoya, JP, ⁶Kanagawa Cancer Center, Yokohama, JP, ⁷Hokkaido University Hospital, Sapporo, JP, ⁸Aichi Cancer Center Hospital, Nagoya, JP, ⁹National Cancer Center Hospital, Tokyo, JP, ¹⁰St. Marianna University School of Medicine, Kawasaki, JP, ¹¹Faculty of Medicine, University of Tsukuba, Tsukuba, Tsukuba, JP, ¹²Kansai Rosai Hospital, Amagasaki, JP, ¹³Hiroshima University Hospital, Hiroshima, JP, ¹⁴Sizuoka Cancer Center, Suidogun, JP

12:00 - 12:00

637P - RBP-J κ in colon cancer cells facilitates tumor associated macrophages (TAMs)-induced cell metastasis by secreting CXCL11

M.J. Liu, X. Fu, S. Wang, L. Jiang, K. Nan, W. Wang, First Affiliated Hospital of Xi'an Jiaotong University (School of Medicine), Xi'an, CN

12:00 - 12:00

638P - Development of a living organoid biobank derived from colorectal cancer patients: towards personalized medicine

F. Papaccio¹, M.F. Gutierrez-Bravo², M. Cabeza-Segura³, V. Gambardella⁴, M. Huerta⁴, C. Martinez Ciarpaglini⁵, S. Rosello Keranen⁴, F. Gimeno-Valiente², T. Fleitas⁴, N. Tarazona Llaverro⁴, D. Roda⁶, A. Cervantes⁴, J. Castillo⁴, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²INCLIVA Biomedical Research Institute, Valencia, ES, ³University of Valencia, Valencia, ES, ⁴Hospital Clinico Universitario de Valencia, Valencia, ES, ⁵INCLIVA Instituto de investigación sanitaria, Valencia, ES, ⁶Biomedical Research Institute INCLIVA, Hospital Clínico València, University of Valencia, Valencia, ES

12:00 - 12:00

639P - Microsatellite Instability Detection in Colorectal Cancer: 44-Center Comparison between the Idylla MSI Assay and Routine Molecular and Immunohistochemistry Tests on Formalin-Fixed Paraffin-Embedded Tissue

X. Matias-Guiu, Hospital Universitario Arnau de Vilanova, Lleida, ES

12:00 - 12:00

640P - Expression profile of EPHB3 and its prognostic significance in colorectal cancer progression (Running head: Prognostic value of EPHB3 in colorectal cancers)

B. Jang, H. Kim, Jeju National University School of Medicine, Jeju-si, KR

- 12:00 - 12:00 **641P - A pan-ErbB family inhibitor, AF8c, promotes apoptosis by DR5/Nrf2 activation via ROS in colorectal cancer cells**
S. Jeong¹, H.K. Yun², Y.A. Jeong², D.Y. Kim², M.J. Jo¹, S.H. Park¹, B.R. Kim¹, J.L. Kim¹, Y.J. Na¹, D.-H. Lee¹, S.C. Oh¹, ¹Korea University Guro Hospital, Seoul, KR, ²Korea University, Seoul, KR
- 12:00 - 12:00 **642P - Frequent BRAF, GNAS and SMAD4 mutations identified in Colorectal Mucinous Carcinomas**
S.M. Lee, Jeju National University Hospital, Jeju-si, KR
- 12:00 - 12:00 **643P - Impact of CCL4 knockout using CRISPR Cas-9 technology on colorectal tumor progression**
R. Barakat¹, D. Habashy², A. Bahaa¹, H. Adwan¹, ¹GERMAN UNIVERSITY IN CAIRO, New Cairo, EG, ²German University in Cairo, Cairo, EG
- 12:00 - 12:00 **644P - Independent clinical validation of a gene expression profile to predict benefit of 5-FU in metastatic colorectal cancer**
I. Buhl¹, G. Carlsson², P. Saksena², B. Gustavsson², I. Christensen³, A. Edsjö⁴, A. Hansen⁵, S. Knudsen⁶, P. Jensen⁷, Y. Wettergren², ¹University of Copenhagen, Copenhagen, DK, ²Sahlgrenska University Hospital, Göteborg, SE, ³Hvidovre Hospital, Hvidovre, DK, ⁴Region Skåne, Malmö, SE, ⁵Oncology Venture, Hørsholm, DK, ⁶Medical Prognosis Inc., Scottsdale, AZ, US, ⁷Oncology Venture ApS, Hoersholm, DK
- 12:00 - 12:00 **645P - WRN mutated Colorectal Cancer (CRC) is characterized by a distinct molecular and immunological profile**
A. Seeber¹, A. Puccini², J. Xiu³, Y. Baca³, G. Spizzo⁴, K. Zimmer⁴, H.J. Lenz⁵, F. Battaglin⁶, R.M. Goldberg⁷, A. Grothey⁸, A. Shields⁹, M. Salem¹⁰, J. Marshall¹¹, W.M. Korn³, D. Wolf⁴, F. Kocher⁴, ¹University Hospital Innsbruck, Innsbruck, AT, ²Ospedale Policlinico San Martino - IRCCS, Genova, IT, ³Caris Life Sciences, Phoenix, US, ⁴Medical University of Innsbruck, Innsbruck, AT, ⁵USC - Norris Comprehensive Cancer Center, Los Angeles, US, ⁶University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, ⁷West Virginia University Cancer Institute, Morgantown, US, ⁸West Cancer Center, Germantown, US, ⁹Karmanos Cancer Institute, Wayne State University, Detroit, US, ¹⁰Lombardi Cancer Center Georgetown University, Washington, US, ¹¹Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, US
- 12:00 - 12:00 **646P - Mutation analysis of B2M gene in colorectal cancer patients with microsatellite instability**
I. Kašubová¹, Z. Šňahničanová¹, M. Kalman², L. Plank³, Z. Lasabová⁴, ¹Biomedical center Martin, Jessenius Faculty of Medicine in Martin, Martin, SK, ²Jessenius Faculty of Medicine in Martin, Martin, SK, ³University Hospital Martin, Martin, SK, ⁴Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Martin, SK
- 12:00 - 12:00 **647P - Selective Wnt/ β -catenin small-molecule inhibitor CWP232228 impairs tumor growth of colon cancer**
J.Y. Kim¹, K.K. Lee¹, E.H. Jung¹, E. Ha², M. Krishnan², K.-S. Chun³, ¹Dongsan Medical Center Kemyung University Hospital, Daegu, KR, ²School of Medicine, Keimyung

University, Daegu, KR, ³College of Pharmacy, Keimyung University, Daegu, KR

12:00 - 12:00

648P - Feasibility and impact of prospective DPYD screening in the Irish population

M. Zameer¹, S. Iqbal², B. Macanovic², D. Bracken Clarke², C. Joyce², S. O'Reilly¹, R. Bambury¹, D. Power², D. Collins¹, ¹Cork University Hospital, Cork, IE, ²Cork University Hospital, cork, IE

12:00 - 12:00

649P - Diet-derived metabolites and the risk of colorectal cancer: a nested case-control study in a population-based cohort, the Singapore Chinese Health Study

D. Chong¹, Y. Lu², A. Jin³, Z. Li⁴, R. Wang⁵, J.M. Yuan⁵, C.N. Ong⁴, W.P. Koh², ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²National University of Singapore, Science Drive, #-, SG, ³DUS-NUS Medical School, Singapore, SG, ⁴National University of Singapore, Singapore, SG, ⁵Graduate School of Public Health, University of Pittsburgh, pittsburgh, US

12:00 - 12:00

650P - Loss of subcutaneous adipose tissue during chemotherapy predicts reduced survival in patients with incurable colorectal cancer undergoing palliative therapy

E.S. Sullivan¹, L. Daly¹, É. Ní Bhuachalla¹, S. Cushen¹, A. Ryan¹, D. Power², ¹University College Cork, Cork, IE, ²Cork & Mercy University Hospitals, Cork, IE

12:00 - 12:00

651P - Obese and overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab.

B. Cybulska-Stopa¹, K. Regulski², R. Wiśniowski³, M. Rajczykowski¹, R. Suwinski¹, M. Domagała-Haduch⁴, K. Piejko⁴, A. Drosik⁵, I. Bar-Letkiewicz⁶, L. Rauch², T. Szczyński⁷, M. Ziobro⁴, J. Mackiewicz⁸, ¹Maria Skłodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, Gliwice, PL, ²Akademia Górniczo-Hutnicza, Kraków, PL, ³Beskidzkie Centrum Onkologii, Bielsko-Biała, PL, ⁴Maria Skłodowska-Curie Institute - Oncology Center (MSCI), Cracov Branch, Krakow, PL, ⁵Jagiellonian University Medical College, Krakow, PL, ⁶Uniwersytet Medyczny w Poznaniu, Poznań, PL, ⁷Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, ⁸Wielkopolskie Centrum Onkologii-Greater Poland Cancer Centre, Poznan, PL

12:00 - 12:00

652P - Patient characteristics associated with poor performance status, ECOG 2-3, and effect on survival in 1086 Finnish metastatic colorectal cancers (mCRC) nationwide (prospective RAXO study)

P. Österlund¹, T. Salminen², A. Algars³, L.-M. Soveri⁴, R. Ristamäki³, R. Kallio⁵, A. Lamminmäki⁶, P. Halonen⁷, T. Poussa⁸, E. Lantto⁹, A. Ovissi¹⁰, A. Nordin¹¹, P. Nyandoto¹², J. Kononen¹³, L. Aroviita¹⁴, A. Jekunen¹⁵, I. Kellokumpu¹⁶, M. Murashev¹⁷, R. Lindvall-Andersson¹⁸, H. Isoniemi¹¹, ¹Tampere University Hospital (Tays), Tampere, FI, ²Tampere University & Hospital (Tays). Helsinki Univeristy & Hospital, Tampere, FI, ³Turku University Hospital TYKS, Turku, FI, ⁴Comprehensive Cancer Center, Helsinki University Central Hospital, Helsinki, FI, ⁵Oulu University Hospital, Oulu, FI, ⁶Kuopio University Hospital, KYS, FI, ⁷Helsinki University Central Hospital, Helsinki, FI, ⁸Stat consulting, Nokia, FI, ⁹Helsinki University Hospital, Helsinki, FI, ¹⁰Meilahti University Hospital, Helsinki, Helsinki, FI, ¹¹Helsinki university hospital and Helsinki university, Helsinki, FI, ¹²Päijät-Häme Central Hospital, Lahti, FI, ¹³Jyväskylä Central Finland

Central Hospital, Jyväskylä, FI, ¹⁴Kanta-Häme Central Hospital, Hämeenlinna, FI,
¹⁵Vaasa Oncology Clinic, Vaasa, FI, ¹⁶Jyväskylä Central Hospital, Jyväskylä, FI,
¹⁷Satasairaala, Pori, FI, ¹⁸Ålands hälso- och sjukvård, Mariehamn, FI

- 12:00 - 12:00 **653P - Discovery and Diagnosis of Metastatic Colorectal Cancer (mCRC) in the Real World: Final Results from a European Survey**
I. Rawicka¹, Z. Maravic², L. Lemmens³, A. Benedict⁴, K. Komlos⁵, P. Rakonczai⁴,
¹EuropaColon Polska, Otwock, PL, ²EuropaColon UK, Salisbury, GB, ³COPE-unlimited, Kermt, BE, ⁴Evidera Inc., Budapest, HU, ⁵Semmelweis University, Budapest, HU
- 12:00 - 12:00 **654P - Adherence to recommended intake of calcium and colorectal cancer risk in the HEXA study**
J. Lee¹, A. Shin¹, J.-Y. Choi¹, D. Kang¹, J.-K. Lee², ¹Seoul National University (SNU), College of Medicine-Yeongjeon Medical Campus, Seoul, KR, ²Seoul National University College of Medicine, Seoul, KR
- 12:00 - 12:00 **655P - Body size, sex and sidedness of incident colorectal cancer in a prospective Swedish cohort study**
C. Siesing¹, J. Berntsson¹, J. Brändstedt¹, K. Jirström², ¹Lund University-Institution of Clinical Sciences-Oncology and Pathology, Lund, SE, ²Lund University, Lund, SE
- 12:00 - 12:00 **656P - Middle East & North Africa Registry to characterize RAS mutation status and tumor specifications in recently diagnosed patients with metastatic colorectal cancer (MORE-RAS Study)**
M. Oukkal¹, K. Bouzid², A. Bounedjar³, A. Alnajjar⁴, F. Abou Taleb⁵, A. Alsharm⁶, H. Mahfouf⁷, B. Larbaoui⁸, A. Abdelaziz⁹, A. Ouamer¹⁰, L. Bashir¹⁰, ¹CHU Beni-Messous, Algiers, DZ, ²Centre Pierre et Marie Curie, Algiers, DZ, ³CHU Blida, Blida, DZ, ⁴Kuwait Cancer Control Center, Kuwait City, KW, ⁵Zagazig University, Zagazig, EG, ⁶King Fahd Medical City-Comprehensive Cancer Care Centre, Riyadh, SA, ⁷EPH Rouiba, Rouiba, DZ, ⁸CAC Emir Abdelkader, Oran, DZ, ⁹Alexandria University Egypt, Alexandria, EG, ¹⁰Amgen, Aknoun, DZ
- 12:00 - 12:00 **657P - Patient Demographics and Management Landscape of Metastatic Colorectal Cancer in the Third Line Setting: real-world data in an Australian Population**
S. Tun Min¹, A. Roohullah², A. Tognela³, A. Jalali⁴, M. Lee⁵, R. Wong⁶, J. Shapiro⁷, M. Burge⁸, D. Yip⁹, L. Nott¹⁰, A. Zimet¹¹, B. Lee¹², A. Dean¹³, S. Steel¹⁴, H.-L. Wong¹⁵, P. Gibbs¹⁶, S. Lim¹⁷, ¹Calvary Mater Hospital Newcastle, Newcastle, AU, ²Campbelltown Hospital, Campbelltown, AU, ³Macarthur Cancer Therapy Centre, Campbelltown, AU, ⁴Walter & Eliza Hall Institute of Medical Research, Parkville, AU, ⁵Footscray Hospital, Western Health, Footscray, AU, ⁶Box Hill Hospital - Main Entrance, Box Hill, AU, ⁷Cabrini Health, Malvern, AU, ⁸Royal Brisbane & Women's Hospital, Brisbane, AU, ⁹The Canberra Hospital, Garran, AU, ¹⁰Royal Hobart Hospital, Tasmania, AU, ¹¹Epworth HealthCare, Richmond, AU, ¹²The Northern Hospital, Epping, AU, ¹³St John of God Subiaco, Subiaco, AU, ¹⁴Peninsula Private Hospital, Frankston, AU, ¹⁵Walter and Eliza Hall Institute WEHI, Parkville, AU, ¹⁶Royal Melbourne Hospital, Melbourne, AU, ¹⁷Liverpool Cancer Therapy Centre, Liverpool, AU

- 12:00 - 12:00 **659P - Quality of Life (QoL) in Metastatic Colorectal Cancer (mCRC) in the Real World: Final Results of a European Survey**
Z. Maravic¹, I. Rawicka², L. Lemmens³, A. Benedict⁴, P. Rakonczai⁴, K. Komlos⁵,
¹EuropaColon UK, Salisbury, GB, ²EuropaColon Polska, Otwock, PL, ³COPE-unlimited, Kermt, BE, ⁴Evidera Inc., Budapest, HU, ⁵Semmelweis University, Budapest, HU
- 12:00 - 12:00 **660TiP - BISQUIT: A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal**
R. Riechelmann¹, M. Camandaroba², C. Mello², V. Silva², V.H. De Jesus², M. Barros³, N. Rodrigues², M. Donadio², M. Cavichioli², V.C. Lima², E. Dias-Neto², D. Nunes², D. Carraro², L. De Brot², S. Aguiar Jr², M.L. Silva², ¹Hospital Sírio-Libanês, Sao Paulo, BR, ²A. C. Camargo Cancer Center, Sao Paulo, BR, ³AC Camargo Cancer Center, Sao Paulo, BR
- 12:00 - 12:00 **661TiP - iSCORE: Immunotherapy Sequencing in Colon and Rectal Cancer**
F. Turkes¹, R. Crux², D. Cunningham³, A. Athauda², E. Kalaitzaki⁴, A. Musallam², R. Begum², K. De Paepe², N. Fotiadis², A. Riddell², K. Von Loga⁵, J. Kinross⁶, J. Marchesi⁷, J. Teare², D. Morganstein², S. Rao², D. Watkins², I. Chau¹, M. Gerlinger⁸, N. Starling²,
¹The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ²Royal Marsden NHS Foundation Trust, Sutton, GB, ³The Royal Marsden NHS Foundation Trust, London, GB, ⁴Research data and Statistics Unit, Sutton, GB, ⁵Biomedical Research Centre, The Royal Marsden NHS Foundation Trust, Sutton, GB, ⁶Research data and Statistics Unit, London, GB, ⁷Imperial College London, London, GB, ⁸Institute of Cancer Research, London, GB
- 12:00 - 12:00 **662TiP - Phase II study of preoperative (PREOP) chemoradiotherapy (CRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA Study**
L. Salvatore¹, M. Bensi², F. Pietrantonio³, A. Boccaccino⁴, C. Barbara⁵, A. Auriemma⁶, M. Ratti⁷, E. Tamburini⁸, R. Bordonaro⁹, M. Clavarezza¹⁰, A. Avallone¹¹, F. Bergamo¹², C. Granetto¹³, S. Bustreo¹⁴, F. Di Fabio¹⁵, V. Smiroldo¹⁶, B. Corvari¹⁷, G. Tortora¹⁸, ¹AOU Integrata Verona "Borgo Roma", Verona, IT, ²Università Cattolica del Sacro Cuore, Rome, IT, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁴University of Pisa, Pisa, IT, ⁵Ospedale di Livorno, Azienda Ospedaliera 6, Livorno, IT, ⁶AOU Integrata Verona "Borgo Trento", Verona, IT, ⁷Istituti Ospitalieri di Cremona, Cremona, IT, ⁸Ospedale Infermi, Rimini, IT, ⁹Azienda Ospedaliera ARNAS Garibaldi, Catania, IT, ¹⁰Ente ospedaliero Ospedali Galliera, Genova, IT, ¹¹Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ¹²Veneto Institute of Oncology IRCCS, Padua, IT, ¹³Azienda Ospedaliera St. Croce e Carle, IT, ¹⁴Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, IT, ¹⁵AOU Policlinico S. Orsola-Malpighi, Bologna, IT, ¹⁶Istituto Clinico Humanitas, Rozzano, IT, ¹⁷Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ¹⁸Fondazione Policlinico Universitario Agostino Gemelli -IRCCS Rome, Rome, IT
- 12:00 - 12:00 **663TiP - A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study.**

M.A. Barbera¹, J. Corbelli², G. Papianni³, E. Grassi⁴, G. Ugolini³, I. Montroni³, M. Di Bartolomeo⁵, S. Cascinu⁶, M. Marzola⁷, A. Bonetti⁸, G.L. Frassinetti⁹, O. Nanni¹⁰, D. Zattoni¹¹, F. Ghignone¹¹, G. Taffurelli¹¹, C. Pinto¹², C. Carli Moretti², G. Rossi¹³, S. Palazzi¹³, S. Tamberi¹⁴, ¹Policlinico S. Orsola-Malpighi, Bologna, IT, ²ospedale degli infermi, faenza, IT, ³Faenza Hospital, Faenza, IT, ⁴AOU Policlinico S. Orsola-Malpighi, Bologna, IT, ⁵Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁶Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ⁷Sant'Anna Hospital CONA-University of Ferrara, Cona FR, IT, ⁸Ospedale Mater Salutis di Legnago, Legnago, IT, ⁹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, IT, ¹⁰Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, IT, ¹¹ospedale degli infermi, Faenza, IT, ¹²Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, ¹³Ravenna Hospital, Ravenna, IT, ¹⁴Ospedale degli Infermi, Faenza, IT

12:00 - 12:00 **664TiP - Open Label Phase III Study of Arfolitixorin vs. Leucovorin in mFOLFOX-6 for First Line Treatment of Metastatic Colorectal Cancer: AGENT**

J. Tabernero¹, G. Prager², S. Stintzing³, H.J. Lenz⁴, H. Nygren⁵, C. Papadimitriou⁶, ¹Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ²Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, ³Charité - Universitätsmedizin Berlin, Berlin, DE, ⁴USC - Norris Comprehensive Cancer Center, Los Angeles, US, ⁵Uppsala University - Rudbecklaboratoriet, Uppsala, SE, ⁶Alexandra Hospital, Athens, GR

12:00 - 12:00 **665TiP - SOLSTICE, a phase 3, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy**

T. Andre¹, M. Saunders², A. Kanehisa³, E. Gandossi⁴, R. Fougerey⁵, N. Causse-Amellal⁵, A. Falcone⁶, ¹Hopital Saint-Antoine, Paris, FR, ²The Christie NHS Foundation Trust, Manchester, GB, ³Servier-France, Suresnes, FR, ⁴Servier France, Suresnes, FR, ⁵Servier, Suresnes, FR, ⁶Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT

12:00 - 12:00 **666TiP - A Phase Ib/ II Trial to Assess the Safety and Efficacy of CXD101 in Combination with the PD-1 Inhibitor Nivolumab in Patients with Metastatic, Previously-Treated, Microsatellite-Stable (MSS) Colorectal Carcinoma (short title CAROSELL)**

M. Saunders¹, J. Graham², D. Cunningham³, R. Plummer⁴, S. Cook⁵, D. Church⁶, R. Kerr⁶, N. La Thangue⁵, D. Kerr⁵, ¹The Christie NHS Foundation Trust, Manchester, GB, ²Beatson West of Scotland Cancer Centre, glasgow, GB, ³The Royal Marsden NHS Foundation Trust, london, GB, ⁴The Newcastle upon Tyne Hospitals NHS Foundation Trust, newcastle, GB, ⁵Celleron Therapeutics, oxford, GB, ⁶Churchill Hospital University of Oxford, oxford, GB

12:00 - 12:00 **667TiP - A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination with FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS Mutation**

H.J. Lenz¹, D. Ahn², M. Erlander³, A. Barzi⁴, ¹USC - Norris Comprehensive Cancer Center, Los Angeles, US, ²Mayo Clinic Cancer Center, Phoenix, US, ³Trovagene, San Diego, US, ⁴University of Southern California Norris Comprehensive Cancer Center, Los

Angeles, US

12:00 - 12:00

668TiP - Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.

E. Martinelli¹, T. Troiani¹, C. Cardone¹, D. Ciardiello¹, N. Zanaletti², C. Borrelli¹, M. Terminiello¹, A. Avallone³, A. Falcone⁴, E. Maiello⁵, R. Bordonaro⁶, D. Santini⁷, C. Garufi⁸, F. Pietrantonio⁹, C. Pinto¹⁰, G. Santabarbara¹¹, N. Normanno¹², F. Ciardiello¹,
¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²INCLIVA Biomedical Research Institute, Valencia, ES, ³Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁴Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT, ⁵Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT, ⁶Azienda Ospedaliera ARNAS Garibaldi, Catania, IT, ⁷Policlinico Universitario Campus Bio-Medico, Rome, IT, ⁸Ospedale Di Pescara, Pescara, IT, ⁹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ¹⁰Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, ¹¹Azienda Ospedaliera S. Giuseppe Moscati, Avellino, IT, ¹²National Cancer Institute 'Fondazione Giovanni Pascale', Napoli, IT

12:00 - 12:00

669TiP - The ORCHESTRA trial; A phase III trial of adding tumor debulking to systemic therapy versus systemic therapy alone in multi-organ metastatic colorectal cancer (mCRC).

L. Bakkerus¹, E. Gootjes², E. Van Der Stok³, T. Buffart⁴, B. Zonderhuis⁵, J. Tuynman⁵, M. Meijerink⁵, P. Van De Ven⁶, C. Haasbeek⁵, A. Ten Tije⁷, J. De Groot⁸, S. Radema⁹, M. Hendriks¹⁰, H. Helgason¹¹, E. Van Meerten¹², J. Nuyttens³, D. Grünhagen³, C. Verhoef³, H. Verheul⁴,
¹VU University Medical Centre, Amsterdam, NL, ²Amsterdam University Medical Centers, Amsterdam, NL, ³Erasmus MC Cancer Institute, Rotterdam, NL, ⁴Vrije University Medical Centre (VUMC), Amsterdam, NL, ⁵Amsterdam University Medical Centers, The Netherlands, NL, ⁶VU University, Amsterdam, NL, ⁷Amphia Ziekenhuis-location Molengracht, Breda, NL, ⁸Isala Clinics, Zwolle, NL, ⁹Radboud University Medical Center, Nijmegen, NL, ¹⁰Medisch Centrum Alkmaar, Alkmaar, NL, ¹¹Medisch Centrum Haaglanden Westeinde Hospital, The Hague, NL, ¹²Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

12:00 - 12:00

670TiP - EMERGE: Epigenetic Modulation of the Immune Response in Gastrointestinal cancers

E. Cartwright¹, F. Turkes², C. Saffery², E. Kalaitzaki³, R. Powell², A. Wotherspoon¹, K. De Paepe², K. Von Loga², M. Hubank², S. Rao², D. Watkins⁴, I. Chau⁵, N. Starling⁴, D. Cunningham⁵,
¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²Royal Marsden Hospital NHS Foundation Trust, Sutton, GB, ³Research data and Statistics Unit, Sutton, GB, ⁴Royal Marsden NHS Foundation Trust, Sutton, GB, ⁵The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

12:00 - 12:00

Gastrointestinal tumours, non-colorectal

12:00 - 12:00

682P - Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for

surgically resected pancreatic adenocarcinoma (APACT): subgroup analyses

M. Tempero¹, M. Reni², H. Riess³, E. O'Reilly⁴, S. Krishnamurthi⁵, P. Österlund⁶, I. Ales-Diaz⁷, M. Milella⁸, S. Siena⁹, J. Taberero¹⁰, E. Van Cutsem¹¹, P. Philip¹², D. Goldstein¹³, J. Berlin¹⁴, M. Li¹⁵, S. Ferrara¹⁵, Y. Le Bruchec¹⁵, D. MCGovern¹⁵, A. Biankin¹⁶, ¹UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ²IRCCS Ospedale San Raffaele, Milan, IT, ³Charité-Universitätsmedizin Berlin; Berlin; Germany; Freie Universität Berlin, Humboldt-Universität zu Berlin; Berlin; Germany; Berlin Institute of Health, Berlin, DE, ⁴Memorial Sloan-Kettering Cancer Center, New York, US, ⁵Case Western Reserve University, Cleveland, US, ⁶Tampere University Hospital, Tampere, FI, ⁷Servicio de Oncología Médica, Hospital Regional Universitario, Malaga, ES, ⁸Università degli Studi di Verona, Verona, IT, ⁹ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, ¹⁰Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ¹¹University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, BE, ¹²Karmanos Cancer Institute, Detroit, US, ¹³Nelune Cancer Centre, Prince of Wales Hospital; University of New South Wales, Randwick, AU, ¹⁴Vanderbilt-Ingram Cancer Center, Nashville, US, ¹⁵Celgene Corporation, Summit, US, ¹⁶University of Glasgow - Wolfson Wohl Cancer Research Centre - Institute of Cancer Sciences, Bearsden, GB

12:00 - 12:00 **683P - FOLFIRINOX in locally advanced (LA) and borderline resectable (BR) pancreatic adenocarcinoma : update of the AGEO cohort.**

E. Auclin¹, L. Marthey², L. Mas³, E. Francois⁴, A. Sa Cunha⁵, J.-B. Bachet⁶, D. Tougeron⁷, A. Vienot⁸, T. Lecomte⁹, V. Hautefeuille¹⁰, J. Forestier¹¹, M. Collins², R. Abdallah², R. Coriat¹², A.-L. Pointet¹, F. Leroy¹³, F. Ksontini¹⁴, N. Williet¹⁵, J. Taieb¹, ¹Hopital European George Pompidou, Paris, FR, ²CHU de Bicêtre, Le Kremlin Bicetre, FR, ³APHP, Paris, FR, ⁴Centre Anticancer Antoine Lacassagne, Nice, FR, ⁵Universite Paris Sud, Orsay, FR, ⁶Groupe Hospitalier Pitié Salpêtrière, Paris, FR, ⁷CHU Poitiers, Jean Bernard Hôpital, Poitiers, FR, ⁸CHRU Besançon - Hopital Jean Minjoz, Besançon, FR, ⁹CHU de Tours, Hôpital Trousseau, Chambray-lès-Tours, FR, ¹⁰CHU Amiens-Picardie Site Nord, Amiens, FR, ¹¹Hopital Edouard Herriot Pav. E bis, Lyon, FR, ¹²Hôpital Cochin, Paris, FR, ¹³Institut Gustave Roussy, Villejuif, FR, ¹⁴APHP Hôpital Pitié Salpêtrière, Paris, FR, ¹⁵University Hospital of Saint-Etienne, Saint Priest en Jarez, FR

12:00 - 12:00 **684P - Impact of adjuvant treatment with nab-paclitaxel and gemcitabine (nab-P+GEM) vs gemcitabine alone (GEM) on health-related quality of life (QoL) in patients (pts) with surgically resected pancreatic adenocarcinoma (PA) in the Adjuvant Pancreatic Adenocarcinoma Clinical Trial (APACT)**

H. Riess¹, J. Braverman², M. Reni³, A. Dueck⁴, A. Hendifar⁵, D.-Y. Oh⁶, C.-P. Li⁷, T. Macarulla Mercade⁸, A. Shah⁹, N. Joshi⁹, M. Botterman⁹, E. Mantovani², B. Lu², M. Tempero¹⁰, ¹Charité-Universitätsmedizin Berlin; Berlin; Germany; Freie Universität Berlin, Humboldt-Universität zu Berlin; Berlin; Germany; Berlin Institute of Health, Berlin, DE, ²Celgene Corporation, Summit, US, ³IRCCS Ospedale San Raffaele, Milan, IT, ⁴Mayo Clinic, Phoenix, US, ⁵Cedars-Sinai Medical Center, Los Angeles, US, ⁶Seoul National University Hospital, Seoul, KR, ⁷Taipei Veterans General Hospital, Taipei, TW, ⁸Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁹Pharmerit International, Bethesda, US, ¹⁰UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

12:00 - 12:00 **(Withdrawn)**

- 12:00 - 12:00 **686P - Early detection of pancreatic ductal adenocarcinoma using methylation signatures in circulating tumor DNA**
X.-D. Liu¹, H. Wu¹, Y. Li¹, X. Liu¹, Z. Zhang¹, L. Yu¹, Z. Qin², Z. Su², R. Liu², Q. He², M. Dai¹, Z. Liang¹, ¹PUMCH-Peking Union Medical College Hospital (East), Beijing, CN, ²Singlera Genomics Inc, Shanghai, CN
- 12:00 - 12:00 **687P - Evaluation of minimal important difference (MID) for the European Organisation for Research and Treatment of Cancer (EORTC) Pancreatic Cancer Module (PAN26) in patients with surgically resected pancreatic adenocarcinoma**
M. Reni¹, J. Braverman², A. Hendifar³, C.-P. Li⁴, T. Macarulla Mercade⁵, D.-Y. Oh⁶, H. Riess⁷, M. Tempero⁸, B. Lu², J. Marcus⁹, N. Joshi⁹, M. Botterman⁹, A. Dueck¹⁰, ¹IRCCS Ospedale San Raffaele, Milan, IT, ²Celgene Corporation, Summit, US, ³Cedars-Sinai Medical Center, Los Angeles, US, ⁴Taipei Veterans General Hospital, Taipei, TW, ⁵Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁶Seoul National University Hospital, Seoul, KR, ⁷Charité-Universitätsmedizin Berlin; Berlin; Germany; Freie Universität Berlin, Humboldt-Universität zu Berlin; Berlin; Germany; Berlin Institute of Health, Berlin, DE, ⁸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ⁹Pharmerit International, Bethesda, US, ¹⁰Mayo Clinic, Phoenix, US
- 12:00 - 12:00 **688P - Multispectral analysis of lymphocyte complexity in periampullary adenocarcinoma**
S. Lundgren¹, J. Elebro¹, M. Heby¹, B. Nodin², K. Leandersson², P. Micke³, K. Jirström², A. Mezheyeuski³, ¹Lund University-Institution of Clinical Sciences-Oncology and Pathology, Lund, SE, ²Lund University, Lund, SE, ³Uppsala University, Uppsala, SE
- 12:00 - 12:00 **689P - Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)**
J.H. Jeong, C. Yoo, K.-P. Kim, H.-M. Chang, B.-Y. Ryoo, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR
- 12:00 - 12:00 **690P - Prognostic factors for predicting early recurrence within the first year of surgery in pancreatic ductal adenocarcinoma**
N. Kim, S.H. Shin, Y. Ryu, I.W. Han, J.S. Heo, D.W. Choi, Samsung Medical Center (SMC), Seoul, KR
- 12:00 - 12:00 **691P - Integrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC)**
C. Lieu¹, K. Brendel², Z. Wainberg³, F. Dayyani⁴, T. Macarulla⁵, B. Zhang⁶, B. Belanger⁶, Y. Moore⁶, A. Pedret-Dunn⁷, F. Maxwell⁸, A. Dean⁹, ¹University of Colorado, Aurora, US, ²Ipsen, Paris, FR, ³Ronald Reagan UCLA Medical Center, Los Angeles, US, ⁴University of California Irvine, Irvine, US, ⁵Vall d'Hebrón University Hospital and Vall d'Hebrón Institute of Oncology, Barcelona, ES, ⁶Ipsen Bioscience, Cambridge, US, ⁷Ipsen Bioinnovation, abingdon, GB, ⁸Ipsen Bioinnovation, Abingdon, GB, ⁹St John of God

Subiaco, Subiaco, AU

- 12:00 - 12:00 **692P - Expression of long noncoding RNA and clinical outcomes of pancreatic cancer patients who received adjuvant chemotherapy by S-1 or GEM after curative resection.**
M. Kamiya¹, Y. Miyagi¹, Y. Kamioka¹, H. Yotsumoto¹, H. Inoue¹, M. Murakawa¹, Y. Nakamura¹, M. Yoshihara¹, T. Yamada¹, N. Yamamoto¹, T. Oshima¹, M. Shiozawa¹, N. Yukawa², Y. Rino², M. Masuda², S. Morinaga¹, ¹Kanagawa Cancer Center, Yokohama, JP, ²Yokohama City University, Yokohama, JP
- 12:00 - 12:00 **693P - POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)**
E. Van Cutsem¹, T. Golan², P. Hammel³, M. Reni⁴, T. Macarulla⁵, M. Hall⁶, J.O. Park⁷, D. Hochhauser⁸, D. Arnold⁹, D.-Y. Oh¹⁰, A. Reinacher-Schick¹¹, G. Tortora¹², H. Algül¹³, E. O'Reilly¹⁴, D. McGuinness¹⁵, K. Cui¹⁶, K. Schlienger¹⁷, G. Locker¹⁸, H. Kindler¹⁹, ¹University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, BE, ²Chaim Sheba Medical Center, Ramat Gan, IL, ³Beaujon Hospital APHP, Clichy, FR, ⁴IRCCS Ospedale San Raffaele, Milan, IT, ⁵Hospital Vall D'Hebron, Barcelona, ES, ⁶Fox Chase Cancer Center, Philadelphia, US, ⁷Samsung Medical Center, Seoul, KR, ⁸UCL Cancer Institute/Paul O'Gorman Building, London, GB, ⁹Asklepios Klinik Altona, Hamburg, DE, ¹⁰Seoul National University Hospital, Seoul, KR, ¹¹Katholisches Klinikum Bochum - St. Josef-Hospital, Bochum, DE, ¹²Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT, ¹³Technical University Munich, Munich, DE, ¹⁴Memorial Sloan-Kettering Cancer Center, New York, US, ¹⁵AstraZeneca, Cambridge, GB, ¹⁶AstraZeneca, Gaithersburg, US, ¹⁷Merck & Co, Rahway, US, ¹⁸AstraZeneca USA, Gaithersburg, US, ¹⁹University of Chicago, Chicago, US
- 12:00 - 12:00 **694P - Diagnostic Value of Digital Multiplexed Detection of Single Nucleotide Variants in Pancreatic Cancer Specimens Collected by Endoscopic Ultrasound Fine-Needle Aspiration**
I. Cazacu¹, A. Semaan², B. Stephens², D. Swartzlander², P. Guerrero², B. Singh², C. Lungulescu³, S. Raileanu¹, M.M. Danciulescu¹, S. Roy-Chowdhuri², A. Maitra², A. Saftoiu⁴, M. Bhutani², ¹Filantropia Hospital Craiova, Craiova, RO, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³ONCOLAB Craiova, Bucharest, RO, ⁴Research Center of Gastroenterology and Hepatology, Craiova, RO
- 12:00 - 12:00 **695P - Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer**
E. Pijnappel¹, R. Klaassen¹, K. Van Der Lee², M. Pleunis - Van Empel³, D. Richel⁴, M. Legdeur³, A. Nederveen¹, H. Van Laarhoven², H. Wilmink¹, ¹Academic Medical Center (AMC), Amsterdam, NL, ²Academic Medical Center, University of Amsterdam, Amsterdam, NL, ³Medisch Spectrum Twente, Enschede, NL, ⁴MST, Haarlem, NL
- 12:00 - 12:00 **696P - Efficacy of platinum-containing chemotherapy and prognosis of pancreatic cancer patients with homologous recombination deficiency: meta-analysis of published clinical studies**
E. Polyanskaya¹, I. Pokataev², M. Fedyanin³, A. Popova³, Y. Agafonova³, A. Tryakin⁴, S.

Tjulandin², ¹N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ²N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ³N.N. Blokhin National Medical Research Centre of Oncology, Moscow, RU, ⁴N. N. Blokhin Russian Cancer Research Center, Moscow, RU

12:00 - 12:00

697P - Plasmatic CXCL8 is a marker for TGFβ-activated kinase 1 (TAK1) activation which may predict resistance to nanoliposomal irinotecan (nal-IRI) in gemcitabine-refractory pancreatic cancer (PC) patients

V. Merz¹, C. Zecchetto², R. Santoro¹, F. Simionato², G. Piro¹, F. Sabbadini¹, A. Cavaliere², S. Casalino², A. Auriemma³, D. Melisi², ¹University of Verona, Verona, IT, ²AOU Integrata Verona "Borgo Roma", Verona, IT, ³AOU Integrata Verona "Borgo Trento", Verona, IT

12:00 - 12:00

698P - A protein level signature of four selected genes associated with survival outcomes of patients with pancreatic ductal adenocarcinoma

J. Hua¹, M. Wei¹, S. Shi², J. Xu¹, X. Yu¹, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Shanghai Cancer Center, Shanghai, CN

12:00 - 12:00

699P - Pre-treatment serum 25-hydroxyvitamin D levels and survival in a Danish cohort of patients with pancreatic cancer

L. Rasmussen¹, M. Yilmaz², U. Falkmer², L. Poulsen¹, S. Bojesen³, B. Vittrup Jensen³, A. Johansen³, I. Chen⁴, C. Hansen⁵, J.P. Hasselby⁵, P. Pfeiffer⁶, J. Bjerregaard⁶, S. Nielsen⁴, F. Andersen⁷, N. Holländer⁸, M. Bøgsted¹, J. Johansen⁴, ¹Aalborg University Hospital, Aalborg, DK, ²Aalborg University hospital, Aalborg, DK, ³Herlev and Gentofte Hospital, Herlev, DK, ⁴Herlev Hospital, Herlev, DK, ⁵Rigshospitalet, University of Copenhagen, Copenhagen, DK, ⁶Odense University Hospital, Odense C, DK, ⁷Hillerød Hospital, Hillerød, DK, ⁸Zealand University Hospital, Næstved, Næstved, DK

12:00 - 12:00

700P - STAR_PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer.

H. Kocher¹, B. Basu², F. Froeling³, D. Sarker⁴, S. Slater⁵, D. Carlin⁶, C. Coetzee¹, N. De Souza⁶, M. Goulart¹, C. Hughes¹, A. Imrali¹, C. Lawrence¹, K. Mousa⁷, B. North¹, A. Prendergast¹, R. Roberts¹, P. Sasieni⁸, D. Propper⁵, ¹QMUL, London, GB, ²Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB, ³Imperial College London - Hammersmith Hospital, London, GB, ⁴Guy's and St. Thomas' Hospital NHS Trust, London, GB, ⁵Barts Health NHS Trust, London, GB, ⁶The Institute of Cancer Research, London, London, GB, ⁷Queen Mary University, London, GB, ⁸Kings College London, London, GB

12:00 - 12:00

701P - Outcomes of First Line FOLFIRINOX (FFX) Versus Gemcitabine and Nab-Paclitaxel (GN) in Patients with Advanced Pancreatic Cancer: Multi-Institutional Canadian Sites Experience

N. Papneja¹, S. Ahmed², P. Mondal¹, I. Barrera³, A. Papneja³, G. Batist³, P. Kavan⁴, ¹University of Saskatchewan, Saskatoon, CA, ²Saskatoon Cancer Centre University of Saskatchewan, Saskatoon, CA, ³Jewish General Hospital McGill University, Montreal, CA, ⁴Jewish General Hospital, Montréal, CA

12:00 - 12:00

702P - Effect of prior cancer on survival outcomes for patients with pancreatic

adenocarcinoma

C. He, Sun Yat-sen University Cancer Center, Guangzhou, CN

12:00 - 12:00 **703P - Association of combination of irreversible electroporation ablation and chemotherapy with outcomes of locally advanced pancreatic cancer: a large cohort study**

C. He, C. He, Sun Yat-sen University Cancer Center, Guangzhou, CN

12:00 - 12:00 **704P - Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer**

Y. Hashimoto¹, S. Hijioka², Y. Hirooka³, E. Ohno⁴, T. Ioka⁵, S. Kobayashi⁶, T. Okusaka², Y. Maruki², J. Yashika⁴, R. Ashida⁵, J. Furuse⁷, M. Ikeda¹, H. Kasuya⁴, M. Tanaka⁸, M. Ueno⁹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²National Cancer Center Hospital, Tokyo, JP, ³Fujita Health University, Toyoake, JP, ⁴Nagoya University Hospital, Nagoya, JP, ⁵Osaka International Cancer Institute, Osaka, JP, ⁶Kanagawa Cancer Center Research Institute, Yokohama, JP, ⁷Kyorin university Hospital, Tokyo, JP, ⁸Takara Bio Inc., Kusatsu, JP, ⁹Kanagawa Cancer Center, Yokohama, JP

12:00 - 12:00 **705P - Multicenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer**

M. Ozaka¹, S. Kobayashi², M. Ikeda³, M. Ueno⁴, ¹Cancer Institute Hospital of JFCR, Tokyo, JP, ²Kanagawa Cancer Center Research Institute, Yokohama, JP, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴Kanagawa Cancer Center, Yokohama, JP

12:00 - 12:00 **706P - Irinotecan Combined with Oxaliplatin and S1 in Patients with Metastatic Pancreatic Adenocarcinoma**

K. Nie¹, X. Guo², X. Zhou¹, Z. Zhang³, C. Zhang¹, K. Lan¹, Y. Ji³, ¹Qingdao Central Hospital, the 2nd Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, CN, ²Pingdu People's Hospital, Qingdao, CN, ³Qingdao Cancer Hospital, Qingdao, CN

12:00 - 12:00 **707P - Cancer-associated thrombosis in patients with pancreatic cancer and its correlation with plasma tissue factor level: A Japanese prospective cohort study**

S. Kobayashi¹, S. Koizume², Y. Miyagi³, M. Ueno³, M. Morimoto³, ¹Kanagawa Cancer Center Research Institute, Yokohama, JP, ²Kanagawa Cancer Center Research Institute, Yokohama, JP, ³Kanagawa Cancer Center, Yokohama, JP

12:00 - 12:00 **708P - A Phase I/Ib, multi-center trial of ARQ-761 (Beta-Lapachone) with gemcitabine/nab-Paclitaxel in patients with advanced pancreatic cancer**

M. Beg¹, D. Boothman², L. Khosama¹, Y. Arriaga¹, U. Verma¹, A. Sanjeeviaiah¹, S. Kazmi¹, F. Fattah¹, S. Pilarski¹, M. Rodriguez¹, D. Lindsey¹, S. Linden¹, B. Schwartz³, D. Laheru⁴, ¹University of Texas Southwestern Medical Center at Dallas, Dallas, US, ²Indiana University, Indianapolis, US, ³ArQule, Burlington, US, ⁴Johns Hopkins University, Baltimore, US

12:00 - 12:00 **709P - Impact of initial liposomal irinotecan (nal-IRI) dose and dose reductions on clinical outcomes among patients with metastatic pancreatic cancer (mPC)**

treated in oncology clinics in the US

A. Surinach¹, P. Cockrum², G. Kim³, D. Mercer¹, J. Koeller⁴, R. Miksad⁵, ¹Genesis Research, Hoboken, US, ²Ipsen Biopharmaceuticals, Basking Ridge, US, ³George Washington University, Washington, US, ⁴University of Texas at Austin, Austin, US, ⁵Flatiron Health, New York, US

12:00 - 12:00 **710P - Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: first-in-human clinical trial**

R. Garcia-Carbonero¹, M. Gil Martín², R. Alvarez Gallego³, T. Macarulla Mercade⁴, M.C. Riesco Martinez¹, C. Guillen-Ponce⁵, N. Vidal⁶, F. Real⁷, R. Moreno⁸, V. Maliandi⁹, A. Mato-Berciano⁹, M. Bazan-Peregrino⁹, G. Capella¹⁰, R. Alemany¹¹, E. Blasi⁹, C. Blasco⁹, M. Cascallo⁹, R. Salazar², ¹University Hospital 12 De Octubre, Madrid, ES, ²ICO - Institut Catala d'Oncologia Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ³Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES, ⁴Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁵Hospital Universitario Ramon y Cajal, Madrid, ES, ⁶Hospital Universitari de Bellvitge, Hospitalet de Llobregat, ES, ⁷Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, ES, ⁸Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, ES, ⁹VCN Biosciences, Sant Cugat del Valles, ES, ¹⁰Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, ¹¹Institut Catala de Oncologia, Barcelona, ES

12:00 - 12:00 **711P - The analysis of genomic signatures of head and body/tail of pancreatic cancer in Chinese patients**

Q. Ling¹, H. Huang², X. Zhang³, T. Rui³, S. Feng³, Q. Wang⁴, Y. Huang⁴, S. Zhang⁴, M. Yao⁴, K. Wang⁵, ¹The First Affiliated Hospital, Zhejiang University, Hangzhou, CN, ²The First Affiliated Hospital, Hangzhou, CN, ³The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ⁴OrigiMed, Shanghai, CN, ⁵OrigiMed, Shanghai, Shanghai, CN

12:00 - 12:00 **712P - MGMT methylation in metastatic pancreatic cancer (mPAC): a single center experience**

M. Niger¹, F. Morano¹, S. Manglaviti¹, F. Nichetti², F. Perrone³, E. Tamborini⁴, M. Marcuzzo⁴, A. Raimondi¹, G. Peverelli¹, M. Brambilla⁵, F. Pagani¹, M. Torchio⁶, M. Prisciandaro¹, M. Antista¹, F. Pietrantonio¹, S. Pusceddu¹, G. Pruneri⁷, F.G. De Braud¹, M. Di Bartolomeo¹, ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ²Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁴Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, IT, ⁵Ospedale S. Maria della Misericordia, Perugia, IT, ⁶Azienda Ospedaliera della Provincia di Pavia, Ospedale Civile di Vigevano, Vigevano, IT, ⁷Istituto Nazionale Tumori, Milano, IT

12:00 - 12:00 **713P - Advantage of three-dimensional image analysis of pancreatic cancer using computed tomography**

S.B. Yoon, M.H. Choi, I.S. Lee, The Catholic University of Korea, College of Medicine, Seoul, KR

12:00 - 12:00 **714P - Phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) with S-1 in patients with stage IV pancreatic cancer.**

S. Hijioka¹, M. Ueno², T. Ioka³, Y. Hirooka⁴, E. Ohno⁵, T. Okusaka¹, Y. Maruki¹, S. Kobayashi⁶, R. Ashida³, J. Yashika⁵, J. Furuse⁷, M. Ikeda⁸, H. Kasuya⁵, M. Tanaka⁹, Y. Hashimoto⁸, ¹National Cancer Center Hospital, Tokyo, JP, ²Kanagawa Cancer Center, Yokohama, JP, ³Osaka International Cancer Institute, Osaka, JP, ⁴Fujita Health University, Toyoake, JP, ⁵Nagoya University Hospital, Nagoya, JP, ⁶Kanagawa Cancer Center Research Institute, Yokohama, JP, ⁷Kyorin university Hospital, Tokyo, JP, ⁸National Cancer Center Hospital East, Kashiwa, JP, ⁹Takara Bio Inc., Kusatsu, JP

12:00 - 12:00 **715P - Impact of anatomic site of biliary tract tumour origin and conditional probability of survival (CS): results from 15 prospective advanced first-line clinical trial**

M. Mcnamara¹, A. Lopes², H. Wasan³, D. Malka⁴, D. Goldstein⁵, J. Shannon⁶, T. Okusaka⁷, J. Knox⁸, A. Wagner⁹, T. Andre¹⁰, D. Cunningham¹¹, M. Moehler¹², L.H. Jensen¹³, D. Koeberle¹⁴, T. Bekaii-Saab¹⁵, J. Bridgewater¹⁶, J. Valle¹, ¹The Christie NHS Foundation Trust, Manchester, GB, ²CRUK & UCL Cancer Trials Centre, London, GB, ³Imperial College London - Hammersmith Hospital, London, GB, ⁴Institute Gustave Roussy, Villejuif, FR, ⁵Nelune Cancer Centre, Prince of Wales Hospital; University of New South Wales, Randwick, AU, ⁶University of Sydney, New South Wales, AU, ⁷National Cancer Center Hospital, Tokyo, JP, ⁸Princess Margaret Cancer Centre, Toronto, CA, ⁹Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ¹⁰Hopital Saint-Antoine, Paris, FR, ¹¹The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ¹²Universitätsmedizin Mainz, Mainz, DE, ¹³Vejle Sygehus Hospital, Vejle, DK, ¹⁴St. Claraspital AG, Basel, CH, ¹⁵Mayo Clinic Cancer Center, Phoenix, US, ¹⁶UCL Cancer Institute/Paul O'Gorman Building, London, GB

12:00 - 12:00 **716P - FOLFOXIRI versus FOLFIRINOX in first-line chemotherapy in patients with advanced pancreatic cancer: a propensity score analysis**

A. Vienot¹, H. Chevalier², C. Bolognini¹, E. Gherga³, A. Meurisse⁴, D. Vernerey⁵, C. Borg⁶, A. Turpin⁷, ¹CHRU Besançon - Hopital Jean Minjoz, Besançon, FR, ²Lille University Hospital, Lille, FR, ³Nord Fanche-Comté Hospital, Montbéliard, FR, ⁴Besançon University Hospital, Besançon, FR, ⁵MSD, FR, ⁶CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, ⁷Hopital Claude Huriez, Lille, FR

12:00 - 12:00 **717P - Cellfree tumor-DNA (cfDNA) as a very early predictor of therapeutic outcome in pancreatic ductal adenocarcinoma (PDAC)**

S. Payr¹, J. Bergelin², J. Beck³, T. Dragovich², A. Azizian¹, M. Brunner¹, U. König¹, B. Naraev², V. Ellenrieder¹, J. Gaedcke¹, E. Schütz³, M.N. Kundranda², A.-O. König¹, ¹Universitätsmedizin Göttingen, Göttingen, DE, ²Banner MD Anderson Cancer Center, Gilbert, US, ³Chronix Biomedical GmbH, Göttingen, DE

12:00 - 12:00 **718P - Comprehensive genomic profiling (CGP) of gall bladder adenocarcinoma (GBAC) in patients from distinct ancestral populations**

M. Javle¹, S. Akumalla², R. Madison², A. Verma³, R. Abdel-Wahab¹, J. Newburg², B. Alexander², J. Chung², V. Miller², J. Lee², J. Ross², A. Schrock², G. Frampton², S. Ali², ¹MD Anderson Cancer Center, Houston, US, ²Foundation Medicine, Cambridge, US, ³Max Super Speciality Hospital, New Dehli, IN

12:00 - 12:00 **719P - Phase II Monotherapy Efficacy of Cancer Metabolism Targeting SM-88 in**

Heavily Pre-Treated PDAC Patients.

A. Ocean¹, M. Noel², A. Wang-Gillam³, S. Chawla⁴, V. Chung⁵, S. Pant⁶, G. Del Priore⁷, V. Picozzi⁸, ¹Weill Cornell Medical College, New York, US, ²University of Rochester Cancer Center, Rochester, US, ³Washington University School of Medicine, St. Louis, US, ⁴Sarcoma Oncology Research Center, Santa Monica, US, ⁵City of Hope, Duarte, US, ⁶MD Anderson Cancer Center, Houston, US, ⁷Tyme Inc, New York, US, ⁸Virginia Mason, Seattle, US

12:00 - 12:00 **720P - Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) cholangiocarcinoma (CCA) treated with pemigatinib in the fight-202 trial**

A. Hollebecque¹, I. Silverman², S. Owens², L. Féliz³, C. Lihou³, H. Zhen³, R. Newton², T. Burn³, D. Melisi⁴, ¹Gustave Roussy, Villejuif, FR, ²Incyte Research Institute, Incyte Corporation, Wilmington, US, ³Incyte Corporation, Wilmington, US, ⁴AOU Integrata Verona "Borgo Roma", Verona, IT

12:00 - 12:00 **721P - Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications**

M. Droz Dit Busset¹, S. Braun², B. El-Rayes³, W. Harris⁴, N. Damjanov⁵, G. Masi⁶, L. Rimassa⁷, S. Bhoori¹, M. Niger⁸, N. Personeni⁷, F. Braiteh⁹, S. Lonardi¹⁰, M. Engelhardt², M. Saulay², B. Schwartz¹¹, W. Shaib¹², V. Mazzaferro¹, K. Papadopoulos¹³, ¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ²Basilea Pharmaceutica AG, Basel, CH, ³Winship Cancer Institute, Atlanta, GA, Atlanta, US, ⁴University of Washington School of Medicine, Seattle, WA, Seattle, US, ⁵Temple University Cancer Center, Philadelphia, US, ⁶Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT, ⁷Istituto Clinico Humanitas, Rozzano, IT, ⁸Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁹Comprehensive Cancer Centers of Nevada, Las Vegas, US, ¹⁰Istituto Oncologico Veneto IRCCS, Padova, IT, ¹¹ArQule Inc., Burlington, US, ¹²Emory University, Atlanta, US, ¹³South Texas Accelerated Research Therapeutics (START), San Antonio, US

12:00 - 12:00 **722P - It's Not Only About Weight Loss: Tackling Pancreatic Cancer-Associated Cachexia**

A.L. Matos¹, L. Fernandes¹, H. Cunha², J. Graca¹, J. Barata¹, M. Neves¹, F. Alves¹, J. Pereira¹, F. Ferreira¹, A. Freire Coelho³, M. Malheiro⁴, M. Mesquita Pinto¹, M. Fontes E Sousa⁴, A. Placido¹, A.M. Henriques Martins C. Mourão¹, ¹Centro Hospitalar de Lisboa Ocidental E.P.E. (CHLO)-Hospital São Francisco Xavier (HSFX), Lisbon, PT, ²Hospital Espirito Santo Évora, Lisbon, PT, ³Hospital de S. João, Porto, PT, ⁴Centro Hospitalar de Lisboa Ocidental(CHLO)-Hospital São Francisco Xavier (HSFX), Lisbon, PT

12:00 - 12:00 **723P - Frequency and clinicopathological characteristics of biliary tract carcinomas harboring the FGFR2-fusion gene: a prospective observational study (PRELUDE study)**

M. Ikeda¹, Y. Maruki², M. Ueno³, T. Ioka⁴, A. Naganuma⁵, M. Furukawa⁶, N. Mizuno⁷, T. Uwagawa⁸, Y. Nakai⁹, M. Kanai¹⁰, A. Asagi¹¹, S. Shimizu¹², A. Miyamoto¹³, S. Yukisawa¹⁴, M. Kadokura¹⁵, T. Yamanaka¹⁶, Y. Arai¹⁷, T. Shibata¹⁷, C. Morizane², T. Okusaka², ¹National Cancer Center Hospital East, Kashiwa, JP, ²National Cancer Center

Hospital, Tokyo, JP, ³Kanagawa Cancer Center, Yokohama, JP, ⁴Osaka International Cancer Institute, Osaka, JP, ⁵Takasaki General Medical Center, National Hospital Organization, Takasaki, JP, ⁶National Kyushu Cancer Center, Fukuoka, JP, ⁷Aichi Cancer Center Hospital, Nagoya, JP, ⁸The Jikei University School of Medicine, Tokyo, JP, ⁹Graduate School of Medicine, The University of Tokyo, Tokyo, JP, ¹⁰Kyoto University Hospital, Kyoto, JP, ¹¹National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, ¹²Saitama Cancer Center, Saitama, JP, ¹³National Hospital Organization Osaka National Hospital, Osaka, JP, ¹⁴Tochigi Cancer Center, Utsunomiya, JP, ¹⁵Kofu Municipal Hospital, Kofu, JP, ¹⁶Yokohama City University Hospital, Yokohama, JP, ¹⁷National Cancer Center Research Institute, Tokyo, JP

12:00 - 12:00

724P - Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized Phase II study

U.-F. Pape¹, S. Kasper², J. Meiler³, M. Sinn⁴, A. Vogel⁵, L. Mueller⁶, O. Burkhard⁷, K. Caca⁸, S. Heeg⁹, V. Rodriguez Laval¹⁰, A. Kuhl¹¹, R. Arsenic¹², H. Jansen¹³, T. Mehrling¹⁴, K. Hilgier¹⁴, I. Wagner¹⁴, N. Utku¹⁵, ¹Asklepios Klinik St. Georg, Hamburg, DE, ²University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ³Klinik Dr. Hancken, Stade, DE, ⁴Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ⁵Hannover Medical School, Hannover, DE, ⁶Onkologische Schwerpunktpraxis Leer-Emden, Leer, DE, ⁷Dr. Oswald Burkhard, Worms, DE, ⁸Klinikum Ludwigsburg Medizinische Klinik I, Ludwigsburg, DE, ⁹Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, Freiburg im Breisgau, DE, ¹⁰CellAct Pharma GmbH, Dortmund, DE, ¹¹iPATH Berlin, Berlin, DE, ¹²Charité Universitätsmedizin Berlin, Berlin, DE, ¹³Charité Universitätsmedizin, Berlin, DE, ¹⁴Mundipharma EDO GmbH, Basel, CH, ¹⁵No place of work provided Iran, Tehran, IR

12:00 - 12:00

725P - Capecitabine +Best supportive care (BSC) or Erlotinib +BSC has Overall survival (OS) benefit over BSC alone in unresectable/metastatic Gall bladder cancer(GBC) patients with ECOG PS-III. Results from a phase II Randomised controlled trial (RCT)

B. Kataria¹, A. Sharma², S. Mishra³, S. Bhatnagar³, S. Thulkar², M. Yadav³, R. Sahoo², R. Pramanik³, C. Prasad⁴, V. Sreenivas², M. S⁴, ¹AIIMS - All India Institute of Medical Sciences, Delhi, IN, ²B.R. Ambedkar Institute Rotary Cancer Hospital (AIMS), New Delhi, IN, ³Dr.,B.R.A.I.R.C.H.,AIIMS - All India Institute of Medical Sciences, New Delhi, IN, ⁴AIIMS - All India Institute of Medical Sciences, New Delhi, IN

12:00 - 12:00

726P - FGFR2 fusions and its effect of patient (pt) outcomes in intrahepatic cholangiocarcinoma (iCCA)

D. Almquist¹, M. Javle², K. Ciombor³, M. Roth³, R. Abdel-Wahab², F.-S. Ou⁴, E. Wolfe⁵, K. Mody⁶, A. Mahipal⁷, M. Borad⁸, T. Bekaii-Saab¹, D. Ahn¹, ¹Mayo Clinic Cancer Center, Phoenix, US, ²MD Anderson Cancer Center, Houston, US, ³Vanderbilt University, Nashville, US, ⁴Mayo Clinic, Scottsdale, US, ⁵Mayo Clinic, Rochester, US, ⁶Mayo Clinic, Jacksonville, US, ⁷H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ⁸Mayo Clinic Cancer Center, Scottsdale, US

12:00 - 12:00

727P - The Clinical Outcomes of Systemic Chemotherapy in Patients with Unresectable or Metastatic Combined Hepatocellular-cholangiocarcinoma (HCC-CCA): Retrospective Study of 120 Patients

E. Kim¹, C. Yoo², B.-Y. Ryoo², ¹Asan Medical Center, Seoul, KR, ²Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR

- 12:00 - 12:00 **728P - High PD-L1 expression is associated with treatment response to pembrolizumab in patients with advanced biliary tract cancer.**
G. Kim, S. Ahn, J.-H. Hwang, J.-C. Lee, J. Kim, Seoul National University Bundang Hospital, Seongnam, KR
- 12:00 - 12:00 **729P - Genomic profiling in Chinese biliary tract cancer patients with PI3K/AKT/mTOR pathway and RAS gene mutations**
J. Cao¹, W. Guo¹, Z. Niu¹, Z. Wang¹, W. Hu¹, X. Ma¹, D. Liu², J. Shi², M. Yao², ¹The Affiliated Hospital of Qingdao University, Qingdao, CN, ²OrigiMed, Shanghai, CN
- 12:00 - 12:00 **730P - Phase II trial of trifluridine/tipiracil (TAS-102) in patients with advanced refractory biliary tract cancer (BTC)**
S. Chakrabarti¹, T. Zemla¹, F.-S. Ou¹, B. Fruth¹, D. Ahn², M. Borad³, M. Hartgers¹, J. Wessling¹, R. Walkes¹, S. Alberts¹, R. McWilliams¹, M. Liu⁴, A. Mahipal⁵, ¹Mayo Clinic, Rochester, US, ²Mayo Clinic Cancer Center, Phoenix, US, ³Mayo Clinic Cancer Center, Scottsdale, US, ⁴Mayo Clinic Rochester, Rochester, US, ⁵H. Lee Moffitt Cancer Center University of South Florida, Tampa, US
- 12:00 - 12:00 **731P - Liver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): Outcomes from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging.**
A. Lamarca¹, A. Santos², K. Utpatel³, A. La Casta⁴, S. Stock³, A. Forner⁵, J. Adeva Alfonso⁶, T. Folseraas⁷, L. Fabris⁸, R. Macias⁹, M. Krawczyk¹⁰, M. Krawczyk¹¹, V. Cardinale¹², C. Braconi¹³, D. Alvaro¹², M. Evert³, J. Bañales¹⁴, J. Valle¹, ¹The Christie NHS Foundation Trust, Manchester, GB, ²Biodonostia, ., ES, ³University of Regensburg, Regensburg, DE, ⁴University Hospital Donostia, San Sebastian, ES, ⁵Hospital Clínic Barcelona, Barcelona, ES, ⁶University Hospital 12 De Octubre, Madrid, ES, ⁷Oslo University Hospital, Oslo, NO, ⁸University of Padua, Padua, IT, ⁹Biology, Salamanca, ES, ¹⁰Universitätsklinikum des Saarlandes, Homburg, DE, ¹¹Medical University of Warsaw, Warsaw, PL, ¹²Sapienza University of Rome, Rome, IT, ¹³The Royal Marsden NHS Trust, London, GB, ¹⁴Biodonostia, San Sebastian, ES
- 12:00 - 12:00 **732P - Is MGMT methylation a new therapeutic target for Biliary Tract Cancer?**
M. Niger¹, F. Morano¹, S. Manglaviti², F. Nichetti³, E. Tamborini⁴, F. Perrone⁵, M. Marcuzzo⁴, G. Peverelli¹, M. Brambilla⁶, F. Pagani¹, M. Torchio⁷, A. Ottini², M. Antista¹, F. Pietrantonio⁵, S. Pusceddu¹, G. Pruneri⁸, M. Di Bartolomeo¹, F.G. De Braud¹, ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ²Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, IT, ³Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁴Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁶Ospedale S. Maria della Misericordia, Perugia, IT, ⁷Azienda Ospedaliera della Provincia di Pavia, Ospedale Civile di Vigevano, Vigevano, IT, ⁸Istituto Nazionale Tumori, Milano, IT

- 12:00 - 12:00 **733P - Biliary Tract Cancers in Portuguese families with BRCA gene mutation: a retrospective study.**
P. Pereira¹, I. Oliveira¹, S. Fernandes², A. Clara³, I. Miguel⁴, S. Bento⁴, S. Fragoso⁵, S. Santos⁶, P. Rodrigues⁷, J. Parreira⁷, F. Rodrigues⁵, I. Silva⁷, P. Louro³, F. Vaz¹, A. Luis⁸,
¹Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, PT, ²Paediatric Hospital from Coimbra Hospital and University Center, Coimbra, PT, ³Instituto Português de Oncologia de Lisboa, Lisboa, PT, ⁴Hospital Distrital de Santarem (HDS), Santarem, PT, ⁵Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, PT, ⁶Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPOLFG EPE), Lisbon, PT, ⁷Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisbon, PT, ⁸Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisboa, PT
- 12:00 - 12:00 **734P - Selection of patients with hepatocellular carcinoma for selective internal radiation therapy based on tumour burden and liver function: a post-hoc analysis of the SARAH trial**
D. Palmer¹, N. Hawkins², V. Vilgrain³, H. Pereira⁴, G. Chatellier⁴, P. Ross⁵, ¹Royal Liverpool University Hospital, Liverpool, GB, ²University of Glasgow, Glasgow, GB, ³Hôpital Beaujon, Clichy, FR, ⁴Hôpitaux Universitaires Paris Ouest (AP-HP), Paris, FR, ⁵Guy's and St. Thomas' Hospital NHS Trust, London, GB
- 12:00 - 12:00 **735P - Second-line chemotherapy (SLC) in Patients with Advanced Biliary tract and Gallbladder Cancers (ABGC) Prolongs Survival: A Retrospective Population-based Cohort Study**
A. Zaidi¹, N. Chandna², G. Narasimhan¹, M. Moser³, K. Haider¹, H. Chalchal⁴, J. Shaw³, S. Ahmed¹, ¹Saskatoon Cancer Centre University of Saskatchewan, Saskatoon, CA, ²McMaster University, Hamilton, CA, ³University of Saskatchewan, Saskatoon, CA, ⁴Saskatchewan Cancer Agency-Allan Blair Cancer Centre at Pasqua Hosp, Regina, CA
- 12:00 - 12:00 **736P - Overall survival of patients with hepatocellular carcinoma receiving sorafenib versus selective internal radiation therapy with predicted dosimetry in the SARAH trial**
N. Hawkins¹, P. Ross², D. Palmer³, G. Chatellier⁴, H. Pereira⁴, V. Vilgrain⁵, ¹University of Glasgow, Glasgow, GB, ²Guy's and St. Thomas' Hospital NHS Trust, London, GB, ³Royal Liverpool University Hospital, Liverpool, GB, ⁴Hôpitaux Universitaires Paris Ouest (AP-HP), Paris, FR, ⁵Hôpital Beaujon, Clichy, FR
- 12:00 - 12:00 **737P - Multicenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy**
N. Okano¹, M. Ueno², C. Morizane³, T. Yamanaka⁴, H. Ojima⁵, M. Ozaka⁶, M. Sasaki³, N. Takahara⁷, S. Kobayashi⁸, M. Morimoto², H. Hosoi³, Y. Nakai⁹, M. Ikeda¹⁰, S. Maeno¹¹, F. Nagashima¹, T. Okusaka³, J. Furuse¹¹, ¹Kyorin university Hospital, Tokyo, JP, ²Kanagawa Cancer Center, Yokohama, JP, ³National Cancer Center Hospital, Tokyo, JP, ⁴Yokohama City University Hospital, Yokohama, JP, ⁵Keio University School of Medicine, Tokyo, JP, ⁶The Cancer Institute of JFCR, Tokyo, JP, ⁷Graduate School of Medicine, The University of Tokyo, Tokyo, JP, ⁸Kanagawa Cancer Center Research Institute,, Yokohama, JP, ⁹The University of Tokyo, Tokyo, JP, ¹⁰National Cancer Center Hospital East, Kashiwa, JP, ¹¹Kyorin University Faculty of Medicine, Tokyo, JP

- 12:00 - 12:00 **738P - Soluble Programmed Death-ligand 1 indicate poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization**
- X. Ma, X. Qu, W. Yang, H. Wang, B. Wang, M. Shen, Y. Zhou, C.Y. Zhang, Y. Sun, J. Chen, B. Hu, Z. Gong, X. Zhang, B. Pan, J. Zhou, J. Fan, X. Yang, W. Guo, Zhongshan Hospital, Fudan University, Shanghai, CN
- 12:00 - 12:00 **739P - The Prognostic Nutritional Index (PNI) is an independent predictor of survival in advanced biliary cancers (ABC) receiving first-line chemotherapy (1L).**
- F. Caputo¹, M. Salati¹, K. Cerma², A. Spallanzani¹, K. Andrikou³, F. Gelsomino¹, G. Orsi¹, G. Rovesti¹, M.L. Riggi², E. Molinaro¹, C. Santini¹, C. Bardasi¹, M. Rimini¹, S. Pipitone¹, G. Cortesi¹, F. Schipilliti¹, F. Canino², A. Casadei-Gardini¹, S. Cascinu¹, ¹Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ²Azienda Ospedaliera - Universitaria Policlinico di Modena, Modena, IT, ³AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, IT
- 12:00 - 12:00 **740P - Impact of centralisation of national cancer services on patient outcomes for hepatobiliary cancers in Ireland 2000 - 2016**
- D. O Reilly¹, S. Deady², P. Walsh², M. Lowery¹, ¹St James's Hospital, Dublin, IE, ²National Cancer Registry of Ireland, Cork, IE
- 12:00 - 12:00 **741P - Genomic analysis of hepatobiliary lithiasis associated cholangiocarcinoma revealed a distinct subtype feature.**
- L. Gu¹, Y. Wang², J. Deng¹, X. Chen¹, J. Zhou², X. Yang², ¹BGI-Shenzhen, Shenzhen, CN, ²Zhongshan Hospital, Fudan University, Shanghai, CN
- 12:00 - 12:00 **742P - Comparison of the impact of stereotactic body radiation therapy vs. radiofrequency ablation on liver function in patients with single hepatocellular carcinoma: A propensity score matching analysis**
- M. Ueno, H. Takabatake, M. Sue, T. Kayahara, Y. Morimoto, M. Mizuno, Kurashiki Central Hospital, Kurashiki, JP
- 12:00 - 12:00 **743P - Exploratory analysis based on tumor location and early metabolic tumor response of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine/platinum-based chemotherapy for advanced and metastatic biliary tract tumors.**
- A. Demols¹, I. Borbath², L. Guillaume², J.L. Van Laethem¹, S. Goldman¹, R. Lhommel², ¹Erasme University Hospital-(Universite Libre de Bruxelles), Brussels, BE, ²Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE
- 12:00 - 12:00 **744P - Predictive Value of Neutrophil-Lymphocyte Ratio (NLR) And Platelet-Lymphocyte Ratio (PLR) In Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab (N)**
- S. Dharmapuri¹, U. Özbek², J.-Y. Lin², M. Schwartz³, A. Branch³, C. Ang², ¹Mount Sinai Hospital, New York City, US, ²Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US, ³Icahn School of Medicine at Mount Sinai, New York, US

12:00 - 12:00

745P - Preliminary Safety and Pharmacokinetics of a New Lysosomotropic Oral Agent, GNS561, in a First-in-Human Study in Advanced Primary Liver Cancer Patients

A. Awada¹, J. Harding², N. Kotecki¹, P. Aftimos¹, T. Decaens³, C. Dreyer⁴, C. Ansaldi⁵, M. Rachid⁵, C. Serdjebi⁵, P. Halfon⁵, G. Abou-Alfa², E. Raymond⁶, ¹Institute Jules Bordet, Brussels, BE, ²Memorial Sloan-Kettering Cancer Center, New York, US, ³CHU de Grenoble-Alpes- Le site nord à La Tronche - Hopital Michallon, La Tronche, FR, ⁴Hôpital Beaujon, Clichy, FR, ⁵Genoscience Pharma, Marseille, FR, ⁶Centre Hospitalier Paris Saint-Joseph, Paris, FR

12:00 - 12:00

747P - A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results

J. Llovet¹, R. Finn², M. Ikeda³, M. Sung⁴, A. Baron⁵, M. Kudo⁶, T. Okusaka⁷, M. Kobayashi⁸, H. Kumada⁸, S. Kaneko⁹, M. Pracht¹⁰, K. Mamontov¹¹, T. Meyer¹², K. Mody¹³, T. Kubota¹⁴, C. Dutcus¹⁵, K. Saito¹³, A. Siegel¹⁶, L. Dubrovsky¹⁷, A. Zhu¹⁸, ¹Mount Sinai Medical College, New York, US, ²UCLA - School of Medicine, Los Angeles, US, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴The Mount Sinai Hospital, Rutenberg Treatment Center, New York, US, ⁵Sutter Health, San Francisco, US, ⁶Kindai University Faculty of Medicine, Osaka, JP, ⁷National Cancer Center Hospital, Tokyo, JP, ⁸Toranomon Hospital, Tokyo, JP, ⁹Kanazawa University, Kanazawa, JP, ¹⁰Centre Eugene - Marquis, Rennes, FR, ¹¹Altai Branch of N. N. Blokhin Russian Cancer Research Centre, Barnaul, RU, ¹²UCL Cancer Institute/Paul O'Gorman Building, London, GB, ¹³Eisai Inc., Woodcliff Lake, US, ¹⁴Eisai Co. Ltd., Tokyo, JP, ¹⁵Eisai Inc, Woodcliff Lake, US, ¹⁶Merck & Co, Rahway, US, ¹⁷Merck, Rahway, US, ¹⁸Massachusetts General Hospital, Harvard Medical School, Boston, US

12:00 - 12:00

748P - Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study

A. Casadei-Gardini¹, G. Marisi², V. Dadduzio³, L. Faloppi⁴, L. Ielasi⁵, C. Vivaldi⁶, M.D. Rizzato³, L. Fornaro⁶, S. Lonardi⁷, L. Gramantieri⁵, I. Pecora⁶, N. Silvestris⁸, F. Fornari⁵, G. Orsi¹, G. Rovesti¹, D. Santini⁹, V. Zagonel⁷, S. Cascinu¹, M. Scartozzi¹⁰, ¹Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ²IRST-IRCCS, Forli, IT, ³IOV Veneto, Padua, IT, ⁴Ospedale Generale Provinciale Macerata, Macerata, IT, ⁵UNIBO, Bologna, IT, ⁶Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT, ⁷Istituto Oncologico Veneto IRCCS, Padova, IT, ⁸Istituto Tumori Giovanni Paolo II, Bari, IT, ⁹Policlinico Universitario Campus Bio-Medico, Rome, IT, ¹⁰AOU Ospedali Riuniti Ancona, Torrette di Ancona, IT

12:00 - 12:00

749P - Prognostic and predictive factors from the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)

T. Meyer¹, R.K. Kelley², M. Mangeshkar³, A.-L. Cheng⁴, A. El-Khoueiry⁵, G. Abou-Alfa⁶, ¹UCL Cancer Institute/Paul O'Gorman Building, London, GB, ²University of California San Francisco, San Francisco, US, ³Exelixis Inc., Alameda, US, ⁴National Taiwan University Hospital, New Taipei city, TW, ⁵USC, Los Angeles, US, ⁶Memorial Sloan-Kettering Cancer Center, New York, US

- 12:00 - 12:00 **750P - A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL.**
D. Pinato¹, T. Cole², B. Bengsch³, P. Tait⁴, A. Sayed², F. Abomeli², D. Gramenitskaya², E. Allara², R. Thomas⁴, C. Ward², C. Wong², A. Akarca⁵, J. Miguens Blanco², T. Marafioti⁵, J. Marchesi², R. Sharma², ¹Imperial College London - Hammersmith Hospital, London, GB, ²Imperial College London, London, GB, ³University Hospital Freiburg, Freiburg, DE, ⁴Imperial College NHS Trust, London, GB, ⁵University College London, London, GB
- 12:00 - 12:00 **751P - Anlotinib for advanced hepatocellular carcinoma: interim results from the phase II ALTER0802 study**
A. Zhou, Y. Sun, W. Zhang, Z. Jiang, B. Chen, J. Zhao, Z. Li, L. Wang, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN
- 12:00 - 12:00 **752P - The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial) and those with BCLC Stage B hepatocellular carcinoma - A nationwide multicenter study in Japan-**
A. Sakamoto¹, M. Kurosaki², K. Tsuchiya², T. Abe³, C. Ogawa⁴, T. Soda⁵, H. Kimura⁶, M. Kondo⁷, K. Tsuji⁸, F. Koichiro⁹, M. Shigeno¹⁰, K. Jyoko¹¹, R. Narita¹², Y. Uchida¹³, H. Yoshida¹⁴, T. Akahane¹⁵, H. Kobashi¹⁶, A. Mitsuda¹⁷, H. Marusawa¹, N. Izumi², ¹Osaka Red Cross Hospital, Osaka, JP, ²Musashino Red Cross Hospital, Tokyo, JP, ³Maehashi Red Cross Hospital, Maehashi, JP, ⁴Takamatsu Red Cross Hospital, Takamatsu, JP, ⁵Fukuoka Red Cross Hospital, Fukuoka, JP, ⁶Kyoto Daiichi Red Cross Hospital, Kyoto, JP, ⁷Otsu Red Cross Hospital, Otsu, JP, ⁸Hiroshima Red Cross Hospital, Hiroshima, JP, ⁹Masuda Red Cross Hospital, Masuda, JP, ¹⁰Nagasaki Genbaku Red Cross Hospital, Nagasaki, JP, ¹¹Matsuyama Red Cross Hospital, Matsuyama, JP, ¹²Oita Red Cross Hospital, Oita, JP, ¹³Matsue Red Cross Hospital, Matsue, JP, ¹⁴Japanese Red Cross Medical Center, Tokyo, JP, ¹⁵Ishinomaki Red Cross Hospital, Ishinomaki, JP, ¹⁶Okayama Red Cross Hospital, Okayama, JP, ¹⁷Tottori Red Cross Hospital, Tottori, JP
- 12:00 - 12:00 **753P - Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase 3 studies (REACH, REACH-2)**
A. Zhu¹, P. Galle², J.M. Llovet³, R. Finn⁴, Y.-K. Kang⁵, C. Yen⁶, E. Assenat⁷, G. Brandi⁸, K. Motomura⁹, I. Ohno¹⁰, B. Daniele¹¹, A. Vogel¹², T. Yamashita¹³, C.-H. Hsu¹⁴, T. Meyer¹⁵, R. Widau¹⁶, W. Schelman¹⁷, C. Wang¹⁸, Y. Hsu¹⁹, M. Kudo²⁰, ¹Massachusetts General Hospital, Harvard Medical School, Boston, US, ²Universitätsmedizin Mainz, Mainz, DE, ³Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁴UCLA - School of Medicine, Los Angeles, US, ⁵Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁶National Cheng Kung University Hospital, Tainan, TW, ⁷ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ⁸University of Bologna, Sant' Orsola-Malpighi Hospital, Bologna, IT, ⁹Aso Iizuka Hospital, Iizuka, JP, ¹⁰National Cancer Center Hospital East, Kashiwa, JP, ¹¹Azienda Ospedaliera G. Rummo, Benevento, IT, ¹²Hannover Medical School, Hannover, DE, ¹³Kanazawa University, Kanazawa, JP, ¹⁴National Taiwan University Hospital, Taipei City, TW, ¹⁵UCL Cancer Institute/Paul O'Gorman Building, London, GB, ¹⁶Eli Lilly, Indianapolis, US, ¹⁷Eli Lilly and Company - Global Headquarters, Indianapolis, US, ¹⁸Eli Lilly and Company, Indianapolis, US, ¹⁹Eli Lilly and Company, Basking Ridge, US, ²⁰Kindai University Faculty of Medicine, Osaka, JP

- 12:00 - 12:00 **754P - Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study**
N. Freemantle¹, G.K. Abou-Alfa², A.-L. Cheng³, R.K. Kelley⁴, V. Valcheva⁵, F. Benzaghoul⁵, P. Mollon⁵, ¹University College London, London, GB, ²Memorial Sloan Kettering Cancer Center, New York, US, ³National Taiwan University Hospital, New Taipei city, TW, ⁴University of California San Francisco, San Francisco, US, ⁵Ipsen Pharma, Boulogne-Billancourt, FR
- 12:00 - 12:00 **755P - Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial**
J. Bruix¹, M. Reig², P. Merle³, M. Kudo⁴, G. Meinhardt⁵, M. Zhang⁵, K. Ozgurdal⁵, ¹Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, Barcelona, ES, ²BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, Barcelona, ES, ³Groupement Hospitalier Lyon Nord, Lyon, FR, ⁴Kindai University Faculty of Medicine, Osaka, JP, ⁵Bayer HealthCare Pharmaceuticals, Whippany, US
- 12:00 - 12:00 **756P - Phase I/II trial of NBTXR3 activated by SBRT in patients with hepatocellular carcinoma or liver metastasis**
M. Pracht¹, E. Chajon¹, Y. Rolland¹, T. De Baere², F. Nguyen², J.-P. Bronowicki³, V. Vendrely⁴, A. Sa Cunha⁵, A.-S. Baumann⁶, V. Croisé-Laurent³, E. Rio⁷, P. Said⁸, S. Le Sourd⁹, P. Gustin², C. Perret⁷, D. Peiffert⁶, E. Deutsch², ¹Centre Eugene - Marquis, Rennes, FR, ²Institut Gustave Roussy, Villejuif, FR, ³CHU Brabois, Vandoeuvre les Nancy, FR, ⁴CHu Bordeaux, Pessac, FR, ⁵Universite Paris Sud, Orsay, FR, ⁶Unicancer - Cancer Institute of Lorraine, Nancy, FR, ⁷Institut de cancerologie de l'Ouest, Nantes, FR, ⁸Nanobiotix SA, Paris, FR, ⁹Centre Eugène Marquis, FR
- 12:00 - 12:00 **757P - Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase 3 trials (REACH and REACH-2)**
M. Kudo¹, P. Galle², K. Motomura³, E. Assenat⁴, P. Merle⁵, G. Brandi⁶, B. Daniele⁷, T. Okusaka⁸, J. Tomasek⁹, C. Borg¹⁰, V. Zagonel¹¹, M. Morimoto¹², M. Pracht¹³, R. Finn¹⁴, J. Llovet¹⁵, G. Homma¹⁶, M.-H. Jen¹⁷, K. Shinozaki¹⁶, R. Yoshikawa¹⁶, A. Zhu¹⁸, ¹Kindai University Faculty of Medicine, Osaka, JP, ²Universitätsmedizin Mainz, Mainz, DE, ³Aso Iizuka Hospital, Iizuka, JP, ⁴ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ⁵Hôpital de la Croix-Rousse, Lyon, FR, ⁶University of Bologna, Sant' Orsola-Malpighi Hospital, Bologna, IT, ⁷Azienda Ospedaliera G. Rummo, Benevento, IT, ⁸National Cancer Center Hospital, Tokyo, JP, ⁹Masaryk Memorial Cancer Institute, Brno, CZ, ¹⁰CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, ¹¹Istituto Oncologico Veneto IRCCS, Padova, IT, ¹²Kanagawa Cancer Center, Yokohama, JP, ¹³Centre Eugene - Marquis, Rennes, FR, ¹⁴UCLA - School of Medicine, Los Angeles, US, ¹⁵Mount Sinai Medical College, New York, US, ¹⁶Eli Lilly Japan K.K., Kobe, JP, ¹⁷Eli Lilly and Company, Surrey, GB, ¹⁸Massachusetts General Hospital, Harvard Medical School, Boston, US
- 12:00 - 12:00 **758P - Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis**
J. Llovet¹, M. Kudo², Y.-K. Kang³, C.-J. Yen⁴, R. Finn⁵, P. Galle⁶, E. Assenat⁷, K.

Motomura⁸, T. Okusaka⁹, T. Berg¹⁰, C.-H. Hsu¹¹, M. Ikeda¹², Y. Hsu¹³, K. Liang¹⁴, R. Widau¹⁵, W. Schelman¹⁶, L. O'Brien¹⁴, L. Gao¹⁵, A. Zhu¹⁷, ¹Mount Sinai Medical College, New York, US, ²Kindai University Faculty of Medicine, Osaka, JP, ³Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁴National Cheng Kung University Hospital, Taiwan, TW, ⁵UCLA - School of Medicine, Los Angeles, US, ⁶Universitätsmedizin Mainz, Mainz, DE, ⁷ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ⁸Aso Iizuka Hospital, Fukuoka, JP, ⁹National Cancer Center Hospital, Tokyo, JP, ¹⁰Universitätsklinikum Leipzig, Leipzig, DE, ¹¹National Taiwan University Hospital, Taipei City, TW, ¹²National Cancer Center Hospital East, Kashiwa, JP, ¹³Eli Lilly and Company, Basking Ridge, US, ¹⁴Eli Lilly and Company, Indianapolis, US, ¹⁵Eli Lilly, Indianapolis, US, ¹⁶Eli Lilly and Company - Global Headquarters, Indianapolis, US, ¹⁷Massachusetts General Hospital, Harvard Medical School, Boston, US

12:00 - 12:00 **759P - Outcomes of Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab: The Mount Sinai Hospital Experience.**

S. Dharmapuri¹, U. Özbek², J.-Y. Lin², M. Schwartz³, A. Branch³, C. Ang², ¹Mount Sinai Hospital, New York City, US, ²Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US, ³Icahn School of Medicine at Mount Sinai, New York, US

12:00 - 12:00 **760P - Pembrolizumab vs Chemotherapy in Patients With Advanced/Metastatic Adenocarcinoma (AC) or Squamous Cell Carcinoma (SCC) of the Esophagus as Second-Line Therapy: Analysis of the Chinese Subgroup in KEYNOTE-181**

J. Chen¹, S. Luo², S. Qin³, Y. Cheng⁴, Z. Li⁵, Y. Fan⁶, X. Yuan⁷, W. Li⁸, Y. Sun⁹, X. Yin¹⁰, X. Lin¹¹, Y. Bai¹², T. Liu¹³, J. Zhang¹⁴, Y. Cui¹⁵, P. Bhagia¹⁶, S.P. Kang¹⁶, W. Lu¹⁵, Y. Zhou¹⁵, L. Shen¹⁷, ¹Jiangsu Cancer Hospital, Nanjing, CN, ²Henan Cancer Hospital, Zhengzhou, CN, ³PLA Cancer Centre of Nanjing Bayi Hospital, Nanjing, CN, ⁴Jilin Cancer Hospital, Changchun, CN, ⁵Shanghai Chest Hospital, Shanghai, CN, ⁶Zhejiang Cancer Hospital, Hangzhou, CN, ⁷Wuhan Tongji Hospital, Wuban, Hubei, CN, ⁸Anhui Provincial Hospital, Hefei, CN, ⁹Anhui Provincial Hospital, Hefei, CN, ¹⁰Hunan Cancer Hospital, Changsha, Hunan, CN, ¹¹Fujian Medical University Union Hospital, Fuzhou, CN, ¹²Harbin Medical University Cancer Hospital, Harbin, CN, ¹³Zhongshan Hospital affiliated to Fudan University, Shanghai, CN, ¹⁴Ruijin Hospital, Shanghai Jiaotong University, Shanghai, CN, ¹⁵MSD R&D (China), Shanghai, CN, ¹⁶Merck & Co., Inc., Kenilworth, US, ¹⁷Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN

12:00 - 12:00 **761P - A national comparative effectiveness study to assess definitive chemoradiation regimens in proximal oesophageal squamous cell cancer**

J. De Vos-Geelen¹, F. Hoebbers¹, S. Geurts¹, A. Hoeben², B. De Greef¹, F. Voncken³, J. Bogers⁴, P. Braam⁵, C. Muijs⁶, M. De Jong⁷, N. Kasperts⁸, T. Rozema⁹, P. Jeene¹⁰, G. Blom¹¹, M. Hulshof¹², H. Van Laarhoven¹³, H. Grabsch¹⁴, V. Lemmens¹⁵, V. Tjan-Heijnen¹, G. Nieuwenhuijzen¹⁶, ¹Maastricht University Medical Center (MUMC), Maastricht, NL, ²Maastricht University Medical Centre (MUMC)-MAASTRO clinic, Maastricht, NL, ³Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ⁴Radiotherapiegroep Arnhem, Arnhem, NL, ⁵RadboudUMC, Nijmegen, NL, ⁶Dept. of Radiotherapy, Groningen, NL, ⁷Leiden University Medical Center, Leiden, NL, ⁸Dept. of Radiotherapy, Utrecht, NL, ⁹Insituut Verbeeten, Tilburg, NL, ¹⁰Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, NL, ¹¹Amsterdam University Medical Centers, VU University, Amsterdam, NL, ¹²Amsterdam UMC, University of Amsterdam, Amsterdam, NL, ¹³Academic Medical Center, University

of Amsterdam, Amsterdam, NL, ¹⁴Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, GB, ¹⁵Integraal Kankercentrum Nederland, Eindhoven, NL, ¹⁶Catharina Hospital Eindhoven, Eindhoven, NL

- 12:00 - 12:00 **762P - Prognostic value of metabolic response assessed by 18FDG-PET after induction chemotherapy and after chemoradiotherapy (CRT) in localized esophageal squamous cell carcinoma (ESCC) patients (pts) receiving definite CRT (dCRT)**
Y. Bang¹, H. Jeong², H.-S. Im¹, S.R. Park¹, ¹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ²Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR
- 12:00 - 12:00 **763P - Comprehensive genomic profiling of early-stage esophageal squamous cell carcinoma**
J. Zuo¹, Z. Fan¹, Y. Jia¹, Y. Wang¹, L. Wang¹, A. Lizaso², B. Li², ¹Fourth Hospital of Hebei Medical University, Shijiazhuang, CN, ²Burning Rock Biotech, Guangzhou, CN
- 12:00 - 12:00 **764P - A novel nomogram and risk classification system predicting radiation pneumonitis in patients with esophageal cancer receiving radiotherapy**
L. Wang, X. Meng, J. Yu, Shandong cancer hospital, Jinan, CN
- 12:00 - 12:00 **765P - Drinking alcohol, smoking, multiple dysplastic lesions and the risk of field cancerization of squamous cell carcinoma in the esophagus and head and neck region**
C. Katada¹, T. Yokoyama², T. Yano³, I. Oda⁴, Y. Shimizu⁵, H. Doyama⁶, T. Koike⁷, K. Takizawa⁸, M. Hirao⁹, H. Okada¹⁰, H. Ishikawa¹¹, A. Yokoyama¹², M. Muto¹³, ¹Kitasato University School of Medicine, Sagami-hara, JP, ²National Institute of Public Health, Wako, JP, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴National Cancer Center Hospital, Tokyo, JP, ⁵Hokkaido University Graduate School of Medicine, Sapporo, JP, ⁶Ishikawa Prefectural Central Hospital, Ishikawa, JP, ⁷Tohoku University Graduate School of Medicine, Sendai, JP, ⁸Shizuoka Cancer Center, Shizuoka, JP, ⁹National Hospital Organization Osaka National Hospital, Osaka, JP, ¹⁰Okayama University Graduate School of Medicine, Okayama, JP, ¹¹Kyoto Prefectural University of Medicine, Kyoto, JP, ¹²National Hospital Organization Kurihama Medical and Addiction Center, Yokosuka, JP, ¹³Kyoto University Graduate School of Medicine, Kyoto, JP
- 12:00 - 12:00 **766P - Neoadjuvant chemotherapy can eliminate the negative impact of postoperative infectious complications on recurrence in patients with esophageal cancer**
K. Kano¹, T. Ogata¹, K. Komori¹, H. Watanabe¹, Y. Shimoda¹, Y. Kumazu¹, H. Fujikawa¹, T. Yamada¹, T. Oshima², ¹Kanagawa Cancer Center, Yokohama, JP, ²Yokohama City University School of Medicine, Yokohama, JP
- 12:00 - 12:00 **767P - Comparison of chemoradiotherapy (CRT) followed by consolidation with cisplatin and 5-fluorouracil (CF) versus definitive CRT with carboplatin and paclitaxel (CP) in esophageal cancer**
M. Cesca¹, N. Pandolfi¹, M. Barros², V.H. De Jesus¹, V. Silva¹, M. Camandaroba¹, T. Felismino¹, N. Rodrigues¹, R. Riechelmann³, ¹A. C. Camargo Cancer Center, Sao Paulo,

BR, ²AC Camargo Cancer Center, Sao Paulo, BR, ³Hospital Sírio-Libanês, Sao Paulo, BR

- 12:00 - 12:00 **768P - Paclitaxel in Combination with Cisplatin and 5-fluorouracil(TPF) Induction Chemotherapy for Locally Advanced Borderline-resectable Esophageal Squamous cell Carcinoma: A Phase II Clinical Trial**
Y. Li¹, Z. Wang², H. Yang³, Q. Li², H. Liu², D.S. Wang², S.Y. Xi², M.Z. Qiu², C. Ren²,
¹Cancer Centre Sun Yat-Sen University, Guangzhou, CN, ²Sun Yat-Sen University Cancer Center, Guangzhou, CN, ³Sun Yat-sen University Cancer Center, Guangzhou, CN
- 12:00 - 12:00 **769P - Prognosis of esophageal squamous cell carcinoma based on local immunity evaluation**
E. Zlatnik¹, O. Kit¹, A. Bazaev¹, I. Novikova¹, A. Demidova², L. Vladimirova¹, ¹Rostov Research Institute of Oncology, Rostov-on-Don, RU, ²Rostov State Medical University, Rostov-on-Don, RU
- 12:00 - 12:00 **770P - Impact of Sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)**
A. Fares¹, K. Taylor², J. Bajwa³, G. Dong³, D. Araujo⁴, K. Hueniken², D. Patel², E. Chen⁵, J. Knox², R. Jang⁴, R. Wong², G. Darling², E. Elimova², W. Xu², D. Rozenberg³, G. Liu², M. Mcinnis³, ¹A. C. Camargo Cancer Center, Sao Paulo, BR, ²Princess Margaret Cancer Centre, Toronto, CA, ³Toronto General Hospital, Toronto, CA, ⁴Princess Margaret Cancer Center, Toronto, CA, ⁵University Health Network, Toronto, CA
- 12:00 - 12:00 **771P - PALAESTRA - A phase II trial with short-course radiotherapy followed by chemotherapy as palliative treatment in esophageal adenocarcinoma**
D. Borg¹, J. Sundberg², E. Brun², E. Kjellén², K. Petersson², M. Hermansson², J. Johansson², J. Eberhard², A. Johnsson², ¹Lund University, Lund, SE, ²Skåne University Hospital, Lund, SE
- 12:00 - 12:00 **772P - Prognostic factors analysis of 343 patients with adenocarcinoma of esophagogastric junction**
Y. Lu, X. Wang, T. Xie, S. Li, Z. Qiu, X. Guo, D. Wu, Chinese PLA General Hospital (301 Military Hospital), Beijing, CN
- 12:00 - 12:00 **773P - Effects of preoperative preparation time on efficacy of neoadjuvant chemotherapy (SOX) in patients with advanced gastric cancer**
X. Wang, T. Xie, X. Guo, S. Li, Y. Lu, Z. Qiu, D. Wu, Chinese PLA General Hospital (301 Military Hospital), Beijing, CN
- 12:00 - 12:00 **774P - The prognostic value of higher absolute lymphocyte counts for patients with surgically resected non-advanced gastric cancer**
S.J. Park¹, I.-H. Kim², J. Lee¹, H. Kim¹, K. Shin¹, ¹Seoul St. Mary's Hospital, of the Catholic University, Seoul, KR, ²Seoul St. Mary's Hospital, Seoul, KR
- 12:00 - 12:00 **775P - Trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy in resectable HER2+ esophageal adenocarcinoma patients: an update on survival and predictive biomarkers in the TRAP study**

C. Stroes¹, A. Creemers², R. Bennink², S. Schokker², R. Verhoeven³, S. Meijer², K. Krisnadath², M. Van Oijen², G.-J. Creemers⁴, M. Van Der Sangen⁵, L. Beerepoot⁶, J. Heisterkamp⁷, M. Los⁸, M. Slingerland⁹, A. Cats¹⁰, G. Hospers¹¹, M. Bijlsma¹², M. Van Berge Henegouwen¹³, M. Hulshof¹³, H. Van Laarhoven¹, ¹Academic Medical Center, University of Amsterdam, Amsterdam, NL, ²Academic Medical Center (AMC), Amsterdam, NL, ³Netherlands Comprehensive Cancer Organization (IKNL), Eindhoven, NL, ⁴Catharina Hospital Eindhoven, Eindhoven, NL, ⁵Catharina Hospital, Eindhoven, NL, ⁶ETZ Elisabeth Hospital, Tilburg, NL, ⁷Elisabeth-TweeSteden Hospital, Tilburg, NL, ⁸Sint Antonius Hospital, Nieuwegein, NL, ⁹Leids Universitair Medisch Centrum (LUMC), Leiden, NL, ¹⁰The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ¹¹University Hospital Groningen (UMCG), Groningen, NL, ¹²Amsterdam UMC, Cancer Center Amsterdam (CCA), University of Amsterdam, Amsterdam, NL, ¹³Amsterdam UMC, University of Amsterdam, Amsterdam, NL

12:00 - 12:00 **776P - Interim analysis of a phase II trial of perioperative chemotherapy plus avelumab in esophagogastric and gastric adenocarcinoma**

T. Alcindor¹, T. Opu¹, C. Mueller¹, V. Marcus¹, P.-O. Fiset¹, S. Camilleri-Broet¹, G. Artho¹, J. Asselah¹, M. Vanhuyse², M. Hickeson¹, A. Awan³, Z. Koulouris¹, L. Ferri¹, ¹McGill University Health Centre - Glen Site, Montreal, CA, ²McGill University Health Centre - Cedar Cancer Centre, Montreal, CA, ³Jewish General Hospital McGill University, Montreal, CA

12:00 - 12:00 **777P - Evaluation of the introduction of primary G-CSF prophylaxis to the FLOT chemotherapy regimen.**

K.-M. Crampton, J. Wood, H. Wong, M. Mckay, A. Madi, The Clatterbridge Cancer Centre, Wirral, GB

12:00 - 12:00 **778P - Subgroup analyses of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer**

T. Hayashi¹, T. Yoshikawa¹, K. Sakamaki², K. Nishikawa³, K. Fujitani⁴, K. Tanabe⁵, Y. Ito⁶, T. Matsui⁷, A. Miki⁸, T. Fukunaga⁹, H. Nemoto¹⁰, Y. Kimura¹¹, N. Hirabayashi¹², ¹National Cancer Center Hospital, Tokyo, JP, ²Tokyo university, Tokyo, JP, ³National Hospital Organization Osaka National Hospital, Osaka, JP, ⁴Osaka General Medical Center, Osaka, JP, ⁵Hiroshima University, Hiroshima, JP, ⁶Aichi Cancer Center Hospital, Nagoya, JP, ⁷Aichi Cancer Center Aichi Hospital, Okazaki, JP, ⁸Kobe City Medical Center General Hospital, Kobe, JP, ⁹St Marianna University School of Medicine, Kawasaki, JP, ¹⁰Showa University Fujigaoka Hospital, Yokohama, JP, ¹¹Sakai City Medical Center, Sakai, JP, ¹²Hiroshima City Asa Citizens Hospital, Asa, JP

12:00 - 12:00 **779P - HER2 Copy Number as Predictor of Disease-Free Survival in HER2-Positive Resectable Gastric Cancer**

Z. Liu¹, M. Shi¹, S. Song¹, J. Gao¹, H. Li², H. Han-Zhang², J. Ye², ¹The Affiliated Hospital of Qingdao University, Qingdao, CN, ²Burning Rock Biotech, Guangzhou, CN

12:00 - 12:00 **780P - Effect of neoadjuvant chemotherapy on the Programmed Death-1 pathway in esophageal and gastric cancer**

M. Svensson¹, A. Lindén², J. Nygaard², C. Hedner², B. Nodin², D. Borg², K. Leandersson², K. Jirstrom², ¹Skane University Hospital-Lund, Lund, SE, ²Lund University, Lund, SE

12:00 - 12:00

781P - A user-friendly nomogram to predict relapse-free survival (RFS) in western patients with resected gastric cancer (GC)

M. Salati¹, S. Pipitone¹, M. Rimini¹, F. Gelsomino¹, A. Casadei-Gardini¹, K. Andrikou², F. Schipilliti¹, G. Cortesi¹, L. Cassanelli¹, E. Caffari¹, F. Serra¹, A. Ricciardolo¹, N. De Ruvo¹, R. Gelmini¹, S. Cascinu¹, A. Spallanzani¹, ¹Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ²AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, IT

12:00 - 12:00

782P - Efficacy and toxicity of weekly carboplatin and paclitaxel as induction or palliative treatment in advanced esophageal cancer patients

F. De Man¹, R. Van Eerden², E. Oomen-De Hoop², J. Veraart², N. Van Doorn², L. Van Doorn², A. Van Der Gaast¹, R. Mathijssen², ¹Erasmus University Medical Center, Rotterdam, NL, ²Erasmus MC Cancer Institute, Rotterdam, NL

12:00 - 12:00

783P - Perioperative chemotherapy with Docetaxel, Oxaliplatin, Fluorouracil and Leucovorin (FLOT) versus Epirubicin, Platinum and Capecitabine or Fluorouracil (EOX/ECF) in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma- Safety and response data from India.

T. Chawla¹, R. Thambudorai¹, A. Ashok², B. Roy¹, J. Ghosh¹, S. Ganguly¹, P. Roy¹, M. Mallath¹, ¹Tata Medical Center, Kolkata, IN, ²Tata Memorial Hospital, Mumbai, IN

12:00 - 12:00

784P - Phase II Study of Preoperative Radiotherapy Combined with S-1 plus Cisplatin in Clinically Resectable Type 4 or Large Type 3 Gastric Cancer: OGS1205

S. Endo¹, M. Imano², H. Furukawa², M. Yokokawa², Y. Nishimura³, M. Shinkai², T. Yasuda², T. Nakagawa⁴, S. Adachi⁴, S.W. Lee⁵, M. Goto⁵, T. Kii⁶, K. Uchiyama⁵, H. Kawakami⁷, T. Shimokawa⁸, D. Sakai⁹, Y. Kurokawa⁹, T. Satoh⁹, ¹Yao Municipal Hospital, Yao, JP, ²Kindai University Faculty of Medicine, Osaka-sayama, JP, ³Kindai University School of Medicine, Osaka, JP, ⁴Higashiosaka City Medical Center, Higashiosaka, JP, ⁵Osaka Medical College, Takatsuki, JP, ⁶Osaka Medical College Hospital, Osaka, JP, ⁷Kindai University Faculty of Medicine, Osaka, JP, ⁸Wakayama Medical University, Wakayama, JP, ⁹Graduate School of Medicine / Faculty of Medicine, Osaka University, Osaka, JP

12:00 - 12:00

785P - Observational Study of the Peritoneal Washing Cytology Positive Gastric Cancer without Gross Peritoneal Metastasis Underwent Radical D2 Gastrectomy.

J.E. Hwang¹, H. Kim², H.-J. Shim², W.K. Bae³, S.-H. Cho², I.-J. Chung², ¹Chonnam National University Medical School & Chonnam National University Hwasun Hospital, Hwasun, KR, ²Chonnam National University Hwasun Hospital, Jeonnam, KR, ³Chonnam National University Hwasun Hospital, Hwasun, KR

12:00 - 12:00

786P - Primary results of multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII)

A. Miki¹, H. Satake², T. Watanabe³, N. Tanaka⁴, K. Hirata⁵, K. Shimozaaki⁵, H. Tanioka⁶, M. Matsuura⁷, T. Kyogoku⁷, M. Tatsumi⁸, K. Matoba⁹, Y. Oka¹⁰, S. Adachi¹¹, H. Yasui¹, M. Kotaka¹², T. Kato¹³, A. Tsuji¹⁴, ¹Kobe City Medical Center General Hospital, Kobe, JP, ²Kansai Medical University, Hirakata, JP, ³Red Cross Society Himeji Hospital, Himeji, JP, ⁴Kagawa Prefectural Central Hospital, Takamatsu, JP, ⁵Keio University School of Medicine, Tokyo, JP, ⁶Kawasaki Medical School Hospital, Kurashiki, JP, ⁷Kobe City Nishi-Kobe Medical Center, Kobe, JP, ⁸Hoshigaoka Koseinenkin Hospital, Hirakata, JP, ⁹Kobe Rosai Hospital, Kobe, JP, ¹⁰Nishinomiya municipal central hospital, Nishinomiya, JP, ¹¹Higashiosaka City Medical Center, Higashiosaka, JP, ¹²Sano Hospital-Gastrointestinal Cancer Centre, Kobe, JP, ¹³Osaka National Hospital, Osaka, JP, ¹⁴Kagawa University Faculty of Medicine/Graduate School of Medicine, Miki, JP

12:00 - 12:00 **787P - Multicenter Phase I/II Feasibility Study of Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction (GMBH-STO-0114)**

K. Heinrich¹, V. Heinemann², L. Müller³, P. Büchner-Steudel⁴, T. Ettrich⁵, S. Stintzing⁶, C. Schulz², ¹University Hospital Munich, LMU, Munich, DE, ²Ludwig Maximilians University - Grosshadern, Munich, DE, ³Studienzentrum Unter Ems, Leer, DE, ⁴Martin-Luther-University Halle-Wittenberg, Halle, DE, ⁵Ulm Medical University, Ulm, DE, ⁶Charité - Universitätsmedizin Berlin, Berlin, DE

12:00 - 12:00 **788P - A phase I study of Docetaxel/Oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction**

K. Hosoda¹, M. Azuma¹, C. Katada¹, K. Ishido², M. Niihara¹, H. Ushiku¹, M. Sakuraya¹, M. Washio¹, T. Wada¹, A. Watanabe¹, H. Harada¹, S. Tanabe¹, W. Koizumi³, K. Yamashita¹, N. Hiki¹, M. Watanabe¹, ¹Kitasato University School of Medicine, Sagamihara, JP, ²Kitasato University East Hospital, Sagamihara, JP, ³Kitasato University School of Medicine, Kanagawa, JP

12:00 - 12:00 **789P - Apatinib combined with docetaxel in second-line treatment of advanced gastric cancer: a prospective clinical study (Data updated)**

M. Yang¹, J. Gao¹, X. Liu¹, Z. Xu¹, H. Lu¹, W. Yang¹, H. Li², Y. Li³, ¹Shanxi Cancer Hospital, Taiyuan, CN, ²Linfen People's Hospital, Linfen, CN, ³Linfen Central Hospital, Linfen, CN

12:00 - 12:00 **790P - A multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604)**

D. Takahari¹, A. Kawazoe², Y. Nakamura³, H. Tamura⁴, M. Fukutani⁴, N. Hirano⁴, M. Wakabayashi⁴, S. Nomura⁵, A. Sato⁴, K. Shitara⁶, ¹Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JP, ²National Cancer Center Hospital, Tokyo, JP, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴National Cancer Center Hospital East, Chiba, JP, ⁵National Cancer Center, Kashiwa, JP, ⁶National Cancer Center Hospital, Kashiwa, JP

12:00 - 12:00 **791P - Impact of Pembrolizumab (pembro) Versus Paclitaxel on Health-Related Quality of Life (HRQoL) in Patients With Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer That Has Progressed After First-Line Chemotherapy (KEYNOTE-061)**

E. Van Cutsem¹, M. Amonkar², C. Fuchs³, M. Alsina⁴, M. Özgüroğlu⁵, Y.-J. Bang⁶, H.C. Chung⁷, K. Muro⁸, E. Goekkurt⁹, A. Benson¹⁰, W. Sun¹¹, Z. Wainberg¹², J. Norquist², X. Chen², C.-S. Shih², K. Shitara¹³, ¹University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, BE, ²Merck & Co., Inc., Kenilworth, US, ³Yale Cancer Center, New Haven, US, ⁴Vall d'Hebron University Hospital & Institute of Oncology (VHIO), University Autònoma de Barcelona, Barcelona, ES, ⁵Istanbul University- Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, TR, ⁶Seoul National University College of Medicine, Seoul, KR, ⁷Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁸Aichi Cancer Center Hospital, Nagoya, JP, ⁹Hematology Oncology Practice Eppendorf (HOPE), University Cancer Center Hamburg, Hamburg, DE, ¹⁰Northwestern Medical Faculty Foundation, Chicago, US, ¹¹University of Kansas, Westwood, US, ¹²David Geffen School of Medicine at UCLA, Los Angeles, US, ¹³National Cancer Center Hospital, Kashiwa, JP

12:00 - 12:00 **792P - Does Nutritional Status Affect Treatment Tolarability, Response and Survival in Metastatic Gastric Cancer Patients? Results of Prospective Multicenter Study**

S. Karabulut¹, I. Doğan¹, C. Usul Afsar², M. Karabulut³, D. Taştekin¹, ¹Istanbul University, Institute of Oncology, İstanbul, TR, ²Acıbadem Bakırkoy Hospital, Faculty of Medicine, İstanbul, TR, ³Health Sciences University, Bakırkoy Dr Sadi Konuk Education and Research Hospital, İstanbul, TR

12:00 - 12:00 **793P - Ramucirumab use in patients with Advanced Gastric Cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study**

F. Longo Munoz¹, M. Jorge Fernandez², R. Yaya Tur³, S. Diaz⁴, M. Ortega⁴, T. Dilla⁴, A. Molero⁴, J.M. Cervera⁴, ¹Hospital Universitario Ramon y Cajal, Madrid, ES, ²Complejo Universitario Hospitalario De Vigo, Vigo, ES, ³IVO - Fundacion Instituto Valenciano de Oncologia, Valencia, ES, ⁴Eli Lilly Spain, Alcobendas, ES

12:00 - 12:00 **794P - Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor: Exploratory analysis in the patients who were enrolled in JCOG0705/KGCA01 phase III trial (REGATTA) and could continue chemotherapy**

T. Yoshikawa¹, K. Fujitani², H.-K. Yang³, J. Mizusawa¹, M. Terashima⁴, T. Tsujinaka⁵, K. Nakamura¹, H. Katayama¹, S.-H. Jin⁶, S.-H. Kong³, Y. Iwasaki⁷, H.-H. Kim⁸, A. Takagane⁹, S.-H. Lee¹⁰, J.-M. Bae¹¹, S.H. Noh¹², M. Sasako¹³, ¹National Cancer Center Hospital, Tokyo, JP, ²Osaka General Medical Center, Osaka, JP, ³Seoul National University Hospital, Seoul, KR, ⁴Shizuoka Cancer Center, Shizuoka, JP, ⁵Kaizuka City Hospital, Kaizuka, JP, ⁶Korea Cancer Center Hospital, Seoul, KR, ⁷Komagome Tokyo Metropolitan Hospital, Tokyo, JP, ⁸Seoul National University Bundang Hospital, Seongnam, KR, ⁹Hakodate Goryokaku Hospital, Hakodate, JP, ¹⁰Kosin University Gospel Hospital, Pusan, KR, ¹¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ¹²Gangnam Severance Hospital, Seoul, KR, ¹³Yodogawa Christian Hospital, Osaka, JP

12:00 - 12:00 **795P - A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab based therapy**

Q. Li, M. Lu, H. Jiang, Y. Wang, S. Yu, Y. Yu, T. Liu, Zhongshan Hospital, Fudan University, Shanghai, CN

- 12:00 - 12:00 **796P - Randomised phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma (SEED)**
- P. Petersen¹, L. Noergaard Petersen², I. Vogelius², J. Bjerregaard³, L. Baeksgaard¹,
¹Rigshospitalet, Copenhagen, DK, ²Rigshospitalet, University of Copenhagen, Copenhagen, DK, ³Odense University Hospital, Odense C, DK
- 12:00 - 12:00 **797P - Ramucirumab in the treatment of refractory metastatic gastric cancer: results from the RamSelGa trial.**
- A. Tryakin¹, E. Perminova², D. Stroyakovsky³, T. Titova¹, D. Yukalchuk⁴, D. Ponomarenko⁵, N. Beliak⁶, G. Teletaeva⁷, E. Ratner⁸, A. Mochalova⁹, O. Gordeeva¹⁰, A. Meshcheryakov¹¹, A. Zhabina⁷, S. Gamayunov¹², A. Smolin¹³, A. Povyshev¹⁴, M. Andrievskih¹⁵, M. Fedyanin¹¹, I. Tsimafeyeu¹⁶, N. Besova¹⁰, ¹N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ²62 City Oncology Hospital, Moscow, Moscow, RU, ³Moscow City Oncology Hospital No. 62, Moscow, RU, ⁴Regional Oncology dispensary, Irkutck, RU, ⁵Irkutsk Regional Oncology dispensary, Irkutck, RU, ⁶SPb SBIH "City Clinical Oncology Dispensary", Saint-Petersburg, RU, ⁷N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU, ⁸Clinical Oncologic Dispensary of Tatarstan, Breast Center, Kazan, RU, ⁹Clinical Hospital № 2 Medsi, RU, ¹⁰FSBI-N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ¹¹N.N. Blokhin National Medical Research Centre of Oncology, Moscow, RU, ¹²National Medical Research Radiological Center of the Ministry of Health of the Russian Federation. A. TSYB MEDICAL RADIOLOGICAL RESEARCH CENTER, Obninsk, RU, ¹³N.N. Burdenko Main Military Clinical Hospital-Ministry of Defence of Russian Federation, Moscow, RU, ¹⁴State Oncology Center, RU, ¹⁵Chelyabinsk Regional Oncology dispensary, Chelyabinsk, RU, ¹⁶Russian Society of Clinical Oncology, Moscow, RU
- 12:00 - 12:00 **798P - Regorafenib in combination with Paclitaxel for beyond first-line treatment of advanced esophagogastric cancer (REPEAT): a phase Ib trial with expansion cohort**
- M. Khurshed¹, C. Stroes², S. Schokker¹, S. Van Der Woude³, R. Mathôt³, M. Slingerland⁴, J. De Vos-Geelen⁵, M. Van Oijen¹, O. Van Delden³, M. Weterman⁶, C. Punt², M. Bijlsma⁶, H. Van Laarhoven², ¹Academic Medical Center (AMC), Amsterdam, NL, ²Academic Medical Center, University of Amsterdam, Amsterdam, NL, ³Amsterdam UMC, University of Amsterdam, Amsterdam, NL, ⁴Leids Universitair Medisch Centrum (LUMC), Leiden, NL, ⁵Maastricht University Medical Center (MUMC), Maastricht, NL, ⁶Amsterdam UMC, Cancer Center Amsterdam (CCA), University of Amsterdam, Amsterdam, NL
- 12:00 - 12:00 **799P - The relationship between the survival and fixed dosing of S-1 in advanced gastric cancer patients by pooled analysis using individual data from four Japanese randomized phase III trials**
- W. Ichikawa¹, M. Takeuchi², Y. Sunakawa³, K. Shitara⁴, K. Oba⁵, Y. Yamada⁶, W. Koizumi⁷, Y. Sakata⁸, H. Furukawa⁹, M. Takeuchi¹⁰, M. Fujii¹¹, ¹Showa University Fujigaoka Hospital, Yokohama, JP, ²Keio University, Fujisawa, JP, ³St.Marianna University School of Medicine, Sagamihara, JP, ⁴National Cancer Center Hospital, Kashiwa, JP, ⁵The University of Tokyo, Tokyo, JP, ⁶Hamamatsu University School of Medicine, Hamamatsu, JP, ⁷Kitasato University School of Medicine, Kanagawa, JP, ⁸Misawa City Hospital, Misawa, JP, ⁹Kindai University Faculty of Medicine, Osaka-sayama, JP, ¹⁰Kitasato University, Tokyo, JP, ¹¹Nihon University School of Dentistry Medecine, Tokyo, JP

- 12:00 - 12:00 **800P - A Phase 1b Study of Oraxol in Combination with Ramucirumab in Patients with Gastric or Esophageal Cancers who failed previous chemotherapy**
M.H. Chen¹, Y. Chao¹, L. Tenner², N. Hung³, D. Cutler⁴, D. Kramer⁴, M.-F. Kwan⁴, C.-T. Hung⁵, ¹Taipei Veterans General Hospital, Taipei City, TW, ²University of Texas Health Science Center at San Antonio, San Antonio, US, ³University of Otago, Dunedin, NZ, ⁴Athenex Inc, Buffalo, US, ⁵Zenith Technology Corporation Limited, Dunedin, NZ
- 12:00 - 12:00 **801P - Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): an analysis of the TAGS study**
M. Alsina¹, J. Tabernero², H.-T. Arkenau³, M. Squadroni⁴, T. Doi⁵, C. Faustino⁶, M. Ghidini⁷, W. Mansoor⁸, K. Shitara⁹, E. Van Cutsem¹⁰, N. Causse-Amellal¹¹, C. Leger¹², D. Skanji¹², D. Ilson¹³, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ³Sarah Cannon Research Institute UK, London, GB, ⁴Humanitas Gavazzeni, Bergamo, IT, ⁵National Cancer Center Hospital East, Chiba, JP, ⁶Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), Porto, PT, ⁷Istituti Ospitalieri di Cremona, Cremona, IT, ⁸The Christie NHS Foundation Trust, Manchester, GB, ⁹National Cancer Center Hospital, Kashiwa, JP, ¹⁰University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, BE, ¹¹Servier, Suresnes, FR, ¹²Institut de Recherches Internationales Servier, Suresnes, FR, ¹³Memorial Sloan Kettering, New York City, US
- 12:00 - 12:00 **802P - Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer**
T. Titova¹, N. Besova², E. Artamonova², E. Perminova³, ¹N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ²FSBI-N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ³62 City Oncology Hospital, Moscow, Moscow, RU
- 12:00 - 12:00 **803P - Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer**
N. Li, PUMCH-Peking Union Medical College Hospital (West), Beijing, CN
- 12:00 - 12:00 **804P - Apatinib in combination with docetaxol and S1 chemotherapy in the first line treatment of metastatic gastric cancer**
L. Xia¹, F. Zhou¹, J. Dai¹, H. Jiang¹, L. Yang¹, W. Wang¹, J. Peng¹, J. Gong², ¹Zhongnan Hospital Wuhan University, Wuhan, CN, ²Huangshi Central Hospital, Huangshi, CN
- 12:00 - 12:00 **805P - Parameters of local cellular immunity in metastatic gastric cancer**
A. Sagakyants, O. Kit, N. Samoylenko, I. Novikova, E. Zlatnik, E. Frantsiyants, E. Bondarenko, L. Vladimirova, Rostov Research Institute of Oncology, Rostov-on-Don, RU
- 12:00 - 12:00 **806P - Germline pathogenic mutations in Chinese patients with gastric cancer identified by next-generation sequencing (NGS)**
X. Zhang¹, J. Zhou², Z. Zhao³, Y. Zhang⁴, S. Cai⁵, ¹Beijing Cancer Hospital, Beijing, CN, ²Peking University People's Hospital, Beijing, CN, ³3D Medicines Inc, Shanghai, CN, ⁴Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ⁵3D Medicines Inc.

Shanghai, P.R. China, Shanghai, CN

- 12:00 - 12:00 **807P - Inhibition of the PI3K pathway in HER2-positive gastric cancer**
S. Toomey¹, M. Mezynski², A. Farrelly¹, P. Armstrong¹, J. Mcauley¹, C. Holohan³, Y. Elamin⁴, S. Rafee⁵, J. Workman¹, M. Cremona¹, L. Grogan⁶, O. Breathnach⁶, P. Morris⁶, J. Fay², E. Kay², B. Hennessy⁷, ¹RCSI Molecular Medicine Laboratories, Dublin, IE, ²Royal College of Surgeons in Ireland, Dublin, IE, ³St James's Hospital, Dublin, IE, ⁴UT MD Anderson Cancer Center, Houston, US, ⁵University Hospital Limerick, Limerick, IE, ⁶BEAUMONT HOSPITAL CANCER CENTRE, DUBLIN, IE, ⁷Beaumont Hospital Cancer Centre, Dublin, IE
- 12:00 - 12:00 **808P - Investigation on gastric cancer susceptibility genes in Chinese early-onset diffuse gastric cancer**
Y. Feng¹, M. Zhang¹, X. Xing¹, W. Chen¹, W. Li¹, S. Jia¹, L. Su², Y. Yang³, ¹Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, ²Genetron Health (Beijing) Co. Ltd., Beijing, China, Beijing, CN, ³Genetron Health gene technology co. LTD, Beijing, CN
- 12:00 - 12:00 **809P - A correlation analysis between survival rate and the characteristic gene of gastric cancer based on bioinformatics analysis**
Y.-W. Zhang, Y.-J. Liu, Zhejiang cancer hospital, Hangzhou, CN
- 12:00 - 12:00 **810P - Phase I study of apatinib combined with POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC)**
R. Lin¹, S. Zhao², N. Fan², H. Li², J. Liu², J. Yu², M. Zhao², ¹Fujian Cancer Hospital, Fuzhou, CN, ²Fujian Cancer Hospital & Fujian University Cancer Hospital, Fuzhou, CN
- 12:00 - 12:00 **811P - Second-line palliative systemic treatment for synchronous metastatic esophagogastric cancer: a population-based study**
W. Dijksterhuis¹, R. Verhoeven², M. Slingerland³, N. Haj Mohammad⁴, J. De Vos-Geelen⁵, L. Beerepoot⁶, T. Van Voorthuizen⁷, G.-J. Creemers⁸, M. Van Oijen⁴, H. Van Laarhoven⁹, ¹Amsterdam University Medical Centers, Amsterdam, NL, ²Netherlands Comprehensive Cancer Organization (IKNL), Eindhoven, NL, ³Leids Universitair Medisch Centrum (LUMC), Leiden, NL, ⁴Academic Medical Center (AMC), Amsterdam, NL, ⁵Maastricht University Medical Center (MUMC), Maastricht, NL, ⁶ETZ Elisabeth Hospital, Tilburg, NL, ⁷Mr. Theo Van Voorthuizen, Arnhem, NL, ⁸Catharina Hospital Eindhoven, Eindhoven, NL, ⁹Academic Medical Center, University of Amsterdam, Amsterdam, NL
- 12:00 - 12:00 **812P - STING Agonist, ADU-S100, Yields Potent Antitumor Activity and Therapeutically Favorable Immune Profile in an Esophageal Adenocarcinoma Model**
A. Zaidi¹, A. Omstead¹, N. Chowdhury¹, J. Kosovec¹, P. Zheng¹, M. Salvitti¹, A. Gorbunova¹, L. Babar¹, R. Kelly², B. Jobe¹, ¹Allegheny Health Network, Pittsburgh, US, ²Charles A. Sammons Cancer Center, Baylor Scott & White Health System, Dallas, US
- 12:00 - 12:00 **813P - Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study**

W. Dijksterhuis¹, R. Verhoeven², N. Van Grieken³, S. Meijer⁴, M. Slingerland⁵, N. Haj Mohammad⁴, J. De Vos-Geelen⁶, L. Beerepoot⁷, T. Van Voorthuizen⁸, G.-J. Creemers⁹, M. Van Oijen⁴, H. Van Laarhoven¹⁰, ¹Amsterdam University Medical Centers, Amsterdam, NL, ²Netherlands Comprehensive Cancer Organization (IKNL), Eindhoven, NL, ³Vrije University Medical Centre (VUMC), Amsterdam, NL, ⁴Academic Medical Center (AMC), Amsterdam, NL, ⁵Leids Universitair Medisch Centrum (LUMC), Leiden, NL, ⁶Maastricht University Medical Center (MUMC), Maastricht, NL, ⁷ETZ Elisabeth Hospital, Tilburg, NL, ⁸Mr. Theo Van Voorthuizen, Arnhem, NL, ⁹Catharina Hospital Eindhoven, Eindhoven, NL, ¹⁰Academic Medical Center, University of Amsterdam, Amsterdam, NL

12:00 - 12:00

814P - Comprehensive molecular characterization of clinical response to ramucirumab treatment in gastric cancer patients

Y. Kim¹, S.Y. Oh², S.H. Park³, J.O. Park³, Y.S. Park⁴, H.Y. Lim⁴, W. Kang¹, K.-M. Kim³, S.T. Kim³, J. Lee³, ¹Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ²Dong-A University College of Medicine, Busan, KR, ³Samsung Medical Center, Seoul, KR, ⁴Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

12:00 - 12:00

815P - A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: a GISCAD trial.

R. Labianca¹, G. Rosati², N. Fazio³, L. Cavanna⁴, D. Ferrari⁵, M. Di Bartolomeo⁶, S. Mosconi⁷, M. Giordano⁸, N. Silvestris⁹, F. Artioli¹⁰, R. Iaffaioli¹¹, E. Veltri¹², D. Amoroso¹³, A. Ciarlo¹⁴, S. Barni¹⁵, S. Cascinu¹⁶, C. Davite¹⁷, A. Di Sanzo¹⁷, A. Casolaro¹⁷, ¹Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT, ²A.O. S.Carlo, Potenza, IT, ³Istituto Europeo di Oncologia, Milan, IT, ⁴Azienda Ospedaliera Piacenza, Piacenza, IT, ⁵A. O. San Paolo, Milano, IT, ⁶Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT, ⁷A.O. Papa Giovanni XXIII, Bergamo, IT, ⁸Presidio Ospedaliero Ospedale Sant'Anna, San Fermo della Battaglia, IT, ⁹Istituto Tumori Giovanni Paolo II, Bari, IT, ¹⁰Ospedale Ramazzini, Carpi, IT, ¹¹Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ¹²Ospedale Santa Maria Goretti, Latina, IT, ¹³Ospedale Versilia USL12, Lido di Camaiore (LU), IT, ¹⁴USL4 Ospedale di Prato, Prato, IT, ¹⁵AO Treviglio-Caravaggio, Treviglio (BG), IT, ¹⁶Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ¹⁷Nerviano Medical Service, Nerviano (MI), IT

12:00 - 12:00

816P - The analysis of T cell subsets and clinical efficacy of immune checkpoint blockades in patients with advanced gastric cancer using multiplex immunohistochemistry

T.-Y. Kim¹, D.-W. Lee¹, D.-Y. Oh², Y. Kwak², H.S. Lee³, W.-H. Kim⁴, Y.-J. Bang², ¹SNUH-Seoul National University Hospital, Seoul, KR, ²Seoul National University Hospital, Seoul, KR, ³Seoul National University Bundang Hospital, Sungnam-si, KR, ⁴Seoul National University, Faculty of Medicine, Seoul, KR

12:00 - 12:00

817P - First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma.

Y. Janjigian¹, S. Maron², J. Chou³, A. Gabler³, M. Simmons³, P. Momtaz³, M. Shcherba³, G. Ku³, E. Won³, F. Sanchez-Vega³, H. Gerdes³, D. Kelsen³, D. Ilson³, D. Solit¹, N. Schultz³, P. Shah³, M. Capanu³, J. Hechtman³, M. Lamendola-Essel³, ¹Memorial Sloan-

Kettering Cancer Center, New York, US, ²The University of Chicago Medical Centre, Chicago, US, ³Memorial Sloan Kettering Cancer Center, New York, US

- 12:00 - 12:00 **818P - Monitoring patient-specific mutation in ctDNA and CTC for tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric cancer (NCT03425058)**
T. Fu, Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN
- 12:00 - 12:00 **819P - Gastric cancer screening in BRCA 2 gene mutation carriers: should it be recommended?**
I. Oliveira¹, S. Fernandes², P. Pereira³, S. Fragoso³, S. Santos⁴, P. Rodrigues³, J. Parreira³, P. Louro³, I. Coelho³, F. Rodrigues³, A. Clara³, A. Luís³, F. Vaz³, ¹Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, PT, ²Centro Hospitalar Universitário de Coimbra, Coimbra, PT, ³Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, PT, ⁴Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPOLFG EPE), Lisbon, PT
- 12:00 - 12:00 **820P - Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)**
Y. Sunakawa¹, Y. Takahashi², E. Inoue³, Y. Sakamoto², R. Kawabata⁴, H. Yabusaki⁵, J. Matsuyama⁶, A. Ishiguro⁷, M. Takahashi⁸, Y. Akamaru⁹, Y. Kito¹⁰, A. Makiyama¹¹, H. Yasui¹², H. Kawakami¹³, T. Nakajima³, K. Muro¹⁴, R. Matoba¹⁵, W. Ichikawa¹⁶, M. Fujii¹⁷, ¹St. Marianna University School of Medicine, Sagamihara, JP, ²Osaki Citizen Hospital, Miyagi, JP, ³St. Marianna University School of Medicine, Kawasaki, JP, ⁴Osaka Rosai Hospital, Sakai, JP, ⁵Niigata Cancer Center Hospital, Niigata, JP, ⁶Higashiosaka City Medical Center, Higashi-Osaka, JP, ⁷Hirosaki University Hospital, Hirosaki, JP, ⁸Yokohama City Citizen's Hospital, Yokohama, JP, ⁹Ikeda Municipal Hospital, Ikeda, JP, ¹⁰Ishikawa Prefectural Central Hospital, Kanazawa, JP, ¹¹National Kyushu Cancer Center, Fukuoka, JP, ¹²Kobe City Medical Center General Hospital, Kobe, JP, ¹³Kindai University Faculty of Medicine, Osaka, JP, ¹⁴Aichi Cancer Center Hospital, Nagoya, JP, ¹⁵DNA Chip Research Inc., Tokyo, JP, ¹⁶Showa University Fujigaoka Hospital, Yokohama, JP, ¹⁷Nihon University School of Dentistry Medicine, Tokyo, JP
- 12:00 - 12:00 **821P - Prediction of S-1 adjuvant chemotherapy efficacy in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis**
M. Terashima¹, K. Nakamura¹, K. Hatakeyama², K. Furukawa¹, K. Fujiya¹, S. Kamiya¹, M. Hikage¹, Y. Tanizawa¹, E. Bando¹, K. Oshima², K. Urakami², N. Machida¹, H. Yasui¹, K. Yamaguchi¹, ¹Shizuoka Cancer Center, Shizuoka, JP, ²Shizuoka Cancer Center Research Institute, Shizuoka, JP
- 12:00 - 12:00 **822P - Assessing the clinical utility of circulating tumour DNA through longitudinal liquid biopsy sampling in Oesophageal adenocarcinoma**
E. Ococks¹, A. Frankell², N. Masque-Soler³, A. Northrop³, G. Devonshire³, C. Hughes³, N. Grehan³, E. Smyth⁴, A. Blasko³, R. Fitzgerald⁵, ¹The Hutchinson/MRC Research Centre - University of Cambridge, Cambridge, GB, ²University College London, London, GB, ³University of Cambridge, Cambridge, GB, ⁴Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB, ⁵University of Cambridge - MRC Cancer Unit, Cambridge, GB

- 12:00 - 12:00 **823P - Molecular subtypes of metastatic(met) gastric cancer(GC) (MoTriGastric): new biomarkers closer to the clinics**
M. Alsina Maqueda¹, F. Ruiz², S. Landolfi³, C. Viaplana¹, J. Miquel⁴, J. Jimenez¹, M. Diez⁵, I. Gullo⁶, O. Mirallas³, J. Taberero⁷, F. Carneiro⁸, P. Nuciforo⁹, A. Vivancos¹, R. Dienstmann¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ³Vall Hebron University Hospital, Barcelona, ES, ⁴Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁵Vall d'Hebron University Hospital. Vall Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁶Centro Hospitalar Universitário São João Faculty of Medicine of the University of Porto Institute of Molecular Pathology and Immunology of the University of Porto Institute for Research and Innovation in Health, Porto, PT, ⁷Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁸IPATIMUP - Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, PT, ⁹Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES
- 12:00 - 12:00 **824P - Exploring candidate signal transduction pathways for targeted therapy in esophageal cancer**
A. Creemers¹, S. Meijer¹, L. Holtzer², M. Stoffels², H. Van Ooijen², A. Van Brussel², E. Aussems-Custers², M. Van Berge Henegouwen³, M. Hulshof³, S. Krishnadath³, A. Van De Stolpe², M. Bijlsma⁴, H. Van Laarhoven⁵, ¹Academic Medical Center (AMC), Amsterdam, NL, ²Philips Research, Eindhoven, NL, ³Amsterdam UMC, University of Amsterdam, Amsterdam, NL, ⁴Amsterdam UMC, Amsterdam, NL, ⁵Academic Medical Center, University of Amsterdam, Amsterdam, NL
- 12:00 - 12:00 **825P - Clinical implication of CLDN18, RhoGAP, and E-cadherin in gastric signet ring cell carcinoma**
H. Kim¹, S. Kim², J.M. Park³, H.H. Lee³, K.Y. Song³, S.-Y. Kim⁴, J.-O. Kim³, S.H. Lee³, I.-H. Kim⁵, ¹Seoul St. Mary's Hospital, of the Catholic University, Seoul, KR, ²St.Mary hospital collage of medicine the catholic university of korea, Seoul, KR, ³St.Mary hospital collage of medicine the catholic university of korea, seoul, KR, ⁴University of Ulsan College of Medicine, Asan Medical Center, Seoul, KR, ⁵Seoul St. Mary's Hospital, Seoul, KR
- 12:00 - 12:00 **826P - Identification of a spectrum of germline mutations for hereditary diffuse gastric cancer in the Russian population by next-generation sequencing.**
I. Efimova¹, E. Ignatova², I. Bykov³, A. Kalinkin³, A. Tanas¹, E. Alekseeva⁴, V. Strelnikov⁴, A. Alakunov³, E. Kuznetsova³, M. Nemtsova³, ¹Federal State Budgetary Institution "Research Centre for Medical Genetics", Moscow, RU, ²FSBI-N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ³IM Sechenov First Moscow State Medical University, Moscow, RU, ⁴Research Centre for Medical Genetics, Moscow, RU
- 12:00 - 12:00 **827P - The molecular profiling and prognostic value of Chinese gastric signet ring cell carcinoma patients**
J. Wei¹, Y. Wang², L. Liu³, C. Qiao⁴, J. Hu⁴, W. Wang⁴, J. Wang⁴, M. Yao⁴, K. Wang⁴, B. Liu⁵, S. Cui⁶, ¹Affiliated Drum Tower Hospital Nanjing University, Nanjing, CN, ²Drum Tower Hospital Affiliated to Nanjing University medical school, nanjing, CN, ³Jiangsu province hospital The first affiliated hospital of Nanjing medical university, Nanjing, CN, ⁴OrigiMed, Shanghai, CN, ⁵Nanjing Drum Tower Hospital, Nanjing, CN, ⁶The Affiliated Hospital of Nanjing Medical University, Nanjing, CN

- 12:00 - 12:00 **828TiP - Simultaneous Resection of Pancreatic Cancer and Liver Oligometastases After Induction Chemotherapy in Stage IV Patients : an Open-Label Prospective Randomized Multicenter phase 3 trial (CSPAC-1)**
M. Wei¹, S. Shi², J. Xu¹, B. Shen³, Y. Mou⁴, R. Qin⁵, W. Fang⁶, R. Chen⁷, W. Wang⁸, C. Shao⁹, X. Yu¹, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Shanghai Cancer Center, Shanghai, CN, ³Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CN, ⁴Zhejiang Provincial People's Hospital, Hangzhou, CN, ⁵Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ⁶The First Hospital of Zhejiang Province, Hangzhou, CN, ⁷Sun Yat-Sen Memorial Hospital Sun Yat-Sen University, Guangzhou, CN, ⁸Huadong Hospital Affiliated to Fudan University, Shanghai, CN, ⁹Shanghai Changzheng Hospital, Shanghai, CN
- 12:00 - 12:00 **829TiP - Multicenter randomized phase II trial of 5-Fluorouracil/leucovorin (5-FU/LV) with or without liposomal irinotecan (nal-IRI) in metastatic biliary tract cancer (BTC) as second-line therapy after progression on gemcitabine plus cisplatin (GemCis): NIFTY trial**
C. Yoo¹, J.H. Jeong¹, K.-P. Kim¹, J. Cheon², I. Kim³, M. Kang³, H. Ryu⁴, B.W. Kang⁵, B.-Y. Ryoo¹, ¹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ²Ulsan University Hospital, Ulsan, KR, ³Inje University College of Medicine, Busan, KR, ⁴Chungnam National University Hospital, Daejeon, KR, ⁵Kyungpook National University, Daegu, KR
- 12:00 - 12:00 **830TiP - A randomized phase II study of Maintenance therapy with multiepitope vaccine Tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced Pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM - PRODIGE 63 GERCOR study)**
C. Neuzillet¹, V. Hautefeuille², A. Lambert³, M.-L. Garcia-Larnicol⁴, D. Vernerey⁵, ¹Hôpital Beaujon, Clichy, FR, ²CHU Amiens-Picardie Site Nord, Amiens, FR, ³Institut de Cancérologie de Lorraine, Vandoeuvre Les Nancy, FR, ⁴GERCOR, Paris, FR, ⁵MSD, FR
- 12:00 - 12:00 **831TiP - A phase 3, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1**
D.-Y. Oh¹, L.-T. Chen², A. He³, T. Okusaka⁴, S. Qin⁵, S. Chin⁶, N. Rokutanda⁶, H. Uchinda⁷, A. Vogel⁸, J. Valle⁹, H. Kim⁷, ¹Seoul National University Hospital, Seoul, KR, ²National Institute of Cancer Research, Tainan, TW, ³Georgetown University Medical Center, Washington, US, ⁴National Cancer Center Hospital, Tokyo, JP, ⁵Cancer Center of People's Liberation Army, Nanjing, CN, ⁶AstraZeneca, Gaithersburg, US, ⁷R & D, AstraZeneca KK, Japan, Osaka, JP, ⁸Hannover Medical School, Hannover, DE, ⁹The Christie NHS Foundation Trust, Manchester, GB
- 12:00 - 12:00 **832TiP - Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial**
G. Abou-Alfa¹, I. Borbath², S. Clarke³, E. Hitre⁴, C. Louvet⁵, T. Macarulla⁶, D.-Y. Oh⁷, J. Spratlin⁸, J. Valle⁹, K.H. Weiss¹⁰, C. Berman¹¹, M. Howland¹¹, Y. Ye¹¹, T. Cho¹¹, S. Moran¹¹, M. Javle¹², ¹Memorial Sloan Kettering Cancer Center, New York, US,

²Cliniques universitaires St Luc Bruxelles, Bruxelles, BE, ³University of Sydney, Sydney, AU, ⁴National Institute of Oncology, Budapest, HU, ⁵Institut Mutualiste Montsouris, Paris, FR, ⁶Hospital Vall D'Hebron, Barcelona, ES, ⁷Seoul National University Hospital, Seoul, KR, ⁸Alberta Health Services, Edmonton, CA, ⁹University of Manchester / The Christie, Manchester, GB, ¹⁰University Hospital Heidelberg, Heidelberg, DE, ¹¹QED Therapeutics Inc, San Francisco, US, ¹²MD Anderson Cancer Center, Houston, US

12:00 - 12:00

833TiP - Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

L. Rimassa¹, A.-L. Cheng², F. Braiteh³, A. Chaudhry⁴, F. Benzaghrou⁵, P. Thuluvath⁶, S. Hazra⁷, A. Borgman-Hagey⁷, B. Tan⁸, Z. Kayali⁹, A. Zhu¹⁰, R.K. Kelley¹¹, ¹Istituto Clinico Humanitas, Rozzano, IT, ²National Taiwan University Hospital, New Taipei city, TW, ³Comprehensive Cancer Centers of Nevada, Las Vegas, US, ⁴Summit Cancer Centers, Spokane, US, ⁵Ipsen Innovation, Les Ulis, FR, ⁶Mercy Medical Center, Baltimore, US, ⁷Exelixis, Alameda, US, ⁸Siteman Cancer Center, St. Louis, US, ⁹Riverside Community Hospital, Rialto, US, ¹⁰Massachusetts General Hospital, Harvard Medical School, Boston, US, ¹¹University of California San Francisco, San Francisco, US

12:00 - 12:00

834TiP - A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment (NCT03126435)

L.-T. Chen¹, E. Hitre², W.-J. Lee³, L.-Y. Bai⁴, Z. Papi⁵, S.Y. Kang⁶, M. Dvorkin⁷, H.J. Choi⁸, S.C. Oh⁹, P. Artru¹⁰, J.-B. Bachet¹¹, ¹National Institute of Cancer Research, Tainan, TW, ²National Institute of Oncology, Budapest, HU, ³National Cancer Center Gyeonggi-do, Gyeonggi-do, KR, ⁴China Medical University Hospital, Taichung, TW, ⁵Hungarian Defence Forces Military Hospital, Budapest, HU, ⁶Ajou University School of Medicine, Suwon, KR, ⁷BHI of Omsk Region Clinical Oncology Dispensary, Omsk, RU, ⁸Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁹Korea University Guro Hospital, Seoul, KR, ¹⁰Hôpital privé Jean Mermoz, Lyon, FR, ¹¹Groupe Hospitalier Pitié Salpêtrière, Paris, FR

12:00 - 12:00

835TiP - Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction - Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.

S. Lorenzen¹, C. Pauligk², T. Goetze³, J. Riera Knorrenschild⁴, E. Goekkurt⁵, F. Kullmann⁶, D. Pink⁷, T. Ettrich⁸, N. Homann⁹, S. Angermeier¹⁰, P. Thuss-Patience¹¹, U. Lindig¹², M. Bitzer¹³, T. Dechow¹⁴, G. Schuch¹⁵, H. Schmalenberg¹⁶, S. Junge², R.D. Hofheinz¹⁷, S.-E. Al-Batran¹⁸, ¹Klinikum rechts der Isar, Technische Universität München, München, DE, ²IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Frankfurt am Main, DE, ³Institut für Klinisch-Onkologische Forschung and IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Frankfurt am Main, DE, ⁴Uniklinikum Giessen und Marburg, Marburg, DE, ⁵Facharztzentrum Eppendorf, Hamburg, DE, ⁶Klinikum Weiden, Weiden in der Oberpfalz, DE, ⁷HELIOS Klinikum Bad Saarow, Bad Saarow, DE, ⁸Ulm Medical University, Ulm, DE, ⁹Klinikum Wolfsburg, Wolfsburg, DE, ¹⁰Klinikum Ludwigsburg, Ludwigsburg, DE, ¹¹Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ¹²University Hospital Jena, Friedrich-Schiller-

University, Jena, DE, ¹³Universitätsklinikum Tübingen Medizinische Universitätsklinik, Tübingen, DE, ¹⁴Onkologie Ravensburg, Ravensburg, DE, ¹⁵Hämatologisch-Onkologische Praxis Altona (HOPA), Hamburg, DE, ¹⁶Städtisches Klinikum Dresden, Dresden, DE, ¹⁷Universitätsklinikum Mannheim, Mannheim, DE, ¹⁸Krankenhaus Nordwest-University Cancer Center, Frankfurt, DE

12:00 - 12:00 **836TiP - GLOW: Randomized Phase 3 Study of Zolbetuximab + CAPOX Compared With Placebo + CAPOX as First-line Treatment of Patients With CLD18.2+/HER2- Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma**

M. Shah¹, J. Ajani², S.-E. Al-Batran³, Y.-J. Bang⁴, D. Catenacci⁵, P. Enzinger⁶, D. Ilson⁷, S. Kim⁸, F. Lordick⁹, K. Shitara¹⁰, E. Van Cutsem¹¹, A. Arozullah¹², J.W. Park¹², R.-H. Xu¹³, ¹Weill Cornell Medical College, New York City, US, ²MD Anderson Cancer Center, Houston, US, ³Krankenhaus Nordwest-University Cancer Center, Frankfurt, DE, ⁴Seoul National University Hospital, Seoul, KR, ⁵University of Chicago, Chicago, US, ⁶Dana-Farber Cancer Institute, Cambridge, US, ⁷Memorial Sloan Kettering, New York City, US, ⁸Memorial Sloan Kettering Cancer Center, Washington, US, ⁹University Cancer Center Leipzig, Leipzig, DE, ¹⁰National Cancer Center Hospital, Kashiwa, JP, ¹¹University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, BE, ¹²Astellas Pharma Global Development, Inc., Northbrook, US, ¹³SunYat-sen University Cancer Center, Guangzhou, CN

12:00 - 12:00 **837TiP - PRODIGE67_UCGI33 ARION: Association of Radiochemotherapy and Immunotherapy for the treatment of unresectable Oesophageal caNcer: a comparative randomized phase II trial**

R. Guimbaud¹, L. Quero², V. Vendrely³, D. Tougeron⁴, K. Benerezy⁵, E. Samalin⁶, T. Aparicio², L. Zitvogel⁷, J. Selves⁸, P. Otal⁹, E. Cohen-Jonathan Moyal¹, J.-P. Delord¹⁰, V. Pezzella¹¹, T. Filleron¹, A. Modesto¹², ¹Centre Claudius-Regaud, Toulouse, FR, ²Hôpital Saint Louis AP-HP, Paris, FR, ³CHU Bordeaux, Pessac, FR, ⁴CHU Poitiers, Jean Bernard Hôpital, Poitiers, FR, ⁵Centre Lacassagne, Nice, FR, ⁶ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ⁷Gustave Roussy Institut de Cancérologie, Villejuif, FR, ⁸Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse, Toulouse, FR, ⁹CHU Toulouse, Toulouse, FR, ¹⁰Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ¹¹Unicancer, Paris, FR, ¹²IUCT ONCOPOLE, FR

12:00 - 12:00 **838TiP - Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT**

K. Hirata¹, Y. Hamamoto¹, K. Tsuchihashi², C. Kondoh³, K. Yamazaki⁴, S. Hironaka⁵, M. Ando⁶, C. Imamura¹, K. Yoshimura⁷, K. Muro⁸, ¹Keio University School of Medicine, Tokyo, JP, ²Kyushu University Graduate School of Medical Sciences, Fukuoka, JP, ³Toranomon Hospital, Tokyo, JP, ⁴Sizuoka Cancer Center, Sundogun, JP, ⁵Oita University, Oita, JP, ⁶Nagoya University Hospital, Nagoya, JP, ⁷Kanazawa University, Kanazawa, JP, ⁸Aichi Cancer Center Hospital, Nagoya, JP

12:00 - 12:00 **839TiP - FRONTiER: A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma**

S. Yamamoto¹, K. Kato², H. Daiko², T. Kojima³, H. Hara⁴, T. Abe⁵, Y. Tsubosa⁶, K.

Nagashima⁷, Y. Kitagawa⁸, ¹National Cancer Center Hospital, Tokyo, Japan, Tokyo, JP, ²National Cancer Center Hospital, Tokyo, JP, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴Saitama Cancer Center, Saitama, JP, ⁵Aichi Cancer Center Hospital, Nagoya, JP, ⁶Shizuoka Cancer Center, shizuoka, JP, ⁷The Institute of Statistical Mathematics, Tachikawa, JP, ⁸Keio University School of Medicine, Tokyo, JP

12:00 - 12:00 **840TiP - A phase Ib/II study of AK104, a PD-1/CTLA-4 Bispecific Antibody, Combined With mXELOX as First-line Therapy for Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma**

J. Ji¹, L. Shen², Z. Li², X. Gao², J. Gong³, D. Liu², X. Wu², S. Xu⁴, X. Jin⁴, B. Li⁴, M. Wang⁴, Y. Xia⁴, ¹Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, ²Peking University Cancer Hospital & Institute, Beijing, CN, ³Peking University Cancer Hospital, Beijing, CN, ⁴Akeso Biopharma, Inc., Zhongshan, CN

12:00 - 12:00 **841TiP - Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.**

S.-E. Al-Batran¹, C. Pauligk², R.D. Hofheinz³, S. Lorenzen⁴, A. Wicki⁵, A. Siebenhuener⁶, M. Schenk⁷, P. Thuss-Patience⁸, A. Kretzschmar⁹, C. Bolling¹⁰, E. Eigendorff¹¹, S. Angermeier¹², D. Pink¹³, M. Geissler¹⁴, E. Goekkurt¹⁵, H. Schmalenberg¹⁶, L. Waberer², J. Talbot¹⁷, T. Goetze¹⁸, N. Homann¹⁹, ¹Krankenhaus Nordwest-University Cancer Center, Frankfurt, DE, ²IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Frankfurt am Main, DE, ³Universitätsklinikum Mannheim, Mannheim, DE, ⁴Klinikum rechts der Isar, Technische Universität München, München, DE, ⁵Universitätsspital Basel, Basel, CH, ⁶Universitätsspital Zürich, Zürich, DE, ⁷Krankenhaus Barmherzige Brüder Regensburg, Regensburg, DE, ⁸Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ⁹Klinikum St. Georg gGmbH, Leipzig, DE, ¹⁰Kliniken Markus-Krankenhaus, Agaplesion, Frankfurt am Main, DE, ¹¹University Hospital Jena, Friedrich-Schiller-University, Jena, DE, ¹²Klinikum Ludwigsburg, Ludwigsburg, DE, ¹³HELIOS Klinikum Bad Saarow, Bad Saarow, DE, ¹⁴Klinikum Esslingen, Esslingen am Neckar, DE, ¹⁵Facharztzentrum Eppendorf, Hamburg, DE, ¹⁶Städtisches Klinikum Dresden, Dresden, DE, ¹⁷F. Hoffmann-La Roche AG, Basel, CH, ¹⁸Institut für Klinisch-Onkologische Forschung and IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Frankfurt am Main, DE, ¹⁹Klinikum Wolfsburg, Wolfsburg, DE

12:00 - 12:00 **842TiP - Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study.**

V. Randrian¹, A. Adenis², J. Desrame³, E. Barbier⁴, F. Di Fiore⁵, A. Lievre⁶, L. Dahan⁷, P. Laurent-Puig⁸, L. Mineur⁹, G. Breysacher¹⁰, G. Roquin¹¹, S. Louafi¹², A. Lopez¹³, C. Louvet¹⁴, C. Borg¹⁵, J.-P. Metges¹⁶, R. Faroux¹⁷, L. Gaba¹⁸, S. Manfredi¹⁹, D. Tougeron²⁰, ¹CHU Estaing, Clermont-Ferrand, FR, ²Institut de Cancérologie de Montpellier, Montpellier, FR, ³Hôpital privé Jean Mermoz, Lyon, FR, ⁴FFCD-, Dijon, FR, ⁵Hop. Charles Nicolle, Rouen, FR, ⁶CHU de Pontchaillou, Rennes, FR, ⁷AP-HM - CHU La Timone Enfants, Marseille, FR, ⁸Paris Descartes University, Paris, FR, ⁹Institut Ste Catherine, Avignon, FR, ¹⁰Hôpitaux Civils de Colmar, Colmar, FR, ¹¹CHU Angers, Angers, FR, ¹²Centre Hospitalier de Longjumeau, Longjumeau, FR, ¹³CHU Brabois, Vandoeuvre les Nancy, FR, ¹⁴Institute Mutualiste Montsouris, Paris, FR, ¹⁵CHU Besançon, Hôpital Jean

Minjoz, Besançon, FR, ¹⁶CHU Morvan - Institut de Cancerologie et d'Hematologie, Brest, FR, ¹⁷CHD Vendee - Hopital Les Oudairies, La Roche sur Yon, FR, ¹⁸UFR des Sciences de Santé, Dijon, FR, ¹⁹CHU de Dijon, Dijon, FR, ²⁰CHU Poitiers, Jean Bernard Hôpital, Poitiers, FR

12:00 - 12:00 **Endocrine tumours**

12:00 - 12:00 **513P - The expression of Versican and its role in pancreatic neuroendocrine tumor**

Z. Sun¹, H. Gao¹, Y. Cheng², C. Bai³, Y. Chen², ¹Peking Union Medical College Hospital, Beijing, CN, ²Department of Medical Oncology, Beijing, CN, ³Beijing Union Medical College Hospital (Xiehe Hospital), Beijing, CN

12:00 - 12:00 **514P - Characteristics of patients with thyroid carcinoma in the united states**

D. El-Habashy, Menoufia University, Menoufia, EG

12:00 - 12:00 **515P - The discrimination of pituitary adenomas and craniopharyngioma on MRI: from image features to texture features**

H. Xu¹, X. Ma², ¹West China Hospital, Chengdu, CN, ²West China Hospital, Sichuan University, Chengdu, CN

12:00 - 12:00 **516P - Proportion of Peripheral Lymphocyte Subsets Correlates with the Progression-free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumor Patients**

Y. Gong, Fudan University Shanghai Cancer Center, Shanghai, CN

12:00 - 12:00 **517P - Immunohistochemical expression of ER- α and PR in papillary thyroid carcinoma**

E. Elkhoully, E. Abdelraziq, T. Rageh, M. Serag, A. Abdou, Faculty of Medicine - Menoufia University, Shebin El Kom, EG

12:00 - 12:00 **518P - SILVELUL Project: Immunohistochemical panel analyses as potential predictive and prognostic factors in Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus**

A. De Jesus-Acosta¹, G. Crespo Herrero², M.L. Gómez-Dorronsor³, V. Alonso⁴, M.C. Riesco Martinez⁵, A. Custodio⁶, C. Lopez⁷, M. Benavent⁸, A. Carmona Bayonas⁹, P. Jimenez-Fonseca¹⁰, M. Llanos¹¹, B. López De San Vicente¹², V. Arrazubi Arrula¹³, R. Grandez¹⁴, I. González-Borja¹⁵, S. Goñi¹⁵, I. Arozarena¹⁵, M. Baretta¹⁶, A. Viudez³, ¹Johns Hopkins Hospital, Baltimore, US, ²Hospital Universitario de Burgos (HUBU), Burgos, ES, ³Complejo Hospitalario de Navarra - Royal Navarre Hospital, Pamplona, ES, ⁴Miguel Servet University Hospital, Zaragoza, ES, ⁵University Hospital 12 De Octubre, Madrid, ES, ⁶Hospital Universitario La Paz, Madrid, ES, ⁷Marques de Valdecilla University Hospital, Santander, ES, ⁸Hospital Universitario Virgen del Rocio, Sevilla, ES, ⁹Hospital Universitario Morales Meseguer, Murcia, ES, ¹⁰Hospital Universitario Central de Oviedo, Oviedo, ES, ¹¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, ES, ¹²Hospital de Basurto, Bilbao, ES, ¹³Complejo Hospitalario de Navarra, Pamplona, ES, ¹⁴Hospital Tudela, Tudela, ES, ¹⁵Navarrabiomed, Pamplona, ES, ¹⁶Istituto Clinico

Humanitas, Rozzano, IT

12:00 - 12:00 **519P - Carcinoid heart disease (CHD): the CRUSOE-NETs, a prospective cohort study from the French Group of Endocrine Tumors (GTE)**

K. Dekeister Geoffroy¹, L. Francois², T. Walter³, O. Hentic Dhome⁴, A. Cachier⁴, G. Cadiot⁵, P. Nazeyrollas⁵, P. Afchain⁶, S. Ederhy⁶, C. Lepage⁷, J.-C. Eicher⁷, R. Coriat⁸, L. Cabanes⁸, E. Baudin⁹, S. Dominguez¹⁰, F. Delelis¹¹, J. Forestier¹², C. Lombard Bohas¹²,
¹Centre Léon Bérard, Lyon, FR, ²Hôpital Louis Pradel / Groupement Hospitalier Est Cardiologie E, Bron, FR, ³Pavillon E, UJOMM, Hôpital Edouard Herriot, Lyon, FR, ⁴Beaujon Hospital APHP, Clichy, FR, ⁵CHU de Reims - Hôpital Robert Debré, Reims, FR, ⁶Hôpitaux Universitaires Est Parisien, Hôpital Saint Antoine, Paris, FR, ⁷CHU Dijon, Dijon, FR, ⁸Hôpital Cochin, Paris, FR, ⁹Gustave Roussy - Cancer Campus, Villejuif, FR, ¹⁰Hôpital St Vincent de Paul, Lille, FR, ¹¹Hospital Saint Philibert GCS-GHICL, Lomme, FR, ¹²Hopital Edouard Herriot Pav. E bis, Lyon, FR

12:00 - 12:00 **520P - Safety of high doses of somatostatin analogs in well differentiated NENs in elderly**

M. Cani¹, L. Incorvaia¹, D. Fanale¹, I. De Luca², F. Gelsomino³, T. Ibrahim⁴, S. Pusceddu⁵, F. Riccardi⁶, S. Tafuto⁷, G. Lamberti⁸, A. Faggiano⁹, A. La Salvia¹⁰, M. Albertelli¹¹, S. Massironi¹², M. Rinzivillo¹³, G. Butturini¹⁴, V. Bazan², D. Campana¹⁵, A. Russo², G. Badalamenti¹, ¹AOU Policlinico "Paolo Giaccone", Palermo, IT, ²University of Palermo, Palermo, IT, ³Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ⁴Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ⁵Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁶AORN Cardarelli, UOC di Oncologia, Napoli, IT, ⁷Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁸AOU Policlinico S. Orsola-Malpighi, Bologna, IT, ⁹sapienza university, rome, IT, ¹⁰Azienda Ospedaliero Universitaria San Luigi Gonzaga, orbassano, IT, ¹¹Università di Genova, genova, IT, ¹²Università degli Studi di Milano, milano, IT, ¹³Azienda Ospedaliero-Universitaria Sant'Andrea, roma, IT, ¹⁴Policlinico "G.B. Rossi", verona, IT, ¹⁵università di bologna, Bologna, IT

12:00 - 12:00 **(Withdrawn)**

12:00 - 12:00 **Neuroendocrine tumours**

12:00 - 12:00 **1387P - Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumors (NETs).**

J. Hernando Cubero¹, E. Grande², D. Castellano Gauna³, T. Ibrahim⁴, N. Fazio⁵, C. Lopez⁶, A. Teulé⁷, J. Valle⁸, V. Alonso⁹, J. Molina-Cerrillo¹⁰, S. Tafuto¹¹, A. Custodio¹², L. Trejo¹, A. Casteras¹, R. Manneh Kopp¹³, C. Miqueo¹⁴, M. Roca Herrera¹, R. Garcia-Carbonero³, R. Salazar¹⁵, J. Capdevila¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²MD Anderson Cancer Center Madrid, Madrid, ES, ³University Hospital 12 De Octubre, Madrid, ES, ⁴Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ⁵Istituto Europeo di Oncologia, Milan, IT, ⁶Marques de Valdecilla University Hospital, Santander, ES, ⁷Institut Catala d'Oncologia (ICO), Hospitalet de Llobregat, ES, ⁸The Christie NHS

Foundation Trust, Manchester, GB, ⁹Miguel Servet University Hospital, Zaragoza, ES, ¹⁰Hospital Universitario Ramon y Cajal, Madrid, ES, ¹¹Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ¹²Hospital Universitario La Paz, Madrid, ES, ¹³Private Practice - Manneh Kopp, Barranquilla, CO, ¹⁴Zaragoza University, Zaragoza, ES, ¹⁵ICO - Institut Catala d'Oncologia Hospital Duran i Reynals, Hospitalet de Llobregat, ES

- 12:00 - 12:00 **1388P - Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen.**
P. Ruszniewski¹, J. Ćwikła², C. Lombard-Bohas³, I. Borbath⁴, T. Shah⁵, U.-F. Pape⁶, X.-M. Truong Thanh⁷, A. Houchard⁷, M. Pavel⁸, ¹Beaujon Hospital APHP, Clichy, FR, ²University of Warmia and Mazury, Olsztyn, PL, ³Hopital Edouard Herriot, Lyon, FR, ⁴Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE, ⁵Queen Elizabeth Hospital Birmingham, Birmingham, GB, ⁶Asklepios Klinik St. Georg, Hamburg, DE, ⁷Ipsen, Boulogne-Billancourt, FR, ⁸Universitätsklinik Erlangen, Erlangen, DE
- 12:00 - 12:00 **1389P - Analysis of PD-1/PD-L1 blockade biomarker and immune infiltrates in Gastroenteropancreatic neuroendocrine carcinoma**
J.Z. Xing¹, C. Bai², Y. Cheng², Z. Sun³, Y. Gao², J. Li², ¹Peking union medical college, Beijing, CN, ²Department of Medical Oncology, Beijing, CN, ³Peking Union Medical College Hospital, Beijing, CN
- 12:00 - 12:00 **1390P - Diabetes Is Associated With Pancreatic Neuroendocrine Tumors Growth and Metastasis**
Z. Fan¹, G. Luo², C. Liu², X. Yu¹, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²shanghai cancer center, Shanghai, CN
- 12:00 - 12:00 **1391P - Investigation of the reclassification of G1/G2 pancreatic neuroendocrine neoplasms by WHO 2017 classification**
T. Yokose, M. Kitago, M. Shinoda, H. Yagi, Y. Abe, G. Oshima, S. Hori, Y. Endo, K. Hayashi, Y. Kitagawa, Keio University School of Medicine, Tokyo, JP
- 12:00 - 12:00 **1392P - Treatment with somatostatin analogues after radiopeptide therapy**
D. Handkiewicz Junak¹, A. Syguła¹, B. Jurecka-Lubieniecka¹, K. Hasse-Lazar¹, B. Jarzab², ¹Maria Sklodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, Gliwice, PL, ²Maria Sklodowska Curie MSC Memorial Cancer Institute in Gliwice, Gliwice, PL
- 12:00 - 12:00 **1393P - Safety and Tolerability of Surufatinib in Western Patients with Solid Tumors**
E. Hamilton¹, J. Wang², D. Li³, N.A. Dasari⁴, S. Paulson⁵, A. Cohn⁶, N. Sauter⁷, M. Kania⁷, J. Kauh⁷, G. Falchook⁸, ¹Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ²Sarah Cannon Research Institute, Sarasota, US, ³City of Hope Comprehensive Cancer Center, Duarte, US, ⁴MD Anderson Cancer Center, Houston, US, ⁵Baylor University Medical Center, Dallas, US, ⁶Rocky Mountain Cancer Centers, Denver, US, ⁷Hutchison Medipharma US, Florham Park, US, ⁸Sarah Cannon Research Institute at HealthONE, Denver, US

- 12:00 - 12:00 **1394P - The impact of tumour absorbed dosimetry with survival outcomes after peptide receptor radionuclide therapy in metastatic neuroendocrine tumours.**
R. Ladwa¹, D. Pattison², J. Smith², S. Goodman², M. Burge², S. Rose³, N. Dowson³, D. Wyld⁴, ¹Mater Hospital Brisbane, Brisbane, AU, ²Royal Brisbane & Women's Hospital, Brisbane, AU, ³CSIRO Health and Biosecurity, Brisbane, AU, ⁴Royal Brisbane and Women's Hospital, Brisbane, AU
- 12:00 - 12:00 **1395P - Opportunist and Serious Infections in Patients with Neuroendocrine Tumors Treated With Everolimus: A Multicenter Study of Real World Patients**
C. Mauro¹, V.H. De Jesus¹, M. Barros², F. Costa³, R. Weschenfelder⁴, N. D'Agustini⁴, M. Angel⁵, R. Luca⁵, J.E. Nuñez⁶, J.M. O'Connor⁵, R. Riechelmann⁷, ¹A. C. Camargo Cancer Center, Sao Paulo, BR, ²AC Camargo Cancer Center, Sao Paulo, BR, ³Hospital Sirio Libanes, Sao Paulo, BR, ⁴Hospital Moinhos de Vento, Porto Alegre, BR, ⁵Instituto Alexander Fleming, Buenos Aires, AR, ⁶Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR, ⁷Hospital Sírio-Libanês, Sao Paulo, BR
- 12:00 - 12:00 **1396P - Establishment of Prognostic Nomogram Based on the Metastatic Lymph Nodes Ratio for Patients with Gastric Neuroendocrine Tumour**
Y. Lin¹, Y. Wang¹, H. Lin², J. Li³, J. Wu², ¹Fujian Cancer Hospital, Fuzhou, CN, ²Fujian Medical University Cancer Hospital, Fuzhou, CN, ³Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, CN
- 12:00 - 12:00 **1397P - Neutrophil-lymphocyte ratio as an independent predictive factor in Neuroendocrine Neoplasms**
S. Ferreira¹, R. Conde¹, S. Esteves², M.T. Marques¹, I. Claro², A. Moreira¹, M. Goncalves¹, ¹Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, PT, ²Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, PT
- 12:00 - 12:00 **1398P - Findings from a new specialist remote Counselling Service for Neuroendocrine Neoplasm (NEN) patients and family members**
C. Bouvier, K. Winter, NET Patient Foundation, Royal Leamington Spa, GB
- 12:00 - 12:00 **1399P - Hematologic malignancies in temozolomide-treated metastatic pancreatic neuroendocrine tumors**
N. Balmaceda, T. Mouw, S. Abhyankar, H. Male, J. Woodroof, S. Williamson, J. Baranda, University of Kansas Medical Center (KUMC), Kansas City, US
- 12:00 - 12:00 **1400P - Efficacy and toxicity of combination chemotherapy with cyclophosphamide, vincristine and an anthracycline in patients with metastatic extrapulmonary neuroendocrine carcinoma**
L. Apostolidis¹, E. Winkler², D. Jäger², ¹University Hospital Heidelberg, Heidelberg, DE, ²Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE
- 12:00 - 12:00 **1401P - An Australian multi-centre experience of the use of peptide receptor radionuclide therapy for bronchial carcinoid tumours.**

L. Lim¹, D. Chan², D. Thomas³, D. Wyld⁴, G. Cehic⁵, W. Macdonald⁶, Y. Du⁵, G. Tincknell³, A. Kuchel⁷, N. Pavlakis², D. Bailey², A. Davis², E. Segelov⁸, ¹Ballarat Base Hospital, Ballarat, AU, ²Royal North Shore Hospital, St Leonards, AU, ³St George Hospital, Kogarah, AU, ⁴Royal Brisbane and Women's Hospital, Brisbane, AU, ⁵The Queen Elizabeth Hospital, Woodville South, AU, ⁶Fiona Stanley Hospital, Murdoch, AU, ⁷Royal Brisbane and Women's Hospital, Herston, AU, ⁸Monash Medical Centre, Clayton, AU

12:00 - 12:00 **1402P - Extra-pulmonary (EP) high grade (HG) neuroendocrine carcinoma (NEC): real-life outcomes of fifty-eight patients from a Portuguese cancer center.**

R. Conde¹, S. Ferreira¹, S. Esteves², I. Claro², A. Moreira¹, M.T. Marques¹, M. Goncalves¹, ¹Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, PT, ²Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, PT

12:00 - 12:00 **1403P - Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNET)**

S. Sherman¹, O. Rotem², A. Zer³, T. Shochat⁴, E. Dudnik², ¹Clalit Health Services, Petah Tikva, IL, ²Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL, ³Princess Margaret Cancer Center, Toronto, CA, ⁴Rabin Medical Center, Peth Tikva, IL

12:00 - 12:00 **1404TiP - HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression**

M. Barros¹, T. Felismino², V.H. De Jesus², C. Mello², V. Silva², M. Camandaroba², N. Rodrigues², M. Donadio², E. Nobrega², L. Chinen², L. De Brot², R. Weschenfelder³, J. Rego⁴, J. Carvalheira⁵, R. Riechelmann⁶, ¹AC Camargo Cancer Center, Sao Paulo, BR, ²A. C. Camargo Cancer Center, Sao Paulo, BR, ³Hospital Moinhos de Vento, Porto Alegre, BR, ⁴Hospital Universitario Onofre Lopes, Natal, BR, ⁵Hospital de Clinica da Universidade Estadual de Campinas, Campinas, BR, ⁶Hospital Sírio-Libanês, Sao Paulo, BR

12:00 - 12:00 **Thyroid cancer**

12:00 - 12:00 **1866P - Clinical utility of Metabolic Tumor Volume in Papillary Thyroid Carcinoma**

N. Takemoto¹, J. Miyabe², T. Fukusumi¹, M. Suzuki³, H. Inohara³, ¹Osaka University Graduate School of Medicine, Suita, JP, ²Osaka International Cancer Institute, Osaka, JP, ³Osaka University, Osaka, JP

12:00 - 12:00 **1867P - Correlation of thyroglobulin (Tg) oscillations with progression-free survival (PFS) in patients with radioactive iodine-refractory (RAI-R) differentiated thyroid carcinoma (DTC) treated with multikinase inhibitors (MKI).**

J. Hernando Cubero¹, A. García Álvarez¹, M. Roca Herrera¹, D. Acosta², M. Diez², R. Ferrer¹, A. Garcia Burillo¹, C. Zafon¹, C. Iglesias¹, J. Capdevila¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron University Hospital. Vall Hebron Institute of Oncology (VHIO), Barcelona, ES

- 12:00 - 12:00 **(Withdrawn)**
- 12:00 - 12:00 **1869P - Analytical validation of a thyroid cancer diagnostic method based on the relative quantification of CLDN10, HMGA2 and LAMB3 expression**
M. Barrosfilho¹, J. Mello¹, V. De Andrade¹, M. Saieg¹, C. Pinto¹, L. Kowalski¹, S. Rogatto², ¹A. C. Camargo Cancer Center, Sao Paulo, BR, ²University of Southern Denmark, Vejle, DK
- 12:00 - 12:00 **1870P - Thyroid Lobectomy versus Total Thyroidectomy among Early-Stage Papillary Thyroid Carcinoma Patient**
S. Ahmed, M. Basha, S. Elshafie, faculty of medicine suez canal university, Ismailia, EG
- 12:00 - 12:00 **1871P - Classification of thyroid nodule using DNA methylation profiling on tissue and circulating tumor DNA**
S. Hong¹, J. Li¹, L. Cheng², S. Yu¹, Z. Zhang², B. Lin¹, Z. Su², Z. Ke¹, R. Liu², S. Peng¹, Q. Li³, Q. Zhang³, Z. Guo³, W. Lv¹, H. Xiao¹, ¹1st Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ²Singlera Genomics Inc. and Singlera Genomics (Shanghai) Ltd., Shanghai, CN, ³Sun Yat-sen University Cancer Center, Guangzhou, CN
- 12:00 - 12:00 **1872TiP - Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Refractory and Progressive Advanced Thyroid Carcinoma. A Phase II Multicohort Trial (DUTHY / GETNE T1812)**
J. Hernando Cubero¹, M. Taberna Sanz², A. Carmona Bayonas³, L. Iglesias⁴, E. Grande⁵, J. Trigo Perez⁶, J. Grau⁷, J.M. Lopez-Picazo⁸, B. Castelo⁹, T. Alonso Gordo¹⁰, I. Lorenzo¹¹, A. Casado Herraiz¹², L. Ugidos¹³, J. Munarriz¹⁴, J. Lavernia¹⁵, J. Capdevila¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²ICO - Institut Catala d'Oncologia Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ³Hospital Universitario Morales Meseguer, Murcia, ES, ⁴University Hospital 12 de Octubre, Madrid, ES, ⁵MD Anderson Cancer Center Madrid, Madrid, ES, ⁶Hospital Universitario Virgen de la Victoria, Málaga, ES, ⁷Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁸Clínica Universidad de Navarra, Pamplona, ES, ⁹Hospital Universitario La Paz, Madrid, ES, ¹⁰Hospital Universitario Ramon y Cajal, Madrid, ES, ¹¹Complejo Hospitalario Universitario de Vigo, Vigo, ES, ¹²Hospital Clinico Universitario San Carlos, Madrid, ES, ¹³HM San Chinarro, Madrid, ES, ¹⁴Hospital General de Castellón, Castellón, ES, ¹⁵Hospital General Universitario Valencia, Valencia, ES

13:00 - 14:30	Type: Industry Satellite Symposium Title: AstraZeneca - Medscape Oncology - Taking the management of stage III NSCLC to the next level: Is your clinic ready? Chair(s): Suresh Ramalingam, US	Pamplona Auditorium (Hall 2)
13:00 - 13:05	Welcome and introductions <u>S. Ramalingam</u> , Emory University Winship Cancer Institute, Atlanta, US	
13:05 - 13:10	What has changed for the patient with unresectable stage II NSCLC? Experience from clinical practice <u>S. Ramalingam</u> , Emory University Winship Cancer Institute, Atlanta, US	
13:10 - 13:25	Expert perspectives across specialties: Are the clinics optimally using CCRT in clinical practice? The radiation oncologist's view <u>S. Senan</u> , Vrije University Medical Centre (VUMC), Amsterdam, NL	
13:25 - 13:40	Expert perspectives across specialties: From data to clinical practice: How is treatment evolving? The oncologist's view <u>S. Ramalingam</u> , Emory University Winship Cancer Institute, Atlanta, US	
13:40 - 13:55	Expert perspectives across specialties: What are the challenges associated with biomarker testing? The pathologist's view <u>M. Tsao</u> , Princess Margaret Cancer Centre, University Health Network, Toronto, CA	
13:55 - 14:10	What could change for the patient with resectable stage III NSCLC? Future Perspectives <u>W. Weder</u> , University Hospital Zürich, Zurich, CH	
14:10 - 14:25	Question and answer session	
14:25 - 14:30	Conclusion	

- 13:00 - 14:30** **Type: Industry Satellite Symposium** **Cordoba Auditorium (Hall 7)**
Title: Janssen Pharmaceutical Companies of Johnson & Johnson - Expanding the therapeutic opportunities in advanced prostate cancer
Chair(s): Noel Clarke, GB; Eleni Efstathiou, US
- 13:00 - 13:15 **Refining the treatment landscape of advanced prostate cancer**
N. Clarke¹, N. Mottet², ¹The Christie and Salford Royal Hospitals, Manchester, GB, ²CHU University hospital of St Etienne, Saint-Étienne, FR
- 13:15 - 14:00 **Optimising therapeutic strategies in mHSPC**
K. Chi¹, A. Pinto Marin², ¹BC Cancer Agency - Vancouver, Vancouver, CA, ²Hospital Universitario La Paz, Madrid, ES
- 14:00 - 14:20 **nmCRPC: Practical identification and current management of patients with nmCRPC**
L.-M. Krabbe, University Hospital of Münster, Münster, DE
- 14:20 - 14:30 **Understanding advances and defining next steps**
E. Efstathiou, The M. D. Anderson Cancer Center, Houston, US
- 13:00 - 14:30** **Type: Industry Satellite Symposium** **Bilbao Auditorium (Hall 5)**
Title: Bayer - Optimizing treatment in the era of precision oncology: A multidisciplinary approach
Chair(s): Marc Peeters, BE
- 13:00 - 13:10 **Welcome and introduction**
M. Peeters, Antwerp University Hospital/Antwerp University, Edegem, BE
- 13:10 - 13:30 **Precision medicine in oncology: Making the most of actionable targets**
D. Hong, University of Texas MD Anderson Cancer Center, Houston, US
- 13:30 - 13:50 **Looking beneath the surface: Optimizing molecular testing**
A. Stenzinger, University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE
- 13:50 - 14:10 **From trials to the clinic: Precision oncology in action**
U. Lassen¹, D. Hong², ¹Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, ²University of Texas MD Anderson Cancer Center, Houston, US
- 14:10 - 14:30 **Panel discussion and Q&A**

13:00 - 14:30 **Type: Industry Satellite Symposium** **Tarragona Auditorium**
Title: Merck Pfizer Alliance - GU 2.0 - Patient care in **(Hall 7)**
2019 and beyond
Chair(s): Manuela Schmidinger, AT

- 13:00 - 13:05 **Introduction**
M. Schmidinger, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT
- 13:05 - 13:25 **The RCC: Patient journey**
M. Schmidinger, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT
- 13:25 - 13:45 **Looking to the future of RCC**
C. Suárez, Vall d'Hebron University Hospital, Barcelona, ES
- 13:45 - 14:10 **Metastatic urothelial cancer - a landscape in transformation**
P. Grivas, University of Washington Seattle Cancer Care Alliance, Seattle, US
- 14:10 - 14:25 **Q&A**
- 14:25 - 14:30 **Conclusions**

- 13:00 - 14:30** **Type: Industry Satellite Symposium** **Alicante Auditorium**
Title: Novartis - Optimising patient outcomes and quality of **(Hall 3)**
life in HR+, HER2- ABC
Chair(s): Nadia Harbeck, DE
- 13:00 - 13:10 **Welcome and introduction**
N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE
- 13:10 - 13:45 **Perspectives on the growing evidence for CDK4/6 inhibitors**
S. Chia¹, L. Fallowfield², ¹University of British Columbia, Vancouver, CA, ²Brighton and Sussex Medical School, University of Sussex, Brighton, GB
- 13:45 - 13:45 **Panelists**
N. Harbeck¹, Y.-S. Lu², ¹Ludwig Maximilians University - Grosshadern, Munich, DE, ²National Taiwan University Hospital, Taipei, TW
- 13:45 - 14:20 **Emerging role of biomarker-driven therapy with PI3K inhibitors**
Y.-S. Lu¹, L. Fallowfield², ¹National Taiwan University Hospital, Taipei, TW, ²Brighton and Sussex Medical School, University of Sussex, Brighton, GB
- 14:20 - 14:20 **Panelists**
S. Chia¹, N. Harbeck², ¹University of British Columbia, Vancouver, CA, ²Ludwig Maximilians University - Grosshadern, Munich, DE
- 14:20 - 14:30 **Audience Q&A and closing**

- 13:00 - 14:30** **Type: Industry Satellite Symposium** **Cartagena Auditorium (Hall 3)**
Title: Daiichi Sankyo - Patient selection and management of advanced breast cancer in the era of next generation HER2 targeted treatments
Chair(s): Javier Cortés, ES
- 13:00 - 13:10 **Welcome and introduction**
J. Cortés, Vall d'Hebron University Hospital, Barcelona, ES
- 13:10 - 13:25 **Differentiating molecular subtypes and the emerging paradigm for HER2 testing**
G. Viale, Istituto Europeo di Oncologia, Milan, IT
- 13:25 - 13:40 **Clinical challenges with current HER2 targeted treatments**
T. Fehm, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, DE
- 13:40 - 13:55 **The role of next generation HER targeted treatments in addressing unmet needs**
G. Curigliano, Istituto Europeo di Oncologia, Milan, IT
- 13:55 - 14:10 **Bringing it all together to optimize personalized treatment of patients with advanced breast cancer**
J. Cortés, Vall d'Hebron University Hospital, Barcelona, ES
- 14:10 - 14:30 **Panel discussion/Q&A/Wrap up**

13:00 - 14:30 **Type: Industry Satellite Symposium** **Salamanca Auditorium (Hall 3)**
Title: Boehringer Ingelheim - Making first- And second-line treatment decisions for advanced NSCLC
Chair(s): James Yang, TW

- 13:00 - 13:05 **Introduction & welcome**
J. Yang, National Taiwan University Hospital, Taipei, Taiwan, Taipei, TW
- 13:05 - 13:20 **Sequencing to prolong the chemotherapy-free period**
B. Melosky, British Columbia Cancer Agency, Vancouver, CA
- 13:20 - 13:35 **Common options for uncommon mutations**
J. Yang, National Taiwan University Hospital, Taipei, Taiwan, Taipei, TW
- 13:35 - 13:45 **Panel discussion: Choosing the first EGFR TKI for advanced non-squamous NSCLC**
J. Yang, National Taiwan University Hospital, Taipei, Taiwan, Taipei, TW
- 13:45 - 14:00 **Squamous NSCLC; Where do EGFR TKIs fit in?**
N. Reguart, Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 14:00 - 14:15 **Non-mutated, non-squamous NSCLC (adenocarcinoma): Failing first-line immunotherapy + chemotherapy, what now? Treatment options and the role of the angio-immunogenic switch**
M. Hochmair, Otto Wagner Spital, Vienna, AT
- 14:15 - 14:25 **Panel discussion: Choosing a second-line treatment for advanced NSCLC**
J. Yang, National Taiwan University Hospital, Taipei, Taiwan, Taipei, TW
- 14:25 - 14:30 **Meeting close**
J. Yang, National Taiwan University Hospital, Taipei, Taiwan, Taipei, TW

13:00 - 14:30 **Type: Patient Advocay Track** **Leon Auditorium (Hall 3)**
Title: Organ-specific immunity and cancer
Chair(s): Bettina Ryll, SE; Olivier Michielin, CH

13:00 - 13:00 **Session DOI**

13:00 - 13:15 **Immune therapies: Introduction to the session**
B. Ryll, Melanoma Patient network Europe, Uppsala, SE

13:15 - 13:30 **Metastasis to the brain (clinical perspective I)**
O. Michielin, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

13:30 - 13:45 **Notorious liver metastasis in melanoma (clinical perspective II)**

13:45 - 14:00 **Host tissue determinants of tumour immunity**

14:00 - 14:15 **Tissue-specific immune memory: The role of tissue-resident T-cells in cancer**
E. Tartour, Hopital European George Pompidou, Paris, FR

14:15 - 14:30 **Panel Discussion- promising future strategies**

14:00 - 15:30 **Type: EONS session** **Oviedo Auditorium**
Title: EONS 12: Clinical cancer nursing based on **(CC5)**
evidence
Chair(s): Grigorios Kotronoulas, GB

14:00 - 14:00 **Session DOI**

14:00 - 14:15 **Managing sialadenitis, xerostomia and oral mucositis in patients undergoing Radioiodine treatment**

A. Christou, Cyprus University of Technology - Nursing Science, Limassol, CY

14:15 - 14:30 **ACC: The role of nursing in genetic cancer care**

M. Katapodi, University of Basel, Faculty of Medicine, Basel, CH

14:30 - 14:45 **New cancer treatments: Nurses' challenge**

C. Llanos Principe, Fundació Hospital Sant Joan de Déu de Martorell, Martorell, ES

14:45 - 15:00 **CN1 - Patients' usage and perception of an interactive app for symptom management and self-care during cancer treatment**

M.-T. Crafoord, M. Fjell, M. Nilsson, M. Nilsson, K. Sundberg, A. Langius-Eklöf, Karolinska Institute, Stockholm, SE

15:00 - 15:15 **CN69 - Nurse-led consultations for patients with gynecological cancer receiving concurrent cisplatin - a pilot study.**

M. Christiansen, H. Roed, C. Phanareth, K. Piil, Rigshospitalet, Copenhagen, DK

15:15 - 15:30 **Discussion**

14:45 - 16:15	Type: Special symposium Title: Where will future technologies take us in metastatic breast cancer? Chair(s): Fabrice André, FR; Jorge Reis-Filho, US	Barcelona Auditorium (Hall 2)
14:45 - 14:45	Session DOI	
14:45 - 14:50	Introduction <u>J. Reis-Filho</u> , Memorial Sloan-Kettering Cancer Center, New York, US	
14:50 - 15:10	Next generation sequencing trials in metastatic breast cancer <u>F. André</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
15:10 - 15:30	Targeting novel pathways in breast cancer <u>J. Reis-Filho</u> , Memorial Sloan-Kettering Cancer Center, New York, US	
15:30 - 15:50	Where are we with liquid biopsies in breast cancer? <u>N. Turner</u> , The Francis Crick Institute, London, GB	
15:50 - 16:10	The role of Artificial Intelligence (AI) <u>N. Paragios</u> , CentraleSupélec - Paris-Saclay campus, Gif sur Yvette, FR	
16:10 - 16:15	Conclusions and perspectives <u>F. André</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	

14:45 - 16:15 **Type: Special symposium** **Madrid Auditorium (Hall 2)**
Title: Update on novel therapies in ovarian cancer
Chair(s): Jonathan Ledermann, GB; Ana Oaknin, ES

14:45 - 14:45 **Session DOI**

14:45 - 14:50 **Introduction**

J. Ledermann, University College London Cancer Institute, London, GB

14:50 - 15:10 **Rationale for, and an orientation to, immunotherapy**

L. Kandalajt, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

15:10 - 15:30 **Results of immunotherapy trials in ovarian cancer: Where do we stand in 2019?**

A. González Martín, Clínica Universidad de Navarra, Madrid, ES

15:30 - 15:50 **Where do we stand with PARP inhibitors in ovarian cancer treatment in 2019?**

J. Ledermann, University College London Cancer Institute, London, GB

15:50 - 16:10 **Do we already have biomarkers that may predict response and/or resistance to PARP inhibitors?**

C. Gourley, Edinburgh Cancer Research UK Centre, Edinburgh, GB

16:10 - 16:15 **Conclusions and perspectives**

A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES

14:45 - 16:15 **Type: Educational session** **Sevilla Auditorium (Hall 2)**
Title: Immunotherapy in thoracic malignancies: What has been achieved in 2019?
Chair(s): Alessandra Curioni, CH

14:45 - 14:45 **Session DOI**

14:45 - 15:10 **Does surgery still have a role in stage III NSCLC in the era of immunotherapy? The surgeon's view**

A. Verhagen, Radboud University Medical Center, Nijmegen, NL

15:10 - 15:35 **Does radiotherapy still have a role in stage III NSCLC in the era of immunotherapy? The radiotherapist's view**

K. Franks, , US

15:35 - 16:00 **Where is immunotherapy for small cell lung cancer and mesothelioma now?**

A. Curioni, University Hospital Zürich, Zurich, CH

16:00 - 16:15 **Discussion**

14:45 - 16:45 **Type: Clinical Practice Guidelines** **Granada Auditorium (Hall 3)**
Title: ESMO Clinical Practice Guidelines 2
Chair(s): George Pentheroudakis, GR; Cristiana Sessa, CH

14:45 - 14:45 **Session DOI**

14:45 - 14:55 **Introduction**

G. Pentheroudakis, University Hospital of Ioannina, Ioannina, GR

14:55 - 15:05 **Questionnaire**

C. Sessa, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

15:05 - 15:15 **Localised melanoma resected: Adjuvant therapy followed by systemic relapse**

R. Lee, The Christie NHS Foundation Trust, Manchester, GB

15:15 - 15:25 **Discussion**

O. Michielin, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

15:25 - 15:30 **Q&A**

- 15:30 - 15:40 **Fatigue in cancer**
J. Brandt, University Hospital Heidelberg, Heidelberg, DE
- 15:40 - 15:50 **Discussion**
F. Roila, Ospedale Santa Maria della Misericordia, Perugia, IT
- 15:50 - 15:55 **Q&A**
- 15:55 - 16:05 **Advanced hepatoma: Sequence of therapies**
D. Hanna, The University of Manchester, Manchester, GB
- 16:05 - 16:15 **Discussion**
A. Vogel, Hannover Medical School, Hannover, DE
- 16:15 - 16:20 **Q&A**
- 16:20 - 16:30 **Stage III colorectal cancer: Duration of therapy, molecular profiling**
- 16:30 - 16:40 **Discussion**
- 16:40 - 16:45 **Q&A**

14:45 - 16:15 **Type: Educational session** **Bilbao Auditorium**
Title: Treatment developments in viral-associated HN malignancies **(Hall 5)**
Chair(s): Anthony Chan, HK

14:45 - 14:45 **Session DOI**

14:45 - 15:10 **EBV monitoring in nasopharyngeal carcinoma: Staging, prognosis, treatment adaptation**

A. Chan, The Chinese University of Hong Kong, Shatin, HK

15:10 - 15:35 **HPV monitoring in HPV-related oropharyngeal cancer**

S. Bhide, The Royal Marsden Hospital (Surrey), Sutton, GB

15:35 - 16:00 **Treatment de-escalation in HPV-related oropharyngeal cancer: Where do we stand?**

C. Simon, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

16:00 - 16:15 **Discussion**

14:45 - 16:15 **Type: Educational session** **Tarragona Auditorium**
Title: The past year in sarcoma: Impact on clinical practice **(Hall 7)**
Chair(s): Robin Jones, GB

14:45 - 14:45 **Session DOI**

14:45 - 15:10 **Bone sarcoma**

J. Whelan, University College London Hospital UCLH NHS Foundation Trust, London, GB

15:10 - 15:35 **Primary soft tissue sarcoma**

A. Gronchi, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

15:35 - 16:00 **Metastatic soft tissue sarcoma**

R. Jones, Royal Marsden Hospital NHS Foundation Trust, London, GB

16:00 - 16:15 **Discussion**

14:45 - 16:15 **Type: Special symposium** **Alicante Auditorium (Hall 3)**
Title: Recent advances in thyroid cancer

14:45 - 14:45 **Session DOI**

14:45 - 14:50 **Introduction**

14:50 - 15:10 **Insights in the biology and pathological diagnosis of thyroid malignancies**
K. Newbold, , US

15:10 - 15:30 **State of the art management of medullary thyroid cancer**
F. Pacini, Azienda Ospedaliera Universitaria Senese - Santa Maria delle Scotte, Siena, IT

15:30 - 15:50 **Targeted therapy in thyroid cancer (including anaplastic): Current standards and emerging novel therapeutics**
J. Capdevila, Vall d'Hebron University Hospital, Barcelona, ES

15:50 - 16:10 **Tumour growth rate as a driver to commence treatment with TKI in RA-refractory differentiated thyroid carcinoma**
S. Filetti, University of Rome Sapienza, Policlinico Umberto I, IT

16:10 - 16:15 **Conclusions and perspectives**

15:00 - 16:15 **Type: Poster Discussion session** **Pamplona Auditorium**
Title: Poster Discussion - Genitourinary tumours, **(Hall 2)**
non-prostate

15:00 - 15:00 **Session DOI**

15:00 - 15:00 **904PD - Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO)**
M. Van Der Heijden¹, N. Van Dijk¹, L. Smit², K. Hendricksen², J. De Feijter², E. Bekers², E. Hooijberg³, C. Van Rooijen², A. Broeks⁴, Y. Lubeck², K. Sikorska⁴, T. Schumacher⁵, P. Kvistborg⁵, T. Boellaard², C. Blank⁵, B. Van Rhijn², ¹Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, ²Netherlands Cancer Institute, Amsterdam, NL, ³Vrije University Medical Centre (VUMC), Amsterdam, NL, ⁴Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ⁵The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

15:00 - 15:00 **905PD - Multiple-cohort analysis investigating FGFR3 alteration as a predictor of non-response to neoadjuvant pembrolizumab (pembro) in muscle-invasive**

bladder cancer (MIBC)

A. Necchi¹, R. Madison², J. Chung², D. Raggi¹, A. Briganti³, F. Montorsi³, J. Boormans⁴, Y. Liu⁵, J. De Jong⁶, J. Chung², P. Black⁷, J. Ross², S. Ali², E. Davicioni⁵, E. Gibb⁵, ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ²Foundation Medicine, Cambridge, US, ³IRCCS Ospedale San Raffaele, Milan, IT, ⁴Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ⁵Decipher Biosciences, Vancouver, CA, ⁶Erasmus MC Cancer Institute, Rotterdam, NL, ⁷Vancouver Prostate Centre, Vancouver, CA

15:00 - 15:00

906PD - Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: comprehensive tumor genomic and transcriptomic analyses

A. Ravaud¹, J.-F. Martini², K. Ching², M. Staehler³, A. Magheli⁴, B. Escudier⁵, X.J. Mu², O. Valota⁶, X. Lin², R. Motzer⁷, ¹CHU Bordeaux Hopital St. André, Bordeaux, FR, ²Pfizer, La Jolla, US, ³University of Munich, Munich, DE, ⁴Charité Universitaetsmedizin Berlin, Berlin, DE, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR, ⁶Pfizer S.r.L, Milan, IT, ⁷Memorial Sloan-Kettering Cancer Center, New York, US

15:00 - 15:10

Invited Discussant 904PD, 905PD and 906PD

15:10 - 15:15

Q&A led by Discussant

15:15 - 15:15

907PD - ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma.

L. Au¹, K. Litchfield², A. Rowan², S. Horswell², F. Byrne², D. Nicol¹, N. Fotiadis³, R. Salgado⁴, S. Hazell¹, J.I. Lopez⁵, E. Hatipoglu⁶, L. Del Rosario¹, L. Pickering¹, M. Gore¹, B. Chain⁷, S. Quezada⁸, J. Larkin¹, C. Swanton², S. Turajlic², ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²The Francis Crick Institute, London, GB, ³Royal Marsden NHS Foundation Trust, Sutton, GB, ⁴St-Augustinus Ziekenhuis, Wilrijk, BE, ⁵Cruces University Hospital, Bilbao, ES, ⁶University College London Cancer Institute, London, GB, ⁷Imperial College London, London, GB, ⁸University College London, London, GB

15:15 - 15:15

908PD - Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): subgroup analysis from the phase 3 JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

L. Albiges¹, B. Rini², J. Haanen³, R. Motzer⁴, C. Kollmannsberger⁵, S. Negrier⁶, F. Nole⁷, J. Bedke⁸, M. Bilen⁹, P. Nathan¹⁰, Y. Tomita¹¹, B. Huang¹², K. Ching¹³, A. Chudnovsky¹⁴, P. Robbins¹⁵, A. Di Pietro¹⁶, D. Thomaidou¹⁷, T. Choueiri¹⁸, ¹Institut Gustave Roussy, Villejuif, FR, ²Cleveland Clinic, Cleveland, US, ³Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ⁴Memorial Sloan-Kettering Cancer Center, New York, US, ⁵BC Cancer Agency - Vancouver, Vancouver, CA, ⁶Centre Léon Bérard, Lyon, FR, ⁷Istituto Europeo di Oncologia, Milan, IT, ⁸University of Tuebingen, Tuebingen, DE, ⁹Emory University Winship Cancer Institute, Atlanta, US, ¹⁰Mount Vernon Cancer Centre and East & North Herts, NHS Trust, London, GB, ¹¹Yamagata University Hospital, Yamagata, JP, ¹²Pfizer Inc., Groton, US, ¹³Pfizer Inc., San Diego, US,

¹⁴Pfizer Inc., Cambridge, US, ¹⁵Pfizer Inc - USA, New London, US, ¹⁶Pfizer Inc., Milano, IT, ¹⁷Pfizer Hellas, Athens, GR, ¹⁸Dana-Farber Cancer Institute, Boston, US

15:15 - 15:15 **909PD - NIVOREN GETUG-AFU 26 translational study:CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N).**

Y. Vano¹, N. Rioux-Leclercq², C. Dalban³, C. Sautès-Fridman⁴, A. Bougoüin⁵, N. Chaput⁶, S. Chouaib⁷, B. Beuselinck⁸, C. Chevreau⁹, M. Gross-Goupil¹⁰, S. Negrier³, B. Laguerre¹¹, D. Borchiellini¹², I. Colina-Moreno⁵, W.H. Fridman¹³, S. Chabaud³, F. Tantot¹⁴, J. Barros Monteiro¹⁵, B. Escudier¹⁶, L. Albiges¹⁷, ¹Hopital European George Pompidou, Paris, FR, ²CHU, Université de Rennes, France, Rennes, FR, ³Centre Léon Bérard, Lyon, FR, ⁴Cordeliers Research Center, Paris, FR, ⁵Team Inflammation, Complement and Cancer, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, FR, ⁶Gustave Roussy Institut de Cancérologie, Villejuif, FR, ⁷Institut Gustave Roussy, Univ. Paris-Sud, Université Paris-Saclay, Villejuif, FR, ⁸University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁹Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ¹⁰CHU Bordeaux Hopital St. André, Bordeaux, FR, ¹¹Centre Eugene - Marquis, Rennes, FR, ¹²Centre Anticancer Antoine Lacassagne, Nice, FR, ¹³INSERM U1138, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, FR, ¹⁴Unicancer, PARIS, FR, ¹⁵UNICANCER, Paris, FR, ¹⁶Gustave Roussy - Cancer Campus, Villejuif, FR, ¹⁷Institut Gustave Roussy, Villejuif, FR

15:15 - 15:15 **910PD - Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): subgroup analysis from the phase 3 JAVELIN Renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)**

T. Choueiri¹, J. Larkin², S. Pal³, R. Motzer⁴, B. Venugopal⁵, B. Alekseev⁶, H. Miyake⁷, G. Gravis⁸, M. Bilen⁹, A. Chudnovsky¹⁰, K. Ching¹¹, M. Mariani¹², P. Robbins¹³, B. Huang¹⁴, A. Di Pietro¹⁵, L. Albiges¹⁶, ¹Dana-Farber Cancer Institute, Boston, US, ²Royal Marsden Hospital NHS Foundation Trust, London, GB, ³City of Hope, Duarte, US, ⁴Memorial Sloan-Kettering Cancer Center, New York, US, ⁵Beatson West of Scotland Cancer Centre, Glasgow, GB, ⁶Hertzen Cancer Research Institute, Moscow, RU, ⁷Hamamatsu University School of Medicine, Hamamatsu, JP, ⁸Institute Paoli Calmettes, Marseille, FR, ⁹Emory University Winship Cancer Institute, Atlanta, US, ¹⁰Pfizer Inc., Cambridge, US, ¹¹Pfizer Inc., San Diego, US, ¹²Pfizer, Milan, IT, ¹³Pfizer Inc - USA, New London, US, ¹⁴Pfizer Inc., Groton, US, ¹⁵Pfizer Inc., Milano, IT, ¹⁶Institut Gustave Roussy, Villejuif, FR

15:15 - 15:30 **Invited Discussant 907PD, 908PD, 909PD and 910PD**

15:30 - 15:35 **Q&A led by Discussant**

15:35 - 15:35 **911PD - A First-in-Human Phase 1/2 Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced RCC**

E. Jonasch¹, E. Plimack², T. Bauer³, J. Merchan⁴, K. Papadopoulos⁵, D. Mcdermott⁶, M.D.

Michaelson⁷, L. Appleman⁸, S. Thamake⁹, N. Zojwalla⁹, T. Choueiri¹⁰, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²Fox Chase Cancer Center, Philadelphia, US, ³Sarah Cannon Research Institute, Nashville, US, ⁴University of Miami, Miami, US, ⁵South Texas Accelerated Research Therapeutics (START), San Antonio, US, ⁶Beth Israel Deaconess Med. Center, Boston, US, ⁷Massachusetts General Hospital, Harvard Medical School, Boston, US, ⁸University of Pittsburgh Cancer Institute, Pittsburgh, US, ⁹Peloton Therapeutics, Inc., Dallas, US, ¹⁰Dana-Farber Cancer Institute, Boston, US

15:35 - 15:35

912PD - Results of the Phase 2 TRAXAR Study: A Randomized Phase 2 Trial of Axitinib and TRC105 (TRAX) versus AXitinib (AX) Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (mRCC)

T. Choueiri¹, J. Kocsis², R. Pachynski³, A. Poprach⁴, M. Deshazo⁵, Y. Zakharia⁶, P. Lara⁷, S. Pal⁸, L. Geczi⁹, T. Ho¹⁰, L. Mangel¹¹, B. Redman¹², C. Ryan¹³, T. Olencki¹⁴, B. Simpson¹⁵, B. Adams¹⁵, L. Robertson¹⁵, M. Darif¹⁵, C. Theuer¹⁶, N. Agarwal¹⁷, ¹Dana-Farber Cancer Institute, Boston, US, ²Debrecen Medical University, Debrecen, HU, ³Siteman Cancer Center, St. Louis, US, ⁴Masaryk Memorial Cancer Institute, Brno, CZ, ⁵University of Alabama-Birmingham, Birmingham, US, ⁶University of Iowa - Hospital, Iowa City, US, ⁷University of California Davis Cancer Center, Sacramento, US, ⁸City of Hope, Duarte, US, ⁹National Institute of Oncology Hungary, Budapest, HU, ¹⁰Mayo Clinic Arizona, Phoenix, US, ¹¹Faculty of Medicine, University of Pecs, PTE AOK, Pecs, HU, ¹²University of Michigan, Ann Arbor, US, ¹³Oregon Health Science University, Portland, US, ¹⁴Ohio State University, Columbus, US, ¹⁵TRACON Pharmaceuticals, Inc., San Diego, US, ¹⁶TRACON Pharmaceuticals Inc., San Diego, US, ¹⁷Huntsman Cancer Institute, Salt Lake City, US

15:35 - 15:50

Invited Discussant 911PD and 912PD

15:50 - 15:55

Q&A led by Discussant

15:55 - 15:55

913PD - APACHE: an open label, randomized, phase 2 study of Durvalumab (Durva), alone or in combination with Tremelimumab (Treme), in patients (pts) with refractory germ cell tumors (GCT): results from the expanded combination therapy cohort

E. Farè¹, D. Raggi¹, P. Giannatempo¹, M. Colecchia¹, G. Calareso², S. Ali³, J. Chung³, J. Ross³, A. Necchi¹, ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ²Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ³Foundation Medicine, Cambridge, US

15:55 - 15:55

914PD - Prognostic factors in metastatic seminomatous germ cell tumors and elevated human chorionic gonadotrophin (HCG) - a study of the G3

C. Seidel¹, G. Daugaard², T. Nestler³, A. Tryakin⁴, C. Fankhauser⁵, T. Hermanns⁵, J. Aparicio⁶, J. Heinzlbecker⁷, P. Pfaffenholz³, U. De Giorgi⁸, R. Cathomas⁹, A. Lorch¹⁰, A. Fingerhut¹¹, F. Gayer¹², F. Bremmer¹², P. Giannatempo¹³, A. Necchi¹³, G. Aurilio¹⁴, C. Oing¹, C. Bokemeyer¹, ¹UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ²Rigshospitalet, Copenhagen University Hospital, Copenhagen, DK, ³University

Hospital Cologne, Cologne, DE, ⁴N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ⁵Universitätsspital Zürich, Zurich, CH, ⁶Hospital La Fe, Valencia, ES, ⁷University Clinic Saarland, Homburg/Saar, DE, ⁸University Clinic Meloda, Meloda, IT, ⁹Kantonsspital Graubünden, Chur, CH, ¹⁰University Hospital Zürich, Zurich, CH, ¹¹University Clinic Düsseldorf, Düsseldorf, DE, ¹²University Clinic Göttingen, Göttingen, DE, ¹³Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ¹⁴Istituto Europeo di Oncologia, Milan, IT

15:55 - 15:55

915PD - Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 countries

R. Giles¹, D. Maskens², R. Bick², R. Martinez³, M. Packer⁴, A. Bex⁵, D. Heng⁶, J. Larkin⁷, S.J. Maclennan⁸, M. Jewett⁹, E. Jonasch¹⁰, ¹International Kidney Cancer Coalition, Ouder-Amstel, NL, ²Kidney Cancer Canada, Toronto, CA, ³Smart Patients Inc, Mountain View, US, ⁴Kidney Cancer UK, Harston, GB, ⁵Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ⁶University of Calgary, Calgary, CA, ⁷Royal Marsden Hospital NHS Foundation Trust, London, GB, ⁸University of Aberdeen, Aberdeen, GB, ⁹Princess Margaret Cancer Centre, Toronto, CA, ¹⁰The University of Texas MD Anderson Cancer Center, Houston, US

15:55 - 16:10

Invited Discussant 913PD, 914PD and 915PD

16:10 - 16:15

Q&A led by Discussant

15:00 - 16:15

Type: Poster Discussion session
Title: Poster Discussion - Gastrointestinal tumours, colorectal

Cordoba Auditorium (Hall 7)

15:00 - 15:00

Session DOI

15:00 - 15:00

One LBA TBC

15:00 - 15:00

One LBA TBC

15:00 - 15:00

526PD - TRIUMPH: Primary Efficacy of a Phase II Trial of Trastuzumab (T) and Pertuzumab (P) in Patients (pts) with Metastatic Colorectal Cancer (mCRC) with HER2 (ERBB2) Amplification (amp) in Tumor Tissue or Circulating Tumor DNA (ctDNA): A GOZILA Sub-study

Y. Nakamura¹, W. Okamoto², T. Kato³, H. Hasegawa³, K. Kato⁴, S. Iwasa⁴, T. Esaki⁵, Y. Komatsu⁶, T. Masuishi⁷, T. Nishina⁸, S. Nomura⁹, M. Fukui¹, S. Matsuda¹, A. Sato¹, S. Fujii⁹, J. Odegaard¹⁰, S. Olsen¹¹, T. Yoshino¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Hiroshima University Hospital, Hiroshima, JP, ³Osaka National Hospital,

Osaka, JP, ⁴National Cancer Center Hospital, Tokyo, JP, ⁵National Kyushu Cancer Center, Fukuoka, JP, ⁶Hokkaido University Hospital Cancer Center, Sapporo, JP, ⁷Aichi Cancer Center Hospital, Nagoya, JP, ⁸Shikoku Cancer Center, Matsuyama, JP, ⁹National Cancer Center, Kashiwa, JP, ¹⁰Guardant Health, Redwood City, US, ¹¹Guardant AMEA, Tokyo, JP

- 15:00 - 15:00 **527PD - Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial**
- J. Strickler¹, T. Zemla², F.-S. Ou², A. Cercek³, C. Wu⁴, F. Sanchez⁵, J. Hubbard², B. Jaszewski², L. Bandel², B. Schweitzer², D. Niedzwiecki⁶, N. Kemeny⁷, P. Boland⁸, K. Ng⁹, T. Bekaii-Saab¹⁰, ¹Duke Cancer Center, Durham, US, ²Mayo Clinic, Rochester, US, ³Memorial Sloan-Kettering Cancer Center, New York, US, ⁴Emory University, Atlanta, US, ⁵Aurora Cancer Care, Milwaukee, US, ⁶Duke University Medical Center, Durham, US, ⁷Memorial Sloan Kettering Cancer Center, New York, US, ⁸Roswell Park Comprehensive Cancer Center, Buffalo, US, ⁹Dana-Farber Cancer Institute, Boston, US, ¹⁰Mayo Clinic Cancer Center, Phoenix, US
- 15:00 - 15:15 **Invited Discussant 526PD, 527PD and 2 LBAs TBC**
- 15:15 - 15:25 **Q&A led by Discussant**
- 15:25 - 15:25 **528PD - Impact of clonality and DNA repair mutations on plasma tumor mutation burden (pTMB) and immunotherapy efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in CCTG CO.26**
- J. Loree¹, D. Jonker², H. Feilotter³, H. Kennecke⁴, P. Brohawn⁵, K. Banks⁶, K. Quinn⁶, D. Tu³, C. O'Callaghan³, E. Chen⁷, ¹British Columbia Cancer Agency, Vancouver, CA, ²Ottawa Hospital Research Institute, University of Ottawa, Ottawa, CA, ³Queen's University, Kingston, CA, ⁴Virginia Mason Medical Center, Seattle, US, ⁵MedImmune, Gaithersburg, US, ⁶Guardant Health, Redwood City, US, ⁷University Health Network, Toronto, CA
- 15:25 - 15:25 **529PD - Early identification of treatment effect by methylated circulating tumor DNA in metastatic colorectal cancer**
- C. Thomsen¹, T. Hansen², R. Andersen², L.H. Jensen³, A. Jakobsen², ¹Vejle Hospital Sygehus Lillebaelt, Vejle Sygehus, Vejle, DK, ²Vejle University Hospital Sygehus Lillebaelt, Vejle Sygehus, Vejle, DK, ³Vejle Sygehus Hospital, Vejle, DK
- 15:25 - 15:25 **530PD - Association between transit-amplifying signature and outcomes of patients treated with anti-epidermal growth factor receptor (EGFR) therapy in colorectal cancer**
- E. Fontana¹, G. Nyamundanda², D. Cunningham¹, D. Jonker³, L. Siu⁴, D. Tu⁵, F. Sclafani¹, K. Eason¹, C. Ragulan¹, S. Hulkki-Wilson¹, J. Loree⁶, M. Giordano⁷, P. Lawrence¹, J. Shapiro⁸, C. Cremolini⁹, N. Starling¹⁰, F. Pietrantonio¹¹, L. Trusolino¹², C. O'Callaghan⁵, A. Sadanandam¹³, ¹The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ²Institute of cancer Research, London, GB, ³Ottawa Hospital Research Institute, University of Ottawa, Ottawa, CA, ⁴Princess Margaret Cancer Centre, Toronto,

CA, ⁵Queen's University, Kingston, CA, ⁶British Columbia Cancer Agency, Vancouver, CA, ⁷Univeristy Degli Studi di Pisa, Pisa, IT, ⁸Cabrini Health, Malvern, AU, ⁹Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT, ¹⁰Royal Marsden NHS Foundation Trust, Sutton, GB, ¹¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ¹²IRCCS Candiolo, Candiolo, IT, ¹³The Institute of Cancer Research (Sutton Site), Sutton, GB

- 15:25 - 15:25 **531PD - Sequential RAS mutation testing in cfDNA in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) treated with panitumumab (P) and chemotherapy (CT) in first line (1L). PERSEIDA study**
M. Valladares-Ayerbes¹, P. García-Alfonso², J. Muñoz Luengo³, P. Pimentel Cáceres⁴, J. Viéitez⁵, J. Cruz-Hernández⁶, M. Llanos⁷, C. Garcia Girón⁸, L. Cirera⁹, A. Lloansí Vila¹⁰, ¹University Hospital Reina Sofia, Cordoba, ES, ²General Universitario Gregorio Marañón, Madrid, ES, ³Hospital San Pedro de Alcántara, Cáceres, ES, ⁴Hospital General Universitario Santa Lucia, Cartagena, ES, ⁵Amgen, Madrid, ES, ⁶Hospital Universitario de Salamanca, Salamanca, ES, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, ES, ⁸Hospital Universitario de Burgos, Burgos, ES, ⁹Hospital Universitario Mutua Terrassa, Terrassa, ES, ¹⁰Amgen, Barcelona, ES
- 15:25 - 15:45 **Invited Discussant 528PD, 529PD, 530PD and 531PD**
- 15:45 - 15:55 **Q&A led by Discussant**
- 15:55 - 15:55 **One LBA TBC**
- 15:55 - 15:55 **532PD - Pre-operative FOLFOX chemotherapy in advanced colon cancer: pathology analysis of the FOxTROT trial**
N. West¹, K. Murakami¹, L. Magill², R. Gray³, K. Handley², M. Seymour⁴, D. Morton², P. Quirke⁵, ¹University of Leeds, Leeds, GB, ²University of Birmingham, Birmingham, GB, ³University of Oxford, Oxford, GB, ⁴St. James's University Hospital Leeds, Leeds, GB, ⁵Leeds University, Leeds, GB
- 15:55 - 15:55 **533PD - BACCI: A Phase II Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Capecitabine (C) Bevacizumab (B) plus Atezolizumab (A) or Placebo (P) in Refractory Metastatic Colorectal Cancer (mCRC): An ACCRU Network Study**
N. Mettu¹, E. Twohy², F.-S. Ou², T. Halfdanarson², H.J. Lenz³, R. Breakstone⁴, P. Boland⁵, O. Crysler⁶, C. Wu⁷, A. Grothey⁸, A. Nixon⁹, E. Bolch¹⁰, D. Niedzwiecki¹¹, B. Fruth², B. Schweitzer², A. Elsing², H. Hurwitz¹², M. Fakih¹³, T. Bekaii-Saab¹⁴, ¹Duke Cancer Center, Durham, US, ²Mayo Clinic, Rochester, US, ³USC - Norris Comprehensive Cancer Center, Los Angeles, US, ⁴The Miriam Hospital, Providence, US, ⁵Roswell Park Comprehensive Cancer Center, Buffalo, US, ⁶University of Michigan, Ann Arbor, US, ⁷Emory University, Atlanta, US, ⁸West Cancer Center, Germantown, US, ⁹Duke University Medical Center - Trent Center, Durham, US, ¹⁰Duke University Medical Center, durham, US, ¹¹Duke University Medical Center, Durham, US, ¹²Genentech, South San Francisco,

US, ¹³City of Hope National Medical Center, Duarte, US, ¹⁴Mayo Clinic Cancer Center, Phoenix, US

15:55 - 16:10 **Invited Discussant 532PD, 533PD and one LBA TBC**

16:10 - 16:20 **Q&A led by Discussant**

15:00 - 16:00 **Type: Multidisciplinary session** **Valencia Auditorium (Hall 5)**
Title: Overcoming symptom burden in upper GI cancer

15:00 - 15:00 **Session DOI**

15:00 - 15:10 **Presentation of case/condition: Jaundice**
S. Pereira, Royal Free Hospital School of Medicine, London, GB

15:10 - 15:12 **Q&A**

15:12 - 15:22 **Presentation of case/condition: Dysphagia**
L. Antonin, Gustave Roussy Institut de Cancérologie, Villejuif, FR

15:22 - 15:24 **Q&A**

15:24 - 15:34 **Presentation of case/condition: Pain control**
A. Wagner, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

15:34 - 15:36 **Q&A**

15:36 - 15:46 **Presentation of case/condition: Peritoneal carcinomatosis**
P. Piso, , US

15:46 - 15:48 **Q&A**

15:48 - 16:00 **General discussion**

15:00 - 16:00 **Type: Multidisciplinary session** **Malaga Auditorium (Hall 5)**
Title: Perioperative therapy in melanoma
Chair(s): Piotr Rutkowski, PL

15:00 - 15:00 **Session DOI**

15:00 - 15:05 **Presentation of case/condition**

P. Rutkowski, The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL

15:05 - 15:20 **The role of surgery**

A. Van Akkooij, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

15:20 - 15:35 **Neoadjuvant treatment**

G. Long, Melanoma Institute Australia, Wollstonecraft, AU

15:35 - 15:50 **Adjuvant therapy: How to wisely choose the treatment and for whom**

A. Eggermont, Institut Gustave Roussy, Villejuif, FR

15:50 - 16:00 **General discussion**

15:00 - 16:00 **Type: Challenge your expert** **Cartagena Auditorium (Hall 3)**
Title: Tumour educated platelets
Chair(s): Ivan Dikic, DE

15:00 - 15:00 **Session DOI**

15:00 - 15:10 **Presentation by expert**

M. Best, Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL

15:10 - 16:00 **Discussion led by Chair**

I. Dikic, Frankfurt, DE

15:00 - 18:00 **Type: Young Oncologist session** **Santander Auditorium**
Title: YO Masterclass: Next generation predictive biomarkers in oncology **(Hall 3)**
Chair(s): Guillem Argiles Martinez, ES; Therese Sorlie, NO

15:00 - 15:00 **Session DOI**

15:00 - 15:25 **The importance of the microbiome in cancer**
P. Nuciforo, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

15:25 - 15:40 **Discussion**

15:40 - 16:05 **Beyond pixels: future of molecular imaging in oncology**
P. Kikingereder, University Hospital Heidelberg, Heidelberg, DE

16:05 - 16:20 **Discussion**

16:20 - 16:40 **Coffee Break**

16:40 - 17:05 **Next generation of tumour circulating biomarkers**
K. Pantel, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

17:05 - 17:20 **Discussion**

17:20 - 17:45 **The total is more than the sum of its parts: the inflammatory microenvironment**
N. Halama, Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE

17:45 - 18:00 **Discussion**

15:45 - 16:45 **Type: EONS session** **Oviedo Auditorium (CC5)**
Title: EONS 12: Collaborative session EONS-ESMO: What is the point of cancer prevention for oncology staff?
Chair(s): Theresa Wiseman, GB

15:45 - 15:45 **Session DOI**

15:45 - 16:00 **Cancer nurses role in prevention**

L. Sharp, Regional Cancer Center Stockholm Gotland, Stockholm, SE

16:00 - 16:15 **Oncologogists role in prevention**

G. Morgan, Skane University Hospital, Lund, SE

16:15 - 16:30 **Patients role in prevention**

M. Järvinen, Association of Cancer Patients in Finland, Helsinki, FI

16:30 - 16:45 **Discussion**

16:30 - 18:00 **Type: Proffered Paper session** **Barcelona Auditorium (Hall 2)**
Title: Presidential Symposium II

16:30 - 16:30 **Session DOI**

16:30 - 18:00 **Type: Educational session** **Pamplona Auditorium (Hall 2)**
Title: Progress in the management of non-melanoma skin cancers
 Chair(s): Reinhard Dummer, CH

16:30 - 16:30 **Session DOI**

16:30 - 16:55 **New therapies for Merkel cell carcinoma**
J. Becker, West german cancer center, Essen, DE

16:55 - 17:20 **Update on basal cell carcinoma**
R. Dummer, Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH

17:20 - 17:45 **Squamous cell carcinoma**
A. Hauschild, UK-SH, Campus Kiel, Kiel, DE

17:45 - 18:00 **Discussion**

16:30 - 17:45 **Type: Poster Discussion session** **Cordoba Auditorium (Hall 7)**
Title: Poster Discussion - NSCLC, metastatic

16:30 - 16:30 **Session DOI**

16:30 - 16:30 **1482PD - Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1-positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042**

A. Mansfield¹, R.S. Herbst², G. Castro Jr³, R. Hui⁴, N. Peled⁵, D.-W. Kim⁶, S. Novello⁷, M. Satouchi⁸, Y.-L. Wu⁹, E.B. Garon¹⁰, M. Reck¹¹, A.G. Robinson¹², A. Samkari¹³, B. Piperdi¹³, V. Ebian¹³, J. Lin¹³, T.S. Mok¹⁴, ¹Mayo Clinic, Rochester, US, ²Yale University School of Medicine, New Haven, US, ³Instituto do Câncer do Estado de São Paulo, São Paulo, BR, ⁴Westmead Hospital and the University of Sydney, Sydney, AU, ⁵Ben Gurion University, Beer-Sheva, IL, ⁶Seoul National University Hospital, Seoul, KR, ⁷Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, IT, ⁸Hyogo Cancer Center, Akashi, JP, ⁹Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangdong, CN, ¹⁰Los Angeles, Los Angeles, US, ¹¹Airway Research Center North, German Center of Lung Research, Grosshansdorf, DE, ¹²Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, CA, ¹³Merck & Co., Inc., Kenilworth, US, ¹⁴Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, CN

16:30 - 16:30 **1483PD - Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407**
S. Powell¹, D. Rodriguez Abreu², C.J. Langer³, A. Tafreshi⁴, L. Paz-Ares⁵, H.-G. Kopp⁶, J.

Rodríguez-Cid⁷, D. Kowalski⁸, Y. Cheng⁹, T. Kurata¹⁰, M.M. Awad¹¹, J. Lin¹², B. Zhao¹², M.C. Pietanza¹³, B. Piperdi¹², M. Garassino¹⁴, ¹Sanford Health, Sioux Falls, US, ²Hospital Universitario Insular de Gran Canaria, Las Palmas, ES, ³Abramson Cancer Center, University of Pennsylvania, Philadelphia, US, ⁴Wollongong Private Hospital and University of Wollongong, Wollongong, AU, ⁵Hospital Universitario 12 de Octubre, CNIO, Universidad Complutense and Ciberonc, Madrid, ES, ⁶Robert-Bosch Cancer Center, RBCT, Klinik Schillerhöhe, Gerlingen, DE, ⁷Medica Sur Hospital, Mexico City, MX, ⁸Maria Skłodowska-Curie Institute of Oncology, Warsaw, PL, ⁹Jilin Cancer Hospital, Changchun, CN, ¹⁰Kansai Medical University Hospital, Hirakata Osaka, JP, ¹¹Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, US, ¹²Merck & Co., Inc., Kenilworth, US, ¹³Merck Sharp & Dohme Corp. USA, Whitehouse Station, US, ¹⁴Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

16:30 - 16:30 **One LBA TBC**

16:30 - 16:30 **One LBA TBC**

16:30 - 16:50 **Invited Discussant 1482PD, 1483PD and 2 LBAs TBC**

16:50 - 17:00 **Q&A led by Discussant**

17:00 - 17:00 **1484PD - Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC**

T.S.K. Mok¹, A. Shaw², R. Camidge³, S. Gadgeel⁴, R. Rosell⁵, R. Dziadziuszko⁶, D.-W. Kim⁷, M. Perol⁸, S.-H. Ou⁹, W. Bordogna¹⁰, V. Smoljanović¹⁰, M. Hilton¹⁰, S. Peters¹¹, ¹Prince of Wales Hospital, Shatin, HK, ²Massachusetts General Hospital, Boston, US, ³University of Colorado, Aurora, US, ⁴University of Michigan, Ann Arbor, US, ⁵Catalan Institute of Oncology, Barcelona, ES, ⁶Medical University of Gdansk, Gdansk, PL, ⁷Seoul National University Hospital, Seoul, KR, ⁸Centre Léon Bérard, Lyon, FR, ⁹University of California, Irvine, US, ¹⁰F. Hoffmann-La Roche, Basel, CH, ¹¹Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

17:00 - 17:00 **1485PD - Safety and efficacy of WX-0593 in ALK-positive or ROS1-positive non-small cell lung cancer**

Y.-K. Shi¹, J. Fang², S. Zhang³, Y. Liu⁴, L. Wang⁵, M. Si⁶, M. Ge⁶, H. Geng⁶, ¹Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing, CN, ²Peking University Cancer Hospital & Institute, Beijing, CN, ³Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, CN, ⁴The First Hospital of China Medical University, Shenyang, CN, ⁵Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ⁶Qilu Pharmaceutical Co.,Ltd, Jinan, CN

- 17:00 - 17:00 **1486PD - Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients**
S. Groenland¹, D. Geel², J. Janssen², J. Beijnen³, S. Burgers¹, E. Smit¹, A. Huitema², N. Steeghs¹, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ³The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 17:00 - 17:00 **1487PD - Intracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting**
D.R. Camidge¹, B. Solomon², E. Felip³, B. Besse⁴, A. Bearz⁵, S. Peters⁶, F. Toffalorio⁷, A. Abbattista⁷, H. Thurm⁸, G. Peltz⁹, R. Wiltshire¹⁰, A. Shaw¹¹, ¹University of Colorado, Aurora, US, ²Peter MacCallum Cancer Centre, Melbourne, AU, ³Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁴Gustave Roussy Cancer Campus, Villejuif, FR, ⁵National Institute for Cancer Research, Aviano, IT, ⁶Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ⁷Pfizer Oncology, Milan, IT, ⁸Pfizer Oncology, La Jolla, US, ⁹Pfizer Oncology, Groton, US, ¹⁰Pfizer Oncology, Tadworth, GB, ¹¹Massachusetts General Hospital, Boston, US
- 17:00 - 17:15 **Invited Discussant 1484PD, 1485PD, 1486PD and 1487PD**
- 17:15 - 17:25 **Q&A led by Discussant**
- 17:25 - 17:25 **1488PD - Entrectinib in Locally Advanced/Metastatic ROS1 and NTRK Fusion-Positive Non-Small Cell Lung Cancer (NSCLC): Updated Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001**
F.G. De Braud¹, S. Siena², F. Barlesi³, A. Drilon⁴, B. Simmons⁵, X. Huang⁶, C. Ye⁶, R.C. Doebele⁷, ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ²ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, ³Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, ⁴Memorial Sloan-Kettering Cancer Center, New York, US, ⁵Genentech, South San Francisco, US, ⁶Genentech, Inc., South San Francisco, US, ⁷University of Colorado, Denver, US
- 17:25 - 17:25 **1489PD - Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: results of the prospective PFROST trial**
L. Landi¹, M. Tiseo², L. Heukamp³, R. Menon³, G. Spitaleri⁴, D.L. Cortinovis⁵, A. Delmonte⁶, D. Galetta⁷, M. D'Arcangelo⁸, F. D'Inca⁹, M. Bertrand³, B. Jóri³, A. Zacher³, C. Gridelli¹⁰, S. Novello¹¹, R. Chiari¹², C. Verusio¹³, L. Crinò⁶, F. Cappuzzo¹⁴, ¹Ospedali Riuniti Livorno, Livorno, IT, ²AOU di Parma, Parma, IT, ³NEO New Oncology, Cologne, DE, ⁴Istituto Europeo di Oncologia, Milan, IT, ⁵Asst Ospedale San Gerardo, Monza, IT, ⁶Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ⁷IRCCS Istituto Oncologico "Giovanni Paolo II", Bari, IT, ⁸The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle upon Tyne, GB, ⁹Fondazione Ricerca Traslazionale, Roma, IT, ¹⁰Azienda Ospedaliera S. Giuseppe Moscati, Avellino, IT, ¹¹Università Degli Studi Di Torino - Orbassano, Orbassano, IT, ¹²Santa Maria della Misericordia Hospital,

Azienda Ospedaliera di Perugia, Perugia, IT, ¹³ASST-Valleolona, Saronno, IT, ¹⁴Ospedale Santa Maria delle Croci, Ravenna, IT

17:25 - 17:25 **1490PD - A Phase 1a/2a Trial of Sym015 - a MET Antibody Mixture - in Patients with Advanced Solid Tumors**

D.R. Camidge¹, F. Janku², A. Martinez Bueno³, D. Catenacci⁴, J. Lee⁵, S.-H. Lee⁶, H.C. Chung⁷, A. Dowlati⁸, K. Rohrberg⁹, E. Felip Font¹⁰, E. Garralda¹¹, Y.-K. Kang¹², Y.W. Moon¹³, M. López Criado¹⁴, C.-F. Chiu¹⁵, T. Poulsen¹⁶, H. Rudbæk¹⁶, L. Alifrangis¹⁶, R.P. Dalal¹⁶, A. Patnaik¹⁷, ¹University of Colorado, Aurora, US, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³Instituto Universitario USP Dexeus, Barcelona, ES, ⁴University of Chicago, Chicago, US, ⁵Samsung Medical Center, Seoul, KR, ⁶Seoul National University Hospital, Seoul, KR, ⁷Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁸UH Case Medical Center, Cleveland, US, ⁹Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, ¹⁰Vall d'Hebron University Hospital, Barcelona, ES, ¹¹Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ¹²Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ¹³Bundang Cha Medical Center, Seongnam, KR, ¹⁴M.D. Anderson Cancer Center Madrid, Madrid, ES, ¹⁵China Medical University Hospital, Taichung, TW, ¹⁶Symphogen A/S, Ballerup, DK, ¹⁷South Texas Accelerated Research Therapeutics (START), San Antonio, US

17:25 - 17:25 **One LBA TBC**

17:25 - 17:40 **Invited Discussant 1488PD, 1489PD, 1490PD and one LBA TBC**

17:40 - 17:50 **Q&A led by Discussant**

16:30 - 18:00 **Type: Educational session** **Valencia Auditorium (Hall 5)**
Title: Management of body resources in patients with advanced cancer
 Chair(s): Stein Kaasa, NO; Florian Scotté, FR

16:30 - 16:30 **Session DOI**

16:30 - 16:55 **Determinants of malnutrition and sarcopenia**
V. Baracos, University of Alberta Cross Cancer Institute, Edmonton, CA

16:55 - 17:20 **Applying ESMO and ESPEN Guidelines: Acting before cachexia hits**
J. Arends, Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, Freiburg, DE

17:20 - 17:45 **Issues the clinician faces in order to apply these guidelines**
S. Kaasa, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO

17:45 - 18:00 **Discussion**

16:30 - 18:00 **Type: Proffered Paper session** **Malaga Auditorium (Hall 5)**
Title: Proffered Paper - Developmental therapeutics

16:30 - 16:30 **Session DOI**

16:30 - 16:42 **4380 - METEOR-1: A Phase I Study of GSK3326595, a First-In-Class Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Advanced Solid Tumors**
L. Siu¹, D. Rasco², S. Postel Vinay³, P. Martin Romano⁴, J. Menis⁵, F. Opdam⁶, K. Heinhuis⁷, J. Egger⁸, S. Gorman⁹, R. Parasrampur¹⁰, K. Wang¹⁰, B. Kremer⁹, M. Gounder¹¹, ¹Princess Margaret Cancer Centre, Toronto, CA, ²The START Center for Cancer Care, San Antonio, US, ³Institut Gustave Roussy, Villejuif, FR, ⁴Gustave Roussy, Villejuif, FR, ⁵Istituto Oncologico Veneto IRCCS, Padova, IT, ⁶NKI-AVL, Amsterdam, NL, ⁷Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ⁸GlaxoSmithKline, Uxbridge, GB, ⁹GlaxoSmithKline USA, Collegeville, US, ¹⁰GlaxoSmithKline, Collegeville, US, ¹¹Memorial Sloan-Kettering Cancer Center, New York, US

16:42 - 16:54 **4390 - A first in human, phase 1 trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors.**
P. Cassier¹, L. Eberst¹, G. Garin¹, Y. Courbebaisse², C. Terret¹, M. Robert³, J.-S. Frenel⁴, S. Depil¹, J.-P. Delord⁵, D. Perol¹, I. Ray-Coquard¹, A.-S. Bidaux¹, S. Tabone-Eglinger⁶, L. Gilles-Afchain¹, I. Treilleux¹, Q. Wang¹, B. Ducarouge⁷, P. Mehlen⁷, J.-Y. Blay¹, C. Gomez-Roca⁵, ¹Centre Léon Bérard, Lyon, FR, ²Société COURBEBAISSSE YANN, Lyon, FR,

³Centre Rene Gauducheau, Nantes, FR, ⁴ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁵Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ⁶Centre Léon-Bérard, Lyon, FR, ⁷Netris Pharma, Lyon, FR

16:54 - 17:06 **4400 - Phase 1 Study of the Arginase Inhibitor INCB001158 (1158) Alone and in Combination with Pembrolizumab (PEM) in Patients (Pts) with Advanced/Metastatic (Adv/Met) Solid Tumors**

A. Naing¹, T. Bauer², K. Papadopoulos³, O. Rahma⁴, F. Tsai⁵, E. Garralda⁶, J. Naidoo⁷, S. Pai⁸, M. Gibson⁹, I. Rybkin¹⁰, D. Wang¹⁰, D. Mcdermott¹¹, A. Fasolo¹², M. De Miguel¹³, M. Shaheen¹⁴, Y. Jenkins¹⁵, H. Kallender¹⁶, S. Gogov¹⁶, E. Kuriakose¹⁷, M. Pishvaian¹⁸, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²Sarah Cannon Research Institute, Nashville, US, ³South Texas Accelerated Research Therapeutics (START), San Antonio, US, ⁴Dana-Farber Cancer Institute, Boston, US, ⁵HonorHealth Research Institute, Scottsdale, US, ⁶Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁷Johns Hopkins Bayview Center, Baltimore, US, ⁸University of South Alabama, Mobile, US, ⁹Vanderbilt University Medical Center, Nashville, US, ¹⁰Henry Ford Cancer Institute, Detroit, US, ¹¹Beth Israel Deaconess Med. Center, Boston, US, ¹²Ospedale San Raffaele, Milan, IT, ¹³START Madrid-HM CIOCC, Madrid, ES, ¹⁴The University of Arizona Cancer Center, Tucson, US, ¹⁵Allakos, Inc., South San Francisco, US, ¹⁶Incyte Corp., Wilmington, US, ¹⁷Calithera Biosciences, Inc., South San Francisco, US, ¹⁸Georgetown University, Washington, US

17:06 - 17:24 **Invited Discussant 4380, 4390 and 4400**

17:24 - 17:36 **4410 - A Platform Trial with a Registry Study for Rare Cancers: MASTER KEY Project**

S. Narita¹, H. Okuma¹, K. Yonemori¹, T. Sukigara¹, A. Hirakawa², W. Munakata¹, N. Okita¹, T. Shimizu¹, T. Shibata³, A. Kawai¹, N. Yamamoto¹, K. Izutsu¹, M. Muto⁴, H. Akita⁵, E. Baba⁶, K. Nakamura¹, H. Mano⁷, T. Nishida¹, Y. Fujiwara⁸, ¹National Cancer Center Hospital, Tokyo, JP, ²The University of Tokyo, Tokyo, JP, ³National Cancer Center, Tokyo, JP, ⁴Kyoto University Graduate School of Medicine, Kyoto, JP, ⁵Hokkaido University Hospital, Sapporo, JP, ⁶Kyushu University Hospital, Fukuoka, JP, ⁷National Cancer Center Research Institute, Tokyo, JP, ⁸Pharmaceutical and Medical Devices Agency, Tokyo, JP

17:36 - 17:48 **4420 - Therapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study**

S. Groenland¹, R. Van Eerden², S. Koolen³, D.J. Moes⁴, I. Desar⁵, D. Touw⁶, A. Imholz⁷, A. Reyners⁸, H. Gelderblom⁹, N. Van Erp⁵, R. Mathijssen², A. Huitema¹⁰, N. Steeghs¹, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²Erasmus MC Cancer Institute, Rotterdam, NL, ³Erasmus University Medical Center, Rotterdam, NL, ⁴Leiden University Medical Center, Leiden, NL, ⁵Radboud University Medical Center, Nijmegen, NL, ⁶University Medical Center Groningen, Groningen, NL, ⁷Deventer Ziekenhuis, Deventer, NL, ⁸University Hospital Groningen (UMCG), Groningen, NL, ⁹Leids Universitair Medisch Centrum (LUMC), Leiden, NL, ¹⁰Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NL

17:48 - 18:00 **Invited Discussant 4410 and 4420**

16:30 - 18:00 **Type: Proffered Paper session** **Tarragona Auditorium (Hall 7)**
Title: Proffered Paper - NETs and endocrine tumours

16:30 - 16:30 **Session DOI**

16:30 - 16:42 **One LBA TBC**

16:42 - 16:54 **One LBA TBC**

16:54 - 17:06 **13800 - 177Lu-DOTATATE plus 166Ho-radioembolization in patients with neuroendocrine tumours; a single center, prospective, interventional, non-comparative, open label, phase II study (HEPAR PLUS study)**

A. Braat¹, R. Van Rooij², R. Bruijnen², M. Braat², F. Wessels², R. Van Leeuwaarde², M. Van Treijen², H. De Jong², M. Lam², ¹UMC-University Medical Center Utrecht, Utrecht, NL, ²University Medical Center Utrecht, Utrecht, NL

17:06 - 17:21 **Invited Discussant 13800 and 2 LBAs TBC**

17:21 - 17:33 **13810 - RNA expression profiles and splicing alterations in grade 1/2 neuroendocrine neoplasms from small intestine origin (siNENs). Final results of the GETNE-NETSEQ study**

J. Capdevila¹, J. Castaño², F. Mancuso³, S. Pedraza-Arevalo², I. Matos¹, H. Palmer³, F. Salva⁴, S. Landolfi⁵, P. Jimenez-Fonseca⁶, R. Garcia-Carbonero⁷, C. Lopez⁸, Z. Ogbah³, P. Nuciforo³, A. Casteras¹, D. Acosta⁹, M. Diez⁹, J. Hernando⁹, R. Luque², A. Vivancos¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Maimonides Biomedical Research Institute of Cordoba. Reina Sofia University Hospital., Cordoba, ES, ³Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁴Mataro University Hospital, Mataro, ES, ⁵Vall Hebron University Hospital, Barcelona, ES, ⁶Hospital Universitario Central de Oviedo, Oviedo, ES, ⁷University Hospital 12 De Octubre, Madrid, ES, ⁸Marques de Valdecilla University Hospital, Santander, ES, ⁹Vall d'Hebron University Hospital. Vall Hebron Institute of Oncology (VHIO), Barcelona, ES

17:33 - 17:45 **5120 - Malignant Non-adrenal Paraganglioma (mPara) and Adrenal Pheochromocytoma (mPheo) a Comparative Comprehensive Genomic Profiling (CGP) Study**

G. Bratslavsky¹, E. Sokol², A. Necchi³, O. Shapiro¹, J. Jacob¹, N. Liu¹, J. Elvin², J.-A. Vergilio², J.K. Killian², N. Ngo², D. Lin², S. Ramkissoon², E. Severson², S. Ali², A. Schrock², J. Chung², P. Reddy², B. Alexander², V. Miller², J. Ross⁴, ¹Upstate Medical University, Syracuse, US, ²Foundation Medicine, Cambridge, US, ³Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁴Albany Medical Center, Albany, US

17:45 - 18:00 **Invited Discussant 13810 and 5120**

16:30 - 17:45 **Type: Poster Discussion session** **Alicante Auditorium (Hall 3)**
Title: Poster Discussion session - Basic science

16:30 - 16:30 **Session DOI**

16:30 - 16:30 **5PD - The role of EGFR inhibitor (EGFRi) in immune cell infiltration and CD8+ T-cell activation in EGFR mutant lung cancer**

F. Li¹, G. Lizee², P. Hwu², X. Du³, L. Deng⁴, A. Talukder², A. Katailaha², Q. Zou⁴, J. Roszik², D. Hawke², K. Jackson², S. Bradley², Y. Wang⁴, R. Ataulakhanov⁵, A. Bagaev⁵, N. Kotlov⁵, V. Svekolkina⁵, N. Mihecheva⁵, F. Frenkel⁵, H. Sonnemann², ¹Baylor College of Medicine, Houston, US, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³Tianjin Beichen Hospital, Tianjin, CN, ⁴Tianjin HengJia Biotechnology Development Co., Ltd., Tianjin, CN, ⁵BostonGene Corporation, Boston, US

16:30 - 16:30 **6PD - The mutational signature of spontaneously developing tumors in MLH1-/- mice - potential consequences for immunotherapeutic approaches**

C. Maletzki¹, Y. Gladbach¹, M. Hamed¹, C. Junghans², ¹Universitätsmedizin Rostock, Rostock, DE, ²Universitätsklinikum Rostock, Rostock, DE

16:30 - 16:30 **7PD - Synergistic anti-cancer activity of auranofin with anti-PD-L1 therapy in triple-negative breast cancer**

P. Raininga¹, A. Lee², D. Sinha¹, Y.-Y. Shin², D. Mittal¹, M. Kalimutho¹, K.K. Khanna¹, ¹QIMR Berghofer Medical Research Institute, Brisbane, AU, ²Radiation Biology Research Center, Taoyuan, TW

16:30 - 16:30 **1982PD - Identification of a Radio-Immune Signature with High Prognostic Value in Surgically Resected NSCLC**

G. Mazzaschi¹, F. Quaini¹, G. Milanese², L. Gnetti³, G. Bocchialini⁴, L. Ampollini², R. Minari¹, M. Silva², N. Sverzellati², G. Roti², M. Tiseo¹, ¹AOU di Parma, Parma, IT, ²University of Parma, Parma, IT, ³Azienda Ospedaliera di Parma, Parma, IT, ⁴Bocchialini, Parma, IT

16:30 - 16:50 **Invited Discussant 5PD, 6PD, 7PD and 1982PD**

16:50 - 17:00 **Q&A led by Discussant**

17:00 - 17:00 **8PD - Automatic interpretation of cancer genomes creates the largest repository of tumor genetic driver events**

F. Martínez Jiménez, F. Muiños, O. Pich, A. González-Perez, N. López-Bigas, Institute for

Research in Biomedicine (IRB Barcelona), Barcelona, ES

- 17:00 - 17:00 **1983PD - Comprehensive genomic profiling (CGP) of carcinoma of unknown primary origin (CUP): Retrospective molecular classification of potentially eligible patients (pts) for targeted or immunotherapy treatment (tx) using the prospective CUPISCO trial's criteria**
J. Ross¹, E. Sokol², H. Moch³, L. Mileshkin⁴, G. Baciarello⁵, F. Losa⁶, A. Beringer⁷, M. Thomas⁷, S. Foser⁷, J. Elvin², N. Danziger⁸, N. Ngo⁸, J. Tse⁸, K. Killian⁸, D. Jin⁸, L. Gay⁸, A. Krämer⁹, ¹Albany Medical Center, Albany, US, ²Foundation Medicine, Cambridge, US, ³University Hospital Zurich, Zurich, CH, ⁴Peter MacCallum Cancer Centre, Melbourne, AU, ⁵Institut Gustave Roussy, Villejuif, FR, ⁶Hospital de Sant Joan Despí Moisès Broggi, Barcelona, ES, ⁷F. Hoffmann-La Roche Ltd, Basel, CH, ⁸Foundation Medicine, Inc., Cambridge, US, ⁹German Cancer Research Center (DKFZ) and University of Heidelberg, Heidelberg, DE
- 17:00 - 17:00 **1984PD - Functional Cell Profiling (FCP) of ~100,000 CTCs from multiple cancer types identifies morphologically distinguishable CTC subtypes within and between cancer types**
A. Jendrisak¹, R. Sutton¹, S. Orr², D. Lu², J. Schonhoff², Y. Wang², ¹Epic Sciences, SAN DIEGO, US, ²Epic Sciences, San Diego, US
- 17:00 - 17:15 **Invited Discussant 8PD, 1983PD and 1984PD**
- 17:15 - 17:22 **Q&A led by Discussant**
- 17:22 - 17:22 **9PD - Aurora-B mediated Snail phosphorylation is essential for mitotic spindle checkpoint and for preventing chromosomal instability in breast cancer**
B. Xu, M. Xiao, X. Li, Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN
- 17:22 - 17:22 **1985PD - Aspartate-β-hydroxylase drives hepatocellular carcinoma progression to metastasis fueling glutamine via HIF1α-mediated mitophagy**
R. Xue¹, J. Wu², Q. Meng², ¹Beijing Cancer Hospital, Beijing, CN, ²Beijing You-an Hospital, Capital Medical University, Beijing, CN
- 17:22 - 17:22 **1986PD - HORAS5 promotes cabazitaxel resistance in castration resistant prostate cancer via a BCL2A1-dependent survival mechanism**
P. Pucci¹, E. Venalainen², I. Alborelli³, L. Quagliata⁴, R. Mather¹, S. Rigas¹, I. Romero¹, Y. Wang⁵, F. Crea¹, ¹The Open University, Milton Keynes, GB, ²BC Cancer Agency Cancer Research Centre, Vancouver, CA, ³University Hospital Basel, Basel, CH, ⁴Institute of Pathology-University Hospital Basel, Basel, CH, ⁵British Columbia Cancer Research Centre, Vancouver, CA
- 17:22 - 17:37 **Invited Discussant 9PD, 1985PD and 1986PD**

17:37 - 17:44 **Q&A led by Discussant**

16:30 - 18:00 **Type: Educational session** **Leon Auditorium (Hall 3)**
Title: The promise of Machine Learning in medical oncology
Chair(s): E.G. Elisabeth De Vries, NL; Fatima Cardoso, PT

16:30 - 16:30 **Session DOI**

16:30 - 16:55 **QuPath in cancer pathology as role model**
M. Salto-Tellez, Belfast City Hospital, Belfast, GB

16:55 - 17:20 **The medical oncologist perspective: What is the future role of artificial intelligence in medical oncology?**
R. Fehrmann, University Hospital Groningen (UMCG), Groningen, NL

17:20 - 17:45 **The European Commission's perspective: Artificial intelligence and progress in cancer**

17:45 - 18:00 **Discussion**

16:45 - 17:45 **Type: Multidisciplinary session** **Cartagena Auditorium (Hall 3)**
Title: Liquid biopsies, tumour dormancy and minimal residual disease detection

16:45 - 16:45 **Session DOI**

16:45 - 16:50 **Presentation of case/condition**

16:50 - 17:05 **Technical validity**

C. Dive, Cancer Research UK Manchester Institute, Manchester, GB

17:05 - 17:20 **Metastases, dormancy and later recurrences**

F. Giancotti, MD Anderson Research Medical Library, Houston, US

17:20 - 17:35 **High-sensitivity ctDNA assays to detect residual disease**

N. Rosenfeld, Cancer Research UK Cambridge Institute, Cambridge, GB

17:35 - 17:45 **General discussion**

17:00 - 18:00 **Type: EONS session** **Oviedo Auditorium (CC5)**
Title: EONS 12: Collaborative session EONS-MASCC: Cancer Survivor vs Survivorship : Clash of cultures or words?
Chair(s): Harald Titzer, AT

17:00 - 17:00 **Session DOI**

17:00 - 17:20 **Long term follow up**

J. Ruíz Pato, European Society for Blood and Marrow Transplantation-EBMT, Barcelona, ES

17:20 - 17:40 **Invited MASCC**

R. Chan, Queensland University of Technology, Brisbane, AU

17:40 - 18:00 **Discussion**

18:15 - 19:45 **Type: Patient Advocay Track** **Leon Auditorium**
Title: How can we better support cancer patients suffering **(Hall 3)**
from fatigue?
Chair(s): Charlotte Roffiaen, FR; Guy Bouquet, FR

18:15 - 18:15 **Session DOI**

18:15 - 18:20 **Introduction**

C. Roffiaen, Lymphoma Coalition Europe, Paris, FR

18:20 - 18:35 **Making fatigue visible: Results of the Lymphoma Coalition 2018 survey**

G. Bouquet, France Lymphome Espoir, Paris, FR

18:35 - 18:50 **Measuring cancer related fatigues: The EORTC QLQ-FA12 and other fatigue assessment instruments**

J. Weis, University Medical Center Freiburg, Freiburg im Breisgau, DE

18:50 - 19:05 **Tackling the many factors that contribute to fatigue**

M. Aapro, Clinique de Genolier, Genolier, CH

19:05 - 19:20 **Is more research needed to support the integration of exercise into the standard health basket for cancer care?**

J. Wiskemann, Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE

19:20 - 19:45 **Round table discussion and conclusions**

G. Bouquet¹, C. Roffiaen², ¹France Lymphome Espoir, Paris, FR, ²Lymphoma Coalition Europe, Paris, FR

18:30 - 20:00 **Type: Industry Satellite Symposium** **Pamplona Auditorium (Hall 2)**
Title: Industry satellite symposium-Slot 35

18:30 - 20:00	Type: ESMO Colloquium Title: ESMO Colloquium supported by Ipsen - Metastatic clear cell renal cell carcinoma How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting? Chair(s): Manuela Schmidinger, AT; Bernard Escudier, FR	Cordoba Auditorium (Hall 7)
18:30 - 18:30	Session DOI	
18:30 - 18:33	Introduction <u>B. Escudier</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
18:33 - 18:48	Present standard of care according to the 2019 ESMO Guidelines <u>M. Schmidinger</u> , Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT	
18:48 - 18:53	Q&A	
18:53 - 19:13	Comparative outcome in 1st line according to prognostic group and criteria for decision making <u>C.G. Porta</u> , IRCCS Istituti Clinici Scientifici Maugeri, Pavia, IT	
19:13 - 19:18	Q&A	
19:18 - 19:33	Options and criteria for treatment choice in 2nd and 3rd lines <u>R. De Wit</u> , Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL	
19:33 - 19:38	Q&A	
19:38 - 19:53	How to the sequence the use of drugs in a multi-lines' strategy for RCC? <u>B. Escudier</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
19:53 - 19:58	Q&A	
19:58 - 20:00	Conclusions <u>M. Schmidinger</u> , Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT	

18:30 - 20:00 **Type: Industry Satellite Symposium** **Bilbao Auditorium (Hall 5)**
Title: Sanofi Genzyme - Sequencing strategies in metastatic prostate cancer: Revealing the cards
Chair(s): Bertrand Tombal, BE; Joan Carles, ES

18:30 - 18:35 **Introduction**

J. Carles¹, B. Tombal², ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE

18:35 - 18:55 **Shuffling the cards in the metastatic castration-resistant prostate cancer (MCRPC) treatment paradigm**

B. Tombal, Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE

18:55 - 19:15 **Raising the stakes in prospective sequencing studies in mCRPC**

K. Chi, BC Cancer Agency - Vancouver, Vancouver, CA

19:15 - 19:30 **Playing the best hand in sequencing strategies for mCRPC: Retrospective and registry studies**

J. Carles, Vall d'Hebron University Hospital, Barcelona, ES

19:30 - 19:45 **An ace in treatment sequencing for metastatic hormone-sensitive prostate cancer (mHSPC)**

A. Morgans, Northwestern University Feinberg School of Medicine, Chicago, US

19:45 - 20:00 **Q&A and closing remarks**

B. Tombal, Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE

18:30 - 20:00 **Type: Industry Satellite Symposium** **Tarragona Auditorium (Hall 7)**
Title: Incyte Biosciences International - Personalized approaches in cholangiocarcinoma
Chair(s): Eric Van Cutsem, BE; Teresa Maraculla Mercade, ES

18:30 - 18:35 **Welcome and introductions**

E. Van Cutsem¹, T. Maraculla Mercade², ¹University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, BE, ²Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, ES

18:35 - 18:55 **Cholangiocarcinoma: not a single disease**

A. Lamarca, The Christie NHS Foundation Trust, Manchester, GB

18:55 - 19:20 **Cholangiocarcinoma treatment: what's new**

E. Van Cutsem, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, BE

19:20 - 19:40 **Cholangiocarcinoma molecular characterization: challenges and opportunities**

N. Normanno, Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT

19:40 - 19:50 **Interactive case study discussion**

T. Maraculla Mercade, Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, ES

19:50 - 20:00 **Q&A, summary and close**

E. Van Cutsem¹, T. Maraculla Mercade², ¹University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, BE, ²Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, ES

18:30 - 20:00	Type: ESMO Colloquium Title: ESMO Colloquium supported by Lilly Oncology - Metastatic gastro-intestinal cancer: Multiple treatment lines, extended pipeline of available drugs and use of predictive markers. How to best sequence the treatment proposal? Chair(s): Florian Lordick, DE	Alicante Auditorium (Hall 3)
18:30 - 18:30	Session DOI	
18:30 - 18:35	Introduction <u>F. Lordick</u> , University Cancer Center Leipzig, Leipzig, DE	
18:35 - 19:00	Metastatic gastro-oesophageal adenocarcinoma	
19:00 - 19:25	Metastatic colorectal cancer	
19:25 - 19:50	Unresectable or relapsed hepato-cellular carcinomas	
19:50 - 20:00	Conclusion	

18:30 - 20:00 **Type: Industry Satellite Symposium** **Cartagena Auditorium (Hall 3)**
Title: Tesaro - No maintenance is not an option anymore: PARP inhibition in ovarian cancer
Chair(s): Nicoletta Colombo, IT; Antonio González-Martín, ES

18:30 - 18:35 **Introduction**

N. Colombo, Istituto Europeo di Oncologia, Milan, IT

18:35 - 18:55 **PARP inhibitors: Are there any differences?**

B. Monk, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital, Phoenix, US

18:55 - 19:15 **PARP inhibitors in front-line therapy**

A. González-Martín, Clínica Universidad de Navarra, Madrid, ES

19:15 - 19:35 **Practical aspects of maintenance therapy: How to handle PARPi**

D. Lorusso, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

19:35 - 19:55 **New options for ovarian cancer patients: Are we ready for chemo-free therapy?**

M.R. Mirza, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK

19:55 - 20:00 **Conclusions**

A. González-Martín, Clínica Universidad de Navarra, Madrid, ES

- 18:30 - 20:00** **Type: Industry Satellite Symposium** **Salamanca Auditorium (Hall 3)**
Title: Medscape Oncology - Servier - Faster intervention and better outcomes in advanced pancreatic cancer: Putting it into practice
Chair(s): Alberto Sobrero, IT
- 18:30 - 18:35 **Welcome and introductions**
A. Sobrero, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT
- 18:35 - 18:50 **Challenges and opportunities in treating advanced pancreatic cancer: why speed counts**
M. Ducreux, Gustave Roussy - Cancer Campus, Villejuif, FR
- 18:50 - 19:05 **What is the evidence for current treatment options?**
C. Yoo, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR
- 19:05 - 19:20 **What is the role of biomarkers in patient and treatment selection?**
A. Sobrero, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT
- 19:20 - 19:35 **Best practice in advanced pancreatic cancer: insights from an expert center**
H. Wilmink, Academic Medical Center (AMC), Amsterdam, NL
- 19:35 - 19:55 **The pancreatic case clinic: expert insights on real case challenges**
- 19:55 - 20:00 **Summary and close**
A. Sobrero, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

18:30 - 20:00	Type: ESMO Colloquium Title: ESMO Colloquium supported by Daiichi Sankyo Europe GmbH - Relapsed/Refractory FLT3-ITD positive Acute Myeloid Leukemias (AML)	Toledo Auditorium (Hall 5)
18:30 - 18:30	Session DOI	
18:30 - 18:35	Introduction	
18:35 - 18:55	Molecular profiling, prognosis and present Guidelines for Relapsed/Refractory AML <u>L. Bullinger</u> , Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE	
18:55 - 19:15	Are FLT3 Mutated AML a special entity? <u>G. Ossenkoppele</u> , Vrije University Medical Centre (VUMC), Amsterdam, NL	
19:15 - 19:45	Recent results with FLT3 Inhibitors in FLT3-ITD positive Relapsed/Refractory AML and future development	
19:45 - 19:55	Question/Answers from the audience to panelists <u>L. Bullinger</u> ¹ , <u>G. Ossenkoppele</u> ² , ¹ Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ² Vrije University Medical Centre (VUMC), Amsterdam, NL	
19:55 - 20:00	Conclusions	

18:30 - 20:00	Type: Industry Satellite Symposium Title: Thermo Fisher Scientific - Precision in practice: a new era for oncology treatment Chair(s): Manfred Dietel, DE	Santander Auditorium (Hall 3)
18:30 - 18:35	Welcome and introduction <u>M. Dietel</u> , University Hospital Charité, Berlin, DE	
18:35 - 18:55	Precision oncology: Where are we today? <u>A. Sartore-Bianchi</u> , Grande Ospedale Metropolitano Niguarda and University of Milan, Milan, IT	
18:55 - 19:15	Leading from the lab: pathology in focus <u>F. Lopez-Rios</u> , Hospital Universitario HM Sanchinarro, Madrid, ES	
19:15 - 19:35	The molecular tumour board: a team effort	
19:35 - 19:55	Informing immunotherapy in future: beyond PDL1 and TMB <u>M. Provencio</u> , Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES	
19:55 - 20:00	Conclusions and Q&A	

30.09.2019

08:00 - 09:00 **Type: EONS session** **Oviedo Auditorium (CC5)**
Title: EONS 12: Collaborative session EONS-SIOG: Meeting the needs of elderly patients with cancer
Chair(s): Wendy Oldenmenger, NL

08:00 - 08:00 **Session DOI**

08:00 - 08:20 **Cancer-related information needs and treatment decision-making experiences of people with dementia in England: A multiple perspective qualitative study**
L. McWilliams, The Christie NHS Foundation Trust, Manchester, GB

08:20 - 08:40 **Invited SIOG**
C. Kenis, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

08:40 - 09:00 **Discussion**

08:30 - 10:00 **Type: Proffered Paper session** **Barcelona Auditorium**
Title: Proffered Paper 2 - Gastrointestinal tumours, **(Hall 2)**
colorectal

08:30 - 08:30 **Session DOI**

08:30 - 08:45 **One LBA TBC**

08:45 - 09:00 **One LBA TBC**

09:00 - 09:15 **5240 - Next-generation sequencing (NGS) in metastatic colorectal cancer (mCRC): novel mutated genes and their effect on response to therapy (Alliance)**
F. Innocenti¹, N. Rashid², M. Wancen², F.-S. Ou³, X. Qu⁴, S. Denning², M. Bertagnolli⁵, C. Blanke⁶, A. Venook⁷, O. Kabbarah⁸, H.J. Lenz⁹, ¹UNC-Institute for Pharmacogenomics and Individualized Therapy, Chapel Hill, US, ²University of North Carolina, Chapel Hill, US, ³Mayo Clinic, Rochester, US, ⁴Genentech, South San Francisco, US, ⁵Brigham and Women's Hospital, Boston, US, ⁶Oregon Health Science University, Portland, US, ⁷UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ⁸ORIC Pharmaceuticals, San Francisco, US, ⁹USC - Norris Comprehensive Cancer Center, Los Angeles, US

09:15 - 09:33 **Invited Discussant 5240 and 2 LBAs TBC**

09:33 - 09:48 **One LBA TBC**

09:48 - 10:00 **Invited Discussant One LBA TBC**

08:30 - 10:00 **Type: Proffered Paper session** **Madrid Auditorium (Hall 2)**
Title: Proffered Paper 2 - NSCLC, metastatic

08:30 - 08:30 **Session DOI**

08:30 - 08:45 **14800 - CTONG 1509 : Phase 3 study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC**
Q. Zhou¹, Y.-L. Wu², Y. Cheng³, Y. Liu⁴, G. Chen⁵, J. Cui⁶, N. Yang⁷, Y. Song⁸, X.-L. Li⁹, S. Lu¹⁰, J. Zhou¹¹, Z. Ma¹², S.-Y. Yu¹³, C. Huang¹⁴, Y. Shu¹⁵, ¹Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, ²Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, ³Jilin Cancer Hospital, Changchun, CN, ⁴The First

Hospital of China Medical University,, Shenyang, CN, ⁵Harbin Medical University Cancer Hospital, Harbin, CN, ⁶The First Hospital of Jilin University, Changchun, CN, ⁷Hunan Cancer Hospital, Changsha, CN, ⁸Jinling Hospital, Nanjing, CN, ⁹Cancer Hospital of China Medical University Liaoning Cancer Hospital & Institute, Shenyang, CN, ¹⁰Shanghai Chest Hospital, Shanghai, CN, ¹¹The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China, Hangzhou, CN, ¹²The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, CN, ¹³Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ¹⁴Fujian Cancer Hospital, The Affiliated Cancer Hospital of Fujian Medical University, Fuzhou, CN, ¹⁵Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, CN

- 08:45 - 09:00 **14810 - Clinical development of molecular-targeted therapies for non-small cell lung cancer through nationwide genome screening in Japan (LC-SCRUM-Japan)**
S. Miyamoto¹, S. Matsumoto², K. Yoh², T. Kato³, K. Nishino⁴, S. Sugawara⁵, M. Nakao⁶, Y. Ohe⁷, T. Seto⁸, J. Sakakibara-Konishi⁹, N. Furuya¹⁰, K. Goto², ¹Japanese Red Cross Medical Center, Tokyo, JP, ²National Cancer Center Hospital East, Kashiwa, JP, ³Kanagawa Cancer Center, Yokohama, JP, ⁴Osaka International Cancer Institute, Osaka, JP, ⁵Sendai Kousei Hospital, Sendai, JP, ⁶Shimane University, Izumo, JP, ⁷National Cancer Center Hospital, Tokyo, JP, ⁸National Kyushu Cancer Center, Fukuoka, JP, ⁹Hokkaido University Hospital, Sapporo, JP, ¹⁰St. Marianna University School of Medicine, Kawasaki, JP
- 09:00 - 09:15 **Invited Discussant 14800 and 14810**
- 09:15 - 09:30 **One LBA TBC**
- 09:30 - 09:45 **One LBA TBC**
- 09:45 - 10:00 **Invited Discussant 2 LBAs TBC**

08:30 - 10:00 **Type: Special symposium** **Sevilla Auditorium**
Title: Targeting tumour metabolism to impact outcome from metastatic prostate cancers **(Hall 2)**
Chair(s): Andrea Alimonti, CH; Pier Paolo Pandolfi, US

08:30 - 08:30 **Session DOI**

08:30 - 08:35 **Introduction**

P.P. Pandolfi, Beth Israel Deaconess Med. Center, Boston, US

08:35 - 08:55 **Metabolic requirements of prostate cancer**

A. Alimonti, IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH

08:55 - 09:15 **Genetics of lipid metabolism in prostate cancer**

P.P. Pandolfi, Beth Israel Deaconess Med. Center, Boston, US

09:15 - 09:35 **Polyamine metabolism in prostate cancer**

A. Carracedo Perez, CIC bioGUNE - Centro de Inv. Cooperativa en Biociencias, Derio, ES

09:35 - 09:55 **Targeting immunometabolism for cancer therapy**

M. Mazzone, KU Leuven, Leuven, BE

09:55 - 10:00 **Conclusions and perspectives**

A. Alimonti, IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH

08:30 - 10:00	Type: Special symposium Title: Survivor care in the times of innovative therapies Chair(s): Antonio Vigano, CA; Matti Aapro, CH	Cordoba Auditorium (Hall 7)
08:30 - 08:50	Session DOI	
08:50 - 08:55	Introduction <u>A. Vigano</u> , McGill University Health Center The Montreal General Hospital, Montreal, CA	
08:55 - 09:15	Lessons from pediatric oncology <u>G. Armstrong</u> , , US	
09:15 - 09:35	Fighting fatigue: Evidence and folklore <u>A. Vigano</u> , McGill University Health Center The Montreal General Hospital, Montreal, CA	
09:35 - 09:55	Sexuality: Practical counselling <u>I. White</u> , The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB	
09:55 - 10:15	Rehabilitation decreases impact of cancer on patient and society <u>N. Barizien</u> , , US	
10:15 - 10:20	Conclusions and perspectives <u>M. Aapro</u> , Clinique de Genolier, Genolier, CH	

08:30 - 10:00	Type: Educational session Title: Management of lymphomas in light of the updated WHO classification Chair(s): Marek Trneny, CZ; Michele Ghilmini, CH	Granada Auditorium (Hall 3)
08:30 - 08:30	Session DOI	
08:30 - 08:55	Aggressive B-cell lymphomas <u>M. Trneny</u> , General Faculty Hospital, VFN Charles University, Prague, CZ	
08:55 - 09:20	Indolent B-cell lymphomas <u>S. Montoto</u> , St. Bartholomew's Hospital, London, GB	
09:20 - 09:45	T-cell lymphomas <u>F. D'Amore</u> , Aarhus University Hospital, Aarhus C, DK	
09:45 - 10:00	Discussion	

08:30 - 10:00 **Type: Collaborative session** **Salamanca Auditorium (Hall 3)**
Title: ESMO-SIOPE/AYA Collaborative session: Genetics and precision medicine for AYA with cancer
Chair(s): Stefan Bielack, DE; Emmanouil Saloustros, GR

08:30 - 08:30 **Session DOI**

08:30 - 08:35 **Introduction**

E. Saloustros, University Hospital of Larissa, Larissa, GR

08:35 - 08:55 **The genetic landscape of AYA malignancies**

T. Grünewald, Pathologisches Institut-LMU München, Munich, DE

08:55 - 09:15 **Hereditary cancer syndromes in AYA**

C. Kratz, Hannover Medical School, Hannover, DE

09:15 - 09:35 **Precision medicine for AYA with cancer**

A. Kattamis, Aghia Sofia Children's Hospital, Athens, GR

09:35 - 09:55 **Genetic counseling and testing/bioethical issues for AYA with cancer**

L. Battistuzzi, Università degli Studi di Genova, Genova, IT

09:55 - 10:00 **Conclusions**

S. Bielack, Klinikum Stuttgart - Olgahospital, Stuttgart, DE

08:30 - 10:00 **Type: Special session** **Toledo Auditorium (Hall 5)**
Title: “Doctor, you need help” - Burnout in practising oncologists and ways to tackle it. Psychological support for oncologists: When, where and how
Chair(s): Michiel Strijbos, BE; Ana Froebe, HR

08:30 - 08:30 **Session DOI**

08:30 - 08:35 **Introduction**

A. Froebe, KBC Sisters of Mercy-Sestre Milosrdnice University Hospital Center, Zagreb, HR

08:35 - 08:55 **Causes and consequences of burnout**

M. Strijbos, A.Z. Klina, Brasschaat, BE

08:55 - 09:15 **How to deal with burnout (availability of and access to support services/tools/measures)**

09:15 - 09:35 **Group psychotherapy: “Psycho-coaching” for oncologists**

A. Froebe, KBC Sisters of Mercy-Sestre Milosrdnice University Hospital Center, Zagreb, HR

09:35 - 09:50 **Q&A**

09:50 - 10:00 **Conclusions**

M. Strijbos, A.Z. Klina, Brasschaat, BE

08:30 - 10:00 **Type: Educational session** **Santander Auditorium (Hall 3)**
Title: Surviving a cancer diagnosis with a good QoL
Chair(s): Lifang Liu, BE

08:30 - 08:30 **Session DOI**

08:30 - 08:45 **The physician's perspective**

J. Nuver, University Medical Center Groningen, Groningen, NL

08:45 - 09:00 **EORTC's work on survivorship**

L. Liu, The European Organisation for Research and Treatment of Cancer (EORTC), Brussels, BE

09:00 - 09:15 **Can value frameworks (such as ESMO-MCBS) contribute to a higher QoL?**

A. Bottomley, EORTC - European Organisation for Research and Treatment of Cancer, Brussels, BE

09:15 - 09:30 **Employment and a cancer diagnosis: How does it work in practice?**

I. Lebrocquy, OPuce, Den Haag, NL

09:30 - 09:45 **The patient's perspective**

R. Wilson, Wolfson Wohl Cancer Research Centre - Institute of Cancer Sciences - University of Glasgow, Bearsden, GB

09:45 - 10:00 **Discussion**

08:45 - 09:45 **Type: Multidisciplinary session** **Pamplona Auditorium**
Title: Treating young patients with BRCA-mutated early breast cancers **(Hall 2)**
 Chair(s): Oreste Gentilini, IT

08:45 - 08:45 **Session DOI**

08:45 - 08:50 **Presentation of case/condition**

08:50 - 09:05 **Caveats in surgical decision-making in patients with BRCA mutated tumours**
O. Gentilini, IRCCS Ospedale San Raffaele, Milan, IT

09:05 - 09:20 **Tailoring radiation treatment in patients with BRCA mutated tumours**
B. Offersen, , US

09:20 - 09:35 **Preserving fertility in young women receiving adjuvant chemotherapy**
A. Partridge, Dana Farber Cancer Institute, Boston, US

09:35 - 09:45 **General discussion**

08:45 - 09:45 **Type: Poster Discussion session** **Malaga Auditorium (Hall 5)**
Title: Poster Discussion 2 - Immunotherapy of cancer

08:45 - 08:45 **Session DOI**

08:45 - 08:45 **1186PD - Safety and Efficacy of the Oral CXCR4 Inhibitor X4P-001 + Axitinib in Advanced Renal Cell Carcinoma Patients: An Analysis of Subgroup Responses by Prior Treatment**

D. McDermott¹, U. Vaishampayan², M. Matrana³, S.Y. Rha⁴, A. Zurita Saavedra⁵, T. Ho⁶, B. Keam⁷, J.-L. Lee⁸, R. Joseph⁹, S. Ali¹⁰, W. Stadler¹¹, N. Haas¹², S. Sundararajan¹³, S.H. Park¹⁴, R. Mowat¹⁵, J. Picus¹⁶, A. Dudek¹⁷, Y. Zakharia¹⁸, L. Gan¹⁹, M. Atkins²⁰, ¹Beth Israel Deaconess Med. Center, Boston, US, ²Barbara Ann Karmanos Cancer Institute, Detroit, US, ³Ochsner Cancer Institute, New Orleans, US, ⁴Yonsei University, Seoul, KR, ⁵The University of Texas MD Anderson Cancer Center, Houston, US, ⁶Mayo Clinic, Phoenix, US, ⁷Seoul National University Hospital, Seoul, KR, ⁸Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁹Mayo Clinic, Jacksonville, US, ¹⁰Franciscan St. Francis Health, Indianapolis, US, ¹¹University of Chicago, Chicago, US, ¹²University of Pennsylvania/Abramson Cancer Center, Philadelphia, US, ¹³University of Arizona Cancer Center, Tucson, US, ¹⁴Samsung Medical Center, Seoul, KR, ¹⁵Toledo Clinic Cancer Center, Toledo, US, ¹⁶Washington University School of Medicine, St. Louis, US, ¹⁷University of Minnesota, Minneapolis, US, ¹⁸University of Iowa - Hospital, Iowa

City, US, ¹⁹X4 Pharmaceuticals, Cambridge, US, ²⁰Lombardi Cancer Center Georgetown University, Washington, US

08:45 - 08:45

1187PD - Phase 2 study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): results of an interim analysis

C.-H. Lee¹, A. Shah², V. Makker¹, M. Taylor³, D. Shaffer⁴, J. Hsieh⁵, A. Cohn⁶, C. Disimone⁷, A. Pinto Marin⁸, D. Rasco⁹, S. Ribe¹⁰, D. Richards¹¹, D. Stepan¹², C. Dutcus¹², J. Wu¹², E. Schmidt¹³, R. Perini¹⁴, R. Motzer¹, ¹Memorial Sloan-Kettering Cancer Center, New York, US, ²MD Anderson Cancer Center, Houston, US, ³OHSU Knight Cancer Institute - Northwest Portland, Portland, US, ⁴Albany Medical Center, New York Oncology Hematology, Albany, US, ⁵Washington University School of Medicine in St. Louis, St. Louis, US, ⁶Rocky Mountain Cancer Centers, Denver, US, ⁷Arizona Oncology, Tucson, US, ⁸Hospital Universitario La Paz, Madrid, ES, ⁹The START Center for Cancer Care, San Antonio, US, ¹⁰Sorlandet Hospital, Kristiansand, NO, ¹¹Texas Oncology P.A., Houston, US, ¹²Eisai Inc, Woodcliff Lake, US, ¹³Merck & Co Inc, North Wales, US, ¹⁴Merck Sharp & Dohme Corp. USA, Whitehouse Station, US

08:45 - 08:45

1188PD - Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis

D. Catenacci¹, H. Park², H. Uronis³, Y.-K. Kang⁴, M. Ng⁵, P. Enzinger⁶, K.W. Lee⁷, K.H. Lim², P. Gold⁸, J. Lacy⁹, S.H. Park¹⁰, K. Huber¹¹, A. Wynter-Horton¹¹, J. Nordstrom¹¹, T. Wu¹¹, J. Wigginton¹¹, J. Baughman¹¹, M. Rosales¹¹, J. Davidson-Moncada¹¹, Y.-J. Bang¹², ¹University of Chicago, Chicago, US, ²Washington University Medical School, St. Louis, US, ³Duke Cancer Center, Durham, US, ⁴Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁵National Cancer Centre Singapore, Singapore, SG, ⁶Dana-Farber Cancer Institute, Cambridge, US, ⁷Seoul National University Bundang Hospital, Seoul, KR, ⁸Swedish Cancer Institute, Seattle, US, ⁹Yale School of Medicine, New Haven, US, ¹⁰Samsung Medical Center, Seoul, KR, ¹¹MacroGenics, Inc., Rockville, US, ¹²Seoul National University Hospital, Seoul, KR

08:45 - 08:45

1189PD - Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

H. Park¹, H. Uronis², Y.-K. Kang³, M. Ng⁴, P. Enzinger⁵, K.W. Lee⁶, S. Rutella⁷, S. Church⁸, J. Nordstrom⁹, K. Knutson¹⁰, C. Erskine¹⁰, T. Wu⁹, J. Yen¹¹, A. Franovic¹¹, J. Muth⁹, M. Rosales⁹, J. Vadakekolathu¹², J. Davidson-Moncada⁹, Y.-J. Bang¹³, D. Catenacci¹⁴, ¹Washington University Medical School, St. Louis, US, ²Duke Cancer Center, Durham, US, ³Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁴National Cancer Centre Singapore, Singapore, SG, ⁵Dana-Farber Cancer Institute, Cambridge, US, ⁶Seoul National University Bundang Hospital, Seoul, KR, ⁷Nottingham Trent University-Clifton Campus, Nottingham, GB, ⁸Nanostring, Seattle, US, ⁹MacroGenics, Inc., Rockville, US, ¹⁰Mayo Clinic, Jacksonville, US, ¹¹Guardant Health, Inc., Redwood City, US, ¹²Nottingham Trent University, Nottingham, GB, ¹³Seoul National University Hospital, Seoul, KR, ¹⁴University of Chicago, Chicago, US

08:45 - 08:45

1191PD - Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm)

metastatic breast cancer (MBC)

S. Domchek¹, S. Postel-Vinay², S.-A. Im³, Y.H. Park⁴, J.-P. Delord⁵, A. Italiano⁶, J. Alexandre⁷, B. You⁸, S. Bastian⁹, M. Krebs¹⁰, D. Wang¹¹, S. Waqar¹², M. Lanasa¹³, H. Angell¹⁴, Z. Lai¹⁵, C. Gresty¹⁴, L. Opincar¹³, P. Herbolzheimer¹³, B. Kaufman¹⁶, ¹Private Practice - Domchek, Philadelphia, US, ²Institut Gustave Roussy, Villejuif, FR, ³Seoul National University Hospital, Seoul, KR, ⁴Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ⁵Institut Universitaire du Cancer -Toulouse-Oncopole, Toulouse, FR, ⁶Institute Bergonié, Bordeaux, FR, ⁷Hôpital Cochin, Paris, FR, ⁸Centre Hospitalier Lyon Sud, Pierre-Bénite, FR, ⁹Kantonsspital Graubünden, Chur, CH, ¹⁰The Christie NHS Foundation Trust, Manchester, GB, ¹¹Henry Ford Medical Center, Detroit, US, ¹²Washington University School of Medicine, St Louis, US, ¹³AstraZeneca USA, Gaithersburg, US, ¹⁴AstraZeneca, Cambridge, GB, ¹⁵AstraZeneca, Boston, US, ¹⁶Chaim Sheba Medical Center, Ramat Gan, IL

08:45 - 09:05 **Invited Discussant 1186PD, 1187PD, 1188PD, 1189PD and 1191PD**

09:05 - 09:20 **Q&A led by Discussant**

09:20 - 09:20 **1192PD - Association of tumor mutational burden with outcomes in patients with select advanced solid tumors treated with pembrolizumab in KEYNOTE-158**

A. Marabelle¹, M. Fakih², J. Lopez³, M. Shah⁴, R. Shapira-Frommer⁵, K. Nakagawa⁶, H.C. Chung⁷, H. Kindler⁸, J. Lopez-Martin⁹, W. Miller¹⁰, A. Italiano¹¹, S. Kao¹², S. Piha-Paul¹³, J.-P. Delord¹⁴, R. McWilliams¹⁵, D. Aurora-Garg¹⁶, M. Chen¹⁶, F. Jin¹⁶, K. Norwood¹⁷, Y.-J. Bang¹⁸, ¹Institut Gustave Roussy, Villejuif, FR, ²City of Hope National Medical Center, Duarte, US, ³The Royal Marsden Foundation Trust and The Institute of Cancer Research, London, GB, ⁴The Ohio State University, Columbus, US, ⁵Chaim Sheba Medical Center, Ramat Gan, IL, ⁶Kindai University School of Medicine, Osaka, JP, ⁷Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁸University of Chicago, Chicago, US, ⁹University Hospital 12 De Octubre, Madrid, ES, ¹⁰Jewish General Hospital and McGill University, Montreal, CA, ¹¹Institute Bergonié, Bordeaux, FR, ¹²Chris O'Brien Lifehouse, Sydney, AU, ¹³The University of Texas, MD Anderson Cancer Center, Houston, US, ¹⁴Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ¹⁵Mayo Clinic, Rochester, US, ¹⁶Merck & Co., Inc., Kenilworth, US, ¹⁷Merck & Co., Inc, Kenilworth, US, ¹⁸Seoul National University Hospital, Seoul, KR

09:20 - 09:20 **1193PD - Analysis of Tumor Hyperprogression (HP) With Nivolumab (Nivo) in Randomized, Placebo (Pbo)-Controlled Trials**

M. Reck¹, Y. Feng², H.R. Kim³, G. Plautz², Y.-K. Kang⁴, T. Owonikoko⁵, P. Nghiem⁶, J. Sheng², ¹Krankenhaus Grosshansdorf, Grosshansdorf, DE, ²Bristol-Myers Squibb, Lawrenceville, US, ³Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁴Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁵Winship Cancer Institute of Emory University, Atlanta, US, ⁶University of Washington & Fred Hutchinson Cancer Research Center, Seattle, US

09:20 - 09:20 **1194PD - Early peripheral T-cell responses predict oncological outcome to**

checkpoint immune blockade in metastatic melanoma

B. Fairfax¹, C. Taylor¹, R. Watson¹, I. Nassiri¹, H. Fang², E. Mahe¹, R. Cooper¹, S. Danielli², V. Woodcock³, Z. Traill⁴, J. Knight², M. Payne⁵, M. Middleton³, ¹The MRC Weatherall Institute of Molecular Medicine Oxford, Oxford, GB, ²Wellcome Centre for Human Genetics, Oxford, GB, ³Churchill Hospital University of Oxford, Oxford, GB, ⁴University of Oxford, Oxford, GB, ⁵John Radcliffe Hospital, Oxford, GB

09:20 - 09:35 **Invited Discussant 1192PD, 1193PD and 1194PD**

09:35 - 09:45 **Q&A led by Discussant**

08:45 - 09:45 **Type: Challenge your expert** **Tarragona Auditorium (Hall 7)**
Title: How do we personalise treatment in stage III NSCLC?
Chair(s): Miklos Pless, CH

08:45 - 08:45 **Session DOI**

08:45 - 08:55 **Presentation by expert**
W. Eberhardt, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

08:55 - 09:45 **Discussion led by Chair**
M. Pless, Kantonsspital Winterthur, Winterthur, CH

08:45 - 09:45 **Type: Challenge your expert** **Alicante Auditorium (Hall 3)**
Title: Are big data, deep learning and AI methods changing cancer care and research?
Chair(s): Stefan Sleijfer, NL

08:45 - 08:45 **Session DOI**

08:45 - 09:00 **Presentation by expert**
S. Sleijfer, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

09:00 - 09:15 **Presentation by expert**
B. Al-Lazikani, , US

09:15 - 09:45 **Discussion led by Chair**
S. Sleijfer, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

08:45 - 09:45 **Type: Challenge your expert** **Cartagena Auditorium (Hall 3)**
Title: Is there a role for immunotherapy in gliomas?
Chair(s): Martin van den Bent, NL

08:45 - 08:45 **Session DOI**

08:45 - 08:55 **Presentation by expert**
M. Weller, Universitätsspital Zürich - Klinik für Neurologie, Zurich, CH

08:55 - 09:45 **Discussion led by Chair**
M. Van Den Bent, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

09:15 - 10:45 **Type: EONS session** **Oviedo Auditorium (CC5)**
Title: EONS 12: Palliative care
Chair(s): Cristina Lacerda, PT

09:15 - 09:15 **Session DOI**

09:15 - 09:30 **Integrating oncology and palliative care: How far or how close are we?**
A. Charalambous, CYPRUS UNIVERSITY OF TECHNOLOGY, Limassol, CY

09:30 - 09:45 **Spirituality in palliative care patients**
T. Lormans, UMC-University Medical Center Utrecht, Utrecht, NL

09:45 - 10:00 **Starting the conversation - Educational innovations to promote conversations about end of life**
J. Armoogum, University of the West of England-Frenchay Campus, Bristol, GB

10:00 - 10:15 **CN47 - Young people's experiences when active cancer treatment ends**
S. Lea¹, A. Martins², M. Bassett³, M. Cable⁴, G. Doig³, L. Fern², S. Morgan³, L. Soanes¹,
S. Smith³, M. Whelan⁴, R. Taylor², ¹University College London Hospital - University
College London Hospitals NHS Foundation Trust, London, GB, ²University College
London Hospital UCLH NHS Foundation Trust, London, GB, ³Teenage Cancer Trust,
London, GB, ⁴Coventry University, Coventry, GB

10:15 - 10:30 **CN34 - Introduction of a Nurse-led Totally Implantable Vascular Access Device (TIVAD) Service for Patients with Metastatic Cancer**
M. Fowler, Heartlands Hospital-Heart of England NHS Foundation Trust, Birmingham, GB

10:30 - 10:45 **Discussion**

10:15 - 11:45 Type: Proffered Paper session Barcelona Auditorium (Hall 2)
Title: Proffered Paper - Immunotherapy of cancer

10:15 - 10:15 **Session DOI**

10:15 - 10:30 **One LBA TBC**

10:30 - 10:45 **Invited Discussant one LBA TBC**

10:45 - 11:00 **11740 - Pembrolizumab in microsatellite instability high cancers: updated analysis of the phase 2 KEYNOTE-164 and KEYNOTE-158 studies**

L. Diaz¹, D. Le², M. Maio³, P. Ascierto⁴, R. Geva⁵, D. Motola-Kuba⁶, T. André⁷, E. Van Cutsem⁸, M. Gottfried⁹, E. Elez¹⁰, J.-P. Delord¹¹, D. Jäger¹², T.W. Kim¹³, R. Guimbaud¹⁴, T. Yoshino¹⁵, M. Chen¹⁶, K. Norwood¹⁷, P. Marinello¹⁶, A. Marabelle¹⁸, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Johns Hopkins University, Baltimore, US, ³Azienda Ospedaliera Universitaria Senese - Santa Maria delle Scotte, Siena, IT, ⁴Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁵Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL, ⁶COMOP A.C., Mexico City, MX, ⁷Saint-Antoine hospital, AP-HP, Paris, FR, ⁸University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, BE, ⁹Meir Medical Center, Kfar Saba, IL, ¹⁰Vall d'Hebron University Hospital, Barcelona, ES, ¹¹Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ¹²Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, ¹³Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ¹⁴Centre Claudius-Regaud, Toulouse, FR, ¹⁵National Cancer Center Hospital East, Kashiwa, JP, ¹⁶Merck & Co., Inc., Kenilworth, US, ¹⁷Merck & Co., Inc, Kenilworth, US, ¹⁸Institut Gustave Roussy, Villejuif, FR

11:00 - 11:15 **11750 - Durvalumab Activity in Previously Treated Patients Who Stopped Durvalumab without Disease Progression**

S. Sheth¹, C. Gao², N. Mueller², P. Martinez², J.-C. Soria³, ¹UNC - Lineberger Cancer Center, Chapel Hill, US, ²AstraZeneca, Gaithersburg, US, ³Medimmune, Gaithersburg, US

11:15 - 11:30 **Invited Discussant 11740 and 11750**

10:15 - 11:45 **Type: Special symposium** **Madrid Auditorium (Hall 2)**
Title: Selecting and sequencing therapy in previously untreated urothelial cancer
 Chair(s): Thomas Powles, GB

10:15 - 10:15 **Session DOI**

10:15 - 10:20 **Introduction**

10:20 - 10:40 **Single agent immune therapy and immune combinations**

J. Bellmunt, Harvard Medical School, Boston, US

10:40 - 11:00 **Immune therapy in combination with chemotherapy**

T. Powles, St. Bartholomew's Hospital, London, GB

11:00 - 11:20 **Immune therapy in combination with targeted therapy**

Y. Loriot, Institut Gustave Roussy, Villejuif, FR

11:20 - 11:40 **Biomarkers beyond PD-L1 expression to predict outcome to immune therapy**

M. Van Der Heijden, 4Netherlands Cancer Institute, Amsterdam, NL

11:40 - 11:45 **Conclusions and perspectives**

10:15 - 11:45 **Type: Proffered Paper session** **Pamplona Auditorium (Hall 2)**
Title: Proffered Paper 2 - Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)

10:15 - 10:15 **Session DOI**

10:15 - 10:35 **One LBA TBC**

10:35 - 10:55 **1841O - 2nd/3rd-line Nivolumab vs Nivo plus Ipilimumab in Malignant Pleural Mesothelioma: long-term results of IFCT-1501 MAPS2 phase 2R trial with a focus on hyperprogression (HPD)**

G. Zalcman¹, J. Mazieres², L. Greillier³, S. Brossseau¹, S. Lantuejoul⁴, P. Do⁵, O. Bylicki⁶, I. Monnet⁷, R. Corre⁸, C. Audigier-Valette⁹, M. Locatelli-Sanchez¹⁰, O. Molinier¹¹, F. Guisier¹², T. Urban¹³, D. Planchard¹⁴, C. Ligeza-Poisson¹⁵, E. Amour¹⁶, F. Morin¹⁷, D. Moro-Sibilot¹⁸, A. Scherpereel¹⁹, ¹Hopital Bichat Claude Bernard, Paris, FR, ²Hospital Larrey, Toulouse, FR, ³Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ⁴Centre Léon Bérard, Lyon, FR, ⁵Cancer Center François Baclesse, CAEN,

FR, ⁶Military Hospital HIA Percy, Clamart, FR, ⁷CH Intercommunal de Créteil, Créteil, FR, ⁸CHU de Pontchaillou, Rennes, FR, ⁹Hôpital Sainte Musse, Toulon, FR, ¹⁰Hôpital Lyon-Sud, Pierre-Benite, FR, ¹¹Centre Hospitalier Du Mans, Le Mans, FR, ¹²Hop. Charles Nicolle, Rouen, FR, ¹³CHU Angers, Angers, FR, ¹⁴Institut Gustave Roussy, Villejuif, FR, ¹⁵Clinique de l'Estuaire, Saint-Nazaire, FR, ¹⁶IFCT, PARIS, FR, ¹⁷French Cooperative Thoracic Intergroup, Paris, FR, ¹⁸CHU Grenoble, La Tronche, FR, ¹⁹CHU Lille, Inserm, U1189 - ONCO-THAI - F-59000, Lille, FR

10:55 - 11:15

18420 - Mutational profile of malignant pleural mesothelioma (MPM) in the phase II RAMES Study

M. Pagano¹, R. Gnani², C. Bonelli¹, F. Zanelli¹, M. Garassino³, G.L. Ceresoli⁴, G. Pasello⁵, M. Tiseo⁶, H.J. Soto Parra⁷, F. Grosso⁸, P. Zucali⁹, M. Larocca¹⁰, F. Torricelli², A. Ciarrocchi², C. Pinto¹, ¹Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, ²AUSL - IRCCS, Reggio Emilia, IT, ³Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁴Humanitas Gavazzeni, Bergamo, IT, ⁵Istituto Oncologico Veneto IRCCS, Padova, IT, ⁶AOU di Parma, Parma, IT, ⁷Azienda Policlinico Università di Catania, Catania, IT, ⁸Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT, ⁹Istituto Clinico Humanitas, Rozzano, IT, ¹⁰Policlinico Universitario A. Gemelli, Rome, IT

11:15 - 11:35

Invited Discussant 18410, 18420 and one LBA TBC

11:35 - 11:55

18430 - SAKK 17/16: Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm Phase II trial.

Y. Metaxas¹, M. Frueh², E.I. Eboulet³, F. Grosso⁴, M. Pless⁵, P. Zucali⁶, G.L. Ceresoli⁷, M. Mark¹, M. Schneider³, A. Roveta⁴, M. Perrino⁶, C. Biaggi Rudolf³, P. Froesch⁸, S. Schmidt², C. Waibel⁹, C. Appenzeller², D. Rauch¹⁰, R. Von Moos¹, ¹Kantonsspital Graubünden, Chur, CH, ²Kantonsspital St. Gallen, St. Gallen, CH, ³Swiss Group for Clinical Cancer Research, Bern, CH, ⁴Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT, ⁵Kantonsspital Winterthur, Winterthur, CH, ⁶Istituto Clinico Humanitas, Rozzano, IT, ⁷Humanitas Gavazzeni, Bergamo, IT, ⁸IOSI Istituto Oncologico Svizzera Italiana, Locarno, CH, ⁹Kantonsspital Baden, Baden, CH, ¹⁰Inselspital - Universitätsspital Bern, Bern, CH

11:55 - 12:15

18440 - Durable anti-tumor activity of the multi-targeted inhibitor lenvatinib in patients with advanced or metastatic thymic carcinoma; Preliminary results from a multicenter phase II (REMORA) trial.

S. Itoh¹, M. Satouchi¹, J. Sato², Y. Okuma³, S. Niho⁴, H. Mizugaki², H. Murakami⁵, Y. Fujisaka⁶, T. Kozuki⁷, K. Nakamura², Y. Nagasaka², M. Kawasaki², T. Yamada², A. Kuchiba², N. Yamamoto², ¹Hyogo Cancer Center, Hyogo, JP, ²National Cancer Center Hospital, Tokyo, JP, ³Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, ⁴National Cancer Center Hospital East, Kashiwa, JP, ⁵Shizuoka Cancer Center, Shizuoka, JP, ⁶Osaka Medical College, Takatsuki, JP, ⁷NHO Shikoku Cancer Center, Matsuyama, JP

12:15 - 12:35

Invited Discussant 18430 and 18440

10:15 - 11:45 **Type: Proffered Paper session** **Cordoba Auditorium (Hall 7)**
Title: Proffered Paper - Head and neck cancer

10:15 - 10:15 **Session DOI**

10:15 - 10:27 **One LBA TBC**

10:27 - 10:39 **11080 - Chemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: a randomized, open-label, phase 3 trial**

M. Chen¹, R. You², L. You-Ping¹, P.-Y. Huang¹, X. Zou², G.-P. Shen³, H.-D. Zhang⁴, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN, ³The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN, ⁴Guangdong Provincial People's Hospital, Guangzhou, CN

10:39 - 10:51 **11090 - A phase II study of Monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).**

R. Galot¹, C. Le Tourneau², E. Saada-Bouزيد³, A. Daste⁴, C. Even⁵, P. Debruyne⁶, S. Henry⁷, S. Zanetta⁸, A. Rutten⁹, L. Licitra¹⁰, J.-L. Canon¹¹, M.-C. Kaminsky-Forrett¹², P. Specenier¹³, S. Rottey¹⁴, L. Dirix¹⁵, T. Raveloarivahy¹⁵, C. Fortpied Lefevre¹⁵, M. Vanlancker¹⁶, A.-S. Govaerts¹⁶, J.-P. Machiels¹, ¹Cliniques Universitaires St. Luc, Brussels, BE, ²Institut Curie, Paris, FR, ³Hopital Lacassagne, Nice, FR, ⁴CHU Bordeaux Hopital St. André, Bordeaux, FR, ⁵Institut Gustave Roussy, Villejuif, FR, ⁶AZ Groeninge Hospital, Kortrijk, BE, ⁷CHU-UCL-Namur Clinique Ste Elisabeth, Namur, BE, ⁸Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁹St-Augustinus Ziekenhuis, Wilrijk, BE, ¹⁰Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ¹¹Grand Hopital de Charleroi Site Notre Dame, Charleroi, BE, ¹²Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, ¹³University Hospital Antwerp, Edegem, BE, ¹⁴UZ Gent, Gent, BE, ¹⁵EORTC, Brussels, BE, ¹⁶EORTC - European Organisation for Research and Treatment of Cancer, Brussels, BE

10:51 - 11:06 **Invited Discussant 11080, 11090 and one LBA TBC**

11:06 - 11:18 **11100 - Personalized treatment according to geriatric assessment in 1st line recurrent and/or metastatic (R/M) Head and Neck Squamous Cell Cancer (HNSCC) patients aged 70 or over. ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials**

J. Guigay¹, A. Auperin², C. Mertens³, C. Even², L. Geoffrois⁴, D. Cupissol⁵, F. Rolland⁶, C. Sire⁷, J. Fayette⁸, F. Peyrade¹, E. Blot⁹, P. Debourdeau¹⁰, L. Bozec¹¹, O. Capitain¹², Y. Pointreau¹³, C. Brard¹⁴, C. Michel¹⁵, D. Schwob¹⁴, C. Ortholan¹⁶, H. Le Caer¹⁷, ¹Centre Anticancer Antoine Lacassagne, Nice, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Institute Bergonié, Bordeaux, FR, ⁴Institut de Cancérologie de Lorraine - Alexis Vautrin,

Vandoeuvre les Nancy, FR, ⁵Institut régional du cancer de Montpellier, Montpellier, FR, ⁶ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁷Centre Hospitalier de Bretagne Sud - Hôpital du Scorff, Lorient, FR, ⁸Centre Léon Bérard, Lyon, FR, ⁹Centre d'Oncologie St. Yves, Vannes, FR, ¹⁰Institut Ste Catherine, Avignon, FR, ¹¹Institut Curie - Hôpital René Huguenin, Saint-Cloud, FR, ¹²Centre Paul Papin, Angers, FR, ¹³Centre Jean Bernard, Le Mans, FR, ¹⁴Gustave Roussy Cancer Campus, Villejuif, FR, ¹⁵GORTEC, NICE, FR, ¹⁶Centre Hospitalier Princesse Grace, Monaco, MC, ¹⁷Hôpital Yves Le Foll, Centre Hospitalier de Saint-Brieuc, Saint Brieuc, FR

11:18 - 11:30 **11110 - Cisplatin reduces costs and provides more quality adjusted life years (QALYs) than cetuximab in chemoradiotherapy for patients with HPV-Positive Oropharyngeal Cancer (HPV+OPC)**

D. Jones¹, H. Mehanna², P. Mistry³, M. Dalby³, T. Fulton-Lieuw⁴, A. Kong⁴, J. Dunn³, A. Gray¹, ¹University of Oxford, Oxford, GB, ²The University of Birmingham Institute for Cancer Studies, Birmingham, GB, ³University of Warwick, Warwick, GB, ⁴University of Birmingham, Birmingham, GB

11:30 - 11:45 **Invited Discussant 1100 and 11110**

10:15 - 11:45 **Type: Educational session** **Granada Auditorium (Hall 3)**
Title: Single cell cancer analysis
 Chair(s): Carlos Caldas, GB

10:15 - 10:15 **Session DOI**

10:15 - 10:40 **Technological advances in single cell technology to dissect molecular circuitry of cancer from primary to metastasis**

A. Trumpp, German Cancer Research Center, Heidelberg, DE

10:40 - 11:05 **Single cell RNA sequencing to decipher epithelial cancers and their microenvironments**

J. Marioni, , US

11:05 - 11:30 **Single cell analysis of epithelial cancers to unravel drug sensitivity and resistance**

C. Caldas, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB

11:30 - 11:45 **Discussion**

10:15 - 11:45 **Type: Special symposium** **Malaga Auditorium**
Title: Individualised dosing of commonly used anti- **(Hall 5)**
cancer agents
Chair(s): Ron Mathijssen, NL; Emiliano Calvo, ES

10:15 - 10:15 **Session DOI**

10:15 - 10:22 **Introduction**

E. Calvo, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES

10:22 - 10:37 **Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKIs)**

M. Joerger, , US

10:37 - 10:52 **Drug-drug interactions: Focus on acid-suppressive agents**

R. Mathijssen, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

10:52 - 11:07 **Drug-food interactions**

M. Del Re, Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT

11:07 - 11:22 **Pharmacogenomics guided adaptive dosing of fluoropyrimidines**

H. Gelderblom, Leids Universitair Medisch Centrum (LUMC), Leiden, NL

11:22 - 11:37 **Optimising dosing of I-O agents**

E. Calvo, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES

11:37 - 11:45 **Conclusions and perspectives**

R. Mathijssen, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

10:15 - 11:45 **Type: Special session** **Toledo Auditorium (Hall 5)**
Title: Practicing oncology: Special issues in real life
Chair(s): Gabor Lakatos, HU; Hendrik van Halteren, NL

10:15 - 10:15 **Session DOI**

10:15 - 10:20 **Introduction**

G. Lakatos, Del-pesti Centrumkorhaz-OHII, Budapest, HU

10:20 - 10:30 **Case presentation - Standards and relapsed hepatocellular carcinoma (HCC)**

G. Lakatos, Del-pesti Centrumkorhaz-OHII, Budapest, HU

10:30 - 10:45 **Standard of care in unresectable and relapsed HCC**

M. Ducreux, Gustave Roussy - Cancer Campus, Villejuif, FR

10:45 - 10:55 **Case presentation - Issues in oncology practice: Thrombosis treatment in cancer patients**

H. Van Halteren, Adrz-Admiraal de Ruijter Hospital-Goes, Goes, NL

10:55 - 11:10 **Overview and different options for thrombosis treatment**

C. Vulsteke, AZ Maria Middelaes AZMMSJ, Gent, BE

11:10 - 11:20 **Practicing oncology in patients with hereditary cancer**

M. Strijbos, A.Z. Klina, Brasschaat, BE

11:20 - 11:40 **Hereditary cancer syndrome: How to deal with in routine clinical practice**

K. Punie, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

11:40 - 11:45 **Conclusion**

H. Van Halteren, Adrz-Admiraal de Ruijter Hospital-Goes, Goes, NL

10:30 - 11:30 **Type: Multidisciplinary session** **Valencia Auditorium (Hall 5)**
Title: Young patients with stage IB2 cervical cancer

10:30 - 10:30 **Session DOI**

10:30 - 10:35 **Presentation of case/condition**

10:35 - 10:50 **The role of surgery: Is there a place for conservative treatment?**

S. Mahner, LMU Klinikum der Universität München, Munich, DE

10:50 - 11:05 **The role of the medical treatment: Is there a place for neoadjuvant chemotherapy?**

M. McCormack, , US

11:05 - 11:20 **The role of radiotherapy treatment: Can modern techniques reduce the burden of toxicity?**

R. Nout, Leiden University Medical Center (LUMC), Leiden, NL

11:20 - 11:30 **General discussion**

10:30 - 11:30 **Type: Poster Discussion session** **Tarragona Auditorium (Hall 7)**
Title: Poster Discussion 2 - Translational research

10:30 - 10:30 **Session DOI**

10:30 - 10:30 **1878PD - Pan-cancer analysis of clinical acquired resistance (AR) in BRAF-driven real-world cases**

F. Pietrantonio¹, J. Lee², L. Boussemart³, C. Schinke⁴, G. Srkalovic⁵, R. Madison², J. Ross², V. Miller², B. Alexander², S. Ali², A. Schrock², G. Daniels⁶, ¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ²Foundation Medicine, Cambridge, US, ³Pontchaillou Hospital, CHU de Rennes, Rennes, FR, ⁴University of Arkansas Medical Center, Little Rock, US, ⁵Sparrow Regional Cancer Center, Lansing, US, ⁶University of California San Diego, La Jolla, US

10:30 - 10:30 **1879PD - Primary ovarian carcinomas arising in BRCA1 mutation carriers contain a small fraction of BRCA1-proficient cells, which rapidly repopulate tumor mass during neoadjuvant chemotherapy but become outgrown by BRCA1-deficient clones during platinum-free intervals**

E. Imyanitov¹, A. Sokolenko², T. Gorodnova², E. Savonevich³, A. Ivantsov², E. Preobrazhenskaya², A. Togo², I. Berlev², ¹N.N. Petrov National Medical Research Center

of Oncology, Saint-Petersburg, RU, ²N.N. Petrov Institute of Oncology, St.-Petersburg, RU,
³Grodno Medical University, Grodno, BY

10:30 - 10:42 **Invited Discussant 1878PD and 1879PD**

10:42 - 10:50 **Q&A led by Discussant**

10:50 - 10:50 **1880PD - Genetic variants in the one-carbon metabolism pathway to predict outcome in patients with metastatic colorectal cancer (mCRC): data from TRIBE and FIRE-3 phase III trials.**

A. Puccini¹, F. Loupakis², S. Stintzing³, S. Cao⁴, J. Millstein⁴, F. Battaglin⁵, M. Berger⁶, R. Togunaka⁴, M. Naseem⁴, W. Zhang⁴, C. Cremolini⁷, A. Falcone⁷, V. Heinemann⁸, H.J. Lenz⁴, ¹IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ²Istituto Oncologico Veneto IRCCS, Padova, IT, ³Charité - Universitätsmedizin Berlin, Berlin, DE, ⁴USC - Norris Comprehensive Cancer Center, Los Angeles, US, ⁵University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, ⁶Inselspital - Universitätsklinik für Medizinische Onkologie, Bern, CH, ⁷Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT, ⁸Ludwig Maximilians University - Grosshadern, Munich, DE

10:50 - 10:50 **1881PD - Oral Intestinal Alkaline Phosphatase Improves Efficacy of 5-FU in a Colorectal Cancer Mouse Model**

C. Furlan Freguia, M. Kaleko, Synthetic Biologics, Rockville, US

10:50 - 10:50 **92PD - Comprehensive pan-cancer analysis of KRAS genomic alterations (GA) including potentially targetable subsets**

S.-H. Ou¹, E. Sokol², R. Madison², J. Chung², J. Ross², V. Miller², B. Alexander², S. Ali², A. Schrock², S. Ramalingam³, ¹Chao Family Comprehensive Cancer Center, Orange, US, ²Foundation Medicine, Cambridge, US, ³Emory University Winship Cancer Institute, Atlanta, US

10:50 - 11:02 **Invited Discussant 1880PD, 1881PD and 92PD**

11:02 - 11:10 **Q&A led by Discussant**

11:10 - 11:10 **93PD - Analysis of the Androgen Receptor status in liquid biopsy to predict the outcome to abiraterone and enzalutamide in CRPC patients**

M. Del Re¹, V. Conteduca², S. Crucitta¹, G. Gurioli², C. Casadei², G. Restante³, G. Schepisi², C. Lolli², R. Morganti⁴, R. Danesi⁵, U. De Giorgi², ¹Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT, ²Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ³University of Pisa, Pisa, IT, ⁴university Hospital of Pisa, Pisa, IT, ⁵Università di Pisa, Pisa, IT

11:10 - 11:10 **1882PD - Comprehensive molecular characterization of brain metastases (BM) from colorectal cancer (CRC)**
F. Battaglin¹, J. Xiu², Y. Baca², R. Goldberg³, A. Grothey⁴, A. Shields⁵, A. Seeber⁶, M. Salem⁷, A. Puccini⁸, R. Tokunaga⁹, M. Naseem⁹, H. Arai⁹, J. Wang⁹, M. Berger¹⁰, W. Zhang⁹, P. Philip¹¹, J. Marshall¹², W.M. Korn², H.J. Lenz⁹, ¹University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, ²Caris Life Sciences, Phoenix, US, ³West Virginia University Cancer Institute, Morgantown, US, ⁴West Cancer Center, Germantown, US, ⁵Karmanos Cancer Institute, Wayne State University, Detroit, US, ⁶University Hospital Innsbruck, Innsbruck, AT, ⁷Lombardi Cancer Center Georgetown University, Washington, US, ⁸IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ⁹USC - Norris Comprehensive Cancer Center, Los Angeles, US, ¹⁰Inselspital - Universitätsklinik für Medizinische Onkologie, Bern, CH, ¹¹Karmanos Cancer Institute, Detroit, US, ¹²Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, US

11:10 - 11:22 **Invited Discussant 93PD and 1882PD**

11:22 - 11:30 **Q&A led by Discussant**

10:30 - 11:30 Type: Multidisciplinary session Alicante Auditorium (Hall 3)
Title: Peritoneal metastases from colorectal cancer
 Chair(s): Julien Taieb, FR

10:30 - 10:30 **Session DOI**

10:30 - 10:35 **Presentation of case/condition**

10:35 - 10:50 **The surgical oncology perspective**
B. Rau, US

10:50 - 11:05 **The medical oncology perspective**
J. Taieb, Hopital European George Pompidou, Paris, FR

11:05 - 11:20 **The pathology perspective**
F. Bibeau, CHU de Caen - Hôpital Côte de Nacre, Caen, FR

11:20 - 11:30 **General discussion**

10:30 - 11:30 Type: Poster Discussion session Cartagena Auditorium (Hall

Title: Poster Discussion - NETs and endocrine tumours

3)

10:30 - 10:30 **Session DOI**

10:30 - 10:30 **1382PD - Relation between objective tumor shrinkage and progression-free survival (PFS) in the NETTER-1 population**

M. Pavel¹, P. Broberg², M. Caplin³, P. Ruzniewski⁴, J. Strosberg⁵, P. Santoro², L. Ravasi², E. Krenning⁶, ¹Universitätsklinik Erlangen, Erlangen, DE, ²Advanced Accelerator Applications, a Novartis company, Geneva, CH, ³Royal Free Hospital School of Medicine, London, GB, ⁴Beaujon Hospital APHP, Clichy, FR, ⁵H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ⁶Erasmus Medical Center, Rotterdam, NL

10:30 - 10:30 **1383PD - Phase I Study of CC-90011 in Patients With Advanced Solid Tumors (STs) and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)**

A. Hollebecque¹, J. De Bono², S. Salvagni³, R. Plummer⁴, N. Isambert⁵, P. Niccoli⁶, J. Capdevila⁷, G. Curigliano⁸, V. Moreno⁹, F.G. De Braud¹⁰, M. López-Brea¹¹, P. Martin-Romano¹², E. Baudin¹³, M. Arias¹⁴, J. De Alvaro¹⁴, J. Parra-Palau¹⁴, T. Sánchez Pérez¹⁴, E. Filvaroff¹⁵, M. Lamba¹⁶, Z. Nikolova¹⁷, ¹Gustave Roussy, Villejuif, FR, ²The Institute of Cancer Research (ICR), London, GB, ³Policlinico S. Orsola-Malpighi, Bologna, IT, ⁴The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle upon Tyne, GB, ⁵Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁶Institut Paoli-Calmettes, Marseille, FR, ⁷Vall d'Hebron University Hospital, Barcelona, ES, ⁸Istituto Europeo di Oncologia, Milan, IT, ⁹University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ¹⁰Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ¹¹H.U.Marqués de Valdecilla, Santander, ES, ¹²Gustave Roussy Cancer Campus, Villejuif, FR, ¹³Gustave Roussy - Cancer Campus, Villejuif, FR, ¹⁴Celgene Institute Translational Research Europe-CITRE, Sevilla, ES, ¹⁵Celgene Corporation, San Francisco, US, ¹⁶Celgene Corporation, Summit, US, ¹⁷Celgene International Switzerland, Boudry, CH

10:30 - 10:30 **1384PD - SUnitinib with EVOfosfamide (TH-302) for G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve for systemic treatment. The SUNEVO phase II trial of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE)**

E. Grande¹, C. Lopez², T. Alonso Gordo³, M. Benavent⁴, J. Capdevila⁵, A. Teulé⁶, A. Custodio⁷, I. Sevilla⁸, P. Gajate³, J. Molina-Cerrillo³, J. Hernando Cubero⁵, R. Garcia-Carbonero⁹, ¹MD Anderson Cancer Center Madrid, Madrid, ES, ²Marques de Valdecilla University Hospital, Santander, ES, ³Hospital Universitario Ramon y Cajal, Madrid, ES, ⁴Hospital Universitario Virgen del Rocío, Sevilla, ES, ⁵Vall d'Hebron University Hospital, Barcelona, ES, ⁶Institut Catala d'Oncologia (ICO), Hospitalet de Llobregat, ES, ⁷Hospital Universitario La Paz, Madrid, ES, ⁸Hospital Clínico Virgen de la Victoria, Málaga, ES, ⁹University Hospital 12 De Octubre, Madrid, ES

10:30 - 10:45 **Invited Discussant 1382PD, 1383PD and 1834PD**

10:45 - 10:50 **Q&A led by Discussant**

- 10:50 - 10:50 **1385PD - New circulating biomarkers in Gastro-Entero-Pancreatic-Neuroendocrine-Tumors**
M. Bocchini¹, M. Mazza¹, F. Foca¹, F. Nicolini¹, R. Calogero², S. Severi¹, G. Paganelli³,
¹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, ²MBC Centro di Biotecnologie Molecolari, Torino, IT, ³Istituto Tumori della Romagna I.R.S.T., Meldola, IT
- 10:50 - 10:50 **1386PD - Longitudinal Increase in Ki67 and High-grade Transformation in Pancreatic Neuroendocrine Tumors (PNETs)**
J. Botling¹, A. Lamarca², D. Bajic¹, O. Norlen¹, V. Lönngren¹, J. Kjaer¹, B. Eriksson¹, S. Welin¹, P. Hellman¹, G. Rindi³, B. Skogseid¹, J. Crona⁴, ¹Uppsala University, Uppsala, SE, ²The Christie NHS Foundation Trust, Manchester, GB, ³Fondazione Policlinico Universitario A. Gemelli IRCCS-Università Cattolica del Sacro Cuore, Roma, IT, ⁴University Hospital Uppsala Akademiska Sjukhuset, Uppsala, SE
- 10:50 - 11:02 **Invited Discussant 1385PD and 1386PD**
- 11:02 - 11:07 **Q&A led by Discussant**
- 11:07 - 11:07 **1862PD - Impact of lung metastasis on overall survival (OS) in the phase 3 SELECT study with lenvatinib (LEN) in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC)**
M. Tahara¹, N. Kiyota², A.O. Hoff³, C. Badiu⁴, T. Owonikoko⁵, C. Dutcus⁶, T. Suzuki⁷, M. Ren⁸, S. Misir⁶, L. Wirth⁹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Kobe University Hospital, Kobe, JP, ³Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina, Universidade de São Paulo, São Paulo, BR, ⁴National Institute of Endocrinology, Bucharest, RO, ⁵Winship Cancer Institute of Emory University, Atlanta, US, ⁶Eisai Inc, Woodcliff Lake, US, ⁷Eisai Co., Ltd., Bunkyo-ku, JP, ⁸Eisai Inc., Woodcliff Lake, US, ⁹Massachusetts General Hospital, Harvard Medical School, Boston, US
- 11:07 - 11:07 **1863PD - Prescription and Treatment Patterns of Lenvatinib (L) in Patients with Radioactive Iodine-Refractory Differentiated Thyroid Cancer (rDTC): A Retrospective Analysis of the Canadian Patient Support Program (PSP)**
S. Hotte¹, E. Winqvist², B. Lemieux³, S. Laurie⁴, N. Bouganim⁵, N. Chua⁶, M. Brassard⁷, J.D. Ruether⁸, N. Lamond⁹, S. Ezzat¹⁰, P. Klimo¹¹, H. Lim¹², M.-H. Massicotte¹³, R. Wong¹⁴, P. Lam¹⁵, B. Yap¹⁶, M. Krzyzanowska¹⁷, ¹Juravinski Cancer Centre, Hamilton, CA, ²London Regional Cancer Program (LRCP) - London Health Science Center (LHSC), London, CA, ³Centre Hospitalier Université de Montréal (CHUM), Montréal, CA, ⁴The Ottawa Hospital Cancer Centre, Ottawa, CA, ⁵McGill University Health Centre, Montréal, CA, ⁶Cross Cancer Institute, Edmonton, CA, ⁷Centre Hospitalier Université Laval (CHUL), Québec, CA, ⁸Tom Baker Cancer Centre, Calgary, CA, ⁹Nova Scotia Health Authority, Halifax, CA, ¹⁰University Health Network, Toronto, CA, ¹¹Continuum Medical Care Clinic, West Vancouver, CA, ¹²BC Cancer Agency - Vancouver, Vancouver, CA,

¹³Centre Hospitalier Universite de Sherbrooke (CHUS), Sherbrooke, CA, ¹⁴St. Boniface General Hospital Cancercare Manitoba, Winnipeg, CA, ¹⁵Eisai Ltd., Mississauga, CA, ¹⁶Innomar Strategies Inc., Okville, CA, ¹⁷Princess Margaret Cancer Centre, Toronto, CA

11:07 - 11:07 **1864PD - Spatiotemporal intratumor genetic heterogeneity and clonal evolution in PTCs and paired DM**

S. Gil Bernabé¹, N. Feás Rodríguez¹, M. Vega Herrero¹, J.J. Estébanez García¹, D. Soto De Prado², J. Fra Rodríguez³, G. García - Rostán¹, ¹University of Valladolid, Valladolid, ES, ²Hospital Clínico Universitario, Valladolid, ES, ³Hospital Universitario Río Hortega, Valladolid, ES

11:07 - 11:07 **1865PD - Specific patterns of long non-coding RNA expression in benign and malignant thyroid nodules**

V. Yakushina, A. Lavrov, Federal State Budgetary Institution "Research Centre for Medical Genetics", Moscow, RU

11:07 - 11:25 **Invited Discussant 1862PD, 1863PD, 1864PD and 1865PD**

11:25 - 11:30 **Q&A led by Discussant**

10:30 - 11:30 **Type: Challenge your expert** **Salamanca Auditorium (Hall 3)**
Title: Drug interaction and the key role of kidney function in onco-haematology
 Chair(s): Ben Sprangers, US

10:30 - 10:30 **Session DOI**

10:30 - 10:40 **Presentation by expert**

V. Launay-Vacher, Groupe Hospitalier Pitié Salpetriere, Paris, FR

10:40 - 11:30 **Discussion led by Chair**

B. Sprangers, , US

11:00 - 12:00	Type: EONS session Title: EONS 12: Patient/public involvement in cancer care Chair(s): Emma Woodford, BE	Oviedo Auditorium (CC5)
11:00 - 11:00	Session DOI	
11:00 - 11:20	Patient and public involvement in health care decisions: What is the difference and why does it matter? <u>M. Fredriksson</u> , University Hospital Uppsala Akademiska Sjukhuset, Uppsala, SE	
11:20 - 11:40	Patient and public involvement in nursing research and practice: Offering the care that people affected by cancer want <u>T. Wiseman</u> , Royal Marsden Hospital NHS Foundation Trust, London, GB	
11:40 - 12:00	Perceived barriers to PPI from the patient perspective <u>K. Mastris</u> , European Cancer Patient Coalition, Brussels, BE	
11:00 - 11:45	Type: Young Oncologist session Title: YO Brunch: How to use social networks and web-based information systems to be up to date in oncology? Chair(s): Matteo Lambertini, IT; Mila Petrova, BG	Santander Auditorium (Hall 3)
11:00 - 11:00	Session DOI	
11:00 - 11:30	How to use social networks and web-based information systems to be up to date in oncology? <u>G. Morgan</u> , Skane University Hospital, Lund, SE	
11:30 - 11:45	Discussion	
12:00 - 12:45	Type: Keynote lecture Title: Caloric restriction mimetics, autophagy and cancer Chair(s): Ian Chau, GB	Madrid Auditorium (Hall 2)
12:00 - 12:00	Session DOI	
12:00 - 12:45	Caloric restriction mimetics, autophagy and cancer <u>G. Kroemer</u> , Université Paris Descartes, Paris, FR	

12:00 - 13:00 **Type: Poster Display session** **Poster Area (Hall 4)**
Title: Poster Display session 3

12:00 - 12:00 **Biomarkers**

12:00 - 12:00 **94P - Two years of BRCA1 and BRCA2 somatic External Quality Assessment with Gen&tiss Tiss scheme in France**

K. Dufrain¹, C. Garrec², C. Egele³, C. Keppens¹, J. Chiesa⁴, A. Lamy⁵, L. Lacroix⁶, A. Harlé⁷, R. Pascal⁴, K. Van Casteren¹, D. Fetique³, E. Dequeker¹, J.-P. Bellocq³, E. Rouleau⁸, ¹University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ²CHU Nantes, Nantes, FR, ³AFAQAP, Strasbourg, FR, ⁴Hôpital CAREMEAU, Nimes, FR, ⁵Hop. Charles Nicolle, Rouen, FR, ⁶Institut Gustave Roussy, Villejuif, FR, ⁷CLCC - Nancy, Nancy, FR, ⁸Gustave Roussy - Cancer Campus, Villejuif, FR

12:00 - 12:00 **95P - Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study**

K. Chi¹, S. Thomas², M. Gormley³, D. Shen⁴, S. Joshi⁴, N. Tran⁵, M. Smith⁶, D. Ricci⁷, K. Fizazi⁸, ¹BC Cancer Agency - Vancouver, Vancouver, CA, ²Janssen, New Jersey, US, ³Janssen R&D/Johnson & Johnson Pharmaceutical R&D, Raritan, US, ⁴Janssen Research & Development, PA, US, ⁵Janssen Research & Development, CA, US, ⁶Janssen Research & Development, NJ, US, ⁷Janssen Research and Development, Spring House, US, ⁸Institut Gustave Roussy, Villejuif, FR

12:00 - 12:00 **96P - LRP2, a potential new biomarker for Chinese younger aged intrahepatic cholangiocarcinoma patients**

X. Shi¹, T. Wang², S. Zhang¹, W. Shi¹, A. Liu¹, W. Zhang², ¹Origimed, Shanghai, CN, ²International Hospital of Zhejiang University (Shulan Hospital), Hangzhou, CN

12:00 - 12:00 **97P - Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability**

A. Moreira¹, S. Vacher², C. Lecerf², M. Frelaut², M.P. Sablin³, D. Loirat², F. Ricci², S. Hescot², E. Borcoman², N. Torossian², J. Masliah-Planchon², C. Callens², A. Salomon⁴, I. Bieche², C. Le Tourneau², M. Kamal², ¹Saint Quentin, Paris, FR, ²Institut Curie, Paris, FR, ³Dr. Marie Paule Sablin, La Défense, FR, ⁴Institut Curie, paris, FR

12:00 - 12:00 **98P - A computational model for harmonization of tumor mutational burden across pan-cancers and targeted panels**

M. Golkaram¹, C. Zhao², S. Zhang², S. Bilke¹, ¹Illumina, San Diego, US, ²Illumina, san diego, US

12:00 - 12:00 **99P - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) From Blood Samples in Patients With Non-Small Cell Lung Cancer (NSCLC)**

J. Baden¹, H. Chang¹, D. Greenawalt¹, S. Kirov¹, S. Pant², A. Seminara³, S. Srinivasan³, G. Green³, ¹Bristol-Myers Squibb, Princeton, US, ²Bristol-Myers Squibb, Hopewell, US,

³Bristol-Myers Squibb, Lawrenceville, US

12:00 - 12:00

100P - Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients

S. Bins¹, W. Van De Geer², J. Van Riet², N. Steeghs³, H. Verheul⁴, C. Van Herpen⁵, P. Witteveen⁶, V. Tjan-Heijnen⁷, M. Lolkema⁸, E. Voest³, S. Sleijfer¹, E. Cuppen⁹, H. Van De Werken², R. Mathijssen², ¹Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ²Erasmus MC Cancer Institute, Rotterdam, NL, ³Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ⁴Vrije University Medical Centre (VUMC), Amsterdam, NL, ⁵Radboud University Medical Center, Nijmegen, NL, ⁶UMC Utrecht Cancer Center, Utrecht, NL, ⁷Maastricht University Medical Center (MUMC), Maastricht, NL, ⁸Erasmus University Medical Center, Rotterdam, NL, ⁹Hartwig Medical Foundation, Amsterdam, NL

12:00 - 12:00

101P - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations

J. Johnson¹, J. Lee², R. Madison², A. Schrock², V. Miller², B. Alexander², J. Ross², J. Chung², S. Ali², ¹Thomas Jefferson University, Philadelphia, US, ²Foundation Medicine, Cambridge, US

12:00 - 12:00

102P - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients

X. Jiao¹, A. Lokker², J. Snider², E. Castellanos³, S. Nanda¹, V. Fisher⁴, J. Zong¹, K. Keating¹, M. Fellous¹, ¹Bayer HealthCare Pharmaceuticals, Inc., Whippany, US, ²Flatiron Health, Inc., New York, US, ³Flatiron Health, New York, US, ⁴Foundation Medicine, Inc., Cambridge, US

12:00 - 12:00

103P - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial

J. Masliah-Planchon¹, M. Kamal¹, E. Borcoman¹, E. Girard², P. Gestraud², G. Bataillon¹, A. Vincent-Salomon¹, C. Lecerf¹, C. Callens¹, S. Antonio¹, C. Franck¹, O. Mariani¹, I. Bieche¹, C. Le Tourneau¹, V. Servois¹, ¹Institut Curie, Paris, FR, ²Institut Curie, Saint-Cloud, FR

12:00 - 12:00

104P - First national External Quality Assesment for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France

E. Rouleau¹, K. Leroy², K. Dufraing³, A. Harlé⁴, L. Lacroix⁵, K. Vanwelden⁶, M. Denis⁷, A. Lamy⁸, E. Dequeker³, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Hôpital Cochin, Paris, FR, ³University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁴Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, ⁵Institut Gustave Roussy, Villejuif, FR, ⁶KU Leuven, Leuven, BE, ⁷CHU du Nantes - Hôtel-Dieu, Nantes, FR, ⁸Hop. Charles Nicolle, Rouen, FR

12:00 - 12:00

105P - Prospective testing of circulating tumor DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology

A. Bujak¹, C.-F. Weng¹, M.-J. Silva², M. Yeung¹, L. Lo¹, S. Ftouni¹, C. Litchfield¹, A. Ko¹, K. Kuykhoven¹, C. Van Geelen¹, S. Chandrashekar¹, M. Dawson¹, S. Loi¹, S. Wong¹, S.-J. Dawson¹, ¹Peter MacCallum Cancer Center, Melbourne, AU, ²Peter MacCallum Cancer Center, Melbourne, PT

- 12:00 - 12:00 **106P - Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer**
B. De Laere¹, A. Crippa¹, C. Ghysel², P. Ost³, P. Rajan⁴, M. Eklund¹, L. Dirix⁵, H. Grönberg¹, J. Lindberg¹, ¹Karolinska Institute, Stockholm, SE, ²AZ Sint-Jan Brugge-Oostende AV, Brugge, BE, ³Ghent University Hospital, Ghent, BE, ⁴Barts Cancer Institute, Queen Mary University of London, London, GB, ⁵GZA Hospitals Sint-Augustinus & University of Antwerp, Antwerp, BE
- 12:00 - 12:00 **107P - High proportion of multiple KRAS mutations in circulating tumor DNA and tumor tissue of pancreatic ductal adenocarcinoma**
M.K. Kim¹, S.M. Woo², Y.H. Kim¹, B. Park¹, J.N. Joo¹, K.-A. Yoon³, S.J. Park², S.-Y. Kong¹, ¹National Cancer Center, Gyeonggi-do, KR, ²National Cancer Center, Goyang, KR, ³Konkuk University, Seoul, KR
- 12:00 - 12:00 **108P - Biological difference of tumor mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs. germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study**
Y. Kawamoto¹, Y. Nakamura², M. Ikeda², H. Bando³, T. Esaki⁴, M. Ueno⁵, T. Nishina⁶, Y. Kagawa⁷, E. Oki⁴, T. Denda⁸, T. Mizukami⁹, N. Takahashi¹⁰, N. Okano¹¹, I. Miki², Y. Sakamoto², M. Lefterova¹², J. Odegaard¹², H. Taniguchi², C. Morizane¹³, T. Yoshino², ¹Hokkaido University Hospital, Sapporo, JP, ²National Cancer Center Hospital East, Kashiwa, JP, ³Aichi Cancer Center Hospital, Nagoya, JP, ⁴National Kyushu Cancer Center, Fukuoka, JP, ⁵Kanagawa Cancer Center, Yokohama, JP, ⁶Shikoku Cancer Center, Matsuyama, JP, ⁷Kansai Rosai Hospital, Amagasaki, JP, ⁸Chiba Cancer Center Hospital, Chiba, JP, ⁹St. Marianna University School of Medicine, Sagami-hara, JP, ¹⁰Saitama Cancer Center, Ina-machi, Kita-Adachi-gun, JP, ¹¹Kyorin university Hospital, Tokyo, JP, ¹²Guardant Health, Redwood City, US, ¹³National Cancer Center Hospital, Tokyo, JP
- 12:00 - 12:00 **109P - Cell-Free DNA to Detect Focal Versus Non-Focal MET Amplification in Metastatic Colorectal Cancer Patients: Combined Analysis from Japan and the United States**
M. Saori¹, A. Kawazoe², Y. Nakamura¹, J. Odegaard³, M. Lefterova³, R. Lanman³, T. Yoshino¹, J. Strickler⁴, ¹National Cancer Center Hospital East, Kashiwa, JP, ²National Cancer Center Hospital, Tokyo, JP, ³Guardant Health, Redwood City, US, ⁴Duke Cancer Center, Durham, US
- 12:00 - 12:00 **110P - Presence of circulating tumor DNA in surgically resected renal cell carcinoma is associated with advanced disease and poor patient prognosis**
A. Correa¹, D. Connolly¹, M. Balcioglu², H.-T. Wu², S. Dashner², S. Shchegrova², E. Kalashnikova², H. Pawar², R. Uzzo¹, Y. Gong¹, D. Kister¹, M. Collins¹, M. Donovan¹, R. Winters¹, A. Aleshin², H. Sethi², R. Salari², M. Louie², B. Zimmermann², P. Abbosh¹, ¹Fox Chase Cancer Center, Philadelphia, US, ²Natera, Inc., San Carlos, US

- 12:00 - 12:00 **111P - Circulating tumor DNA (ctDNA) mutation and epigenomic patterns in early stage lung cancer patients and its utility in identifying patients at high risk for early recurrence**
J. Lee¹, I.-J. Kim², J.H. Cho¹, H.K. Kim³, J. Lee³, S.-H. Lee⁴, M. Shultz², A. Jaimovich², J. Odegaard², S. Olsen², A. Talasaz², J. Kim³, ¹Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ²Guardant Health, Redwood City, US, ³Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁴Seoul National University Hospital, Seoul, KR
- 12:00 - 12:00 **112P - DEMo: a prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy.**
A. Prelaj¹, C. Proto¹, G. Lo Russo¹, D. Signorelli¹, R. Ferrara¹, G. Galli¹, A. De Toma¹, G. Randon¹, F. Pagani¹, B. Trivisan¹, M. Ganzinelli¹, N. Zilembo¹, F.G. De Braud¹, M. Mensah¹, V. Torri², M. Garassino¹, G. Sozzi¹, M. Boeri¹, ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ²IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, IT
- 12:00 - 12:00 **113P - Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)**
C. Yang¹, M. Iafolla², S. Dashner³, W. Xu⁴, A. Hansen², P. Bedard², S. Lheureux⁵, A. Spreafico², A.A. Razak², H.-T. Wu³, S. Shchegrova³, Z.A. Liu², P. Ohashi¹, D. Torti⁶, M. Louie³, H. Sethi³, A. Aleshin³, L. Siu⁴, S. Bratman⁴, T. Pugh⁶, ¹University of Toronto, Toronto, CA, ²Princess Margaret Cancer Center, Toronto, CA, ³Natera, Inc., San Carlos, US, ⁴Princess Margaret Cancer Centre, Toronto, CA, ⁵UHN-Princess Margaret Hospital, Toronto, CA, ⁶Ontario Institute for Cancer Research, Toronto, CA
- 12:00 - 12:00 **114P - Dynamic changes in whole-genome cell-free DNA (cfDNA) to identify disease progression prior to imaging in advanced solid tumors**
A. Davis¹, W. Iams², D. Chan³, M. Oh¹, R. Lentz¹, N. Peterman⁴, A. Robertson⁴, A. Shah⁴, R. Srivas⁴, N. Lambert⁵, T. Wilson⁵, P. George⁵, B. Wong⁵, J. Close⁵, H. Wood⁵, A. Tezcan⁵, J. Spinosa⁵, H. Tezcan⁵, Y.K. Chae¹, ¹Northwestern University Feinberg School of Medicine, Chicago, US, ²Vanderbilt University, Nashville, US, ³Cancer Care Associates, Redondo Beach, US, ⁴Lexent Bio, Inc., San Francisco, US, ⁵Inc., San Francisco, US
- 12:00 - 12:00 **115P - Evaluation of Microsatellite Instability Testing Through cell-free DNA sequencing**
S. Zhang, J. Lococo, A. Mentzer, B. Crain, S. Katz, G. Berry, Y. Fu, T. Jiang, C. Zhao, S. Bilke, T. Pawlowski, K. Kruglyak, Illumina, San Diego, US
- 12:00 - 12:00 **116P - Longitudinal changes in cell-free DNA (cfDNA) methylation levels identify early non-responders to treatment in advanced solid tumors**
A. Davis¹, W. Iams², D. Chan³, M. Oh¹, R. Lentz¹, R. Srivas⁴, N. Lambert⁵, A. Robertson⁴, N. Peterman⁴, A. Shah⁴, T. Wilson⁵, J. Close⁵, P. George⁵, H. Wood⁵, B. Wong⁵, A. Tezcan⁵, J. Spinosa⁵, H. Tezcan⁵, Y.K. Chae¹, ¹Northwestern University Feinberg School of Medicine, Chicago, US, ²Vanderbilt University, Nashville, US, ³Cancer Care

Associates, Redondo Beach, US, ⁴Lexent Bio, Inc., San Francisco, US, ⁵Inc., San Francisco, US

12:00 - 12:00

117P - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.

G. Tsaousis¹, N. Tsoulos², E. Papadopoulou³, K. Agiannitopoulos⁴, G. Pepe⁴, N. Diamantopoulos⁵, T. Floros⁶, R. Iosifidou⁵, C. Markopoulos⁷, K. Papazisis⁸, V. Venizelos⁹, G. Xepapadakis¹⁰, E. Banu¹¹, D.T. Eniu¹², D. Stanculeanu¹³, A. Ungureanu¹⁴, S. Tansan¹⁵, M. Tekinel¹⁶, S. Yalcin¹⁷, G. Nasioulas¹⁸, ¹Genekor, Athens, GR, ²Genekor, ATHENS, GR, ³Genekor s.a, Pallini, GR, ⁴Genekor Medical SA, Athens, Gerakas, GR, ⁵Theagenio Cancer Hospital, Thessaloniki, GR, ⁶Naval and Veterans Hospital of Athens, Athens, GR, ⁷(private address), Athens, GR, ⁸Euromedica General Clinic, Thessaloniki, GR, ⁹Metropolitan Hospital, Athens, GR, ¹⁰Mitera Maternity Hospital, Athens, GR, ¹¹Spitalul Sfântul Constantin Brasov, Brasov, RO, ¹²Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, RO, ¹³National Institute of Oncology A.Treistoreanu, Bucharest, RO, ¹⁴SC Medisprof S.R.L., Cluj-Napoca, RO, ¹⁵Tansan Oncology, Instabul, TR, ¹⁶Private Practice, Fulya Sisli, TR, ¹⁷Hacettepe University Faculty of Medicine, Ankara, TR, ¹⁸GENEKOR Medical SA, Athens, GR

12:00 - 12:00

118P - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors

J. Quintanilha¹, A. Racioppi², J. Wang², S. Denning², A. Etheridge², C. Peña³, D. Crona², D. Lin², F. Innocenti², ¹UNC-Institute for Pharmacogenomics and Individualized Therapy, Chapel Hill, US, ²University of North Carolina, Chapel Hill, US, ³Bayer HealthCare Pharmaceuticals, Whippany, US

12:00 - 12:00

119P - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.

N. Chic¹, T. Pascual², F. Brasó-Maristany³, P. Villagrasa Gonzalez⁴, L. Pare Brunet¹, F. Schettini⁵, B. Conte⁶, B. Adamo⁷, M. Vidal⁷, M. Muñoz⁷, O. Martínez⁷, B. Gonzalez-Farre⁷, J. Cortés⁸, A. Llombart-Cussac⁹, V. Rodrik-Outmezguine¹⁰, M.A. Izquierdo Delso¹¹, R. Schiff¹², C.K. Osborne¹², M. Rimawi¹², A. Prat¹, ¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ²Institut d'Investigaciones Biomèdiques August Pi i Sunyer, Barcelona, ES, ³Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, ES, ⁴SOLTI, Barcelona, ES, ⁵Azienda Universitaria Ospedaliera Federico II, Napoli, IT, ⁶Ospedale Policlinico San Martino, University of Genova, Genova, IT, ⁷Hospital Clinic, Barcelona, ES, ⁸Vall d'Hebron University Hospital, Barcelona, ES, ⁹Hospital Universitario Arnau de Vilanova, Lleida, ES, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, US, ¹¹Novartis Pharma AG, Basel, CH, ¹²Baylor College of Medicine, Houston, US

12:00 - 12:00

120P - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer

S. Pernas¹, S. Goel², N. Johnson³, B. Harrison⁴, J. Guerriero², J. Hu², G. Winship², A. Sokolov⁵, M. Regan⁶, E.A. Mittendorf⁷, B. Overmoyer⁶, ¹ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ²Dana-Farber

Cancer Institute, Boston, US, ³Harvard Program in Therapeutic Science; Dana-Farber Cancer Institute, Boston, US, ⁴Brigham and Women's Hospital, Boston, US, ⁵Harvard Program in Therapeutic Science, Boston, US, ⁶Dana Farber Cancer Institute, Boston, US, ⁷MD Anderson Cancer Center, Houston, US

- 12:00 - 12:00 **121P - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)**
- C. Cardone¹, B. Blauensteiner², V. Moreno-Viedma², P.P. Vitiello¹, G. Martini¹, D. Ciardiello¹, V. Simeon¹, A.M. Rachiglio³, D. Rizzi⁴, E. Maiello⁵, T. Latiano⁵, C. Cremolini⁶, G. Argiles Martinez⁷, E. Elez⁷, A. Falcone⁶, J. Tabernero⁸, N. Normanno³, M. Sibilìa², F. Ciardiello¹, E. Martinelli¹, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²Medical University of Vienna, Austria, AT, ³National Cancer Institute 'Fondazione Giovanni Pascale', Napoli, IT, ⁴GOIM, Bari, IT, ⁵Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT, ⁶Azienda Ospedaliera Universitaria S.Chiara, Pisa, IT, ⁷Vall d'Hebron University Hospital, Barcelona, ES, ⁸Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES
- 12:00 - 12:00 **122P - Prevalence of EGFR mutations and its correlation with Egyptian patients' human kinetics (PEEK Study)**
- A. Ibrahim¹, M. Youssef², A. Helal¹, S. Waguhi², M. Khalifa¹, R. Aziz³, ¹Cairo University, Cairo, EG, ²AstraZeneca, Cairo, EG, ³Ain Shams University, Cairo, EG
- 12:00 - 12:00 **123P - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)**
- S. Rutella¹, S. Church², J. Vadakekolathu³, S. Reeder³, A. Sullivan², S. Warren⁴, J. Baughman⁵, J. Muth⁵, H. Park⁶, H. Uronis⁷, Y.-K. Kang⁸, M. Ng⁹, P. Enzinger¹⁰, K.W. Lee¹¹, K. Huber⁵, A. Wynter-Horton⁵, D. Li⁵, Y.-J. Bang¹², J. Davidson-Moncada⁵, D. Catenacci¹³, ¹Nottingham Trent University-Clifton Campus, Nottingham, GB, ²Nanostring, Seattle, US, ³Nottingham Trent University, Nottingham, GB, ⁴NanoString Technologies, Seattle, US, ⁵MacroGenics, Inc., Rockville, US, ⁶Washington University Medical School, St. Louis, US, ⁷Duke Cancer Center, Durham, US, ⁸University of Ulsan, Seoul, KR, ⁹National Cancer Centre, Singapore, SG, ¹⁰Dana-Farber Cancer Institute, Cambridge, US, ¹¹Seoul National University Bundang Hospital, Seoul, KR, ¹²Seoul National University Hospital, Seoul, KR, ¹³University of Chicago, Chicago, US
- 12:00 - 12:00 **124P - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).**
- B. Rousseau¹, J. Cohen², J. Calderaro², A. Dupuy², R. Bourgoin², C. Tournigand¹, I. Baumgaertner¹, S. Ropert³, A. Thiot Bidault⁴, C. Klotz⁵, C. Le Foll⁶, H. BouSSION⁷, L. Diaz⁸, M. Ollier², A. Pujals¹, ¹Centre hospitalier universitaire Henri-Mondor, Créteil, FR, ²Henri Modor Hospital, Creteil, FR, ³Hôpital Privé d'Antony, Antony, FR, ⁴Private Practice - Anne Thiot Bidault, Fontenay-aux-Roses, FR, ⁵HIA Percy, Clamart, FR, ⁶GHEF Marne la Vallée, Jossigny, FR, ⁷Assistance Publique - Hopitaux De Paris, Paris, FR, ⁸Memorial Sloan Kettering Cancer Center, New York, US

- 12:00 - 12:00 **125P - Tumor mutation burden and microsatellite instability in colorectal cancer**
F. Fenizia¹, R. Esposito Abate¹, R. Pasquale¹, C. Roma¹, M. Lambiase¹, N. Chicchinelli¹, P. Graziano², G. Botti¹, F. Tatangelo¹, G. Scognamiglio¹, F. Pietrantonio³, N. Normanno⁴,
¹Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ²IRCCS " Casa Solievo della Sofferenza" Hospital, San Giovanni Rotondo, IT, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁴Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT
- 12:00 - 12:00 **126P - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma**
D. Mallardo¹, S. Ong², M. Capone¹, G. Madonna¹, S. Warren², A. Cesano², J. Beechem², P. Ascierto¹,
¹Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ²NanoString Technologies, Seattle, US
- 12:00 - 12:00 **127P - IFN- γ /IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients**
E. Giunta¹, G. Barra², V. De Falco¹, P. Vitale¹, N. Zanaletti¹, M. Terminiello¹, V. Caputo², S. Napolitano¹, P.P. Vitiello¹, D. Ciardiello¹, V. Belli¹, G. Brancaccio¹, G. Argenziano¹, R. De Palma¹, F. Ciardiello¹, T. Troiani¹,
¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²AOU Seconda Università degli Studi di Napoli (AOU-SUN), Napoli, IT
- 12:00 - 12:00 **128P - Multiplex Chromogenic Immunohistochemistry (IHC) for Spatial Analysis of Checkpoint-Positive Tumor Infiltrating Lymphocytes (TILs)**
S. Ely¹, G. Lee¹, L. Menard¹, J. Yan¹, P. Fischer², B. Kakrecha³, D. Locke¹, P. Patah¹, K. Urbanska¹,
¹Bristol-Myers Squibb, Princeton, US, ²Bristol-Myers Squibb, Lawrenceville, US, ³Bristol-Myers Squibb, Cambridge, US
- 12:00 - 12:00 **129P - The role of PD-L1 expression as a predictive biomarker in advanced renal cell carcinoma: a meta-analysis of randomized clinical trials.**
A. Carretero-Gonzalez, I. Martín Sobrino, I. Sáez Sanz, D. Castellano Gauna, G.A. De Velasco Oria De Rueda, University Hospital 12 De Octubre, Madrid, ES
- 12:00 - 12:00 **130P - Radiomic Features as a Non-invasive Biomarker to Predict Response to Immunotherapy in Recurrent or Metastatic Urothelial Carcinoma**
K.J. Park, Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR
- 12:00 - 12:00 **131P - Integrative combination of high-plex digital profiling techniques and cluster analysis to reveal complex immune biology in the tumor microenvironment of mesothelioma**
C. Ballesteros-Merino¹, T. Herz², S. Church³, M. Widmaier², A. Budco⁴, D. Medrikova⁴, I. Kanchev⁴, A. Spitzmueller⁴, A. Shaepe⁴, A. White³, J. Reeves³, A. Sullivan³, M. Bailey³, S. Jensen¹, J. Handy¹, R. Sanborn¹, C. Bifulco¹, S. Warren⁵, J. Beechem⁵, B. Fox¹,
¹Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, US, ²Definiens Inc, Munich, DE, ³Nanostring, Seattle, US, ⁴Definiens AG, Munich, DE, ⁵NanoString Technologies, Seattle, US

- 12:00 - 12:00 **132P - Predictive factors of response to immunotherapy in 198 patients with metastatic non-microcytic lung cancer (mNSCLC): real world data from 2 university hospitals in Spain**
J.F. Cordoba Ortega¹, A. Gasol Cudos², S. Morales Murillo², O. Pallise², M.A. Salud Salvia², J. Brunet Vidal³, H. Pla Juher³, A. Carbó Bagué³, R. Porta Balanya³, A. Izquierdo Font³, A. Hernández Martínez³, A. Franquesa³, J. Bosch-Barrera³, E. Girona⁴, ¹Hospital Arnau de Vilanova, Lleida, ES, ²Hospital Universitario Arnau de Vilanova, Lleida, ES, ³Institut Català d'Oncologia (ICO) Hospital Universitari Dr. Josep Trueta, GIRONA, ES, ⁴ICO - Institut Català d'Oncologia Girona (Hospital Universitari Josep Trueta Hospital Universitari Josep Trueta), Girona, ES
- 12:00 - 12:00 **133P - Evaluating Lung CT Density Changes Among Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Treated with Thoracic Radiotherapy (TRT) alone or TRT Followed by Combined Ipilimumab (IPI) and Nivolumab (NIVO).**
K. Latifi¹, S. Kim¹, T. Dilling¹, S. Rosenberg¹, J. Gray¹, S. Antonia², B. Perez¹, ¹H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ²Duke University Medical Center - Trent Center, Durham, US
- 12:00 - 12:00 **134P - Immuno-oncology therapy biomarkers differences between polyoma-virus positive and negative Merkel cell carcinomas**
Z. Gatalica¹, J. Xiu², E. Contreras², J. Swensen², ¹Caris Life Sciences, New York, US, ²Caris Life Sciences, Phoenix, US
- 12:00 - 12:00 **135P - Can we improve patient selection for phase 1 clinical trials (Ph1) based on Immuno-Oncology score prognostic index (VIO)?**
I. Matos Garcia¹, C. Hierro², J. Martin-Liberal³, C. Viaplana², A. Azaro⁴, I. Brana², M. Vieito Villar⁵, O. Saavedra⁶, I. Gardeazabal⁷, J. Ros², P. Prieto³, R. Berché³, E. Muñoz-Couselo⁸, M. Oliveira⁹, E. Elez Fernández¹⁰, E. Felip², J. Carles², J. Tabernero¹¹, R. Dienstmann², E. Garralda¹², ¹Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Vall d' Hebron University Hospital Institut d'Oncologia, Barcelona, ES, ⁴NO institution, NO City, CH, ⁵Vall d'Hebron University Hospital - Vall d'Hebron Institute of Oncology VHIO, Barcelona, ES, ⁶Vall d'Hebron University Hospital, NO City, ES, ⁷Clinica Universitaria de Navarra, Pamplona, ES, ⁸Vall d' Hebron University Hospital, Barcelona, ES, ⁹Vall d'Hebron University Hospital, Barcelona, ES, ¹⁰Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ¹¹Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ¹²Vall d' Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES
- 12:00 - 12:00 **136P - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.**
R. Sun¹, A. Lancia², N. Sundahl³, M. Milic¹, A. Carre⁴, M. Lerousseau⁵, T. Estienne⁵, E. Battistella⁵, G. Klausner⁶, R. Bahleda⁷, E. Alvarez-Andres⁵, C. Robert⁵, C. Boutros¹, M. Vakalopoulou⁵, N. Paragios⁸, P. Ost⁹, C. Massard⁷, E. Deutsch¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Policlinico Tor Vergata, Rome, IT, ³Gent University Hospital, Gent, BE, ⁴Gustave Roussy Cancer Campus, Villejuif, FR, ⁵Gustave Roussy-CentraleSupélec-TheraPanacea Center of Artificial Intelligence in Radiation Therapy and Oncology, Villejuif, FR, ⁶Assistance Publique - Hopitaux De Paris, Paris, FR, ⁷Gustave Roussy -

Cancer Campus, Villejuif, FR, ⁸CentraleSupélec - Paris-Saclay campus, Gif sur Yvette, FR,
⁹UZ Gent, Gent, BE

- 12:00 - 12:00 **137P - Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine.**
S. Suekane¹, M. Noguchi², M. Terasaki², S. Yutani², Y. Narita³, A. Yamada¹, S. Shichijo², T. Igawa², K. Itoh², ¹Kurume University, Kurume, JP, ²Kurume University School of Medicine, Kurume, JP, ³National cancer center hospital, Tokyo, JP
- 12:00 - 12:00 **138P - Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumor tissues**
S. Yu, M. Shi, J. Feng, Jiangsu Cancer Hospital, Nanjing, CN
- 12:00 - 12:00 **139P - Patient's perspective on digital biomarkers in advanced urologic malignancies**
S. Rodler¹, A. Buchner¹, M. Schott¹, G. Schulz¹, C. Stief¹, M. Staehler², J. Casuscelli³, ¹LMU Klinikum der Universität München, Munich, DE, ²University of Munich, Munich, DE, ³University Hospital Munich, LMU, Munich, DE
- 12:00 - 12:00 **140P - NMR-based metabolomics in real-time monitoring of treatment induced toxicity and cachexia in head and neck cancer**
L. Boguszewicz, M. Ciszek, A. Bielen, J. Mrochem-Kwarciak, K. Składowski, A. Wygoda, T. Rutkowski, A. Kotylak, M. Sokół, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, PL
- 12:00 - 12:00 **141P - A comprehensive Pan-cancer study of FGFR Aberrations in Chinese cancer patients**
Y. Gao¹, W. Zhu², Q. He², Y. Liu¹, X. Chen³, D. Xiao², H. Han-Zhang⁴, J. Lin⁴, ¹Xiang Ya Hospital Central South University, Changsha, CN, ²Xiangya Hospital Central South University, Changsha, CN, ³Hainan General Hospital, Haikou, CN, ⁴Burning Rock Biotech, Guangzhou, CN
- 12:00 - 12:00 **143P - A Systemic Inflammation Response Index (SIRI) correlates with survival and could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer (PC)**
V. Pacheco-Barcia¹, R. Mondejar¹, T. France², J. Asselah³, O. Donnay¹, G. Zogopoulos², N. Bouganim², K. Guo², E. Martin¹, T. Alcindor³, R. Colomer Bosch¹, ¹Hospital Universitario de La Princesa, Madrid, ES, ²McGill University Health Centre, Montreal, CA, ³McGill University Health Centre - Glen Site, Montreal, CA
- 12:00 - 12:00 **144P - Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced Non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel)**
A. Pavan¹, L. Calvetti², A. Dal Maso³, A. Fabozzi¹, L. Piccin¹, V. Chiarion-Sileni⁴, G. Pasello¹, G. Aprile⁵, V. Guarneri¹, P.F. Conte¹, L. Bonanno¹, ¹Istituto Oncologico Veneto IRCCS, Padova, IT, ²AOU Integrata Verona "Borgo Roma", Verona, IT, ³Università degli Studi di Padova, Padova, IT, ⁴Istituto Oncologico Veneto - IRCCS, Padua, IT, ⁵ULSS 8 Berica - Vicenza-Ospedale Civile "San Bortolo", Vicenza, IT

- 12:00 - 12:00 **145P - Breast cancer in young women of Kazakh population depending on germline mutations: results of next-generation sequencing**
D. Kaidarova¹, N. Omarbayeva², G. Zhunussova³, A. Abdrakhmanova¹, Z. Chingissova¹, L. Djansugurova³, ¹kazakh institute of oncology and radiology, almaty, KZ, ²Ms. Nazgul Omarbayeva, Taraz, KZ, ³institute of common genetics and cytology MES RK, almaty, KZ
- 12:00 - 12:00 **146P - Discovery of an ImmunoTranscriptomics signature in blood for early colorectal cancer detection**
P. Angelino¹, S. Hosseinian Ehrensberger², L. Ciarloni², J. Despraz³, G. Dorta⁴, A. Perez-Uribe³, S. Morgenthaler⁵, M. Delorenzi¹, ¹Swiss Institute of Bioinformatics, Lausanne, CH, ²Novigenix, Epalinges, CH, ³School of Management and Engineering Vaud, Yverdon-les-Bains, CH, ⁴Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, CH, ⁵Ecole Polytechnique Fédérale de Lausanne, Lausanne, CH
- 12:00 - 12:00 **147P - Serum Netrin-1 as a Biomarker for Colorectal Cancer Detection**
J. Zhu¹, L. Xi¹, A. Wu¹, X. Ma², J. Zhang³, ¹The First Affiliated Hospital of Soochow University, Suzhou, CN, ²Suqian Affiliated Hospital of Xuzhou Medical University, Suqian, CN, ³China-Japan Union Hospital of Jilin University, Changchun, CN
- 12:00 - 12:00 **148P - Salivary metabolomics for colorectal cancer detection**
H. Kuwabara, A. Iwabuthi, R. Soya, M. Enomoto, T. Ishizaki, A. Tsuchida, Y. Nagakawa, K. Katsumata, M. Sugimoto, Tokyo Medical University, Tokyo, JP
- 12:00 - 12:00 **149P - Evaluation and diagnostic potential of plasma biomarkers in bladder cancer**
V. Voronova¹, K. Peskov¹, P. Glybochko², A. Svistunov², V. Fomin², P. Kopylov², D. Enikeev², E. Gitel², A. Ragimov², E. Poddubskaya², M. Sekacheva², ¹M&S Decisions LLC, Moscow, RU, ²I.M. Sechenov First Moscow State Medical University, Moscow, RU
- 12:00 - 12:00 **150P - Liquid biopsy assays using combined circulating tumor cells and circulating tumor DNA in the same patients for the diagnosis of primary lung cancer**
Y. Suh¹, J.-S. Bae², H.S. Lee¹, J.-M. Moon¹, H.-J. Kwon², J. Kim², S.M. Moon³, B.-H. Jeong³, K. Lee³, M.-S. Lee², B.H. Jeon¹, S. Lee², J.C. Park¹, S.-W. Um³, ¹Cytogen, Inc., Seoul, KR, ²EONE-Diagnostics, Incheon, KR, ³Samsung Medical Center, Seoul, KR
- 12:00 - 12:00 **151P - Peripheral Cytotoxic T Cell Correlates with Tumor Mutational Burden and is Predictive for Progression Free Survival in Advanced Breast Cancer**
X.-R. Liu¹, G. Song², H. Jiang³, L.-J. Di⁴, J. Yu⁵, S. Jia⁵, H. Li⁴, X. Liang¹, ¹Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, ²Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, CN, ³Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, BEIJING, CN, ⁴Peking University Cancer Hospital & Institute, Beijing, CN, ⁵Predicine, Inc, Hayward, US

- 12:00 - 12:00 **152P - The prognostic value of the tumor-stroma ratio validates in subgroups of breast cancer, especially in grade III tumors.**
W. Mesker, Leiden University Medical Center (LUMC), Leiden, NL
- 12:00 - 12:00 **154P - Splenic Metabolic Activity as Biomarker in Cervical Cancer**
E. De Jaeghere¹, F. Laloo², L. Lippens², K. De Man², M. Van Bockstal³, K. Van De Vijver², P. Tummers², A. Makar², P. De Visschere², O. De Wever², F. Amant⁴, H. Denys⁵, K. Vandecasteele², ¹Université de Gand, Gent, BE, ²Ghent University Hospital, Gent, BE, ³Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe, BE, ⁴University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁵UZ Gent, Gent, BE
- 12:00 - 12:00 **155P - Identification of distinct subtypes revealing prognostic and therapeutic relevance in diffuse type gastric cancer**
S.-K. Kim¹, J.-R. Park¹, H.-J. Kim¹, J.-H. Kim¹, S.-Y. Kim¹, S.-I. Lee², K.-S. Song², W.-H. Kim³, Y.S. Kim¹, ¹KRIBB-Korea Research Institute of Bioscience and Biotechnology, Daejeon, KR, ²Chungnam National University, College of Medicine, Daejeon, KR, ³Seoul National University, Faculty of Medicine, Seoul, KR
- 12:00 - 12:00 **156P - Recurrence risk evaluation in stage IB/IIA gastric cancer with TP53 codon 72 polymorphisms**
S. Nishizuka¹, Y. Ohmori², T. Iwaya¹, K. Koeda¹, ¹Iwate Medical University School of Medicine, Morioka, JP, ²Iwate Medical University, Morioka, JP
- 12:00 - 12:00 **157P - Identification and validation of a prognostic 4 genes signature for hepatocellular carcinoma: integrated ceRNA network analysis**
Y. Yan, K. Mao, P. Huang, J. Wang, Z. Xiao, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, CN
- 12:00 - 12:00 **158P - Plasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805)**
W. Xu¹, M. Puligandla², N. Haas³, K. Flaherty⁴, R. Uzzo⁵, V. Sabbisetti⁶, J. Dutcher⁷, R. Dipaola⁸, R. Bhatt¹, ¹Beth Israel Deaconess Med. Center, Boston, US, ²ECOG-ACRIN Biostatistics Center, Boston, US, ³University of Pennsylvania/Abramson Cancer Center, Philadelphia, US, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, US, ⁵Fox Chase Cancer Center, Philadelphia, US, ⁶Brigham and Women's Hospital, Boston, US, ⁷Cancer Research Foundation, Chappaqua, US, ⁸University of Kentucky, Lexington, US
- 12:00 - 12:00 **159P - Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting**
K. Nekolla¹, N. Brieu¹, C. Gavriel², M. Widmaier¹, A. Budco¹, D. Medrikova¹, I. Kanchev¹, M. Testori¹, J. Chan¹, P. Dundee³, P. Anderson⁴, N. Lawrentschuk⁵, L.-M. Wong⁶, P. Phan⁷, P. Gibbs⁷, D. Harrison⁸, M. Baehner¹, P. Caie², B. Tran⁹, G. Schmidt¹, ¹Definiens AG, Munich, DE, ²University of St Andrews, St Andrews, GB, ³Royal Melbourne Hospital, Parkville, AU, ⁴Royal Melbourne Hospital, Melbourne, AU, ⁵PeterMacCallum Cancer Centre, Melbourne, AU, ⁶St Vincent's Hospital Melbourne, Fitzroy, AU, ⁷The Walter and Eliza Hall Institute of Medical Research, Parkville, AU, ⁸University of St Andrews, St

Andrews, Scotland, GB, ⁹Peter MacCallum Cancer Centre, Melbourne, AU

- 12:00 - 12:00 **160P - Molecular profiling and prognostic significance of TP53 mutations in Diffuse Large B Cell Lymphoma: identifying a high-risk subgroup**
Y.-K. Shi¹, S. Jiang², Y. Qin², H. Jiang³, B. Liu³, J. Shi³, F. Meng⁴, P. Liu², J. Yang², S. Yang², X. He², S. Zhou², L. Gui², H. Liu⁵, J. Lin⁵, ¹Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing, CN, ²National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ³Suzhou Municipal Hospital, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, CN, ⁴Tianjin medical university general hospital, Tianjin, CN, ⁵Burning Rock Biotech, Guangzhou, CN
- 12:00 - 12:00 **161P - Differential expression of various miRNAs in Pediatric Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)**
V. Gaur¹, S. Chaudhary², A. Tyagi², S. Bakhshi³, P. Sharma¹, S. Kumar³, ¹Amity University, Noida, IN, ²All India Institute of Medical Sciences, DELHI, IN, ³All India Institute of Medical Sciences, Delhi, IN
- 12:00 - 12:00 **162P - Circulating tumour cells in head and neck and non-small cell lung cancer**
K. O'Byrne, Princess Alexandra Hospital, Woolloongabba, AU
- 12:00 - 12:00 **163P - OX40/OX40L protein expression in Non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers**
X. Zhang¹, Y. He¹, F. Hirsch², C. Zhou³, ¹Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN, ²Mount Sinai New York, New York, US, ³Tongji University, Shanghai, CN
- 12:00 - 12:00 **164P - Effect of Serum Survivin on Survival among Non-Small Cell Lung Cancer Patients; NCI Experience**
R. Rashed, M. Rahouma, R. Abo Elfetouh, H. Aziz, M. Kamel, National Cancer Institute-Cairo University, Cairo, EG
- 12:00 - 12:00 **165P - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning.**
H. Vanacker¹, E. Angevin², A. Hollebecque³, R. Sun⁴, E. Deutsch⁴, A. Zynovyev⁵, L. Calzone⁵, E. Barillot⁵, C. Massard², L. Verlingue⁴, ¹Centre Léon Bérard, Lyon, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³Gustave Roussy, Villejuif, FR, ⁴Institut Gustave Roussy, Villejuif, FR, ⁵Institut Curie, Paris, FR
- 12:00 - 12:00 **166P - Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer After Adjuvant Chemotherapy**
S. Jacobs¹, H. Sethi², T. Kolveska³, T. George⁴, S. Shchegrova², A. Tin², J. Lee⁵, A. Olson⁶, D. Renner⁶, E. Kalashnikova⁷, G. Yothers⁵, N. Wolmark⁸, K. Pogue-Geile¹, A. Srinivasan¹, J. Kortmanský⁹, M. Louie², R. Salari², B. Zimmermann², A. Aleshin², C. Allegra¹, ¹National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, US, ²Natera, Inc., San Carlos, US, ³Kaiser Permanente, Vallejo, US, ⁴University of Florida, Gainesville, US, ⁵University of Pittsburgh, Pittsburgh, US, ⁶Natera, San Carlos, US, ⁷Natera, San Carlos, US, ⁸Allegheny General Hospital, Pittsburgh, US, ⁹Yale Cancer Center, New Haven, US

- 12:00 - 12:00 **167P - Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites**
H.S. Han¹, H.B. Chae², J. Yun³, H.J. Kim⁴, S.-I. Go⁴, W.S. Lee⁴, W.K. Bae⁵, S.H. Cho⁵, E.-K. Song⁶, ¹College of Medicine, Chungbuk National University, Cheongju, KR, ²Chungbuk National University College of Medicine, Cheongju, KR, ³College of Science Engineering, Cheongju University, Cheongju, KR, ⁴Gyeongsang National University School of Medicine, Jinju, KR, ⁵Chonnam National University Hwasun Hospital, Hwasun-Gun, KR, ⁶Chonbuk National University Medical School, Jeonju, KR
- 12:00 - 12:00 **168P - Results from TRIO030, a Pre-Surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide**
H.-W. Chen¹, E. Von Eeuw², P. Millan³, R. Fresco³, S. Carrez⁴, K. Afenjar⁴, H. Fung⁵, M. Burton⁵, A. Santiago¹, R. Guzman¹, I. Villalobos¹, M. Press⁶, W. Eiermann⁷, D. Slamon⁸, ¹Norris Comprehensive Cancer Center, Los Angeles, US, ²UCLA JCCC-Translational Oncology Research Labs, Los Angeles, US, ³TRIO-Translational Research in Oncology, Montevideo, UY, ⁴TRIO-Translational Research in Oncology, Paris, FR, ⁵TRIO-Translational Research in Oncology, Edmonton, CA, ⁶Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, US, ⁷No place of work provided Iran, Tehran, IR, ⁸UCLA - School of Medicine, Los Angeles, US
- 12:00 - 12:00 **169P - JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer**
Y. Sato¹, T. Nakagawa², T. Tanahashi², S. Kitamura², H. Miyamoto², K. Okamoto², N. Muguruma², T. Takayama², ¹Tokushima University Graduate School, Tokushima, JP, ²Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, JP
- 12:00 - 12:00 **171TiP - Phase 2 study of olaparib in previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002**
D. Hyman¹, A. Hendifar², H. Cheol Chung³, M. Maio⁴, A. Leary⁵, I. Spanggaard⁶, J. Rhee⁷, M. Marton⁸, M. Chen⁸, S. Krishnan⁹, R. Shapira¹⁰, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Cedars-Sinai Medical Center, Los Angeles, US, ³Yonsei University College of Medicine, Seoul, KR, ⁴A.O. Universitaria Senese, Senese, IT, ⁵Institut Gustave Roussy, Villejuif, FR, ⁶University Hospital Copenhagen, Copenhagen, DK, ⁷AstraZeneca, Gaithersburg, US, ⁸Merck & Co., Inc., Kenilworth, US, ⁹Merck Research Laboratories, Rahway, US, ¹⁰Chaim Sheba Medical Center, Ramat Gan, IL
- 12:00 - 12:00 **172TiP - The K-BASKET trial: A prospective phase II biomarker-driven multiple basket trial in Korean solid cancer patients.**
S. Kim¹, H.J. Choi², M.H. Kim³, M. Jung⁴, S.-H. Beom⁵, G.M. Kim¹, S.J. Shin⁶, H.C. Chung², ¹Yonsei Cancer Center Yonsei University, Seoul, KR, ²Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ³Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, ⁴Yonsei University, Seoul, KR, ⁵Yonsei Cancer Center, Seoul, KR, ⁶Yonsei University College of Medicine, Seoul, KR
- 12:00 - 12:00 **173TiP - Cambridge Liquid biopsy "CALIBRATION" study: Can changes in**

circulating tumour DNA (ctDNA) predict durable tumour responses in patients with advanced oesophageal cancer receiving MEDI4736?

C. Linossi¹, A. Williams², R. Baird³, S. Dovedi⁴, R. Fitzgerald⁵, S. Pacey⁶, ¹The Hutchinson/MRC Research Centre - University of Cambridge, Cambridge, GB, ²Cambridge Cancer Trials Centre, Cambridge, GB, ³Cambridge University, Cambridge, GB, ⁴AstraZeneca, Cambridge, GB, ⁵University of Cambridge - MRC Cancer Unit, Cambridge, GB, ⁶University of Cambridge, Cambridge, GB

12:00 - 12:00 **New diagnostic tools**

12:00 - 12:00 **1405P - Validation of a tumour mutational burden workflow on routine histological samples of colorectal cancer and assessment of a cohort with synchronous hepatic metastases**

A. Mafficini¹, C. Cantù¹, D. Antonello¹, M. Simbolo¹, L. Piredda¹, V. Lever¹, B. Rusev¹, S. Pecori¹, M. Milella², R. Lawlor¹, A. Scarpa¹, ¹AOU Integrata Verona "Borgo Roma", Verona, IT, ²Università degli Studi di Verona, Verona, IT

12:00 - 12:00 **1406P - Microsatellite Instability Testing and Lynch Syndrome Screening For Colorectal Cancer Patients Through Tumor Sequencing**

L. Liu¹, C. Garbutt², M. Golkaram¹, S. Kaplan¹, M. Martins³, S. Casino³, A. Mansinho³, D. Macedo³, C. Alvim⁴, A. Costa⁴, A. Fernandes³, C. Ferreira⁴, F. Aldeia⁴, A. Quintela⁴, L. Costa³, A. So¹, S. Zhang⁵, T. Pawlowski¹, ¹Illumina, San Diego, US, ²Illumina, SAN DIEGO, US, ³Faculdade de Medicina da Universidade de Lisboa, Lisboa, PT, ⁴Hospital de Santa Maria, Lisboa, PT, ⁵Illumina, san diego, US

12:00 - 12:00 **1407P - "Liquid Withdarw" technique in CT-guided cutting needle lung biopsy: decreased incidence of complications and increased tissue amount for lung cancer molecular testing.**

X. Wang¹, L. Wang¹, W. Ren¹, R. Li², B. Liu³, ¹The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China, Nanjing, CN, ²Nanjing Drum Tower Hospital - Nanjing University, School Of Medicine, Nanjing, CN, ³Nanjing Drum Tower Hospital, Nanjing, CN

12:00 - 12:00 **1408P - WGS Implementation in standard cancer Diagnostics for Every cancer patient (WIDE)**

P. Roepman¹, L. Bosch², K. Samsom², L. Schipper², E. De Bruijn¹, L. Hoes³, I. Riethorst¹, L. Schoenmaker¹, L. Van Der Kolk², H. Van Snellenberg¹, E. Voest³, E. Cuppen¹, K. Monkhorst⁴, G. Meijer³, ¹Hartwig Medical Foundation, Amsterdam, NL, ²Netherlands Cancer Institute, Amsterdam, NL, ³Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ⁴The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

12:00 - 12:00 **1409P - Known and unknown gene fusion detection capabilities of solid tumor laboratories conducting next generation sequencing in 6 countries**

S. Finucane, S. Haridas, L. Handley, J. Clark, A. Jack, S. Munksted, Diaceutics, Belfast, GB

- 12:00 - 12:00 **1410P - Clinical and Analytical Accuracy of a 523 Gene Panel Next-Generation Sequencing (NGS) Assay on Formalin-Fixed Paraffin-Embedded (FFPE) Solid Tumor Samples**
I. Deras, T. Du, C. Zhao, N. Haseley, A. Yazdanparast, T. Jiang, A. Mentzer, A. Purdy, B. Crain, C. Echegaray, D. Lee, J. Lee, J. Silhavy, K. O'Brien, R. Vijayaraghavan, R. Garcia, R. Haigis, T. Pawlowski, J. Dockter, Illumina, San Diego, US
- 12:00 - 12:00 **1411P - Methylation analysis of MLH1 using droplet digital PCR and methylation sensitive restriction enzyme.**
C. De Rop, G. Beniuga, J. Radermacher, K. Dahan, P. Vannuffel, Institut de Pathologie et de Génétique, Gosselies, BE
- 12:00 - 12:00 **1412P - Analytical performance of the Resolution-HRD plasma assay used to identify mCRPC patients with biallelic disruption of DNA repair genes for treatment with niraparib**
I. Pekker¹, L. Lim¹, J. Simon², M. Gormley³, Z. Li⁴, J. Pollak¹, K. Potts¹, S. Watford¹, J. Posey¹, P. Chan¹, K. Urtishak³, K. Garg¹, A. Hosseini¹, M. Li¹, ¹Resolution Bioscience, Kirkland, US, ²Janssen R&D/Johnson & Johnson Pharmaceutical R&D, Spring House, US, ³Janssen R&D/Johnson & Johnson Pharmaceutical R&D, Raritan, US, ⁴Resolution Bioscience, Clyde Hill, US
- 12:00 - 12:00 **1413P - Results of a global external quality assessment scheme for EGFR testing on liquid biopsy**
N. Normanno¹, J. Fairley², M. Cheetham³, M. Denis⁴, E. Dequeker⁵, C. Keppens⁵, F. Fenizia¹, S. Patton³, E. Rouleau⁶, E. Schuurin⁷, K. Van Casteren⁵, Z. Deans², ¹Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, ²UKNEQAS, Edinburgh, GB, ³EMQN, Manchester, GB, ⁴CHU du Nantes - Hôtel-Dieu, Nantes, FR, ⁵University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁶Gustave Roussy - Cancer Campus, Villejuif, FR, ⁷University Hospital Groningen (UMCG), Groningen, NL
- 12:00 - 12:00 **1414P - Clinical impact of plasma Next-Generation Sequencing (NGS) in advanced Non-small cell lung cancer (aNSCLC)**
L. Bonanno¹, A. Pavan¹, A. Ferro², L. Calvetti³, S. Frega¹, G. Pasello¹, G. Aprile⁴, V. Guarneri¹, P.F. Conte¹, ¹Istituto Oncologico Veneto IRCCS, Padova, IT, ²Università degli Studi di Padova, Padova, IT, ³Ospedale San Bortolo di Vicenza, Vicenza, IT, ⁴ULSS 8 Berica - Vicenza-Ospedale Civile "San Bortolo", Vicenza, IT
- 12:00 - 12:00 **1415P - Feasibility study of a ctEGFR prototype assay on the fully automated Idylla™ platform**
M. Reijans¹, S. Gestel¹, E. Haes¹, C. Vandesteene¹, J.M. Castro Gomez¹, C. Gouedard², S. Patera³, S. Murray⁴, G. Maertens¹, ¹Biocartis, Mechelen, BE, ²BioPath Innovations, Athens, GR, ³BioPath Innovations SA, Athens, GR, ⁴BioMarker Solutions Ltd, London, GB
- 12:00 - 12:00 **1416P - Enhanced Access to EGFR Molecular Testing in NSCLC using a Cell-Free DNA Tube for Liquid Biopsy**
T. May¹, S. Scudder¹, S.J. Joshi², M. Kohlmann³, N. Shrestha², N. Lee², J. Højbjerg⁴, J. Lai⁵, A. Madsen⁴, M. Clement⁴, P. Meldgaard⁴, M. Tsourounis⁶, B. Sørensen⁴, A.

Kohlmann⁶, P. O'Donnell¹, H. Halait¹, ¹Roche Molecular Systems Inc - USA, Pleasanton, US, ²Roche Molecular Solutions, Pleasanton, US, ³AstraZeneca, Gaithersburg, US, ⁴Aarhus University, Aarhus, DK, ⁵Roche Molecular Systems, Inc, Pleasanton, US, ⁶AstraZeneca PLC, Gaithersburg, US

12:00 - 12:00 **1417P - Analysis of circulating tumor DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients**

C. Grech¹, K. Hackner², M. Strieder³, A. Buder⁴, M. Hochmair⁵, M. Filipits⁶, P. Errhalt², ¹Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT, ²Universitätsklinikum Krems, Krems, AT, ³University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems, AT, ⁴Institut Tumorbiologie-Krebsforschung, Vienna, AT, ⁵Otto Wagner Spital, Vienna, AT, ⁶Institute of Cancer Research - Medical University of Vienna, Vienna, AT

12:00 - 12:00 **1418P - Liquid biopsy and Array Comparative Genomic Hybridization (aCGH)**

P. Apostolou¹, D.-A. Ntanovasilis², I. Papasotiriou², ¹Research Genetic Cancer Centre Ltd, Filotas, GR, ²Research Genetic Cancer Centre S.A., Florina, GR

12:00 - 12:00 **1419P - Next-generation sequencing panel verification to detect low frequency single nucleotide and copy number variants from mixing cell line studies**

R. Rosas-Alonso, C. Rodriguez-Antolin, I. Esteban Rodriguez, P. Cruz Castellanos, J. De Castro Carpeño, I. Ibanez De Caceres, Hospital Universitario La Paz, Madrid, ES

12:00 - 12:00 **1420P - Automated rarefaction analysis for precision B and T cell receptor repertoire profiling from peripheral blood and FFPE-preserved tumor**

L. Quagliata¹, T. Looney², D. Topacio-Hall³, G. Lowman⁴, ¹Institute of Pathology-University Hospital Basel, Basel, CH, ²Fisher Scientific Pte. Ltd. - Thermo Fisher Scientific, Singapore, SG, ³Thermo Fisher Scientific, Carlsbad, US, ⁴Thermo Fisher Scientific, Calsbad, US

12:00 - 12:00 **1421P - A Heptamethine cyanine dye is a potential diagnostic marker for Myeloid-Derived Suppressor Cells**

C. Jung¹, Y.-S. Cho², H. Kim³, H.H. Ha³, ¹Chonnam National University Medical School-Gwangju, Gwangju, KR, ²Chonnam National University Medical School, Gwangju, KR, ³Sunchon National University, Suncheon, KR

12:00 - 12:00 **1422P - Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)” : a prospective pilot study.**

J.-M. Nabholtz¹, K. Alsaleh², S. Kullab³, N. Abdel-Aziz⁴, A. Abdelwarith¹, A. Al Diab¹, M. Hilal¹, F. Dabouz⁵, V. Bajic⁶, R. Incitti⁶, M. Bahadoor³, A. Azeer⁷, ¹King Saud University Medical City, Riyadh, SA, ²King Khalid University Hospital - King Saud University Medical City, Riyadh, SA, ³Centre Jean Perrin, Clermont-Ferrand, FR, ⁴King Saud University Medical City (KSUMC), Riyadh, SA, ⁵International Cancer Research Group, Sharjah, AE, ⁶Computational Bioscience Research Centre, King Abdallah University for Science and Technology (KAUST), Thuwal, Saudi Arabia, Thuwal, SA, ⁷King Saud University, Riyadh, SA

- 12:00 - 12:00 **1423P - Inferring the correlation between incidence rates of melanoma and the average tumor-specific epitope binding ability of HLA class I molecules in different populations**
I. Miklos¹, L. Molnar², J. Toth², O. Lorincz³, Z. Csiszovszki², P. Pales², K. Pántya², M. Megyesi², E. Somogyi², E. Tóke², ¹MTA Rényi Institute, Budapest, HU, ²Treos Bio Zrt., Veszprém, HU, ³Treos Bio Inc., Bethesda, US
- 12:00 - 12:00 **1424P - Thermal Liquid Biopsy as a Valuable Tool in Lung Cancer Screening Programs**
A. Rodrigo¹, S. Vega², J. Ojeda Cabrera², O. Sanchez-Gracia², A. Callejo³, A. Fernandez⁴, P. Iranzo⁵, M. Cruellas Lapena⁶, E. Quilez Bielsa⁶, A. Velazquez-Campoy⁷, O. Abian⁸, D. Isla⁶, ¹Hospital Universitario Arnau de Vilanova, Lleida, ES, ²Instituto BIFI, Zaragoza, ES, ³Vall d'Hebron Institute of Oncology and University Hospital, Barcelona, ES, ⁴Hospital Clínico Universitario Lozano Blesa, Zaragoza, ES, ⁵Vall d'Hebron Institute of Oncology and University Hospital, barcelona, ES, ⁶Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, ⁷ARAID foundation, Zaragoza, ES, ⁸IACS-ISS Aragón, Zaragoza, ES
- 12:00 - 12:00 **1425P - Towards a screening test for cancer by circulating DNA analysis**
R. Tanos¹, A. Otandault¹, C. Mollevi¹, A. Bauer¹, G. Tusch¹, L. Picque Lasorsa¹, S. El Messaoudi¹, J. Colinge¹, P.-E. Colombo¹, W. Jacot¹, T. Mazard¹, J.M. Sayagués², B. Gillet³, D. Pezet³, M. Ychou¹, A. Thierry¹, ¹ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ²University Hospital, Salamanca, ES, ³CHU Clermont-Ferrand, Clermont-Ferrand, FR
- 12:00 - 12:00 **1426P - Evaluation of a successful launch of the MammaPrint and BluePrint NGS kit**
L. Delahaye¹, A. Witteveen¹, M. Snel¹, T. Cavness², B. Chan², L. Mittempergher¹, A. Glas¹, ¹Agendia Inc., Amsterdam, NL, ²Agendia Inc., Irvine, US
- 12:00 - 12:00 **1427P - Analysis of prognostic factors on overall survival in elderly women treated for early breast cancer using data mining and machine learning**
P. Heudel¹, D. Hooijenga², R. Phan², V. Augusto², X. Xie², C. Terret¹, C. Faure¹, S. Racadot¹, O. Tredan¹, T. Bachelot¹, ¹Centre Léon Bérard, Lyon, FR, ²Ecole des Mines, Saint Etienne, FR
- 12:00 - 12:00 **1428P - Circulating tumor cell detection in epithelial ovarian cancer using dual-component antibodies targeting EpCAM and FR α**
N. Li¹, M. Peng², L. Chen², H. Zuo², Y. Weng², J. Zhou², H. Liu², Q. Song¹, Y. Cheng², ¹Hubei General Hospital (Wuhan University Renmin Hospital), Wuhan, CN, ²Renmin Hospital of Wuhan University, Wuhan, CN
- 12:00 - 12:00 **1429P - CEUS of the breast: Is it feasible in improved performance of BI-RADS evaluation of critical breast lesions?—A multi-center prospective study in China**
J. Luo, Sichuan Provincial People's Hospital, Chengdu, CN

- 12:00 - 12:00 **1430P - Classification of abnormal findings on ring-type dedicated breast PET for detecting breast cancer**
S. Sasada¹, N. Masumoto², M. Nishina¹, Y. Kimura¹, A. Amioka¹, T. Itagaki¹, A. Emi¹, T. Kadoya¹, M. Okada², ¹Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, JP, ²Hiroshima University, Hiroshima, JP
- 12:00 - 12:00 **1431P - Prediction of benign and malignant breast masses using digital mammograms texture features**
C. Yanhua¹, Y. Li², J. Zhu³, J. Dong⁴, ¹university of jinan, Jinan, CN, ²Shandong Tumor hospital affiliated to Shandong University, jinan, CN, ³Shandong Cancer Hospital affiliated to Shandong University, jinan, CN, ⁴university of jinan, jinan, CN
- 12:00 - 12:00 **1432P - Nanomaterials Augmented LDI-TOF-MS for Hepatocellular Carcinoma Diagnosis and Classification**
J. Zhou¹, W. Liu¹, L. Zhao¹, J. Jiang¹, Y. Lu¹, J. Hu¹, H. Zhang², J. Bai³, X. Li¹, ¹Zhongshan Hospital, Fudan University, Shanghai, CN, ²West China Hospital - Sichuan University, Chengdu, CN, ³Tsinghua University, Beijing, CN
- 12:00 - 12:00 **1433P - Development and Validation of an RNA-Seq Assay for Gene Fusions Detection in Formalin-Fixed Paraffin-Embedded Samples**
H. Peng¹, C. Wang², Y. Guo³, B. Li³, C. Chen², L. Xiong², H. Dong³, F. Li³, L. Tian⁴, Q. Xu², ¹The First People's Hospital of Yunnan Province, Yunnan, CN, ²3DMed Inc, Shanghai, CN, ³3D medicines Inc., Shanghai, CN, ⁴The First Affiliated Hospital of Chongqing Medical University, Chongqing, CN
- 12:00 - 12:00 **1434P - A Pilot Study to Implement an Artificial Intelligence (AI) System for Gastrointestinal Cancer Clinical Trial Matching**
Z. Jin¹, T. Haddad¹, J. Hubbard¹, M. Hartgers¹, K. Leventakos¹, K. Cornwell¹, K. King¹, B.A. Franke¹, K. Pomerleau¹, V. Bibeau², S. Coverdill³, M. Rammage⁴, J. Helgeson¹, A. Mahipal⁵, ¹Mayo Clinic, Rochester, US, ²Mayo Clinic, Jacksonville, US, ³IBM, Cambridge, US, ⁴IBM, Jacksonville, US, ⁵H. Lee Moffitt Cancer Center University of South Florida, Tampa, US
- 12:00 - 12:00 **1435P - A Blinded Comparison of Patient Treatments to Therapeutic Options Presented by an Artificial Intelligence-based Clinical Decision-support system**
S. Suwanvecho¹, H. Suwanrusme¹, T. Jirakulaporn¹, N. Taechakraichana¹, P. Lungchukiet¹, N. Thanakarn¹, W. Decha¹, W. Boonpakdee¹, A. Preininger², I. Dankwa-Mullan³, M. Solomon², S. Wang², G. Jackson², V. Patel⁴, E. Shortliffe⁴, N. Kiatikajornthada¹, ¹Bunrungrad International Hospital, Bangkok, TH, ²IBM Corporation, Cambridge, US, ³IBM Watson Health, Bethesda, US, ⁴Columbia University, New York, US
- 12:00 - 12:00 **1436P - OncOS: scalable and accurate next-generation sequencing analytics for precision oncology and personalized patient care**
J. Thompson, J.H. Farmery, H. Dobson, S. Frost, J. Cassidy, N. Patel, H. Thompson, H. Clifford, Cambridge Cancer Genomics, Cambridge, GB
- 12:00 - 12:00 **1437P - The association between wearable device physical activity metrics and**

performance status in oncology: a systematic review

M. Kos¹, E. Pijnappel², C. Kampshoff³, L. Buffart⁴, H. Wilmink², H. Van Laarhoven⁵, M. Van Oijen², ¹Amsterdam University Medical Centers, Amsterdam, NL, ²Academic Medical Center (AMC), Amsterdam, NL, ³Cancer Center Amsterdam, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, NL, ⁴Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, NL, ⁵Academic Medical Center, University of Amsterdam, Amsterdam, NL

12:00 - 12:00 **1438P - SomaticNET: neural network evaluation of somatic mutations in cancer**

G. Dubourg-Felonneau, D. Rebergen, C. Parsons, H. Thompson, J. Cassidy, N. Patel, H. Clifford, Cambridge Cancer Genomics, Cambridge, GB

12:00 - 12:00 **Translational research**

12:00 - 12:00 **1883P - Is there a role for Next-generation sequencing (NGS) profiling on metastatic non-colorectal gastrointestinal carcinomas (MNCGIC) in developing countries? A single center experience.**

M. Ribeiro¹, L. Gadotti², C. Godoy², A. Pereira³, D. De Freitas², M. Crosara³, L. Dib³, F. Costa¹, F. Capareli², D. Jardim², B. Gumz³, G. Fernandes³, ¹Hospital Sirio Libanes, Sao Paulo, BR, ²Hospital Sírio-Libanês, Sao Paulo, BR, ³Hospital Sírio-Libanês, Brasília, BR

12:00 - 12:00 **1884P - Metastatic Cancer Whole-Exome Sequencing in daily practice**

M. Réda¹, C. Richard², J. Niogret², J.-D. Fumet², A. Bertaut², J. Blanc², C. Truntzer², I. Desmoulins¹, S. Ladoire¹, L. Bengrine-Lefevre², N. Isambert¹, A. Hervieu¹, C. Lepage³, P. Foucher⁴, C. Borg⁵, L. Arnould², S. Nambot⁶, L. Faivre⁶, R. Boidot², F. Ghiringhelli¹, ¹Centre Georges-François Leclerc (Dijon), Dijon, FR, ²Centre Georges-François Leclerc, DIJON, FR, ³CHU Dijon, Dijon, FR, ⁴CHU Le Bocage (Dijon), Dijon, FR, ⁵CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, ⁶CHU Dijon, DIJON, FR

12:00 - 12:00 **1885P - Genomic-Guided Individualized Precision Therapy in Refractory Metastatic Solid Tumor Patients with Extensively Poor Performance Status: A Chinese single institutional prospective observational real-world study**

H. Wang, The second hospital of Tianjin Medical university, Tianjin, CN

12:00 - 12:00 **1886P - Prospective pathological experience with research biopsies in the context of clinical trials at Vall d'Hebron Institute of Oncology**

P. Nuciforo¹, J. Jimenez², R. Fasani³, F. Ruiz³, C. Sevillano¹, G. Sanchez¹, P. Martinez¹, X. Serres², C. Saura⁴, E. Elez², E. Felip², A. Oaknin², I. Brana², E. Muñoz-Couselo⁵, T. Macarulla Mercade¹, M. Alsina Maqueda², J. Carles², R. Dienstmann², J. Tabernero⁶, E. Garralda³, ¹Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁴Vall d'Hebron University Hospital Institut d'Oncologia, Barcelona, ES, ⁵Vall d'Hebron University Hospital, Barcelona, ES, ⁶Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES

12:00 - 12:00

1887P - Development of a comprehensive next-generation targeted sequencing assay for detection of gene-fusions in solid tumors

V. Mittal¹, S. Myrand¹, D. Cyanam¹, P. Williams¹, G. Bee², A. Marcovitz³, R. Gottimukkala³, F. Hyland⁴, C. Allen⁵, E. Wong-Ho³, S. Sadis¹, C. Van Loy², J. Kilzer², N. Khazanov¹, ¹Thermo Fisher Scientific, Ann Arbor, US, ²Thermo Fisher Scientific, Carlsbad, US, ³Thermo Fisher Scientific, South San Francisco, US, ⁴Thermo Fisher Scientific, San Francisco, US, ⁵Thermo Fisher Scientific, Paisley, GB

12:00 - 12:00 **1888P - Next-generation sequencing for better treatment strategy of cancer of unknown primary (CUP)**

K.K. Lee¹, M. Kim², K.-M. Kim³, S.T. Kim⁴, J. Lee⁴, S.J. Lee⁵, ¹Dongsan Medical Center Kemyung University Hospital, Daegu, KR, ²Sungkyunkwan University, Seoul, KR, ³Samsung Medical Center, Seoul, KR, ⁴Samsung Medical Center, Seoul, KR, ⁵EWHA Womans University Seoul Hospital, Seoul, KR

12:00 - 12:00 **1889P - Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.**

M. Ghidini¹, J. Hahne², C. Senti³, A. Lampis⁴, M. Ratti¹, C. Pizzo³, G. Tomasello⁵, R. Passalacqua¹, N. Valeri⁴, ¹Istituti Ospitalieri di Cremona, Cremona, IT, ²The Institute of Cancer Research, London, London, GB, ³ASST of Cremona, Hospital of Cremona, Cremona, IT, ⁴The Institute of Cancer Research, London, Sutton, GB, ⁵ASST Grande Ospedale Metropolitano Niguarda, Milan, IT

12:00 - 12:00 **1890P - Ultra-sensitive detection of circulating tumor DNA identifies patients in high risk of recurrence in early stages melanoma**

F. Janku¹, H. Huang¹, I. Treskova², K. Pivovarcikova², S. Call¹, F. Meric-Bernstam¹, M. Pesta³, J. Polivka³, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²Charles University Hospital Pilsen, Pilsen, CZ, ³Charles University Faculty of Medicine in Pilsen, Pilsen, CZ

12:00 - 12:00 **1891P - Identification of the founder BRCA1 mutation c.4117G>T (p.Glu1373*) recurring in Abruzzo and Lazio regions of Central Italy and predisposing to breast/ovarian and BRCA1-related cancers**

D. Di Giacomo¹, M. Calicchia², S. Candria³, G. Bruera³, S. Ferella⁴, E. Lucci Cordisco², M. Tosi⁵, M. Genuardi⁶, E. Ricevuto⁷, ¹Ospedale Civile San Salvatore, L'Aquila, IT, ²Catholic University, Rome, IT, ³S. Salvatore Hospital, ASL1 Abruzzo, L'Aquila, IT, ⁴University of L'Aquila, L'Aquila, IT, ⁵University of Rouen, Rouen, FR, ⁶Catholic University, Rome, IT, ⁷S. Salvatore Hospital, ASL1 Abruzzo and University of L'Aquila, L'Aquila, IT

12:00 - 12:00 **1892P - Enzalutamide (ENZA) and Apalutamide (APA) In vitro chemical reactivity studies and Activity in a Mouse Drug Allergy Model (MDAM)**

M. Guha¹, C. Ji², X. Zhu³, J. Whritenour³, M. Hemkens⁴, S. Tse³, G. Walker³, E. Evans³, N. Khan⁵, M. Finkelstein⁵, E. Callegari³, R.S. Obach³, ¹Pfizer La Jolla Laboratories, San Diego, US, ²Pfizer Inc., San Diego, US, ³Pfizer, Inc., Groton, US, ⁴Pfizer, Inc., San Diego, US, ⁵Pfizer, Inc., Pearl River, US

- 12:00 - 12:00 **1893P - Influence of genetic variation in COMT on cisplatin-induced nephrotoxicity in cancer patients.**
B. Agema¹, S. Koolen², M. De With³, N. Heersche¹, N. Van Doorn³, E. Oomen-De Hoop³, S. Visser⁴, J. Aerts², S. Bins¹, R. Van Schaik², R. Mathijssen¹, ¹Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ²Erasmus University Medical Center, Rotterdam, NL, ³Erasmus MC Cancer Institute, Rotterdam, NL, ⁴Amphia Ziekenhuis-location Molengracht, Breda, NL
- 12:00 - 12:00 **1894P - Cardioprotective and anti-inflammatory effects of Empagliflozin during treatment with Doxorubicin: a cellular and preclinical study**
V. Quagliariello¹, C. Coppola¹, D. Rea¹, C. Maurea², A. Barbieri¹, G. Botti¹, N. Maurea², ¹Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ²Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT
- 12:00 - 12:00 **1895P - Breast Cancer Organoids Model Treatment Response of HER2 Targeted Therapy in HER2-mutant Breast Cancer**
X. Li¹, B. Pan², J. Ma², Z. Zhao², M. Li¹, ¹DALIAN MEDICAL UNIVERSITY, Dalian, CN, ²Department of Oncology & Department of Breast Surgery, Dalian, CN
- 12:00 - 12:00 **1896P - Preclinical in vivo screening to predict responder patients depend on EGFR status**
Y. Kim¹, D. Kim², K. Lee³, Y. Lim⁴, D. Nam², ¹Samsung Medical Center (SMC), Seoul, KR, ²Samsung Medical Center, Seoul, KR, ³SungkyunKwan University, Seoul, KR, ⁴MOGAM Biotechnology Institute, Yongin, KR
- 12:00 - 12:00 **1897P - Interplay between miR-17-5p and MALAT-1 Shapes The Cytokine Storm in Triple Negative Breast Cancer (TNBC) Tumor Microenvironment**
R. Soliman, R. Youness, H. Handoussa, M. El-Shazly, M. Gad, German University in Cairo, Cairo, EG
- 12:00 - 12:00 **1898P - Clinical verification on the relationship between lipid metabolism and the immune microenvironment of breast cancer**
W. Goto¹, Y. Kamei², C. Watanabe², S. Kashiwagi³, K. Ikeda², Y. Ogawa², ¹Osaka City University Medical School, Osaka, JP, ²Osaka City General Hospital, Osaka, JP, ³Osaka City University Graduate School of Medicine, Osaka, JP
- 12:00 - 12:00 **1899P - The clinical and transcriptional signatures of human CD204 reveal an applicable marker for tumor associated macrophage in breast cancer**
Y. He¹, J. Tang², ¹Jiangsu Province Hospital, Nanjing, CN, ²First Affiliated Hospital with Nanjing Medical University, Jiangsu, CN
- 12:00 - 12:00 **1900P - Activated effector T cells co-expressing multiple inhibitory receptors (IRs) are enriched in the tumor immune microenvironment in high grade serous ovarian cancer (HGSOC)**
A. Bergamini¹, E. Tassi², J. Wignall², L. Bocciolone¹, M. Candiani¹, A. Potenza², F. Manfredi², G. Taccagni³, F. Scalisi³, C. Doglioni³, G. Mangili¹, C. Bonini², ¹IRCCS Ospedale San Raffaele, Milan, IT, ²San raffaele Scientific Institute, MILANO, IT, ³IRCCS Ospedale San Raffaele, MILANO, IT

- 12:00 - 12:00 **1901P - Oncolytic reovirus as a new anti-tumor strategy in castration resistant prostate cancer**
Y. Kim¹, B.-M. Kim², J.-H. Han¹, C.-S. Kim¹, ¹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ²ASAN MEDICAL CENTER, Seoul, KR
- 12:00 - 12:00 **1902P - Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21**
A. Memarian¹, H. Samiei², B. Sedighi-Moghaddam², S. Mohammadi¹, A. Gharavi¹, S. Abdolmaleki³, M. Jeddi-Tehrani⁴, ¹Golestan University of Medical Sciences, Gorgan, IR, ²Semnan University of medical Sciences, semnan, IR, ³Mazandaran University of Medical Sciences, Sari, IR, ⁴Monoclonal Antibody Research Center, Avicenna Research Institute,, Tehran, IR
- 12:00 - 12:00 **1903P - Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma**
C. Borg¹, L. Spehner², M. Kroemer², S. Kim¹, M. Jary¹, A. Vienot³, E. Klajer¹, M. Ramseyer², O. Adotevi², Y. Godet², T. Andre⁴, B. Buecher⁵, E. Francois⁶, R. Loyon², ¹CHU Besançon, Hôpital Jean Minjot, Besançon, FR, ²UMR1098, Besançon, FR, ³CHRU Besançon - Hopital Jean Minjot, Besançon, FR, ⁴Hopital Saint-Antoine, Paris, FR, ⁵Institut Curie, Paris, FR, ⁶Centre Antoine Lacassagne, Nice Cedex, FR
- 12:00 - 12:00 **1904P - Evaluation of immune responses among responders (R) and non-responders (non-R) in a humanized mouse model with colorectal cancer (CRC) xenografts treated with combination immunotherapy**
J. Marín Jiménez¹, A. Capasso², S. Bagby³, S. Hartman³, J. Shulman³, J. Barkow³, B. Yacob³, P. Blatchford³, T. Pitts³, J. Lang³, ¹ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ²Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ³University of Colorado, Anschutz Medical Campus, Aurora, US
- 12:00 - 12:00 **1905P - --Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy**
H. Lee¹, I. Silva², M. Batten², U. Palendira¹, A. Ferguson¹, M. Carlino³, A. Menzies⁴, R. Saw⁴, A. Spillane⁴, R. Scolyer⁵, G. Long⁶, J. Wilmott², ¹University of Sydney, Camperdown, AU, ²Melanoma Institute Australia, Sydney, AU, ³The Crown Princess Mary Cancer Centre, Westmead, AU, ⁴Melanoma Institute Australia, University of Sydney, North Sydney, AU, ⁵Royal Prince Alfred Hospital, Camperdown, AU, ⁶Melanoma Institute Australia, Wollstonecraft, AU
- 12:00 - 12:00 **1906P - Basal NK activity and early Treg function inhibition predicts Nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial.**
S. Santagata¹, A.M. Trotta¹, G. Rea¹, M. Napolitano¹, C. D'Alterio¹, M. Di Napoli¹, S. Rossetti², S. Pignata³, S. Scala⁴, ¹Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Naples, IT, ²Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ³Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, ⁴Istituto

Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

- 12:00 - 12:00 **1907P - Low NK Cell Abundance Correlates with High Expression of PD-1 in CD8+ T Cells**
M.H. Lee¹, P. Järvinen², H. Nísen², O. Bruck¹, M. Ilander³, S. Mustjoki¹, A. Kreutzman¹,
¹University of Helsinki, Helsinki, FI, ²Peijas Hospital, Helsinki University Hospital, University of Helsinki, Vantaa, FI, ³University of Helsinki, Helsinki University Central Hospital Comprehensive Cancer Center, Translational Immunology Research Program, Helsinki, FI
- 12:00 - 12:00 **1908P - Tobacco smoking is associated with the immune suppressive microenvironment in head and neck squamous cell carcinoma (HNSCC)**
C. Chung¹, J. De La Iglesia¹, X. Wang¹, F. Song¹, R. Chaudhary¹, J. Masannat¹, J. Conejo-Garcia¹, J. Hernandez-Prera¹, R. Slebos², ¹H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ²Moffitt Cancer Center, Tampa, US
- 12:00 - 12:00 **1909P - Evaluation of Antibody-Dependent Cell Cytotoxicity (ADCC) in lung cancer cell lines treated with combined anti-EGFR and anti-PD-L1 therapy.**
F. Sparano¹, G. Barra², C.M. Della Corte¹, R. Di Liello¹, M. Fasano¹, F. Ciardiello¹, F. Morgillo¹, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²AOU Seconda Università degli Studi di Napoli (AOU-SUN), Napoli, IT
- 12:00 - 12:00 **1910P - Radiomic Signatures for Identification of Tumors Sensitive to Nivolumab or Docetaxel in Squamous Non-Small Cell Lung Cancer (sqNSCLC)**
L. Derclé¹, M. Fronheiser², L. Lu³, S. Du², W. Hayes², D. Leung², A. Roy², L. Schwartz⁴, B. Zhao³, ¹Columbia University Medical Center/New York Presbyterian Hospital, New York, US, ²Bristol-Myers Squibb, Princeton, US, ³Columbia University Medical Center, New York, US, ⁴Columbia University College of Physicians and Surgeons, New York, US
- 12:00 - 12:00 **1911P - Analysis of gut microbiota in advanced non-small cell lung cancer (NSCLC) patients treated with immune-checkpoints blockers**
F. Zhang¹, N. Dong², S. Gallach², S. Calabuig Fariñas², M. Mosqueda², E. Escorihuela², M. Meri³, F. De Asís³, A. Blasco³, J. Garde³, E. Jantus-Lewintre¹, C. Camps³, ¹Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES, ²Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES, ³Hospital General Universitario de Valencia, Valencia, ES
- 12:00 - 12:00 **1912P - Pathogenesis of Myocarditis Following Treatment with Immune Checkpoint Inhibitors in a Cynomolgus Monkey Model**
C. Ji, Pfizer La Jolla Laboratories, San Diego, US
- 12:00 - 12:00 **1913P - Effects of dietary restriction in cancer patients receiving irinotecan**
R. Van Eerden¹, F. De Man², G. Van Doorn², E. Oomen-De Hoop¹, S. Koolen², J. Olieman², P. De Bruijn¹, J. Veraart¹, H. Van Halteren³, Y. Sandberg⁴, A. Moelker¹, J. Ijzermans², M. Lolkema², T. Van Gelder¹, M. Dollé⁵, R. De Bruin², R. Mathijssen¹, ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²Erasmus University Medical Center, Rotterdam, NL, ³Adrz-Admiraal de Ruijter Hospital-Goes, Goes, NL, ⁴Maasstad Ziekenhuis, Rotterdam, NL, ⁵

⁵National Institute of Public Health and Environment (RIVM), Bilthoven, NL

- 12:00 - 12:00 **1914P - Investigating the Link between Burn Injury and Tumorigenesis**
L. Barrett¹, J. Waithman², V. Fear², V. Willis³, N. Kutub³, G. Jackson³, F. Wood⁴, M. Fear¹,
¹University of Western Australia, Perth, AU, ²Telethon Kids Institute, Perth, AU, ³IBM Corporation, Cambridge, US, ⁴University of Western Australia, perth, AU
- 12:00 - 12:00 **1915P - Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in male breast cancer patients**
J. Huszno¹, Z. Kolosza¹, J. Mrochem-Kwarciak², A. Zajusz³, ¹Maria Sklodowska Curie MSC Memorial Cancer Institute in Gliwice, Gliwice, PL, ²Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, PL, ³Maria Sklodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, Gliwice, PL
- 12:00 - 12:00 **1916P - Platelets from metastatic cancer patients have increased aggregation and activation**
M. Chauhan¹, A. Thomas², A. Goodall², J. Wright², D. Adlam², ¹University Hospitals of Leicester NHS Trust Leicester Royal Infirmary, Leicester, GB, ²University of Leicester, Leicester, GB
- 12:00 - 12:00 **1917P - Luminal B breast cancer prognosis prediction by comprehensive analysis of Homeobox genes**
A. Nakashoji, T. Hayashida, S. Yamaguchi, Y. Kitagawa, Keio University School of Medicine, Tokyo, JP
- 12:00 - 12:00 **1918P - Long non-coding RNA E2F4as promotes tumor progression and predicts patient prognosis in human ovarian cancer**
S.-A. Park¹, L.K. Kim¹, H.J. Kim², ¹The Catholic University of Korea, Bucheon, KR, ²Yonsei University College of Medicine, Seoul, KR
- 12:00 - 12:00 **1919P - FGF19 promotes esophageal squamous cell carcinoma progression by inhibiting autophagy**
L. Ying¹, M. Huang¹, J. Jin², Y. Wu¹, D. Su², ¹Zhejiang cancer research institution, Hangzhou, CN, ²Department of Pathology, Hangzhou, CN
- 12:00 - 12:00 **1920P - Clinical Perspective and Prognostic Factors in Desmoplastic Small Round Cell Tumor**
N. Yan¹, F. Zhang², X. Li³, Y. Xu⁴, ¹Shanghai Ruijin Hospital, Shanghai Jiao Tong University, College of Medicine, Shanghai, CN, ²Suzhou Kowloon hospital, Shanghai Jiaotong University School of Medicine, Suzhou, CN, ³the First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ⁴Renji hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CN
- 12:00 - 12:00 **1921P - Proof of concept on the role of ex vivo lung cancer spheroids, cytokines expression and PBMCs profiling in monitoring disease history and response to treatments.**
R. Di Liello¹, V. Ciaramella¹, G. Barra², M. Fasano¹, F. Sparano¹, G. Viscardi³, C.M. Della

Corte¹, F. Ciardiello¹, F. Morgillo¹, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²AOU Seconda Università degli Studi di Napoli (AOU-SUN), Napoli, IT, ³INCLIVA Biomedical Research Institute, Valencia, ES

12:00 - 12:00 **1922P - Circulating microRNAs related to DNA damage response as predictors of survival in metastatic non- small cell lung cancer patients treated with platinum-based chemotherapy**

D. Mavroudis¹, C. Papadaki², A. Monastirioti², K. Rounis¹, G. Stoupis¹, D. Makrakis¹, M. Markaki³, K. Kalbakis¹, S. Agelaki¹, ¹University Hospital of Heraklion (PAGNI), Heraklion, GR, ²University of Crete, Heraklion, GR, ³Democritus University of Thrace, Alexandroupoli, GR

12:00 - 12:00 **1923P - Prognostic value of CTCs in advanced NSCLC patients treated with platinum-based chemotherapy**

S. Calabuig-Fariñas¹, L. Muinelo-Romay², A. Abalo², R. Lago², M. Mosqueda³, C. Rodriguez Lopez⁴, E. Escorihuela⁵, S. Gallach Garcia⁶, J. Garcia⁷, A. Blasco⁸, E. Jantus-Lewintre⁵, R. López⁹, C. Camps¹, ¹Fundación de Investigación Hospital General Universitario de Valencia, Molecular Oncology Laboratory-CIBERONC, Valencia, ES, ²Health Research Institute of Santiago (IDIS), Complejo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, ES, ³Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES, ⁴CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, ⁵Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES, ⁶FIHGUV - Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES, ⁷HOSPITAL CLINICO UNIVERSITARIO SANTIAGO DE COMPOSTELA, Santiago de Compostela, ES, ⁸Hospital General Universitario de Valencia, Valencia, ES, ⁹Hospital Clínico Universitario de Santiago (CHUS), Santiago de Compostela, ES

12:00 - 12:00 **1924P - Exosomes in NSCLC as a source of biomarkers**

E. Duréndez¹, S. Calabuig-Fariñas², C. Suarez³, M. Mosqueda⁴, A. Moreno-Manuel¹, S. Torres Martinez¹, A. Herreros Pomares⁵, S. Gallach⁴, E. Escorihuela⁴, E. De La Cueva⁶, A. Martinez-Romero⁶, E. Serna⁷, J.M. Paramio⁸, E. Jantus-Lewintre¹, C.J. Camps Herrero⁹, ¹Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES, ²Fundación de Investigación Hospital General Universitario de Valencia, Molecular Oncology Laboratory-CIBERONC, Valencia, ES, ³Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, ES, ⁴Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES, ⁵FIHGUV - Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES, ⁶Centro de Investigación Príncipe Felipe, Valencia, ES, ⁷Universitat de Valencia, Valencia, ES, ⁸Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, ES, ⁹Hospital General Universitario Valencia, Valencia, ES

12:00 - 12:00 **1925P - The role of Pim-1 in the development and progression of papillary thyroid carcinoma**

X. Zhu¹, K. Yang¹, Q. Wen¹, F. Xiang², J. Shuai², ¹Zhejiang Cancer Hospital, Hangzhou, CN, ²Zhejiang Chinese Medical University, Hangzhou, CN

- 12:00 - 12:00 **1926P - Development and Validation of a RNA-Seq Based Prognostic Signature in Neuroblastoma**
J.-G. Zhou¹, H. Ma², ¹Zunyi Medical College Affiliated Hospital, Zunyi, CN, ²Zunyi Medical University Affiliated Hospital, Zunyi, CN
- 12:00 - 12:00 **1927P - Identification of meningioma patients in high risk of tumor recurrence using microRNA profiling**
J. Srovnal¹, H. Slavik², V. Balik², M. Vaverka³, L. Hrabalek³, K. Staffova², J. Vrbkova², M. Hajduch², ¹Institute of Molecular and Translational Medicine, University Hospital Olomouc Palacky University, Faculty of Medicine, Olomouc, CZ, ²Palacky University, Olomouc, CZ, ³University Hospital Olomouc, Olomouc, CZ
- 12:00 - 12:00 **1928P - Antecedent of cancer and mortality after the first st segment elevation acute myocardial infarction treated with primary coronary angioplasty. A prospective cohort study**
I. Sillero¹, M. López Flores², L.F. Sánchez-Cousido², M. Rojas Piedra², I. Prieto-Salvador², A. López González², C. Castañón González², A. García-Palomo², F. Fernández Vazquez², I. Iglesias², ¹Hospital Universitario de León, Leon, ES, ²Complejo Asistencial Universitario de León, Leon, ES
- 12:00 - 12:00 **1929P - Genomic characterisation of locally advanced pancreatic adenocarcinoma**
S. Picardo¹, G. O'Kane², S. Fischer³, A. Zhang⁴, R. Denroche⁴, G. Jang⁴, A. Dodd¹, R. Grant¹, B. Gruenwald⁴, S. Moura¹, Y. Wang⁵, E. Elimova⁶, R. Prince¹, G. Zogopoulos⁷, F. Notta⁴, J. Wilson⁴, S. Gallinger⁸, J. Knox⁶, ¹Princess Margaret Cancer Center, Toronto, CA, ²Mount Sinai Hospital - Women's Unit, Toronto, CA, ³Princess Margaret Cancer Centre, c, CA, ⁴Ontario Institute for Cancer Research, toronto, CA, ⁵McGill Univeristy Health, Montreal, CA, ⁶Princess Margaret Cancer Centre, Toronto, CA, ⁷McGill University Health Centre, Montreal, CA, ⁸Sinai Health System, Toronto, CA
- 12:00 - 12:00 **1930P - Comparison of freshly prepared and frozen cells from colorectal cancer surgical samples for phenotyping experiments- a pilot study**
S. Mersakova¹, J. Strnádel¹, M. Grendár¹, M. Kalman², A. Mikolajčík², E. Gabonová², Ľ. Laca², Z. Lasabova³, ¹Biomedical center Martin, Jessenius Faculty of Medicine in Martin, Martin, SK, ²Jessenius Faculty of Medicine in Martin, Martin, SK, ³Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Martin, SK
- 12:00 - 12:00 **1931P - Hyaluronan (HA) Accumulation in the Tumor Microenvironment (TME) is Increased in Colorectal Cancer (CRC) and Associated with Consensus Molecular Subtypes (CMS) 4 Molecular Subtype**
B. Blouw¹, L. Ryner², R. Johnson², D. Taverna¹, Y. Wang², ¹Halozyme Therapeutics, Inc., San Diego, US, ²Genentech, Inc., South San Francisco, US
- 12:00 - 12:00 **1932P - Evaluation of CT-based radiomics in patients with renal cell carcinoma**
A. Zhao¹, J. Yan², Y. Xu³, G. Li⁴, X. Cheng³, ¹Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, CN, ²Shanghai University of Medicine and Health Sciences, Shanghai, CN, ³Zhejiang cancer hospital, Hangzhou, CN, ⁴University of Jean-Monnet,

Saint-etienne, FR

- 12:00 - 12:00 **1933P - Detection of Double Protein Expression in Diffuse Large B Cell Lymphoma**
M. Gouda¹, A. Mohamed², S. Gohar³, H. Alagizy⁴, M. Shehata¹, ¹Faculty of Medicine - Menoufia University, Shebin El Kom, EG, ²Faculty of Medicine, Menoufia University, Shebin El Kom, EG, ³Faculty of Medicine, Menoufia University, Shebin AlKom, EG, ⁴Faculty of Medicine, Menoufia University, Shebin Al-Kom, EG
- 12:00 - 12:00 **1934P - Encyclopedic Tumor Analysis for organ agnostic treatment with Axitinib in combination regimens for advanced cancers**
T. Crook¹, D. Akolkar², D. Patil³, A. Bhatt⁴, A. Ranade⁵, V. Datta³, S. Schuster³, A. Srinivasan³, R. Datar³, ¹Royal Surrey County Hospital, Guildford, GB, ²Datar Cancer Genetics, Nashik, IN, ³Datar Cancer Genetics Limited, Nasik, IN, ⁴Avinash Cancer Clinic, Pune, IN, ⁵Jupiter Hospital, Pune, IN
- 12:00 - 12:00 **1935P - Computational model to predict response rate of clinical trials**
O. Lorincz¹, J. Toth², M. Megyesi², K. Pántya², I. Miklos³, E. Somogyi², Z. Csiszovszki², P. Pales², L. Molnar², E. Tóke², ¹Treos Bio Inc., Bethesda, US, ²Treos Bio Zrt., Veszprém, HU, ³MTA Rényi Institute, Budapest, HU
- 12:00 - 12:00 **1936P - Analysis of BRCA genes and homologous recombination deficiency (HRD) scores in tumours from patients (pts) with metastatic breast cancer (mBC) in the OlympiAD trial**
M. Robson¹, Z. Lai², S. Dearden³, J.C. Barrett², E. Harrington⁴, K. Timms⁵, J. Lanchbury⁶, W. Wu⁷, A. Allen⁷, C. Goessl⁸, E. Senkus⁹, S. Domchek¹⁰, D. Hodgson², ¹Memorial Sloan-Kettering Cancer Center, New York City, US, ²AstraZeneca, Boston, US, ³Astrazeneca, Macclesfield, GB, ⁴AstraZeneca, Cambridge, GB, ⁵Myriad Genetics Inc, Salt Lake City, US, ⁶Myriad Genetics, Salt Lake City, US, ⁷AstraZeneca, Gaithersburg, US, ⁸BN ImmunoTherapeutics, Inc., Mountain View, US, ⁹Medical University of Gdańsk, Gdansk, PL, ¹⁰Private Practice - Domchek, Philadelphia, US
- 12:00 - 12:00 **1937P - A 3D co-culture platform of breast cancer and patient derived immune cells to analyse the response to chemotherapy and immunotherapies**
D. Saraiva¹, A. Jacinto², S. Braga³, M. Cabral², ¹CEDOC, Lisbon, PT, ²NOVA Medical School, Lisbon, PT, ³J Mello Saude, Lisbon, PT
- 12:00 - 12:00 **1938P - Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models.**
A. Fiascarelli¹, G. Merlino¹, S. Capano¹, A. Paoli¹, A. Bressan¹, M. Bigioni¹, M. Scaltriti², J. Arribas³, C. Bernadó Morales³, A. Pellacani¹, M. Salerno¹, M. Binaschi¹, ¹Menarini Ricerche S.p.A, Pomezia, IT, ²Memorial Sloan-Kettering Cancer Center, New York, US, ³Vall d'Hebron University Hospital, Barcelona, ES
- 12:00 - 12:00 **1939P - Neat-1: culprit lncRNA tying PIG-C, MSLN, CD80 in TNBC**
N. Hussein¹, H. El Tayebi¹, M. De Bruyn², ¹German University in Cairo, Cairo, EG,

²University Hospital Groningen (UMCG), Groningen, NL

- 12:00 - 12:00 **1940P - A novel RAF/MEK inhibitor CH5126766 in phase 1 clinical trial has an effectiveness in the combination with eribulin for the treatment of triple negative breast cancer**
H. Ono, M. Horinaka, S. Yasuda, M. Morita, E. Nishimoto, T. Sakai, Kyoto Prefectural University of Medicine, Kyoto, JP
- 12:00 - 12:00 **1941P - Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer**
E. Galan-Moya¹, M. Nuncia-Cantarero², L. Serrano-Oviedo¹, S. Morcillo-García², C. Nieto-Jiménez², M. Burgos², B. Gyórfy³, A. Ocaña⁴, ¹University of Castilla-La Mancha, Albacete, ES, ²Complejo Hospitalario Universitario de Albacete, Albacete, ES, ³MTA TTK Lendület Cancer Biomarker Research Group, Budapest, HU, ⁴Hospital Clínico San Carlos, Madrid, ES
- 12:00 - 12:00 **1942P - Preclinical Evaluation targeting both IGF1R and IR in Triple Negative Breast Cancer**
A. Eustace¹, S. Roche¹, N. Mukherjee¹, F. O'Neill¹, N. Conlon², J. Meiller¹, D. Collins¹, P. Gaule¹, A. Canonici¹, S. Madden³, N. O'Donovan¹, J. Crown⁴, ¹Dublin City University, Dublin, IE, ²National Institute for Cellular Biotechnology - Dublin City University, Dublin, IE, ³Royal College of Surgeons, Dublin, IE, ⁴St Vincents University Hospital, Dublin, IE
- 12:00 - 12:00 **1943P - Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.**
J.-H. Chen, Tri-Service General Hospital, National Defense Medical Center, Taipei, TW
- 12:00 - 12:00 **1944P - Pharmacological screening with Chk1 inhibitors identify synergistic agents to overcome resistance to platinum in basal breast and ovarian cancer**
A.L. Sanabria¹, C. Nieto-Jiménez¹, V. Corrales-Sanchez¹, J.C. Montero², M. Burgos¹, E.M. Galán-Moya³, A. Pandiella², A. Ocaña⁴, ¹Complejo Hospitalario Universitario de Albacete, Albacete, ES, ²Centro de investigación del cáncer, Salamanca, ES, ³Universidad de Castilla-La Mancha, Albacete, ES, ⁴Hospital Clínico San Carlos, Madrid, ES
- 12:00 - 12:00 **1945P - Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: data from the randomized CHIVA trial (a GINECO-GCIG study)**
P. Robelin¹, M. Tod², O. Colombari³, I. Ray-Coquard⁴, G. De Rauglaudre⁵, J. Florence⁶, A. Chevalier⁷, P. Combe⁸, A. Lortholary⁹, S. Hamizi¹, N. Raban¹⁰, G. Ferron¹¹, J. Meunier¹², D. Berton-Rigaud¹³, J. Alexandre¹⁴, M.-C. Kaminsky-Forrett¹⁵, C. Dubot¹⁶, A. Leary¹⁷, E. Mauraie¹⁸, B. You¹, ¹Centre Hospitalier Lyon Sud, Pierre Bénite, FR, ²Hôpital de la Croix Rousse, Hospices civils de Lyon, LYON, FR, ³Université Claude Bernard Lyon 1, OULLINS, FR, ⁴Centre Léon Bérard, Lyon, FR, ⁵Institut Sainte-Catherine, Avignon, FR, ⁶Centre Francois Balesse, CAEN, FR, ⁷Centre Oscar Lambret, Lille, FR, ⁸Hopital European George Pompidou, Paris, FR, ⁹Centre Catherine de Sienne, Nantes, FR, ¹⁰CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR, ¹¹Institut Universitaire du Cancer -Toulouse-Oncopole, Toulouse, FR, ¹²C.H.R. Orleans - La Source, Orleans, FR, ¹³ICO Institut de

Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹⁴Hôpital Cochin, PARIS Cédex, FR, ¹⁵Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, ¹⁶Hôpital René Huguenin - Institut Curie, St. Cloud, FR, ¹⁷Gustave Roussy Cancer Center, INSERM U981, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Villejuif, FR, ¹⁸CH Intercommunal de Créteil, Créteil, FR

- 12:00 - 12:00 **1946P - Inhibiting Ehmt2 and Ezh2 histone methyltransferases alters the immune microenvironment in a Trp53-/- murine ovarian cancer model**
P. Spiliopoulou¹, S. Spear², S. Dowson³, S. Mason³, K. Blyth³, M. Fuchter², B. Brown², I. Mcneish², ¹Beatson West of Scotland Cancer Centre, Glasgow, GB, ²Imperial College London, London, GB, ³University of Glasgow, Glasgow, GB
- 12:00 - 12:00 **1947P - Fenofibrate impairs pro-tumorigenic potential of cancer stem cell-like cells within drug-resistant prostate cancer cell populations.**
T. Wróbel, E. Karnas, J. Catapano, M. Luty, K. Piwowarczyk, E. Zuba-Surma, D. Ryszawy, J. Czyż, Jagiellonian University, Krakow, PL
- 12:00 - 12:00 **1948P - Effect of docetaxel-resistance on the reactivity of prostate cancer cells to metformin**
J. Catapano, T. Wróbel, M. Luty, J. Czyż, Jagiellonian University, Krakow, PL
- 12:00 - 12:00 **1949P - Cell plasticity and taxanes resistance in metastatic prostate cancer: ESRP1 as a predictive biomarker of taxane response**
N. Jimenez¹, O. Reig², R. Montalbo¹, M. Milà-Guasch¹, L. Nadal-Dieste¹, I. Victoria³, A. Font⁴, A. Rodriguez-Vida⁵, J. Carles⁶, C. Suárez⁶, M. Domenech⁷, N. Sala-González⁸, P.L. Fernández³, A. Prat⁹, M. Marín-Aguilera⁹, B. Mellado³, ¹Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, ES, ²Hospital Clínic Barcelona, Barcelona, ES, ³Hospital Clínic de Barcelona, Barcelona, ES, ⁴Catalan Institute of Oncology (ICO), Badalona, ES, ⁵Hospital del Mar, Barcelona, ES, ⁶Vall d'Hebron University Hospital, Barcelona, ES, ⁷Fundació ALTHAIA, Manresa, ES, ⁸Catalan Institute of Oncology (ICO), Girona, ES, ⁹Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 12:00 - 12:00 **1950P - Effect of Selumetinib plus AZD8186 treatment on Cabazitaxel sensitivity in docetaxel-acquired resistant metastatic prostate cancer cell lines**
V. Ruiz De Porras¹, F. Lagúa¹, M. Marín-Aguilera², N. Jiménez³, B. Mellado⁴, J.L. Ramirez⁵, E. Martinez-Balibrea⁶, A. Font⁵, ¹Germans Trias i Pujol Research Institute, Badalona, ES, ²Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ³Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, ES, ⁴Hospital Clínic de Barcelona, Barcelona, ES, ⁵Catalan Institute of Oncology (ICO), Badalona, ES, ⁶Catalan Institute of Oncology, Germans Trias i Pujol Health Research Institute, Badalona, ES
- 12:00 - 12:00 **1951P - Anti-tumor activity of cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, in pancreatic ductal adenocarcinoma cells**
M. Momeny¹, Z. Alishahi², H. Eyvani², S. Hamzelou², S. Ghaffari², ¹Turku Center for Biotechnology, Turku, FI, ²Tehran University of Medical Sciences, Tehran, IR

- 12:00 - 12:00 **1952P - The molecular mechanisms of EpCAM in regulating tumor progression and development of anti-EpCAM antibodies for colon cancer diagnosis and therapy**
H.-C. Wu¹, K.H. Liang², H.P. Hsieh³, W.S. Li², ¹Academia Sinica, Taipei City, TW, ²Academia Sinica, Taipei, TW, ³National Health Research Institutes, Zhunan, TW
- 12:00 - 12:00 **1953P - Detection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients**
J. Hahne¹, A. Lampis², M. Ghidini³, M. Ratti³, M. Salati⁴, C. Senti³, R. Passalacqua³, L. Cascione⁵, C. Braconi⁶, O. Sansom⁷, M. Fassan⁸, N. Valeri⁹, ¹The Institute of Cancer Research, London, London, GB, ²The Institute of Cancer Research, London, Sutton, GB, ³Istituti Ospitalieri di Cremona, Cremona, IT, ⁴Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ⁵Institute of Cancer Research, Belinzola, CH, ⁶The Royal Marsden NHS Trust, London, GB, ⁷Beatson Institute for Cancer Research, Glasgow, GB, ⁸University of Padua, Padua, IT, ⁹The Institute of Cancer Research (Sutton), Sutton, GB
- 12:00 - 12:00 **1954P - Serum exosomal microRNA-199b-5p as a novel circulating biomarker to predict response of preoperative chemoradiotherapy for locally advanced rectal cancer**
D.W. Baek, H.J. Cho, J.H. Baek, S.J. Lee, B.W. Kang, Y.S. Chae, J.G. Kim, Kyungpook National University Hospital, Daegu, KR
- 12:00 - 12:00 **1955P - Live biobank of patient-derived organoids from Thai colorectal cancer patients enables clinical outcome prediction**
P. Tanjak, S. Rung In, O. Acharayothin, A. Mongkhonsupphawan, W. Chadbunchachai, A. Pongpaibul, W. Chalermwai, N. Kunapinun, D. Lohsiriwat, A. Trakarnsanga, V. Lohsiriwat, C. Iramaneerat, S. Prapasrivorakul, I. Chowchankit, K. Korphaisarn, S. Jirawatnotai, V. Chinswangwatanakul, W. Riansuwan, S. Sampattavanich, Siriraj Hospital, Bangkok, TH
- 12:00 - 12:00 **1956P - The biological implications of PDCD6 dysregulation in colorectal cancer**
R. Briffa¹, J. Camps², I.H. Um¹, E. Asensio², S. Lahoz², S. Ariff³, N. Refalo⁴, J. Degaetano⁵, S. Mifsud⁴, K. Grima⁴, M. Hocking¹, G. Grech³, D.J. Harrison⁶, ¹University of St Andrews, St Andrews, GB, ²Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, ES, ³University of Malta, Msida, MT, ⁴Sir Anthony Mamo Oncology Centre, Msida, MT, ⁵Mater Dei Hospital, Msida, MT, ⁶University of St Andrews, St Andrews, Scotland, GB
- 12:00 - 12:00 **1957P - Comparative molecular analyses between microsatellite stable BRAFV600E mutant colorectal cancers and BRAFV600E mutant melanomas.**
M. Salem¹, J. Xiu², A. Puccini³, A. Grothey⁴, R. Goldberg⁵, J. Hwang⁶, Z. Gatalica⁷, R. Feldman², M. Saul², W.M. Korn⁸, M. Hall⁹, W. El-Deiry¹⁰, A. Shields¹¹, J. Marshall¹², H.J. Lenz¹³, A. Vanderwalde⁴, ¹Lombardi Cancer Center Georgetown University, Washington, US, ²Caris Life Sciences, Phoenix, US, ³IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ⁴West Cancer Center, Germantown, US, ⁵West Virginia University Cancer Institute, Morgantown, US, ⁶Levine Cancer Institute, Charlotte, US, ⁷Caris Life Sciences, New York, US, ⁸UCSF-Diller Cancer Research Building, Mount Zion, San Francisco, US, ⁹Fox Chase Cancer Center, Philadelphia, US,

¹⁰Warren Alpert Medical School, Brown University, Providence, US, ¹¹Karmanos Cancer Institute, Wayne State University, Detroit, US, ¹²Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, US, ¹³USC - Norris Comprehensive Cancer Center, Los Angeles, US

- 12:00 - 12:00 **1958P - A novel preclinical model of RAF-independent MEK1 mutant tumors and its treatment with novel ATP competitive MEK inhibitor**
L. Hegedus¹, Ö. Okumus², E. Livingstone³, J. Tóvári⁴, Á. Bánkfalvi⁵, C. Aigner², B. Hegedus², ¹University Duisburg Essen, Essen, DE, ²University Medicine Essen - Ruhrlandklinik, Essen, DE, ³University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ⁴Department of Experimental Pharmacology, Budapest, HU, ⁵University Hospital Essen, Essen, DE
- 12:00 - 12:00 **1959P - HER2 inhibition in Aggressive Squamous Cell Carcinomas driven by a common MET Sema Domain Polymorphism**
N.A. Mohamed Salleh¹, L.R. Kong², Y. Huang³, J. Ho⁴, J. Lim³, S.G. Lim⁵, R. Soo⁴, D. Kappei¹, S.C. Lee³, B.-C. Goh⁴, ¹NUS-National University of Singapore-Cancer Science Institute (CSI), Singapore, SG, ²National University of Singapore, Singapore, SG, ³NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG, ⁴National University Cancer Institute Singapore (NCIS), Singapore, SG, ⁵Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SG
- 12:00 - 12:00 **1960P - ADAM9 as a target for lung cancer treatment**
Y.-P. Sher¹, J.-P. Liu², C.-C. Lo², T.-T. Kuo², S.-J. Liu³, ¹China Medical University, Taichung City, TW, ²China Medical University, Taichung, TW, ³National Health Research Institutes, Miaoli, TW
- 12:00 - 12:00 **1961P - Novel polyurea/polyurethane nanocapsules loaded with a tambjamine analog to improve cancer chemotherapy delivery and safety in lung cancer**
M. Perez Hernandez¹, C. Cuscó², J. Bonelli², B. Farcic¹, A. Arias¹, A. Andreu³, D. Martínez García³, V. Soto Cerrato³, J. Rocas², R. Pérez Tomás³, ¹Universitat de Barcelona, Barcelona, ES, ²Ecopol Tech, S.L, L'Arboç del Penedès, Tarragona, ES, ³Universitat de Barcelona, Hospitalet, Barcelona, ES
- 12:00 - 12:00 **1962P - Discovery of Clinical Candidate DBPR112, a Furanopyrimidine-based Epidermal Growth Factor Receptor Inhibitor for the Treatment of Non-Small Cell Lung Cancer**
H.-P. Hsieh¹, J.-Y. Chang², C.-T. Yeh³, S.-Y. Lin¹, Y.-Y. Ke¹, W.-H. Lin¹, T.-A. Hsu¹, S.-Y. Wu¹, T.-K. Yeh¹, ¹National Health Research Institutes - Zhunan Campus, Zhunan, TW, ²National Cheng Kung University, Tainan, TW, ³Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW
- 12:00 - 12:00 **1963P - Different Chromatin Accessibility between Early and Late Stage Lung Adenocarcinomas of Non-Smokers**
C. Wang¹, B. Zhang¹, C. Li¹, N. Li², R. Lin², T. Wang², D. Yue¹, ¹Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, ²Hangzhou Repugene Technology Inc., Hangzhou, CN

- 12:00 - 12:00 **1964P - Molecular characteristics in lung squamous cell carcinomas dependent on TP53 status - putative targets**
V. Haakensen¹, A. Khadse², V. Sandhu-Baveja², A.R. Halvorsen², L. Jørgensen², S. Solberg², O.T. Brustugun³, E. Kure², A. Helland⁴, ¹Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ²Oslo University Hospital, Oslo, NO, ³Radiumhospitalet, Oslo, NO, ⁴University of Oslo, Institute of Clinical medicine, Oslo, NO
- 12:00 - 12:00 **1965P - Comparison of molecular profiles between primary tumour and matched metastasis in non-small cell lung cancer**
A. Kawachi¹, L. Colmet-Daage¹, T. Dayris¹, M. Semeraro², C. Henon¹, L. Verlingue¹, N. Dorvault¹, N. Droin¹, D. Planchard¹, A. Hollebecque³, C. Massard⁴, V. Thomas De Montpreville⁵, O. Mercier⁶, B. Besse¹, J.-C. Soria⁷, S. Postel Vinay¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Hopital Necker enfants malades, Paris, FR, ³Gustave Roussy, Villejuif, FR, ⁴Gustave Roussy - Cancer Campus, Villejuif, FR, ⁵Hôpital Marie Lannelongue, Le Plessis-Robinson, FR, ⁶Hôpital Marie Lannelongue, Le Plessis-Robinson, FR, ⁷Medimmune, Gaithersburg, US
- 12:00 - 12:00 **1966P - Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in Patients with RET-altered Non-Small Cell Lung Cancer (NSCLC) and Thyroid Cancer**
G. Curigliano¹, V. Subbiah², J.F. Gainor³, D.H. Lee⁴, M.H. Taylor⁵, V. Zhu⁶, R.C. Doebele⁷, G. Lopes⁸, C. Baik⁹, E. Garralda¹⁰, S.M. Gadgeel¹¹, D.-W. Kim¹², C.D. Turner¹³, M. Palmer¹³, S. Miller¹⁴, ¹European Institute of Oncology, Milan, IT, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³Massachusetts General Hospital, Boston, US, ⁴University of Ulsan College of Medicine, Asan Medical Center, Seoul, KR, ⁵The Knight Cancer Institute, Oregon Health & Science University, Portland, US, ⁶University of California, Irvine School of Medicine, Orange, US, ⁷University of Colorado, Aurora, US, ⁸Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, US, ⁹University of Washington/Seattle Cancer Care Alliance, Seattle, US, ¹⁰Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, ES, ¹¹University of Michigan, Ann Arbor, US, ¹²Seoul National University Hospital, Seoul, KR, ¹³Blueprint Medicines Corporation, Cambridge, US, ¹⁴Blueprint Medicines, Cambridge, US
- 12:00 - 12:00 **1967P - Triple MET/SRC/PIM inhibition in MET addicted tumors**
I. Attili¹, L. Bonanno¹, J. Bracht², J. Berenguer², C. Codony-Servat³, J. Codony-Servat², M. Ito³, P.F. Conte¹, J.J. Cui⁴, N. Karachaliou⁵, R. Rosell⁶, ¹Istituto Oncologico Veneto IRCCS, Padova, IT, ²Pangaea Oncology, Barcelona, ES, ³Quirón-Dexeus University Institute, Barcelona, ES, ⁴TP Therapeutics, Inc., San Diego, US, ⁵Merck KgaA, Darmstadt, DE, ⁶Institut for Health Sciences Germans Trias i Pujol, Badalona, ES
- 12:00 - 12:00 **1968P - Bioactivation of napabucasin triggers reactive oxygen species-mediated cancer cell death**
F. Froeling¹, I.I.C. Chio², M. Yao³, M. Lucito³, P. Alagesan³, J. Li⁴, A.-Y. Chang⁴, Y. Park³, H. Rogoff⁴, D. Tuveson⁵, J. Watson³, ¹Imperial College London - Hammersmith Hospital, London, GB, ²Columbia University, New York, US, ³Cold Spring Harbor Laboratory, Cold Spring Harbor, US, ⁴Boston Biomedical Inc, Cambridge, US, ⁵Cold Spring Harbor

Laboratory, New York, US

- 12:00 - 12:00 **1969P - Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option**
S.V. Liu¹, M. Duruisseaux², K. Tolba³, E. Branden⁴, Y. Goto⁵, B.A. Weinberg⁶, D.J. Renouf⁷, R.C. Doebele⁸, C. Heining⁹, R.F. Schlenk⁹, P.K. Cheema¹⁰, J. Cadranel¹¹, M.R. Jones¹², A.E. Drilon¹³, D. Trombetta¹⁴, L.A. Muscarella¹⁴, A. Cseh¹⁵, F. Solca¹⁶, J.J. Laskin⁷, ¹Lombardi Cancer Center Georgetown University, Washington, US, ²Hospices Civils de Lyon Cancer Institute, Université Claude Bernard Lyon 1; UMR INSERM 1052 CNRS 5286 CRCL, Lyon, FR, ³Oregon Health and Science University, Portland, US, ⁴Gävle Hospital, Gävle, SE, ⁵National Cancer Center Hospital, Tokyo, JP, ⁶Georgetown University Medical Center, Washington, US, ⁷University of British Columbia, Vancouver, CA, ⁸University of Colorado Cancer Center, Aurora, US, ⁹National Center for Tumor Diseases Dresden, Dresden, DE, ¹⁰William Osler Health System, University of Toronto, Toronto, CA, ¹¹Hôpital Tenon, Paris, FR, ¹²Bioinformatic Business Area, QIAGEN Inc., Redwood City, US, ¹³Memorial Sloan Kettering Cancer Center, New York, US, ¹⁴Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Foggia, IT, ¹⁵Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, AT, ¹⁶Boehringer Ingelheim RCV GmbH & Co KG, Vienna, AT
- 12:00 - 12:00 **1970P - Aspirin and Ticagrelor for the prevention of tumour cell induced platelet aggregation**
M. Chauhan¹, A. Thomas², A. Goodall², J. Wright², D. Adlam², ¹University Hospitals of Leicester NHS Trust Leicester Royal Infirmary, Leicester, GB, ²University of Leicester, Leicester, GB
- 12:00 - 12:00 **1971P - Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study**
M. Maio¹, S. Groenland², T. Bauer³, D. Rischin⁴, I. Gardezabal⁵, V. Moreno⁶, J. Trigo Perez⁷, M. Chisamore⁸, J. Sadik Shaik⁹, F. Rigat¹⁰, C. Ellis¹¹, H. Chen¹¹, R. Gagnon¹², S. Scherer¹¹, D. Turner¹¹, S. Yadavilli¹¹, M. Ballas¹¹, A. Hoos¹¹, E. Angevin¹³, ¹Azienda Ospedaliera Universitaria Senese - Santa Maria delle Scotte, Siena, IT, ²Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ³Sarah Cannon Research Institute, Nashville, US, ⁴Peter MacCallum Cancer Centre, Melbourne, AU, ⁵Clinica Universitaria de Navarra, Pamplona, ES, ⁶University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ⁷Hospital Universitario Virgen de la Victoria, Málaga, ES, ⁸Merck Sharp & Dohme Corp. USA, Whitehouse Station, US, ⁹GlaxoSmithKline, Collegeville, US, ¹⁰GlaxoSmithKline, Stevenage, GB, ¹¹GlaxoSmithKline USA, Collegeville, US, ¹²GlaxoSmithKline, Collegeville, US, ¹³Gustave Roussy - Cancer Campus, Villejuif, FR
- 12:00 - 12:00 **1972P - In vitro functional interrogation of viable Circulating Tumor Associated Cells (C-TACs) for evaluating Platin resistance.**
S. Schuster¹, D. Akolkar², S. Patil¹, D. Patil¹, V. Datta¹, A. Srinivasan¹, R. Datar¹, ¹Datar Cancer Genetics Limited, Nasik, IN, ²Datar Cancer Genetics, Nashik, IN
- 12:00 - 12:00 **1973P - Targeting ARG2 as a novel therapeutic approach for cancer**

M. Grzybowski¹, J. Pęczkiewicz-Szyska², P. Wolska², P. Stańczak², M. Welzer², E. Nikolaev², A. Siwińska², R. Błaszczak², B. Borek², M. Dzięgielewski², A. Gzik², J. Nowicka², J. Brzezińska², K. Jędrzejczak², J. Chrzanowski², A. Gołębiowski², J. Olczak², K. Dzwonek², P. Dobrzański², ¹OncoArendi Therapeutics S.A., Warsaw, PL, ²OncoArendi Therapeutics SA, Warsaw, PL

12:00 - 12:00 **1974P - MPS1 and PLK1 as new therapy targets in TP53 mutated solid tumors**

B. Gyorffy, A. Nagy, A. Osz, Semmelweis University, Budapest, HU

12:00 - 12:00 **1975P - The Tumor Static Exposure (TSE) concept & utility: application to combination treatment of radiation and radiosensitizing agent in tumor xenograft experiments**

S. El Bawab¹, T. Cardilin², M. Jirstrand², A. Zimmermann³, F. Lignet³, J. Gabrielsson⁴, ¹Merck KGaA - Germany, Darmstadt, DE, ²Fraunhofer-Chalmers Centre, Göteborg, SE, ³Merck Healthcare KGaA, Darmstadt, DE, ⁴Swedish University of Agricultural Sciences, Uppsala, SE

12:00 - 12:00 **1976P - General Methodology to Optimize Tumor Treating Fields Delivery Utilizing Numerical Simulations**

N. Urman¹, Z. Bomzon¹, H. Hershkovich¹, E. Kirson¹, A. Naveh¹, R. Shamir¹, E. Fedorov¹, C. Wenger², U. Weinberg¹, ¹Novocure, Haifa, IL, ²Novocure GmbH, Park , Root D, CH

12:00 - 12:00 **1977TiP - The Australian Exceptional Responders Program: a National collaboration**

M. Barnett¹, S. Pathmanandavel², C. Goodnow³, A. Joshua⁴, ¹The Kinghorn Cancer Centre, Darlinghurst, AU, ²St George Hospital Cancer Care Centre, Kogarah, AU, ³The Garvan Institute of Medical Research, Darlinghurst, AU, ⁴Kinghorn Cancer Centre, Darlinghurst, AU

12:00 - 12:00 **1978TiP - A Window of Opportunity Trial of Atorvastatin Targeting p53 Mutant Malignancies**

J. Baranda¹, A. Bur², T. Tsue², L. Shnayder², K. Kakarala², M. Telfah³, T. Lin⁴, S. Williamson⁴, M. Al-Kasspoles², J. Ashcraft², N. Lakis², R. Madan², Q. Khan³, A. Saeed³, G. Reed⁵, S. Weir², A. Godwin⁵, S. Thomas², T. Komiya⁶, T. Iwakuma², ¹University of Kansas Medical Centre-Westwood Campus, Westwood, US, ²University of Kansas Medical Center, Kansas City, US, ³University of Kansas Cancer Center, Westwood, US, ⁴University of Kansas Cancer Center, Fairway, US, ⁵University of Kansas Cancer Center, Kansas City, US, ⁶Parkview Cancer Institute, Fort Wayne, US

12:00 - 12:00 **1979TiP - Randomized Phase II Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies.**

C. Heilig¹, D. Hübschmann², H.-G. Kopp³, K. Metzeler⁴, S. Richter⁵, B. Hermes⁶, N. Von Bubnoff⁷, T. Kindler⁸, J. Siveke⁹, S. Wagner¹⁰, S. Ochsenreither¹¹, H. Süße¹², B. Brors², A. Benner², D. Jäger¹³, C. Von Kalle¹⁴, H. Glimm¹³, S. Gröschel¹⁵, S. Fröhling¹⁶, R. Schlenk¹³, ¹University of Heidelberg, Heidelberg, DE, ²German Cancer Research Center (DKFZ), Heidelberg, DE, ³Robert-Bosch-Krankenhaus, Stuttgart, DE, ⁴Ludwig

Maximilians University - Grosshadern, Munich, DE, ⁵Universitätsklinikum Dresden, Dresden, DE, ⁶Universitätsklinikum Tübingen Medizinische Universitätsklinik, Tübingen, DE, ⁷Universitätsklinikum Freiburg, Freiburg, DE, ⁸Universitätsmedizin Mainz, Mainz, DE, ⁹University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ¹⁰Universitätsklinikum Frankfurt, Frankfurt, DE, ¹¹Charite-Universitätsmedizin Berlin, Berlin, DE, ¹²National Center for Tumor Diseases (NCT), Heidelberg, DE, ¹³Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, ¹⁴German Cancer Research Center, Heidelberg, DE, ¹⁵Heidelberg University Hospital, Heidelberg, DE, ¹⁶HI-STEM gGmbH im Deutschen Krebsforschungszentrum DKFZ, Heidelberg, DE

12:00 - 12:00

1980TiP - Homogenisation of Leftover Surgical Tissue across multiple cancer types: a Feasibility Study (HoLST-F)

L. Spain¹, L. Gallegos², Z. Tippu³, S. Hill⁴, K. Litchfield⁵, L. Au¹, A. Gilchrist³, V. Primus³, A. Barhoumi⁴, S. Stanislaw⁴, S. Agrawal³, N. Shaikh³, N. Patel³, M.-F. Mendoza⁴, G. Noel-Storr³, J. Larkin¹, N. Alexander⁴, S. Turajlic⁵, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²Ventana Medical Systems (Subsidiary of Roche), Tuscon, US, ³Royal Marsden NHS Foundation Trust, London, GB, ⁴Roche, Tuscon, US, ⁵The Francis Crick Institute, London, GB

12:00 - 12:00

Immunotherapy of cancer

12:00 - 12:00

1195P - Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumors: updated results from ILLUMINATE-101

H. Babiker¹, E. Borazanci², V. Subbiah³, O. Maguire⁴, S. Rahimian⁵, H. Minderman⁴, C. Haymaker³, C. Bernatchez³, G. Bindra⁵, I. Iverson⁵, S. Chunduru⁵, P. Anderson⁶, I. Puzanov⁴, A. Diab³, ¹University of Arizona Cancer Center, Tucson, US, ²HonorHealth, Scottsdale, US, ³The University of Texas MD Anderson Cancer Center, Houston, US, ⁴Roswell Park Comprehensive Cancer Center, Buffalo, US, ⁵Idera Pharmaceuticals, Exton, US, ⁶Cleveland Clinic, Cleveland, US

12:00 - 12:00

1196P - Phase 1 Dose Escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumors: Updated results

E. Borazanci¹, A. Schram², I. Brana³, M. Vieito Villar⁴, E. Garralda⁵, A. Spreafico⁶, M. Oliva⁶, N. Lakhani⁷, R. Wasserman⁸, K. Hoffman⁹, R. Hallett¹⁰, J. Anido¹⁰, P. Giblin¹⁰, N. Pandya¹⁰, A. Kelly¹⁰, J. Seoane¹¹, D. Von Hoff¹², L. Siu¹³, D. Hyman¹⁴, J. Tabernero¹⁵, ¹HonorHealth, Scottsdale, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Vall d'Hebron University Hospital - Vall d'Hebron Institute of Oncology VHIO, Barcelona, ES, ⁵Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO, Barcelona, ES, ⁶Princess Margaret Cancer Center, Toronto, CA, ⁷START - Midwest, Grand Rapids, US, ⁸Northern Biologics Inc., Toronto, CA, ⁹Northern Biologics, Toronto, CA, ¹⁰NORTHERN BIOLOGICS, Toronto, CA, ¹¹Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ¹²NDA Consulting Corp., Scottsdale, US, ¹³Princess Margaret Cancer Centre, Toronto, CA, ¹⁴MSKCC, New York, US, ¹⁵Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES

12:00 - 12:00

1197P - A phase 1 study of Sym021, an anti-PD-1 antibody (Ab), alone and in

combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)

A. Spreafico¹, F. Janku², J. Rodon³, A. Tolcher⁴, S. Chandana⁵, M. Oliva¹, S. Musalli⁶, L. Knauss⁶, M. Kragh⁶, L. Alifrangis⁶, C. Fröhlich⁶, M. Melander⁶, T. Blondal⁶, M. Pedersen⁶, J. Lantto⁶, D. Wood⁷, P. Nadler⁸, I. Horak⁶, L. Siu⁹, N. Lakhani⁵, ¹Princess Margaret Cancer Center, Toronto, CA, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁴NEXT Oncology™, San Antonio, US, ⁵START - Midwest, Grand Rapids, US, ⁶Symphogen A/S, Ballerup, DK, ⁷Nadler Pharma Associates, Randolph, US, ⁸Formation Biologics, Austin, US, ⁹Princess Margaret Cancer Centre, Toronto, CA

12:00 - 12:00 **1198P - FPA150 (B7-H4 antibody) Phase 1 Update in Advanced Solid Tumors: Monotherapy and in Combination with Pembrolizumab**

Z. Wainberg¹, J. Sachdev², T. Bauer³, S. Pant⁴, S. Chawla⁵, N. Marina⁶, H. Xiang⁷, W. Deng⁷, M. Schmidt⁶, A. Patnaik⁸, P. Lorusso⁹, ¹David Geffen School of Medicine at UCLA, Los Angeles, US, ²Virginia G. Piper Cancer Center Clinical Trials, Scottsdale, US, ³Sarah Cannon Research Institute, Nashville, US, ⁴MD Anderson Cancer Center, Houston, US, ⁵Sarcoma Oncology Research Center, Santa Monica, US, ⁶FivePrime Therapeutics, South San Francisco, US, ⁷Five Prime Therapeutics, South San Francisco, US, ⁸South Texas Accelerated Research Therapeutics (START), San Antonio, US, ⁹Yale Cancer Center, New Haven, US

12:00 - 12:00 **1199P - MG1124, a novel CEACAM1-targeted monoclonal antibody, has therapeutic potential as a combination partner of PD-1 inhibitors in NSCLC patients**

E.H. Lee¹, J. Lee¹, M. Hur¹, H.-Y. Park¹, H.I. Yum¹, H. Nam¹, M.-Y. Oh¹, H. Choi², J. Kim³, B.C. Cho⁴, Y. Lim¹, J. Won¹, ¹MOGAM Institute for Biomedical Research, Yongin, KR, ²GC Pharma, Yongin, KR, ³Yonsei Cancer Center, Seoul, KR, ⁴Yonsei University, Seoul, KR

12:00 - 12:00 **1200P - Tumor stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumors.**

M. Fabre¹, C. Ferrer¹, S. Domínguez-Hormaetxe¹, R. Kontermann², K. Pfizenmaier², O. Seifer², M. Vivanco³, S.-Y. Lee³, P. López-Casas⁴, M. Abbas⁵, W. Richter⁶, L. Simon¹, M. Hidalgo⁷, ¹Oncomatrix Biopharma S.L, Derio, ES, ²Stuttgart University, Stuttgart, DE, ³CIC BioGUNE, Derio, ES, ⁴Spanish National Cancer Research Centre (CNIO), Madrid, ES, ⁵TUBE Pharmaceuticals, Wien, AT, ⁶TUBE Pharmaceuticals GmbH, Vienna, AT, ⁷CNIO - Centro Nacional de Investigaciones Oncológicas, Madrid, ES

12:00 - 12:00 **1201P - Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)**

M. Cho¹, J. Bendell², S.-W. Han³, J. Naidoo⁴, C. Lieu⁵, B. Carneiro⁶, E. Varga⁷, X. Li⁸, P. Kourtesis⁸, S. Abdullah⁹, S. Patel¹⁰, ¹University of California at Davis Comprehensive Cancer Center, Sacramento, US, ²Sarah Cannon Research Institute, Nashville, US, ³Seoul National University Hospital, Seoul, KR, ⁴Johns Hopkins Bayview Center, Baltimore, US, ⁵University of Colorado, Denver, US, ⁶Lifespan, Providence, US, ⁷Debreceni Egyetem Klinikai Központ, Debrecen, HU, ⁸AstraZeneca, Gaithersburg, US, ⁹Medimmune, Gaithersburg, US, ¹⁰UC San Diego Health, San Diego, US

12:00 - 12:00 **1202P - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with**

non-small cell lung cancer (NSCLC) and melanoma pretreated with anti-PD-1/L1 therapy

N. Mach¹, G. Curigliano², A. Santoro³, D.-W. Kim⁴, D. Tai⁵, S. Hodi⁶, S. Wilgenhof⁷, T. Doi⁸, T. Longmire⁹, H. Sun¹⁰, A. Xyrafas¹¹, S. Gutzwiller¹¹, L. Manenti¹⁰, C.-C. Lin¹²,
¹University Hospital Geneva, Geneva, CH, ²Istituto Europeo di Oncologia, Milan, IT, ³Humanitas University, Rozzano-Milan, IT, ⁴Seoul National University Hospital, Seoul, KR, ⁵National Cancer Centre Singapore, Singapore, SG, ⁶Dana Farber Cancer Institute, Boston, US, ⁷Antoni van Leeuwenhoek, Amsterdam, NL, ⁸National Cancer Center Hospital East, Chiba, JP, ⁹Novartis Institutes for BioMedical Research, Cambridge, US, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, US, ¹¹Novartis Pharma AG, Basel, CH, ¹²National Taiwan University Hospital, Taipei City, TW

12:00 - 12:00 **1203P - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.**

C. Massard¹, P. Cassier², J. Bendell³, D. Marie⁴, M. Blery⁴, C. Morehouse⁵, M. Ascierto⁶, R. Zerbib⁴, E. Mitry⁷, A. Tolcher⁸, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Centre Léon Bérard, Lyon, FR, ³Sarah Cannon Research Institute, Nashville, US, ⁴Innate Pharma, Marseille, FR, ⁵MedImmune, Gaithersburg, US, ⁶Astra Zeneca, Gaithersburg, US, ⁷F. Hoffmann-La Roche AG, Basel, CH, ⁸NEXT Oncology™, San Antonio, US

12:00 - 12:00 **1204P - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis**

P. Correale¹, N. Staropoli², P. Pastina³, R. Giannicola⁴, C. Botta², E. Francini⁵, L. Ridolfi⁶, E. Mini⁷, D. Ciliberto⁸, R.M. Agostino⁹, A. Strangio¹⁰, D. Azzarello¹¹, V. Nardone¹, A. Falzea¹⁰, P. Tassone⁸, A. Giordano¹², L. Pirtoli¹³, G. Francini¹⁴, P.S. Tagliaferri¹⁵,
¹Azienda Ospedaliera Universitaria Senese - Santa Maria delle Scotte, Siena, IT, ²Departement of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, IT, ³Azienda Ospedaliera Universitaria Senese-Istituto Toscano Tumori, Siena, IT, ⁴Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, IT, ⁵Dana-Farber Cancer Institute, Boston, US, ⁶Centro Oncologico Romagnolo, Forlì, IT, ⁷Azienda Ospedaliera Universitaria Careggi, Firenze, IT, ⁸A.O. Policlinico Mater Domini Università Degli Studi, Catanzaro, IT, ⁹Centro Oncologico Ospedale Papardo, Messina, IT, ¹⁰"Bianchi-Melacrino-Morelli" Grand Metropolitan Hospital, Reggio Calabria, IT, ¹¹Home, Reggio Calabria, IT, ¹²Hollings Cancer Center at the Medical University of South Carolina, Charleston, US, ¹³College of Science and Technology, Temple University, USA, US, ¹⁴Unità Sanitaria Locale 7 Siena, Siena, IT, ¹⁵Zetatours International, Milan, IT

12:00 - 12:00 **1205P - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)**

L. Harshyne¹, A. Luginbuhl¹, J. Curry¹, Y. Kim², A. Argiris³, S. Shukla¹, U. Rodeck¹, J. Johnson¹, ¹Thomas Jefferson University, Philadelphia, US, ²Vanderbilt University, Nashville, US, ³Hygeia Hospital, Athens, GR

12:00 - 12:00 **1206P - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts)**

with advanced malignancies

J. Powderly¹, A. Spira², R. Gutierrez³, D. Drenth⁴, A. Udyavar⁴, J. Karakunnel⁴, A. Rieger⁴, J. Colabella⁴, D. Lai⁴, P. De Souza⁵, ¹Carolina BioOncology Institute, Huntersville, US, ²Virginia Cancer Specialist, Fairfax, US, ³The Angeles Clinic and Research Institute, Los Angeles, US, ⁴Arcus Biosciences, Hayward, US, ⁵Western Sydney University, KOGARAH, AU

12:00 - 12:00 **1207P - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC**

A. Rajan¹, J. Gray², S. Devarakonda³, J. Gurtler⁴, R. Birhiray⁵, E. Paschold⁶, A. Dasgupta⁷, C. Heery⁸, C. Pico-Navarro⁹, M. Piechatzek¹⁰, E. Wagner¹¹, E. Menius¹², R. Donahue¹³, J. Schlom¹⁴, J. Gulley¹³, ¹National Cancer Institute, Bethesda, MD, US, ²H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ³Washington University School of Medicine, St. Louis, US, ⁴Community Practice, Metairie, LA, US, ⁵Investigative Clinical Research of Indiana, Indianapolis, IN, US, ⁶Forsyth Memorial Hospital, Winston-Salem, NC, US, ⁷Millennium Oncology, Houston, TX, US, ⁸Bavarian Nordic, Morrisville, US, ⁹Bavarian Nordic, Cancer Immunotherapy Division, Madrid, ES, ¹⁰Bavarian Nordic GmbH, Munich, DE, ¹¹Bavarian Nordic GmbH, Martinsried (Planegg), DE, ¹²Bavarian Nordic Inc, Morrisville, NC, US, ¹³Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, US, ¹⁴Center for Cancer Research, National Cancer Institute, Bethesda, US

12:00 - 12:00 **1208P - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts**

H. Conter¹, L. Macdonald², S. Fiset³, Y. Bramhecha³, M. Chaney⁴, G. Rosu³, ¹William Osler Health System Foundation, Brampton, CA, ²Immunovaccine Inc, Halifax, CA, ³IMV Inc., Dartmouth, CA, ⁴Merck & Co., Inc., Kenilworth, US

12:00 - 12:00 **1209P - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1**

V. Radhakrishnan¹, S. Banavali², S. Gupta³, A. Kumar⁴, C. Deshmukh⁵, S. Nag⁶, S. Beniwal⁷, M. Gopichand⁸, R. Naik⁹, K. Lakshmaiah¹⁰, D. Mandavia⁴, M. Ramchandra⁴, K. Prabhash², ¹TMC Kolkata, Kolkata, IN, ²Tata Memorial Hospital, Mumbai, IN, ³Tata Memorial Hospital Centre, Mumbai, IN, ⁴Aurigene Discovery Technologies Limited, Bangalore, IN, ⁵Deenanath Mangeshkar Hospital & Research Centre, Pune, IN, ⁶Jehangir Hospital, Pune, IN, ⁷Acharya Tulsi Regional Cancer Treatment & Research Institute, Bikaner, IN, ⁸City cancer Center, Vijayawada, IN, ⁹HCG Bangalore Institute of Oncology Speciality Centre, Bangalore, IN, ¹⁰Srinivasam Hospital, Bangalore, IN

12:00 - 12:00 **1210P - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers**

C. Le Tourneau¹, J.-P. Delord², P. Cassier³, D. Loirat¹, A. Tavernaro⁴, B. Bastien⁴, K. Bendjama⁴, ¹Institut Curie, Paris, FR, ²Institut Universitaire du Cancer -Toulouse-Oncopole, Toulouse, FR, ³Centre Léon Bérard, Lyon, FR, ⁴TRANSGENE, Illkirch-Graffenstaden, FR

- 12:00 - 12:00 **1211P - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410**
T. Kojima¹, T. Marafioti², T. Fujiwara³, Y. Shirakawa³, T. Nakatsura⁴, K. Kato⁵, I. Puccio², T. Hikichi⁶, S. Yoshimura⁶, T. Nakagawa⁷, M. Furukawa⁷, K. Stoeber⁸, M. Nagira⁷, N. Ide⁷, H. Daiko⁹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²University College London Hospital, London, GB, ³Okayama University Hospital, Okayama, JP, ⁴National Cancer Center, Kashiwa, JP, ⁵National Cancer Center Hospital, Tokyo, JP, ⁶Cancer Precision Medicine, Inc., Kanagawa, JP, ⁷Shionogi & Co., Ltd, Osaka, JP, ⁸Business Development, London, GB, ⁹National Cancer Center Hospital, Tokyo, Japan, Tokyo, JP
- 12:00 - 12:00 **1212P - Final results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer**
U. Wiedermann¹, E. Garner-Spitzer¹, Y. Chao², I. Bulat³, A. Dechaphunkul⁴, W. Arpornwirat⁵, C. Charoentum⁶, C. Yen⁷, T. Yau⁸, M. Maglakelidze⁹, S. Tanasanvimon¹⁰, J. Maneechavakajorn¹¹, A. Sookprasert¹², L.-Y. Bai¹³, W.-C. Chou¹⁴, T. Ungtrakul¹⁵, C. Zielinski¹⁶, L. Chong¹⁷, N. Ede¹⁷, A. Good¹⁷, ¹Medizinische Universität Wien, Vienna, AT, ²Taipei Veterans General Hospital, Taipei City, TW, ³ARENZIA Exploratory Medicine Research Unit, Chisinau, MD, ⁴University of Alberta, Edmonton, CA, ⁵National Cancer Institute, Bangkok, TH, ⁶Maharaj Nakorn Chiang Mai Hospital, Mueang Chiang Mai District, TH, ⁷National Cheng Kung University Hospital, Tainan, TW, ⁸Queen Mary Hospital, Hong Kong, HK, ⁹ARENZIA Exploratory Medicine LLC, Tbilisi, GE, ¹⁰King Chulalongkorn Memorial Hospital, Bangkok, TH, ¹¹Rajavithi Hospital, Bangkok, TH, ¹²Srinagarind Hospital, Khon Kaen, TH, ¹³China Medical University Hospital, Taichung, TW, ¹⁴Linkou Chang Gung Memorial Hospital, Taoyuan, TW, ¹⁵HRH Princess Chulabhorn College of Medical Science, Bangkok, TH, ¹⁶Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, ¹⁷Imugene, Sydney, AU
- 12:00 - 12:00 **1213P - Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity**
A. Samson¹, E. West², S. Turnbull³, K. Scott², E. Tidswell¹, J. Kingston³, M. Johnpulle³, K. Bendjama⁴, N. Stojkowitz⁴, M. Lusky⁴, G. Toogood², C. Twelves¹, C. Ralph², A. Anthony², A. Melcher⁵, F. Collinson², ¹St. James's University Hospital Leeds, Leeds, GB, ²University of Leeds, Leeds, GB, ³Leeds Teaching Hospitals, Leeds, GB, ⁴TRANSGENE, Illkirch-Graffenstaden, FR, ⁵Institute of Cancer Research, London, GB
- 12:00 - 12:00 **1214P - Randomized phase 2 clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients**
S. Kageyama¹, Y. Nagata², T. Ishikawa³, T. Abe⁴, M. Murakami⁵, T. Kojima⁶, K. Taniguchi⁷, H. Shimada⁸, S. Hirano⁹, S. Ueda¹⁰, K. Kanetaka², H. Wada¹¹, H. Yamaue¹², E. Sato¹³, Y. Miyahara¹⁴, N. Goshima¹⁵, H. Ikeda², T. Yamada¹¹, M. Osako¹⁶, H. Shiku¹⁴, ¹Mie University Hospital, Tsu, JP, ²Nagasaki University, Nagasaki, JP, ³Kyoto Prefectural University of Medicine, Kyoto, JP, ⁴Aichi Cancer Center, Nagoya, JP, ⁵Showa University, Tokyo, JP, ⁶National Cancer Center Hospital East, Kashiwa, JP, ⁷Nagasaki Medical Center, Ohmura, JP, ⁸Toho University, Tokyo, JP, ⁹National Center for Global Health and Medical, Tokyo, JP, ¹⁰Kitano Hospital, Osaka, JP, ¹¹Osaka University, Suita, JP, ¹²Wakayama Medical University, Wakayama, JP, ¹³Tokyo Medical University, Tokyo, JP, ¹⁴Mie

University, Tsu, JP, ¹⁵National Institute of Advanced Industrial Science and Technology, Tokyo, JP, ¹⁶FiveRings CO., Osaka, JP

- 12:00 - 12:00 **1215P - T cell repertoire sequencing reveals dynamics of response to dendritic cell vaccine plus dasatinib for checkpoint blockade resistant metastatic melanoma**
L. Quagliata¹, T. Looney², W. Storkus³, J. Taylor³, D. Topacio-Hall⁴, G. Lowman⁵,
¹Institute of Pathology-University Hospital Basel, Basel, CH, ²Fisher Scientific Pte. Ltd. - Thermo Fisher Scientific, Singapore, SG, ³University of Pittsburg Medical School, Pittsburg, US, ⁴Thermo Fisher Scientific, Carlsbad, US, ⁵Thermo Fisher Scientific, Calsbad, US
- 12:00 - 12:00 **1216P - Ixovex, a novel oncolytic E1B-mutated adenovirus**
M. Anwar¹, G. Alusi², D. Oberg³, ¹Chelsea and Westminster Hospital - NHS Trust, London, GB, ²UCH, London, GB, ³Uppsala Biomedical Centre, Uppsala, Sweden, Uppsala, SE
- 12:00 - 12:00 **1217P - Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumors: a comparative oncology trial**
F. Riccardo¹, L. Tarone¹, G. Barutello¹, M. Arigoni¹, D. Giacobino², S. Iussich², S. Occhipinti¹, S. Ferrone³, P. Buracco², F. Cavallo¹, ¹Università degli Studi di Torino, Torino, IT, ²Università degli Studi di Torino, Grugliasco, IT, ³Harvard Medical School, Boston, US
- 12:00 - 12:00 **1218P - Antitumor immune activity of a novel PD-1 vaccine in syngeneic Balb/c and C57Bl/6 models challenged with CT-26 and MC38 carcinoma cell line. The safety profile of the PD-1 vaccine was tested in canine and non-human primates**
P. Kaumaya¹, J. Overholser², L. Guo², Y. Yang², M. Penichet³, B. Sayanjali², N. Ede⁴, L. Chong⁵, T. Bekaii-Saab⁶, ¹Ohio State University Medical Center, Columbus, US, ²The Ohio State University Medical Center, Columbus, US, ³UCLA, Los Angeles, US, ⁴Imugene, Carlton, AU, ⁵Imugene, Sydney, AU, ⁶Mayo Clinic Cancer Center, Phoenix, US
- 12:00 - 12:00 **1219P - Maternal immunization against ALK as a weapon to fight neuroblastoma**
G. Barutello¹, F. Riccardo¹, C. Voena², R. Chiarle², F. Cavallo¹, ¹Università degli Studi di Torino, Torino, IT, ²Center for Experimental Research and Medical Studies, Torino, IT
- 12:00 - 12:00 **1220P - Phase 1 study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumors**
J. Luke¹, L. Fong², K. Chung³, A. Tolcher⁴, K. Kelly⁵, A. Hollebecque⁶, C. Le Tourneau⁷, V. Subbiah⁸, F. Tsai⁹, S. Kao¹⁰, P. Cassier¹¹, M. Khasraw¹², K. Allaire², F. Fan², H. Fang¹³, M. Patel¹³, W. Henner¹³, J. Hayflick¹³, M. Mcdevitt¹⁴, F. Barlesi¹⁵, ¹The University of Chicago Medical Centre, Chicago, US, ²University of California, San Francisco, San Francisco, US, ³GHS Cancer Institute, Greenville, US, ⁴NEXT OncologyTM, San Antonio, US, ⁵Davis Comprehensive Cancer Center, Sacramento, US, ⁶Gustave Roussy, Villejuif, FR, ⁷Institut Curie, Paris, FR, ⁸The University of Texas MD Anderson Cancer Center, Houston, US, ⁹HonorHealth Research Institute, Scottsdale, US, ¹⁰Chris O'Brien Lifehouse, Sydney, AU, ¹¹Centre Léon Bérard, Lyon, FR, ¹²Andrew Love Cancer Centre,

Geelong, AU, ¹³AbbVie Inc., Redwood City, US, ¹⁴AbbVie, Redwood City, US, ¹⁵Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR

- 12:00 - 12:00 **1221P - Anti-PD-L1/IL-15 fusion protein generates robust adaptive immune gene signatures in tumors leading to tumor inhibition and memory responses**
S. Martomo, X.-J. Feng, D. Lu, Z. Polonskaya, X. Luna, M. Poyurovsky, K. Mccracken, F. Miyara, L. Li, S. Aggarwal, J. Patel, Kadmon Corporation - Kadmon Holdings, Inc., New York City, US
- 12:00 - 12:00 **1222P - Evaluation of the anti-tumor efficacy and immune effects of N-809, a novel IL-15 superagonist/anti-PD-L1 bispecific agent**
K. Hicks, K. Knudson, Y. Ozawa, J. Schlom, S. Gameiro, Center for Cancer Research, National Cancer Institute, Bethesda, US
- 12:00 - 12:00 **1223P - GI101, a novel triple-targeting bispecific CD80-IgG4-IL2variant fusion protein, elicits synergistic anti-tumor effects in preclinical models**
J.C. Park¹, K.H. Pyo², Y.J. Song³, W.J. Lee³, J. Kim³, H.N. Ji³, S.S. Park³, Y.J. Koh³, K. Lee³, B. Cho², B.-H. Chun³, Y.M. Oh³, B.-G. Yang³, S.Y. Nam³, M.H. Jang³, ¹GI-Innovation, Inc., Seoul, KR, ²Yonsei Cancer Center, Seoul, KR, ³GI innovation - HQ-Central Research and Development Center, Seoul, KR
- 12:00 - 12:00 **1224P - Phase 1b, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumors**
J. Strauss¹, Y. Vugmeyster², M. Sznol³, R. Pachynski⁴, K. Trang⁵, S. Chennoufi⁶, J. Gulley⁷, ¹Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, US, ²EMD Serono, Billerica, US, ³Yale University School of Medicine Medical Oncology, New Haven, US, ⁴Siteman Cancer Center, St. Louis, US, ⁵Merck Healthcare KGaA, Darmstadt, DE, ⁶Merck KGaA - Germany, Darmstadt, DE, ⁷National Cancer Institute, Bethesda, US
- 12:00 - 12:00 **1225P - THOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome (VLS)**
M. Milla, J. Ptacin, L. Ma, C. Caffaro, H. Aerni, K. San Jose, M. Pena, R. Herman, Y. Pavlova, D. Chen, T. Ismaili, S. Li, J. Nguyen, N. Singh, L. Shawver, L. Koriazova, I. Joseph, Synthorx, Inc., La Jolla, US
- 12:00 - 12:00 **1226P - A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells**
A. Curioni¹, C. Britschgi¹, S. Hiltbrunner², L. Bankel¹, P. Gulati³, W. Weder¹, I. Schmitt-Opitz¹, O. Lauk⁴, C. Caviezel⁴, A. Knuth⁵, C. Münz⁶, C. Renner⁷, R.A. Stahel¹, M. Manz¹, U. Petrausch⁸, ¹University Hospital Zürich, Zurich, CH, ²UZH - Universität Zurich Schlieren (WAA), Schlieren, CH, ³F. Hoffmann-La Roche AG, Basel, CH, ⁴University Hospital Zurich, Zurich, CH, ⁵Hamad Medical Corporation (HMC)-National Center for Cancer Care and Research (Al Amal Hospital), Doha, QA, ⁶University of Zurich, Zurich, CH, ⁷Klinik Im Park Oncology Center, Zurich, CH, ⁸OnkoZentrum Zürich, Zurich, CH
- 12:00 - 12:00 **1227P - HPV16 E6-specific TCR-T armored with checkpoint blockade in the treatment of cervical cancer**

P. Bryson¹, Q. Jia², G. Chen³, S. Li¹, J. Fang¹, L. Zhao⁴, B. Wolff⁴, R. Chen⁴, Y. Wan⁵, Q.-J. Li⁴, B. Zhu², ¹TCRCure Biopharma Corp., Los Angeles, US, ²Southwest Hospital, 3rd Military Medical University, Chongqing, CN, ³TCRCure Biopharma Corp., Chongqing, CN, ⁴TCRCure Biopharma Corp., Durham, US, ⁵College of Basic Medicine, Third Military Medical University (Army Medical University), Chongqing, CN

12:00 - 12:00 **1228P - the Mutant Neoantigen Specific T Cell Is a Personalized Immunotherapy in Refractory Solid Tumor**

Q. Song¹, T. Zhang², J. Li³, W. Sheng³, J. Wang³, Q. Gan³, L. Han³, Q. Sun³, N. Zhou³, X. Zhou³, Y. Zhou³, L. Wu³, J. Li⁴, L. Chang⁴, Z. Zhou², Y. Song⁴, L. Zhang³, S. Jiao⁵, ¹Chinese PLA General Hospital (301 Military Hospital), Beijing, CN, ²Beijing DCTY Biotech Co.,Ltd., Beijing, CN, ³the General Hospital of People's Liberation Army, Beijing, CN, ⁴Geneplus-Beijing Institute, Beijing, CN, ⁵Chinese People's Liberation Army General Hospital, Beijing, CN

12:00 - 12:00 **1229P - NY-ESO-1 and LAGE1A -an emerging target for cell therapies in solid tumours**

I. Eleftheriadou¹, S. Brett², A. Domogala², L. Patasic², M. Kijewska², K. Soor², M. Georgouli², J. Dopierala², P. Fisher², J. Jing³, J. Euesden², K. Auger³, R. Roberts², S. O'Sullivan², L. Castelletti¹, M. Damm¹, D. Pankov³, L. Johnson³, A. Shalabi³, C. Britten¹, ¹GlaxoSmithKline GSK Stevenage - UK, Stevenage, GB, ²GlaxoSmithKline, NY, GB, ³GlaxoSmithKline, Colleagueville, US

12:00 - 12:00 **1230P - Targeting myeloid-derived suppressor cells and T cells: combination treatment with MTL-CEBPA and PD-1 antibody in a mouse syngeneic CT26 model**

M. Sodergren¹, C. Tan², V. Reebye², R. Habib², D. Blakey², N. Habib¹, ¹Imperial College London - Hammersmith Hospital, London, GB, ²MiNA Therapeutics, London, GB

12:00 - 12:00 **1231P - Master Checkpoint Cbl-b Inhibition: Anti-tumor Efficacy in a Murine Colorectal Cancer Model Following siRNA-based Cell Therapy**

K. Thell¹, M. Urban¹, J. Harrauer¹, I. Haslinger¹, M. Kuttke², J. Brunner², A. Vogel², G. Schabbauer², J. Penninger³, A. Gaweco¹, ¹Apeiron Biologics AG, Vienna, AT, ²Medical University Vienna, Vienna, AT, ³University of British Columbia, Vancouver, CA

12:00 - 12:00 **1232P - Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy**

M. Zuazo¹, H. Arasanz², M.J. García Granda¹, A.I. Bocanegra¹, G. Fernández-Hinojal², M. Gato-Cañas³, M. Martínez Aguillo², B. Hernández Marín², L. Teijeira⁴, I. Morilla Ruiz⁵, R. Vera⁴, G. Kochan¹, D. Escors¹, ¹Navarrabiomed, Pamplona, ES, ²Complejo Hospitalario de Navarra, Pamplona, ES, ³Centro de Investigación Médica Aplicada, Pamplona, ES, ⁴Complejo Hospitalario de Navarra - Royal Navarre Hospital, Pamplona, ES, ⁵Institut Catala de Oncologia, Barcelona, ES

12:00 - 12:00 **1233P - Landscape of PD-L1 expression status in Chinese solid tumor patients.**

Y. Zhong¹, Y. Zhou², Y. Bai², B. Zhang³, Y. Zhang⁴, ¹Shanghai TCM-Integrated Hospital,

Shanghai, CN, ²3D Medicines Co., Ltd, Shanghai, CN, ³3D Medicine, Shanghai, CN,
⁴Jiangsu Province Hospital, Nanjing, CN

- 12:00 - 12:00 **1234P - Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer**
C.-Y. Liu¹, K.-Y. Lau¹, J.-L. Chen¹, P.-Y. Chu², C.-T. Huang³, W.-L. Wang¹, P.-J. Lien⁴, L.-M. Tseng⁴, ¹Taipei Veterans General Hospital, Taipei city, TW, ²Show Chwan Memorial Hospital, Changhua, TW, ³Yang-Ming Branch of Taipei City Hospital, Taipei, TW, ⁴Taipei Veterans General Hospital, Taipei, TW
- 12:00 - 12:00 **1235P - Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics**
J. Adashek¹, C. Szeto², S. Reddy³, P. Spiess⁴, ¹H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ²NantOmics, LLC, Santa Cruz, US, ³NantHealth, Culver City, US, ⁴Moffitt Cancer Center, Tampa, US
- 12:00 - 12:00 **1236P - Insights into the Tumor Immune Microenvironment using Tissue Phenomics to Drive Cancer Immunotherapy**
M. Groher¹, J. Zimmermann², H. Musa³, A. Ackermann³, M. Surace⁴, J. Rodriguez-Canales⁴, K. Steele⁴, A. Kapil², N. Brieu¹, L. Rognoni², F. Segerer², A. Spitzmüller², T.-H. Tan², A. Schäpe², G. Schmidt¹, ¹Definiens AG, Munich, DE, ²Definiens AG, Muenchen, DE, ³Böhringer-Ingelheim GmbH & Co KG, Ingelheim am Rhein, DE, ⁴Medimmune, Gaithersburg, US
- 12:00 - 12:00 **1237P - Immune competent somatic mosaic model of colorectal cancer**
S. Napolitano¹, F. Carbone², D.G. Menter², T. Troiani¹, G. Genovese², S. Kopetz², ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²University of Texas MD Anderson Cancer Center, Houston, US
- 12:00 - 12:00 **1238P - Genomic correlates of response to anti-PDL1 Atezolizumab in non-small-cell lung cancer OAK and POPLAR trials**
H. Singhal¹, O. Ekinici², C. Alcorn³, D. Gandara⁴, ¹Mundipharma EDO GmbH, Basel, CH, ²Roche Molecular Systems, Santa Clara, US, ³Roche Molecular Systems, Belmont, US, ⁴University of California Davis Cancer Center, Sacramento, US
- 12:00 - 12:00 **1239P - High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program**
C. Tournigand¹, A. Flechon², S. Oudard³, E. Saada-Bouzig⁴, D. Pouessel⁵, C. Le Tourneau⁶, P. Augereau⁷, M. Beylot-Barry⁸, J.J. Grob⁹, B. Chibaudel¹⁰, J.-C. Soria¹¹, C. Simon¹², D. Couch¹², N. Hoog-Labouret¹³, C. Tiffon¹³, S. Chevret¹⁴, T. Andre¹⁵, A. Marabelle¹⁶, ¹Centre hospitalier universitaire Henri-Mondor, Créteil, FR, ²Centre Léon Bérard, Lyon, FR, ³Hopital European George Pompidou, Paris, FR, ⁴Hopital Lacassagne, Nice, FR, ⁵Institut Claudius Régaud, TOULOUSE, FR, ⁶Institut Curie, Paris, FR, ⁷Institut de cancérologie de l'Ouest, ANGERS, FR, ⁸Hôpital Saint-André - CHU de Bordeaux, BORDEAUX, FR, ⁹Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ¹⁰Institut Hospitaliser Franco-britannique, Levallois-Perret, FR,

¹¹Medimmune, Gaithersburg, US, ¹²UNICANCER, Paris, FR, ¹³Institut National du Cancer (INCa), Boulogne-Billancourt, FR, ¹⁴Hôpital Saint Louis, Paris, FR, ¹⁵Hopital Saint-Antoine, Paris, FR, ¹⁶Institut Gustave Roussy, Villejuif, FR

12:00 - 12:00 **1240P - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer**

Y. Chen¹, G. Chen², J. Li³, C. Huang⁴, Y. Li⁴, J. Lin¹, L.Z. Chen¹, J.P. Lu², Y.Q. Wang³, C.X. Wang³, L.K. Pan⁵, X.F. Xia³, X. Yi³, C.B. Chen¹, X.W. Zheng², Z.Q. Guo¹, J.J. Pan¹, ¹Fujian Medical University Cancer Hospital, Fuzhou, CN, ²Fujian Cancer Hospital, Fuzhou, CN, ³Genepplus-Beijing Institute, Beijing, China, Beijing, CN, ⁴Fujian Medical University, Fuzhou, CN, ⁵Hui Xian Medical Center, Macao, CN

12:00 - 12:00 **1241P - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients**

R. Laza-Briviesca¹, A. Cruz-Bermudez², M. Casarrubios², E. Nadal³, M.A. Insa Molla⁴, M.-R. García-Campelo⁵, G. Huidobro⁶, M. Domine Gomez⁷, M. Majem Tarruella⁸, D. Rodriguez Abreu⁹, A. Martinez-Marti¹⁰, J. De Castro Carpeno¹¹, M. Cobo Dols¹², G. López Vivanco¹³, E. Del Barco Morillo¹⁴, R. Bernabé¹⁵, N. Viñolas¹⁶, I.C. Barneto Aranda¹⁷, B. Massuti Sureda¹⁸, M. Provencio¹⁹, ¹ Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadahonda, madrid, ES, ²Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, ES, ³Institut Catala d'Oncologia (ICO), Barcelona, ES, ⁴Hospital Clinico Universitario de Valencia, Valencia, ES, ⁵Complejo Hospitalario Universitario A Coruna (CHUAC), La Coruña, ES, ⁶Hospital Universitario Alvaro Cunqueiro, Vigo, ES, ⁷University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ⁸Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁹Hospital Universitario Insular de Gran Canaria, Las Palmas, ES, ¹⁰Vall d'Hebron Institute of Oncology and University Hospital, Barcelona, ES, ¹¹Hospital Universitario La Paz, Madrid, ES, ¹² Hospital Regional Universitario de Málaga, Málaga, ES, ¹³Hospital Universitario Cruces, Barakaldo, ES, ¹⁴Instituto de Investigación Biomédica de Salamanca, Salamanca, ES, ¹⁵Hospital Universitario Virgen del Rocío, Sevilla, ES, ¹⁶Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹⁷University Hospital Reina Sofia, Cordoba, ES, ¹⁸Hospital General Universitario de Alicante, Alicante, ES, ¹⁹Hospital Universitario Puerta de Hierro, Majadahonda, ES

12:00 - 12:00 **1242P - Clinical utility of precision immunoprofiling and monitoring of the tumor microenvironment using flow cytometry and CyTOF in patients with advanced NSCLC treated with atezolizumab: results from a phase II study for biomarker analysis (EPOC1702)**

K. Kirita¹, E. Sugiyama¹, Y. Togashi², H. Udagawa¹, T. Irie¹, S. Iida¹, M. Nakamoto¹, S. Nomura³, T. Ikeda¹, Y. Zenke¹, S. Matsumoto¹, K. Yoh¹, S. Niho¹, A. Sato¹, H. Nishikawa¹, K. Goto¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Kindai University School of Medicine, Osaka, JP, ³National Cancer Center, Kashiwa, JP

12:00 - 12:00 **1243P - Tumor mutation burden (TMB), PD-L1, IFN-γ signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)**

C. Massard¹, H. Si², Q. Zhang², B. Higgs³, R. Raja², S. Abdullah⁴, A. Gupta², W. Li², M.

Van Der Heijden⁵, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²AstraZeneca, Gaithersburg, US, ³Medimmune + LAP&P, Gaithersburg, US, ⁴Medimmune, Gaithersburg, US, ⁵Netherlands Cancer Institute, Amsterdam, NL

- 12:00 - 12:00 **1244P - The decrease of TMB, TNB and HLA expression are the Mechanism of Drug Resistance of NSCLC to immunosuppressive PD-1/PD-11.**
S. Yu, Henan Cancer Hospital, Zhengzhou, CN
- 12:00 - 12:00 **1245P - Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)**
R. Kizawa¹, Y. Miura¹, Y. Oda¹, Y. Nagaoka¹, J. Masuda², Y. Ozaki², C. Kondoh², S. Moriguchi², Y. Takahashi², K. Ogawa², Y. Tanabe Hashimoto³, S. Taniguchi², T. Okaneya², A. Kishi², N. Hayashi², H. Takaya², T. Takano¹, ¹Toranomon hospital, Tokyo, JP, ²Toranomon Hospital, Tokyo, JP, ³National Cancer Center Hospital, Tokyo, JP
- 12:00 - 12:00 **1246P - (Withdrawn)**
- 12:00 - 12:00 **1247P - A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumors.**
J. Pérez-Peña¹, J. Fekete², R. Páez³, J.A. García-Sáenz³, V. García-Barberán⁴, P. Pérez-Segura⁵, A. Pandiella⁶, B. Györffy⁷, A. Ocaña⁸, A. Manzano³, ¹IBSAL - Instituto de Investigación Biomédica de Salamanca, Salamanca, ES, ²Semmelweis University-2nd Department of Paediatrics, Budapest, HU, ³Hospital Clínico San Carlos, Madrid, ES, ⁴Hospital Clinico Universitario San Carlos. CIBERONC Instituto de Salud Carlos III, Madrid, ES, ⁵Hospital Clinico Universitario San Carlos, Madrid, ES, ⁶Centro de investigación del cáncer, Salamanca, ES, ⁷Semmelweis University, Budapest, HU, ⁸GEICAM, San Sebastian de los Reyes, ES
- 12:00 - 12:00 **1248P - Alterations of TMB and TCR repertoires during Chemotherapy in East Asian lung cancer patients without TKI-related driver gene mutations**
L. Song¹, Y. He², X. Li¹, C. Zhou³, ¹Haplox, Shenzhen, CN, ²Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN, ³Tongji University, Shanghai, CN
- 12:00 - 12:00 **1249P - Association of SCFA in gut microbiome and clinical response in solid cancer patients treated with anti-PD-1 antibody.**
M. Nomura¹, R. Nagatomo², K. Inoue², K. Doi³, J. Shimizu³, K. Baba³, T. Saito³, S. Matsumoto³, M. Muto³, ¹Kyoto University-Graduate school of medicine, Kyoto, JP, ²Ritsumeikan University, Kusatsu, JP, ³Kyoto University Graduate School of Medicine, Kyoto, JP
- 12:00 - 12:00 **1250P - Extracellular matrix and tissue derived metabolites in a liquid biopsy identifies endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment**
N. Willumsen¹, C. Bager², C. Jensen¹, M. Karsdal¹, D. Madsen³, M. Hansen³, H. Schmidt⁴, I.M. Svane³, ¹Nordic Bioscience A/S, Herlev, DK, ²Nordic Bioscience, Herlev, DK, ³University of Copenhagen, Herlev, DK, ⁴Aarhus University Hospital, Aarhus C, DK

- 12:00 - 12:00 **1251P - Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy**
J. Stein¹, S. Signoretti², M. Sznol³, Y. Ishii⁴, D. McDermott⁵, T. Choueiri⁶, J. Taube¹,
¹Johns Hopkins University, Baltimore, US, ²Brigham and Women's Hospital, Boston, US,
³Yale University School of Medicine Medical Oncology, New Haven, US, ⁴Bristol-Myers Squibb, Princeton, US, ⁵Beth Israel Deaconess Med. Center, Boston, US, ⁶Dana-Farber Cancer Institute, Boston, US
- 12:00 - 12:00 **1252P - PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy**
Y. Fan¹, K. Chen², ¹Zhejiang Cancer Hospital, Hangzhou, CN, ²ZHEJIANG CANCER HOSPITAL, Hangzhou, CN
- 12:00 - 12:00 **1253P - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors**
C. Huang¹, Y. Chen², X. Gao³, Y. Li¹, J. Lin², L.Z. Chen², L.P. Chang³, G. Chen⁴, Y.F. Guan³, L.K. Pan⁵, X.F. Xia³, Z.Q. Guo², J.J. Pan², X. Yi³, C.B. Chen², ¹Fujian Medical University, Fuzhou, CN, ²Fujian Medical University Cancer Hospital, Fuzhou, CN, ³Genepplus-Beijing Institute, Beijing, China, Beijing, CN, ⁴Fujian Cancer Hospital, Fuzhou, CN, ⁵Hui Xian Medical Center, Macao, CN
- 12:00 - 12:00 **1254P - Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation**
H.-J. Cui¹, S.-Y. Zheng², ¹China-Japan Friendship Hospital, Beijing, CN, ²Beijing University of Chinese Medicine, Beijing, CN
- 12:00 - 12:00 **1255P - Neutrophil to Lymphocyte Ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N).**
A. Simonaggio¹, R. Elaidi², L. Fournier¹, E. Fabre¹, V. Ferrari³, D. Borchiellini⁴, C. Thibault¹, P. Barthelemy⁵, J. Thouvenin⁶, E. Tartour¹, S. Oudard¹, Y. Vano⁷, ¹Hopital European George Pompidou, Paris, FR, ²ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Paris, FR, ³CENTRE ANTOINE LACASSAGNE, FR, ⁴Centre Anticancer Antoine Lacassagne, Nice, FR, ⁵C.H.U. Strasbourg-Nouvel Hopital Civil, Strasbourg, FR, ⁶CHU Hautepierre, Strasbourg, FR, ⁷Hôpital Européen Georges Pompidou, Paris, FR
- 12:00 - 12:00 **1256P - Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours**
A. Pender¹, E. Titmuss², E. Pleasance², K. Fan², H. Pearson², M. Bonakdar², G. Taylor², K. Mungall², R. Moore², J.-M. Lavoie¹, S. Yip³, H. Lim⁴, D. Renouf³, S. Jones², M. Marra², J. Laskin³, ¹BC Cancer Agency, Vancouver, CA, ²Canada's Michael Smith Genome Sciences Centre, Vancouver, CA, ³University of British Columbia, Vancouver, CA, ⁴BC Cancer Agency - Vancouver, Vancouver, CA
- 12:00 - 12:00 **1257P - Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a**

multi-cancer Phase I IO Cohort

D. Araujo¹, A. Wang², D. Torti³, J. Huang², A. Leon³, K. Marsh³, A. Mccarthy¹, H. Berman¹, A. Spreafico¹, A. Hansen¹, A.A. Razak¹, P. Bedard¹, L. Wang¹, E. Plackmann⁴, H. Chow⁴, H. Bao², X. Wu², T. Pugh³, L. Siu⁴, ¹Princess Margaret Cancer Center, Toronto, CA, ²Geneseeq Technology Inc., Toronto, CA, ³Ontario Institute for Cancer Research, Toronto, CA, ⁴Princess Margaret Cancer Centre, Toronto, CA

12:00 - 12:00 **1258P - Analysis of Molecular Profile Complexities for Immunotherapy Decision Support**

R. Dóczy¹, D. Tihanyi¹, P. Filotas¹, A. Dirner¹, B. Pálházi¹, E. Várkondi¹, Z. Farkas¹, J. Deri¹, E. Lengyel², C. Hegedus¹, I. Petak¹, ¹Oncompass Medicine Hungary Kft., Budapest, HU, ²Bajcsy-Zsilinszky Cancer Center, Budapest, HU

12:00 - 12:00 **1259P - The Role of Tumor Neoantigens in the Differential Response to Immunotherapy (IO) in EGFR and BRAF Mutated Lung Cancers - Quantity or Quality?**

K. Case¹, K. Kennedy², L. Kujtan³, J. Subramanian², ¹Pembroke Hill School, Kansas City, US, ²St. Luke's Hospital, Kansas City, US, ³UMKC(University of Missouri Kansas City), Kansas City, US

12:00 - 12:00 **1260P - Impact of previous corticosteroid (CS) exposure on efficacy of Programmed Cell Death-(Ligand) 1 blockade in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): a single Center retrospective analysis**

F. Nelli¹, M. Fabbri², D. Alesini², I. Sperduti³, F. Primi¹, M.G. Chilelli¹, S. Giacinti⁴, D. Padalino¹, C. Signorelli², T. Ranalli², E. Ruggeri¹, ¹Ospedale Belcolle, Viterbo, IT, ²Central Hospital of Belcolle, Viterbo, IT, ³Bio-Statistics Unit, Regina Elena National Cancer Institute, Roma, IT, ⁴Azienda Ospedaliera St. Andrea, Rome, IT

12:00 - 12:00 **1261P - Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors**

S. Vari¹, A. Annovazzi², D. Giannarelli², R. Pasqualoni², R. Sciuto², S. Carpano¹, V. Ferraresi¹, F. Cognetti¹, ¹Istituto Nazionale Tumori Regina Elena, Rome, IT, ²Regina Elena National Cancer Institute, Rome, IT

12:00 - 12:00 **1262P - Predictive model for survival in advanced non-small-cell lung cancer (NSCLC) treated with frontline pembrolizumab**

X. Mielgo Rubio¹, M.E. Olmedo Garcia², M. Sereno Moyano³, C. Aguado⁴, J.A. Núñez⁵, M. Domine Gomez⁶, A.M. Sánchez Peña⁷, I. Nalda Ariza⁸, S. Cerezo Gonzalez⁹, R. Alvarez Cabellos¹⁰, L. Cabezón Gutiérrez¹¹, C. Pangua Mendez¹², R. Cervera¹³, A. Calles Blanco¹⁴, R. López Castro¹⁵, J.M. Sanchez Torres¹⁶, A. Lopez Martin¹⁷, A. Velastegui Ordonez¹⁸, E. Pérez Fernández¹, P. Cruz¹⁹, ¹Hospital Universitario Fundación Alcorcón, Alcorcon, ES, ²Hospital Universitario Ramon y Cajal, Madrid, ES, ³Hospital Infanta Sofia, Madrid, ES, ⁴Hospital Clinico Universitario San Carlos, Madrid, ES, ⁵Hospital Universitario 12 de Octubre, Madrid, ES, ⁶University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ⁷Hospital Universitario Getafe, Getafe, ES, ⁸Hospital Universitario Guadalajara, Guadalajara, ES, ⁹Hospital General Mancha Centro, Alcazar de San Juan, ES, ¹⁰Hospital Virgen de la Salud, Toledo, ES, ¹¹Hospital Universitario de Torrejón,

Madrid, ES, ¹²Hospital Universitario Infanta Leonor, Madrid, ES, ¹³Hospital Universitario del Henares, Coslada, ES, ¹⁴Hospital General Universitario Gregorio Marañón, Madrid, ES, ¹⁵Hospital Clínico Universitario de Valladolid, Valladolid, ES, ¹⁶Hospital Universitario de La Princesa, Madrid, ES, ¹⁷Hospital Universitario Severo Ochoa, Leganes, ES, ¹⁸Hospital Rey Juan Carlos, Mostoles, ES, ¹⁹Hospital Universitario La Paz, Madrid, ES

12:00 - 12:00

1263P - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.

J. Riedl¹, D. Barth¹, V. Foris¹, F. Posch², S. Mollnar¹, M. Stotz¹, M. Pichler¹, H. Stöger¹, G. Absenger³, H. Olschewski¹, A. Gerger², ¹Medical University of Graz, Graz, AT, ²LKH-Univ.Klinikum Graz - Universitätsklinik für Innere Medizin, Graz, AT, ³Medical University Graz, Graz, AT

12:00 - 12:00

1264P - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab

M. Klabusay¹, J. Skacel², P. Coupek², ¹University of Health Sciences Faculty of Palacky University - Faculty of Medicine, Olomouc, CZ, ²Palacky University- Faculty of Medicine, Olomouc, CZ

12:00 - 12:00

1265P - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome

M.D.M. Noblejas López¹, C. Nieto-Jiménez¹, S. Morcillo-García¹, J. Pérez-Peña¹, M. Nuncia-Cantarero¹, E.M. Galán-Moya², E. Amir³, A. Pandiella⁴, B. Gyórfy⁵, A. Ocaña⁶, ¹Complejo Hospitalario Universitario de Albacete, Albacete, ES, ²Universidad de Castilla-La Mancha, Albacete, ES, ³Princess Margaret Cancer Center, Toronto, CA, ⁴Centro de investigación del cáncer, Salamanca, ES, ⁵MTA TTK Lendület Cancer Biomarker Research Group, Budapest, HU, ⁶Hospital Clínico San Carlos, Madrid, ES

12:00 - 12:00

1266P - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy

N. Üskent¹, S. Ayla², N. Molinas Mandel³, M. Ozkan⁴, M. Teomete⁵, H. Baloglu⁶, C. Aydinçer⁶, H. Yergok³, E. Dogan⁴, B. Berk⁷, A. Yazar⁵, ¹Anadolu Medical Center Hospital, Gebze, TR, ²School of Medicine, Istanbul Medipol University, İstanbul, TR, ³School of Medicine Koc University, İstanbul, TR, ⁴School of Medicine Erciyes University, Kayseri, TR, ⁵School of Medicine, Acibadem University Hospital, İstanbul, TR, ⁶Anadolu Medical Center Hospital, Kocaeli, TR, ⁷School of Pharmacy, İstanbul Medipol University, İstanbul, TR

12:00 - 12:00

1267P - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy

C. Jiménez Cortegana¹, N. Palazón Carrión¹, E. Nogales Fernández¹, M.A. Nieto García², V. Sánchez Margalet¹, M.D.C. Álamo De La Gala¹, M. Suengas Martínez De Ilárduya¹, E. Montilla Burgos¹, I. Araújo Fernández¹, F. Henao Carrasco³, A. Martín García-Sancho⁴, F. Carnicero⁵, E. Rios Herranz⁶, F. De La Cruz Vicente⁷, R. Fernández⁸, A. Rueda Dominguez⁹, L. De La Cruz Merino³, ¹Hospital Universitario Virgen Macarena, Seville,

ES, ²University of Seville, Seville, ES, ³Hospital Universitario Virgen Macarena, Sevilla, ES, ⁴Hospital Universitario de Salamanca, Salamanca, ES, ⁵Hospital San Pedro de Alcántara, Cáceres, ES, ⁶Hospital Universitario Virgen Valme, Sevilla, ES, ⁷Hospital Universitario Virgen del Rocío, Seville, ES, ⁸Hospital de Cabueñes, Gijón, ES, ⁹Hospital Costa del Sol, Marbella, ES

12:00 - 12:00

1268P - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas

L. Shen¹, J. Li², N. Xu³, B. Xing⁴, Q. Zhang⁵, Y. Zhao⁶, J. Cao⁷, J. Ding⁸, J. Wang⁹, Y. Wang⁹, H. Dai⁹, ¹Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, ²Shanghai East Hospital, Tongji University School of Medicine, Shanghai, CN, ³1st Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, ⁴3rd Xiangya Hospital of Central South University, Changsha, CN, ⁵Harbin Medical University Cancer Hospital, Harbin, CN, ⁶Henan Cancer Hospital, Zhengzhou, CN, ⁷Fudan University Shanghai Cancer Center, Shanghai, CN, ⁸Stone Pharmaceuticals (Su Zhou) Co., Ltd., Suzhou, CN, ⁹Stone Pharmaceuticals (Su Zhou) Co., Ltd., Shanghai, CN

12:00 - 12:00

1269P - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)

M. Voss¹, A. Azad², A. Hansen³, J. Gray⁴, S. Welsh⁵, I. Achour⁶, H. Hu⁶, L. Lewis⁶, F. Walcott⁶, S. Oosting⁷, ¹Memorial Sloan-Kettering Cancer Center, New York, US, ²Monash Medical Centre, Clayton, AU, ³Princess Margaret Cancer Center, Toronto, CA, ⁴H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ⁵Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB, ⁶AstraZeneca, Gaithersburg, US, ⁷University Hospital Groningen (UMCG), Groningen, NL

12:00 - 12:00

1270P - Pembrolizumab in Advanced Rare Cancers

A. Naing¹, F. Meric-Bernstam², D. Karp³, J. Rodon¹, S. Piha-Paul⁴, V. Subbiah², D. Hong⁵, S. Pant⁶, S. Fu⁷, F. Janku², T. Yap², A.M. Tsimberidou², E. Ileana Dumbrava², R. Colen², K. Hess², M. Campbell⁸, S.-M. Tu², C. Jimenez², M. Habra², G. Varadhachary², ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³UT MD Anderson Cancer Center, Houston, US, ⁴The University of Texas, MD Anderson Cancer Center, Houston, US, ⁵University of Texas MD Anderson Cancer Center, Houston, US, ⁶MD Anderson Cancer Center, Houston, US, ⁷MD Anderson Cancer Center, Houston, US, ⁸The M. D. Anderson Cancer Center, Houston, US

12:00 - 12:00

1271P - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study

J.-Y. Blay¹, N. Penel², I. Ray-Coquard¹, R. Schott³, E. Saada-Bouزيد⁴, F. Bertucci⁵, C. Chevreau⁶, E. Bompas⁷, E. Coquan⁸, S. Cousin², P. Soulié⁹, A. Le Cesne¹⁰, O. Mir¹⁰, T. Rycckewaert², M. Brahmi¹, N. Hoog-Labouret¹¹, D. Couch¹², S. Chevret¹³, J.-C. Soria¹⁴, C. Massard¹⁵, ¹Centre Léon Bérard, Lyon, FR, ²Centre Oscar Lambret, Lille, FR, ³Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, ⁴Hopital Lacassagne, Nice, FR, ⁵Institute Paoli Calmettes, Marseille, FR, ⁶Institut Universitaire du Cancer -

Toulouse- Oncopole, Toulouse, FR, ⁷ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁸Centre Francois Baclesse, Caen, FR, ⁹Centre Paul Papin, Angers, FR, ¹⁰Institut Gustave Roussy, Villejuif, FR, ¹¹Institut National du Cancer (INCa), Boulogne-Billancourt, FR, ¹²UNICANCER, Paris, FR, ¹³Hôpital Saint Louis, Paris, FR, ¹⁴Medimmune, Gaithersburg, US, ¹⁵Gustave Roussy - Cancer Campus, Villejuif, FR

- 12:00 - 12:00 **1272P - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.**
J. Lin¹, X. Yang¹, S. Zhao², J. Long³, J. Pan³, K. Hu³, L. Zhao³, L. Huo³, X. Sang³, K. Wang², H. Zhao³, ¹Peking Union Medical College Hospital, Beijing, CN, ²Origimed, Shanghai, CN, ³PUMCH-Peking Union Medical College Hospital (East), Beijing, CN
- 12:00 - 12:00 **1273P - Durvalumab and Paclitaxel Combination for treatment of metastatic triple negative breast cancer is safe with very promising efficacy**
H. Ghebeh, A. Alsayed, K. Suleman, D. Ajarim, L. Cabangon, A. Tulbah, T. Al-Tweigeri, King Faisal Specialist Hospital and Research Center, Riyadh, SA
- 12:00 - 12:00 **1274P - A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients**
D. Hurkmans¹, E. Basak², T. Van Dijk², D. Mercieca³, M. Schreurs¹, A. Wijkhuijs⁴, S. Bins⁵, E. Oomen-De Hoop¹, R. Debets², M. Joerger⁶, A. Odink², A. Van Der Veldt², C. Van Der Leest⁷, J. Aerts², R. Mathijssen¹, S. Koolen², ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²Erasmus University Medical Center, Rotterdam, NL, ³Mater Dei Hospital, Msida, MT, ⁴Erasmus University Medical Hospital, Rotterdam, NL, ⁵Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ⁶Kantonsspital St. Gallen, St. Gallen, CH, ⁷Amphia Ziekenhuis-location Molengracht, Breda, NL
- 12:00 - 12:00 **1275P - Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small-cell lung cancer (NSCLC) and urothelial carcinoma (UC)**
B. Cho¹, K. Penkov², I. Bondarenko³, M. Korozan⁴, A. Kurochkin⁵, J. Pikiel⁶, Y. Kulyaba⁷, H. Ahn⁸, S. Odintsova⁹, J. Davda¹⁰, A. Forgie¹¹, X. Wang¹¹, R. Li¹², I. Jacobs¹³, F. Kazazi¹¹, J. Chou¹⁴, M. Johnson¹⁵, ¹Yonsei Cancer Center, Seoul, KR, ²NHI Railway Hospital St.Petersburg, St. Petersburg, RU, ³Dnipropetrovsk city multidisciplinary clinical hospital №4, Dnipro, UA, ⁴Specialist Hospital, ul. Rydygiera, Grudziadz, PL, ⁵Sumy Oncological Dispensery, Sumy, UA, ⁶Szpital Morski, Gdynia, PL, ⁷Dobriy Prognoz, Kyiv, UA, ⁸Gachon University Gil Medical Center, Incheon, KR, ⁹Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, RU, ¹⁰Pfizer Inc - USA, San Diego, US, ¹¹Pfizer Inc, South San Francisco, US, ¹²Pfizer Inc, Cambridge, US, ¹³Pfizer Inc - USA, New York, US, ¹⁴Pfizer Inc: Wang Susan, South San Francisco, US, ¹⁵Sarah Cannon Research Institute-Cancer Centre, Nashville, US
- 12:00 - 12:00 **1276P - Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs**
A. Hansen¹, K. Ala-Leppilampi², C. Mckillop³, L. Siu⁴, P. Bedard¹, A. Abdul Razak¹, A. Spreafico¹, S. Sridhar⁵, N. Leigh⁴, M. Butler⁵, D. Hogg¹, A. Sacher⁴, A. Oza⁶, R. Nisenbaum², K. Webster⁷, D. Cella⁷, J. Parsons², ¹Princess Margaret Cancer Center, Toronto, CA, ²St. Michael's Hospital University of Toronto, Toronto, CA, ³Turalt Inc,

Toronto, CA, ⁴Princess Margaret Cancer Centre, Toronto, CA, ⁵Princess Margaret Hospital, Toronto, CA, ⁶Princess Margaret Cancer Centre, University Health Network, Toronto, CA, ⁷Northwestern University, Chicago, US

- 12:00 - 12:00 **1277P - Immune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumors**
F.J. Ros Montana¹, I. Matos¹, G. Vilacampa², A. Azaro³, J. Martin-Liberal⁴, C. Hierro¹, I. Brana¹, C. Viaplana¹, M. Vieito Villar⁵, I. Gardeazabal⁶, C. Saura⁴, L. Fariñas Madrid¹, T. Macarulla Mercade⁷, O. Saavedra⁸, N. Pardo⁹, M. Ochoa De Olza¹, E. Muñoz-Couselo⁹, J. Tabertero¹⁰, R. Dienstmann¹, E. Garralda¹¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron University Hospital, BARCELONA, ES, ³NO institution, NO City, CH, ⁴Vall d'Hebron University Hospital Institut d'Oncologia, Barcelona, ES, ⁵Vall d'Hebron University Hospital - Vall d'Hebron Institute of Oncology VHIO, Barcelona, ES, ⁶Clinica Universitaria de Navarra, Pamplona, ES, ⁷Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁸Vall d'Hebron University Hospital, NO City, ES, ⁹Vall d'Hebron University Hospital, Barcelona, ES, ¹⁰Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ¹¹Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES
- 12:00 - 12:00 **1278P - Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers**
P.S. Kok¹, W.-H. Yoon², I. Marschner³, S. Lord⁴, M. Friedlander⁵, C. Lee⁶, ¹Macarthur Cancer Therapy Centre, Campbelltown, AU, ²Wollongong Hospital, Wollongong, AU, ³National Health and Medical Research Council Clinical Trials Centre, Camperdown, AU, ⁴NHMRC Clinical Trials Centre, Camperdown, AU, ⁵Prince of Wales Clinical School UNSW, Sydney, AU, ⁶St George Hospital Cancer Care Centre, Kogarah, AU
- 12:00 - 12:00 **1279P - Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies**
M. Migden¹, A. Paccaly², K. Papadopoulos³, F. Yang⁴, J. Davis², R. Rippley⁴, I. Lowy⁵, M. Fury², E. Stankevich⁶, D. Rischin⁷, ¹University of Texas MD Anderson Cancer Center, Houston, US, ²Regeneron Pharmaceuticals, Inc, Tarrytown, US, ³South Texas Accelerated Research Therapeutics (START), San Antonio, US, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, US, ⁵Regeneron Pharmaceuticals Inc, Tarrytown, US, ⁶Regeneron Pharmaceuticals, Inc, Basking Ridge, US, ⁷Peter MacCallum Cancer Centre, Melbourne, AU
- 12:00 - 12:00 **1280P - A burst of highly differentiated CD4 TL identifies a subset of fast progressors, and correlates with hyperprogressive disease in NSCLC patients treated with ICI**
H. Arasanz¹, M. Zuazo², M. Martínez Aguillo¹, B. Hernández Marín¹, G. Fernández-Hinojal¹, A.I. Bocanegra², I. Morilla Ruiz³, M. Gato-Cañas⁴, L. Teijeira⁵, P. Sala¹, M.J. García-Granda², R. Vera⁵, G. Kochan², D. Escors², ¹Complejo Hospitalario de Navarra, Pamplona, ES, ²Navarrabiomed, Pamplona, ES, ³Institut Catala de Oncologia, Barcelona, ES, ⁴Centro de Investigación Médica Aplicada, Pamplona, ES, ⁵Complejo Hospitalario de Navarra - Royal Navarre Hospital, Pamplona, ES
- 12:00 - 12:00 **1281P - Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): a French nationwide retrospective cohort (UNIVOC Study)**

C. Chouaid¹, M. Giaj Levra², R. Corre³, C. Calvet⁴, A.-F. Gaudin⁴, V. Grumberg⁵, R. Jolivel⁶, B. Jouaneton⁶, J.-B. Assié¹, F.-E. Cotté⁴, ¹CH Intercommunal de Créteil, Créteil, FR, ²CHU Grenoble Alpes - Site Nord La Tronche, La Tronche, FR, ³CHU de Pontchaillou, Rennes, FR, ⁴Bristol-Myers Squibb, Rueil-Malmaison, FR, ⁵University Grenoble Alpes, La Tronche, FR, ⁶HEVA, Lyon, FR

- 12:00 - 12:00 **1282P - Dissociated responses in patients with metastatic solid tumors treated with immunotherapy**
P. Vaflard¹, X. Paoletti², V. Servois¹, E. Pons-Tostivint³, M.P. Sablin⁴, F. Ricci¹, D. Loirat¹, S. Hescot¹, N. Torossian¹, E. Borcoman¹, C. Le Tourneau¹, ¹Institut Curie, Paris, FR, ²Institut Gustave Roussy, Villejuif, FR, ³University Paul Sabatier, Toulouse, FR, ⁴Dr. Marie Paule Sablin, La Défense, FR
- 12:00 - 12:00 **1283P - Patterns and outcomes related to rapid progressive disease in a cohort of advanced solid tumors treated with immune checkpoint inhibitors (ICIs).**
L. Ghiglione¹, C. Cabrera Galvez¹, O. Reig², A. Soler-Perromat¹, J. Soler-Perromat¹, M. Sánchez¹, A. Arcocha¹, N. Viñolas¹, A. Prat¹, B. Mellado³, N. Reguart¹, ¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ²Hospital Clínic Barcelona, Barcelona, ES, ³Hospital Clínic de Barcelona, Barcelona, ES
- 12:00 - 12:00 **1284P - Real World Outcomes of Immune-Related Adverse Events (irAEs) among Patients Receiving Immune Checkpoint Inhibitors (ICIs) in Hospital Settings**
S. George¹, Y. Zheng², R. Kim³, T. Yu², J. Dreyfus⁴, J. Gayle⁴, C. Wassel⁴, H. Phatak⁵, ¹Roswell Park Comprehensive Cancer Center, Buffalo, US, ²EMD Serono, Inc., Rockland, US, ³Pfizer, Inc., New York, US, ⁴Premier, Inc., Charlotte, US, ⁵EMD Serono Research Center, Billerica, US
- 12:00 - 12:00 **1285P - Sex-based heterogeneity of efficacy of anticancer immunotherapy**
F. Conforti, L. Pala, Istituto Europeo di Oncologia, Milan, IT
- 12:00 - 12:00 **1286P - Comparative efficacy and safety of PD-1/PD-L1 inhibitors for patients with solid tumors: a systematic review and Bayesian network meta-analysis**
Q. Huang, Fudan University Shanghai Cancer Center, Shanghai, CN
- 12:00 - 12:00 **1287P - Excess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients**
J. Rogado¹, N. Romero Laorden², J.M. Sanchez Torres¹, A. Ramos-Levi¹, V. Pacheco-Barcia¹, A.I. Ballesteros Garcia¹, R. Arranz¹, A. Lorenzo³, P. Gullon⁴, A. Garrido¹, J.M. Serra¹, O. Donnay¹, M. Adrados¹, P. Costas¹, J. Aspa¹, A. Alfranca¹, R. Mondejar¹, R. Colomer Bosch¹, ¹Hospital Universitario de La Princesa, Madrid, ES, ²CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, ES, ³Hospital General de Segovia, Segovia, ES, ⁴Alcala University, Alcala de Henares, ES
- 12:00 - 12:00 **1288P - Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma**

A. Italiano¹, P. Cassier², D. Roda³, C.-C. Lin⁴, K. Peltola⁵, A. Gazzah⁶, H.-S. Shiah⁷, E. Calvo⁸, D. Tosi⁹, B. Gao¹⁰, L. Warburton¹¹, M. Tanner¹², S. Englert¹³, S. Lambert¹⁴, A. Parikh¹⁴, D. Afar¹⁴, G. Vosgian¹⁵, V. Moreno¹⁶, ¹Northwestern University Feinberg School of Medicine, Chicago, US, ²Centre Léon Bérard, Lyon, FR, ³Biomedical Research Institute INCLIVA, Hospital Clínico València, University of Valencia, Valencia, ES, ⁴National Taiwan University Hospital, Taipei City, TW, ⁵Helsinki University Central Hospital, Helsinki, FI, ⁶Gustave Roussy, Université Paris-Saclay, Villejuif, FR, ⁷Taipei Medical University, Taipei, TW, ⁸Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, ⁹ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ¹⁰Blacktown and Westmead Hospitals, Sydney, AU, ¹¹University of Western Australia, Nedlands, AU, ¹²Tampere University Hospital, Tampere, FI, ¹³AbbVie Inc., Ludwigshafen, DE, ¹⁴AbbVie Inc., Redwood City, US, ¹⁵AbbVie, Redwood City, US, ¹⁶University Hospital "Fundacion Jimenez Diaz", Madrid, ES

12:00 - 12:00 **1289P - Efficacy and safety of immune checkpoint inhibitors (ICIs) for treatment of advanced solid tumours in octogenarian patients**

S. Mebarki¹, M. Gisselbrecht², E. Fabre¹, E. Mercadier¹, S. Oudard¹, E. Paillaud³, ¹Hopital European George Pompidou, Paris, FR, ²APHP, Hôpital Européen Georges Pompidou, Paris, FR, ³Assistance Publique - Hopitaux De Paris, Paris, FR

12:00 - 12:00 **1290P - Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies**

A. Torres¹, R. Mathur¹, K. Maignan², M. Tucker¹, K. Ciofalo¹, S. Khozin³, K. Carson², ¹Flatiron Health Inc., New York City, US, ²Flatiron Health, New York, US, ³FDA Oncology Center of Excellence, New York, US

12:00 - 12:00 **1291P - Clinical outcomes of immune checkpoint inhibitors in older and younger patients with advanced solid tumours in a real-life setting**

P. Corboux¹, D. Maillet², A. Boespflug², M. Locatelli Sanchez², M. Perier Muzet², M. Duruisseaux³, L. Kiakouama Maleka⁴, S. Dalle⁵, C. Falandry², J. Peron⁶, ¹Hospices Civiles de Lyon, Lyon, FR, ²Centre Hospitalier Lyon Sud, Pierre Bénite, FR, ³Hôpital Louis Pradel-Hospices Civils de Lyon, Bron, FR, ⁴Hôpital de la Croix-Rousse, Lyon, FR, ⁵Hospices Civils, Lyon, FR, ⁶Lyon Sud Hospital Center, Pierre Bénite, FR

12:00 - 12:00 **1292P - Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer**

J. Mosquera Martinez¹, M. Riuvadets², M.-R. García-Campelo³, J. Serra Lopez², G. Anguera Palacios², P. Gallardo Melo², I. Sullivan², A. Barba Joaquin², M. Majem Tarruella², C. Reboredo Rendo¹, P. Cordeiro González¹, ¹CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ²Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ³Complejo Hospitalario Universitario A Coruna (CHUAC), La Coruña, ES

12:00 - 12:00 **1293P - The landscape of immuno-oncology clinical trials in China**

D. Wu¹, H. Huang², N. Li², S. Wang², H. Fang², Y. Yu², Y. Bai², B. Xu³, Y. Sun², ¹Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, ²National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ³Cancer Hospital,

Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN

12:00 - 12:00

1294P - Clinical Significance of Immune-related Creatine Phosphokinase Increase Associated with Anti PD1/PD-L1 immunotherapies.

S. Hajem¹, C. Baldini², S. Ederhy³, M. Berhoune⁴, F. Troalen², P. Romano-Martin⁴, P. Vuagnat⁴, S. Champiat², A. Varga², A. Hollebecque², C. Cauquil⁵, C. Mateus⁴, C. Robert⁴, C. Massard⁶, O. Lambotte⁷, J.-M. Michot⁴, ¹Paris Descartes University, Paris, FR, ²Gustave Roussy, Villejuif, FR, ³Hôpitaux Universitaires Est Parisien, Hôpital Saint Antoine, Paris, FR, ⁴Institut Gustave Roussy, Villejuif, FR, ⁵Hôpital Kremlin-Bicêtre, Paris, FR, ⁶Gustave Roussy - Cancer Campus, Villejuif, FR, ⁷CHU de Bicêtre, Le Kremlin Bicetre, FR

12:00 - 12:00

1295P - Thyroid toxicity and anti-thyroid antibodies as predictive markers for patients treated with anti-PD1 checkpoint therapy

W. Meer¹, E. Basak², D. Hurkmans¹, M. Schreurs¹, E. Oomen-De Hoop¹, A. Van Der Veldt², S. Bins³, A. Joosse⁴, S. Koolen², R. Debets², R. Peeters¹, J. Aerts², R. Mathijssen³, M. Medici², ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²Erasmus University Medical Center, Rotterdam, NL, ³Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ⁴Leiden University Medical Center (LUMC), Leiden, NL

12:00 - 12:00

1296P - Treatment-related adverse events and tolerability in patients with advanced renal cell carcinoma treated with first-line combination therapy with checkpoint inhibitors

T. Win Htut¹, S. Swarup², A. Sultan², F. Mogollon-Duffo², S. Meda², M. Arevalo², N. Adhikari², P. Naing³, P. Hlaing², Y. Mon Myat⁴, F. Hardwicke², N. D'Cunha², L. Tijani², K. Thein², ¹Colchester Hospital, Colchester, GB, ²Texas Tech University, Lubbock, US, ³New York-Presbyterian Hospital Queens, New York, US, ⁴University College Dublin, Ireland, Dublin, IE

12:00 - 12:00

1297P - Immune-related adverse events (irAEs) with single-agent PD-1 vs PD-L1 inhibitors: a meta-analysis of 8,730 patients from clinical trials

G. Sonpavde¹, P. Grivas², Y. Lin³, D. Hennessy⁴, J. Hunt⁵, ¹Dana-Farber Cancer Institute, Boston, US, ²University of Washington Seattle Cancer Care Alliance, Seattle, US, ³PharmStats Ltd, San Diego, US, ⁴EMD Serono, Inc, Rockland, US, ⁵EMD Serono, Rockland, US

12:00 - 12:00

1298P - EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy

M. Kostine¹, A. Finckh², C. Bingham³, K. Visser⁴, J. Leipe⁵, H. Schulze-Koops⁶, E. Choy⁷, K. Benesova⁸, T. Radstake⁹, A. Cope¹⁰, O. Lambotte¹¹, J.-E. Gottenberg¹², Y. Allenbach¹³, S. Jamal¹⁴, A. Marabelle¹⁵, J. Larkin¹⁶, J. Haanen¹⁷, L. Calabrese¹⁸, X. Mariette¹⁹, T. Schaeferbeke¹, ¹CHU de Bordeaux Pellegrin, Bordeaux, FR, ²University Hospitals of Geneva, Geneva, CH, ³Johns Hopkins University, Baltimore, US, ⁴Haga Hospital, The Hague, NL, ⁵University Medical Centre Mannheim, Mannheim, DE, ⁶University of Munich, Munich, DE, ⁷Cardiff University School of Medicine, Cardiff, GB, ⁸University Hospital Heidelberg, Heidelberg, DE, ⁹University Medical Center Utrecht, Utrecht, NL, ¹⁰King's College London, London, GB, ¹¹CHU de Bicêtre, Le Kremlin Bicetre, FR, ¹²University Hospital of Strasbourg, Strasbourg, FR, ¹³Pitié-Salpêtrière Hospital, Paris,

FR, ¹⁴University of British Columbia, Vancouver, CA, ¹⁵Institut Gustave Roussy, Villejuif, FR, ¹⁶Royal Marsden Hospital NHS Foundation Trust, London, GB, ¹⁷Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ¹⁸Cleveland Clinic, Cleveland, US, ¹⁹CHU Paris-Sud - Hôpital de Bicêtre, LE KREMLIN-BICÊTRE, FR

12:00 - 12:00 **1299P - Radiographic characteristics and poor prognostic factors of interstitial lung disease (ILD) in nivolumab-treated patients with non-small cell lung cancer (NSCLC)**

S. Sasaki¹, K. Oikado², Y. Saito³, J. Tominaga⁴, M. Sata⁵, F. Sakai⁶, T. Kato⁷, T. Iwasawa⁸, H. Kenmotsu⁹, M. Kusumoto¹⁰, T. Baba⁸, M. Endo⁹, Y. Fujiwara¹⁰, H. Sugiura¹¹, N. Yanagawa¹², Y. Ito¹³, T. Sakamoto¹³, Y. Ohe¹⁰, K. Kuwano¹⁴, ¹Juntendo University Urayasu Hospital, Chiba, JP, ²Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JP, ³Nippon Medical School, Tokyo, JP, ⁴Tohoku University School of Medicine, Sendai, JP, ⁵Jichi Medical University Hospital, Tochigi, JP, ⁶Saitama Medical University, International Medical Center, Saitama, JP, ⁷Kanagawa Cancer Center, Yokohama, JP, ⁸Kanagawa Cardiovascular and Respiratory Center, Yokohama, JP, ⁹Shizuoka Cancer Center, Shizuoka, JP, ¹⁰National Cancer Center Hospital, Tokyo, JP, ¹¹Keio University School of Medicine, Tokyo, JP, ¹²Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, ¹³Ono Pharmaceutical Co., Ltd., Osaka, JP, ¹⁴The Jikei University School of Medicine, Tokyo, JP

12:00 - 12:00 **1300P - Use of Checkpoint Inhibitors (CPI) in Allogeneic Stem Cell Transplant Recipients: An Institutional Experience and A Systemic Review of the Literature**

C. Saberian¹, N. Abdel-Wahab¹, M. Suarez-Almazor², G. Al-Atrash², A. Aabudayyeh¹, A. Diab², ¹The M. D. Anderson Cancer Center, Houston, US, ²The University of Texas MD Anderson Cancer Center, Houston, US

12:00 - 12:00 **1301P - Deep Learning Radiomics distinguishes intrapulmonary Disease from Metastases in Immunotherapy-treated Melanoma Patients**

T.D.L. Nguyen-Kim¹, S. Trebeschi², J. Pouw², G. Milanese³, L. Topff², Z. Bodalal⁴, J. Mangana⁵, T. Frauenfelder¹, J. Haanen⁴, C. Blank⁶, H. Aerts², R. Beets-Tan⁶, R. Dummer⁷, ¹University Hospital Zürich, Zurich, CH, ²The Netherlands Cancer Institute, Amsterdam, NL, ³University of Parma, Parma, IT, ⁴Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ⁵Universitätsspital Zürich - Klinik für Neurologie, Zurich, CH, ⁶The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁷Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH

12:00 - 12:00 **1302P - Sarcoidosis-Like Reaction Mimics Progression in patients treated with immune checkpoint inhibitors**

S. Hans¹, L. Dercle², S. Champiat³, A.-L. Voisin³, C. Noémie⁴, A. Marabelle⁵, J.-M. Michot⁵, L. Sara⁵, B. Corinne⁵, S. Ammari³, ¹Assistance Publique - Hopitaux De Paris, Paris, FR, ²Columbia University Medical Center/New York Presbyterian Hospital, New York, US, ³Gustave Roussy, Villejuif, FR, ⁴Bicêtre Hospital, Kremlin Bicêtre, FR, ⁵Institut Gustave Roussy, Villejuif, FR

12:00 - 12:00 **1303P - Tissue-based activation of mucosal-associated invariant T (MAIT) cells**

in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis.

S. Sasson¹, V. Cheung², T. Gupta², J. Zaunders³, K. Nahar⁴, C.M.-L. Munier⁵, A. Olsson-Brown⁶, G. Ahlenstiel⁷, U. Palendira⁸, R. Scolyer⁹, M. Carlino¹⁰, G. Long¹¹, A. Menzies¹², A. Kelleher⁵, M. Payne², B. Fairfax¹³, M. Middleton¹⁴, P. Klenerman¹, O. Brain²,
¹University of Oxford, Oxford, GB, ²John Radcliffe Hospital, Oxford, GB, ³St Vincent's Hospital, Sydney, AU, ⁴The Melanoma Institute Australia, Sydney, AU, ⁵The Kirby Institute, Sydney, AU, ⁶Liverpool Hospital, Liverpool, GB, ⁷Blacktown Hospital, Sydney, AU, ⁸Centenary Institute, Sydney, AU, ⁹Royal Prince Alfred Hospital, Camperdown, AU, ¹⁰The Crown Princess Mary Cancer Centre, Westmead, AU, ¹¹Melanoma Institute Australia, Wollstonecraft, AU, ¹²Melanoma Institute Australia, University of Sydney, North Sydney, AU, ¹³The Churchill Hospital, Oxford, GB, ¹⁴Churchill Hospital University of Oxford, Oxford, GB

12:00 - 12:00 **1304P - Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: temporal trends and clinical significance.**

L. Zubiri¹, G. Molina², K. Reynolds³, ¹Clinica Universitaria de Navarra, Pamplona, ES, ²Massachusetts General Hospital, Boston, US, ³MGH, Boston, US

12:00 - 12:00 **1305P - Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events**

A. Olsson-Brown¹, T. Guinan², M. Mckay², K. Thurston², S. Chow², R. Lord², J. Sacco²,
¹Royal Liverpool University Hospital, Liverpool, GB, ²Clatterbridge Cancer Centre, Wirral, GB

12:00 - 12:00 **1306P - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor Pembrolizumab and Trastuzumab in preclinical models**

N. Maurea¹, V. Quagliariello², M. Passariello³, C. Coppola², D. Rea², A. Barbieri², C. De Lorenzo³, G. Monti⁴, M. De Laurentiis¹, P. Ascierto², G. Botti², ¹Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, ²Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ³ceinge, Napoli, IT, ⁴University Federico II, Napoli, IT

12:00 - 12:00 **1307P - Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases**

A. Yamagata, T. Yokoyama, Y. Fukuda, T. Ishida, Kurashiki Central Hospital, Kurashiki, JP

12:00 - 12:00 **1308TiP - A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy**

C. Annunziata¹, C. Dansky-Ullmann², A. Ghobadi³, D. Weng², J. Vanas², I. Ekwede¹, M. Pavelova⁴, R. Keefe², M. Kuo², R. Hassan¹, P. Thaker¹, ¹National Cancer Institute, Bethesda, US, ²MaxCyte Inc, Gaithersburg, US, ³Washington University School of Medicine, St. Louis, US, ⁴University of Maryland, Baltimore, College Park, US

12:00 - 12:00 **1309TiP - Trial in progress: First-in-human study of a novel anti-NY-ESO-1-anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-**

positive advanced solid tumors (IMCnyeso-101)

J. Lopez¹, R. Shinde¹, M. Burgess², T. Sato³, F. Thistlethwaite⁴, B. Van Tine⁵, J. Rodon⁶, J. Dukes⁷, R. Easton⁸, S. Marshall⁸, ¹The Royal Marsden Foundation Trust and The Institute of Cancer Research, London, GB, ²University of Pittsburgh, Pittsburgh, US, ³Jefferson College of Life Sciences, Philadelphia, US, ⁴The Christie NHS Foundation Trust, Manchester, GB, ⁵Washington University in St Louis, St Louis, US, ⁶The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁷Immunocore Ltd, Abingdon-on-Thames, GB, ⁸Immunocore, Conshohocken, US

12:00 - 12:00 **Head and neck cancer, excluding thyroid**

12:00 - 12:00 **1121P - Nimotuzumab-Cisplatin-Radiation versus Cisplatin-Radiation in HPV negative oropharyngeal cancer**

K. Prabhash¹, V. Patil², V. Noronha¹, A. Joshi¹, A. Bhattacharjee¹, V. Mathrudev¹, A. Bhelekar¹, K. Nawale¹, J.P. Agarwal¹, S. Ghosh-Laskar¹, A. Budrukkar³, A. Mahajan², A. Agarwal¹, N. Purandare¹, P. Chaturvedi¹, P. Pai¹, D. Chaukar¹, ¹Tata Memorial Hospital, Mumbai, IN, ²Tata Memorial Hospital Centre, Mumbai, IN, ³Tata Memorial Centre, Mumbai, IN

12:00 - 12:00 **1122P - Interim analysis of a single arm phase 2 study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy.**

T. Wise-Draper¹, S. Haque², A. Steele¹, S. Desai¹, T. Harris¹, M.K. Riaz¹, J. Morris¹, V. Takiar¹, M. Nagasaka³, R. Jandarov¹, A. Sukari⁴, ¹Cincinnati Hematology Oncology, Cincinnati, US, ²Merck, Riverside, US, ³Karmanos Cancer Institute, Detroit, US, ⁴Karmanos, Detroit, US

12:00 - 12:00 **1123P - A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in combination with Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN); A Result of Dose Escalation Cohort**

N. Ngamphaiboon¹, C. Jiarpinitnun¹, T. Siripoon², S. Lukerak¹, A. Jinawath³, N. Jinawath¹, L. Arsa¹, J. Konmun⁴, N. Kongsuphon¹, N. Sankaseam¹, E. Sirachainan⁴, P. Witoonpanich¹, A. Kositwattanarerk¹, P. Pattaranutaporn¹, ¹Ramathibodi Hospital, Pathumwan, TH, ²Ramathibodi Hospital, Mahidol University, Bangkok, TH, ³AstraZeneca Thailand, Bangkok, TH, ⁴Ramathibodi Hospital, Bangkok, TH

12:00 - 12:00 **1124P - Single cycle induction treatment with Cisplatin/Docetaxel plus Durvalumab/Tremelimumab in Stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial)**

M. Hecht¹, A.-O. Gostian², M. Eckstein¹, S. Rutzner², J. Von Der Grün³, T. Illmer⁴, M. Hautmann⁵, T. Brunner⁶, S. Laban⁷, G. Klautke⁸, B. Tamaskovics⁹, B. Frey², A. Hartmann¹, C. Rödel³, W. Budach⁹, U. Gaipl², H. Iro², R. Fietkau², ¹Universitätsklinik Erlangen, Erlangen, DE, ²University Hospital Erlangen, Erlangen, DE, ³University Hospital Frankfurt, Frankfurt, DE, ⁴Medical Oncology Clinic Dresden Freiberg, Dresden, DE, ⁵University Hospital Regensburg, Regensburg, DE, ⁶University Hospital Magdeburg, Magdeburg, DE, ⁷University Medical Center Ulm, Ulm, DE, ⁸Hospital Chemnitz,

Chemnitz, DE, ⁹University Hospital Düsseldorf, Düsseldorf, DE

- 12:00 - 12:00 **1125P - Radiotherapy plus cisplatin (CDDP) or cetuximab (C225) in human papilloma-virus (HPV)-associated oropharyngeal cancer (OPC)? A dilemma finally resolved. An updated meta-analysis.**
P. Suton¹, M. Skelin², I. Luksic³, ¹University Hospital for Tumors, University Hospital Center Sestre Milosrdnice, Zagreb, HR, ²OB General Hospital Sibenik, Sibenik, HR, ³University Hospital Dubrava, Zagreb, HR
- 12:00 - 12:00 **1126P - Treatment outcomes of head and neck cancer patients 70 years and older receiving different chemo-radiation combinations.**
M. Issa, L. Mousa, D. Blakaj, B. Klamer, J. Pan, M. Old, S. Kang, R. Rupert, D. Mitchell, E. Ozer, A. Agrawal, P. Bhateja, M. Gamez, E. Miller, S. Jhawar, R. Carrau, J. Rocco, M. Bonomi, The Ohio State University James Cancer Hospital, Columbus, US
- 12:00 - 12:00 **1127P - Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs**
J. Yu¹, C. Tsay¹, C. Sasaki², Y. Son², R. Decker¹, S. Mehra², B. Burtness¹, ¹Yale University School of Medicine, New Haven, US, ²Yale University School of Medicine and Section of Otolaryngology, New Haven, US
- 12:00 - 12:00 **1128P - Final results of a phase II study of induction chemotherapy (CT) with paclitaxel (PTX) and panitumumab (P) followed by radiotherapy (RT) and P in patients (pts) with locally advanced head and neck cancer (LAHNC) no candidates to platinum: study PANTERA**
J. Martinez Trufero¹, R. Mesia Nin², M. Ortega Izquierdo³, A. Lozano⁴, B. Cirauqui Cirauqui⁵, J. Rubió Casadevall⁶, M. Taberna Sanz⁷, M. Pastor Borgoñon⁸, J. Lambea Sorrosal⁹, L. Iglesias¹⁰, S. Vázquez⁷, E. Del Barco Morillo¹¹, P. Perez Segura¹², A. Lopez Pousa¹³, J. Ponce¹⁴, J. Cruz-Hernández¹⁵, ¹Hospital Miguel Servet, Zaragoza, ES, ²Institut Català d'Oncologia, Badalona, ES, ³Hospital Universitario Miguel Servet, Zaragoza, ES, ⁴Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ⁵Catalan Institute of Oncology (ICO)., Badalona, ES, ⁶University Hospital Josep Trueta, Girona, ES, ⁷Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, ONCOBELL, IDIBELL, L'Hospitalet Barcelona, ES, ⁸Hospital Universitario y Politecnico La Fe, Valencia, ES, ⁹Hospital Clínico Universitario de Zaragoza, Zaragoza, ES, ¹⁰University Hospital 12 de Octubre, Madrid, ES, ¹¹Instituto de Investigación Biomédica de Salamanca, Salamanca, ES, ¹²Hospital Clinico Universitario San Carlos, Madrid, ES, ¹³Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹⁴UCMORA Zaragoza, Zaragoza, ES, ¹⁵Hospital Universitario de Salamanca, Salamanca, ES
- 12:00 - 12:00 **1129P - Window of Opportunity for Durvalumab (MEDI4736) plus Metformin Trial in Squamous Cell Carcinoma of the Head and Neck (SCCHN): interim safety analysis**
T. Richa¹, J. Johnson², D. Cagnetti², A. Argiris³, A. Luginbuhl², R. Zinner², R. Axelrod², V. Bar-Ad², R. Goldman², U. Rodeck², U. Martinez-Outschoorn², J. Curry², ¹Thomas Jefferson Univ Hospital, Philadelphia, US, ²Thomas Jefferson University, Philadelphia, US, ³Hygeia Hospital, Athens, GR

- 12:00 - 12:00 **1130P - Severe Oral Mucositis (SOM) Mitigation by Genetically Modified Lactococcus Lactis Bacteria (LLB) Producing Human Trefoil Factor 1 (hTFF1; AG013) in Patients Being Treated With Concomitant Chemoradiation (CRT) for Oral and Oropharyngeal Cancers (OCOPC)**
S. Singh¹, S. Nuyts², R. Doline³, S. Satti⁴, M. Schwartz⁵, S. Thatcher⁶, Y. Chen⁷, S. Katz⁸, M. Garg⁹, J. Wagemans¹⁰, P. Specenier¹¹, C. Wittekindt¹², L. Lee¹³, J. Reifler¹⁴, S. Sonis¹⁵, M. Emanuel¹⁶, F. Cilli¹⁶, A. Joslyn¹⁷, J. Wade¹⁸, ¹Multicare Regional Cancer Center, Tacoma, US, ²University Hospital Leuven, Leuven, BE, ³CaroMont Health System, Gastonia, US, ⁴Ochsner Medical Center, New Orleans, US, ⁵Comprehensive Cancer Centers of Nevada-Henderson, Henderson, US, ⁶Cancer Care Northwest, Spokane Valley, US, ⁷University of Rochester Medical Center, Rochester, US, ⁸Willis-Knighton Cancer Center, Shreveport, US, ⁹Montifiore Medical Center, Bronx, US, ¹⁰St. Maarten General Hospital, Mechelen, BE, ¹¹University Hospital Antwerp, Edegem, BE, ¹²University Hospital Giessen, Giessen, DE, ¹³The Christie NHS Foundation Trust, Manchester, GB, ¹⁴PSI, Inc., King of Prussia, US, ¹⁵Primary Endpoint Solutions, Watertown, US, ¹⁶Oragenics, Tampa, US, ¹⁷Oragenics, Inc., Tampa, US, ¹⁸Decatur Memorial Hospital, Decatur, US
- 12:00 - 12:00 **1131P - Transcriptome signatures of treatment responses in a preoperative window of opportunity trial of nivolumab and tadalafil in resectable squamous cell carcinoma of the head and neck**
S. Shukla¹, J. Johnson¹, J. Curry¹, Y. Kim², A. Argiris³, A. Luginbuhl¹, L. Harshyne¹, U. Rodeck¹, ¹Thomas Jefferson University, Philadelphia, US, ²Vanderbilt University, Nashville, US, ³Hygeia Hospital, Athens, GR
- 12:00 - 12:00 **1132P - Risk and Impact of Renal Impairment of Locally Advanced Head and Neck Squamous Cell Carcinoma Patients Who Received Chemoradiotherapy with Cisplatin**
T. Patimarattananan¹, P. Pattaranutaporn², N. Unwanatham², C. Jiarpinitnun², A. Nongnuch², N. Ngamphaiboon², ¹Ramathibodi Hospital, Bangkok, TH, ²Ramathibodi Hospital, Pathumwan, TH
- 12:00 - 12:00 **1133P - Systemic bevacizumab for the treatment of recurrent respiratory papillomatosis: A retrospective analysis from an academic tertiary care center**
S. Trivedi¹, C. Steuer², A. Tkaczuk¹, D. Shin², A. Klein¹, N.F. Saba², ¹Emory University, Atlanta, US, ²Winship Cancer Institute of Emory University, Atlanta, US
- 12:00 - 12:00 **1134P - Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data.**
R. Cohen¹, G. Lefebvre², M. Posner³, J. Bauman⁴, S. Salas⁵, C. Even⁶, E. Saada-Bouزيد⁷, T. Seiwert⁸, D. Colevas⁹, F. Calmels¹⁰, R. Zerbib¹⁰, P. André¹⁰, A. Boyer-Chammard¹⁰, J. Fayette¹¹, ¹Abramson Cancer Center, Philadelphia, US, ²Centre Oscar Lambret, Lille, FR, ³Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US, ⁴Fox Chase Cancer Center, Philadelphia, US, ⁵Ap-hm, Marseille, FR, ⁶Institut Gustave Roussy, Villejuif, FR, ⁷Hopital Lacassagne, Nice, FR, ⁸The University of Chicago Medical Centre, Chicago, US, ⁹Stanford University Medical Center, Stanford, US, ¹⁰Innate Pharma, Marseille, FR, ¹¹Centre Léon Bérard, Lyon, FR

- 12:00 - 12:00 **1135P - Updated results of a phase II study evaluating accelerator-based boron neutron capture therapy (AB-BNCT) with borofalan(10B) (SPM-011) in recurrent squamous cell carcinoma (R-SCC-HN) and recurrent and locally advanced non-SCC (R/LA-nSCC-HN) of the head and neck**
K. Hirose¹, A. Konno², S. Yoshimoto³, K. Ono⁴, N. Otsuki⁵, J. Hatazawa⁶, J. Hiratsuka⁷, Y. Takai¹, ¹Southern Tohoku BNCT Research Center, Koriyama, JP, ²Southern Tohoku General Hospital, Koriyama, JP, ³National Cancer Center Hospital, Tokyo, JP, ⁴Osaka Medical College, Kansai BNCT Medical Center, Takatsuki, JP, ⁵Kobe University Graduate School of Medicine, Kobe, JP, ⁶Osaka University Graduate School of Medicine, Osaka, JP, ⁷Kawasaki Medical School, Kurashiki, JP
- 12:00 - 12:00 **1136P - Phase 3 KEYNOTE-048 Study of First-Line (1L) Pembrolizumab (P) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Asia vs Non-Asia Subgroup (subgrp) Analysis**
M. Tahara¹, R.-L. Hong², W.Z. Wan Ishak³, C.-J. Yen⁴, V. Sriuranpong⁵, S. Takahashi⁶, V. Srimuninnimit⁷, S.-P. Yeh⁸, N. Oridate⁹, M.-H. Yang¹⁰, K. Tanaka¹¹, N. Nohata¹², Y. Koh¹², A. Roy¹³, B. Gumuscu¹³, R. Swaby¹³, N. Ngamphaiboon¹⁴, ¹National Cancer Center Hospital East, Kashiwa, JP, ²National Taiwan University Hospital, Taipei, TW, ³University of Malaya, Kuala Lumpur, MY, ⁴National Cheng Kung University Hospital, Tainan, TW, ⁵Chulalongkorn University, Bangkok, TH, ⁶Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, JP, ⁷Siriraj Hospital, Mahidol University, Bangkok, TH, ⁸China Medical University Hospital, Taichung, TW, ⁹Yokohama City University Graduate School of Medicine, Yokohama, JP, ¹⁰Taipei Veterans General Hospital, Taipei, TW, ¹¹Kindai University Faculty of Medicine, Osaka-sayama, JP, ¹²MSD K.K, Tokyo, JP, ¹³Merck & Co., Inc., Kenilworth, US, ¹⁴Ramathibodi Hospital, Mahidol University, Bangkok, TH
- 12:00 - 12:00 **1137P - Integrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).**
J. Johnson¹, D. Cognetti¹, J. Curry¹, F. Mott², S. Kochuparambil³, D. McDonald³, M. Fidler⁴, N. Vasan⁵, M. Razaq⁵, M. Tahara⁶, M. Biel⁷, M. Tello⁷, M. Garcia-Guzman⁸, E. Sun⁸, A. Gillenwater², ¹Thomas Jefferson University, Philadelphia, US, ²University of Texas MD Anderson Cancer Center, Houston, US, ³Virginia Piper Cancer Institute, Minneapolis, US, ⁴Rush University Medical Center, Chicago, US, ⁵University of Oklahoma Health Sciences Center, Oklahoma City, US, ⁶National Cancer Center Hospital East, Kashiwa, JP, ⁷Rakuten Medical, San Mateo, US, ⁸Rakuten Medical, Inc., San Diego, US
- 12:00 - 12:00 **1138P - First line versus second line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck**
C. Even¹, N. Torossian², T. Ibrahim³, N. Martin⁴, L. Mayache Badis¹, F.R. Ferrand⁵, M. Iacob⁶, J. Guigay⁴, C. Le Tourneau², A. Daste⁷, E. Saada-Bouزيد⁸, K. Saleh¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Institut Curie, Paris, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR, ⁴Centre Anticancer Antoine Lacassagne, Nice, FR, ⁵Bégin Military Teaching Hospital, Saint-Mandé, FR, ⁶Gustave Roussy Cancer Center, Villejuif, FR, ⁷CHU Bordeaux Hopital St. André, Bordeaux, FR, ⁸Hopital Lacassagne, Nice, FR
- 12:00 - 12:00 **1139P - Sensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy**

T. Rampias¹, L. Hoxhallari², M. Avgeris³, Z. Kanaki², D. Telios⁴, E. Giotakis⁵, I. Giotakis⁴, A. Scorilas³, A. Psyrris⁶, A. Klinakis², ¹Biomedical research Foundation of the Academy of Athens (BRFAA), Athens, GR, ²Biomedical research Foundation of the Academy of Athens (BRFAA), papagou, athens, GR, ³National and Kapodistrian university of Athens, Ilisia, Athens, GR, ⁴National and Kapodistrian University of Athens, General Hospital "Attikon", Chaidari, GR, ⁵National and Kapodistrian University of Athens, University General Hospital "Hippocraton", Athens, GR, ⁶Attikon University Hospital, Athens, GR

12:00 - 12:00 **1140P - A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial with Nivolumab in Subjects with Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck.**

P. Bossi¹, M. Merlano², M.G. Ghi³, G. Rinaldi⁴, F. Caponigro⁵, F. Morelli⁶, M. Airoidi⁷, A. Farnesi⁸, A. Cassano⁹, D. Ferrari¹⁰, A. Mirabile¹¹, A. Tosoni¹², D. Galizia¹³, G. Moretti¹⁴, A.P. Sponghini¹⁵, G. Calareso¹⁶, A. Vingiani¹⁷, F. Perrone¹⁶, A. Falletta¹⁸, L. Licitra¹⁹, ¹Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT, ²Azienda Ospedaliera St. Croce e Carle, Cuneo, IT, ³Istituto Oncologico Veneto IRCCS, Padova, IT, ⁴Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, PALERMO, IT, ⁵Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁶Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT, ⁷AOU S. Giovanni Battista - Molinette, Torino, IT, ⁸Azienda Ospedaliera Universitaria S. Chiara, Pisa, IT, ⁹Policlinico Universitario A. Gemelli, Rome, IT, ¹⁰A. O. San Paolo, Milano, IT, ¹¹IRCCS Ospedale San Raffaele, Milan, IT, ¹²Ospedale Bellaria, Bologna, IT, ¹³Istituto di Candiolo - FPO - IRCCS, Candiolo, IT, ¹⁴AUSL-IRCCS, Reggio Emilia, reggio emilia, IT, ¹⁵Azienda Ospedaliera Universitaria Maggiore della Carità, Novara, IT, ¹⁶Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ¹⁷IEO- Istituto Europeo di Oncologia, milan, IT, ¹⁸AO S. Croce e Carle, Cuneo, Confreria - Cuneo, IT, ¹⁹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

12:00 - 12:00 **1141P - Long-term Results of Phase 2 Trial of Reduced Modified Clinical Target Volume in Low-risk Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy**

J. Miao¹, M. Di¹, Y. Cao², L. Wang¹, W. Xiao¹, M. Zhu¹, B. Chen¹, S. Huang¹, F. Han¹, X. Deng¹, Y. Xiang¹, M. Chua³, X. Guo¹, C. Zhao¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, CN, ³National Cancer Centre Singapore; Duke-NUS Medical School, Singapore, SG

12:00 - 12:00 **1142P - To compare two oral mucosa contouring methods in predicting acute oral mucocitis in nasopharyngeal carcinoma treated with helical tomotherapy**

Y.-Y. Chen¹, P.-J. Li², ¹Zhejiang Cancer Hospital, hangzhou, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN

12:00 - 12:00 **1143P - Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC)**

G. Kaval¹, M. Altun², K. Ibis², K. Ozkaya², R. Meral², A. Karadeniz², M. Sari³, M. Ekenel³, M. Basaran³, S. Bavbek³, ¹Istanbul University Institute of Oncology - Istanbul Universitesi Onkoloji Enstitüsü, Istanbul, TR, ²Istanbul University Institute Of Oncology,

Istanbul, TR, ³Istanbul University Institute of Oncology, Istanbul, TR

- 12:00 - 12:00 **1144P - Efficacy of different nutritional intervention on nutritional status and quality of life for local advanced nasopharyngeal carcinoma patients: a prospective clinical trial**
Y.-Y. Chen¹, S. Huang¹, X. Chen², Q. Hu², ¹Zhejiang cancer hospital, Hangzhou, CN, ²Zhejiang cancer hospital, Hangzhou, CN
- 12:00 - 12:00 **1145P - Apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma**
C. Tao¹, X. Chen², ¹Zhejiang cancer hospital, Hangzhou, CN, ²Zhejiang cancer hospital, Hangzhou, CN
- 12:00 - 12:00 **1146P - Impact of tumor site and adjuvant radiotherapy on survival of adenoid cystic carcinoma: a SEER database analysis**
J. Tasoulas¹, K. Divaris², S. Theocharis³, D. Farquhar², T. Hackman², A. Amelio², ¹University of Thessaly, Larissa, GR, ²University of North Carolina at Chapel Hill, Chapel Hill, US, ³National and Kapodistrian University of Athens, Athens, GR
- 12:00 - 12:00 **1147P - Efficacy and safety of anlotinib for patients with recurrent and/or metastatic salivary gland carcinomas**
W. Jiang, S. Dou, R. Li, L. Zhang, G. Zhu, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CN
- 12:00 - 12:00 **1148P - ACCURACY a phase (P) 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): preliminary safety and efficacy data.**
R. Ferrarotto¹, A. Ho², L. Wirth³, J. Muzaffar⁴, C. Rodriguez⁵, E. Dekel⁶, R. Walker⁶, C. Nadri-Shay⁶, A. Vergara-Silva⁶, ¹The University of Texas, Houston, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Massachusetts General Hospital Cancer Center, Harvard University, Boston, US, ⁴H. Lee Moffitt Cancer Center & Research Institute, Tampa, US, ⁵University of Washington School of Medicine, Seattle, US, ⁶Ayala Pharmaceuticals, Inc., Wilmington, US
- 12:00 - 12:00 **1149P - Pathologic Staging Changes in Oral Cavity Squamous Cell Carcinoma—Stage Migration and Implications for Adjuvant Treatment**
Z. Husain¹, N. Lee², A. Eskander¹, H. Park², S. Mehra², B. Burtness², ¹Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA, ²Yale University School of Medicine, New Haven, US
- 12:00 - 12:00 **1150P - Expression of immune response biomarkers in head and neck squamous cell carcinoma (HNSCC) in irradiated area**
C. Pflumio¹, J. Thomas², J. Salleron³, J.-C. Faivre³, C. Borel⁴, G. Dolivet³, X. Sastre-Garau³, L. Geoffrois¹, ¹Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, ²Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, FR, ³Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, FR, ⁴Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR

- 12:00 - 12:00 **1151P - HLA-Ligandome analysis reveals target antigens of oropharyngeal squamous cell carcinoma**
S. Laban¹, J. Eziç¹, L. Bichmann², D. Mytilineos¹, A. Fürstberger³, H. Kestler³, P. Schuler¹, T. Hoffmann¹, H.-G. Rammensee², S. Stevanovic², L. Mühlenbruch²,
¹University Medical Center Ulm, Ulm, DE, ²University of Tübingen, Tübingen, DE, ³Ulm University, Ulm, DE
- 12:00 - 12:00 **1152P - Topographical distribution of sentinel lymph nodes in early tongue squamous cell carcinomas**
H. Goda¹, K.-I. Nakashiro², D. Uchida², ¹Ehime University Graduate School of Medicine, Ehime, JP, ²Ehime University Graduate School of Medicine, Toon, JP
- 12:00 - 12:00 **1153P - Role of follow-up (FU) FDG-PET/CT (FU-FDG-PET/CT) in patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) treated with chemotherapy and radiotherapy (RT), either concurrent (CRT) or sequential (ST).**
B. Van Den Heuvel¹, C. Van Laer², P. Specenier³, ¹University of Antwerp, Antwerp, BE, ²University Hospital Antwerp, Edegem, BE, ³Antwerp University Hospital, Grimbergen, BE
- 12:00 - 12:00 **1154P - Expression of estrogen receptor and programmed cell death-ligand 1 can be complementary prognostic factors in HPV-positive oropharyngeal squamous cell carcinoma**
S. Kwon¹, E.S. Kim¹, S.-H. Ahn², W.-J. Jeong¹, Y.H. Jung¹, J.H. Paik¹, H. Kim², ¹Seoul National University Bundang Hospital, Seongnam, KR, ²Seoul National University Hospital, Seoul, KR
- 12:00 - 12:00 **1155P - Real-world data of clinicopathologic characteristics of young oropharyngeal cancer patients.**
M. Nieva¹, C. Fabregat², S. Tous², M. Mena², A. Teulé³, A. Lozano², X. León⁴, M. Guix⁵, T. Bonfill⁶, R. Mesia Nin⁷, L. Alemany², M. Taberna⁷, ¹ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ²Catalan Institute of Oncology (ICO Hospitalet), Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ³Institut Català d'Oncologia (ICO), Hospitalet de Llobregat, ES, ⁴Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁵Hospital del Mar, Barcelona, ES, ⁶Corporacio Sanitaria Parc Taul, Barcelona, ES, ⁷Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES
- 12:00 - 12:00 **1156P - The clinical significance and biological mechanisms of miR-499a in high-tobacco exposed head and neck squamous cell carcinoma**
S. Gong¹, M. Xu², M. Xiang³, Y. Shan³, H. Zhang³, ¹Ruijin Hospital of Shanghai, Shanghai, CN, ²the First Affiliated Hospital, Anhui Medical University, Hefei, CN, ³Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, CN
- 12:00 - 12:00 **1157P - Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic squamous cell carcinoma of the head and neck**

R. Galot¹, C. Van Marcke De Lummen², R. Helaers³, A. Mendola⁴, R.-M. Goebbels⁴, X. Caignet⁴, J. Ambroise⁴, K. Wittouck⁴, M. Vikkula³, N. Limaye³, J.-P. Machiels¹, ¹Cliniques Universitaires St. Luc, Brussels, BE, ²Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE, ³De Duve Institute, Université Catholique de Louvain, Brussels, BE, ⁴Université Catholique de Louvain, Bruxelles, BE

12:00 - 12:00 **1158P - Blood-based testing of mutations in patients with Head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology**

F. Fostira¹, P. Oikonomopoulou², A. Kladi³, D. Edelstein⁴, K. Stieler⁴, D. Heim⁴, M. Gkatzamanidou³, M. Anastasiou⁵, I. Kotsantis⁶, G. Kavourakis⁶, N. Gavrielatou⁶, E. Kousidou⁶, E. Vagia⁶, F. Holtrup⁴, A. Psyrri⁶, ¹NCSR Demokritos, athens, GR, ²Hellenic Cooperative Oncology Group (HeCOG), Athens, GR, ³Attikon, Athens, GR, ⁴Sysmex, Hamburg, DE, ⁵Hôpital du Valais (RSV), Sion, CH, ⁶Attikon University Hospital, Athens, GR

12:00 - 12:00 **1159P - The head and neck Lung Immune Prognostic Index (HN-LIPI): a prognostic Score for Immune Checkpoint Inhibitors (ICI) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) patients.**

R.G. Herrera Gomez¹, L. Mezquita², E. Auclin³, L. Heraudet⁴, M. Plana⁵, S. Salas⁶, V. Cristina⁷, A. Garcia Castano⁸, V. Arrazubi⁹, J. Grau¹⁰, K. Saleh¹¹, B. Cirauqui Cirauqui¹², R. Mesia Nin¹³, C. Even¹¹, M. Taberna¹³, A. Daste¹⁴, S. Peters⁷, B. Besse¹¹, N. Baste-Rotllan¹¹, ¹CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ²Gustave Roussy, Villejuif, FR, ³Hopital European George Pompidou, Paris, FR, ⁴Hôpital Saint-André, Bordeaux, FR, ⁵Institut Català d'Oncologia de Bellvitge, Barcelona, ES, ⁶Ap-hm, Marseille, FR, ⁷Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ⁸Hospital Universitario Marques de Valdecilla, Santander, ES, ⁹International Meetings S L, Barcelona, ES, ¹⁰Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹¹Institut Gustave Roussy, Villejuif, FR, ¹²Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, ¹³Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, ¹⁴CHU Bordeaux Hopital St. André, Bordeaux, FR

12:00 - 12:00 **1160P - Immune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI)**

N. Baste Rotllan¹, A. Auperin¹, M. Iacob², A. Sampetorean³, D. Bouguetta², L. Mayache Badis¹, F.R. Ferrand⁴, O. Casiraghi², P. Blanchard¹, F. Bidault⁵, P. Gorphe¹, S. Temam⁶, S. Champiat⁶, C. Even¹, A. Marabelle¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Gustave Roussy Cancer Center, Villejuif, FR, ³Oncology Institute, Cluj-Napoca, RO, ⁴Bégin Military Teaching Hospital, Saint-Mandé, FR, ⁵Gustave Roussy Institute, Villejuif, FR, ⁶Gustave Roussy, Villejuif, FR

12:00 - 12:00 **1161P - Intratumoral and peripheral exploratory biomarker analysis in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) treated with RM-1929 photoimmunotherapy**

J. Bui¹, N. Suslov², D. Yadav², J. Fong², E. Sun², M. Haedo², M. Garcia-Guzman², ¹University of California San Diego - UCSD, La Jolla, US, ²Rakuten Medical, Inc., San Diego, US

- 12:00 - 12:00 **1162P - A nomogram based prognostic score to predict overall survival (OS) in recurrent-metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with immune checkpoint inhibitors (ICI).**
L. Mousa, M. Issa, B. Klamer, J. Pan, M. Old, S. Kang, A. Agrawal, E. Ozer, R. Carrau, P. Bhateja, R. Rupert, S. Jhawar, D. Mitchell, M. Gamez, J. Rocco, D. Blakaj, M. Bonomi, The Ohio State University James Cancer Hospital, Columbus, US
- 12:00 - 12:00 **1163P - Changes of the Commensal Microbiome during Treatment are Associated with Clinical Response in the Nasopharyngeal Carcinoma Patients**
T. Huang¹, J. Debelius¹, A. Ploner¹, X. Xiao², T. Zhang², K. Hu², Z. Zhang², R. Wang², W. Ye¹, ¹Karolinska Institute, Stockholm, SE, ²Guangxi Medical University First Affiliated Hospital, Nanning, CN
- 12:00 - 12:00 **1164P - Development and validation a nomogram based on pathological microscopic features to predict survival in nasopharyngeal carcinoma and guide treatment decision**
K. Liu¹, X. Lv², X. Guo¹, Y. Li¹, C. Li¹, H. Cheng³, M. Qiang¹, X. Chen¹, T. Zhang¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Sun Yat-sen University Cancer Center, 广州市, CN, ³Chenzhou NO.1 People's Hospital, Chenzhou, CN
- 12:00 - 12:00 **1165P - Deep learning in nasopharyngeal carcinoma: a retrospective cohort study of 3D convolutional neural networks on magnetic resonance imaging**
M.Y. Qiang, X. Lv, C.F. Li, K.Y. Liu, X. Chen, X. Guo, Sun Yat-sen University Cancer Center, Guangzhou, CN
- 12:00 - 12:00 **1166P - Combined androgen blockade in patients with advanced androgen receptor-positive salivary gland carcinoma: Exploratory biomarker analyses**
C. Fushimi¹, D. Kawakita², H. Takahashi¹, T. Nagao³, H. Hirai³, N. Saigusa³, T. Masubuchi¹, T. Matsuki¹, T. Okada¹, D. Baba¹, K. Miura¹, T. Saotome⁴, Y. Tada¹, ¹International University of Health and Welfare Mita Hospital, Tokyo, JP, ²Nagoya City University Graduate School of Medical Sciences, Nagoya, JP, ³Tokyo Medical University School of Medicine, Tokyo, JP, ⁴Matsudo City General Hospital, Matsudo, JP
- 12:00 - 12:00 **1167P - Classification of esthesioneuroblastoma (ENB) based on chromosome (chr) arm gain and loss (CNA) in the setting of a hypomutated genomic landscape**
R. Madison¹, D. Pavlick¹, J. Johnson², S. Khan³, J. Lee¹, J. Ross¹, V. Miller¹, B. Alexander¹, J. Chung¹, A. Schrock¹, S. Ali¹, ¹Foundation Medicine, Cambridge, US, ²Thomas Jefferson University, Philadelphia, US, ³UT Southwestern Medical center, Dallas, US
- 12:00 - 12:00 **1168P - Trastuzumab plus docetaxel in patients with advanced HER2-positive salivary duct carcinoma: Exploratory biomarker analyses**
H. Takahashi¹, D. Kawakita², C. Fushimi¹, T. Nagao³, H. Hirai³, N. Saigusa³, T. Masubuchi¹, T. Matsuki¹, T. Okada¹, D. Baba¹, K. Miura¹, T. Saotome⁴, Y. Tada¹, ¹International University of Health and Welfare Mita Hospital, Tokyo, JP, ²Nagoya City University Graduate School of Medical Sciences, Nagoya, JP, ³Tokyo Medical University School of Medicine, Tokyo, JP, ⁴Matsudo City General Hospital, Matsudo, JP

- 12:00 - 12:00 **1169P - Development and characterization of salivary gland cancer organoid cultures**
W. Boxtel¹, T. Aalders², G. Lassche¹, I. Van Engen - Van Grunsven¹, G. Verhaegh², C. Van Herpen¹, J. Schalken¹, ¹Radboud University Medical Center, Nijmegen, NL, ²Radboud university medical center, Nijmegen, NL
- 12:00 - 12:00 **1170P - A parent-of-origin effect of the RB1 mutations in retinoblastoma with low penetrance and variable expressivity**
E. Alekseeva¹, O. Babenko¹, V. Kozlova², T. Ushakova², T. Kazubskaya², S. Sahakyan³, A. Tanas⁴, D. Zaletaev⁵, V. Strelnikov¹, ¹Research Centre for Medical Genetics, Moscow, RU, ²Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology» of the Ministry of Health of the Russian Federation, Moscow, RU, ³Federal State Budgetary Institution «Helmholtz Moscow Research Institute of Eye Diseases», Moscow, RU, ⁴Federal State Budgetary Institution "Research Centre for Medical Genetics", Moscow, RU, ⁵Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, RU
- 12:00 - 12:00 **1171P - The humanistic burden reported by patients diagnosed with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) in Europe**
P. Singh¹, B. Bennett², T. Bailey³, G. Taylor-Stokes⁴, L. Hennessy⁵, I. Rajkovic⁵, M. Contente⁶, ¹Bristol Myers Squibb, Lawrence, US, ²Adelphi Values, Cheshire, GB, ³Adelphi, Macclesfield, GB, ⁴Adelphi Real World, Bollington, GB, ⁵Adelphi Real World, Macclesfield, GB, ⁶Bristol-Myers Squibb, Ladeuze, BE
- 12:00 - 12:00 **1172TiP - Concurrent Chemotherapy and External Radiation Therapy: An Open Label Non-Inferiority Phase III Randomized Controlled Trial of Weekly versus Three Weekly Cisplatin and Radical Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: CONCERT trial**
A. Sharma¹, M. Chaudhary², A. Thakar¹, S. Bhaskar³, K. Sikka¹, R. Pramanik¹, A. Biswas¹, C. Singh¹, R. Sahoo⁴, S. Deo⁵, R. Kumar¹, S. Thulkar¹, A. Kakkar¹, S. Seth¹, V. Sreenivas⁴, ¹All India Institute of Medical Sciences, Delhi, IN, ²Army Hospital, New Delhi, IN, ³B.R. Ambedkar Institute Rotary Cancer Hospital (AIIMS), Delhi, IN, ⁴B.R. Ambedkar Institute Rotary Cancer Hospital (AIMS), New Delhi, IN, ⁵All India Institute of Medical Sciences, New Delhi, IN
- 12:00 - 12:00 **1173TiP - A randomized phase II study on the OPTimization of IMMunotherapy in squamous carcinoma of the head and neck (SCCHN) - OPTIM (AIO-KHT-0117)**
V. Grünwald¹, D. Hahn², J. Alt³, G. Schuch⁴, P. Ivanyi⁵, ¹University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ²Klinikum Stuttgart - Katharinenhospital Klinik f. Onkologie, Stuttgart, DE, ³Universitätsmedizin Mainz, Mainz, DE, ⁴Hämatologisch-Onkologische Praxis Altona (HOPA), Hamburg, DE, ⁵Hannover Medical School, Hannover, DE
- 12:00 - 12:00 **Genitourinary tumours, prostate**
- 12:00 - 12:00 **852P - Overall Survival (OS) and Metastasis-Free Survival (MFS) in men with**

Biochemically Relapsed (BCR) Prostate Cancer after radical prostatectomy (RP) managed with deferred Androgen Deprivation Treatment (ADT): A combined Johns Hopkins and CPDR study

C. Marshall¹, Y. Chen², J. Cullen³, I. Rosner², M. Markowski¹, B. Trock¹, M. Eisenberger¹, ¹Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US, ²Center for Prostate Disease Research, USUHS, Bethesda, US, ³Center for Prostate Disease Center, Rockville, US

12:00 - 12:00

853P - ARCHES - the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups

A. Stenzl¹, R. Szmulewitz², D. Petrylak³, J. Holzbeierlein⁴, A. Villers⁵, A. Azad⁶, A. Alcaraz⁷, B. Alekseev⁸, T. Iguchi⁹, N. Shore¹⁰, B. Rosbrook¹¹, B. Baron¹², G. Haas¹³, R. Morlock¹³, K. Ramaswamy¹⁴, A. Armstrong¹⁵, ¹Eberhard Karls University, Tübingen, DE, ²The University of Chicago Medical Centre, Chicago, US, ³Yale Cancer Center, New Haven, US, ⁴The University of Kansas Medical Center, Kansas City, US, ⁵University Hospital Centre, Lille University, Lille, FR, ⁶Monash Medical Centre, Clayton, AU, ⁷Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁸Hertzen Cancer Research Institute, Moscow, RU, ⁹saka City University Graduate School of Medicine, Osaka, JP, ¹⁰Carolina Urologic Research Center, Myrtle Beach, US, ¹¹Pfizer Inc., San Diego, US, ¹²Astellas, Leiden, NL, ¹³Astellas Pharma USA, Northbrook, US, ¹⁴Pfizer Inc - USA, New York, US, ¹⁵Duke University, Durham, US

12:00 - 12:00

854P - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study).

O. Caffo¹, E. Palesandro², F. Nole³, D. Gasparro⁴, C. Mucciarini⁵, M. Aieta⁶, V. Zagonel⁷, R. Iacovelli⁸, U. De Giorgi⁹, S. Rossetti¹⁰, L. Fratino¹¹, P. Ermacora¹², M. Nicodemo¹³, M. Giordano¹⁴, D. Sartori¹⁵, D. Scapoli¹⁶, E. Verri³, F. Maines¹, G. Pappagallo¹⁷, M. Aglietta¹⁸, ¹Ospedale Santa Chiara, Trento, IT, ²IRCCS Candiolo, Candiolo, IT, ³Istituto Europeo di Oncologia, Milan, IT, ⁴AOU di Parma, Parma, IT, ⁵Ospedale Ramazzini, Carpi, IT, ⁶Centro di Riferimento Oncologico Basilicata IRCCS, Rionero in Vulture, IT, ⁷Istituto Oncologico Veneto IRCCS, Padova, IT, ⁸Fondazione Policlinico Agostino Gemelli, Rome, IT, ⁹Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ¹⁰Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ¹¹Centro di Riferimento Oncologico - CRO, Aviano, IT, ¹²AOU Udine, na, IT, ¹³Negrar Cancer Center, Negrar, IT, ¹⁴Presidio Ospedaliero Ospedale Sant'Anna, San Fermo della Battaglia, IT, ¹⁵Ospedale Civile di Dolo, Dolo, IT, ¹⁶Azienda Ospedaliera di Ferrara St. Anna, Ferrara, IT, ¹⁷Unita Locale Socio Sanitaria 13 P.O Mirano, Mirano, IT, ¹⁸Istituto di Candiolo - FPO - IRCCS, Candiolo, IT

12:00 - 12:00

855P - Deferred androgen deprivation treatment (ADT) versus early ADT in men with bone metastasis (BM) following biochemically relapsed prostate cancer (BCRP)

J. Cullen¹, Y. Chen², C. Kuo³, S. Streicher², G. Conti², I. Rosner², J. Forsberg⁴, ¹Center for Prostate Disease Center, Rockville, US, ²Center for Prostate Disease Research, USUHS, Bethesda, US, ³Center for Prostate Disease Center, Bethesda, US, ⁴USU, Bethesda, US

- 12:00 - 12:00 **856P - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence**
A. Morgans¹, H. Divan², A. Birtle³, T. Dorff⁴, A. Ozatilgan⁵, J. Graff⁶, ¹Northwestern University Feinberg School of Medicine, Chicago, US, ²Real World Evidence Generation, Cambridge, US, ³Royal Preston Hospital-Lancashire Teaching Hospitals NHS Foundation Trust, Preston, GB, ⁴City of Hope National Medical Center, Duarte, US, ⁵Sanofi-Genzyme Center - USA, Cambridge, US, ⁶OHSU Knight Cancer Institute, Portland, US
- 12:00 - 12:00 **857P - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial**
J. Brown¹, C. Handforth¹, J. Walsh², C. Pezaro³, M. Sydes⁴, N. Clarke⁵, N. James⁶, E. McCloskey³, ¹Weston Park Hospital Cancer Research Centre, Sheffield, GB, ²University of Leeds, Sheffield, GB, ³University of Sheffield, Sheffield, GB, ⁴MRC Clinical Trials Unit at UCL, London, GB, ⁵The Christie and Salford Royal Hospitals, Manchester, GB, ⁶Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, Birmingham, GB
- 12:00 - 12:00 **858P - Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents - a meta-analysis of randomized controlled trials.**
R. Coutinho Mariano¹, L. Gomes¹, C. Oliveira¹, A. Galdino², J.A. Araújo¹, D. Vargas², F. Maluf¹, G.A. De Velasco Oria De Rueda³, F.A. Schutz⁴, ¹Hospital Beneficencia Portuguesa of Sao Paulo, Sao Paulo, BR, ²BP - A Beneficência Portuguesa de São Paulo, Sao Paulo, BR, ³University Hospital 12 De Octubre, Madrid, ES, ⁴Sirio Libanes Hospital, Sao Paulo, BR
- 12:00 - 12:00 **859P - Pain progression at initiation of chemotherapy in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA**
N. Delanoy¹, D. Robbrecht², K. Fizazi³, F. Mercier⁴, O. Sartor⁵, R. De Wit⁶, S. Oudard¹, ¹Hopital European George Pompidou, Paris, FR, ²Erasmus MC Cancer Institute, Rotterdam, NL, ³Institut Gustave Roussy, Villejuif, FR, ⁴Stat process, Paris, FR, ⁵Tulane University, New Orleans, US, ⁶Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL
- 12:00 - 12:00 **860P - Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study**
H. Palmedo¹, S. Eschmann², A. Werner³, I. Selinski⁴, M.-O. Möllers⁵, J. Kalinovsky⁶, A. Benson⁷, T. Poeppel⁸, ¹Institute of Radiology and Nuclear Medicine, Bonn, DE, ²Marienhospital, Stuttgart, DE, ³Radiologie Schwetzingen, Schwetzingen, DE, ⁴Goethe-University Hospital Frankfurt, Frankfurt, DE, ⁵Klinikum Westfalen, Dortmund, DE, ⁶Bayer Consumer Care Switzerland, Basel, CH, ⁷Bayer Corporation Pharmaceutical, Burlington, US, ⁸University Hospital Essen, Essen, DE
- 12:00 - 12:00 **861P - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders**
V. Conteduca¹, O. Caffo², E. Scarpi¹, P. Sepe³, L. Galli⁴, L. Fratino⁵, F. Maines², V.

Chiuri⁶, M. Santoni⁷, E. Zanardi⁸, F. Massari⁹, I. Toma¹⁰, G. Schepisi¹, A. Sbrana⁴, S. Kinspergher¹¹, M.C. Cursano¹², C. Modonesi¹³, D. Santini¹², G. Procopio¹⁴, U. De Giorgi¹, ¹Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ²Ospedale Santa Chiara, Trento, IT, ³Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, IT, ⁴Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT, ⁵Centro di Riferimento Oncologico - CRO, Aviano, IT, ⁶Ospedale Vito Fazzi, Lecce, IT, ⁷AOU Ospedali Riuniti Ancona, Torrette di Ancona, IT, ⁸IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ⁹AOU Policlinico S. Orsola-Malpighi, Bologna, IT, ¹⁰Arcispedale Sant'Anna University Hospital, Ferrara, IT, ¹¹AOU Integrata Verona "Borgo Roma", Verona, IT, ¹²Policlinico Universitario Campus Bio-Medico, Rome, IT, ¹³Ospedale di Monselice, Monselice, IT, ¹⁴Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

12:00 - 12:00 **862P - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE**

H. Mintz¹, C. Amos², R. Brannan³, C. Brawley², J. Calvert², M. Gannon⁴, L. Hounsome³, F. Ingleby², S. Mcphail³, M. Parmar², H. Parsons¹, P. Patel⁵, M. Rauchenberger², M. Sydes², H. Wu⁶, N. James⁷, ¹University of Warwick, Coventry, GB, ²MRC Clinical Trials Unit at UCL, London, GB, ³Public Health England, London, GB, ⁴London School of Hygiene and Tropical Medicine, London, GB, ⁵University Hospital Birmingham NHS Foundation Trust, Birmingham, GB, ⁶University College London, London, GB, ⁷Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, Birmingham, GB

12:00 - 12:00 **863P - Cabazitaxel For Octogenarian Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC).**

P. Tralongo¹, S. Bordonaro², G. Di Lorenzo³, N. Borsellino⁴, G. Facchini⁵, S. Rossetti³, V. Martelli⁶, V. Longo⁷, A.C. Tralongo⁸, F. Caspani⁹, A. Tuzi¹⁰, M. Spada¹¹, N. Calvani¹², P. Carlini¹³, U. De Giorgi¹⁴, ¹Ospedale G. Di Maria, Avola, IT, ²Azienda Ospedaliera Umberto I (Siracusa), Siracusa, IT, ³Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ⁴Ospedali Buccheri la Ferla, Palermo, IT, ⁵Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁶IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ⁷Istituto Tumori Giovanni Paolo II, Bari, IT, ⁸University of Insubria-Ospedale del Circolo, Varese, IT, ⁹University of Pavia-Ospedale del Circolo, Varese, IT, ¹⁰ASST - Sette Laghi, Varese, IT, ¹¹Fondazione Istituto San Raffaele - G. Giglio di Cefalù, Cefalù, IT, ¹²Ospedale A. Perrino, Brindisi, IT, ¹³Istituto Nazionale Tumori Regina Elena, Rome, IT, ¹⁴Istituto Tumori della Romagna I.R.S.T., Meldola, IT

12:00 - 12:00 **864P - External Validation of a Prognostic Score in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)**

D. Lorente¹, R. Lozano Mejorada², G.A. De Velasco Oria De Rueda³, A. Sanchez Hernandez⁴, M. Rodrigo Aliaga⁵, Á. Sánchez Iglesias⁶, M. De Julián Campayo⁶, F. Lopez Campos⁷, N. Romero Laorden⁸, E. Castro⁹, D. Olmos Hidalgo⁹, ¹The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ²Hospital Universitario de Salamanca, Salamanca, ES, ³University Hospital 12 De Octubre, Madrid, ES, ⁴Hospital Provincial Castellon, Castellón, ES, ⁵Hospital General de Castellón, Castellón de la Plana,

ES, ⁶Hospital Provincial de Castellón, Castellón de la Plana, ES, ⁷Hospital Universitario Ramon y Cajal, Madrid, ES, ⁸CNIO - Centro Nacional de Investigaciones Oncológicas, Madrid, ES, ⁹CNIO- Spanish National Cancer Center, Madrid, ES

- 12:00 - 12:00 **865P - Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: results from the Dutch CAPRI-registry**
- J. Notohardjo¹, M. Kuppen², H. Westgeest³, A.J.M. Van Den Eertwegh⁴, J. Van Moorselaar¹, N. Mehra⁵, J.L. Coenen⁶, I. Van Oort⁷, A. Van Den Bergh⁸, K. Aben⁹, D.M. Somford¹⁰, R. De Wit¹¹, A.M. Bergman¹², L. Lavalaye¹³, C. Uyl-De Groot¹⁴, W. Gerritsen⁵, ¹Vrije University Medical Centre (VUMC), Amsterdam, NL, ²Erasmus School of Health Policy and Management, Rotterdam, NL, ³Amphia Ziekenhuis-location Langendijk, Breda, NL, ⁴Amsterdam UMC, Vrije Universiteit, Amsterdam, NL, ⁵Radboud University Medical Center, Nijmegen, NL, ⁶Isala ziekenhuis, Zwolle, NL, ⁷Radboudumc, Nijmegen, NL, ⁸University Medical Center Groningen, University of Groningen, Groningen, NL, ⁹Netherlands Comprehensive Cancer Organization, Nijmegen, NL, ¹⁰Canisius Wilhemina Ziekenhuis, Nijmegen, NL, ¹¹Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ¹²The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ¹³St Antonius Hospital, Nieuwegein, NL, ¹⁴Institute for Medical Technology Assessment, Erasmus University, Rotterdam, NL
- 12:00 - 12:00 **866P - Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: a propensity score matching analysis from SEER database**
- J. Chen¹, Z. Wang¹, J. Zhao¹, S. Zhu¹, G. Sun¹, J. Liu¹, H. Zhang¹, X. Zhang¹, P. Shen², H. Zeng¹, ¹West China Hospital, Sichuan University, Chengdu, CN, ²West China Hospital, Chengdu, CN
- 12:00 - 12:00 **867P - Multi-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT**
- M. Guibert-Broudic¹, T. Dubergé², A. Autret³, P. Carrier⁴, N. Salem³, J. Walz⁵, I. Brenot-Rossi³, G. Gravis⁵, ¹Institut Paoli-Calmettes, Marseille, FR, ²Croix-Rouge Française, TOULON, FR, ³Institut Paoli-Calmettes, MARSEILLE, FR, ⁴Centre hospitalier Toulon - La Seyne, TOULON, FR, ⁵Institute Paoli Calmettes, Marseille, FR
- 12:00 - 12:00 **868P - Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): a network meta-analysis of randomized controlled trials (RCT)**
- A. Altavilla¹, M. Di Maio², M. Tucci³, C. Lolli¹, G. Schepisi¹, C. Buttigliero³, F. Vignani⁴, U. De Giorgi⁵, ¹Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ²Università degli Studi di Torino, Torino, IT, ³Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT, ⁴University of Turin, Ordine Mauriziano Hospital, Turin, IT, ⁵University Clinic Meloda, Meloda, IT
- 12:00 - 12:00 **869P - Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): results from the Dutch CAPRI registry**
- M. Kuppen¹, H. Westgeest², A.J.M. Van Den Eertwegh³, J. Van Moorselaar⁴, N. Mehra⁵, J.L. Coenen⁶, I. Van Oort⁷, A.C.M. Van Den Bergh⁸, J. Lavalaye⁹, K. Aben¹⁰, D.M.

Somford¹¹, R. De Wit¹², A.M. Bergman¹³, C. Uyl-De Groot¹⁴, W. Gerritsen¹⁵, ¹Erasmus School of Health Policy and Management, Rotterdam, NL, ²Amphia Ziekenhuis-location Langendijk, Breda, NL, ³Amsterdam UMC, Vrije Universiteit, Amsterdam, NL, ⁴Vrije University Medical Centre (VUMC), Amsterdam, NL, ⁵Radboud University Medical Center, Nijmegen, NL, ⁶Isala ziekenhuis, Zwolle, NL, ⁷Radboudumc, Nijmegen, NL, ⁸University Medical Center Groningen, Groningen, NL, ⁹St. Antonius Hospital, Nieuwegein, NL, ¹⁰Netherlands Comprehensive Cancer Organization, Nijmegen, NL, ¹¹Canisius Wilhemina Ziekenhuis, Nijmegen, NL, ¹²Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ¹³The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ¹⁴Institute for Medical Technology Assessment, Erasmus University, Rotterdam, NL, ¹⁵Radboud University Medical Centre Nijmegen, Nijmegen, NL

12:00 - 12:00 **870P - A phase 2a study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)**

D. Petrylak¹, U. Vaishampayan², K.R. Patel³, C. Higano⁴, C. Albany⁵, N.A. Dawson⁶, B.A. Mehlhaff⁷, D.I. Quinn⁸, L. Nordquist⁹, V. Wagner¹⁰, J. Shen¹¹, L. Trandafir¹², O. Sartor¹³, ¹Yale Cancer Center, New Haven, US, ²Karmanos Cancer Institute, Detroit, US, ³Urology, Tucson, US, ⁴University of Washington Seattle Cancer Care Alliance, Seattle, US, ⁵Indiana University, Indianapolis, US, ⁶Georgetown University, Washington D.C., US, ⁷Oregon Urology Institute, Springfield, US, ⁸University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, ⁹Urology Cancer Center and GU Research Network, Omaha, US, ¹⁰Bayer Consumer Care AG, Basel, CH, ¹¹Bayer Corporation Pharmaceutical, Lexington, US, ¹²Bayer Consumer Care Switzerland, Basel, CH, ¹³Tulane University, New Orleans, US

12:00 - 12:00 **871P - Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival**

C. Mercier¹, C. Billiet², M. Strijbos³, T. Van Den Mooter³, F. Vandaele², I. Joye², A. Buys⁴, C. Rypens¹, S. Oeyen⁵, S. Van Laere⁶, P. Vermeulen⁵, P. Dirix², ¹GZA Hospital Sint-Augustinus, Antwerpen, BE, ²Iridium Kankernetwerk, Wilrijk, BE, ³GZA Ziekenhuizen Sint Augustinus, Antwerp, BE, ⁴GZA Ziekenhuizen, Antwerpen, BE, ⁵University of Antwerp, Antwerpen, BE, ⁶University of Antwerp, Antwerp, BE

12:00 - 12:00 **872P - Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA**

R. Tauber¹, B. Feuerecker², K. Knorr², A. Beheshti², C. Seidl², C. D'Alessandria², F. Bruchertseifer³, M. Retz⁴, J.E. Gschwend⁵, W. Weber², A. Morgenstern³, M. Eiber², ¹Klinikum rechts der Isar TUM, Muenchen, DE, ²Klinikum rechts der Isar, Technical University Munich, Munich, DE, ³European Commission, Joint Research Centre, Karlsruhe, Eggenstein-Leopoldshafen, DE, ⁴Klinikum rechts der Isar, Technical University Munich, Muenchen, DE, ⁵Universitätsklinikum rechts der Isar, TUH München, Munich, DE

12:00 - 12:00 **873P - Phase II trial of SM 88 in Non-Metastatic Biochemical Recurrent Prostate Cancer.**

B. Gartrell¹, G. Del Priore², A. Retter³, W.-T. Chen⁴, G. Sokol⁵, A. Vandell⁶, M. Roach⁷, H.

Scher⁸, ¹Montefiore Medical Center, New York, US, ²Tyme Inc, New York, US, ³Eastchester Cancer Care Center, New York, US, ⁴Vitatex, Stony Brook, US, ⁵Uniformed Services University of the Health Sciences, Bethesda, US, ⁶Tyme Inc., New York, US, ⁷UCSF, San Francisco, US, ⁸Memorial Sloan-Kettering Cancer Center, New York, US

12:00 - 12:00

874P - A phase 1 study of Ad5 PSA/MUC-1/Brachyury Vaccine in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

M. Bilusic¹, R. Madan², F. Karzai², S. McMahon², R. Donahue², J. Strauss², M. Gatti-Mays², J. Redman², L. Cordes², C. Palena², E. Gabitzsch³, F. Jones³, J. Balint³, P. Soon-Shiong⁴, S. Rabizadeh⁴, M. Policard², J. Schlom⁵, J. Gulley², ¹Center for cancer research, Bethesda, US, ²Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, US, ³Etubics Corporation, Seattle, US, ⁴NantCell, Culver City, US, ⁵Center for Cancer Research, National Cancer Institute, Bethesda, US

12:00 - 12:00

875P - Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer

D. Mcneel¹, B. Saraiya², M. Schweizer³, J. Eickhoff¹, E. Wargowski¹, R. Lesniewski⁴, B. Olson⁵, C. Kyriakopoulos¹, ¹University of Wisconsin-Madison, Madison, US, ²Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, US, ³Seattle Cancer Care Alliance, Seattle, US, ⁴Madison Vaccines, Inc, Madison, US, ⁵Emory University, Atlanta, US

12:00 - 12:00

876P - Impact of germline mutations in Homologous Recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)

E. Castro¹, R. Lozano Mejorada², M. Saez³, U. De Giorgi⁴, I. Aragón⁵, N. Romero Laorden⁶, G.A. De Velasco Oria De Rueda⁷, L. Magraner⁸, M.I. Pacheco⁸, J. Puente⁹, A. González Del Alba¹⁰, P. Borrega Garcia¹¹, V. Conteduca⁴, J.C. Villa Guzman¹², E. Fernandez Parra¹³, A. Rodriguez-Vida¹⁴, A. Medina Colmenero¹⁵, R. Morales Barrera¹⁶, D. Lorente¹⁷, D. Olmos Hidalgo¹, ¹CNIO- Spanish National Cancer Center, Madrid, ES, ²Hospital Universitario de Salamanca, Salamanca, ES, ³Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga, ES, ⁴Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ⁵Instituto de Investigación Biomédica de Málaga (IBIMA) and Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Malaga, ES, ⁶CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, ES, ⁷University Hospital 12 De Octubre, Madrid, ES, ⁸Spanish National Cancer Research Centre (CNIO), Madrid, ES, ⁹Hospital Clinico Universitario San Carlos, Madrid, ES, ¹⁰Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES, ¹¹Hospital San Pedro De Alcantara, Carceres, ES, ¹²Hospital General Ciudad Real, Ciudad Real, ES, ¹³Hospital Universitario Virgen de Valme, Sevilla, ES, ¹⁴Hospital del Mar, Barcelona, ES, ¹⁵Fundacion Centro Oncologico de Galicia, A Coruna, ES, ¹⁶Vall d'Hebron University Hospital, Barcelona, ES, ¹⁷Hospital Provincial de Castellón, Castellón, ES

12:00 - 12:00

877P - Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with Radium-223 (Ra223): Results from a prospective multicentre study

N. Romero Laorden¹, R. Lozano Mejorada², A. Hernández Jorge³, N. Lainez⁴, E. Almagro

Casado⁵, O. Fernández Calvo⁶, S. Hernando⁷, A. Fernández Freire⁸, E. Gonzalez Billalabeitia⁹, I. Chirivella¹⁰, R. García Domínguez², U. Anido Herranz¹¹, F. Vazquez Mazon¹², S. Ros¹³, A. Montesa¹⁴, G.A. De Velasco Oria De Rueda¹⁵, R. Morales Barrera¹⁶, D. Lorente¹⁷, E. Castro¹⁸, D. Olmos Hidalgo¹⁸, ¹CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, ES, ²Hospital Universitario de Salamanca, Salamanca, ES, ³Hospital Universitario Virgen del Rocío, Sevilla, ES, ⁴Complejo Hospitalario de Navarra - Royal Navarre Hospital, Pamplona, ES, ⁵Hospital Universitario Quirón Salud, Madrid, ES, ⁶Complejo Hospitalario de Orense, Ourense, ES, ⁷Fundación Hospital Alcorcón, Madrid, ES, ⁸Hospital Universitario Torrecádenas, Almería, ES, ⁹Hospital Universitario Morales Meseguer, Murcia, ES, ¹⁰Hospital Clínico Universitario de Valencia, Valencia, ES, ¹¹Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, ES, ¹²Hospital General Universitario de Elche, Elche, ES, ¹³Hospital Universitario Virgen de la Arrixaca, Murcia, ES, ¹⁴Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga, ES, ¹⁵University Hospital 12 De Octubre, Madrid, ES, ¹⁶Vall d'Hebron University Hospital, Barcelona, ES, ¹⁷Hospital Provincial de Castellón, Castellón, ES, ¹⁸CNIO- Spanish National Cancer Center, Madrid, ES

12:00 - 12:00 **878P - Prognostic value of tumor suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer**

M. Gonzalez Velez¹, H. Kosiorek¹, J. Egan², A. Bryce³, ¹Mayo Clinic Cancer Center, Phoenix, US, ²Mayo Clinic, Rochester, US, ³Mayo Clinic, Phoenix, US

12:00 - 12:00 **879P - Germline sequencing of advanced prostate cancer patients in the BARCODE2 trial**

S. Benafif¹, R. Rageevakumar², I. Whitmore², C. Cieza-Borrella², E. Saunders², Z. Kote-Jarai², R. Eeles¹, ¹Royal Marsden Hospital Institute of Cancer Research, Sutton, GB, ²Institute of Cancer Research, Sutton, GB

12:00 - 12:00 **880P - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): data from the prospective PROREPAIR-B study.**

C. Cattrini¹, N. Romero Laorden², E. Castro³, I. García-Carbonero⁴, J. Piulats⁵, J. Puente⁶, B. P. Valderrama⁷, J.C. Villa Guzman⁸, E. Gonzalez Billalabeitia⁹, R. Morales Barrera¹⁰, R. Lozano Mejorada¹¹, R. Luque¹², E. Martinez Ortega¹³, J. Arranz Arija¹⁴, E. Gallardo Diaz¹⁵, A. Pinto Marin¹⁶, E. Almagro Casado¹⁷, M.J. Mendez Vidal¹⁸, D. Olmos Hidalgo³, D. Lorente¹⁹, ¹IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ²CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, ES, ³CNIO- Spanish National Cancer Center, Madrid, ES, ⁴Hospital Virgen de la Salud de Toledo, Toledo, ES, ⁵Institut Català d'Oncologia-IDIBELL-CIBERONC, Barcelona, ES, ⁶Hospital Clínico Universitario San Carlos, Madrid, ES, ⁷Hospital Universitario Virgen del Rocío, Sevilla, ES, ⁸Hospital General Ciudad Real, Ciudad Real, ES, ⁹Hospital Universitario Morales Meseguer, Murcia, ES, ¹⁰Vall d'Hebron University Hospital, Barcelona, ES, ¹¹Hospital Universitario de Salamanca, Salamanca, ES, ¹²Hospital Universitario Virgen de las Nieves, Granada, ES, ¹³Complejo Hospitalario de Jaen Universidad de Jaen, Jaen, ES, ¹⁴Hospital General Universitario Gregorio Marañón, Madrid, ES, ¹⁵Hospital de Sabadell Corporacis Parc Tauli, Sabadell, ES, ¹⁶Hospital Universitario La Paz, Madrid, ES, ¹⁷Hospital Universitario Quirón Salud, Madrid, ES, ¹⁸Reina Sofía University Hospital, Cordoba, ES, ¹⁹Hospital Provincial de Castellón,

Castellón, ES

12:00 - 12:00

881P - Implications of Single Nucleotide Polymorphisms (SNPs) in Androgen Related-Genes in Outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with Abiraterone (Abi) and Enzalutamide (Enza)

I. Aragon¹, Y. Cendón², D. Lorente³, R. Lozano Mejorada⁴, N. Romero Laorden¹, A. Medina Colmenero⁵, J. Puente⁶, R. Villatoro⁷, S. Vazquez Estevez⁸, J. Piulats⁹, N. Lainez¹⁰, E. Fernandez-Parra¹¹, A. González Del Alba¹², A. Hernández Jorge¹³, B. Olmos¹, L. Rivera², M.I. Pacheco², D. Olmos Hidalgo¹⁴, E. Castro¹⁴, ¹CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, ES, ²Spanish National Cancer Research Centre (CNIO), Madrid, ES, ³Hospital Provincial de Castellón, Castellón, ES, ⁴Hospital Universitario de Salamanca, Salamanca, ES, ⁵Fundacion Centro Oncologico de Galicia, A Coruna, ES, ⁶Hospital Clinico Universitario San Carlos, Madrid, ES, ⁷Hospital Costa del Sol, Marbella, ES, ⁸Hospital Xeral Calde of Lugo, Lugo, ES, ⁹Institut Català d'Oncologia-IDIBELL-CIBERONC, Barcelona, ES, ¹⁰Complejo Hospitalario de Navarra - Royal Navarre Hospital, Pamplona, ES, ¹¹Hospital Universitario Nuestra Señora de Valme, Seville, ES, ¹²Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES, ¹³Hospital Universitario Virgen del Rocio, Sevilla, ES, ¹⁴CNIO- Spanish National Cancer Center, Madrid, ES

12:00 - 12:00

882P - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)

S. Fu¹, A. Murtha², C. Herberts², S. Yip³, A. Angeles³, S. Hotte⁴, A. Alshangiti⁴, B. Tran⁵, S. Taavitsainen⁶, M. Annala⁶, F. Saad⁷, N. Iqbal⁸, A. Wyatt⁹, K. Chi¹⁰, ¹Auckland City Hospital, Auckland, NZ, ²Vancouver Prostate Centre, Vancouver, CA, ³BC Cancer, Vancouver, Vancouver, CA, ⁴Juravinski Cancer Centre, Hamilton, CA, ⁵Peter MacCallum Cancer Centre, Melbourne, AU, ⁶University of Tampere, Tampere, FI, ⁷Hospital St. Luc du CHUM, Montreal, CA, ⁸Saskatoon Cancer Centre University of Saskatchewan, Saskatoon, CA, ⁹University of British Columbia, Vancouver, CA, ¹⁰BC Cancer Agency - Vancouver, Vancouver, CA

12:00 - 12:00

883P - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN

K. Chi¹, S. Thomas², N. Agarwal³, F. Feng⁴, G. Attard⁵, A.W. Wyatt⁶, M. Gormley⁷, D.S. Ricci², A. Lopez-Gitlitz⁸, K. Deprince⁹, J. Larsen¹⁰, W. Chen², B. Miladinovic¹¹, V. Naini¹², S. Chowdhury¹³, ¹BC Cancer Agency - Vancouver, Vancouver, CA, ²Janssen Research & Development, Spring House, US, ³Huntsman Cancer Institute, Salt Lake City, US, ⁴University of California, San Francisco, US, ⁵University College London Cancer Institute, London, GB, ⁶University of British Columbia, Vancouver, CA, ⁷Janssen R&D/Johnson & Johnson Pharmaceutical R&D, Raritan, US, ⁸Janssen Research & Development, Los Angeles, US, ⁹Janssen EMEA Belgium, Beerse, BE, ¹⁰Janssen Research & Development, Raritan, US, ¹¹Janssen Research & Development, San Diego, US, ¹²Janssen Research and Development, San Diego, US, ¹³Guy's and St. Thomas' Hospital NHS Trust, London, GB

12:00 - 12:00

884P - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients

A. De Jong¹, M. Segbers², M. Smits³, T. Brabander⁴, R. De Wit⁵, N. Mehra³, A. Van Der

Veldt⁴, M. Lolkema⁴, ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²Erasmus MC, Rotterdam, NL, ³Radboud University Medical Center, Nijmegen, NL, ⁴Erasmus University Medical Center, Rotterdam, NL, ⁵Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

- 12:00 - 12:00 **885P - Spatial-Temporal Change in Quantitative Total Bone Imaging (QTBI) and Circulating Tumor Cells (CTCs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide (ENZA)**
G. Liu¹, C. Kyriakopoulos², J. Lang³, J. Sperger³, A. Singh¹, E. Heath⁴, S. Perlman¹, T. Mayer⁵, K. Modelska⁶, A. Porcari⁷, W. Duggan⁸, R. Jeraj³, ¹University of Wisconsin Carbone Cancer Center, Madison, US, ²UW Carbone Cancer Center, Kettering, US, ³University of Wisconsin, Madison, US, ⁴Karmanos Cancer Institute, Detroit, US, ⁵Cancer Institute of New Jersey, New Brunswick, US, ⁶Medivation, Inc., San Francisco, US, ⁷Pfizer, Inc., New York, US, ⁸Pfizer, Inc., Groton, US
- 12:00 - 12:00 **886P - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.**
S. Osanto¹, C. Alvarez¹, H. Bloem¹, T. Van Der Hulle¹, M. Jonker¹, M. Ozdemir¹, K. Goossens², M. Wijffelman², R. Pelger¹, H. Van Poppel³, K. Burggraaf⁴, ¹Leids Universitair Medisch Centrum (LUMC), Leiden, NL, ²Alrijne Hospital, Leiderdorp, NL, ³University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁴Center for Human Drug Research, Leiden, NL
- 12:00 - 12:00 **887P - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result**
J. Woo¹, S. Santasusagna¹, J. Banks¹, A. Dominguez-Andres¹, K. Yadav², R. Pippa¹, M. Carceles-Cordon¹, C. Lallas¹, G. Luyao¹, V. Rodriguez-Bravo¹, A. Tewari², S. Pastor-Lopez³, W. Kelly¹, B. Leiby¹, J. Prats³, L. Gomella¹, J. Domingo-Domenech¹, ¹Kimmel Cancer Center-Thomas Jefferson University, Philadelphia, US, ²Icahn School of Medicine at Mount Sinai, New York, US, ³Hospital Sant Jaume Calella, Barcelona, ES
- 12:00 - 12:00 **888P - Circulating tumor cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis**
V. Conteduca¹, S.-Y. Ku², Y. Wang³, L. Fernandez³, M. Kearney³, J. Lee³, R. Jiles³, A. Rodriguez³, D.M. Nanus⁴, S. Tagawa⁵, R. Dittamore⁶, H. Beltran², ¹Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ²Dana Farber Cancer Institute and Harvard Medical School, Boston, US, ³Epic Sciences, San Diego, US, ⁴Weill Cornell Medicine, New York, US, ⁵NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, ⁶Epic Sciences Inc., San Diego, US
- 12:00 - 12:00 **889P - Circulating Tumor Cells (CTC) count and Prostate-Specific Antigen (PSA) response measures in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients (pts) treated with Docetaxel (Doc)**
R. Lozano Mejorada¹, D. Lorente², E. Castro³, D. Bianchini⁴, P. Nombela⁵, S. Sandhu⁶, N. Romero Laorden⁷, Y. Cendón⁵, A. Sharp⁸, E. Almagro Casado⁹, M.I. Pacheco⁵, P. Rescigno¹⁰, C. Llácer¹¹, M. Saez¹¹, L. Rivera⁵, F. Vitrone⁵, C. Moreno⁵, J. Mateo¹², J. De Bono¹³, D. Olmos Hidalgo³, ¹Hospital Universitario de Salamanca, Salamanca, ES, ²Hospital Provincial de Castellón, Castellón, ES, ³CNIO- Spanish National Cancer Center,

Madrid, ES, ⁴The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, GB, ⁵Spanish National Cancer Research Centre (CNIO), Madrid, ES, ⁶Peter MacCallum Cancer Centre, Melbourne, AU, ⁷CNIO - Centro Nacional de Investigaciones Oncológicas, Madrid, ES, ⁸The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ⁹Hospital Universitario Quirón Salud, Madrid, ES, ¹⁰Azienda Ospedaliera Universitaria Federico II, Napoli, IT, ¹¹Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga, ES, ¹²Vall d'Hebron University Hospital, Barcelona, ES, ¹³The Institute of Cancer Research (ICR), London, GB

12:00 - 12:00

890P - Assessing the clinical relevance of drug-drug interactions (DDI) with darolutamide (DARO)

C. Zurth¹, K. Fizazi², R. Fricke¹, H. Gieschen¹, K. Graudenz¹, M. Koskinen³, B.A. Ploeger⁴, O. Prien¹, M. Smith⁵, T. Tammela⁶, N. Shore⁷, ¹Bayer AG, Berlin, DE, ²University of Paris-Sud, Villejuif, FR, ³Orion Corporation Orion Pharma, Espoo, FI, ⁴Bayer Pharma AG, Berlin, DE, ⁵Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, US, ⁶University of Tampere, Tampere, FI, ⁷Carolina Urologic Research Center, Myrtle Beach, US

12:00 - 12:00

891TiP - KEYNOTE-921: phase 3 study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

D. Petrylak¹, B. Li², C. Schloss², K. Fizazi³, ¹Yale University School of Medicine, New Haven, US, ²Merck & Co., Inc., Kenilworth, US, ³Institut Gustave Roussy, Villejuif, FR

12:00 - 12:00

892TiP - KEYNOTE-641: Phase 3 Study of Pembrolizumab (pembro) Plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

J. Graff¹, J. Burgents², L.W. Liang³, A. Stenzl⁴, ¹OHSU Knight Cancer Institute, Portland, US, ²Merck, Sharpe & Dohme NA, Kenilworth, US, ³MSD, China, Beijing, CN, ⁴University of Tuebingen Medical School, Tuebingen, DE

12:00 - 12:00

893TiP - KEYLYNK-010: Phase 3 Study of Pembrolizumab (pembro) Plus Olaparib (OLA) vs Enzalutamide (ENZA) or Abiraterone (ABI) in ENZA- or ABI-Pretreated Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Had Progression on Chemotherapy (CTx)

E. Yu¹, L. Xu², J. Kim³, E. Antonarakis⁴, ¹University of Washington Seattle Cancer Care Alliance, Seattle, US, ²Merck & Co., Inc., Kenilworth, US, ³Merck, Sharpe & Dohme NA, New York, US, ⁴Johns Hopkins University, Baltimore, US

12:00 - 12:00

894TiP - PROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastatic hormone-sensitive prostate cancer.

J. Arranz Arija¹, B. P. Valderrama², T. Alonso Gordo³, E. Gallardo Diaz⁴, J. Sepulveda Sanchez⁵, E. Fernandez-Parra⁶, J. Piulats⁷, M.J. Mendez Vidal⁸, N. Sala González⁹, S. Vazquez Estevez¹⁰, N. Lainez¹¹, F. Zambrana¹², M. Lázaro Quintela¹³, M.A. Climent Duran¹⁴, I. García-Carbonero¹⁵, C. Caballero Diaz¹⁶, J. Puente¹⁷, J. García Sánchez¹⁸, J.A. Virizuela¹⁹, J. Carles²⁰, ¹Hospital General Universitario Gregorio Marañón, Madrid, ES, ²Hospital Universitario Virgen del Rocío, Sevilla, ES, ³Hospital Universitario Ramon y

Cajal, Madrid, ES, ⁴Hospital de Sabadell Corporacis Parc Tauli, Sabadell, ES, ⁵University Hospital 12 De Octubre, Madrid, ES, ⁶Hospital Universitario Nuestra Señora de Valme, Seville, ES, ⁷Institut Català d'Oncologia-IDIBELL-CIBERONC, Barcelona, ES, ⁸Reina Sofía University Hospital, Cordoba, ES, ⁹Institut Català d'Oncologia, Girona, ES, ¹⁰Hospital Xeral Calde of Lugo, Lugo, ES, ¹¹Complejo Hospitalario de Navarra - Royal Navarre Hospital, Pamplona, ES, ¹²Hospital Infanta Sofia, Madrid, ES, ¹³Hospital Álvaro Cunqueiro, Vigo, ES, ¹⁴Fundación Instituto Valenciano de Oncología, Valencia, ES, ¹⁵Hospital Virgen de la Salud de Toledo, Toledo, ES, ¹⁶Hospital General Universitario Valencia, Valencia, ES, ¹⁷Hospital Clinico Universitario San Carlos, Madrid, ES, ¹⁸Hospital Arnau de Vilanova, Valencia, ES, ¹⁹Hospital Universitario Virgen Macarena, Sevilla, ES, ²⁰Vall d'Hebron University Hospital, Barcelona, ES

12:00 - 12:00 **895TiP - A phase 1 study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)**

B. Tran¹, H. Kouros-Mehr², A. Fermin², L. Horvath³, F. Roncolato⁴, M. Rettig⁵, T. Dorff⁶, S. Tagawa⁷, S. Subudhi⁸, E. Antonarakis⁹, A. Armstrong¹⁰, D. Petrylak¹¹, K. Fizazi¹², M. Salvati², H. Scher¹³, ¹Peter MacCallum Cancer Centre, Melbourne, AU, ²Amgen (Headquarters) - USA, Thousand Oaks, US, ³Chris O'Brien Lifehouse, Camperdown, AU, ⁴Scientia Clinical Research Ltd, Randwick, AU, ⁵University of California Los Angeles, Los Angeles, US, ⁶City of Hope National Medical Center, Duarte, US, ⁷NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, ⁸University of Texas MD Anderson Cancer Center, Houston, US, ⁹Johns Hopkins University, Baltimore, US, ¹⁰Duke University, Durham, US, ¹¹Yale Cancer Center, New Haven, US, ¹²Gustave Roussy Cancer Center, Villejuif, FR, ¹³Memorial Sloan Kettering Cancer Center, New York, US

12:00 - 12:00 **896TiP - ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer (EudraCT: 2018-002350-78, NCT03903835)**

J. Lindberg, B. De Laere, A. Crippa, M. Eklund, H. Grönberg, Karolinska Institute, Stockholm, SE

12:00 - 12:00 **897TiP - A phase 3 randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)**

K. Chi¹, D. Rathkopf², G. Attard³, M. Smith⁴, E. Efstathiou⁵, D. Olmos⁶, E. Small⁷, J.Y. Lee⁸, P. Sieber⁹, C. Dunshee¹⁰, D. Ricci¹¹, J. Simon¹², X. Zhao¹³, N. Kothari¹⁴, S. Cheng¹⁵, S. Sandhu¹⁶, ¹BC Cancer Agency - Vancouver, Vancouver, CA, ²Memorial Sloan-Kettering Cancer Center, New York, US, ³University College London Cancer Institute, London, GB, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, US, ⁵The M. D. Anderson Cancer Center, Houston, US, ⁶CNIO-IBIMA, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Malaga, ES, ⁷UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ⁸St. Mary's Hospital of Catholic University, Seoul, KR, ⁹Lancaster Urology, Lancaster, US, ¹⁰Urological Associates of Southern Arizona, Tucson, US, ¹¹Janssen Research and Development, Spring House, US, ¹²Janssen R&D/Johnson & Johnson Pharmaceutical R&D, Spring House, US, ¹³Janssen R&D, Fremont, US, ¹⁴Janssen R&D, Los Angeles, US, ¹⁵Bristol-Myers Squibb, Princeton, US, ¹⁶Peter MacCallum Cancer Centre, Melbourne, AU

- 12:00 - 12:00 **898TiP - The Extended/Phase II Study of Safety And Tolerability Of Proxalutamide (GT0918) In Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone (Abi) Or Enzalutamide (Enza)**
N. Vogelzang¹, N. Gabrail², Z. Malik³, F. Volterra³, L. Nordquist⁴, R. Levin⁵, P. Zhang⁶, K. Zhou⁶, ¹US Oncology Research c/o Comprehensive Cancer Crts of NV, Las Vegas, US, ²Gabrail Cancer Center, Canton, US, ³New York Cancer and Blood Specialists, Port Jeferson St, US, ⁴Urology Cancer Center and GU Research Network, Omaha, US, ⁵Chesapeake Urology Associates, Towson, US, ⁶Suzhou Kintor Pharmaceuticals Inc., Suzhou, CN
- 12:00 - 12:00 **899TiP - Addition of an oral docetaxel treatment (ModraDoc006/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients with high risk N+M0 prostate cancer**
M. Vermunt¹, J. Janssen², G. Vrijenhoek¹, H. Van Der Poel³, B. Thijssen⁴, J. Beijnen⁵, B. Van Triest⁴, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ³Netherlands Cancer Institute - Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, ⁴Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ⁵The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 12:00 - 12:00 **900TiP - A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen therapy with apalutamide in patients with biochemical progression after radical prostatectomy.**
P. Dirix¹, M. Strijbos², K. Fransis³, N. Liefhooghe⁴, S. Van Bruwaene⁴, P. Uvin⁵, C. Ghysel⁵, D. Ost⁶, B. Engels⁷, R. Van Den Begin⁸, F.-X. Otte⁹, T. Roumeguere¹⁰, S. Palumbo¹¹, Y. Neybuch¹², V. Fonteyne¹³, L. Renard¹⁴, W. Everaerts¹⁵, B. Tombal¹⁶, P. Ost¹³, L. Dirix¹⁷, ¹Iridium Kankernetwerk, Antwerpen, BE, ²GZA Ziekenhuizen Sint Augustinus, Antwerp, BE, ³University Hospital Antwerpen, Edegem, BE, ⁴AZ Groeninge Hospital, Kortrijk, BE, ⁵AZ Sint-Jan Hospital, Brugge, BE, ⁶Sint-Blasius Hospital, Dendermonde, BE, ⁷UZ Brussel, Jette, BE, ⁸Institut Jules Bordet, Brussel, BE, ⁹Institute Jules Bordet, Brussels, BE, ¹⁰Erasmus University Hospital-(Universite Libre de Bruxelles), Brussels, BE, ¹¹Hôpital Sainte Elisabeth, Namur, BE, ¹²Hôpital Jolimont, Haine-Saint-Paul, BE, ¹³UZ Gent, Gent, BE, ¹⁴Cliniques Universitaires Saint Luc, Sint-Lambrechts-Woluwe, BE, ¹⁵University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹⁶Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE, ¹⁷St-Augustinus Ziekenhuis, Wilrijk, BE
- 12:00 - 12:00 **Genitourinary tumours, non-prostate**
- 12:00 - 12:00 **916P - Health-Related Quality of Life (HRQoL) and Updated Follow-Up From KEYNOTE-057: Phase 2 Study of Pembrolizumab (pembro) for Patients (pts) With High-Risk (HR) Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG)**
R. De Wit¹, G. Kulkarni², E. Uchio³, J. Boormans¹, M. Roumiguié⁴, L. Krieger⁴, E. Singer⁵, D. Bajorin⁶, A. Kamat⁷, P. Grivas⁸, H.K. Seo⁹, H. Nishiyama¹⁰, B. Konety¹¹, T.

Saretsky¹², H. Li¹², K. Nam¹², E. Sbar¹², A. Balar¹³, ¹Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ²UHN Princess Margaret Cancer Centre, University of Toronto, Toronto, CA, ³UC Irvine Health, Orange, US, ⁴Institut Universitaire du Cancer Toulouse Oncopole CHU, Toulouse, FR, ⁵Rutgers Cancer Institute of New Jersey, New Brunswick, US, ⁶Memorial Sloan Kettering Cancer Center, New York, US, ⁷The University of Texas MD Anderson Cancer Center, Houston, US, ⁸University of Washington, Seattle, US, ⁹National Cancer Center, Goyang, KR, ¹⁰University of Tsukuba, Tsukuba, JP, ¹¹University of Minnesota, Minneapolis, US, ¹²Merck & Co., Inc., Kenilworth, US, ¹³Perlmutter Cancer Center, NYU Langone Health, New York, US

12:00 - 12:00

917P - Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22

A. Siefker-Radtke¹, I. Lugowska², K. Tupikowski³, Z. Andric⁴, A. Rezazadeh Kalebasty⁵, G. Curigliano⁶, D. Vaena⁷, F. Vogl⁸, G. Currie⁹, S. Abella¹⁰, W. Kelly¹¹, ¹MD Anderson Cancer Center, Houston, US, ²Maria Sklodowska-Curie Memorial Cancer Centre-Institute of Oncology, Warsaw, PL, ³Dolnoslaskie Oncology Center, Wroclaw, PL, ⁴Clinical Hospital Center Bezanijska Kosa, Belgrade, RS, ⁵Norton Cancer Institute, Louisville, US, ⁶Istituto Europeo di Oncologia, Milan, IT, ⁷University of Tennessee, Memphis, US, ⁸BioClin Therapeutics, Therwil, CH, ⁹Dynavax Technologies Corporation, Berkeley, US, ¹⁰BioClin Therapeutics, Inc., San Leandro, US, ¹¹Thomas Jefferson University Hospital, Philadelphia, US

12:00 - 12:00

918P - Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the Phase III IMvigor211 study

M. Van Der Heijden¹, Y. Loriot², I. Duran³, A. Ravaud⁴, M. Retz⁵, N. Vogelzang⁶, B. Nelson⁷, J. Wang⁷, X. Shen⁷, T. Powles⁸, ¹Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, ²Institut Gustave Roussy, Villejuif, FR, ³Hospital Universitario Virgen del Rocío, Sevilla, ES, ⁴CHU Bordeaux Hopital St. André, Bordeaux, FR, ⁵Technische Universität München, München, DE, ⁶US Oncology Research c/o Comprehensive Cancer Ctr of NV, Las Vegas, US, ⁷Genentech, South San Francisco, US, ⁸Barts Cancer Institute, London, GB

12:00 - 12:00

919P - Three-Year Follow-Up From the Phase 3 KEYNOTE-045 Trial: Pembrolizumab (Pembro) Versus Investigator's Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (UC)

A. Necchi¹, Y. Fradet², J. Bellmunt³, R. De Wit⁴, J.-L. Lee⁵, L. Fong⁶, N. Vozelgang⁷, M. Climent⁸, D. Petrylak⁹, T. Choueiri¹⁰, W. Gerritsen¹¹, H. Gurney¹², D. Quinn¹³, S. Culine¹⁴, C. Sternberg¹⁵, K. Nam¹⁶, T. Frenkl¹⁶, J. Godwin¹⁶, D. Bajorin¹⁷, D. Vaughn¹⁸, ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ²CHU de Québec - Université Laval, Québec City, CA, ³PSMAR-IMIM Research Institute, Barcelona, ES, ⁴Erasmus MC Cancer Institute, Rotterdam, NL, ⁵Asan Medical Center and University of Ulsan College of Medicine, Seoul, KR, ⁶University of California, San Francisco, San Francisco, US, ⁷Comprehensive Cancer Centers of Nevada, Las Vegas, US, ⁸Fundación Instituto Valenciano de Oncología, Valencia, ES, ⁹Smilow Cancer Hospital at Yale University, New Haven, US, ¹⁰Dana-Farber Cancer Institute, Boston, US, ¹¹Radboud University Medical Center, Nijmegen, NL, ¹²Westmead Hospital and Macquarie

University, Sydney, AU, ¹³USC Norris Comprehensive Cancer Center, Los Angeles, US, ¹⁴Hôpital Saint-Louis, Paris, FR, ¹⁵Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian, New York, US, ¹⁶Merck & Co., Inc., Kenilworth, US, ¹⁷Memorial Sloan Kettering Cancer Center, New York, US, ¹⁸Abramson Cancer Center, Penn Medicine, Philadelphia, US

12:00 - 12:00

920P - First Report of Efficacy and Safety From a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma (UC) in Asian Patients

D. Ye¹, J. Liu², A. Zhou³, Q. Zou⁴, H. Li⁵, C. Fu⁶, H. Hu⁷, J. Huang⁸, S. Zhu⁹, J. Jin¹⁰, L. Ma¹¹, J. Guo¹², J. Xiao¹³, S.H. Park¹⁴, D. Zhang¹⁵, X. Qiu¹⁶, Y. Bao¹⁶, L. Zhang¹⁶, W. Shen¹⁶, B. Feng², ¹Fudan University - Shanghai Cancer Center (FUSCC), Shanghai, CN, ²West China Hospital, Leshan, CN, ³Chinese Academy of Medical Sciences and Peking Union Medical College - Cancer Institute & Hospital, Beijing, CN, ⁴Jiangsu Cancer Hospital, Nanjing, CN, ⁵Peking Union Medical College Hospital, Beijing, CN, ⁶Liaoning Cancer Hospital & Institute, Shenyang, CN, ⁷The Second Hospital of Tianjin Medical University, Tianjin, CN, ⁸Sun Yat-sen University - Sun Yat-Sen Memorial Hospital, Guangzhou, CN, ⁹Zhejiang Cancer Hospital, Hangzhou, CN, ¹⁰Peking University First Hospital, Beijing, CN, ¹¹Peking University Third Hospital, Beijing, CN, ¹²Fudan University - Zhongshan Hospital, Shanghai, CN, ¹³Anhui Provincial Hospital, Hefei, CN, ¹⁴Samsung Medical Center, Seoul, KR, ¹⁵Zhejiang Provincial People's Hospital, Hangzhou, CN, ¹⁶BeiGene (Beijing) Co., Ltd., Beijing, CN

12:00 - 12:00

921P - Quality of Life of Metastatic Urothelial Cancer (mUC) Patients Treated with Enfortumab Vedotin (EV) Following Platinum-Containing Chemotherapy and a Checkpoint Inhibitor (CPI): Data from EV-201 Cohort 1

B. Mcgregor¹, P. O'Donnell², A. Balar³, D. Petrylak⁴, J. Rosenberg⁵, E. Yu⁶, D. Quinn⁷, S. Shah⁸, J. Pinelli⁹, Z. Hepp¹⁰, M. Galsky¹¹, ¹Dana Farber Cancer Institute, Boston, US, ²University of Chicago, Chicago, US, ³NYU Langone, New York, US, ⁴Yale Cancer Center, New Haven, US, ⁵Memorial Sloan Kettering Cancer Center, New York, US, ⁶University of Washington Seattle Cancer Care Alliance, Seattle, US, ⁷USC Norris Comprehensive Cancer Center, Los Angeles, US, ⁸Astellas Pharma Inc., Northbrook, US, ⁹Seattle Genetics, Bothell, US, ¹⁰Seattle Genetics, Seattle, US, ¹¹Icahn School of Medicine at Mount Sinai Hospital, New York, US

12:00 - 12:00

922P - Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma

Y. Loriot¹, C. Sternberg², D. Castellano Gauna³, H. Dumez⁴, R. Huddart⁵, K. Vianna⁶, T. Alonso Gordo⁷, I. Skoneczna⁸, A. Fay⁹, C. Sacco¹⁰, F. Nole¹¹, F. Massari¹², B. Brasiuniene¹³, P. Maroto¹⁴, S. Oosting¹⁵, S. Fear¹⁶, F. Di Nucci¹⁷, S. De Ducla¹⁸, E. Choy¹⁹, ¹Institut Gustave Roussy, Villejuif, FR, ²Weill Cornell Medicine, New York, US, ³University Hospital 12 De Octubre, Madrid, ES, ⁴University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁵The Royal Marsden Hospital, London, GB, ⁶CIONC-Centro Integrado de Oncologia, Curitiba, BR, ⁷Hospital Universitario Ramon y Cajal, Madrid, ES, ⁸The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, ⁹PUCRS School of Medicine, Porto Alegre, BR, ¹⁰Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia,

Udine, IT, ¹¹Istituto Europeo di Oncologia, Milan, IT, ¹²AOU Policlinico S. Orsola-Malpighi, Bologna, IT, ¹³National Cancer Institute, Vilnius, LT, ¹⁴Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹⁵University Hospital Groningen (UMCG), Groningen, NL, ¹⁶F Hoffmann-La Roche Ltd, Basel, CH, ¹⁷Genentech, Inc, South San Francisco, US, ¹⁸Roche, Basel, CH, ¹⁹Cardiff University School of Medicine, Cardiff, GB

12:00 - 12:00

923P - Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors

R. Morales Barrera¹, I. Matos¹, M. Gonzalez¹, C. Suárez¹, J. Ros¹, C. Valverde¹, C. Fernandez¹, C. Hierro¹, E. Serra¹, J. Mateo¹, S. Gutierrez¹, J. Martín Liberal¹, A. Quintana¹, R. Dienstmann¹, C. Serrano¹, E. Garralda², J. Carles¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

12:00 - 12:00

924P - Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer

J. Matulay¹, M. Campbell², V. Narayan¹, M. Seif¹, A. Lim¹, A. Shah³, P. Msaouel¹, J. Gao¹, A. Siefker-Radtke³, C. Dinney¹, A.M. Kamat⁴, N. Navai¹, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²The M. D. Anderson Cancer Center, Houston, US, ³MD Anderson Cancer Center, Houston, US, ⁴The University of Texas MD Anderson Cancer Center, Houston, US

12:00 - 12:00

925P - Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)

A. Siefker-Radtke¹, B. Zhong², W. Shalaby³, P. De Porre⁴, A. O'Hagan⁵, P. Mahadevia⁶, Y. Lorient⁷, ¹The M. D. Anderson Cancer Center, Houston, US, ²Janssen Research & Development, LLC, Spring House, US, ³Janssen Research & Development, LLC, Horsham, US, ⁴Janssen EMEA Belgium, Beerse, BE, ⁵Janssen Research & development, Spring House, US, ⁶Janssen Pharmaceuticals, Raritan, US, ⁷Institut Gustave Roussy, Villejuif, FR

12:00 - 12:00

927P - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)

J. Hoffman-Censits¹, J. Rosenberg², M. Van Der Heijden³, R. Dreicer⁴, J.L. Perez Gracia⁵, D. Petrylak⁶, M. Retz⁷, R. Sabbatini⁸, E. Naglieri⁹, C. Caserta¹⁰, M. Maruzzo¹¹, R. Iacovelli¹², L. Galli¹³, R. Mcdermott¹⁴, R. Morales Barrera¹⁵, T. Bonfill¹⁶, S. De Ducla¹⁷, B. Ding¹⁸, J. Linsenmeier¹⁹, C. Sternberg²⁰, ¹Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Netherlands Cancer Institute, Amsterdam, NL, ⁴University of Virginia Cancer Center, Charlottesville, US, ⁵Clinica Universidad de Navarra, Navarra, ES, ⁶Yale Cancer Center, New Haven, US, ⁷Technische Universitat München, München, DE, ⁸A.O. Universitaria Policlinico Di Moderna, Modena, IT, ⁹IRCCS IST. TUMORI GIOVANNI PAOLO II, Bari, IT, ¹⁰Azienda Ospedaliera S. Maria - Terni, Terni, IT, ¹¹Istituto Oncologico Veneto, Padova, IT, ¹²Fondazione Policlinico Agostino Gemelli, Rome, IT, ¹³Azlenda Ospendaliero-Universitaria Pisana, Santa Maria, IT, ¹⁴Adelaide and Meath Hospital, Tallaght, IE, ¹⁵Vall d'Hebron University Hospital, Barcelona, ES, ¹⁶Corporacio Sanitaria Parc Taul, Barcelona, ES, ¹⁷Roche, Basel, CH, ¹⁸Genentech, South San Francisco, US, ¹⁹Genentech, Inc., South San Francisco, US, ²⁰Weill Cornell Medicine, New York, US

- 12:00 - 12:00 **928P - National Small Cell Bladder Cancer Audit: Results from 26 UK institutions**
- C. Chau¹, Y. Rimmer², A. Law³, D. Leaning⁴, J. Lim⁵, T. Young⁶, S. Hafeez⁷, D. Mitchell⁸, J. Mcgrane⁹, M. Beresford¹⁰, N. Vasudev¹¹, V.-R. Sim¹², A. Koutalopoulou¹³, S. Hilman¹⁴, C. Manetta¹⁵, S. Rajagopalan¹⁶, A. Sharma¹⁷, C. Eswar¹⁸, D. Henderson¹⁹, S. Crabb²⁰,
1Queen Alexandra Hospital Portsmouth Oncology Centre, Portsmouth, GB, 2Cambridge University Hospital NHS Trust, Cambridge, GB, 3Western General Hospital, Scotland, GB, 4South Tees Hospital NHS Foundation Trust, South Tees, GB, 5Nottingham University Hospital NHS Trust, Nottingham, GB, 6Guys St Thomas Hospital Trust, London, GB, 7Royal Marsden Hospital, London, GB, 8Belfast Health and Social Care Trust, Belfast, IE, 9Royal Cornwall Hospital Trust, Cornwall, GB, 10Royal United Hospital Bath NHS Foundation, Bath, GB, 11Leeds Institute of Cancer, Leeds, GB, 12Maidstone and Tunbridge Wells NHS Trust, Maidstone, GB, 13Portsmouth Hospital Trust, Portsmouth, GB, 14Weston General Hospital, Bristol, GB, 15Brighton University Hospital, Brighton, GB, 16University Hospital Coventry, Coventry, GB, 17Mount Vernon Hospital, Northwood, GB, 18Clatterbridge Cancer Centre, Clatterbridge, GB, 19University Hospital Birmingham, Birmingham, GB, 20Southampton General Hospital Southampton University Hospitals NHS Trust, Southampton, GB
- 12:00 - 12:00 **929P - Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase 3 study.**
- M. Van Der Heijden¹, T. Powles², D. Petrylak³, R. De Wit⁴, K. Chi⁵, A. Necchi⁶, C. Sternberg⁷, N. Matsubara⁸, H. Nishiyama⁹, D. Castellano Gauna¹⁰, S. Hussain¹¹, A. Bamias¹², R. Hozak¹³, R. Rhodes¹⁴, M.S. Xia¹³, E. Rasmussen¹⁵, A. Aggarwal¹³, S. Wijayawardana¹³, K. Bell-Mcguinn¹⁶, A. Drakaki¹⁷,
14Netherlands Cancer Institute, Amsterdam, NL, 2St. Bartholomew's Hospital, London, GB, 3Yale Cancer Center, New Haven, US, 4Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, 5BC Cancer Agency - Vancouver, Vancouver, CA, 6Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, 7Azienda Ospedaliera S. Camillo Forlanini, Rome, IT, 8National Cancer Center Hospital East, Chiba, JP, 9Tokyo University of Science, Tokyo, JP, 10University Hospital 12 De Octubre, Madrid, ES, 11Royal Liverpool University Hospital, Liverpool, GB, 12Alexandra Hospital - National & Kapodistrian University of Athens, Athens, GR, 13Eli Lilly and Company, Indianapolis, US, 14Marian University, Indianapolis, US, 15Eli Lilly and Company, New York, US, 16Eli Lilly, Indianapolis, US, 17Ronald Reagan UCLA Medical Center, Los Angeles, US
- 12:00 - 12:00 **930P - Comparison of Immuno-Oncology (IO) Biomarkers in Adenocarcinoma (ACB), Urothelial Carcinoma (UCB) and Squamous Cell Carcinoma (SCCB) of the Bladder, with interim results from PURE01**
- D. Raggi¹, J. Ross², S. Ali², J. Chung², A. Schrock², R. Madison², B. Alexander², P. Grivas³, A. Necchi¹,
1Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, 2Foundation Medicine, Cambridge, US, 3University of Washington Seattle Cancer Care Alliance, Seattle, US
- 12:00 - 12:00 **931P - Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients**

A. Font¹, M. Domenech², J.L. Ramirez³, J. Gago⁴, C. Carrato⁴, B. Cadenas⁵, R. Benítez⁶, T. Lobato⁷, S. Pineda⁶, V. Ruiz De Porras⁷, M.L. Calle⁵, N. Malats⁶, F. Real⁸, ¹ICO - Institut Català d' Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ²Fundació ALTHAIA, Manresa, ES, ³Catalan Institute of Oncology (ICO), Badalona, ES, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, ES, ⁵Universitat de Vic- Universitat Central de Catalunya, Vic, ES, ⁶Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, ES, ⁷Germans Trias i Pujol Research Institute, Badalona, ES, ⁸Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, ES

12:00 - 12:00

932P - Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Anti-tumor Activity Among Patients (Pts) with Advanced Urothelial Carcinoma (UC)

S. Tagawa¹, A. Siefker-Radtke², A.-G. Dosne³, B. Zhong⁴, W. Shalaby⁵, A. O'Hagan⁶, P. De Porre⁷, P. Mahadevia⁸, Y. Loriot⁹, ¹NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, ²MD Anderson Cancer Center, Houston, US, ³Janssen R&D, Belgium, US, ⁴Janssen R&D US, Pennsylvania, US, ⁵Janssen Biotech, Inc, Horsham, US, ⁶Janssen R&D, pennsylvania, US, ⁷Janssen EMEA Belgium, Beerse, BE, ⁸Janssen Pharmaceuticals, Raritan, US, ⁹Institut Gustave Roussy, Villejuif, FR

12:00 - 12:00

933P - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting

F. Roghmann¹, R. Wirtz², J. Jarczyk³, M. Kriegmair³, T. Worst³, D. Sikic⁴, S. Wach⁴, H. Taubert⁴, B. Wullich⁴, V. Weyerer⁴, R. Stoehr⁴, F. Zengerling⁵, C. Bolenz⁵, J. Breyer⁶, M. Burger⁶, S. Porubsky⁷, A. Hartmann⁴, P. Erben⁸, M. Eckstein⁴, H. Juetten⁹, ¹Marienhospital Herne, Herne, DE, ²STRATIFYER Molecular Pathology GmbH, Cologne, Cologne, DE, ³University Hospital Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim, Mannheim, DE, ⁴Universitätsklinik Erlangen, Erlangen, DE, ⁵University Hospital Ulm, University of Ulm, Ulm, Ulm, DE, ⁶University of Regensburg, Regensburg, DE, ⁷Department of Pathology, University Hospital Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim, Mannheim, DE, ⁸Medical Faculty Mannheim, University of Heidelberg, Mannheim, DE, ⁹Ruhr University Bochum, Bochum, DE

12:00 - 12:00

934P - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)

J.-M. Lavoie¹, G. Vandekerkhove², M. Annala³, S. Taavitsainen³, N. Sundahl⁴, S. Walz⁵, T. Sano², D. Khalaf⁶, T. Todenhöfer⁷, P. Ost⁸, C. Kollmannsberger⁹, K. Chi⁹, P. Black², A. Wyatt¹⁰, B. Eigl⁹, ¹BC Cancer Agency, Vancouver, CA, ²Vancouver Prostate Centre, Vancouver, CA, ³University of Tampere, Tampere, FI, ⁴Gent University Hospital, Gent, BE, ⁵Eberhard-Karls-University, Tuebingen, DE, ⁶BC Cancer, Vancouver, CA, ⁷University of Tuebingen, Tübingen, DE, ⁸UZ Gent, Gent, BE, ⁹BC Cancer Agency - Vancouver, Vancouver, CA, ¹⁰University of British Columbia, Vancouver, CA

12:00 - 12:00

935P - (Withdrawn)

12:00 - 12:00

936P - Comparative analysis of tumor mutational burden (TMB) prediction methods and its association with determinants of the tumor immune microenvironment of urothelial bladder cancer (UBC)

M. Eckstein¹, A. Hartmann¹, P. Strissel¹, R. Strick¹, S. Wach¹, H. Taubert¹, B. Wullich¹, C. Geppert¹, V. Weyerer¹, R. Stoehr¹, M. Rübner¹, P.A. Fasching², S. Rabizadeh³, S. Benz³, F. Haller¹, E. Moskalev¹, L. Toegel¹, ¹Universitätsklinik Erlangen, Erlangen, DE, ²University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, ³NantCell, Culver City, US

12:00 - 12:00

937P - The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival

E. Nassif¹, B. Mlecnik², C. Thibault³, X. Barthere⁴, M. Auvray³, D. Bruni², E. Comperat⁵, A. Colau⁶, F. Hermitte⁷, P. Camparo⁸, P. Colin⁹, D. Bruno¹⁰, M. Bennamoun¹¹, F. Audenet¹², A. Mejean¹, V. Verkarre³, R. Zakopoulou¹³, A. Bamias¹⁴, S. Oudard³, J. Galon¹⁵, ¹Paris Descartes University, Paris, FR, ²Inserm, Paris, FR, ³Hopital European George Pompidou, Paris, FR, ⁴UPMC Université Pierre et Marie Curie, Paris, FR, ⁵Sorbonne University, GRC n°5, ONCOTYPE-URO, PARIS, FR, ⁶Diaconesses, Paris, FR, ⁷HaliDx, Marseille, FR, ⁸Centre de Pathologie, Amiens, FR, ⁹Hôpital privé de la Louvière, Lille, FR, ¹⁰saint jean de dieu, Paris, FR, ¹¹Institute Mutualiste Montsouris, Paris, FR, ¹²Université Paris Descartes, PARIS, FR, ¹³University of Athens, Athens, GR, ¹⁴Alexandra Hospital - National & Kapodistrian University of Athens, Athens, GR, ¹⁵Laboratory of Integrative Cancer Immunology, Paris, FR

12:00 - 12:00

938P - Genomic analysis of urothelial cancer and associations with treatment choice and outcome

D. Sarid¹, R. Berger², M. Levertovsky³, M. Gadot³, C. Maurice-Dror⁴, A. Peer⁴, R. Perets⁴, O. Purim⁵, M. Sarfaty⁶, E. Rosenbaum⁵, V. Neiman⁵, H. Ligumsky¹, K. Rouvinov⁷, E. Romanov⁷, W. Marmelstein⁷, N. Shani-Shrem⁷, G. Weiner⁸, R. Leibowitz-Amit², ¹Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL, ²Chaim Sheba Medical Center, Ramat Gan, IL, ³Chaim Sheba Medical Center, RAMAT-GAN, IL, ⁴Rambam Health Care Center, Haifa, IL, ⁵Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL, ⁶Rabin Medical Center, Peth Tikva, IL, ⁷Soroka University Medical Center, Beer Sheva, IL, ⁸Hadassa Medical Center, Jerusalem, IL

12:00 - 12:00

940P - cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)

S. Pal¹, D. Bajorin², J. Hoffman-Censits³, D. Quinn⁴, D. Petrylak⁵, M. Galsky⁶, U. Vaishampayan⁷, U. De Giorgi⁸, S. Gupta⁹, H. Burris¹⁰, H. Soifer¹¹, G. Li¹¹, C. Dambkowski¹¹, S. Moran¹¹, H. Wang¹¹, S. Daneshmand¹², J. Rosenberg², ¹City of Hope Comprehensive Cancer Center, Duarte, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, US, ⁴USC Norris Comprehensive Cancer Center, Los Angeles, US, ⁵Yale Cancer Center, Smilow Cancer Hospital, New Haven, US, ⁶Mount Sinai School of Medicine, New York, US, ⁷Wayne State University, Detroit, US, ⁸Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, IT, ⁹Huntsman Cancer Institute - University of Utah Health Care, Salt Lake City, US, ¹⁰Sarah Cannon Research Institute, Nashville, US, ¹¹QED Therapeutics Inc, San Francisco, US, ¹²Keck School of Medicine of USC, Los Angeles, US

12:00 - 12:00

941P - Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from

the multicentric, retrospective FOsMIC trial

J. Jarczyk¹, R. Wirtz², F. Roghmann³, H. Juetten⁴, M. Kriegmair⁵, T. Worst⁵, D. Sikic⁶, S. Wach⁷, H. Taubert⁷, B. Wullich⁷, V. Weyerer⁷, R. Stoehr⁷, F. Zengerling⁸, C. Bolenz⁹, J. Breyer¹⁰, M. Burger¹⁰, S. Porubsky¹¹, A. Hartmann⁷, P. Erben¹¹, M. Eckstein⁷,

¹Universitätsklinikum Mannheim, Mannheim, DE, ²STRATIFYER Molecular Pathology GmbH, Cologne, Cologne, DE, ³Marienhospital Herne, Herne, DE, ⁴Ruhr University Bochum, Bochum, DE, ⁵University Hospital Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim, Mannheim, DE, ⁶University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, DE, ⁷Universitätsklinik Erlangen, Erlangen, DE, ⁸University Hospital Ulm, University of Ulm, Ulm, Ulm, DE, ⁹University of Ulm, Ulm, DE, ¹⁰University of Regensburg, Regensburg, DE, ¹¹Medical Faculty Mannheim, University of Heidelberg, Mannheim, DE

12:00 - 12:00 **942P - A differential bladder microbiota composition is associated with tumor grade in bladder cancer.**

M. Parra-Grande¹, M. Oré-Arce², V. Sánchez-Hellín³, ¹HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE, Albacete, ES, ²Hospital General Universitario de Elche, Elche, ES, ³HOSPITAL GENERAL UNIVERSITARIO DE ELCHE, ELCHE, ES

12:00 - 12:00 **943P - Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS)**

V. Sacristan Santos¹, J. Esther², B. Maughan³, S. Wesolowski², E. Lin⁴, A. Hahn⁴, D. Sirohi⁴, N. Rathi³, U. Swami⁵, R. Nussenzweig⁴, N. Agarwal³, ¹Complejo Hospitalario de Pontevedra, Pontevedra, ES, ²University of Utah, Salt Lake City, US, ³Huntsman Cancer Institute, Salt Lake City, US, ⁴Huntsman Cancer Institute, University of Utah, Salt Lake City, US, ⁵University of Iowa Hospitals and clinics, Iowa city, US

12:00 - 12:00 **944P - Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency Results based on multiple RNA extraction kits and mutation detection methods**

V. Weyerer¹, R. Stoehr¹, H. Juetten², R. Wirtz³, M. Eckstein¹, F. Roghmann⁴, J. Breyer⁵, S. Porubsky⁶, D. Sikic⁷, C. Bolenz⁸, M. Kriegmair⁹, A. Hartmann¹, P. Erben⁶, ¹Universitätsklinik Erlangen, Erlangen, DE, ²Ruhr University Bochum, Bochum, DE, ³STRATIFYER Molecular Pathology GmbH, Cologne, Cologne, DE, ⁴Marienhospital Herne, Herne, DE, ⁵University of Regensburg, Regensburg, DE, ⁶Medical Faculty Mannheim, University of Heidelberg, Mannheim, DE, ⁷University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, DE, ⁸University of Ulm, Ulm, DE, ⁹University Hospital Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim, Mannheim, DE

12:00 - 12:00 **945P - Title: Genomic characterization of non-schistosomiasis-related squamous cell carcinoma (NSR-SCC) of the urinary bladder: a retrospective study of potential prognostic and predictive biomarkers**

E. Al-Ezzi¹, Z. Veitch¹, S. Salah², T. Van Der Kwast³, T. Stockley³, E. Malone⁴, S. Sridhar⁵, A. Sacher¹, N. Fallah-Rad¹, G. Kulkarni¹, A. Zlotta⁶, A. Finelli¹, A. Hansen⁴, ¹Princess Margaret Cancer Centre, Toronto, CA, ²King Hussain Cancer Foundation and Center, Amman, JO, ³Toronto General Hospital, Toronto, CA, ⁴Princess Margaret Cancer Center, Toronto, CA, ⁵Princess Margaret Hospital, Toronto, CA, ⁶Mount Sinai hospital, Toronto,

CA

- 12:00 - 12:00 **946P - Updated results of the KEYNOTE-426 study of pembrolizumab plus axitinib versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC)**
T. Powles, St. Bartholomew's Hospital, London, GB
- 12:00 - 12:00 **947P - TiNivo: Tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC). Final Results.**
P. Barthelemy¹, B. Escudier², S. Negrier³, A. Ravaud⁴, M. Needle⁵, L. Albiges⁶, ¹C.H.U. Strasbourg-Nouvel Hopital Civil, Strasbourg, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³Centre Léon Bérard, Lyon, FR, ⁴CHU Bordeaux Hopital St. André, Bordeaux, FR, ⁵AVEO Pharmaceuticals Inc, Cambridge, US, ⁶Institut Gustave Roussy, Villejuif, FR
- 12:00 - 12:00 **948P - First-Line Pembrolizumab (pembro) Monotherapy for Advanced Non-Clear Cell Renal Cell Carcinoma (nccRCC): Updated Follow-Up for KEYNOTE-427 Cohort B**
C. Suárez¹, J.-L. Lee², M. Ziobro³, R. Gafanov⁴, V. Matveev⁵, F. Donskov⁶, F. Pouliot⁷, B. Alekseev⁸, P. Wiechno⁹, P. Tomczak¹⁰, M. Climent¹¹, S.J. Shin¹², R. Kloss Silverman¹³, R. Perini¹³, C. Schloss¹³, D. Mcdermott¹⁴, M. Atkins¹⁵, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Asan Medical Center and University of Ulsan College of Medicine, Seoul, KR, ³Centrum Onkologii-Instytut im. Marii Skłodowskiej, Cracow, PL, ⁴Russian Scientific Center of Roentgenoradiology, Moscow, RU, ⁵N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ⁶Aarhus University Hospital, Aarhus, DK, ⁷Universite Laval, CHU de Quebec, Quebec, CA, ⁸Hertzen Cancer Research Institute, Moscow, RU, ⁹Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, ¹⁰Szpital Kliniczny Przemienienia Panskiego UM im.Ka Marcinkowskiego-Klinika Onkologii, Poznan, PL, ¹¹Fundación Instituto Valenciano de Oncología, Valencia, ES, ¹²Yonsei University College of Medicine, Seoul, KR, ¹³Merck & Co., Inc., Kenilworth, US, ¹⁴Beth Israel Deaconess Med. Center, Boston, US, ¹⁵Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC, US
- 12:00 - 12:00 **949P - First-Line Pembrolizumab (pembro) Monotherapy in Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Updated Follow-Up For KEYNOTE-427 Cohort A**
J. Larkin¹, S. Tykodi², F. Donskov³, J.-L. Lee⁴, C. Szczylik⁵, J. Malik⁶, B. Alekseev⁷, V. Matveev⁸, R. Gafanov⁹, P. Tomczak¹⁰, P. Geertsens¹¹, P. Wiechno¹², S.J. Shin¹³, F. Pouliot¹⁴, T. Alonso Gordo¹⁵, R. Kloss Silverman¹⁶, R. Perini¹⁶, C. Schloss¹⁷, D. Mcdermott¹⁸, M. Atkins¹⁹, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²University of Washington and Fred Hutchinson Cancer Research Center, Seattle, US, ³Aarhus University Hospital, Aarhus, DK, ⁴Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁵Military Medical Institute, Warsaw, PL, ⁶Edinburgh Cancer Centre, Western General Hospital, Edinburgh, GB, ⁷Hertzen Cancer Research Institute, Moscow, RU, ⁸N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ⁹Russian Scientific Center of Roentgenoradiology, Moscow, RU, ¹⁰Szpital Kliniczny Przemienienia Panskiego UM im.Ka Marcinkowskiego-Klinika Onkologii, Poznan, PL, ¹¹Herlev Hospital, University of Copenhagen, Herlev, DK, ¹²Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, ¹³Yonsei University College of Medicine,

Seoul, KR, ¹⁴Universite Laval, CHU de Quebec, Quebec, CA, ¹⁵Hospital Universitario Ramon y Cajal, Madrid, ES, ¹⁶Merck & Co., Inc., Kenilworth, US, ¹⁷Merck Sharp & Dohme Corp. USA, Whitehouse Station, US, ¹⁸Beth Israel Deaconess Med. Center, Boston, US, ¹⁹Lombardi Cancer Center Georgetown University, Washington, US

- 12:00 - 12:00 **950P - Association Between Depth of Response and Overall Survival: Exploratory Analysis in Patients With Previously Untreated Advanced Renal Cell Carcinoma (aRCC) in CheckMate 214**
V. Grünwald¹, T. Choueiri², B. Rini³, T. Powles⁴, S. George⁵, M.-O. Grimm⁶, M.B. Mchenry⁷, M. Maurer⁷, R. Motzer⁸, H. Hammers⁹, N. Tannir¹⁰, L. Albiges¹¹, ¹University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ²Dana-Farber Cancer Institute, Boston, US, ³Cleveland Clinic, Cleveland, US, ⁴Barts Cancer Institute, London, GB, ⁵Roswell Park Cancer Institute, Buffalo, US, ⁶Universitaetsklinikum Jena, Jena, DE, ⁷Bristol Myers Squibb, Princeton, US, ⁸Memorial Sloan-Kettering Cancer Center, New York, US, ⁹UT Southwestern Medical Center, Dallas, US, ¹⁰MD Anderson Cancer Center, Houston, US, ¹¹Institut Gustave Roussy, Villejuif, FR
- 12:00 - 12:00 **951P - Quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: updated results**
D. Cella¹, B. Escudier², C. Ivanescu³, M. Mauer⁴, J. Lord-Bessen⁵, K. Gooden⁵, ¹Northwestern University, Chicago, US, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³IQVIA, Herikerbergweg, NL, ⁴Bristol-Myers Squibb, Lawrenceville, US, ⁵Bristol-Myers Squibb, Princeton, US
- 12:00 - 12:00 **952P - Results of phase 1 clinical trial of high doses of Seleno-L-methionine (SLM) in sequential combination with Axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients**
Y. Zakharia¹, R. Garje², J. Brown², K. Nepple², A. Bellizzi², J. Bonner², D. Parr², J. Born², J. Sieren², J. Park², M. Milhem³, Y. Rustum², ¹University of Iowa - Hospital, Iowa City, US, ²University of Iowa, Iowa City, US, ³University of Iowa Hospitals And Clinics, Iowa City, US
- 12:00 - 12:00 **953P - Safety and Efficacy of CDX-014 , an Antibody-Drug Conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced Renal Cell Carcinoma**
B. Mcgregor¹, N. Agarwal², M. Gordon³, S. George⁴, D. Quinn⁵, M. Rogalski⁶, T. Keler⁷, T. Hawthorne⁶, T. Choueiri⁸, ¹Dana Farber Cancer Institute, Boston, US, ²Huntsman Cancer Institute, Salt Lake City, US, ³Honorhealth Research Institute, Scottsdale, US, ⁴Roswell Park Comprehensive Cancer Center, Buffalo, US, ⁵Univeristy of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, ⁶Celldex Therapeutics, New Haven, US, ⁷Celldex Therapeutics, Hampton, US, ⁸Dana-Farber Cancer Institute, Boston, US
- 12:00 - 12:00 **954P - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz).**
B. P. Valderrama¹, S. Perez Ramirez², A. Rodriguez-Vida³, A. González Del Alba⁴, M.J. Mendez Vidal⁵, S. Vazquez Estevez⁶, E. Martinez Ortega⁷, J.A. Virizuela⁸, O. Fernández Calvo⁹, A. Hernández Jorge¹, F. Vazquez Mazon¹⁰, M.B. Gonzalez Gragera¹¹, M.

Campayo¹², O. Etxaniz Ulazia¹³, E. Almagro Casado¹⁴, M. Sereno Moyano¹⁵, M.T. Abad Villar¹⁶, C. Suarez Rodriguez¹⁷, E. Gallardo Diaz¹⁸, J. Arranz Arijia², ¹Hospital Universitario Virgen del Rocío, Sevilla, ES, ²Hospital General Universitario Gregorio Marañón, Madrid, ES, ³Hospital del Mar, Barcelona, ES, ⁴Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES, ⁵Reina Sofía University Hospital, Cordoba, ES, ⁶Hospital Xeral Calde of Lugo, Lugo, ES, ⁷Complejo Hospitalario de Jaen Universidad de Jaen, Jaen, ES, ⁸Hospital Universitario Virgen Macarena, Sevilla, ES, ⁹Complejo Hospitalario de Orense, Ourense, ES, ¹⁰Hospital General Universitario de Elche, Elche, ES, ¹¹Hospital de Son Llätzer, Palma de Mallorca, ES, ¹²Hospital Mutua de Terrassa, Terrassa, ES, ¹³Hospital Universitario Germans Trias i Pujol, Barcelona, ES, ¹⁴Hospital Universitario Quirón Salud, Madrid, ES, ¹⁵Hospital Infanta Sofia, Madrid, ES, ¹⁶Hospital Universitario de Basurto, Bilbao, ES, ¹⁷Vall d'Hebron University Hospital, Barcelona, ES, ¹⁸Hospital de Sabadell Corporacis Parc Tauli, Sabadell, ES

12:00 - 12:00 **955P - Effect of Antacid Intake on the Therapeutic Efficacy of Sunitinib (SUN) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts): a Sub-Analysis of the STAR-TOR Registry**

K. Schlack¹, M. Boegemann¹, M. Woike², G. Krekeler², T. Fischer³, L. Bergmann⁴, M. Rink⁵, M. Schmid⁶, A. Strauss⁶, ¹University Hospital of Münster, Münster, DE, ²Pfizer - Germany, Berlin, DE, ³Winicker-Norimed GmbH, Nürnberg, DE, ⁴Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, ⁵Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, ⁶Universitätsmedizin Göttingen, Göttingen, DE

12:00 - 12:00 **956P - Randomized phase 3 trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN Renal 101 Japanese subgroup analysis**

M. Uemura¹, Y. Tomita², H. Miyake³, S. Hatakeyama⁴, H.-O. Kanayama⁵, K. Numakura⁶, T. Takagi⁷, T. Kato⁸, M. Eto⁹, W. Obara¹⁰, H. Uemura¹¹, R. Motzer¹², Y. Fujii¹³, Y. Kamei¹⁴, M. Oya¹⁵, ¹Osaka University Graduate School of Medicine, Suita, JP, ²Yamagata University Hospital, Yamagata, JP, ³Hamamatsu University School of Medicine, Hamamatsu, JP, ⁴Hirosaki Univ. School of Med., Hirosaki, JP, ⁵Tokushima University Graduate School of Biomedical Sciences, Tokushima, JP, ⁶Akita University Graduate School of Medicine, Akita, JP, ⁷Tokyo Women's Medical University, Tokyo, JP, ⁸Yamagata University Faculty of Medicine, Yamagata, JP, ⁹Kyushu University Graduate School of Medical Sciences, Higashi-ku Fukuoka, JP, ¹⁰Iwate Medical University School of Medicine, Morioka, JP, ¹¹Kindai University Faculty of Medicine, Osaka, JP, ¹²Memorial Sloan-Kettering Cancer Center, New York, US, ¹³Pfizer R&D Japan, Tokyo, JP, ¹⁴Pfizer Japan, Tokyo, JP, ¹⁵Keio University, Tokyo, JP

12:00 - 12:00 **957P - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)**

J. Finek¹, A. Poprach², B. Melichar³, J. Kopecky⁴, M. Zemanova⁵, T. Buchler⁶, K. Kopeckova⁷, T. Mlcoch⁸, T. Dolezal⁹, O. Fiala¹, ¹University Hospital Plzen, Plzen, CZ, ²Masaryk Memorial Cancer Institute, Brno, CZ, ³University Hospital Olomouc, Olomouc, CZ, ⁴University Hospital (Fakultni Nemocnice), Hradec Kralove, CZ, ⁵General University Hospital in Prague, Prague, CZ, ⁶Thomayer University Hospital, Prague, CZ, ⁷Motol University Hospital, Prague, CZ, ⁸Institute of Health Economics and Technology Assessment, Prague, CZ, ⁹Institute of Health Economics and Technology Assessment and

Faculty of Medicine, Masaryk University, Prague, CZ

12:00 - 12:00 **958P - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials**

K. Thein¹, F. Mogollon-Duffo¹, S. Swarup¹, A. Sultan¹, R. Yendala¹, N. Jahan¹, M. Quirch¹, S. Ball¹, T. Win Htut², N. D'Cunha¹, S. Rehman¹, F. Hardwicke¹, S. Awasthi¹, L. Tijani¹, ¹Texas Tech University, Lubbock, US, ²Colchester Hospital, Colchester, GB

12:00 - 12:00 **959P - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)**

V. Grünwald¹, C. Grüllich², P. Ivanyi³, M. Wirth⁴, P. Staib⁵, M. Schostak⁶, P. Dargatz⁷, L. Müller⁸, M. Metz⁹, L. Bergmann¹⁰, M. Welslau¹¹, P. Schütt¹², M.-R. Rafiyan¹³, E. Hellmis¹⁴, A. Hinke¹⁵, J. Meiler¹⁶, T. Kretz¹⁷, W.C. Loidl¹⁸, A. Flörcken¹⁹, T. Steiner²⁰, ¹University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ²Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, ³Hannover Medical School, Hannover, DE, ⁴Uniklinikum Dresden, Dresden, DE, ⁵St. Antonius Hospital Klinik für Hämatologie/Onkologie, Eschweiler, DE, ⁶DKG-zertifiziertes Prostatakrebszentrum, Magdeburg, DE, ⁷Johannes Wesling Klinikum Minden, Minden, DE, ⁸Studienzentrum Unter Ems, Leer, DE, ⁹OSP Göttingen, Göttingen, DE, ¹⁰Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, ¹¹Klinikum Aschaffenburg, Aschaffenburg, DE, ¹²Onkologie Gütersloh, Gütersloh, DE, ¹³Nordwest-Krankenhaus, Frankfurt am Main, DE, ¹⁴Urologicum Duisburg, Duisburg, DE, ¹⁵CCRC, Berlin, DE, ¹⁶Klinik Dr. Hancken, Stade, DE, ¹⁷Urologische Gemeinschaftspraxis Heinsberg, Berlin, DE, ¹⁸Krankenhaus der Barmherzigen Schwestern Linz (bhslinz), Linz, AT, ¹⁹Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ²⁰Helios Klinikum Erfurt, Erfurt, DE

12:00 - 12:00 **960P - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)**

S. Hans¹, A. Simonaggio², K. Hamidatou², L. Fournier², C. Thibault², R.-T. Elaidi³, S. Oudard², Y. Vano⁴, ¹Assistance Publique - Hopitaux De Paris, Paris, FR, ²Hopital European George Pompidou, Paris, FR, ³ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Paris, FR, ⁴Hôpital Européen Georges Pompidou, Paris, FR

12:00 - 12:00 **961P - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES Study**

C. Masini¹, P. Ciammella², G. Timon², R. Gnoni³, U.F.F. De Giorgi⁴, S.R. Bellia⁴, S. Buti⁵, F. Salaroli⁶, M. Milella⁷, R. Mazzarotto⁸, C. Mucciardini⁹, M.G. Vitale¹⁰, A. Bruni¹⁰, G. Procopio¹¹, S. Kinspergher¹², F. Nole¹³, F. Morelli¹⁴, G. Pappagallo¹⁵, C. Buttigliero¹⁶, C. Pinto¹, ¹Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, ²Radiation Oncology Unit, AUSL - IRCCS di Reggio Emilia, Italy, Reggio Emilia, IT, ³Medical Oncology Unit, Clinical Cancer Centre, AUSL-IRCCS, Reggio Emilia, Italy, Reggio Emilia, IT, ⁴Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ⁵AOU di Parma, Parma, IT, ⁶Radiotherapy Unit, University Hospital of Parma, Parma, Italy, Parma, IT, ⁷Università degli Studi di Verona, Verona, IT, ⁸Azienda Ospedaliera Universitaria integrata di Verona, Verona, IT, ⁹Ospedale Ramazzini di Capri, Carpi, IT, ¹⁰Azienda

Ospedaliera Universitaria di Modena, Modena, Italy, Modena, IT, ¹¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ¹²Santa Chiara Hospital, Trento, Italy, Trento, IT, ¹³Istituto Europeo di Oncologia, Milan, IT, ¹⁴Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza, SAN GIOVANNI ROTONDO (FG), IT, ¹⁵Unita Locale Socio Sanitaria 13 P.O Mirano, Mirano, IT, ¹⁶Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT

12:00 - 12:00 **962P - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review**

J. Hack¹, S. Hill², J. Broadfoot², C. Chau², T. Geldart³, J. Gale⁴, K. Fife⁵, M. Wheeler⁶,
¹Salisbury District Hospital NHS Trust, Salisbury, GB, ²Queen Alexandra Hospital Portsmouth Oncology Centre, Portsmouth, GB, ³Royal Bournemouth Hospital, Bournemouth, GB, ⁴St. Mary's Hospital Portsmouth Oncology Centre, Portsmouth, GB, ⁵Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB, ⁶Southampton General Hospital Southampton University Hospitals NHS Trust, Southampton, GB

12:00 - 12:00 **963P - "A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC)."**

M. Campbell¹, S. Martin², A. Tam³, R. Sheth³, S. Singh³, K. Ahrar³, B. Slack Tidwell³, P. Rao³, J. Karam⁴, C. Wood³, N. Tannir³, E. Jonasch⁵, J. Gao⁶, A. Shah³, J. Blando³, F. Duan³, S. Basu³, J. Allison³, P. Sharma³, S. Singh³, ¹The M. D. Anderson Cancer Center, Houston, US, ²The University of Texas MD Anderson Cancer Center, HOUSTON, US, ³MD Anderson Cancer Center, Houston, US, ⁴MD Anderson Cancer Center, HOUSTON, US, ⁵The University of Texas MD Anderson Cancer Center, Houston, US, ⁶The University of Texas M. D. Anderson Cancer Center, Houston, US

12:00 - 12:00 **964P - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience**

A. Wiele¹, J. Ross¹, J. Chahoud¹, Z. Lim², L. Xiao¹, M. Campbell³, A. Shah², A. Zurita Saavedra⁴, E. Jonasch⁴, N. Tannir², ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²MD Anderson Cancer Center, Houston, US, ³The M. D. Anderson Cancer Center, Houston, US, ⁴The University of Texas MD Anderson Cancer Center, Houston, US

12:00 - 12:00 **965P - Weight loss is an underestimated adverse event with cabozantinib in patients with metastatic renal cell carcinoma (mRCC).**

E. Colomba¹, C. Alves Costa Silva², G. Le Teuff¹, A. Benchimol-Zouari³, A. Guida⁴, L. Derosa¹, B. Raynard¹, B. Escudier⁵, L. Albiges⁶, ¹Gustave Roussy, Villejuif, FR, ²Instituto de Oncologia Sao Paulo, Sao Paulo, BR, ³Gustave Roussy Institute, Villejuif, FR, ⁴Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR, ⁶Institut Gustave Roussy, Villejuif, FR

12:00 - 12:00 **966P - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.**

F. Lefort¹, C. Dalban², M. Gross-Goupil³, B. Laguerre⁴, P. Barthelemy⁵, V. Sarradin⁶, B. Chanez⁷, S. Negrier², L. Geoffrois⁸, P. Gillon⁹, M. De Vries¹⁰, S. Ladoire¹¹, C. Bolognini¹², M. Laramas¹³, F. Priou¹⁴, S. Oudard¹⁵, S. Chabot¹⁶, F. Tantot¹⁷, B. Escudier¹⁸, L. Albiges¹⁹, ¹CHU Bordeaux - Hopital St. André, Bordeaux, FR, ²Centre Léon Bérard, Lyon, FR, ³CHU Bordeaux Hopital St. André, Bordeaux, FR, ⁴Centre Eugene - Marquis, Rennes, FR, ⁵C.H.U. Strasbourg-Nouvel Hopital Civil, Strasbourg, FR, ⁶Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ⁷Institute Paoli Calmettes, Marseille, FR, ⁸Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, ⁹Centre Antoine Lacassagne, Nice, FR, ¹⁰Institut de cancérologie de l'Ouest - Paul Papin, Angers, FR, ¹¹Centre Georges-François Leclerc (Dijon), Dijon, FR, ¹²CHRU Besancon - Hopital Jean Minjoz, Besançon, FR, ¹³Grenoble Alpes University Hospital, La Tronche, FR, ¹⁴CHD Vendee - Hopital Les Oudairies, La Roche sur Yon, FR, ¹⁵Hopital European George Pompidou, Paris, FR, ¹⁶Centre Léon Bérard, LYON, FR, ¹⁷Unicancer, PARIS, FR, ¹⁸Gustave Roussy - Cancer Campus, Villejuif, FR, ¹⁹Institut Gustave Roussy, Villejuif, FR

12:00 - 12:00

967P - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma

C. Alves Costa Silva¹, D. Afonso², E. Colomba³, G. Le Teuff³, L. Derosa⁴, B. Raynard³, A. Guida⁵, A. Benchimol-Zouari², B. Escudier⁶, F. Bidault², L. Albiges⁴, ¹Instituto de Oncologia Sao Paulo, Sao Paulo, BR, ²Gustave Roussy Institute, Villejuif, FR, ³Gustave Roussy, Villejuif, FR, ⁴Institut Gustave Roussy, Villejuif, FR, ⁵Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ⁶Gustave Roussy - Cancer Campus, Villejuif, FR

12:00 - 12:00

968P - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).

M. Hackl¹, H. Karim-Kos², S. Madersbacher³, M. Rauchenwald⁴, M. Marszalek⁵, ¹Statistic Austria, Vienna, AT, ²Erasmus MC University Medical Center, Rotterdam, NL, ³KFJ, Vienna, AT, ⁴Sozialmedizinisches Zentrum Ost - Donauspital, Vienna, AT, ⁵SMZ Ost, Vienna, AT

12:00 - 12:00

969P - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany

P. Goebell¹, L. Mueller², C. Grüllich³, D. Reichert⁴, M. Bögemann⁵, S. Dörfel⁶, E. Von Der Heyde⁷, A. Binniger⁸, M. Jänicke⁸, M. Merling⁸, N. Marschner⁹, M. Staehler¹⁰, V. Grünwald¹¹, ¹Universitätsklinik Erlangen, Erlangen, DE, ²Onkologische Schwerpunktpraxis Leer-Emden, Leer, DE, ³Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, ⁴Gemeinschaftspraxis für Hämatologie und Onkologie, Westerstede, DE, ⁵Universitätsklinikum Münster AöR, Münster, DE, ⁶Onkozentrum Dresden, Dresden, DE, ⁷Onkologische Schwerpunktpraxis, Hannover, DE, ⁸iOMEDICO, Freiburg, DE, ⁹iOMEDICO AG, Freiburg, DE, ¹⁰University of Munich, Munich, DE, ¹¹University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

12:00 - 12:00

970P - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate

M. De Vries-Brilland¹, E. Menand¹, V. Seegers¹, J. Dauvé¹, C. Passot¹, J.-M. Marion², P.

Chauvet², A. Morel³, M. Gross-Goupil⁴, A. Ravaud⁴, E. Boughalem¹, B. Escudier⁵, L. Albiges⁶, ¹Centre Paul Papin, Angers, FR, ²Université Catholique de l'Ouest, Angers, FR, ³Integrative Center for Oncology, Angers, FR, ⁴CHU Bordeaux Hopital St. André, Bordeaux, FR, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR, ⁶Institut Gustave Roussy, Villejuif, FR

12:00 - 12:00 **971P - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma**

M. Regan¹, M. Atkins², T. Powles³, L. Werner⁴, C. Mantia⁵, S. Yang⁶, J. Johansen⁷, S. Rao⁷, K. Gooden⁷, D. Mcdermott⁸, ¹Dana Farber Cancer Institute, Boston, US, ²Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC, US, ³Barts Cancer Institute, London, GB, ⁴Dana-Farber Cancer Institute, Harvard University, Boston, US, ⁵Beth Israel Deaconess Medical Center, Boston, US, ⁶Bristol Myers Squibb, Princeton, US, ⁷Bristol Myers Squibb, Princeton, US, ⁸Beth Israel Deaconess Med. Center, Boston, US

12:00 - 12:00 **972P - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome**

A. Desnoyer¹, A. Larive¹, D. Drubay¹, E. Lanoy², Y. Vano³, N. Rioux-Leclercq⁴, S. Chouaib⁵, B. Beuselinck⁶, F. Tantot⁷, B. Escudier⁸, N. Chaput⁹, L. Albiges², ¹Gustave Roussy Cancer Campus, Villejuif, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Hôpital Européen Georges Pompidou, Paris, FR, ⁴CHU, Université de Rennes, France, Rennes, FR, ⁵Institut Gustave Roussy, Univ. Paris-Sud, Université Paris-Saclay, Villejuif, FR, ⁶University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁷Unicancer, PARIS, FR, ⁸Gustave Roussy - Cancer Campus, Villejuif, FR, ⁹Gustave Roussy Institut de Cancérologie, Villejuif, FR

12:00 - 12:00 **973P - Advanced clear-cell renal cell carcinoma (accRCC): association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome.**

A. Verbiest¹, V. Van Hoef², D. Lambrechts³, C. Rodriguez Antona⁴, O. Grana-Castro⁴, L. Inglada-Perez⁴, M. Albersen³, M. Baldewijns³, A. Laenen¹, P. Schoeffski³, A. Wozniak⁵, G. Couchy⁶, S. Caruso⁶, J. Zucman-Rossi⁷, B. Beuselinck⁵, ¹KU Leuven, Leuven, BE, ²VIB, Leuven, BE, ³University Hospitals Leuven, Leuven, BE, ⁴CNIO, Madrid, ES, ⁵University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁶INSERM, Paris, FR, ⁷Université Paris Descartes, Paris, FR

12:00 - 12:00 **974P - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota 'guilds' in renal cell carcinoma (RCC) patients**

V. Iebba¹, L. Albiges¹, L. Alla², E. Colomba³, C. Alves Costa Silva⁴, N. Pons², G. Baciarello³, E. Le Chatelier², K. Fizazi¹, B. Routy⁵, B. Escudier⁶, L. Zitvogel⁷, L. Derosa¹, ¹Institut Gustave Roussy, Villejuif, FR, ²INRA French National, Magny-les-Hameaux, FR, ³Gustave Roussy, Villejuif, FR, ⁴Instituto de Oncologia Sao Paulo, Sao Paulo, BR, ⁵University of Montreal Research Center, Montreal, CA, ⁶Gustave Roussy - Cancer Campus, Villejuif, FR, ⁷Gustave Roussy Institut de Cancérologie, Villejuif, FR

12:00 - 12:00 **975P - mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors**

C. Suarez Rodriguez¹, J. Arranz Arika², R. Morales Barrera¹, J. Puente³, O. Reig⁴, L. Faez⁵, A. González Del Alba⁶, B. P. Valderrama⁷, E. Gallardo⁸, B. Mellado⁹, E. Esteban⁵, J. Jimenez¹, A. Vivancos¹, J. Carles¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Hospital General Universitario Gregorio Marañón, Madrid, ES, ³Hospital Clinico Universitario San Carlos, Madrid, ES, ⁴Hospital Clínic Barcelona, Barcelona, ES, ⁵Hospital Universiatrio Central Asturias, Oviedo, ES, ⁶Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES, ⁷Hospital Universitario Virgen del Rocío, Sevilla, ES, ⁸Hospital Parc Taulí, Sabadell, ES, ⁹Hospital Clinic y Provincial de Barcelona, Barcelona, ES

12:00 - 12:00

976P - Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in Advanced Renal Cell Carcinoma (RCC)

A.-K. Lalani¹, Z. Bakouny¹, S. Farah¹, W. Xie¹, R. Flippot², J. Steinharter³, P.V. Nuzzo⁴, J. Fleischer¹, S. Pal⁵, N. Rathi⁶, A. Hansen⁷, F. Donskov⁸, S. Dudani⁹, T. Yuasa¹⁰, U. Vaishampayan¹¹, M. Subasri¹², J. Wells¹³, N. Basappa¹⁴, D. Heng¹⁵, T. Choueiri¹, ¹Dana-Farber Cancer Institute, Boston, US, ²Institut Gustave Roussy, Villejuif, FR, ³Dana Farber Cancer Institute, Boston, US, ⁴IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ⁵City of Hope, Duarte, US, ⁶Huntsman Cancer Institute, Salt Lake City, US, ⁷Princess Margaret Cancer Center, Toronto, CA, ⁸Aarhus University Hospital, Aarhus, DK, ⁹The Ottawa Hospital Regional Cancer Centre, Ottawa, CA, ¹⁰Japanese Foundation for Cancer Research, Tokyo, JP, ¹¹Barbara Ann Karmanos Cancer Institute, Detroit, US, ¹²Western, London, CA, ¹³Canadian Cancer Trials Group, Kingston, CA, ¹⁴University of Alberta Cross Cancer Institute, Edmonton, CA, ¹⁵University of Calgary, Calgary, CA

12:00 - 12:00

977P - Finding the Right Biomarker for Renal Cell Carcinoma (RCC): Nivolumab treatment induces the expression of specific peripheral lymphocyte microRNAs in patients with durable and complete response.

L. Incorvaia¹, D. Fanale¹, G. Badalamenti¹, J.L. Iovanna², L. Corsini³, A. Simonato³, V. Bazan³, C.G. Porta⁴, A. Russo³, ¹AOU Policlinico "Paolo Giaccone", Palermo, IT, ²Centre de Recherche en Cancérologie de Marseille, Marseille, FR, ³University of Palermo, Palermo, IT, ⁴IRCCS Istituti Clinici Scientifici Maugeri, Pavia, IT

12:00 - 12:00

978P - Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)

I.H. Um¹, L. Scott-Hayward¹, M. Mackenzie¹, P.H. Tan², R. Kanesvaran³, Y. Choudhury⁴, M.-H. Tan⁴, M. O'Donnell⁵, P. Caie¹, G. Stewart⁶, D.J. Harrison⁷, ¹University of St Andrews, St Andrews, GB, ²Singapore general hospital, Singapore, SG, ³NCCS - National Cancer Centre Singapore, Singapore, SG, ⁴Lucence Diagnostics, Singapore, SG, ⁵Western general hospital, Edinburgh, GB, ⁶University of Cambridge, Cambridge, GB, ⁷University of St Andrews, St Andrews, Scotland, GB

12:00 - 12:00

979P - High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma

A. Drljevic-Nielsen, F. Rasmussen, J. Mains, K. Thorup, F. Donskov, Aarhus University Hospital, Aarhus, DK

- 12:00 - 12:00 **980P - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)**
D. George¹, M. Casey², E. Degtyarev³, M. Lechuga Frean⁴, P. Aimone⁵, A. Ravaud⁶, S. Halabi⁷, R. Motzer⁸, ¹Duke University Medical Center, Durham, US, ²Pfizer Inc, Collegeville, US, ³Novartis Pharm AG, Basel, CH, ⁴Pfizer, Milan, IT, ⁵Novartis International AG - Basel, Basel, CH, ⁶CHU Bordeaux Hopital St. André, Bordeaux, FR, ⁷Duke University, Durham, US, ⁸Memorial Sloan-Kettering Cancer Center, New York, US
- 12:00 - 12:00 **981P - TERT gene fusions characterize a subset of metastatic Leydig cell tumors**
B. Kruslin¹, Z. Gatalica², O. Hes³, J. Xiu⁴, E. Florento⁴, J. Swensen⁴, ¹Clinical Hospital Centre, Zagreb, HR, ²Caris Life Sciences, New York, US, ³Biopticka Laborator, Plzen, CZ, ⁴Caris Life Sciences, Phoenix, US
- 12:00 - 12:00 **982P - Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): final results of phase II trial.**
A. Tryakin¹, M. Fedyanin², Y. Segeev², A. Bulanov³, V. Matveev¹, M. Volkova¹, A. Klimov², I. Fainstein², B. Akhmedov², S. Menshikova⁴, T. Zakharova², A. Garin¹, D. Chekini⁴, A. Chekini⁴, O. Sekhina⁴, S. Tjulandin⁵, ¹N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ²N.N. Blokhin National Medical Research Centre of Oncology, Moscow, RU, ³No place of work provided Iran, Teheran, IR, ⁴FSBI-N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ⁵N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU
- 12:00 - 12:00 **983P - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy**
L. Nappi¹, M. Thi², B. Eigl³, K. Chi³, M. Gleave⁴, A. So², P. Black², R. Hamilton⁵, S. Daneshmand⁶, C. Nichols⁷, C. Kollmannsberger³, ¹British Columbia Cancer Agency, Vancouver, CA, ²Vancouver Prostate Centre, Vancouver, CA, ³BC Cancer Agency - Vancouver, Vancouver, CA, ⁴University of British Columbia Faculty of Medicine, Vancouver, CA, ⁵Princess Margaret Cancer Centre, Toronto, CA, ⁶University of South California, Los Angeles, US, ⁷Testicular Cancer Commons, New York, US
- 12:00 - 12:00 **984P - Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)**
E. Garcia Torralba¹, D. Castellano Gauna², N. Sobrevilla³, J. Guma⁴, M.I. Luengo⁵, J. Aparicio⁶, A. Sanchez-Muñoz⁷, B. Mellado⁸, A. Saenz⁹, C. Valverde¹⁰, A. Fernández¹¹, M. Margeli¹², I. Duran¹³, S. Fernandez¹⁴, J. Sastre¹⁵, S. Ros¹⁶, P. Maroto¹⁷, J.L. Aguilar³, X. Garcia Del Muro¹⁸, E. Gonzalez Billalabeitia¹, ¹Hospital Universitario Morales Meseguer, Murcia, ES, ²University Hospital 12 De Octubre, Madrid, ES, ³Instituto Nacional de Cancerología, Mexico DF, MX, ⁴Hospital San Joan, Reus, ES, ⁵Hospital Santa Lucía, Cartagena, ES, ⁶Hospital La Fe, Valencia, ES, ⁷Hospital Virgen de la Victoria, Málaga, ES, ⁸Hospital Clínic de Barcelona, Barcelona, ES, ⁹Hospital Clinico Lozano Blesa, Zaragoza, ES, ¹⁰Vall d'Hebron University Hospital, Barcelona, ES, ¹¹Complejo Hospitalario Universitario de Albacete, Albacete, ES, ¹²Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, ES, ¹³Hospital Universitario Virgen del Rocio, Sevilla, ES, ¹⁴Hospital Central de Asturias, Oviedo, ES, ¹⁵Hospital Clínico San Carlos, Madrid, ES, ¹⁶Hospital Universitario Virgen de la Arrixaca, Murcia, ES, ¹⁷Hospital de la

Santa Creu i Sant Pau, Barcelona, ES, ¹⁸ICO - Institut Catala d'Oncologia Hospital Duran i Reynals, Hospitalet de Llobregat, ES

- 12:00 - 12:00 **985P - The Effects Of Primary Testicular Tumor Localization On Prognosis In Patients With Nonseminomatous Testis Cancer**
B. Yildiz¹, E. Esin², B. Basgoz³, I. Erturk³, R. Acar³, N. Karadurmuş⁴, ¹Ege University Medical School, Izmir, TR, ²ANKARA DR.A.Y. ONCOLOGY HOSPITAL, ANKARA, TR, ³Gülhane medicine hospital, ANKARA, TR, ⁴Gulhane Education and Research Hospital, Ankara, TR
- 12:00 - 12:00 **986P - Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastatic Adrenal Tumors.**
M. Campbell¹, W. Xie², A. Shah³, M. Habra⁴, C. Jimenez⁴, A. Venkatesan⁵, G. Bubley⁶, R. Mckay⁷, T. Choueiri², B. Mcgregor⁸, K. Killbridge², A. Mortazavi⁹, M. Bilen¹⁰, ¹The M. D. Anderson Cancer Center, Houston, US, ²Dana-Farber Cancer Institute, Boston, US, ³MD Anderson Cancer Center, Houston, US, ⁴The University of Texas MD Anderson Cancer Center, Houston, US, ⁵The University of Texas MD Anderson Cancer Center, HOUSTON, US, ⁶Beth Israel Deaconess Medical Center, Boston, US, ⁷University of California San Diego, La Jolla, US, ⁸Dana Farber Cancer Institute, Boston, US, ⁹The Ohio State University, Columbus, US, ¹⁰Emory University Winship Cancer Institute, Atlanta, US
- 12:00 - 12:00 **987TiP - NEMIO: a randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma**
C. Thibault¹, F. Audenet², D. Borchiellini³, O. Huillard⁴, P. Barthelemy⁵, D. Pouessel⁶, A. Flechon⁷, H. Blons¹, C. Sautès-Fridman⁸, C.-M. Sun⁸, V. Verkarre¹, N. Pallet¹, A. Mejean⁹, M. Rouabah¹⁰, I. Helali¹¹, R.-T. Elaidi¹¹, S. Oudard¹, ¹Hopital European George Pompidou, Paris, FR, ²Université Paris Descartes, PARIS, FR, ³Centre Anticancer Antoine Lacassagne, Nice, FR, ⁴Hôpital Cochin, Paris, FR, ⁵C.H.U. Strasbourg-Nouvel Hopital Civil, Strasbourg, FR, ⁶Institut Claudius Régaud, TOULOUSE, FR, ⁷Centre Léon Bérard, Lyon, FR, ⁸Cordeliers Research Center, Paris, FR, ⁹Paris Descartes University, Paris, FR, ¹⁰Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Paris, FR, ¹¹ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Paris, FR
- 12:00 - 12:00 **988TiP - KEYNOTE-866: Phase 3 Study of Perioperative Pembrolizumab (pembro) or Placebo (pbo) in Combination With Neoadjuvant Chemotherapy in Cisplatin (cis)-Eligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)**
A. Siefker-Radtke¹, G. Steinberg², J. Bedke³, H. Nishiyama⁴, J. Martin⁵, R. Kataria⁶, T. Frenkl⁵, C. Hoimes⁷, ¹The M. D. Anderson Cancer Center, Houston, US, ²Stanford Moyamoya Center, Stanford, US, ³University of Tuebingen, Tuebingen, DE, ⁴Tokyo University of Scient, Tokyo, JP, ⁵Merck & Co., Inc., Kenilworth, US, ⁶MSD-Merck Sharp & Dohme, Kenilworth, US, ⁷Case Western Reserve University / University Hospitals, Cleveland, US
- 12:00 - 12:00 **989TiP - KEYNOTE-905: A Phase 3 Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin (cis)-Ineligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)**

M. Galsky¹, A. Necchi², N. Shore³, F. Witjes⁴, K. Nam⁵, J. Godwin⁵, T. Frenkl⁵, E. Plimack⁶, ¹Icahn School of Medicine at Mount Sinai Hospital, New York, US, ²Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ³Carolina Urologic Research Center, Myrtle Beach, US, ⁴Radboudumc, Nijmegen, NL, ⁵Merck & Co., Inc., Kenilworth, US, ⁶Fox Chase Cancer Center, Philadelphia, US

12:00 - 12:00 **990TiP - Phase 3 LEAP-011 trial: First-Line Pembrolizumab With Lenvatinib in Patients With Advanced Urothelial Carcinoma Ineligible to Receive Platinum-Based Chemotherapy**

Y. Loriot¹, A. Balar², R. De Wit³, J. Garcia⁴, P. Grivas⁵, N. Matsubara⁶, T. Frenkl⁷, E. Sbar⁷, X.C. Jia⁷, T. Fouad⁸, A. Siefker-Radtke⁹, ¹Institut Gustave Roussy, Villejuif, FR, ²NYU Langone, New York, US, ³Erasmus Medical Center, Rotterdam, NL, ⁴Cleveland Clinic, Cleveland, US, ⁵University of Washington Seattle Cancer Care Alliance, Seattle, US, ⁶National Cancer Center East, Chiba, JP, ⁷Merck & Co., Inc., Kenilworth, US, ⁸The University of Texas MD Anderson Cancer Center, Houston, US, ⁹The M. D. Anderson Cancer Center, Houston, US

12:00 - 12:00 **991TiP - PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (mSCPC).**

N. Gassian¹, G. Mouillet¹, D. Vernerey², O. Manseur³, A. Frontczak¹, A. Meurisse⁴, D. Berthod¹, E. Robert¹, F. Calcagno¹, A. Thiery-Vuillemin¹, ¹CHRU Besançon - Hopital Jean Minjoz, Besançon, FR, ²MSD, FR, ³Franche Comté, Besançon, FR, ⁴Besançon University Hospital, Besançon, FR

12:00 - 12:00 **Melanoma and other skin tumours**

12:00 - 12:00 **(Withdrawn)**

12:00 - 12:00 **1318P - Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti-PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)**

D. Rischin¹, A. Lim², C. Schmults³, N. Khushalani⁴, B. Hughes⁵, D. Schadendorf⁶, L. Dunn⁷, A.L. Chang⁸, A. Hauschild⁹, C. Ulrich¹⁰, T. Eigentler¹¹, M. Migden¹², A. Pavlick¹³, J. Geiger¹⁴, E. Stankevich¹⁵, S. Li¹⁵, I. Lowy¹⁶, M. Fury¹⁵, A. Guminski¹⁷, ¹Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, AU, ²Sir Charles Gairdner Hospital, Perth, AU, ³Brigham and Women's Hospital, Harvard Medical School, Boston, US, ⁴Roswell Park Comprehensive Cancer Center, Buffalo, US, ⁵Royal Brisbane & Women's Hospital and University of Queensland, Brisbane, AU, ⁶University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ⁷Memorial Sloan Kettering Cancer Center, New York, US, ⁸Stanford University School of Medicine, Redwood City, US, ⁹UK-SH, Campus Kiel, Kiel, DE, ¹⁰Charité Universitätsmedizin Berlin, Berlin, DE, ¹¹University Medical Center Tübingen, Tübingen, DE, ¹²University of Texas MD Anderson Cancer Center, Houston, US, ¹³New York University Langone Medical Center, New York, US, ¹⁴Cleveland Clinic, Cleveland, US, ¹⁵Regeneron Pharmaceuticals, Inc., Tarrytown, US, ¹⁶Regeneron Pharmaceuticals Inc, Tarrytown, US, ¹⁷Royal North Shore Hospital, St Leonards, AU

- 12:00 - 12:00 **1319P - Avelumab for advanced Merkel cell carcinoma in the Netherlands; a nationwide survey**
S. Levy¹, M. Aarts², F. Eskens³, K. Keymeulen⁴, L. Been⁵, D. Grünhagen⁶, A. Van Akkooi⁷, M. Jalving⁸, M. Tesselaar¹, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²Atrium Medisch Centrum, Maastricht, NL, ³Erasmus University Medical Center, Rotterdam, NL, ⁴Maastricht University Medical Center (MUMC), Maastricht, NL, ⁵UMCG, Groningen, NL, ⁶Erasmus MC Cancer Institute, Rotterdam, NL, ⁷The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁸University Medical Center Groningen, University of Groningen, Groningen, NL
- 12:00 - 12:00 **1320P - Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data**
S. D'Angelo¹, S. Nolte², M. Schlichting³, M. Henry-Szatkowski², M. Hennessy⁴, M. Bharmal⁵, ¹Memorial Sloan-Kettering Cancer Center, New York, US, ²ICON plc, London, GB, ³Merck Germany, Darmstadt, DE, ⁴EMD Serono Research Center, Billerica, US, ⁵Merck KGaA - Germany, Darmstadt, DE
- 12:00 - 12:00 **1321P - A Phase 2, Randomized Study of Nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and Stereotactic Body Radiation Therapy (SBRT) for Metastatic Merkel Cell Carcinoma (MCC, NCT03071406) - a preliminary report.**
S. Kim¹, N. Khushalani², Z. Eroglu³, J. Russell⁴, E. Wuthrick³, J. Caudell³, L. Harrison³, M. Aoki³, H. Shah⁵, D. Blakaj⁶, J. Markowitz³, D.-T. Chen³, J. Messina³, T. Rose³, K. Tsai³, A. Brohl³, ¹H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ²Roswell Park Comprehensive Cancer Center, Buffalo, US, ³H. Lee Moffitt Cancer Center, Tampa, US, ⁴Jansen, Philadelphia, US, ⁵Ohio State University, Columbus, US, ⁶The Ohio State University James Cancer Hospital, Columbus, US
- 12:00 - 12:00 **1322P - Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma**
K. Bol¹, E. Ellebaek², M. Donia³, H. Schmidt⁴, L. Bastholt⁵, J. Kiilgaard⁶, I.-M. Svane³, ¹Radboud University Medical Center, Nijmegen, NL, ²Copenhagen University Hospital, Herlev, DK, ³Herlev Hospital, Herlev, DK, ⁴Aarhus University Hospital, Aarhus, DK, ⁵Odense University Hospital, Odense C, DK, ⁶Copenhagen University Hospital, Copenhagen, DK
- 12:00 - 12:00 **1323P - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients**
M. Saint-Ghislain¹, L. Geoffrois², L. Gastaud³, T. Lesimple⁴, S. Negrier⁵, N. Penel⁶, J.-E. Kurtz⁷, Y. Le Corre⁸, S. Gardrat⁹, R. Barnhill⁹, N. Cassoux⁹, P. Mariani⁹, V. Servois⁹, S. Piperno-Neumann⁹, M. Rodrigues⁹, ¹Centre Henri Becquerel, Rouen, FR, ²Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, ³Centre Antoine Lacassagne, Nice, FR, ⁴Centre Eugene - Marquis, Rennes, FR, ⁵Centre Léon Bérard, Lyon, FR, ⁶Centre Oscar Lambret, Lille, FR, ⁷CHU Hautepierre, Strasbourg, FR, ⁸CHU Angers, Angers, FR, ⁹Institut Curie, Paris, FR

- 12:00 - 12:00 **1324P - Incidence and survival of Uveal Melanoma occurring as single cancer versus its occurrence as a first or second primary neoplasm**
A. Alfaar¹, A. Saad², S. Elzouki³, ¹Charité - Universitätsmedizin Berlin, Berlin, DE, ²Ain Shams University, Cairo, EG, ³Ulm University, Braunschweig, DE
- 12:00 - 12:00 **1325P - Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) Model for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma**
E. Mulder¹, J. Dwarkasing², L. Hollestein¹, D. Tempel², L. Bosman², D. Verver¹, A. Mooyaart¹, A. Van Der Veldt³, C. Verhoef¹, T. Nijsten¹, D. Grünhagen¹, ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²SkylineDx, Rotterdam, NL, ³Erasmus University Medical Center, Rotterdam, NL
- 12:00 - 12:00 **1326P - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the Surveillance, Epidemiology and End Results (SEER) Program**
A. Tjokrowidjaja¹, L. Browne², H. Soudy³, ¹NHMRC Clinical Trials Centre, Camperdown, AU, ²St George Hospital, Kogarah, AU, ³Faculty of Medicine Cairo University, Cairo, EG
- 12:00 - 12:00 **1327P - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).**
I. Pires Da Silva¹, S. Lo², M. Carlino³, R. Scolyer⁴, A. Menzies⁵, G. Long⁶, ¹Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, PT, ²The University of Sydney School of Public Health, Sydney, AU, ³The Crown Princess Mary Cancer Centre, Westmead, AU, ⁴Royal Prince Alfred Hospital, Camperdown, AU, ⁵Melanoma Institute Australia, University of Sydney, North Sydney, AU, ⁶Melanoma Institute Australia, Wollstonecraft, AU
- 12:00 - 12:00 **1328P - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.**
I. Reijers¹, E. Rozeman², A. Menzies³, J. Versluis², B. Van De Wiel², K. Sikorska², H. Eriksson⁴, K. Shannon³, C. Bierman², H. Van Tinteren², M. Gonzalez³, A. Spillane³, R. Saw³, R. Scolyer⁵, A. Van Akkooi⁶, J. Hansson⁴, G. Long⁷, C. Blank⁶, ¹Netherlands Cancer Institute, Amsterdam, NL, ²Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ³Melanoma Institute Australia, University of Sydney, North Sydney, AU, ⁴Karolinska Institutet, Stockholm, SE, ⁵Royal Prince Alfred Hospital, Camperdown, AU, ⁶The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁷Melanoma Institute Australia, Wollstonecraft, AU
- 12:00 - 12:00 **1329P - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)**
J. Versluis¹, I. Reijers², E. Rozeman¹, A. Van Akkooi³, W. Van Houdt⁴, C. Bierman¹, B. Van De Wiel¹, G. Long⁵, C. Blank⁶, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²Netherlands Cancer Institute, Amsterdam, NL, ³Netherlands Cancer Institute/Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL,

⁴Royal Marsden Hospital NHS Foundation Trust, London, GB, ⁵Melanoma Institute Australia, Wollstonecraft, AU, ⁶The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

12:00 - 12:00

1330P - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice

T. Hieken¹, C. Day¹, M. Block², E. Habermann¹, ¹Mayo Clinic, Rochester, US, ²Mayo Clinic, ROCHESTER, US

12:00 - 12:00

1331P - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial

J. Weber¹, M. Kurt², M. Edmondson-Jones³, A. Amadi⁴, M. Lobo², A. Moshyk⁵, S. Kotapati⁵, P. Mohr⁶, ¹NYU Langone Medical Center, New York, US, ²Bristol-Myers Squibb, Princeton, US, ³Parexel, Waltham, US, ⁴Bristol-Myers Squibb, Uxbridge, London, GB, ⁵Bristol Myers Squibb, Princeton, US, ⁶Dermatologic Center Buxtehude, Buxtehude, DE

12:00 - 12:00

1332P - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis

C. Dutriaux¹, C. Robert², J.J. Grob³, L. Mortier⁴, O. Dereure⁵, C. Lebbe⁶, S. Mansard⁷, F. Grange⁸, E.-M. Neidhardt⁹, T. Lesimple¹⁰, L. Machet¹¹, C. Bedane¹², H. Maillard¹³, S. Dalac-Rat¹⁴, C. Nardin¹⁵, A. Szenik¹⁶, A. Denden¹⁷, P. Saiag¹⁸, ¹CHU Bordeaux - Hopital St. André, Bordeaux, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ⁴Hopital Claude Huriez, Lille, FR, ⁵Hopital Saint-Eloi (Montpellier), Montpellier, FR, ⁶Hôpital Saint Louis, Paris, FR, ⁷CHU Estaing, Clermont-Ferrand, FR, ⁸CHU Reims-Hôpital Robert Debre, Reims, FR, ⁹Centre Léon Bérard, Lyon, FR, ¹⁰Centre Eugene - Marquis, Rennes, FR, ¹¹CHRU Tours, Tours Cedex, FR, ¹²CHU Limoges - Hopital Dupuytren, Limoges, FR, ¹³CHU Le Mans, Le Mans, FR, ¹⁴CHU Dijon, Dijon, FR, ¹⁵GUSTAVE ROUSSY, Villejuif, FR, ¹⁶Novartis Pharma - France, Rueil-Malmaison, FR, ¹⁷Novartis Pharma S.A.S., Rueil-Malmaison, FR, ¹⁸Hopital Ambroise Pare, Boulogne-Billancourt, FR

12:00 - 12:00

1333P - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting

J.J. Grob¹, V. Atkinson², C. Robert³, D. Schadendorf⁴, P. Nathan⁵, M. Davies⁶, R. Kefford⁷, R. Dummer⁸, J. Kirkwood⁹, K. Flaherty¹⁰, A. Ribas¹¹, P. Burgess¹², E. Gasal¹³, G. Long¹⁴, A. Hauschild¹⁵, ¹Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ²Princess Alexandra Hospital, Woolloongabba, AU, ³Institut Gustave Roussy, Villejuif, FR, ⁴University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ⁵Mount Vernon Cancer Centre, Northwood, GB, ⁶The University of Texas MD Anderson Cancer Center, Houston, US, ⁷Macquarie University, Macquarie Park, AU, ⁸Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, ⁹University of Pittsburgh, Pittsburgh, US, ¹⁰Massachusetts General Hospital, Harvard Medical School, Boston, US, ¹¹Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US, ¹²Novartis Pharma AG, Basel, CH, ¹³Novartis Pharmaceuticals Corporation, New Jersey, US, ¹⁴Melanoma Institute Australia, Wollstonecraft, AU, ¹⁵UK-SH, Campus Kiel, Kiel, DE

- 12:00 - 12:00 **1334P - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma**
P. Rutkowski¹, P. Pauwels², J. Kerger³, B. Jacobs⁴, G. Maertens⁵, V. Gadeyne⁶, S. Liebert⁶, B. Neyns⁷, ¹The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, ²University Hospital Antwerp (UZA), Edegem, BE, ³Institute Jules Bordet, Brussels, BE, ⁴Biocartis NV Generaal de Wittelaan, Mechelen, BE, ⁵Biocartis, Mechelen, BE, ⁶NV Roche, Brussels, BE, ⁷Vrije Universiteit Brussel-Campus Jette, Brussels, BE
- 12:00 - 12:00 **1335P - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting - Interim results of the non-interventional COMBI-r study**
C. Berking¹, E. Livingstone², M. Weichenthal³, U. Leiter⁴, K. Wittmann⁵, T. Eigentler⁶, P. Mohr⁷, F. Kiecker⁸, C. Loquai⁹, D. Debus¹⁰, R. Gutzmer¹¹, ¹LMU Munich, Munich, DE, ²University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ³University of Kiel, Kiel, DE, ⁴University of Tuebingen, Tuebingen, DE, ⁵Novartis Pharma GmbH, Nürnberg, DE, ⁶Universitätsklinikum Tübingen, Tübingen, DE, ⁷Dermatologic Center Buxtehude, Buxtehude, DE, ⁸Charite-Universitätsmedizin Berlin, Berlin, DE, ⁹Universitätsmedizin Mainz, Mainz, DE, ¹⁰Klinikum Nürnberg, Nürnberg, DE, ¹¹Hannover Medical School, Klinik für Dermatologie, Allergologie und Venerologie, Hannover, DE
- 12:00 - 12:00 **1336P - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma**
O. Straume¹, J. Lorens², G. Gausdal³, B.T. Gjertsen², C. Schuster⁴, ¹Helse Bergen - Haukeland University Hospital, Bergen, NO, ²University of Bergen, Bergen, NO, ³BerGenBio ASA, Bergen, NO, ⁴Centre for Cancer Biomarkers, Bergen, NO
- 12:00 - 12:00 **1337P - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials**
C. Robert¹, D. Schadendorf², R. Dummer³, K. Flaherty⁴, H. Tawbi⁵, A. Menzies⁶, A. D'Amelio⁷, E. De Jong⁸, E. Gasal⁹, G. Long¹⁰, ¹Institut Gustave Roussy, Villejuif, FR, ²University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ³Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, US, ⁵The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁶Melanoma Institute Australia, University of Sydney, North Sydney, AU, ⁷Novartis Pharmaceuticals Corporation, East Hanover, US, ⁸Novartis, East Hanover, US, ⁹Novartis Pharmaceuticals Corporation, New Jersey, US, ¹⁰Melanoma Institute Australia, Wollstonecraft, AU
- 12:00 - 12:00 **1338P - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study**
P. Saiag¹, C. Robert², J.J. Grob³, L. Mortier⁴, O. Dereure⁵, C. Lebbe⁶, S. Mansard⁷, F. Grange⁸, E.-M. Neidhardt⁹, T. Lesimple¹⁰, L. Machet¹¹, C. Bedane¹², H. Maillard¹³, S. Dalac-Rat¹⁴, C. Nardin¹⁵, A. Szenik¹⁶, A. Denden¹⁷, C. Dutriaux¹⁸, ¹Hopital Ambroise Pare, Boulogne-Billancourt, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Hopital St.

Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ⁴Hopital Claude Huriez, Lille, FR, ⁵Hopital Saint-Eloi (Montpellier), Montpellier, FR, ⁶Hôpital Saint Louis, Paris, FR, ⁷CHU Estaing, Clermont-Ferrand, FR, ⁸CHU Reims-Hôpital Robert Debre, Reims, FR, ⁹Centre Léon Bérard, Lyon, FR, ¹⁰Centre Eugene - Marquis, Rennes, FR, ¹¹CHRU Tours, Tours Cedex, FR, ¹²CHU Limoges - Hopital Dupuytren, Limoges, FR, ¹³CHU Le Mans, Le Mans, FR, ¹⁴CHU Dijon, Dijon, FR, ¹⁵GUSTAVE ROUSSY, Villejuif, FR, ¹⁶Novartis Pharma - France, Rueil-Malmaison, FR, ¹⁷Novartis Pharma S.A.S., Rueil-Malmaison, FR, ¹⁸CHU Bordeaux - Hopital St. André, Bordeaux, FR

- 12:00 - 12:00 **1339P - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors**
P. Cheng¹, S. Freiburger², C. Panetti¹, A. Irmisch¹, R. Dummer¹, M. Levesque¹,
¹Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, ²University Hospital Zurich, Zurich, CH
- 12:00 - 12:00 **1340P - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region**
V. Franke¹, E. Stahlie², D. Berger², W. Klop², L. Zuur³, B. Van Der Hiel², B. Van De Wiel², M. Wouters⁴, W. Van Houdt², A. Van Akkooi⁵, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, NL, ³The Netherlands Cancer Institute, Amsterdam, NL, ⁴DICA - Dutch Institute for Clinical Auditing, Leiden, NL, ⁵The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 12:00 - 12:00 **1341P - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective**
V. Franke¹, E. Stahlie², B. Van Der Hiel², B. Van De Wiel¹, M. Wouters³, W. Van Houdt¹, A. Van Akkooi⁴, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, NL, ³DICA - Dutch Institute for Clinical Auditing, Leiden, NL, ⁴The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 12:00 - 12:00 **1342P - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study**
M. Middleton¹, K. Harrington², M. Ross³, K. Ohrling⁴, H.-S. Radcliffe⁵, F. Collichio⁶,
¹Churchill Hospital University of Oxford, Oxford, GB, ²The Institute of Cancer Research, London, GB, ³University of Texas MD Anderson Cancer Center, Houston, US, ⁴Amgen (Europe) GmbH, Rotkreuz, CH, ⁵Amgen Ltd, Uxbridge, GB, ⁶The University of North Carolina Chapel Hill, Chapel Hill, US
- 12:00 - 12:00 **1343P - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland**
C. Hoeller¹, J. Ressler², M. Karasek³, V. Aedo Lopez⁴, L. Koch⁵, H. Kehrer⁶, P. Koelblinger⁷, F. Weihsengruber⁸, J. Kofler⁹, E. Richtig¹⁰, O. Michielin¹¹, C. Hafner¹²,
¹Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT, ²Medical University of Vienna, Vienna, AT, ³University Hospital St. Poelten, St. Poelten, AT, ⁴CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ⁵Medical University of Graz,

Graz, AT, ⁶Krankenhaus der Elisabethinen, Linz, AT, ⁷Paracelsus Medical University, Salzburg, AT, ⁸Bristol Myers Squibb - Austria, Vienna, AT, ⁹Landeskrankenhaus LKH Klagenfurt am Woerthersee, Klagenfurt, AT, ¹⁰Institute of Pathology, Medical University of Graz, Graz, AT, ¹¹Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ¹²University Hospital St. Pölten, Karl Landsteiner University of Health Sciences, St Pölten, AT

12:00 - 12:00

1344P - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)

P. Saiag¹, L. Mortier², C. Dutriaux³, L. Benmahammed⁴, O. Morsli⁴, C. Train⁵, A. Spampinato⁴, M.T. Leccia⁶, N. Meyer⁷, J.J. Grob⁸, ¹Université de Versailles Saint Quentin en Yvelines, Boulogne, FR, ²Hopital Claude Huriez, Lille, FR, ³CHU Bordeaux - Hopital St. André, Bordeaux, FR, ⁴MSD France, Courbevoie, FR, ⁵ClinSearch, MALAKOFF, FR, ⁶CHU Albert Michalon, La Tronche, FR, ⁷IUCT-Oncopole, Toulouse, FR, ⁸Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR

12:00 - 12:00

1345P - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)

S. Knispel¹, M. Gassenmaier², A. Menzies³, C. Loquai⁴, D. Johnson⁵, C. Franklin⁶, R. Gutzmer⁷, J. Hassel⁸, C. Weishaupt⁹, T. Eigentler², P. Schummer¹⁰, F. Kiecker¹¹, C. Owen¹², M. Schmidgen¹³, K. Kähler¹⁴, C. Cann⁵, D. Niebel¹⁵, P. Mohr¹⁶, D. Schadendorf¹⁷, L. Zimmer¹, ¹University Hospital of Essen, Essen, DE, ²University Medical Center Tübingen, Tübingen, DE, ³Melanoma Institute Australia, University of Sydney, North Sydney, AU, ⁴Universitätsmedizin Mainz, Mainz, DE, ⁵Vanderbilt University Medical Center, Nashville, US, ⁶University Hospital Cologne, Cologne, DE, ⁷Hannover Medical School, Klinik für Dermatologie, Allergologie und Venerologie, Hannover, DE, ⁸University Hospital Heidelberg, Heidelberg, DE, ⁹University Clinic Münster, Münster, DE, ¹⁰University Hospital Würzburg, Würzburg, DE, ¹¹Charite-Universitätsmedizin Berlin, Berlin, DE, ¹²Melanoma Institute Australia and The University of Sydney, Wollstonecraft NSW, AU, ¹³University Medical Center of the Johannes, Mainz, DE, ¹⁴University Hospital UKSH, Kiel, DE, ¹⁵University Hospital Bonn, Bonn, DE, ¹⁶Dermatologic Center Buxtehude, Buxtehude, DE, ¹⁷University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

12:00 - 12:00

1346P - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma

J. Moser¹, G. Wei², S. Colonna³, K. Grossmann⁴, S. Patel³, J. Hyngstrom³, ¹HonorHealth Research Institute, Scottsdale, US, ²University of Utah, Salt Lake City, US, ³Huntsman Cancer Institute, Salt Lake City, US, ⁴Moffitt McKinley Outpatient Center, Tampa, US

12:00 - 12:00

1347P - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis

P. Mohr¹, K. Toor², S. Goring², K. Chan³, M. Besada³, H. Johnson⁴, A. Moshyk⁵, S. Kotapati⁵, ¹Dermatologic Center Buxtehude, Buxtehude, DE, ²Precision Health Economics, Vancouver, CA, ³Precision Xtract, Vancouver, CA, ⁴Bristol Myers Squibb, London, GB, ⁵Bristol Myers Squibb, Princeton, US

- 12:00 - 12:00 **1348P - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study**
- S. Dalle¹, L. Mortier², P. Corrie³, M. Lotem⁴, R. Board⁵, A. Arance⁶, F. Meiss⁷, P. Terheyden⁸, R. Gutzmer⁹, J. Brokaw¹⁰, T. Le¹⁰, S. Mathias¹¹, J. Scotto¹⁰, J. Lord-Bessen¹⁰, A. Moshyk¹², S. Kotapati¹², M. Middleton¹³, ¹Hospices Civils, Lyon, FR, ²Université de Lille, Lille, FR, ³Addenbrooke's Hospital, Cambridge, GB, ⁴Hadassah Ein Kerem, Jerusalem, IL, ⁵Royal Preston Hospital, Preston, GB, ⁶Hospital Clínic Barcelona, Barcelon, ES, ⁷University of Freiburg, Freiburg, DE, ⁸University SH.-Lübeck, Lübeck, DE, ⁹Hannover Medical School, Klinik für Dermatologie, Allergologie und Venerologie, Hannover, DE, ¹⁰Bristol-Myers Squibb, Princeton, US, ¹¹Health Outcomes Solutions, Winter Park, US, ¹²Bristol Myers Squibb, Princeton, US, ¹³Churchill Hospital University of Oxford, Oxford, GB
- 12:00 - 12:00 **1349P - Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study**
- R. Marconcini¹, A. Nuzzo¹, S. Manacorda¹, F. De Rosa², P. Fava³, C. Astrua³, L. Di Guardo⁴, A. Raimondi⁵, S. Stucci⁶, A. Todisco⁶, A. Cortellini⁷, M. Bersanelli⁸, O. Nigro⁹, M. Palla¹⁰, G. Palmieri¹¹, A. Falcone¹, ¹Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT, ²Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ³AOU Citta della Salute e della Scienza di torino, Torino, IT, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (Italy), Milano, IT, ⁵Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁶University of Bari, Bari, IT, ⁷Ospedale Civile San Salvatore, L'Aquila, IT, ⁸University Hospital of Parma, Parma, IT, ⁹Ospedale di Circolo Fondazione Macchi, Varese, IT, ¹⁰Istituto Nazionale Tumori Fondazione "G Pascale, Napoli, IT, ¹¹Istituto Chimica Biomolecolare, Sassari, IT
- 12:00 - 12:00 **1350P - Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy**
- A. Hepner¹, M. Carlino², D. Johnson³, C. Gérard⁴, S. Lo⁵, L. Pallan⁶, I. Silva⁷, O. Michielin⁸, G. Long⁹, A. Menzies¹⁰, ¹Hospital Sirio Libanes, Sao Paulo, BR, ²The Crown Princess Mary Cancer Centre, Westmead, AU, ³Vanderbilt University Medical Center, Nashville, US, ⁴Lausanne University Hospital CHUV, Lausanne, CH, ⁵The University of Sydney School of Public Health, Sydney, AU, ⁶Melanoma Institute Australia, The University of Sydney, NSW, Australia, Sydney, AU, ⁷Melanoma Institute Australia, Sydney, AU, ⁸Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ⁹Melanoma Institute Australia, Wollstonecraft, AU, ¹⁰Melanoma Institute Australia, University of Sydney, North Sydney, AU
- 12:00 - 12:00 **1351P - Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy.**
- K. Nahar¹, R. Rawson², N. Sandanayake³, S. Tattersal³, M. Carlino⁴, U. Palendira¹, R. Scolyer², G. Long⁵, A. Menzies⁶, ¹University of Sydney, Camperdown, AU, ²Royal Prince Alfred Hospital, Camperdown, AU, ³Royal North Shore Hospital, St Leonards, AU, ⁴The Crown Princess Mary Cancer Centre, Westmead, AU, ⁵Melanoma Institute Australia, Wollstonecraft, AU, ⁶Melanoma Institute Australia, University of Sydney, North Sydney, AU

12:00 - 12:00 **(Withdrawn)**

12:00 - 12:00 **1353P - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands**

M. Van Zeijl¹, M. Wouters², A.J.M. Van Den Eertwegh³, L.C. De Wreede¹, M. Aarts⁴, A. Van Akkooi⁵, F. Van Den Berkmortel⁶, J. De Groot⁷, M. Boers-Sonderen⁸, J. Van Der Hoeven⁸, G. Hospers⁹, E. Kapiteijn¹⁰, D. Piersma¹¹, R. Van Rijn¹², K. Suijkerbuijk¹³, A. Ten Tije¹⁴, A. Van Der Veldt¹⁵, G. Vreugdenhil¹⁶, J. Haanen¹⁷, ¹Leiden University Medical Center (LUMC), Leiden, NL, ²DICA - Dutch Institute for Clinical Auditing, Leiden, NL, ³Amsterdam UMC, Vrije Universiteit, Amsterdam, NL, ⁴Atrium Medisch Centrum, Maastricht, NL, ⁵The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁶Zuyderland Medical Center - Heerlen, Heerlen, NL, ⁷Isala Clinics, Zwolle, NL, ⁸Radboud University Medical Centre, Nijmegen, NL, ⁹University Hospital Groningen (UMCG), Groningen, NL, ¹⁰Leids Universitair Medisch Centrum (LUMC), Leiden, NL, ¹¹Medisch Spectrum Twente (MST) - Radiological Examination (only), Enschede, NL, ¹²Medical Center Leeuwarden, Leeuwarden, NL, ¹³University Hospital Utrecht, Utrecht, NL, ¹⁴Amphia Ziekenhuis-location Molengracht, Breda, NL, ¹⁵Erasmus University Medical Center, Rotterdam, NL, ¹⁶Maxima Medisch Centrum -Veldhoven, Veldhoven, NL, ¹⁷Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

12:00 - 12:00 **1354P - Utilization of Real-World Data to Assess the Effectiveness of Immune Checkpoint Inhibitors (ICIs) in Elderly Patients with Metastatic Melanoma**

D.S. Ernst¹, H. Mcconkey², L. Liu³, M. Butler⁴, T. Petrella⁵, T. Baetz⁶, R. Koneru⁷, X. Song⁸, T. Cheng⁹, M. Smylie¹⁰, S. Rajagopal¹¹, C. Mihalcioiu¹², F. Gwadry-Sridhar¹³, ¹London Regional Cancer Program (LRCP) - London Health Science Center (LHSC), London, CA, ²Global Melanoma Research Network, London, CA, ³Pulse Infoframe, London, CA, ⁴Princess Margaret Hospital, Toronto, CA, ⁵Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA, ⁶Kingston Health Sciences Centre, Kingston, CA, ⁷Lakeridge Health, Oshawa, CA, ⁸University of Ottawa, Ottawa, CA, ⁹Alberta Health Services, Calgary, CA, ¹⁰University of Alberta Cross Cancer Institute, Edmonton, CA, ¹¹Peel Regional Cancer Centre, Credit Valley Hospital, Mississauga, CA, ¹²McGill University Health Centre - Glen Site, Montreal, CA, ¹³Pulse Infoframe Inc., London, CA

12:00 - 12:00 **1355P - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.**

L. Dousset¹, L. Boussemart², C. Robert³, S. Mansard⁴, C. Lebbe⁵, J.-P. Merlio⁶, E. Routier⁷, A. Dupuy², J. Rouanet⁸, M. Battistella⁵, D. Capellen⁶, M.-D. Galibert², C. Allayous⁹, A. Lespagnol², G. Villechenoux¹, E. Gerard¹, I. Kerneuzet², S. Roy⁷, B. Vergier⁶, M. Beylot-Barry¹, ¹CHU Bordeaux - Hopital St. André, Bordeaux, FR, ²Pontchaillou Hospital, CHU de Rennes, Rennes, FR, ³Institut Gustave Roussy, Villejuif, FR, ⁴CHU Estaing, Clermont-Ferrand, FR, ⁵Hôpital Saint Louis, Paris, FR, ⁶CHU de Bordeaux-Hôpital Haut-Lévêque, Pessac, FR, ⁷Gustave Roussy Cancer Campus, Villejuif, FR, ⁸Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, FR, ⁹Hôpital St. Louis, Paris, FR

- 12:00 - 12:00 **1356P - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.**
E. Rozeman¹, R. Moritz¹, S. Wilgenhof², J. Van Thienen¹, J. Haanen¹, M. Van Den Heuvel³, C. Blank⁴, H. Van Rossum¹, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²Antoni van Leeuwenhoek, Amsterdam, NL, ³Radboud University Medical Center, Nijmegen, NL, ⁴The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 12:00 - 12:00 **1357P - Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma**
G. Prado-Vázquez¹, L. Trilla-Fuertes¹, A. Gámez-Pozo¹, R. López-Vacas¹, E. López-Camacho¹, A. Zapater-Moros¹, J. M. Arevalillo², H. Navarro², M. Díaz-Almirón¹, P. Maín³, J. Feliu Batlle¹, J.A. Fresno Vara¹, E. Espinosa¹, ¹Hospital Universitario La Paz, Madrid, ES, ²National Distance Education University (UNED), Madrid, ES, ³Faculty of Mathematics, Complutense University of Madrid, Madrid, ES
- 12:00 - 12:00 **1358P - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy**
S. Sandhu¹, V. Atkinson², M. Gonzalez Cao³, T. Medina⁴, A. Soria Rivas⁵, I. Caro⁶, L. Roberts⁷, Y. Song⁸, Y. Yan⁹, G. Long¹⁰, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²Gallipoli Medical Research Foundation, Brisbane, AU, ³Dexeus University Hospital, Barcelona, ES, ⁴University of Colorado, Aurora, US, ⁵University Hospital Ramón y Cajal Minimize, Madrid, ES, ⁶Roche Genentech, San Francisco, US, ⁷Genentech, Inc., South San Francisco, US, ⁸Roche, South San Francisco, US, ⁹Genentech, South San Francisco, US, ¹⁰Melanoma Institute Australia, Wollstonecraft, AU
- 12:00 - 12:00 **1359P - The Impact of Targeted Therapies and Immunotherapy in Melanoma Brain Metastases: a Systematic Review and Meta-Analysis**
M. Mandala¹, L. Legramandi², L. Salvati³, E. Rulli², ¹Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT, ²Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, IT, ³University of Florence, Florence, IT
- 12:00 - 12:00 **1360P - Intracranial Anti-Tumor Activity in Melanoma Brain Metastases with Encorafenib Plus Binimetinib: A Multicenter, Retrospective Analysis**
J. Lutzky¹, K. Holbrook², A. Amin³, J. Davis³, M. Davies⁴, A. Diab⁴, I. Glitza⁴, R. Amaria², S. Patel⁵, H. Tawbi⁵, ¹Mount Sinai Comprehensive Cancer Center, Miami Beach, US, ²The M. D. Anderson Cancer Center, Houston, US, ³Levine Cancer Institute, Charlotte, US, ⁴The University of Texas MD Anderson Cancer Center, Houston, US, ⁵The University of Texas M. D. Anderson Cancer Center, Houston, US
- 12:00 - 12:00 **1361P - Outcomes of Patients with Melanoma Brain Metastases (MBM) Treated with Standard of Care Therapy After Being Excluded from MBM-Specific Clinical Trials**
K. Holbrook¹, M. Shephard², L. Haydu¹, I. Glitza Oliva³, R. Amaria¹, S. Patel², A. Diab³, P. Hwu³, C. Brown², I. Boesch Arnold², E. Burton³, M. Davies³, H. Tawbi², ¹The M. D. Anderson Cancer Center, Houston, US, ²The University of Texas M. D. Anderson Cancer

Center, Houston, US, ³The University of Texas MD Anderson Cancer Center, Houston, US

12:00 - 12:00

1362P - The analysis of current treatment outcomes in melanoma patients with brain metastases

J. Placzke¹, P. Teterycz², I. Lugowska³, T. Morysinski⁴, A. Borkowska⁴, T. Switaj⁵, A. Klimczak⁶, K. Kozak⁷, P. Rogala⁸, H. Kosela-Paterczyk⁷, M. Dudzisz-Sledz⁹, M. Spalek¹⁰, A. Czarnecka¹¹, P. Rutkowski¹², ¹ECZ-Postgraduate Medical Center European Health Center, Otwock, PL, ²The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, PL, ³Maria Sklodowska-Curie Memorial Cancer Centre-Institute of Oncology, Warsaw, PL, ⁴Maria Sklodowska Curie Institute - Oncology Centre (MSCI), Warsaw, PL, ⁵No place of work provided Iran, Teheran, IR, ⁶Maria Sklodowska Curie Institute - Oncology Centre (MSCI), Warsaw, PL, ⁷Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, ⁸MSC Memorial Cancer Centre and Institute Maria Skłodowska-Curie, Warsaw, PL, ⁹Central Clinical Hospital MSWIA-Warsaw Medical University of Warsaw, Warsaw, PL, ¹⁰Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, ¹¹Military Medical Institute, Warsaw, PL, ¹²The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL

12:00 - 12:00

1363P - A multivariate model to define prognostic groups among patients with melanoma brain metastases: a 10-year retrospective cohort study

G. Pelizzari¹, E. Bertoli², M.G. Vitale³, S. Buriolla¹, L. Palmero³, M. Bartoletti¹, D. Zara⁴, D. Basile⁵, D. Iacono³, G. Pascoletti⁶, M. Cinausero³, E. Poletto⁶, S. Bolzonello¹, A. Freschi⁵, F. Puglisi⁷, G. Fasola³, A.M. Minisini⁶, ¹Centro di Riferimento Oncologico - CRO, Aviano, IT, ²Dipartimento di Oncologia, Azienda Sanitaria Universitaria Integrata di Udine; University of Udine, Udine, IT, ³Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT, ⁴Dipartimento di Oncologia, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy;, Udine, IT, ⁵CRO di Aviano, Aviano, IT, ⁶Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia, Udine, IT, ⁷Department of Medicine (DAME), University of Udine, Udine, Italy;, Aviano, IT

12:00 - 12:00

1364P - The immune landscape of melanoma significantly influences survival in patients with highly mutated tumors.

R. Ferguson¹, L. Morales², D. Simpson², J. Cadley², E. Esteva², V. Chat², C. Martinez², J. Weber³, I. Osman², T. Kirchhoff², ¹New York University Medical Center, New York City, US, ²New York Langone Health, New York, US, ³NYU Langone Medical Center, New York, US

12:00 - 12:00

1365P - Final Results from Phase II of Combination with Canerpaturev (formerly HF10), an Oncolytic Viral Immunotherapy, and Ipilimumab in Unresectable or Metastatic Melanoma in 2nd-or later line treatment

K. Yokota¹, T. Isei², H. Uhara³, Y. Fujisawa⁴, T. Takenouchi⁵, Y. Kiyohara⁶, H. Uchi⁷, H. Saruta⁸, H. Ihn⁹, T. Inozume¹⁰, D. Watanabe¹¹, A. Takahashi¹², S. Fukushima¹³, M. Tanaka¹⁴, N. Yamazaki¹², ¹Nagoya University school of medicine, Aichi, JP, ²Osaka International Cancer Institute, Osaka, JP, ³Sapporo Medical University Hospital, Hokkaido, JP, ⁴University of Tsukuba, Ibaraki, JP, ⁵Niigata Cancer Center Hospital, Niigata, JP, ⁶Shizuoka Cancer Center, Shizuoka, JP, ⁷Kyushu University Hospital, -, JP, ⁸Kurume University Hospital, -, JP, ⁹Kumamoto Universtiy Hospital, -, JP, ¹⁰University of Yamanashi Hospital, -, JP, ¹¹Aichi Medical University, Aichi, JP, ¹²National Cancer Center

Hospital, Tokyo, JP, ¹³Kumamoto University Hospital, Kumamoto, JP, ¹⁴Takara Bio Inc., Kusatsu, JP

- 12:00 - 12:00 **1366P - Evaluating polygenic risk score prediction model for melanoma prognosis**
M. Potrony¹, N. Calbet-Llopart¹, M. Combalia², G. Tell-Martí³, J. Puig-Butille⁴, A. Barreiro², S. Podlipnik², C. Carrera³, J. Malveyh³, S. Puig³, ¹Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, ES, ²Hospital Clínic of Barcelona, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, ES, ³Hospital Clínic of Barcelona, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERER, Barcelona, ES, ⁴Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 12:00 - 12:00 **1367P - Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy**
M.G. Vitale¹, D. Basile², E. Bertoli³, M. Giavarra¹, G. Pelizzari⁴, L. Palmero¹, D. Zara⁵, G. Targato⁶, G. Pascoletti³, M. Cinausero¹, E. Poletto³, D. Iacono¹, F. Puglisi⁷, G. Fasola¹, A.M. Minisini³, ¹Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT, ²CRO di Aviano, Aviano, IT, ³Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia, Udine, IT, ⁴Centro di Riferimento Oncologico - CRO, Aviano, IT, ⁵Dipartimento di Oncologia, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy;, Udine, IT, ⁶University of Udine, Udine, IT, ⁷Department of Medicine (DAME), University of Udine, Udine, Italy;, Aviano, IT
- 12:00 - 12:00 **1368P - Ancillary evaluation of systemic immune antitumor response (SIAR) and tumor growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase 1 study Mel-Ipi-Rx.**
C. Boutros¹, N. Chaput², E. Lanoy¹, A. Larive³, C. Mateus¹, E. Routier³, S. Roy³, R. Sun¹, A. Lancia⁴, Y. Tao¹, N. Ibrahim³, R.M. Khoury-Abboud³, C. Massard⁵, R. Bahleda⁵, D. Schwob³, C. Caramella¹, L. Cassard¹, J.-C. Soria⁶, C. Robert¹, E. Deutsch¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Gustave Roussy Institut de Cancérologie, Villejuif, FR, ³Gustave Roussy Cancer Campus, Villejuif, FR, ⁴Policlinico Tor Vergata, Rome, IT, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR, ⁶Medimmune, Gaithersburg, US
- 12:00 - 12:00 **1369P - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma**
F. Costa Svedman¹, I. Das², R. Tuominen², E. Ramqvist¹, J. Hansson³, V. Höiom², S. Egyhazi Brage⁴, ¹Karolinska University Hospital-Solna, Solna, SE, ²Karolinska Institute, Stockholm, SE, ³Karolinska Institutet, Stockholm, SE, ⁴Karolinska Institutet - Dept of Oncology-Pathology, Stockholm, SE
- 12:00 - 12:00 **1370P - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy**
J. Hassel¹, C. Berking², T. Eigentler³, R. Gutzmer⁴, P. Ascierto⁵, B. Schilling⁶, F.

Hermann⁷, R. Bartz⁸, D. Schadendorf⁹, ¹University Hospital Heidelberg, Heidelberg, DE, ²LMU Munich, Munich, DE, ³Universitätsklinikum Tübingen, Tübingen, DE, ⁴Hannover Medical School, Klinik für Dermatologie, Allergologie und Venerologie, Hannover, DE, ⁵Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁶University Hospital Würzburg, Würzburg, DE, ⁷4SC AG, Martinsried (Planegg), DE, ⁸4SC AG, Planegg, DE, ⁹University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

12:00 - 12:00 **1371P - Genomic landscape of primary malignant melanoma of esophagus**

J. Dai¹, L. Si¹, C. Cui¹, X. Sheng², Y. Kong¹, Z. Chi¹, L. Mao², X. Wang¹, B. Lian¹, S. Li¹, X. Yan¹, B. Tang², X. Bai², L. Zhou³, J. Guo², ¹Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, ²Beijing Cancer Hospital, Beijing, CN, ³Beijing Cancer Hospital, CN

12:00 - 12:00 **1372TiP - A Phase 3, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC)**

D. Rischin¹, M. Fury², I. Lowy³, E. Stankevich², S. Li², H. Han², S. Porceddu⁴, ¹Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, AU, ²Regeneron Pharmaceuticals, Inc., Tarrytown, US, ³Regeneron Pharmaceuticals Inc, Tarrytown, US, ⁴School of Medicine, University of Queensland, Herston, AU

12:00 - 12:00 **1373TiP - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy**

M. Butler¹, C. Robert², S. Negrier³, G. In⁴, J. Walker⁵, I. Krajsova⁶, V. Atkinson⁷, J. Hansson⁸, E. Kapiteijn⁹, C. Loquai¹⁰, H. Shaw¹¹, T. Cheng¹², S. Mansard¹³, J.J. Grob¹⁴, M. Guidoboni¹⁵, M. Mehta¹⁶, P. Ascierto¹⁷, A. Diab¹⁸, ¹Princess Margaret Hospital, Toronto, CA, ²Institut Gustave Roussy, Villejuif, FR, ³Centre Léon Bérard, Lyon, FR, ⁴Norris Comprehensive Cancer Center, Los Angeles, US, ⁵University of Alberta Cross Cancer Institute, Edmonton, CA, ⁶General Faculty Hospital, VFN Charles University, Prague, CZ, ⁷Gallipoli Medical Research Foundation, Brisbane, AU, ⁸Karolinska Institutet, Stockholm, SE, ⁹Leids Universitair Medisch Centrum (LUMC), Leiden, NL, ¹⁰Universitätsmedizin Mainz, Mainz, DE, ¹¹University College London Hospital UCLH NHS Foundation Trust, London, GB, ¹²Tom Baker Cancer Centre, Calgary, CA, ¹³CHU Estaing, Clermont-Ferrand, FR, ¹⁴Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ¹⁵Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ¹⁶Idera Pharmaceuticals, Exton, US, ¹⁷Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ¹⁸The University of Texas MD Anderson Cancer Center, Houston, US

12:00 - 12:00 **1374TiP - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy**

A. Van Der Westhuizen¹, M. Graves², R. Levy¹, A. Majid¹, R. Vilain³, N. Bowden², ¹Calvary Mater Hospital Newcastle, Newcastle, AU, ²University of Newcastle, Callaghan, AU, ³John Hunter Hospital, Newcastle, AU

12:00 - 12:00 **1375TiP - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study**

A. Eggermont¹, M. Carlino², A. Hauschild³, P. Ascierto⁴, A. Arance⁵, A. Daud⁶, S. O'Day⁷, M. Taylor⁸, A. Smith⁹, A. Rodgers¹⁰, B. Homet Moreno¹⁰, S. Diede¹¹, H. Kluger¹²,
¹Institut Gustave Roussy, Villejuif, FR, ²The Crown Princess Mary Cancer Centre, Westmead, AU, ³UK-SH, Campus Kiel, Kiel, DE, ⁴Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁵Hospital Clinic de Barcelona, Barcelona, ES, ⁶University of California San Francisco UCSF, San Francisco, US, ⁷John Wayne Cancer Institute, Santa Monica, US, ⁸OHSU Knight Cancer Institute - Northwest Portland, Portland, US, ⁹Eisai Ltd., Hatfield, GB, ¹⁰Merck & Co., Inc., Kenilworth, US, ¹¹Merck & Co Inc, North Wales, US, ¹²Yale Breast Center, New Haven, US

12:00 - 12:00

1376TiP - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma

S. Huijberts¹, L. Wang¹, S. Wilgenhof², H. Rosing¹, B. Nuijen¹, J. Beijnen³, R. Leite De Oliveira¹, R. Bernards³, J. Schellens³, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²Antoni van Leeuwenhoek, Amsterdam, NL, ³The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

12:00 - 12:00

1377TiP - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).

L. Si¹, L. Mao², L. Zhou³, C. Li¹, X. Wang¹, C. Cui¹, X. Sheng², Z. Chi¹, B. Lian¹, B. Tang², X. Yan¹, S. Li¹, X. Bai², J. Dai¹, Y. Kong¹, L. Lin⁴, J. Zhang⁵, Z. Wu⁴, A. Hui⁴, J. Guo²,
¹Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, ²Beijing Cancer Hospital, Beijing, CN, ³Beijing Cancer Hospital, CN, ⁴Fosun Pharma, Beijing, CN, ⁵Fosun Pharma, Shanghai, CN

12:00 - 12:00

1378TiP - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma

S. Agarwala¹, S. O'Day², Y. Zakharia³, B. Voorhies⁴, M. Milhem⁵, ¹St. Luke's Hospital & Health Network, Bethlehem, US, ²John Wayne Cancer Institute, Santa Monica, US, ³University of Iowa - Hospital, Iowa City, US, ⁴University of Utah, Utah, US, ⁵University of Iowa Hospitals And Clinics, Iowa City, US

12:00 - 12:00

1379TiP - A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis (MBM) (POLARIS)

M. Davies¹, J. Weber², K. Flaherty³, G. McArthur⁴, M. Reddy⁵, A. Golden⁵, J. Culbertson⁵, C. Thomas⁵, H. Tawbi⁶, G. Long⁷, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²NYU Langone Medical Center, New York, US, ³Massachusetts General Hospital, Harvard Medical School, Boston, US, ⁴Peter MacCallum Cancer Centre, Melbourne, AU, ⁵Array BioPharma Inc., Boulder, US, ⁶The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁷Melanoma Institute Australia, Wollstonecraft, AU

12:00 - 12:00

Public policy

- 12:00 - 12:00 **1644P - Continuation of annual screening mammograms and breast-cancer mortality in women over 70**
X. Garcia De Albeniz¹, M. Hernán², R. Logan², M. Price³, J. Hsu³, ¹RTI Health Solutions, Barcelona, ES, ²Harvard T.H. Chan School of Public Health, Boston, US, ³Massachusetts General Hospital, Boston, US
- 12:00 - 12:00 **1645P - Introducing standardized medical procedure and dynamic decision support program in precision oncology for the community of practice**
I. Petak¹, C. Hegedus¹, E. Várkondi¹, Z. Farkas¹, D. Tihanyi¹, R. Dóczy¹, D. Mathiasz¹, E. Lengyel², G. Pajkos¹, R. Schwab¹, J. Deri¹, I. Vályi-Nagy³, ¹Oncompass Medicine Hungary Kft., Budapest, HU, ²Bajcsy-Zsilinszky Cancer Center, Budapest, HU, ³Centrum Hospital of Southern Pest, Budapest, HU
- 12:00 - 12:00 **1647P - Effectively using primary care givers in oncology care through capacity building, task sharing and techno-mentoring.**
D. Pendharkar, Asian Cancer Institute Somaiya Hospital, Mumbai, IN
- 12:00 - 12:00 **1648P - A single institution review of capecitabine related acute admissions and cost analysis**
G. Dart, D. Swinson, St. James's University Hospital Leeds, Leeds, GB
- 12:00 - 12:00 **1649P - Health status of middle-aged and older cancer survivors in China: results from the China Health and Retirement Longitudinal Study (CHARLS)**
J. Li¹, L. Zhao², C. Bai², H. Pang¹, Z. Sun¹, ¹PUMCH-Peking Union Medical College Hospital (East), Beijing, CN, ²Beijing Union Medical College Hospital (Xiehe Hospital), Beijing, CN
- 12:00 - 12:00 **1650P - Crossed looks on lung cancer perception and knowledge from general public and physicians in France: results of a two-fold survey**
C. Mascaux¹, S. Sauvajeon², J. Cadranel³, C. Chouaid⁴, J.B. Stern⁵, A. Vergnenegre⁶, C. Cortot⁷, L. Guery⁷, K. Belkhiria⁸, I. De La Porte⁷, M. Urbietta⁷, M. Perol⁹, ¹Hôpitaux Universitaires de Strasbourg, Strasbourg, FR, ²De l'Air, Oullins, FR, ³Hôpital Tenon, Paris, FR, ⁴CH Intercommunal de Créteil, Créteil, FR, ⁵Institut Mutualiste Montsouris, Paris, FR, ⁶CHU Limoges - Hopital Dupuytren, Limoges, FR, ⁷Astrazeneca France, Courbevoie, FR, ⁸Astrazeneca, Paris, FR, ⁹Centre Léon Bérard, Lyon, FR
- 12:00 - 12:00 **1651P - Knowledge and perception of clinical trials (CTs) and attitude towards participation among Polish oncological patients - A pilot survey**
A. Kotowski¹, D. Świetlik², M. Kotowska³, M. Wronowski³, A. Fal⁴, ¹Roche Polska Sp. z o.o. - Poland, Warsaw, PL, ²Biostatistics, Medical University of Gdańsk, Gdańsk, PL, ³Medical University of Warsaw, Warsaw, PL, ⁴Cardinal Stefan Wyszyński University, Warsaw, PL
- 12:00 - 12:00 **1652P - Achieving best possible cancer treatment outcomes in care pathways through benchmarking; ABC-Benchmarking**

A. Wind¹, M. Bessems², R. Van Eekeren¹, C. Wijburg¹, J. Mattson³, J. Halamkova⁴, M. Svoboda⁴, J. Oliveira⁵, J. Abreu De Sousa⁵, W. Van Harten¹, ¹Rijnstate Hospital Arnhem, Arnhem, NL, ²Maastricht University Medical Center (MUMC), Maastricht, NL, ³Helsinki University Hospital, Helsinki, FI, ⁴Masaryk Memorial Cancer Institute, Brno, CZ, ⁵IPO Porto, Porto, PT

- 12:00 - 12:00 **1653P - Impact of 10-day Fulbright Specialist Program (FSP) and Project Pink Blue (PPB) Education Sessions on Medical Oncology knowledge among Doctors that treat cancer in Nigeria**
M. Martin¹, R. Chidebe², T. O'Connor³, ¹West Cancer Center, Memphis, US, ²Project Pink Blue, Abuja, NG, ³Roswell Park, Buffalo, US
- 12:00 - 12:00 **1654P - Lung Cancer in Europe: strengthening policy responses to address unmet needs**
M. Bussell, A. Lovell, The Economist Intelligence Unit, London, GB
- 12:00 - 12:00 **1655P - Curative treatment timelines for breast, colorectal, lung and prostate cancer: Implications for medical leave coverage**
S. Wong¹, J. Hamm¹, A. Shokoohi², C. Mcgahan², C. Ho², ¹BC Cancer Agency - Vancouver, Vancouver, CA, ²BC Cancer Agency, Vancouver, CA
- 12:00 - 12:00 **1656P - Acute Diagnostic Oncology Clinic: A Unique Primary Care-Oncology Service**
A. Gill¹, R. Sharkey¹, J. Simmons¹, M. Bower¹, A. Sita-Lumsden², J. Evans¹, T. Newsom-Davis³, ¹Chelsea & Westminster Hospital, NH, GB, ²Imperial College London - Hammersmith Hospital, London, GB, ³Chelsea and Westminster Hospital - NHS Trust, London, GB
- 12:00 - 12:00 **1657P - THE NEW MUTATIONAL MODEL IN ONCOLOGY. What changes in welfare, clinical practice, research, and regulatory procedures**
N. Normanno¹, G. Curigliano², C. Jommi³, N. Martini⁴, A. Marchetti⁵, P. Marchetti⁶, A. Pedrini⁴, G. Pruneri⁷, ¹Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, ²Istituto Europeo di Oncologia, Milan, IT, ³SDA Bocconi School of Management, Milano, IT, ⁴Fondazione Ricerca&Salute, Roma, IT, ⁵P.O. Clinicizzato Ss. Annunziata Universita' Degli Studi, Chieti, IT, ⁶Azienda Ospedaliera St. Andrea, Rome, IT, ⁷Istituto Nazionale Tumori, Milano, IT
- 12:00 - 12:00 **1658P - Selection of a set of quality indicators (QI) for oncological clinical pathway**
A. Fourcade¹, M. Ferrua¹, M. Chirrane², M.J. De La Cruz Vega³, E. Minvielle¹, M. Di Palma³, ¹Institut Gustave Roussy, Villejuif, FR, ²Novartis, Rueil-Malmaison, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR
- 12:00 - 12:00 **1659P - Sustainable drug prices at market launch: policy proposals and their empirical evidence**
N. Fanzen¹, W. Van Harten¹, V. Retel², W. Schats¹, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²The Netherlands Cancer Institute, Amsterdam, NL

- 12:00 - 12:00 **1660P - Impact of financial considerations on French physicians' prescription choices for advanced non-small cell lung cancer (NSCLC)**
N. Olympios¹, M. Lacaud², S. Cousse³, J.-C. Dupont⁴, ¹Centre Henri Becquerel, Rouen, FR, ²Centre Henri Becquerel, ROUEN, FR, ³Rouen University Hospital, ROUEN, FR, ⁴Hospinnomics - Paris School of Economics, Paris, FR
- 12:00 - 12:00 **1661P - The direct medical cost of breast cancer in a Belgian hospital**
H. Lemhouer¹, D. Verhoeven², V. Corluy³, D. De Graeve⁴, ¹University of Antwerp, Antwerp Area, Belgium, BE, ²A.Z. Klina, Brasschaat, BE, ³AZ KLINA, Brasschaat, BE, ⁴University of Antwerp, Antwerp, BE
- 12:00 - 12:00 **1662P - Does the healthcare system approaches cancer patients for using private services during diagnostic process?**
K. Osowiecka¹, R. Sroda¹, A. Saied¹, M. Szwiec², S. Mangold³, D. Osuch³, S. Nawrocki³, M. Rucinska⁴, ¹University of Warmia and Mazury in Olsztyn, Olsztyn, PL, ²Opolskie Centrum Onkologii Oddzial Onkologii Klinicznej, Opole, PL, ³Medical University of Silesia in Katowice, Katowice, PL, ⁴ZOZ MSWiA z Warmi?sko-Mazurskim Centrum Onkologii, Olsztyn, PL
- 12:00 - 12:00 **1663P - Measuring financial toxicity of cancer in the Italian health care system: initial results of the patient reported outcome for Fighting Financial Toxicity of cancer project (proFFiT).**
S. Riva¹, M. Di Maio², F. Efficace³, L. Frontini⁴, C. Gallo⁵, D. Giannarelli⁶, V. Montesarchio⁷, F. De Lorenzo⁸, L. Del Campo⁸, E. Iannelli⁹, F. Traclò¹⁰, L. Gitto¹¹, C. Jommi¹², C.M. Vaccaro¹³, J. Bryce¹⁴, A. Gimigliano¹⁴, L. Sparavigna¹⁴, F. Perrone¹⁴, ¹University of Wolverhampton, Wolverhampton, GB, ²Università degli Studi di Torino, Torino, IT, ³Fondazione GIMEMA Onlus, Roma, IT, ⁴Dr. Luciano Frontini, Milan, IT, ⁵Università della Campania Luigi Vanvitelli, Napoli, IT, ⁶Regina Elena National Cancer Institute, Rome, IT, ⁷Azienda Ospedaliera Dei Colli-Monaldi, Napoli, IT, ⁸Federazione Italiana Delle Associazioni Di Volontariato In Oncologia, Roma, IT, ⁹AIMaC - Associazione Italiana Malati di Cancro, Roma, IT, ¹⁰AIMaC - Associazione Italiana Malati di Cancro, Roma, IT, ¹¹Università degli Studi di Messina, Messina, IT, ¹²SDA Bocconi School of Management, Milano, IT, ¹³Centro Studi Investimenti Sociali (CENSIS), Roma, IT, ¹⁴Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT
- 12:00 - 12:00 **1664P - Implementing a Population-Based Cancer Registries Network in Mexico**
A. Palafox-Parrilla¹, H. Brau-Figueroa², P. Parrilla-Taylor¹, E. Montelongo-Terriquez¹, R. Rangel-Velázquez³, D. Palami-Antunez¹, ¹Instituto Nacional de Cancerología, Mexico City, MX, ²UNAM-Universidad Nacional Autonoma de Mexico, Ciudad de Mexico, MX, ³Instituto Nacional de Cancerología, Mexico city, MX
- 12:00 - 12:00 **1665P - Awareness of cancer risk factors among high school students**
M. Rucinska¹, R. Sroda², O. Wilk², J. Miloszewski², K. Osowiecka², ¹ZOZ MSWiA z Warmi?sko-Mazurskim Centrum Onkologii, Olsztyn, PL, ²University of Warmia and Mazury in Olsztyn, Olsztyn, PL

12:00 - 12:00

1666TiP - COMPRAVA: Dutch nationwide infrastructure for COMPREhensive health outcome and intervention research among patients with Adolescent and Young Adult cancer

O. Husson¹, M. Ligtenberg², L. Van De Poll-Franse³, J. Prins², M. Van Den Bent⁴, M. Van Eenbergen⁵, E. Manten-Horst⁶, R. Bijlsma⁷, S. Kaal², J. Tromp⁸, A. Verschoor⁹, M. Bos¹⁰, J. Nuver¹¹, Y. Jauw¹², R.I. Lalisang¹³, S. Sleeman⁶, C. Vlooswijk⁵, J. Gietema¹⁴, W. Van Der Graaf¹⁵, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²Radboud University Medical Center, Nijmegen, NL, ³Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁴Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ⁵Netherlands Comprehensive Cancer Center, Utrecht, NL, ⁶National AYA "Young and Cancer" Platform, Utrecht, NL, ⁷UMC - University Medical Center Utrecht, Utrecht, NL, ⁸Amsterdam Medical Center, Amsterdam, NL, ⁹Leids Universitair Medisch Centrum (LUMC), Leiden, NL, ¹⁰ErasmusMC, Rotterdam, NL, ¹¹University Medical Center Groningen, Groningen, NL, ¹²Vrije University Medical Centre (VUMC), Amsterdam, NL, ¹³Maastricht University Medical Center (MUMC), Maastricht, NL, ¹⁴University Hospital Groningen (UMCG), Groningen, NL, ¹⁵Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NL

- 13:00 - 14:30** **Type: Industry Satellite Symposium** **Pamplona Auditorium (Hall 2)**
Title: F. Hoffmann - La Roche - From triple-negative to Dx-positive breast cancer: Perspectives and experience with cancer immunotherapy for patients with metastatic triple negative disease
Chair(s): David Miles, GB
- 13:00 - 13:05 **Introduction: TNBC landscape and recent approvals of new therapeutics**
D. Miles, Mount Vernon Cancer Centre, Northwood, GB
- 13:05 - 13:20 **Overview of current CIT treatments and biomarkers in mTNBC**
P. Schmid¹, L. Emens², ¹Barts Cancer Institute, London, GB, ²UPMC Hillman Cancer Center, Pittsburgh, US
- 13:20 - 13:35 **Why should you talk to your pathologist about PD-L1 testing in mTNBC?**
L. Emens¹, G. Viale², ¹UPMC Hillman Cancer Center, Pittsburgh, US, ²Istituto Europeo di Oncologia, Milan, IT
- 13:35 - 13:55 **Treatment decisions in clinical practice**
C. Barrios, PUCRS-Pontifícia Universidade do Rio Grande do Sul, Porto Alegre, BR
- 13:55 - 14:10 **Future evolution of mTNBC treatment**
P. Schmid, Barts Cancer Institute, London, GB
- 14:10 - 14:25 **Question & answer session**
- 14:25 - 14:30 **Wrap-up and summary**
D. Miles, Mount Vernon Cancer Centre, Northwood, GB

13:00 - 14:30	Type: Industry Satellite Symposium Title: F. Hoffmann - La Roche - Right treatment, right time: Improving outcomes for patients with advanced lung cancer Chair(s): Luis Paz-Ares, ES	Cordoba Auditorium (Hall 7)
13:00 - 13:10	Welcome and introduction <u>L. Paz-Ares</u> , University Hospital 12 De Octubre, Madrid, ES	
13:10 - 13:25	Sequencing ALK tyrosine kinase inhibitors: What's best for our patients? <u>S. Gadgeel</u> , University of Michigan, Ann Arbor, US	
13:25 - 13:40	Time to look for rare alterations in our NSCLC patients: Know your options for ROS1 and NTRK <u>R. Dziadziuszko</u> , Medical University of Gdansk, Gdansk, PL	
13:40 - 13:55	Knowing your patient, optimising today's cancer immunotherapies in NSCLC <u>M. Reck</u> , Airway Research Center North, German Center of Lung Research, Grosshansdorf, DE	
13:55 - 14:10	Looking towards a new standard of care in extensive-stage SCLC	
14:10 - 14:25	Faculty and audience Q&A	
14:25 - 14:30	Summary and close <u>L. Paz-Ares</u> , University Hospital 12 De Octubre, Madrid, ES	

13:00 - 14:30 **Type: Industry Satellite Symposium** **Bilbao Auditorium (Hall 5)**
Title: AstraZeneca - Evolving the treatment practice of advanced EGFRm NSCLC'
Chair(s): Johan Vansteenkiste, BE

- 13:00 - 13:10 **Introduction**
J. Vansteenkiste, University Hospital KU Leuven, Leuven, BE
- 13:10 - 13:30 **Newly diagnosed advanced EGFRm NSCLC: What information will help improve our treatment decision?**
P. Jänne, Dana Farber Cancer Institute, Boston, US
- 13:30 - 13:45 **Planning the patient journey: How can we maximize all of the treatment opportunities?**
F. Griesinger, Pius Hospital, Oldenburg, DE
- 13:45 - 14:00 **Exploring treatment options beyond progression**
R. Sanborn, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, US
- 14:00 - 14:15 **Expert opinions on hot topics: A panel discussion moderated by**
J. Vansteenkiste, University Hospital KU Leuven, Leuven, BE
- 14:15 - 14:25 **Your opportunity to question the panel further: Audience Q&A moderated by**
J. Vansteenkiste, University Hospital KU Leuven, Leuven, BE
- 14:25 - 14:30 **Closing remarks**
J. Vansteenkiste, University Hospital KU Leuven, Leuven, BE

13:00 - 14:30 **Type: Industry Satellite Symposium** **Tarragona Auditorium**
Title: Pfizer - EGFR+, ALK+ and ROS1 NSCLC: More options, right choices **(Hall 7)**
Chair(s): Federico Cappuzzo, IT

13:00 - 13:05 **Welcome and introduction**
F. Cappuzzo, Ospedale Santa Maria delle Croci, Ravenna, IT

13:05 - 13:15 **More options, right choices**
F. Cappuzzo, Ospedale Santa Maria delle Croci, Ravenna, IT

13:15 - 13:40 **EGFR: The dilemma of choice**
D. Tan, National Cancer Centre Singapore, Singapore, SG

13:40 - 14:10 **ALK and ROS1: Sequencing our options to maximise outcomes**
B. Besse, Gustave Roussy Cancer Campus, Villejuif, FR

14:10 - 14:25 **Panel discussion facilitated by**
F. Cappuzzo, Ospedale Santa Maria delle Croci, Ravenna, IT

14:25 - 14:30 **Conclusions**
F. Cappuzzo, Ospedale Santa Maria delle Croci, Ravenna, IT

13:00 - 14:30 **Type: ESMO Colloquium** **Alicante Auditorium (Hall 3)**
Title: ESMO Colloquium supported by Celgene - Pancreatic cancer: Can better understanding of biology improve resectability and survival?
Chair(s): Margaret Tempero, US

13:00 - 13:00 **Session DOI**

13:00 - 13:05 **Introduction**

M. Tempero, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

13:05 - 13:20 **What are the biological reasons for treatment resistance in pancreatic adenocarcinoma?**

13:20 - 13:25 **Q&A**

13:25 - 13:40 **What have we achieved with recent medical approaches to improve survival**

T. Conroy, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR

13:40 - 13:45 **Q&A**

13:45 - 14:00 **How can surgery improve resectability criteria?**

M. Falconi, IRCCS Ospedale San Raffaele, Milan, IT

14:00 - 14:05 **Q&A**

14:05 - 14:20 **What benefit can we expect from emerging targeted agents including ICI to improve survival?**

M. Tempero, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

14:20 - 14:25 **Q&A**

14:25 - 14:30 **Conclusion**

M. Tempero, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

13:00 - 14:30 **Type: Industry Satellite Symposium** **Cartagena Auditorium (Hall 3)**
Title: Pierre Fabre - Optimising treatment outcomes in patients with advanced BRAF-mutated melanoma
Chair(s): Georgina Long, AU; Ana Arance, ES

13:00 - 13:05 **Introduction**

A. Arance, Hospital Clínic Barcelona, Barcelon, ES

13:05 - 13:30 **What is the evidence for targeted therapies in advanced BRAF-mutated melanoma?**

N. Meyer, IUCT-Oncopole, Toulouse, FR

13:30 - 13:50 **Targeted therapies in clinical practice: What have we learned? A clinical case (1)**

P. Mohr, Dermatologic Center Buxtehude, Buxtehude, DE

13:50 - 14:10 **Targeted therapies in clinical practice: What have we learned? A clinical case (2)**

M. Mandala, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT

14:10 - 14:25 **Panel discussion**

14:25 - 14:30 **Conclusion**

A. Arance, Hospital Clínic Barcelona, Barcelon, ES

13:00 - 14:30 **Type: Industry Satellite Symposium** **Salamanca Auditorium (Hall 3)**
Title: Clovis Oncology - PARP inhibitors in ovarian cancer: Expert perspectives on current clinical questions
Chair(s): Ana Oaknin, ES

13:00 - 13:05 **Welcome and introduction**

A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES

13:05 - 13:30 **Exploring the evidence for maintenance therapy in recurrent ovarian cancer**

A. Leary, Gustave Roussy Cancer Center, INSERM U981, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Villejuif, FR

13:30 - 13:45 **Surveillance or maintenance? An interactive discussion**

R. Kristeleit, UCL Cancer Institute/Paul O'Gorman Building, London, GB

13:45 - 14:05 **Applying the evidence: case-based decision making in recurrent ovarian cancer**

A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES

14:05 - 14:20 **Where next? Exploring new frontiers for PARP inhibitors in ovarian cancer**

F. Marmé, Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE

14:20 - 14:30 **Panel Q&A and close**

A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES

13:00 - 14:30 **Type: Industry Satellite Symposium** **Toledo Auditorium (Hall 5)**
Title: Samsung Bioepis Co. - Quality assurance to optimize HER2+ breast cancer treatment
Chair(s): Diana Lüftner, DE

13:00 - 13:10 **Welcome and introduction poll**
D. Lüftner, Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE

13:10 - 13:25 **Building confidence in biosimilars**
G. Lyman, Fred Hutchinson Cancer Research Center, Seattle, US

13:25 - 13:40 **Acknowledging importance of biologics quality in clinical practice**
J. Gonçalves, Universidade de Lisboa, Lisbon, PT

13:40 - 14:00 **Reassuring biosimilarity based on clinical evidence**
X. Pivot, Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR

14:00 - 14:15 **Interactive discussion: Perspective on biosimilars in oncology**
D. Lüftner¹, G. Lyman², J. Gonçalves³, X. Pivot⁴, ¹Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE, ²Fred Hutchinson Cancer Research Center, Seattle, US, ³Universidade de Lisboa, Lisbon, PT, ⁴Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR

14:15 - 14:25 **Q&A**
D. Lüftner, Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE

14:25 - 14:30 **Closing remarks & post-survey**
D. Lüftner, Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE

13:00 - 14:30 **Type: Patient Advocay Track** **Leon Auditorium (Hall 3)**
Title: The Hans Keulen Memorial Debate: How far would you go in your treatment?
Chair(s): Kathy Oliver, GB

13:00 - 13:00 **Session DOI**

13:00 - 14:30	Type: Industry Satellite Symposium Title: Illumina Productos de Espana SLU - Changing paradigms: The benefits of comprehensive genomic profiling Chair(s): Frederique Penault-Llorca, FR	Santander Auditorium (Hall 3)
13:00 - 13:05	Introduction <u>F. Penault-Llorca</u> , Centre Jean Perrin, Clermont-Ferrand, FR	
13:05 - 13:30	Transforming oncology with comprehensive genomic profiling <u>G. Hampton</u> , Illumina, San Diego, US	
13:30 - 13:55	The landscape of IO biomarkers TMB and MSI in lung cancer: Recent findings and considerations on testing on clinical decisions <u>M. Perol</u> , Centre Léon Bérard, Lyon, FR	
13:55 - 14:20	The clinical value of fusions in lung cancer: Some are rare, novel and promiscuous. Why does that matter? <u>U. Lassen</u> , Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK	
14:20 - 14:30	Q&A	

14:00 - 15:30	Type: EONS session Title: EONS 12: Creating a safety culture in cancer care Chair(s): Lena Sharp, SE	Oviedo Auditorium (CC5)
14:00 - 14:00	Session DOI	
14:00 - 14:15	Being Safe - Feeling Safe - Psychological Safety the importance of it for nurses to nurse - What it is and how can it be supported <u>R. Verity</u> , King's College London, London, GB	
14:15 - 14:30	Occupational safety <u>J. De Munter</u> , Gent University Hospital, Gent, BE	
14:30 - 14:45	Patient safety culture, the nurses perspective from the RECaN projec <u>W. Oldenmenger</u> , Erasmus Medical Centre, Rotterdam, NL	
14:45 - 15:00	ONS Guidelines on safety <u>L. Kennedy Sheldon</u> , Oncology Nursing Society, Pittsburgh, US	
15:00 - 15:15	CN33 - Patient safety and the power of nursing presence <u>L. Fennimore</u> , University of Pittsburgh Cancer Institute, Pittsburgh, US	
15:15 - 15:30	Discussion	

14:45 - 16:15	Type: Special session Title: Adjuvant treatment duration for high-risk stage II colon cancer Chair(s): Takayuki Yoshino, JP	Barcelona Auditorium (Hall 2)
14:45 - 15:00	How do you treat high-risk stage II colon cancer patients? Nothing vs. FP vs. doublet including MSI high patients	
15:00 - 15:05	IDEA collaboration for HR stage II	
15:05 - 15:15	SCOT trial	
15:15 - 15:25	5250 - ACHIEVE-2 trial: a randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC) T. Yoshino ¹ , T. Yamanaka ² , M. Shiozawa ³ , D. Manaka ⁴ , M. Kotaka ⁵ , M. Gamoh ⁶ , A. Shiomi ⁷ , A. Makiyama ⁸ , Y. Munemoto ⁹ , T. Rikiyama ¹⁰ , M. Fukunaga ¹¹ , T. Ueki ¹² , K. Shitara ¹³ , H. Shinkai ¹⁴ , N. Tanida ¹⁵ , K. Yamazaki ¹⁶ , E. Sunami ¹⁷ , A. Ohtsu ¹ , Y. Maehara ¹⁸ , ¹ National Cancer Center Hospital East, Kashiwa, JP, ² Yokohama City University Hospital, Yokohama, JP, ³ Kanagawa Cancer Center, Yokohama, JP, ⁴ Kyoto-Katsura Hospital, Kyoto, JP, ⁵ Sano Hospital-Gastrointestinal Cancer Centre, Kobe, JP, ⁶ Osaki Citizen Hospital, Osaki, JP, ⁷ Shizuoka Cancer Center, Shizuoka, JP, ⁸ National Kyushu Cancer Center, Fukuoka, JP, ⁹ Fukui Saiseikai Hospital, Fukui, JP, ¹⁰ Jichi Medical University Saitama Medical Center, Saitama, JP, ¹¹ Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, JP, ¹² Hamanomachi Hospital, Fukuoka, JP, ¹³ National Cancer Center Hospital, Kashiwa, JP, ¹⁴ Chigasaki Municipal Hospital, Chigasaki, JP, ¹⁵ Japanese red cross kochi hospital, Kochi, JP, ¹⁶ Sizuoka Cancer Center, Sundogun, JP, ¹⁷ KYORIN UNIVERSITY, SCHOOL OF MEDICINE, TOKYO, JP, ¹⁸ Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, JP	
15:25 - 15:35	TOSCA trial	
15:35 - 15:45	HORG trial I. Souglakos, University Hospital of Heraklion (PAGNI), Heraklion, GR	
15:45 - 16:05	Panel discussion	
16:05 - 16:15	New IDEA collaboration 'CIRCULATE IDEA' T. Yoshino, National Cancer Center Hospital East, Kashiwa, JP	

14:45 - 16:15 **Type: Educational session** **Madrid Auditorium**
Title: The next horizon in metastatic non-small cell **(Hall 2)**
targeted therapy

Chair(s): David Planchard, FR; Luis Paz-Ares, ES

14:45 - 14:45 **Session DOI**

14:45 - 15:05 **The optimal sequence: Does overall survival matter?**
T.S.K. Mok, Prince of Wales Hospital, Shatin, HK

15:05 - 15:25 **Targeted KRAS mutation**
P. Jänne, Dana Farber Cancer Institute, Boston, US

15:25 - 15:45 **Uncommon targets: BRAF, MET and NTRK**
D. Planchard, Institut Gustave Roussy, Villejuif, FR

15:45 - 16:05 **How to manage co-occurrence of drivers**
L. Paz-Ares, University Hospital 12 De Octubre, Madrid, ES

16:05 - 16:15 **Discussion**

14:45 - 16:15 **Type: Special symposium** **Sevilla Auditorium (Hall 2)**
Title: Tumour neoantigens
Chair(s): Alberto Bardelli, IT

14:45 - 14:45 **Session DOI**

14:45 - 14:50 **Introduction**

14:50 - 15:10 **MMR repair driven neoantigens**

A. Bardelli, Istituto di Candiolo - FPO - IRCCS, Candiolo, IT

15:10 - 15:30 **Cancer genomes and neoantigens**

A. Ribas, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US

15:30 - 15:50 **From tumour antigens to HLA peptides in melanoma**

Y. Samuels, Weizmann Institute of Science, Rehovot, IL

15:50 - 16:10 **Functional basis of neopeptides immune surveillance**

P. Kvistborg, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

16:10 - 16:15 **Conclusions and perspectives**

A. Bardelli, Istituto di Candiolo - FPO - IRCCS, Candiolo, IT

14:45 - 16:15 **Type: Special session** **Pamplona Auditorium**
Title: Which are the preferred platforms for IO **(Hall 2)**
biomarkers discovery?
 Chair(s): John Haanen, NL

14:45 - 14:50 **Introduction**

14:50 - 15:10 **Tumour fragments to predict response or resistance in IO**

15:10 - 15:30 **Liquid biopsies to predict response or resistance in IO**

15:30 - 15:50 **Flow and IHC to unravel biomarkers of response or resistance in IO**

15:50 - 16:10 **Single cell RNA sequencing to unravel biomarkers of response or resistance in IO**

16:10 - 16:15 **Conclusions and perspectives**

14:45 - 16:15 **Type: Proffered Paper session** **Valencia Auditorium (Hall 5)**
Title: Proffered Paper - Sarcoma

14:45 - 14:45 **Session DOI**

14:45 - 14:57 **One LBA TBC**

14:57 - 15:09 **16670 - Results of the TAPPAS trial: An adaptive enrichment Phase 3 trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS)**

R. Jones¹, V. Ravi², A. Brohl³, S. Chawla⁴, K. Ganjoo⁵, A. Italiano⁶, S. Attia⁷, M. Burgess⁸, K. Thornton⁹, L. Cranmer¹⁰, L. Liu¹¹, C. Theuer¹², R. Maki¹³, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³H. Lee Moffitt Cancer Center, Tampa, US, ⁴Sarcoma Oncology Research Center, Santa Monica, US, ⁵Stanford University, STANFORD, US, ⁶Institute Bergonié, Bordeaux, FR, ⁷MAYO CLINIC IN FLORIDA, Jacksonville, US, ⁸University of Pittsburgh Medical Center, PITTSBURGH, US, ⁹Dana-Farber Cancer Institute, BOSTON, US, ¹⁰UNIVERSITY OF WASHINGTON, SEATTLE, US, ¹¹TRACON Pharmaceuticals, SAN

DIEGO, US, ¹²Tracon Pharmaceuticals, Inc., SAN DIEGO, US, ¹³Northwell Health/Cold Spring Harbor Laboratory, LONG ISLAND, US

15:09 - 15:27 **16680 - CRYODESMO-O1: A French nationwide phase II study on cryoablation in progressing desmoid tumor (DT) patients (pts)**

J.-E. Kurtz¹, X. Buy², E. Sauleau³, M. Toulmonde⁴, F. Deschamps⁵, C. Honoré⁶, A. Bouhamama⁷, J.-Y. Blay⁷, A. Gangi³, ¹CHU Hautepierre, Strasbourg, FR, ²Institut bergonié, Bordeaux, FR, ³Hôpitaux Universitaires de Strasbourg, Strasbourg, FR, ⁴Institute Bergonié, Bordeaux, FR, ⁵Institut Gustave Roussy, Villejuif, FR, ⁶Gustave Roussy - Cancer Campus, Villejuif, FR, ⁷Centre Léon Bérard, Lyon, FR

15:27 - 15:39 **Invited Discussant 16670, 16680 and one LBA TBC**

15:39 - 15:51 **16690 - IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in advanced soft tissue and bone sarcomas: Results of the phase II- Soft-tissue sarcoma cohort**

J. Martin Broto¹, N. Hindi², G. Grignani³, J. Martinez Trufero⁴, A. Redondo⁵, C. Valverde⁶, A. Lopez Pousa⁷, S. Stacchiotti⁸, E. Palmerini⁹, E. De Alava², D. Moura¹⁰, H. Perez Vega², P. Collini¹¹, I. Otero¹², P. Ledesma¹³, E. Marchesi¹⁴, L. D'Ambrosio³, J.A. Lopez Martin¹², ¹Hospital Universitario Son Espases, Palma de Mallorca, ES, ²Hospital Universitario Virgen del Rocío, Sevilla, ES, ³Istituto di Candiolo - FPO - IRCCS, Candiolo, IT, ⁴Hospital Miguel Servet, Zaragoza, ES, ⁵Hospital Universitario La Paz, Madrid, ES, ⁶Vall d'Hebron University Hospital, Barcelona, ES, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁸Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁹IRCCS Istituto Ortopedico Rizzoli, Bologna, IT, ¹⁰Instituto de Biomedicina de Sevilla, Sevilla, ES, ¹¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ¹²Hospital Universitario Doce de Octubre, Madrid, ES, ¹³Sofpromed, Palma de Mallorca, ES, ¹⁴Italian Sarcoma Group, Bologna, IT

15:51 - 16:03 **16700 - ADP-A2M4 (MAGE-A4) in patients with Synovial Sarcoma**

B. Van Tine¹, M. Butler², D. Araujo³, M. Johnson⁴, J. Clarke⁵, D. Liebner⁶, K. Odunsi⁷, A. Olszanski⁸, S. Basu⁹, F. Brophy⁹, T. Holdich¹⁰, T. Trivedi⁹, R. Amado¹¹, D. Hong¹², ¹Washington University School of Medicine, St. Louis, US, ²Princess Margaret Hospital, Toronto, CA, ³MD Anderson Cancer Center, Houston, US, ⁴Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ⁵Duke University School of Medicine, Durham, US, ⁶Ohio State University, Columbus, US, ⁷Roswell Park Cancer Institute, Buffalo, US, ⁸Fox Chase Cancer Center, Philadelphia, US, ⁹Adaptimmune, Philadelphia, US, ¹⁰Adaptimmune Ltd, Abingdon, GB, ¹¹Adaptimmune LLC, Philadelphia, US, ¹²University of Texas MD Anderson Cancer Center, Houston, US

16:03 - 16:15 **Invited Discussant 16690 and 16700**

14:45 - 16:15 **Type: Special symposium** **Malaga Auditorium**
Title: How to use the available results of precision **(Hall 5)**
medicine clinical trials
Chair(s): Emiliano Calvo, ES

14:45 - 14:45 **Session DOI**

14:45 - 14:52 **Introduction**

14:52 - 15:07 **Including biomarkers in clinical trials: The biostatistician's view**
X. Paoletti, Institut Gustave Roussy, Villejuif, FR

15:07 - 15:22 **Basket trials**
P. Schoeffski, University Hospitals Leuven, Leuven, BE

15:22 - 15:37 **Umbrella trials**
T. Maughan, Oxford Institute for Radiation Oncology, Oxford, GB

15:37 - 15:52 **Other platform trials of precision medicine**
C. Le Tourneau, Institut Curie, Paris, FR

15:52 - 16:07 **Precision medicine: Counterpoint**
E. Calvo, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES

16:07 - 16:15 **Conclusions and perspectives**

14:45 - 16:15 **Type: Proffered Paper session** **Bilbao Auditorium (Hall 5)**
Title: Proffered Paper - Breast cancer, early stage

14:45 - 14:45 **Session DOI**

14:45 - 15:00 **One LBA TBC**

15:00 - 15:15 **One LBA TBC**

15:15 - 15:30 **Invited Discussant 2 LBAs TBC**

15:30 - 15:45 **1740 - Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoire in HER2+ breast cancer: a correlative analysis of the CALGB 40601 clinical trial (Alliance).**

A. Fernandez-Martinez¹, M. Tanioka², C. Fan², J. Parker², K. Hoadley², I. Krop³, A. Partridge³, L. Carey⁴, C. Perou⁴, ¹UNC Lineberger Comprehensive Cancer Center, Chapel Hill, US, ²Lineberger Comprehensive Center, University of North Carolina, Chapel Hill, NC, USA, Chapel Hill, US, ³Dana Farber Cancer Institute, Boston, US, ⁴UNC - Lineberger Cancer Center, Chapel Hill, US

15:45 - 15:58 **1750 - Prognostic value of tumor infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy**

J.H. Park¹, S.F. Jonas², M.V. Dieci³, G. Bataillon⁴, C. Criscitiello⁵, G. Viale⁵, R. Salgado⁶, H.J. Lee¹, S. Loi⁷, S.-B. Kim⁸, G. Curigliano⁵, A. Vincent-Salomon⁴, F. André⁹, S. Michiels³, ¹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ²Gustave Roussy, Inserm U1018, University Paris-Sud, University Paris-Saclay, Villejuif, France., Villejuif, FR, ³Gustave Roussy, Villejuif, FR, ⁴Institut Curie, Paris, FR, ⁵Istituto Europeo di Oncologia, Milan, IT, ⁶St-Augustinus Ziekenhuis, Wilrijk, BE, ⁷Peter MacCallum Cancer Center, Melbourne, AU, ⁸Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ⁹Gustave Roussy - Cancer Campus, Villejuif, FR

15:58 - 16:13 **Invited Discussant 1740 and 1750**

14:45 - 16:15	Type: Young Oncologist session Title: ESMO Fellowship Programme Chair(s): Evandro de Azambuja, BE; Guillem Argiles Martinez, ES	Santander Auditorium (Hall 3)
14:45 - 14:45	Session DOI	
14:45 - 14:50	Introduction <u>E. De Azambuja</u> , Institute Jules Bordet, Brussels, BE	
14:50 - 15:10	ESMO Fellowship programme: Practical tips from a former fellow <u>A. Lamarca</u> , The Christie NHS Foundation Trust, Manchester, GB	
15:10 - 15:30	Best ESMO Fellowship Project	
15:30 - 15:50	Best Publication deriving from an ESMO Fellowship	
15:50 - 15:55	Conclusions <u>G. Argiles Martinez</u> , Vall d'Hebron University Hospital, Barcelona, ES	
15:55 - 16:15	Awards Ceremony: ESMO 2019 Fellowship Awards and Best Exam Award 2018	

15:00 - 16:00 **Type: Multidisciplinary session** **Tarragona Auditorium (Hall 7)**
Title: Treatment of pelvic node-positive prostate cancer
Chair(s): Chris Parker, GB

15:00 - 15:00 **Session DOI**

15:00 - 15:05 **Presentation of case/condition**

A. Briganti, IRCCS Ospedale San Raffaele, Milan, IT

15:05 - 15:20 **Is there a role for radical surgery?**

A. Briganti, IRCCS Ospedale San Raffaele, Milan, IT

15:20 - 15:35 **Advances in pelvic nodal radiotherapy**

G. De Meerleer, , US

15:35 - 15:50 **Systemic treatment: The role of chemotherapy and androgen receptor targeted therapy**

S. Gillessen, The Christie NHS Foundation Trust, Manchester, GB

15:50 - 16:00 **Discussion**

15:00 - 16:00 **Type: Challenge your expert** **Alicante Auditorium (Hall 3)**
Title: Squamous cell carcinoma of the oesophagus
Chair(s): Per Pfeiffer, DK

15:00 - 15:00 **Session DOI**

15:00 - 15:10 **Presentation by expert**

T. Crosby, Velindre Cancer Centre Velindre Hospital, Cardiff, GB

15:10 - 16:00 **Discussion led by Chair**

P. Pfeiffer, Odense University Hospital, Odense C, DK

15:00 - 16:00	Type: Challenge your expert Title: The promise of cure: Chemotherapy free therapies in CLL Chair(s): John Gribben, US	Cartagena Auditorium (Hall 3)
15:00 - 15:00	Session DOI	
15:00 - 15:10	Presentation by expert <u>M. Hallek</u> , University Hospital Cologne, Köln, DE	
15:10 - 16:00	Discussion led by Chair <u>J. Gribben</u> , , US	
15:00 - 16:15	Type: Multidisciplinary session Title: Options and limitations in oligometastatic disease and metastatic colorectal cancer (mCRC) Chair(s): Demetris Papamichael, CY	Salamanca Auditorium (Hall 3)
15:00 - 15:00	Session DOI	
15:00 - 15:15	The radiation oncology perspective <u>M. Hawkins</u> , , US	
15:15 - 15:30	The surgical perspective <u>R. Raab</u> , , US	
15:30 - 15:45	The medical oncology perspective <u>R. Wilson</u> , Wolfson Wohl Cancer Research Centre - Institute of Cancer Sciences - University of Glasgow, Bearsden, GB	
15:45 - 16:00	The interventional radiology perspective <u>T. De Baere</u> , Institut Gustave Roussy, Villejuif, FR	
16:00 - 16:15	General discussion	

15:00 - 16:00 **Type: Challenge your expert** **Toledo Auditorium (Hall 5)**
Title: Relevance of patient reported outcomes
Chair(s): Bettina Ryll, SE

15:00 - 15:00 **Session DOI**

15:00 - 15:10 **Presentation by Expert**
D. Schrag, Dana Farber Cancer Institute, Boston, US

15:10 - 16:00 **Discussion led by Chair**
B. Ryll, Melanoma Patient network Europe, Uppsala, SE

15:45 - 17:15 **Type: EONS session** **Oviedo Auditorium (CC5)**
Title: EONS 12: Closing session
Chair(s): Lena Sharp, SE; Andreas Charalambous, CY

15:45 - 15:45 **Session DOI**

15:45 - 16:00 **Introduction to the session**
A. Charalambous, CYPRUS UNIVERSITY OF TECHNOLOGY, Limassol, CY

16:00 - 16:15 **Awards**

16:15 - 16:30 **RECaN award**

16:30 - 16:45 **Life-time achievement award**

16:45 - 17:00 **Closing remarks**

16:30 - 18:00 **Type: Proffered Paper session** **Barcelona Auditorium (Hall 2)**
Title: Presidential Symposium III

16:30 - 16:30 **Session DOI**

16:30 - 18:00 **Type: Educational session** **Madrid Auditorium (Hall 2)**
Title: Optimal adjuvant and neo-adjuvant therapy in HER-2+ patients
Chair(s): Aleix Prat, ES

16:30 - 16:30 **Session DOI**

16:30 - 16:55 **Dissecting the heterogeneity of HER2+ breast cancer**
A. Prat, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

16:55 - 17:20 **Lessons learned and opportunities from the neo-adjuvant setting**
L. Carey, UNC - Lineberger Cancer Center, Chapel Hill, US

17:20 - 17:45 **Optimal current regimens in the adjuvant setting**
N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE

17:45 - 18:00 **Discussion**

16:30 - 18:00 **Type: Educational session** **Pamplona Auditorium (Hall 2)**
Title: How to handle comorbidities in the treatment decision of stages I to III NSCLC

16:30 - 16:30 **Session DOI**

16:30 - 16:55 **Pulmonary risk assessment**
P. Baas, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

16:55 - 17:20 **Cardiac risk assessment**
A. Brunelli, St. James's University Hospital Leeds, Leeds, GB

17:20 - 17:45 **Other significant comorbidities**
T. Berghmans, Institute Jules Bordet, Brussels, BE

17:45 - 18:00 **Discussion**

16:30 - 18:00 **Type: Educational session** **Granada Auditorium (Hall 3)**
Title: Bronchial neuroendocrine tumours

16:30 - 16:30 **Session DOI**

16:30 - 16:55 **Challenges in pathological and molecular classifications**
M. Milione, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

16:55 - 17:20 **The genomic landscape**
C. Thirlwell, Royal Free Hospital School of Medicine, London, GB

17:20 - 17:45 **Seeking the optimal treatment sequence in advanced disease**
E. Segelov, Monash Medical Centre, Clayton, AU

17:45 - 18:00 **Discussion**

16:30 - 18:00 Type: Proffered Paper session Salamanca Auditorium (Hall 3)
Title: Proffered Paper - Public policy

16:30 - 16:42 **16260 - ESMO-MCBS and Health Technology Assessment (HTA): Does value for physicians correspond to value for payers?**

A. Ambavane¹, A. Benedict², S. Rivolo³, P. Rakonczai², V. Kapetanakis¹, ¹Evidera Inc, Dubai, AE, ²Evidera Inc., Budapest, HU, ³Evidera (European Headquarter), London, GB

16:42 - 16:54 **16270 - Change in Magnitude of Clinical Benefit, Overall Survival (OS) and Quality of Life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015.**

A. Bujosa Rodríguez¹, J.C. Tapia¹, T. Hwang², C. Molto Valiente¹, A. Templeton³, A. Barnadas¹, E. Amir⁴, A. Tibau¹, ¹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ²Harvard Medical School, Boston, US, ³St. Claraspital AG, Basel, CH, ⁴Princess Margaret Cancer Center, Toronto, CA

16:54 - 17:06 **16280 - Consistency of ESMO-MCBS scores with drug access recommendations in Catalonia**

C. Salazar¹, M. Obach², J.M. Fontanet², G. Garrido², A. Feliu³, M. Riba³, M. Umbria², M. Gasol², A. Prat², A. Vallano², C. Pontes², ¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ²CatSalut, Barcelona, ES, ³Hospital de la Santa Creu i Sant Pau, Barcelona, ES

17:06 - 17:21 **Invited Discussant 16260, 16270 and 16280**

17:21 - 17:33 **16290 - The price of added value for new anti-cancer drugs in France 2004-17**

P. Marino¹, A.-C. Jalbert¹, S. Duran², J. Mancini³, A. Gonçalves⁴, M. Rodwin⁵, ¹Institut Paoli-Calmettes, Marseille, FR, ²Institute Paoli Calmettes, Marseille, FR, ³UMR 1252 SESSTIM AMU, INSERM, IRD, Marseille, FR, ⁴Institut Paoli Calmettes, Marseille, FR, ⁵Suffolk University, Boston, US

17:33 - 17:45 **16300 - Reimbursement Reality for Off-label use in cancer care - A systematic empirical investigation**

A. Herbrand¹, A. Schmitt¹, A. Hoogkamer¹, M. Joerger², S. Diem², U. Novak³, L. Hemkens⁴, B. Kasenda⁵, ¹Universitatsspital Basel, Basel, CH, ²Kantonsspital St. Gallen, St. Gallen, CH, ³University Hospital Bern, Bern, CH, ⁴University Hospital Basel, Basel, CH, ⁵Klinikum Stuttgart, Stuttgart, DE

17:45 - 18:00 **Invited Discussant 16290 and 16300**

16:45 - 17:45 **Type: Multidisciplinary session** **Valencia Auditorium (Hall 5)**
Title: Treatment of locally recurrent head and neck cancers

16:45 - 16:45 **Session DOI**

16:45 - 16:50 **Presentation of case/condition**

16:50 - 17:05 **Molecular insights into treatment decisions**

I. Tinhofer-Keilholz, Charité - Universitätsmedizin Berlin, Berlin, DE

17:05 - 17:20 **Improving patient selection for surgical candidates**

H. Mehanna, The University of Birmingham Institute for Cancer Studies, Birmingham, GB

17:20 - 17:35 **Indications for re-irradiation**

P. Blanchard, Institut Gustave Roussy, Villejuif, FR

17:35 - 17:45 **General discussion**

16:45 - 17:45 **Type: Multidisciplinary session** **Tarragona Auditorium (Hall 7)**
Title: Precision medicine for sarcoma: Are we there yet?
 Chair(s): Enrique De Alava, ES

16:45 - 16:45 **Session DOI**

16:45 - 16:50 **Presentation of case/condition**
D. Katz, Assaf Harofeh Medical Center, Be'er Ya'akov, IL

16:50 - 17:05 **Insights from basic research**
O. Delattre, Institut Curie, Paris, FR

17:05 - 17:20 **Insights from oncology**
D. Katz, Assaf Harofeh Medical Center, Be'er Ya'akov, IL

17:20 - 17:35 **Insights from pathology**
E. De Alava, Hospital Universitario Virgen del Rocio, Sevilla, ES

17:35 - 17:45 **General discussion**

16:45 - 17:45 **Type: Poster Discussion session** **Cartagena Auditorium (Hall 3)**
Title: Poster Discussion - Haematological malignancies

16:45 - 16:45 **Session DOI**

16:45 - 16:45 **1068PD - Non-Hodgkin lymphoma in HIV-positive patients treated with antiretroviral therapy and chemotherapy: a single institution retrospective study**

D. Dalu¹, C. Fasola¹, D. De Francesco², G. Bombonati¹, L. Ammoni¹, N.M. La Verde¹,
¹ASST Fatebenefratelli Sacco, Milan, IT, ²UCL, London, GB

16:45 - 16:45 **1069PD - Obstetric and maternal outcome of 134 patients with Hodgkin lymphoma diagnosed during pregnancy: results from the INCIP registry**

F. Amant¹, C. Maggen², D. Dierickx², E. Lugtenburg³, A. Laenen⁴, E. Cardonick⁵, R. Shmakov⁶, M. Bellido Casado⁷, A. Garcia⁸, M. Gziri⁹, M. Halaska¹⁰, P. Ottevanger¹¹, K. Van Calsteren¹², A. L'Hauglin⁵, E. Polushkina⁶, L. Van Dam³, P. Vandenberghe², S. Woei-A-Jin², ¹University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ²University Hospitals Leuven and Department of Oncology, KU Leuven, Leuven, BE, ³Erasmus University Medical Center, Rotterdam, NL, ⁴KU Leuven, Leuven, BE, ⁵Cooper University Hospital, Philadelphia, US, ⁶National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, RU, ⁷University Medical Centre Groningen,

Groningen, NL, ⁸Hospital Regional de Alta Especialidad de Ixtapaluca (HRAEI), Mexico City, MX, ⁹Cliniques Universitaires St Luc, Brussels, BE, ¹⁰3rd Medical Faculty Charles University and Faculty Hospital Kralovske Vinohrady, Prague, CZ, ¹¹Radboud UMC Nijmegen, Nijmegen, NL, ¹²University Hospitals Leuven and Department of Development and Regeneration, KU Leuven, Leuven, BE

16:45 - 16:55 **Invited Discussant 1068PD and 1069PD**

16:55 - 17:05 **Q&A led by Discussant**

17:05 - 17:05 **1070PD - Treatment outcomes and pattern of failure in primary gastric diffuse large B cell lymphoma with complete remission following R-CHOP chemotherapy**

H.J. Kang¹, B.-O. Choi², S.-E. Jung², K.-S. Park², J.-H. O², H.H. Lee², Y.-W. Jeon², S.-G. Cho², ¹Seoul St. Mary's Hospital, of the Catholic University, Seoul, KR, ²Catholic University Lymphoma Group, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, KR

17:05 - 17:05 **1071PD - Treatment outcome for gastric mucosa-associated lymphoid tissue lymphoma with Helicobacter Pylori negative**

S.-N. Lim¹, S. Ko¹, B.S. Sohn², ¹Inje University Haeundae Paik Hospital, Busan, KR, ²Inje University Sanggye Paik Hospital, Seoul, KR

17:05 - 17:15 **Invited Discussant 1070PD and 1071PD**

17:15 - 17:25 **Q&A led by Discussant**

18:30 - 20:00	Type: Industry Satellite Symposium Title: MSD - Enhancing patient access to innovative cancer therapies: Collaborative solutions	Cordoba Auditorium (Hall 7)
----------------------	---	------------------------------------

18:30 - 20:00 **Type: Industry Satellite Symposium** **Bilbao Auditorium (Hall 5)**
Title: MSD - Redefining survival: Latest advances in the treatment of melanoma
Chair(s): Antoni Ribas, US

18:30 - 18:35 **Welcome & introduction**

A. Ribas, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US

18:35 - 18:50 **The evolving adjuvant melanoma treatment landscape**

R. Dummer, Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH

18:50 - 19:10 **Translating adjuvant melanoma data into clinical practice**

G. Long, Melanoma Institute Australia, Wollstonecraft, AU

19:10 - 19:25 **Long term survival in advanced melanoma**

C. Robert, Institut Gustave Roussy, Villejuif, FR

19:25 - 19:45 **Implications of advanced melanoma data into clinical practice**

M. Ross, The University of Texas MD Anderson Cancer Center, Houston, US

19:45 - 19:55 **Q&A and panel discussion**

19:55 - 20:00 **Closing remarks**

A. Ribas, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US

- 18:30 - 20:00** **Type: Industry Satellite Symposium** **Tarragona Auditorium**
Title: MSD - Defining biomarker-guided immuno- **(Hall 7)**
oncology treatments
Chair(s): Roy S. Herbst, US
- 18:30 - 18:40 **Welcome and introductions. Biomarker driven patient management in ImmunoOncology: An overarching view**
R.S. Herbst, Yale University School of Medicine, New Haven, US
- 18:40 - 19:10 **PD-L1: From controversial to foundational biomarker in ImmunoOncology treatment**
W. Weichert¹, G. Vainer², ¹Technische Universität München-Institute of Pathology, Munich, DE, ²Hadassah Medical Centre, Jerusalem, PS
- 19:10 - 19:25 **New horizon for biomarkers: What is now and next?**
R.S. Herbst, Yale University School of Medicine, New Haven, US
- 19:25 - 19:50 **Experiences with precision medicine in ImmunoOncology (panel discussion)**
F. Rojo¹, N. Reguart², ¹IIS-Fundación Jiménez Díaz, Madrid, ES, ²Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 19:50 - 20:00 **Question and answer**
R.S. Herbst, Yale University School of Medicine, New Haven, US

18:30 - 20:00	Type: Industry Satellite Symposium Title: F. Hoffmann - La Roche - An era of change in GU cancers: Immunotherapy combination strategies and newer treatment approaches Chair(s): Enrique Grande, ES	Alicante Auditorium (Hall 3)
18:30 - 18:35	Welcome and introduction <u>E. Grande</u> , MD Anderson Cancer Center Madrid, Madrid, ES	
18:35 - 18:55	Advances in first-line urothelial cancer: Evolving immunotherapy combination strategies <u>E. Grande</u> , MD Anderson Cancer Center Madrid, Madrid, ES	
18:55 - 19:15	Optimising treatment of urothelial cancer: Translating data into clinical practice <u>Y. Loriot</u> , Institut Gustave Roussy, Villejuif, FR	
19:15 - 19:35	Future directions in prostate cancer: Immunotherapy and beyond <u>J. Puente</u> , Hospital Clinico Universitario San Carlos, Madrid, ES	
19:35 - 19:55	Panel discussion	
19:55 - 20:00	Summary and close <u>E. Grande</u> , MD Anderson Cancer Center Madrid, Madrid, ES	

18:30 - 20:00 **Type: Industry Satellite Symposium** **Cartagena Auditorium (Hall 3)**
Title: AstraZeneca - Taking the next step in lung cancer: Combination approaches with immune checkpoint inhibition

18:30 - 18:35 **Introduction and opening remarks**

18:35 - 18:50 **Evolving role of immune checkpoint inhibitors in first-line extensive-stage SCLC**
S. Novello, University of Turin, Turin, IT

18:50 - 19:05 **Emerging biomarkers with potential to aid in treatment decisions in first-line metastatic NSCLC**
D. Gandara, University of California Davis Cancer Center, Sacramento, US

19:05 - 19:20 **Novel combination approaches with immune checkpoint inhibitors in first-line metastatic NSCLC**
F. Barlesi, Aix-Marseille University, Marseille, FR

19:20 - 19:55 **Incorporating combination regimens into clinical practice: Patient cases with panel discussion**
S. Novello¹, D. Gandara², F. Barlesi³, ¹Università Degli Studi Di Torino - Orbassano, Orbassano, IT, ²University of California Davis Cancer Center, Sacramento, US, ³Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR

19:55 - 20:00 **Closing remarks**

18:30 - 20:00	Type: ESMO Colloquium Title: ESMO Colloquium supported by Apogenix - Recurrent glioblastoma management: Challenges and opportunities Chair(s): Matthias Preusser, AT	Salamanca Auditorium (Hall 3)
18:30 - 18:30	Session DOI	
18:30 - 18:33	Introduction <u>M. Preusser</u> , Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT	
18:33 - 18:48	Present standard of care for recurrent glioblastoma <u>E. Le Rhun</u> , Roger Salengro Hospital, Lille, FR	
18:48 - 18:53	Q&A	
18:53 - 19:13	Novel systemic treatment approaches for recurrent glioblastoma <u>M. Preusser</u> , Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT	
19:13 - 19:18	Q&A	
19:18 - 19:33	Biology of CD95/Fas/CD95L <u>M. Weller</u> , Universitätsspital Zürich - Klinik für Neurologie, Zurich, CH	
19:33 - 19:38	Q&A	
19:38 - 19:53	CD95L/Fas ligand selective inhibition: Rationale and clinical results <u>W. Wick</u> , University of Heidelberg, Heidelberg, DE	
19:53 - 19:58	Q&A	
19:58 - 20:00	Conclusions	

18:30 - 20:00 **Type: Industry Satellite Symposium** **Toledo Auditorium**
Title: MSD - The expanding role of immune-checkpoint inhibitors across GU cancers **(Hall 5)**
Chair(s): Thomas Powles, GB

18:30 - 18:45 **Introduction & opening: The expanding role of immune-checkpoint inhibitors across GU cancers**

T. Powles, Barts Cancer Institute, London, GB

18:45 - 19:00 **Evolving treatment landscape in mUC**

J. Bellmunt, Harvard Medical School, Boston, US

19:00 - 19:10 **Panel discussion (UC) &&**

19:10 - 19:25 **Evolving treatment landscape in mRCC**

B. Rini, Cleveland Clinic, Cleveland, US

19:25 - 19:35 **Panel discussion (RCC) &&**

19:35 - 19:55 **Case studies: UC, RCC patient management**

I. Duran Martinez, Hospital Universitario Marques de Valdecilla, Santander, ES

19:55 - 20:00 **Conclusions**

T. Powles, Barts Cancer Institute, London, GB

01.10.2019

09:00 - 13:00 **Type: Congress highlights** **Madrid Auditorium (Hall 2)**
Title: Congress Highlights 1 - The best of ESMO 2019

Chair(s): Emile Voest, NL; Fatima Cardoso, PT

09:00 - 09:00 **Session DOI**

09:00 - 09:20 **Basic Science**

C. Dive, Cancer Research UK Manchester Institute, Manchester, GB

09:20 - 09:40 **Translational research**

S. Linn, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

09:40 - 10:00 **Developmental therapeutics**

E. Garralda, Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

10:00 - 10:20 **GU prostate**

J. Mateo, Vall d'Hebron University Hospital, Barcelona, ES

10:20 - 10:40 **GU non-prostate**

J. Oldenburg, Akershus universitetssykehus HF, Lorenskog, NO

10:40 - 11:00 **Break**

11:00 - 11:20 **Head and neck cancer**

S. Oosting, University Hospital Groningen (UMCG), Groningen, NL

11:20 - 11:40 **CNS tumours**

E. Le Rhun, Roger Salengro Hospital, Lille, FR

11:40 - 12:00 **Breast cancer, early stage**

W. Janni, Ulm Medical University, Ulm, DE

12:00 - 12:20 **Breast cancer, metastatic**

R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

12:20 - 12:40 **Gynaecological cancers**

I. Ray-Coquard, Centre Léon Bérard, Lyon, FR

12:40 - 13:00 **Immunotherapy of cancer**

F. Herrera, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

09:00 - 12:40 **Type: Congress highlights** **Sevilla Auditorium (Hall 2)**
Title: Congress Highlights 2 - The best of ESMO 2019
Chair(s): Fortunato Ciardiello, IT; Jean-Yves Blay, FR

09:00 - 09:00 **Session DOI**

09:00 - 09:20 **GI colorectal**

C.-H. Koehne, Klinikum Oldenburg, Oldenburg, DE

09:20 - 09:40 **GI non-colorectal**

I. Chau, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

09:40 - 10:00 **NETs and endocrine tumours**

E. Baudin, Gustave Roussy - Cancer Campus, Villejuif, FR

10:00 - 10:20 **Public policy**

10:20 - 10:40 **Haematological malignancies**

M. Ghielmini, IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH

10:40 - 11:00 **Break**

11:00 - 11:20 **Sarcoma**

J. Martin Broto, Hospital Universitario Son Espases, Palma de Mallorca, ES

11:20 - 11:40 **Supportive and palliative care**

F. Scotté, Hopital Foch, Suresnes, FR

11:40 - 12:00 **Melanoma and other skin tumours**

P. Rutkowski, The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL

12:00 - 12:20 **Non-metastatic NSCLC and other thoracic malignancies**

S. Novello, Università Degli Studi Di Torino - Orbassano, Orbassano, IT

12:20 - 12:40 **NSCLC, metastatic**

S. Ekman, Karolinska University Hospital-Solna, Solna, SE